<SEC-DOCUMENT>0000950170-25-030913.txt : 20250303
<SEC-HEADER>0000950170-25-030913.hdr.sgml : 20250303
<ACCEPTANCE-DATETIME>20250303163618
ACCESSION NUMBER:		0000950170-25-030913
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250303
DATE AS OF CHANGE:		20250303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptive Biotechnologies Corp
		CENTRAL INDEX KEY:			0001478320
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				270907024
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38957
		FILM NUMBER:		25698632

	BUSINESS ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-659-0067

	MAIL ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptive TCR Corp
		DATE OF NAME CHANGE:	20091209
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>adpt-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-03T02:18:08.6429+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:adpt="http://www.adaptivebiotech.com/20241231">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_2b3d04cf-0171-48b7-899e-f79d40eacafb" name="dei:EntityCentralIndexKey" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164">0001478320</ix:nonNumeric><ix:nonNumeric id="F_89ce6b46-9c36-4233-8c67-a6f4ff7d2345" name="dei:AmendmentFlag" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164">false</ix:nonNumeric><ix:nonNumeric id="F_7b4121c4-bfa1-49e5-b9d7-ab6e646012dc" name="dei:DocumentFiscalPeriodFocus" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164">FY</ix:nonNumeric><ix:nonFraction id="F_eef839ed-813e-4faa-9738-c5a903618713" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c58c92e1-6822-4816-bcb5-bc958b91adbe" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ae197273-22ff-4091-95b7-abf2afa45c8a" name="us-gaap:PreferredStockValue" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b34944cc-62c5-46f4-b074-a8bc0e8fd618" name="us-gaap:PreferredStockValue" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_9272d326-ab2d-442b-b3a2-82c6a66a936a">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_6a683fd2-b719-4e8e-9163-23af35cb1311" name="adpt:RevenueRecognitionExpectedPeriod" contextRef="C_c8814a61-92ce-4b2b-8aa0-402f4c13d4de">P9Y</ix:nonNumeric><ix:nonNumeric id="F_66782f0d-d53d-4c13-bd13-17f76499cf21" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535">http://fasb.org/us-gaap/2024#ImpairmentOfLongLivedAssetsHeldForUse</ix:nonNumeric><ix:nonNumeric id="F_8759c879-be95-43bb-8de5-203e18a7141c" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_75bb2233-9ac9-45f1-8031-2e009382d5f2" name="adpt:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0">http://fasb.org/us-gaap/2024#RestructuringCharges</ix:nonNumeric><ix:nonNumeric id="F_83fd51e3-9860-4816-b7d4-990a29a9c263" name="adpt:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08">http://fasb.org/us-gaap/2024#RestructuringCharges</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="adpt-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_800a8d4f-a9fc-4ca6-8af0-3cd02f0dd56b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81bb5afe-4560-45fd-bd67-49459a4983ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_826be3c4-b05f-4764-b189-9b17a0ed4f47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_830ceebd-b448-4556-8cc3-345699e93087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_845f3c97-7e7c-4286-9701-ee7332f3f413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_848613df-8ebc-4107-bbad-5a337d92718b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8493c832-b379-44de-b19a-4bb6d192e6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8672005a-0af6-4c35-b305-e5625f4ced55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_874675f7-b27f-4f96-93aa-3186a0017df4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_880b4bee-c006-4cb8-8920-ecb8a97fc49d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88922b78-bf40-483b-ba74-3b67fea9b4fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89099e56-2c94-45a0-bf9b-0e1751243cd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8949417c-8327-42ad-9e79-5c74d95818aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a711a70-7835-4547-9b99-bc3f849a6ee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ae2ed18-baf4-42dd-a344-3979e49ff066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c08d7f9-6ece-4397-98cb-7a4e690601d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dd592c7-dd5c-4673-a9f3-c1849fefa514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f46490b-2478-46c6-9c66-ca4d59a7e377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9055c1c2-d88e-4bbe-b0ba-ea4735bc60b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90e7cb01-e413-4073-b348-b2397b9dd2f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90f05e58-9e8e-464c-86a0-007bf79714f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9272d326-ab2d-442b-b3a2-82c6a66a936a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_938538bd-3388-44c9-b50d-231541782951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93957bc6-8913-431a-aa08-83e39673bc72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93a61f54-9fc1-4164-ad0a-ecd149ef96a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9449b797-84c6-46c5-a338-60738ca67a56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9574ad63-2e26-40ad-9358-463b4132a65d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9636194e-e351-4fcc-97ab-4e132d735d9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96e4eb5a-1de1-40a2-8f39-b8260ca0c7ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99584d81-0d39-482d-9529-479e97a39b00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9abadd97-9d4e-4600-a895-663eefee5344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bed03af-b144-4cd1-8808-efb75597dec9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c86f6ae-1650-46f6-a8e7-0baaca9c4d6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d69ac12-b7e7-4fba-a6e8-17f59c20625b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dadad4b-2404-454e-8619-6c7106da8dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9eec2a01-b68b-4cd4-9ae8-af29e919f6c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0289be5-fa32-463c-acef-732918e4cece"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1e0e792-7995-4a69-9664-7d62b49d7305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a46c0838-63e1-46ff-badd-1a080dcfd4e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a49d0116-6be0-4342-bb34-064f2cb1779c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6daf5ec-996f-44a9-a1a1-176861ff844f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7d99817-f47e-4c17-8910-f27cddac34f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8b15cb2-7331-4388-b91a-39842959aeaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9e6d9f0-f84d-4295-b3ac-f1ae0043be0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab192050-c968-4f59-b97c-0347bf2e6704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abf475fb-d18b-494c-bb9c-bf8ac3104ace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac141085-19dd-4092-b7b5-3caab7439cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ade00613-56f9-431a-ba97-2bc4f44cf6b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae8e1030-1ab7-4183-8173-e30e69f625b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af621409-f3a9-456c-8964-3694f64ce437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b03c96cb-2be3-4399-a5cc-ad4279252dd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0da9317-56fb-4a02-9287-ece7f5f4b6bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b171d937-1d83-4b19-9289-84b0ac31bda2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b28752cf-076a-4931-ad68-b484eab79e15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2e59962-3ddd-4060-85da-417d16f3db74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b986fb51-c7d8-4885-ad77-406faf3a7217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb6cf174-eaac-4064-a305-81f3eb2a9aeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc03cecf-836f-4bee-b7f1-33ef96865307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc1bccb4-0e9a-42e9-b42b-84b9f3eb6d85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc1ec203-aeac-49ca-bbbc-3d860034cbec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc4f3373-536d-41d1-b3a3-421bacc254af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd08a3f3-19f2-4f0f-9fdc-39c4d781f8d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd3ac93b-1e22-485d-bfed-003c41a39739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd7b1034-af6a-470b-8700-f6950a6eba00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdf418ac-63a7-4d7a-a22c-01620319ca13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be240297-154f-4383-9264-3588023daa8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c00eaa13-213e-4380-87d4-07983d165569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c147eb1f-f94e-4397-b028-6165d4ff279b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c231ef4e-80b4-4315-a315-4a98c8a5a33b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c46025e5-021b-4f7b-a2ef-444e78692785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-29</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c57a4b94-c81c-408b-81ae-f08bfc651eca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8814a61-92ce-4b2b-8aa0-402f4c13d4de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8c4442e-e5ce-488d-9683-4a18e9b3cd7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8ff48b7-0993-480b-9ebf-68a92b4acfce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb262e8f-a1c3-4acd-b4cf-58e1bcae091b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb4e71eb-46c4-41f6-9ca9-4467ec43dcfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb867f2c-9a12-4675-ab77-495ff41044b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc530114-c6ce-4f99-b1da-fe2970aacb2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc544eb2-c862-4117-ae53-7167dec34569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccbf3cec-810a-407c-8e46-299bdc89be19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdd9919b-7ab5-4a3b-856b-38b155fb4234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfbee4bf-0f67-4e80-8986-2a8c42354e22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfd24335-f1d6-459a-a81e-c4653a33dd6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2e2d8d1-07f1-4212-9f71-7af175f378a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3e396ad-f474-4619-9772-0d0cf9c0f093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3e4b471-6ad7-4d54-aafa-1c355daee1b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d536e9b5-ed0c-483d-9d06-83c84f459d93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6ec2ad5-f515-4f06-84a0-2aa770767702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8181a55-5e75-41e9-9ce9-c8d6ef15af36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da165782-cf35-4126-a330-0965f4347274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da3ff03b-c852-4729-b32f-d1e13c53f431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db18a52f-bcfe-46a3-89ae-80288cdff126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc2d580a-7814-47b1-a90a-9db3f5a070a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de48bc4d-6614-4d5d-ba6b-44f4d8a7fb54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dec1c67a-a4a6-4150-87ca-ce929f12f0f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df6ab829-80ae-4fe6-8c59-0c879baee98e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df90d480-536f-44ca-97f1-bc8815b053e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfdfb869-6506-40d7-affa-2d14196aab88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0cd05cf-7df4-4d8f-b77a-87c83fce22a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e16d035a-df2e-4300-bb99-13a2fe409ebb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e30f0baf-e7ad-4a6d-8333-cd12494dfbb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4bc6147-a322-4ac9-983f-0be3e4e33863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4fca2f4-8e1d-432d-80ec-6c3440952998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e59b5618-2d7c-4271-a133-4a54a274bfa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adpt:DigitalBiotechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9191c9f-9e40-4eef-8bb8-8c5bff219c41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb217ce2-c0bd-4ee9-98ca-e04bd1a4c870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebc8e107-4003-4674-8227-7ec4caf59826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockExerciseOfOutstandingStockOptionsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edda825c-90de-4c1f-b5b3-c767c222382e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eddbf21f-640d-4187-9c5f-398cd390ba4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee233ba5-9cea-4a85-9f15-e4b103298328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef70f5dc-4521-45f8-a731-f46544a75c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f01c0215-4e04-4a37-b6a0-43ec834d33fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2113807-0eb7-481d-81da-8e883e379e25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3a08a4e-1038-45b8-8a45-c1295cbf5ecb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4324bd6-f036-4a55-a048-f63024a406bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6bd00d1-b48a-4bf4-8057-810a2bb6684a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb3ea207-d43b-4520-9dbf-4b33f273a3e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb6ff782-0ca3-4143-ad9b-7c8ef89ed646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbb5807f-dfac-429b-964f-d08eebca81e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc40783a-89f6-4d6a-8cdb-a7280da7107a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd06ba76-408d-423e-bf02-573512c6c45c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd819420-41b4-40d4-9e84-63652fd8d5a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd9b1278-cc4e-43c9-a7cf-005a24cec79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fea8d0de-6b48-42cf-a187-18acba215cd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0029b7a6-ee35-412e-80b4-c83f66b83283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_013827d3-b15c-4f85-88a8-bbae4386a47c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01f6ee6c-fba7-496b-80dc-8365c221c856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02627e80-13ae-4972-9edc-6d2d1f0cdb33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03002793-4de6-465a-b177-09dbb4ca58f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05929f03-5f49-44c6-99b2-b6ac0648d6a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05b25161-4405-4484-9a79-0c9ef7d93c2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06fe2942-7d85-4654-9ab0-33bc82a8bcd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07b2fa42-3cff-4d55-9da4-b7ec997c914f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_099bbd21-af0c-4f39-ba1c-26dd5d66531e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a49afd5-b03f-4f5c-bc78-5dfce07d3fbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b1f2c34-a18a-449b-9a8f-3aa8bfcadbc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bdc5c5e-908e-4299-8ae3-da0932a02def"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c9ad877-d4fd-4667-9562-04fee6ec1601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0df3cf5d-7b89-4a27-bcce-445ba936b692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e18d051-aeae-44cb-ba16-8f0a32e2f029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1119d75f-ac1e-4443-a095-4f4846ec2ff9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_115005c9-cf96-423b-b5e8-3aaf79d6b164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16299617-ee7c-4dc4-96f4-999a18550372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16e28997-7e3b-4c9b-81c4-971e637e2f39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a256318-aca1-4e30-8e79-987a0c9de60a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1acd60e0-7824-477a-940e-96fcce72212e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1aeca0d4-12fc-4e19-b717-44dc51c65479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c7dad97-0dc1-49c3-8e6a-213606328313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e9897c4-5275-417c-8724-b96563d5a101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fb577e9-9c40-4d2b-bc4e-1fc3181e8bb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20a3dc1a-a419-4e0f-a290-0890b8721905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22b5dd10-ae86-4ea2-9caa-a6986a38f552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23197216-2be1-412a-babd-a86284108614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_236a64e1-b094-4db0-b4b0-f4b9a7cae648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2447145f-f97a-4de4-9722-96b5a9481f34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_256c43d6-4366-49a5-8b14-90aef18be10f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26c9b550-cdb1-4568-b071-8fda1b1e79ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28287282-43af-4ee0-9eb6-97361dbf3a49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28466158-15a5-4c86-9df3-08250c20e264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28c5bcc4-c729-4e8c-bce9-751448cc3f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29395044-cf96-4b99-9148-86cf3018ed50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29808493-b539-4763-a0cc-0c411c398bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29b153aa-6e60-459b-8d8b-3607e4aecaf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29e591f1-b6b5-44c0-9273-a6ab4ed69a29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ac1d2a6-7485-444c-b87e-886ba5dc3b3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30a5bbbe-6a9c-4d08-a5bf-c0ca07f38d71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31033074-d98e-4051-a1dd-9611d85c39b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31434234-729f-49fb-9bc5-a4c2db285d76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3242f9e3-dcb0-4a64-a6a1-9e8c5aa997e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_333af4a3-cffa-49c3-8566-6302b765c42b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3371457f-35a0-478d-ad1d-6b89373e6edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_348cb82b-d5ac-43f4-a398-22620b3796c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3505aa94-9150-444b-91e7-c7847006ec3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_355bb8fa-16f0-474d-b4fd-4b16eacb34a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35bf3362-af08-41ac-b5ae-d51683a82d48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_374a2a9a-0d8a-4c0a-bd27-2a810ec44e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a1d8a90-cba6-4a27-8976-dff0b00c047d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b97b1d4-62a9-4c60-be60-2108f97f8fb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c36ec93-0b98-4985-917c-84fa8ef6964c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d00688c-415e-4822-a136-7b16fe0014b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3da0eaaf-abe5-400c-a7d1-218bca3b9652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ed4ebec-bba3-4eee-a2b7-b31d8032bc49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4038584b-af9b-45c7-a179-a1aac6d8e18e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_419c90ac-d4cc-4e42-adb9-be55df808d8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41d2ea93-dc38-4500-b0a7-cd99c27e6352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4209531b-b000-47fb-8aa6-738c91148064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_425da08a-cc18-4b6b-b559-af896468cf59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43334088-5e2d-486b-bae0-78c2ee15f270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43977db9-b2fc-4eb0-8c06-461f1b087616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46f8f010-ed88-453e-905a-2c7a307eadfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_485a9291-5f30-4382-b6a6-6d39f1a103e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48e2fe0d-2cdf-4541-8c48-496992bb429b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a469c78-301a-4529-b28e-24903923c651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c968389-ac05-4e80-a351-de3893d81820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e62fea1-8195-4797-84f6-8e80fbc5903d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_518ea4ca-bec1-4e07-8773-307a90cb3d09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_538c62e7-e31b-49fc-a740-3611b3bdd5b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_569de780-6224-4d27-819f-c41e8e9a86d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57585e88-6f33-40e2-a08a-7f48691bb39b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57cc43f2-a758-4e93-85a5-3570f3deb3df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5849a7e8-d209-4520-ae06-42818b55c73d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c67024c-2523-482e-9f70-804bcc6d8184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d904410-055f-498e-b598-0be6c4b19349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ec5d924-4867-4b17-91e0-bd4130ea3d71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fb3a979-ff4c-4253-8408-395fb698c93b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6058a09d-5c33-4856-9a87-634891fd1ff1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60932611-3f39-47dd-9da8-86fe5e9898f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61e08594-2216-4ede-9093-11ef2ff2f063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_621e5196-e15c-4321-8f5f-959090207c65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64e80de6-0e67-4131-8ace-44a4d0c8b34e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_656c98bc-1902-4c80-b4fc-1e9db82df492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6591b0ed-3cfb-45af-b746-4190d5d17981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6712d8a7-de54-47f0-b34a-c94d59831861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6761f29f-952e-4394-b160-1a416c1945ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68e4bc9a-5ec1-4697-aa56-4ddc7bb9b1f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69a8c3ab-a441-40a7-8a5f-6b8e7d9071e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69fe0b18-2ecf-4cb8-92b2-378c77fd872e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a9f91b0-4738-40f9-b68a-82bd5973e387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">adpt:MichelleGriffinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b2d4707-21b9-4599-a35b-221f9e77a609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b74a919-15ca-422a-bdd2-8538b4633aa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bf4218c-4293-4f50-84e5-e19d61af2275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-12</xbrli:startDate><xbrli:endDate>2022-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dc97585-6690-424d-b20a-80823243e590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ee41dc2-3749-4243-b0eb-1ba3135232f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f1910b3-9154-4298-8382-eeed229f5b9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f1d2824-9131-43aa-aab8-2a0a4ed4adce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70d180be-d136-46d0-a6f1-b5c952fe6c15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70fe95bd-0b9c-4b16-aab2-e8db1c249769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7159e6a5-a720-4e55-b4d1-ebcad9b281df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7364eb6e-22be-4204-8475-fec3ce145680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_752e690e-a58f-4330-872e-b0e7486ee008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76aa1ad9-be8e-41ac-91df-576de65c2d91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78553a5c-8e8c-41d6-9e26-df90b6ee5bb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7869d22e-be80-4ab4-88aa-2651f1bd991b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_791187a1-62e6-4444-ac40-4fce1c79f12a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79c39ab7-5350-4de3-9055-afde44e88b1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a426cce-3933-463c-a1eb-b6accca81255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7be5ebc7-1646-49da-a85c-c1f9911464ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c1e94f7-1563-46d1-9179-65444a8457d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cc0feec-e028-49cb-9eb1-10aee43d5810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f50006e-3aac-4a89-bd88-97a6fda0febc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f583a8c-c6f5-48ba-af7b-80283f1ac4cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fc08718-7fea-4e2c-bb3c-69007782863d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adpt:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>adpt:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employee"><xbrli:measure>adpt:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="U_Performance_Obligation"><xbrli:measure>adpt:Performance_Obligation</xbrli:measure></xbrli:unit><xbrli:unit id="U_Unit"><xbrli:measure>adpt:Unit</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>adpt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38" fromRefs="F_4438e2f0-9d58-4599-8f57-e22efbed9cda F_b2cbe0a4-434b-4068-990b-ad81f9366b7a F_b99294fd-d7bb-4937-8c90-b08044e85551"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53" fromRefs="F_74ff7f71-2430-4605-9e04-027595fb1748 F_384876e2-fe72-44d1-8909-963c883b7b5f F_7c24df4d-9a6d-4cef-936a-d6ab503d8c61 F_fb6cf031-e6b5-47fc-affd-47c52b311ce4 F_6cedab5a-035d-4c63-89e7-abd4a482b92c F_cb99609e-f987-4efd-ad72-7c5cb386d178 F_40b0137c-2980-4840-93bf-339330caf6b1 F_867fcb0d-4c7f-4360-a60c-7ec9f6f55b5d F_b8b15491-84e6-4093-a3dc-f6e4e3658c9a F_4ed001e3-66e3-4969-8e54-995698d5b0e4 F_bf83b944-d68e-48d4-bda8-c3986baaf736 F_4aa2c192-033b-4ea8-94ff-28f5a51ea829 F_d35974e6-5809-4ae2-a57a-55bc3d676e32 F_806a258d-2394-4d13-9b00-dcf6e6a2afe4 F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7 F_80e9fe5b-1f9c-4343-85f9-ec20ab7c395f F_629e47f6-ada6-4b91-b878-080425e24779 F_71c477a7-f00d-434a-bd81-caf1f718e054 F_db33ce64-269a-49ea-a4af-63a49a604a55 F_54f910ac-ddd1-4976-81c3-5ea636082b15 F_92c52fe6-c1cf-429e-b534-2bcd9b87c577 F_807fcd58-d6d5-4803-b9c2-0fd4abe33853 F_65d343e9-bdf0-47a3-81b1-24c409997f28 F_cb03b45e-d983-4f77-9458-0b027a46cdcb F_ea6e0b37-84f2-44d8-aef5-ffe0db092982 F_3970881c-267c-4c47-aa23-6eeb7b471754 F_19d4a5a5-e0e3-430a-946a-aac10afdbff3 F_402df673-cbb4-4da2-8903-26c31f8f1d22 F_c76bc330-bc03-47cd-b81d-78b57ae2d63a F_77d9a80b-fad8-4746-a3fd-19f012a01870 F_c3876f27-0b6e-4215-92be-69496800fdf2 F_16f04e89-4028-40ca-bca2-293ab8b9b4fd F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838 F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599 F_1bf1199f-3bac-4b1a-a27b-7888cad246a7 F_5f934cfc-c961-465f-ab88-396d638ad6c1 F_17429eec-094a-43ea-927d-ef3fece81b04 F_2d0ea309-cb98-4f04-b949-55dbe6294d3d F_795a954e-d486-46e7-a250-bdfa6ebc1cfc F_cfa836ec-6129-479e-a5ea-493663968b30 F_4de633d5-d71d-466c-859a-cd7f030ebc81 F_19c4e4ee-ca66-4b67-bf95-485edb301cb1 F_bd5458aa-1382-474e-8c10-6cc0ac924c2f F_a064aff8-4d29-465b-8316-a8a35b77bc17 F_5f91837c-ddd6-4581-bca7-a80e98e6e794 F_64e78d1b-cc17-45b4-810d-d6c1e95bc0ad F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39 F_7fd498b3-a25d-4a01-aac6-ade8e1e6f17a F_51daeb26-7fb0-4369-9fd3-dddef7716b18 F_b4031824-8297-44ef-ba38-857587db2044 F_84e4227f-a8d5-4b52-b64b-050736891da1 F_bd249654-3957-4805-bdf6-1da2df6b29a6 F_dd9c5691-45e8-4094-8bf5-7c8622edfff2 F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08 F_a731ef80-93e5-44a8-9679-4a4c2c298fc8 F_9ddbf605-964c-47bd-aba2-66217d8b9853 F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00 F_50718092-9e01-48a5-8e98-6b71a52c48db F_3637051c-7816-4b47-b5fb-f4e7c6985ade F_6bd89d63-e965-4b90-9d0d-f1a53f27d8db F_d81a33d0-17e3-43cd-898f-047561248f8c F_05d1ab54-5f1d-4c3a-8fb0-4e8733fcf463 F_5cfea8e3-9a33-4b9b-bbd5-a25a7e04afbd F_09ad6b64-fb8b-4678-8f92-59036e1480ab F_51279202-faae-46b6-bb41-f7bdde771b6d F_94c50ece-9355-4a71-870f-c11753e361c8 F_97abe44c-69b9-4c80-82b1-c30839f23053 F_b7ddfab1-e5c2-4703-a546-88821c27493c F_eab68962-5a93-4f45-816f-53a003d9d744 F_8dd0f46f-0033-4e86-b816-356a96205ae4 F_d5f6c67b-b008-42db-8396-bd5613e347b5 F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4 F_54732a37-6c04-468b-8af4-d2b05eb94ad3 F_3c0ff92a-11a4-4a2c-a6e8-8f27665470e5 F_4904d016-10c5-4490-9bce-ce972d3156f6 F_696d352b-815e-4bee-a1ad-5340543c473c F_13603129-bb53-47d1-9eb7-6f62807645d1 F_41433281-99f1-4efb-a27b-d8892c89e29c F_32d528e5-a231-49d7-97ff-426af9382caf"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4" fromRefs="F_e89a95e0-f206-4819-856f-aaabb6b695ce F_b58366a1-3f90-4a0f-b814-ec4b8778b77a F_96c3782c-44fa-417a-8f0c-ac63623e40eb"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_084cfe7e-e0f2-4045-be6c-16380249a676" fromRefs="F_384876e2-fe72-44d1-8909-963c883b7b5f F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838 F_13603129-bb53-47d1-9eb7-6f62807645d1 F_bd249654-3957-4805-bdf6-1da2df6b29a6 F_5f934cfc-c961-465f-ab88-396d638ad6c1 F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39 F_09ad6b64-fb8b-4678-8f92-59036e1480ab F_40b0137c-2980-4840-93bf-339330caf6b1 F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08 F_51279202-faae-46b6-bb41-f7bdde771b6d F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00 F_d35974e6-5809-4ae2-a57a-55bc3d676e32"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e" fromRefs="F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4 F_6cedab5a-035d-4c63-89e7-abd4a482b92c F_54732a37-6c04-468b-8af4-d2b05eb94ad3 F_4904d016-10c5-4490-9bce-ce972d3156f6 F_bf83b944-d68e-48d4-bda8-c3986baaf736 F_a731ef80-93e5-44a8-9679-4a4c2c298fc8 F_32d528e5-a231-49d7-97ff-426af9382caf F_c3876f27-0b6e-4215-92be-69496800fdf2"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9" fromRefs="F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7 F_a064aff8-4d29-465b-8316-a8a35b77bc17 F_629e47f6-ada6-4b91-b878-080425e24779 F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599 F_696d352b-815e-4bee-a1ad-5340543c473c F_9ddbf605-964c-47bd-aba2-66217d8b9853"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_c863f931-5324-4e7c-879c-cbda888d3579" fromRefs="F_92c52fe6-c1cf-429e-b534-2bcd9b87c577 F_19c4e4ee-ca66-4b67-bf95-485edb301cb1"/></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.4in;position:relative;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27420c95-316b-4636-9c4b-e2366ac268bb" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_04335601-bce9-4769-9b9d-928ec17057c0" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2c5e1a5-3014-4859-84dc-2b73a01e58d2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_deefa33e-3d20-4a29-b24d-51d83f859156" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1069b09a-7df2-4c35-8504-0a1465d3e75f" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_638a78d4-d389-40c2-8466-3032bc637f68" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from _____to _____</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65476870-a320-450e-b24f-41d59a2447c2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-38957</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee71f4d0-2f42-4206-a3fe-30e9e705fd4b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADAPTIVE BIOTECHNOLOGIES CORPORATION</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8bb7bf69-4d6c-4ee6-8daa-ca7f97654660" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Washington</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_29e25ed9-3598-4fff-891c-f7556a4fa0c5" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">27-0907024</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_572d217f-8955-4381-afd4-781f6a7fa12e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1165 Eastlake Avenue East</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_05ef40c5-7dab-4748-b563-9c32b4c5b4f8" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Seattle</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_a6fbb6a2-b48a-4df9-8afb-1cac3865a7aa" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Washington</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f3148605-08f7-4ed7-b09f-e51677cd76b8" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">98109</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d52bf324-41fe-4928-bfbd-e32416459235" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(206)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84a201f7-ae85-4d23-8f9c-946324fa70bf" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">659-0067</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.2%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:9.64%;box-sizing:content-box;"/>
    <td style="width:2.96%;box-sizing:content-box;"/>
    <td style="width:42.2%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dc6e2795-1dd5-4a0a-9c7c-a0827b2bd15f" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bbcf3a42-65ce-4406-a85e-2088b63261fa" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ADPT</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4af6807b-946f-4c7a-aa70-f133c05d4397" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40a1f70c-afff-425c-a989-d75171fab657" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d20544fc-56b2-4151-8796-9b8e433cce48" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75e296d9-285f-4685-8cfe-c7d532bf201e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c73f319b-cddf-41f1-a64d-28a368f5ddc3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:55.86%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:20.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0a84a384-c184-4acd-b4ef-5e5920c18a42" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_550dc3ba-fcd5-4b60-ab4d-2962766d70ed" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_68217281-b8d2-435b-97e3-717a8781b187" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ed5f1b14-0570-4c1d-8a7d-c44fcffac805" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1576d61c-6c19-4c69-bd68-46867db29bbe" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e31fda89-1f04-49e1-98c3-4077005396a4" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Global Select Market on June 28, 2024 (the last business day of the Registrant&#8217;s most recently completed second fiscal quarter), was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a1d430d-39f5-4b84-88ea-83e86cf9f931" contextRef="C_115005c9-cf96-423b-b5e8-3aaf79d6b164" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">416,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 26, 2025, the Registrant had </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39888bc5-bc13-4970-9666-9d9d4ba514cb" contextRef="C_d6ec2ad5-f515-4f06-84a0-2aa770767702" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">148,582,201</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_af79a80f-47d0-40b3-b65a-cf786ddfe3b0" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the Registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2025.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.4in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;box-sizing:content-box;"/>
    <td style="width:82.82%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and_suppleme"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information available to management. Some of the statements in the &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections and elsewhere in this Annual Report on Form 10-K contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements expressed or implied in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our significant investments in our continued research and development of new products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of developing, commercializing and achieving commercial market acceptance of clonoSEQ, Adaptive Immunosequencing, T cell receptor (&#8220;TCR&#8221;)-based cellular therapies, antibody-based therapeutics products and additional products beyond our portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential for our identified research priorities to advance our proprietary immune medicine ("IM") platform or our future products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success, cost and timing of our research and development activities, preclinical and clinical studies and, in certain instances, clinical trials and clinical validations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits of collaborations, our ability to enter into collaborations or arrangements and our ability to attract collaborators with development, manufacturing, regulatory and commercialization expertise; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability and willingness of our collaborators to continue development, manufacturing, distribution and commercialization activities relating to our jointly developed products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop products and services, including new targets in autoimmunity and neurodegenerative disorders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of our products following approval where required;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain equipment and materials (including reagents or other materials that may also require additional internal validation) from our suppliers, and in some cases single suppliers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenue and obtain funding for our operations, including funding necessary to complete further development of our current and future products, and if successful, commercialization;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manage operating expenses;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth potential of the markets for our products, and our ability to serve those markets, either alone or in combination with others;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance of our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection for our immune medicine platform, products, and related technologies and the direction of such protection;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments in the United States (&#8220;U.S.&#8221;) and foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competing products or services that are or may become available;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain key scientific or management personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of laws and regulations; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, you should refer to the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements herein represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Annual Report on Form 10-K, unless the context requires otherwise, all references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Adaptive&#8221; and the &#8220;Company&#8221; refer to Adaptive Biotechnologies Corporation.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, we reorganized our company around two main businesses: the "MRD business," consisting of clinical assessment of minimal residual disease (&#8220;MRD&#8221;) in lymphoid malignancies, and "Immune Medicine" or the "IM business," built on drug discovery and development driven by immune medicine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MRD business focuses on the use of our highly sensitive, next-generation sequencing (&#8220;NGS&#8221;) assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ assay, offered to biopharmaceutical partners to advance drug development efforts (&#8220;MRD Pharma&#8221;).  We believe the total addressable market for the MRD business is approximately $5.5 billion, approximately $4.8 billion of which is derivable from clinical testing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clonoSEQ is the first test authorized by the Food and Drug Administration (&#8220;FDA&#8221;) for the detection and monitoring of MRD in patients with multiple myeloma (&#8220;MM&#8221;), B cell acute lymphoblastic leukemia (&#8220;ALL&#8221;) and chronic lymphocytic leukemia (&#8220;CLL&#8221;), and it is also available as a CLIA-validated laboratory developed test (&#8220;LDT&#8221;) for patients with other lymphoid cancers, including diffuse large B cell lymphoma (&#8220;DLBCL&#8221;) and mantle cell lymphoma (&#8220;MCL&#8221;). With its industry-leading sensitivity, we believe clonoSEQ is uniquely situated for MRD testing in lymphoid cancers, both in the clinic and in biopharmaceutical trials. With the use of clonoSEQ, we are transforming how lymphoid cancers are treated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases. Our strategic priorities in the IM business include supporting our partner, Genentech, Inc. (&#8220;Genentech&#8221;), in its development of TCR-based cell therapies in oncology and developing targeted therapies using our differentiated precision immunology approach in select autoimmune indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IM business leverages our proprietary ability to sequence, map, pair and characterize TCRs and B cell receptors (&#8220;BCRs&#8221;) at scale. We have created a powerful data engine to drive the development of novel therapies. These datasets, which we own, include more than 100,000 signatures of cancer and autoimmune disease and more than 2,000,000 matches of TCRs to disease-related antigens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that by tapping into these datasets, there is tremendous value in the development of immune-based therapeutics. In cancer, we are working with Genentech under our worldwide collaboration and license agreement (the &#8220;Genentech Agreement&#8221;) to develop TCR-based cell therapies to treat patients with solid tumors. Our role is to discover and characterize TCRs against cancer antigens. In 2023, Genentech secured the first FDA-cleared investigational new drug (&#8220;IND&#8221;) for a cell therapy product candidate under the Genentech Agreement. This milestone established an important TCR-based cell therapy product candidate proof of concept that supports our antigen-specific TCR discovery approach. In autoimmunity, we apply our immune medicine platform to discover the specific T cells that are attacking &#8216;self&#8217; or healthy tissue. We focus on select autoimmune indications, such as multiple sclerosis (&#8220;MS&#8221;) and type 1 diabetes (&#8220;T1D&#8221;), among others, where we believe there is still a high unmet need to develop better, more targeted therapies with a better side effect profile. In MS and T1D, for example, we have successfully identified the subset of autoreactive TCRs that are likely causing these devastating diseases. Therapeutically, our goal is to eliminate or block the activation of these problem T cells and directly stop them from attacking healthy tissue.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selected 2024 Results</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, our revenue was $179.0 million, compared to $170.3 million in 2023. The increase was primarily driven by the MRD business, partially offset by a reduction in revenue recognized by the IM business mainly attributed to a decline in the amortization of the upfront payment from Genentech. Our operating expenses were significantly reduced as a result of continued streamlining of our operations during the year. Operating expenses were $341.5 million in 2024, including $7.2 million of non-cash asset impairment charges and $2.0 million in other restructuring charges, as compared to $397.3 million in 2023, of which $25.4 million represented non-cash asset impairment charges. As of December 31, 2024, cash, cash equivalents and marketable securities was $256.0 million.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MRD Business Highlights</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total MRD revenue in 2024 was $145.5 million, representing 42% growth from 2023, which included $12.5 million in revenue from milestones. We grew clonoSEQ test volume by 35% year over year. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payor coverage has extended to over 300 million lives in ALL and MM, over 200 million lives in CLL and over 70 million lives in DLBCL. In addition, we obtained Medicare coverage for MCL and initiated promotional efforts in MCL in the fourth quarter of 2024.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We obtained a new Medicare Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;) rate of $2,007 per test for clonoSEQ and MolDX updated the clonoSEQ episode pricing to $8,029 for all covered indications. This represents a 17% increase from the previous episode price and the previous implied per test rate under the episode structure.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have integrated the clonoSEQ&#8239;clinical diagnostic test via the Epic System Corporation's (&#8220;Epic&#8221;) comprehensive electronic medical record (&#8220;EMR&#8221;) system into the records systems of 18 accounts through 2024 to enable easier test ordering. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clonoSEQ assay was being used in more than 170 active trials being conducted by over 40 biopharmaceutical partners, including more than 85 trials where MRD is a clinical endpoint (14 of which use MRD as a primary endpoint).</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IM Business Highlights</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In oncology, we are jointly pursuing with Genentech the development and delivery of the highest impact antigen-directed TCR based cell therapy for the treatment of patients with different solid tumor types. In 2024, we made significant progress to improve turnaround times and reduce costs, which we believe will enhance the profile of potential cell therapy product(s).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In autoimmunity, we narrowed our focus to select T-cell medicated indications with high unmet clinical and commercial need, such as MS and T1D, among others. In these indications we successfully identified a subset of autoreactive or problem T cell receptors that are likely causing disease. Our therapeutic strategy is to eliminate or block the activation of these problem T cells and directly stop them from attacking healthy tissue. To date, we completed several antibody mouse immunization campaigns and successfully selected and functionally tested a subset of antibodies to a number of disease-causing targets in prioritized indications. Based on the data we collected, we nominated a lead indication and are focusing on the preclinical development of antibody therapeutic candidates in this first indication.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Immunosequencing Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adaptive immune system is comprised of specific immune cells, called T cells and B cells, that hold the instructions for diagnosing and treating most diseases. These instructions enable specialized receptors that sit on the surface of TCRs and BCRs to identify, bind and destroy pathogens or human cells presenting foreign signals of disease (&#8220;antigens&#8221;). Unlike all other genes in the human genome, the genetic sequences of TCRs and BCRs rearrange over time creating massive genetic diversity. In contrast to the static human genome that is made up of approximately 30,000 genes, the adaptive immune repertoire of a healthy adult consists of more than 100 million different genes. This massive genetic diversity gives the immune system the ability to detect and respond to millions of different antigens associated with human disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our immunosequencing platform combines a suite of proprietary chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. It extracts and interprets insights from the adaptive immune system with the scale, precision and speed required to enable the design of clinical products tailored to the specific genetics of each patient&#8217;s immune system.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A Primer: The Adaptive Immune System</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Over millions of years, the adaptive immune system has evolved an elegant solution to keeping people healthy. It recognizes and responds to most antigens, whether they come from outside the body, such as a virus, or inside the body, such as mutations that drive cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The innate and adaptive immune systems both play a role in human immunity. However, the adaptive immune system alone provides a specific response to signals of disease, or antigens. These disease specific antigens are primarily fragments of proteins that are recognized as foreign, such as proteins from a virus. However, antigens can be recognized as foreign even if they are not from a virus or pathogen. In cancer cells, tumor associated antigens (&#8220;TAAs&#8221;) are normal proteins that are aberrantly expressed in a tumor; neoantigens are mutated versions of normal proteins that are specific to the cancer and not found in healthy normal cells. Both TAAs and neoantigens are recognized by the immune system as foreign. For autoimmune disorders, the immune system loses the ability to distinguish between &#8216;self&#8217; and &#8216;non-self&#8217; and mistakenly recognizes normal protein fragments (&#8220;self-antigens&#8221;) as foreign, which results in attacking otherwise healthy tissue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Adaptive Immune Response</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key cells of the adaptive immune system that enable our bodies to mount responses against antigens are called T cells and B cells. T cells can destroy target cells directly, and B cells secrete antibodies, activating other parts of the immune system to destroy targets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each T cell and B cell has a unique Y-shaped receptor, which can recognize one or a small number of the millions of antigens to which our bodies are continuously exposed. When an adaptive immune response is initiated against a particular disease, the T cells and B cells encoding the disease-specific targeting receptors rapidly multiply through clonal expansion, allowing for a powerful immune response. Some of these expanded cells directly attack the disease, and others form long-term memory to allow rapid recognition of the same antigens in the future and protect against reinfection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unlike all other genes in the human genome, the genetic sequences of TCRs and BCRs rearrange over time through a complex biological process resulting in massive diversity. The diversity of these receptors is made possible by a unique reshuffling of their genetic code known as V(D)J recombination (V=Variable, D=Diversity, J=Joining). This recombination process only occurs in T cells and B cells, and it results in each cell clone having a unique receptor-associated deoxyribonucleic acid (&#8220;DNA&#8221;) sequence. This unique DNA sequence acts like a barcode that can be used to identify and track an individual receptor over time, as shown in the figure below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img64161509_0.jpg" alt="img64161509_0.jpg" style="width:691px;height:389px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adaptive immune response requires millions of these unique receptors to be widely distributed and present in the blood in order to have the ability to rapidly respond to many different diseases simultaneously. Even after a specific TCR binds to an antigen and clonally expands, the frequency of these expanded T-cell clones containing the TCR remains relatively low in relation to the estimated trillions of other T cells that are circulating. We now know that disease-specific TCRs that are clonally expanded in a patient&#8217;s blood are present, on average, at less than 1 cell out of 100,000 cells. Despite their relatively low abundance, disease-specific TCRs can mount a systemic, persistent response to most perturbations because of the highly specialized properties of the immune response, as summarized in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img64161509_1.jpg" alt="img64161509_1.jpg" style="width:691px;height:389px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to fully leverage the natural properties of the immune system to develop clinical products, the enormous diversity and scale of the adaptive immune system must be taken into consideration, including the ability to accurately and reliably measure the relative frequency of each disease-specific T cell or B cell in the blood. For example, cancer-specific TCRs circulating in the blood of a cancer patient are only present at 1 out of 100,000 cells. Auto-reactive T cells specific to any given autoimmune disorder circulating in the blood are only present at 1 out of 1,000,000 cells. Accordingly, the ability to detect disease-specific T cells requires a technology that can quantitatively probe a minimum of hundreds of thousands to millions of blood cells from each sample. Our technology was built and validated to address this need.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed a combination of technologies to perform the following key functions that broaden our understanding of immune-mediated biology:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sequencing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our proprietary NGS-based immunosequencing methods provide sequences for single chains of &#8220;Y-shaped&#8221; TCRs or BCRs, which enables understanding of the quantity and diversity of T cells and B cells in a biological sample. In the context of hematologic malignancies, where B cells and T cells are the cancer cells, our platform technology allows us to identify and quantify residual disease burden (MRD) by sequencing BCR and TCR rearrangements within those cells with a high degree of sensitivity and precision. Our sequencing capabilities, together with our massive clinical immunomics database of immune receptor sequences, provide deep insights into individual and collective immune responses at a scale that is thousands of times greater than was previously possible.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Antigen Identification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have developed powerful approaches to identify disease-related antigens which trigger a T-cell response, even at levels of one T-cell in a million (as may occur in autoimmune disorders).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.6262181994953586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human leukocyte antigen (&#8220;HLA&#8221;)-presented disease specific antigens. By applying proprietary screening methods, we can identify TCRs which cluster around a presumably identical HLA-presented antigen and identify that antigen by a process we call &#8220;de-orphanization&#8221;. Our massive database of TCRs and healthy control samples enables us to rapidly confirm whether such antigens are disease-specific, even if the antigen or its relationship to the disease was previously unknown.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.6262181994953586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Antigen-TCR mapping. MIRA (Multiplexed Identification of TCR Antigen Specificity) maps millions of TCRs to thousands of clinically relevant Class I and Class II antigens. MIRA is another proprietary method which enables us to elucidate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in silico</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> what potential diseases a patient&#8217;s immune system has been exposed to or is actively fighting.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pair.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pairSEQ provides a combinatorial strategy to accurately pair both chains of Y-shaped immune cell receptors at high-throughput, which is challenging to do at scale using other methods because the two chains of the Y-shaped receptors are located on different chromosomes. The ability to accurately pair both chains of the receptors in a sample enables us to reconstruct receptors for therapeutic purposes.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Characterize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our platform characterizes binding, functionality and safety properties of antigen-specific, paired TCRs or BCRs. Our high-throughput sequencing and antibody discovery process allows us to select from a diversity of potent, naturally occurring, full length human receptors. We identify and focus on a subset of therapeutic-grade candidates to designate and further develop as TCR or antibody based therapeutic products. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MRD Business</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MRD business focuses on the use of our highly sensitive, FDA-authorized NGS assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic testing service for clinicians and our MRD Pharma service, which consists of offering our clonoSEQ assay to biopharmaceutical partners to advance drug development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe clonoSEQ is the preeminent MRD testing choice for hematological malignancies with industry leading sensitivity of 1 out of 1,000,000 cells, given sufficient sample input. By taking a baseline measurement prior to starting therapy and then tracking the number of cells at several time points following therapy initiation, hematologists can improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time and detect potential relapse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the use of clonoSEQ, we are transforming how lymphoid cancers are treated by working with providers, biopharmaceutical partners and payors. For instance, our clonoSEQ assay has the potential to assist physicians with critical clinical decisions, accelerate the development of drugs in lymphoid cancers and enable treatment decisions which may lower payor cost through the discontinuation of costly drugs that are no longer needed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clonoSEQ leverages our next-generation sequencing-based platform to sequence the patient's immune repertoire (B cells and/or T cells) with the goal of identifying and quantifying malignant B cells or T cells. The testing process begins with analysis of a high disease burden sample (typically bone marrow, blood or tissue) collected at the time of a patient's initial diagnosis or relapse. This sample is used to identify the patient-specific sequence(s) that are associated with the malignancy. We do this by assessing the distribution and frequency of sequences found on the B cell or T cell receptors present in the sample and "tagging" the sequences that meet our validated criteria. Once we have tagged the relevant disease-associated sequence(s) for a given patient, they can be used as a unique "bar code" to track the presence and level of disease burden for that patient over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the steps required to perform a clonoSEQ MRD test is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DNA is extracted from a fresh biological specimen, typically bone marrow (gDNA), blood (gDNA) or plasma (cell-free DNA).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extracted DNA quality is assessed, and rearranged immune receptors are amplified using a multiplex polymerase chain reaction (&#8220;PCR&#8221;). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reaction-specific index barcode sequences for sample identification are added to the amplified receptor sequences by PCR. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sequencing libraries are prepared from barcoded amplified DNA which are then sequenced by synthesis using NGS. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Raw sequence data are uploaded from the sequencing instrument to our analysis pipeline. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sequence data is analyzed in a multi-step process, where a sample&#8217;s sequence data is first identified using the sample index sequences and the data is then processed using a proprietary algorithm with in-line controls to remove amplification bias. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following completion of these data processing steps, a report is issued to indicate the presence or absence of malignant cells, to quantify their level and (in the case of longitudinal monitoring) to compare that level to previous results for the patient. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer our core clonoSEQ technology to two primary customer segments: we work with clinicians to provide clonoSEQ clinical diagnostic testing services to patients and we partner with biopharmaceutical companies to advance drug development efforts through use of our clonoSEQ assay in clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Utility</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For both clinical diagnostic testing and drug development, clinical data is core to the value of clonoSEQ as a decision-making tool, empowering clinicians to select the best patient treatment options based on MRD status and enabling biopharmaceutical companies to optimize the application of novel therapies. Some examples of recent expanded clinical use cases and advances in drug development efforts by our biopharmaceutical partners include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEPHEUS is a phase 3 study evaluating the efficacy and safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) or VRd in patients with newly diagnosed MM who are transplant ineligible. Data presented at the 21</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International Myeloma Society Annual Meeting (Usmani et al 2024) showed that the MRD negativity rate at 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-5 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as measured by clonoSEQ was significantly higher with D-VRd versus VRd (60.9% versus 39.4%), meeting the primary endpoint of the study at a median follow-up of 58.7 months. The D-VRd arm also demonstrated higher rates of sustained MRD-negativity, progression free survival, and overall survival ("OS"). If approved, this new indication for daratumumab would be the first FDA-approved treatment regimen for newly diagnosed MM based on a study with MRD-negativity as the primary endpoint.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from the FELIX study indicate that achieving deep molecular remission, defined as MRD levels below 10&#8315;&#8310;, correlates with improved outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel. These findings were presented at the American Society of Hematology ("ASH") annual meeting in 2024 in an oral session titled Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes. The study found that 84% of treatment responders who had a clonoSEQ MRD test achieved MRD &lt;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8315;&#8310;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This result was associated with more durable responses, and higher event-free survival and OS rates than those observed in patients with MRD &#8805;10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and between 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 data from the ECOG-ACRIN EA4151 trial indicate that autologous hematopoietic cell transplantation (auto-HCT) may not provide additional benefit for MCL patients in first complete remission (CR) who have undetectable minimal residual disease (uMRD) at a sensitivity of 10&#8315;&#8310;. The findings were presented at ASH 2024 in a late-breaking abstract titled, Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial (Abstract LBA6). Patients in CR with uMRD at 10&#8315;&#8310; sensitivity by clonoSEQ in peripheral blood were randomized to receive either auto-HCT plus three years of maintenance rituximab (MR) or MR alone. Interim analysis, with a median follow-up of 2.7 years, showed no significant difference in OS between the two groups, suggesting that auto-HCT may be unnecessary for patients achieving deep remission as measured by highly sensitive MRD assessment.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe this clinical utility data shows that clonoSEQ is uniquely situated in MRD testing to help hematologists improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time and detect potential relapse. Further, we believe that our clonoSEQ assay has the potential to accelerate the development of drugs in lymphoid cancers and enable treatment decisions which may lower payor cost through the discontinuation of costly drugs that are no longer needed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">clonoSEQ Clinical Diagnostic Testing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercially Promoted Indications</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clonoSEQ diagnostic test detects and monitors the remaining number of cancer cells that are present in a patient&#8217;s body during and after treatment, known as MRD. We believe clonoSEQ has broad applicability across all lymphoid malignancies, including ALL, CLL, MM, and Non-Hodgkins Lymphoma (&#8220;NHL&#8221;) conditions, such as DLBCL, MCL and cutaneous T cell lymphoma (&#8220;CTCL&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, clonoSEQ was granted marketing authorization from the FDA, under the de novo process, for patients with MM and ALL to monitor their MRD from bone marrow samples. In August 2020, the clonoSEQ label was expanded to include patients with CLL from bone marrow and blood samples.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, we launched commercial promotion of clonoSEQ as a CLIA-validated LDT to detect MRD in blood for patients with DLBCL by measuring circulating tumor DNA (&#8220;ctDNA&#8221;), which provides patients and clinicians with a powerful blood-based prognostic tool. We are advancing the regulatory strategy for our DLBCL test to support clinical adoption and increase its usage by our biopharmaceutical partners.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we launched commercial promotion of clonoSEQ as a CLIA-validated LDT to detect MRD in blood for patients with MCL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical penetration of the patient opportunity with clonoSEQ has grown over the years in each indication.  As of December 31, 2024, we believe our penetration in the United States was as follows</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ALL</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MM</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CLL</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">DLBCL</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MCL</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2%</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Percentages are an approximation and include US clinical use only and exclude patients in trials. Penetration is calculated as the number of annual clonoSEQ patients tested out of the prevalent population pool by indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that we are still in the early stages of clonoSEQ penetration in the indications identified above with significant opportunities to expand adoption.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adoption Strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a multi-pronged strategy to deepen penetration of clonoSEQ and improve our commercial and operational infrastructure through efforts to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Increase clinical testing in blood to facilitate adoption for clinicians in the community setting and increase frequency of testing across treatment settings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Testing with blood is less invasive for patients and less expensive as compared to MRD testing from bone marrow samples. Therefore, blood-based MRD testing may enable more frequent monitoring of patients over longer periods of time. We believe continued validation of clonoSEQ in blood will increase usage, particularly by clinicians in the community setting who perform fewer bone marrow aspirations. A study reported at the ASH annual meeting in 2023 demonstrated that MRD negativity confirmed by clonoSEQ in the blood of MM patients in early treatment for MM correlated well with progression free survival.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Expand clonoSEQ in NHL. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the end goal of clonoSEQ becoming a universal MRD test for all lymphoid malignancies, we have developed a robust lifecycle development plan to generate sufficient clinical evidence to support increased adoption across lymphoid malignancies. NHL is a key area of focus for us, as it represents approximately 50% of all newly diagnosed patients with lymphoid malignancies in the U.S. DLBCL and MCL, our two current commercially promoted and Medicare-covered NHL subtypes, represent approximately 30% and 6% of NHL patients respectively. Going forward, we will continue to generate data demonstrating the clinical utility of clonoSEQ in these and other NHL subtypes, and we will aim to further develop the emerging market for MRD testing for both clinical and biopharmaceutical use cases.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expand patient use cases by continuing to generate clinical evidence in clonoSEQ utility throughout the patient continuum of care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. clonoSEQ MRD testing has the potential to inform patient management and support drug development in a wide range of contexts and at multiple time points, both for newly diagnosed and relapsed/refractory patients and both during and after treatment. In addition to expanding the indications for which clonoSEQ has shown clinical utility, our evidence generation strategy also addresses the goal of expanding patient use cases within existing promoted indications. Our strategy for expanding use cases is informed by provider and biopharmaceutical feedback on current unmet needs as well as by the evolving treatment landscape. For example, in multiple myeloma, patients have traditionally been prescribed indefinite maintenance therapy; however, in recent years novel treatment regimens are enabling newly diagnosed patients to achieve deeper and more sustained responses, which has increased provider interest in offering patients time off therapy. To address this emerging trend, Adaptive and its collaborators have generated and will continue to generate data demonstrating the role of clonoSEQ to determine which patients can safely discontinue treatment and to monitor patients in treatment-free remission.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enhance customer experience with EMR integrations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In October 2022, we entered into a partnership with Epic to integrate clonoSEQ into Epic&#8217;s EMR system, which we believe will enable easier test ordering and results access for the clonoSEQ test. As of December 2024, clonoSEQ is integrated into the Epic instances at 18 customer accounts. In 2024, we entered into a partnership with Flatiron Health, Inc. (&#8220;Flatiron&#8221;), a leading provider of electronic health records (&#8220;EHR&#8221;) software and services for community oncology, to integrate clonoSEQ into Flatiron&#8217;s OncoEMR&#153; system. Through 2025 we expect to integrate more Epic accounts and launch the integration with Flatiron in the community to drive further clonoSEQ adoption.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to these strategies, in January 2025, we entered into a multi-year exclusive strategic commercial collaboration with NeoGenomics, Inc. (&#8220;NeoGenomics&#8221;) that will integrate clonoSEQ with NeoGenomics&#8217; COMPASS&#174; and CHART&#174; offerings in complex blood cancers. We have begun to collaborate with NeoGenomics to implement the commercial and operational infrastructure to support our partnership and expect to launch cross-promotional efforts later in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strategies described above are geared toward driving adoption of clonoSEQ in the U.S., where reimbursement is well-established. Opportunities to expand clinical MRD testing using clonoSEQ also exist outside the U.S., although reimbursement for NGS MRD remains in nascent stages in most non-U.S. markets. We have secured IVDR certification for the clonoSEQ assay to facilitate use of the assay in Europe, and we have licensed our technology to academic and commercial partner labs in Europe, Australia and Japan as a means to make clonoSEQ available locally, primarily for research purposes though some limited clinical testing is available in selected regions. In 2025 we expect to license our technology to a new site in Israel. As our non-U.S. market access efforts continue to progress, we also anticipate expanding clinical use with our current lab partners in several countries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and National Comprehensive Cancer Network (&#8220;NCCN&#8221;) guidelines for longitudinal monitoring in MM and ALL. clonoSEQ is now incorporated in NCCN guidelines and used by all 33 NCCN cancer centers. Over the years since, we have secured additional payor coverage for clonoSEQ aligned with our FDA label with Medicare, national private payors and large regional plans, expanding coverage to over 300 million covered lives for ALL and MM, over 200 million covered lives for CLL and over 70 million covered lives for DLBCL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, MolDX published its local coverage decision (&#8220;LCD&#8221;) for MRD testing. This LCD not only affirmed the importance of MRD and clonoSEQ coverage in ALL, MM and CLL in bone marrow and blood, but it also provided a clear and efficient pathway for seeking expanded clonoSEQ coverage through technical assessments in NHL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, coverage expansion continued as we secured Medicare coverage for DLBCL, the most common form of NHL. We secured clonoSEQ coverage with Medicare for DLBCL patients regardless of line of therapy, treatment regimen or testing timepoint. clonoSEQ is the first and only MRD test to receive Medicare coverage in DLBCL. We received Medicare coverage for another NHL condition, MCL, effective July 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, clonoSEQ was granted a Proprietary Laboratory Analysis (&#8220;PLA&#8221;) code. The code was routed to Medicare&#8217;s gapfill pricing process in 2023, and this process was completed in 2024. The clonoSEQ PLA code was published on Medicare&#8217;s CLFS with a price of $2,007, effective January 2025. This price represents a 17% increase over our previously determined Medicare rate. Correspondingly, our Medicare episode rate for clonoSEQ was increased from $6,870 to $8,029.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to enhance our average selling price (&#8220;ASP&#8221;) for clonoSEQ as we are increasing our investments in revenue cycle management to improve claims collection such as prior authorizations and the appeals process. Further, we will continue to sign new contracts with private payors who are not currently contracted with us and improve contracted rates for existing contracted private payors over time.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also maintain a patient support program, Adaptive Assist, to facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by clonoSEQ Clinical Testing. Patients can call to discuss their individual circumstances with one of our dedicated patient support representatives in order to better understand their coverage prior to clonoSEQ testing and to navigate the insurance process, including appeals for denied claims. We also offer financial assistance for qualified uninsured and under-insured patients who cannot afford their patient financial responsibility for clonoSEQ.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MRD Pharma</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MRD Pharma focuses on offering our clonoSEQ assay to biopharmaceutical partners to advance drug development efforts. Through 2024, clonoSEQ was being used by over 40 biopharmaceutical companies in more than 170 active clinical trials and is used as a clinical endpoint in over 85 of these studies. Penetration of active industry sponsored clinical trials in lymphoid cancers as of December 31, 2024 varied per indication, with penetration in MM trials being the highest at over 40%.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, FDA&#8217;s Oncologic Drug Advisory Committee (&#8220;ODAC&#8221;) voted unanimously in favor of the use of MRD as a primary endpoint to support the accelerated approval of new therapies for patients with MM. ODAC&#8217;s recommendation has the potential to accelerate MM patient access to novel therapies and to reduce drug development costs. clonoSEQ is the only FDA-cleared MRD assay for patients with MM, it is also the singular assay that can consistently deliver the sensitivity and standardization needed to meet the FDA&#8217;s performance standards. We believe these considerations distinguish clonoSEQ as a leading assay for MM drug developers.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immune Medicine Business</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The goal of our IM business is to scale our target discovery and drug discovery efforts to bring transformative therapies into the clinic either on our own or with a partner. The engine driving the immune medicine platform is our immunosequencing technology that allows us to tap into the massive diversity of the immune repertoire at unparalleled scale and specificity. Our immunosequencing approach utilizes multiplex, bias-controlled PCR to accurately and quantitatively sequence, map, pair and characterize millions of TCRs and BCRs at scale. The proprietary datasets we have generated to date include more than 100,000 signatures of disease (such as cancer and autoimmune conditions) and over 2,000,000 matches of paired TCRs to disease-related antigens.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a comprehensive map of the interaction between the immune system and disease (the &#8220;TCR-Antigen Map&#8221;) for use in identifying and validating disease signatures to improve the treatment of various immune-mediated diseases. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supported in part by a collaboration agreement with Microsoft Corporation (&#8220;Microsoft&#8221;) that we entered into in December 2017 (the &#8220;Microsoft Agreement&#8221;), we </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">worked with Microsoft through 2024 to enable access to the necessary machine learning and computational infrastructure to build our TCR-Antigen Map, initially for diagnostic purposes. While the collaboration activities have since wound down, we own all data that we generated under the Microsoft Agreement and retain all rights, including commercialization rights, to the algorithms and products that we develop. Given our focus in drug discovery (discussed below)</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we have strategically repurposed our infrastructure, sizable immunomics database and AI and machine learning models and continue to map at scale TCR sequences to the disease antigens they bind to enable our discovery efforts where we believe we have the greatest opportunity to succeed and create long-term value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We expect to evolve our work with Microsoft and continue to access cloud services and super computing power to help scale our data generation and machine learning modeling efforts. We aim to accelerate development of a &#8216;digital&#8217; TCR-antigen binding prediction model that will allow us to pursue multiple high-value therapeutic applications and achieve our business goals.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Discovery</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are focusing our drug discovery programs to develop therapies on our own or in partnership. In these respects, our proprietary data and capabilities uniquely position the IM business to discover and develop differentiated therapeutic candidates such as TCR-based modalities, antibodies and potentially vaccines to better understand immune-mediate biology and treat challenging conditions such as cancer and autoimmune disorders.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img64161509_2.jpg" alt="img64161509_2.jpg" style="width:691px;height:388px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Genentech Agreement, the IM business supports Genentech in the development of cancer antigen-directed TCR-based cancer cell therapies for the treatment of patients with solid tumors. In 2023, a first FDA-cleared investigational new drug (&#8220;IND&#8221;) for a cell therapy product candidate was secured by Genentech. This milestone established an important TCR-based cell therapy product candidate proof of concept that supports our antigen-specific TCR discovery approach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IM business is also advancing a pipeline of potential immune-based therapies in autoimmune disorders such as MS and T1D, among other indications. In autoimmunity, the immune system attacks self-antigens, which are human proteins normally found in our body. Specifically, T cells lose their ability to distinguish &#8216;self&#8217; from &#8216;non-self&#8217; antigens which may cause disease. Both MS and T1D, for example, are T-cell mediated diseases that involve mostly unknown self-antigens for which current treatments lack specificity to disease-causing targets, leading to suboptimal efficacy and risk of significant side effects. In MS and T1D, we&#8217;ve successfully identified the subset of &#8216;autoreactive&#8217; TCRs that are likely causing these devastating diseases. Therapeutically, our goal is to develop antibodies that directly eliminate or block the activation of these problem T cells and stop them from attacking healthy tissue. Functional characterization of select antibodies is ongoing with the goal of developing a robust preclinical data package, following which we aim to designate a therapeutic candidate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IM Pharma Partnering</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focused on partnering with major pharmaceutical and well-capitalized biotechnology companies to offer our sequencing services ("IM Pharma"). Specifically, we use our core immune repertoire sequencing capabilities to deliver to our customers rich immune receptor data that help to inform their drug development programs. A key application of our immune receptor data is to understand and monitor a patient&#8217;s immune response to a given drug in a clinical trial. Our datasets combined with our deep expertise in understanding the adaptive immune system enables us to support our partners in advancing their own pipeline of innovative medicines across indications and drug modalities. We use revenue from our IM Pharma partnerships to directly offset our own internal research and development investments in the drug discovery efforts of our IM business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Competitive Strengths</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We harness the inherent biology of the adaptive immune system to develop clinical products and services that improve human health by leveraging our core competitive strengths.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our clonoSEQ test is the only NGS based assay with broad reimbursement in the U.S. used to monitor MRD in multiple lymphoid malignancies that can obtain a sensitivity of detection of 1 in 1,000,000 cancer cells</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This uniquely positions us to continue to gain clinical adoption in diagnostic testing for hematologic malignancies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL continued to be demonstrated as referenced in 69 abstracts at the most recent ASH meeting in December of 2024.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expanding regulatory and reimbursement expertise will help inform future clinical product development. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Having obtained FDA marketing authorization and expanded coverage to greater than 300 million covered lives for multiple indications of clonoSEQ from Medicare, national private payors and large regional plans, we believe we have developed valuable core capabilities that will facilitate future product development through to regulatory approval and reimbursement.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our proprietary immunomics database provides a robust product development engine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are using the adaptive immune system to build a dynamic clinical immunomics database that is machine learning/AI-enabled. We translate the natural capabilities of the immune system into the clinic by capturing the millions of diverse unique receptors present in a patient&#8217;s blood. The combination of our large, quality data and our ability to generate additional insights creates a data foundation which we will continue to leverage to accelerate our target and drug discovery efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strong intellectual property protects our immune medicine platform and its applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2024, we had filed 847 patent applications, 416 of which were issued and active as of that date, covering improvements in sequencing methods and new ways to leverage adaptive immune receptors for our MRD and IM business areas.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are well capitalized and believe we are on a path to profitability for our MRD business. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $256.0 million in cash, cash equivalents and marketable securities. In 2024, we focused on reducing our operating expense growth rate and improving margin profile.  </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Collaborations and Other Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Genentech Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, we entered into the Genentech Agreement to develop, manufacture and commercialize novel neoantigen directed T cell therapies for the treatment of a broad range of cancers. Pursuant to the Genentech Agreement, we are responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific neoantigens, while Genentech is responsible for clinical, regulatory and commercialization efforts. During the term of the Genentech Agreement, we have agreed to certain defined exclusivity obligations or restrictions with respect to the development and commercialization of certain cell therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2019, we received a $300.0 million upfront payment from Genentech and, in 2023, we received a $10.0 million milestone payment for FDA IND acceptance of the first cell therapy product candidate under our Genentech Agreement. The Genentech Agreement provides that we also may be eligible to receive approximately $1.8 billion over time, including payments of up to $65.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones, and up to $1.4 billion upon the achievement of specified commercial milestones. The Genentech Agreement further provides that Genentech will pay us tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of the products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. The Genentech Agreement accounted for 8%, 25% and 34% of our revenue for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Genentech Agreement will continue until the expiration of all royalty payments, but may be terminated by mutual agreement, upon an uncured material breach by either party, upon insolvency of either party, or by Genentech for convenience upon prior written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, we entered into a Revenue Interest Purchase Agreement (the "Purchase Agreement") with OrbiMed Royalty &amp; Credit Opportunities IV, LP ("OrbiMed"), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, we received $124.4 million from the Purchasers (the "First Payment"), net of expenses. We will also be entitled to receive up to $125.0 million in subsequent installments as follows: (i) $75.0 million upon our request occurring no later than September 12, 2025 (the &#8220;Second Payment&#8221;) and (ii) $50.0 million upon our request in connection with certain permitted acquisitions occurring no later than September 12, 2025 (the &#8220;Third Payment&#8221;), in each case subject to certain funding conditions. To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from us based on a percentage (the &#8220;Applicable Payment Percentage&#8221;) of all GAAP revenue (the &#8220;Revenue Base&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base. Payments in respect of the Revenue Interests shall be made quarterly within 45 days following the end of each fiscal quarter (each, a &#8220;Revenue Interest Payment&#8221;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;Cumulative Purchaser Payments&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OrbiMed will be entitled to 100% of the Revenue Interest Payments until it has received a total cumulative value of 165% of the Cumulative Purchaser Payments (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by September 12, 2032, in which case the Return Cap shall be increased to 175% of the Cumulative Purchaser Payments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incurred interest expense of $11.6 million, $13.8 million and $4.2 million under the Purchase Agreement for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Processing and Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We process both clinical and research use samples in our laboratory in Seattle, Washington. Our Seattle laboratory is CLIA-certified, CLEP-certified, College of American Pathologists (&#8220;CAP&#8221;)-accredited and International Organization for Standardization (&#8220;ISO&#8221;) 13485-certified, and IVDR-certified. After we intake samples sent to us from healthcare providers or research and biopharmaceutical customers, we extract DNA from the sample if required, amplify it and otherwise prepare it for our sequencing and data analysis. Throughout our processes, we apply a rigorous quality management system, which is designed to comply with the Quality System Regulation (&#8220;QSR&#8221;) and the requirements of the Clinical Laboratory Improvements Amendment of 1988 ("CLIA"), the College of American Pathologists ("CAP") and other applicable state licensing and accreditation requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to process and sequence immune receptors in samples submitted to us, we utilize a combination of proprietary primer mixes and commercial materials, including a multiplex PCR master mix, enzymes, high throughput multi-cycle sequencing reagents and other materials, which we obtain and assemble as needed from various third-party vendors on customary terms. A number of our processing steps utilize automated equipment to help ensure consistency and efficiency. Sequencing is performed using the Illumina NextSeq System, which we have appropriately qualified for the intended uses of our products and services. During 2024 we worked on a key program to reduce operational costs in the lab by changing our NextSEQ sequencers to NovaSEQ X sequencers, which we expect to begin using in the second half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our TCR-antigen binding and drug discovery initiatives, we conduct our operations at our laboratories in Seattle, Washington and South San Francisco, California. These laboratories have cell sorting, tissue culture and other processing equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use a limited number of suppliers, or in some cases, single suppliers, for our laboratory equipment and materials. We manage this concentration risk by targeting or building to levels of surplus stock that, we believe, would allow us to locate alternative suppliers if needed. However, if one of our suppliers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers and may face delays in processing samples or developing and commercializing our products and services. For example, we have purchased the Illumina NextSeq System, and Illumina, Inc. (&#8220;Illumina&#8221;) also supplies us with reagents that have been designed for use solely with this sequencer. While we acquire these reagents from Illumina on customary terms, if we had to replace the reagents we use, we may also need to acquire and qualify a replacement sequencer, validate the reagents and potentially revalidate aspects of our existing assays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an extensive global portfolio of intellectual property rights to protect our immune medicine platform, the products and services that draw on it and our reputation in the industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we owned or controlled 416 active issued patents and 70 patent applications whose claims are intended to cover what we do, what we plan to do and what others might do to compete with us. From our earliest patent filings in 2009, our portfolio has been tailored to reflect our efforts to harness the adaptive immune system for research, diagnostic and therapeutic applications. Our patent claims extend to not only adaptive immune receptor molecules, but also to uniquely powerful techniques for sequencing immune cell receptors, determining clonality and immune competency, diagnosing disease, predicting responses to immunotherapy and identifying new drug candidates. Our granted patent protection generally expires in years ranging from 2029 to 2040.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical know-how we develop is protected by a trade secrecy program to ensure against inappropriate disclosure or use. Encompassed in our know-how is our proprietary database of coding sequences, antigen reactivities and safety profiles for immune receptors, which is vast and growing. Even with collaborators, access to our immune medicine platform technology is limited and tightly controlled through contracts and careful communication. We own our immune medicine platform, including improvements we or collaborators make to it, and retain rights in data resulting from its use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also pursue trademark registration for our product and service names and promotional slogans in our existing and projected markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Portfolio by the Numbers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our intellectual property portfolio consisted of the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">847 patent applications filed worldwide directly or in conjunction with a co-owner or licensor since 2009; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70 pending patent applications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">416 issued and allowed patents across our immune medicine platform, including more than 151 patents related to diagnostic approaches in lymphoid malignancies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24 patent families directed to methods and tools useful in our immune medicine platform for non-target specific immunosequencing and research; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17 patent families directed to methods and tools useful in diagnosis, prognosis and disease monitoring, including clonoSEQ, certain diagnostic methods and TCR-antigen binding; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 patent families directed to methods and tools useful in drug discovery, including our drug discovery screening processes, MIRA and pairSEQ; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1 patent family directed to SARS-CoV-2 vaccines;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11 patent families directed to novel antigen targets and immune medicine-based therapeutic modalities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4 patent families directed to gene sequencing technology; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28 trademarks registered and pending registration worldwide. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Portfolio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed an expansive patent portfolio in commercially important markets with claims to critical aspects of our technology, beginning with our first patent applications exclusively licensed from Fred Hutchinson Cancer Research Center (&#8220;Fred Hutch&#8221;) in 2009. Our ongoing patent strategy is to generate a return on our patenting investments, which values substantive quality over volume to build a defensible moat around technology we use as well as what others might develop to design around our position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We prioritize pursuing patent claims with a reasonable likelihood of being granted. Where patentability for a particular invention is questionable, we often choose to protect it as a trade secret instead. In some instances, however, we may seek to push the patentability envelope when the state of the applicable patent laws are in flux, such as patent eligibility for naturally occurring molecules, including TCRs, in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Methods of Measuring Adaptive Immunity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2009, a U.S. provisional patent application was filed to pursue protection for immunosequencing by our co-founder, Dr. Harlan Robins. The invention broadly relates to methods for assessing the adaptive immune system status of individuals. Rearranged V and J segment genes of TCRs or BCRs are targeted as biomarkers for assessing the status of the immune system at one or more points in time. Granted claims extend to the use of particular sets of amplification primers, while pending claims are being pursued to capture additional assessment techniques. Licensed exclusively to us by Fred Hutch, the application has since spawned 28 additional patent applications, many of which have been granted as of December 31, 2024, including U.S. Patent No. 9,809,813.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Optimizing Nucleic Acid Amplification Reactions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amplification of nucleic acids can result in over- or under-representation of the amplified molecules, misrepresenting the number present in the source material, such as a blood sample. Dr. Robins invented a method to correct for such bias, thereby improving the precision of PCR-based quantification of TCR and BCR coding sequences in a sample. The claimed approach utilizes synthetic templates, reflecting nucleic acid sequences for rearranged V and J receptor segments in the sampled cells. Twenty-three related patent applications have since been filed, many of which have been granted as of December 31, 2024, including U.S. Patent Nos. 9,371,558 and 10,214,770.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Diagnosing and Monitoring Disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our acquisition (&#8220;Sequenta Acquisition&#8221;) of Sequenta, Inc. (&#8220;Sequenta&#8221;) in 2015, we purchased Sequenta&#8217;s extensive patent portfolio. The portfolio includes 124 patent applications which disclose and claim methods to identify and quantify T cell-based immune responses to antigen exposure using NGS. TCR and BCR DNA, ribonucleic acid or cell-free DNA from samples, including blood and bone marrow, are used to detect, prognose and monitor disease, including autoimmune disease, infection and cancer. Sixty-two patents have been granted in the portfolio as of December 31, 2024, including U.S. Patent Nos. 8,628,927 and 8,236,503.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our diagnostic methods also apply to the detection of MRD (the target of our B cell-based clonoSEQ diagnostic test for assessing how disease burden changes in response to treatment or during remission) and T-Detect (our T cell-based diagnostic tests). Multiple patents have been granted from additional applications relating to MRD assessment, diagnostic methods and diagnostically significant TCRs filed by us, including U.S. Patent Nos. 9,824,179 and 11,047,008. Additional patent applications are pending to TCR-based diagnostic signals in specific indications, including COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TCR-Antigen Binding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to make significant progress in our understanding of the T-cell mediated response across different indications. We filed 10 related patent applications for methods to produce antigen-exposed enriched T cell populations and identify their antigen specificities by comparison to a pre-exposure population of cells or by use of an algorithm. We have filed additional patent applications relating to algorithmic-based methods to characterize antigen specificities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MIRA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We developed and are pursuing patent protection for bioinformatic-based methods to determine the antigen specificity of TCRs by exposing T cells to a panel of multiple antigens. Antigen exposure can be performed by incubation or presentation; for example, it can be performed via recombinant expression in another cell. These methods may also be used to pair the two TCR chains as well as to identify high avidity TCRs. Several patents have been granted as of December 31, 2024, including U.S. Patent No. 10,066,265.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pairSEQ</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In nature, TCRs and BCRs exist as a heterodimer of paired chains, each of which is encoded on a different chromosome. Immunosequencing reveals the nucleotide structure of each individual chain, but not which chains match as cognate pairs. We developed and are pursuing patent protection for multiple bioinformatic-based approaches to pairing the two chains of TCRs and BCRs, including one deployed in our pairSEQ technique. Our methods also allow for identification of receptor chain pairs which are specific to particular antigen targets. Thirty-one related patent applications have been filed, 12 of which have matured into granted patents as of December 31, 2024, including U.S. Patent No. 10,077,478.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assessing Responsiveness to Immunotherapy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leveraging our immunosequencing technologies, we developed methods for predicting responses to immunotherapy, vaccines and infection. To those ends, rearranged TCR or BCR sequences are quantified and their levels or frequencies compared at different points in time. Twenty-one related patent applications have been filed, 8 of which have been granted as of December 31, 2024, including U.S. Patent No. 10,221,461.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutic Antibodies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We developed a therapeutic antibody discovery process called TruAB from which neutralizing antibodies have been and are being produced against target antigens in conditions such as SARS-CoV-2, Type 1 diabetes, influenza, Respiratory Syncytial Virus, inflammatory bowel disease and MS. Patent applications across 11 patent families to a number of these antibodies have been filed and are pending.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vaccines</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Together with our partner Nykode Therapeutics, we filed a patent application which is pending and directed to COVID-19 vaccines, the development of which was informed by our immunosequencing-based drug discovery efforts.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutic TCRs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a granted patent application to TCRs responsive to WT-1 antigens with potential utility in cell therapy against WT-1 related cancers. We have pursued a patent application to TCRs responsive to other cancer antigens which are of interest in our collaboration with Genentech.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-Licensed and Acquired Intellectual Property Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have developed the majority of our immune medicine platform, products and services, we occasionally license or acquire third-party owned inventions to bolster the strength of our patent estate and ensure freedom to operate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early work by Dr. Robins with Fred Hutch led to discoveries around immunosequencing methods and tools covered by 128 patents and patent applications in the U.S. and abroad which we exclusively licensed. Our rights are for all fields of use worldwide and are sublicensable. To the extent any licensed granted patent rights extend to products or services sold by us, we pay Fred Hutch a royalty rate of 0.75% of net sales on licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through our Sequenta Acquisition, we also obtained an exclusive paid-up license, with rights to sublicense, to patents filed in the U.S., Europe, Australia and China owned by iRepertoire, Inc. The license is for worldwide use in diagnosis, prognosis, treatment and monitoring of any proliferative disorder for which rearranged nucleic acids capable of encoding an immune receptor, whether productive or unproductive, or functional or nonfunctional, of a cell, excluding tumor infiltrating lymphocytes, of the proliferative disorder can be used as markers for the disorder, including, but not limited to, lymphoid and myeloid proliferative disorders, such as ALL, CLL, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin&#8217;s and NHL, plasma cell neoplasms, such as MM, monoclonal gammopathy of undetermined significance, monoclonal B cell lymphocytosis and myelodysplastic syndromes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the patent estate acquired from Sequenta, we also acquired ownership of immunosequencing-related patent portfolios from Imdaptive, Inc. and ImmunID S.A.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own various trademarks, applications and unregistered trademarks in the U.S. and other commercially important markets, including our company name, product and service names and other trade or service marks. Our trademark portfolio is designed to protect the brands for our products and services, both current and in the pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trade Secrecy Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a trade secrecy program to prevent disclosure of our trade secrets to others, except under stringent conditions of confidentiality when disclosure is critical to our business. Our trade secrets include the composition of certain reagents, assay protocols and immunosequencing-related data, such as immune receptor sequences. We protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual&#8217;s or entities&#8217; relationship with us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Accordingly, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Relating to our Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries, including the fields of life sciences research, clinical diagnostics and drug discovery, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and product and service offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase. However, we believe our scale, precision and speed, and the resulting clinical applicability, distinguish us from our competitors. The MRD business also benefits from an established commercial footprint and reputation in our target market, our demonstrated regulatory and reimbursement know-how and our extensive patent portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In clinical diagnostics, clonoSEQ faces competition primarily from customers utilizing either conventional and next-generation flow cytometry in-house or via a reference lab or contract research organization. We may also face competition from new market entrants developing blood-based tools for disease monitoring based on protein, circulating tumor DNA or circulating tumor cells.  Other future competitors that elect to develop and commercialize their products for lymphoid malignancies may include companies marketing early cancer detection testing products for indications that do not currently compete with clonoSEQ, such as methods for MRD assessment directed at solid tumors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In drug discovery, clinical trials in the field of immune medicine are being pursued by a number of industry and academic players.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do. Mergers and acquisitions involving life sciences research, clinical diagnostics or drug discovery companies in the immune medicine space may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize research or diagnostic products or services that are more accurate, more convenient to use or more cost-effective than our products or services. Competitor therapeutic products could also prove safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the relevant market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Life Sciences Research Use Only Technologies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our core research product in IM, Adaptive Immunosequencing, is a research use only (&#8220;RUO&#8221;) tool in the U.S. that provides data to third parties such as biopharmaceutical companies that are themselves engaged in the research and development of potential diagnostic and therapeutic products and services for which they may later pursue investigation and clearance, authorization or approval from regulatory authorities, such as the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RUO products belong to a separate regulatory classification under a long-standing FDA regulation. From an FDA perspective, products that are intended for research use only and are labeled as RUO are exempt from most regulatory controls and are therefore not subject to the regulatory requirements discussed below for clinical diagnostic products. Thus, RUO products may be used or distributed for research use without first obtaining FDA clearance, authorization or approval. The products must bear the statement: &#8220;For Research Use Only. Not for use in diagnostic procedures.&#8221; RUO products cannot make any claims related to safety, effectiveness or diagnostic utility, and they cannot be intended for human clinical diagnostic use. Accordingly, a product labeled RUO but intended or promoted for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and subject to FDA enforcement action. The FDA will consider the totality of the circumstances surrounding distribution and use of an RUO product, including how the product is marketed and to whom, when determining its intended use. If the FDA disagrees with a company&#8217;s RUO status for its product, the company may be subject to FDA enforcement activities, including, without limitation, requiring the company to seek clearance, authorization or approval for the products. If the FDA determines an RUO product is adulterated and misbranded, enforcement may also include a warning letter, seizure, an injunction and/or criminal fines for FDCA violations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Diagnostics in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our first diagnostic product, clonoSEQ, was granted marketing authorization by the FDA for the detection and monitoring of MRD in bone marrow samples in patients with MM and ALL under the de novo process in September 2018, which classified clonoSEQ and future DNA-based tests to measure MRD in hematological malignancies as Class II devices, as explained further below. In August 2020, we received FDA clearance for clonoSEQ, following a 510(k) submission, for CLL in bone marrow as well as blood samples. We also received FDA clearance in 2021 for ALL from blood samples, launched in DLBCL and MCL, subtypes of NHL, under CLIA as a LDT and are actively advancing validation studies in certain other NHL sub-types such as CTCL.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., medical devices are subject to extensive regulation by the FDA under the FDCA and its implementing regulations, and other federal and state statutes and regulations. The FDA regulates the design, development, preclinical, analytical and clinical testing, manufacture, safety, effectiveness, clearance, authorization or approval, record-keeping, packaging, labeling, storage, adverse event reporting, advertising, promotion, marketing, sales, distribution and import and export of medical devices. In vitro diagnostic products (&#8220;IVDs&#8221;) are a type of medical device and include reagents and instruments used in the diagnosis or detection of diseases, conditions or infections, including, without limitation, the presence of certain chemicals, genetic information or other biomarkers. Predictive, prognostic and screening tests can also be IVDs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After a medical device is placed on the market, numerous regulatory requirements apply. These include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with the FDA&#8217;s QSR, which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">labeling regulations, which prohibit the promotion of products for uncleared, or unapproved uses, or &#8220;off-label&#8221; uses, and impose other restrictions on labeling; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obligations to investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions, including but not limited to, warning letters; fines, injunctions, and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or premarket approvals (&#8220;PMAs&#8221;) of new devices; withdrawal of clearance or approval; and civil or criminal prosecution.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Position outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union (&#8220;EU&#8221;), IVDs can be placed on the market by obtaining a &#8220;CE mark,&#8221; which demonstrates conformity via a self-certification with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> In vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diagnostic Medical Device Directive (&#8220;IVDD&#8221;). On May 26, 2017, the EU released a new regulatory framework, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;), which will replace the IVDD. clonoSEQ obtained a CE mark in May 2019 for all B-cell malignancies with blood and bone marrow, and in August 2024, we announced that clonoSEQ received IVDR 2017/746 Class C risk certification issued by the Notified Body (BSI), which will be a requirement as of May 2026. The IVDR requires, among other things, that clonoSEQ meet conformity assessments, performance evaluations, and performance studies to improve health and safety and adopt a systematic post-market surveillance plan and report that includes the manufacturer&#8217;s trend reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Federal and State Regulation of Laboratories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given that aspects of our business at certain facilities involve acting as a clinical laboratory, we are required to hold certain federal and state licenses, certifications and permits to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As to federal certifications, CLIA establishes rigorous quality standards for all laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of, or assessment of health. As a clinical laboratory, we must obtain a CLIA certificate based on the complexity of testing performed at the laboratory, such as a Certificate of Compliance for high-complexity testing. CLIA also mandates compliance with various operational, personnel, facilities administration, quality and proficiency requirements, intended to ensure that their clinical laboratory testing services are accurate, reliable and timely. CLIA compliance and certification is also a prerequisite to be eligible to bill for services provided to government payors and for many private payors. Furthermore, we are subject to survey and inspection every two years to assess compliance with program standards and may be subject to additional unannounced inspections. Laboratories performing high-complexity testing are required to meet more stringent requirements than laboratories performing less complex tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to CLIA requirements, we elect to participate in the accreditation program of the CAP. The U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the agency that oversees CLIA, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of CMS inspections for accredited laboratories. Therefore, because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. Select states, including Washington, have laboratory regulations that have been deemed by the federal government to be at least as stringent as CLIA, and thus laboratories licensed under those state regimes are exempt from CLIA and the state Department of Health is permitted to issue a CLIA number, along with a state Medical Test Site license, rather than a certificate being issued by CMS. Our laboratory holds the required Washington license. State laws may require that laboratory personnel meet certain qualifications, specify certain quality control procedures, facility requirements or prescribe record maintenance requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several states additionally require the licensure of out-of-state laboratories that accept specimens from those states. For example, New York requires a laboratory to hold a permit which is issued after an on-site inspection and approval of each LDT offered by a laboratory, and has various, more stringent requirements than CLIA and CAP, including those for personnel qualifications, proficiency testing, physical facility and equipment and quality control standards. Our laboratory holds the required licenses for Maryland, Rhode Island, Pennsylvania, New York and California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, other states may require out-of-state laboratories to obtain licensure in order to accept specimens from the state. If we identify any other state with such requirements, or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how we should comply with such requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a clinical laboratory is found to be out of compliance with CLIA certification, CAP accreditation or a state license or permit, the applicable regulatory agency may, among other things, suspend, restrict or revoke the certification, accreditation, license or permit to operate the clinical laboratory, assess civil monetary penalties and impose specific corrective action plans, among other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LDTs in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has historically exercised enforcement discretion to not regulate most LDTs. As such, LDTs have not been subject to FDA&#8217;s marketing clearance and approval processes, or post-marketing controls, for medical devices. LDTs are generally considered to be tests that are designed, developed, validated and used within a single laboratory. Laboratories certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and run LDTs. clonoSEQ is available as an LDT for use in assessing MRD for other lymphoid malignancies, including NHL and use in other specimen types, at our Seattle, Washington laboratory.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has historically exercised enforcement discretion to not regulate most LDTs. As such, LDTs have not been subject to FDA&#8217;s marketing clearance and approval processes, or post-marketing controls, for medical devices. LDTs are generally considered to be tests that are designed, developed, validated and used within a single laboratory. Laboratories certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and run LDTs. clonoSEQ is available as an LDT for use in assessing MRD for other lymphoid malignancies, including NHL and use in other specimen types, at our Seattle, Washington laboratory.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 6, 2024, the FDA issued a final rule that amended the definition of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostics (IVDs) in its regulations to state that IVDs are medical devices under the federal Food, Drug, and Cosmetic Act including when the manufacturer of the IVD is a laboratory (the &#8220;LDT Final Rule&#8221;). FDA proposed to phase out its general enforcement discretion for LDTs over a four-year period, subject to targeted enforcement discretion policies. LDTs that do not fall within the final rule&#8217;s targeted enforcement discretion policies are expected to comply with certain medical device regulatory requirements such as medical device reporting and complaint handling requirements beginning on May 6, 2025, and other requirements such as registration and listing and premarket authorization, among others, will become phased in over the next three years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On the legislative front, Congress introduced the Verifying Accurate Leading-edge IVCT Development Act (&#8220;VALID Act&#8221;) several times to establish a framework for the FDA to oversee marketing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical tests (&#8220;IVCTs&#8221;), such as test kits and LDTs. Under this proposed legislation, FDA would oversee IVCTs, by requiring premarket review for high-risk IVCTs which expose patients to serious or irreversible harm, requiring abbreviated premarket review or technology certification for new moderate-risk IVCTs, and exempting low-risk IVCTs from premarket review. If enacted, certain categories of LDTs would have been grandfathered and exempt from certain regulatory requirements including premarket review, labeling requirements, test design requirements, and quality requirements. The VALID Act bill has yet to be passed in any form.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal and State Privacy, Security and Breach Notification Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many state and federal laws govern the processing of personal information or individually identifiable health information. At the federal level, under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) issued regulations that establish standards for protecting the privacy and security of &#8220;protected health information&#8221; used or disclosed by certain healthcare providers and other &#8220;covered entities&#8221; and their &#8220;business associates.&#8221; Three principal data protection-related regulations with which we are required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations and security breach notification regulations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The privacy regulations govern the use and disclosure of protected health information by covered healthcare providers, as well as health insurance plans. They also set forth certain rights that an individual has with respect to his or her protected health information maintained by a covered health care provider, including the right to access or amend certain records containing protected health information or to request restrictions on the use or disclosure of protected health information. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of protected health information that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify HHS and each affected individual of a breach of unsecured protected health information and must also notify the media if the breach involves more than 500 individuals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA violations are subject to civil and criminal penalties. Additionally, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5(a) of the Federal Trade Commission Act (&#8220;FTCA&#8221;) has also been used to regulate data privacy and security at the federal level. According to the U.S. Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure or using or disclosing personal information in violation of a company&#8217;s privacy notice may constitute unfair or deceptive acts or practices in or affecting commerce in violation of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Although we have and maintain a system for compliance with privacy laws and regulations, failure to comply with them could expose us to potential FTC enforcement action and fines.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain state laws govern the privacy and security of health information and personal information. Some of the state laws governing health information privacy and security are more stringent than HIPAA (including providing a private right to litigate for patients under these state laws) and often differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. There has also recently been an influx of state privacy and security laws that introduce similar compliance complexities, including the Washington state My Health My Data Act, the California Consumer Privacy Act in combination with the California Privacy Rights Act and associated regulations and the Colorado Privacy Act. In addition, there are state breach notification laws in every state, as well as in the District of Columbia, Guam and Puerto Rico. Failure to comply with these laws, where applicable, can result in the imposition of significant civil or criminal penalties and private litigation as further detailed in the &#8220;Risk Factors&#8221; section.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to laws that directly impose privacy and data protection obligations on companies, there is also a growing interest in laws and regulations that govern data areas that are related to, but not completely related to data privacy. One area of these laws relates to use and testing of genetic and genomic data. In addition to the federal Genetic Information Nondiscrimination Act, there are a number of state laws that have recently passed (e.g., the California Genetic Information Privacy Act) and that continue to make appearances on states&#8217; legislative schedules. There have been similar draft bills at the state level that would regulate machine learning, artificial intelligence, the Internet of Things, and human specimen use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Data Protection Regulation in the EU and other International Privacy Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Data Protection Regulation (&#8220;GDPR&#8221;) is a legal framework that sets requirements for the collection and processing of personal information of individuals within the European Economic Area (&#8220;EEA&#8221;). The GDPR sets out the principles for data management and the rights of the individual, while also imposing very significant fines that can be revenue-based. It applies to U.S. companies that process personal information of persons in the EEA in connection with the offer of products or services to those persons, or the monitoring of such persons&#8217; behavior. It may also apply when a U.S. company processes personal information in the context of the activities of an entity established in the EEA. The GDPR became enforceable on May 25, 2018. The regulation is a comprehensive privacy law, meaning that it applies to all types of personal information, including the human resources record of employees and even the Internet Protocol addresses of people using online services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many other countries and regions also have privacy and data protection laws, some of which are modeled after the European framework. This includes countries within Europe that are not part of the EEA, such as the United Kingdom and Switzerland, and therefore operate under different privacy and data protection frameworks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In response to the advancements in artificial intelligence and machine learning, there are also global efforts to regulate the use of these technologies. One prominent law that has been finalized is the European Union's AI Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal, State and Foreign Fraud and Abuse Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., there are various fraud and abuse laws with which we must comply and we are subject to regulation by various federal, state and local authorities, including CMS, other divisions of HHS, such as the Office of Inspector General (&#8220;OIG&#8221;), the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ, and state and local governments. We also may be subject to foreign fraud and abuse laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for patient referrals for, or purchasing, leasing, ordering or arranging for the purchase, lease or order of, any healthcare item or service reimbursable under a governmental payor program. Courts have stated that a financial arrangement may violate the AKS if any one purpose of the arrangement is to encourage patient referrals or other federal healthcare program business, regardless of whether there are other legitimate purposes for the arrangement. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including gifts, discounts, meals, travel, credit arrangements, payments of cash, consulting fees, waivers of co-payments, ownership interests and providing anything at less than its fair market value. Recognizing that the AKS is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the OIG issued a series of regulatory &#8220;safe harbors.&#8221; These safe harbor regulations set forth certain provisions, which, if met, will assure healthcare providers and other parties that they will not be prosecuted under the AKS. The failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the AKS will be pursued. In those instances, arrangements will be evaluated on a case-by-case basis to determine whether enforcement will be pursued. Penalties for AKS violations are severe and can include imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. The regulations establishing safe harbor protection are subject to change and could affect future operations. Many states also have anti-kickback statutes, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers as well as patient self-pay. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The civil monetary penalties statute is another potential statute under which a clinical laboratory may be subject to enforcement. Among other things, the civil monetary penalties statute imposes fines against any person who is determined to have presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent. The civil monetary penalties statute also prohibits a person from offering or providing remuneration to any Medicare or Medicaid beneficiary that is likely to influence the individual to order or receive its items or services from a particular provider or supplier.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exclusion statute requires the exclusion of entities and individuals who have been convicted of federal-program related crimes or healthcare felony fraud or controlled substance charges. The statute also permits the exclusion of those that have been convicted of any form of fraud, the AKS, for obstructing an investigation or audit, certain controlled substance offenses, those whose healthcare license has been revoked or suspended and those who have filed claims for excessive charges or unnecessary services. If we were to be excluded, our products and services would be ineligible for reimbursement from any federal programs, including Medicare and Medicaid, and no other entity participating in those programs would be permitted to enter into contracts with us. In order to preserve access to beneficial healthcare items and services, the government may elect to exclude officers and key employees of manufacturers, rather than excluding the organization. Such enforcement actions would prohibit us from engaging those individuals, which could adversely affect operations and result in significant reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Congress has also enacted statutes that impose criminal liability for healthcare fraud and abuse. The Health Care Fraud Statute prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs such as the Medicare and Medicaid programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefit programs, items or services-public or private. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental payor program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government by submitting a false claim to the federal government and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement. Qui tam complaints are filed under seal, and the cases may progress for a number of years before a complaint is unsealed and a healthcare provider or supplier becomes aware of its existence. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each false claim. The False Claims Act is the federal government&#8217;s primary civil tool in healthcare fraud cases. False Claims Act liability is not limited to direct providers of health items or services. The government has asserted liability under the False Claims Act against manufacturers and other third parties who caused another party to file a false claim.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, various states have enacted false claim laws analogous to the federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a governmental payor program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 25, 2018, the Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act of 2018 (&#8220;SUPPORT Act&#8221;) was enacted. The SUPPORT Act included the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions and directs agencies to develop further exceptions. Current exceptions in some cases reference and in others differ from the AKS safe harbors. Significantly, the prohibitions apply with respect to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities, or clinical laboratories, whether or not related to treating substance use disorders. Further, the prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of, such providers. This law creates additional risk that relationships with referral sources could be problematic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For anti-corruption legislation, the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) has historically been widely enforced. It is the first to introduce corporate liability, responsibility for third parties and extraterritoriality for corruption offences, meaning companies and persons can be held criminally and civilly responsible for corruption offences committed abroad. It was enacted for the purpose of making it unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business. With the enactment of certain amendments in 1998, the anti-bribery provisions of the FCPA now also apply to foreign firms and persons who cause, directly or through agents, an act in furtherance of such a corrupt payment to take place within the territory of the U.S. The FCPA also requires companies whose securities are listed in the U.S. to meet its accounting provisions, which were designed to operate in tandem with the anti-bribery provisions, and require corporations covered by the provisions to (a) make and keep books and records that accurately and fairly reflect the transactions of the corporation and (b) devise and maintain an adequate system of internal accounting controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties or significant fines, for individuals or companies committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which came into effect in July 2011, a bribery offense occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under this regime, an individual found in breach of the Bribery Act 2010 faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, if found to have committed an offense, as can commercial organizations that are found to have failed to prevent bribery. In 2016, France passed an anti-bribery and compliance law (&#8220;Sapin II&#8221;), and the French anti-corruption agency (&#8220;AFA&#8221;) was established. The Sapin II law makes it compulsory for companies within the scope of the law to implement internal procedures to fight corruption. One of the items that must be prepared is a corruption risk map, as well as an anti-corruption code of conduct. These documents are subject to investigation by the AFA and failure to comply with the requirements can lead to significant fines for companies and executives. If we were to have future growth in the European market, this law could potentially become applicable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Physician Referral Prohibitions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Physician Self-Referral Law (&#8220;Stark Law&#8221;) prohibits physicians from referring patients to entities with which the physician or an immediate family member has a financial relationship, such as ownership, investment or compensation, for designed health services (&#8220;DHS&#8221;) payable by Medicare and Medicaid, unless the financial arrangement meets an applicable exception. DHS includes clinical laboratory tests. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Relating to Government Regulation&#8212;We are subject to various laws and regulations, such as healthcare fraud and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Practice of Medicine in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and employing or engaging physicians to practice medicine, generally referred to as the prohibition against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed physician. For example, California&#8217;s Medical Board has indicated that determining what diagnostic tests are appropriate for a particular condition and taking responsibility for the ultimate overall care of the patient, including providing treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these corporate practice of medicine laws may result in civil or criminal fines, as well as sanctions imposed against us or the professional through licensure proceedings. Typically, such laws are only applicable to entities that have a physical presence in the state.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Regulatory Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our laboratory is subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our partners in the development of therapeutic agents are responsible for developing and manufacturing those products. In so doing, they are subject to FDA and Medicare regulatory requirements related to, among other things, manufacture, promotion, price reporting and fraud and abuse laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our laboratories are subject to extensive requirements related to workplace safety established by the U.S. Occupational Safety and Health Administration. These include requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., a number of legislative and regulatory changes at the federal and state levels have sought to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Affordable Care Act (&#8220;ACA&#8221;) became law. This law substantially changed the way healthcare is financed by both commercial and government payors, and it has significantly impacted our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payors to reduce costs while trying to expand individual healthcare benefits. If enacted, some such proposals could expand or contract the insured population, increasing or decreasing demand for our products and services. On the other hand, some proposals could impose additional limitations on the prices we will be able to charge for our tests or on the coverage of or the amounts of reimbursement available for our tests from payors, including commercial payors and government payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal physician payment transparency requirements (&#8220;Physician Payments Sunshine Act&#8221;) and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to covered recipients, defined to include doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, certified nurse-midwives, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also state transparency and gift ban laws that require manufacturers to provide reports to state governments on pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our sales, marketing and other activities by imposing administrative and compliance burdens on us. Although we have a system for tracking and reporting &#8220;sunshine&#8221; law required information, if we fail to do so as required, we could be subject to government enforcement action and potential penalties.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement Generally</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement and billing requirements of applicable laws and payors for diagnostic services are highly complex. Laboratories must bill various payors, such as private third-party payors, including managed care organizations (&#8220;MCO&#8221;) and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements. Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our services may be a third party who provides coverage to the patient, such as an insurance company or MCO, a state or federal healthcare program, or the patient. Additionally, the audit requirements we must meet to ensure compliance with applicable laws and regulations, as well as our internal compliance policies and procedures, add further complexity to the billing process. As such, we are at risk of being paid less or no part of our price for our products for reasons including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variability in coverage and information requirements among various payors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient financial assistance programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">missing, incomplete or inaccurate billing information provided by ordering physicians; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">billings to payors with whom we do not have contracts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes with payors as to which party is responsible for payment; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes with payors as to the appropriate level of reimbursement.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may not be free to determine the price charged for our products. For instance, the No Surprises Act (&#8220;NSA&#8221;) was enacted on December 27, 2020 and took effect on January 1, 2022. One of the goals of the NSA is to protect patients from &#8220;surprise&#8221; medical bills resulting from gaps in coverage for services provided by out-of-network providers, such as laboratories, related to patient visits at in-network facilities. The NSA limits the amount out-of-network laboratories may charge a patient for laboratory services ordered during an in-network facility visit. In addition, the NSA establishes an independent dispute resolution process for determining the amount of reimbursement for the laboratory service in the event that the laboratory and insurer cannot agree on a rate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products. Additionally, some countries require approval of the maximum sale price of a product before it can be marketed, and this price may be reviewed during the product lifecycle, or mandatory discounts or profit caps may be applied. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. We may therefore be constrained in our pricing strategies in markets outside of the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on coverage and reimbursement in the U.S., see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Relating to Government Regulation&#8212;Future Medicare payment rates are uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Compliance Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compliance program is intended to prevent and detect violations of law or our policies. It was developed in view of both adopting the principles of the AdvaMed Code of Ethics and addressing the HHS OIG&#8217;s elements of a compliance program. We have designed our compliance program to fit the size, resources, market position and other unique aspects of our company. Our code of conduct is our statement of ethical and compliance principles that guide our daily operations. In addition, we have developed policies and procedures, and corresponding education and training, to effectively communicate our standards to employees as it relates to job functions and legal obligations under applicable state and federal healthcare program requirements, as well as those outside the U.S. We regularly perform live and process monitoring activities on a risk-based approach, and audit capabilities are built into our transparency procedures. We maintain a hotline available via multiple channels to report any known or suspected compliance violations, and we have a strict non-retaliation policy for all claims brought forward in good faith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our People and Culture</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees, internally referred to as &#8220;Adapters,&#8221; are passionate about immune medicine, empowered by scientific discipline and fueled by our foresight and curiosity about the adaptive immune system.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 619 full-time employees of which 94 hold medical or doctoral degrees. None of our employees are subject to a collective bargaining agreement and we have not experienced any work stoppages. We believe relations with our employees are good.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our talented employees drive our mission and share core values that both stem from, and define, our culture. These core values are threaded throughout the &#8220;Adapter lifecycle,&#8221; from candidate screening, to rewards and recognition and employee development and promotions, all in an effort to operationalize and reinforce their importance in our organization:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Make it happen. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual ownership and accountability keep us moving forward</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Innovate fearlessly. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Push against boundaries and think boldly to achieve world-changing results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debate openly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Value discussions inspired by different points of view</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Work together. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Demonstrate you care about the success of others. The same goes for our partners and customers&#8212;together we can achieve more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Follow True North. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Show up with integrity and do the right thing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Have fun.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Fun makes everything better</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our employees are highly engaged, and we were recognized consecutively from 2018 to 2022 by the Puget Sound Business Journal as one of Washington State&#8217;s Best Places to Work. We were also nationally certified as a Great Place to Work in 2021 and 2022, and we won GeekWire&#8217;s Workplace of the Year Award in 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continually strive to maintain a culture of excellence, empathy and belonging. We believe Adapters can be their best when they can be themselves, and we celebrate what everyone brings to the table.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also strive to provide compensation, benefits, and incentives that will both attract and retain talented employees. Our total rewards package includes market-competitive base pay, performance-based short-term incentives, health care, retirement benefits, paid time off, family leave, and access to a variety of health and wellness resources. Additionally, we offer employees recurring equity grants to reinforce a sense of &#8220;shared ownership, shared success.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. In January 2015, we acquired Sequenta, a San Francisco, California-based company that was also developing an NGS test for MRD. Our principal executive offices are located at 1165 Eastlake Avenue East, Seattle, Washington 98109, and our telephone number is (206) 659-0067.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a website at www.adaptivebiotech.com. The contents of our website are not incorporated in, or otherwise to be regarded as part of, this Annual Report on Form 10-K. We make available, free of charge on our website, access to our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practicable after we file or furnish them electronically with the Securities and Exchange Commission (&#8220;SEC&#8221;). Investors and others should note that we announce material financial information to our investors using our investor relations website (http://investors.adaptivebiotech.com), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on social media channels.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk </span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our Company involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section, before investing in our Company. Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations, prospects or the trading price of our securities. The risks described below are not the only ones we face and additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results, prospects and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, the risks described below relate to the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our significant net losses since inception, expected net losses in the future and need for significant investments in products and services, as well as our ability to manage operating expenses in light of profitability goals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market acceptance and our ability to increase the adoption of our products and services, including via coverage or reimbursement decisions related to our clinical diagnostic products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to increase our capacity, manage the evolution of our products and services, stay current in our rapidly changing industry and otherwise manage our growth;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our laboratory operations, including errors or defects in our products or services and our reliance on a limited number of suppliers, and in some cases single suppliers, for our equipment and materials, some of which include reagents or other materials that may also require additional internal validation prior to use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaboration with Genentech and ability to develop and commercialize cellular therapeutics, including our ability to achieve milestones and realize the intended benefits of the collaboration;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our limited experience with the development and commercialization of therapeutic products, including cellular therapies and antibodies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expected and potential reliance on collaborators for development and clinical testing of therapeutic product candidates, which may fail at any time due to a number of possible unforeseen events;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extensive regulation of our industry, including fraud and abuse laws and data privacy regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the loss of any member of our senior management team, or of the support of key opinion leaders; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the validity of our patents, protection of our trade secrets and related intellectual property matters.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Relating to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception. For the year ended December 31, 2024, 2023 and 2022, we incurred a net loss of $159.6 million, $225.3 million and $200.4 million, respectively. As of December 31, 2024, we had an accumulated deficit of $1.3 billion. We have funded our operations to date principally from the sale of convertible preferred stock and common stock, including the sale of common stock in our initial public offering and follow-on offering, and, to a lesser extent, revenue as well as transactions pursuant to the Purchase Agreement. We expect to continue to incur significant expenses and operating losses as we continue to invest in the development of products and services utilizing our immune medicine platform to support the validation of additional clinical therapeutic and diagnostic products and services. We will need to generate significant additional revenue to achieve and sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Annual Report on Form 10-K:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our clinical sales teams to continue converting physicians from using incumbent products in the market to clonoSEQ and new diagnostic products and services we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to continue driving repeat usage of the clonoSEQ diagnostic test by physicians and get reimbursed for that repeat usage by commercial and government payors for monitoring of MRD;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manage our growth and operating expenses;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcomes of research initiatives, clinical trials or other product development or approval processes conducted by our customers, us or our collaborators;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain positive coverage decisions for our tests from additional commercial payers; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of upfront payments from our collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and that of our collaborators to develop and successfully commercialize our products, including therapeutic products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve collaboration-based milestones on currently contemplated timelines, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability and extent of reimbursement by governmental and private payors for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our relationships, and any associated exclusivity terms, with collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our contractual or other obligations to provide resources to fund our products and services and to provide resources to our collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or failures in advancement of future products in clinical trials by us or our collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks associated with any future international expansion of our business, including the potential to conduct clinical trials and commercialize our products and services in multiple international locations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and that of our collaborators to consistently manufacture our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our dependence on, and the need to attract and retain, key management and other personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain, protect and enforce our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain additional capital that may be necessary to expand our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to accurately report our financial results in a timely manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions such as power outages, strikes, acts of terrorism or natural disasters; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards to offset future taxable income. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While as a general matter we intend to periodically report on the status of our development initiatives, including anticipated next steps, we may not provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosure of any such milestones related to any of our products that are managed by our collaborators. Any disclosure by us or our collaborators of data that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may decline as a result of unexpected clinical trial results in one or more of our products, including adverse safety events reported for any of our products.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If third-party payors, including private payors and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our clinical diagnostic products, our commercial success will be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our diagnostic revenue depends in part on achieving broad coverage and reimbursement for our clonoSEQ tests from payors, including both private and government payors. Certain large private payors have issued policies that decline to cover testing methods that they regard as experimental or investigational. Other payors may issue similar non-coverage policies. If payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the price of our diagnostic tests, we may need to seek payment from the patient where this is not precluded by law or contract, which may adversely affect demand for our tests. Coverage determinations by a payor may depend on a number of factors, including, but not limited to, a payor&#8217;s determination that a certain diagnostic test is appropriate, medically necessary or cost-effective. If we are unable to provide payors with sufficient evidence of the clinical utility and validity of our diagnostic tests, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our tests and new diagnostic products may decrease as we encounter pricing pressure from our competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each payor makes its own decision regarding coverage of our tests and the applicable payment rates, and payors may not provide adequate coverage or reimbursement for our current or future products. Although we may contract with certain payors, working with payors through contract or otherwise to assure reimbursement is time-consuming and costly and outcomes are uncertain. In addition, the determinations by a payor whether to cover our clinical diagnostic product and the amount it will reimburse for them are often made on an indication-by-indication basis. In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the test, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection. Through our Adaptive Assist patient support program, we provide clonoSEQ diagnostic tests for reduced rates or without charge to eligible low-income patients that may result in payors requiring us to provide evidence of eligibility of such patients to pay reduced out-of-pocket amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our claims for reimbursement from payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming, expensive and may not result in payment. Payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the payors believe the funds were paid in error or determine that our clonoSEQ diagnostic tests or other clinical diagnostic products were medically unnecessary. In addition, similar to federal payors, state and federal laws permit commercial payors to seek civil and criminal penalties against a manufacturer if they feel they have been defrauded. If a payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We do not have a mechanism to dispute these retroactive adjustments and we cannot predict when, or how often, a payor might engage in these reviews.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not successful in leveraging our platform to expand clonoSEQ in new indications or sample types and discover, develop and commercialize additional products and services, our ability to grow our business and achieve our strategic objectives would be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy is to leverage our immune medicine platform to discover, develop and potentially commercialize additional therapeutic and diagnostic products and services for various disease states. In particular, for clonoSEQ we are attempting to generate sufficient clinical evidence to support the utility of MRD in additional lymphoid cancers beyond ALL, MM, CLL, DLBCL and MCL while also demonstrating the clinical utility of blood as a sample type for all lymphoid cancers. If we are unable to generate compelling evidence supporting clonoSEQ use in other indications or sample types, we may not succeed in expanding our clonoSEQ product platform.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our immune medicine business, our focus on target antigen discovery and development of therapeutic products, including antibodies and cellular therapies, faces significant challenges in the identification, validation, development, clinical testing and marketing approval of new products. If we or our collaborators are unable to discover novel targets and develop transformative immune-based therapies, we may not succeed in commercializing new therapeutic products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying new products and services requires substantial technical, financial and human resources, whether or not any products or services are ultimately developed or commercialized. We may pursue what we believe is a promising opportunity to leverage our platform only to discover that certain of our risk or resource allocation decisions were incorrect or insufficient, or that individual products, services or our science in general has technology or biology risks that were previously unknown or underappreciated. Our strategy of pursuing the value of our immune medicine platform over a long time horizon and across a broad array of human diseases may not be effective. In the event material decisions in any of these areas turn out to be incorrect or sub-optimal, we may experience a material adverse impact on our business and ability to fund our operations and we may never realize what we believe is the potential of our immune medicine platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to make significant investments in our continued research and development of new products and services, which may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are seeking to leverage our immune medicine platform to develop a pipeline of future disease-specific research, therapeutic and diagnostic products. For example, we continually expand our immunomics database and TCR-antigen binding with a view toward advancing target antigen discovery to leverage in developing therapies such as prophylactic or therapeutic antibodies. In addition, we are developing certain therapeutic product candidates under our collaboration agreement with Genentech by leveraging our platform to identify TCRs that can be engineered into personalized cellular therapeutic products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also attempting to leverage our immune medicine platform to discover and develop potential therapeutic antibodies in autoimmune indications. This effort was informed by our previous investment in discovering, making and testing antibodies for the treatment of COVID-19. Our antibody discovery and development efforts in autoimmunity are early, and we continue to evolve and mature our programs. As we generate and analyze data on our antibody discovery work and programs, we may find that our initial hypotheses regarding any disease state are not supported by a larger data set or further analysis. If we are unable to demonstrate compelling data regarding the effectiveness of our antibody discovery and development capabilities, we may incur substantial costs but not be able to commercialize any related product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing new products is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in development and repeat clinical studies before we identify a potentially successful product or service. Therapeutic product development is expensive, may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development, a product or service appears successful, we or our collaborators (if any) may, depending on the nature of the product or service, still need to obtain FDA and other regulatory clearances, authorizations or approvals before we can market it. The clearance, authorization or approval pathways at the FDA and other regulatory authorities are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA or other regulatory authorities may not clear, authorize or approve any future product we develop. Even if we develop a product that receives regulatory clearance, authorization or approval, we or our collaborators would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product may never be commercially successful. Additionally, development of any product may be disrupted or made less viable by the development of competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because new potential products may fail at any stage of development or commercialization and if we determine that any of our current or future products are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful in developing additional products, our potential for growth may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on a limited number of suppliers or, in many cases, single suppliers, for laboratory equipment and materials and may not be able to find replacements or immediately transition to alternative suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on a limited number of suppliers, or in many cases single suppliers, to provide certain sequencers, reagents, equipment and other materials that we use in our laboratory operations and product development. An interruption in our laboratory operations, kit distribution, technology transfer, or development activities could occur if we encounter delays, quality issues or other difficulties in securing these sequencers, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In such an event, we would likely be required to incur significant costs and devote significant efforts to find new suppliers, acquire and qualify new equipment, validate new reagents and revalidate aspects of our existing assays, which may cause delays in our processing of samples or development and commercialization of products. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. Internal changes in processes or compositions of our reagents or other materials may also require validation efforts by us and supply of new materials from our suppliers which could impact timing of production and levels of inventory while such changes are being implemented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we have purchased and rely on the Illumina NextSeq System and plan to rely in the future on the NovaSeq X system. Illumina supplies us with reagents that have been designed for use solely with this sequencer and Illumina is the sole provider of maintenance and repair services for the Illumina NextSeq System. We also license our laboratory information management software from Illumina and receive services from Illumina related to that software. In addition, Illumina is not obligated to meet all of our requirements for reagent supply. In the event Illumina ceases or slows its production of, or is otherwise unwilling or unable to continue to supply the sequencer reagents necessary for and currently used in our business at or near current pricing, we may be required to purchase different reagents from Illumina or to purchase from a different reagent vendor under terms and conditions which could be less favorable to us. Any disruption in Illumina&#8217;s operations or the suppliers of our reagents, materials or other equipment could impact our ability to do business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe there are only a few other equipment manufacturers that are currently capable of supplying the equipment necessary for our laboratory operations and product development, including sequencers and various associated reagents. The use of sequencers manufactured by a company other than Illumina would require us to alter our laboratory operations. Transitioning to and qualifying a new sequencer would be time-consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate the reagents we use in immunosequencing, potentially including our clonoSEQ diagnostic testing services, and could require us to obtain additional clearance, authorization, approval, accreditation, or licensure for the changes. We may not be able to secure and implement alternative sequencers, associated reagents and other materials without experiencing interruptions in our workflow. In the case of an alternative supplier to Illumina, any replacement sequencers and various associated reagents may not be available or may not meet our quality control and performance requirements for our laboratory operations. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our products and services, our business, financial condition, results of operations and reputation could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are creating new products, many of which are initially based on largely untested technologies. As all of our products and services progress, we or others may determine that we made product or service level scientific or technological mistakes or omissions. The testing processes utilize a number of complex and sophisticated biochemical, informatics, optical and mechanical processes, many of which are highly sensitive to external factors and variation between testing runs. Refinements to our processes may initially result in unanticipated issues that reduce the efficiency or increase variability. In particular, DNA sequencing, which is a key component of these processes, could be inefficient with higher than expected variability thereby increasing total sequencing costs and reducing the number of samples we can process in a given time period, which may negatively impact customer turnaround time. Therefore, inefficient or variable processes can cause variability in our operating results and damage our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our development laboratory operations could result in any number of errors or defects. Our quality assurance system or product development processes may fail to prevent us from inadvertent problems with samples, sample quality, lab processes including sequencing, software, data upload or analysis, raw materials, reagent manufacturing, assay quality or design, or other components or processes. In addition, our assays may have quality or design errors, and we may have inadequate procedures or instrumentation to process samples, assemble our proprietary primer mixes and commercial materials, upload and analyze data, or otherwise conduct our development laboratory operations. If we provide products or services with undiscovered errors to our customers, our clinical diagnostics may falsely indicate a patient has a disease or fail to detect disease in a patient who requires treatment. We believe our customers are likely to be particularly sensitive to product and service defects, errors and delays, including if our products and services fail to indicate the presence of residual disease with high accuracy from clinical specimens or if we fail to list or inaccurately indicate the presence or absence of disease in our test report. In drug discovery, such errors may interfere with our collaborators&#8217; clinical studies or result in adverse safety or efficacy profiles for their products in development. This may harm our customers&#8217; businesses and may cause us to incur significant costs, divert the attention of key personnel, encourage regulatory enforcement action against us, create a significant customer relations problem for us and cause our reputation to suffer. We may also be subject to liability claims for damages related to errors or defects in our products. Any of these developments could harm our business and operating results.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our efforts to develop products leveraging our TCR-antigen binding data may not be successful, and it may not yield the insights that we expect or on a timetable that allows development or commercialization of new therapeutic or diagnostic products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are using our immunosequencing capabilities, proprietary computational analyses and machine learning models to map and computationally predict at scale binding of TCR sequences to disease antigens, which we believe has multiple high-value therapeutic applications and is relevant to our drug discovery work. However, we may not be successful in developing a sufficiently comprehensive data set or the performance of our &#8216;digital&#8217; TCR-antigen prediction models may be insufficient for any number of reasons, which may include difficulty in validating signals and challenges in making progress toward algorithmic-based methods that accurately define TCR-antigen signatures of disease. In addition, we may not succeed in accelerating the development of a &#8216;digital&#8217; TCR-antigen binding prediction model that will allow us to pursue multiple high-value therapeutic applications and achieve our business goals in a timetable that is commercially viable for our products or our collaborators&#8217; products, or at all. As we continue to grow our immunomics database and advance our prediction modeling activities, we may be unable to translate these efforts into commercialization opportunities. Moreover, as our collaboration activities under the Microsoft Agreement are winding down, we may be less successful in pursuing these opportunities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the performance of our computational and machine learning modeling efforts do not meet our expectations or our needs to accurately validate TCR to antigen associations in a reasonable timeframe, our business model may not be commercially viable. Even if we accelerate our efforts, products derived from our platform technologies may have product specific limitations. If we are unable to make meaningful progress in leveraging our prediction models to successfully develop and in the future commercialize new therapeutic products, diagnostic products or services, our business results will be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are exposed to risks associated with our agreement with Genentech, and we may not realize the advantages we expect from it.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, we entered into the Genentech Agreement with the goal to develop and commercialize cancer antigen-specific and neoantigen directed TCR-based cell therapies for the treatment of a broad range of tumor types. Under the terms of the Genentech Agreement, we received an upfront payment of $300.0 million in February 2019 and a $10.0 million milestone payment in May 2023, and we may be eligible to receive up to approximately $1.8 billion in additional payments over time upon achievement of specified development, regulatory and commercial milestones. In addition, we are eligible to receive royalty payments on sales of products that Genentech commercializes under the agreement. We may not be successful in achieving these milestones, and products that Genentech develops under the Genentech Agreement may not be commercialized in the timeframe we expect, may not achieve significant sales, or may not be commercialized at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to numerous risks associated with the Genentech Agreement, including Genentech having sole control over the clinical development and commercialization of any products developed under the Genentech Agreement. For instance, in 2021, Genentech suspended development of a first product candidate against a shared cancer antigen target in response to recently published data specific to that target, following which Genentech selected to advance a second product candidate. The Genentech Agreement also prevents us from developing or commercializing TCR-based cellular therapies in the field of oncology on our own or with any third party. Our collaboration involves risks that are different from the risks associated with independently advancing therapeutic candidates and related operations, including that Genentech may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have or develop economic or business interests that are inconsistent with ours; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">take actions contrary to our instructions, requests, policies or objectives; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">take actions that reduce our return on investment for this collaboration; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fail to distinguish itself from biosimilar competition; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">take actions that harm our reputation or restrict our ability to run our business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genentech&#8217;s degree of control of the collaboration, clinical development and commercialization efforts may impact the payment amounts that we receive under the Genentech Agreement. For example, Genentech may suspend development of product candidates or decide not to pursue commercialization of product candidates at all, or it may agree to pay royalties to third parties or adopt a pricing model that reduces the amount of royalties we might otherwise expect. It is also possible that effective cell therapies will not be developed under the Genentech Agreement or, if developed, approved by the FDA or comparable regulatory authorities outside of the U.S. Genentech may also terminate the Genentech Agreement at its convenience, at any time and without cause.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to perform our research, development and commercialization related obligations under the Genentech Agreement, including performing TCR screening activities for product candidates being developed and commercialized under the Genentech Agreement. For example, in the event Genentech commercializes a under this agreement, as the volume of product sales grows, we will likely need to continue to increase our workflow capacity and general process improvements, and expand our internal quality assurance program to support TCR screening on a larger scale within expected turnaround times. These process enhancements and increases in scale, expansion of personnel, laboratory space and equipment, among others, may not be successfully implemented, and we may not have adequate laboratory facilities or resources to accommodate all the requirements that we currently anticipate needing to be successful. If we cannot satisfy our obligations, Genentech is entitled to trigger a technology transfer of our TCR screening process or terminate the Genentech Agreement. In addition, due to our significant obligations under the Genentech Agreement, we may face challenges in meeting the needs of existing customers, collaborators and suppliers and securing new customers, including any biopharmaceutical customers that are actual or potential competitors with Genentech.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we support Genentech in late-stage clinical development or the commercialization of one or more products under the Genentech Agreement, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business, both under the Genentech Agreement and otherwise. As a result, our relationship with Genentech may not result in the realization of its anticipated benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience supporting the development and commercialization of cellular therapeutics, and future TCR-based cellular therapies may never be successfully developed and commercialized under our Genentech collaboration.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in supporting the development of cellular therapeutics, and no experience with the commercialization, marketing and distribution of cellular therapeutics. Our therapeutic product candidates are at an early stage of discovery and development under our Genentech collaboration, and we are continuing to develop our process to develop TCR-based cellular therapies for the treatment of patients with cancer. Under our Genentech collaboration, Genentech has invested significant financial resources to develop future TCR-based cellular therapies, including conducting preclinical studies and other early research and development activities, and providing general and administrative support for these operations. Our future success is dependent on our and Genentech&#8217;s ability to successfully develop therapeutic product candidates and advance those product candidates into the clinic, and Genentech&#8217;s ability, where applicable, to obtain regulatory and marketing approval for, and then to successfully commercialize, cellular therapeutics. We and Genentech have not yet developed and commercialized any cellular therapeutics, and we may not be able to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience with the development and commercialization of antibody-based therapeutics, and future such products may never be successfully developed and commercialized by us or our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience with the development of antibodies, and no experience with the commercialization, marketing and distribution of antibody-based therapeutic products. Our antibody-based therapeutic product candidates are at an early stage of discovery and development. We and any of our collaborators we work with to develop and commercialize therapeutic antibody products may not be able to do so.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently use, and in the future expect to continue using, collaborators for several aspects of our operations as well as to commercially leverage our drug discovery platform, and if we cannot maintain current and enter new relationships with collaborators when necessary or desirable to do so, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited resources to conduct our operations in both the MRD business and IM business areas, and have not yet fully established infrastructure for sales, marketing or distribution in connection with all of our current or future potential products. We have entered into collaboration agreements under which our collaborators have provided, and may in the future provide, funding and other resources for developing and potentially commercializing our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to pursue additional collaborators to secure patient sample cohorts that could help further accelerate our TCR-antigen binding, signal generation and validation for our immune-based diagnostics or drug discovery product or services pipeline. These collaborations may result in our incurring significant expenses in pursuit of potential products and services, and we may not be successful in identifying, developing or commercializing any potential products or services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are pursuing potential drug discovery and development opportunities with pharmaceutical companies to develop and commercialize therapeutic products that leverage our immune medicine platform, including TCR-based and antibody-based therapeutic modalities, among others. We may not succeed in discovering targets or advancing therapeutic product candidates in these collaborations and our collaborators may not succeed in developing and commercializing such products, which may cause us not to realize the expected monetary benefits of the collaborations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many factors may impact the success of such collaborations, including our ability to perform our obligations, our collaborators&#8217; satisfaction with our products and services, our collaborators&#8217; performance of their obligations to us, our collaborators&#8217; internal priorities, resource allocation decisions and competitive opportunities, the ability to obtain regulatory approvals, disagreements with collaborators, the costs required of either party to the collaboration and related financing needs, and operating, legal and other risks in any relevant jurisdiction. In addition to negatively impacting our revenue or delaying the development of our future products and services, the loss of one or more of these relationships may reduce our growth potential. All of the risks relating to product development, regulatory clearance, authorization or approval and commercialization described herein apply to us derivatively through the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage in conversations with companies regarding potential collaborations on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, and any products and services developed as part of the collaboration may not produce successful outcomes. Speculation in the industry about our existing or potential collaborations can be a catalyst for adverse speculation about us or our products, which can adversely affect our reputation and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant additional research and development and, in certain instances, clinical trials or validation will be required before we or our collaborators can potentially seek regulatory clearance, authorization or approval for, or commercialize any of our products or services in development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a pipeline of immune-based diagnostics and therapeutics, including TCR-based cellular therapies in oncology and antibodies in autoimmunity. However, significant additional research and development activities, validations, and clinical trials are required before we and, as pertinent, our collaborators will have a chance to achieve additional commercially viable products. Our research and development efforts remain subject to all of the risks associated with drug development in general and specific to products that we pursue on our own or in collaboration. Development of the underlying technology may be affected by unanticipated technical or other problems, among other research and development issues, and the possible lack of funds needed to complete development of these products. Safety, regulatory and efficacy issues, clinical hurdles or other challenges may result in delays and cause us to incur additional expenses that would increase our losses. If we and our collaborators cannot complete, or if we experience significant delays in developing, our clinical diagnostics or therapeutics, including T-cell based cellular therapies and antibodies, particularly after incurring significant expenditures, our business may fail and investors may lose the entirety of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining regulatory clearances, authorizations or approvals for the commercial sale of any new therapeutic products or services, we must demonstrate that our products are both safe and effective for use in each target disease indication. Clinical studies will be necessary to demonstrate that a product is safe and effective. Research and development, clinical testing and validation are expensive, can take many years to complete and the outcomes are inherently uncertain. Failure can occur at any time. For therapeutics, the results of preclinical studies and early clinical trials of products and services in development may not be predictive of the results of later-stage clinical trials, and initial success in clinical trials may not be indicative of results obtained when clinical trials are completed. There is typically an extremely high rate of failure as therapeutic products in development proceed through clinical trials. Products in later stages of clinical trials or validation also may fail to show the desired safety and efficacy profile despite convincing data generated in non-clinical studies and initial clinical trials or validations. Any delays in the development of our products and services may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or our collaborators experience any of a number of possible unforeseen events in connection with clinical trials, our or their ability to conduct further clinical trials of, obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products, could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to conduct further clinical trials or obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products and services, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evolving Regulatory Requirements and Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the area of &#8220;precision medicine&#8221; or &#8220;personalized medicine&#8221; and its regulation may be subject to ongoing changes in terms of regulatory requirements and governmental policies, in ways we cannot predict; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trial Design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities or ethical review boards, including IRBs, may not authorize commencement of a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there may be delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities may disagree with a clinical trial design or a sponsor&#8217;s interpretation of data and may change the requirements for product clearance, authorization or approval even after they have reviewed and commented on the clinical trial design; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differences in trial design between early stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities may disagree about whether study endpoints are clinically meaningful; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients, or amount of data, required for clinical trials, or improvements to current products, may be larger than anticipated, patient enrollment in these clinical trials may be slower than anticipated or patients may drop out of clinical trials at a higher rate than anticipated; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Testing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes may be made to product candidates after commencing clinical trials, which may require that previously completed stages of clinical testing be repeated or delay later stages of testing, for example, we, or our collaborators, may pursue one or more different product development pathways for our T cell therapeutic products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials may fail to satisfy the applicable regulatory requirements of the FDA or other regulatory authorities responsible for oversight of the conduct of clinical trials in other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may elect to impose a clinical hold, or governing IRBs, data safety monitoring board or ethics committees may elect to suspend or terminate our clinical research or trials for various reasons, including non-compliance with regulatory requirements or a finding that the participants are being exposed to unacceptable risks to their health or the privacy of their health information being disclosed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of future products, or improvements to current products, may be greater than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not have sufficient capacity in our laboratories to perform testing as requested or volumes requested or with the requested turnaround times necessary for clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of materials or data necessary to conduct clinical trials of future products, or improvements to current products, may be insufficient or inadequate; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trial Outcomes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome of our collaborators&#8217; preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates may be associated with negative or inconclusive results in clinical trials, and we or our collaborators may decide to deprioritize or abandon these product candidates, or regulatory authorities may require us to abandon them or impose onerous changes or requirements, which could lead to deprioritization or abandonment; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates may have undesirable side effects which could lead to serious adverse events, or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us, our collaborators or their investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials may suggest or demonstrate that our products are not as efficacious or safe as other similar diagnostics or therapies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical and clinical data are often susceptible to varying interpretations and analyses, and our products may fail to obtain regulatory clearance, authorization or approval, even if they perform satisfactorily in preclinical studies and clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays of this nature could also allow competitors to bring products to market before we or our collaborators do, potentially impairing our ability to successfully commercialize products and harming our business and results of operations. Any delays in the development of our products or those jointly developed with our collaborators may significantly harm our business, financial condition and prospects. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory clearance, authorization or approval of products in development.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to expand our workforce, commercial infrastructure and laboratory operations over time to support demand for our products. We may encounter difficulties in managing this and in meeting fluctuations in this demand.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 619 full-time employees, and we reduced our workforce last year as part of restructuring plans. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If demand for our products and services increases in the future, we may need to expand our workforce, commercial infrastructure and laboratory operations to support demand for our products. If we are unable to support fluctuations in the demand for our products and services, including ensuring that we have adequate capacity to meet potential increased demand as well as other customer requirements (such as turnaround time and service level), our business could suffer. Consequently, we may be required to increase the number of employees, including potential contingent employees as needed, to address demand fluctuations. As we and our collaborators commercialize additional products and services, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher service costs, declining service quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and services and could damage our reputation and the prospects for our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the technical proficiency required from much of our workforce, we may not be able to effectively recruit, train, and retain additional qualified personnel. This may result in weaknesses in our infrastructure, operational mistakes, slower development of our products and services, missed or delayed milestone achievement, significant cost overruns, loss of business opportunities, loss of employees and contingent workers, inability to execute on hiring plans and reduced productivity among remaining employees and contingent workers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future products and services may never achieve significant commercial market acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends on the market&#8217;s confidence that we can provide immune-driven research, therapeutic and diagnostic products and services that improve clinical outcomes, lower healthcare costs and enable better biopharmaceutical development. Failure of our products and services, or those jointly developed with our collaborators, to perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or associated with our products and services. Furthermore, inadequate performance of these products or services may result in lower confidence in our immune medicine platform in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our collaborators may not succeed in achieving significant commercial market acceptance for our current or future products and services due to a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the agreement by third-party payors to reimburse our diagnostics, the scope and extent of which will affect patients&#8217; willingness or ability to pay for our diagnostics, even in markets that we expect to be primarily self-pay, and will likely heavily influence physicians&#8217; decisions to recommend our tests; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate of adoption of our immune medicine platform and related products and services by academic institutions, clinicians, key opinion leaders, advocacy groups and biopharmaceutical companies; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of our investments in product innovation and commercial growth. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our customers and collaborators may decide to decrease or discontinue their use of our products and services due to changes in their research and development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our products and services, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful in addressing these or other factors that might affect the market acceptance of our products, services and technologies. Failure to achieve widespread market acceptance of our immune medicine platform and related products and services would materially harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have estimated the sizes of the markets for our current and future products and services, and these markets may be smaller than we estimate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our estimates of the annual total addressable markets for our current products and services and those under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients who have developed one or more of a broad range of cancers, the number of individuals who are at a higher risk for developing one or more of a broad range of cancers, and the number of individuals who have developed or are at a higher risk of developing certain autoimmune disorders, as well as the proportion of patients in each market whose needs can be addressed by our or our collaborators&#8217; products, and the assumed prices at which we can sell our current and future products and services for markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. In presenting our total addressable market, we are not making any claim that we can realistically serve that market. If the actual number of patients who would benefit from our products, the price at which we can sell future products and services or the annual total addressable market for our products or services is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience in marketing and selling certain products and services, and if we are unable to expand our direct sales and marketing force or partner with collaborators in certain product areas and markets to adequately address our customers&#8217; needs, our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our sales and marketing efforts are targeted at a large and diverse market with highly specialized segments, including department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As a result, we believe it is necessary for our sales representatives to have relevant, specialized market experience. Competition for experienced sales and marketing personnel is intense, and new members of our sales organization may require intense training to apply their experience and expertise to our products and services. We may not be able to attract and retain personnel or be able to build or adequately train an efficient and effective sales organization, which could negatively impact sales and market acceptance of our clinical diagnostics and limit our revenue growth and potential profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no experience marketing and selling therapeutic products. Accordingly, we or our drug discovery and development collaborators may not be able to market and sell our current or future products and services effectively enough to support our planned growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, under the Genentech Agreement, Genentech has the sole right and authority to commercialize products developed under that agreement. It will be Genentech&#8217;s responsibility to locate, qualify and engage distribution partners, clinicians and local hospitals with industry experience and knowledge to effectively market and sell products developed under that agreement. Genentech may not be able to engage distribution partners, clinicians or hospitals on favorable terms, or at all. If Genentech&#8217;s sales and marketing efforts with respect to products developed under the Genentech Agreement are not successful, we may not achieve significant market acceptance for our drug discovery services and platform, which would materially and adversely impact our business operations. We face similar risks in our pharmaceutical services collaborations where milestone payments to us are dependent on successful commercialization of drugs by our collaborators.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not compete effectively with our competitors, we may not be able to successfully commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries in the field of drug discovery are intense and highly competitive. These fields are characterized by rapidly advancing technologies and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including diagnostic, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and current and potential product offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For instance, in clinical diagnostics, our clonoSEQ MRD test faces competition from both conventional and next-generation flow cytometry performed either in-house by our target customers or by reference labs, as well as from labs and institutions advancing research-use-only MRD technologies for clinical applications and commercial-stage oncology diagnostics companies extending the application of their solid tumor (ctDNA) MRD products into the hematology MRD space. In drug discovery, clinical trials of immune medicines are being undertaken by a number of industry and academic players.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors may have or obtain the knowledge necessary to generate and characterize similar data to our known data for the purpose of identifying and developing products or services that could compete with any of our products or services. Further, immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could be adversely affected if we do not develop our drug discovery and clinical diagnostic products, obtain required regulatory and other clearances, authorizations or approvals, obtain or enforce patents covering our discoveries and launch our products before our competitors. Moreover, our competitors may succeed in developing clinical diagnostics and therapies that circumvent our intellectual property rights. Our competitors may succeed in developing and commercializing therapies or diagnostic products that are more accurate, more convenient to use or more cost-effective than our products or could prove to be safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators or that would render our products less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known. For additional information regarding our competition, see the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; section of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to retain regulatory approval of clonoSEQ in the EU and may never obtain approval in any other foreign country for any of our products or services and, even if we do, we or our collaborators may never be able to commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any of our current or future products and services in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding quality, safety, performance and efficacy. In addition, clinical trials or clinical investigations conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory clearance, authorization or approval in one country does not guarantee regulatory clearance, authorization or approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seeking foreign regulatory clearance, authorization or approval could result in difficulties and costs for us and our collaborators and require additional preclinical studies, clinical trials or clinical investigations which could be costly and time-consuming. Regulatory requirements and ethical approval obligations can vary widely from country to country and could delay or prevent the introduction of our products and services in those countries. The foreign regulatory clearance, authorization or approval process involves all of the risks and uncertainties associated with FDA clearance, authorization or approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have licensed our technology to certain international sites including but not limited to France, Germany, Italy, the United Kingdom, Spain, and Australia for research use only of our clonoSEQ assay and in some cases, for clinical use of clonoSEQ. In August 2024, clonoSEQ received IVDR certification in the EU, but our collaborators are only beginning to use clonoSEQ as an IVDR-compliant test in local EU clinical trials. We do not know how long we will be able to retain IVDR certification if regulatory requirements change or necessitate additional validations or approvals. Additionally, aside from this achievement, we have limited experience in obtaining regulatory clearance, authorization or approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required regulatory clearances, authorizations or approvals in international markets, or if those approvals are delayed, our target market will be reduced and our ability to realize the full market potential of our products and services will be unrealized.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends on the skills, experience and performance of key members of our senior management team, including our co-founders and executive officers. The individual and collective efforts of these employees will be important as we continue to develop products and services based on our immune medicine platform. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Our executive officers have signed employment agreements with us, but their service is at-will and may end at any point in time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development initiatives and laboratory operations depend on our ability to attract and retain highly skilled scientists, technicians and software engineers. We may not be able to attract or retain qualified scientists, technicians or software engineers in the future due to the competition for qualified personnel among life sciences and technology businesses, particularly near our facilities located in Seattle, Washington and in South San Francisco, California. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting, training and retention difficulties can limit our ability to support our research and development and commercialization efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory and commercialization strategies. Our consultants and advisors may provide services to other organizations and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current consultants or advisors might impede the achievement of our research, development, regulatory and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we lose the support of key thought leaders, it may be difficult to establish products and services enabled by our immune medicine platform as industry standards, which may limit our revenue growth and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established relationships with leading oncology, hematology, immunology, autoimmunity or inflammatory disease, transplantation and solid tumor thought leaders at premier academic and research institutions. If these key thought leaders determine that our immune medicine platform or our current or future products or services are not clinically effective, determine that alternative technologies are more effective or elect to use internally developed services, we could encounter significant difficulty validating our products or services, driving adoption or establishing our immune medicine platform as an industry standard, which would limit our revenue growth and our ability to achieve profitability. In addition, negative publications or reviews by clinicians, industry groups or other important stakeholders may negatively impact our revenue growth and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The life sciences industry is subject to rapid change, which could make our immune medicine platform and related products that we develop obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product and service introductions and enhancements and evolving industry standards, all of which could make our current and future products obsolete. For example, there have been numerous advances in technologies relating to life sciences research, MRD technologies and assays and the diagnosis and treatment of cancer and autoimmune disorders. There have also been advances in technologies used to computationally analyze very large amounts of biologic information. Our future success will depend on our ability to keep pace with evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. If we do not update our platform and products to reflect new scientific knowledge about DNA sequencing, immunology, computational biology, software development, new disease diagnostics and therapies or the diseases we seek to treat or assist in the treatment of, such as lymphoid malignancies, our products and technology could become obsolete so products and services based on our immune medicine platform could decline or fail to grow as expected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our laboratory facilities are damaged, become inoperable or we are required to vacate our existing facilities, our ability to support our customers, conduct our laboratory processes and pursue our research and development efforts may be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate laboratory facilities located in Seattle, Washington and South San Francisco, California. Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure or terrorism, which may render it difficult or impossible for us to operate our immune medicine platform for some period of time. The inability to perform our laboratory processes that could develop if our facilities are inoperable, for even a short period of time, or to replace or repair inventory such as reagents or customer samples may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify new facilities or license or transfer our proprietary technologies to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct our laboratory processes, we may be unable to negotiate commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which increase with the volume of material and sample transfers and could cause an interruption of our commercialization efforts, research and development programs, and business operations, as well as environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. While our property insurance policy provides limited coverage in the event of contamination from hazardous and biological products and the resulting cleanup costs, we do not currently have any additional insurance coverage for legal liability for claims arising from the handling, storage or disposal of hazardous materials. Accordingly, in the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to raise additional capital to fund our existing operations, develop additional products and services, commercialize new products and services or expand our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities will be sufficient to meet our anticipated cash requirements over at least the next 12 months. If our available cash and investment balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of lower demand for our products and services as a result of risks described herein, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increase our sales and marketing efforts to drive market adoption of our life sciences research, clinical diagnostics and therapeutics; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fund development efforts for our current and future products and services; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our products and services into other disease indications and clinical applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire, license or invest in technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or invest in complementary businesses or assets; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finance capital expenditures, such as our corporate headquarters expansion, and general and administrative expenses. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our present and future funding requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve revenue growth; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our rate of continued progress in establishing payor coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors for our clonoSEQ diagnostic test; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our rate of progress in supporting the development of cellular therapies developed under the Genentech Agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our rate of progress in, and research and development expenses associated with, products and services in research and early development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological, product and market developments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to international expansion; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products and services. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products and services or grant licenses on terms that are not favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our shareholders&#8217; ownership, increase our debt or cause us to incur significant expense.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may pursue acquisitions of businesses and assets. We also may pursue joint ventures or investments that leverage our immune medicine platform and industry experience to expand our offerings or distribution. We have no experience forming joint ventures and limited experience investing in or acquiring other companies. We may not be able to find suitable joint ventures, investment or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate the acquired company successfully into our existing business, and we could assume unknown or contingent liabilities, including regulatory violations such as the FCPA or similar laws. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, collaboration or joint venture.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our shareholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our NOL carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, losses incurred will carry forward until such losses expire (for losses generated prior to January 1, 2018) or are used to offset future taxable income, if any. Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 (&#8220;Section 382&#8221;) and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through December 31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2024. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience ownership changes in the future as a result of shifts in our stock ownership, which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and financial markets. Changes in these economic conditions can arise suddenly, such as in the case of recent inflation fluctuations. A severe or prolonged economic downturn, as result of a global pandemic or otherwise, could result in a variety of risks to our business, including weakened demand for our products and services and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could also strain our collaborators, possibly resulting in supply disruption, or cause delays in their payments to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The marketing, sale and use of our products and services could lead to the filing of product or professional liability claims were someone to allege that our products or services failed to perform as designed or intended. We could also be potentially exposed to claims relating to therapeutic failures of products commercialized under our collaborations, such as a cellular therapy marketed by Genentech that is manufactured based on TCR-related sequences and data we provide. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Regardless of merit or eventual outcome, product liability and professional liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any products, services or clinical solutions that we have developed or may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to patients or their families; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant time and costs to defend related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any products, services or clinical solutions that we have developed or may develop; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause current collaborators to terminate existing agreements or potential collaborators to seek other companies, any of which could impact our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on our information technology systems and any failure of these systems could harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on information technology and telecommunications systems, including third-party cloud computing infrastructure, operating systems and artificial intelligence platforms, for significant elements of our operations, including our laboratory information management system, clinical immunomics database, TCR-antigen binding, laboratory workflow tools, customer and collaborator reporting and related functions. We also depend on our proprietary workflow software to support new product launches and regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use complex software processes and pipelines to manage samples and evaluate sequencing result data. These are subject to initial design or ongoing modifications which may result in unanticipated issues that could cause variability in patient results, leading to service disruptions or errors, resulting in liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. In addition to these business systems, we have installed, and intend to extend, the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation and general administrative activities. In addition, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the risks directly relevant to our vendors, systems, and information technology, there are risks associated with the outside vendors and third parties with whom they subcontract. For example, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors. Subcontractors can be a vector of vulnerability, as any weaknesses in their organization&#8217;s technical and organizational controls could affect vendor operations as well as data management, in turn impacting our own operations and ability to safeguard critical data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information technology and telecommunications systems are vulnerable to attack in a variety of forms and from a variety of sources, including telecommunications or network failures, malicious human acts (such as ransomware) and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of these systems or those used by our collaborators or subcontractors could prevent us from conducting our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or our collaborators may be adversely affected by natural or man-made disasters or other business interruptions, such as cybersecurity attacks, and our business continuity and disaster recovery plans, or those of our collaborators, may not adequately protect us from the effects of a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Natural and man-made disasters and other events beyond our control could severely disrupt our operations, or those of our collaborators, and have a material adverse impact on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our laboratory facilities or those of our collaborators, limited our or our collaborators&#8217; ability to access or use our respective digital information systems or that otherwise disrupted our respective operations, it may be difficult or, in certain cases, impossible for us or our collaborators to continue our respective businesses for a substantial period of time. The disaster recovery and business continuity plans we and our collaborators currently have in place are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. Our cybersecurity liability insurance may not cover any or all damages, depending on the severity and extent, we or our collaborators could sustain based on any breach of our respective computer security protocols or other cybersecurity attack, including potential liability arising out of third parties&#8217; negatively impacted data privacy rights. We may incur substantial expenses as a result of the limited nature of our respective disaster recovery and business continuity plans, which could have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The use of artificial intelligence and machine learning presents new risks and challenges to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of artificial intelligence (&#8220;AI&#8221;) and machine learning is increasingly being embedded in standard business processes, including in the life sciences and healthcare industries. While we do not use AI or machine learning as an element of any product or service, we do use them to assist in a range of other contexts, such as to enhance our operations, technology, and internal workflows. We also anticipate AI to be adopted more broadly throughout our organization to manage operational efficiencies, particularly as the technology evolves and improves. However, the use of AI and machine learning presents risks and challenges that could impact our business. For example, the improper use of data (including personal information, PHI or confidential information) to train AI algorithms could result in violations of our privacy and confidentiality obligations, jeopardize our intellectual property rights, or put us at risk of violating applicable laws and regulations. Furthermore, AI models may be poorly trained or compromised. This could create output from AI tools that might be flawed without appropriate human oversight, resulting in biased data, misinformation or disinformation or the introduction of cybersecurity threats such as malware. AI practices and machine learning tools used by our commercial partners could present similar risks, and any of these outcomes could have a material adverse effect on our business, results of operations, or financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Relating to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We conduct our business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The life sciences industry is highly regulated, and the regulatory environment in which we and our collaborators operate may change significantly and adversely to us in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation, federal and state laws relating to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory testing, including CLIA and state laboratory licensing laws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development, testing, use, distribution, promotion and advertising of research services, kits, clinical diagnostics and pharmaceutical therapies, including certain LDTs, and related services, which are regulated by the FDA under the FDCA and the FTC; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">test ordering, documentation of tests ordered, billing practices and claims payment under CMS and the HHS OIG enforcing those laws and regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cellular therapies, medical device and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostic clearance, marketing authorization or approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory anti-mark-up laws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the handling and disposal of medical and hazardous waste; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fraud and abuse laws such as the False Claims Act, the AKS, EKRA, and the Stark Law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Occupational Safety and Health Administration rules and regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA and other federal and state data privacy and security laws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal and state genetic information laws, such as the Genetic Information Nondiscrimination Act (&#8220;GINA&#8221;) and similar state laws; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and restrictions on coverage and reimbursement for clinical diagnostics and pharmaceutical therapies and Medicare, Medicaid, other governmental payors and private insurers reimbursement levels. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, the laws, regulations and policies governing the marketing of RUO products, LDTs and clinical diagnostic tests and services are extremely complex and are subject to interpretation by the courts and governmental agencies. Our failure to comply could lead to civil or criminal penalties, exclusion from participation in state and federal health care programs, or prohibitions or restrictions on our laboratories&#8217; ability to provide or receive payment for our services. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved products, in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products could limit our ability, and that of our collaborators, to fully commercialize our products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford the clinical diagnostic tests and therapeutics that we and our collaborators plan to develop and sell. In addition, because our clinical diagnostics and some of our potential therapeutic products will represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our products and services, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our products will depend substantially, both domestically and internationally, on the extent to which the costs of our products and services are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our products or services. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment in any of our products or services. If we adopt a self-pay strategy with respect to any products or services, we may experience similar difficulties in the establishment or maintenance of sufficiently high pricing. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved products and services. In the U.S., many significant decisions about reimbursement for new diagnostics and medicines are typically made by CMS, an agency within the HHS, and its contractors. CMS and its contractors decide whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS policies to a substantial degree. It is difficult to predict what CMS and its contractors will decide with respect to reimbursement for novel products and services such as ours. Additionally, reimbursement agencies in Europe may be more conservative than CMS. These inherent limitations could affect our ability to realize revenues from our clinical products, including new indications addressed for clonoSEQ.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., the reimbursement process and timelines vary significantly. Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products, or medicinal products, as they are commonly referred to in the EU, with limited participation from the marketing authorization or Conformit&#233; Europ&#233;ene (&#8220;CE&#8221;) mark holders, or may take decisions that are unfavorable to the authorization or CE mark holder where they have participated in the process. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products and services in those countries would be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increasing number of countries, including the U.S. and the EU, are pursuing initiatives to attempt to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors, in the U.S. and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics or the cellular therapies to be sold by us or our collaborators. For example, the U.S. government introduced the Lower Drug Costs Now Act of 2019 to reduce the cost of drugs. This blueprint contains certain measures that HHS is already working to implement. In addition, the No Surprises Act (&#8220;NSA&#8221;) took effect in January 2022. One of the goals of the NSA is to protect patients from &#8220;surprise&#8221; medical bills resulting from gaps in coverage for services provided by out-of-network providers, such as laboratories, related to patient visits at in-network facilities. The NSA limits the amount out-of-network laboratories may charge a patient for laboratory services ordered during an in-network facility visit and establishes an independent dispute resolution process for determining the amount of reimbursement for the laboratory service in the event that the laboratory and insurer cannot agree on a rate. To the extent the NSA limits the price charged for our diagnostic products or cellular therapeutics, the commercial viability of those products may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological program pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to experience pricing pressures on our clinical diagnostics and cellular therapies sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business could be harmed by the loss, suspension or other restriction on a license, certification or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal law requires virtually all clinical laboratories to comply with CLIA, which generally involves becoming certified by the federal and state government for the testing that will be performed and complying with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate and reliable. CLIA certification is also a prerequisite to be eligible to bill state and federal healthcare programs, as well as many private third-party payors, for laboratory research and clinical diagnostic testing services. As a condition of our CLIA certification, our Seattle, Washington laboratory is subject to survey and inspection every other year, additional random inspections and surprise inspections based on complaints received by state or federal regulators. The biennial survey and inspection is conducted by CMS, a CMS agent or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization, such as CAP. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant civil, administrative or criminal sanctions against the lab, its owners and other individuals. In addition, we are subject to regulation under certain state laws and regulations governing laboratory licensure. Some states, including Washington, have enacted laboratory licensure and compliance laws that are more stringent than CLIA. Changes in state licensure laws that affect our ability to offer and provide research and diagnostic products and services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any sanction imposed under CLIA, its implementing regulations or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in law relating to health insurance coverage and payment may adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. clinical diagnostic and biopharmaceutical industries. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and medical devices, including laboratory kits, and promoted a new Medicare Part D coverage gap discount program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the provisions of the ACA have been subject to judicial and Congressional challenges. It is also unclear how regulatory provisions and sub-regulatory guidance, both of which fluctuate continually, may affect interpretation and implementation of the ACA and its practical effects on our business. In addition, changes in the number of patients that can look to third-party payment to help afford our products and services may affect the demand for these products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase downward pressure on drug and device pricing. Such reforms could have an adverse effect on anticipated revenues from our products and services, including those that we jointly develop with our collaborators, and may affect our overall financial condition and ability to develop or obtain regulatory clearance, authorization or approval for our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and clear, authorize or approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. In addition, government funding of agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and devices to be reviewed and cleared, authorized or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We must maintain compliance with marketing authorization requirements of the FDA and equivalent foreign and state regulatory authorities for our products and services whose sale is subject to their authority and failure to maintain compliance with FDA requirements may prevent or delay the marketing of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even after we have obtained marketing authorization (as we did for clonoSEQ) we must comply with the scope of that clearance, authorization or approval. Failure to comply with those limitations or the additional, extensive and ongoing post-marketing obligations imposed by the FDA or other regulatory requirements of other regulatory agencies, such as the Clinical Laboratory Evaluation Program for New York State, could result in unanticipated compliance expenditures, a range of administrative enforcement actions, injunctions and criminal prosecution. FDA post-market obligations include, among other things, compliance with the FDA QSR, establishing registration and device listings, labeling requirements, reporting of certain adverse events and malfunctions, and reporting of certain recalls. In addition, circumstances may arise that cause us to recall equipment used in connection with our products and services. Such recalls could have an adverse effect on our ability to provide those products and services, which in turn would adversely affect our financial condition. Our collaborators will also be required to maintain FDA clearance and possibly also other authorizations or approvals for the products and services that we jointly develop. Any failure by us or our collaborators to maintain such clearance, authorization or approval could impair or cause a delay in our ability to profit from these collaborations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Products and services offered RUO may be subject to regulatory scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our products are currently provided on a RUO basis, not for use in the diagnosis or treatment of disease. Pursuant to FDA guidance on RUO products, a company may not make clinical or diagnostic claims about an RUO product or provide clinical directions or clinical support services to customers of RUO products. If the FDA were to disagree with our RUO classification or modify its approach to regulating RUO products, we could experience reduced revenue or increased compliance and other costs, which could adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA requires marketing authorization of our RUO products in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA&#8217;s Final LDT Rule and targeted enforcement discretion policies for LDTs could subject our operations to much more significant regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to offering the cleared version of clonoSEQ as a test for MRD in certain blood cancers, we also currently offer LDT versions of this test for other indications. For years, the FDA has exercised enforcement discretion with respect to LDTs that are marketed in the United States and has not actively enforced its medical device regulatory requirements for such tests, provided that the LDTs met certain conditions. On May 6, 2024, FDA issued the final rule that amended the definition of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostics (IVDs) in its regulations to state that IVDs are medical devices under the federal Food, Drug, and Cosmetic Act including when the manufacturer of the IVD is a laboratory. Under this nuanced approach, FDA proposed to phase out its general enforcement discretion for LDTs over a four-year period, subject to targeted enforcement discretion policies. In the absence of a successful legal challenge, LDTs that do not fall within the final rule&#8217;s targeted enforcement discretion policies are expected to comply with certain medical device regulatory requirements such as medical device reporting and complaint handling requirements beginning on May 6, 2025, and other requirements such as registration and listing and premarket authorization, among others, will become phased in over the next three years. As a result, our NGS MRD tests may become subject to extensive FDA requirements, or our business may otherwise be adversely affected. If the FDA were to disagree with our LDT status or modify its approach to regulating LDTs, we could experience reduced revenue or increased costs, which could adversely affect our business, prospects, results of operations and financial condition. If required, the regulatory marketing authorization process required to bring our current or future LDTs into compliance may involve, among other things, successfully completing additional clinical validations and submitting to and obtaining clearance from the FDA for a premarket clearance (510(k)) submission or authorization for a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or approval of a PMA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, Congress is working on legislation that, if enacted, would clarify the FDA&#8217;s authority with respect to LDTs. In this regard, the VALID Act was first introduced in March 2020, and most recently reintroduced in March 2023. The bill proposes a risk-based approach that would subject many LDTs to FDA regulation by creating a new </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical test, or IVCT, category of regulated products. As proposed, the bill would grandfather many existing LDTs from certain proposed requirements but would require such tests to comply with certain other regulatory requirements such as registration and listing, adverse event reporting. This legislation could create new or different regulatory and compliance burdens on us and could have a negative effect on our ability to develop new products, which could have a material effect on our business. In the event that the FDA requires marketing authorization of our LDTs in the future, the FDA may not ultimately grant any clearance or approval requested by us in a timely manner, or at all. In addition, if the FDA inspects our laboratory in relation to the marketing of our FDA-cleared clonoSEQ test, any enforcement action the FDA takes might not be limited to the FDA-cleared clonoSEQ test and could encompass our LDT testing service.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">For each product we are developing that requires FDA premarket review or equivalent regulatory approval, the FDA or other regulatory authority may not grant clearance, authorization or premarket approval and failure to obtain necessary approvals for our future products and services would adversely affect our ability to grow our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we begin to manufacture, label and market additional clinical diagnostic products for commercial diagnostic use in the U.S., we may be required to obtain either clearance, marketing authorization or approval from the FDA and state regulatory authorities with jurisdiction over such products, unless an exemption applies or, in the case of the FDA, it exercises its enforcement discretion and refrains from enforcing its requirements. For example, the FDA currently refrains from enforcing its medical device requirements with respect to LDTs, which the FDA considers to be a type of in vitro diagnostic test that is designed, manufactured and used within a single properly licensed laboratory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining PMA from the FDA is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. Conversely, in the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally marketed &#8220;predicate&#8221; device in order for the product to be cleared for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics or if it has different technological characteristics as the predicate device, the proposed device must be as safe and effective as, and not raise different questions of safety or effectiveness than, the predicate device. Clinical data is sometimes required to support substantial equivalence. For lower-risk devices that would otherwise automatically be placed into Class III, which require a PMA because no predicate device is available and the devices do not fall within an existing 510(k)-exempt classification, an applicant may submit a de novo request to down classify the device into Class II or Class I, which would not require a PMA. In the de novo process, the FDA must determine that general and special controls are sufficient to provide reasonable assurance of the safety and effectiveness of a device, which is low to moderate risk and has no predicate. In other words, the applicant must justify the &#8220;down-classification&#8221; to Class I or II for a new product type that would otherwise automatically be placed into Class III, but is lower risk. Clinical data may be required. For laboratory tests for which FDA clearance, authorization or approval is required, the FDA may also require data to support analytical and clinical validity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 510(k), de novo and PMA processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA&#8217;s 510(k) clearance pathway usually takes from three to nine months from submission, but it can take longer for a novel type of product. The FDA&#8217;s de novo classification pathway usually takes from six to 12 months, but for many applicants can take up to 18 months or more.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory clearances, authorizations or approvals would have a material adverse effect on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA can delay, limit or deny clearance, authorization or approval of a device for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to demonstrate to the satisfaction of the FDA that the products are safe or effective for their intended uses; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the disagreement of the FDA with the design, conduct or implementation of the clinical trials or the analysis or interpretation of data from preclinical studies, analytical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">serious and unexpected adverse device effects experienced by participants in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data from preclinical studies, analytical studies and clinical trials may be insufficient to support clearance, authorization or approval, where required; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to demonstrate that the clinical and other benefits of the device outweigh the risks; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an advisory committee, if convened by the FDA, may recommend against approval of a PMA or other application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee makes a favorable recommendation, the FDA may still not approve the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may identify deficiencies in our marketing application; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may identify deficiencies in our or our collaborators&#8217; manufacturing processes, facilities or analytical methods; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential for policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering clinical data or regulatory filings insufficient for clearance, authorization or approval; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or foreign regulatory authorities may audit clinical trial data and conclude that the data is not sufficiently reliable to support a PMA. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are numerous FDA personnel assigned to review different aspects of marketing submissions, which can present uncertainties based on their ability to exercise judgment and discretion during the review process. During the course of review, the FDA may request or require additional data and information, and the development and provision of these data and information may be time-consuming and expensive. The process of obtaining regulatory clearances, authorizations or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances, authorizations or approvals on a timely basis, or at all for our products in development. If we are unable to obtain clearance, authorization or approval for any products for which we plan to seek clearance, authorization or approval, our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Modifications to our products with FDA clearance may require new FDA clearances, authorizations or approvals, or may require us to cease marketing or recall the modified clinical diagnostic products or future clinical products until clearances are obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any modification to a 510(k)-cleared device that significantly affects its safety or effectiveness, or that constitutes a major change in its intended use, could require a new 510(k) clearance, a new de novo authorization or approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new clearances, authorizations or approvals are necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any product approved pursuant to a PMA, we would be required to seek supplemental approval for many types of modifications to the approved product. The FDA requires manufacturers in the first instance to determine whether a PMA supplement or other regulatory filing is needed or whether the change may be reported via the PMA Annual Report, but may disagree with a company&#8217;s assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA disagrees with our determination, which it may not review until we submit an annual report or the FDA conducts an inspection or other inquiry, and requires us to seek new clearances, authorizations or approvals for modifications to our previously cleared, authorized or approved clinical diagnostic products for which we have concluded new clearances, authorizations or approvals are unnecessary, we may be required to cease marketing or distribution of these clinical diagnostic products or to recall the modified products until we obtain clearance, authorization or approval. We may also be subject to enforcement action, including, among other things, significant regulatory fines or penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, consultants and collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, consultants and those of our collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the U.S. and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent improper marketing, fraud, misconduct, kickbacks, bribery, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees and suppliers, but it is not always possible to identify and deter misconduct. In addition, our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such investigations or actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, which could have a significant impact on our business. We currently have a compliance program in accordance with the elements of an effective program outlined by the HHS OIG, which could help mitigate damages, but cannot prevent all misconduct. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, suffer adverse publicity and reputational harm, and have the attention of management diverted in defending ourselves against any of these claims or investigations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Medicare payment rates are uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2020, CMS revised the National Coverage Determination (&#8220;NCD&#8221;) for molecular diagnostic laboratory testing services utilizing a NGS methodology, which includes our clinical diagnostic products, for Medicare beneficiaries with advanced cancer. CMS revised the NCD to extend specific coverage for germline (inherited) testing. CMS stated that it is continuing to make other technical, clarifying and conforming changes in the NCD manual and they are also clarifying the existing policy related to diagnostic tests for Somatic (Acquired) Cancer. If CMS were to make material revisions to policy, this could potentially impact the scope of clonoSEQ coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Medicare Part B, payment for most diagnostic laboratory tests is made under the Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;), which assigns payment amounts to tests based on billing codes. Under the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), certain laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or Medicare&#8217;s Physician Fee Schedule are required to report to CMS every three years, or annually for &#8220;advanced diagnostic laboratory tests,&#8221; commercial payor payment rates and volumes for tests they perform and that are assigned specific billing codes. PAMA has special provisions relating to &#8220;advanced diagnostic laboratory tests,&#8221; as defined by the statute, and these provisions affect the rate-setting at the time of launch and the periodicity of rate reporting and revision. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. If, in the future, clonoSEQ or any of our tests are assigned a specific code we would be required to report commercial payor payment data on those tests. Payments for tests billed under miscellaneous codes are determined by the MACs, which also have discretion to change those payment rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMS uses the data reported by laboratories to calculate a payment rate for each CLFS test, other than those coded with miscellaneous codes and certain others, based on the volume-weighted median of the private payor rates. These rates apply for three years, except that payment rates for advanced diagnostic laboratory tests apply for one year. If we offer tests with specific codes, this apparatus will apply. Under these circumstances, Medicare&#8217;s payment rates would be determined by the rates we and other laboratories, if any, with tests that share the specific codes we use, obtain from commercial payors. In that case, if we are unable to obtain and maintain adequate reimbursement rates from commercial payors, this may adversely affect our Medicare rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some circumstances, our tests may be furnished to hospital inpatients and paid by Medicare under different rules. For example, when a specimen is obtained from a patient who is at the time classified by Medicare as a hospital inpatient, Medicare would not make a separate payment for the test and we would have to look to the hospital for payment. We do not know how often this will occur or whether hospitals will resist paying us for our tests. In this situation, Medicare coverage would be determined by the MAC for the jurisdiction where the hospital is located, which may not cover our tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our products, and those jointly developed with our collaborators, may in the future be subject to product or service recalls. A recall of products or services, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our or our collaborators&#8217; products or services, could have a significant adverse impact on us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has the authority to require the recall of commercialized products or services that are subject to FDA regulation. Manufacturers may, under their own initiative, recall a product or service if any deficiency is found. The FDA requires that certain corrections and removals, including recalls intended to reduce a health risk, be reported to the FDA within ten working days of initiating such correction or removal. For reportable corrections and removals, companies are required to make additional periodic submissions to the FDA after initiating the recall, and often engage with the FDA on their recall strategy prior to initiating the recall. A government-mandated or voluntary recall by us, one of our distributors or our collaborators could occur as a result of an unacceptable health risk, component failures, failures in laboratory processes, malfunctions, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our commercialized products or services or those jointly developed with our collaborators would divert managerial and financial resources and adversely affect our reputation, results of operations and financial condition. We may also be subject to liability claims, be required to bear other costs or take other actions that may negatively impact our future sales and our ability to generate profits. Companies are also required to maintain certain records of corrections and removals, even if these do not require reporting to the FDA. We or our collaborators may initiate voluntary recalls involving our commercialized products or services in the future that we determine do not require FDA notification. If the FDA disagrees with our determinations, they may require us to report those actions as recalls. A future recall announcement by us or our collaborators could harm our reputation with customers and negatively affect our results of operations and financial condition. In addition, the FDA or other agency could take enforcement action for failing to report the recalls when they were conducted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our collaborators initiate a recall, including a correction or removal, for one of our commercialized products or services, issue a safety alert, or undertake a field action or recall to reduce a health risk, this could lead to increased scrutiny by the FDA, other governmental and regulatory enforcement bodies, and our or our collaborators&#8217; customers regarding the quality and safety of our products and services, and to negative publicity, including FDA alerts, press releases, or administrative or judicial actions. Furthermore, the submission of these reports could be used against us by competitors and cause customers to delay purchase decisions or cancel orders, which would harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any additional commercialized products or any future products that obtain regulatory clearance, authorization, approval, accreditation or licensure will remain subject to regulatory scrutiny and our failure to maintain our regulatory clearances, authorizations, approvals, accreditations or licensures could adversely affect our reputation, business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we or our collaborators obtain regulatory clearance, authorization, approval, accreditation or licensure in a jurisdiction for our products and services, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our products and services, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance of our or our collaborators&#8217; manufacturing and distribution. Advertising for certain devices and labeling, including promotional labeling, for all devices must comply with FDA requirements. In addition, device advertising and promotion may also be subject to other federal and state laws. For example, the FDA shares jurisdiction over the regulation of device advertising with the FTC. Advertising for devices characterized as restricted by the FDA is subject to specified FDA requirements, while advertising for non-restricted devices is regulated by the FTC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our collaborators fail to comply with applicable regulatory requirements following clearance, authorization, approval, accreditation or licensure of any of our products and services, a regulatory agency may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiate an inspection of our or our collaborators&#8217; facilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue an untitled or warning letter asserting that we or our collaborators are in violation of law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend or withdraw regulatory clearance, authorization or approval, or revoke a license or accreditation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend any ongoing clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or refuse clearance, authorization or approval of a pending regulatory submission or supplement submitted by us or our collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose restrictions on our or our collaborators&#8217; cleared, authorized, approved, accredited or licensed products or services; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seize or recall the product or service; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">partially suspend or entirely shut down our or our collaborators&#8217; manufacturing or laboratory operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue advisories or other field actions; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose operating restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to allow us or our collaborators to enter into supply contracts, including government contracts; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refer matters to the DOJ or other enforcement or regulatory bodies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our and our collaborators&#8217; ability to commercialize any cleared, authorized or approved products and services and generate revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our diagnostic products or services cause or contribute to a death or serious injury, or malfunction in certain ways, we will be required to report such death, serious injury or malfunction under applicable medical device reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or one of our similar devices were to recur. If such a death, serious injury or malfunction were to occur, and we or our collaborators are unable to demonstrate that the adverse events were caused by factors other than our or our collaborator&#8217;s products and services, regulatory authorities could order us to cease further development of, or deny clearance, authorization or approval of, any of our or our collaborators&#8217; products and services for any or all targeted indications. Even if we and our collaborators are able to demonstrate that any serious adverse events are not related to our products and services, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial of any product in development, the commercial prospects of such product in development may be harmed and our ability to generate product revenues may be delayed or eliminated. Any of these occurrences may harm our and our collaborators&#8217; ability to identify and develop future products and services, and may significantly harm our business, financial condition, result of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to various laws and regulations, such as healthcare fraud and abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians, hospitals and third-party payors often play a primary role in the recommendation and prescription of any currently marketed products and services for which we may obtain clearance, authorization or approval. Our current and future arrangements with healthcare providers, physicians, hospitals and third-party payors, and our sales, marketing and educational activities related to our products and services, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations at the federal and state level that may constrain our business or financial arrangements, and the relationships through which we market, sell and distribute our products and services. In addition, our operations are also subject to various federal and state fraud and abuse, physician payment transparency, and privacy and security laws, including, without limitation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The AKS, which prohibits, among other things, persons and entities, including clinical laboratories, from knowingly and willfully soliciting, receiving, offering or paying remuneration, whether directly or indirectly, overtly or covertly, in case or in kind, to induce or reward or in return for either the referral of an individual or the purchase, lease, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program such as Medicare or Medicaid. The AKS has been interpreted broadly to apply to, among other things, arrangements between clinical laboratories and prescribers and purchasers of our tests. The term &#8220;remuneration&#8221; expressly includes kickbacks, bribes or rebates and has been broadly interpreted to include anything of value, including gifts, discounts, waivers of payment, ownership interests and any goods or services provided at less than their fair market value. There are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, these exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> per se</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of the facts and circumstances to determine whether one purpose of the remuneration in the arrangement was to induce referrals or generate business that is payable by a federal healthcare program. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the False Claims Act. Moreover, certain AKS safe harbors currently protecting rebates paid by device manufacturers to third parties and other arrangements between device manufacturers and third parties may later be modified or repealed pursuant to a pending regulatory proposal, which could require us to revisit or modify our business practices. Our practices may not meet all of the criteria for safe harbor protection from AKS liability in all cases. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate any AKS provisions to have committed a violation. In addition, renumeration may not be offered or provided to beneficiaries under the monetary penalty law provision prohibiting inducements to beneficiaries.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8122 of the SUPPORT Act, EKRA, which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current EKRA exceptions in some cases reference, and in others differ from, the AKS safe harbors. Significantly, the EKRA prohibitions apply to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities or clinical laboratories, whether or not related to the treatment of substance use disorders. Further, the EKRA prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of such providers. EKRA creates additional risk that relationships with referral sources could be problematic. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. The False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In addition, AKS violations implicate the False Claims Act. Conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Criminal Health Care Fraud Statute, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the AKS, a person or entity does not need to have actual knowledge or specific intent to violate the Criminal Health Care Fraud Statute. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Stark Law, which is directed at &#8220;self-referral,&#8221; prohibits, with certain exceptions, referrals for certain DHS, including laboratory services, that are covered by Medicare and Medicaid by physicians who personally, or through a family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests. The prohibition also extends to payment for any testing referred in violation of the Stark Law. Because the Stark Law is a strict liability statute, proof of specific intent to violate the law is not a required element of a violation. Any person who engages in a scheme to circumvent the Stark Law&#8217;s referral prohibition may be subject to significant fines for each such arrangement or scheme. In addition, any person who presents or causes to be presented a claim to Medicare or Medicaid in violation of the Stark Law is subject to civil monetary penalties applied to each bill submission, an assessment of up to three times the amount claimed and possible exclusion from participation in federal governmental payor programs, and those claims are considered false claims for which the parties to the arrangement may be liable under the False Claims Act. Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and any person collecting any amounts with respect to any such prohibited bill is obligated to refund such amounts. Many states have comparable laws that are not limited to Medicare and Medicaid referrals. The Stark Law also places an annual cap on the amount of non-monetary compensation, which consists of meal spend and educational items, that a company can spend on a physician in the aggregate. We occasionally enter into financial relationships, usually compensation relationships, such as a consulting arrangement, with physicians who refer patients for testing. If these arrangements do not meet the Stark Law&#8217;s requirements, any claims submitted to Medicare or Medicaid could violate the law and put both the physician referral source and us at risk. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The administrative simplification provisions of HIPAA, as amended and supplemented by HITECH, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of protected health information (&#8220;PHI&#8221;) held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and their respective business associates. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA regulation and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. The HHS Office for Civil Rights (&#8220;OCR&#8221;) has increased its focus on compliance and continues to train state attorneys general for enforcement purposes.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GINA, which restricts employers and health insurance companies from requiring or using the results of genetic tests in specific contexts and does not provide a private right of action. A number of states have also adopted laws regarding genetic tests, some aligned with GINA and some with broader applicability, including granting broader rights to individuals and imposing strict obligations on organizations to safeguard genetic data and the results of any such testing. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Physician Payments Sunshine Act created under the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The Physician Payments Sunshine Act has been extended to payments and transfers of value to physician assistants, nurse practitioners and other mid-level healthcare providers for payments and other transfers of value made to these practitioners. In addition, certain state and local laws may impose additional transparency and healthcare compliance requirements on medical device manufacturers, as well as certain restrictions or limits on interactions with healthcare professionals. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FTCA, which the FTC interprets to require taking appropriate steps to secure consumers&#8217; personal information and considers the failures to do so to constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Health information is considered sensitive data that merits stronger safeguards, and the FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is consistent with what is required by the HIPAA Security Rule. Many states have passed comprehensive privacy laws, some states, most notably Massachusetts and Nevada, also have adopted laws requiring the implementation of security measures to protect personal information, and all 50 states and the District of Columbia, Puerto Rico and Guam, have adopted breach notification laws. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Analogous state laws and regulations, such as state anti-kickback, self-referral and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases even in self-pay scenarios. In addition, some state laws require life sciences companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to impose transparency requirements or restrictions on marketing activities. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various state, federal and foreign laws and regulations govern our ability to communicate, prospect, advertise and market our products and services through email, phone, text messages, facsimile and online methods. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the exceptions and safe harbors available under them, it is possible that certain of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of the ongoing interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that business arrangements with third parties comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert management&#8217;s attention from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> actions brought by individual whistleblowers in the name of the government and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our collection, use and disclosure of personal information, including health and employee information, is subject to state, federal and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The privacy and security of personal information stored, maintained, received or transmitted, including electronically, is a major issue in the U.S. and abroad. While we strive to comply with all applicable privacy and security laws and regulations, including, in our case, our own posted privacy policies, legal standards for privacy, including but not limited to &#8220;unfairness&#8221; and &#8220;deception,&#8221; as enforced by the FTC and state attorneys general, these laws and regulations continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose customers, which could have a material adverse effect on our business. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the data-collection activities of various government agencies and in the number of private privacy-related lawsuits filed against companies (including a private right of action under the California Consumer Privacy Act ("CCPA") and other similar state laws, as described below). Concerns about our practices with regard to the collection, use, retention, disclosure or security of personal information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business. Additionally, we receive personal information, including PHI from third parties, and if such third parties breach their representations to us regarding their compliance with applicable privacy and security laws, we could be exposed to proceedings or actions by government agencies or others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous foreign, federal and state laws and regulations govern the collection, dissemination, use and confidentiality of personal information, including genetic, biometric and health information, including state privacy, data security and breach notification laws, federal and state consumer protection and employment laws, HIPAA, GINA, CCPA and foreign data protection laws like the GDPR. These laws and regulations are increasing in complexity and number, may change frequently and sometimes conflict.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The HIPAA privacy, security and breach notification regulations, including the expanded requirements under HITECH, establish comprehensive federal standards with respect to the uses and disclosures of PHI by health plans, healthcare providers, including laboratories, and healthcare clearinghouses, in addition to setting standards to protect the confidentiality, integrity and security of PHI. The regulations establish a complex regulatory framework on a variety of subjects, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a patient&#8217;s rights to access, amend and receive an accounting of certain disclosures of PHI; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to notify individuals if there is a breach of their unsecured PHI; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the contents of notices that must be provided to patients regarding our privacy practices for PHI; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">administrative, technical and physical safeguards required of entities that use or receive PHI; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safeguarding of PHI. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include substantial per violation civil monetary penalties for each provision of HIPAA that is violated up to a statutory cap and, in certain circumstances, significant criminal penalties with fines per violation and potential imprisonment. A single breach can result in findings of violations of multiple provisions, leading to possible penalties in excess of any applicable cap for violations in a calendar year. Any person who knowingly obtains or discloses PHI in violation of HIPAA may face a significant criminal penalty and up to one year of imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm. In addition, responding to government investigations or related third-party private rights of action regarding alleged violations of these and other laws and regulations, even if they ultimately result in no findings of violations or no penalties imposed, can consume our resources and impact our business and, if public, harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Computer networks are vulnerable to breach and unauthorized persons may in the future be able to exploit weaknesses in the security systems of our computer networks and gain access to PHI. Additionally, we share PHI with third-party contractors, and while they are contractually obligated under business associate agreements to safeguard and maintain the confidentiality of PHI, their indemnification of us would not insulate us from reputational harm. Unauthorized persons may be able to gain access to PHI stored in such third-party contractors&#8217; computer networks. Any wrongful use or disclosure of PHI by us or our third-party contractors, including disclosure due to data theft or unauthorized access to our or our third-party contractors&#8217; computer networks, could subject us to fines or penalties that could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, we could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information or other private personal information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, various states, such as Washington, California and Colorado, have implemented similar privacy laws and regulations (such as the California Confidentiality of Medical Information Act, CCPA and California Privacy Rights Act) that impose restrictive requirements regulating the use and disclosure of personal information, while other states are considering adoption of similar provisions. These laws and regulations are not necessarily preempted by HIPAA, but they have a wider scope and afford greater protection to individuals than HIPAA. Where state laws are more protective, we and our collaborators must comply with the stricter provisions where they apply. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our customers and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy, security and data use issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our immune medicine platform and related products and services could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as PHI, along with increased customer demand for enhanced data security infrastructure, could greatly increase the cost of providing our products and services, decrease demand for our products and services, reduce our revenue and subject us to additional liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently operate in some and may eventually operate in additional countries outside of the U.S. whose laws may in some cases be more stringent than the requirements in the U.S. For example, the GDPR imposes strict rules on the transfer of personal data out of the EU to the U.S., and the obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practice. In addition, some countries have stricter consumer notice or consent requirements relating to personal data collection, use or sharing, have more stringent requirements relating to organizations&#8217; privacy programs and provide stronger individual rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, international privacy and data security regulations are becoming more complex and may result in greater penalties. For instance, the GDPR governs the collection and use of personal data of data subjects in the EU and the EEA. The GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to obtain consent or other legal bases from individuals to process their personal data, provide robust disclosures to individuals, accommodate a set of individual data rights, provide data security breach notifications after becoming aware of the breach, limit retention of personal information and apply enhanced protections to health data and other special categories of personal data. The GDPR also applies to pseudonymized data, which is defined as &#8220;the processing of personal data in such a way that the data can no longer be attributed to a specific data subject without the use of additional information,&#8221; and imposes additional obligations when we contract with third-party processors in connection with the processing of any personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data, could cause our costs to increase and could harm our financial condition. Compliance with the GDPR requires us to put in place and maintain additional policies, procedures and documentation as the law and updates to it require, which may result in other substantial expenditures. This may be onerous and adversely affect our business. Failure to comply with the GDPR and other countries&#8217; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payors, and have an adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the GDPR, we continue to expand our business into several countries that have or are developing data privacy laws. Compliance with such laws may be onerous and adversely impact expansion of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, within the U.S., an increasing number of states and the federal government are considering or have proposed adoption of new data privacy laws. While not all of these bills become law, they add significant uncertainty about additional obligations or potential penalties which we may face in conducting our business. These uncertainties are confounded by parallel changes in laws adjacent to privacy, such as those impacting machine learning and artificial intelligence or data use, and we may incur substantial expense or experience disruption as related to compliance with these laws, which would adversely affect our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Security and cybersecurity breaches, loss of data and other disruptions could compromise confidential, personal and sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we and our collaborators collect and store sensitive data, including PHI, personal information, financial information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, third-party payors, our collaborators, government entities, insurance companies and other parties. We manage and maintain our applications and data through a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage components of our data centers. We also transmit sensitive data, including patient data, telephonically, through our website and pursuant to arrangements with multiple third-party vendors and their subcontractors. These applications and data encompass a wide variety of critical business information, including research and development information, patient data, commercial information and financial information. We face a number of risks related to protecting this critical information, including loss-of-access risk, unauthorized access, use, disclosure or modification, and the risk of our inability to adequately monitor, audit and modify our respective control over our critical information. This risk extends to the data we entrust to the third-party vendors and subcontractors that help us manage this sensitive data or otherwise process it on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive and proprietary data from unauthorized access, use or disclosure, no security measures can be perfect and our respective information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, such as HIPAA or HITECH, and regulatory penalties. Notice of breaches may be required to be provided to affected individuals, the Secretary of HHS or other federal, state and foreign regulators, the media or state attorneys general. Such a notice could harm our reputation and ability to compete. Although we have implemented security measures and formal, dedicated enterprise security programs to prevent unauthorized access to patient and other personal data, including policies and procedures to safeguard us from various types of cybersecurity threats, such data is currently accessible through multiple channels and we may experience one or more data or cybersecurity breaches. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, which could adversely affect our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a growing number of states and countries are considering or have adopted cybersecurity requirements for cloud-based provision of services which we may be required to comply with as a condition of doing business with government-affiliated organizations, such as state universities. Implementation of the controls required by such laws can be onerous and may affect our ability to provide services to government-affiliated organizations in such states, adversely affecting our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No TCR-based cellular therapies have been approved in this new potential category of medicines and may never be approved as a result of efforts by others or us. TCR-based cellular therapy drug discovery has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of immune medicines.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a potential new category of medicines, no TCR-based cellular therapies have been approved to date by the FDA or other regulatory agency. Successful discovery and development of TCR-based cellular therapies by us and our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our and their control. We and our collaborators have made and will continue to make a series of business decisions and take calculated risks to advance our development efforts and pipeline of immune-driven therapeutic product candidates, including those related to TCR-based cellular therapies, delivery technology and manufacturing processes, which may be shown to be incorrect based on further work by us, our collaborators or others. Our cellular therapeutics product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds or fail to reach the market for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discovery efforts identifying potential TCR-based cellular therapies may not be successful; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nonclinical or preclinical study results may show potential TCR-based cellular therapies to be less effective than desired or to have harmful or problematic side effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials may fail to meet one or more endpoints, or results may show the TCR-based cellular therapies to be less effective than expected or to have unacceptable side effects or toxicities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effects relating to any one of our therapeutic product candidates or adverse effects relating to our therapeutics discovery process may lead to delays in or termination of one or more of our products or services; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of our translational models to reduce risk or predict outcomes in humans, given that each component of our therapeutic product candidates may have a dependent or independent effect on safety, tolerability and efficacy, and that such effects may, among other things, be species-dependent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing failures or insufficient supply of current good manufacturing practices (&#8220;cGMP&#8221;) materials for future clinical trials, or higher than expected cost, could delay or set back clinical trials or make TCR-based cellular therapies commercially unattractive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaborators&#8217; improvements in the manufacturing processes for this new class of potential immune medicines may not be sufficient to satisfy the clinical or commercial demand of our jointly developed TCR-based cellular therapies or regulatory requirements for clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes that we or our collaborators make to optimize manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability and efficacy of our therapeutic products in development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing or reimbursement issues or other factors that delay clinical trials or make any TCR-based cellular therapies uneconomical or noncompetitive with other therapeutic products; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to timely advance our or our collaborators&#8217; therapeutic products or receive the necessary regulatory clearances, authorizations or approvals or a delay in receiving such clearances, authorizations or approvals due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, Biologics License Application or the equivalent application, discussions with the FDA or the European Medicines Agency, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proprietary rights of others and their competing products and services that may prevent our TCR-based cellular therapies from being commercialized or threaten future commercialization activities. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be adversely affected by violations of the FCPA and other worldwide anti-bribery laws.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we expand geographically, commercialize our products and services, and attempt to obtain required clearances, authorizations or approvals required to offer products and services for sale, we or our collaborators may be deemed to do business outside the U.S., including because international customers may be able to order our products and services. As a result, we or our collaborators would be subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, our collaborators or any third-party distributors could be deemed to be our agents and we could be held responsible for their actions, including violations of the FCPA. Other U.S. companies in the life sciences industry have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with non-U.S. government officials. We may also become subject to similar anti-bribery laws in the jurisdictions in which we may operate, including the United Kingdom&#8217;s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws. Accordingly, our expansion internationally will demand a high degree of vigilance, and any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition or results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Relating to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining sufficient intellectual property protection for our products, services and technologies and uses thereof, and the scope of the intellectual property protection obtained may not be sufficiently broad.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other companies engaged in the life sciences industry, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or license from third parties, particularly patents, in the U.S. and other countries with respect to our products, services and technologies. We rely on patent protection in addition to trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or enable us to gain or maintain any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate barriers to competition, our competitive position could be adversely affected, as could our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply for and have in-licensed patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents is costly, time-consuming and complex, and we may fail to apply for patents on important products, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications or to maintain the rights to patents licensed from third parties. Consequently, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we own or have rights to 416 active patents and patent applications filed in the U.S., Europe and elsewhere. Of these, there are 70 pending patent applications. Our pending patent applications may not result in issued patents in a timely fashion or at all. Even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is also possible that others will design around our current or future patented technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our patents, licensed patents or patent applications may be challenged in the future, and we may not be successful in defending any such challenges. For example, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights. Any successful third-party challenge to our patents could result in patent claims being narrowed, or patents being invalidated or held unenforceable, in whole or in part, which could lead to increased competition to our business. Conversely, we may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or services. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Inconsistent policies regarding the eligibility for patent protection and the breadth of patentable claims in such companies&#8217; patents has emerged to date in the U.S. or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of diagnostic methods and biological molecules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of companies engaged in the development and commercialization of clinical diagnostic tests (like our clonoSEQ diagnostic test) and of biologic material (such as TCRs) are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the eligibility and scope of patentability of certain inventions or discoveries relating to certain diagnostic tests, naturally-occurring molecules and related technology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular immune receptors and cancer) may not be patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of our clinical diagnostics would be considered natural laws. The evolving case law in the U.S. may adversely affect our ability to obtain patents or defend patents we have obtained or have licensed and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign countries do not protect intellectual property rights to the same extent or for the same subject matter as the laws of the U.S., and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on our products and services in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or in interpretations of patent laws in the U.S. or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, a third party that files a patent application before us could be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our products or services or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may also submit prior art to the USPTO during patent prosecution to attack the validity of a patent and it is also possible in the U.S. and other countries for third parties to challenge granted patents through Patent Office proceedings such as, in the U.S., post-grant review, inter partes review and derivation proceedings. In the U.S., a lower evidentiary standard is imposed in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim. As such, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent U.S. Supreme Court rulings have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including with respect to naturally occurring biological molecules such as the immune cell receptors which are a focus of our immune medicine platform. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents covering our products and services could be found invalid or unenforceable if challenged.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the U.S. and abroad, in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products or technologies, the defendant could counterclaim that the patent covering our product is invalid or unenforceable. In patent litigation in the U.S., counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. In addition, the U.S. now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our immune medicine platform, products and services. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#8217;s attention and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on a third party license in relation to certain sequencing technology and if we lose these licenses then we may be subjected to future litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to a license agreement that grants us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. Some of those licensed rights could provide us with freedom to operate for aspects of our products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success may depend in part on the ability of our licensor to obtain, maintain and enforce patent protection for our licensed intellectual property. Our licensor may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether, and the extent to which, our products, services, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreement under which we currently license intellectual property or technology from third parties is complex and certain provisions in such agreements may be susceptible to multiple interpretations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, collaborators, academic institutions, life sciences research partners and, when needed, our advisers as well as other third parties. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Besides the possibility that these security measures could be breached, such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may also not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain former employees have obtained employment with companies or academic institutions that could be considered competitive with us. This competition may be limited by contractual provisions which may or may not be enforceable by us in certain jurisdictions. In addition, we may not be aware of such competitive employment arrangements until after our trade secrets have been disclosed to potentially competitive companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ, and expect to employ in the future, individuals who were previously employed at universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect and enforce our trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered Adaptive Biotechnologies, our corporate logo, clonoSEQ, pairSEQ and other trademarks in the U.S., the EU and a number of other countries and are seeking to register additional trademarks, including our new corporate logos and certain slogans. As we apply to register our unregistered trademarks in the U.S. and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In certain countries outside of the U.S., trademark registration is required to enforce trademark rights. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Ownership disputes may arise, for example, from conflicting obligations of employees, consultants or others who are involved in developing our future products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation may be necessary to defend against these and other claims by a third party challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product or services. Alternatively, we may need to obtain one or more additional licenses from the third party which will be time-consuming and expensive and could result in substantial costs and diversion of resources and could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our development and commercialization efforts of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the life sciences, clinical diagnostics and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings, ex parte reexaminations, post-grant review and inter partes review, as well as corresponding proceedings in foreign courts and foreign patent offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our industry expands, more patents are issued, the number of products or services increases and the level of competition in our industry increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of our business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses) or royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we move into new markets and expand our products or services offerings, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. Given that clinical diagnostics and drug discovery fields are intense and highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our immune medicine platform, products and services. One or more third-party patent owners or licensees may pursue or threaten to pursue litigation against us to enforce one or more patents. It would be costly and time-consuming to defend such claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future products, technologies and services may infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products or services infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorneys&#8217; fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products and services for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products and services are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new products and services, patents protecting such products and services might expire before or shortly after such products and services are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Relating to our Common Stock and Capital Structure</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock is volatile and is likely to continue to fluctuate substantially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock has been and is likely to continue to be highly volatile, with a 52-week high closing price of $8.52 and a 52-week low closing price of $2.34, in each case as of February 26, 2025, and may fluctuate substantially due to many factors, many of which are beyond our control. These factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement or termination of our collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of achievement of specified milestones in the development of our products and services; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introductions of new or expanded products or services or new pricing policies by us or by our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the status of our regulatory clearances, authorizations, approvals or applications, or those jointly developed with our collaborators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">where required, the results of clinical trials of our future products and services, those jointly developed with our collaborators or those of our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, collaborators or divestitures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in governmental regulations and regulatory or legal developments in the U.S. and other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the life sciences, clinical diagnostics or drug discovery industry; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our securities, including sales by our directors, officers or significant shareholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">speculation about our business in the media or the investment community; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other factors, including factors unrelated to our operating performance or the operating performance of our competitors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. If the market for stock in our industry or the stock market in general experiences uneven investor confidence, the market price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. The market price of our common stock might also decline in reaction to events that affect other companies within, or outside, our industry even if these events do not directly affect us. Any decline in the market price of our common stock may impair our ability to raise capital through the sale of equity securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation, if instituted against us, could result in substantial costs to us and divert our management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Purchase Agreement with OrbiMed could limit cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations under the Purchase Agreement could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring the dedication of a portion of our cash flow from operations to service the Purchase Agreement obligations, which will reduce the amount of cash available for other purposes, and if our cash inflows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay additional investments in our operations or seek additional capital;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increasing our vulnerability to adverse economic and industry conditions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limiting our ability to obtain additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we fail to comply with the terms of the Purchase Agreement, resulting in an event of default that is not cured or waived, the Purchasers could seek to enforce their security interest. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Purchase Agreement contains customary affirmative and negative non-financial covenants and events of default, including covenants and restrictions that, among other things, grant a first-position security interest in our core assets and restrict our ability to incur liens, incur additional indebtedness, make loans and investments, make certain restricted payments or transfer core assets. Additionally, the Purchasers under the Purchase Agreement have an option (the "Put Option") to terminate the Purchase Agreement and to require us to repurchase future Revenue Interests at a price of 120% to 175% of Cumulative Purchaser Payments, less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, upon enumerated events such as a bankruptcy event, a material judgment against us, a material divestiture or a change of control. The triggering of the Put Option, including by our failure to comply with these covenants, could permit the Purchasers to declare certain amounts to be immediately due and payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, industry group or the general or financial press, our stock price may decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock and potentially impair our ability to raise capital through the sale of equity securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Substantial future sales or perceived potential sales of our common stock or other equity securities in the public market could cause the price of our common stock to decline significantly.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of substantial amounts of our common stock or other equity securities in the public market, particularly by our directors, executive officers and significant shareholders, including upon the expiration of any lock-up periods entered into in connection with offerings of our common stock or other equity securities, or the perception that these sales could occur, could materially and adversely affect the price of our common stock and impair our ability to raise capital through the sale of equity securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.551%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our compliance with Section 404 necessitates that we incur substantial accounting expense and expend significant management efforts. We will continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also required to maintain disclosure controls and procedures. Disclosure controls and procedures means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. We do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. We believe a control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (&#8220;ESG&#8221;) matters, may expose us to reputational and other risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors, shareholders, customers, suppliers and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. In particular, third party proxy advisory services which focus on shareholder rights provisions, such as majority voting, annual election of directors, and overboarding of outside directors, have recommended against voting for our directors in past elections as a result of our governance profile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition and/or stock price of a company being materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business, or certain shareholders reducing or eliminating their holdings of our stock. Additionally, an allegation or perception that we have not taken sufficient action in these areas could negatively harm our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies across all industries are facing increasing scrutiny relating to their ESG policies. If we are perceived to have not responded appropriately to the growing concern for governance issues, investors may reconsider their capital investment as a result of their assessment of our practices, and our reputation, business, financial condition, results of operations and cash flows may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our charter documents and Washington law could make an acquisition of our company more difficult and limit attempts by our shareholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated articles of incorporation (&#8220;Articles of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;), as well as Washington law, contain provisions that may have the effect of deterring takeovers or delaying or preventing a change in control of us or changes in our management that a shareholder might deem to be in his or her best interest. Our Articles of Incorporation and Bylaws contain provisions that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without shareholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create a classified board of directors whose members serve staggered three-year terms, with one class being elected each year by our shareholders; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that special meetings of our shareholders can be called only by our board of directors, the Chairperson of our board of directors, our chief executive officer or our president; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that a director may only be removed from the board of directors for cause and then only by the affirmative vote of our shareholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that only our board of directors may change the size of our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that no shareholder is permitted to cumulate votes at any election of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expressly authorize our board of directors to modify, alter or repeal our Bylaws; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.462824270053186%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our Articles of Incorporation and Bylaws. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management or our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in the State of Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act (&#8220;WBCA&#8221;), which prohibits certain business combinations between us and certain significant shareholders unless specified conditions are met. These provisions may also have the effect of delaying or preventing a change in control of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our Articles of Incorporation or Bylaws or Washington law that has the effect of delaying or deterring a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Articles of Incorporation provide that the state courts located in King County, Washington and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Articles of Incorporation provide that, unless we consent in writing to the selection of an alternative forum, the state courts located in King County, Washington (or, if the state courts located within King County, Washington do not have jurisdiction, the federal district court for the Western District of Washington) shall be the sole and exclusive forum for commencing and maintaining any proceeding (1) asserting a claim based on a violation of a duty under the laws of the State of Washington by any of our current or former directors, officers or shareholders in such capacity, (2) commenced or maintained in the right of our corporation, (3) asserting a claim arising pursuant to any provision of the WBCA, our Articles of Incorporation or our Bylaws (as either may be amended from time to time) or (4) asserting a claim concerning our internal affairs that is not included in clauses (1) through (3) above, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Articles of Incorporation provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), subject to applicable law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our shareholders will not be deemed to have waived our compliance with these laws, rules and regulations. These exclusive-forum provisions may limit a shareholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees or cause shareholders to incur additional costs to bring claims in the forums designated in our Articles of Incorporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a court were to find these exclusive-forum provisions in our Articles of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a jurisdiction other than those designated in the exclusive forum provision, and the provision may not be enforced by a court in that jurisdiction. It is unclear whether Washington courts would reach a similar conclusion under Washington law. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Articles of Incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Washington law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as permitted by Section 23B.08.510 through Section 23B.08.570 of the WBCA, our Articles of Incorporation and our indemnification agreements that we have entered into with most of our directors and officers provide that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Washington law. Washington law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rights conferred in our Articles of Incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not retroactively amend our Articles of Incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business, and do not anticipate paying any cash dividends on our common stock for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Un</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resolved Staff Comments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b6f88ed-21a3-49fc-b0ee-c7bd08c0c3e3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As trusted partners to healthcare providers, patients, biopharmaceutical companies, academic and non-profit institutions, business partners and employees, we appreciate the importance of maintaining a comprehensive and trustworthy information security program. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55533769-fbf9-459f-8575-690528b8fb2a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true" continuedAt="F_55533769-fbf9-459f-8575-690528b8fb2a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security program is fully </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae1950d8-c9ea-4697-9097-fcb1c3b89c91" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our operations, and a hallmark of our program is its cross-functional approach with our internal privacy objectives and stakeholders.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_55533769-fbf9-459f-8575-690528b8fb2a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is based on the ISO 27001 security controls set, and in particular, it focuses on the principles of confidentiality, integrity and availability. We maintain an ISO 27001 certification with a fully integrated set of operational policies and procedures to adhere to the domains of ISO 27001. This includes but is not limited to the organization of information security to assign roles and responsibilities within Adaptive, access control to restrict employees&#8217; access to view only that information that is relevant to their roles, information security incident management, and compliance to broadly ensure alignment with applicable laws and regulations.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2da873c3-95af-4e99-8d63-42081b23ddb6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We perform an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dc36e81-09fd-4156-a1ad-8f638f9013b6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annual risk assessment conducted by an outside assessor and conduct vendor risk assessments for third party vendors</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to evaluate how their systems may impact our business in the event of a cybersecurity incident. We also provide annual, mandatory cybersecurity training for employees to equip our workforce with the knowledge to identify and respond to cybersecurity threats, such as phishing attempts.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_880e8c03-a194-4f36-9ce4-2475b6262d66" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><div><ix:nonNumeric id="F_25f38f39-e87d-4e8e-8c1a-9bb7b9e76042" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#8220;PISSC&#8221;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c47f4e2-bfc4-436c-ba62-ee84d45d2e24" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PISSC is made up of our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fb3143a-04c5-4e95-ba92-3f658369f9fa" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.</span></ix:nonNumeric></span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_7aa61e2e-bed4-4645-a840-acf64406096e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38dbc03f-84a4-4d72-8eec-84a338b91b5d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b7bf0f3-4759-4549-aa9f-50d43f401a82" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2efbdb09-76d3-4d21-9b59-8989ad4aa50d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding our information security and privacy governance and reports on information security and privacy incidents.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cybersecurity threats, including as a result of any past cybersecurity incidents</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9474a859-55c4-4dbd-8f53-b9dd9cfda404" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#8220;Risk Factors&#8221; section.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters is located in Seattle, Washington, where we lease approximately 100,000 square feet. The lease expires in August 2033, subject to our option to twice extend the lease for five years. In a separate Seattle, Washington location, we lease approximately 65,500 square feet pursuant to a lease that expires October 2032, subject to our option to twice extend the lease for five years. Both of our Seattle, Washington locations contain office and laboratory space.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also lease approximately 27,000 square feet of a warehouse in Bothell, Washington. The lease expires in October 2031, subject to an early termination option in 2028 and an option to twice extend the lease for five years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we lease approximately 33,300 square feet of laboratory and office space in South San Francisco, California, pursuant to an amended lease that expires March 2026, subject to our option to extend the lease for five years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock began trading on The Nasdaq Global Select Market under the symbol &#8220;ADPT&#8221; on June 27, 2019. Prior to that date, there was no public trading market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 26, 2025, there were approximately 73 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We do not intend to pay cash dividends to our shareholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our future ability to pay cash dividends on our common stock may also be limited by the terms of any future debt securities, preferred stock or credit facility.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The graph below compares the cumulative total shareholder return on our common stock with the cumulative total return on the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes $100 was invested in our common stock at the market close on June 27, 2019, which was our initial trading day. Data for the NASDAQ Composite Index and the NASDAQ Biotechnology Index assume reinvestment of dividends. The offering price of our common stock in our initial public offering, which had a closing stock price of $40.30 on June 27, 2019, was $20.00 per share. The stock price performance below is based on historical data and is not necessarily indicative of, nor intended to forecast, future performance of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img64161509_3.jpg" alt="img64161509_3.jpg" style="width:582px;height:286px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This graph shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of Adaptive Biotechnologies Corporation under the Securities Act or the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. [Re</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">served]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated financial statements and related notes and the other financial information appearing elsewhere in this Annual Report on Form 10-K, as well as the other financial information we file with the Securities and Exchange Commission (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">) from time to time. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties relating to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This section generally discusses 2024 and 2023 items and year-to-year comparisons between 2024 and 2023. Discussions of 2022 items and year-to-year comparisons between 2023 and 2022 may be found in Part II, Item 7 under the caption </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 29, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients. Our existing and future commercial products and services are aligned to two business areas which we refer to as MRD and Immune Medicine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current product and service offerings in MRD related to the MRD market are our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ or MRD assay, offered to biopharmaceutical partners to advance drug development efforts. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the FDA for the detection and monitoring of MRD in patients with MM, B cell ALL and CLL, and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers, including DLBCL and MCL. In the fourth quarter of 2024, we obtained Medicare coverage for MCL and initiated promotional efforts in MCL. We also recently obtained a new Medicare CLFS rate of $2,007 per test for clonoSEQ and MolDX updated the clonoSEQ episode pricing to $8,029 for all covered indications. This represents a 17% increase from the previous episode price and the previous implied per test rate under the episode structure. With the use of clonoSEQ, we are transforming how lymphoid cancers are treated by working with providers, pharmaceutical partners and payors. In an effort to enable easier test ordering, we have worked to integrate the clonoSEQ&#8239;clinical diagnostic test via Epic's comprehensive EMR system into the records systems of numerous accounts, and continue to make more progress.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immune Medicine leverages our proprietary ability to sequence, map, pair and characterize TCRs and BCRs at scale to drive opportunities in cancer and autoimmune disorders. Our immunosequencing technology, which includes our Adaptive Immunosequencing research product, serves as the research and development engine driving our immune medicine platform and generates revenue from biopharmaceutical and academic customers. We are applying AI and machine learning models to map at scale TCR sequences to the diseases they bind to enable our drug discovery efforts. Also in our drug discovery programs, we use our proprietary capabilities to discover new drug targets and leverage our validated TCR and BCR discovery approaches to discover and develop TCR or antibody therapeutic assets. Our drug discovery efforts include the Genentech Agreement under which we support Genentech in the development of cancer antigen-directed TCR-based cancer cell therapies for the treatment of patients with solid tumors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized revenue of $179.0 million and $170.3 million for the year ended December 31, 2024 and 2023, respectively. Net loss attributable to Adaptive Biotechnologies Corporation was $159.5 million and $225.3 million for the year ended December 31, 2024 and 2023, respectively. We have funded our operations to date principally from the sale of convertible preferred stock and common stock, including the sale of common stock in our initial public offering and follow-on offering, and, to a lesser extent, revenue and proceeds from the Purchase Agreement. As of December 31, 2024 and 2023, we had cash, cash equivalents and marketable securities of $256.0 million and $346.4 million, respectively.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restructurings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we implemented various restructuring plans which better aligned our organization to our two operating segments, impacted certain planned software enhancements and resulted in the consolidation of certain research and development workflows, among other things. The software enhancements were primarily associated with our laboratory information management systems. As part of these restructurings, we reduced our workforce, had long-lived assets that were no longer being utilized and vacated certain leased space in South San Francisco, California. In total, we recognized $9.2 million of restructuring costs during the year ended December 31, 2024. Of the $9.2 million restructuring costs recognized, $7.2 million related to impairment charges. The activities related to these restructurings were completed as of December 31, 2024. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information regarding our restructuring expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, in connection with an organizational realignment, we began operating our business as two reportable segments: MRD and Immune Medicine. These segments are organized by market opportunity in commercial diagnostics and drug discovery, respectively. See Note 19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information regarding our segments and the assumptions used to allocate shared expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our MRD and Immune Medicine business areas. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. We disclose our clonoSEQ test volume, which includes the number of clonoSEQ reports and results we have provided to ordering physicians in the U.S. and international technology transfer sites. These volumes do not include sample results from our biopharmaceutical customers or academic institutions utilizing our MRD services. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. We bill commercial, government and medical institution payors based on reports delivered to ordering physicians. Amounts paid for clonoSEQ by commercial, government and medical institution payors vary based on respective reimbursement rates and patient responsibilities, which may differ from our targeted list price. We recognize clinical revenue by evaluating customer payment history, contracted reimbursement rates, if applicable, and other adjustments to estimate the amount of revenue that is collectible.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our research customers, which include biopharmaceutical customers and academic institutions for both our MRD and Adaptive Immunosequencing services, delivery of the respective test results may include some level of professional support and analysis. Terms with biopharmaceutical customers generally include non-refundable payments made in advance of services (&#8220;upfront payments&#8221;), which we record as deferred revenue. For all research customers, we recognize revenue as we deliver sequencing results. From time to time, we offer discounts in order to gain rights and access to certain datasets. Revenue is recognized net of these discounts and costs associated with these services are reflected in cost of revenue. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered. Certain of our MRD revenue arrangements with biopharmaceutical customers include cash consideration from the achievement of regulatory milestones of the respective biopharmaceutical customers&#8217; therapeutics. Such revenue is constrained from recognition until it becomes probable that such milestone will be achieved.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain agreements with our biopharmaceutical customers who seek access to our platform to support their therapeutic development activities, revenues are generated from research and development support services that we provide. These agreements may include substantial non-refundable upfront payments, which we recognize over time as we perform the respective services. Revenue recognized from these activities relate primarily to the Genentech Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our MRD revenue to increase in the long term as we continue to increase our MRD clinical testing volume through enhanced penetration in our existing covered patient populations, expand into new patient populations and optimize payor coverage. Our MRD revenue may fluctuate period to period due to the uncertain timing of receipt of our biopharmaceutical customer samples, which may cause uncertainty in the delivery of our products and services, the recognition of milestones related to regulatory approvals of our biopharmaceutical customers&#8217; therapeutics and changes in estimates of our clinical revenue reimbursement rates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our Immune Medicine revenue to increase in the long term as we or our collaborators advance therapies to commercialization. Our Immune Medicine revenue may fluctuate from period to period due to the timing of expenses incurred, changes in estimates of total anticipated costs related to the Genentech Agreement and other events not within our control, including the recognition of milestones under the Genentech Agreement and the timing of receipt of customer samples from our biopharmaceutical customers.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition. As such, cost of revenue and related volume does not always trend in the same direction as revenue recognition and related volume. Additionally, costs to support the Genentech Agreement are a component of our research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect cost of revenue to increase in absolute dollars in the long term as we grow our sample testing volume, but the cost per sample to decrease over the long term due to the efficiencies we may gain as assay volume increases from improved utilization of our laboratory capacity, automation and other value engineering initiatives. If our sample volume throughput is reduced, cost of revenue as a percentage of total revenue may be adversely impacted due to fixed overhead costs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. We are currently conducting research and development activities for several products and services and we typically use our laboratory materials, personnel, facilities, information technology and other development resources across multiple development programs. Additionally, certain of these research and development activities benefit more than one of our product opportunities. We have not historically tracked research and development expenses by specific product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs to support the Genentech Agreement are a component of our research and development expenses. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. Some of these activities have generated and may in the future generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect research and development expenses to decrease in the short term and to decrease as a percentage of revenue in the long term, although the percentage may fluctuate from period to period due to the timing and extent of our development and commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales and Marketing Expenses</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect sales and marketing expenses to increase in the short term. In the long term, we expect sales and marketing expenses to increase in absolute dollars as we increase marketing activities to drive awareness and adoption of our products and services. However, we expect sales and marketing expenses to decrease as a percentage of revenue in the long term, subject to fluctuations from period to period due to the timing and magnitude of these expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for our personnel in executive, legal, finance and accounting, human resources and other administrative functions, including third-party clinical billing services. In addition, these expenses include insurance costs, external legal costs, accounting and tax service expenses, consulting fees and allocated facility and information technology costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect general and administrative expenses to moderately increase in the short term and to decrease as a percentage of revenue in the long term.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets expenses include our impairment charges for certain leased office and laboratory space, related long-lived assets (including leasehold improvements and laboratory equipment) and long-lived assets associated with our halted software enhancements. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details regarding our impairment assessments and considerations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability related to the Purchase Agreement and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Operations Data and Other Financial and Operating Data</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our statements of operations data and other financial and operating data for the periods presented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Statements of Operations Data:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,957</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,276</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,308</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,080</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,553</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,909</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,953</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,117</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,756</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,759</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,579</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,603</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,806</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,934</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,527</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,703</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,699</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,699</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,205</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">341,506</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,311</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,494</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(162,549</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(227,035</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(200,186</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,534</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,531</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,056</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,580</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,800</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,238</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(159,595</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(225,304</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(200,368</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: Net loss attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(159,492</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(225,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(200,191</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.08</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.56</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.40</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,101,648</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,383,294</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,515,917</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Financial and Operating Data:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,371</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(116,413</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(121,589</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense and share-based compensation expense. See &#8220;Adjusted EBITDA&#8221; below for a reconciliation between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.92%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.880000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.119999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.140000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.140000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MRD revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,029</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,290</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total MRD revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,529</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,790</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Immune Medicine revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,976</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,959</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,983</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,452</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,578</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,126</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(68</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,428</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,537</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(34,109</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(51</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,957</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,276</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,681</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* Not applicable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $42.8 million increase in MRD revenue was primarily due to a $26.3 million increase in revenue generated from providing clonoSEQ to clinical customers, a $12.5 million increase in revenue recognized upon the achievement of regulatory milestones by certain of our biopharmaceutical customers, and a $5.8 million increase in revenue generated from providing MRD sample testing services to biopharmaceutical customers. These increases were partially offset by a $1.6 million decrease in revenue generated from providing MRD sample testing services to investigator-led clinical trials. Our clonoSEQ test volume increased by 35% to 76,105 tests delivered in the year ended December 31, 2024 from 56,496 tests delivered in the year ended December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $34.1 million decrease in Immune Medicine revenue was primarily due to a $29.1 million decrease in revenue generated from the Genentech Agreement, which resulted from decreased collaboration expenses and decreased revenue recognized from the $10.0 million regulatory milestone achieved in May 2023, and a $5.0 million decrease in revenue generated from our biopharmaceutical and academic customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:7.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.161%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,080</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,553</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,473</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $3.5 million decrease in cost of revenue was primarily attributable to a $10.4 million decrease in overhead costs, which was largely driven by laboratory relocation and consolidation activities. This decrease was partially offset by a $3.2 million increase related to higher usage of our production laboratory to process revenue samples versus research and development samples, a $2.8 million increase in cost of materials, $2.5 million of which resulted from increased revenue sample volume and $0.3 million of which was primarily related to an increase in inventory reserve expense, and a $0.4 million increase in shipping and handling expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:7.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.161%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,953</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,117</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,164</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16)%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents disaggregated research and development expenses by cost classification for the periods presented:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.32%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development materials and allocated production laboratory expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,844</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,243</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,399</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,742</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,385</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,643</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocable facilities and information technology expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,839</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,617</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(778</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software and cloud services expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,908</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,394</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,514</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and other expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,620</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,478</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,858</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,953</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,117</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,164</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $19.2 million decrease in research and development expenses was primarily attributable to an $11.6 million decrease in personnel costs and a $4.4 million decrease in laboratory materials and allocated production laboratory expenses, which was driven primarily by decreased investments in drug discovery efforts, including collaboration efforts with Genentech, and decreased investments in TCR-antigen binding development activities, partially offset by an increase in investments related to the MRD business. There was also a $3.9 million decrease in depreciation and other expenses, inclusive of a $2.6 million decrease in costs related to collaboration studies primarily related to Immune Medicine, and a $0.8 million decrease in allocable facilities expenses. These decreases were partially offset by a $1.5 million increase in software and cloud services expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales and Marketing</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:7.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.161%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,759</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,579</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,820</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $3.8 million decrease in sales and marketing expenses was primarily attributable to a $4.1 million decrease in personnel costs and a $2.0 million decrease in marketing expenses, which was largely driven by reduced clonoSEQ marketing activities, followed by reduced research and corporate marketing activities. There was also a $0.8 million decrease in travel and customer event related expenses. These decreases were partially offset by a $2.1 million increase in computer and software expenses and a $1.1 million increase in allocated facility and overhead expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:7.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.161%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,806</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,934</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,128</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13)%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $11.1 million decrease in general and administrative expenses was primarily attributable to a $5.7 million decrease in personnel costs, a $3.0 million decrease in building, facility, overhead and depreciation related expenses largely driven by office space transitions made to support laboratory consolidation activities, a $1.8 million decrease in legal fees, a $1.1 million decrease in insurance costs and a $0.9 million decrease in consultant costs. These decreases were partially offset by a $1.7 million increase in third-party billing service fees.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.901%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:7.702%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.161%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,205</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,224</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72)%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* Not applicable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $18.2 million decrease in impairment of long-lived assets expenses was primarily due to a $25.4 million decrease in impairment costs related to us vacating certain leased space in Seattle, Washington in October 2023, which was partially offset by a $7.2 million increase in impairment costs resulting from various restructuring activities implemented in 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and Other Income, Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.12%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:9.68%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,534</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,531</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(997</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $1.0 million decrease in interest and other income, net was primarily attributable to a decrease in net interest income and investment amortization driven by decreased holdings of and interest rates pertaining to our cash, cash equivalents and marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.12%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:9.68%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,580</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,800</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,220</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $2.2 million decrease in interest expense was attributable to a change in our assumptions regarding the timeframe in which our Purchase Agreement will be fully repaid.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Adjusted EBITDA</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.129%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.8580000000000005%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.8580000000000005%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.8580000000000005%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.459%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MRD Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,223</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(88,844</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,621</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54)%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Immune Medicine Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,005</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,128</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,877</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Adjusted EBITDA&#8221; below for an explanation of how it is calculated and used by management. Adjusted EBITDA related to our unallocated corporate category is included in the calculation of consolidated Adjusted EBITDA but not shown above in the breakout of segment Adjusted EBITDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $47.6 million reduction in MRD Adjusted EBITDA deficit was primarily attributable to a $42.8 million increase in MRD revenue and a reduction in operating expenses, excluding those identified as reconciling items between net loss and adjusted EBITDA. The primary driver of the operating expense reduction relates to general and administrative activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $11.9 million increase in Immune Medicine Adjusted EBITDA deficit was primarily attributable to a $34.1 million reduction in Immune Medicine revenue, which was partially offset by a reduction in operating expenses, excluding those identified as reconciling items between net loss and adjusted EBITDA. The primary driver of the operating expense reduction relates to research and development activities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense and share-based compensation expense. We define our segment Adjusted EBITDA in the same way to the extent the net loss attributable to Adaptive Biotechnologies Corporation and adjustments are allocable to each segment. See Note 19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information regarding segment Adjusted EBITDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management uses Adjusted EBITDA, including segment Adjusted EBITDA, to evaluate the financial performance of our business and segments and to evaluate the effectiveness of our strategies. We present these figures because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA, including segment Adjusted EBITDA, has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments we make. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA, including segment Adjusted EBITDA, does not reflect:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all expenditures or future requirements for capital expenditures or contractual commitments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in our working capital needs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interest expense, which is an ongoing element of our costs to operate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the noncash component of employee compensation expense;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">long-lived assets impairment costs; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, such as our restructuring activities and reductions in workforce.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Adjusted EBITDA, including segment Adjusted EBITDA, may not be comparable to similarly titled measures used by other companies in our industry or across different industries.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the periods presented (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(159,492</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(225,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(200,191</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,534</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,531</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,056</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,256</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,231</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,920</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,205</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,610</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,908</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,477</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,371</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(116,413</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(121,589</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on the Purchase Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents impairment costs for certain long-lived assets. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our impairment expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents personnel-related expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our restructuring expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our share-based compensation expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred losses since inception and have incurred negative cash flows from operations since inception through the year ended December 31, 2018, and again in the years ended December 31, 2020 through December 31, 2024. As of December 31, 2024, we had an accumulated deficit of $1.3 billion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have funded our operations to date principally from the sale of convertible preferred stock and common stock, and, to a lesser extent, revenue and proceeds from the Purchase Agreement. Pursuant to the Purchase Agreement entered into in September 2022, we received net cash proceeds of $124.4 million, after deducting issuance costs. We are also entitled to receive up to $125.0 million in subsequent installments as follows: (i) $75.0 million upon our request occurring no later than September 12, 2025 and (ii) $50.0 million upon our request in connection with certain permitted acquisitions occurring no later than September 12, 2025, in each case subject to certain funding conditions. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $256.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our available cash, cash equivalents and marketable securities balances and anticipated cash flows are insufficient to satisfy our liquidity requirements, we may request an additional installment under the Purchase Agreement, seek to sell additional equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our shareholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. This additional capital may not be available on reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our commercial and marketing activities associated with clonoSEQ, our continued investments in streamlining our laboratory operations and our continued research and development initiatives related to drug discovery. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to capital preservation and liquidity. Currently, our funds are held in money market funds and marketable securities consisting of U.S. government treasury securities, corporate bonds and commercial paper.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we may experience variability in revenue in the near term, over the long-term we expect revenue from our current and future products and services to grow. Accordingly, we expect our accounts receivable and inventory balances to increase. Our levels of accounts receivable may fluctuate relative to our revenue for a number of reasons, including the timing of milestone triggers and related payment of those milestones, as well as reductions in revenue derived from the upfront payment received under the Genentech Agreement and an increase in revenue generated from clinical customers, which may result in more billings in arrears as opposed to upfront payments. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contractual obligations as of December 31, 2024 include operating lease obligations of $107.6 million, which reflects the minimum commitments for our office and laboratory spaces in Seattle, Washington and South San Francisco, California and our warehouse lease in Bothell, Washington. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information, including the timing of cash payments related to these lease obligations. In connection with certain of our lease agreements, we have $2.1 million in letters of credit with one of our financial institutions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, pursuant to the Purchase Agreement, the Purchasers have a right to receive Revenue Interests from us based on the Applicable Payment Percentage of the Revenue Base. If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base. Revenue Interest Payments shall be made quarterly within 45 days following the end of each fiscal quarter. If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the Cumulative Purchaser Payments on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments. OrbiMed will be entitled to 100% of the Revenue Interest Payments until it has received the Return Cap, unless full repayment of the amount of the Return Cap has not been made by September 12, 2032, in which case the Return Cap shall be increased to 175% of the Cumulative Purchaser Payments. As projected revenues change from our initial estimates, the amount of the obligation and timing of payment is likely to change. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have minimum commitments for laboratory material suppliers, which are generally fulfilled within one year, software and service license commitments, which are generally fulfilled within one to three years, and royalty commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our uses and sources of cash for the years ended December 31, 2024 and 2023 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.392%;box-sizing:content-box;"/>
    <td style="width:2.561%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.243%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.561%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.243%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(95,212</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(156,324</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,792</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,647</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,245</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities during the year ended December 31, 2024 was $95.2 million, which was primarily attributable to a net loss of $159.6 million and a net change in operating assets and liabilities of $17.5 million, partially offset by noncash share-based compensation of $53.6 million, noncash depreciation and amortization of $11.0 million, noncash impairment of long-lived assets of $7.2 million related to our restructuring activities, noncash lease expense of $5.3 million, noncash interest expense related to the Purchase Agreement of $2.6 million and inventory reserve expense of $1.9 million. The net change in operating assets and liabilities was primarily driven by a $10.5 million reduction in deferred revenue driven largely by revenue recognized from the Genentech Agreement, a $9.4 million decrease in operating lease right-of-use assets and liabilities and a $3.7 million increase in accounts receivable, net. These changes were partially offset by a $5.4 million decrease in inventory and a $0.7 million increase in accounts payable and accrued liabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities during the year ended December 31, 2023 was $156.3 million, which was primarily attributable to a net loss of $225.3 million and a net change in operating assets and liabilities of $46.2 million, partially offset by noncash share-based compensation of $62.9 million, noncash impairment of right-of-use and related long-lived assets of $25.4 million, noncash depreciation and amortization of $13.0 million, noncash lease expense of $6.9 million, noncash interest expense related to the Purchase Agreement of $5.3 million and inventory reserve expense of $1.4 million. The net change in operating assets and liabilities was primarily due to a $29.3 million reduction in deferred revenue driven largely by revenue recognized from the Genentech Agreement, an $8.7 million decrease in operating lease right-of-use assets and liabilities, a $5.4 million reduction in accounts payable and accrued liabilities, a $2.8 million increase in inventory and a $1.9 million increase in prepaid expenses and other current assets driven largely by an increase in prepaid software charges. These changes were partially offset by a $2.0 million decrease in accounts receivable, net.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by investing activities during the year ended December 31, 2024 was $77.8 million, which was primarily attributable to proceeds from maturities of marketable securities of $325.7 million, partially offset by purchases of marketable securities of $244.3 million and purchases of property and equipment of $3.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by investing activities during the year ended December 31, 2023 was $129.6 million, which was primarily attributable to proceeds from maturities of marketable securities of $569.9 million, partially offset by purchases of marketable securities of $429.6 million and purchases of property and equipment of $10.7 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities during the year ended December 31, 2024 was $0.2 million, which was attributable to proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities during the year ended December 31, 2023 was $2.2 million, which was attributable to proceeds from the exercise of stock options.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Operating Loss Carryforwards</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through December 31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2024. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have prepared the consolidated financial statements in accordance with GAAP. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the consolidated financial statements, as well as revenue and expense recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas, including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, imputing interest for the Purchase Agreement, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are critical to the judgments and estimates used in the preparation of the consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenue arrangements may include upfront payments for the performance of services in the future, which have both fixed and variable consideration. Non-refundable upfront fees and funding for related development services are generally considered fixed consideration, while milestone payments are identified as variable consideration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we fulfill our obligations under these agreements, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For our biopharmaceutical customers, our performance obligations may include sequencing services and services associated with regulatory submission and approval processes. Significant management judgment is applied to determine (1) the measurement of the transaction price, including the constraint on variable consideration, (2) the allocation of the transaction price to the performance obligations and (3) the appropriate input- or output-based method to recognize revenue and the extent of progress to date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is not constrained to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To select the measure of progress, we consider the expectations of the performance period which may be based on customer-dependent estimates of samples or internal estimates of the performance period based on both the customer and our expected development timeframes. For our collaboration with Genentech, we estimate the extent of progress using a proportional performance model that uses an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. These estimates are based on our internal estimates and development timeframes, which are subject to revision based on the potential outcomes for both product pathways, decisions made by Genentech, regulatory feedback or other factors not currently known. We regularly review our expectations of the extent of progress, including whether any variable consideration is no longer constrained, and, if any changes in estimates are made, we recognize revenue using the cumulative catch-up method.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements with our commercial payors, the payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities. As such, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 with OrbiMed is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. The estimates of future revenues and resulting Revenue Interest Payments are based on key assumptions including population, penetration, probability of success and sales price, among others. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment. As of December 31, 2024, a hypothetical ten percent</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> increase in forecasted quarterly revenue would not result in a material change in projected annual interest expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1 and upon any occurrence of triggering events or substantive changes in circumstances that could indicate a potential impairment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount. We evaluate certain qualitative factors such as macroeconomic conditions, the market and industry in which we operate, cost factors, overall financial performance and other relevant entity- and reporting unit-specific events to determine if there are any negative trends or events that could indicate impairment. Key assumptions in this analysis include anticipated demand for our products and services, including industry and regulatory changes, revenue growth and financial performance trends. These assumptions are determined based on our historical performance and management&#8217;s forecasted results. Management&#8217;s estimates of forecasted results are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. If we determine that it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the allocated goodwill is reduced to fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have not recognized any impairment of goodwill.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recoverability and Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. To test for recoverability, we compare the carrying amount of the asset or asset group to projected future net undiscounted cash flows. If the carrying amount is found to be unrecoverable, we then assess the asset's or asset group's fair value. We utilize the income approach to measure fair value, which requires management to make estimates regarding cash flow projections and discount rates. The extent to which the asset's or asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. During the year ended December 31, 2024, we recognized $7.2 million in impairment expense related to certain long-lived assets that were impaired in connection with restructuring activities. During the year ended December 31, 2023, we recognized $25.4 million in impairment expense related to certain right-of-use and related leasehold improvement assets. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents and marketable securities. As of December 31, 2024 and 2023, we had cash and cash equivalents of $47.9 million and $65.1 million, respectively, held primarily in cash deposits and money market funds. As of December 31, 2024, we had short-term and long-term marketable securities of $208.0 million, held in U.S. government treasury securities, corporate bonds and commercial paper. As of December 31, 2023, we had short-term marketable securities of $281.3 million, held in U.S. government treasury and agency securities, commercial paper and corporate bonds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the U.S. As of December 31, 2024, a hypothetical 100 basis point increase in interest rates would have resulted in a $1.0 million decline in fair value of our available-for-sale securities, as compared to a $1.2 million decline as of December 31, 2023. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. Such losses would only be realized if we sold the investments prior to maturity. We do not enter into investments for trading purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and_suppleme"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Fin</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ancial Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023 and</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Years Ended December 31, 2024, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(PCAOB ID: </span><span><ix:nonNumeric id="F_ab6b4862-33e0-4377-9461-ec12b3626405" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Shareholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements_december_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Adaptive Biotechnologies Corporation (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 3, 2025 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30.76%;box-sizing:content-box;"/>
    <td style="width:69.24%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Genentech Agreement</span></p></td>
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As more fully described in Note 3 of the consolidated financial statements, the Genentech Agreement revenue is estimated to be recognized over a period of nine to ten years from the effective date. The non-refundable consideration of $310.0 million is recognized using a proportional performance model through an input method based on costs incurred relative to the total estimated costs of research and development efforts. For the year ended December 31, 2024, total revenue recognized was $13.5 million and the related deferred revenue at December 31, 2024 totaled $41.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing management&#8217;s estimate of the total expected research and development costs at completion is complex and requires judgment as a result of the uncertainties of the ultimate development and commercialization decisions, which are controlled by Genentech.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process to evaluate the likely path of future development based on significant decisions made by Genentech communicated through the joint committees and any resulting impacts on the total costs of research and development efforts for the collaboration.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To test the estimate of total expected research and development costs, we performed audit procedures that included, among others, observing the quarterly meetings with accounting and the Company collaboration managers discussing the status of the collaboration and the likely path of future development. We also reviewed supporting documentation to corroborate progress and status of the collaboration, including meeting minutes or summaries from the joint committees.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8125c5e7-066a-41f0-8a52-856a7bcd53b3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2015.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b322f5c2-e366-4c99-935c-5466481163e4" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seattle, Washington</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.25in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance </span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.594%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.622%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.622%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b12acb2d-86b7-42ef-a789-dfabb0cb0044" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,920</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f1d77ce-138e-418a-a065-63208368f832" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,064</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities (amortized cost of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa15377d-187f-411d-978b-af5951fe1e2d" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,186</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a636ed4-a452-4873-acb0-2f41feba611d" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,122</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adf00c88-05c8-43f1-9b01-bac4531dcbef" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1343d625-d672-46db-a923-830813f4e92a" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,337</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367b3f2b-0324-486a-a1b1-066cd1c36f79" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d17e39d7-393a-42b7-a0e7-bf088222df07" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,969</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cd243d6-8feb-48f4-b9cc-0d0accd36b69" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,440</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ff4f23-638c-4d3a-aa34-262432c6f0f7" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b2dea60-672e-42aa-ad87-99a2a0edd5db" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,287</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf964cb-d811-477e-8114-af16ce6c9fe4" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,370</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cba47b3-9f27-46e6-82fc-8a5663bfb6ae" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">283,752</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d57613d4-ae13-4aff-b244-faa34bd8b92e" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410,188</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1828030d-5a9a-40ee-bed1-ec9324df85ca" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,616</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876ccb9b-01d2-43bf-84a1-ecb164b8cb91" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,227</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69a3c76c-fb29-4508-8d00-97e40516bf30" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,767</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b0ca5bc-4e07-4f27-b26d-5861581026d7" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,096</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities (amortized cost of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fba5c33-d799-4ddd-bdae-30d5c343c0b6" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,682</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_146e3399-ef6a-40c4-83dc-bbc085986a84" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,660</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddbaa52-0e5a-4f10-a570-3868082ab5ac" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,897</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6afd20-8042-43a7-98cf-c2887257775f" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,932</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13bd30e8-1189-4aec-8bdd-d2b745f9d555" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,425</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66841e7d-7f57-4a0f-aa95-6a190c7cbdc2" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a363d4d0-94f4-46df-becd-bbe5b586326c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,972</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a55a158e-a346-440c-aa61-52ef791885f3" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,972</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce8e2f5-f89c-4b9b-97c5-5ea619f96f44" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,287</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddd4b66c-d5a7-4dcd-bb4b-42843e5b34fa" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,591</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cf35dbe-8988-40be-8a47-03f671ea09b6" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a272995-6e8a-4139-96be-0de63146bac1" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661,134</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbbd7ff7-a1e7-4c2f-b169-7432089e8a8e" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,265</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24bfb5d5-8e51-40d3-a25c-4d9c821c850a" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,719</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30d63c7d-59ce-4e95-8b8e-2c27102e03ae" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,157</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c40f7d-1a49-4835-91c2-c1f1e2124031" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,597</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e49cb20-4993-4e78-b9f2-4b2e22e68a27" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,838</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71d1087c-003c-4d01-b200-742de7cddf58" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e13a2b87-9800-40db-8915-5d4f6f67df43" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,239</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5c860fd-b83e-4f0e-9555-5b9e39271cd0" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,384</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17c54e3f-ed7d-4f68-b5ae-4c35bc5c1551" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,689</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d4c45bd-52c9-4628-bbd7-43c5bc76de06" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,630</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of revenue interest liability, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f43c2c8-f4c7-4d5b-ac2c-dd7803ab153d" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83dda324-67a1-45ae-9769-f9fd2e7c4100" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,053</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_032e0671-d3ac-4a5b-8963-ae626a929026" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,015</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e252891-8d91-4e22-b3cc-4a4c4ba74cb3" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,148</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5b49d21-f151-49ea-b1ea-9cdf7bc59245" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,388</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue, less current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bce55f9-c97d-476a-b079-87ed4ce4fe25" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,256</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cc5bf6e-8925-45b1-a6f1-26bf9776c0ba" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,793</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net, less current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57fbd79-5f6f-4e6f-b1ea-94ce70f5470c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,414</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1fc7327-79e6-4667-a6f7-c6ec280c10d8" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,660</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_624a5bb2-d003-480e-b3b8-8b13197d21df" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_791ad43b-f76c-45c9-85f7-c626f4f09a1e" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336,891</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02b066c1-455b-4f9b-9bc2-5cb93aacd40f" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352,856</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_eef839ed-813e-4faa-9738-c5a903618713;"><span style="-sec-ix-hidden:F_c58c92e1-6822-4816-bcb5-bc958b91adbe;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Note 12)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock: $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8516796-0827-444e-a3ee-f0878442be4b" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4"><ix:nonFraction id="F_99ed71b5-71e2-4199-906e-fe07556b2304" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13115d43-f5b9-4965-8653-c6ac0d6f4604" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2771fbeb-5e7b-4aca-b890-cf03bd456ee2" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at December 31, 2024 and 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd48479a-db28-4fdb-818f-184bfedab095" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9b16b443-9eff-4d69-8172-caba7b1b65ed" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2766bfeb-85c0-46b3-a727-a94d433bd818" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b835e752-95cd-4023-809b-8ff7c45b8f70" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ae197273-22ff-4091-95b7-abf2afa45c8a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b34944cc-62c5-46f4-b074-a8bc0e8fd618;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock: $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a9d7f22-4a8f-4433-a0d7-4a0c88267d9f" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4"><ix:nonFraction id="F_42776a1f-efbe-417d-97d6-bd17c368ec29" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95df3118-fa73-4bb3-804d-9e340350947e" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6524a096-133b-4666-bc62-2c50ca6bf01a" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">340,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at December 31, 2024 and 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d254c895-ef46-45bf-94b8-69fab1c6989c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_37f9463f-44c3-4a4c-9be6-e68aaa10d2c6" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">147,773,744</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_928b022d-2c21-4e2f-8baa-f8e2730bd12b" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e4e8454-c6c9-4c7e-9d6c-63517646978d" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,082,271</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de885df0-01ff-4303-a723-07e9f1a84592" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_987e92a4-6e8b-4dd4-aae5-52762103ca60" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e238d77-a0fa-4ac9-8b5b-26652d9cb912" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,506,353</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb03746-96cc-4e9d-b99c-7ca00f8b8b17" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,452,502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_657db199-76de-4a24-a8f8-72b9d59c9b29" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e068c2a0-be36-45e8-ac44-666951d0012f" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f69b544-cef5-4c21-8ebc-2861f3dcee25" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,303,824</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce8bf3f8-9e23-4aa0-84bb-8551fb773d48" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,144,332</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Adaptive Biotechnologies Corporation shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8b7d8ca-3815-436c-953b-8db2c746a2bc" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,709</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f14d1337-12bc-45ae-a279-635172e708e3" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,399</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75ba96a4-f05a-43ca-9557-83e860724344" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c41b9a34-37da-49a9-8375-ccbd17850f67" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_553c73d7-08b3-4fda-932f-a393e5681263" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,485</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6a52b4a-7a2a-473e-8787-eb7f8446efb6" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,278</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed210051-1b97-4cab-bda2-4a474a0a4e48" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de1fed0c-0f7d-4f87-a6d7-f44a3da715a3" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661,134</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements o</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.131%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.762%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.762%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.762%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc0d00bd-593a-4858-b826-8e0dbec2b3d5" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,957</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a5b9879-bed1-47cf-a9e7-4a7067a44b4f" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,276</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b06be17b-24cb-4426-b925-f73cfb0805bf" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,308</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a9ec8f4-6c09-4c80-b107-b65de1f84517" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,080</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bc59b55-d570-49a5-85ce-5f6b13c264ad" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,553</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3412f8ea-73d4-483b-86cf-878a464f479c" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,909</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56c887ed-f4d8-496e-85e3-ff4e632137c9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,953</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d56c660-14e2-4837-8f38-d514f617124e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,117</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd324f99-b8d4-4d0c-b255-6e6638f417d1" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,756</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a45230cd-4574-43bf-b650-081f9baf451b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,759</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e701c86a-f7e1-47c5-95fb-d21871351fe7" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,579</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bef76ac-e196-4364-9227-776c375adb4f" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,603</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20df25e3-b4e8-4999-bc0b-8242bd3db0c6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,806</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_790ace4e-3493-4180-a92e-26eef2b50acc" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,934</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c1f3243-0ecf-41e7-ad98-1b9266c0e402" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,527</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_190edab8-2bec-409e-b915-4dff954c7ee8" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,703</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c030725d-74b5-4e8c-889f-fbd22d32075c" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65b83756-a614-437d-b024-4222a3b5f80d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d956cf78-5ea4-42d6-9cfc-f4b0631d96b9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,205</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b1fea4-38ea-44c2-a1ec-23590227dab4" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,429</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09dc8cce-8f2e-478a-a862-f82082bb137d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341,506</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1196de10-5b8c-4a8a-af89-6e410f9e6fdf" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,311</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f66f43f2-d2ac-40bd-8eb1-89318fcd2770" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,494</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f421e8b-3db9-4660-9aa5-5a0aa53084dc" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">162,549</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c3283cd-a777-4b90-8d9e-d2c6fdcd12f7" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">227,035</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91bb1c6e-2608-4249-9787-aee69e7c5639" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1b64ee3-79a0-4359-a398-b59dcac7a42a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,534</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7b94c5c-702e-49c9-8460-98083c097710" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6944338-9456-4497-b4a3-b2ddefaaf31e" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,056</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4569ac3e-a273-4ff9-84e0-e23ae48c2c57" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,580</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a43f7f7-d0e3-486e-8999-4850abecacf5" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,800</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d737adf-fa0e-449a-b01a-efe3f7e88f3a" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,238</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e71fd1c4-4851-4f37-bbb5-6098419392de" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,595</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65a641ee-2957-47e9-9b62-9bce8139d13d" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c6c07f4-5a31-409a-828b-6dcf7986e5b2" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: Net loss attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ea8002-ee65-4ae5-8a0d-96e0cb208f9a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9899ddc-ba02-4a52-8dbf-24011f1b7c1a" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9c91fc-13e5-4455-9290-72e41c685a86" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff0ec71-e8f2-44a1-a782-c14df98265da" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,492</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a86e15a5-20f0-4b4f-95dc-1f366fd63fdf" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17c5d280-3b2f-458d-834c-0a0605b339e0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0fbda20-151d-41b1-b713-30299bd913cc" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a04898da-86b5-441c-a031-374899793eda" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.08</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0b1edb3-4a4a-4f6a-bc0b-404b3bc2ee10" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1d20fd4b-5b62-41ab-853f-d63ab4e20135" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0511417d-65cd-4da1-8def-066ba40a1a11" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eca7da3c-276a-42a4-b70a-f903d16d8da1" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.40</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8d12acb-2f79-4cf4-899c-b94a6a90d5b2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e6c965b4-a01d-4662-b3f8-942ddbeaba0c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">147,101,648</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb8c0951-465d-4189-9284-a89254fb688e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bcd58fc2-f2c8-4f14-b93b-f4fa0b6cffe5" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">144,383,294</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2a2692b-35dc-4057-afcf-7a4e1d4364e1" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3d5db281-d1f5-4188-b229-3bc2a46a1801" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">142,515,917</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_comprehensive_loss"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Co</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_318919f8-4c3b-4998-8f84-fefe0526b1ef" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,595</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66a0f0d9-1176-4820-b293-3ac96c79b027" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_885bc2fa-aafb-4158-abf5-5189d327ef70" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive (loss) income</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in unrealized gains and losses on investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e49bd3-be87-45e7-878f-f2fa82ea7afd" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52f53038-4f50-44ba-94c1-6ac09804a869" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83efcb90-d5d7-4b4e-b308-7b00172a7905" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,979</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ed6421c-5ff2-4234-87cb-3b452641ea25" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,644</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e265b65e-41b8-4569-99a8-f42a1ec487d4" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220,973</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f1a5a0d-5350-4813-9d82-9e6793c181b3" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203,347</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: Comprehensive loss attributable to noncontrolling interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_946a0f7e-22e7-41da-a2b9-7916e4cd4ed6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e5dc364-94d7-487c-86c9-52bf31f49c8d" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10f4ba03-ddec-4afa-8d99-5da49407c975" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b0b5f39-a082-4fa9-b466-9045b153a43e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,541</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28eec2fa-5add-46f9-b354-f05fbd2e69a2" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220,919</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a40e1cd3-21bc-445c-9da4-ecb83f5ea1a1" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203,170</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Shareholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.747%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.581%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.101000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.101000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.101000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.101000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.101000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.161%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Noncontrolling</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Shareholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Loss) Gain</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Interest</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3ca8647-4b3f-4f03-9503-dd9b6d96c97c" contextRef="C_4a469c78-301a-4529-b28e-24903923c651" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,393,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9ab9e1a-7bc3-4eca-b34c-824d7a994d98" contextRef="C_4a469c78-301a-4529-b28e-24903923c651" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2fc3983-1c2c-4866-a6ca-5c6bbadfeded" contextRef="C_29e591f1-b6b5-44c0-9273-a6ab4ed69a29" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,324,006</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18d8cc09-d029-4e71-b4c6-9165d8644cce" contextRef="C_bd08a3f3-19f2-4f0f-9fdc-39c4d781f8d6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,137</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0000fea5-a05c-44a4-bbc0-e2ca0a0bc0ab" contextRef="C_8949417c-8327-42ad-9e79-5c74d95818aa" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">718,891</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aed5b7c8-7312-4b05-b72c-c1e26b78c3aa" contextRef="C_48e2fe0d-2cdf-4541-8c48-496992bb429b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfb86504-1542-400e-bc4f-bfe0df041abf" contextRef="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604,102</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for cash upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c5dd246-ae65-4175-b622-2c1e68ebc4ba" contextRef="C_9449b797-84c6-46c5-a338-60738ca67a56" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,406,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b5f6206-b3a6-4907-990b-57ffe4626813" contextRef="C_05b25161-4405-4484-9a79-0c9ef7d93c2d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f677e32c-58cb-4128-9a8d-382bf0f09b29" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8e1e29e-4762-4cf6-be31-a3f8a7aefbfb" contextRef="C_9449b797-84c6-46c5-a338-60738ca67a56" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">304,637</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f8f29bb-e0be-41d7-8f60-26a86432b200" contextRef="C_05b25161-4405-4484-9a79-0c9ef7d93c2d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_732eb027-f2e7-455d-8a87-ebb55c53e124" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66ee7050-c91e-4873-b460-f4fe9b6d8628" contextRef="C_c8ff48b7-0993-480b-9ebf-68a92b4acfce" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,979</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9e16c45-6489-4af1-a0a1-1a1051078166" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,979</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d158c92b-bead-4702-9545-1c21fc6361e5" contextRef="C_9c86f6ae-1650-46f6-a8e7-0baaca9c4d6a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5788549-071e-4585-a689-5078a0022cb4" contextRef="C_fb3ea207-d43b-4520-9dbf-4b33f273a3e4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef0a3f00-dd5b-40e7-874f-03184902fc77" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3361e752-f938-4f6a-8e5a-ab4adbd7bf83" contextRef="C_93957bc6-8913-431a-aa08-83e39673bc72" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,105,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5bfbee9-ebaf-4187-9207-b1bf8c0c3354" contextRef="C_93957bc6-8913-431a-aa08-83e39673bc72" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c034cd1-e399-4930-8920-e8ca7682222d" contextRef="C_a49d0116-6be0-4342-bb34-064f2cb1779c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b03b797c-d385-49d9-a082-c7433b0b4a80" contextRef="C_28287282-43af-4ee0-9eb6-97361dbf3a49" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,116</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00b29c33-9677-4058-b5e8-58c140e6bb4e" contextRef="C_78553a5c-8e8c-41d6-9e26-df90b6ee5bb0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">919,082</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7360d64d-db0c-4473-99e3-76f747232cd2" contextRef="C_485a9291-5f30-4382-b6a6-6d39f1a103e1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf898d6-4507-475d-ab80-aaad2e791f97" contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for cash upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c494312-83e9-4b43-8c69-e5a5800cf89c" contextRef="C_16299617-ee7c-4dc4-96f4-999a18550372" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">470,405</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5412ecc3-d9b7-4b7d-85bd-28cdf223f295" contextRef="C_656c98bc-1902-4c80-b4fc-1e9db82df492" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a510f3e-0a99-41b2-a833-16ae57655172" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56ec5867-3fbe-458d-9a3b-41143884990c" contextRef="C_16299617-ee7c-4dc4-96f4-999a18550372" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,506,864</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_291e7add-d59f-45e1-94c9-3ce4f85c9f78" contextRef="C_656c98bc-1902-4c80-b4fc-1e9db82df492" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7244cd06-7c3e-497c-9d22-9097555f7eb3" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_143a86e7-6b42-4a65-83bf-b3227f970a97" contextRef="C_93a61f54-9fc1-4164-ad0a-ecd149ef96a3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4cec416-c48d-4bb3-8dc0-29c281d1f22e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee09f0c2-ea28-4728-8939-cbc83da3dbb5" contextRef="C_46f8f010-ed88-453e-905a-2c7a307eadfc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ec80e73-5b34-4c69-807c-886e25c0a85e" contextRef="C_3a1d8a90-cba6-4a27-8976-dff0b00c047d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5168c7fa-82b3-4df4-8bc2-e6879fd3483e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e78e858a-5fb9-4d45-8c53-f04d3c071e9a" contextRef="C_cb262e8f-a1c3-4acd-b4cf-58e1bcae091b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,082,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_529250e3-3139-4978-9cc4-d0944cb7019e" contextRef="C_cb262e8f-a1c3-4acd-b4cf-58e1bcae091b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_788d8f35-479d-42f6-981f-1e14ccbb0a87" contextRef="C_bd7b1034-af6a-470b-8700-f6950a6eba00" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,452,502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baf8d9ae-0866-461b-8f79-17b1d2baec80" contextRef="C_bd3ac93b-1e22-485d-bfed-003c41a39739" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f49534bc-362c-4520-be7c-2d960d2dcbbd" contextRef="C_2447145f-f97a-4de4-9722-96b5a9481f34" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,144,332</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d27c63a-6696-4bae-934f-b0eedb87e412" contextRef="C_7364eb6e-22be-4204-8475-fec3ce145680" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6656565-36df-4d4e-9c5b-76a610f8b7fd" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,278</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for cash upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_061f3350-297e-4b58-8464-759bafd2e247" contextRef="C_348cb82b-d5ac-43f4-a398-22620b3796c6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">103,800</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f707a9-6521-44f3-9ccc-cdb97f550f2f" contextRef="C_7be5ebc7-1646-49da-a85c-c1f9911464ad" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b46a5cb2-008e-4374-9698-a1419f7463b4" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ab10938-6131-4b15-a6b6-036b597af4c8" contextRef="C_348cb82b-d5ac-43f4-a398-22620b3796c6" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,587,673</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b2eca53-e6e8-45b3-b804-17932675c536" contextRef="C_7be5ebc7-1646-49da-a85c-c1f9911464ad" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,610</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03ea8d81-40f9-41a0-ade8-0f60d0db99d1" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,610</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cbfba65-430b-404e-aeff-5fb1f903be51" contextRef="C_7a426cce-3933-463c-a1eb-b6accca81255" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ea952a-81e5-462e-856e-c31d5c27f3da" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e8511bf-eb3d-46c2-9f46-e677ffbdda2c" contextRef="C_ee233ba5-9cea-4a85-9f15-e4b103298328" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,492</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c59128-e052-4110-8c4f-09a9572d285f" contextRef="C_7159e6a5-a720-4e55-b4d1-ebcad9b281df" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38dcfdde-65cb-401a-976e-40c9304274d2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,595</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_310986f4-906c-4db0-96df-5fb50f7f814f" contextRef="C_89099e56-2c94-45a0-bf9b-0e1751243cd9" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">147,773,744</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c7cf02-589a-4f55-afaf-307f2f0857e7" contextRef="C_89099e56-2c94-45a0-bf9b-0e1751243cd9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ed9f3c-3960-48b9-9c93-1f5f0c449175" contextRef="C_31033074-d98e-4051-a1dd-9611d85c39b8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,506,353</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2582e7cd-13fd-4638-8a92-6ad6145771e6" contextRef="C_a6daf5ec-996f-44a9-a1a1-176861ff844f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b261cb1e-3bc7-47b0-a929-4611c60f13f0" contextRef="C_3c36ec93-0b98-4985-917c-84fa8ef6964c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,303,824</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8996dc76-105b-40a8-9550-fdb2b5818760" contextRef="C_96e4eb5a-1de1-40a2-8f39-b8260ca0c7ee" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd71d63d-1b40-456e-bc14-86b8dba87a03" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,485</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements o</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.782%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55c2baf7-e352-4575-8ce0-02cfb29d5221" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,595</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da942d8b-f3ea-4c0e-ab3a-a66150816c4b" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ea1369-50e3-4907-9fe3-0410a8b73594" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_786057ef-221d-4760-8499-6d288879e154" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,553</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c60c39-a6ac-47b1-8573-7ebed393b776" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,532</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1b15d9-c5f5-4df1-b678-f742c54bb318" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,221</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_841b0eea-230e-4e38-bc91-8aadabe4a068" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,277</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea34117b-9521-4fb8-ade6-6d460ba6aed9" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,920</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_116d341c-7903-4e62-913d-574d7331efd3" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,227</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c15c74a-b113-41a9-bfee-74a1383be06d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,610</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367982fd-3be6-493f-a29c-458f17bcb31e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a95abb5b-3047-4f09-85f0-08b962d6c333" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3e6e3b4-29d8-4a10-b51e-374de13e3065" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,703</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_939a7b2c-6325-409f-ae15-815190524496" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e44547f-0839-46e3-85c9-7cd03889441f" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ffcf36-ed74-43f6-a554-d518ed181c2b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,208</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26cf4a5f-f24b-4b6f-9aca-15a1e876cf16" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,184</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f4ac818-4c7c-49dc-a0f6-84a5aa553d91" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">741</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45c769e4-1894-42dd-85b3-fae4eeea0389" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ImpairmentOfLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,205</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0a47128-0683-4783-a119-e1522beee8e4" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:ImpairmentOfLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,429</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory reserve</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ad7e1d7-2ddf-470c-9a69-5d7cf2088955" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:InventoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dc1b9e5-4761-4fce-9812-46f67d94d499" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:InventoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa37bcfd-d5c1-414e-9dcc-7464d05503c1" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:InventoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,638</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncash interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dc431f1-9775-4fe3-b5e0-4bde00fd0b29" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:NoncashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,618</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ac1e8f5-75f6-4600-a332-105c74fa0d66" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:NoncashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d5cef5e-b8c7-4fae-9abd-99fdcd1634e0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:NoncashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">985</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8743c903-fa65-483a-bc57-dd5974a73ab9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a15e6a09-7df4-444f-98e3-e5bce929969b" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5353531-07e5-45c2-a8f8-a57ad36cdb12" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63463d43-c25a-4e25-a3d1-94ee07d96a58" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,744</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a3783e6-4a7a-4a18-ad42-94ef6f7f8fa8" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4dff39-ea39-438b-bfb3-02b2c1832c1d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,648</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47d3ea35-63e4-4d1e-956e-dc5122a8991d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a6440f7-e492-4951-8985-2a81f19eb10b" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,838</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_413b86a1-4c2e-4504-b1ba-b0efee60bc92" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bcbcc25-18de-45db-a811-3ad76348e6c7" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f73dd00c-44ac-4664-a9f4-3478fba8b52a" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,930</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aafc52fc-1ecc-4c3b-846e-87b43cef3d4e" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,551</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_668ad215-7089-4b14-bb8a-a4ba4b1fad47" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">671</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86eb2be5-70e4-443b-b8fb-54c24d8188ec" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,407</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8e63725-adf1-4ca0-896f-37da7c656d35" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,111</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets and liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7885627-94f8-4dd2-adf7-d347dbdc4c0d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a29725a6-2112-47e3-ad33-208a010b38ed" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,676</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11704bb9-c38b-4321-9fec-442a184e36cd" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,050</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94557ebf-03b4-4017-9737-d44c901ddbd7" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,478</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_688db365-e534-4de9-9870-3aa85a76b3fb" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,291</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae7f722-7b84-4bec-9f5d-aa7f46b9ec07" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de7359eb-c0f7-4e97-8d95-409f8987d435" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e211dd41-cf44-444c-918c-608eb6630b0e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af080fa-4b5b-4fe8-aec0-d9df69297c51" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96c88d3-5cf3-460e-80c2-441d969595e1" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,212</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62310785-dec2-436a-a49d-5dbc211ce2c3" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">156,324</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5b10af3-44d6-4b7a-88a6-b219ad1ec082" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">183,945</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_255557c9-ace5-488d-8ee5-60fc690db96b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,664</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d800f27c-e9d4-49bb-bc9b-f941ec4f6f68" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,697</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7366a3a-a7cc-4127-96bc-03d78826869d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cbc0ceb-f2ab-48b5-9e27-962aec1dbf69" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244,257</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfc16f53-d00a-4da8-a204-d7a7247b70ab" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429,558</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6639863-f0ed-48fc-9dec-fe0b1d9b307c" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,778</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5961d1b3-dff9-4930-a1ef-44ae1229d38b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325,713</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1be72c8-bce5-4cfc-b886-a7d8d963d10d" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">569,902</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc2efbc-9903-4539-ad52-1caaaf563099" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d221df9-5f91-4299-bf25-2dc09dfbc2bf" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b54b9f0-74a9-4002-8d8b-e8e7a70662b6" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,647</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d9728b4-789e-4980-acc9-82ba8cba5f04" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,905</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a96207e-4021-403b-9a91-b2d1a9e12863" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_309e3fb9-beef-49ed-82c7-86fb9adeec1f" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b4669b1-8c3c-4e9b-b7f3-2860c260330c" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from revenue interest purchase agreement, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd98eb8-7692-489c-91c5-977b25075b9c" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,375</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07523bdc-d1cc-41bf-b917-210c760d98b0" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a366bb7a-fe01-42fc-af3a-34fc2f89e123" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed49a443-c7f8-41bd-aebc-f28db7c4cd29" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,265</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e352ede8-f335-4492-b3d4-106e817da696" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,179</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf8094fa-1a61-4fd9-ba2d-0c76951c2c81" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,432</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbc916cb-9777-44c9-8f01-07672576f149" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c449cae8-2e6e-4efd-8857-af041150a211" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,996</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1160525-01bc-4ba9-86b5-6c347f5169dc" contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,428</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_463c7f3c-500c-4f46-828f-1bf78fdc339a" contextRef="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,203</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78571b74-8bbd-462f-b9aa-d5cc9fab31fa" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,817</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7128189-a1b6-478c-a159-7e38f5381001" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,996</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a81db82d-e1dc-49b4-95c5-1a50c2287e12" contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,428</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Noncash investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of equipment included in accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21feb4a3-ee7f-49a2-82b1-650774fe9d99" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,275</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36d26a4e-c9b6-4ef4-a581-f350093d0b49" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5300d4fd-a44d-45c0-8a80-b6b9b6ae12e2" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,719</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3c5b213-6bcf-4f3b-89f6-bd1f81a984df" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,864</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce461447-f53d-4166-891a-27be3298bfdd" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,985</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b13b631-70b8-4182-9aed-da6332586b47" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements_december_3"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial State</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0093788a-776c-409d-9782-89029d7a4289" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_dc930d26-1e36-4400-bbfc-dc908becd842" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_dc930d26-1e36-4400-bbfc-dc908becd842_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75f65355-da29-4628-b12e-1122c208f9e8" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daa23742-c7b7-4b49-928c-485e578b5ebb" contextRef="C_e59b5618-2d7c-4271-a133-4a54a274bfa0" name="us-gaap:MinorityInterestOwnershipPercentageByParent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32d73065-5815-4509-a068-c98c9b479b4b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#8220;Purchase Agreement&#8221;), the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae36c902-ef38-422b-bfae-9c4a48366883" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7dad336-dffa-456e-aead-d2c5854387ca" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:NumberOfOperatingAndReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segments: Minimal Residual Disease (&#8220;MRD&#8221;) and Immune Medicine. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM regularly reviews operating results and other financial information presented at the MRD and Immune Medicine segment level, as well as on a consolidated basis, to make resource allocation decisions. The MRD and Immune Medicine segments are also our two reporting units.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24b87219-5f52-4f81-a720-7f12e307fdef" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_564c1005-7f73-434c-8d1d-1547b556870c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had a restricted cash balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61ff6843-8f26-4251-877f-17a7a1f1747a" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2b199b4f-eb98-4088-8738-4bc9554d5105" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our facility leases.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_dc930d26-1e36-4400-bbfc-dc908becd842_1" continuedAt="F_dc930d26-1e36-4400-bbfc-dc908becd842_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47485b53-b83a-4f12-8c7c-f298e7cb0715" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are classified as available-for-sale, consist of United States (&#8220;U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0c8f6ce-b8a4-4f27-844b-1f8ca5a787fc" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2024 or 2023.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b04ecf29-51e8-4354-9298-5a6af9e9d2b2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively. There were no customers that represented more than ten percent of our accounts receivable, net balances as of December 31, 2024 or 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2404800-d44a-4409-a83c-36418f8d0f52" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.211%;box-sizing:content-box;"/>
          <td style="width:1.48%;box-sizing:content-box;"/>
          <td style="width:12.783%;box-sizing:content-box;"/>
          <td style="width:1.48%;box-sizing:content-box;"/>
          <td style="width:12.783%;box-sizing:content-box;"/>
          <td style="width:1.48%;box-sizing:content-box;"/>
          <td style="width:12.783%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc77b06d-c1b5-48b5-a2f8-aeb1b593d8fd" contextRef="C_41d2ea93-dc38-4500-b0a7-cd99c27e6352" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc26350-84be-43fe-b8c6-98d6ca31f0fe" contextRef="C_1a256318-aca1-4e30-8e79-987a0c9de60a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.6</ix:nonFraction></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Genentech, Inc. and Roche Group</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f7a09d6-8820-4fff-ac75-5549aa78151b" contextRef="C_0df3cf5d-7b89-4a27-bcce-445ba936b692" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">27.8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_229790b9-3560-40e2-ba1d-3968e1fa956d" contextRef="C_9abadd97-9d4e-4600-a895-663eefee5344" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">36.4</ix:nonFraction></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by our MRD segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by both our MRD and Immune Medicine segments.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_dc930d26-1e36-4400-bbfc-dc908becd842_2" continuedAt="F_dc930d26-1e36-4400-bbfc-dc908becd842_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7508ae34-1421-49dc-85f2-bebeede4ea99" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c05fed39-f746-4d9c-bcc0-c4dcb7b8ac5a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6909d4c-93b6-4abb-b933-4e8413455e40" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OtherInventoryNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dab2607-9420-4afd-802c-21ea2a889d06" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OtherInventoryNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included within the other assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfdd7305-6795-4231-8d0c-288c4ad52e44" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_590e35b2-4806-4e02-b888-a893e31d4965" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;box-sizing:content-box;"/>
          <td style="width:1.72%;box-sizing:content-box;"/>
          <td style="width:49.14%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_db6c13fa-ed06-4ca1-8e12-21756afa5fe9" contextRef="C_57585e88-6f33-40e2-a08a-7f48691bb39b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_1c979d66-d1dd-40ae-8767-d5638867916c" contextRef="C_374a2a9a-0d8a-4c0a-bd27-2a810ec44e11" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_7d6c7707-c6df-4358-b268-616cfbd80a59" contextRef="C_20a3dc1a-a419-4e0f-a290-0890b8721905" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_ef9a68f9-ac14-4fa3-be28-0c818c1862df" contextRef="C_eddbf21f-640d-4187-9c5f-398cd390ba4b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f700a16c-5b7d-486c-8b94-b671a354a684" contextRef="C_e0cd05cf-7df4-4d8f-b77a-87c83fce22a0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_7f20d50b-46ee-45ba-95a9-1dba3fc0924e" contextRef="C_d8181a55-5e75-41e9-9ce9-c8d6ef15af36" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8660fb18-51ea-4e85-b02d-7eb9ecd448be" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8876fd84-9eb9-4fa8-8669-db9f0becd37a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment losses on intangible assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c0132e5-4598-43b5-9d8a-b81529a6beee" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of attributed identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of one or both of our reporting units below its respective carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the allocated goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb07a17d-a711-4ab5-9fb5-f8eab1a1c7be" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment of goodwill.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_dc930d26-1e36-4400-bbfc-dc908becd842_3" continuedAt="F_dc930d26-1e36-4400-bbfc-dc908becd842_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_359cc961-eccf-42c4-addd-ca8b143a9ebf" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdc21854-edc8-4040-9bd8-a49f41d6c966" contextRef="C_1e9897c4-5275-417c-8724-b96563d5a101" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for commenced leases that existed as of our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7aa0c729-205b-4665-b95b-c5999c86b28f" contextRef="C_1e9897c4-5275-417c-8724-b96563d5a101" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 842).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the right-of-use asset and related long-lived asset impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36c7a5aa-6e8b-45ab-8819-0fc100505ca0" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_ce5cef36-60d5-483d-b10a-1130a0c86e8b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true" continuedAt="F_ce5cef36-60d5-483d-b10a-1130a0c86e8b_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our MRD and Immune Medicine business areas. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#8220;Genentech&#8221;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_dc930d26-1e36-4400-bbfc-dc908becd842_4" continuedAt="F_dc930d26-1e36-4400-bbfc-dc908becd842_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ce5cef36-60d5-483d-b10a-1130a0c86e8b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#8217; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#8217; therapeutic development efforts, including regulatory support where our technology is intended to be utilized as part of our customers&#8217; registrational trials, developing analytical plans for our data, participating on joint committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#8217; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For research customers who utilize either our MRD or Adaptive Immunosequencing services, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cd56bef-98e1-4d0a-af0e-dafdc7a81a3a" contextRef="C_fbb5807f-dfac-429b-964f-d08eebca81e7" name="adpt:NumberOfRevenuePerformanceObligation" unitRef="U_Performance_Obligation" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> typical performance obligations under the terms of our research service contracts: (1) the delivery of our MRD data or Adaptive Immunosequencing for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e759fa64-a4de-4f8c-bee2-ae9963412604" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ContractBalancesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract Balances</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_dc930d26-1e36-4400-bbfc-dc908becd842_5" continuedAt="F_dc930d26-1e36-4400-bbfc-dc908becd842_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7023cc32-f6d6-427b-bc7e-0149091a692b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6989b3e3-04aa-4cdc-b8c6-96240114ac7a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising costs are expensed as incurred. Advertising expenses were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4248db64-cc24-4f99-9f66-f823d4334391" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea39e9bd-b338-4e35-82d3-a63eafc8ee6d" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9701cc38-2245-48e8-9f96-91f59a6cad76" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64b97e5a-a6f5-43fd-8106-66bbd80ddc70" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0952709c-ac39-4d17-8e55-5989040999de" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b79f42bb-6f5e-464c-b66e-77a8d4e29daf" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:SalesAndMarketingExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales and Marketing Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ce9f312-f519-4585-a85e-52f6abe1479b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets expenses include our impairment charges for certain leased office and laboratory space, related long-lived assets (including leasehold improvements and laboratory equipment) and long-lived assets associated with our halted software enhancements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_887c758c-1e5f-4b38-b3ac-c57d2cdeaa80" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InterestExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_dc930d26-1e36-4400-bbfc-dc908becd842_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cd83df5-de58-4e14-a2f2-edc1edb94e3c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f081cd69-fe1d-4e55-8348-2040635482f3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a065ff9e-3801-4907-b233-8bf18dd2450e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 280): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which intends to enhance reportable segment disclosures with an emphasis on significant segment expenses. We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7558bdca-001a-4fed-be89-767eb717c766" contextRef="C_5ec5d924-4867-4b17-91e0-bd4130ea3d71" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this guidance in the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e173676d-3a9f-4782-ab15-d8fd5df202d5" contextRef="C_5ec5d924-4867-4b17-91e0-bd4130ea3d71" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt-sec:datequarterend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fourth quarter of 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and applied it retrospectively. See Note 19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more information.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">: Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_7303db50-ff35-4053-8454-9327123d490a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_7303db50-ff35-4053-8454-9327123d490a_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c33ac91e-48ab-4de6-9ac3-1568f08f4907" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our disaggregated revenue for the periods presented (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MRD revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd9a37d4-1ff8-4844-bd2b-d9c9f412d79c" contextRef="C_6ee41dc2-3749-4243-b0eb-1ba3135232f3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,029</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f39fbf5b-ae6f-4405-b0ab-16a26adc6baf" contextRef="C_9574ad63-2e26-40ad-9358-463b4132a65d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2541e382-2a02-4c9a-ad8f-f87bea82ad00" contextRef="C_01f6ee6c-fba7-496b-80dc-8365c221c856" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_374e0ead-2ea7-4110-ad83-2b8f76c6ae9d" contextRef="C_cdd9919b-7ab5-4a3b-856b-38b155fb4234" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_387c4db1-6c5f-4ecf-a2c3-6fbd8ca6c800" contextRef="C_e30f0baf-e7ad-4a6d-8333-cd12494dfbb4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total MRD revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c053d0cb-518d-4198-bea2-0ec91bbbbd33" contextRef="C_d3e4b471-6ad7-4d54-aafa-1c355daee1b0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,529</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1682d4c-251b-480d-b344-d56a669d0c46" contextRef="C_02627e80-13ae-4972-9edc-6d2d1f0cdb33" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfe6a809-607f-4ced-9882-80a981e1aae0" contextRef="C_6b2d4707-21b9-4599-a35b-221f9e77a609" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Immune Medicine revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e05227-2c51-4570-b6bd-ca116058165e" contextRef="C_cb867f2c-9a12-4675-ab77-495ff41044b1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,976</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb7f8f5-bb65-4061-9e81-61bae568c5ec" contextRef="C_c8c4442e-e5ce-488d-9683-4a18e9b3cd7f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,959</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_720ec592-0d8e-4bc9-b944-a345fd77531f" contextRef="C_9dadad4b-2404-454e-8619-6c7106da8dfc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,777</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e62a0b8f-1b76-4ff5-b486-325448242639" contextRef="C_be240297-154f-4383-9264-3588023daa8f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,452</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25816ead-ce1b-4bf1-a892-df54936ebc6c" contextRef="C_a7d99817-f47e-4c17-8910-f27cddac34f0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,578</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1459a05c-21e4-4f2a-9ca5-ebba5f81fa82" contextRef="C_6f1d2824-9131-43aa-aab8-2a0a4ed4adce" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,387</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_359c4f50-9ca4-4a0d-b01f-905f45c8fbd8" contextRef="C_3ed4ebec-bba3-4eee-a2b7-b31d8032bc49" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,428</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3711c5fa-7278-4b17-b30a-81724f692034" contextRef="C_64e80de6-0e67-4131-8ace-44a4d0c8b34e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c37c5958-d31f-4a6e-9a99-619b81c15a16" contextRef="C_6712d8a7-de54-47f0-b34a-c94d59831861" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,164</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d02f5b41-5a5b-4669-a064-74ca248db096" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,957</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f37b28-7294-4fea-a457-1966d8b57076" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b581649-2092-44f6-a51d-0401ecc09b5c" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,308</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae861d54-19b0-4c70-90f3-8e7451588b9a" contextRef="C_9bed03af-b144-4cd1-8808-efb75597dec9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2024, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71e677d9-44f4-45c1-8d3e-42754b4505a3" contextRef="C_90f05e58-9e8e-464c-86a0-007bf79714f8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and cancelled customer contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94cf8fe7-1d10-4240-ab6a-ac179c02b3c4" contextRef="C_b171d937-1d83-4b19-9289-84b0ac31bda2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2524294c-64af-4c38-b847-e37d7c13f7e5" contextRef="C_dec1c67a-a4a6-4150-87ca-ce929f12f0f9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6eff38b-0d01-4115-bffd-a04f3a4fb9c0" contextRef="C_df90d480-536f-44ca-97f1-bc8815b053e9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1082494-08c3-4502-86d0-0b1a30fb96c3" contextRef="C_f6bd00d1-b48a-4bf4-8057-810a2bb6684a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we could receive up to an additional </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15798856-6558-4ed1-b509-d20e2993a0d7" contextRef="C_68e4bc9a-5ec1-4697-aa56-4ddc7bb9b1f9" name="adpt:AdditionalMilestonePayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">418.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestone payments in future periods if certain regulatory approvals are obtained by our customers&#8217; therapeutics in connection with MRD data generated from our MRD product.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Genentech Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the &#8220;Genentech Agreement&#8221;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc17ee4-9a3c-447a-be35-52ceae5ded17" contextRef="C_eb217ce2-c0bd-4ee9-98ca-e04bd1a4c870" name="adpt:NonRefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in February 2019. We also received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_547624a3-fe5c-4f96-a4e3-b824b667053c" contextRef="C_cc530114-c6ce-4f99-b1da-fe2970aacb2e" name="adpt:AdditionalTransactionPriceOfRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone in 2023. We may be eligible to receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d43ae1d-5916-4f1c-9366-78e5bc14f998" contextRef="C_29395044-cf96-4b99-9148-86cf3018ed50" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="9" decimals="INF" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion over time, including payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffd4eabb-93c7-4e16-93a5-da01df1458ef" contextRef="C_1aeca0d4-12fc-4e19-b717-44dc51c65479" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">65.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified regulatory milestones, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6caf5ef6-73fe-4c43-b4b7-4045e039933b" contextRef="C_81bb5afe-4560-45fd-bd67-49459a4983ba" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified development milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd185b6-4b60-4812-9331-13b5438128f2" contextRef="C_fd9b1278-cc4e-43c9-a7cf-005a24cec79b" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">1,430.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell therapeutic products in which Genentech intends to use T cell receptors (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;TCRs&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) screened by our immune medicine platform to engineer and manufacture cellular medicines:</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shared Products. The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). </span></div></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7303db50-ff35-4053-8454-9327123d490a_1" continuedAt="F_7303db50-ff35-4053-8454-9327123d490a_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;ASC&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) Topic 808, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 808&#8221;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#8217;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;ASC 606&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to account for the activities related to the Genentech Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In applying ASC 606, we identified the following performance obligations at the inception of the agreement:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to existing shared antigen data packages. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development services for Shared Products development, including expansion of shared antigen data packages. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development services for private product development. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations to participate on various joint research, development and project committees. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#8217;s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined the initial transaction price shall be made up of only the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9af4ccaf-2ea4-44c9-90f4-c327075bbd8e" contextRef="C_0b1f2c34-a18a-449b-9a8f-3aa8bfcadbc2" name="adpt:NonRefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_426ed651-a194-46a3-b154-79724a12d648" contextRef="C_fd819420-41b4-40d4-9e84-63652fd8d5a7" name="adpt:AdditionalTransactionPriceOfRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million addition to the transaction price, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7bd959d-4cab-4fd5-9a07-18815ae67bfa" contextRef="C_9636194e-e351-4fcc-97ab-4e132d735d9a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which was recognized as revenue in the three months ended June 30, 2023, with the remainder included in deferred revenue to be recognized as revenue over the remaining research and development period. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize revenue generated from the Genentech Agreement over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6a683fd2-b719-4e8e-9163-23af35cb1311;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nine</span></span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db5a94ee-f891-4e86-8073-c30f5e626cf3" contextRef="C_69a8c3ab-a441-40a7-8a5f-6b8e7d9071e2" name="adpt:RevenueRecognitionExpectedPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7303db50-ff35-4053-8454-9327123d490a_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In total, we recognized </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aaf8472-3c44-4b71-af20-578b258f2220" contextRef="C_61e08594-2216-4ede-9093-11ef2ff2f063" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63dfdef7-46a4-4988-b828-8593de5c0c16" contextRef="C_28466158-15a5-4c86-9df3-08250c20e264" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.6</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8524da8b-b97e-47f0-ae09-b47301168830" contextRef="C_69fe0b18-2ecf-4cb8-92b2-378c77fd872e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine collaboration revenue during the year ended December 31, 2024, 2023 and 2022, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92cd2468-ffe3-4f03-ac68-c03ffa4513da" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:DeferredRevenueTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue from the Genentech Agreement represents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e284005-0723-4cc9-ba9e-a7df56222e98" contextRef="C_8a711a70-7835-4547-9b99-bc3f849a6ee6" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35830fb5-ade7-42dc-827e-230ff3e53511" contextRef="C_8a711a70-7835-4547-9b99-bc3f849a6ee6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a00afffe-334c-4abd-a8a2-ba3c2675860a" contextRef="C_ccbf3cec-810a-407c-8e46-299bdc89be19" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32a1e1c5-6b9b-4638-b390-a4b25815180f" contextRef="C_ccbf3cec-810a-407c-8e46-299bdc89be19" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2023. We expect our current deferred revenue to be recognized as revenue within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73227e0a-0787-45a7-8040-97bf4aa3dc05" contextRef="C_4c968389-ac05-4e80-a351-de3893d81820" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_541cefcb-2078-43fd-9a8f-6f77d35b6372" contextRef="C_90e7cb01-e413-4073-b348-b2397b9dd2f7" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from December 31, 2024. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df5fdb9b-ca16-4e3e-8614-8004106ea49b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in deferred revenue during the year ended December 31, 2024 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bd7bbcf-6ac6-4bb4-be0b-171927fb989f" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,423</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccd6832b-8d4c-4a78-b810-3845b2e2f4be" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,936</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_290e8e49-26ba-46f0-8bfc-9fae36df3b1a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,414</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda88ece-0c99-46d9-a4ef-4fa2471a30ff" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,945</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef00d756-42e1-4d0c-9a4c-816dee1115d3" contextRef="C_c46025e5-021b-4f7b-a2ef-444e78692785" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized as revenue that was included in the deferred revenue balance at December 31, 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e35790b6-70e6-42d7-9d09-08c689c0debe" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_191bce4e-07a9-4e48-ba50-7f45cdf84776" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair values of financial assets as of December 31, 2024 and 2023 that were measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b9a4a48-8db8-41e4-8b77-070a83f3a70e" contextRef="C_a0289be5-fa32-463c-acef-732918e4cece" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d1b2d73-4a26-4da9-bed9-232e81220fc0" contextRef="C_5c67024c-2523-482e-9f70-804bcc6d8184" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6e76f7-ebf4-4c51-b32f-ca8105249e76" contextRef="C_bc03cecf-836f-4bee-b7f1-33ef96865307" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,479</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d61b25b-70d8-4f85-82e7-0b86a7b62e55" contextRef="C_880b4bee-c006-4cb8-8920-ecb8a97fc49d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,479</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38856ec5-6472-492b-be18-3fc204bb7e72" contextRef="C_a9e6d9f0-f84d-4295-b3ac-f1ae0043be0d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,181</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49780576-b1b8-4629-abbf-615856a04766" contextRef="C_518ea4ca-bec1-4e07-8773-307a90cb3d09" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,181</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee69812d-d12f-4313-99f6-5c0704e52ebe" contextRef="C_06fe2942-7d85-4654-9ab0-33bc82a8bcd5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f27538-4ebc-45e4-8321-4e54ad0f0885" contextRef="C_da165782-cf35-4126-a330-0965f4347274" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2e77fc2-4caf-4b33-83df-1a31a0e4a262" contextRef="C_9d69ac12-b7e7-4fba-a6e8-17f59c20625b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,790</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a75ae07c-8d38-4539-b675-a6b6a061871f" contextRef="C_0bdc5c5e-908e-4299-8ae3-da0932a02def" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,034</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f770e9f-de4a-4508-b22c-d9c9ff6f7271" contextRef="C_1c7dad97-0dc1-49c3-8e6a-213606328313" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243,824</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e07bc55-b52f-4329-86fc-a0d5d981379f" contextRef="C_5d904410-055f-498e-b598-0be6c4b19349" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,123</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1af73408-1d76-4649-bcb4-5f21485c22e3" contextRef="C_3da0eaaf-abe5-400c-a7d1-218bca3b9652" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,123</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18b8e69-e27b-4a8b-90e3-0b2fce71cc66" contextRef="C_29b153aa-6e60-459b-8d8b-3607e4aecaf2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_592f71d4-6898-44c6-b85f-4f8822327d78" contextRef="C_538c62e7-e31b-49fc-a740-3611b3bdd5b3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074e3ce8-d9af-47ee-8b1d-1d308c761332" contextRef="C_e4bc6147-a322-4ac9-983f-0be3e4e33863" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efe2a5fc-82b9-4053-98f5-348f3c989538" contextRef="C_6761f29f-952e-4394-b160-1a416c1945ba" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da54e7e8-d126-4436-b437-ffa5de407326" contextRef="C_a1e0e792-7995-4a69-9664-7d62b49d7305" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f46b84cb-ac89-406f-92ac-d13618f853df" contextRef="C_7f583a8c-c6f5-48ba-af7b-80283f1ac4cc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf6238e6-aad3-4130-95ab-9467a571057f" contextRef="C_d2e2d8d1-07f1-4212-9f71-7af175f378a4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,123</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b28919d-f32b-44c3-9794-42d79919f94b" contextRef="C_791187a1-62e6-4444-ac40-4fce1c79f12a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,337</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_207e598f-7317-4a81-a6bf-7eb9fae3c080" contextRef="C_abf475fb-d18b-494c-bb9c-bf8ac3104ace" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,460</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed31ab51-22b4-4bbc-8e1e-1e0291cbba84" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19aee3a6-5ae2-4f34-8c36-ade1544a78d5" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available-for-sale investments consisted of the following as of December 31, 2024 and 2023 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_285a84b9-0005-4052-acfb-dbe039678b36" contextRef="C_6591b0ed-3cfb-45af-b746-4190d5d17981" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c51a635-2c5e-4a35-b3ef-975e4e00249f" contextRef="C_6591b0ed-3cfb-45af-b746-4190d5d17981" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9862e804-1f51-4a0b-b7aa-23fb38bb7094" contextRef="C_6591b0ed-3cfb-45af-b746-4190d5d17981" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,479</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c64a511b-55e8-481e-a523-e444a41faa39" contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153,353</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85d70a55-5cc2-4a66-be48-bd203c9196d6" contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4be0a724-d3cf-4636-9765-2ed68fc6724c" contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfe1eaa3-46e4-435c-9f15-37aef4fab108" contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">153,521</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acf3dbcc-3b2d-4eee-abf8-ffbbeae9bc30" contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,357</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_219c2b15-91e1-4972-8579-b84e6d56f454" contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21b23119-1908-4d3c-883c-b0813104dd50" contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27be3ca3-1862-4e3d-8b5e-835ed7f1f2ae" contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df177235-621d-48ca-b96f-117fafd36fbe" contextRef="C_af621409-f3a9-456c-8964-3694f64ce437" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,186</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee45bff-392d-4bd1-872d-dd5a5d8739d7" contextRef="C_af621409-f3a9-456c-8964-3694f64ce437" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ef58590-3dc3-48c7-a21c-bcb341d17568" contextRef="C_af621409-f3a9-456c-8964-3694f64ce437" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5b7e1e7-8fcf-44c6-b3e3-eed52fb6883a" contextRef="C_af621409-f3a9-456c-8964-3694f64ce437" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,374</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47df524f-57d8-44c8-847b-9cfdb934d3e6" contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34a30351-f1a1-48c3-8bb7-52ba570d7ab6" contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_539e397f-a2da-4ba1-93d4-5f44fae1a15c" contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f79c2711-232a-417c-8706-a135902fdc7f" contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,660</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf1c815-e829-40d1-bd8c-9a9a2960722e" contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,682</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72403fc6-df65-4b9b-bfa0-0e065110ae7d" contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fab749f7-4d5a-4f0f-9491-ed02759c0257" contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bf8b36c-8492-485b-be21-a0b6b7d18f97" contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,660</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c8f0333-d0f5-4589-b9f8-0b1c785cbc99" contextRef="C_b2e59962-3ddd-4060-85da-417d16f3db74" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55ff150e-b9e7-4ebc-acae-33002b19db27" contextRef="C_b2e59962-3ddd-4060-85da-417d16f3db74" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c8c7e06-2c59-48a5-9722-d38aef22b92d" contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed4f6025-92d3-41c7-9b33-c85e06b1fc71" contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd0fc991-09eb-4267-b6da-169c37f4873e" contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1c4bc27-ebfc-4600-8997-cd12e47b8009" contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eec4782-6105-4474-85e2-0927f2f8d12f" contextRef="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,278</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41e837f5-079e-40e1-a4f4-5534c2a0b256" contextRef="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29553f33-c7fd-4082-98f2-5f523a079cff" contextRef="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bf1bd92-f386-47ee-8eae-0a6aaf5cc78b" contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecdcc0be-504a-4252-ac93-5c71915f2092" contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae01eec3-b869-4055-8c5c-557da8cd92eb" contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f3bc259-dd12-4b0b-ad6c-3f51f55bd4c5" contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,337</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43016ff3-4e8a-47a6-a53c-809fff79cc4b" contextRef="C_419c90ac-d4cc-4e42-adb9-be55df808d8d" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3f2f3f1-9077-4f39-9505-1697e27f8910" contextRef="C_848613df-8ebc-4107-bbad-5a337d92718b" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was presented separately within the prepaid expenses and other current assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc464964-f1d8-443e-a053-76ec4327217e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2024 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months Or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_977622ce-9d0e-4f2b-b4ea-d30e96251739" contextRef="C_874675f7-b27f-4f96-93aa-3186a0017df4" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,782</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95606858-fe46-4c7f-8057-c7d116152d8d" contextRef="C_874675f7-b27f-4f96-93aa-3186a0017df4" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697a743c-e216-4bf8-b8b7-00a100e1020f" contextRef="C_4209531b-b000-47fb-8aa6-738c91148064" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53ec68c8-08fd-4273-a269-01f42e941dcf" contextRef="C_4209531b-b000-47fb-8aa6-738c91148064" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_275b40e6-9662-4f3e-84db-156f79d771aa" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab610ac2-22d6-4e56-a92e-644be6332875" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2024 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e6b0561-e140-4dc3-8fb5-70617b6c94a9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67782f26-e2c1-4552-a54c-5bdf805dbd32" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net as of December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8aaceea-0b73-4181-b8e0-29090c647ded" contextRef="C_b0da9317-56fb-4a02-9287-ece7f5f4b6bb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,950</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8088fd1-360e-4a01-9a3b-0773e1a5ad17" contextRef="C_ade00613-56f9-431a-ba97-2bc4f44cf6b1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,567</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a4f44b-49f5-4e07-b2d4-16b8bd23eb0a" contextRef="C_8ae2ed18-baf4-42dd-a344-3979e49ff066" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,337</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93946990-f74a-441a-98e9-ff8eb7eef16c" contextRef="C_23197216-2be1-412a-babd-a86284108614" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c66a00-07b0-447c-9d80-ae0885ec22c1" contextRef="C_bc1ec203-aeac-49ca-bbbc-3d860034cbec" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,040</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2ced14b-66b6-45aa-9da9-90b6d4e25825" contextRef="C_bc1bccb4-0e9a-42e9-b42b-84b9f3eb6d85" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,820</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fac8bed-72c2-48f8-b208-a2659da5f075" contextRef="C_fc40783a-89f6-4d6a-8cdb-a7280da7107a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b10e0ca-a27c-4735-80ca-731b6ac87af7" contextRef="C_621e5196-e15c-4321-8f5f-959090207c65" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,965</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df755c72-547a-4976-bf0f-94425ba6c62a" contextRef="C_845f3c97-7e7c-4286-9701-ee7332f3f413" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,571</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4738498-9c87-48e6-ae74-a851bb98ff30" contextRef="C_bb6cf174-eaac-4064-a305-81f3eb2a9aeb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,405</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dabe44a1-1a44-44e3-9f7b-0eec5ae8b81f" contextRef="C_9272d326-ab2d-442b-b3a2-82c6a66a936a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,277</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b86a827f-cc32-49be-a194-a2ab0c688815" contextRef="C_28c5bcc4-c729-4e8c-bce9-751448cc3f7e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,734</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e480c6-2445-42b1-83be-3257b333eceb" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_153501de-3dba-4e89-8f8c-ab7007bc6ef6" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,461</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e86336c-db4b-4922-bb40-e3965131f3e3" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,817</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9d94804-f724-4194-b200-6aa4d00704a5" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,234</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ac7a603-767e-4945-b194-44ff8d0e2adc" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,616</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_239401ba-2485-46af-9f03-bb14c8a3dabe" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce80cd84-9d28-4b33-bf77-4a05db3543ff" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96572ec2-56a1-4d16-a0cf-8d7769cfcb19" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95f992f1-4cc3-4d5c-b739-2e288838b22d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_dcff5cd2-69a8-4492-8295-ce54941b3ed4" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill and Intangible Assets</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ce8b94-7067-4f50-b563-fd40acd4e9f3" contextRef="C_99584d81-0d39-482d-9529-479e97a39b00" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> changes in the carrying amount of goodwill since its recognition in 2015. In conjunction with our organizational realignment in 2024, we allocated goodwill among our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9465d44-f8de-4679-8ba6-4d4cc380d922" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NumberOfReportingUnits" unitRef="U_Unit" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reporting units using a relative fair value approach. Goodwill allocated to the MRD and Immune Medicine reporting units as of December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_208d8da3-11e6-41ca-a802-c3b1c21f8d8b" contextRef="C_236a64e1-b094-4db0-b4b0-f4b9a7cae648" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26450225-aae0-404f-8c0b-1c8e4f0c7a55" contextRef="C_569de780-6224-4d27-819f-c41e8e9a86d5" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5dc8e950-38a2-43a8-a07c-dc90c2d428b9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets subject to amortization as of December 31, 2024 and 2023 consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df237992-22e2-4a58-95c8-a6c6e17fdc82" contextRef="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da386e01-d68c-4e16-a24a-7af6ac600875" contextRef="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_371c5917-6048-4a8c-97af-8d68b2dab453" contextRef="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,359</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9d9595e-26f3-46b7-9069-82cdb6a4f0cf" contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0faad2e-a863-4303-a75d-63d9147984ba" contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e574e0c5-107b-4d2d-827d-a4e5501724df" contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b453aa85-b75d-4e5e-b899-edb8c78f2ffe" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,325</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f5b9faa-cfe6-4ff5-a54f-69fb83840940" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,900</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a24ddc-729d-4a66-8b24-5b019137c436" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_038bf05e-7730-4052-a742-c1d7d542c276" contextRef="C_ae8e1030-1ab7-4183-8173-e30e69f625b5" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09929e30-1698-47a8-a52c-00f4a8af764c" contextRef="C_ae8e1030-1ab7-4183-8173-e30e69f625b5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f7a5eed-7d2e-4d41-82c8-a02ff7631005" contextRef="C_ae8e1030-1ab7-4183-8173-e30e69f625b5" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,030</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ea74f2b-4c68-452e-8fdc-14881e9483e4" contextRef="C_43977db9-b2fc-4eb0-8c06-461f1b087616" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bbb9499-ad1d-48e6-a623-4db24f10d0fc" contextRef="C_43977db9-b2fc-4eb0-8c06-461f1b087616" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ec2031e-0071-44d7-bd72-ee98662a38ba" contextRef="C_43977db9-b2fc-4eb0-8c06-461f1b087616" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6619ed30-3bc1-40ce-ac82-1856cbf60572" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,325</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b5fd3fb-5652-4947-bc41-25e48edf4afa" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,197</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f02c84e9-d60f-412c-9a0c-b6d182356697" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed technology and the purchased intellectual property is expected to be amortized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d84168f-f556-40df-8a8b-9f1e8800bf46" contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, approximately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e9d686b-b62a-4528-90ad-ff86fe4a5986" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true" continuedAt="F_4e9d686b-b62a-4528-90ad-ff86fe4a5986_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, expected future amortization expense for intangible assets was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b9e1709-61b1-4636-8092-0a157ee3c67c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_431898f1-0437-43a9-a665-6f97ecab1672" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_052cf842-4255-4fbc-8e12-55efab8d944d" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdbcbc94-e615-474f-bfe1-eab23c683c32" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,425</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_4e9d686b-b62a-4528-90ad-ff86fe4a5986_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cebf14bd-d6b0-44e8-9bc0-f1ee41198874" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98daca14-1dd5-4e60-bc7e-6e1b20063dfb" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43680e0a-578d-4826-a7d9-bfe6ce0fc6b5" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,922</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e93a830-b748-4961-abc0-b224ea4aa9fc" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,920</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical and contract research organization costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a033c1-c82d-4799-8329-f95af4a86223" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebe345a8-d7b6-4efa-a2ab-97a19244f941" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">863</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Travel and entertainment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e437d08-6b48-406f-b6f1-0275fa8de6a6" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24cbeee5-faf7-434a-a191-a41b9189147a" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47f7ce78-d3c1-418d-abba-d8f54553e262" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9dd4e0a-afa3-440e-9176-5d4ba757c26b" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f85b41fc-1d55-4aac-8bdf-d8896473c5be" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb28ff52-d6a1-4d6a-9815-610691e5e21d" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b44cba6-9db6-4b06-984d-cd79143353ba" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:ComputerAndSoftware" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,065</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e364a803-4b10-48ea-94c8-198aef45b5ea" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:ComputerAndSoftware" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_080d422e-eb20-41f5-9e29-be0e0272440d" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1e90aab-8ac9-4f53-9a48-6d1bdb5f9a9b" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">763</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d5a11a-3508-402a-b1f7-be2976c8b598" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eea805cd-637e-483a-9155-824f386bc8d9" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,597</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_2a86b840-0e16-46e3-94cb-ba2a65744d0c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_2a86b840-0e16-46e3-94cb-ba2a65744d0c_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b179d7-8c48-4c6f-9ba7-0bd054956156" contextRef="C_07b2fa42-3cff-4d55-9da4-b7ec997c914f" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">65,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a92b3e7a-268d-4c5d-b6e6-4b2da7a6e743" contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash payment for rent of the expanded premises commenced </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b963713c-e540-44b3-b812-ec00625c916e" contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9" name="adpt:LesseeOperatingLeaseRentCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da94f5b8-0092-4b13-b919-7917251e2ca4" contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to our option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad6670cd-8b10-4bfc-b6c5-fa6eca0ae770" contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount of the asset group to future net undiscounted cash flows projected to be generated over the remaining lease term. These projections include management's estimates of cash inflows from potential sublease income and outflows for operating and maintenance expenses. The carrying amount was found to be unrecoverable, thus we assessed the asset group's fair value. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Fair value was determined using the income approach, whereby we discounted estimated net cash flows using a rate commensurate with our estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, we determined that the asset group was to be fully impaired. As such, an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_66782f0d-d53d-4c13-bd13-17f76499cf21;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment charge</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50850346-ae66-43c8-854b-9c874b430f12" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized during the year ended December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ae0132f-a370-471a-a623-b5c427d023a7" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which related to the right-of-use asset and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e2e5eb9-f271-4dbc-bbb7-f18e90f8925f" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ImpairmentOfLeasehold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which related to the long-lived leasehold improvements, all of which were held for use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2019, we entered into an agreement to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4481ddd7-650b-49d9-9e59-d673960c7996" contextRef="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31c4ddce-b2c1-44f2-9752-a4f5770e8e9c" contextRef="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million letter of credit with one of our existing financial institutions. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e995599-2aaf-4e67-b25c-5a300f901165" contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198" name="adpt:LeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5130c4cb-4830-4f89-9aaf-cadc1e55b359" contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash payment for rent began in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a795a71-30a6-42df-9862-1aa1d0f593f3" contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198" name="adpt:LesseeOperatingLeaseRentCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the lease term ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42af2e2f-8a35-40d9-88ab-02ffc685b96d" contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to our option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a95437c-a3bd-40eb-a983-393a365a7c80" contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_328c67b4-f6b2-4ed6-9d07-66ceaf8a9e3c" contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twice extend the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_647254ed-bc99-46d5-8577-443827761596" contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with this lease, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d704d85f-ccb4-4eee-a009-b1d08a0fc0a5" contextRef="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in improvements, which was subsequently reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f0790af-9d76-4abc-a9f7-d4f608d716f8" contextRef="C_3505aa94-9150-444b-91e7-c7847006ec3b" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as a result of our change requests made during landlord construction of the building, net of an administration fee. We incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_647c90e0-5783-4cad-a92f-697528bc7321" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:TenantImprovementCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_300b0afb-1754-4dec-b26d-07c1994dd1ad" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:ProceedsFromLandlordReimbursements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in certain tenant improvement costs, all of which had been reimbursed by the landlord as of December 31, 2022. The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2018, we entered into a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d148c87-cbdd-4d94-938d-17e5e0ba8c70" contextRef="C_f2113807-0eb7-481d-81da-8e883e379e25" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">13,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet in South San Francisco, California. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_189bb81f-3c06-40e9-9f76-f5f03b890e63" contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term is through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67825add-7a6f-4c53-bd72-a27f22f300b1" contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and provides for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45a89834-07b4-42e1-a41b-e8c8b82ea86d" contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1eea147-8858-441b-9b7f-d3b1d5800b66" contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> extension option</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are responsible for our share of allocable operating expenses, tax expenses and utilities costs during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3c7dbe2-b1ed-4ec3-81fa-8fe4689cd13c" contextRef="C_f2113807-0eb7-481d-81da-8e883e379e25" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a22f328e-034b-4748-9542-f6850ae3360f" contextRef="C_7869d22e-be80-4ab4-88aa-2651f1bd991b" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">19,900</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional square feet and provides for a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a737faf-e5d6-4cd8-9925-5883e011bd5e" contextRef="C_d3e396ad-f474-4619-9772-0d0cf9c0f093" name="adpt:TenantImprovementAllowanceAndCommenced" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million tenant improvement allowance. In 2024, as part of a restructuring, we vacated certain of the leased space in South San Francisco, California and incurred a related impairment charge. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2a86b840-0e16-46e3-94cb-ba2a65744d0c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, we executed a lease to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_359546ff-f28c-40cd-bb08-38d57c293380" contextRef="C_7cc0feec-e028-49cb-9eb1-10aee43d5810" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">27,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31de8320-0164-406a-b3ce-8b39813bf582" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the lease expires </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2453dd52-b7e3-41e0-9cd2-cac30ecb77fc" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ddad7bb0-3ff6-486d-8d8b-33801d8a21fa" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to an early termination option after the seventh year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_244025a9-47ca-4e17-94b2-e7429bd7eb28" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee45fe6a-cf27-4dab-9f36-5c3ba70f9c38" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f96fdea0-8aeb-4e57-9e63-1c17f25a792c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in improvements in connection with this lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we were not party to any finance leases. Our leases have remaining terms ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76a37903-ce9a-41d8-a059-439694f12b6d" contextRef="C_bdf418ac-63a7-4d7a-a22c-01620319ca13" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b8f7c79-f4f4-4a5a-9dab-499726e974b3" contextRef="C_cfd24335-f1d6-459a-a81e-c4653a33dd6e" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and include </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbe35225-2e87-484a-980d-cab7062e3fd4" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">options to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7c29e0b-5972-4667-ab8e-ae815a3e170d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend certain of the leases</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_233cfdfd-3531-408e-93e7-7acb894846a2" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and terminate certain of the leases after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b4e5514-9f7e-497e-8785-5a5bf6787e94" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years of leasing. We adjust lease terms for these options only when it is reasonably certain we will exercise these options.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2af053b4-fbcb-4f21-bcdf-3c051d807b43" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other information related to our operating leases as of December 31, 2024 and 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.379999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.379999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a76c4d9c-c690-4697-9364-501f147905f5" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.06</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4cfdf0e4-45cc-43a4-8f52-6b5dc7508888" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.91</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8ce7f9f-7fee-40ff-be5e-1598c654cdb4" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81d0ab9d-2069-410d-8a18-720ce6244c65" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b34ce157-9026-4db3-8d66-1f1ac6bf1f2d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac95b468-a66b-4e2d-9569-58d5103ce7ae" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,098</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7afc5626-4fc5-42ca-b489-b455748a8b0b" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2054cd0e-6e67-4c63-ae57-5434644347d1" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,944</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_188b7ab2-cb49-4030-a9c8-857a03d5bfe6" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,282</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_645cbc64-2e5c-4637-a828-a236e3fe6989" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb5b5a43-3e80-418d-bbb7-982a5ea2cc1e" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,332</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34d58262-3c00-463a-a618-b1bc66f59793" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,616</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8814dc4-c69c-45ab-b626-4940a6360ad1" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,229</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef0dff10-17c7-4e59-bd19-00d49b897a18" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,387</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cff40f48-e87d-453c-902d-9bc8eb67fc6e" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7bfd148-1a4b-4f81-a904-a8db6b6ce3d2" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,148</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c89d2e1-be66-475f-bc7b-3d06a63ff14c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2427a4a-c2d9-47fa-8bf0-cc3fe83a2d3f" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_604576ac-84db-480f-958f-8ded64f30f5f" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively. Variable lease expense for operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5c9cc4a-cd05-46fe-a0e4-879f490c34a3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:OperatingLeaseVariableLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceb6f4bd-7f13-45fc-a116-bee5f50fa5d9" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:OperatingLeaseVariableLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5be3cf3c-577b-4406-8e2e-e3730abb1f49" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:OperatingLeaseVariableLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8851b41-ae91-4ab6-b1a5-a35d62623e9e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f5c1402-1350-4ac0-aa8c-10721ea4f320" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22c09ee2-bb9e-4036-8522-bff8624af46d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb1788df-9cdd-497d-90e8-c21b24fa60b4" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash received for tenant improvement allowances during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_4d09d14d-710b-48f3-9908-edab84f90682" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:RevenueInterestPurchaseAgreementTextBlock" escape="true" continuedAt="F_4d09d14d-710b-48f3-9908-edab84f90682_1"><div class="item-list-element-wrapper" style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty &amp; Credit Opportunities IV, LP (&#8220;OrbiMed&#8221;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6d2c965-4533-43ce-8e7e-f7660a286cbc" contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275" name="adpt:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Purchasers at closing (the &#8220;First Payment&#8221;), less certain transaction expenses. We are also entitled to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee07bde4-827b-4236-aeb9-a9892aac81d7" contextRef="C_1fb577e9-9c40-4d2b-bc4e-1fc3181e8bb2" name="adpt:PotentialRevenueInterestPaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in subsequent installments as follows: (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89acf6e4-022f-4e10-ad9d-56aa85413231" contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948" name="adpt:PotentialRevenueInterestSecondPaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon our request occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_212d0a36-b081-4b8e-aa84-ae1557d48624" contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275" name="adpt:PurchaseAgreementSecondPaymentDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 12, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Second Payment&#8221;) and (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acaf2e28-edbb-427e-b813-1c9e40ed8b8b" contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948" name="adpt:PotentialRevenueInterestThirdPaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon our request in connection with certain permitted acquisitions occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e463e0f-7c26-4592-a870-d3902516f0f5" contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275" name="adpt:PurchaseAgreementThirdPaymentDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 12, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Third Payment&#8221;), in each case subject to certain funding conditions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_4d09d14d-710b-48f3-9908-edab84f90682_1" continuedAt="F_4d09d14d-710b-48f3-9908-edab84f90682_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Payments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from us based on a percentage (the &#8220;Applicable Payment Percentage&#8221;) of all GAAP revenue (the &#8220;Revenue Base&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments in respect of the Revenue Interests shall be made quarterly within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d85067b-74a1-476b-ac59-08d5ea24b771" contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275" name="adpt:RevenueInterestPaymentTerm" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days following the end of each fiscal quarter (each, a &#8220;Revenue Interest Payment&#8221;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;Cumulative Purchaser Payments&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Return Cap</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OrbiMed will be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e18ed711-8430-494e-9a56-0de220b8b2c1" contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948" name="adpt:PercentageOfRevenueInterestPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Revenue Interest Payments until it has received a total cumulative value of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1e65d7-2158-471a-9116-06528d2388e9" contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948" name="adpt:PercentageOfCumulativePurchaserPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">165</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Cumulative Purchaser Payments (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79efe166-bdc4-4a83-8427-3722f35cfe86" contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275" name="adpt:CumulativePurchaserPaymentsRepaymentDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 12, 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in which case the Return Cap shall be increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8ada9fb-73ac-4c50-8819-09eb0c948e09" contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948" name="adpt:IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">175</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Put/Call Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by us, a change in control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation ("the Put Option") to require us to repurchase all of the outstanding Revenue Interests at the applicable price (the &#8220;Put/Call Price&#8221;). Additionally, at any time following receipt of the First Payment, we may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap. For a change of control or a material divestiture, the Put/Call Price shall be equal to the applicable Return Cap.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Treatment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the terms of the Purchase Agreement and concluded that the features of the Cumulative Purchaser Payments are similar to those of a debt instrument. Accordingly, we accounted for the transaction as debt recorded at amortized cost using the effective interest rate method. We further evaluated the terms of the debt and determined that the Put Option that is exercisable by the Purchasers upon certain contingent events requires bifurcation as a derivative. However, the value of the Put Option was determined to be immaterial due to the remote possibility of exercise. We assess the value of the Put Option periodically.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eacf0ca1-30f3-4faf-a370-d4cd46191f63" contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec" name="adpt:AmortizationOfPurchaseAgreementObligation" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> over the amortization period. The calculated effective interest rate as of December 31, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db953369-9149-463b-b868-d27649f6e090" contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Purchase Agreement, we incurred debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b13bc2f-dff6-49c3-bf6d-f3dfe2d237eb" contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Debt issuance costs have been recorded to debt and are being amortized over the estimated term of the debt using the effective interest method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the issuance costs, as well as the effective interest rate.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_4d09d14d-710b-48f3-9908-edab84f90682_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bcd05089-756e-4fed-96db-5f99cea80a46" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea54a1fc-0e74-4ff7-9c54-3410bdec72f2" contextRef="C_7f50006e-3aac-4a89-bd88-97a6fda0febc" name="adpt:RevenueInterestLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,360</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_221ba1d6-c431-457c-aa04-5cb5e416b0e0" contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81b20960-7280-4516-b5fd-74670bf48069" contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a" name="adpt:RevenueInterestPaid" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3927d96-3128-4966-92fc-bcf0e00c7945" contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb6c4fe7-104a-45bd-8c91-6ae3549bb345" contextRef="C_8f46490b-2478-46c6-9c66-ca4d59a7e377" name="adpt:RevenueInterestLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,660</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afbb3bb4-2ecd-496a-8132-21769ae1c676" contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,580</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f2a3a9d-8605-4461-b762-2660ef36ed2f" contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec" name="adpt:RevenueInterestPaid" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,589</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3245881d-52a4-4434-9bad-35c27d21a644" contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_411af40b-aa8e-46f5-a7e3-8c827a7b93bf" contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6" name="adpt:RevenueInterestLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,279</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_450d16d1-6297-4194-82bb-5d2897315c53" contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6" name="adpt:RevenueInterestLiabilityNetCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">865</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net, less current portion at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4baea06b-f1ba-48e3-93dd-ee245f5464fe" contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6" name="adpt:RevenueInterestLiabilityNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,414</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29d1f144-2104-4d28-85cb-2555059d2d43" contextRef="C_752e690e-a58f-4330-872e-b0e7486ee008" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2022. Revenue interest payable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc194db8-314e-4539-80a1-b7775c9ab377" contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43ba7091-8c3e-40d0-ba48-80fcb01e8a61" contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75df5473-c85f-48fa-aac8-6818a0b431fa" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_88f73eb6-4639-4709-86b0-7074ba0e4e8e" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_88f73eb6-4639-4709-86b0-7074ba0e4e8e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders&#8217; Equity</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has no preferences or privileges and is not redeemable. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1a65c8e-2a02-4888-ab6f-60e5b08a5de2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CommonStockVotingRights"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a988ed61-9ace-45ee-a92d-a8c806e11557" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:NumberOfCommonStockVotingRights" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share of common stock held</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f09d709f-38e3-44a7-8e0d-1dbfd5c0db69" contextRef="C_70fe95bd-0b9c-4b16-aab2-e8db1c249769" name="adpt:PercentageOfAnnualIncreasesInNumberOfShares" unitRef="U_pure" scale="-2" decimals="INF">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0d04c4f-01e7-4e19-89ce-5683b81138c8" contextRef="C_6058a09d-5c33-4856-9a87-634891fd1ff1" name="adpt:PercentageOfAnnualIncreasesInNumberOfShares" unitRef="U_pure" scale="-2" decimals="2">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective January 1, 2024, our 2019 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e2a8385-ad74-4a32-8580-721cfa05664a" contextRef="C_30a5bbbe-6a9c-4d08-a5bf-c0ca07f38d71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,254,113</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91b90c99-573d-4222-8299-dea0e8cec86e" contextRef="C_db18a52f-bcfe-46a3-89ae-80288cdff126" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,450,822</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. Our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2025.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_88f73eb6-4639-4709-86b0-7074ba0e4e8e_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_376f13d0-e41d-4cde-8fa8-565644fbad16" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock" escape="true" continuedAt="F_376f13d0-e41d-4cde-8fa8-565644fbad16_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had reserved shares of common stock for the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issuable upon the exercise of outstanding stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25864832-cbb8-4983-9728-4bba4366e496" contextRef="C_ebc8e107-4003-4674-8227-7ec4caf59826" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,295,297</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_972d449f-f85d-4264-847f-6210e75b6234" contextRef="C_f01c0215-4e04-4a37-b6a0-43ec834d33fd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,005,966</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grant under the 2019 Equity Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc2566b-558f-4434-b9a3-43cb5a28ccc2" contextRef="C_fea8d0de-6b48-42cf-a187-18acba215cd4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,018,312</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grant under the Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c90f8b4a-9855-4d9f-9c85-adc1e09ee812" contextRef="C_1119d75f-ac1e-4443-a095-4f4846ec2ff9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,686,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e3099c0-a7e5-42d8-aeac-5ecd3df94cfb" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,005,745</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_376f13d0-e41d-4cde-8fa8-565644fbad16_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_b96a069f-49b9-4999-8ac8-49ea8276582c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_b96a069f-49b9-4999-8ac8-49ea8276582c_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2009 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We adopted an equity incentive plan in 2009 (the &#8220;2009 Plan&#8221;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa2173fc-6748-4afc-a5ef-d80837132ee2" contextRef="C_4e62fea1-8195-4797-84f6-8e80fbc5903d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd7539e-d42a-4323-a403-1b94a5ce613b" contextRef="C_76aa1ad9-be8e-41ac-91df-576de65c2d91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e80170cd-7ee8-4a4a-bf1d-2f945a2a7653" contextRef="C_6dc97585-6690-424d-b20a-80823243e590" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date and vesting is established at the time of grant. Except for certain awards granted to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ae7106d-8d92-470a-bb5a-4287fd6d42d2" contextRef="C_7fc08718-7fea-4e2c-bb3c-69007782863d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period, subject to continuous service through each applicable vesting date. As of December 31, 2024, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46875355-7034-4a29-be21-01187f37ef3f" contextRef="C_fea8d0de-6b48-42cf-a187-18acba215cd4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,683,842</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock authorized for issuance under the 2019 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9af5c0ad-6b34-4c68-96f7-65833a68ecfe" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in shares available for grant during the year ended December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Available for Grant</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4814e17-75db-4225-96bb-84fa2dc7512d" contextRef="C_6b74a919-15ca-422a-bdd2-8538b4633aa6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,299,763</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan reserve increase effective January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_858a7111-d42c-4ef3-8193-440ca92bf288" contextRef="C_013827d3-b15c-4f85-88a8-bbae4386a47c" name="adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,254,113</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aef913d-5f92-46a8-9c83-ee548b1688d0" contextRef="C_013827d3-b15c-4f85-88a8-bbae4386a47c" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">8,841,392</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cae9003-a357-475f-af12-8b3292740a27" contextRef="C_013827d3-b15c-4f85-88a8-bbae4386a47c" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,305,828</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_048dc2c5-df04-4298-a855-62b746f28349" contextRef="C_b03c96cb-2be3-4399-a5cc-ad4279252dd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,018,312</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e4e398b-cff8-4b15-8c8b-093803b1c9b2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2024 was as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.2%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.780000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.780000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Subject to<br/>Outstanding Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise<br/>Price per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f9ce59b-e494-4dd2-a273-7abc5d974c08" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,875,045</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_446ddf01-b178-4315-afa3-8cb1361d9435" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.90</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21f44144-f179-40ba-8614-aeb9b1f6ba02" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,008,364</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71e21c2f-39e1-4201-9b28-5f42178edd2b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.99</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1465a66e-03b2-4a64-98c9-4ff74f2efca0" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">718,920</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f84d3537-8622-4131-9ff4-40f89f9a93c7" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_485f4d05-8c60-4392-b8fd-6d210a1a828c" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">765,392</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e09e81-27ba-4599-9524-1a8642085a3a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.61</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82ffb42f-cada-43e3-8ce3-9673fb3c7e0a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">103,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e8edec4-3e66-44c3-9faf-8d8509ebc72d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.32</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ef08cd9-7144-4c97-9a61-aee441105f70" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,295,297</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4475acc4-7754-4cf0-9053-c897393df525" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd75ff00-a42b-4792-b1b2-9d5e1d6be657" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested and exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c760635-c9a6-4c7f-95ba-2109ac8b513c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,027,350</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d718cd0c-f1ae-4b27-b3b9-cd879286f1f1" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bb66791-0a3f-497a-aed9-157bd11ce9d0" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">497</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b96a069f-49b9-4999-8ac8-49ea8276582c_1" continuedAt="F_b96a069f-49b9-4999-8ac8-49ea8276582c_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining contractual life for stock options outstanding as of December 31, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b60c74a0-a239-48d6-b6d6-1ccb1c31e5da" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The weighted-average remaining contractual life for vested and exercisable stock options as of December 31, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fe0a300-d1cf-48ab-9969-241a1fa79107" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.9</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value of stock options exercised during the year ended December 31, 2024, 2023 and 2022 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61df55a-89b1-4293-b61d-a8830de8f884" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e1e3e67-87dd-4983-8afc-c038dc1ed353" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ac2f9ae-dcfd-4414-8653-a27db604e4ba" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa6c4d3b-c2c7-4dc6-8c0a-317a162347e2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true" continuedAt="F_fa6c4d3b-c2c7-4dc6-8c0a-317a162347e2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units<br/>Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a3cd839-ba65-4f14-87fb-f53f79afc361" contextRef="C_938538bd-3388-44c9-b50d-231541782951" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,669,460</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5917b864-404e-4b04-9ff2-3f96f69f4d1b" contextRef="C_938538bd-3388-44c9-b50d-231541782951" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.32</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04d26330-dc31-46e2-b54e-0f60b759d5db" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,619,008</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_606468b0-62e8-4ad4-a8f3-2464cdc3df3d" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38678f89-2b45-4df5-a6a1-ff21f934af1b" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,525,936</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4777eaf7-00f7-4739-8fe3-c943ec333cef" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.91</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66555471-d7ae-4a75-90c3-35b75f427737" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,587,680</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8137d61e-466d-49ab-b108-b799f6dcb548" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.28</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1282e36-8fd6-4ece-9e28-c5467feb15d8" contextRef="C_0c9ad877-d4fd-4667-9562-04fee6ec1601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,174,852</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e44a746-d264-47a0-bd1b-fbf31ebde5eb" contextRef="C_0c9ad877-d4fd-4667-9562-04fee6ec1601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of restricted stock units vested during the year ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f71e4b8-ca15-4520-b719-f6f8c472d428" contextRef="C_4038584b-af9b-45c7-a179-a1aac6d8e18e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc1b4bc2-f9ac-487b-8d70-77a887d05dda" contextRef="C_a8b15cb2-7331-4388-b91a-39842959aeaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7657c6f9-7ec4-4e40-a2bb-aca9d306a9c8" contextRef="C_5849a7e8-d209-4520-ae06-42818b55c73d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market-Based Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our executive officers have been granted awards of market-based restricted stock units. The number of shares of common stock that may be earned under the respective awards range</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1e4c96b-f567-4746-8081-87696ec9bfa6" contextRef="C_e9191c9f-9e40-4eef-8bb8-8c5bff219c41" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares to a defined maximum number of shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and are c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alculated based on our total shareholder return during a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22865e16-f178-4d26-a83f-d9aba9875879" contextRef="C_fb6ff782-0ca3-4143-ad9b-7c8ef89ed646" name="adpt:SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance period as measured against that of the group of companies comprising the S&amp;P Biotechnology Select Industry Index as of the grant date or other applicable date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fa6c4d3b-c2c7-4dc6-8c0a-317a162347e2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market-based restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maximum Market-Based Restricted Stock Units Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested maximum market-based restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29b5c0ba-5024-4df2-a487-6cdfecf046c4" contextRef="C_0a49afd5-b03f-4f5c-bc78-5dfce07d3fbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,912,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbba250c-0558-4591-bdaf-bbe87da96327" contextRef="C_0a49afd5-b03f-4f5c-bc78-5dfce07d3fbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.13</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum market-based restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b945f559-d87a-4077-8990-234ac08929d8" contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,214,020</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32be3a21-4e96-4774-ba3e-bb49d80e6054" contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum market-based restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f56e5b55-ffb3-413a-8df4-8c1ccde3667a" contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">295,580</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99f43c1c-6726-4682-ac38-bba7e19cb03f" contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested maximum market-based restricted stock units outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c72bc661-5530-4046-bb4b-de16ebfdfe17" contextRef="C_0029b7a6-ee35-412e-80b4-c83f66b83283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,831,114</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1deca409-a626-4470-8207-a0dc935d5466" contextRef="C_0029b7a6-ee35-412e-80b4-c83f66b83283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29ed6452-88aa-41dd-bd9e-c9da3c931417" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated grant date fair values of stock options granted during the years ended December 31, 2024, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.189%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.238%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.258%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.258%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_845a7e07-1ea1-42e8-9eaa-f1a9c3489399" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.99</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e350a257-e526-48c2-af47-0fbb14368056" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.46</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55e1a85c-dbf2-4262-8e47-97a7112797a0" contextRef="C_bc4f3373-536d-41d1-b3a3-421bacc254af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f4fadb-9868-4836-9f05-d0c24117eabc" contextRef="C_8dd592c7-dd5c-4673-a9f3-c1849fefa514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.95</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7cabfb42-b4ba-4a27-9d32-4631a3bfd450" contextRef="C_79c39ab7-5350-4de3-9055-afde44e88b1a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_5758daf0-17f4-47c8-aa31-896dbf687a26" contextRef="C_cb4e71eb-46c4-41f6-9ca9-4467ec43dcfb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0769750b-2bea-42fb-8d2e-f057eb11a84a" contextRef="C_e16d035a-df2e-4300-bb99-13a2fe409ebb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><ix:nonNumeric id="F_8c274192-9e32-4e29-9849-7efc7277cdb6" contextRef="C_31434234-729f-49fb-9bc5-a4c2db285d76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c7fbccd0-5c78-45e4-b0fd-2122c6f153a8" contextRef="C_bc4f3373-536d-41d1-b3a3-421bacc254af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_69880cbd-4579-4bd2-8748-00d2862eedc2" contextRef="C_8dd592c7-dd5c-4673-a9f3-c1849fefa514" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe4d3a4-89b6-4158-acf5-62c05cb03804" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14718e8b-863c-4f5a-b1e9-5bf5a053cd2f" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e13b5c47-8eed-4ce2-87e4-5ad98d2d1f04" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f6bd8f-0bd2-4c33-8ff6-d6099a844d39" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fb06c1d-2525-4aeb-ad1a-4d8ca254275a" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_106f0036-0cd8-4f1a-870f-595a82a8d496" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">74.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da486138-89b1-4b7d-bb24-9e4898a5356b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_828aa817-5d64-495f-b2b8-e3ce9437d20e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee18999a-fcf8-4107-94ce-d5347fe90ccf" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac8014a3-3e1f-4eeb-8432-61941388b753" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">68.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05a909a3-8336-4e8d-aa70-0bd904935ecc" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b96a069f-49b9-4999-8ac8-49ea8276582c_2" continuedAt="F_b96a069f-49b9-4999-8ac8-49ea8276582c_3"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are subjective and generally require judgment to determine. The valuation assumptions were determined as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value of common stock&#8212;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term of stock options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based on the midpoint between the vesting date and the end of the contractual term of the stock option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Until 2024, as we did not have sufficient trading history for our common stock, expected volatility was based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning in 2024, expected volatility was based on a weighted average of our historical volatility and the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend yield</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c575638-58a0-4c2b-9fa1-223f23a3231a" contextRef="C_dc2d580a-7814-47b1-a90a-9db3f5a070a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the option valuation model.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2024, 2023 and 2022 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27a97d29-83f8-4b62-83b1-d3342627773a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_950735d5-2522-4b0e-bf21-748b19685ba3" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.61</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be588453-3e7f-4214-b54e-7954c845c915" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.36</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant date fair value of restricted stock units granted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace5efc9-3618-4576-a37a-3b38c54e832d" contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da456697-6b6c-49d7-a75e-b53175f5129b" contextRef="C_05929f03-5f49-44c6-99b2-b6ac0648d6a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.29</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c390fc93-273a-4eb3-9cfe-1af01eb5c34b" contextRef="C_800a8d4f-a9fc-4ca6-8af0-3cd02f0dd56b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.43</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of the market-based restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3b1041c-2c90-44d2-9547-1faf6fdb8234" contextRef="C_c147eb1f-f94e-4397-b028-6165d4ff279b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215357b4-87ce-4b72-ad89-cec3d71e577b" contextRef="C_8672005a-0af6-4c35-b305-e5625f4ced55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7db58e6a-9998-4c65-b1e3-59038be1f862" contextRef="C_f3a08a4e-1038-45b8-8a45-c1295cbf5ecb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The aggregate share-based compensation expense of the market-based restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49c714d7-92c9-4a77-9316-42c7c012652e" contextRef="C_df6ab829-80ae-4fe6-8c59-0c879baee98e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0453a52c-0479-4d85-970f-4d1774ce19e3" contextRef="C_b986fb51-c7d8-4885-ad77-406faf3a7217" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a524105-025e-4492-9eff-30cd2ce2b226" contextRef="C_60932611-3f39-47dd-9da8-86fe5e9898f4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million respectively. Aggregate share-based compensation expense is calculated based on the target payout level of shares granted and is recognized on a straight-line basis over the respective grants' performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense is reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78466b83-d9c9-41ba-bcd6-e0b2e02928bc" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2024, 2023 and 2022 are included on the consolidated statements of operations as follows (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30c16fd9-5a3b-4e7e-ae7a-4cf9dbae25ae" contextRef="C_830ceebd-b448-4556-8cc3-345699e93087" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,632</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe98620-79d9-4ae8-baa4-f855778b3826" contextRef="C_cc544eb2-c862-4117-ae53-7167dec34569" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e2b6898-fc62-4693-9a47-a33be9ab9796" contextRef="C_2ac1d2a6-7485-444c-b87e-886ba5dc3b3c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,910</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f15545-f094-4afa-af5a-af010f8e3e96" contextRef="C_88922b78-bf40-483b-ba74-3b67fea9b4fb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6bb8892-51ff-49e4-ba7a-1d9fa30703b0" contextRef="C_6f1910b3-9154-4298-8382-eeed229f5b9b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,465</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b09a6736-1ff7-4300-b92e-c8e9fa5a7624" contextRef="C_3b97b1d4-62a9-4c60-be60-2108f97f8fb8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cacbd3c-d9ae-402e-8389-cc8fa5ef50a3" contextRef="C_ac141085-19dd-4092-b7b5-3caab7439cf4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,370</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78502f5d-e0b3-4c30-bcf2-c2afec090314" contextRef="C_7c1e94f7-1563-46d1-9179-65444a8457d4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,553</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_508a32d6-326d-4073-9c9e-1ca2eec24b1e" contextRef="C_355bb8fa-16f0-474d-b4fd-4b16eacb34a6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,597</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b96424b8-5cb2-4465-b5cc-908443fcf51a" contextRef="C_9eec2a01-b68b-4cd4-9ae8-af29e919f6c0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e39ea0fb-c36d-4c33-bd17-f512fe735b93" contextRef="C_22b5dd10-ae86-4ea2-9caa-a6986a38f552" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,704</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_260bc098-85ba-41cd-8f24-f24588759f81" contextRef="C_1acd60e0-7824-477a-940e-96fcce72212e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf466c88-0074-419d-852a-1475d3e43c2a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,610</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_568aba40-1245-4601-9d76-b42e09f71a2e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fef3d1a-459c-41d9-9dea-8fd71e7bafc6" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_b96a069f-49b9-4999-8ac8-49ea8276582c_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8247b64-7ae7-4a1b-b844-0e0a83b1a777" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" escape="true" continuedAt="F_b8247b64-7ae7-4a1b-b844-0e0a83b1a777_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Share-Based<br/>Compensation Expense<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Weighted-Average<br/>Recognition Period<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dae7c15a-55c1-4865-9f4d-5157b4ee0338" contextRef="C_8c08d7f9-6ece-4397-98cb-7a4e690601d7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,943</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b2052300-0a0f-48b8-a2ab-bc2e530ba2fa" contextRef="C_26c9b550-cdb1-4568-b071-8fda1b1e79ec" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0052623f-18b1-4501-83a3-6cba04e8e637" contextRef="C_826be3c4-b05f-4764-b189-9b17a0ed4f47" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,803</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_816c7c93-51da-4add-919f-32f2a25afad5" contextRef="C_3371457f-35a0-478d-ad1d-6b89373e6edd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.23</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested market-based restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74a44a79-a10e-4e3c-bb2d-a16d78247d41" contextRef="C_16e28997-7e3b-4c9b-81c4-971e637e2f39" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,611</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f3642102-2761-4557-a351-b80fbfe06e37" contextRef="C_d536e9b5-ed0c-483d-9d06-83c84f459d93" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.66</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_b8247b64-7ae7-4a1b-b844-0e0a83b1a777_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_279d2a7f-78c1-43f5-8505-1bcf50ee0275" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restructurings</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f638eb5-5a05-425f-8223-c34a174ec26b" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Employee" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> employees. We incurred aggregate restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_602a6d4d-e245-49e4-865e-0d283effea7f" contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees&#8217; execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to this reduction in workforce were primarily completed in March 2022 and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30262436-ed79-402e-8217-bde4ca08a045" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate restructuring costs were paid as of December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2024, we implemented a restructuring plan to better align our organization to our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c68b4da1-c105-4b71-aa4b-fe1b17e709af" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segments: MRD and Immune Medicine. We incurred aggregate restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bd5f84c-91b5-48c2-8a22-a916ceea0183" contextRef="C_cfbee4bf-0f67-4e80-8986-2a8c42354e22" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, primarily related to one-time termination benefits and ongoing benefit arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended June 30, 2024, we implemented additional restructuring initiatives which impacted certain planned software enhancements and resulted in the consolidation of certain research and development workflows. The impacted software enhancements were primarily associated with our laboratory information management systems. As part of these restructurings, we had long-lived assets that were no longer being utilized and we vacated certain leased space in South San Francisco, California. As such, we assessed the related assets for impairment by first comparing their carrying amounts to the future net undiscounted cash flows projected to be generated over their remaining lease terms or depreciable lives, as applicable. The carrying amounts were all found to be unrecoverable, thus we assessed the fair values of the assets. The extent to which the carrying amounts of the assets exceed their fair values represents the impairment costs to be recognized. As a result of our assessments, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5901db2b-686f-46f9-8cd8-32e5ef276efe" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of impairment charges. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87c36c68-cf35-48f6-b5ed-a680994219eb" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million charges recognized, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb9c5c5c-84a1-41d3-a4fb-79ea8ec8a372" contextRef="C_edda825c-90de-4c1f-b5b3-c767c222382e" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd886e3f-e134-4d63-a3cb-c3d90648701e" contextRef="C_ab192050-c968-4f59-b97c-0347bf2e6704" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million relates to the right-of-use asset and related long-lived assets (namely laboratory equipment and leasehold improvements), respectively, associated with certain of our leased space in South San Francisco, California. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_303f8b0f-f69e-4c0a-a44d-153ae8eb9d91" contextRef="C_c00eaa13-213e-4380-87d4-07983d165569" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized relates to the impairment of long-lived assets associated with our halted software enhancements. We also incurred an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97fe3ee1-13c7-4533-9d30-26b8d516a50d" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in restructuring costs primarily related to one-time termination benefits and ongoing benefit arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended December 31, 2024, we incurred an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdb3bbd0-b6f8-48b9-9d81-7d30a27932b2" contextRef="C_03002793-4de6-465a-b177-09dbb4ca58f5" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate restructuring costs, which primarily related to one-time termination benefits and ongoing benefit arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In total, we recognized restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74dc7026-9dcd-4790-922e-0292966fbed2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024. The activities and payments related to these restructurings were completed and paid as of December 31, 2024.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_46db21ea-4240-455e-b0a1-dff2989c4bb3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_46db21ea-4240-455e-b0a1-dff2989c4bb3_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3be247c-62ef-451b-bc63-452dbc1c2016" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of loss before provision for income taxes for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e79980be-a10c-4e2e-a47b-fd7f232974b9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,635</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57027b27-316f-4f29-b1f8-f82d9d4b0a8c" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,335</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76a779ba-67f0-408c-b345-0c6a0763da52" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,427</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f75e57b-4603-41fa-87a2-22b3a72e8efc" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_555b9d7e-2730-46ac-bd35-521b0909cca1" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03796521-6783-4978-ab71-0fb1dfff7bd0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total loss before provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd30d579-cf3c-44f6-8f96-c1f0236ebe23" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d92786a-cb1d-4141-ad37-3dd705946b33" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3de0b4a8-0a0f-4f04-aad0-a783ae3f03af" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_46db21ea-4240-455e-b0a1-dff2989c4bb3_1" continuedAt="F_46db21ea-4240-455e-b0a1-dff2989c4bb3_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28de6449-18e7-4918-9bb7-286be4a9fdfa" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ff4c4a9-6d08-4e15-b8f7-1401b9f5562f" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,535</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22744083-64fc-4daf-9357-cb09ee5b03f7" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,724</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit carryforward</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a93857b-95c6-4a87-a84c-262d1af6e20c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,942</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc8392f7-01cf-4721-b3f6-ed9a7d5f306a" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,528</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonqualifying stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34131363-99f2-448a-980d-024106a9fdcd" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:DeferredTaxAssetsNonQualifiedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,010</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e32c07bc-2ff0-4ea1-bef7-b770d2054d57" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:DeferredTaxAssetsNonQualifiedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,166</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_450e353c-546b-4a28-bda9-4eaf954f1830" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,912</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_142aa08f-418e-4d89-a6d8-a35cc78dc64e" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,357</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa8e44bc-1b58-4cc9-a3f3-9d49a7816238" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,996</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5c5268-a401-422b-ba0e-379bea88350c" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,874</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd468981-3b12-40f5-a864-37f8356f025a" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:Deferredtaxassetscapitalizedresearchanddevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,550</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc9f82c2-1568-47b6-9526-627c24418c2c" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:Deferredtaxassetscapitalizedresearchanddevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,134</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9647efc8-7059-4295-a36d-2bd08edc6b9c" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:DeferredTaxAssetTangibleAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,963</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efdc3d1f-8994-4248-8ca8-a52389d8c059" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:DeferredTaxAssetTangibleAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f72435d5-1eae-4476-be44-2e9bd1e04858" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,182</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2771be9e-4bef-4077-863f-e6fe61412387" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,146</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c85134d-b759-4d16-b018-912c2b51ffb1" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">447,090</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6b43b64-b641-4123-b6c1-9ee25f79f633" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416,929</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2d8a381-6fd9-408e-9812-a8d8185234cb" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,509</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4f392e-0f82-4b27-b934-56581b75b222" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402,424</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad479862-3c53-482d-890f-e08ab6cfe0cd" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,581</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0239ffe5-f033-47c5-b813-eecbb846c7a6" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,505</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d8d3ae-f1de-40f0-a052-e64c1119dc90" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2536bd83-e363-4dd4-9d89-f17ac44ca7bf" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efe346f6-023e-4da2-9aab-4686a41b59ee" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="adpt:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,581</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47648c64-f10e-4254-bc84-101bf5e150df" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="adpt:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,224</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa8879b1-1ea9-4050-bfe7-7c44c84579c2" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61903787-73ae-4cfb-9d26-6c1c73516c92" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_758842e0-f1a3-4a21-a709-1d62832b7819" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55f3d2b3-a116-4892-80ac-5bcdf7986874" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebc46338-48b2-4368-af92-56e51cbdd158" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:NetOperatingLossCarryforwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of December 31, 2024, we had U.S. federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96f0284a-853b-4185-9e48-b030854dd2bb" contextRef="C_de48bc4d-6614-4d5d-ba6b-44f4d8a7fb54" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and U.S. federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_057ef4a5-ce83-4a7e-ae71-10624bd89424" contextRef="C_de48bc4d-6614-4d5d-ba6b-44f4d8a7fb54" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">51.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dc2ebf6-56b9-46b8-af1f-0181fc9c5fe7" contextRef="C_fd06ba76-408d-423e-bf02-573512c6c45c" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><ix:nonNumeric id="F_19b76014-babe-42c9-bd75-615f07bf6d2a" contextRef="C_fd06ba76-408d-423e-bf02-573512c6c45c" name="adpt:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47987ab5-608d-4286-bb14-130620452ecc" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">856.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of NOLs as of December 31, 2024 that do not expire.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_819c96c1-5dfc-491c-af47-088534226716" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.36%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:14.4%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:14.4%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:14.4%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db2037c4-a7af-4acb-9990-a1f0a1ae0f82" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ccc914-ce65-4d80-a666-712c3517f3c2" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c92390e5-7450-4592-b549-79ab9bc53eab" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bcfab35-10ae-4a45-8a75-058da4f12bf6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_289e494b-0481-42ac-9737-522e2da0e755" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53063ee4-7b15-478d-ac27-983356938dc9" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_410d08f0-a5f9-4645-ad28-3214870ac2f3" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_383b51c2-8ab3-4c46-88b0-2f3de3258da2" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91921fb1-7dd7-4e8c-a564-24b6576a80c0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53a5f629-6e90-4700-a07b-8de758c6861a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ee15589-92f6-45b7-a00d-ed6466330425" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d961c596-2bb5-4b22-adc5-66ad53dddbe3" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Credits</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df653879-e140-4298-ac1a-9e967f219a8a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df7111e-035e-4140-bb0b-bf95509991ce" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d29c8776-60e3-4410-8292-e40e550073f0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7daed51-9dfd-415a-a8b3-b064d2c81f07" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcb85a27-21af-4f1a-9620-71d7117a381e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15e00dba-4af4-4692-9404-fcb507a9d2d0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c56d8f0b-86da-446f-a22e-22e4b8b8f689" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">20.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e2354e-9dca-42b2-a749-89fc61a3efab" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">25.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f433b42-3482-49e4-828a-a72744aa2817" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cf40bf0-a867-4c90-adbc-12d66ec9721a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2f3222-5c31-4a09-8116-cc72ce9ee195" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec07e9e3-027b-4fb6-afb9-5595ee93ef64" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for global intangible low-taxed income as period costs when incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1c036f9-3cc2-48c8-8577-eaa5aacb0435" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_46db21ea-4240-455e-b0a1-dff2989c4bb3_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_953857ef-8d5d-46dc-a40f-8852e7feeef2" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"/>
        <td style="width:2.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf111243-2384-40b5-995e-98350720c9b0" contextRef="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,915</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5dc326d-cd5b-4d1e-8695-e34d05f504bf" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c94f5764-ed35-445a-9e8f-9fa45af98e62" contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58cb774f-3a95-442c-b63b-f2e4ce4f9dbd" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81791bcb-4915-4dac-b59e-63e064b02017" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c870d34-3630-44e8-bd84-eea0fb171539" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,407</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7a96271-2227-466e-b127-c2142a982403" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,710</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, 2023 and 2022, we recognized uncertain tax positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe37879d-46fd-4ea3-accd-77fdac92e4ed" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef21817a-0075-46b6-8439-b04450e4febd" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88ea27b9-2f02-4a97-ab3e-37b4ebd1dc9c" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea0fd234-a12b-4a71-b187-cbaea14c949a" contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fb103323-3222-4428-ac91-a845546d8264" contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties related to uncertain tax positions as of December 31, 2024 and 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_fe5cac4b-e97a-446b-86e0-0e017389aa95" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_921b9e69-bc78-45ce-9390-f73fd1e4d76b" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022 (in thousands, except share and per share amounts):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.782%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf58a510-ae93-4de9-83ed-b9250c80c771" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a740cd21-abf8-45a9-96c2-096df79cd3c4" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80d67ac8-13aa-4b62-abd8-4e462fcacab4" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6c54f49-ecb8-44fa-aec9-72b9a62a34d9" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_afcc211a-6f4c-48ad-8a85-a3c6f9ec9f36" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">147,101,648</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af31e1da-d588-4f78-afc2-2c7bb4da7b2b" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_77a27fbe-6e06-4484-8dab-d2cc186c586e" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">144,383,294</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a313222d-a0a6-4ca5-8b60-9347cd85347d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a0fc13f0-e911-4bee-a1db-2fe2f6deff00" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">142,515,917</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfa24e49-c228-46a8-af96-9fe63216004a" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ec902ce1-d3c1-4dd4-a5fc-c21d3f3f7480" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.08</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df2128ab-08ae-40b9-8cae-55ee91f5036d" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ff2a88d7-bac6-4f58-916d-f8030befba80" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9edb4a04-500a-49a1-bdf2-a95f5117f618" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_60809b76-6081-4a0f-b7f2-ea5f6f80bfe0" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.40</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_667f1d31-e80a-4995-a2f1-98733cfc3448" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_667f1d31-e80a-4995-a2f1-98733cfc3448_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022, as they had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.255%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.255%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.255%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4822089-c09a-45b6-a2b4-35d9d1f85b8b" contextRef="C_c57a4b94-c81c-408b-81ae-f08bfc651eca" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,744,898</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51368ff4-2624-4c45-845e-ce37270d8e3d" contextRef="C_3242f9e3-dcb0-4a64-a6a1-9e8c5aa997e4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,839,067</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fb1be18-4cc9-410d-8226-78d90e67b3a5" contextRef="C_c231ef4e-80b4-4315-a315-4a98c8a5a33b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,892,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_960d7d33-a909-4e1b-bac5-c7aad8e17bf5" contextRef="C_29808493-b539-4763-a0cc-0c411c398bb5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,584,853</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_916d6684-4a44-42ca-8a6f-1bde2aabb1e0" contextRef="C_099bbd21-af0c-4f39-ba1c-26dd5d66531e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,630,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b129c90-edd6-4162-b3e1-e63d9e9f6cb0" contextRef="C_57cc43f2-a758-4e93-85a5-3570f3deb3df" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,799,850</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum nonvested market-based restricted stock units outstanding eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdd5f0ac-1462-44b6-bfba-8a8d6fdca75f" contextRef="C_425da08a-cc18-4b6b-b559-af896468cf59" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,497,226</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94e0ed93-4b2d-4e08-9970-dcc95de198cc" contextRef="C_9055c1c2-d88e-4bbe-b0ba-ea4735bc60b3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,663,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71f801b8-3d9b-4e80-be08-8e07d7881faf" contextRef="C_dfdfb869-6506-40d7-affa-2d14196aab88" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">410,282</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b99fd65f-eb9e-4492-89e9-76949d5e7b65" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,826,977</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_369b0c36-6efd-4de8-85df-1aa3eac9f5fa" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,133,607</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f2708af-217a-4cae-bae3-303af8719909" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,102,419</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_667f1d31-e80a-4995-a2f1-98733cfc3448_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19bf5ea4-ad38-450b-9bbd-c5df590fed14" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retirement Plan</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a salary deferral 401(k) plan (&#8220;401(k) Plan&#8221;) covering employees who have met certain eligibility requirements. Employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d912c895-b799-4a0c-875e-c6e76df7a226" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2">100</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their compensation to the 401(k) Plan, subject to federal limits. We made $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#231f20;"><ix:nonFraction id="F_f8768a9e-fa51-49a7-9328-a6b5096e3900" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8985db6-f6a4-41b4-9da1-2845f14e9e65" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0353bcd-5c21-4626-9ee2-8d5f1f106479" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in discretionary contributions during the year ended December 31, 2024, 2023 and 2022, respectively, which are fully vested after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_552cadbe-d43f-4448-b356-1b45d172f777" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_17e0b354-45a2-4bd1-85dc-a893e33f0b9d" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_be250134-b2e5-4314-ae13-fc512c9b7cc3" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one year</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of employee service.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_f2d2fafe-cd53-4604-87a4-66d2fbd32077" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_f2d2fafe-cd53-4604-87a4-66d2fbd32077_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, in connection with an organizational realignment, we began operating our business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfe53bdd-6b90-47d7-a5af-daa51ae7aaf6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segments: MRD and Immune Medicine. These segments are organized by market opportunity in commercial diagnostics and drug discovery, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MRD business focuses on the use of our highly sensitive, next-generation sequencing assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ assay, offered to biopharmaceutical partners to advance drug development efforts. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Immune Medicine business leverages our proprietary ability to sequence, map, pair and characterize TCRs and B cell receptors at scale. We have created a powerful data engine to drive the development of novel therapies. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_008d7ba1-91f9-49a8-a5be-73307122acdf" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="us-gaap:Revenues" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> inter-segment revenues. See Note 3, Revenue for more information about each segment's revenue. Our CODM, which is our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8759c879-be95-43bb-8de5-203e18a7141c;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5feb4ad-3c56-4621-9373-b1fdf0a827ce" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluates performance of the MRD segment based on both revenue and Adjusted EBITDA and evaluates performance of the Immune Medicine segment based on Adjusted EBITDA. These measures help our CODM assess the trends and operating margin profile of the respective segments, which helps drive the level of investment made in each business. These measures also help our CODM assess and manage the potential capital utilization of each segment. Adjusted EBITDA for each of our segments includes costs that are directly aligned to each segment, as well as certain allocated shared expenses.</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6a1b0c9-c110-4046-becc-697cb00e8055" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions.</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, we do not allocate costs related to our idle facility in Seattle, Washington, interest expense related to our Purchase Agreement nor interest and other income, net. Given these unallocated costs and income are not included in the measurements reviewed by the CODM to assess each segment's performance, they are included in an "Unallocated Corporate" category. Our allocation methodology will be periodically evaluated and may change. Our CODM is not regularly provided and does not review assets to assess each segment's performance, make strategic decisions or allocate resources. As such, assets for reportable segments are not disclosed.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment information for the years ended December 31, 2023 and 2022 are presented on a comparable basis to that of the current period and is based on judgments and allocation methods from our organizational changes implemented during the three months ended March 31, 2024.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f2d2fafe-cd53-4604-87a4-66d2fbd32077_1" continuedAt="F_f2d2fafe-cd53-4604-87a4-66d2fbd32077_2"><div><ix:nonNumeric id="F_384582ec-88e0-41cd-abca-c946cd4a297d" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_384582ec-88e0-41cd-abca-c946cd4a297d_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></p><p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.1%;box-sizing:content-box;"/>
        <td style="width:1.32%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.32%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.32%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cc82bba-86f8-4f46-a7bf-43313bd64b7a" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,529</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f827f3d1-23bc-4b13-b02d-9d9ee3650b8d" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8a8f31f-b0ee-4608-8b8c-de24420d9955" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9ed500-b172-4b2d-9af9-9b41e3f69da1" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,177</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d48e2cd5-cefc-4a64-b3f0-8a213d2ad8d0" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b03e7da4-35e1-49e4-919d-708e59b4b581" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,606</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c06a4e6-0b81-4792-a5fc-3e70cb09492c" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f424d95-31e9-4cca-af5e-6e8d2eede1ed" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,153</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b23168b3-446e-48ad-8051-ad47791f4b6e" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,768</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c724e13f-e0ca-4d89-a6a2-0a299cb96608" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c39f1e7-22ac-485e-89fc-785b228f2d75" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85cc692b-3eb3-49f3-bb2d-5b43eebe61de" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,558</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90c420f7-8cd5-4483-93bc-4afea2a99546" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,446</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c76fce-778c-4ec6-bd45-814534c83827" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be9b01ef-fa43-4545-9d9c-3a6da679b4b2" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2cbe0a4-434b-4068-990b-ad81f9366b7a" contextRef="C_6a9f91b0-4738-40f9-b68a-82bd5973e387" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b99294fd-d7bb-4937-8c90-b08044e85551" contextRef="C_b28752cf-076a-4931-ad68-b484eab79e15" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4438e2f0-9d58-4599-8f57-e22efbed9cda" contextRef="C_70d180be-d136-46d0-a6f1-b5c952fe6c15" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add back:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Items to reconcile net loss to adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94c50ece-9355-4a71-870f-c11753e361c8" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="adpt:ItemsToReconcileNetLossToAdjustedEBITDA" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea6e0b37-84f2-44d8-aef5-ffe0db092982" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="adpt:ItemsToReconcileNetLossToAdjustedEBITDA" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,546</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65d343e9-bdf0-47a3-81b1-24c409997f28" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="adpt:ItemsToReconcileNetLossToAdjustedEBITDA" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd9c5691-45e8-4094-8bf5-7c8622edfff2" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,223</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41433281-99f1-4efb-a27b-d8892c89e29c" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,844</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c24df4d-9a6d-4cef-936a-d6ab503d8c61" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,496</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f00149bf-217b-44c8-86fb-64cdde225bdb" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,428</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51697d37-c357-4078-9cbb-78d70bc137a8" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b52d3c56-8e36-43f8-995e-581b022835ff" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,164</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1067544-2889-48ea-b465-2b2a1ee7133e" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,210</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29a6ea78-341d-4f40-8002-6edad7640ceb" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,964</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06498528-abb1-4843-9f44-4b923464ffff" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96c3782c-44fa-417a-8f0c-ac63623e40eb" contextRef="C_0e18d051-aeae-44cb-ba16-8f0a32e2f029" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,842</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e89a95e0-f206-4819-856f-aaabb6b695ce" contextRef="C_a46c0838-63e1-46ff-badd-1a080dcfd4e8" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,067</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b58366a1-3f90-4a0f-b814-ec4b8778b77a" contextRef="C_256c43d6-4366-49a5-8b14-90aef18be10f" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,016</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add back:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Items to reconcile net loss to adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17429eec-094a-43ea-927d-ef3fece81b04" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="adpt:ItemsToReconcileNetLossToAdjustedEBITDA" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,619</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64e78d1b-cc17-45b4-810d-d6c1e95bc0ad" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="adpt:ItemsToReconcileNetLossToAdjustedEBITDA" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,366</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80e9fe5b-1f9c-4343-85f9-ec20ab7c395f" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="adpt:ItemsToReconcileNetLossToAdjustedEBITDA" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71c477a7-f00d-434a-bd81-caf1f718e054" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d0ea309-cb98-4f04-b949-55dbe6294d3d" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,128</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3637051c-7816-4b47-b5fb-f4e7c6985ade" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,654</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ff7f71-2430-4605-9e04-027595fb1748" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,223</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_795a954e-d486-46e7-a250-bdfa6ebc1cfc" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4031824-8297-44ef-ba38-857587db2044" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,143</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16f04e89-4028-40ca-bca2-293ab8b9b4fd" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,371</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,848</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,051</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d35974e6-5809-4ae2-a57a-55bc3d676e32" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,711</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40b0137c-2980-4840-93bf-339330caf6b1" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,610</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54732a37-6c04-468b-8af4-d2b05eb94ad3" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a731ef80-93e5-44a8-9679-4a4c2c298fc8" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d528e5-a231-49d7-97ff-426af9382caf" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cedab5a-035d-4c63-89e7-abd4a482b92c" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,386</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4904d016-10c5-4490-9bce-ce972d3156f6" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,205</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b15491-84e6-4093-a3dc-f6e4e3658c9a" contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfa836ec-6129-479e-a5ea-493663968b30" contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54f910ac-ddd1-4976-81c3-5ea636082b15" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,733</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb03b45e-d983-4f77-9458-0b027a46cdcb" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,256</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a064aff8-4d29-465b-8316-a8a35b77bc17" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,580</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,580</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd89d63-e965-4b90-9d0d-f1a53f27d8db" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,534</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_806a258d-2394-4d13-9b00-dcf6e6a2afe4" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,534</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cfea8e3-9a33-4b9b-bbd5-a25a7e04afbd" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd5458aa-1382-474e-8c10-6cc0ac924c2f" contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c76bc330-bc03-47cd-b81d-78b57ae2d63a" contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf1199f-3bac-4b1a-a27b-7888cad246a7" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,844</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e4227f-a8d5-4b52-b64b-050736891da1" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,128</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d4a5a5-e0e3-430a-946a-aac10afdbff3" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,441</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4de633d5-d71d-466c-859a-cd7f030ebc81" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,413</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13603129-bb53-47d1-9eb7-6f62807645d1" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_384876e2-fe72-44d1-8909-963c883b7b5f" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,657</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92c52fe6-c1cf-429e-b534-2bcd9b87c577" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,429</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19c4e4ee-ca66-4b67-bf95-485edb301cb1" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,429</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3970881c-267c-4c47-aa23-6eeb7b471754" contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aa2c192-033b-4ea8-94ff-28f5a51ea829" contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,436</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_402df673-cbb4-4da2-8903-26c31f8f1d22" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb99609e-f987-4efd-ad72-7c5cb386d178" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,231</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddbf605-964c-47bd-aba2-66217d8b9853" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_696d352b-815e-4bee-a1ad-5340543c473c" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,800</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97abe44c-69b9-4c80-82b1-c30839f23053" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,531</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7ddfab1-e5c2-4703-a546-88821c27493c" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,531</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51daeb26-7fb0-4369-9fd3-dddef7716b18" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb6cf031-e6b5-47fc-affd-47c52b311ce4" contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77d9a80b-fad8-4746-a3fd-19f012a01870" contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f2d2fafe-cd53-4604-87a4-66d2fbd32077_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_384582ec-88e0-41cd-abca-c946cd4a297d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.096%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_807fcd58-d6d5-4803-b9c2-0fd4abe33853" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,496</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db33ce64-269a-49ea-a4af-63a49a604a55" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,654</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d81a33d0-17e3-43cd-898f-047561248f8c" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,439</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d1ab54-5f1d-4c3a-8fb0-4e8733fcf463" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="adpt:AdjustedEbitda" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,589</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51279202-faae-46b6-bb41-f7bdde771b6d" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09ad6b64-fb8b-4678-8f92-59036e1480ab" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,892</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd249654-3957-4805-bdf6-1da2df6b29a6" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,586</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f934cfc-c961-465f-ab88-396d638ad6c1" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_75bb2233-9ac9-45f1-8031-2e009382d5f2;"><span style="-sec-ix-hidden:F_83fd51e3-9860-4816-b7d4-990a29a9c263;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span></span></span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf83b944-d68e-48d4-bda8-c3986baaf736" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,023</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3876f27-0b6e-4215-92be-69496800fdf2" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,023</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fd498b3-a25d-4a01-aac6-ade8e1e6f17a" contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dd0f46f-0033-4e86-b816-356a96205ae4" contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,294</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ed001e3-66e3-4969-8e54-995698d5b0e4" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,984</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eab68962-5a93-4f45-816f-53a003d9d744" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,920</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,238</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629e47f6-ada6-4b91-b878-080425e24779" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,238</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c0ff92a-11a4-4a2c-a6e8-8f27665470e5" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,056</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5f6c67b-b008-42db-8396-bd5613e347b5" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,056</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_867fcb0d-4c7f-4360-a60c-7ec9f6f55b5d" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50718092-9e01-48a5-8e98-6b71a52c48db" contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f91837c-ddd6-4581-bca7-a80e98e6e794" contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes MRD impairment of long-lived assets expenses.</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </span><ix:footnote id="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></ix:footnote></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><ix:footnote id="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes all Immune Medicine operating expenses, other than research and development expenses.</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) </span><ix:footnote id="FNT_084cfe7e-e0f2-4045-be6c-16380249a676" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</span></ix:footnote></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) </span><ix:footnote id="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</span></ix:footnote></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) </span><ix:footnote id="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on the Purchase Agreement.</span></ix:footnote></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)</span><ix:footnote id="FNT_c863f931-5324-4e7c-879c-cbda888d3579" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on our impairment expense.</span></ix:footnote></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Control</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of December 31, 2024. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2024 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with GAAP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by an independent registered public accounting firm, as stated in their report, which is included below.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was not any change in our internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act, during the three months ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited Adaptive Biotechnologies Corporation&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Adaptive Biotechnologies Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2024 consolidated financial statements of the Company and our report dated March 3, 2025 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seattle, Washington</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_f5c052f7-3dcb-4353-8eab-87eccc1e2c67" contextRef="C_e4fca2f4-8e1d-432d-80ec-6c3440952998" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0817447b-5c58-427d-9999-084f099b8400" contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 18, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_646a88ee-994e-4dac-b2c3-dde917703ac2" contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michelle Griffin</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a member of our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de68bcd9-eb1f-4f0e-b2e8-80245fcaf16d" contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_012dd716-ad4b-401c-bf5e-63d2d3af2170" contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading plan. Ms. Griffin&#8217;s plan provides for the sale of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed3ed606-5b70-4e2d-94e2-f058b061d575" contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9" name="adpt:PercentageOfNetVestedSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net vested shares of our common stock received in connection with the vesting of certain restricted stock units. The plan's expiration date is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_626595a7-eb43-4814-b7df-afca35b31fbb" contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 14, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding transactions in our securities.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Di</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 10 of the Annual Report on Form 10-K will be included in our definitive proxy statement to be filed with the SEC in connection with the solicitation of proxies for our 2025 Annual Meeting of Shareholders (&#8220;2025 Proxy Statement&#8221;) and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 11 of the Annual Report on Form 10-K will be included in our 2025 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 12 of the Annual Report on Form 10-K, including with respect to our equity compensation plans, will be included in our 2025 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Transactions, and Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 13 of the Annual Report on Form 10-K will be included in our 2025 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ting Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> information required by this Item 14 of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Annual Report on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form 10-K will be included in our 2025 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.2934249759943395%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The following documents are filed as part of this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.3733813100144348%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Financial Statements</span></div></div>
  <p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Index to Consolidated Financial Statements in Part II, Item 8 of this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.3733813100144348%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Financial Statement Schedules</span></div></div>
  <p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All financial statement schedules have been omitted since the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements or the accompanying notes.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.3733813100144348%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Exhibits</span></div></div>
  <p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index to Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.62%;box-sizing:content-box;"/>
    <td style="width:39.38%;box-sizing:content-box;"/>
    <td style="width:13.48%;box-sizing:content-box;"/>
    <td style="width:6.52%;box-sizing:content-box;"/>
    <td style="width:10.94%;box-sizing:content-box;"/>
    <td style="width:8.66%;box-sizing:content-box;"/>
    <td style="width:11.4%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:76.95pt;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="margin-left:76.95pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.8pt;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0in;text-indent:8.8pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="padding-top:0in;text-indent:5.9pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/Furnished</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">With This</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Report</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Articles of Incorporation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/1/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/1/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Seventh Amended and Restated Investors' Rights Agreement among the Registrant and certain of its shareholders, dated May 30, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-ex43_880.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/26/2020</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Strategic Collaboration and License Agreement between Genentech, Inc. and the Registrant, dated December 19, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Side Letter Agreement among Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Fund Master Ltd. and the Registrant, dated May 8, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Amended and Restated Employment Agreement between the Registrant and certain of its executive officers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Amended and Restated Employment Agreement between the Registrant and Francis T. Lo</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restated Non-Employee Director Change in Control Agreement between the Registrant and each of its non-employee directors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459020038958/adpt-ex101_139.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Executive Severance Agreement between the Registrant and certain of its executive officers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2020</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and its directors and executive officers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/14/2023</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.62%;box-sizing:content-box;"/>
    <td style="width:39.38%;box-sizing:content-box;"/>
    <td style="width:13.48%;box-sizing:content-box;"/>
    <td style="width:6.52%;box-sizing:content-box;"/>
    <td style="width:10.94%;box-sizing:content-box;"/>
    <td style="width:8.66%;box-sizing:content-box;"/>
    <td style="width:11.4%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:76.95pt;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="margin-left:76.95pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.8pt;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0in;text-indent:8.8pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="padding-top:0in;text-indent:5.9pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/Furnished</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">With This</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Report</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan and form of award agreement thereunder</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459019031827/adpt-ex1012_196.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/13/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-ex1016_340.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement for Non-U.S. Participants</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/24/2021</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-ex1017_339.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Agreement for Non-U.S. Participants</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/24/2021</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459022017870/adpt-ex101_95.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance Units Agreement and Notice of Grant of Performance Units</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/4/2022</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519174174/d706383dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/17/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459022031433/adpt-ex101_62.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement, made and entered into as of September 12, 2022, by and among Adaptive Biotechnologies Corporation, the Purchasers from time to time party hereto, and OrbiMed Royalty &amp; Credit Opportunities IV, LP</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/12/2022</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement between ARE-Seattle No. 11, LLC and Adaptive TCR Corporation, dated July 21, 2011, as amended by Amendment No. 1, dated August 26, 2011, Amendment No. 2, dated June 30, 2014, Amendment No. 3, dated November 5, 2015, Amendment No. 4, dated December 23, 2015, and Amendment No. 5, dated June 6, 2016</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-231838</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519215526/d777595dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sixth Amendment to Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 11, LLC, dated August 2, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/7/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519215526/d777595dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 12, LLC, dated August 2, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/7/2019</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policies and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/14/2023</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on the signature page)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a&#8209;14(a) or Rule 15d&#8209;14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="adpt-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a&#8209;14(a) or Rule 15d&#8209;14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.62%;box-sizing:content-box;"/>
    <td style="width:39.38%;box-sizing:content-box;"/>
    <td style="width:13.48%;box-sizing:content-box;"/>
    <td style="width:6.52%;box-sizing:content-box;"/>
    <td style="width:10.94%;box-sizing:content-box;"/>
    <td style="width:8.66%;box-sizing:content-box;"/>
    <td style="width:11.4%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:76.95pt;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="margin-left:76.95pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.8pt;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0in;text-indent:8.8pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="padding-top:0in;text-indent:5.9pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/Furnished</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">With This</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Report</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000095017024023095/adpt-ex97_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation Policy for the Recovery of Erroneously Awarded Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-38957</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/29/2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.9pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Management contract or compensation plan or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K promulgated under the Securities Act because the information is not material and would be competitively harmful if publicly disclosed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGN</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on March 3, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.32%;box-sizing:content-box;"/>
    <td style="width:2.56%;box-sizing:content-box;"/>
    <td style="width:86.12%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Chad Robins</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chad Robins</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chad Robins, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.56%;box-sizing:content-box;"/>
    <td style="width:1.12%;box-sizing:content-box;"/>
    <td style="width:43.34%;box-sizing:content-box;"/>
    <td style="width:1.12%;box-sizing:content-box;"/>
    <td style="width:18.86%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Chad Robins</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chad Robins</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Piskel</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kyle Piskel</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michelle Griffin</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michelle Griffin</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Robert Hershberg</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert Hershberg, PhD, MD</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Peter Neupert</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Peter Neupert</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Katey Owen</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Katey Owen, PhD</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Pellini</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Pellini, MD</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>2
<FILENAME>adpt-ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html>
 <head>
  <title>EX-19</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.49in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:8.6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img83932212_0.jpg" alt="img83932212_0.jpg" style="width:179px;height:46px;"></p>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.139%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING POLICY</font></p>
  <p style="margin-left:29.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.963%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adopted by the Board of</font></p>
  <p style="margin-left:29.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:28.935%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[&#x25cf;]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2024</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#365f91;white-space:pre-wrap;font-size:16pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Table of Contents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:16pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:77%;box-sizing:content-box;"></td>
    <td style="width:6%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Employees, Officers, Directors and their Family Members and Affiliates Are Subject to this Policy</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trading in Adaptive Securities While in Possession of Material Nonpublic Information is Prohibited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trading in Other Public Companies&#x2019; Securities While in Possession of Material Nonpublic Information is Prohibited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certain Types of Transactions Are Prohibited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sharing Material Nonpublic Information is Prohibited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recommendations Regarding Trading in Company Securities are Prohibited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Only Designated Company Spokespersons Are Authorized to Disclose Material Nonpublic Information</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employees Must Follow Company Guidelines Pertaining to Electronic Communications</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Transactions in Company Securities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Directors, Officers and Certain Named Employees Are Subject to Additional Restrictions</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Policy Violations Must Be Reported</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 12.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Officers</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Definition of &#x201c;Material Nonpublic Information&#x201d;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 14.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adaptive May Suspend All Trading Activities by Employees</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 15.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Violations of Insider Trading Laws or This Policy Can Result in Severe Consequences</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 16.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">This Policy Is Subject to Revision</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 17.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Persons Must Acknowledge Their Agreement to Comply with This Policy</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">APPENDIX I</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">APPENDIX II</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EXHIBIT A</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.96%;text-indent:-12.258%;padding-left:10.467%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.185%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:6.87%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1. All Employees, Officers, Directors and their Family Members and Affiliates Are Subject to this Policy.</font></p>
  <p style="margin-left:3.427%;text-indent:6.135%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.389%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy (&#x201c;Policy&#x201d;) applies to all employees, outside directors, officers, and consultants of Adaptive Biotechnologies Corporation, a Washington corporation (&#x201c;Adaptive&#x201d; or the &#x201c;Company&#x201d;), their family members and entities over which such individuals have or share voting or investment control. This Policy also applies to any other person who receives material nonpublic information from any Adaptive insider or is otherwise designated by the Compliance Officer (as appointed per Section 12 of this Policy). Adaptive is also subject to Appendix I of this Policy to ensure fair practices when Adaptive transacts in securities. For purposes of this Policy, &#x201c;family members&#x201d; include people who live with you, or are financially dependent on you, and also include those whose transactions in securities are directed by you or are subject to your influence or control.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy continues to apply following termination of employment or other relationship with Adaptive until after the second trading day that any material non-public information in your possession has become public or is no longer material. Each employee, officer, consultant and director is </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">personally responsible</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the actions of their family members and other persons with whom they have a relationship who are subject to this Policy, including any pre-clearances required.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2. Trading in Adaptive Securities While in Possession of Material Nonpublic Information is Prohibited.</font></p>
  <p style="margin-left:2.587%;text-indent:6.844%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purchase or sale of securities by any person who possesses material nonpublic information is a violation of U.S. federal and state securities laws. It is important to avoid the appearance, as well as the fact, of trading based on material nonpublic information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No person subject to this Policy who is aware of material nonpublic information relating to Adaptive may, directly or indirectly (through family members, other persons, entities or otherwise) buy, sell, or otherwise trade in the securities of Adaptive, or advise anyone else to do so, other than pursuant to a trading plan that complies with Rule 10b5-1 promulgated by the Securities and Exchange Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or as specifically exempted in Section 9(B) of this Policy, or otherwise engage in any action to take personal advantage of that information. For purposes of this Policy, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">trade</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; includes any transaction in Adaptive securities, including gifts and pledges.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Each person subject to this Policy may, from time to time, be required to forego a proposed transaction upon learning new material nonpublic information even if he or she planned to make the transaction before learning such information, even though the employee may suffer economic loss or forego anticipated profit by waiting.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.  Trading in Other Public Companies&#x2019; Securities While in Possession of Material Nonpublic Information is Prohibited.</font></p>
  <p style="margin-left:2.587%;text-indent:6.984%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.963%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No person subject to this Policy who possesses material nonpublic information relating to other publicly traded companies, including our vendors, customers and partners, as a result</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of employment with Adaptive or the performance of services on our behalf, may, directly or indirectly (through family members, other persons, entities or otherwise) buy or sell securities of such companies, or advise anyone else to do so, or otherwise engage in any action to take personal advantage of that information.</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.	Certain Types of Transactions Are Prohibited.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Short sales of Adaptive securities are prohibited, as short sales evidence the seller&#x2019;s expectation that Adaptive securities will decline in value, signal to the market that the seller has no confidence in the Company or its short-term prospects, and may reduce the seller&#x2019;s incentive to improve Adaptive performance. In addition, Section 16(c) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), prohibits executive officers and directors from engaging in short sales.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publicly Traded Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Transactions in puts, calls or other derivative securities involving Adaptive stock are prohibited, as any such transaction is, in effect, a bet on the short-term movement of the Company&#x2019;s stock, creates the appearance of trading based on inside information, and may focus attention on short-term performance at the expense of Adaptive long-term objectives.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Hedging or monetization transactions (including but not limited to zero-cost collars, prepaid variable forwards, equity swaps, puts, calls, collars, forwards and other derivative instruments) are prohibited, as such transactions allow you to continue to own Adaptive securities without the full risks and rewards of ownership and as a result, you may not have the same objectives as other shareholders.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin Accounts and Pledges</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Directors, officers and other employees are prohibited from holding Company securities in a margin account or pledging Company securities as collateral for a loan, as such securities may be traded without your consent (for failing to meet a margin call or if you default on the loan) at a time when you possess material nonpublic information or otherwise are not permitted to trade.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-Term Trading</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Executive officers and directors who purchase Adaptive securities in the open market may not sell any Adaptive securities of the same class during the six months following the purchase (or vice versa), as short-term trading of the Company&#x2019;s securities may be distracting and may unduly focus the person on short-term stock market performance, instead of Adaptive long-term business objectives. Legal liability, including a requirement to disgorge any &#x201c;short swing&#x201d; profits, may attach to short-term trading.</font></div></div>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.	Sharing Material Nonpublic Information is Prohibited.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No person subject to this Policy who possesses material nonpublic information relating to Adaptive or any other publicly traded companies may directly or indirectly (through family members, other persons, entities or otherwise) pass that information on to others outside the</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company, including friends, family, or other acquaintances (referred to as </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) until such information has been disseminated to the public. You must treat material nonpublic information about our business partners with the same care required with respect to such information related directly to Adaptive.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tipping includes passing information under circumstances that could suggest that you were trying to help another profit or avoid a loss. Exercise care when speaking with others who do not &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">need to know</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, even if they are subject to this Policy, as well as when communicating with family, friends and others not associated with Adaptive. To avoid the appearance of impropriety, refrain from discussing our business or prospects or making recommendations about buying or selling our securities or the securities of other companies with which we have a relationship. Inquiries about Adaptive should be directed to our Corporate Communications, Investor Relations, or Legal teams.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6. Recommendations Regarding Trading in Company Securities are Prohibited.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No person subject to this Policy may make recommendations or express opinions on trading in Adaptive securities while in possession of material nonpublic information, except to advise others not to trade in Adaptive securities if doing so might violate the law or this Policy.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7. Only Designated Company Spokespersons Are Authorized to Disclose Material Nonpublic Information.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal securities laws prohibit the Company from selectively disclosing material nonpublic information. Adaptive has established procedures for releasing material information in a manner that is designed to achieve broad dissemination of the information immediately upon its release. Employees may not, therefore, disclose material nonpublic information to anyone outside the Company, including family members and friends, other than in accordance with those established procedures. Any inquiries about the Company should be directed to our Corporate Affairs and Communications and Investor Relations teams. Additionally, the Legal team is responsible for handling legal matters that may involve certain disclosures.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8. Employees Must Follow Company Guidelines Pertaining to Electronic Communications.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees must follow the Adaptive Disclosure and Regulation FD Policy before participating in any Internet electronic communication forums concerning the Company.</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.	Other Transactions in Company Securities.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Rule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy applies to all transactions in Adaptive securities, including any securities the Company may issue from time to time, such as preferred stock, warrants and convertible debentures, as well as to derivative securities relating to the Company&#x2019;s stock, whether or not issued by Adaptive, such as exchange- traded options.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:16.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.962403410923075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Benefit Plans.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:16.269%;text-indent:8.17%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.093692897493162%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The trading restrictions set forth in this Policy do not apply to the cash exercise of stock options or other equity awards, but do apply to all sales of securities acquired through the exercise of stock options or other equity awards, including &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">same-day sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or cashless exercise of Company stock options.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:16.269%;text-indent:8.17%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.093692897493162%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The trading restrictions set forth in this Policy do not apply to purchases of Company securities pursuant to the employee&#x2019;s advance instructions under employee stock purchase plans or employee benefit plans (e.g., a pension or 401(k) plan). However, no alteration to instructions regarding the level of withholding or the purchase of Company securities in such plans is permitted while in the possession of material nonpublic information. Any sale of securities acquired under such plans remains subject to the prohibitions and restrictions of this Policy.</font></div></div>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10. Directors, Officers and Certain Named Employees Are Subject to Additional Restrictions.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16 Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#x2019;s directors and officers (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 16 Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are subject to the reporting provisions and trading restrictions of Section 16 of the Exchange Act and the underlying rules and regulations promulgated by the SEC.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Adaptive has designated persons with the roles/titles listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as employees who have frequent access to material nonpublic information concerning the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insider Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company will amend </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from time to time as necessary.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Because Section 16 Insiders and Insider Employees regularly possess material nonpublic information about the Company, and in light of the reporting requirements to which Section 16 Insiders are subject under Section 16 of the Exchange Act, Section 16 Insiders and Insider Employees are subject to the additional restrictions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix II</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto. For purposes of this Policy, Section 16 Insiders and Insider Employees are each referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insiders.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font></div></div>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11. Policy Violations Must Be Reported.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person who violates this Policy, the Company&#x2019;s Disclosure and Regulation FD Policy or any federal or state laws governing insider trading, or knows of any such violation by any other person, must report the violation immediately to the Compliance Officer. Upon learning of any such violation, the Compliance Officer will determine whether the Company should release any material nonpublic information or whether the Company should report the violation to the SEC or other appropriate governmental authority.</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12. Insider Trading Compliance Officers.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the Board of Directors provides otherwise, the Company&#x2019;s General Counsel (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall act as the Company&#x2019;s initial Insider Trading Compliance Officer; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, however, that if the General Counsel is a party to a proposed trade, transaction or inquiry relating to this Policy, the Company&#x2019;s [Chief Executive Officer] shall act as the Insider Trading Compliance Officer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to such proposed trade, transaction or inquiry. The Compliance Officer may delegate his or her authority to act as the Compliance Officer as he or she deems necessary or appropriate in his or her sole discretion. The duties of the Compliance Officer and his or her delegees may include the following:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administering, monitoring and enforcing compliance with the Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responding to all inquiries relating to this Policy and its procedures.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designating and announcing special trading blackout periods during which no Insiders may trade in Company securities.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Providing copies of this Policy and other appropriate materials to all current and new directors, officers and employees, and such other persons as the Compliance Officer determines have access to material nonpublic information concerning the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administering, monitoring and enforcing compliance with federal and state insider trading laws and regulations.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assisting in the preparation and filing of all required SEC reports relating to trading in Company securities, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintaining as Company records originals or copies of all documents required by the provisions of this Policy or the procedures set forth herein, and copies of all required SEC reports relating to insider trading, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revising the Policy as necessary to reflect changes in federal or state insider trading laws and regulations.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintaining the accuracy of the list of roles/titles as set forth on Exhibit A, and updating such list periodically as necessary to reflect additions or deletions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designing and requiring training about the obligations of this Policy as the Compliance Officer considers appropriate.</font></div></div>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13. Definition of &#x201c;Material Nonpublic Information&#x201d;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Material&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information about the Company is &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; if it would be expected to affect the investment or voting decisions of a reasonable shareholder or investor, or if the disclosure of the information would be expected to significantly alter</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the total mix of the information in the marketplace about Adaptive. In simple terms, material information is any type of information which could reasonably be expected to affect the market price of Adaptive securities or an investor&#x2019;s decision to buy or sell Adaptive securities. Both positive and negative information may be material. While it is not possible to identify all information that would be deemed material, the following information ordinarily would be considered material:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial performance, including operating results and changes in performance or liquidity.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Projections of future earnings or losses, or other earnings guidance, and any changes to previously announced earnings guidance.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant changes to the Company&#x2019;s products or pipeline or other asset advances / signal generation, including products or pipeline advances reliant upon collaborators.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical, scientific, or medical information that significantly prejudices key Company objectives, hypotheses, or plans.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company projections and strategic plans.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New major contracts, collaborators, suppliers, or finance sources or the loss thereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development or release of a significant new service, including significant new data or signal generation.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant pricing or cost changes.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential mergers or acquisitions, the sale of Company assets or subsidiaries or major partnering agreements.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in senior management or the Board of Directors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock splits, public or private securities/debt offerings, or changes in Company dividend policies or amounts.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant cybersecurity incident, such as a data breach or a significant disruption or unauthorized access to information technology infrastructure.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:17.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.045001092259522%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual or threatened major litigation, or the resolution of such litigation.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Nonpublic&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Material information is &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nonpublic</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; if it has not been widely disseminated to the general public through a report filed with the SEC or through major newswire services, national news services or financial news services. For</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purposes of this Policy, information will be considered public after the close of trading on the second full trading day following the Company&#x2019;s widespread public release of the information.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consult Compliance Officer When in Doubt</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any employees who are unsure whether the information that they possess is material or nonpublic must consult the Compliance Officer for guidance before trading in any Company securities.</font></div></div>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.  Adaptive May Suspend All Trading Activities by Employees.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to avoid any questions and to protect both employees and the Company from any potential liability, from time to time Adaptive may impose a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">blackout</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; period during which some or all employees may not buy or sell Adaptive securities. The Compliance Officer will impose such a blackout period if, in his or her judgment, there exists nonpublic information that would make trades by Adaptive employees (or certain employees) inappropriate in light of the risk that such trades could be viewed as violating applicable securities laws. If you are made aware of such a blackout period, do not disclose its existence to anyone.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 15. Violations of Insider Trading Laws or This Policy Can Result in Severe Consequences.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Civil and Criminal Penalties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The consequences of prohibited insider trading or tipping can be severe. Persons violating insider trading or tipping rules may be required to disgorge profit made or loss avoided, pay civil penalties up to three times the profit made or loss avoided, face private action for damages, as well as be subject to criminal penalties, including up to 20 years in prison and fines of up to $5 million. The Company and/or the supervisors of the person violating the rules may also be required to pay major civil or criminal penalties.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;text-indent:7.553%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0630987411225914%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Discipline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Violation of this Policy or federal or state insider trading laws by any director, officer or employee may subject the director to removal proceedings and the officer or employee to disciplinary action by the Company, including termination for cause.</font></div></div>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16.  This Policy Is Subject to Revision.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive may change the terms of this Policy from time to time to respond to developments in law and practice, and will take steps to inform all affected persons of any material changes.</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 17. All Persons Must Acknowledge Their Agreement to Comply with This</font></p>
  <p style="margin-left:2.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy.</font></p>
  <p style="margin-left:9.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Policy will be available on the Company&#x2019;s internal website, delivered to all persons</font></p>
  <p style="margin-left:2.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.176%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to this Policy upon adoption, and to all new other persons at the start of their employment or relationship with the Company. Upon first receiving a copy of the Policy or any revised versions, each such person must sign an acknowledgment that he or she has</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">received a copy and agrees to comply with the Policy&#x2019;s terms. The Compliance Officer may periodically require written certifications by those subject to this Policy, including as to their compliance with this Policy or to refresh their acknowledgment of and agreement to comply with this Policy. Any acknowledgment and agreement hereunder will constitute consent for Adaptive to impose sanctions for violation of this Policy and to issue any necessary stop- transfer orders to the Company&#x2019;s transfer agent to enforce compliance with this Policy.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APPENDIX I</font></p>
  <p style="margin-left:7.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.704%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy Regarding Company Transactions in Securities</font></p>
  <p style="margin-left:0.92%;text-indent:6.803%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1. General Statement. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of Adaptive Biotechnologies Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) recognizes the importance of adhering to fair practices when the Company transacts in securities. As the &#x201c;ultimate insider&#x201d; with respect to information regarding the Company, and as an investor when transacting in securities for its own account, the Company may find itself in circumstances that could raise insider trading, market manipulation, or other deceptive or unfair practices. The Company&#x2019;s policy is to comply with all laws applicable to its transactions in securities, to avoid the appearance of impropriety in connection with its transactions, and to ensure appropriate Board oversight of such transactions. While this policy describes the Company&#x2019;s general approach to the main anticipated circumstances in which it will transact in securities, this policy applies to any direct or indirect transaction by or for the benefit of the Company. In grey areas, management of the Company is expected to seek direction from the Board and its legal and financial advisors, and to develop a thoughtful compliance strategy.</font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.803%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2. Equity Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity awards (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) under the Company&#x2019;s equity compensation plans (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including stock options, stock appreciation rights, restricted stock, or restricted stock units (including performance-based restricted stock and restricted stock units), must generally be granted (a) during open trading windows, and (b) more than four business days before, and more than one business day after, the Company&#x2019;s release of earnings for the most recently completed fiscal period or filing with the SEC of an annual report on Form 10-K, quarterly report on Form 10-Q, or current report on Form 8-K that discloses material nonpublic information (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). As administrator of the Equity Plans, the Compensation Committee of the Board and any of its designees may determine that special circumstances require different timing, provided that such exceptions comply with all applicable law. Equity Awards may not be backdated or otherwise manipulated. When Equity Awards are granted in a number intended to approximate an aggregate dollar value, due regard shall be given as to whether the per share price used in such calculations reasonably reflects fair market value. The release of material nonpublic information may not be timed or otherwise manipulated with the intent of affecting the value of an Equity Award.</font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3. Share Repurchases. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any repurchases of the Company&#x2019;s securities will be approved by the Board in the context of the Company&#x2019;s then-existing financial condition and general market conditions. While the Board may approve any repurchase structure consistent with applicable law, the Board anticipates that Company share repurchases would generally be made pursuant to a Rule 10b5-1 trading plan, comply with Rule 10b5-18, and be administered by an independent third- party broker-dealer reasonably satisfactory to the Board. The Company will not establish a Rule 10b5-1 trading plan at a time when the Company possesses material nonpublic information. In addition, the Company will generally announce the size, time horizon, method of repurchase, and other material terms of a Company repurchase program before commencing repurchases, and the timing of repurchases will generally avoid the four business days before, and the business day after, the planned filing of any SEC Report. The Company will generally suspend sale transactions by directors and executive officers while Company repurchases are pending; when such</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspensions are impracticable or would impose an undue hardship on directors and officers, the Company will generally avoid repurchase dates in the two days prior to anticipated sales by directors or executive officers. The release of material nonpublic information may not be timed or otherwise manipulated with the intent of affecting the repurchase price of the Company&#x2019;s securities in a repurchase transaction.</font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4. Offerings of the Company&#x2019;s Securities. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any offers and sales of the Company&#x2019;s securities in a public offering, private offering, strategic transaction, or similar circumstances will be approved by the Board in the context of the proposed transaction. In any such transaction, the Company&#x2019;s disclosure to the applicable purchasers must not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading. The Company will comply with all applicable laws relating to the offer and sale of securities. The Company will generally suspend purchases and sales of securities by directors and executive officers a reasonable period before and after the Company&#x2019;s transactions. Material nonpublic information disclosed in connection with a sale of Company securities will be so disclosed sufficiently in advance of the sale for the purchaser to digest the information.</font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5. Purchases or Sales of Securities of Other Issuers. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will maintain an investment policy related to securities purchased or sold for its account, overseen by the Audit Committee of the Board. Such transactions will generally be conducted by an independent registered broker-dealer, who will certify compliance with the investment policy to the Audit Committee of the Board each quarter.</font></p>
  <p style="font-size:10pt;margin-top:1.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company obtains material nonpublic information regarding a vendor, distributor, strategic partner or other company, the Company will take reasonable steps to safeguard such information and to avoid trading in the securities of the applicable company until such time as the Company reasonably concludes the information is either publicly known or no longer material.</font></p>
  <p style="font-size:10pt;margin-top:1.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6. Controls and Procedures. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will maintain disclosure controls and procedures regarding its transactions in securities, including internal control over financial reporting. Without limiting the foregoing, the Company shall ensure there are appropriate controls and procedures regarding:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">access to Company funds to purchase securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authorization of Company brokers or agents to sell Company securities,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure of required information prior to a Company transaction;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accurate and timely documentation and recordation of transactions; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure of consummated transactions.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APPENDIX II</font></p>
  <p style="margin-left:21.507%;text-indent:-24.367%;padding-left:13.013%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:12.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Restrictions on Transactions in Company Securities by Insiders</font></p>
  <p style="margin-left:2.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To minimize the risk of apparent or actual violations of the rules governing insider trading, we have adopted these special restrictions relating to transactions in our securities by Insiders. Insiders are responsible for ensuring compliance with this Appendix II, including restrictions on all trading during certain periods, by family members and members of their households and by entities over which they exercise voting or investment control. Insiders should provide each of these persons or entities with a copy of this Policy.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.  Trading Window</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any trade by an Insider that is subject to this Policy will be permitted only during an open &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">trading window</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; Even when the window is open, all Company personnel are prohibited from trading in Adaptive securities while in possession of material nonpublic information. The trading window generally opens </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following the close of trading on the second full trading day </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following the public issuance of the Company&#x2019;s earnings release for the most recent fiscal quarter and closes at the close of trading on the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16th day of the last month </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of a fiscal quarter. In addition to when the trading window is scheduled to be closed, the Company may impose a special blackout period at its discretion due to the existence of material nonpublic information. The Compliance Officer may advise Insiders when the trading window opens and closes; provided that in any event, Insiders are charged with the knowledge of and compliance to this Policy.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2. Trade Pre-Clearance Required</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As part of this Policy, all purchases and sales of equity securities of the Company by Insiders, other than transactions that are not subject to this Policy or transactions pursuant to a Rule 10b5-1 trading plan (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) authorized by the Compliance Officer, must be pre-cleared by the Compliance Officer. This requirement is intended to prevent inadvertent Policy violations, avoid trades involving the appearance of improper insider trading, facilitate timely Form 4 reporting by Section 16 Insiders and avoid transactions that are subject to disgorgement under Section 16(b) of the Exchange Act.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Requests for pre-clearance must be submitted via email to the Compliance Officer at least </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business days in advance of each proposed transaction. If the Insider does not receive a response from a Compliance Officer within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hours, the Insider must follow up to ensure that the message was received. Each Insider request for pre-clearance should include the nature of the proposed transaction and the expected date of the transaction. In addition, each request by a Section 16 Insider for pre-clearance should also include the following information:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The nature of the proposed transaction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected date of the transaction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Number of shares involved.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the transaction involves a stock option exercise, the specific option to be exercised.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contact information for the broker who will execute the transaction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A confirmation that the Insider has carefully considered whether he or she may be aware of any material nonpublic information relating to the Company (describing any borderline matters or items of potential concern) and has concluded that he or she does not.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether the transaction complies with all rules and regulations, including Rule 144, Rule 701, Form S-8, and Section 16 of the Exchange Act, applicable to securities transactions by the Insider.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any other information that is material to the Compliance Officer&#x2019;s consideration of the proposed transaction.</font></div></div>
  <p style="margin-left:2.92%;text-indent:7.023%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer may withhold or condition pre-clearance in his or her sole discretion. Once the proposed transaction is pre-cleared, the Insider may proceed with it on the approved terms, which will generally require the transaction to occur within 4 trading days unless a longer or shorter period is specified by the Compliance Officer. The Insider must comply with all other securities law requirements, such as Rule 144 and prohibitions regarding trading on the basis of inside information, and with any special trading blackout imposed by the Company prior to the completion of the trade.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3. Pre-Clearance of Rule 10b5-1 Plans Required</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pre-clearance by the Compliance Officer is required for an Insider to enter into or modify a 10b5-1 Plan. Plans that are not pre-cleared may not be used by an Insider. Pre-clearance must be requested at least </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">full trading days prior to entry into or modification of the plan. However, pre-clearance will not be required for individual transactions effected pursuant to a pre-cleared Rule 10b5-1 trading plan. All Section 16 Insiders must immediately report the results of transactions effected under a trading plan to the Compliance Officer since they will be reportable on Form 4 within two business days following execution. Notwithstanding the foregoing, any 10b5-1 Plan for the Compliance Officer shall be subject to pre-clearance by the [Chief Executive Officer].</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.  Hardship Exemptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Compliance Officer may, on a case-by- case basis, exempt a transaction by an Insider from this Policy due to financial or other hardship. Any request for a hardship exemption must be in writing and must describe the amount and nature of the proposed transaction and the circumstances of the hardship. The Insider requesting the hardship exemption must also certify to the Compliance Officer he or she is not in possession of material nonpublic information concerning Adaptive or (such as in the case of a gift or other non-monetization transaction to a party who promises not to sell the securities received for some time or to a party subject to this Policy) that the transaction does not misuse the Company&#x2019;s information. The existence of this process does not in any way obligate the Compliance Officer to approve any hardship exemption requested by an Insider, and all Insiders are cautioned that this exemption is intended to address limited and unusual circumstances.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5. Brokers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All Insiders must ensure that their broker does not execute any transaction for the Insider (other than under a pre-cleared Rule 10b5-1 Plan) until the broker has verified with the Compliance Officer that the transaction has been pre-cleared.</font></p>
  <p style="margin-left:2.96%;text-indent:7.026%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.157%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6. Reporting of Transactions Required</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To facilitate timely reporting under Section 16 of the Exchange Act, Section 16 Insiders are required to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">on the same day as the trade date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or, with respect to transactions effected pursuant to a Rule 10b5-1 Plan, on the day the Insider is advised of the terms of the transaction, (a) report the details of each transaction to the Compliance Officer and (b) arrange with persons whose trades must be reported by the Insider under Section 16 (such as immediate family members living in the Insider&#x2019;s household) to immediately report directly to the Company and to the Insider the following transaction details:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction date (trade date).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Number of shares involved.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Price per share at which the transaction was executed (before addition or deduction of brokerage commission and other transaction fees).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock option exercises, the specific option exercised.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contact information for the broker who executed the transaction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A specific representation that the Insider is not in possession of material nonpublic information.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6870284740812855%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a Section 16 Insider, a specific representation whether the transaction was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).</font></div></div>
  <p style="margin-left:2.96%;text-indent:7.028%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.185%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction details must be reported to the Compliance Officer, with copies to Adaptive personnel who will assist the Section 16 Insider in preparing his or her Form 4.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7. Oversight by the Audit Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Audit Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of the Board of Directors will be responsible for monitoring and recommending any modification to this Policy, if necessary or advisable, to the Board of Directors. The Board of Directors will also review, at least annually, those individuals who are deemed to be executive officers for purposes of Section 16.</font></p>
  <p style="margin-left:2.96%;text-indent:7.027%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8. Named Employees Considered Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Committee will review, at least annually, those individuals deemed to be &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; for purposes of this Appendix II. Insiders shall include persons subject to Section 16 and such other persons as the Committee deems to be Insiders. Generally, Insiders shall be any person who by function of their employment is </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">consistently </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in possession of material nonpublic information </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performs an operational role, such as head of a division or business unit, that is material to the Company as a whole.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:7.028%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.176%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9. Special Guidelines for 10b5-1 Trading Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding the foregoing, an Insider will not be deemed to have violated this Policy for transactions pursuant to a 10b5-1 Plan that has been pre-cleared by the Compliance Officer. The Compliance Officer may withhold or condition pre-clearance of any proposed 10b5-1 Plan (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proposed Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for any reason, in his or her sole discretion.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer will not pre-clear a Proposed Plan if he or she concludes that the Proposed Plan:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fails to comply with the requirements of Rule 10b5-1, as amended from time to time;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Would permit a transaction to occur before the </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">later</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of (i) 90 days after adoption (including deemed adoption) of the Proposed Plan or (ii) two business days after disclosure of the issuer&#x2019;s financial results in a Form 10-Q or Form 10-K for the quarter in which the Proposed Plan was adopted (subject to a maximum of 120 days after adoption of the Proposed Plan).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Is established during a &#x201c;closed&#x201d; window period or a special &#x201c;blackout&#x201d; period, or the Insider is unable to represent to the satisfaction of the Compliance Officer that the Insider is not in possession of material nonpublic information regarding the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Would result in overlapping Plans except in limited scenarios, such as two separate Plans in which the second Plan may not commence trading until the expiration of the first.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lacks appropriate mechanisms to ensure that the Insider complies with all rules and regulations, including Rule 144, Rule 701, Form S-8, and Section 16 of the Exchange Act, applicable to securities transactions by the Insider.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Does not provide the Company the right to suspend all transactions under the Proposed Plan if the Compliance Officer, in his or her sole discretion, deems such suspension necessary or advisable, including suspensions to comply with any &#x201c;lock-up&#x201d; agreement the Company agrees to in connection with a financing or other similar events.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exposes the Company to liability under any other applicable state or federal rule, regulation or law;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Creates any appearance of impropriety;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fails to meet guidelines established by the Company; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Otherwise fails to satisfy the Compliance Officer for any reason.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 Plan must be established at a time when the trading window is open and the person is not in possession of material nonpublic information.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 Plan must provide appropriate mechanisms to ensure that the Insider complies with all rules and regulations, including Rule 144, Rule 701 and Section 16(b), applicable to securities transactions under the 10b5-1 Plan by the Insider.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 Plan must provide for the suspension of all transactions under such 10b5-1 Plan in the event that the Company, in its sole discretion, deems such suspension necessary and advisable, including suspensions necessary to comply with trading restrictions imposed in connection with any lock-up agreement required in connection with a securities issuance transaction or other similar events.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any modifications to or deviations from a 10b5-1 Plan are deemed to be the Insider entering into a new 10b5-1 Plan and, accordingly, require pre-clearance of such modification or deviation pursuant to Section 2 of this Appendix II.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any termination of a 10b5-1 Plan must be immediately reported to the Compliance Officer. If an Insider has pre-cleared a new 10b5-1 Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Second Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) intended to succeed an earlier pre-cleared 10b5-1 Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Insider may not affirmatively terminate the First Plan without pre-clearance pursuant to Section 2 of this Appendix II, because such termination is deemed to be entering into the Second Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">G.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of the Company, the Compliance Officer, nor any of the Company&#x2019;s officers, employees or other representatives shall be deemed, solely by their pre-clearance of a Proposed Plan, to have represented that it complies with Rule 10b5-1 or to have assumed any liability or responsibility to the Insider or any other party if the 10b5-1 Plan fails to comply with Rule 10b5-1.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">H.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon entering into or amending a 10b5-1 Plan, the director or officer must promptly provide a copy of the plan to the Company and, upon request, confirm the Company&#x2019;s planned disclosure regarding the entry into or termination of a plan (including the date of adoption or termination of the plan, duration of the plan, and aggregate number of securities to be sold or purchased under the plan.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.51in;z-index:-3;min-height:0.85in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:32.373%;text-indent:23.545%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:25.722%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A INSIDER EMPLOYEES</font></p>
  <p style="margin-left:0.747%;font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as of [&#x25cf;], 2024)</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:2.204%;border-spacing:0;table-layout:auto;width:73.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt dotted #000000;padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Company directors and more senior executives, including all members of the Adaptive Leadership Council</font></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Company employees in the finance department, including Investor Relations [and Corporate Affairs and Communications]</font></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Company employees in the legal department</font></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Company employees who regularly attend the Monthly Business / Revenue review</font></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All administrative assistants to Company executives</font></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Managers in Business Development</font></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt dotted #000000;text-indent:6pt;border-left:0.5pt dotted #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt dotted #000000;"><p style="margin-left:1.107%;text-indent:0;font-size:12pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Managers in Research</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.53in;min-height:0.67in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>adpt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-269767) pertaining to the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-232495) pertaining to the Sequenta, Inc. 2008 Stock Plan, the Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan, the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our reports dated March 3, 2025, with respect to the consolidated financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seattle, Washington</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 3, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>adpt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER <br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Chad Robins, certify that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:22.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.909%;box-sizing:content-box;"></td>
    <td style="width:1.01%;box-sizing:content-box;"></td>
    <td style="width:4.263%;box-sizing:content-box;"></td>
    <td style="width:46.818%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:46%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>adpt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER <br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Kyle Piskel, certify that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.909%;box-sizing:content-box;"></td>
    <td style="width:1.01%;box-sizing:content-box;"></td>
    <td style="width:4.263%;box-sizing:content-box;"></td>
    <td style="width:46.818%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Piskel</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kyle Piskel</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:22.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>adpt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:17.8pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p></div>
  <p style="font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Adaptive Biotechnologies Corporation (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.878%;box-sizing:content-box;"></td>
    <td style="width:4.041%;box-sizing:content-box;"></td>
    <td style="width:4.263%;box-sizing:content-box;"></td>
    <td style="width:46.818%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:13.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>adpt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:17.8pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p></div>
  <p style="font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Adaptive Biotechnologies Corporation (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.465%;box-sizing:content-box;"></td>
    <td style="width:1.01%;box-sizing:content-box;"></td>
    <td style="width:5.717%;box-sizing:content-box;"></td>
    <td style="width:46.808%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 3, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kyle Piskel</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kyle Piskel</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:13.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img64161509_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img64161509_0.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **JZCJ<>FIYLS!5R!DY/)[ #)/X=N>E<Q8?$B*YG\IE*1, %=NH;ONP2
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MM#V>:&/F;L; #]W&<Y(]: -BBN6L_B);W;K"JR9=E49"XRQP/XJZF@ HHHH
M***S]8UV+2%\R9L9S@#EB0,X _J< 9&2,T :%%86A^,X-8<PIN5\9 < 9]<8
M)Z>G7'/8XW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF+[XB6M
MJWEC<^.I0 KG.,9)&?J,CT- '3T5#9WB7B":,AD89!'^?S'4'@U-0 4444 %
M%%% !1110 4444 %%%% !1110 445SVK>.K;37,1+.P)#", X([$D@?EG!!!
MP: .AHJGI6JQZI&)XCE3^8/<$=B/_KC((-7* "BBB@ HHHH **** "BLG7/$
M\&C8\TG<1D*HRQ&<9[ ?B1G!QDBL;_A9UM_<D_[Y7_XNBP'7T55TS44U*-;B
M/.UQQD8/!P1^!&/3TXJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%8_B#Q/%H>SS0Q\S=C8 ?NXSG)'
MK0!L45RUG\1+>[=8563+LJC(7&6.!_%74T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDJVZ*X9\X+!0. 3V8^E='0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16/X@\3Q:'
ML\T,?,W8V '[N,YR1ZUD?\+.MO[DG_?*_P#Q=.P7.OHHHI %%%% !14-Y="T
M1IFSA%9CCKA1DURW_"SK;^Y)_P!\K_\ %T6 Z^BJ>DZHNJ1+<("%?. V >"1
MV)]*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !14-Y>)9H9I"%11D
MD_Y_(=2>!7/0?$2UFD$/S $XWL $]CG.0#[CCOCFBP'3T444 %%8>M^,+?1V
M\MR6?C*H,D ]SD@#Z9SR#C%9T?Q,MG(!60 D<E5P/?AB?R!-.P7.MHJJ^IQQ
MQ?:F8"+:&W'(X/(XZ\YX'7/&,UA0?$2UFD$/S $XWL $]CG.0#[CCOCFE8#I
MZ*** "BBB@ HHHH **** "BBB@ HKG-6\=P:7*UNZN63&2H4CD ]V'K4VA>,
M8=:<PQJX(4M\P4# ('9CZT6 W:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK"UWQC#HKB&17)*AOE"D8)([L/2@#=HKG-)\=P:I*MNBN&?."P
M4#@$]F/I71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKR'QY_Q^R_\  /\ T!:]>KR'QY_Q^R_\ _\ 0%IQ$S0^&/\ Q\O_ -<6_P#0
MDKTZO,?AC_Q\O_UQ;_T)*].HEN""L#QY_P >4O\ P#_T-:WZP/'G_'E+_P
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MO7JF0T%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDDG))/4YKU#X>Z*MI +DC]Y+DY(P0N>!SV.-V>,Y'7 I[(6YYW)H=Q&"S12
M $DF-@ !U.<53CD,9#*2""""#@@CH<U[W62?"]N9Q>;!Y@)/^R6./FQTR,=?
M4DG)P0N8=B3P]//- C7*A9".?4CL2,<$]Q_+H./\>^+F9FL(3A1Q(P/7U48Z
M =&[DY' !SW&J71M(9)EQE(W89Z95217ATDAD)9B22222<DD]3FA(&$<9D(5
M0220  ,DD]!BKDFAW$8+-%(  228V  '4YQ7HGP]T5;2 7)'[R7)R1@A<\#G
ML<;L\9R.N!75T.06/!(Y#&0RD@@@@@X((Z'->K>"_%7]LH8Y,"6,#/0;A_>
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MES78W1QNX!QE49AGTR!5KPSIJZE<QP/]UB2?<*"Q'!'7&,]NM>SQQB,!5
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M2W5F]H=LBLA(SAE*G'K@U-I6JR:7()XCAA^1'<$=P?\ ZXP0#7L>LZ2FJQ-
MX'(X)&=K=F'3I]>1QT->(4)W!JQ[KI]\M_&LZ?=< CI^1QGD=#Z&O&O$'_'S
M-_UVD_\ 0C7IW@/_ (\HO^!_^AM1X\_X\I?^ ?\ H:U*T8V>0T45[;X?_P"/
M:'_KC'_Z"*INPDBAX#_X\HO^!_\ H;5SGCWQ<S,UA"<*.)&!Z^JC'0#HW<G(
MX .>XU2Z-I#),N,I&[#/3*J2*\.DD,A+,222223DDGJ<TEJ-A'&9"%4$DD
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M]<$=G_PLZV_N2?\ ?*__ !=4VQ'F<D9C)5@002"",$$=1BO2O ?BLZ@/LL[
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M$BD["0'7KE?ID<CL?7V)!]ECD$@#*000""#D$'H<UX)7MOA__CVA_P"N,?\
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M*%'/\2AB?J<X^@'I4VNQ]#GKR\>\<S2$L['))_S^0Z <"KUIX8N;M3*D3%0
M<D8R",C&<;O^ Y[>HIN@7$%M*)+I6=%&0J@'+<8R"1D=>/7&<C(KO/\ A9UM
M_<D_[Y7_ .+JF(\UGMVMV,;J58=0P((SST-=QX \5G(L9F&,8C9CSGLG_P 3
MGI]T9R *'B_Q);:V@**ZRH>&95Y7NI(?\1P>?3)-<I'(8R&4D$$$$'!!'0YH
MW ][KQ+Q!_Q\S?\ 7:3_ -"->SV=T+M%F7.'56&>N&&17C'B#_CYF_Z[2?\
MH1I1&RO%?-%&\ X60J6Z\[-V!].<_4#TISZ7-&GG-&X3 .XHP7!Z'.,<YXKI
M_AMI*7<KSN ?)"[01_$V<-^&WCCJ<\$"O3*&[ D>!5ZEX!\1MJ<9@E.98L<G
MJ5['KDD'@G'<9R2:X[QUI*:;<E8P LBAPH& ,D@C\QGL!G &!5[X8_\ 'R__
M %Q;_P!"2AZH2+_Q5_Y8?]M/_9*X&O?:\A\>?\?LO_ /_0%HBQLP*Z_X8_\
M'R__ %Q;_P!"2CX8_P#'R_\ UQ;_ -"2O3J&P2,#QY_QY2_\ _\ 0UKR&O7O
M'G_'E+_P#_T-:\AHB#/;?#__ ![0_P#7&/\ ]!%>)5[;X?\ ^/:'_KC'_P"@
MBL#XG?\ 'LG_ %V7_P!!>DGJ#/,:**]]JF["2/ J*]>\>?\ 'E+_ , _]#6O
M(:$[@SVWP_\ \>T/_7&/_P!!%<YX[\7-8?Z' <2,,LP/*@]AZ,>N>PP1R01T
M?A__ (]H?^N,?_H(KQK4+YK^1IW^\Y)/7\AG/ Z#T%2EJ-D,<9D(50220  ,
MDD]!BM1O"ETJ"7R7P3C &6[]5'S#IU(Q^8J_X0URVT?,TR.TN<*5"D!<=LD<
MGG)].!U.>I_X6=;?W)/^^5_^+JFV(\SCD,9#*2""""#@@CH<UZQX,\3_ -LQ
M[)"/.3J!QN'&'Q^AQT/ID"O/O%6HP:C+Y]NK+N'SAE RW][ACU[\#D9Y)-.\
M%WWV.[B)SACL('?>,#/MNP?PSUH>J!'KUQ.MNK2N<*@))ZX &3TKQKQ!X@DU
MN3S7X4?=4=%']2>Y[^P  ] ^(]T8;7:,8DD53GT&6X_%1^%>6QQF0A5!))
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW9'X8ZUH?#>^\BY\HYQ*A&!TROS GZ $#Z^YJWL3U/4JS_$'_'M-_P!<9/\
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M (_8O^!_^@-7KU>0^ _^/V+_ ('_ .@-7KU*0(Y#XG?\>R?]=E_]!>N!\/\
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M!GMOA_\ X]H?^N,?_H(KR;Q/ T%U,K#!,C'\&.X?F"*]9\/_ /'M#_UQC_\
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M !._X^4_ZXK_ .A/7))&9.%!)P3P,\ 9)_ #)]JM;$GO=-DD$8+,0  223@
M#J<UY+I/CJYTU!$"KJ  HD!. .P((/YYP  ,"H=;\87&L+Y;D*G&508!([G)
M)/TSC@'&:GE'<SM4NA=S23+G#R.PSUPS$BN^^%UJ%ADFYRT@4^F%4$?^A']*
M\]L[-[QQ#&"SL< #_/YGH!R:]IT72QI4*6RDL$!Y/&222>/J>/;N:<@1Y_\
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M4GD>O'4?B ,FI6X^AYWHFC-K$GD(RJV"1O)&<=A@')[_ $!K?_X5C<_WX_\
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M >H(/!!'0UVWAWQM<:M=10/M5#OR$7KA"1DL2>".V/?--H$SH/'G_'E+_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC^)_#_\ ;D0@W;-KAL[=W0$8QD>M<Q_PJK_IO_Y#_P#LZ[^BG<+!6/XG\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC9G&%"]=P]/2K'ACP5_8<IG\S?N0KC9MZD'.=Q]*Z>BBX[!1112 ;)&) 58
M@@@@C((/48KAM5^&*N2]L^WT5^1U_O#D #ID$\<GGCNZ*$P/.[#X7.3^_D4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .0U[P!_:TS7/F[=^WC9G&%"]=P]/2K'ACP
M5_8<IG\S?N0KC9MZD'.=Q]*Z>BG<+!1112 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYP&P#P2.Q/I7AU>O> _^/*+_ ('_ .AM5-6$F;]%%%2,**** "BBB@ HHHH
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M8^E>2UO^ _\ C]B_X'_Z U)I#N>O4445(PHHHH **** "BBB@ HHHH ****
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MDCJ,ALX5B!_%0E<#T2BL+P=KKZU"TT@4$2%?E! P%4]R?6MV@ HHHH ****
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M+=U0*^[)4,#PI/=CZ4[!<[NBBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117F/
M_"SKG^Y'_P!\M_\ %TTKA<].HK+\-:HVJ6Z7#@!GW9"Y X8CN3Z5J4@"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#"UWQC#HKB&17)*AOE"D8)([L/2H
M=)\=P:I*MNBN&?."P4#@$]F/I7*?$[_CY3_KBO\ Z$]9_@/_ (_8O^!_^@-5
M6T%<]>HHHJ1A1110 4444 %%%% !1110 4444 8_B#Q/%H>SS0Q\S=C8 ?NX
MSG)'K6=9_$2WNW6%5DR[*HR%QEC@?Q5D_%7_ )8?]M/_ &2N1\/_ /'S#_UV
MC_\ 0A5):"N>VT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBLOQ+JC:7;O<( 63;@-DCE@.Q'K0!J45YC_PLZY_N
M1_\ ?+?_ !=>G4VK!<*Y[5O'5MIKF(EG8$AA& <$=B20/RS@@@X-=#7B6NZ;
M)ITSQ2Y+9)W-_$"3ANIZ_4\Y!Y!H2N)GL.E:K'JD8GB.5/Y@]P1V(_\ KC((
M-7*X;X76;QI+,P(1R@4GOMW9Q],]>F>.QKN:3&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 8'_">67_/7_P <?_XFM/2]6BU13+"VY0<$X(Y
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MM7-*UZ'5MWD-NV8S\K#&<X^\!Z&O(O$'_'S-_P!=I/\ T(UUWPJ_Y;_]L_\
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M$CUYK1TK7H=6W>0V[9C/RL,9SC[P'H:\B\0?\?,W_7:3_P!"-==\*O\ EO\
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MZI#:6[+)(B$RDX9U4XVKS@FNSM;Q+L;HV5P#C*L&&?3(KPBO3OAC_P >S_\
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MA@01GGH:Z?P5XN;36%M*<PN<#)QL)/7)_A]1VZCN".(7/4))!&"S$  $DDX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2  !DDGH,5<DT.XC!9HI  "23&P  ZG.*?*A7.P^*O\ RP_[:?\ LE<CX?\
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M >AJQ?WZ6"&>4X1<9.">I ' !/4UQ'PJ_P"6_P#VS_\ 9ZZ#QY_QY2_\ _\
M0UHMJ ?\)Y9?\]?_ !Q__B:OW6OP6L:W$C@(X!7.<D''1?O'J,\<=Z\2JTSR
MZDRI\SL%"J ,G:@X  ] /YD\YI\H7/1H_B9;.0"L@!(Y*K@>_#$_D":Z/3M3
MCU)/-A8,N2,C(Y'8@X(_'MSTKQ">W:W8QNI5AU# @C//0U>T/7Y=%<R1$<C!
M5N5/ID CIV/7\"03E"YZ[JFM0Z4 T[A0QP."2<=> "?QZ=/6L"/XF6SD K(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD)!'7!!P>E*(V=#X0URVT?,TR.TN<*5"D!<=LD<GG)].!U.>I_X6=;?W)/\
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M&('Y@GWCQP.2._7D'&<<UU/Q0@99XY2/E:/ /NK$G_T(5RVF6!U"18%*J7.
M7.%SC@9P>O0>IP*:V$ST*/XE6L8"JD@    5  !T&-]97B?Q=::U$8]CB0<H
MQ5>#W'#]#T/7UP2!5?\ X5C<_P!^/_OIO_B*/^%8W/\ ?C_[Z;_XBEH/4Y"O
M:?#%]]NMHI>22@!+=25^5CWZD$UPO_"L;G^_'_WTW_Q%=]H&E_V7 EOG)0<G
MKR3EL<#C)./:B3!'(?%7_EA_VT_]DKD?#_\ Q\P_]=H__0A77?%7_EA_VT_]
MDKD?#_\ Q\P_]=H__0A36PGN>VT445!1XEX@_P"/F;_KM)_Z$:Z[X5?\M_\
MMG_[/7(^(/\ CYF_Z[2?^A&NN^%7_+?_ +9_^SU;V)6Y!\4+YC+';_P!-^.>
M221SVX X],GUKGO"^D_VK<)"P.S.6P#]U>2#C&,],]B:W?BA RSQRD?*T> ?
M=6)/_H0K-\!ZC]BNE!QB4%#D$_>P5QCU8 >F#^-);!U/6HXQ& J@     8
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M#. >IQ[#D^PKN/BG S+#*!\JEP3[L%(_]!-<?X<U'^SKB.<XPK<D@G"M\K'
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MI<XN)64A V A)Y(QSE1Q@G\<4-JPBQ\3O^/9/^NR_P#H+UYK;P-<,L2#+.0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO#__ !\P_P#7:/\ ]"%>VTY @HHHJ1A1110!YC\3O^/E/^N*_P#H3U@>'_\
MCYA_Z[1_^A"M_P")W_'RG_7%?_0GK \/_P#'S#_UVC_]"%6MB>I[;1114%'
M?%7_ )8?]M/_ &2N!KVW5=!AU;;YZ[MF<?,PQG&?ND>@JA_P@=E_SR_\??\
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M7Z$&J9)UO_"SK;^Y)_WRO_Q=<#KL\-Q*TEL"L;<[2 ,'N!@GCOVQG &!6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP/<U!11\1?9%57O-N$.5W9)SQG '+#D9&".F164_Q%M+;]V@<JH !1 %QCH
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M2/E:/ /NK$G_ -"%2MQLY;3&B213<!C$#\P3[QXX')'?KR#C..:]"C^)5K&
MJI(    %0  =!C?7GNF6!U"18%*J7. 7.%SC@9P>O0>IP*Z7_A6-S_?C_P"^
MF_\ B*IV$BQXG\76FM1&/8XD'*,57@]QP_0]#U]<$@5Q%=?_ ,*QN?[\?_?3
M?_$4?\*QN?[\?_?3?_$4)H#L=-U@O8"[7)9(&/S\Y:,$$GG)R5]<D>]>/U[
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M:'_KC'_Z"*<@1E?$&S2:T:1@"T94J>XRR@_F#TZ=.X%>3UZ]X\_X\I?^ ?\
MH:UY#1'8&>P^#]*CL+=&0?-*B,Q/4DC/Y#/ _J236^(-FDUHTC %HRI4]QEE
M!_,'ITZ=P*U?#_\ Q[0_]<8__015#QY_QY2_\ _]#6EU#H>0U[;X?_X]H?\
MKC'_ .@BO$J]M\/_ /'M#_UQC_\ 013D"/&M0OFOY&G?[SDD]?R&<\#H/05N
M^$-<MM'S-,CM+G"E0I 7';)')YR?3@=3GGKB!K=FB<89"01UP0<'I6OH/A*7
M6U:2)D&TX(9B&Z9!P%/![?0^E-B.S_X6=;?W)/\ OE?_ (NN*\5:C!J,OGVZ
MLNX?.&4#+?WN&/7OP.1GDDUK?\*QN?[\?_?3?_$4?\*QN?[\?_?3?_$4E8>I
ME^"[[['=Q$YPQV$#OO&!GVW8/X9ZU[%7GVB?#N:TGCFE9-B,&^0MNRO(ZKCK
MC/MFO0:3!!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'C?B_2?[,N73 "N=ZX  VL3Q@=,'(_#.,54TO6IM*):!
MRI88/ (..G!!'X]>OK7K^L:%%JZ^7,N<9P1PP)&,@_T.0<#(.*X>Z^%TRG]W
M(C#'5@RG/T ;^?X528K&3JOCBYU)3&6"HPP508S^)RW/0\X(XQUSA/&8^&!!
MP#R,<$9!_$'(]J]*T/X<QVA\RX(D.!A<$*#U/?YO3D 8SD<\.U[P!_:TS7/F
M[=^WC9G&%"]=P]/2BZ"QG_"K_EO_ -L__9ZZ#QY_QY2_\ _]#6CPKX5_L#?\
M^_S-O\.W&W/N?6K^O:5_:T+6V[;OV\XSC#!NF1Z>M*^H=#Q*O;?#_P#Q[0_]
M<8__ $$5R'_"JO\ IO\ ^0__ +.NWT^T^QQ)!G/EHJYQC.T 9Q3;!%BO J]]
MK@/^%5?]-_\ R'_]G23!G0> _P#CRB_X'_Z&U<_\5?\ EA_VT_\ 9*Z_0=*_
MLF%;;=NV;N<8SEBW3)]?6J'BKPK_ &_L^?9Y>[^'=G=CW'I1?4.AYCX?_P"/
MF'_KM'_Z$*]MKB-/^&OV.5)_.SY;JV/+QG:0<9WUV]#8(\=\7>'SHTQ4?ZM\
MLG7@9^[D]U^IXP3UQ5#3=7ETQM\+E2>N.AZ]0>#C/&1Q7L^HZ9'J2>5,H9<@
MX.1R.X(P1^';CI7$:C\+B.;>08R.)!C QS\R@YY_V1QWXY:86,Z?XE74JE0$
M4GNJG(_[Z8C]*YJXD>?]](68L<;F).2H'&3UP"/H,5VVG?"XGFXD&,GB,9R,
M<?,P&.?]D\=^>&?$FS2S2WAC 5%$@ '_  #_ "3U)Y-%T(Y;P_\ \?,/_7:/
M_P!"%>VUXEX?_P"/F'_KM'_Z$*]MHD-'E?Q#TG['<>< -DPR, #YA@,/Y$GC
M)/UK T[4Y--?S86*M@C(P>#V(.0?Q[\]:]IU'3(]23RIE#+D'!R.1W!&"/P[
M<=*X6_\ A<X/[B12"3Q("I [<J&S[\#Z>@F#1DW?C^[N%$>X+P02B@,<C&23
MG!_W=O7Z8YYHRF"00&&1D=1DC(_$$?45Z%HWPS6(A[E@_!RBY"Y[?-D$\>PY
M[XZZ'B/P,-8=9%<1A(P@4)D8!)'\0QUQC%%T%CFOAC_Q\O\ ]<6_]"2O1M0L
M5OXV@?[K@@]/S&<\CJ/0U@>&/!7]ARF?S-^Y"N-FWJ0<YW'TKIZ3>H(\0UG2
M7TJ5H'!X/!(QN7LPZ]?KP>.HJ[HGC"XT=?+0ADYPKC(!/<8((^F<<DXS7JVI
M:1%J:[)D# =,]1TZ$<C..<'FN,O_ (7=3!+Z860?3.67\?X?;WIW06,Z3XF7
M+@@+&"0>0K9'ORQ'Y@BLJP\436UP+UV+L,@AB<%3G*\=!SD#& <''%;MK\+I
MF/[R1%&.JAF.?H0O\_PKJ=#\%6^E8?&^08^9^<'CH.@Y&0>2/6BZ#4V[>;SE
M63!&X X8889&<$=B.]2445(PKEO'GAO^TX_/C!,L0X  RRD\CUXZC\0!DUU-
M% '@57H]<N(P%660    2,  .@QFO3+O1;+Q*6E4AG& 6C;YA@D#(Y'." 2#
MD=#C!JK'\,[9""6D(!'!9<'VX4'\B#570K'G,=J]X))^2(P&=CDY+,%Z^I)S
MSU )JK7IGCN>/2[064:@"0@*!G@(0Q/0YYQG)R2<\\UYK'&9"%4$DD  #))/
M08IIB9[7X?\ ^/:'_KC'_P"@BN'^(?AO[._VZ,'8Y^? &%;@ \?WN_\ M=3\
MP%>A6=J+1%A7.$55&>N%&!4DD8D!5@""""",@@]1BIN4>':=J<FFOYL+%6P1
MD8/![$'(/X]^>M=+_P +.N?[D?\ WRW_ ,770ZQ\.8+P[X28B3R -R]R?ER,
M=>QP .!6!)\,+@$[7C(R<$E@<=N-IQ^9^M.Z8M3&UKQ7<:O\LC83^XG"]NHZ
MGD9Y)P>F*]"\#Z\VK0X<'=%A2QR0W'7)_B_O?4'O@9^F_#**!MTSF0=@!L'?
MK@DGVP1T[UU\%NMNHC10JCH%  &>>@I-H$4_$'_'M-_UQD_]!->)5[KJ%I]L
MB>#./,1ESC.-P(SBN(_X55_TW_\ (?\ ]G33!G0> _\ CRB_X'_Z&U;]9^@Z
M5_9,*VV[=LW<XQG+%NF3Z^M:%2QGB7B#_CYF_P"NTG_H1KOOAC_Q[/\ ]=F_
M]!2J^H?#7[9*\_G8\QV;'EYQN).,[ZW_  QX?_L.(P;M^YRV=NWJ ,8R?2J;
MT$D1^+O#XUF$J/\ 6)EDZ<G'W<GLWU'.">F*\@DC,9*L"""001@@CJ,5[W6/
MK7A2WU?YI%P_]].&[=3T/ QR#@=,4D[ T<#8_$2ZM5\L[7QT+@EL8QC((S]3
MD^IHOOB)=72^6-J9ZE 0V,8QDDX^HP?0UH7?PNE7'E2JW7.\%/IC&[/Z5)8_
M"YCS-*!SR$!.1_O'&#^!QUYZ4] U*/@/Q$]M/Y#!G%PW/)+!N[__ !1ZX&<\
M8/J%9NC^'H-(&(5 .,%CRQZ9Y]\9P,#/05I4F-''?$S3O/@6X&<Q-SR,;7P"
M?7J%''J?P\SKWN2,2 JP!!!!!&00>HQ7#:K\,5<E[9]OHK\CK_>'( '3()XY
M//#3$T8G_"Q;O9Y>5W?W]HW=<]/N^WW>GOS7JU>;VOPNF8_O)$48ZJ&8Y^A"
M_P _PKTBD[ CQ+Q!_P ?,W_7:3_T(UUWPJ_Y;_\ ;/\ ]GJQJ'PU^V2O/YV/
M,=FQY><;B3C.^MCPKX5_L#?\^_S-O\.W&W/N?6FWH%A_B[P^-9A*C_6)EDZ<
MG'W<GLWU'.">F*\@DC,9*L"""001@@CJ,5[W6/K7A2WU?YI%P_\ ?3ANW4]#
MP,<@X'3%).P-'GNF^/KJQ782)!V\T%B.O<$$]>Y/MBJNL^+KC5@8Y& 0D'8H
MPO'YD\\X)(S]!C>N_A=*N/*E5NN=X*?3&-V?TJ73OA<3S<2#&3Q&,Y&./F8#
M'/\ LGCOSP[H6IF> -4G@G%O&"\;G+KV Z%\]L?^/<#KC'JE4]-TB+3%V0H%
M!ZXZGKU)Y.,\9/%7*3=RD%9^NZ.NKQ-;OQGD' )!'0\_D>F02,C-:%%(#PB\
MLWLW,,@*NIP0?\_D>A'(K7T?QI<Z6-BL'0# 63+ = ,'((P!P,X]J].UCP]!
MJXQ,H)Q@,.&'7'/MG.#D9ZBN/OOA<PYAE!YX#@C _P!X9R?P&>O'2JNF*QAZ
MKXXN=24QE@J,,%4&,_B<MST/.".,=<P^%-4GL9U%N"Y<@%.S#^F.N[MSGC(/
M06'PN<G]_(H (XC!8D=^6"X]N#]/7LM'\/0:0,0J <8+'ECTSS[XS@8&>@HN
M@L.UW1UU>)K=^,\@X!((Z'G\CTR"1D9KQB\LWLW,,@*NIP0?\_D>A'(KW>LW
M6/#T&KC$R@G& PX8=<<^V<X.1GJ*2=@:/,='\:7.EC8K!T P%DRP'0#!R",
M<#./:C6/&ESJ@V,P1",%8\J#U!R<DG(/(SCVK>OOA<PYAE!YX#@C _WAG)_
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M )V4J<D'^Z2.I7V_D<CG&:R-'^',%F=\Q,I!X!&U>Q'RY.>G<X(/(KJXXQ&
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M. PX!Q@D>A[9!R.F156O0O VE1ZI9202C*F9OJ#L7!![$?\ UCD$BJ9)D?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\_G8\QV;'EYQN).,[Z28V5_A5_RW_P"V?_L]=!X\_P"/*7_@'_H:T>%?"O\
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M&00>HQ7*:Q\.8+P[X28B3R -R]R?ER,=>QP .!0F#1SW_"SKG^Y'_P!\M_\
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M,.F.G"GDGID8YYQT.C_#F"S.^8F4@\ C:O8CY<G/3N<$'D5U<<8C 50
M,  =!BAL$AU%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#D/B=_Q[)_UV7_ -!>O,:]E\3^'_[<B$&[9M<-G;NZ C&,CUKF/^%5?]-_
M_(?_ -G5)B:._HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** (Y)-O%,\\T3]?PJ.@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ
M.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3
MSS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YY
MJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"
M3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1Y
MYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@
M"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1
MYYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B
M@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS
M1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ
M.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3
MSS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"W1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 03]?PJ.I)
M^OX5'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*?I5?RSZ&@"[15$C%*$)[4 7:*AME(SFEFFV<#K0!*3BF[P>]5"2_O1L([4
M7:*II*4^E6U;=S0 M%%4I&W'- %VBJMN^#CUJP_(/TH =15+RSZ&D(Q0!>HJ
MD$)[5/;*1G- $U!.*BFFV<#K5<DO[T 6]X/>G52V$=J5)2GTH N44BMNYJ&6
M?' H F)QUH#@]ZI\M[T%".U %VBJD<Q7Z58F&10 ^BJ7EGT-)TH O452V$]J
ML6XP.?6@"6D)QUJ&6?' J'EO>@"X'![TM4BA':G1S%?I0!;HHI"<<T +15$G
M/-36S]J +%%%(S;>: %I"X'>JLDQ?Z4T(3VH N YZ4M4N5]JGAFW<&@":BBH
M)9\<"@"8G'6@.#WJGRWO04([4 7:*J1S%?I5N@ HI"<<U2)SS0!>HJO;/VJ6
M89!H ?15+RSZ&DZ4 7J*I;">U6+<8'/K0!+2$XZU#+/C@5#RWO0!<#@]Z6J1
M0CM3HYBOTH MT44A..: %HJB3GFIK9^U %BBBD9MO- "TA<#O5628O\ 2FA"
M>U %P'/2EJEROM4\,V[@T 3445!+/C@4 3$XZT!P>]4^6]Z"A':@"[152.8K
M]*FN!N''K0!+15+RSZ&FT 7Z*I>6?0U:A^4<T /I"P'6JTEP6Z<4P*3TH N!
M@>E+5(@K4T,V>#0!/1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<<U<89&*HT 6XHMGUJ2CK10 QX@_6G]*** $)QS5/[Q^M3W+X&/6H8F"G)H
M69-AJ>!]P^E132AZ2W?!QZT 6)&VC-5$7<<58N!D5#!U% %I$V\"EHJ"?.>,
M].U $GE '-/JF7([FK,)R!0!7F;<:F@BQSWJL1CBKD?0?2@!U->,/UIU% "
M8XI:** *D_WC4\'W14$_WC4\'W10 ]C@9JE]X_6K<PR#55."/K0!;CCV<4ZB
MB@!C1 G-/HHH CG;:/K4$*;S2W#Y./2B&4)0 S[I^E7%;=S525PYR*FMGR,>
ME $U5)_O&K=5)_O&@">#[HI[' S3(/NBEF&0: *GWC]:N1Q[.*J)P1]:NT %
M,:($YI]% #9&VC-5$7<<58N!D5#!U% %I$V\"EHJ"?.>,].U $GE '-/JF7(
M[FK,)R!0 ^J4G4_6KM4I.I^M %N/H/I1(VT9HCZ#Z4RX&10!71=QQ5Q$V\"J
ML'45;H *9Y0!S3Z* "H;EL#'K4U5)GW&@ ACWY^E-1MIS4L4P08J*0[CD4 7
M>M5[ENU20/N'TJ&X&#0 L$6[DU9J&VZ?C4U ",N[@TB1A.E5OF'K^M".21SW
MH LR-M&:J(NXXJQ<#(J&#J* +2)MX%+110 SR@#FGT44 0W+8&/6HH8]^?I1
M,^XT^*8(,4 1(VTYJ[UJE(=QR*LP/N'TH DJE)U/UJ[5*3J?K0!;CZ#Z42-M
M&:(^@^E,N!D4 5T7<<5<1-O JK!U%6Z "F>4 <T^B@ J&Y; QZU-529]QH (
M8]^?I34;:<U+%,$&*BD.XY% %WK5>Y;M4D#[A]*AN!@T +!%NY-6:AMNGXU-
M0 C+NX-(D83I5;YAZ_K0CDD<]Z +,C;1FJB+N.*L7 R*A@ZB@"TB;>!2T44
M,\H YI]%% !5"K]4* +]0W+8&/6IJKW(Y!H 9#'O/L*M]*KVO>K%  1FFI$$
MZ4ZB@ HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBMN&:BE@+'(I\*%!@T 1W7;\:+7O^%.FB+XQ1#$4SF@"6JDT>TY[5;I",\4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO/M)^)K,X6Y1
M0A(^:/(V^Y!+9[=,$#/7I7?QR"0!E(((!!!R"#T.:35ACJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()^OX5'4D_7\*CH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <A\1%EMXUNH7==IVL$9@
M,'H3@X&#QG'.0,\"N!_X2"Y_Y[2?]_&_QKU_6]._M*"2WXRZG&20-PY4\<\$
M UXE)&8R58$$$@@C!!'48JHB9[3X<U'^T;>.<YRR\D@#++\K' XY(./;TK2K
M@OA=J.1):'&00XX.3G"MSTXPOOR>O;O:3&@KC/B/K;6:QP1,5=B6)1RK  8
M('."3_X[^79UX[XRU4:E<NZG*+A5Z=%ZX(Z@MD@^A_"A"94_X2"Y_P">TG_?
MQO\ &O7]$MGMH(XY"S.%&XNVYMQY(SWP3@>V*\I\(:3_ &G<HF 50[VR 1M4
MCC!ZY.!^.<8KV2G($%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KB/B5J$MGY/E.R;O,SL8KG&S&<&NWK@/BK_RP_P"VG_LE-;B9
MR/\ PD%S_P ]I/\ OXW^->VUX%7OM.0(****D84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  K&V_OR?]]+_P#$4?\ "L;;^_)_WTO_ ,177T4786.0_P"%8VW]^3_OI?\
MXBC_ (5C;?WY/^^E_P#B*Z^BB["QR'_"L;;^_)_WTO\ \11_PK&V_OR?]]+_
M /$5U]%%V%CD/^%8VW]^3_OI?_B*/^%8VW]^3_OI?_B*Z^BB["QR'_"L;;^_
M)_WTO_Q%'_"L;;^_)_WTO_Q%=?11=A8Y#_A6-M_?D_[Z7_XBC_A6-M_?D_[Z
M7_XBNOHHNPL<A_PK&V_OR?\ ?2__ !%'_"L;;^_)_P!]+_\ $5U]%%V%CD/^
M%8VW]^3_ +Z7_P"(H_X5C;?WY/\ OI?_ (BNOHHNPL<A_P *QMO[\G_?2_\
MQ%'_  K&V_OR?]]+_P#$5U]%%V%CD/\ A6-M_?D_[Z7_ .(H_P"%8VW]^3_O
MI?\ XBNOHHNPL<A_PK&V_OR?]]+_ /$4?\*QMO[\G_?2_P#Q%=?11=A8Y#_A
M6-M_?D_[Z7_XBC_A6-M_?D_[Z7_XBNOHHNPL<A_PK&V_OR?]]+_\11_PK&V_
MOR?]]+_\177T4786.0_X5C;?WY/^^E_^(H_X5C;?WY/^^E_^(KKZ*+L+'(?\
M*QMO[\G_ 'TO_P 11_PK&V_OR?\ ?2__ !%=?11=A8Y#_A6-M_?D_P"^E_\
MB*/^%8VW]^3_ +Z7_P"(KKZ*+L+'AFJ6HM)I(5SA)'49ZX5B!7L?A_\ X]H?
M^N,?_H(KR+Q!_P ?,W_7:3_T(UZ[X?\ ^/:'_KC'_P"@BG(2-"BBBI&%%%%
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M68MP.E %AI0O>D$P/>JRQENE#1%><4 7**JPR%3BK5 !3=X'>E9MHS5(G/-
M%T'/2EJO;/@X]:L4 %%%% !1110!;HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR7Q[I1
ML;EG PDWS#KU/WN3WW<X'0$?2O6JY3XBZ4;RW$RC+0G/?.T\-P/P)ST //JU
MN)GG_AS4?[.N(YSC"MR2"<*WRL<#G@$X]_6O:Z\"KV7PGJ?]HVT<A.6 VM\V
MXY7C)/J?O<^O?K3D")O$>H_V=;R3C.57@@ X9OE4X/'!(S[>M>*5WWQ0U3_5
MV8'_ $T)_-5 Y^N>/3!ZUPMO UPRQ(,LY  Z9).!UHB)GHGPSTGR8VNV S*<
M+P,[5)R<]>3VX^Z#SQ7:U5TNP&GQ);KC"*!D#&2.IQ[GD^YJU4LH**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y#XG?\>R?]=E
M_P#07KS&O3OB=_Q[)_UV7_T%Z\QJX[$L]M\/_P#'M#_UQC_]!%:%9_A__CVA
M_P"N,?\ Z"*T*@HIZKI4>J1F"494_F#V(/8C_P"L<@D5XUJ^FMIDKV[=4.,^
MHZ@]3C(P<=J]QKRWXE0+%=!@.7C4GW.67^0%5$3(?A_J1M+I8\@)*"IR<#."
M5[XSG@?4@=:]8KQ+P_\ \?,/_7:/_P!"%>VTI @HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N ^*O\ RP_[:?\ LE=_7 ?%7_EA_P!M/_9*:W$S@:]]KP*O?:<@
M04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4\'W10!)1110!4G^\:G@^Z*@G^\:G@^Z* %F;:*JQKN.*L7 R/I4,)P10!:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"A&O7?#_\ Q[0_]<8__0152$C0HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $$_7\*CJ2?K^%1T %%%% !1110!4G^\:G@^
MZ*22#><YI\:[!B@!U%%% %2?[QJ>#[HI)(-YSFGQKL&* '$9XJG)'LXJY2,H
M;@T 01W&.#3C<BD:U]#2"V/>@!GG$G-6L9'--CA"?6GT 4Y(]G%21W&.#4[*
M&X-0M:^AH 4W(J!VW'-2BV/>I$A"T +", "H9XL<]JLT=: *L4VSCM4OVD>]
M(UL#TIGV8T -DG+^U6(F+#)IJ6X'7FI&&: *DK[CFI%ML]Z46OO4] $'V7W_
M $J%AM./2KM120;SF@!Z-N&:BNNWXU)%'LXI)8O,H 9:]_PJ>HXHO+J2@"M/
M%CGM213;..U6NM0M; ]* %^TCWJ&2<O[4[[,:D2W Z\T .B8L,FJ\L6SZ5;I
M",\4 5XI]O!I_P!I%(UMZ4T6QH 9))O.:GMQ@4);A?>I: (IXMW(J".39S5R
MHW@#<]Z &_:137N,\"D-L:<MMZT +;L3QVIMR^3CTJ<#'%1-;[N<T 1QP;^:
M?]E]_P!*F1=HQ2T 4Y8]E3V[Y&/2G2Q>938X=ASF@!9_NFH(/O"K,B[QBF1P
M;#G- $M13Q;N14M% %..39S4WVD4YX W/>HC;&@!7N,\"G6[$\=J1;;UJ8#'
M H K3ON/TI4M]PS3OLV>]3@8XH @^R^_Z5#(FPXJ[4<L._F@!87W"J\L6SZ5
M/%%Y=/(SQ0!7BGV\&G_:12-;>E-%L: &22;SFI[<8%"6X7WJ6@"*>+=R*@CD
MV<U<J-X W/>@!OVD4U[C/ I#;&G+;>M "V[$\=JCG?<?I5D#' J'[-GO0 U+
M?<,T[[+[_I4X&.** *4B;#BK4+[A22P[^:(HO+H 2YZ?C4=MU_"II8]XQ38H
M=AS0!+1110!%<]/QJ.VZ_A4TL>\8IL4.PYH EJ*>+=R*EHH IQR;.:F^TBG/
M &Y[U$;8T *]QG@4ZW8GCM2+;>M3 8XH AN(OXA4<<NRK=1/;@].* #[2/>H
MI9M_':E^S&GK; =: &VPYS4TJ;QBG 8HH I<H?<5.MR.]2/$'ZU";4]C0 K7
M/I^M-AD)/KFE6U]34R($Z4 17+]JCBBWU,\&\YS3XTV#% $7V7W_ $J.6+RZ
MMTV1-XQ0!%;/VJ63H?I4:6^TYS4K#(Q0!3CZCZU=J%;;!SFIJ &RIO&*J<H?
M<5=IKQ!^M $:W([TC7/I^M(;4]C0MKZF@!(9"3ZYJ6:/>/<4Y$"=*=0!25BA
MS4XN13Y(0_UJ(VQ[4 $EQG@5'$,D5*MKZFIE0+TH 4C/%4Y(]G%7*1E#<&@"
M".XQP:<;D4C6OH:06Q[T ,\XDYJQ*^T9[T1PA/K22Q;^] %9$WG%3?9??]*?
M%#LYJ2@"L]OM&:; ^T_6K9&>*@^R^_Z4 3U2DZGZU=J%K;)SF@"2/H/I3B,\
M4BC Q2T 4Y(]G%21W&.#4[*&X-0M:^AH 4W(J+SB3FGBV/>I8X0GUH )7VC/
M>JJ)O.*LRQ;^]$4.SF@!GV7W_2FO;[1FK-!&>* *D#[3]:GFCWCW%,^R^_Z5
M/0!25BAS4XN13Y(0_P!:B-L>U !)<9X%1Q#)%2K:^IJ94"]* !UW#%4V4H<5
M=IKH'ZT 1)<^M*UR.U-:U]#0+4]S0 U)23GUJ>5]HI4B"=*;+%O[T 5D3><5
M-]E]_P!*?%#LYJ2@"L]OM&:; ^T_6K9&>*@^R^_Z4 3T444 %%%% %NBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#"\;:=]NM9!QF,;QDD8V\GI_LY [9/XUX_7OM
M9_\ PC]M_P \8_\ OVO^%-.PFCQS2[ ZA*ENN<NP&0,X!ZG'L.3["O<8XQ&
MJ@     8  Z#%58-'@MV$B1(K#H5101GCJ!5RANX)!1112&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <A\3O^/9/^NR_^@O7
MF->[W5FEV-LBJX!SAE##/K@U5_X1^V_YXQ_]^U_PIIV$T>)45[;_ ,(_;?\
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MMZ!_'_P'^M<^'_WY^LOU-*G\#Y(UZ***]PX3Q+Q!_P ?,W_7:3_T(UZ[X?\
M^/:'_KC'_P"@BO(O$'_'S-_UVD_]"->N^'_^/:'_ *XQ_P#H(JI"1H4445(P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""?K^%1U)
M/U_"HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"W1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P'Q5_Y8?]M/\
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M^8Z?P1] HHHK$LT-#^^?]T_S%&N??'^Z/YFC0_OG_=/\Q1KGWQ_NC^9KT?\
MF!^9S_\ +_Y&?1117G'0%6])_P!:OX_R-5*MZ3_K5_'^1K;#?QH>J_,BI\$O
M0Z*BBBOISS K.US[@_WA_(UHUG:Y]P?[P_D:Y\;_  )^AI1^-&'6MH'\?_ ?
MZUDUK:!_'_P'^M>+EW^\1^?Y,[,1_#9KT445]$>>%86N??'^Z/YFMVL+7/OC
M_='\S7#FG\!^J-\+_$,^NATG_5+^/\S7/5T.D_ZI?Q_F:X<I_C/T_5&^+^!>
MI<K(U_\ @_X%_2M>LC7_ .#_ (%_2O1S'_=Y?+\T<V'_ (B,FMS0_N'_ 'C_
M "%8=;FA_</^\?Y"O+RO^.O1G5BO@-&BBBO?. R-?_@_X%_2LFM;7_X/^!?T
MK)KYW,?]XE\OR1Z&'_AH****Y#8EL_OK_O#^==17+V?WU_WA_.NHKV<H^"7J
M<>+W1SNK?ZUOP_D*MZ!_'_P'^M5-6_UK?A_(5;T#^/\ X#_6N?#_ ._/UE^I
MI4_@?)&O1117N'">)>(/^/F;_KM)_P"A&O7?#_\ Q[0_]<8__017D7B#_CYF
M_P"NTG_H1KUWP_\ \>T/_7&/_P!!%5(2-"BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 03]?PJ.I)^OX5'0 4444 %%%13R[.
M!UH >T@7K3/M(]ZKJI>I/LQ]J )TE#=*=5)XRG6K,))'- $E->4+UJ*>7' J
M%$+]* +'VD>]/60-TJ#[,?:HV4IUH N,VWDTSSU]:"I=<'K47V8^U $OGKZT
M>>OK54C'%2"W)YH LJX;D4O2HXD\L<U7DE+_ $H L-< 4@N :A2 MS2M;D4
M6@<T54A)!P*MT %1^>OK2S/M%4Z +RMNY%+4%LW:IZ "FM(%ZTR>79P.M5U4
MO0!8^TCWIZ2ANE0?9C[5&\93K0!=HJ.$DCFG2/L&: %9MO)J,W(%5V8O3Q;$
MT 3+.&_^O4E5'A*U);$].U $AF XI//7UJ-K<DYJ.2(IUH L>>OK2K*&X%5H
MXB_2I8X"IS0!/37E"]:BGEQP*A1"_2@"Q]I'O3UD#=*@^S'VJ-E*=: +M%-C
M)(YZTZ@!K2!>#0L@;@55D?<<TD;;3F@"[1103CF@ Z5&UP!5>24O]*5("W-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@/BK_P L/^VG_LE'PJ_Y
M;_\ ;/\ ]GH^*O\ RP_[:?\ LE'PJ_Y;_P#;/_V>JZ"ZG?T445(PKDJZVN2K
MR<X^Q\_T.O!_:^1+9_?7_>'\ZZBN7L_OK_O#^==1591\$O46+W05R]Y]]O\
M>/\ .NHKE[S[[?[Q_G1F_P $?4,)NR*NMKDJZVIR?[?R_4>,^S\S"US[X_W1
M_,UGUH:Y]\?[H_F:SZX<;_'GZF]'^&@HHHKF-#K:***^M/),[7/N#_>'\C6'
M6YKGW!_O#^1K#KP,T_COT1WX7X#0T/[Y_P!T_P Q4VO_ ,'_  +^E0Z']\_[
MI_F*FU_^#_@7]*VA_P B^7K^J(?^\+^NADT445Y9U'0Z3_JE_'^9JY5/2?\
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MU:H 0N!WI-X]144D!8YJ C'% %QVP,U349.*M%=RX]JK*<'- %P#'%+1UHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@#@/BK_RP_P"VG_LE'PJ_Y;_]L_\ V>CXJ_\
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MHHK8@Y>\^^W^\?YU%4MY]]O]X_SJ*OE:OQR]3U([(****@H*UM._U#_\"_\
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MOO4B0A: "+..:?110!2DZGZU;CZ#Z4PVX/-2 8XH &7=Q522/9Q5RD9=W!H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLN/^[^I_QK7\,>'(+V0I(F0$)^\PYR!V(]:FI@YPBY.VAI1S:E5FH).[]/\
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M_$TO]EQ_W?U/^-']EQ_W?U/^-'U"?E_7R#^VZ':7X?YB?\)Y>_\ /7_QQ/\
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M4_XT?V7'_=_4_P"-'U"?E_7R#^VZ':7X?YB?\)Y>_P#/7_QQ/_B:/^$\O?\
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M=V1N8=%)[&E+!3C%O30JGG%&I.,$I7;MTZ_,S_\ A/+W_GK_ ..)_P#$T?\
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M'U"?E_7R#^VZ':7X?YB?\)Y>_P#/7_QQ/_B:/^$\O?\ GK_XXG_Q-+_9<?\
M=_4_XU/I^C12R(C+D,Z@\GH2 >])X&:5]/Z^0XYU1DTK2U]/\RO_ ,)Y>_\
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M0KT(Y75DD[K\?\CG>*BGU-?_ (3R]_YZ_P#CB?\ Q-'_  GE[_SU_P#'$_\
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M\,6^I0M),FYA(1G<PXVJ>Q'K65? SH0YG:WE_P ,73KJ;LC!_P"$\O?^>O\
MXXG_ ,31_P )Y>_\]?\ QQ/_ (FN_P#^$#LO^>7_ (^__P 51_P@=E_SR_\
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M(",GH6 /2O2_^$#LO^>7_C[_ /Q5<N)PTL.TI6U[&M.HJBT. _X3R]_YZ_\
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M_P".)_\ $UW_ /P@=E_SR_\ 'W_^*H_X0.R_YY?^/O\ _%47069P'_">7O\
MSU_\<3_XFC_A/+W_ )Z_^.)_\37?_P#"!V7_ #R_\??_ .*K.\0^#K6T@>6.
M/##;@[W/5@.[4U9NQ%2?LX.3V2N<C_PGE[_SU_\ '$_^)H_X3R]_YZ_^.)_\
M347]GIZ?J?\ &C^ST]/U/^-:>Q9YW]LT>TOP_P R7_A/+W_GK_XXG_Q-'_">
M7O\ SU_\<3_XFHO[/3T_4_XT?V>GI^I_QH]BP_MFCVE^'^9+_P )Y>_\]?\
MQQ/_ (FC_A/+W_GK_P".)_\ $U%_9Z>GZG_&MGPIX>@OY2DJ9 0G[S#G('8C
MUI2I-*YI1S2E5FH).[]/\S+_ .$\O?\ GK_XXG_Q-'_">7O_ #U_\<3_ .)K
MO_\ A [+_GE_X^__ ,51_P ('9?\\O\ Q]__ (JL[H]"S. _X3R]_P">O_CB
M?_$T?\)Y>_\ /7_QQ/\ XFN__P"$#LO^>7_C[_\ Q5'_  @=E_SR_P#'W_\
MBJ+H+,X#_A/+W_GK_P".)_\ $T?\)Y>_\]?_ !Q/_B:[_P#X0.R_YY?^/O\
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M'/&]O,X#_A/+W_GK_P".)_\ $T?\)Y>_\]?_ !Q/_B:[_P#X0.R_YY?^/O\
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M)Y>_\]?_ !Q/_B:B_L]/3]3_ (T?V>GI^I_QH]BP_MFCVE^'^9+_ ,)Y>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!!/U_"HZDGZ_A4= !1110 445#<2XX% #WF"U']J]OUJ%(R_2I
MOLOO^E #TG#>U254DA*?2IX00.: )*:\@3K22R;!57EC[T 3&Z]J5;D'K31:
M^](]N1TYH L@YHJ"V!Z]JGH 1VVC-1_:1[TRY?M4.* +W6HWG"G%$#[A]*22
M#><YH /M(]Z/M(]ZBEAV#--BCWG% $XN >*EJ%;;!SFBXEQP* 'O,%K)UW3(
M]8C\MQAA]UAU4_U![CO]<$7$C+]*F^R^_P"E 'CNHZ<^GN8I!@C\B.Q!]/\
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MJVX59RBKI7.C_M6'_GHG_?:_XT?VK#_ST3_OM?\ &N&O-'ELAOD7 )QU!Y_
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M Z\A@"/H>E<-_P (S<?W/_'E_P :Y<)AZ=7FYY<MOZZFM6I*-K*YV7]JP_\
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M10[QFI8H=AS0!+TJ)[@#IS44TNXX'2DCA+\]J )/M7M4B2AZB^R^]1F,J<4
M7*"<4@X'-5)9-Y]J )FN0.E(+KVID<!;FG&U]Z )DD#]*=514(..]6Z "HWG
M"^]1W$N>!4<<1>@"7[5[?K4B3!JC^R^_Z5$\16@"Y138P0.>M*S;>: &/.%.
M*6.4/TJI]ZG1/M- %LG'-1_:1[U(PR,5#]E]_P!* '?:1[T?:1[U7D78<5)'
M!O&<T 31RA^E/)Q4<47EYJO+)O/M0!,UR!TI!=>U,C@+<TXVOO0!,D@?I3JJ
M*A!QWJR[[!DT *SA>M0FZ]!4)):I5ML]: '+<@]:E5MW(JNUL1THMU.?;O0!
M9H)Q1TJG+)O/M0!,UR!TI!=>U,C@+<TXVOO0!,D@?I3JJ*A!QWJW0 5$;@#B
MGR/M&:I@9H N1R!^E#OLY-5[=\''K4\L>\8H ;]I'O1]I'O3?LOO^E5Z +7V
MD>]2(VX9J'[+[_I3_P#5"@![.%ZU";KT%0DEJE6VSUH <MR#UJ56W<BJ[6Q'
M2BW4Y]N] %FBBB@ HHHH MT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9^NZPND1-</SC@#(
M!)/0<_F>N "<'%:%>1^-M?\ [5G*J08HB0F,<]-S9!.<D<=L8XSFFE<3,K5=
M5DU20SRG+'\@.P [ ?\ USDDFNT\*> !A;F[!SD%8STQ_M#]=O;HV<D"#X=>
M&_./VZ0 JI(0$'[PQ\_IQT'7G/0J*]$IM@D-CC$8"J     !@ #H,5F>*/\
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MT7^U[A8C]P?,_P#NCJ.H/)P..1G/:O1O%NMC0K?]U@.V%C  P,=3MXX4=."
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M_P#Z":\PKT_6/]1+_P!<W_\ 037F%=%#9GA9W\</0****V/("BBB@#7\*?\
M'S'_ ,"_] :O1*\[\*?\?,?_  +_ - :O1*YJ_Q'T&2_P)?XOT04445D>H%%
M%% !61XK_P"/:3_@/_H:UKUD>*_^/:3_ (#_ .AK50^)&&+_ (%3_"_R/.Z*
M**[#Y(**** "NB\#?Z]O^N9_]"6N=KHO W^O;_KF?_0EJ*GPLZL!_O$/4[FB
MBBN0^J"BBB@ HHHH R/%?_'M)_P'_P!#6O.Z]$\5_P#'M)_P'_T-:\[KIH?"
M?/9U_'C_ (?U84445J>8%%%% '1>!O\ 7M_US/\ Z$M=S7#>!O\ 7M_US/\
MZ$M=S7+6^(^DRC_=UZL****S/0"BBB@ KG?'/^H7_KH/_06KHJYWQS_J%_ZZ
M#_T%JNG\2.7'_P"[S]#AJ***ZSY4**** "NB\#?Z]O\ KF?_ $):YVNB\#?Z
M]O\ KF?_ $):BI\+.K ?[Q#U.YHHHKD/J@HHHH **** .=\<_P"H7_KH/_06
MKAJ[GQS_ *A?^N@_]!:N&KJH_"?-YO\ [P_1!1116AYX4444 =;X!_Y:_P#
M/_9JZZN1\ _\M?\ @'_LU==7+5^-GT^5_P"ZP^?YL****S.TR=?\-Q:TA5P
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MC=G'(/3KT)]:WO!/_+3_ (!_[-79B,!R4/:*?,EMVWMW,:>(YI\O+9LZ9W"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^*"BBB@ HHHH *U?"_\ Q\)_P+_T$UE5J^%_^/A/^!?^@FLJ_P##EZ,WP?\
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M6N=KHO W^O;_ *YG_P!"6HJ?"SJP'^\0]3N:***Y#ZH**** "BBB@#G?'/\
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M1117TYY@4444 9&O_P '_ OZ5DUK:_\ P?\  OZ5DU\[F/\ O$OE^2/0P_\
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M_7\*S?[!M_\ GC'_ -^U_P *TI^OX5'0!1_L&W_YXQ_]^U_PJY'&(P%4  #
M X  Z#%.HH ;)&) 58 @C!!Y!!ZC%9\OAZW;I%'G_<7_  K2HH QH])AB(98
MT#*<@A%R"._2M#[2?:IVC#=:9]F% %.[A6[&V10PSG# $9]<&F0:!!U,4?\
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M:B@#%_L: ?\ +*/_ +]K_A3_ .RX/^>,7_?M?\*U6C#=:9]F% %=Y"_6N?\
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MY[GIUJOX8OOLTP4GY9/E/7K_  ].^>/Q-=M+$)04;D,"#]#UKFO^$)_Z:?\
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MGOL;AEY!'Z$'_/YUV.BZ(=,+?-N#8_AP>.G.3ZU<U#34OQMD&<9P1P1GT/\
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M_:RI_(9KL=?!XI)STE_74Q5.M2TCJAVJ>+1.ICC7A@02W7D$' !_7/X5DZ+
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M #BH8GVG-7*C\A?2@"2J%7ZC\A?2@"2D9=PQ2T4 4Y(]G%.6X(JT1FHC;@T
M0M.6_P#K4L"DG(J98 *DZ4 %%%% !1110!;HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,!_]"%:4/XD?5&&,_W>I_A?Y' T445[I\:%%%% !1110 5O^"_]<W_7,_\
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MLT-#^^?]T_S%&N??'^Z/YFC0_OG_ '3_ #%&N??'^Z/YFO1_Y@?F<_\ R_\
MD9]%%%><= 5;TG_6K^/\C52K>D_ZU?Q_D:VPW\:'JOS(J?!+T.BHHHKZ<\P*
MSM<^X/\ >'\C6C6=KGW!_O#^1KGQO\"?H:4?C1AUK:!_'_P'^M9-:V@?Q_\
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M% &3JWWQ_N_U-4ZN:M]\?[O]35.OF\;_ !Y^IZ5'^&@HHHKF- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** +&G?ZP?C_(UM5BZ=_K!^/\C6U7N93_!?K^B.
M'%_&O0****]$YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_R*I?''U/5J***^7/3"BBB@ K"\;_\ 'G+_ , _]#6MVL+QO_QYR_\  /\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5B^*O#HUR+R\@.IRC$=_0]\'OCN ><8K:HH \&
M^:V;NKH?<,"#^8(->G>$?&JZDHAG(688&3@!\\#'^UZCOU'<";Q5X+36?WR$
M)*!UQPV!P#_CR<<8/&/+[[3Y+!O*E4JP[$>^,CU''4<&JW)V/=:RO%'_ ![O
M_P !_P#0A7!:)\0YK!?+E'FKS@LQ#\_[7.1UZC//7 Q6]J?CBVU*!XU)5R5
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MG4 ;N2P ^Z>Y-9UIQ]G+7HS;"4IJO3=G\2Z>9Z-16?\ \)!;?\]H_P#OXO\
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M?1I+&Q=0 ZY)88ZBIG./*]2Z5*?M(Z/==#T^BL__ (2"V_Y[1_\ ?Q?\:/\
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M '\7_&C_ (2"V_Y[1_\ ?Q?\: -"O-_B1_Q\+_UR7_T)J[C_ (2"V_Y[1_\
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M  D%M_SVC_[^+_C61Z9H45G_ /"06W_/:/\ [^+_ (T?\)!;?\]H_P#OXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4****V(.7O/OM_O'^=15+>??;_>/\ZBKY6K\<O4]2.R"BBBH*"M;3O\ 4/\
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MI/\ T(UZ[X?_ ./:'_KC'_Z"*\B\0?\ 'S-_UVD_]"->N^'_ /CVA_ZXQ_\
MH(JI"1H4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@""?K^%1U)/U_"HZ "BBB@ IDK[13ZK7+Y./2@!D2[C4ERG>H0<=*4L3U
MH FMG[5/5*-MI!J[0!!==OQHM>_X477;\:+7O^% $]46.3FKU4Y5VF@"U$,
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M_6K= $%UV_&BU[_A1==OQHM>_P"% $S' S5&K_6J++MXH O 8XHIL<F\4Z@
MHIKN$ZT[K0 R5]HJM$NXT^Y?)QZ5$#CI0!-<IWI;9^U0EB>M$;;2#0!/='@"
MH[89/X5+<+D?2H87V'- %NHWG"G%2=:C> ,<T )]I'O3]W&?:JC#!Q5M.0/I
M0!2J^!CBJ++MXJY')O% #J**:[A.M #J*.M% %2?[QJ>#[HJ"?[QJ>#[HH 2
MX.!]:AA&2*L3+N%58VVG- %VBD!SS2T %%-,@!QWIU $%R_:DME[U'(^XYI
MQ'2@!94VFK,+[A50G/6I;9L''K0!9JI/]XU;JI/]XT 3P?=%+*< TD'W13W7
M<,4 4T&2![U=JB#M/TJZC[N10 M%%-:0+P: &7!P/K4,(R15B9=PJK&VTYH
MNTQY@G!IP.>::\(?DT -^TCWJ1&W#-5)%VG%6(/NB@"2J4G4_6KM4I.I^M %
MN/H/I3+@X'UI\?0?2DF7<* *\(R15NJ4;;3FK@.>: %HHIID ..] #JKW+Y.
M/2K!..:HLV[F@">V3C/K4++L./2@.1WI"<T 7$;<,U7N#D_2GVS=127*\YH
M=;#C/O4U5[>3'RU8H B^TCWH%P#Q36MP!FH8^H^M %BX.!]:AA&2*L3+N%58
MVVG- %VBD!SS2T %%-,@!QWIQ..: *]R^3CTI;9.,^M0,V[FE#D=Z !EV''I
M5M&W#-4R<U/;-U% $]4I.I^M7:I2=3]: +<?0?2F7!P/K3X^@^E),NX4 5X1
MDBK=4HVVG-7 <\T +1133( <=Z '57N7R<>E6"<<U19MW- $]LG&?6H678<>
ME <CO2$YH N(VX9JO<')^E/MFZBDN5YS0 ZV'&?>IJKV\F/EJQ0!%]I'O0+@
M'BFM;@#-0Q]1]: +%P<#ZU#",D58F7<*JQMM.: +M%(#GFEH **:9 #CO3J
M&R=#]*J1]1]:MR=#]*J1]1]: +M5[H\@58J"Y7O0 EJ.IJQ56"3:>>]6J "B
MBFK(&X% #J*** "BBB@"W1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]2TB+4UV3(&
M Z9ZCIT(Y&<<X/-7** //M1^%Q'-O(,9'$@Q@8Y^90<\_P"R.._'/-W?A&[M
M<;HF.<_<P_3UV9Q^->RT4^9BL>)?\(_<_P#/&3_OVW^%'_"/W/\ SQD_[]M_
MA7MM%/F"QXE_PC]S_P \9/\ OVW^%'_"/W/_ #QD_P"_;?X5[;11S!8\2_X1
M^Y_YXR?]^V_PH_X1^Y_YXR?]^V_PKVVBCF"QXE_PC]S_ ,\9/^_;?X4?\(_<
M_P#/&3_OVW^%>VT4<P6/$O\ A'[G_GC)_P!^V_PH_P"$?N?^>,G_ '[;_"O;
M:*.8+'B7_"/W/_/&3_OVW^%'_"/W/_/&3_OVW^%>VT4<P6/$O^$?N?\ GC)_
MW[;_  H_X1^Y_P">,G_?MO\ "O;:*.8+'B7_  C]S_SQD_[]M_A1_P (_<_\
M\9/^_;?X5[;11S!8\2_X1^Y_YXR?]^V_PH_X1^Y_YXR?]^V_PKVVBCF"QXE_
MPC]S_P \9/\ OVW^%'_"/W/_ #QD_P"_;?X5[;11S!8\2_X1^Y_YXR?]^V_P
MH_X1^Y_YXR?]^V_PKVVBCF"QXE_PC]S_ ,\9/^_;?X4?\(_<_P#/&3_OVW^%
M>VT4<P6/$O\ A'[G_GC)_P!^V_PH_P"$?N?^>,G_ '[;_"O;:*.8+'B7_"/W
M/_/&3_OVW^%'_"/W/_/&3_OVW^%>VT4<P6/$O^$?N?\ GC)_W[;_  H_X1^Y
M_P">,G_?MO\ "O;:*.8+'B7_  C]S_SQD_[]M_A1_P (_<_\\9/^_;?X5[;1
M1S!8\2_X1^Y_YXR?]^V_PH_X1^Y_YXR?]^V_PKVVBCF"QXE_PC]S_P \9/\
MOVW^%'_"/W/_ #QD_P"_;?X5[;11S!8\2_X1^Y_YXR?]^V_PH_X1^Y_YXR?]
M^V_PKVVBCF"QXE_PC]S_ ,\9/^_;?X4?\(_<_P#/&3_OVW^%>VT4<P6/$O\
MA'[G_GC)_P!^V_PH_P"$?N?^>,G_ '[;_"O;:*.8+'B7_"/W/_/&3_OVW^%'
M_"/W/_/&3_OVW^%>VT4<P6/$O^$?N?\ GC)_W[;_  H_X1^Y_P">,G_?MO\
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MO\*/^$?N?^>,G_?MO\*]MHHY@L>)?\(_<_\ /&3_ +]M_A1_PC]S_P \9/\
MOVW^%>VT4<P6/$O^$?N?^>,G_?MO\*/^$?N?^>,G_?MO\*]MHHY@L>)?\(_<
M_P#/&3_OVW^%'_"/W/\ SQD_[]M_A7MM%',%CQ+_ (1^Y_YXR?\ ?MO\*/\
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M<3LA49(!R23SQD_>8^N!GJ!7-?#?P^%7[>_5LJ@XZ="WKG.1VXSU!JA\1?$
MNW%DGW8CECP06QT_X#D@\]201P*'JPV.4U"^:_D:=_O.23U_(9SP.@]!7I'P
M]T#[#$;EP-\P!'0X3J.W&>I&>FWH17%>$?#YUF8*?]6F&?KR,_=R.[?4<9(Z
M8KV*B3!'.>.+N:.'R+=&9I<ABJ%L+CGIT)S@<=,]#BO-?^$?N?\ GC)_W[;_
M  KVVBDG8+'B7_"/W/\ SQD_[]M_A1_PC]S_ ,\9/^_;?X5[;13Y@L>)?\(_
M<_\ /&3_ +]M_A1_PC]S_P \9/\ OVW^%>VT4<P6/$O^$?N?^>,G_?MO\*/^
M$?N?^>,G_?MO\*]MHHY@L>)?\(_<_P#/&3_OVW^%'_"/W/\ SQD_[]M_A7MM
M%',%CQ+_ (1^Y_YXR?\ ?MO\*/\ A'[G_GC)_P!^V_PKVVBCF"QXE_PC]S_S
MQD_[]M_A1_PC]S_SQD_[]M_A7MM%',%CQ+_A'[G_ )XR?]^V_P */^$?N?\
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M^>,G_?MO\*/^$?N?^>,G_?MO\*]MHHY@L>)?\(_<_P#/&3_OVW^%'_"/W/\
MSQD_[]M_A7MM%',%CQ+_ (1^Y_YXR?\ ?MO\*/\ A'[G_GC)_P!^V_PKVVBC
MF"QXE_PC]S_SQD_[]M_A1_PC]S_SQD_[]M_A7MM%',%CQ+_A'[G_ )XR?]^V
M_P */^$?N?\ GC)_W[;_  KVVBCF"QXE_P (_<_\\9/^_;?X5LV'PYNK@_O
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M?6GDF=KGW!_O#^1K#K<US[@_WA_(UAUX&:?QWZ([\+\!H:']\_[I_F*FU_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% $$_7\*CJ2?K^%1T %%%%
M3CFJ1.XY]:ND9INP#M0 BQ <8I?+'H*=10!3E7::L0-N'TIY4'K0% Z4 0W7
M;\:+7O\ A4Q4'K0% Z4 +3)8M_UI]% %(@I[4[SV]:M$9ZTWR!Z4 522_O5F
M&/8*>% Z4M $4T._D=:K@E/:KM(5!ZT 5?/;UIH!?WJUY ]*<!CI0 R&/9^-
M2444 5KGK^%26W3\:D*@]: ,=* %J*:'?R.M2T4 4@2GM3O/;UJT5!ZTWR!Z
M4 50"_O5D#REIX&.E!&>M %-1N./6K?ECTI0@':EH ;Y8]!51EVG%7:0H#VH
M 1&WC-5Y8=O(Z59 QTI: *:R%>E#2EN,U::(-VI!$!VH K)$7^E6P,<4M% $
M4T._D=:K@E/:KM(5!ZT 5?/;UIH!?WJUY ]*<!CI0 P#REJLHW''K5PC/6@(
M!VH 3RQZ4>6/04ZB@"DR[3BK<;;AFE* ]J ,=* (;KM^-%KW_"IBH/6@*!TH
M 6HIH=_(ZU+10!2!*>U.\]O6K14'K3?('I0!5 +^]6HU\L<TX#'2E(S0!2)W
M'/K5I8@.,4NP#M3J &^6/055E7::N4A4'K0 R%MP_2H98=O(Z59"@=*6@"FL
MA7I0TI;C-6FB#=J01 =J *R1%_I5L#'%+10!%-#OY'6JX)3VJ[2%0>M %7SV
M]:: 7]ZM>0/2G 8Z4 )$FP8IU%% %2?[QJ>#[HIY0'M2@8H *KS08Y%6** *
M2R%>E.,Q/>K+1ANM((0.U %:.,O5B5M@J3I2%0>M %2)-QQ5KRQZ"E"@=*6@
M!IB![53!VGZ5>INP'M0 H.>:JS_>-6P,4A0'M0 R#[HJ2@#%% $,T.>14"L4
MZ5=I&0-UH J^>?6FJA>K0A [4\#% "(NT8J":#'(JQ10!260KTIQF)[U9:,-
MUI!"!VH JI&7Z5;1=HQ3NE% !5*3J?K5VF[ >U !'T'TIU'2B@"O-!CD5$LA
M7I5VFM&&ZT 5C,3WI(XR]61"!VI_2@"*=MHQ4,";C]*M%0>M 4#I0 GECT%-
MDB!!P*DHH I1MM.:N.F[@TGECT%.Z4 4Y(RE*)B.]6^M,,(/:@"JTA;K4D,)
MSDU.L87I3J "J\T&.15BB@"DLA7I3C,3WJRT8;K2"$#M0!6CC+U/.VT8J7I2
M%0>M %6!-Q^E6?+'H*4*!TI: (Y(@0<"JT;;3FKM-\L>@H =5*3J?K5WI3=@
M/:@ CZ#Z4ZCI10!7F@QR*B60KTJ[36C#=: *QF)[TD<9>K(A [4_I0!%.VT8
MJ&!-Q^E6BH/6@*!TH 3RQZ"FR1 @X%244 4HVVG-7'3=P:3RQZ"G=* *<D92
ME$Q'>K?6F&$'M0!5:0MUJ2&$YR:G6,+TIU !5>:#'(JQ10!260KTIQF)[U9:
M,-UI!"!VH K1QEZN 8HZ44 -DZ'Z54CZCZU=ZTW8!VH =2$9XI:* *DL6SZ4
MBRE>,U<IAB![4 5FD+=:?!$2<U.L07M3J "BBB@ HHHH MT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY#8ZVBBBOK3R0K.US[@_WA_(UHUG:Y]P?[P_D:Y\;_ GZ&E'XT8=:&A_?/\
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MN,?_ *"*\B\0?\?,W_7:3_T(UZ[X?_X]H?\ KC'_ .@BJD)&A1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()^OX5'4D_7\*C
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>(/^/F;_ *[2?^A&O7?#_P#Q[0_]<8__ $$5Y%X@_P"/F;_KM)_Z$:]=\/\
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MCUJS0 4444 %%%% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^[R.1C)/=:]"HHN%@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <!\5?^6'_;3_ -DH
M^%7_ "W_ .V?_L]'Q5_Y8?\ ;3_V2CX5?\M_^V?_ +/5=!=3OZ***D85R5=;
M7)5Y.<?8^?Z'7@_M?(EL_OK_ +P_G745R]G]]?\ >'\ZZBJRCX)>HL7N@KE[
MS[[?[Q_G745R]Y]]O]X_SHS?X(^H83=D5=;7)5UM3D_V_E^H\9]GYF%KGWQ_
MNC^9K/K0US[X_P!T?S-9]<.-_CS]3>C_  T%%%%<QH=;1117UIY)G:Y]P?[P
M_D:PZW-<^X/]X?R-8=>!FG\=^B._"_ :&A_?/^Z?YBIM?_@_X%_2H=#^^?\
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MX'R1KT445[APGB7B#_CYF_Z[2?\ H1KUWP__ ,>T/_7&/_T$5Y%X@_X^9O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @
MGZ_A4=23]?PJ.@ HHHH **** *D_WC4\'W14E% !1110!4G^\:G@^Z*DHH *
MAF@W<BIJ* *7*^U!<GO5TC-(% Z4 58X2WTJV!CBBB@"O+!W%1 E:NTA&>M
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MTW<&EHH IO$4^E)O([U=I"@/:@"F 7]ZL0Q;.3UJ7I10!2=MQS5N--HQ3J*
M"JURN#GUJ#4+IH6 4X&/0>IJK_:,GK^@_P *X:N94J<W%IW7I_F;QPTI)/0U
M+9\C'I2S0[^1UK*_M&3U_0?X4?VC)Z_H/\*C^UJ/9_A_F/ZI/R+I!3VHWD]Z
MI?V@Y[_H/\*07SCO^@_PH_M:CV?X?YA]4GY%](B]6HTV#%8_]HR>OZ#_  H_
MM&3U_0?X4?VM1[/\/\P^J3\C9=-W!JH\13Z51_M&3U_0?X4?VC)Z_H/\*/[6
MH]G^'^8?5)^1=WD=Z "_O5$WSGO^@_PI?[0<=_T'^%']K4>S_#_,/JD_(U88
MMG)ZU7=MQS5+^T9/7]!_A1_:,GK^@_PH_M:CV?X?YA]4GY&Q&FT8IU8O]HR>
MOZ#_  H_M&3U_0?X4?VM1[/\/\P^J3\C1N5P<^M/MGR,>E9?]HR>OZ#_  H_
MM&3U_0?X4?VM1[/\/\P^J3\C5N>GXU';=?PK._M&3U_0?X4?VC)Z_H/\*/[6
MH]G^'^8?5)^1M45B_P!HR>OZ#_"C^T9/7]!_A1_:U'L_P_S#ZI/R-6YZ?C4=
MMU_"L[^T9/7]!_A1_:,GK^@_PH_M:CV?X?YA]4GY&U2.F[@UC?VC)Z_H/\*/
M[1D]?T'^%']K4>S_  _S#ZI/R+SQ%/I2;R.]4O[1D]?T'^%(;YSW_0?X4?VM
M1[/\/\P^J3\B\ 7]ZL0Q;.3UK*_M!QW_ $'^%']HR>OZ#_"C^UJ/9_A_F'U2
M?D;$D>_BJCQE.M4O[1D]?T'^%']HR>OZ#_"C^UJ/9_A_F'U2?D7?,/J:%4OT
MJC]M<]_T'^%+_:,GK^@_PH_M:CV?X?YA]4GY&M##LY[U)UK%_M&3U_0?X4?V
MC)Z_H/\ "C^UJ/9_A_F'U2?D:,L&.1TJ,,1TJE_:,GK^@_PI#?N>I_0?X4?V
MM1[/\/\ ,/JD_(O$EJEA@[FLP7[CH?T'^%+_ &C)Z_H/\*/[6H]G^'^8?5)^
M1H7#Y./2I+9,#/K67_:,GK^@_P */[1D]?T'^%']K4>S_#_,/JD_(VJAN5R,
M^E9?]HR>OZ#_  H_M&3U_0?X4?VM1[/\/\P^J3\C0MWP<>M6).A^E8_]HR>O
MZ#_"C^T9/7]!_A1_:U'L_P /\P^J3\B['U'UJ[6+_:,GK^@_PH_M&3U_0?X4
M?VM1[/\ #_,/JD_(VNM5I8,<CI6=_:,GK^@_PH_M&3U_0?X4?VM1[/\ #_,/
MJD_(NAB.E!):J)OW/4_H/\*!?N.A_0?X4?VM1[/\/\P^J3\C3A@[FIR,\5C?
MVC)Z_H/\*/[1D]?T'^%']K4>S_#_ ##ZI/R+\D)7Z4T.1WJE_:,GK^@_PI#?
M.>I_0?X4?VM1[/\ #_,/JD_(O<M[U-%!CDUF#4''?]!_A1_:,GK^@_PH_M:C
MV?X?YA]4GY&U4,T&[D5E_P!HR>OZ#_"C^T9/7]!_A1_:U'L_P_S#ZI/R+O*^
MU!<GO5(Z@Y[_ *#_  I!?..A_0?X4?VM1[/\/\P^J3\C0CA+?2I;AMHVUE_V
MC)Z_H/\ "MJNG#8N&(ORWT[F=2DZ=KE6W3)SZ5:HHKH,QLB[@151&VG-7:*
M#K5*3J?K5VB@!L?0?2G444 5Y8.XJ($K5VD(SUH IEB>M2109Y/2K 4#I2T
M0W+X&/6H[=,G/I5JB@ ILB[@13J* *2-M.:MLH<8IU% %-XBGTI-Y'>KM(4!
M[4 4P"_O4\,.WD]:FZ44 %5Y8.XJQ10!2!*T%B>M7",]: H'2@"O%!GD]*6Y
M?M5BB@"O;)WJQ110!'.NX?2J\3[35RB@ HHHH **** +=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 <!\5?^6'_;3_V2CX5?\M_^V?\ [/1\5?\
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MJT0M32\.>-(M:/E8*2XSM)R#UZ'C.!R1@'TR 36CK&NQ:0OF3-C.< <L2!G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9.K??'^[_4U3JYJWWQ_N_U-4Z^;QO\ 'GZGI4?X:"BBBN8T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Z*N=KHJ]?)_M_+]3DQGV?F%%%%>L
M<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %NBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,?,/_7:/_T(5W'Q,U;R8UM%(S*<MR,[5(P,=>3WX^Z1SS6=X4\"2^8EU/\
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M&T<?,<#/'')QR[1/"LUS/'')$ZH6&XNKJNT<D9QQD# ]\5Z#_P ('9?\\O\
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M@_X^9O\ KM)_Z$:]=\/_ /'M#_UQC_\ 0152$C0HHHJ1A1110 4444 %%%%
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ME<-:C&CB.67PI_A_PQO";G3NM[?B<_\ \)M_TS_\?_\ L:/^$V_Z9_\ C_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI;2U@HHHKK,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,C7_X/^!?TK)KK:*\[$9;[:HY\UK^7_!.BGB>2*5CDJ*ZVBLO['_O_ (?\
M$OZYY?B<O9_?7_>'\ZZBBBNS!X3ZO%J][F-:K[1IV.=U;_6M^'\A5O0/X_\
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MP+ZK\IQ_L]/TQ7'G%'2-1>C-L'/>)IUYSJO^ND_ZZ/\ ^A&O1J\YU7_72?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBHKBX6V4R.<*HY)H$VDKLEK.U^SDNX6CB.&/;^\.ZY[9_^L>":ATGQ+'J3
M&-<J>P;'(QST[CT].?7&O5:Q9DI4\13=G=/30\F="A*D8(."#UKJO#_A$Y$U
MP.,9"=_^!?X?GW!Z&318Y)A=$9< #MC(Z-TY(_P]!5ZM)UKK0\_"Y3&G-RGK
M9Z+_ #"BBBL3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** . ^*O_+#_MI_[)5#P!KT.D^;Y[;=^S'RL<XW9^Z#ZBNM\8^%SKJ+
ML8*\9.-WW2&QG. 2.G'Y8YR."_X0.]_YY?\ CZ?_ !54K6%U._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[,S6)UN)Y94.5>1R#TR"Q(ZU[#X?_X]H?\ KC'_ .@BO.;'X>74[;9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?R-'V9_[I_(T>RGV8<R[D=%2?9G_ +I_(T?9G_NG\C1[*?9AS+N1T5)]F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ&-[*^X4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^AY%/K@/;3OJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWV'- %VJKS$$CWJ=90>]#3!?_K4 5_/;UJTW3BJ-7Z *%7ZIRIL/M4L,_8T
M3T4WS!ZBHI+CTH GHIL;[QFG4 4I.I^M6X^@^E5).I^M6X^@^E #+CI4,'WA
M5IUW#%4^5/N* +M%1QSANO6G&4#O0 ZBJYN>?:I]W&: *]R^3CTH@<)R:B)W
M'ZT_R&]* "8@G(J:V;(QZ5"82.:(&VGZT /N>HI;7O\ A3YTW#W%5HWV'- %
MVJKS$$CWJ=90>]#3!?\ ZU %?SV]:L3=#5.KY&>* *4?4?6KM4G38<58BGSP
M>M $M%-\P>M1/<^E $]%(K;AFEH I2=3]:MQ]!]*J2=3]:MQ]!]* '$XYJBS
M;N:LW+8&/6JZH6Z4 3^8N-N?TJN#CFG^0WI36C*=: +@.>:I'WJS;-D8]*BG
M3:<]C0!8CZ#Z4DK;1D5##-MX/2I_,'J* *WGMZU)!(6.#Z4D\H;@4EMU_"@"
MS1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG5"<:D5*+NF%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMT9J"G;1]1*<6[=2W1116904444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M41B([5<HH J+ 34\<(3GO4E% !3)(M]/HH J- 12"(GM5RB@"".WQR:GHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_%5A@+8?GA-I._5EU_WEG'4[GP1_P ><7_ _P#T-J=XF\3+HRX&&E8?*O\
M[,?;^?0=R.?DU]O#MJED /M(#9&0P0,Q()QD$D'('XGL#Q<\[7!+N2S'J6))
M].IK.E@/;595)?#=V\]?R*G7Y(**WL.N[MKMC+(2S,<DG_/Y#M72_#^UG:4R
MQG$0X?(RI]% _O>_;OUP8/"WA ZO^]DRL(S@C[S'VSG@=S^ [X])M+1;11%&
M JJ, #_/YGO6F/QD(1=*.KV\D30HR;YF34445XIVA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%9VK:]'I> ^26[+@G'KR1Q_GUJY;W"W*B1#E6'!%.SM<A582
MDXIZK=''>-[>02"0DF,C"^@/<?4XSGOT[5AV%@]^XBC&2?R ]3[?YZUZ;<6Z
MW*F-QE6'(-5]+TB/3%V1CJ>2>I^I]NW_ .NM8UK1MU/,KY4ZN(Y[^Z]7W]/Z
MV*V@Z"NEKGK(P^9OZ#V_GU/8#6HHK)MMW/3I4HTHJ,59(****184444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@""?K^%1U)/U_"HZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"W1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^OPRS0.EN<2D?*<
MX[\@'L2,@'L>XZUXM<;MS>9G?D[MV=V<\YSSG/7->\UCZAX4M]0E6ZD7++U'
M\+8Z;AWQ^O0Y'%-.PFCB_"G@,Z@%N;C*QD@A?XF'KGL#^9&<8X->E1QB,!5
M     P !T&*=10W<9YC\3O\ CY3_ *XK_P"A/1\,?^/E_P#KBW_H25Z=11?0
M5@KSGQKX*^S9N[8?)U=!_#ZL!_=]1_#U'R_=]&HH3L,\$CC,A"J"22  !DDG
MH,5[7H$,L,")<',H'S'.>_ )[D# )[GN>M5]/\*6^GRM=1KAFZ#^%<]=H[9_
M3H,#BMBANXD@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BE0L
M>*9Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'
ME&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L
M44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!
M7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC
M1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&
MK%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44
M 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\
MHT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y
M1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%
M% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5
M_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT
M>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1J
MQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%%
M%?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*
M-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4
M:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9'B+6O[/3:A'F-T]A_>Q_
M+/ZX(K!T/Q,ULVV8ED;N221[^N/4?B/0[7B'P\+\>;'Q(/R;V/OZ'\#QTXNX
MMVMV,;C#+U!KTL+3I5*7+UZ]SP,RKXJCB%/:*V[?,]-1PX# Y!Z$=*=7+^#(
M9%W.>(CT![MZC\.#_7''45PUJ?LYN-[GL86NZ])3:M<****S-PHHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &7JGB6WTMA%,^UB,@;6/!)'8'THTOQ+;ZH
MQBA?<P&2-K#@$#N!ZUPOQ._X^4_ZXK_Z$]'PQ_X^7_ZXM_Z$E.V@KGIU%%%(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 51U'18]0*M(.5[C@D>A]OU]"*O44XR<7=:$U*<:D>62NAJ(
M$ 4# '0#I4-]?)8H97. /S)]![_YZ58KBO%\DC2!7&$&=F.0<XR<^OJ.WZG7
M#TO:SLSFQV)>&HN25WLNWS.JT_4X]0&Z,YQC(/!&?4?Y'H:MUYI8WSV+B5#@
MC\B/0^W^>M=[I.KIJ2[EX(QN![9SWZ'I_P#JK3$X5TM5JC'+\RCB5RRTG^?H
M7J***Y3T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJM?WZ6"&60X _,GT'O_GI0E<4I**;>B1)<7"VRF1SA5')-5]+U>/4
MUWQGH>0>H^H]^W_ZZX'5]:DU-BS'"YX4'@>GU/O_ $XINBR31R!H 2_H!D$9
M'7V_EUR*W]C[OF>0\XO62BKQ_%^9Z;69;>'8;:0S*O)((!Y"]^!VY_+M@5IT
M5BFT>K.G";3:O;8****184444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!PGCOPU<:I.LL*;E$8!.Y1R&8]R/6CP)X:N-+G:69-JF,@'<IY+*>Q/I7=T4
M[BL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %5[ZQ2^0Q.,@_F#ZCW_P ]*L44TVG="E%2
M33U3.&N_"LL4@C3YE;HV, >N>N/Z]N>*ZW2M-73D$2\]R3W/K[?Y^M7**VJX
MF=6*3.3#9?1P\W*.[_ **Y3Q+XA96-O$<;?O,#SGT!'3'?OGCZVM"\4"Z(AE
MX?LW9C_0_H3Z<"AX6HH<XEF5!UG2OKM?I?L=#1116!VA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445D:[XA335(&&D[+GI[GT'ZGMZAI-N
MQ%6K"E%RD[(UZBN+=;E3&XRK#D&N+T3Q8\#D3DLCG))Y*D]Q[>PZ=O0]NCAP
M&!R",@CI3E!P9CAL53Q4';YIG 77A:9)O)125)^5OX<>YQP1W_0'(SV>D:0F
MF)L7DG[S=R?\/0=OKDF]13E4<E8G#8"E0FY+=_@%%%%0=84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <QXG\:_V'*(/+W[D#9W[>I(QC:?2C
MPQXU_MR4P>7LVH6SOW="!C&T>M<Q\3O^/E/^N*_^A/1\,?\ CY?_ *XM_P"A
M)56T%?4].HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '':]X8^RCSH<E1G<#R
M1[CV_4=>><<[7J=9L7AZ&*3SU7!'0?PYSUQZ^G8=AFN^CCN6-I:]CQ<7DRG-
M2IV2>Z[>G^1)H@D\I?.^_P"XYQVS[X^A]><U>HJCJ.M1Z>560\MV') ]3[?K
MZ UQV=23LM7T1ZMXT*:YGHM+LO44U'#@,#D'H1TIU0:A1110 45!->QP':[J
MI]&8 _K21:A'*=JNI)[!@3^0-/E=KV)]I"]KJY8HHHI%!1110 4444 %%%%
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M '2G4IS<F;8/!PPT;+5O=A1114'4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!S'B?P5_;DHG\S9M0+C9NZ$G.=P]:/#'@K^PY3/YF_
M<A7&S;U(.<[CZ5T]%.X6"BBBD 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXP^/Q]B1V/J/Y=!=HHKF;N>_"/+%*][=6%%%%!04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!QWC'QC-HLRPQJA!C#?,&)R68=
MF'I1X.\8S:U,T,BH (RWRA@<AE'=CZURWCW5%O[D[ 1Y0\LYQU5FR1@GCG_Z
MU0^#M=319FFD#$&,K\H!.2RGN1Z55M!7/8**IZ3JBZI$MP@(5\X#8!X)'8GT
MJY4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M']WA\8R3M/Y8!)/''ID:%H;:E<+:D$<_/P05"_>['![#(ZD U6C)U/9XY!(
MRD$$ @@Y!!Z'-.IL<8C 50     ,  =!BG5)04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M37<("Q. .I/2G52UJ(2P2 ]-C'\0,C]13BKM(FI)Q@VNB'?VK#_ST3_OM?\
M&FRZU!$-QD7 ]&!/Y#)KSFBO2_LZ/=G@O/:G\J.ZN/$%K<*8W;*MU!5O\*H6
M6HV>D@M&6=FZG'S8_$*,?K_3E**T6"@E:[MV,)YM5E)2Y8\RV=G?\S:\1ZTF
MI[-@(V[L[@.^/0GTJCH[E)HR#CYUZ>YP?TJG6EI6GR>9&^QMN]#G:<8R#G..
ME:.$:=/EZ:G.JE2O74WJ[K8]!HHHKQ#Z\**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9+$)04;D,"#]#P:?10#5]#*_P"$7M_[G_CS?XU/#H<$
M(P(U_P"!#<?S;)J]15NM4?5_>8QPM&+NH17R14_LJ'_GFG_?"_X58BB$0VJ
M .P&!^0I]%2Y-[LTC3C'5)(****104444 %%%% !1110 4444 %%%% !1110
M 5YOJO\ KI/^NC_^A&O2*\WU7_72?]='_P#0C7=EWQ2]#QL]_AP]2I1117IG
MSX4444 %%%% !7J=>65ZG7G9C]GY_H>[D/\ R\^7ZA1117GGN'*?$C_CW7_K
MJO\ Z"U>;UZ1\2/^/=?^NJ_^@M7F]>_E?\!>K.#%?Q HHHKO,#U;P1_QYQ?\
M#_\ 0VK=K"\$?\><7_ __0VK=KY?$_QI^K_,].E\$?0****Q+/)****[CXL*
M*** "K>C_P"OB_ZZ)_Z$*J5;T?\ U\7_ %T3_P!"%)[%TOCCZH]0HHHKB/L0
MHHHH **** "BBB@ HHHH **** "FN@<%2,@C!!Z4ZB@"G_8\'_/-/^^%_P *
M;+H4$HVF-<'T4*?S&#5ZBGS,S=&F_LK[C(_X1.V_N?\ CS_XUHVEHMHHBC&%
M&<#)/4Y[U-10Y-A"A3IN\8I/R04444C0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\=\1:!<VKO<3)P[L2R<IRWXD D\;L'\:]BHI
MIV!HX#X::']Z^<>JID?]]-R/P!!_O UW]-2,1\* !DG@8Y)R3^).3[TZDW<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CGN%M
MU,CL%4=2Q  SQU- $E%9_P#PD%M_SVC_ ._B_P"-7HY!( RD$$ @@Y!!Z'-
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2V87#G;Q]WG)!!X/IV..??!KIJX<;&G&L^1Z?D;T')P7-N1QVZQ$LH +=2
M3]?6I***YVVS4****0!1110 4444 %%%% %ZRU9H/E;E?U%;<,ZS#<IR*Y:G
M1RF/E202"./>N_"YC.E[LM5^)A5P\9ZK1E_6];\K,,9^;N1V]A[_ ,OKTYNI
M9H#'SVJ*L,1B)5Y<S^2/1PU*%.%H_>%%%%8FP5-9VQNG$8_B/_ZS^ J)5+'
MY)]*ZS1-*^Q LWWVZ^P],_S_ /K9KHPF&=>=NBW.?%8A487Z]#1CC$8"CH
M/PIU1SW"VXW.0![U@7?B@MQ$,#U;D_ET&/QKW*V)I4%J_D>/2P]2L]%\SHZ*
MX6>\>X^^Q/.<$\?ETJ&N%YNKZ1_'_@'8LK=M9?@>@45Y_12_M?\ N?C_ , ?
M]E_WOP_X)Z!17/>%[9U)EZ(1CZG/7'MSS_\ 7KH:]##UG5IJ=K7.&O25*;C>
MX4445L9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4453U;5%TN)KAP2J8R%
MP3R0.Y'K0!<HKD/^%G6W]R3_ +Y7_P"+KJ;.Z%VBS+G#JK#/7##(HL!-1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,H88/(/
MK2T4 <IK.C&T/F)RA_3V^GH?P/OE5W[*&&#R#ZURNLZ,;0^8G*']/;Z>A_ ^
M_BX[ \EYQVZKM_P#U\%C>?W);]'W,JBBBO..\*FM+MK1A(AY'Y'V-0T4XR<7
M=;B:4E9G9:9JRWXXX8=1G]?>DU72A?#T<=#_ $/M_+^?(PS&$AU.".AKKM*U
M47P]''4?U'M_+^?L87%1Q,?9SW_/_@GE8C#2P\O:0V_+_@'(S0F$E&&".HIE
M=CJNE"^'HXZ'^A]OY?SYB.TV_>ZC\17G8O"O#RMT>S.RAC(U(7Z]4,@MMW)Z
M5; Q2T5RF<YN;"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH 8T08AB 2N
M<''(SUP:?113N!A>+87FC5$4M\V3MY(P#C@>N>OM[UR$UNT!VN"I]&!!_6O3
M**[\+F3H04.6Z]3GJX95)7N<;X-_US?]<S_Z$M8->H45I'->6I*?+O;KVOY$
MO"7BE?8\SAMVG.U 6/HH)/Z5Z3%)Y@#8(R <'@C/8CUI]%<^-QOUFVEK&E&A
M[*^M[D<\"W"F-QE3U!J*TTZ.T_U:@>_?UZGFK-%<JG)+EOIV->57N%%%%2,*
M*** "BBB@ HHHH **** "BBB@ HHHH 0C-5)[;;R.E7**"H3<&9E*JEC@<D^
ME69[;/*_E70Z-HPM!YC\N?T]OKZG\![].%PTL1*RVZLUJXN%.'-U[!HVC"T'
MF/RY_3V^OJ?P'O;U#4%L5W-U/0=S_GN:-0U!;%=S=3T'<_Y[FN/N[MKMC(YY
M/Y#V%>GB,1#"0]G#?^M6<-"A/%3YY[?UHA;N]>[.YSGT'8?05!117C2DY.[W
M/6C%15EL%%%%(85JZ-HQNSYC\(/U]OIZG\![&C:,;L^8_"#]?;Z>I_ >W5*H
M48' 'I7HX' \]IRVZ+O_ , X,;C>3W([]7V!5"C X ]*6BBO:/("BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *P/'G_ !Y2_P# /_0UK?K+\2Z6VJ6[
MVZ$!GVX+9 X8'L#Z4(#Q:O;?#_\ Q[0_]<8__017 _\ "L;G^_'_ -]-_P#$
M5Z)I=J;2&.%L92-%..F54 U4F)%JBBBI&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***S]>U7^R86N=N[9MXSC.6"]<'U]* -"BN _X6K_ -,/_(G_
M -A7;Z?=_;(DGQCS$5L9SC< <9IV L4444@"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&4,,'D'UI:* .4UG1C:'S$
MY0_I[?3T/X'WRJ[]E##!Y!]:Y;5=%^S,"OW&[9Y'M[_YS[^+C\#[.]2.W5=C
MUL'C>9<LM^_<S[>#?R>E7:15V\"EKS"ZDW-W"BBB@@**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5S!M^8=*NTA&>*"Z<W!
MW,VM71M&-V?,?A!^OM]/4_@/9=*T7[2Q+'Y%]^3[>P]_R]NI50HP. /2O3P&
M!]I:I+;HNY&,QO*N6._?L"J%&!P!Z4M%%>T>2%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6!X\_X\I?^ ?^AK6_6?KVE?VM"UMNV[]O
M.,XPP;ID>GK0@/$J]M\/_P#'M#_UQC_]!%<A_P *J_Z;_P#D/_[.NWT^T^QQ
M)!G/EHJYQC.T 9Q5-B18HHHJ1A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -=P@+'H!FN<OKPW3;NPZ"KNM7F3Y
M([8)_P /ZUE5XF9XKGE[-;+?U.W#4K+F>X4445YITA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $]E=&V8-VZ'
MZ5TB.' 8=",URE:FC7NW]TW0]/KZ?Y_K7I99BN27LWL]O4YL32YES+<V:***
M]LX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q_%M
M^]A:R3Q'#KMP< ]74'@@CH: -BBO(?\ A/+W_GK_ ..)_P#$UZEH\[7$$4KG
M+/&A)Z9)4$]*;5@N7****0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_0_459KG=,NOL[\]&X/]#_GMFNBKZ+ XCVU+7=:,\ZO3Y)>04445UF04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5@>//^/*7_@'_ *&M;]5[
M^P2_0P2C*-C(R1T((Y!!ZB@#PJO;?#__ ![0_P#7&/\ ]!%4/^$#LO\ GE_X
M^_\ \56W;P+;JL2#"H  .N !@=:;=Q)$E%%%(84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4]3NOLZ<=6X']3_GOBN>J
M[J]QYKX'1>/Q[_Y]JI5\]F%?VM9]EHCT,/#EAZA1117&;!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %=#IEU]H3GJO!_H?\]\USU7-*N?)<#LW!_I79@*_LJJ[/1F->GSP]#H:
M***^A//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL#QY_Q
MY2_\ _\ 0UH WZ*\"KVWP_\ \>T/_7&/_P!!%-JPDS0HHHI#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+VX\A"W?''U/2I
MZQM<N,D1CH.3]?\ /\ZY\96]E2E+KLC2C#GFD9=%%%?-'I!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!TMA<?:$#'KW^H_SFK%8NASX)C/<9'/I[?YZ5M5]+@ZWM
M:,9==F>;6AR3:"BBBN@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MP/'G_'E+_P  _P#0UK?HH \"KVWP_P#\>T/_ %QC_P#016A13;N)(****0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEKJ;
MSF+^I_3M^E;^IR^7&Q]1CGWX_E7.5X^;U=8P^9V82.CD%%%%>4=04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 /@E\E@X[&NI!W<CH:Y.NBTN;S8QZCC\O_K5ZN45
M;2E#OJ<N+CHF6Z***]@XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJ]_?I8(9Y3A%QDX)ZD < $]35BL#QY_QY2_\ _\ 0UH /^$\LO\ GK_XX_\
M\36W;SK<*LJ'*N 0>F01D=:\&KVWP_\ \>T/_7&/_P!!%-JPDS0HHHI#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,C7I?NI^
M)_D/ZUDU<U:3?(?08'^?QJG7S>-J<]>3\[?=H>E1CRP04445S&@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %:NA3?>C_$?R/]*RJM:7)LD7T/'Y]/UKHP=3DKQ?
MG;[S.M'F@T='1117TIYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M/XML'O[62"(9=MN!D#HZD\D@=!6Q10!Y#_P@=[_SR_\ 'T_^*KU+1X&MX(HG
M&&2- 1UP0H!Z5<HIMW"P4444@"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***AO'V(QSCY3_+BE*7*F^PTKNQS4DGF$L>I)/YTVBBO
ME&[NYZH4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT<GED,.H(/Y4VBFG9
MW ZVBH+%P\:D?W0/RX-3U]5"7-%/N>4U9V"BBBJ$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^^C_ (U8_P"$?G_N?^/+_C52[LWM#M<8)&>H/\J]:$J$W9<K?E8Y&JBWN/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #J*;)((P68@  DDG  '4YJC_P )!;?\]H_^_B_XT :%%48]<MY"%66,DD
M2*22>@QFKU !14-U>):#=(RH"<99@HSZ9-5?^$@MO^>T?_?Q?\: -"BJMKJD
M-V=L<B.0,X5U8X]< U:H **JW6J0VAVR2(A(SAG53CUP34/_  D%M_SVC_[^
M+_C0!H45#:WB78W1LK@'&58,,^F14U !15&37+>,E6EC!!((,B@@CJ,9IO\
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M0!H45G_\)!;?\]H_^_B_XUH4 %%1SW"VZF1V"J.I8@ 9XZFJ?_"06W_/:/\
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M4OM+2]^^.1T(X/\ GZUY^,R]57SQT?YG=A<<Z:Y9:K\CBJ*V+KPS)']PAO\
MQT_J<?K^%9TUC)#DLI '4X./SZ5Y-3#U:>\6>I"O3GLT04445D:!5FR'7\*K
M59LN_P"%)F=;X&6J***1QA1110 4444 %%%% !1110 4444 %%%% !1110 5
MRGBK_6C_ '!_,UU=<IXJ_P!:/]P?S-=^5_QUZ,PQ7\,QJ]$KSNO1*Z,Y_P"7
M?S_0SP?VOD%%%%>0=84444 %%%% #68*,G@#UK@[RZ-T[2G^(_\ ZA^ KL-;
ME,4+D>F/^^C@_P ZXFO9R>FN64_D<>+EJHDEO ;AA&O5CBNUT[3EL5VKU/4]
MS_GL*P_"EN'=I#_" !Q_>[_I^M=/6.:XB3G[-;+<K"TTH\P4445YAU$%Y9K=
MJ8W'!_,>XK,TOPZ+5C(Y#$'Y?3Z_7^7OVVJ*VAB*D(.">C(E3C)IO<***QO$
M.JFU'E(<.W?T'U]?\\<5-&C*K-06['.:@KLLZCK<=E\IY;T'Z9/;^?M6-)XK
MD)^55 ]\D_GD?RK$J[!HTTXW*IQ[D#^9%>W# 8:C'W[/S9Q.O4F]/P-*W\6,
M#^\4$<?=R/KUSG]*W++4$O1N0].H[C_/Y5Q5U9O:G:X(_E^?0TR&8P$.IP1T
M-36RVC5C>&C\MAPQ,XNS/0:SO$'^H?\ X#_Z$*L:?>B]02#OU'H?3_/:J_B#
M_4/_ ,!_]"%>30BXXB">ZDOS.J;3IM^1QE=GX?\ ]0G_  +_ -"-<979^'_]
M0G_ O_0C7K9O_!7^+]&<N$^-^A8U+_5/_N-_(UPE=WJ7^J?_ '&_D:X2HR?X
M)>H\9\2.J\*_ZH_[Y_D*VJQ?"O\ JC_OG^0K:KSL;_'GZG30_AH****YC0**
M** "BBB@ HHHH **** "BBB@ HHHH JWO;\:K59O>WXU6IH[*/P(****9H%%
M2Q6KS#*J2/8$_P JTK;PU))]_"C\S^0X_6M*="I4^%-F=2O3I[M(R54L<#DG
MTKJM&T86@\Q^7/Z>WU]3^ ][=CIJ60P@Y]3U_.K5>O@\O5)\TM7^1Y>*QSJ+
MECHOS"BBBO0.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Y#XG?\ 'LG_ %V7_P!!>NOJGJFDQ:HHBF7<H.0,D<@$=B/6I0SPZNO^&/\
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MB!;A6B<95P01TR",'I6)_P ('9?\\O\ Q]__ (JA.P-'F/A__CYA_P"NT?\
MZ$*]MK#M_!=I;LLJ1X9""#O<X(.1U:MRANX)'(?$[_CV3_KLO_H+UYC7N.J:
M3%JBB*9=R@Y R1R 1V(]:S/^$#LO^>7_ (^__P 533L#1R'PQ_X^7_ZXM_Z$
ME>G5EZ7X:M]+8RPIM8C!.YCP2#W)]*U*3=QH\Q^)W_'RG_7%?_0GKD*]IU3P
MU;ZHPEF3<P& =S#@$GL1ZU4_X0.R_P">7_C[_P#Q5-,5C/\ AC_Q[/\ ]=F_
M]!2NOJGI>DQ:6IBA7:I.2,D\D =R?2KE2QGB7B#_ (^9O^NTG_H1K/KV&X\%
MVEPS2O'EG)).]QDDY/1J9_P@=E_SR_\ 'W_^*JN85B_X?_X]H?\ KC'_ .@B
MCQ!_Q[3?]<9/_035RW@6W58D&%0  =< # ZT7$"W"M$XRK@@CID$8/2I&>#5
MH>'_ /CYA_Z[1_\ H0KT[_A [+_GE_X^_P#\53[?P7:6[+*D>&0@@[W."#D=
M6JN85C<K \>?\>4O_ /_ $-:WZKW]@E^A@E&4;&1DCH01R"#U%2,\*K?\!_\
M?L7_  /_ - :N_\ ^$#LO^>7_C[_ /Q53V'A*UL'$\4>'7.#N<]00>"Q'0U7
M,*QL5P'Q5_Y8?]M/_9*[^L_5=!AU;;YZ[MF<?,PQG&?ND>@I(;/$J[[X5?\
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M>OH<=/?/Z5J>(/\ 4/\ \!_]"%4/#^ER6DA9UP"I'4'N/0U?\0?ZA_\ @/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4]5TJ/5(S!*,J?S![$'L1_P#6.02*\U_X5_<?:/LW\'7S<?+M
M]?\ >_V<YS_L_-7JU%-.P6*>E:5'I<8@B&%'YD]R3W)_^L,  5<HHI %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"M_9L7]Q?^^1_A1_9L7]Q?\
MOD?X59HJ_:S[LGECV"BBBH*"BBB@ J&6T28Y95)]P#_.IJ*:;6J$U<ABM$A.
M550?8 ?RJ:BBAMO5@E8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH I79RWT%0UU=MHD4BAF7)(!SDCK]#4O]@0?W?\ QYO\
M:]"&5UI13NM?7_(:S&E%6L]/Z[G'T5V']@0?W?\ QYO\:/[ @_N_^/-_C5?V
M56[K\?\ (?\ :=+L_P /\SCZ*[#^P(/[O_CS?XT?V!!_=_\ 'F_QH_LJMW7X
M_P"0?VG2[/\ #_,X^BNP_L"#^[_X\W^-']@0?W?_ !YO\:/[*K=U^/\ D']I
MTNS_  _S.2AF,)#J<$=#79:7>F]02$8/3V..X]O_ -51?V!!_=_\>;_&KL,(
MA 11@#H*[,%A*M"3NU;LCEQF*I5HJR=^['T445WG"%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <FZ%"5/4'%)5G4XO+D8>ISS[\_SJM7RM6')-Q[,]2+YDF%%%%04%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !0!NX'4T58TZ/S)%'OG\N?Z55.'/)1[NPI.
MR;.C1 @"CH!BG445]6E8\H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#'UZ+E7]L>W'(_K6570ZM#YL9]5Y_+K^E<]7@9G3Y*[??4[\
M-*\/0****X3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M/08\LS>@Q^?\ ^JLR
MN@TB+RXP?[Q)Y_+^0KMRVGSUT^VICB96AZEVBBBOH#SPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** $(W<'H:Y:>+R6*'L:ZJL/7(=K!
M_P"\/U'_ -;%>=FM+FIJ?9_F=&%E:5NYG4445X9W!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 Z./S"%'4D#\ZZE$" *.@&*Q-$@WN7_ +H_GQ6[7MY32Y:;GW_0
MXL5.\DNP4445Z1S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5=2M_/0@=1R/P_P#K5:HJ:D%.+B^HXRY6F<E15G4;?R'(['D?0U6K
MY:I!PDXO='J1:DDPHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%6+"V^T.%[=3]!50@Y
MR45NQ2:BKFUIEMY" 'J>3^-6Z**^HIP5.*BMD>7*3DVPHHHJQ!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'5[;SDW#JO/X=Z
MP*ZVN:O[;[.Y7MU'T->/FN'LU47H_P!#LPM33E*]%%%>4=04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6[HUOY:;CU8_IVK*L+;[0X7MU/T%=(!MX'05ZN58>\G5?31'+BJFG*
M+1117L'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5/4[7[0G'5>1_4?Y[XJY145*:J0<7LQQDXM,Y*BM#6+3RFWCHW
M\_\ Z_\ C6?7S-:DZ4W!]#TX34XIA1116904444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445?TBS\UMYZ*?U[?
ME6E&E*K-074F<E%-LTM+M/LZY/WFY/\ 05<HHKZ:E35."BMD>9*3DVV%%%%6
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF]
M;UOS<PQGY>Y'?V'M_/Z=<<1B(T(\S^2-:%"5:5D&MZWYN88S\O<CO[#V_G].
MN'117SU>O*M+F9[M&C&E'E19M9_X3^%6JS*MVTV[@]:R9G6I?:18HHHI'.%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56ZF
M_A'XT^XGV<#K5.FC>C2^TPKI-$UOS<0R'YNQ/?V/O_/Z]>;HK?#XB5"7,OFC
M2O0C6C9GH%%8>B:WYN(9#\W8GO['W_G]>NY7T%"O&M'F1X5:C*E+E84445J9
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *L0Z:]PI=>W3/<_Y_
M7\<49;GRO<^AZ5U&FWZWBY7C'!7T_P#K>E=F P].M-J3^1G7<Z<5)+0XMP5)
M!ZCKGK25U>LZ,+L>8G#C]?;Z^A_ ^W*LI4X/!'K48G#2H2L]NC.W#XB-:-UO
MU0E%%%8&X5TFB:WYN(9#\W8GO['W_G]>O-T5MA\1*A+F7S1E7H1K1LST"BL/
M1-;\W$,A^;L3W]C[_P _KUW*^@H5XUH\R/"K494I<K"BBBM3,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBL+Q+J!CQ O&X9/TZ8_GG_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<[XKD!*+W )_/&/Y&NBKE_%'^M'^X/YFN+,G:@_.QUY>KUU\S'HHHK
MP3VPK5T;1C=GS'X0?K[?3U/X#V-&T8W9\Q^$'Z^WT]3^ ]NJ50HP. /2O1P.
M!Y[3EMT7?_@'!C<;R>Y'?J^P*H48' 'I2T45[1Y 4444 %17%LMP-K#_ !%2
MT4I14E9ZH:;3N85UHS1\I\P_7_Z_^>*SR-O!ZBNMJ&>T2?[PS_/\Q7FU\JC+
M6#MY/8Z*>*:W.8HK3N=$*\H<^QZ_GT_E6=+"8CM88/O7EUL-4HOWE_D=4*D9
M[,;1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%.BA,IVJ,GVK1M]#9N7./8<G_  _G6U+#U*OPJY$ZD8;LS -W ZFM"UT9
MI.7^4?K_ /6_SQ6M;6:V_P!T<^O>IZ]/#Y5&.LW?R1S5,4WHB&VM5MAA1]?4
MU-117IQBHJR5D<S;;NPHHHIB"D90PP>0?6EHH Y36=&-H?,3E#^GM]/0_@??
M*KOV4,,'D'UKE=9T8VA\Q.4/Z>WT]#^!]_%QV!Y+SCMU7;_@'KX+&\_N2WZ/
MN95%%%><=YM^%I2'9.Q7/Y'']:Z6N7\+_P"M/^X?YBNHKWLM?[A>K/$S!?OG
MZ(****[3D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N7\4?ZT?[@_F:ZBN8\4J?,4]MG\B:XLS_@/U1V
M9=_&7H8U:NC:,;L^8_"#]?;Z>I_ >QHVC&[/F/P@_7V^GJ?P'MU2J%&!P!Z5
MQ8' \]IRVZ+O_P  Z\;C>3W([]7V!5"C X ]*6BBO:/("BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?Q1_K1_N
M#^9K'K8\4?ZT?[@_F:QZ^<QO\>?J>_A/X,?0****YS<ZCPO_ *H_[Y_D*/%'
M^J'^^/Y&CPO_ *H_[Y_D*/%'^J'^^/Y&O;_Y@?D>/_S&?,Y>BBBO$/8"MCPO
M_K3_ +A_F*QZV/"_^M/^X?YBNC!?QX>IAB_X,O0ZBBBBOHSP HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?
MQ1_K1_N#^9K'K8\4?ZT?[@_F:QZ^<QO\>?J>_A/X,?0***LZ=9F\<1]N_L!U
M_P ^M81BY245NS:4E%-O9'4:'#Y4*Y&"<G\SP?RQ2ZW!YT+#C(&>?;D_IFKJ
MJ%&!P!Z4M?2JBO9>S\K'SWM7[7VGG<\_HJSJ-F;-S'V[>X/3_/K5:OFI1<9.
M+W1]#&2DDULPK8\+_P"M/^X?YBL>MCPO_K3_ +A_F*WP7\>'J8XO^#+T.HHH
MHKZ,\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .7\4?ZT?[@_F:QZV/%'^M'^X/YFL>OG,;_'GZGOX3^#'T
M"NMT32OL0+-]]NOL/3/\_P#ZV:K:)HGE8FD'S=@>WN??^7UZ;E>AE^"</WDM
M^B.''8OF]R.W4****],\XS]:TW[:G'WU^[SCZC\?YUR#*5.#P1ZUW]96LZ,+
ML>8G#C]?;Z^A_ ^WG8_!.I[\=^J[G?@<7[/W);?D<I6QX7_UI_W#_,5D,I4X
M/!'K6OX7_P!:?]P_S%>;@_X\/4]#%_P9>AU%%%%?1G@!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOB2S>5
MPRJ2-N.!GH3Z?6IM$T3RL32#YNP/;W/O_+Z]-RBN58&G[9U'KY'2\9/V2IK0
M****ZCF"BBB@ HHHH RM9T878\Q.''Z^WU]#^!]J^@:7):N7<8&W'4'J0>V?
M2MVBN=X.FZJJ=3=8JHJ;I] HHHKH, HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img64161509_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img64161509_1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZB
MWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  LBW_NR?]\K_P#%4?\ "R+?^[)_WRO_ ,57F]%']ET//[P^M5#TC_A9%O\
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M_A9%O_=D_P"^5_\ BJ\WHH_LNAY_>'UJH>D?\+(M_P"[)_WRO_Q5'_"R+?\
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MG_?*_P#Q5'_"R+?^[)_WRO\ \57F]%']ET//[P^M5#TC_A9%O_=D_P"^5_\
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M]\K_ /%5YO11_9=#S^\/K50](_X61;_W9/\ OE?_ (JC_A9%O_=D_P"^5_\
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MM_[LG_?*_P#Q5>;T4?V70\_O#ZU4/2/^%D6_]V3_ +Y7_P"*H_X61;_W9/\
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M  LBW_NR?]\K_P#%4?\ "R+?^[)_WRO_ ,57F]%']ET//[P^M5#TC_A9%O\
MW9/^^5_^*H_X61;_ -V3_OE?_BJ\WHH_LNAY_>'UJH>D?\+(M_[LG_?*_P#Q
M5'_"R+?^[)_WRO\ \57F]%']ET//[P^M5#TC_A9%O_=D_P"^5_\ BJ/^%D6_
M]V3_ +Y7_P"*KS>BC^RZ'G]X?6JAZ1_PLBW_ +LG_?*__%4?\+(M_P"[)_WR
MO_Q5>;T4?V70\_O#ZU4/2/\ A9%O_=D_[Y7_ .*H_P"%D6_]V3_OE?\ XJO-
MZ*/[+H>?WA]:J'I'_"R+?^[)_P!\K_\ %4?\+(M_[LG_ 'RO_P 57F]%']ET
M//[P^M5#TC_A9%O_ '9/^^5_^*H_X61;_P!V3_OE?_BJ\WHH_LNAY_>'UJH>
MD?\ "R+?^[)_WRO_ ,51_P +(M_[LG_?*_\ Q5>;T4?V70\_O#ZU4/2/^%D6
M_P#=D_[Y7_XJC_A9%O\ W9/^^5_^*KS>BC^RZ'G]X?6JAZ1_PLBW_NR?]\K_
M /%4?\+(M_[LG_?*_P#Q5>;T4?V70\_O#ZU4/2/^%D6_]V3_ +Y7_P"*H_X6
M1;_W9/\ OE?_ (JO-Z*/[+H>?WA]:J'I'_"R+?\ NR?]\K_\51_PLBW_ +LG
M_?*__%5YO11_9=#S^\/K50](_P"%D6_]V3_OE?\ XJC_ (61;_W9/^^5_P#B
MJ\WHH_LNAY_>'UJH>D?\+(M_[LG_ 'RO_P 51_PLBW_NR?\ ?*__ !5>;T4?
MV70\_O#ZU4/2/^%D6_\ =D_[Y7_XJC_A9%O_ '9/^^5_^*KS>BC^RZ'G]X?6
MJAZ1_P +(M_[LG_?*_\ Q5'_  LBW_NR?]\K_P#%5YO11_9=#S^\/K50](_X
M61;_ -V3_OE?_BJ/^%D6_P#=D_[Y7_XJO-Z*/[+H>?WA]:J'I'_"R+?^[)_W
MRO\ \51_PLBW_NR?]\K_ /%5YO11_9=#S^\/K50](_X61;_W9/\ OE?_ (JC
M_A9%O_=D_P"^5_\ BJ\WHH_LNAY_>'UJH>D?\+(M_P"[)_WRO_Q5'_"R+?\
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MG_?*_P#Q5'_"R+?^[)_WRO\ \57F]%']ET//[P^M5#TC_A9%O_=D_P"^5_\
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MR+?^[)_WRO\ \51_PLBW_NR?]\K_ /%5YO11_9=#S^\/K50](_X61;_W9/\
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M3_OE?_BJ\WHH_LNAY_>'UJH>D?\ "R+?^[)_WRO_ ,51_P +(M_[LG_?*_\
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M?_BJ/^%D6_\ =D_[Y7_XJO-Z*/[+H>?WA]:J'I'_  LBW_NR?]\K_P#%4?\
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M_P +(M_[LG_?*_\ Q5>;T4?V70\_O#ZU4/2/^%D6_P#=D_[Y7_XJC_A9%O\
MW9/^^5_^*KS>BC^RZ'G]X?6JAZ1_PLBW_NR?]\K_ /%4?\+(M_[LG_?*_P#Q
M5>;T4?V70\_O#ZU4/2/^%D6_]V3_ +Y7_P"*H_X61;_W9/\ OE?_ (JO-Z*/
M[+H>?WA]:J'I'_"R+?\ NR?]\K_\51_PLBW_ +LG_?*__%5YO11_9=#S^\/K
M50](_P"%D6_]V3_OE?\ XJC_ (61;_W9/^^5_P#BJ\WHH_LNAY_>'UJH>D?\
M+(M_[LG_ 'RO_P 51_PLBW_NR?\ ?*__ !5>;T4?V70\_O#ZU4/2/^%D6_\
M=D_[Y7_XJC_A9%O_ '9/^^5_^*KS>BC^RZ'G]X?6JAZ1_P +(M_[LG_?*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!A>-_\ CSE_X!_Z&M>4UZMXW_X\
MY?\ @'_H:UY37NY1_!?K^B.'%_&O0****]$YPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#=\$?\?D7_ __0&KU:O*?!'_ !^1?\#_ /0&KU:O"S?^,O3]6=V$
M^!^H4445YQT!1110 4444 %%%% !1110 4444 >-Z]_Q\3?]=9/_ $(U0J_K
MW_'Q-_UUD_\ 0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?T
M'_CXA_ZZQ_\ H0KV2O&]!_X^(?\ KK'_ .A"O9*\7-_CCZ'9A-F%%%%>6=04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!A>-_^/.7_ (!_Z&M>4UZMXW_X
M\Y?^ ?\ H:UY37NY1_!?K^B.'%_&O0****]$YPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#=\$?\ 'Y%_P/\ ] :O5J\I\$?\?D7_  /_ - :O5J\+-_XR]/U
M9W83X'ZA1117G'0%%%% !1110 4444 %%%% !1110!XWKW_'Q-_UUD_]"-4*
MOZ]_Q\3?]=9/_0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?
MT'_CXA_ZZQ_^A"O9*\;T'_CXA_ZZQ_\ H0KV2O%S?XX^AV839A1117EG4%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 87C?_CSE_X!_P"AK7E->K>-_P#C
MSE_X!_Z&M>4U[N4?P7Z_HCAQ?QKT"BBBO1.<**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH W?!'_'Y%_P #_P#0&KU:O*?!'_'Y%_P/_P! :O5J\+-_XR]/U9W8
M3X'ZA1117G'0%%%% !1110 4444 %%%% !1110!XWKW_ !\3?]=9/_0C5"K^
MO?\ 'Q-_UUD_]"-4*^KI?!'T/*ENPHHHJQ!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %_
M0?\ CXA_ZZQ_^A"O9*\;T'_CXA_ZZQ_^A"O9*\7-_CCZ'9A-F%%%%>6=0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!A>-_P#CSE_X!_Z&M>4UZMXW_P"/
M.7_@'_H:UY37NY1_!?K^B.'%_&O0****]$YPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#=\$?\?D7_ __ $!J]6KRGP1_Q^1?\#_] :O5J\+-_P",O3]6=V$^
M!^H4445YQT!1110 4444 %%%% !1110 4444 >-Z]_Q\3?\ 763_ -"-4*OZ
M]_Q\3?\ 763_ -"-4*^KI?!'T/*ENPHHHJQ!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M_0?^/B'_ *ZQ_P#H0KV2O&]!_P"/B'_KK'_Z$*]DKQ<W^./H=F$V84445Y9U
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9<DN%^8@C!#'LH]*Y(8^E.?(KWV-70FHW.2HHHKK,B[I&DOJL@@CQD@G)S@
M#J2 <>GU(KM/^%:1[,>8WF?WL#;U_N]>G^UUY]JJ?#.<*TL>?F8(0/920?\
MT(5WM>-C\;5A5Y(NR7XG9AZ,)0N]3QO6=&DTB3R9,9P""IR"#^1Z@CD?I5"N
MX^)L@)A7(R Y([X.W!Q[X/Y&N'KTL)5=6E&;W9S58*$VD%%%%;D!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% %_0?^/B'_ *ZQ_P#H0KV2O&]!_P"/B'_KK'_Z$*]D
MKQ<W^./H=F$V84445Y9U!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%XW
M_P"/.7_@'_H:UY37JWC?_CSE_P" ?^AK7E->[E'\%^OZ(X<7\:] HHHKT3G"
MBBB@ HHHH **** "BBB@#J_AO_Q\-_UR;_T):](KS?X;_P#'PW_7)O\ T):]
M(KY_-/X[]$=^%_AG-^,/$DFB^7Y84[]^=P)^[MQT(]:YO_A9%Q_=C_[Y;_XJ
MK_Q._P"6/_;3_P!DKA:[L#A:4Z$9.*;U_-F%>K.,VDSJ_P#A9%Q_=C_[Y;_X
MJNO\.^)X]:!P-LB]4)SQZ@\9'KQP>O8GR6NA\"3F.[10>'#@^XVEOY@4\7@:
M7LI.*LTKA1KSYDF[W/4JY#XBZ6)8EN@/FC.">/NMZ]SAL8],GBNOK"\;_P#'
MG+_P#_T-:\G!S<:\&NZ7WG565X,\IHHKT'PMX6MKZV2:1,NV[)W,.C$#@$#H
M*^@Q&(C0CS.^]M#@ITW4=D>?45ZM_P (19_\\_\ Q]__ (JN*\-^$)-7Q*WR
MPYY/\1QUV_RR>![X(K*EF%&<92U27<J6'G%I;W.>HKUNR\)VMH,"-6.!DN-Y
M.._.0,]\ 5YCK48CGE50 !*X '  #' Q3PV-AB)-)/0*E%TTFRE1175:'X"E
MO<239C3/0CYS@CL>F><$_D16U6M"DKR=B(0E-V1RM%>M67@^UM.1&&.,9?YL
M^^#QGZ >W%6O[!M_^>,?_?M?\*X99O3OHF;K"2[GC=%>E:A\/()^8BT9P.AW
M+UZD-ST]Q_CPVM:'+H[".4#D9#+RI]<' Z=Q_0BNK#XVE7=D]>S,JE&4-S.H
MHHKI,PHKU;_A"+/_ )Y_^/O_ /%5E>*?"UM8VSS1IAUVX.YCU8 \$D=#7!3S
M2E.2BD]7;I_F;RPLTF]#SZBNQT3X>M< 27!**1G:OW^_7/"]CC!]#@UV$'AN
MVA 01)@?WE#'\VR3^=%;,Z5-V6OH$,-.2OL>/45ZW>^$[6[&#&JG!P4&PC/?
MC ..V0:X;Q-X/;2/WJ$O$3UQRO/ /^/'/8<9K#YA2K/EV?F*IAY05]T<[111
M7:8A13HXS(0J@DDX '))/08KM-&^'1D&^Y8J3GY4QD>A+<CUX ].>U8UL13H
MJ\F5"G*;T.)HKU^V\,6MN-JQ(1G/S#>?S;)_"G3^&[:8%#$F#_=4*?S7!'YU
MQ?VO3O\ "[&_U27<\>HKO=8^'2D%[9CNY.QL$'T /&/QSGC)'6N(N[1K1C%(
M"K*<$'_/Y'O790Q5.NO=?RZF,Z4H;D-%%=#X)TJ/4IFCF7<HC)QDCG<H[$>M
M75J*G!R>R)C%R:1SU%>K?\(19_\ //\ \??_ .*KE/$7A<?:DM+5,;HPQY)
M^9@6)).!P/Z#)KFHYC2JRLKKKK;_ #-9X><5<Y2BO2]'\!0VH#3#S)."<D[
M1S@#C(]=V<XZ#.*QOB)81VGD^6BIGS,[5"YQMQT%%/,*=2JJ<;^H2P\HQYF<
M;7I7PYC*VS$@@-*Q&>XVJ,C\01^%-_X5O;_WI/\ OI?_ (FNEM+1;11%& JJ
M, #_ #^9[UQ8_'4ZU/DCW-J%"4)796U[_CWF_P"N4G_H)KQNO;;NV%TC0MG#
MJ5..N&&#7-?\*WM_[TG_ 'TO_P 34Y?BZ=",E+JQXBE*;5CS>BMOQ;HB:/*L
M,98@H&^8@G)+#L!Z5B5[-.HJD5);,XY1<79F_I?C6XTY1$"K*   X)P!V!!!
M_/., #%5-:\1S:OCS2-H.0JC"@XQGU/XDXR<8KT+_A"+/_GG_P"/O_\ %5E>
M*?"UM8VSS1IAUVX.YCU8 \$D=#7G4L9A954U%\S>]EU^9T2HU5'5Z(\^HHHK
MU#F"BMWP_P"$9=7P_P!R+GYR,YQV R">>_3KSD8KM]/\$6MGSM+D$\R'=U&,
M8&%/XC^E<=?'TJ+MN^R-:>'G/7H>5T5[)_8-O_SQC_[]K_A65J/@*VNLE 8V
M.?NGY<GI\ISP/08]/3&,,VI-ZIHMX22V/,**UM=\-RZ.?G&4)PKCH>_3L?8^
MAQD#-9-=\)QG'F3NC"47%V8445V.B?#UK@"2X)12,[5^_P!^N>%['&#Z'!J:
MU>%%7D[#A3E-V1QU%>NVOA6UML[8E.<?>^?I_O9Q^%32>'K9P5,4>",<(H//
MN!D?45PO-Z=_A9O]4EW/'**]&U;X>13C,!,; ="2RGKZY(SQSDX':N(U;19=
M);9*,9S@CE3@XR#_ $.#R,@9KJH8RE7T3U[/<RJ490W*%%%%=)F%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7]!_X^(?\
MKK'_ .A"O9*\;T'_ (^(?^NL?_H0KV2O%S?XX^AV839A1117EG4%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF_ZZR?\ H1JA4UI;&Z=85QEV"C/3+' KVL)@OJSE+FOIV.*K6]K96.R\ ^'
M_P#ITH!&?W?.>02"V/8]/Q..AKNZC@@%NHC4850 ![ 8'6JVL:F-,B:X()"
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M-M0'RW&5ZGZKDCL?KP1DYK$KTWX@60GMC+QF)E(XR<,=I&>W4'\!7!^']/\
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M\?"_]<E_]":N4HHKW*%+V5-0WL<,Y<TFSW.L+QO_ ,><O_ /_0UK=K"\;_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** -WP1_Q^1?\#_] :O5J\I\$?\
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M/A/C?H;M1_+;KV5$'L%  _( "I*\N\7^)&U&5HD8^2IP #PV.K'!(/(X]L<
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MH:'J7]I0I<8P6'/U!P<<GC(./:K]>9&4J-2_5,Z6E./DSPRBBBOJCRPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +^@_P#'Q#_UUC_]
M"%>R5XWH/_'Q#_UUC_\ 0A7LE>+F_P <?0[,)LPHHHKRSJ"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,+QO\ \><O_ /_ $-:\IKU;QO_ ,><O_ /_0UK
MRFO=RC^"_7]$<.+^->@4445Z)SA1110 4444 %%%% !1110!U?PW_P"/AO\
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MC_\ 0A5"IK2Y-JZS+C*,&&>F5.17K35XM>1RQ=FCVVN4^)'_ ![K_P!=5_\
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MX.#TJ<GDN6:ZCQBU3(Z***]8Y3W.L+QO_P ><O\ P#_T-:W:PO&__'G+_P
M_P#0UKY?#?QH>J_,].K\$O0\IKV30?\ CWA_ZY1_^@BO&Z]8\&ZA]MM4/&8Q
ML. ?X>!U_P!G!/U_"O5S>+=.+\SEPC]YHVZ**\MUW[9H\GEO+(5/W6#MAA^?
M!'<=OI@GS,+AO;R<;I,Z:M3V:O8]2HKQO^WKC_GM)_W\;_&C^WKC_GM)_P!_
M&_QKL_LB?\R,?K:['LE8'CF0+:2 D L4 SW.\' _ $_A7&ZC#?:=$EQ+)(%<
MXQYC;@>H!&>,@9[X[X/%8USJ<MT-LDCL <X9BPSZX)JL/EWOQFI)I/IY"J8G
M1QL01R&,AE)!!R"."".AS7H7A_Q['.!%<G;)TW8^0] "<?=/K_#QG(Z#SNMB
M\\*7%I$MPR':P)(&2R@<Y88XXY]N^#Q7=BJ-&JE&;L^AA2G.-VCUF.02 ,I!
M!&01R"#T.:=7C.GZS-I_^J=E&2< Y7)&,E3P?Q%=;H'CZ2>1()U!WE5#+P<G
MC)'0Y..F,<\'I7EU\KJ03:=U^)U0Q49:/0ZS5-(BU13'*H/!P?XAGN#VZ?CW
MR*\T\3>&6T9LC+1,?E;_ -E/O_/J.X'K%8WC"R^UVL@XRHW#/;;R<>^,C\<=
M*SP.*G2FHW]UO8JO24HM]3R6BBBOHCSPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -WP1_Q^1?\#_\
M0&KU:O*?!'_'Y%_P/_T!J]6KPLW_ (R]/U9W83X'ZA1117G'0%%%% !1110
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MUYU2G5PT[/1G1&4:D?(\>UW0I-'D\M^5/W6'1A_0CN.WTP3U'PQ_Y;?]L_\
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MQR>I]Z;J5Z+&)YSC"*3@G&2.@S[G@5\O4?M*LFNKT^;/4BN6*OT1XK5_0?\
MCXA_ZZQ_^A"J%7]!_P"/B'_KK'_Z$*^GJ_!+T/,CNCV2N4^)'_'NO_75?_06
MKJZP/&^G_;+5B,YC(<8('W>#G/HI)_SBOF\))1KP;[GHUE>#/*Z***^G/-.K
M^&__ !\-_P!<F_\ 0EKTBO-_AO\ \?#?]<F_]"6O2*^?S3^._1'?A?X9YO\
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M HHHH **** "BBB@ HHHH OZ#_Q\0_\ 76/_ -"%>R5XWH/_ !\0_P#76/\
M]"%>R5XN;_''T.S";,****\LZ@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -_B#P,#%>9CLO=5\\-^J.FAB%%<KV/2+W38KX;945A@@;ADC/7!ZCZBLO\
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MB,/5=6;47N^C[GHTZD%!:K8\IHHHKZ,\X**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"_H/_ !\0_P#76/\ ]"%>R5XWH/\ Q\0_]=8_
M_0A7LE>+F_QQ]#LPFS"BBBO+.H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH PO&_\ QYR_\ _]#6O*:]6\;_\ 'G+_ , _]#6O*:]W*/X+]?T1PXOXUZ!1
M117HG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >YUA>-_P#CSE_X!_Z&M;M87C?_ (\Y?^ ?
M^AK7R^&_C0]5^9Z=7X)>AY31117U!Y@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH OZ#_Q\0_]=8__ $(5[)7C>@_\
M?$/_ %UC_P#0A7LE>+F_QQ]#LPFS"BBBO+.H**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH PO&__'G+_P  _P#0UKRFO5O&_P#QYR_\ _\ 0UKRFO=RC^"_
M7]$<.+^->@4445Z)SA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110!XWKW_'Q-_P!=9/\ T(U0J_KW_'Q-_P!=9/\
MT(U0KZNE\$?0\J6["BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5U>B>.O[+A6W\K=LSSOQG+$]-I]:Y2BLJU&
M%:/+)714)R@[H[K_ (6=_P!,?_(G_P!A7"T44J.&IT;\JM<<ZDI[A1116Q 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 7]!_X^(?^NL?_H0KV2O&]!_X^(?^NL?_ *$*]DKQ<W^./H=F$V84445Y
M9U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &%XW_X\Y?^ ?\ H:UY37JW
MC?\ X\Y?^ ?^AK7E->[E'\%^OZ(X<7\:] HHHKT3G"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** -WP1_Q^1?\  _\ T!J]6KRGP1_Q^1?\#_\ 0&KU:O"S?^,O
M3]6=V$^!^H4445YQT!1110 4444 %%%% !1110 4444 >-Z]_P ?$W_763_T
M(U0J_KW_ !\3?]=9/_0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!?T'_ (^(?^NL?_H0KV2O&]!_X^(?^NL?_H0KV2O%S?XX^AV839A1117E
MG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 87C?\ X\Y?^ ?^AK7E->K>
M-_\ CSE_X!_Z&M>4U[N4?P7Z_HCAQ?QKT"BBBO1.<**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH W?!'_'Y%_P/_P! :O5J\I\$?\?D7_ __0&KU:O"S?\ C+T_
M5G=A/@?J%%%%><= 4444 %%%% !1110 4444 %%%% 'C>O?\?$W_ %UD_P#0
MC5"K^O?\?$W_ %UD_P#0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!?T'_CXA_P"NL?\ Z$*]DKQO0?\ CXA_ZZQ_^A"O9*\7-_CCZ'9A-F%%
M%%>6=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;_A"+/_GG_P"/O_\
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M ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_ ,??_P"*H_X0BS_YY_\
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M?X?YA]4GY'E-%>K?\(19_P#//_Q]_P#XJC_A"+/_ )Y_^/O_ /%4?VO1[/\
M#_,/JD_(\IHKU;_A"+/_ )Y_^/O_ /%4?\(19_\ //\ \??_ .*H_M>CV?X?
MYA]4GY'E-%>K?\(19_\ //\ \??_ .*H_P"$(L_^>?\ X^__ ,51_:]'L_P_
MS#ZI/R/*:*]6_P"$(L_^>?\ X^__ ,51_P (19_\\_\ Q]__ (JC^UZ/9_A_
MF'U2?D>4T5ZM_P (19_\\_\ Q]__ (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\
M,/JD_(\IHKU;_A"+/_GG_P"/O_\ %4?\(19_\\__ !]__BJ/[7H]G^'^8?5)
M^1Y317JW_"$6?_//_P ??_XJC_A"+/\ YY_^/O\ _%4?VO1[/\/\P^J3\CRF
MBO5O^$(L_P#GG_X^_P#\51_PA%G_ ,\__'W_ /BJ/[7H]G^'^8?5)^1Y317J
MW_"$6?\ SS_\??\ ^*H_X0BS_P">?_C[_P#Q5']KT>S_  _S#ZI/R/*:*]6_
MX0BS_P">?_C[_P#Q5'_"$6?_ #S_ /'W_P#BJ/[7H]G^'^8?5)^1Y317JW_"
M$6?_ #S_ /'W_P#BJ/\ A"+/_GG_ ./O_P#%4?VO1[/\/\P^J3\CRFBO5O\
MA"+/_GG_ ./O_P#%4?\ "$6?_//_ ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\
M"$6?_//_ ,??_P"*H_X0BS_YY_\ C[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0
MBS_YY_\ C[__ !5'_"$6?_//_P ??_XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_S
MS_\ 'W_^*H_X0BS_ .>?_C[_ /Q5']KT>S_#_,/JD_(\IHKU;_A"+/\ YY_^
M/O\ _%4?\(19_P#//_Q]_P#XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_ ,\__'W_
M /BJ/^$(L_\ GG_X^_\ \51_:]'L_P /\P^J3\CRFBO5O^$(L_\ GG_X^_\
M\51_PA%G_P \_P#Q]_\ XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_P \_P#Q]_\
MXJC_ (0BS_YY_P#C[_\ Q5']KT>S_#_,/JD_(\IHKU;_ (0BS_YY_P#C[_\
MQ5'_  A%G_SS_P#'W_\ BJ/[7H]G^'^8?5)^1Y317JW_  A%G_SS_P#'W_\
MBJ/^$(L_^>?_ (^__P 51_:]'L_P_P P^J3\CRFBO5O^$(L_^>?_ (^__P 5
M1_PA%G_SS_\ 'W_^*H_M>CV?X?YA]4GY'E-%>K?\(19_\\__ !]__BJ/^$(L
M_P#GG_X^_P#\51_:]'L_P_S#ZI/R/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\
MSS_\??\ ^*H_M>CV?X?YA]4GY'E-%>K?\(19_P#//_Q]_P#XJC_A"+/_ )Y_
M^/O_ /%4?VO1[/\ #_,/JD_(\IHKU;_A"+/_ )Y_^/O_ /%4?\(19_\ //\
M\??_ .*H_M>CV?X?YA]4GY'E-%>K?\(19_\ //\ \??_ .*H_P"$(L_^>?\
MX^__ ,51_:]'L_P_S#ZI/R/*:*]6_P"$(L_^>?\ X^__ ,51_P (19_\\_\
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M (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;_A"+/_GG_P"/O_\
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M ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_ ,??_P"*H_X0BS_YY_\
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M_P#//_Q]_P#XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_ ,\__'W_ /BJ/^$(L_\
MGG_X^_\ \51_:]'L_P /\P^J3\CRFBO5O^$(L_\ GG_X^_\ \51_PA%G_P \
M_P#Q]_\ XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_P \_P#Q]_\ XJC_ (0BS_YY
M_P#C[_\ Q5']KT>S_#_,/JD_(\IHKU;_ (0BS_YY_P#C[_\ Q5'_  A%G_SS
M_P#'W_\ BJ/[7H]G^'^8?5)^1Y317JW_  A%G_SS_P#'W_\ BJ/^$(L_^>?_
M (^__P 51_:]'L_P_P P^J3\CRFBO5O^$(L_^>?_ (^__P 51_PA%G_SS_\
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M%G_SS_\ 'W_^*H_X0BS_ .>?_C[_ /Q5']KT>S_#_,/JD_(\IHKU;_A"+/\
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M )Y_^/O_ /%4?VO1[/\ #_,/JD_(\IHKU;_A"+/_ )Y_^/O_ /%4?\(19_\
M//\ \??_ .*H_M>CV?X?YA]4GY'E-%>K?\(19_\ //\ \??_ .*H_P"$(L_^
M>?\ X^__ ,51_:]'L_P_S#ZI/R/*:*]6_P"$(L_^>?\ X^__ ,51_P (19_\
M\_\ Q]__ (JC^UZ/9_A_F'U2?D>4T5ZM_P (19_\\_\ Q]__ (JC_A"+/_GG
M_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;_A"+/_GG_P"/O_\ %4?\(19_\\__
M !]__BJ/[7H]G^'^8?5)^1Y317JW_"$6?_//_P ??_XJC_A"+/\ YY_^/O\
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M^/O_ /%4?\(19_\ //\ \??_ .*H_M>CV?X?YA]4GY'E-%>K?\(19_\ //\
M\??_ .*H_P"$(L_^>?\ X^__ ,51_:]'L_P_S#ZI/R/*:*]6_P"$(L_^>?\
MX^__ ,51_P (19_\\_\ Q]__ (JC^UZ/9_A_F'U2?D>4T5ZM_P (19_\\_\
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M_P#GG_X^_P#\51_PA%G_ ,\__'W_ /BJ/[7H]G^'^8?5)^1Y317JW_"$6?\
MSS_\??\ ^*H_X0BS_P">?_C[_P#Q5']KT>S_  _S#ZI/R/*:*]6_X0BS_P">
M?_C[_P#Q5'_"$6?_ #S_ /'W_P#BJ/[7H]G^'^8?5)^1Y317JW_"$6?_ #S_
M /'W_P#BJ/\ A"+/_GG_ ./O_P#%4?VO1[/\/\P^J3\CRFBO5O\ A"+/_GG_
M ./O_P#%4?\ "$6?_//_ ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_
M ,??_P"*H_X0BS_YY_\ C[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0BS_YY_\
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M_P#\51_:]'L_P_S#ZI/R/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\ SS_\??\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>0^//\ C]E_X!_Z M>O5Y#X\_X_9?\
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M%% !1110 4444 %%%% !1110 4444 %>?_%;_EA_VT_]DKT"O/\ XK?\L/\
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M"4SV(R6 X[CGJ "/4T- I:V9Z-6';^-;2X98DDRSD #8XR2<#JM;E>(>'O\
MCY@_Z[1_^ABDE<).Q[?1112*,.X\:VENS1/)AD)!&QS@@X/1:W*\0\0_\?,_
M_7:3_P!#->WTVK$Q=S'O_%UKI[F"63:ZXR-KGJ 1R%(Z&M :A'Y8N"P$; $,
MQVC#8QUQC.>]>4>/?^/V7_@'_HM:;9VMSXI985QMAC51G(10!@>O+8]R?H.'
MRAS:GH/_  GME_SU_P#')/\ XFMBQU"._7S8F#*>X/MG!]#ST/(KS63X972
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M-(JG ."<M@G&0HR3SZ"H]3NET2V9UP!%'A <D9 VH/7K@=?Q[UY):VL_B&?
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MEXGMM,;RY9 &] "Q'0\A0<=>,XSVJK'XYLI"%$HR2!RK@<^Y4 ?4\5Y]X?\
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M="0>" >HJ:201 NQ  !)).  .IS4/R:=%_=CB3W.%0?B3@#ZUY1XF\32>(9
MB B,'"(.22> 2!U8]AVZ#N2)7&W8]!D\<V49*F49!(X5R./<*0?J.*M:;XGM
MM3;RXI 6]""I/4\!@,].<9QWKB;#X7RRC,TBH2!@*-YYZ@\J!CV)']<KQ!X+
MFT9?-.'CSC<N>/0L".,_4C/&>F79"NSU^BN#^'_BMKAC93L68Y,9.23C)92W
MZC/N,]!7>4FK#3N8=OXUM+AEB23+.0 -CC))P.JUH:EJ\.F+OF<*#TSU/0<
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MN<*@))ZX &3TKQ:ZNI_$,^3EY'.%4= /0>@'^))ZFFE<4G8]-_X3VR_YZ_\
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M_P#UQ;_T-*] \0_\>T__ %QD_P#0#7G_ ,+_ /CY?_KBW_H:5Z!XA_X]I_\
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M:;XCM]2XBD4DD@*?E8X&3A6P3QWQC\JTJ\6USPQ/HN#*!M)P&4Y4G&<=B/Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O(?'G_ !^R_P# /_0%KUZO(?'G_'[+_P  _P#0%IQ$S HJ]H<8
MDN(58 @RQ@@C((+#(Q7K_P#PC]M_SQC_ ._:_P"%4W821XE17MO_  C]M_SQ
MC_[]K_A1_P (_;?\\8_^_:_X4N8=CQ*N^^%7_+?_ +9_^SUP-=]\*O\ EO\
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MKWVG($%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_%5#<^#M/M<%T W,JC+R<LQP /F_R.>@I70VF8_PJD)$Z9. 8R!GC)W9./?
M_(5WU9^DZ##I.[R%V[\9^9CG&<?>)]36A2;NRDK(*IZEJ\.F+OF<*#TSU/0<
M 9)QGG X[U<KQCQ=?->74I?^!V0#G "$@=<^F3[DFA*X2=CL;KXI0J,Q1NQS
MT8J@Q]06_E^-8>J?$>:]5XE1%212O.YF 88/.0/IQ^==)I/PXM[=!YX,CD#/
MS%5!]L8/Y]<9P.E3>)M-M-+M7;RD!V%4.U=VXC"\GDD=2<YP":>@M3B/ 7_'
M[%_P/_T6U>JZK=&TADF7&4C=AGIE5)%>5> O^/V+_@?_ *+:O5=5M3=PR0KC
M+QNHSTRRD"B6X1V/'O#&FKJ=S' _W6))]PH+$<$=<8SVSFO:Z\0T#5/[+GCN
M<9"'D=>""&QR.<$X]Z]MCD$H#J000""#D$'H<T2" ZO)/'^FK8W3%>DH#X]"
MQ(/4GJ03^..U>MUY!XYU9=2N69"&1 %4KWQR?K\Q/(X(QCU)'<)['?\ @+_C
MRB_X'_Z,:MRXN%MU,CL%4=2Q  SQU-8?@+_CRB_X'_Z,:N7^*-\QECMOX F_
M'/))(Y[< <>F3ZTK787LC:O/B9;0Y5 [D#@@ *3CU)!'/!^7\#6+=_%.5L>5
M$J]<[R7^F,;,?K3O!G@>._C%W.2P8G:@) P"5.2.>O3!'3DG.!UT/ABSL5/[
MI-HR29 &QQS\SYP./7%/1!JSQZ\NC=NTS8R[,QQTRQR:]YKPC4)EFE>2,;49
MV*C & 22!@<# ]*]WHD*'4\@\>_\?LO_  #_ -%K7?\ @?25L+9&P-\H#,1W
MSRO7T4CCIG/KD\!X]_X_9?\ @'_HM:[OP#JPOK94)R\/RGIT'W>!VV\9/4@_
M6A[!'<Z2N3^)&FK<6WGG[T)!'N'(4CK]#GGICO765R/Q'U9+>W-KD%Y2O&>0
MJG.[\QCMGG'0TEN5+8P?A=<,L\D0/RM'DCW5@!_Z$?SKTRO-?A;:EII)N,+&
M%/KEV!'_ *"?TKTJB6XH['D'CW_C]E_X!_Z+6O3_  ]_Q[0?]<8__0!7F'CW
M_C]E_P" ?^BUKT_P]_Q[0?\ 7&/_ - %-[(([LT*\@\>_P#'[+_P#_T6M>OU
MY!X]_P"/V7_@'_HM:([A/8[_ ,!?\>47_ __ $8U9_Q+TO[1 +D'F$]/4.0#
MVZYQZ<9]JT/ 7_'E%_P/_P!&-6Y<6ZW"M$XRK@@CID$8/2ELQVNCS?X9ZL89
MFM&/RR E1S]Y?3L,KG/K@<UU7CW4OL5HX&<RD(, '[V2V<^J@CUR?QKS!XWT
M6?# ;X) >0<$J<@]C@]1TR*W/B%K(U"9$0DHD:D9&.9 &R._*E>O0CIZTUJ2
MGH1_#_2?M]R'8';"-_0XW _*,C&.>??:1C&:]/U6Z-I#),N,I&[#/3*J2*P_
MA_I/V"V#L!NF._H,[2/E&1G/'/MN(QG-;FJVINX9(5QEXW49Z992!4MZCBK(
M\.MW5&5G&Y002N<9 /(R.F?6N[_X6M_TP_\ (G_V%<59E;:4"="55L.IR#CH
MPX*D$=N1SUXKU./P-8R@.L8((!!$CD$'H<[JIV)C<P?^%K?],/\ R)_]A7$:
MA.MQ(TB+L5B2%R#C/88"\>G' X]Z]7_X0*R_YY?^/R?_ !50Q^#M/D=H50%T
M"E@'DXW9QGYN^.G7'/<4DTAM-FQH4AEMX78DDQ1DDG))*C)S5ZH[>W6W58D&
M%0  =< # ZU)4EA7B'B'_CYG_P"NTG_H9KV^O$/$/_'S/_UVD_\ 0S51)F>O
M^'O^/:#_ *XQ_P#H KS_ .*'_'RG_7%?_0WKT#P]_P >T'_7&/\ ] %>?_%#
M_CY3_KBO_H;T1W"6QU'PZL5@M5E'WI2Q8\?PL5 ^@QGZD^M=17/^ O\ CRB_
MX'_Z,:N@I/<:V/'/&UNL%Y*JC )!_%E#'KZDFO3_  O;K!:PJHP#&I_%AN/7
MU)->:>/?^/V7_@'_ *+6O3_#W_'M!_UQC_\ 0!3>R)CNS0KP2WN&MV65#AD(
M(/7!!R.M>]UX!1$)GO\ 7D'CW_C]E_X!_P"BUKU^O(/'O_'[+_P#_P!%K1'<
M<]CT?PC8K9VL03^-%<GC)+@$],>N![ "MBL_P]_Q[0?]<8__ $ 5H5+*1X9K
M-NMO/+$@PJ2. .N &('6O;[>W6W58D&%0  =< # ZUXIXA_X^9_^NTG_ *&:
M]OJI$1ZF?XA_X]I_^N,G_H!KR3PO<-!=0LIP3(H_!CM/7U!->M^(?^/:?_KC
M)_Z :\@\/?\ 'S!_UVC_ /0Q1'8);H]OKQ#P]_Q\P?\ 7:/_ -#%>WUX9I\W
M]GSI)("/*D4L,?-\K D8..>.]$0GT/<Z*;'()0'4@@@$$'((/0YJ.\O$LT,T
MA"HHR2?\_D.I/ J2SQ;Q#_Q\S_\ 7:3_ -#->WUX)<7#7#-*YRSDDGIDDY/2
MO>ZJ1$.IY!X]_P"/V7_@'_HM:]%\'6 LK2)1C+J') QDO\W/K@$#/H/PKSKQ
M[_Q^R_\  /\ T6M>G^'O^/:#_KC'_P"@"A[(([LT*\H^(UIY%V7SGS$5NG3
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M<VAXE5MT3' )X8'D@'UX'4>AX'&>I^&FK/=Q/;N2?)*[23_"V<+^&WCGH<<
M"AKJ";O8J_%#22ZI>*/N_*YYZ'E?8 '(SQR0.>Q\+]6+J]FQ^[\R#GH>&]@
M<'''))Y[=AJ^FKJ<+VS='&,^AZ@\$9P0#COTKR#0+TZ3<QRN-NQ\-N!X!RK<
M#G(!/X]NU"U0GH[G<_$W4O(@6W&<RMSP,;4P2/7J5/'H?QQ_AEI/G2-=L#B(
M87@XW,#DYZ<#MS]X'CBLCQOJ7VZ[D/.(SL&0!C9P>G^UDCO@_A7H_A#2?[,M
MD3!#.-[9!!W,!Q@],# _#.,T;(%K(N:YIO\ :4$EOQEU.,D@;ARIXYX(!KQQ
M'FT.;(RDT9(Y .,C'?(.0>#TQR*]QJC?Z9!JZ[955P"1GN"#@@,.1R,'![8-
M).PY*YQ^F_%('BXC.<'F,YR<\?*Q&./]H\]N>.RTW5X=37?"X8#KCJ.HY!P1
MG'&1SVKE]6^&<,P+6[%&[*QW)TZ?WAD]\G'/%<-IM_)H,^\9#1L5=01R <,I
M/(YQUYP>1R!3LF*[6Y[;7E_Q0_X^4_ZXK_Z&]>H5Y?\ %#_CY3_KBO\ Z&]*
M.XY;'8> O^/*+_@?_HQJZ"N?\!?\>47_  /_ -&-704/<:V/)OB)=&:\9#C$
M:HHQZ$;N?Q8_A4WASQRNB0B!8=QR2S>9C)/MM.. !^&:C^(MBT%TTI^[*%*G
MG^%0I'U&,_0CUK9\&Z%9:S &>,>:AVO\[CZ-@/W'T&0<# JM+$:W&_\ "UO^
MF'_D3_["L#Q3XH77MK>5L=,C=O#9!['Y0>#TYXR>.:[_ /X0*R_YY?\ C\G_
M ,54-SX.T^UP70#<RJ,O)RS'  ^;_(YZ"E=#:9C_  JD)$Z9. 8R!GC)W9./
M? _(4WXK?\L/^VG_ +)78:3H,.D[O(7;OQGYF.<9Q]XGU-<?\5O^6'_;3_V2
MA.[&U:)8^%UBHBDN?XR^S/'  !X[\D\^N!Z5W%<?\+_^/9_^NS?^@)784GN.
M.QY9\2[=8KH,HY>-2WN<LO\ )177_#VW6*S1E'+ERWN=Q7^2BN3^*'_'RG_7
M%?\ T-Z[#P%_QY1?\#_]&-3>Q*^(Z"O$/$/_ !\S_P#7:3_T,U[?7B'B'_CY
MG_Z[2?\ H9HB.9['HUPUQ!%*YRSQH2>F25!/2KE9_A[_ (]H/^N,?_H K0J2
M@KR#Q[_Q^R_\ _\ 1:UZ_7D'CW_C]E_X!_Z+6JCN3/8[_P !?\>47_ __1C5
MPWQ$NC->,AQB-448]"-W/XL?PKN? 7_'E%_P/_T8U<-\1+4PWC.<8D5&&/0#
M;S^*G\*%N*7PG>^"]-6PM8PO)D =C[N ?4]!@>^,]ZW*YWP+K U&V5.-\("$
M>P'RG&2>1WXR0<5T5)[E+8Y/XD::MQ;>>?O0D$>X<A2.OT.>>F.]<W\+_P#C
MY?\ ZXM_Z&E=!\2=66"#[*"-\I&1WV@YS[?, .>O..G'/_"__CY?_KBW_H:4
MUL2_B.V\971MK.9UQDKMY]'(4_H>/>O)M(OEL)DG9=X0YV[MO(Z<C/0X/OC%
M>M^+K%KZUEB3EB 0.>=K!L#&>3C ]Z\J\/&'ST6Y4-$QVG)*XST;(9<8/7/&
M,\9Q1'8);G6_\+6_Z8?^1/\ ["FR?%(2@HUN""""#)D$'J,;*Z+_ (0*R_YY
M?^/R?_%4?\(%9?\ /+_Q^3_XJBZ':1Y)YOEMOCRN#E>?F&#D<@#D>H _"O>Z
MYFW\':?<[@B [&*MAY.& !(^]VSSZ'CJ#734I.X15CQ#Q#_Q\S_]=I/_ $,U
M[+I=@-/B2W7&$4#(&,D=3CW/)]S7C7B'_CYG_P"NTG_H9KV^G(4=V%>,>+[3
M[+=S)G.7W=,??&_'X9Q7L]>0>/?^/V7_ (!_Z+6B.XY['J>C7#7$$4KG+/&A
M)Z9)4$]*C\0_\>T__7&3_P! -'A[_CV@_P"N,?\ Z */$/\ Q[3_ /7&3_T
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M%"Q.2< $'\CCN3C).3715):U"O!KRZ-V[3-C+LS''3+')KWFO"KRS;393#(
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M%/TQ@CKFN?\ B/!;V:)#$B+(S;OD50=H!'.,'DGCL<'TIJPG>P[X4_\ +?\
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MNGW?VR))\8\Q%;&<XW '&>/6O&/#W_'S!_UVC_\ 0Q1'J$NA[;'&(@$4
M #  '08K-\46ZSVLRL,@1L?Q4;AT]"!6I6?XA_X]I_\ KC)_Z :E%L\L\$VZ
MSWD2L,@$G\54L.GH0*]CKR#P%_Q^Q?\  _\ T6U>OU4MR8;''_%#_CV3_KLO
M_H#UA_"ZX99Y(@?E:/)'NK #_P!"/YUN?%#_ (]D_P"NR_\ H#US_P +_P#C
MY?\ ZXM_Z&E"V$_B/4*YO4O']K8ML!,A[^4 P'0]20#U[$^^*C^(M\UK:X3C
MS'"$\YP02>GKC!]B17%>#?"PUUVWL52,#.W[Q+9QC(('3G\L<Y EU&V[V-N\
M^*A.1%$ <_*7;/&>Z@#M_M<'N:Y37M>?6W$TH4$*%^4$# )/<GUKU.U\&V=L
M=RQ*21CYLN/R8D?CUKSSQVT(N3' JJ(U"ML"A=V23]WTR >^01VIJPI7L=[X
M"_X\HO\ @?\ Z,:L_P"*'_'LG_79?_0'K0\!?\>47_ __1C5G_%#_CV3_KLO
M_H#U/4?V3G_A?_Q\O_UQ;_T-*] \0_\ 'M/_ -<9/_0#7G_PO_X^7_ZXM_Z&
ME>@>(?\ CVG_ .N,G_H!IRW".QY!X>_X^8/^NT?_ *&*]OKQ#P]_Q\P?]=H_
M_0Q7M]$@@%%%8_BZ^:QM994X8  'GC<P7(QCD9R/>I*(=8\:VVEG8S%W!P5C
MPQ'4')R ,$<C.?:N?O/BH!D11$C'REVQSCNH![_[7([BN6\*Z!_;<WDD[54%
MF/? (&![G/?IUYZ'TFS\#V=KAA&&*CJY+9XQDJ3M_3&>F*JR1*;9YMX@\42Z
M[L\T*/+W8V C[V,YR3Z5V_PO_P"/9_\ KLW_ * E<_\ $=8()(X(4564$OL5
M1][&T''<8SSV(QUKH/A?_P >S_\ 79O_ $!*'L)?$:'CW_CRE_X!_P"C%KB/
MAU8K=767Y\M"X'&,@@#KZ9R/< UV_CW_ (\I?^ ?^C%KC_A?_P ?+_\ 7%O_
M $-*%L#^)'J%<7\4;=6@CE(^99, ^S*2?_01^5=I7'_%#_CV3_KLO_H#TEN5
M+8R_A7;JS32D?,H0 ^S%B?\ T$?E7HE>?_"G_EO_ -L__9Z] HEN$=CR_P"*
M'_'RG_7%?_0WKI/AI<-+:E6/"2,%]AA6_FQKF_BA_P ?*?\ 7%?_ $-ZZ#X7
M_P#'L_\ UV;_ - 2F]B5\1RWQ$NC->,AQB-448]"-W/XL?PKO?!>FK86L87D
MR .Q]W /J>@P/?&>]<)\1;%H+II3]V4*5//\*A2/J,9^A'K7:^!=8&HVRIQO
MA 0CV ^4XR3R._&2#BA[ MV=%7/^.-)6_MG; WQ LI/;'+=/50>.F<>F1T%<
MWX^U86-LR X>;Y1TZ'[W![;>,CH2/K26Y3V..^'%^;>Z$7.)58$9P,J-P.._
M0C\3^/:^/?\ CRE_X!_Z,6N*^'%@;BZ$O.(E8DXR,L-H&>W4G\#^';^.8S)9
M2A02<*>!G@.I)_ #)]J;W)7PG&_"_P#X^7_ZXM_Z&E>H5Y1\.KY;6ZP_'F(4
M!XQDD$=?7&![D"O5Z4MQPV,_Q#_Q[3_]<9/_ $ UYAX"_P"/V+_@?_HMJ[WQ
MWJ8LK5TW /*-JCJ2"1OX_P!W//;(YR17!> O^/V+_@?_ *+:FMA2W1Z_7A&G
MVGVR5(,X\QU7.,XW$#../6O=Z\0\/?\ 'S!_UVC_ /0Q1$)]#VV.,1 (H
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MV@X[C&>>Q&.M=!\+_P#CV?\ Z[-_Z E#V$OB-#Q[_P >4O\ P#_T8M<-\/+
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MD <CU 'X5[W7,V_@[3[G<$0'8Q5L/)PP )'WNV>?0\=0:Z:E)W"*L>(>(?\
MCYG_ .NTG_H9KV72[ :?$ENN,(H&0,9(ZG'N>3[FO&O$/_'S/_UVD_\ 0S7M
M].0H[L*\8\7VGV6[F3.<ONZ8^^-^/PSBO9Z\@\>_\?LO_ /_ $6M$=QSV/4]
M&N&N((I7.6>-"3TR2H)Z5<K/\/?\>T'_ %QC_P#0!6A4E!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW'@FSG8N8AD_W2RCTZ*0!^5:UK9I:#9$JH"<X50HSZX%+F0<K91\-Z(NC0K
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M'O\ Q^R_\ _]%K7K]4[C1H+AC(\2,QZED4DXXZD4)V"2N1^'O^/:#_KC'_Z
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MU%?;G&]0V,]<9!]*$Q.-SS2X^)=U*I4!%)_B53D?]],P_2LNRANO$$P=2S2
MCYR3A.20<C[H') '_ 1GBO2[?P39P,'$0R/[Q9AZ=&)!_*MBWMUMU$:*%4=
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M8B-BN#\R-]W((R"IZ'C!(P>V16M=?$F[F&%V(<]57)^GS%A^F:])OM'AO_\
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MMPIC=0RGJ& (..>AJ&UTJ&T.^*-$)&,JBJ<>F0*2>@VM;EJL_P 0_P#'M/\
M]<9/_0#6A39(Q*"C $$$$$9!!ZC%(9Y%X"_X_8O^!_\ HMJ]?JG;Z-!;L)$B
M16'0JB@C/'4"KE-NXHJQQOQ+TE[N)+A 3Y);< /X6QEOPV\\=#G@ UQ&A^)Y
M]%R(B-I.2K#*DXQGL1^!&<#.0*]IK)O_  I:WYWR1+G))*Y0DGJ25(S^.::8
MG'6YD^!O$<VMM,TI&%\O:JC &=V?4\X[D^U9?Q6_Y8?]M/\ V2NVL-+BT\;8
M45!@ [1@G'3)ZGZG)IUWI\5YCS45]N<;U#8SUQD'TI7U';2QP_PI_P"6_P#V
MS_\ 9Z[J\LTO$,,@#(PP0?\ /Y'J#R*;::?%9Y\I%3=C.Q0N<=,X ]:DN+A;
M=3([!5'4L0 ,\=30W=@E9'DWB7P9+I+DH&>'!(8#. .H;'3'KT(Y]0,N/7;B
M(!%ED    $C  #H,9KUG1_%=OJS&.-OF!( ;Y2PZ[E'<<'W'<"MBGS$\IY);
M^$9I(Y;VZS&JH[#><.S\X!SR,MUSR<@#KD1^ O\ C]B_X'_Z+:NI^(_B!(XS
M8J07<J6'7:H.X<YX)(''/&>F167\,--,DKW1 VHNT$C^)L=#C' !SSG!'8T[
MZ!;4]*KR_P 8>"7LF:Y@&Z$Y8@8!3GD8&/EYXP.!UZ9/J%%2G8IJYX]H_C6Y
MTL;%8.@& LF6 Z 8.01@#@9Q[5)J7CV[O?EW",$#B,;>ASG<26'X$#'XUZ3?
M>&+:^_UD2Y)R2!M8GW9<$]>YHL?#%M8_ZN)<@Y!(W,#[,V2.G8T[HGE9QOP[
MT>YBD^T\I"1A@V1O!4E2!CG!(.>."0">17HU%%)NY25CQ#Q#_P ?,_\ UVD_
M]#->WU1DT*WE)=HHR2223&I))ZG.*O4-W!*P5Y!X]_X_9?\ @'_HM:]?JG<:
M-!<,9'B1F/4LBDG''4BA.P25R/P]_P >T'_7&/\ ] %:%-CC$0"*     !@
M#H,4ZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Y!X]_X_9?^ ?\ HM:]/\/?\>T'
M_7&/_P! %:%%-NXDK,****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(
M/$&LW-O<S1^;*H$CX&]Q@$DK@9Z8QCVH\+^$9-:8,P*PCDOCKSC"YZGCKT'?
ML#Z_15<Q/*1V]NMNJQ(,*@  ZX &!UJ2BBI*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#SOXC:A/9SIY;NB-&/NLRJ2&;/0@9P1G\*Y:PTV?7I,+N=B
M1N=B2!QP68YQP..YQ@9/%>VT52D2XW,WP_H::+$($)/.6)[L< G';IP/3U.2
M=*BBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ!H::U$
M8')'.5([,,@''?KR/3T."-*B@#QS6_!]QI;'*EXQDAT&1@<Y(&=OOGWP2!FJ
M?_"0W/\ SVE_[^/_ (U[?15<Q/(>.:)X/N-4884I&<$NXP,'G(!QN]L>V2 <
MUZOI.DQZ5&((AA1^9/<D]R?_ *PP !5RBDW<:C8****0PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &R1B0%6 (((((R"#U&*Q9_!5G.Q<Q#)_NEE'Y
M*0!^5;E% &%'X'LXR&$0R"#RSD<>Q8@_0\5LP6ZVZB-%"J.@4  9YZ"I** "
MBBB@ HHHH **** "BBFB0$E<C( )&><'.#CWP?R- #J*** "BBB@ HHHH **
M:) 25R,@ D9YP<X./?!_(TZ@ HHHH **** "BBB@ HIHD!)7(R "1GG!S@X]
M\'\C3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#FOB!J3V-MF,E2\BKD$A@,%N"",?=Q],UY3'(8R&4D$$$$'!!'0YKV_5=*CU
M2,P2C*G\P>Q![$?_ %CD$BN6M?AA%&^YY&9,\+C:>O +9.>.#@ ]QBJ3$T=3
MH\[7$$4KG+/&A)Z9)4$]*N4V.,1@*H     &  .@Q3JD9@?\)Y9?\]?_ !Q_
M_B:U["_2_03Q'*-G!P1T)!X(!ZBO"J]>\!_\>47_  /_ -#:FU829OUS7Q U
M)[&VS&2I>15R"0P&"W!!&/NX^F:Z6J>JZ5'JD9@E&5/Y@]B#V(_^L<@D4D,\
M0CD,9#*2""""#@@CH<U[?H\[7$$4KG+/&A)Z9)4$]*Y:U^&$4;[GD9DSPN-I
MZ\ MDYXX. #W&*[..,1@*H     &  .@Q3;N)(=1112&%%%% !7-?$#4GL;;
M,9*EY%7()# 8+<$$8^[CZ9KI:IZKI4>J1F"494_F#V(/8C_ZQR"10@/$(Y#&
M0RD@@@@@X((Z'->WZ/.UQ!%*YRSQH2>F25!/2N6M?AA%&^YY&9,\+C:>O +9
M.>.#@ ]QBNSCC$8"J     !@ #H,4V[B2'5@?\)Y9?\ /7_QQ_\ XFM^O J$
MK@V>ZV%^E^@GB.4;.#@CH2#P0#U%6*P/ ?\ QY1?\#_]#:M^D,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#Q3^U[KS_,WOY^=O?=G=G9M]-W\.,=L5[76/_:%CO\_?!YG]
M_='NZ8^]G/3CZ5L4VQ15@HJG<:S!;L8WE16'4,Z@C//0FK4<@E =2"" 00<@
M@]#FD,=16?\ \)#;?\]HO^_B?XU>CD$H#J000""#D$'H<T .HHHH *KZA=_8
MXGGQGRT9L9QG:"<9Y]*L5@Z[KMO+;S(LL9)BD  D4DDJ<#&: 9FZ#\0?[6F2
MV\K;OW<[\XPI;IM'IZUV%>.>"KA;>[CD=@JC?DL0 ,HPZFO5[?68+AA&DJ,Q
MZ!74DXYZ TY(F+N7*\ KW^O *<13/?Z*CN+A;=3([!5'4L0 ,\=356/7;>4A
M%EC))  $BDDGH,9J2R]1110 4457N]0BL\>:ZINSC>P7..N,D>M %BBJ,>NV
M\I"++&22  )%))/08S5Z@ HHHH *\@\>_P#'[+_P#_T6M>OUY!X]_P"/V7_@
M'_HM:J.Y,]CO_ 7_ !Y1?\#_ /1C5T%<_P" O^/*+_@?_HQJT/\ A(;;_GM%
M_P!_$_QI/<:V-"BH[>X6X42(P93T*D$'''45)2&%%%% !16?_P )#;?\]HO^
M_B?XU:M;Q+L;XF5P#C*L&&?3(H FHHHH ***S_\ A(;;_GM%_P!_$_QH T*\
M0\0_\?,__7:3_P!#->UV]PMPHD1@RGH5((...HKQ3Q#_ ,?,_P#UVD_]#-5$
MF9[?139)!$"[$  $DDX  ZG-4X]=MY2$66,DD  2*22>@QFI*+U%%% !15.X
MUF"W8QO*BL.H9U!&>>A-6+>X6X42(P93T*D$'''44 24444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1BK#9@J2",NHZBLCX;:TUU&UJYR8L%<GG:>,8ZX4CKSU X %:GCS_CRE_P"
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MT87Q$O'M+=6C9D)E RK%3C:W&17G?_"07/\ SVD_[^-_C7??$[_CV3_KLO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM5'<F>Q335;B\B33DR4&<(BY+')?)QDG&>G3@'&1FKG_  @5[_SR_P#'X_\
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M"G(4%U"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"OJ%BM_&T#_ '7!!Z?F,YY'4>AKR+Q!X8ET
M5OG&8R<*XZ'OT['V/H<9 S7LM8=IXRMKJ4VJO\V0 2/E8^S?ISC)QMS33$SQ
MZNCTKQ[<V) 9O,0=GY/7)^;[V>PSD#TZ5W.H^ [6]^;:4)(YC.WH,8VD%1^
M!S^->;^(M$_L:4V^\/P#D<$9[$9.#^/0@]ZJZ8MCU/P]XCCUM-T>0R@;U.?E
M)SWQ@]#C';J >*YCXJ2$"%<G!,A(SQD;<''MD_F:YCP??FSNHF&<.P0@'&0_
MR\^N"0<>H_&NS^)FG>? MP,YB;GD8VO@$^O4*./4_@K68^AYG6__ ,)Y>_\
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MSG/SC/\ ">"%R0<XR.]>1UH7.L-<01VAX6$N>">=QR,CU'.#Z''KF;POI/\
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MH]3TC2UTN);9"2J9P6P3R2>P'K5RBBI+"O(/'O\ Q^R_\ _]%K7K]>0>/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.<X.#QMU]+\-6^EL984VL1@G<QX)![D^E:E#>H6/ JO1ZY<1@*LL@    D8
M =!C->NZCX<M]1YEC4DD$D?*QP,#++@GCMG'Y5A?\*QMO[\G_?2__$4^9!8\
MQKT3X;Z ]MNO9 1O7"#U4D$L1CO@8YZ9.,$&M_3?!]KIY#I&"Z@?,Q+'(P=V
M#P#D=0!CMBMJAL$CD/B=_P >R?\ 79?_ $%Z\QKW'5-)BU11%,NY0<@9(Y (
M[$>M9G_"!V7_ #R_\??_ .*H3L#1?\/_ /'M#_UQC_\ 015RX@6X5HG&5<$$
M=,@C!Z46\"VZK$@PJ  #K@ 8'6I*D9XAK.DOI4K0.#P>"1C<O9AUZ_7@\=15
M&O<=2TB+4UV3(& Z9ZCIT(Y&<<X/-<])\,[9R2&D )/ 9<#VY4G\R35<PK&;
M\*O^6_\ VS_]GK0^)W_'LG_79?\ T%ZW]*T&'2=WD+MWXS\S'.,X^\3ZFI-4
MTF+5%$4R[E!R!DCD CL1ZTKZA;0\.KVWP_\ \>T/_7&/_P!!%4/^$#LO^>7_
M (^__P 56W;P+;JL2#"H  .N !@=:&[@D25Y7\0])^QW'G #9,,C  ^88##^
M1)XR3]:]4JCJFBPZJ LZ!@IR.2",]>00?PZ=/2A.PV>(5Z)\,M)V(]XP.6.Q
M<@CY1@DCL<GCIP5Z]:VO^$#LO^>7_C[_ /Q5:]A8)8(((AA%S@9)ZDD\DD]3
M3;$D6*Y#XG?\>R?]=E_]!>NOJGJFDQ:HHBF7<H.0,D<@$=B/6I0SPZO;?#__
M ![0_P#7&/\ ]!%4/^$#LO\ GE_X^_\ \56W;P+;JL2#"H  .N !@=:;=Q)!
M<0+<*T3C*N"".F01@]*\4UG27TJ5H'!X/!(QN7LPZ]?KP>.HKV^J>I:1%J:[
M)D# =,]1TZ$<C..<'FA.P-'AU=]\*O\ EO\ ]L__ &>M*3X9VSDD-( 2> RX
M'MRI/YDFMW2M!ATG=Y"[=^,_,QSC./O$^IIM@D:%<I\1=*-Y;B91EH3GOG:>
M&X'X$YZ 'GUZNL+QGJR:?;.K$;I59%7/)W#!/?H#GTZ#.2*2&SQ^NE\ :3]O
MN0[ [81OZ'&X'Y1D8QSS[[2,8S7-5ZI\/-)^QV_G$'?,<G((^49"C^9!XR#]
M*I[$HZFBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5.XT:"X8R/$C,>I9%)...I%7** ([>W
M6W41HH51T"@ #//05)110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 1SMM!(JI]I;U_E5JX&5(%4_*/H?RH =]I;U_E1]I;U_E3?*/H?RH\H^A_
M*@!WVEO7^5'VEO7^5-\H^A_*CRCZ'\J '?:6]?Y4?:6]?Y4WRCZ'\J/*/H?R
MH =]I;U_E1]I;U_E3?*/H?RH\H^A_*@!WVEO7^5'VEO7^5-\H^A_*CRCZ'\J
M '?:6]?Y4?:6]?Y4WRCZ'\J/*/H?RH =]I;U_E1]I;U_E3?*/H?RH\H^A_*@
M!WVEO7^5'VEO7^5-\H^A_*CRCZ'\J '?:6]?Y4?:6]?Y4WRCZ'\J/*/H?RH
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M[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\ *F^4?0_E1Y1]#^5 #OM+>O\
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M^TMZ_P J/M+>O\J;Y1]#^5'E'T/Y4 .^TMZ_RH^TMZ_RIOE'T/Y4>4?0_E0
M[[2WK_*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\ *F^4?0_E1Y1]#^5
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MIOE'T/Y4>4?0_E0 [[2WK_*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\
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M [[2WK_*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\J;Y1]#^5'E'T/Y4
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M[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\ *F^4?0_E1Y1]#^5 #OM+>O\
M*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\J;Y1]#^5'E'T/Y4 .^TMZ_R
MH^TMZ_RIOE'T/Y4>4?0_E0 [[2WK_*C[2WK_ "IOE'T/Y4>4?0_E0!)'<,2!
MGO5VJ$<9!'!ZCM5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/-#'S-V-@!^[C.<D>M &Q17(?\ "SK;^Y)_WRO_ ,71_P +.MO[DG_?*_\
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M/$\6A[/-#'S-V-@!^[C.<D>M &Q17(?\+.MO[DG_ 'RO_P 71_PLZV_N2?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(RN.W')]<$8K1^&_A\*OV]^K95!QTZ%O7.<CMQGJ#7=TVP2.0_X5C;?WY/\
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MN-V[H <YP/6EK89L445DZYXG@T;'FD[B,A5&6(SC/8#\2,X.,D4AFM17 ?\
M"U?^F'_D3_["KVG?$R"?B96C.3R/G7&.Y !Z\<*?KZ.S%<[&BFQR"0!E(((!
M!!R"#T.:CO+Q+-#-(0J*,DG_ #^0ZD\"D,FHKBK_ .)\41Q#&SC)R6.P<=".
M&)S[@'^D,'Q35F >$A>Y5PQ_(JO\Z=F*YW=%4]*U6/5(Q/$<J?S![@CL1_\
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MZ*X2#XIJS /"0O<JX8_D57^==?INKQ:FN^%PP'7'4=>H/(SCC(YIV"Y<HHK
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M0J1A1110 45R6L?$:"S.R$&4@\D':O<'YL'/3L,$'@UF_P#"U?\ IA_Y$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0^//\
MC]E_X!_Z M>O5Y#X\_X_9?\ @'_H"TXB9D:?=_8Y4GQGRW5L9QG:0<9KMO\
MA:O_ $P_\B?_ &%<''&9"%4$DD  #))/08J]_P (_<_\\9/^_;?X532$==_P
MM7_IA_Y$_P#L*/\ A:O_ $P_\B?_ &%<C_PC]S_SQD_[]M_A1_PC]S_SQD_[
M]M_A19!=F?7??"K_ );_ /;/_P!GK@:[[X5?\M_^V?\ [/0]@1W]>)>(/^/F
M;_KM)_Z$:]MKQ+Q!_P ?,W_7:3_T(THC9O\ PQ_X^7_ZXM_Z$E>F22",%F(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGK[5T^KZDNF1/<-T09QZGH!T.,G SVKSWX8_\?+_ /7%O_0DKH?B9(4ME )
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M\'V4D;XB<#OM)SGW^8D<=.,]>>OH>XT%%%%( HHHH \Q^)W_ !\I_P!<5_\
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M%*["QF^'M,?38$@D<NRCKV'^R.^!VSS]!@#S/QY_Q^R_\ _] 6O7J\A\>?\
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M(\+&&3.8R5P3G&"<@=NN>G&>:]WKRWXE0+%=!@.7C4GW.67^0%"8-'9^ _\
MCRB_X'_Z&U;]8'@/_CRB_P"!_P#H;5OU+&%<M>?#NWNW:9FDR[,QP5QECD_P
MUU-% 'AFEVHNYHX6SAY$4XZX9@#7I5G\.[>T=9E:3*,K#)7&5.1_#7G?A_\
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MG&#TSGG&":[+0?B0ER1%<J$8G&]?N<YZY.5[#.2.YP*>H:'9QQB,!5
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M7(89';*LN>1R,C//J*]MKQWQK L%Y*JC )!_%E#'\R37J7A__CVA_P"N,?\
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MY6,GYE/) Y/RM^0&0<<DD]#V-G9I9H(8P%11@ ?Y_,]2>37$:/\ $W>=MT@
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M ,?L7_ __0&KUB\NA:(TS9PBLQQUPHR:\G\!_P#'[%_P/_T!J[_QY_QY2_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_+#_MI_[)7?UQ'Q*T^6\\GRD9]OF9V*6QG9C.!36XF6/AC_ ,>S_P#79O\
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MF5N.1C:F0#Z]2PY]!^.)\2=',$PNQDK* #[,HQCI@9 &.<DANU>E1QB,!5
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ME ZXX; X!_QY..,'C'G<^D76CL9"CH4_C7.!GC[Z\<YQU]J-PV/9Y)!&"S$
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MT/(J/5=5CTN,SRG"C\R>P [D_P#US@ FO)[S1KO0&+8= !@O&3MP3@?,O3)
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M22IP,5Y;H>AW$=Q"S12 "6,DF-@  PR<XH0,]@HHHJ1GB7A__CYA_P"NT?\
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MT$>8>!CL0.O.>>,8'6O3*3&CR'QY_P ?LO\ P#_T!:].\/\ _'M#_P!<8_\
MT$5Y[XTT>>XNY)$B=E.S!5&(.$4=0*]$T.,QV\*L""(HP01@@A1D8IO82+U>
M8_$[_CY3_KBO_H3UZ=7G?Q$TN:[N%:.-W B RJ,PSN;C(%*.X,Z7P'_QY1?\
M#_\ 0VK?K#\%V[6]I'&ZE6&_(8$$9=CT-;E)C"O,?B=_Q\I_UQ7_ -">O3J\
MQ^)W_'RG_7%?_0GIQW$RQ\._$<=D&M9B%#'<K'@9QA@23@< 8_'G.!7HU>6P
M>"FU&TBNK?F4[@RDXW8=@""> 0.HZ$>_7$FN+FP7[.[2(I!^1BRC!SGY3C@\
M_7FG:X7.^\>^)ULXVLT.99!AL8^53USUY8< =<'/'&>>^&VG?:+@SG.(5/((
M^\WR@$=>F[IW'YYNB^$+C5&&%*1G!+L,#!YR <;O;'MD@'->I:%HZZ1$MNG.
M.2< $D]3Q^0ZX  R<4/1!N'B#_CVF_ZXR?\ H)KS'P'_ ,?L7_ __0&KU#7(
MS);S*H))BD  &225.!BO._!>CSV]W'(\3JHWY+(P RC#J10M@9ZE4-Y:B[1H
M6SAU93CKAA@U-14C/$OWNA7'I)"_N <?D2K#Z9!]Z]?TG68M5021,#P,C^)<
M]B.W0^Q[9%9'BKP6FL_OD(24#KCAL#@'_'DXXP>,>=SZ1=:.QD*.A3^-<X&>
M/OKQSG'7VJMQ;'L\D@C!9B  "22<  =3FL?3O%<&H3O:QL"5 P<\,>=VWUQQ
M]>2!@9KRS_2=7_YZ3;/]Z3&?SQG'XXKKO"_P^>%UN+D[2A#*JD$Y5L_,>1CC
MH,YSU&,4K6"YW]9>G^);?4':&-P64XQG&[C.5_O#KT],]"";FH62WT;0-D*X
M(.TX//O_ )!Z$$<5Y7K'@:YT\_*ID0G@Q@D]\97J.!SU SC-"0,].U'1(-2_
MUR*QP!DC#8!S@,,$<^AKQS5[:.VE>.%M\:GAO7_''3(X/4<&IDU2ZO?W*R2N
M6!&T.[9&.1C)SQU]JW?#'@*2\82W*E(ASM/#-STQU4<<DX..G7(:T#<[2ZT]
M]8LA#)D221(3GY?G #<C''S#D8Z9Q7F&A:HVB7"RD$;3M=>0<=&&,CD=0#W
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M<5YYX.U_^QIPSD^4XP_4_1L ]C]3@G R:]@K@O$_P\\PF>TQDD9CX YZE22
M/H>.N#T%),&=S!<+<*)$8,IZ%2"#CCJ*COM0CL%\V5@JCN3[9P/4\=!R:\:_
MTG2/^>D._P#WH\X_+.,_AFI(-(NM882!'<O_ !MG!QQ]]N.,8Z^U/E"YZKH'
MB"/6D,D?!!(*G[PY.TGZCGC(ZC)P:=XCT[^T;>2 9RR\ $#++\RC)XY(&?;T
MK*\(>#?[$)F=LRL"I"_< )![@$GCKQZ8[UT](9XIX>U@Z1.DXS@'# =U/48R
M,^HSQD U[+9WB7B":,AD89!'^?S'4'@UR'C'P-]M)N;8#S"?F3( ;/\ $,X
M/KV/7K][@_W^DM_'$Y'^TC$$_@<9'Z4]Q;'LNJZK'I<9GE.%'YD]@!W)_P#K
MG !->,:I?G4)7N&SEV)P3G /09]AP/85IV'AB[UMO,(;Y@#YDI(!&.#DY+<#
M' /;H*-:\)364K11)(Z*%^8(Q!)4$]!CKGUQTR:%H#/4/#__ ![0_P#7&/\
M]!%:%4=#C,=O"K @B*,$$8((49&*O5(PKR/QSHYT^Y9N=DQ+@^Y/S#. .#VY
MP",UZY67X@\/QZW'Y3\,/NL.JG^H/<=_8@$-.PF4/!7B-=5B$3']]&,,#U('
M ;DG.>,GU[#(ST=>/ZMX,N=/<J$:1<G:T:ELCW R1U[]\X)'-4O[0N=1_<;Y
M)-W\&YGSCG[N3G&,T[!<Z?XB>(X[T+:PD,%.YF'(SC"@$'!X)S^'.<BK?PQT
MHHKWC#[WRJ>>@Y;V()P,\\@CCOE:'\/)KP[KC,28![%CGMC/R\>O(..#SCTR
MW@6W58D&%0  =< # ZT/L".$^*O_ "P_[:?^R5H?#'_CV?\ Z[-_Z"E5_B5I
M\MYY/E(S[?,SL4MC.S&<"KWP[LWM+=ED5D)E)PRE3C:O.#1T#J=37(?$[_CV
M3_KLO_H+UU]<M\1+-[NW58U9R)0<*I8XVMS@4EN-F3\*O^6__;/_ -GKOZXC
MX:Z?+9^=YJ,F[R\;U*YQOSC(KMZ'N)!1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*;)&) 58 @@@@C((/48IU% 'FOB/X>R6[-+:C='UV9^<=20,_>'ISNYQ@]3R
M$]NUNQC=2K#J&!!&>>AKWFBGS"L>"1QF0A5!))   R23T&*Z?0? $]\0\P,<
M>>=W#D<YPO;I_%CKD UZI13Y@L0V=FEF@AC 5%& !_G\SU)Y-3445(PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .@-7KU-JPD%%%%(84444 %%%% !1110 445Y;H_C2[N)XHGDRKR("-B#(+
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-ATW36\R)H0WJ90Q'4<%F..O..O>NCKP*O;?$'_'M-_UQD_]!-#0)F!\3O\
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MH>'_ /CYA_Z[1_\ H0H:N),]CNM4AM#MDD1"1G#.JG'K@FHX]<MY"%66,DD
M 2*22>@QFN4^)ND[T2\4'*G8V 3\IR03V&#QTY+=>E>?V\[6[+*APR$$'K@@
MY'6DE<=SWFBJ^GWRW\:SI]UP".GY'&>1T/H:DN)UMU:5SA4!)/7  R>E(97G
MUB"W8QO*BL.H9U!&>>A-$&L07#"-)49CT"NI)QST!KQ2\NC=NTS8R[,QQTRQ
MR:[CX7Z7_K+PG_IF!^3,3Q],<^N1TJFA7._HHHJ1A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M49^I/JQY$@;.V_X6=;?W)/\ OE?_ (NM+1_&EMJAV*Q1R<!9,*3T P<D')/
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M+VYW@#[V<8P3Z5L5@>%?"O\ 8&_Y]_F;?X=N-N?<^M9?COQ<UA_H<!Q(PRS
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M8QK N2J  ;CD\>_^0.@ '%)V!&5KOC&'17$,BN25#?*%(P21W8>E6;;Q'#+
M+UCLC;.-^ ?E)&, G)X. ,DUPOQ._P"/E/\ KBO_ *$]8FFV4^N%+6/D1@X!
M("J"WS'\SSC)^N!3MH%SO)/B9;(2 LA )Y"K@^_+ _F :T-'\:6VJ'8K%')P
M%DPI/0#!R0<D\#.?:N=_X55_TW_\A_\ V=<UXB\*RZ&07PR,3M=>GT/H<<XY
M'H3@T60:GLE%<EX"\3G4D-M*298QD$CJO R3W()P>F1@\G)K=UW6%TB)KA^<
M< 9 ))Z#G\SUP 3@XJ;#)-2U>+3%WS.%!Z9ZGIT Y.,\X'%<Y_PLZV_N2?\
M?*__ !=<3_I'BFX_O.WX*JC\\*,_4GU8\]A:_"Z%1^\D=CGJH51CZ$-_/\*J
MR0KFQH_C2VU0[%8HY. LF%)Z 8.2#DG@9S[5NUY'XH\'/H063<'1CC.-I#<G
M&,GJ!U^N<<9Z7X<>(&N5-D^28QN4G^Z,#;Z\$\=>.. !2:"YV]5[[4([!?-E
M8*H[D^V<#U/'0<FC4+Y;"-IW^Z@)/3\AG')Z#U->1ZIJD_B><  DDX1%Z ?Y
MY9C^@  $K@V=O)\3+9"0%D(!/(5<'WY8'\P#5BP^(5K=':2T9R /,7 .?=2P
M&.Y.!^M8%G\+GD0-)*$<CE0F['MG<,^_;/3/6J>L?#F>S&^$B4 <@#:W<GY<
MG/3L<DG@4[(-3TZ.02 ,I!! ((.00>AS7,7GQ$M[1VA99,HS*<!<94X/\50_
M#JTN(8BTIQ"W,:D?-SU8>BGT[]1C^*OJ'PU^V2O/YV/,=FQY><;B3C.^EH!P
M>EW0M)HYFSA)$8XZX5@37I5G\1+>[=8563+LJC(7&6.!_%7F>GVGVR5(,X\Q
MU7.,XW$#.*[[3_AK]CE2?SL^6ZMCR\9VD'&=]-V$CMZY:\^(EO:.T++)E&93
M@+C*G!_BKJ:\2\0?\?,W_7:3_P!"-)*XV>QQWXDA%TH8@QAPH&6(*[@,9Z^V
M>M8%G\1+>[=8563+LJC(7&6.!_%6SX?_ ./:'_KC'_Z"*\H\4:3_ &5</"H.
MS.5R#]UN0!G.<=,]R*$@9[/16;X<U'^T;>.<YRR\D@#++\K' XY(./;TJQJE
M^-/B>X;&$4G!.,D=!GW/ ]S2&8FI^/[?3Y&@8.Q0X)0*5SCD9W#IT/H<BMO3
M+\:A&LZAE#C(#C#8SP<9/7J/48->.6%H^MW CS\\SDL<#OEF;' X&3CCT%>T
M_+;+V5$'L%  _( "FU82">X6W4R.P51U+$ #/'4US$_Q*M8F*@.P'=5&#_WT
MP/Z5QGB;Q-)X@D"*"(P<(@Y))X!('5CV';H.Y._I7PQ#*'N7()'*IC@_[QR#
MQUP.O0D#DM8+FQ8_$2UNF\L[DST+@!<YQC()Q]3@>IKI8Y!( RD$$ @@Y!!Z
M'-><^(?AW]A1[B!RRH,E6 #;0/F.X8!QUQ@<>IZT? GB!M.F$!R8YB%P.S$@
M!N?R/3CGG %%@N>K5X%7OM>!4X@SW/4[\:?&T[!F"#)"#+8SR<9'3J?09-8V
MD^.X-4E6W17#/G!8*!P">S'TK?N(%N%:)QE7!!'3((P>E>*7D#Z/.4!(>&3@
MD8^Z<JV#GKP1U&/6DE<&>WT5#9W0NT69<X=589ZX89%9_BC5O[*MWF4C?C"Y
M(^\W (SG..N.X%(9E7'Q(MH6:/#G:2,J%*G!QD'=R#VKI[>;SE63!&X X888
M9&<$=B.]>/\ A#2?[3N43 *H=[9 (VJ1Q@]<G _'.,5[)3:L)!1112&%8'CS
M_CRE_P" ?^AK6_6!X\_X\I?^ ?\ H:T(#@/ ?_'[%_P/_P! :N]U;QU;::YB
M)9V!(81@'!'8DD#\LX((.#7DJ2&/E20<$<''!&"/Q!P?:NOTGX;2W:"25Q'N
M (7;N;\1E<=N.3ZX(Q5-(E'0P?$JUE8*0Z@]V48'_?+$_I72V=XEX@FC(9&&
M01_G\QU!X-><ZM\-I;1#)$XDV@DKMVM^ RV>_'!],DXK+\)>)&T>4;B?*8X8
M$G SC+@#/(QZ$D<46'<]@KG-6\=P:7*UNZN63&2H4CD ]V'K71UY#X\_X_9?
M^ ?^@+22N#/6+.Z%VBS+G#JK#/7##(J:L_P__P >T/\ UQC_ /016A2&86N^
M,8=%<0R*Y)4-\H4C!)'=AZ5HZ3JBZI$MP@(5\X#8!X)'8GTKSWXG?\?*?]<5
M_P#0GKK_  '_ ,>47_ __0VIM:"*MY\1+>T=H663*,RG 7&5.#_%7FNEW0M)
MHYFSA)$8XZX5@37>:A\-?MDKS^=CS'9L>7G&XDXSOK@=/M/MDJ09QYCJN<9Q
MN(&<4U83/3+/XB6]VZPJLF795&0N,L<#^*NIKB-/^&OV.5)_.SY;JV/+QG:0
M<9WUV])V*05#>70M$:9LX168XZX49-35G^(/^/:;_KC)_P"@FD!F:3X[@U25
M;=%<,^<%@H' )[,?2IM8\:6VEG8S%W!P5CPQ'4')R ,$<C.?:O);2\>S;S(R
M58 @$=1N!!_0]>H[<UUNE?#62[C$LK^6S?P[-Q [9^88/MV[\Y II"N;\'Q*
MM96"D.H/=E&!_P!\L3^E=3'() &4@@@$$'((/0YKR_Q!\/Y-+C\]&\Q5^]A=
MI ]<9.1Z^G7IDB;X;:P8)C:')64$CV91G/7 R <\9)"]J5@N>F4V201@LQ
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MX _LF9;GS=VS=QLQG*E>NX^OI1\3O^/9/^NR_P#H+TM+@:NA^*X=8#L@91$
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MM$98Y5<[AD%5!7K@C)8<CO\ 4>M87PWU][G=92$G8N4/HH(!4G/;(QQTR,X
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MZ'@Y!^A'7H02[)A=GM-4]6U1=+B:X<$JF,A<$\D#N1ZUE>"_$9UJ(^9CS8R
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M#_UVC_\ 0A0D#9[;7+7GQ$M[1VA99,HS*<!<94X/\5=37B7B#_CYF_Z[2?\
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M>4O_  #_ -#6J?@WQE_:W^CS8$J@8.?O]<G&, @8R,\\D  <7/'G_'E+_P
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M "[X!STR>:HH2L%R]HFH_P!FSQW'.$89P 3M/##GCD$BO;9)!&"S$  $DDX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M _\ 0UHO=AT. \!_\?L7_ __ $!J]>KR'P'_ ,?L7_ __0&KUZB0(\"KWVO
MJ]]IR!'DOB_PO)IDK2JN87)8%1A5R?ND#IC.!V/;N [2?']S885B)%R/]9DM
MC.3ANO.>^['&!CBO4$U"-Y#;A@9% )7/(!Z?Y[9&>HSFW_@^UO!@QJIP<&,;
M",]_EP#CMD$?K1<+%30?'D&J$1-F.1C@!N5).< -_B!R<#-=+7C'B?11H\Y@
M5@PP"/[P!Z!O?^8P>,XKT_PE?-?6L4K\L003SSM8KDYSR<9/O2:!,V**:) 2
M5R,@ D9YP<X./?!_(TZD,**** /$O$'_ !\S?]=I/_0C7L>EV T^)+=<810,
M@8R1U./<\GW->.>(/^/F;_KM)_Z$:]MJI"05XMXGG:>ZF9CDB1A^"G:/R %>
MTUX[XSTUK"ZD!Y$A+@^SDGU/0Y'OC/>E$&7-/^($]A&L")'M0 #Y6_,X8<GJ
M?4U8_P"%G7/]R/\ [Y;_ .+KI?"B6NL0*YBB,B@!QY:9SZXVC[V,\<=1V-;/
M_"/VW_/&/_OVO^%.Z \FU[Q ^MLLLBJ&48RFX9&<C.6/3)Z>O/:NZ^&/_'L_
M_79O_04K2NX+&TDCMGCB#RGY1Y:>AY/'&2,#N3P.^->ULTM!MC54!.<*H49]
M<"DV%CSOQ[X7DBE:\C7,;\MM'W2!R2!V.,EO7.>Q.3H_C2YTL;%8.@& LF6
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MKQ+Q!_Q\S?\ 7:3_ -"->VUXEX@_X^9O^NTG_H1HB#/7?#__ ![0_P#7&/\
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M8_\ T$5H5A^#-26_M8R.#& A'N@ ]!U&#[9QVK<J6,\Q^)W_ !\I_P!<5_\
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M[Y-.Z \B\/\ _'S#_P!=H_\ T(5[;7B7A_\ X^8?^NT?_H0KVVB0(\A\>?\
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M:8,BC('W@06^@_G@<9S7 >!;#[9=ID96/+GG&-H^4]?[V/Z\9IK8&>G>(/\
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M_A5_RW_[9_\ L]=!X\_X\I?^ ?\ H:US_P *O^6__;/_ -GKH/'G_'E+_P
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MC]!S[UM5F^'-._LZWC@.<JO()!PS?,PR.."3CV]:TJ3&%<!\5?\ EA_VT_\
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MI[J9F.2)&'X*=H_( 4DKL-CI;KXI.P_=Q*ISU9BPQ] %_G^%8NH>.;J]#(6
M1P0555Q@C!Y(+<_7Z5Z#I/@RVT] I19&P-S2*&R?8'('7MVQDD\T>+[Y-,M'
M7  =?+51P/F!'88&!D^G&*=T!Y]X#_X_8O\ @?\ Z U>O5Y#X#_X_8O^!_\
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MSTJSO$$T<43(PR"(U_P_,=0>#5,E'#_\+.N?[D?_ 'RW_P 77,:A>&]D:<@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/3.>&Q'>_P#">67_ #U_\<?_ .)KA/&'BS^W&5$!6).0#U)/<@$CCH.O?GG
MYZ2,QDJP(()!!&"".HQ4UCI\E^WE1*68]@/?&3Z#GJ>!0DD%PT^Q:_D6!/O.
M0!U_,XSP.I]!7N/V==OE;1LQMVX&W&,8QTQCC%<YX,\)?V,OG2?ZYQ@@'A1P
M=ON>.3^ ]3T]2V-(\0UG27TJ5H'!X/!(QN7LPZ]?KP>.HK9\&>+?[&;R9/\
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M?2#B92!G 8<J>N.??&<'!QU%-.Y.QZ9_PGEE_P ]?_''_P#B:YW7/B4=P6T
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M0-Q&3CHHSCT XKTCP5X=DT6-O-;)DVG8.BD9SSG!)&,X';J1@UT,<8C 50
M   ,  =!BG4-A8*\S\3^ 'M"9K8%XR1\@R77/MW _/GD<$UZ910G89XQ8>*K
MJQ&V.5L8 PV&  Z !@<?ABH;N_N-;<!RTC\X4#/;G"J,#@<X';)KV6[T^*\Q
MYJ*^W.-ZAL9ZXR*D@MUMU$:*%4= H  SST%/F%8Y3P9X,;26^TS']X1@*I.
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MP_[:?^R5H?#'_CV?_KLW_H*5U]%.^@K!7D/CS_C]E_X!_P"@+7KU%"=ALP/
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MI'9AD X[]>1Z>AP1Y9JFB7'AYPQRN.DD9.WD'@-Q@]>.#^%>RT4T[":/'?\
MA-;S;Y?FG&,=%W8QC[V-V??.>^<TS2O#EQK;;E!P^XF1\A3SS\V#DD^F3G\:
M]9_L>#=YOE)OSNW;%W9SG.<9SGG-7*?,%C/T+1UTB);=.<<DX ))ZGC\AUP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *;)&) 58 @@@@C((/48IU% #8XQ& J@
M   8  Z#%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._B)I<UW
M<*T<;N!$!E49AG<W&0*ZCP7;M;VD<;J58;\A@01EV/0UN44[A8****0!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %>*2>&[F,E3#)D$CA&(X]P"#]1Q7M=%-.PFCSWPCX"9F%Q=KA1
M@K&>_?+#L!_=/)/4 #!]"HHI-W&%1O;J["0J"R9VD@$C/!P>V>]244 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5R7B?P$FI$SPD)*Q&0?N'U/ )!/J.#CD9)-=;10!XQ=>%+JV.
MUH7)QGY1O'YKD?AUHM?"EU<G:L+@XS\PV#\VP/PZU[/15<PK',>$O!BZ-^^E
MPTQS@C[JCVR!R>Y_ =\]/114C"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KR_QOH<\UV\B1NRL$(*J6'"@'IG'(/!Y_"O4**:=@/)]
M\#3Z@X\U6CB!^8L,-QC@*>><]<8'/4C!]2L[-+-!#& J*, #_/YGJ3R:FHH;
MN%@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %1SVZW"F-U#*>H8 @XYZ&I** ,__ (1^V_YX
MQ_\ ?M?\*N06ZVZB-%"J.@4  9YZ"I** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &R1B0%6 (((((R"#U&*H_\ "/VW_/&/_OVO^%:%% $-K9I:#;&J
MH"<X50HSZX%3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #6;;R:9]I7U_G1<_=/^>]4* +_VE?7^='VE
M?7^=4** +_VE?7^='VE?7^=4** +_P!I7U_G1]I7U_G5"B@"_P#:5]?YT?:5
M]?YU0HH O_:5]?YT?:5]?YU0HH O_:5]?YT?:5]?YU0HH O_ &E?7^='VE?7
M^=4** +_ -I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G
M5"B@"_\ :5]?YT?:5]?YU0HH O\ VE?7^='VE?7^=4** +_VE?7^='VE?7^=
M4** +_VE?7^='VE?7^=4** +_P!I7U_G1]I7U_G5"B@"_P#:5]?YT?:5]?YU
M0HH O_:5]?YT?:5]?YU0HH O_:5]?YT?:5]?YU0HH O_ &E?7^='VE?7^=4*
M* +_ -I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@
M"_\ :5]?YT?:5]?YU0HH O\ VE?7^='VE?7^=4** +_VE?7^='VE?7^=4**
M+_VE?7^='VE?7^=4** +_P!I7U_G1]I7U_G5"B@"_P#:5]?YT?:5]?YU0HH
MO_:5]?YT?:5]?YU0HH O_:5]?YT?:5]?YU0HH O_ &E?7^='VE?7^=4** +_
M -I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_\
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MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?%PIXS4M9T74?45HT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #67=P:9]F7T_G4M% $7V9?3^='V9?3^=2T4
M1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E
M]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT
M?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]
M/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+
M10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%
M]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T
M_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]
MF7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_
MG4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M%
M $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V
M9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^
M='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9
M?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=
M2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4
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MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"(6ZCG%2T44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7(:]X_\ [)F:V\K=LV\[\9RH;IM/KZUU]>0^//\ C]E_X!_Z M-(3.EL
M_BBDCA9(BB$\L'W8]\;1GW[XZ9Z5W->!5WWP_P#%?_+C.WH(B?\ T#/Y;?RS
M]T4V@3._HHHJ1G(:]X__ +)F:V\K=LV\[\9RH;IM/KZT:#X__M:9;;RMN_=S
MOSC"ENFT>GK7(>//^/V7_@'_ * M'@/_ (_8O^!_^@-565A7/7J***D84444
M %%%% !117.>.]6ETN!986VL9 "< \%6/<'TH Z.BO+='\:7=Q/%$\F5>1 1
ML09!8 ]%KU*FU8+A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M(U#XE?8Y7@\G/ENRY\S&=I(SC97;UXEX@_X^9O\ KM)_Z$::0F>G>%?%7]O[
M_DV>7M_BW9W9]AZ5OUP'PJ_Y;_\ ;/\ ]GKOZ'N-!1112 **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** .'U#XE_8Y7@\G/ENRY\S&=I(SC8?2NPT^[^V1)/C'
MF(K8SG&X XSQZUXQXA_X^9_^NTG_ *&:]?\ #W_'M!_UQC_] %4T3%MLT***
M*DHY_P 5^*_[ \OY-_F;OXMN-N/8^M'A3Q7_ &_YGR;/+V_Q;L[L^P]*Y_XK
M?\L/^VG_ +)1\*?^6_\ VS_]GJK:$W?-8] HHHJ2@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,_7M6_LF%[G;NV;>,XSE@O7!]?2N?T'X@_P!K
M3);>5MW[N=^<84MTVCT]:T/'O_'E+_P#_P!&+7 > O\ C]B_X'_Z+:J2T);=
MSU^BBBI*"BBB@#F=?\=Q:1)]GVL[ KNQP ",]^IQ@XX'/W@:W-,U)-2C6XCS
MM<<9&#P<$?@1CT].*Y/Q9X#?5)C<PLH+@;@Y(P0 !@@'J!W[]^<#J-$TH:5"
MELI+! >3QDDDGCZGCV[GK3=K"5[EZBBBD,**** "BBB@ HHHH *X?3_B7]LE
M2#R<>8ZKGS,XW$#.-@]:[BO$/#W_ !\P?]=H_P#T,4TB9.Q[?7,Z_P".XM(D
M^S[6=@5W8X !&>_4XP<<#G[P-=-7$^+/ ;ZI,;F%E!<#<')&"  ,$ ]0._?O
MS@"L-W.LTS4DU*-;B/.UQQD8/!P1^!&/3TXJU5'1-*&E0I;*2P0'D\9)))X^
MIX]NYZU>I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKR_XH?\?*?]
M<5_]#>NP\!?\>47_  /_ -&-3MH)/6QT%<OXH\;?V%*(/+W[D#9W[>I(QC:?
M2NHKR_XH?\?*?]<5_P#0WH2NPD[([CPOX@_MV(S[-FURN-V[H <YP/6MBN/^
M%_\ Q[/_ -=F_P#0$KL*'N"V"BBBD,**** "BBB@ HHHH **** "BBB@"OJ%
MW]CB>?&?+1FQG&=H)QGGTKE]!^(/]K3);>5MW[N=^<84MTVCT]:Z#Q#_ ,>T
M_P#UQD_] ->8> O^/V+_ ('_ .BVII:$MZH]?KD]3^(L-C,8-K,$+!V&!@CT
M!Z\\'./49KK*X'6OAP]W.TT;J$D;<V[.X%CEL #!]N1Z'U(K#=SNK>X6X594
M.5< @],@C(ZU)4-G:BT185SA%51GKA1@5-2&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %74]2338VN),[4'.!D\G 'XDX]/
M7BL/0/'<6KR?9]K(Q+;<\@@#/;H<9..1Q]XFMC6]*&JPO;,2H<#D<X(((X^H
MY]NXZUR_A/P&^ES"YF924!VA"3DD$')('0'MW[\8+5K"=[G;5E^(/$$>B1^:
M_+'[JCJQ_H!W/;W) .I7F/Q0D)N$3)P(@0,\9+-DX]\#\A0E=A)V02?%"X))
M5(P,G (8G';G<,_D/I7:>$]?.N0F9E"E6VG!R"0JDGVZ].?J:YOP9X,M[VW%
MS."YD)P,E0H4E?X2,YQGGV '4GKM-T*'3D:"-?W;DDJWS#E0I'.>#COGJ>W%
M-V%&YS__  LRW\WR]K>7TWX[YQG;UVXYSU[;:["O._\ A5S>=_K!Y&>O/F8]
M,8VY[9S[X[5Z)2=AJX4444AA1110 4444 <OXH\;?V%*(/+W[D#9W[>I(QC:
M?2L?_A:W_3#_ ,B?_85T6O>#8=;<32LX(4+\I4# )/=3ZUF_\*OMO[\O_?2?
M_$52L2^8S_\ A:W_ $P_\B?_ &%'_"UO^F'_ )$_^PKGO&6@IHDRPQ%B#&&^
M8@G)9AV ]*W?#/@.#5+=+EV<,^[(4J!PQ'=3Z4[(5Y7)/^%K?],/_(G_ -A7
M8:#JW]K0I<[=N_=QG.,,5ZX'IZ5S_P#PJ^V_OR_]])_\172:1I:Z7$MLA)5,
MX+8)Y)/8#UJ78:N7****104444 %%%% !1110 4444 %%%% !7/^*_%?]@>7
M\F_S-W\6W&W'L?6N@KS_ .*W_+#_ +:?^R4UN*3LCH/"GBO^W_,^39Y>W^+=
MG=GV'I6AKVK?V3"]SMW;-O&<9RP7K@^OI7'_  I_Y;_]L_\ V>N@\>_\>4O_
M  #_ -&+0UJ)/0S]!^(/]K3);>5MW[N=^<84MTVCT]:["O(/ 7_'[%_P/_T6
MU>OT25@B[H****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M#Z?\2_MDJ0>3CS'5<^9G&X@9QL'K7<5XAX>_X^8/^NT?_H8II$R=CV^BBBD4
M%<OXH\;?V%*(/+W[D#9W[>I(QC:?2NHKR_XH?\?*?]<5_P#0WII78I.R-#_A
M:W_3#_R)_P#84?\ "UO^F'_D3_["H_ ?AFWU2!I9DW,)" =S#@*I[$>M=)_P
M@5E_SR_\?D_^*IZ$KF9CV/Q1CE;;+&44_P 0;?CGN,+Q],GV-=E9WB7B":,A
MD89!'^?S'4'@UYSXK\!+I<1NH7)5-N5?!/)QD$ >HXQZG/:H?AQJSV]P+7)*
M2AN,\!E&=WY#';/&>@H:5AIM.S/4J***DH**** "BBB@ HHHH **** "BBB@
M HHHH S]>U;^R87N=N[9MXSC.6"]<'U]*Y_0?B#_ &M,EMY6W?NYWYQA2W3:
M/3UK0\>_\>4O_ /_ $8M<!X"_P"/V+_@?_HMJI+0EMW/7Z\__P"%K?\ 3#_R
M)_\ 85Z!7@%$5<)-H]_HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_7OB#_9,
MSVWE;MFWG?C.5#=-I]?6NPKR#Q[_ ,?LO_ /_1:TXJY,G9'J^GW?VR))\8\Q
M%;&<XW '&>/6K%9_A[_CV@_ZXQ_^@"M"D4%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KVK?V3"]SMW;-O&
M<9RP7K@^OI7/Z#\0?[6F2V\K;OW<[\XPI;IM'IZUH>/?^/*7_@'_ *,6N \!
M?\?L7_ __1;526A+;N>OT45Y_P#%;_EA_P!M/_9*25QMV1Z!17'_  O_ ./9
M_P#KLW_H"5V%)@G<S];UN/1H_/ESC( "C))/Y#H">2.GK6?X9\8QZZ3&%*2*
M,E3R,9QPW'J,Y Z\9ZU8\5:!_;</D@[64AE/;(!&#['/;IUYZ'+\&>#&T1FG
ME8%V&T!,[<9!))(!SD?A[YX>E@UN=91112&%%%% !1110!Q^O?$'^R9GMO*W
M;-O._&<J&Z;3Z^M=!H.K?VM"ESMV[]W&<XPQ7K@>GI7F'CW_ (_9?^ ?^BUK
MO_ 7_'E%_P #_P#1C536A*;N=!1114E!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%>0>/?\ C]E_X!_Z+6FE<3=CU^BL_P /?\>T'_7&
M/_T 5H4AG/\ B;QC'H1$94O(PR%' QG'+<^AQ@'ISCK6AHFMQZS'Y\6<9((8
M8((_,="#P3U]:P_&?@QM;99XF =1M(?.W&2000"<Y/X^V.=3PKH']B0^23N9
MB68]LD 8'L,=^O7CH'I86MS8HHHI#"BBB@ KE_%'C;^PI1!Y>_<@;._;U)&,
M;3Z5U%>7_%#_ (^4_P"N*_\ H;TTKL4G9'<>%_$']NQ&?9LVN5QNW= #G.!Z
MT>*/$']A1"?9OW.%QNV]03G.#Z5C_"__ (]G_P"NS?\ H"4?%#_CV3_KLO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_4<\'I]#D#6KQ+3;^309]XR&C8JZ@CD X92>1SCKS@\CD"O:;>X6X594.5<
M@],@C(ZTFK%1=SA_$WCR?2[A[9%0JFW!8,3RH/9AZUU'AG5&U2W2Y< ,^[(7
M('#$=R?2O-/'O_'[+_P#_P!%K7?^ O\ CRB_X'_Z,:FUH)/4K^-O%$NA>7Y0
M4^9OSO!/W=N,8(]:KZ5X]4VQNKK ;S"JK&.3@*>C-VSR<@=.Y&<_XK?\L/\
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M^('B!]+B6.(D/,2-P[*N-V#G@\C!],]#@UR'@KPK_;3F23(AC(SU&X_W0?\
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M3BM"O%O"^LG2)UER I(5\C/R$C=TYXQD8[CN.#[#?WZ:>AGE.U%QDX)ZD <
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MX,UTZ3.O39(0KY.  3][T^7W[9'&<T63"[3U/8:S=<\01:*@DE)Y. J\L?7
M)'3N>GXD W+RZ%HC3-G"*S''7"C)KQJ:XF\27 W',DA '7:H^@SA1U/7N3DY
M-)*Y4G8W[CXHSLQ*1H%[!MS'\P5_D*DL?BC*&_?1J4[^7D,.>O)(/';C/J*Z
MC2? ]M8*,H)'Q@LXSGOG:<J/;C..YYS5\0^!(+Q'>! DV,KMX4D#[NW(49]1
MCGD]\NZ%:1M:-KL.L+YD+9QC<#PP)&<$?U&0<'!.*T*\6\+ZR=(G67("DA7R
M,_(2-W3GC&1CN.XX/M-)JPXNY3U;5H]*C,\IPH_,GL .Y/\ ]<X )K@[[XHR
MEOW,:A.WF9+'GKP0!QVYQZFL#Q!K<FOS;N2N<1H!T!/' S\QXSUR>.@ ';Z-
M\-X;=?\ 2/WCG'0LJCCD#!!//<^W YR[)$W;V,.W^*,ZL"\:%>X7<I_,EOY&
MNR\.>*HM<!"95U W(W7ZCU&>,\'U R*HWWPZM9UVQ@QMV8,S=NX8G(^F#[BL
M_P ,^ 6T^<SRMQ&?W>PD;N.IQT'."O<YSE?O#L-<R.D\3:HVEV[W* %DVX#9
M(Y8#L1ZUR_AGQY/JEPELZH%?=DJ&!X4GNQ]*W/'O_'E+_P  _P#1BUP'@+_C
M]B_X'_Z+:A+0&]3T'QEKSZ)"LT04DR!?F!(P58]B/2O,->UY];<32A00H7Y0
M0, D]R?6O8=4TB+5%$4R[E!R!DCD CL1ZUYAX\TB+2YUBA7:IC!(R3R68=R?
M2B-A2N&D>/)]+B6V14*IG!8,3R2>S#UJW_PM"Y_N1?\ ?+__ !=;'A'PC:ZA
M:QSRQ[G;=D[G'1V X# =!6Q_P@5E_P \O_'Y/_BJ&T"3.9TKXC7%W-'"RQX>
M1%.%;.&8 _Q5Z-7B'A[_ (^8/^NT?_H8KV^B2'%W(;R\2S0S2$*BC))_S^0Z
MD\"N!U+XHL6Q;Q@*.\N23T[*1C'/<Y]JRO'7B!]0G:#)$4+%0O3YAPS'DYYS
MCT'8$G._X:^'<>P3766+J#L^9=N>>2""3CMP <CG@T62!MMZ&7'\4+@$%DC(
MR,@!@<=^=QQ^1^E=9X;\:Q:T?*P4EQG:3D'KT/&<#DC /ID FFW'P]LY5*A"
MI/\ $KMD?]]%A^E8>F?#9K>X#2/F)-K!ERK,?3@Y7!')!Z8QR3M-&'O(] HH
MHJ2@HHHH \O^*'_'RG_7%?\ T-Z[#P%_QY1?\#_]&-7'_%#_ (^4_P"N*_\
MH;UV'@+_ (\HO^!_^C&JGL2OB9T%%%5[^_33T,\IVHN,G!/4@#@ GJ:DHL45
MS_\ PGME_P ]?_')/_B:/^$]LO\ GK_XY)_\33LQ71T%%9>E^)K?5&,4+[F
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ME=-X0UDZO;K*Y!<$J^!CD?IR""<<9/;H.9^*W_+#_MI_[)26XY;!\*?^6_\
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M ?O29P>O100?0@D@]BM9\?Q0N 062,C(R &!QWYW''Y'Z5N:%\.88DS<@N[
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M<D]!CTHB@DSUOPQJ$VHP"XG"J7)*A0P^7L2&)Z\D=B,&M:H[>W6W58D&%0
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MF"O\A6!-<3>)+@;CF20@#KM4?09PHZGKW)R<FO0=-^'-M;IME!D?)RQ+)]
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MEP SXR%R!P .Y/I7K^J>&;?5&$LR;F P#N8< D]B/6O+/%U@FGW4D$0VHNW
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M#CMD$?K7E"2/HL^5(WP2$<$X)4X(['!Z'ID4[)BNT>XUY?\ %#_CY3_KBO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  #_ - 6O7J\A\>?\?LO_ /_ $!:408> _\ C]B_X'_Z U>O5Y#X#_X_8O\
M@?\ Z U>O42!&!X\_P"/*7_@'_H:UY#7K'Q#NA#:,ISF1D48]0=W/X*?QKR>
MG'8&>V^'_P#CVA_ZXQ_^@BN!^)W_ !\I_P!<5_\ 0GKOO#__ ![0_P#7&/\
M]!%<#\3O^/E/^N*_^A/26X/8Y2W@:X98D&6<@ =,DG ZU['H'AN+14"H 7Q\
MSD?,<XS]!QP.GU.2?*/#_P#Q\P_]=H__ $(5[;3D""FR1B0%6 (((((R"#U&
M*=7 ?$+Q.T;&PB.!@>81G//.SZ8P3CKG'J#*5QFM;3:=X:8A64.Q8'!:1A@Y
MVG&=N.F."<<Y(S4-Q\3;=-P178C.. %..G).0#],^W:O.].TR34G\J%2S8)P
M,#@=R3@#\>_'6NGL_AE/)@R.B CG&68<=,8 //!^;'IFJLA7.:U>^6_E>=5V
M!SG;G=R>O/'4Y/MG%='\,?\ CY?_ *XM_P"A)6!KVE?V3,UMNW;-O.,9RH;I
MD^OK6_\ #'_CY?\ ZXM_Z$E-["ZGIU>)>(/^/F;_ *[2?^A&O;:\2\0?\?,W
M_7:3_P!"-*(V==\*O^6__;/_ -GKOZX#X5?\M_\ MG_[/7?TGN""BBBD,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&O&5J+:\F1<X+;N?5P&/ZGCVKTWPA
M=_:K2%\8PFWKG[AV9_'&:Y?XF:']V^0>BO@?]\L<#\"2?[H%8G@[Q;_8;,C@
MM$_) Z@CN 2!ST/3MSQ@UNB%HSUNBL^W\06UP 5E0Y&<;P#@#)R"<C Y.>G>
MJ.K>-+;3T+AUD;!VK&P;)]R,A>O?MG )XJ;%7.9^*EPK-#$#\RAR1[,5 _\
M03^53?"J,@3O@X)C ..,C=D9]LC\Q7%7][)J\QF89DD(X4?0  #\ .I^IKUO
MPIHO]D6ZQ'[Y^9_]X]1U(X&!QP<9[U3T5B5J[FQ7A6E(DDT:RXV&1 V3@;2P
MSSQCCO7NM> 41"9[_17,^%_&D6I(L<C!9\ $-QN/ R#@#YB?N]<YP,#-;E_J
MD6GC=,ZH,$C<<$XZX'4_09-38JYP_P 58P# ^!DB0$XYP-N!GVR?S-:7PO\
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M21GC(9<''MD_F:WOBA_Q[)_UV7_T!ZC^&NB-:QM=.,&7 7(YVCG.>N&)Z<=
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M*<5H*3U/;Z\@\>_\?LO_  #_ -%K7K]>0>/?^/V7_@'_ *+6B.XY['?^ O\
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MWY# @C+L>AK/3XB027 @!_=$?ZP@@;CC'7&%'()(Z^@&3UE#8XI'(^+/'?\
M9#FVB4-( ,EL[5S@@8&"<CW ''7D#D!XBU#5051I&"D$^4F",YQDQ@'UX/'Y
M5F^(?^/F?_KM)_Z&:]CTCR?)3[/CRL?+MZ8_GG/7/.<YYS1L+5L\JO/"M[(I
MNI48C;N9G=2V ,\@MNX Z=>V*=X"_P"/V+_@?_HMJ[/Q]XB6SA:V1@99/E(!
M!*J1EB1@XR#@9P><CI7&> O^/V+_ ('_ .BVIWNA6LSUNXMUN%:)QE7!!'3(
M(P>E>7:]\/Y[ EX09(\\;>7 XQE>_7^'/3) KT^\O$LT,TA"HHR2?\_D.I/
MK%T3QM;ZJ=F=CDD!7XR,X7!Z$G(XSG.>H&3*;1;29YM:ZW=Z*?*5W0J,;&'
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MI%4X!P3EL$XR%&2>?047'R^9Y!)H5U*2[12DDDDF-R23U.<5Z[XA_P"/:?\
MZXR?^@&LOPWXTCUEWA^XV3L!ZLH [Y^]U)'8=,X)KH+BW6X5HG&5<$$=,@C!
MZ4FPBCR+P-&)+V(, 1ECR,\A&(/X$9'O7L->(7]H^AW!CS\\+@J<#MAE;'(Y
M&#CGT->KZ%XIAUA5*L%D;K&6&[(&3@=QWR.WH<@.0H/H;%%4]2U>'3%WS.%!
MZ9ZGH. ,DXSS@<=ZYO2/B/#=R-'*/+4D>6Q[C@8;'0]\] .">,E6*NC0\>_\
M>4O_  #_ -&+7 > O^/V+_@?_HMJ[_Q[_P >4O\ P#_T8M<!X"_X_8O^!_\
MHMJ:V)E\2/7Z\O\ BA_Q\I_UQ7_T-Z]0KR_XH?\ 'RG_ %Q7_P!#>E'<<MCL
M/ 7_ !Y1?\#_ /1C5T%<_P" O^/*+_@?_HQJZ"A[C6QXAX>_X^8/^NT?_H8K
MV^O$/#W_ !\P?]=H_P#T,5[?3D*!X=H48EN(48 @RQ@@C((+#(Q7N->,>*]%
M_LBX:(?</S)_NGH.I/!R.>3C/>O0_"WC"+4XU61@LPVJ0Q W$\ KTSGT'0\>
MA)+44=-#I**KWVH1V"^;*P51W)]LX'J>.@Y-<K!\2H7G:-@1#CY7P2<C.25
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M$UQ/_"J?^F__ )#_ /LZ[JSM1:(L*YPBJHSUPHP*FI7L5:YY_P#\*I_Z;_\
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M,8Z=B<\\;/PI_P"6_P#VS_\ 9Z?V2;WD=!X]_P"/*7_@'_HQ:X#P%_Q^Q?\
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MH%'_ -;J23CFO7]#TW^S8([?C**,X)(W'ECSSR235/8B.K/+O'O_ !^R_P#
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M\_\ D6H;JSO[L;)5G< YPRR,,^N#7L/VA=OF[ALQNW9&W&,YSTQCG-<SKGQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI4>O5L ?G74Z%\,SG?=D8P"$0\YZD,<?A\IY[,,<^A44W)B44-CC$0"*
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M SSU/)]L 5U%%%3<I*P4444 %8?B;PI'KJC)VR+T<#/'<$9&1Z<\'IW!W**
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M+CUG,R_)-C@_PMCIN&/PR.1[X KI**0VKGCE]X*N[/DQEAG ,>'S[X&6QQW
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M#AL<]@?;FO8Z*KF9/(CF_"_@N/1L3-\\V.3_  KGKM&/PR>3[9(KHI(Q*"C
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M69\;F/? [#L.3ZGGDGBMBBBI*.;\4>"X]9S,OR38X/\ "V.FX8_#(Y'O@"N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YSI7PYN+2:.9FCPDB,<,V<*P)_AKT:BFG835PHHHI#"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L'QEH+ZW"L,14$2!OF) P%8=@?6MZB@&<OX)\+
MRZ%YGFE3YFS&PD_=W9SD#UKJ***'J"5@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ,'QEH+ZW"L,14$2!OF) P%8=@?6JO@
MGPO+H7F>:5/F;,;"3]W=G.0/6NHHIW%;6X4444AA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5=
M5M3=PR0KC+QNHSTRRD"N-\,^ Y]+N$N79"J;LA2Q/*D=U'K7>44[B:N%%%%(
M84444 %%%% '"^*/ <VJ7#7,3)APO#%@00 O8'/3/;TQW)X?^&WV9Q+=,K[3
MPBY*GI@DD#/?Y<8/&21D5W5%.[%RH****0PHHHH **** "BBB@ HHHH ****
M "BBB@#!\9:"^MPK#$5!$@;YB0,!6'8'UJKX)\+RZ%YGFE3YFS&PD_=W9SD#
MUKJ**=Q6UN%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A^+] ;6
MX1"A 97##=G!P",9&<=<]#TQ[UN44 >9V_PNG9@'D0+W*[F/Y$+_ #%>@:3I
M,>E1B"(84?F3W)/<G_ZPP !5RBFW<2204444AA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2NDH!.X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4453U;5H]*C,\IPH_,GL .Y/_ -<X )H N45P,GQ5 )"P
MDC)P3)@X[<;3C\S]:ZKP[KZZY%YZ K@[2#CJ "<$=1SUX^@IV8DTS4HHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBL_6==AT=?,F;&<[0.6) S@#^IP
M!D9(S0!H45GZ-KL.L+YD+9QC<#PP)&<$?U&0<'!.*T* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***Q=7\7V^E.(9&.\D9"C.T'N?\.6P00*
M -JBH;.\2\031D,C#((_S^8Z@\&IJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHJGJ^J+I<37+@E4QD+@GD@=R/6@"Y17-Z1X
M\@U25;9%<,^<%@H' )[,?2NDH!.X45Q__"T+;^Y+_P!\I_\ %UV%%A)W"BBB
M@84444 %%%% !115/5]472XFN7!*IC(7!/) [D>M %RBN;TCQY!JDJVR*X9\
MX+!0. 3V8^E=)0"=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BL'7O&4.B.(95<DJ&^4*1@DCNP]*
MN:#KR:VAFB# !BOS  Y ![$^M%A7-*BBB@84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1139)!$"[$  $DDX  ZG- #J*X>^^*,<3;8HRZC^(M
MLSSV&&X^N#["M3POXT776,.PHZ@MU#+@$#KP<Y/3'XT[,7,CI****0PHHHH
M***Q_$'BB+0MGFACYF[&P _=QG.2/6@#8HK-T'7DUM#-$& #%?F !R #V)]:
MN7EXEFAFD(5%&23_ )_(=2>!0!-16+I'B^WU5S#&QW@G 88W =Q_APV 216U
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7+60%6EB((((,B$$'J,9J;ZCL>.:?8M?R+ GWG( Z_F<9X'4^@KW6LFPO+.
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M$RYQTSA*Z>AL2"BBJM_JD6GC=,ZH,$C<<$XZX'4_09-(9:HK _X3RR_YZ_\
MCC__ !-6;#Q5:WQVQRKG(&&RI)/0 ,!G\,T6 UJ*** "BLO5/$MOI;"*9]K$
M9 VL>"2.P/I5>W\:6EPRQ))EG( &QQDDX'5:+ ;E%4]2U>+3%WS.%!Z9ZGIT
M Y.,\X'%9G_">67_ #U_\<?_ .)HL!OT5'!<+<*)$8,IZ%2"#CCJ*DH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_B<UPRQ)!EG( 'FXR2<#JE"5P;2-SQ[_P >4O\ P#_T8M<!X"_X_8O^!_\
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M"@C&06_P!Y&#BG9BYD=-17 Q_%4$@-"0,C)$F3COQM&?S'UKL-)UJ+5D$D+
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MAS7MNK:-%JJ&.50>#@_Q+GN#VZ#V/?(KQ:\M3:.T+8RC,IQTRIP:$[@T>O\
MA36O[7MUE/WQ\K_[PZGH!R,'C@9QVJQX@_X]IO\ KC)_Z":Y+X5R$B9<G ,9
M SQD[LG'O@?D*ZWQ!_Q[3?\ 7&3_ -!-2]QGB57HM9EAA-HC%4+%FV\$[E"X
M)],#ITYYSQBC78^ O"J:EF[EP41L!/5@ <GV&1QW/7@8-,1QU%>]QQB,!5
M    P !T&*X3QSX-1$-Y;@+L WHHX(Z;@!TQW[8YX(.4I#L4/ WBM[>1;25B
MT;D*NXDE3C"@=>#P,=!UXYSZ97@5>U^'-1_M&WCG.<LO)( RR_*QP..2#CV]
M*)($<'\3O^/E/^N*_P#H3UG^ _\ C]B_X'_Z U:'Q._X^4_ZXK_Z$]9_@/\
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M+_C]B_X'_P"BVKT'QS(8[*4J2#A1P<<%U!'X@X/M3DM0B]#S;6-9F\1S#/\
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MXZX/?D/^$]O?^>O_ (Y'_P#$T?\ ">WO_/7_ ,<C_P#B:=F%XE'1M5?0YQ,
M<H2&4Y7(Z%3_ /7Z$ XXKVN.02@.I!! ((.00>AS7A%Y=M>.9GP68Y) "Y/K
M@ #Z^IYZU[3X>_X]H/\ KC'_ .@"E((&A1139)!$"[$  $DDX  ZG-26>;WG
MPWGEG(5P8F.[S'.6Y/((ZEN^> ?4$X'10_#FTC4H0S$YPQ8[AD=L87CKR#[Y
M'%9.L?$_8=MJ@(!^])G!Z]%!!]""2#V*UB2>-K[46,<;$%P0$B0$].<<%O?.
M<CMBJU(]U$/C'PR-"D4(28Y!E2V,Y'WAQCU!S@=<=C7>^!-6?4[8-(26C8H6
M)R3@ @_D<=R<9)R:\RU;[3\OVKS>^WS=_MG&[\,X]J[_ .%__'L__79O_0$I
MO8([FAX]_P"/*7_@'_HQ:\JTVU>\<6\6<RD+WQC(/.,\#&3Z8SVKU7Q[_P >
M4O\ P#_T8M<;\,HP]TQ(!*Q,1D=#N49'X$CZ&DM@EJS>M_A= J@/(Y;N5VJ/
MR(;^9KDO%WAC^P74 EDD!*D@ \'E>#S@$<X .>!7L-<?\4/^/9/^NR_^@/0F
M[C<58X;1=+E\0RK!N/RKU8YVHO' )[9X [GL,D=S_P *OMO[\O\ WTG_ ,16
M?\*?^6__ &S_ /9Z] H;U"*5CQ+Q!H;Z+*8'(/&5([J<@'';IR/7U&"?6?#&
MI-J=M'._WF!!]RI*D\ =<9QVSBN#^*'_ !\I_P!<5_\ 0WKH/A?_ ,>S_P#7
M9O\ T!*'JA1T9>\:^)#HL0\O'FR$A<]@.K=,'&1@'N<\@$5YYH'AV7Q$[$,
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M97D2$(P]G('H>AP??&.]>NWEJ+M&A;.'5E..N&&#7B6LVZV\\L2#"I(X ZX
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M 8-\I .0".X/K7F'C+04T2988BQ!C#?,03DLP[ >E>PUY?\ %#_CY3_KBO\
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MJ,CK@+CK[D_7UY3QGX/71 DL18HQVG=C(;J.F.HSVXQUY%-F^(%[=L!&0I.
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M?',ACLI2I(.%'!QP74$?B#@^U(;/-M8UF;Q',,_Q$+&@/ W' &3CD]R>OL
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MJ-K'!_$ _45.[*T2T.$:2?Q/< $@R2' R<*H&3@>@ R>Y/N3SW]A\.+6W&)
MTA(&2S%1D=<!<=?<GZ^OFVEZO+I;&6%MK$8)P#P2#W!]*U/^$]O?^>O_ (Y'
M_P#$U33)31L^+/ *6,;75N6PI)9#\WRD]L#/R]\YXYSQS3^'>NFSF^RMC9,>
MYQA@#C';YNGJ3CGC!H2>.;R4%&D!!!!!CC((/48VU1\/?\?,'_7:/_T,46T"
MZOH>WUYK>?#>>6<A7!B8[O,<Y;D\@CJ6[YX!]03@>D22"(%V(  )))P !U.:
MX/6/B?L.VU0$ _>DS@]>B@@^A!)![%:E7*E8UH?AS:1J4(9B<X8L=PR.V,+Q
MUY!]\CBN(\8^&1H4BA"3'(,J6QG(^\.,>H.<#KCL:FD\;7VHL8XV(+@@)$@)
MZ<XX+>^<Y';%9.K?:?E^U>;WV^;O]LXW?AG'M5),EM'IO@35GU.V#2$EHV*%
MB<DX (/Y''<G&2<FN;^*5^2\=MSA5+GG@EB5''MM//N?QUOA?_Q[/_UV;_T!
M*N>-O#+:W&K1G]Y%N*@]&SC(SV/ P>G8]<A;,K>)S?@7PC#J<;7,WS\E0@++
M@C!R2,9//&. .N3P-;6/AK#<#-N3&P'0DLAZ^I)&3CG) '\.:X+_ $C09?XH
MI!^&0#^3*2/<''>NCTGXF30D+<*'7NRC:_7K_=.!VP,\<TVF)-'<>'_#\>B1
M^4G+'[S'JQ_H!V';W))-'QKXD.BQ#R\>;(2%SV ZMTP<9& >YSR 16MI.K1Z
MK&)XCE3^8/<$=B/_ *XR"#7GOQ0D)N$3)P(@0,\9+-DX]\#\A4K5C;LC,\,>
M'7\12DLQV*09&)RQW9X&>I.#R>!U.> >[3X=V:IL*L3@_.7.[GOQA>.W&/7-
M>=:7XFN-+4Q0OM4G)&U3R0!W!]*N?\)[>_\ /7_QR/\ ^)JFF2FB3QCX2_L-
ME="6B?@$]01V)  YZCIWXXR>I^'&NF\C-H^,P@;3GYBI)['^[P..,$# [\1J
M7BJYU)/)F<,N0<%$'([@A01^';CI6S\+_P#CY?\ ZXM_Z&E#6@)ZGHUUJL-H
M=DLB(2,X9U4X]<$U#_PD-M_SVB_[^)_C7.^,O!LVMS+-$R ",+\Q8'(9CV4^
MM8/_  J^Y_OQ?]]/_P#$5-D4VST#_A(;;_GM%_W\3_&KEO<+<*)$8,IZ%2"#
MCCJ*\S_X5?<_WXO^^G_^(KO/#.EMI=NELY!9-V2N2.6)[@>M#2&FSR[QC?F]
MNY6.<(Q0 G. GR\>F2"<>I_&NUT'P%:F%'E'FLX#;LNHPP!  !7CZC)]N@H^
M.O!LEU(;V#+E@-Z\9&U<9'KP.G7/3.>.0T_6[C1BR1.R')!4C(SQGY6! /&,
MXSVJMT1L]3M;SX7QO(&C<K&3\RGD@<GY6_(#(..22>A[*SLTLT$,8"HHP /\
M_F>I/)KA]'^)^\[;I  3]Z/.!TZJ23ZDD$GL%KO(Y!* ZD$$ @@Y!!Z'-2[E
MJQY%X]_X_9?^ ?\ HM:=X7\+/XA;>S$1H5#,<EB .%7((X  Z_*".#TIOCW_
M (_9?^ ?^BUKTGPI:BVM(47.#&&Y]7^8_J>/:J;LB4KLQ?\ A5]M_?E_[Z3_
M .(KBO$_AA]!<*Q#(X.U@,9QC((R<8S]"/Q ]EKF_B%;K+9NS#E"A7V.X+_)
MC23=QN*L1^ ?$#:K"8Y,F2' +'G<&SM/U&,'/7KDDG&EXGUS^Q8#/@%B0J@Y
MP6/T] ">V<8R":X7X7_\?+_]<6_]#2M+XJR$"!,G!,A(SQD;<''MD_F:+:A?
MW3EM+TZ;Q-<$%LLWS.[=@, G'X@ #V' Y'H-K\.[.$896<YZLY!^GR[1^F:\
MVTG7IM)W>0VW?C/RJ<XSC[P/J:T/^$]O?^>O_CD?_P 33:9*:+OC#P0-'07$
M)9DSA@W)!/0Y  QVYZ''7/&A\,]=.38-C&"R$GG/&5 /XMQT^8\YXYR\\8W5
MXAAD<,C#!!1/_B?R/4'D5-X"_P"/V+_@?_HMJ+:!?4])\3ZY_8L!GP"Q(50<
MX+'Z>@!/;.,9!->6:?I\_B:=@"#(P+,SG P,#L/H  ... !QU?Q5D($"9."9
M"1GC(VX./;)_,U:^%UNJP22@?,TF"?95!'_H1_.DM%<;U=AT?POMP &>0G R
M05 SWXVG'YGZUCZ]\-GM@9;9BZ@9V-]_C'3 PW<XP#V&37I5%+F97*C!\&Z)
M)I$ CE8DDYV\%4SV!_4\XST[D\[\5O\ EA_VT_\ 9*] KS_XK?\ +#_MI_[)
M0MQ2V#X4_P#+?_MG_P"SUT6O>#8=;<32LX(4+\I4# )/=3ZUSOPI_P"6_P#V
MS_\ 9Z] H>X16AX5JMJ+2:2%<X21U&>N%8@5Z+_PJ^V_OR_]])_\17 >(?\
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M@8C#1D X*L6&3TR&ST]B/KZ<5_PGM[_SU_\ '(__ (FC_A/;W_GK_P".1_\
MQ-.S%>)G_O=!N/22%_< X_(E6'TR#[U[+I=^-0B2X7&'4' .<$]1GV/!]Q7B
MFI:G)J3^=*07( )"JN<=,[0,_7KCCM7JO@+_ (\HO^!_^C&I2"&YQ_Q0_P"/
ME/\ KBO_ *&]=!\+_P#CV?\ Z[-_Z E<_P#%#_CY3_KBO_H;UT'PO_X]G_Z[
M-_Z E#V!?$'Q0_X]D_Z[+_Z ]<_\+_\ CY?_ *XM_P"AI70?%#_CV3_KLO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_\ CYA_Z[1_^A"O;:\2\/\ _'S#_P!=H_\ T(5[;3D"/$O$'_'S-_UVD_\
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MF<\9QQZ8S[55KDIM'L.K:U%I*&29@.#@?Q-CL!WZCV'? HT75DU:);A".1R
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M7GDYW)@$^G0J./0_CS5]J;7B11L3B%"HRQ/\1.<=N"%^BCZ#U/QSI+:E;,J
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M%+,=F H))PZGH*5K,=[H\\\!?\?L7_ __1;5Z_7EG@K1I[>[CD>)U4;\ED8
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M-[2W9)59"96.&4J<;5YP:3V!7N6O'O\ QY2_\ _]&+7'_"__ (^7_P"N+?\
MH:5VGC6W:XM)(T4LQV8"@DG#J>@KE?ASI4UI<,\L;H#$PRR,HSN7C)%"V&_B
M/1JX_P"*'_'LG_79?_0'KL*Y7XC6;W=NJ1*SD2J<*I8XVMS@4EN.6QD_"G_E
MO_VS_P#9Z] KA_AII\MGYWFHR;O+QO4KG&_.,@>M=Q1+<(['E_Q0_P"/E/\
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M@\'(/X$9]/7BDAL\L\":;%?W(2;!"J652>&8$<8[\9./;GC(KUN.,1 (H
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M9_B'_CVG_P"N,G_H!K0JCKL9EMYD4$DQ2  #))*G Q4E,\N\!?\ '[%_P/\
M]%M7K]>6>"M&GM[N.1XG51OR61@!E&'4BO4ZJ6Y,-CS_ .*W_+#_ +:?^R5>
M^%\@-NZ9&1*21GG!5<''O@_D:T/&OALZU$/+QYL9)7/<'JO7 S@8)[C' )->
M83V<^CN"P>)P2 W*].#AAUZ]0<8/O0M583T=SW&O/_BM_P L/^VG_LE6OAO'
M,?.FF#YD$1#2!OF #<@GKQC\,4WXEZ?+>>3Y2,^WS,[%+8SLQG /I0M&-ZHK
M_"G_ );_ /;/_P!GK4^(^DF\MQ,HRT)SWSM/#<#\"<] #SZT_AII\MGYWFHR
M;O+QO4KG&_.,@>M=Q2;U!+0\D\$^)ET21ED'[N7:&(ZKC.#CN.3D=>XZ8/I,
M?B2UD 831X(!Y=0>?8D$?0\UR?B7X<F9S-:;0""2A..?]GC'/H< 'OC@<]_P
M@5[_ ,\O_'X__BJ>C$KHV_'GC".\3[';G<"?G8?=^4\*,CGD Y'' P3DXQ/
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MN$]CT/P]_P >T'_7&/\ ] %:%4="C,5O"C @B*,$$8((49&*O5)2"O(/'O\
MQ^R_\ _]%K7K]>6>-=&GN+N21(G93LP51B#A%'4"JCN3/8[/P%_QY1?\#_\
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M%JC:'<+*01M.UUY!QT88R.1U /<#/2O9;.\2\031D,C#((_S^8Z@\&N3\6>
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M .'GBA+0-9SL%7.Y"QPH_O+DG ]1T&<\Y(KT:O+/$'P^FL#O@S+'[#YQS@#
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MT%K=GJ5>?_$3Q0LBG3XCDY'F$8QQSL^N<$XZ8QZ@<==WEQ$/LLK2   ;'9@
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M'-Y +A<DP$DC_9;&XX /3 /8 9-<UX \2+IDA@E;$4N.3T5NQZX (X)QV&<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,\9/^_;?X5ZCX+MVM[2.-U*L-^0P((R['H:W**;=Q)!1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KF?B!<2QVQ2)6(<X=E&=J@9.<'(SC!.",9!QD5TU%"!G"_#GP
MUY(^WR@AF!" @?=./G]>>@Z<9ZAA7=444V[B2L%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >0>/?\ C]E_X!_Z+6O3_#W_ ![0?]<8_P#T 5P_B[PC=:A=23Q1[D;;
M@[D'1%!X+ ]17>:-;M;P11.,,D: CK@A0#TJGL3%:LN4445)04444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5G^(/\ CVF_ZXR?^@FM"B@#
MP*O3OAC_ ,>S_P#79O\ T%*Z^BFW<204444AA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7*V?Q&M[MUA59,NRJ,JN,L<#^*NJKQ#P]_Q\P?]=H__ $,4TKDR=CV^BBBD
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#?^-K6QD^SNYR"0Q5
M254@="1^7&<'@XK<CD$H#J000""#D$'H<UYKKW@*YGN7>(!DE<MNR%V[B200
M3GCV!R/?@>B:?:?8XD@SGRT5<XQG: ,XY]*;L)-F3KWC*'1'$,JN25#?*%(P
M21W8>E7-!UY-;0S1!@ Q7Y@ <@ ]B?6N!^*'_'RG_7%?_0WKH/A?_P >S_\
M79O_ $!*=M!)ZV.PHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *AO+H6B-,V<(K,<=<*,FIJS_$/_'M/_UQD_\ 0#0!BV?Q&M[MUA59,NRJ
M,JN,L<#^*NJKQ#P]_P ?,'_7:/\ ]#%>WTY*Q,7<****105@Z]XRAT1Q#*KD
ME0WRA2,$D=V'I6]7E_Q0_P"/E/\ KBO_ *&]-*XI.R.^T'7DUM#-$& #%?F
M!R #V)]:TJX_X7_\>S_]=F_] 2NPH>X+8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHJ.XN%MU:5SA4!)/7  R>E %/6==AT=?,F;&<[0.
M6) S@#^IP!D9(S7(R?%4 D+"2,G!,F#CMQM./S/UKD-2OY->GWG):1@J*2.
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MGD%N>1[ \\=<XR8_BJ"0&A(&1DB3)QWXVC/YCZUS7AGPI)KK'!VQKU<C//8
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MCWH:5KC3=[,]$JKJ6IQZ:GG3,%7(&3D\GL ,D_AVYZ5-<7"VZM*YPJ DGK@
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M)CNUN>WUY?\ %#_CY3_KBO\ Z&]>D:??+?QK.GW7 (Z?D<9Y'0^AKS?XH?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN,*S*?7+@$?^@G]*2W&]BU\+_P#CV?\ Z[-_Z E=A7GOPPU@)OLFP"QWK[G
M##KZ $ #H&)KT*B6XX[''_%#_CV3_KLO_H#UG_"G_EO_ -L__9ZS?B)KJ:C(
MD,6&$0/S @J2X4\8STQ^>1CCG2^%/_+?_MG_ .ST_LDW]XZ#Q[_QY2_\ _\
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M4F",YQDQ@'UX/'Y5N_#3289U>X8!I5<  X.T  A@.Q)SS[<8YSWTD@B!=B
M"22<  =3FAM(239X5?\ F[SY^[S.,^9G=T&,[N>F/PKV?P]_Q[0?]<8__0!7
MD&OZI_:D\ESC <\#IP  N>3S@#/O7K_A[_CV@_ZXQ_\ H HEL$=SS_XH?\?*
M?]<5_P#0WKJOAW:B&S5QG,C.QSZ@[>/P4?C7*_%#_CY3_KBO_H;UV'@+_CRB
M_P"!_P#HQJ'L"^(Z"O+_ (H?\?*?]<5_]#>O4*X/XH:275+Q1]WY7//0\K[
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MZ***DL*\0\0_\?,__7:3_P!#->WUXAXA_P"/F?\ Z[2?^AFJB3,]MCC$0"*
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M;4/4DGDJ3U-6/^$]O?\ GK_XY'_\374_#_Q0DD8LY6 =#A-QQN4G@ D\D$X
MXXQ@'!KMJ&Q)7ZGB6J^(I]5 6=@P4Y'R(",]>0 ?PZ=/05UOPI_Y;_\ ;/\
M]GKIM<\60:051V!<L 5!R5!QECC)& <@8R>W<C8CD$H#J000""#D$'H<T-Z#
M2U'4445)1Y%X_D+WL@))"A ,GH-@.!^))^IJK8>+KK3T$$4FU%S@;4/4DGDJ
M3U-;/Q*T<V\PNQDK* #[,H QTP,@#'.20W:MCX?^*$DC%G*P#H<)N.-RD\ $
MGD@G ''&, X-7T,[:G+?\)[>_P#/7_QR/_XFJ.J^(I]5 6=@P4Y'R(",]>0
M?PZ=/05[;6+KGBR#2"J.P+E@"H.2H.,L<9(P#D#&3V[D)/R&X^9S/PI_Y;_]
ML_\ V>NF\1^*HM# #Y9V!VHO7ZGT&>,\GT!P:V(Y!* ZD$$ @@Y!!Z'->2>/
MY"][("20H0#)Z#8#@?B2?J:%JQOW46[SXF7,V50(@)X(!+ 9]22#QP?E_ 54
M;4]2U+$RF8@C ,:LJG!/]P 'GOU[=J[WP7I,-K;QS1 %Y$!9^"V3C<N>P!&,
M=L<\Y-7O$.L#2('N#C(&%![L>@QD9]3CG )HN%F>1>'O^/F#_KM'_P"ABO;Z
M\0\/?\?,'_7:/_T,5[?1(('F?C#P3,DK7, ,B2$L0.64L>1@<D9/&!P.O3)P
MM)\4W&E86)SL!'RM\R\'.,'IG/.,$UZJGB:W>9K/>/,7'4X!).-H/=AQD>^.
MH.+5_I<6H#;,BN,$#<,D9ZX/4?48-%PY>QR>@_$E+DB*Y4(Q.-Z_<YSUR<KV
M&<D=S@5VU>,>*].AT^X:*!MRCJ.NT]TSWQ^G0\@UZ;X-=WLX3)G.W R,?*"0
MO_CN,'N.:&@BWL>5>(?^/F?_ *[2?^AFO7_#W_'M!_UQC_\ 0!7D'B'_ (^9
M_P#KM)_Z&:]?\/?\>T'_ %QC_P#0!1+84=V>?_%#_CY3_KBO_H;UT'PO_P"/
M9_\ KLW_ * E<_\ %#_CY3_KBO\ Z&]=!\+_ /CV?_KLW_H"4/8%\1T&OZ7_
M &I!);9P7'!Z<@@KG@\9 S[5Y-X6U;^RKA)F)V9PV"1\K<$G&<XZX[D5[37D
MGC[238W+.!A)OF'7J?O<GONYP.@(^E$>PY=SO?&^I?8;20\9D&P9!.=_!Z?[
M.2.V1^%<!X"TW[;=H3C$0+G)(^[@+C'HQ!],#\*A\1^(#JR0(>L4>&)R6W9P
M22>N0H;\2"37;_#C239VYF88:8Y[YVCA>#^)&.H(Y]#9"W9UE%%%26%>(>(?
M^/F?_KM)_P"AFO;Z\0\0_P#'S/\ ]=I/_0S51)F>VQQB(!%      P !T&*=
M114E'B'A[_CY@_Z[1_\ H8KV^O$/#W_'S!_UVC_]#%>WU4B8'/\ CW_CRE_X
M!_Z,6N \!?\ '[%_P/\ ]%M7?^/?^/*7_@'_ *,6N \!?\?L7_ __1;4+84O
MB1Z#XYD,=E*5)!PHX.."Z@C\0<'VKR:POWT]Q/$=KKG!P#U!!X((Z&O9]?TO
M^U()+;."XX/3D$%<\'C(&?:O)-"U1M#N%E((VG:Z\@XZ,,9'(Z@'N!GI1'8)
M;ES_ (3V]_YZ_P#CD?\ \31_PGM[_P ]?_'(_P#XFO5['4([]?-B8,I[@^V<
M'T//0\BI+BX6W4R.P51U+$ #/'4T7\A\K[G@TC^82QQDDG@ #GV& /H.*][D
MD$0+L0  223@ #J<UDZ%XHAUEG2,\H> >"R\?/CTSD>HXSC.*A\<R&.RE*D@
MX4<''!=01^(.#[4-W!*R.?UCXG[#MM4! /WI,X/7HH(/H020>Q6L23QM?:BQ
MCC8@N" D2 GISC@M[YSD=L5'X$TV*_N0DV"%4LJD\,P(XQWXR<>W/&17K<<8
MB 10     ,  =!BAV0E=GB6K?:?E^U>;WV^;O]LXW?AG'M7?_"__ (]G_P"N
MS?\ H"5SOQ'U@7DXMUP1 ""?]IL;AD$], =B#D5T7PO_ ./9_P#KLW_H"4WL
M"W-CQ5H']MP^2#M92&4]L@$8/L<]NG7GH?*+NPN-#<%PT;\X8'';G#*<'@\X
M/?!KV/5M6CTJ,SRG"C\R>P [D_\ US@ FI+'4([]?-B8,I[@^V<'T//0\BI3
ML-I,\UTWXE7%OQ*%D&3G(V-TX *C'7G[I/\ 3T#0_$$6M(9(B>#@JW##TR 3
MU['I^(('/^-?#5I' UQA8G4?*5& QYPNT<'/KC(ZDX!%<Q\.W=;Q0F<%7#X&
M?EQGGT^8#GUX[T[)H5VG8ZGXH?\ 'LG_ %V7_P! >L_X4_\ +?\ [9_^SUK?
M$FU,UIO&,1R*QSZ'*\?BP_"N7^'&L"SG-NV )P #_M+G:,DCKDCN2<"A; _B
M/4JY_P >_P#'E+_P#_T8M=!7GOQ+UU)@MDF&*MN8@@@$;EV\=^N<XQQUSPEN
M5)Z%'X7_ /'R_P#UQ;_T-*] \0_\>T__ %QD_P#0#7G_ ,+_ /CY?_KBW_H:
M5Z!XA_X]I_\ KC)_Z :<MQ1V/*O!MJ+F\A1LX#;N/5 6'ZCGVKV6O(/ 7_'[
M%_P/_P!%M7K]$MPAL%<3KWQ)2V)BME#L#C>WW.,=,'+=QG('<9%=1KLABMYG
M4D$12$$'!!"G!S7D7ABRCOKF.&8_(Q.><9X) S[G ]>>.:$@DS4F^(%[=L!&
M0I. %C0'))_VMQR>G'Y5EZI]KVC[3YVS/'F[]N<'^]QG&?UKV>WMUMU$:*%4
M= H  SST%<#\3]8#[+)<$J=[>QP0HZ^A)((Z%2*$Q-:#OA3_ ,M_^V?_ +/7
M8>(?^/:?_KC)_P"@&N/^%/\ RW_[9_\ L]=AXA_X]I_^N,G_ * :3W''8\>T
M*,2W$*, 098P01D$%AD8KW&O!+>X:W994.&0@@]<$'(ZU[7HFMQZO&)8R,X!
M90<E2>QZ'J#@X&<9'%.0H&A7EOQ-C"72D  M$I.!U.YAD_@ /H*].N+A;=3(
M[!5'4L0 ,\=37CWB[7/[9G,J@;%&U<9Y4$D$YQUSGH,#CWHCN.>QW?PVNC-:
M;#C$<C*,>APW/XL?PKF?BA_Q\I_UQ7_T-Z[;P=IITZUCC8 .06;C!RQR,Y .
M0, ^F,=JXGXH?\?*?]<5_P#0WH6XG\)T'PO_ ./9_P#KLW_H"5@_%"0FX1,G
M B! SQDLV3CWP/R%;WPO_P"/9_\ KLW_ * E4?B?HY?9>KDA1L;V&25/3U)!
M)/4J!1U!_"<EI?B:XTM3%"^U2<D;5/) '<'TJY_PGM[_ ,]?_'(__B:V?AYX
MH2T#6<[!5SN0L<*/[RY)P/4=!G/.2*]&H;!*ZW/%M2\57.I)Y,SAER#@H@Y'
M<$*"/P[<=*V?A?\ \?+_ /7%O_0TKNO$'B6+14+.07Q\J _,<YQ]!QR>GU.
M="SO$O$$T9#(PR"/\_F.H/!HOH-1U)J*KWVH1V"^;*P51W)]LX'J>.@Y-%CJ
M$=^OFQ,&4]P?;.#Z'GH>14E%BBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,">< 'Z'=UXKO**+Z6#EUN%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7F_B[PC=:A=23Q1[D;;@[D'1%!X+ ]17I%%-.PFKE/1K=K>"*)QADC0$=
M<$* >E7***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** .%\>>%[C5)DF@4,!&%/S
M$$,3_$1USV]#GMG'TGX<7%PX\\"- 1GY@S$>V,C\^F<X/2O4J*?,R>5$-G9I
M9H(8P%11@ ?Y_,]2>34U%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BHK@X4D53\T^I_.@#1HK.\T^I_.CS3
MZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z
M -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&B
ML[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3
MZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z
M/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J
M?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH
MT:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*S
MO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J
M?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\
MT^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_
M.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1
MHK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\
MT^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_
M.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3
MZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z
M -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&B
MJUHY;.?:K- !1110 4444 %%%% !1110 4444 %%%% !15"20@GD]3WIOFGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT50CD)(Y/4=Z
MOT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)DWC JM]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"&WA,><]ZFHHH **** "BBB@ HHHH **** "BBB@ HHHH J/:%B3QR:3[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %1+0J0>.#5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !Y1?\#_ /0VK?J6,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ' 53V ]:Z.N0^&/_'L__79O_04KKZ'N-!1112 **** "BBB@ HHHH ****
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M>N !D]*DK/\ $'_'M-_UQD_]!- %>P\6VM^X@BDR[9P-KCH"3R5 Z"MBO(?
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M*;L(AU"^6PC:=_NH"3T_(9QR>@]37D^K>,[G4'+!VC7)VK&Q7 ]R,$]._?.
M!Q7H/CS_ (\I?^ ?^AK7%?#FS2YN27 .R,LN>S!E /X9X]^>H%- R;P1K]Q+
M=) \C,C[LASN^ZC$8+9(Y],9[UZ=36C#X) )4Y&1T.",C\"1]#3J38PHHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YSXM\6W5A=201281
M=N!M0]44GDJ3U->C5Y#X\_X_9?\ @'_H"TXB9ZEH\[7$$4KG+/&A)Z9)4$]*
MN5G^'_\ CVA_ZXQ_^@BM"D,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"J]_?I8(9Y3A%QDX)ZD < $]35BL#QY_QY2_\ _]#6@"WI?B6WU1C%"^Y@,D
M;6' ('<#UK4KS'X8_P#'R_\ UQ;_ -"2O3J;5@04444@"BBB@ HHHH ****
M"BBB@ K#N/&EI;LT3R89"01L<X(.#T6MRO$O$'_'S-_UVD_]"--*XFSVVBBB
MD,**** ,_5=>ATG;Y[;=^<?*QSC&?N@^HJ32]6BU13+"VY0<$X(Y ![@>M<9
M\5?^6'_;3_V2M#X8_P#'L_\ UV;_ -!2G;05]3KZYSQWJTNEP++"VUC( 3@'
M@JQ[@^E='7(?$[_CV3_KLO\ Z"]"W&RGX$\2W&J3M%,^Y1&2!M4<AE'8#UKN
MZ\Q^&/\ Q\O_ -<6_P#0DKTZA[B04444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=#]#D4-7$F>XR1B0%6 (((((R"#U&*=7FNE?$N6$A;A0Z]RHVOUZ_P!TX';
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M1H%[!MS'\P5_E6)XMOFO+J4O_"[(!S@!"0.OYGW)-5]$T2369/(BQG!)+'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K@/BK_ ,L/^VG_ +)7?UP'Q5_Y8?\ ;3_V2FMQ
M,T/AC_Q[/_UV;_T%*Z^N0^&/_'L__79O_04KKZ'N-!7D/CS_ (_9?^ ?^@+7
MKU>0^//^/V7_ (!_Z M$1,FM?&\EA;QVD "E0VYR 3DN6& >.G7(/7@#&3E?
M\)!<_P#/:3_OXW^-=M\/?#D?E"]D 9W)V9YVA3C.".&W \\\8QCFNUDC$@*L
M 00001D$'J,4[A8\W\.?$*2W98KH[H^F_'SCH 3C[P]>-W.<GH?2J\=\8:(N
MCW!B3[C ,HSD@'(Q^!!QUXQDYKTCP;=&YM(6;&0NWCT0E1^@Y]Z3!&I>7B6:
M&:0A449)/^?R'4G@5YCKWC^>^)2$F.//&WAR.,9;MT_AQUP2:M?$O53-*MJ#
M\L8!(Y^\WKV.%QCTR>:L^ 8+:S3[7-)&)6)"AG4%5Z=#C!///]W&,9.6E8#G
M'O+^-/.9IPF =Q:0+@]#GISGBM;0_B++:8CG'F)P,]' X'7HW&>O))Y:N^_X
M2"V_Y[1_]_%_QKSWQ];0-(+FW=&\S.\(RGYNN[ )^]WXQD9)RU&X'IUO.MPJ
MRH<JX!!Z9!&1UKG/&?BW^QE\F/\ USC()'"CD;O<\<#\3Z&C\,+\RQ26YSB-
M@02<\/G@#M@J3]3^?/?$6%H[LECD,BE1DG QC'M\P)X]<]322U"^A335[[4V
M+H\S$8SY6[ ].$X&<>G-.@\47NE.59WR",K-EO?&&Y&0>V"1^%=3X)\4VT$2
MVK8B<9R2,*QYYW$GG &<XYX7C '5W6GPZFJM(JR+P5) /H>#Z' SV(X.13N%
MB'P]J;ZE D\B%&8=.Q_VAWP>V>?J,$W+R\2S0S2$*BC))_S^0ZD\"IJ\U^)>
MJF:5;4'Y8P"1S]YO7L<+C'ID\TDKC*NO>/Y[XE(28X\\;>'(XQENW3^''7!)
MK/>\OXT\YFG"8!W%I N#T.>G.>*Z/P#!;6:?:YI(Q*Q(4,Z@JO3H<8)YY_NX
MQC)SV/\ PD%M_P ]H_\ OXO^-.]A' Z'\19;3$<X\Q.!GHX' Z]&XSUY)/+5
MZ5;SK<*LJ'*N 0>F01D=:\Q\?6T#2"YMW1O,SO",I^;KNP"?O=^,9&2<M6[\
M,+\RQ26YSB-@02<\/G@#M@J3]3^8UU!':T445(RGJNJQZ7&9Y3A1^9/8 =R?
M_KG !->7ZQXYN=0/RL8T!X$9(/?&6ZG@\] <9Q3O'NJF^N60'*0_*.O4?>X/
M?=QD=0!]:Z?P4EII40E:6/SI!EB9%R >0O.,8XR/7N<#%6L(XZZO+^T&Z1IT
M!.,LTBC/IDUT&@_$ET(CN@&4G[ZC##KR5'![=,$#U-=I_P )!;?\]H_^_B_X
MUY?XQLH;><O;LC1R#.(V4A3W& 3CU'0<X'2C<-CV"O._'D=SIDGGQRR"*4\
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MQG()%)+J#*]K>7]V-T;3N <95I&&?3(JQH_CFYT\_,QD0GD2$D]LX;J.!QU
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M*\>TR :A.JS.%#MEW=L<=6.XYY/;/4XS22!LMKK=[J3G8\K-C)$98<# SM3
M'Y=?>G0^);S2Y/F=]PQE)2QXX."K=,^HP<=#7IEGJMG9H(8Y8E11@ 2+_C^9
MZD\FH-9NK/58F@>:+D<$NIVMV8?,.GUY''0T[A8A\)^,%US,3+ME49('*D<
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M@N?^>TG_ '\;_&KNG>-KJQ_C+C).)/FSD8ZGYOP! S^->O1QB,!5      P
M!T&*Q]>\*0:P"64+(1PZCYL\8STW=,<]NA'6G=!8F\/^((];C\U.&'WE/53_
M %!['O[$$#G/B5J$MGY/E.R;O,SL8KG&S&<&NKTK2H]+C$$0PH_,GN2>Y/\
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M009&((/48S56"X:W82(Q5AT*D@C/'45[3X@_X]IO^N,G_H)KS'P'_P ?L7_
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M(&<]EX'L.!Z5Z5JGA&WU.07$JG<!@X. W&!G'/'8@@]CD "KTVH06&(G=(\
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MI&)XCE3^8/<$=B/_ *XR"#7+>/\ PPDD9O(E =#E]HQN4GDD <D$Y)XXSDG
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M[)2:L""BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/7M7<:'XG@UG/E$[@,E6&& SC/<'\"<9&<$UYGK?@^XT=?,<!DXRR'(!/8Y
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M!G! ]<]2!V&2U<#MO"OB(:Y%YF '4X=0>_J.^#VSW!'.,UYWX\_X_9?^ ?\
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MD]"?X>3T/;'\1Z'/'HU)JQ1X9I=T+2:.9LX21&..N%8$U[G7@D<9D(50220
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M??'S)_O#H.H'(R.>!G/:O+M$UB309O- Y&5=6&,C/*^H.1^!'.1D$6P,V_\
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M CM:***D9YOXS\9RF5K6!BB(=I*\,6&,\X!&",<=>>2#QEZ3X%N=202@*BD
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M">E>XUY/XYT!]/G:?!,4S$ANOS'EE/ QSG'J.Y(.-;PO\05M8UM[D'Y,*K*
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M:Z!! K+&,DCNV #R!G 7!/4CN<8XI^ _^/V+_@?_ * U"6@=3T[Q!_Q[3?\
M7&3_ -!->1>'_P#CYA_Z[1_^A"O7?$'_ ![3?]<9/_037D7A_P#X^8?^NT?_
M *$*(@SVFXG6W5I7.%0$D]< #)Z5Y#K7B>XUQO+R0C'"QITY(P#CECD#KWZ
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M%'((7/7_ (%@$<= "#S3V0;LI_%7_EA_VT_]DJY\+YU:"2('YEDR1[,H _\
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MQW@+Q4^I;K:;)=0SA_4%N0?3!;C'&.,#'/8TF""BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!I/V"V#L!NF._H,[2/E&1G/'/MN(QG-='(VP$@$D \#&3[<D#\R!1'&(P%4
M    #  '08IU04>,>)-<EU:4M*"NPD!/[OJ.>_J>N?0  6=*\<7.FJ(PP9%&
M KC./Q&&XZ#G '&.F/2-<\,0:SCS0=P& RG# 9SCN#^(.,G&":Y&_P#A<X/[
MB12"3Q("I [<J&S[\#Z>E70K,P]<\9SZP@A?:J9R0@(SZ9R3T].F>>PQB1QF
M0A5!))   R23T&*[.U^%TS']Y(BC'50S'/T(7^?X5U>@>#H-&Q(N6E ^^WN
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MQ1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_>.,'\#CKSTKT*BG=BL9^CZ%%I"^7"N,XR3RQ(&,D_T& ,G &:T***0S@/\
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M1"O8MN4_D W\Z]*HIW8K'':3\-HK1Q)*YDVD$+MVK^(RV>W' ]<@XKKXXQ&
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M$*]BVY3^0#?SK7TWX910-NF<R#L -@[]<$D^V".G>NSHIW8K#8XQ& J@
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MG1L8RQ);@N"2<YY88Z_3I@#OUM%%P/-[7X73,?WDB*,=5#,<_0A?Y_A6_=^
M(G@%I$Q3]X'+L-S-@, #@KTW<=O;))KJ:*=V*Q@>%?"O]@;_ )]_F;?X=N-N
M?<^M;]%%(9FZYH$6M((Y0>#D,O##UP2#U[CI^(!'$W7PNF4_NY$88ZL&4Y^@
M#?S_  KTBBFF%C'\,>'_ .PXC!NW[G+9V[>H QC)]*V***0'*:W\/(;]O,B/
ME-QD*H*<?[/&#TZ'''3)S6!_PJ^?=CS$V9Z_-NQGKMQC..V?;/>O2J*=V*QR
M6C_#F"S.^8F4@\ C:O8CY<G/3N<$'D5UM%%*XPHHHH *XS6OAM'=,98&\LG)
MVD93/8#&"HSUZ]>  ,5V=%%P. T3X<2VTJSRR*/+=& 0%L[3D@D[<=/>N_HH
MH;N!P'_"JO\ IO\ ^0__ +.N_HHHN 5Q&H?#7[9*\_G8\QV;'EYQN).,[Z[>
MBBX!7(:]X _M:9KGS=N_;QLSC"A>NX>GI77T47 KZ?:?8XD@SGRT5<XQG: ,
MXJQ110 5RFM_#R&_;S(CY3<9"J"G'^SQ@].AQQTR<UU=% 'FO_"KY]V/,39G
MK\V[&>NW&,X[9]L]ZZ'1OA[!8$229E8 \,!LY[[>>WJ2._7&.IHIW8K!1112
M&<]XC\%Q:T?-R4EQC<!D'IU'&<#@'(/KD "N83X73%\-(@3)Y 8MCM\N /K\
MW'J:](HIW86.>TWP7%I\,D*$EYHRK2,,GE<<#C SSC.3W)P,4=!\ ?V3,MSY
MN[9NXV8SE2O7<?7TKKZ*+A8*JZCID>I)Y4RAER#@Y'([@C!'X=N.E37&[:WE
MXWX.W=G;G'&<<XSUQ7D-]JUY87'G2LRS@8R0,;>G QM*Y'88)YZ\T)7$SM9/
MAG;.20T@!)X#+@>W*D_F2:T=.\.6V@*9@.4!)=_F8  DXP.."1\H&1US7,P?
M%-E4!X06[E7*C\BK?SK%\1^-)=:'E8"19SM!R3TZGC.#R!@#UR0#3LPT,JW1
MM4G57/S32 %L=W;DX&/7IQ7N-<!\/?##1L+^48&#Y8.<\\;_ *8R!GKG/H3W
M]*3!'(:]X _M:9KGS=N_;QLSC"A>NX>GI6_H.E?V3"MMNW;-W.,9RQ;ID^OK
M6A12N,*YCQ/X*_MR43^9LVH%QLW="3G.X>M=/10!GZ#I7]DPK;;MVS=SC&<L
M6Z9/KZUH444 <IK?P\AOV\R(^4W&0J@IQ_L\8/3H<<=,G-8'_"KY]V/,39GK
M\V[&>NW&,X[9]L]Z]*HIW8K'+:-\/8+ B23,K 'A@-G/?;SV]21WZXQU-%%(
M85SWB/P7%K1\W)27&-P&0>G4<9P. <@^N0 *Z&B@#S=/A=,7PTB!,GD!BV.W
MRX ^OS<>IKI]-\%Q:?#)"A)>:,JTC#)Y7' XP,\XSD]R<#'0T4[L+'(:#X _
MLF9;GS=VS=QLQG*E>NX^OI77T44K@4]5TJ/5(S!*,J?S![$'L1_]8Y!(KA[_
M .%S@_N)%()/$@*D#MRH;/OP/IZ>B44T[!8Y[PCX6.@A]SAC($R , %<YYSS
MU]!]*Z&BBD 4444 <9K7PVCNF,L#>63D[2,IGL!C!49Z]>O  &*IZ)\.);:5
M9Y9%'ENC ("V=IR02=N.GO7?T4[L5@K@/^%5?]-__(?_ -G7?T4KC"BBB@#B
M-0^&OVR5Y_.QYCLV/+SC<2<9WUV]%%%P(Y[=;A3&ZAE/4, 0<<]#7%:E\,$D
M):"0J,'"L-PSS@;L@@=!T)[\UW-%%P/-[7X73,?WDB*,=5#,<_0A?Y_A75Z!
MX.@T;$BY:4#[[>X .!T'ZG!(R16[13NPL%%%%( KD->\ ?VM,USYNW?MXV9Q
MA0O7</3TKKZ*+@<M)X BFMTMG8[X@VV11@_,2V",G(!/3.?0C)K NOA=,I_=
MR(PQU8,IS] &_G^%>D44[L5CDM'^',%F=\Q,I!X!&U>Q'RY.>G<X(/(KK:**
M5QA6'X@\(PZR-S#;)_?4#)XP-W]X=/?C (YK<HH \WNOA=,I_=R(PQU8,IS]
M &_G^%:.F?#&./#3N6/RG:GRK[@GDD'U&T_T[>BG=BL1P6ZVZB-%"J.@4  9
MYZ"I***0S%\1>%8M< +Y5U!VNO7Z'U&><<'T(R:X^?X7SJQ"2(5[%MRG\@&_
MG7I5%.X6.2T?X<P69WS$RD'@$;5[$?+DYZ=S@@\BJNH?#7[9*\_G8\QV;'EY
MQN).,[Z[>BB["P445Q&H?$K['*\'DY\MV7/F8SM)&<;*5@*_Q1\K]U_SVYZ8
M^Y[]^OW>WWJB^&6D[W>\8#"C8N0#\QP21W&!QTY#=>M<Q=74_B&?)R\CG"J.
M@'H/0#_$D]37K/A[1QI$"0#&0,L1W8]3G SZ#/. !5/1"ZFE1114C"BBB@#-
MUS0(M:01R@\'(9>&'K@D'KW'3\0".)NOA=,I_=R(PQU8,IS] &_G^%>D44TP
ML8_ACP__ &'$8-V_<Y;.W;U &,9/I6Q112 Y36_AY#?MYD1\IN,A5!3C_9XP
M>G0XXZ9.:P/^%7S[L>8FS/7YMV,]=N,9QVS[9[UZ513NQ6.6T;X>P6!$DF96
M /# ;.>^WGMZDCOUQCJ:**0PHHHH Q_$_A_^W(A!NV;7#9V[N@(QC(]:H>&/
M!7]ARF?S-^Y"N-FWJ0<YW'TKIZ*+@%8OB+PK%K@!?*NH.UUZ_0^HSSC@^A&3
M6U10!YK/\+YU8A)$*]BVY3^0#?SK=T?X<P69WS$RD'@$;5[$?+DYZ=S@@\BN
MMHIW8K'$:A\-?MDKS^=CS'9L>7G&XDXSOKMZ**5QD<]NMPIC=0RGJ& (..>A
MKBM2^&"2$M!(5&#A6&X9YP-V00.@Z$]^:[FBBX'F]K\+IF/[R1%&.JAF.?H0
MO\_PKJ] \'0:-B1<M*!]]O< ' Z#]3@D9(K=HIW86"N8\3^"O[<E$_F;-J!<
M;-W0DYSN'K73T4@,_0=*_LF%;;=NV;N<8SEBW3)]?6M"BB@# \5>%?[?V?/L
M\O=_#NSNQ[CTJ?PQX?\ [#B,&[?N<MG;MZ@#&,GTK8HHN 5SWB/P7%K1\W)2
M7&-P&0>G4<9P. <@^N0 *Z&B@#S=/A=,7PTB!,GD!BV.WRX ^OS<>IKT#3[3
M['$D&<^6BKG&,[0!G%6**;=PL<1J'PU^V2O/YV/,=FQY><;B3C.^NOT^T^QQ
M)!G/EHJYQC.T 9Q5BBE<#/U[2O[6A:VW;=^WG&<88-TR/3UK(\,>"O[#E,_F
M;]R%<;-O4@YSN/I73T47 ***YCQ/XU_L.40>7OW(&SOV]21C&T^E %CQUY7V
M1_-]MF,9WY^7&?UQSMW5YUX0TG^T[E$P"J'>V0"-JD<8/7)P/QSC%.\3>*I-
M=89&V->B YY[DG R?3C@=.Y/;^ ?#C:9&9Y1B67'!ZA>PZ9!)Y(SV&<$&JV0
MMV=71114C"BBB@#DM<^'D>HOYT;&,L26X+@DG.>6&.OTZ8 [XEK\+IF/[R1%
M&.JAF.?H0O\ /\*](HIW8K'+7?@")X!:1,4_>!R[#<S8#  X*]-W';VR2:M>
M%?"O]@;_ )]_F;?X=N-N?<^M;]%%QV,_7M*_M:%K;=MW[><9QA@W3(]/6LCP
MQX*_L.4S^9OW(5QLV]2#G.X^E=/12N 57U"T^V1/!G'F(RYQG&X$9Q5BB@#D
M-!\ ?V3,MSYN[9NXV8SE2O7<?7TKKZ**+@9NN:!%K2".4'@Y#+PP]<$@]>XZ
M?B 1Q-U\+IE/[N1&&.K!E.?H W\_PKTBBFF%CBM)^&<<.&N&+G ^5<JN<<\Y
MR>>GW>G(YQ4FM?#P:C*TZR! 0H"B/( 50H'WAZ>E=C11=A8KZ?:?8XD@SGRT
M5<XQG: ,XJQ112 *\Q^)W_'RG_7%?_0GKTZO,?B=_P ?*?\ 7%?_ $)Z<=Q,
MW?#^@1:U80QR@\%R&7AA^\;."0>O<=/Q (R+KX73*?W<B,,=6#*<_0!OY_A7
M4^ _^/*+_@?_ *&U;]%PL<9HOPVCM6$L[>81@[0,)GN#G)89Z=.G((.*[&.,
M1@*H     &  .@Q3J*5QF?KVE?VM"UMNV[]O.,XPP;ID>GK61X8\%?V'*9_,
MW[D*XV;>I!SG<?2NGHHN 4444 4=6T:+54,<J@\'!_B7/<'MT'L>^17%WWPN
M8<PR@\\!P1@?[PSD_@,]>.E>A44TPL>?:=\+B>;B08R>(QG(QQ\S 8Y_V3QW
MYX[/2=&BTI!'$H' R?XFQW)[]3[#M@5>HHN%@ILD8D!5@""""",@@]1BG44@
M.$U7X8JY+VS[?17Y'7^\.0 .F03QR>>)O"_@)]+E6ZD=<H6^502""I'WCC'7
MT/U].UHIW8K!67K?AR'65VRCYN,.N XQVS@\<G@Y'.>O-:E%(9YS=_"Z5<>5
M*K=<[P4^F,;L_I4]A\+NAGE]<K&/KC#-^'\/M[UW]%.[%8JZ=ID>FIY4*A5R
M3@9/)[DG)/X]N.E6J**0S+UOPY#K*[91\W&'7 <8[9P>.3P<CG/7FN-N_A=*
MN/*E5NN=X*?3&-V?TKT:BG<+' 6'PNZ&>7URL8^N,,WX?P^WO7;V.GQV"^5$
MH51V ]L9/J>.IY-6**&P"N>\1^"XM:/FY*2XQN R#TZCC.!P#D'UR !70T4@
M/-T^%TQ?#2($R>0&+8[?+@#Z_-QZFO0-/M/L<209SY:*N<8SM &<58HIMW"P
M4444@*>JZ5'JD9@E&5/Y@]B#V(_^L<@D5P]_\+G!_<2*02>) 5(';E0V??@?
M3T]$HIIV"QSWA'PL=!#[G#&0)D 8 *YSSGGKZ#Z59\3^'_[<B$&[9M<-G;NZ
M C&,CUK8HI7 YCPQX*_L.4S^9OW(5QLV]2#G.X^E=/110!GZ]I7]K0M;;MN_
M;SC.,,&Z9'IZUD>&/!7]ARF?S-^Y"N-FWJ0<YW'TKIZ*+@%9>M^'(=97;*/F
MXPZX#C';.#QR>#D<YZ\UJ44 ><W?PNE7'E2JW7.\%/IC&[/Z5/8?"[H9Y?7*
MQCZXPS?A_#[>]=_13NQ6*NG:9'IJ>5"H5<DX&3R>Y)R3^/;CI5JBBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6L_AW;VCK,K
M291E89*XRIR/X:ZFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J>I:1%J:[)D# =,]1TZ$<C..<'FKE
M% ')2?#.V<DAI "3P&7 ]N5)_,DU<T[P':V7S;2Y!/,AW=1C&T *?Q!.?PKH
M:*=V%@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5S&H?#VWO9&G)<%R20K#&3UZJ3R>>O
MTXKIZ* ,G0_#$&C9\H'<1@LQRQ&<X[ ?@!G SDBM:BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "L/7O"$.MLLLA8,HQE"!D9R,Y!Z9/
M3UY[5N44 <]I/@6VTUQ* SL""ID(.".X  'YYP0",&NAHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+7?!T.M.)I&<$*%^4
MJ!@$GNI]:W:* *>DZ6NEQ+;H253."V">23V ]:N444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
M'>+/'3:5)]FA5690"Q;.!D$[<#';!SG'.,9HL!V-%<1X0\<R:C*+6=02P^5E
M&.5!)W#..0.V,'M@\=O0U8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW/)''&>>10!OT5@>$?%/]O*V5VO'MS@Y4[@>1W'(/'...36_0 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HKSO2_B)<7<T<++'AY$4X#9PS '^*O1*&K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!X%7OM>!5W?B#XD,Q\NTX'=V'/7^$'C&/49YZ BJ:N)'H5%>0_\)Y>_P#/
M7_QQ/_B:ZOPS\01?MY%R KL0$* [220 I')!SWZ>N,<JP7.SHHILD@C!9B
M"22<  =3FD,=17G>O?$EW)CM0%4'[[#+'IR%/ []<DCT-8O_  GE[_SU_P#'
M$_\ B:?*Q7/7J*\]T7XEL&$=TH*G WJ""/5BO.<\9QC'. >!7H$<@D 92""
M00<@@]#FDU88ZBBN$\1_$7R6:"U ../,/(SSG:.^.,$\'G@C!H2N!W=%>0_\
M)Y>_\]?_ !Q/_B:Z/PY\1?.98+H 9X\P<#/&-P[9YR1P.. ,FGRL5SC?#_\
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MU]P?I7H'A_Q!'K<?FIPP^\IZJ?Z@]CW]B" -6'<U**IZKJL>EQF>4X4?F3V
M'<G_ .N< $UYWJ/Q)N+CB(+&,C&!N;IR"6XZ\_=!_J)7"YZA17D<?CZ\0@F0
M$ C@HF#[< '\B#7:^$O&:ZS^YEPLPS@#[K#VR3R.X_$=\#0KG3UY#X\_X_9?
M^ ?^@+7KU>0^//\ C]E_X!_Z M$09W_@/_CRB_X'_P"AM7/_ !5_Y8?]M/\
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M+P_X@CUN/S4X8?>4]5/]0>Q[^Q! 35AW-2BBL/Q-XJCT)1D;I&Z(#CCN2<'
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M/ZU-8?$:ZMS^\*R D<,H4X'7!7'7W!^E+E87/5**HZ/K,>KIYT))&<'(((.
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M.0(****D845R'B?Q\NFL;> !Y!]XD_*ISTP.IZYY&#ZG(')2>/KQR2)  2>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,222223DDGJ<U5M17+FC:2^JRK @/)Y(&=J]V/3I]>3QU->SZ?8K81K GW4
M Z?F<8Y/4^IK&\'>&!H\89P//<?,<YP,\*#^6<=3W( KH:ENXTCR'QY_Q^R_
M\ _] 6L))#'RI(.".#C@C!'X@X/M6[X\_P"/V7_@'_H"U#X1T8:M<+$X)0 L
M^#C@?KR2 <<X/;J*Z"(M-\,W.I+YD49*^I(4'J."Q&>G..G>H]4T"?2\><A4
M'H>"O.>-PR,\=,YKVN.,1@*H     &  .@Q4=Y9I>(89 &1A@@_Y_(]0>12Y
MAV/"HY#&0RD@@@@@X((Z'->Q^%-:_M>W64_?'RO_ +PZGH!R,'C@9QVKRK7]
M+_LN=[?.0AX/7@C*YX'.",^]=+\+KHK-)#QAHPQ]<JP _P#0C^E#V$CMO$,$
M\T#K;,%D(X]2.X!SP3V/\NH\8^SMN\K:=^=NW!W9SC&.N<\8KWFN:U37K'3)
M6G;:TX !V+N?C*XST! R#D@XX/84DQM'$0> KN9#)L X!"LP#'/MVQW#8/X\
M5C7VGR6#>5*I5AV(]\9'J..HX-=Y=?%)%/[N)F&.K,%.?H W\_PKD_$?B1M<
M8.Z*NW(&T'=@G@$D\X^@ZGCFJ5Q&CX UXV,XMV)\N8XQV#'[IQ@]?N]NH)Z5
MZI7B7A__ (^8?^NT?_H0KVVID-'F/Q._X^4_ZXK_ .A/7*6\[6[+*APR$$'K
M@@Y'6NK^)W_'RG_7%?\ T)ZYK2[47<T<+9P\B*<=<,P!JEL)DVEZ!/JF?)0L
M!U/ 7C'&XX&>>F<U#?Z7+IYVS(R') W# ..N#T/U&17N,<8C 50     ,  =
M!BL?QA8"\M95.,HI<$C."GS<>F0",^A_"ES#L>2:??-82+.GWD((Z_D<8X/0
M^HKV^SNA=HLRYPZJPSUPPR*\(KU[P'_QY1?\#_\ 0VHD"..^(VK//<&UR0D0
M7C/!9AG=^1QWQSCJ:YBSLWO'$,8+.QP /\_F>@')KI_B-I+P7!NL$I*%YQP&
M48V_D,]L\XZ&N8L[Q[-Q-&2KJ<@C_/YCH1P::V$S=F^']Y'C"!L@$X=>"?X3
MDCD>V1Z$U2T/PW+JTI@4%=A^<L/N]N1Z^@ZY] "1T>D_$UTPMR@88'S1\-P.
MI!.#DXZ;0.?I79:/XA@U<9A8$XR5/##IGCVSC(R,]#2NQV1:T^R6QC6!<E4
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M.M?"MU=)YZ1,4QGL"1C.0"03D=, Y[5FSV[6[&-U*L.H8$$9YZ&O>:X;XHV
M*1W/&58H>.2&!8<^VT\>Y_%)CL<YX&U@Z?<JO.R8A"/<GY3C('![\X!.*]<K
MP*O?:) @HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]=H__0A7MM>)>'_^/F'_ *[1_P#H0KVVG(2/&_%^D_V9<NF %<[UP !M8GC
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MS_!?AP:U*?,SY48!;'<GHO7(S@Y([#'!(-=;\3O^/9/^NR_^@O6?\*O^6_\
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MJ@C$2-M'5U5F/N21_P#6],"N4^%<@!F7(R1&0,\X&[)Q[9'YBO0:38(Y[6/
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MY_XJ_P#+#_MI_P"R5T'@/_CRB_X'_P"AM7/_ !5_Y8?]M/\ V2A;AT#X5?\
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M=L_SQGC/3/&<\5W7P]\3?:%%A)]Y =A)Z@?P\GJ.V/X1T&.39 =K'&(P%4
M   #  '08K@OBK_RP_[:?^R5W]<!\5?^6'_;3_V2DMP8?"K_ );_ /;/_P!G
MKH/'G_'E+_P#_P!#6N?^%7_+?_MG_P"SUT'CS_CRE_X!_P"AK0]PZ'E^BZ6=
M5F2V4A2Y/)YP "3Q]!Q[]Q7K-GX5MK5!&(D;:.KJK,?<DC_ZWI@5P_PQ_P"/
ME_\ KBW_ *$E>G4Y,$<1X\\+PQPF[B4(T>,A  K L!R!CD9Z_@<\8R/AI?\
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M9Y",0?P(R/>O8*J3$B%(TLDPH5$4$\ *H'4GL!ZFO&M1OY->GWG):1@J*2.
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M@\!_\>47_ __ $-JY_XJ_P#+#_MI_P"R4+<.AB>"O#*ZU(S2']W%M+ =6SG
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MCCG/7&1QU P>EHJ;C/%M"U1M$N%E((VG:Z\@XZ,,9'(Z@'N!GI7M->)>(/\
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MCG/':O&/#_\ Q\P_]=H__0A36J!GI'C_ %;[!;%%(W3'9U&=I'S'!SGCCVW
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MPKFAX\M;0JDULT>X':RQ%>002#A3QC&,XYR.>!5_X63LRS1$_*I0@>[!@?\
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M8KS/XG?\?*?]<5_]">O3J\Q^)W_'RG_7%?\ T)Z4=P9O_#'_ (]G_P"NS?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKA=5U635)#/*<L?R [ #L!_]<Y))I*X:$GA__CYA_P"NT?\ Z$*]MKQ+P_\
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M'_H"TEN-[!X#_P"/V+_@?_H#5Z%XU@:>SE51D@ _@K!C^0!KSWP'_P ?L7_
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \"KT3PAXYB2-+6X)5D&T,1\I ("C(Z8''/&!DMDUE?\*QN?[\?_?3?_$5
MJZ_\-_M+F6U94W'E&R%'7)! ..W&,=<$# JFTQ:G0WWBVULU\PRJWH$8.Q.,
MXP#^IP/4UYEXG\0-K4IDY$8X13V'<\=SU/7TR0!5U/AY=L^PJH&3\Y<;>._&
M6Y[<9]<5UOASP#'IC+/*=\J\CCY >.0.I(.<$X]< C-&B#5E_P 'Z(VCVXB?
M[[$LPSD G Q^  SUYS@XQ7.?$O0_NWR#T5\#_OEN!^!)/]T"N_ILD8D!5@""
M""",@@]1BE<=CS7P1XQ73 ;6?(C))5N3M/<8&>#[#@DYZY'<?\)/:[?,\Y,8
MS]X;L8S]W[V?;&>V,US&M_#02MOM6"@X^1R<#U(;D^G!'KST%8'_  K^\W;-
M@QG&[>NW&?O==V._3/MGBGHQ:ESQGXS755^S09$8.68\;L9P,9^[WYYSC@8Y
MT_AIHC1!KYNC@JG/49^8D?4 #GUXZ&G:-\,UB(>Y8/P<HN0N>WS9!/'L.>^.
MO;QQB,!5      P !T&*38'/>.]%;4[?,8S)&=P &6(Z,!_/ ZX QG%>?>%?
M$1T.7S,$HPPZ@]O4=LCMGL2.,YKV2N0\3^ 5U)C<0$)(?O CY6.>N1T/7/!R
M?0Y)$P:-FU\5VMR-RS(!G'S'8?R;!_'I7+>+O'B3QFWM3N\P$,Q!& >"H# <
MGN>PZ<\C$_X5_>;MFP8SC=O7;C/WNN['?IGVSQ72Z#\-TMB);E@[ YV+]SC/
M7(RW8XP!V.13T0:G#^'_ /CYA_Z[1_\ H0KVVO.]+^'=Q:31S,T>$D1C@MG"
ML"?X:]$I2!$-Y:B[1H6SAU93CKAA@UXY!))X>N02/GA?D=,CH<9'1E/!QT.1
M7M->8_$NT2*X613\\B L,'M\H;/3D#&!TVY[T1!F%HM@=9N$A8G,C$L2><#+
M,<X/) .,]^M>UUPGPQTHHKWC#[WRJ>>@Y;V()P,\\@CCOW=$@04444AF%XJ\
M5)H:8&&E8?*O_LQ]OU)X'<B/1_'-MJ ^9A&X'(D( [9PW0\GCH3C.*OZYH$6
MM((Y0>#D,O##UP2#U[CI^(!' ZC\-KBWYB*R#(Q@[6Z<DAN.O'WB?Z-6%J=#
MXU\06LEN8LK*S_=",#M(_C)&<8S^/3IG'+?#RU,UVK#&(U=CGT(V\?BP_"IK
M'X;W,_,FV,9P<G<V/4!<@_0D?AUKOO#_ (?CT2/RDY8_>8]6/] .P[>Y))>R
M U*\S^).CF"878R5E !]F48QTP,@#'.20W:O3*P/'5HEQ:.9#C9AE."?FS@#
M ]<[>>!G/:DMP9Y?J.K/?K$CDXACV#GC@G!QP!Q@>IV@DUZAX'TO[!:IDY,O
M[P^GS 8'0?P@9]\\XKS7PUI1U2X2'&5R"_7&T<MR.F>@]R.:]IIR!#9)!&"S
M$  $DDX  ZG-<<GQ+B\XQE3Y/ 5P.<YY8K_=]._'3G [.N*U[X;I<DRVS!&)
MSL;[G..F!E>YQ@CL,"DK SHX_$EM( PFCP0#RZ@\^Q((^AYKRSQ7J$6H7#2P
M+M4]3TW'N^.V?UZGDFK?_"O[S=LV#&<;MZ[<9^]UW8[],^V>*Z'0/AO]F<2W
M3*^T\(N2IZ8)) SWXQCIDD9%/1!N;_@VU-M:0JV,E=W'HY+#]#S[UE?$[_CV
M3_KLO_H+UU]5=3TY-2C:WDSM<<X.#P<@_@1GT]>*5]1GG?P\UV+36DCF;;YN
MS!/W<@D8)[?>ZGC@Y(KT"UUN"[?R(W5W"[OE.X8SCJ..O;.?:O/=1^&UQ;\Q
M%9!D8P=K=.20W'7C[Q/]-OP/X3GTJ0W$VT!HRNT'+ [@><<=!V)INPD:WC70
M_P"U;<[1F2/YEP.3CJO0GD= .I KSKPKXB.AR^9@E&&'4'MZCMD=L]B1QG->
MR5RWB3P''J>98L1RDDD\E6..X[<]Q[D@FDF#1HV/BVUO%\P2JOJ'8(P.,XP3
M^HR/0UF:U\0H+12L)\R3D# .P$<9)XR/3;G..HSFN2NOAY=PG"JKC'57 'T^
M;:?TQ6AIOPRED(,[JJX!(7YF[97H .,\Y(SV(IV0:G5^$?$8UJ+G/FQA0^>Y
M/1A@ <X/'8\=,$M\>?\ 'E+_ , _]#6M'2=&BTI!'$H' R?XFQW)[]3[#M@5
M#XETMM4MWMT(#/MP6R!PP/8'TI=1G"_#'_CY?_KBW_H25Z=7'>#O!TVBS--(
MR$&,K\I8G)93W4>E=C0Q(Y#XG?\ 'LG_ %V7_P!!>L_X5?\ +?\ [9_^SUT7
MC'0GUJ%88RH(D#?,2!@*P[ ^M5?!7AB70_,\TJ?,V8V$G[N[.<@>M'0.IT]>
M8_$[_CY3_KBO_H3UZ=7'>,?!TVM3+-&R ",+\Q8'(9CV4^M"!COAC_Q[/_UV
M;_T%*/B=_P >R?\ 79?_ $%ZTO!VA/HL+0R%23(6^4DC!51W ]*/&.A/K4*P
MQE01(&^8D# 5AV!]:.H=#COAC_Q\O_UQ;_T)*[SQ#HXU>!X#C)&5)[,.AS@X
M]#CG!(K \'>#IM%F::1D(,97Y2Q.2RGNH]*[&AO4$>*:-JCZ'.)0#E"0RG*Y
M'0J?_K]" <<5ZC8>,+6\&1(JG R)#L(SV^; ..^"1^E1>(O!L6LYD^Y+Q\X&
M<@=BN0#QWZ\#G Q7$7?PZNX,;0KYS]Q@,?7?MZ^V:>C#8ZW7O'\%B"D)$DF.
M-O* \8RW?K_#GI@D4WP?XS_M;%O*#YP!)8#Y2!CDX^Z?TST(R%KG+#X:7$V#
M*RQ@YR,[F'7' ^4Y_P![I[\5WVCZ%%I"^7"N,XR3RQ(&,D_T& ,G &:3L&IP
M/Q._X^4_ZXK_ .A/6_\ #S586@6U! E!;(. 6R201_>^7@]QCGC%;/B+PZFN
M((W)4J258 9!QCOVZ$@$9P.:\_N_AU=P8VA7SG[C 8^N_;U]LT]T!W.O>+X-
M,1L.K2@,%4?-\PXPV#Q@]<D'&<<UY#)(9"68DDDDDG))/4YKN=%^&C%A)=,
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M&TE-*B6! .!R0,;F[L>O7Z\#CH*;5A(O4444AGD/CS_C]E_X!_Z M>G>'_\
MCVA_ZXQ_^@BN4\2^!)]4N'N$9 K[<!BP/"@=E/I78Z7:FTACA;&4C13CIE5
M--["1:KQ+Q!_Q\S?]=I/_0C7MM>=ZI\.[B[FDF5H\/([#);.&8D?PT1!GHE9
M_B#_ (]IO^N,G_H)K0JKJEJ;N&2%<9>-U&>F64@4AGCGA_\ X^8?^NT?_H0K
MUWQ!_P >TW_7&3_T$UQ>E_#NXM)HYF:/"2(QP6SA6!/\->B4VQ(\6\,WL=C<
MQS3?<4G/&<<$ X]C@^O''->OMJD*()C(@1C@,77:3SP#G'8_E7&:Y\-C,_F6
MS* Q)*OP 2<_+M7IVQCC'4YXQ+7X>7<QPRJ@QU9P1]/EW'],4W9AL2>.O$ZZ
MNZQPDF)!G.",L>^#Z#@9 .2W8UJ_"K_EO_VS_P#9ZFN_AOM@$,+*93("SOE?
ME 8;0 &QU'U/)/  TO!7AB70_,\TJ?,V8V$G[N[.<@>M%U8.IK^(/^/:;_KC
M)_Z":\<TNU%W-'"V</(BG'7#, :]IU2U-W#)"N,O&ZC/3+*0*X72_AW<6DT<
MS-'A)$8X+9PK G^&A,&=Q_9$7E?9-@\K&-O;'\\YYSUSSG->3:WI;^'KC:#]
MTAXSP>,_*3QU&.>.H]*]EK%\5>'1KD7EY =3E&([^A[X/?'< \XQ23!HD\-Z
M^FM1"12-X #KTPWTR>#V/I[@@<M\5?\ EA_VT_\ 9*L>&/"-WHLHDWH8SPZA
MFY'8\IU'4=/3(!-:'C7PQ+KGE^45'E[\[R1][;C& ?2CJ'0Q_A5_RW_[9_\
ML]=!X\_X\I?^ ?\ H:U7\%>&)=#\SS2I\S9C82?N[LYR!ZUI^)=+;5+=[="
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M"<^E2&XFV@-&5V@Y8'<#SCCH.Q-=#XETMM4MWMT(#/MP6R!PP/8'TI=0/-?
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M<ZA\-YYI7DC,81G8J,L, DD# 7 P/2O1J4F"/(?'G_'[+_P#_P! 6N_\!_\
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M'&))&88]!A>?Q4_A6/I/PR97#7+J4!'RQY.[V)(7';IDD9Z=:[^.,1@*H
M  &  .@Q0V"/(_'G_'[+_P  _P#0%KO_  '_ ,>47_ __0VK#\2^!)]4N'N$
M9 K[<!BP/"@=E/I73^&M+;2[=+=R"R;LE<D<L3W ]:&] 6YRGQ5_Y8?]M/\
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M_P#T(5[;7G>E_#NXM)HYF:/"2(QP6SA6!/\ #7HE*0(*S_$'_'M-_P!<9/\
MT$UH44AGBWAF]CL;F.:;[BDYXSC@@''L<'UXXYKU]M4A1!,9$",<!BZ[2>>
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M<89E4>N5!)_]"'ZU7^*.G8,=V,X(*'D8&,LO'7G+>W Z=^[L[-+-!#& J*,
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M+.1PQ4A5SG/#8)([<8YZG&*YJ?X?WD3%0@8#NKK@_P#?1!_2MC3?A>Q;-Q(
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M=0<YY[#'O6'_ ,('>_\ /+_Q]/\ XJO7J*?,Q6//=-^%[%LW$@"CM%DD]>[
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M+*>ZCTKL:*=Q6"L+QCH3ZU"L,94$2!OF) P%8=@?6MVBD,\Q_P"%8W/]^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([AV169!N8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ><^+?"5U?W4D\4>4;;@[D'1%!X+ ]11X2\)7
M5A=1SRQX1=V3N0]48#@,3U->C44[BL%%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !13)7V#-0?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH
M M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^
MWZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]
M: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?M
MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV
M_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157
M[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M
M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M45
M5^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?
M;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5
M%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M
M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"
MU157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?
MK1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH
M M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^
MWZT?;?;]: +5%5?MOM^M'VWV_6@"U144$_FYXZ5+0 4444 %%%% !1110 44
M44 %%%% !1110 456>[VDC'3WI/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJLEWN(&.OO5F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH BN?NG_/>J%:9&>#3?*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@""R[_A5JFJ@7I3J "BBB@ HHHH **** "BBB@ HHHH **** ,Z
M7J?J:96D8P>P_*D\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J *,74?45HTT1@=A^5.H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y#7O'_]DS-;>5NV;>=^,Y4-TVGU]:Z^O(?'G_'[+_P#_P! 6FD)F_\
M\+5_Z8?^1/\ ["C_ (6K_P!,/_(G_P!A7 T55D*YWW_"U?\ IA_Y$_\ L*VM
M)\?VU_A6)C; _P!9@+G&3ANG&.^W/&!GBO)Z*.5!<]]HK@/A[XG:1A82G(P?
M+)SGCG9],9(STQCT [^H:L4%%%% !1110 4444 %%%% !1110 4444 %%%%
M%?4+Y;"-IW^Z@)/3\AG')Z#U-<1+\4\-\L.4YZOACR,'[I XSD<]>O'/4^*=
M.?4;:2"/&]@, G&=K!L9]\<=L]<5Y!_9\N_R-C>9_<VG=TS]W&>G/TJDD)GM
M>F:BFI1K<1YVN.,C!X."/P(QZ>G%6JR?"VG/IUM'!)C>H.0#G&YBV,^V>>V>
MF:UJD84444 %%%% !15/6)VMX)94.&2-R#UP0I(ZUY;_ ,)Y>_\ /7_QQ/\
MXFFE<+GKU%4]'G:X@BE<Y9XT)/3)*@GI5RD 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!%I"RR(A5D96!#L>5(/0DCG&#QT]ZIV0M3=HHHJ1A117B7A__CYA_P"NT?\
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MM:\^'=O=NTS-)EV9C@KC+')_AJ'_ (5C;?WY/^^E_P#B*K06IG_\+5_Z8?\
MD3_["C_A:O\ TP_\B?\ V%<7JEJ+2:2%<X21U&>N%8@5Z)_PK&V_OR?]]+_\
M11H&IG_\+5_Z8?\ D3_["N_KD/\ A6-M_?D_[Z7_ .(KKZ3L""BBBD,****
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M_B5]LE2#R<>8ZKGS,XW$#.-E=/X@_P"/:;_KC)_Z":\B\/\ _'S#_P!=H_\
MT(4) SVVBBBD,**** "BBB@ HHKS'XG?\?*?]<5_]">FE<&>G45@> _^/*+_
M ('_ .AM6_2 P/%7BK^P-GR;_,W?Q;<;<>Q]:/"OBK^W]_R;/+V_Q;L[L^P]
M*Y_XJ_\ +#_MI_[)1\*O^6__ &S_ /9Z=M!=3OZ***0PHHHH **** "BBB@
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M?S'F=%%4E81ZEH_C2TMX(HGDPR1H"-CG!"@'HM='87Z7Z">(Y1LX.".A(/!
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MPSTRIR*:6@KGK^M>*[?2/ED;+_W$Y;MU'0<'/)&1TS61_P +.MO[DG_?*_\
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M_KM)_P"A&NK\(>!$NXQ=7.2'Y5.5XY&2>#SU&".,')S@4R2G_P +.N?[D?\
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MCXQFT6988U0@QAOF#$Y+,.S#TKKXXQ& J@     8  Z#%>9_$[_CY3_KBO\
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MFT6988U0@QAOF#$Y+,.S#TKSF\NC=NTS8R[,QQTRQR:]CU3PU;ZHPEF3<P&
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M\D-Z#C@@G /). >OT+1UTB);=26QU)/<]<#L/8?J<DIV!%Z201@LQ  !)).
M .IS7":Q\3=AVVJ @'[TF<'KT4$'T()(/8K53XC:^\DAL5)"(%+#IN8C<.<\
M@ CCCG/7 J?P=X&CNHQ<W()#CY4RRX&?O'&#SV[8YYSP6 I?\+.N?[D?_?+?
M_%UU.@^/(-4(B;,<C' #<J2<X ;_ ! Y.!FK]UX4M;D;6A0#.?E&P_FN#^'2
MO+O$^A_V-.8,DJ0&4G&2I^GH01VSC. #3T8:H]GKS'XG?\?*?]<5_P#0GKM/
M".LG5K=97(+@E7P,<C].003CC)[=!Q?Q._X^4_ZXK_Z$]);@S?\ AC_Q[/\
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MWXH,&Q<1@J>\601U[,3G/'<8]ZWX/A_9Q*%*%B.[.V3_ -\D#]*Y;QOX.73
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M+_Z"]8'PQ_X^7_ZXM_Z$E-;!U.^\0?\ 'M-_UQD_]!->1>'_ /CYA_Z[1_\
MH0KUWQ!_Q[3?]<9/_037D7A__CYA_P"NT?\ Z$*(@SVVN2\2>/TTQS!$HD<
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M_BZ=21T!>@:G7>)=4;2[=[A "R;<!LD<L!V(]:\SUWQC-K2"&14 #!OE# Y
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MFM?VO;K*?OCY7_WAU/0#D8/' SCM6Q4C"O,?B=_Q\I_UQ7_T)Z].KS'XG?\
M'RG_ %Q7_P!">G'<3-_X8_\ 'L__ %V;_P!!2NOKD/AC_P >S_\ 79O_ $%*
MF\?Z^^EQ+'$2'E)&X=E7&<'/!Y&#Z9Z'!H>X=!OB/Q]'IC-!$-\J\'GY >>"
M>I(.,@8],@C%<Y_PLZY_N1_]\M_\75'PEX2.NEF9BL:$9(&22>H!Z=.IYQD<
M'-=[_P ('9?\\O\ Q]__ (JGH@U,/2OB<KD)<IM]63D=?[IY  ZX)/' YX[F
M.02 ,I!! ((.00>AS7F_B[P)]@4W-MDQC)93R5'J/51WSR.I)&<3?#;7BCFQ
M<DJP)3/8CE@..XYZX!'J:30'=:I=&TADF7&4C=AGIE5)%<9X>\?S:A.L,HC5
M"&+$!A@*I;.2Q Z<^U=;X@_X]IO^N,G_ *":\6MX&N&6)!EG( '3))P.M-(&
M=YK'Q-V';:H" ?O29P>O100?0@D@]BM4H/BA.K O&A7N%W*?S);^5;^E?#RW
M@C"SCS).I.Y@/H ".!ZGD]>.@I^*/ <,<+36XV-$"Q!+$, ,D<DX/''Y'KD&
M@:G3Z/KL6KKYD+9QC(/# D9P1_49!P<$XK0KR?X?ZD;2Z6/("2@J<G S@E>^
M,YX'U('6O5I)!&"S$  $DDX  ZG-)JP(S?$'B"/1(_-?EC]U1U8_T [GM[D@
M'B9_BA.S$I&@7L&W,?S!7^5<]J-_)KT^\Y+2,%121P"<*H/ XSUXYY/)-=]I
M/PYMX$'G@R.0,_,54'VQ@_GUQG Z4[)!N9^C_$W>=MT@ )^]'G Z=5))]22"
M3V"T>(?'\VGSM#$(V0!2I(8Y#*&SD, >O'M6AJWPYMYT/D QN <?,64GWSD_
METSG!Z5YC)&8R58$$$@@C!!'48H5F&I[CI=T;N&.9L9>-&..F64$U:K/\/\
M_'M#_P!<8_\ T$5H5(RKJET;2&29<92-V&>F54D5Y?JWCN?5(FMW5 KXR5#
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MXZ LD&YB6/Q0E#?OHU*=]F0PYZ\D@\=N,^HKNM*U6/5(Q/$<J?S![@CL1_\
M7&00:XGQKX*BL8OM5O\ *$P&4DG.3@$$Y.<GD=,>A',/PRU(QRO:DC:Z[@"?
MXEQT&<<@G/&< =A0TK >D4445(PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:%24>/\ C;4?MUU(><1G8,@#&W@]/]K)'?!_"HO"QMEFWW9_=J"0,$@MD8!
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M3VQRW3U4'CIG'ID;]9_B#_CVF_ZXR?\ H)J"CQ*O8/ \ADLXBQ).&')SP'8
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M9O\ KM)_Z$:]MKR7Q[I1L;EG PDWS#KU/WN3WW<X'0$?2G$3/6(XQ& J@
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M,_W1GYL\<\?-BN0^'B.UVI3. KE\''RXQSZ_,1QZ\]J>Z M?$[_CY3_KBO\
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M/;:P/'G_ !Y2_P# /_0UK?K \>?\>4O_  #_ -#6I0SD/AC_ ,?+_P#7%O\
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M)J4;6\F=KCG!P>#D'\",^GKQ7G?PQ_X^7_ZXM_Z$E>A:KJL>EQF>4X4?F3V
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M&0D*3@D%1T]?NG..G>NS2X5V,88%DQN ()&>1D=L]J'N-'*?$[_CV3_KLO\
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MDI+<&'PJ_P"6_P#VS_\ 9Z[^N ^%7_+?_MG_ .SUW]#W!'(?$[_CV3_KLO\
MZ"]9_P *O^6__;/_ -GK0^)W_'LG_79?_07K/^%7_+?_ +9_^ST^@=0^*O\
MRP_[:?\ LE<GI<=T 6MA+@G!,0?&1V)7TS^M>B?$#1?M]OYJ_?@RP_W?XQU
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MO_04JN@NIU]>8_$[_CY3_KBO_H3UZ=7F/Q._X^4_ZXK_ .A/2CN#.O\  ?\
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MQ4C ,+8&2) 3CG VX&?;)_,UI?#'_CV?_KLW_H*5G_%7_EA_VT_]DK0^&/\
MQ[/_ -=F_P#04JN@NIU]>)>(/^/F;_KM)_Z$:]MKQ+Q!_P ?,W_7:3_T(T1!
MGMM%5;75(KI//1U* 9+9X'&3GTP.H.".]6(Y!( RD$$ @@Y!!Z'-2,\2T.,2
M7$*L 098P01D$%AD8KV^O&O%>B_V1<-$/N'YD_W3T'4G@Y'/)QGO7H7A?Q?%
MJ<:K(P6884AB!N)X!7IG/H.AX]":8D='7%?%%$,,;'&\2$#GG:5.[CZA>>W'
MK76WVH1V"^;*P51W)]LX'J>.@Y->5^-/$8UJ4>7GRHP0N>Y/5NF1G P#V&>"
M2*2!F_\ "N0D3+DX!C(&>,G=DX]\#\A7>USG@316TRWS(,22'<01A@.B@_SP
M>F2,9S71T/<:"O,?B=_Q\I_UQ7_T)Z].KS'XG?\ 'RG_ %Q7_P!">B.XF;_P
MQ_X]G_Z[-_Z"E8'Q._X^4_ZXK_Z$];_PQ_X]G_Z[-_Z"E5_B7HOFHMZO6/"M
M_ND\'KV8XX&3N]!3ZAT-;P#&$LXR  6+DX'4[R,G\ !]!70UYCX!\3KIK&VF
M.(Y""&XPK=#GV/'.<#'H21Z5!<+<*)$8,IZ%2"#CCJ*3!#;Q$D1EDQL*L&R<
M#:1SSQCCO7C7AN0QW,)4D'S4'!QP6 (_$'!]J[;QGXSB$36L#!W<;25Y4*<9
MYP0<@XXZ<\@CG"^'NBM=SBY(_=Q9.2,@MC@<]QG=GG&!TR*:T0,]"\0?\>TW
M_7&3_P!!->7^!XQ)>1!@",L>1GD(Q!_ C(]Z]0\0?\>TW_7&3_T$UYCX#_X_
M8O\ @?\ Z U"V!GKU-DC$@*L 00001D$'J,4ZBI&>)>'_P#CYA_Z[1_^A"O7
M?$'_ ![3?]<9/_037D7A_P#X^8?^NT?_ *$*]KDC$@*L 00001D$'J,54A(\
M?\%;?MD6_&,G[V,9VG;U[[L8]\8YKV*O%-1L)-!GV'(:-@R,0.0#E6 Y'..G
M//!Y!KOM)^(UO.@\\F-P!GY2RD^V,G\^F<9/6AH$=;7BWB?;]JFV9QYC?>QG
M.?FZ=MV<>V,\UWFK?$:W@0^03(Y!Q\I50??.#^77&,CK7F,DAD)9B22222<D
MD]3FB*!GM?A__CVA_P"N,?\ Z"*T*S_#_P#Q[0_]<8__ $$5H5(PK \>?\>4
MO_ /_0UK?K \>?\ 'E+_ , _]#6A <A\,?\ CY?_ *XM_P"A)7IU>4_#W4([
M*X+2L%#1L 6.!G*GKT' /7Z=:]2>X5&$98!GSM!(!..3@=\=Z<MQ(X3XJ_\
M+#_MI_[)7)Z7'= %K82X)P3$'QD=B5],_K7HGQ T7[?;^:OWX,L/]W^,=0.@
MSW/&!UKBO!?B,:+*?,SY4@ ;'8CHW3)QDY ['/) %-; ]QO_ !,O^GG_ ,BT
MV2/49 587!!!!!$I!!ZC%>L6.H1WZ^;$P93W!]LX/H>>AY%9>M>+[?2U.6#R
M#("*<G(XP2,[??/O@$C%%PL<3X+T>>WNXY'B=5&_)9& &48=2*]"\0?\>TW_
M %QD_P#034/AO7TUJ(2*1O  =>F&^F3P>Q]/<$";Q!_Q[3?]<9/_ $$TGN!Y
M;X*@6>\B5AD D_BJEA^1 KV*O(? ?_'[%_P/_P! :O7J) @KQ+Q!_P ?,W_7
M:3_T(U[;7B7B#_CYF_Z[2?\ H1IQ!GMM%%%2,\2\/_\ 'S#_ -=H_P#T(5[;
M7B7A_P#X^8?^NT?_ *$*]MJI"1@>//\ CRE_X!_Z&M<!X#_X_8O^!_\ H#5W
M_CS_ (\I?^ ?^AK7 > _^/V+_@?_ * U"V![GKU%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCC!V_P!T=??G!)XK<I,H\"KOOA5_RW_[9_\ L]8'_"!WO_/+_P ?3_XJNO\
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M$[E'(9CW(]:R-'\%W=O/%*\>%21"3O0X 8$]&IIZ"/4JS_$'_'M-_P!<9/\
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M[PY'HB;8\EF WL<_,1GMG ZG&.W4D\UK444AG)>)_ 2:D3/"0DK$9!^X?4\
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M9 R,\Y)!_AQ7HEA8)8(((AA%S@9)ZDD\DD]35BBANX['.>.])EU2!8H5W,)
M2,@<!6'<CUK'\">&KC2YVEF3:IC(!W*>2RGL3Z5W=%%PL4]8@:X@EB099XW
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MCS'2OAO/.P,^(TSR,@OCVQE>>G)XZX/?T+2M*CTN,01#"C\R>Y)[D_\ UA@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<=XQ\'3:U,LT;( (POS%@<
MAF/93ZUV-% &7X:TMM+MTMW(+)NR5R1RQ/<#UK4HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_$'A&'61N8;
M9/[Z@9/&!N_O#I[\8!'-<C/\+YU8A)$*]BVY3^0#?SKTJBG<+'G=A\+G)_?R
M* ".(P6)'?E@N/;@_3U[C2M*CTN,01#"C\R>Y)[D_P#UA@ "KE%#=PL%%%%(
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN(T_XE?;)4@\G'F.JY
M\S.-Q SC918#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***Q_$_B#^PXA/MW[G"XW;>H)SG!]* -BBN8\,>-?[<E,'E[-J%L[]W0@8Q
MM'K73T %%%% !1110 4444 %%%% !1110 45E^(/$$>B1^:_+'[JCJQ_H!W/
M;W) /#R?$^X).U(P,G (8G';G<,_D/I32"YZ916+X4U\ZW"9F4*5;:<'()"@
MD^W7IS]36U2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**XC4/B5]CE>#R<^6[+GS,9VDC.-E=O18 HHHH **YK7O'46D2?9]K.P*[L<
M  C/?J<8..!S]X&MO3-134HUN(\[7'&1@\'!'X$8]/3BBP%JBBB@ HHHH **
M** "BBB@ HHHH ***Y#7O'_]DS-;>5NV;>=^,Y4-TVGU]:+ =?16?H.J_P!K
M0K<[=N_=QG.,,5ZX'IZ5H4 %%%% !1110 4444 %%%% !116!XJ\5?V!L^3?
MYF[^+;C;CV/K0!OT5@>%?%7]O[_DV>7M_BW9W9]AZ5OT %%%% !15?4+O['$
M\^,^6C-C.,[03C-<AI_Q*^V2I!Y./,=5SYF<;B!G&RBP';T444 %%%% !111
M0 4444 %%%% !1110 4444 %%5]0N_L<3SXSY:,V,XSM!.,US&@^/_[6F6V\
MK;OW<[\XPI;IM'IZT6 Z^BBB@ HHHH **** "BN0U[Q__9,S6WE;MFWG?C.5
M#=-I]?6NGT^[^V1)/C'F(K8SG&X XS18"Q1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17$:A\2OL<KP>3GRW9<^9C.TD9QLKMZ+ %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=&[=IFQEV9CCIECDUU/_  LZY_N1_P#?+?\ Q=4T),].KR'QY_Q^R_\  /\
MT!:]>KR'QY_Q^R_\ _\ 0%I1!G?^ _\ CRB_X'_Z&U;]>?:-XTBT6SBBP7EP
MYV@X _>-U/.,CD#!/K@$&J7_  LZY_N1_P#?+?\ Q=%F%STZBN4\.>/H]398
M)1LE;@<_(3QP#U!)S@'/IDDXKJZ0PHHKBM>^)"6Q,5LH=@<;V^YQCI@Y;N,Y
M [C(HL!VM%>8_P#"SKG^Y'_WRW_Q=;^A_$6*[Q'./+?@9ZH3P.O5><]> !RU
M.S%<Z^BBBD,*X#XJ_P#+#_MI_P"R5W]<!\5?^6'_ &T_]DIK<3#X5?\ +?\
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M_9?^ ?\ H"UZ=X?_ ./:'_KC'_Z"*\O\<2"2\D92""(R"#D$&-<'->H>'_\
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M,C#((_S^8Z@\&DT,FHHHH ***XK7OB0EL3%;*'8'&]ON<8Z8.6[C.0.XR*+
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M']1D'!P3BAH+FA117+:_X_BTMS"BF1U/S8.U1UR,X/([C&/?((I =317F/\
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M<8__ $$5H5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,\X.W!Q[X/Y&DMP9I?#'_CV?_KLW_H*4?$[_ (]D_P"NR_\ H+T?#'_CV?\
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M;< KG)^H'; QVKJ:X#X5?\M_^V?_ +/7?T/<:"L>_P#"5K?N9Y8\NV,G<XZ
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M((/7!!R.M"U!GM/B#_CVF_ZXR?\ H)KR+P__ ,?,/_7:/_T(5Z[X@_X]IO\
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MG')SQG^ _P#C]B_X'_Z U>F>)(Q);3!@"/*<\C/(4D'\",CWKS/P'_Q^Q?\
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M-R"0X^5,LN!G[QQ@\]NV.><\<GX@_P"/F;_KM)_Z$:NQQZC& JBX     E
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M+%%F%STJ.,1@*H     &  .@Q3JAL[Q+Q!-&0R,,@C_/YCJ#P:FJ1A7)>*?
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MC+<_[1^;Z'.1VKA?'7A1-)VSP@B-SM()SM;&1@DY.0#]".O( H_\3+_IY_\
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MH4 SGY1L/YK@_ATKR[Q/H?\ 8TY@R2I 92<9*GZ>A!';.,X -6?^)E_T\_\
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M I.W&>IZ9SC(!Z=3\WW=#QY_QY2_\ _]#6M^L#QY_P >4O\ P#_T-:.HC@/
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M'!]AO+H6B-,V<(K,<=<*,FO&I-#NI"6:*4DDDDQN22>ISBO3/'G_ !Y2_P#
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M$+C&>J_>_3WZ<UZ#X:\(QZ'\P):4@@N<C@D' 7) Z#U.>^.*32 W:\2\/_\
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MS#3K"37I]@R6D8L[ #@$Y9B.!QGIQSP.2*MZ=X)NK[^ H,D9D^7&!GH?F_$
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MHIEVL9"0,@\%5'8GTH\=Z3+JD"Q0KN82 D9 X"L.Y'K2ZAT,/X5?\M_^V?\
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M@+D<[1SG/7#$]..@/((JO\3M*+JEXH^[\K'GH>5]@ <C/') Y[=S'&(P%4
M   #  '08HDC$@*L 00001D$'J,4KZA8\S\ ^)UTUC;3'$<A!#<85NAS['CG
M.!CT)(](2\21/.5E*8)W!@5P.ISTXQS7GNO_  YDC<O:@,A/"E@&7.<\M@$#
MMSGGH<9KGH/#%U.P00OD_P!Y2H_-L ?G3LF!U7CSQ='.ALH2'W8+,#E1@A@
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MB0@'+<MR/[H/Y@D$9_"G9!<YR\NC=NTS8R[,QQTRQR:]G\/_ /'M#_UQC_\
M017G^M> 9TE86T9,0"[277)^49/)!ZY[ >G%>B:/ UO!%$XPR1H".N"% /2A
M@CA?B7HOE.MZO23"M_O <'KW48X&!M]34G@3Q?':)]CG.T _(Q^[\QY4X'')
M)R>.3DC SWEY9I>(89 &1A@@_P"?R/4'D5YWK?PWE@;=:_.AQPQ <>O)PI'Y
M'G&.,T)W ]&^T+M\W<-F-V[(VXQG.>F,<YKFM;\?P6)5(B)#N&XKRH7@G!X!
M)'3!P#U/&#Y__P (Q=;O+\E\YQ]T[<YQ][[N/?..^<5NZ/\ #::<YN"(U!Z
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M[Y.$/3@YYXQVK:C^',D=N[L TY"[$5@ .06R3@$XR/3W)(P[) 0_#'_CY?\
MZXM_Z$E>G5PG@3PU<:7.TLR;5,9 .Y3R64]B?2N[I/<$>8_$[_CY3_KBO_H3
MUU_@/_CRB_X'_P"AM6'X[\-7&J3K+"FY1& 3N4<AF/<CUKH_"5@]A:QP2C#K
MNR,@]78CD$CH:'L'4V*Y#XG?\>R?]=E_]!>NOK/UW1UU>)K=^,\@X!((Z'G\
MCTR"1D9I(9Q/PRU".W:6)V"M)Y>T$XS@L,#WY''4]J]"^T+N\K<-^-VW(W8S
MC..N,\9KR/4?!-U8_P !<9 S'\V<C/0?-^) &?PKH?A[H$]E*;B5"J-&P&[
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M/E/^N*_^A/7IU<YXP\)_VXJNA"RIP">A![$@$\=1U[\<Y#0F1_#_ %".6U2
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M0P:N,PL"<9*GAATSQ[9QD9&>AK.\3^#(]9S*OR38X/\ "V.FX8_#(Y'O@"N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5STGCZS0$B0D@'@(^3[<@#\R!70UY
MG)\,+@$[7C(R<$E@<=N-IQ^9^M-6$S UG5'UR<RD'+D!5&6P.@4?_6ZDDXYK
MUO0-+_LN!+?.2@Y/7DG+8X'&2<>U97A7P6FC?OG(>4CKCA<CD#_'@XXP.<]+
M0V"04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img64161509_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img64161509_2.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;\2[K;''#C[SE
MLY_NC&,>^[]*[*O._B3.6F2//RK'D#W9B#_Z"*[,NCS8B/EJ8XAVILYW1K+[
M;,D1Z%N<Y' Y(X]A7IU<)X*B#SDGJJ$CZY _D37=UVYA*]1+LCDIK0****XB
M@HHHH **** "O.O$]E]EN']'.X9Q_%U_7(KT6N-\>0!6CD[LK#V^4@C_ -"-
M=> G:K;N3-:%OX:WI#R6_."H8<\ J0#Q[Y'/L/P[^O+O 5R8;I5&,2*RG/H!
MNX_%17J-<V:0Y:]^Z3.K"N\ HHHKA-PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:SA>IQ]:C-VH[_S
MIJ+8G)(FHJM]O7W_ ,_C3#J'M^M5[.78GVL.Y<HJG_:'M^O_ -:C^T/;]?\
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ME4G 'W!Z'D DCU/3/3(!KJ:**\FM6G5ES2=V=<(*"L@HHHK,H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D+;>33)IA$,FL^:<RGGIZ
M5<*;D9SJ*/J337N>%_.JI.:**Z(Q4=CFE)RW"BBBF2%%%% !1110 4444 %%
M%% !1110 445'<7"VRF1SA5')--*X!<7"VRF1SA5')->?:]KS:HV.D:GY5_J
M??\ ET'<DU[7FU1L=(U/RK_4^_\ +H.Y.37JX3">S]Z6_P"1E*5PHHHKL)"B
MBB@ IT<9D(5022< #DDGH,4VNK^'^C?:I3<L/DBZ9'!8].HQ\HYZY!VFLJ]5
M4J;F^A4(.<DCO]-LA8Q) ,810,@8R1U./<\FK-%%?+MMMMGJ)6"BBBD 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEBIOR.K_ .%D7']V/_OEO_BJ/^%D7']V/_OEO_BJY2BMOJ5#^5$>VJ=SJ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6EHUVPBC!9F. !_G\SVKUW0=.;3H5@D<NRCKV'^R.^!VS^@P!'H_AR'22S1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI^5?ZGW_ )=!W)R:]7"83V?O2W_(RE*X4445V$A1110 445+;V[7+"-!EF/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !3)ONGZ&GTR;[I^AIK<3V9E4445UG"%%%% !
M1110 445'<7"VRF1SA5')--*X!<7"VRF1SA5')->?:]KS:HV.D:GY5_J??\
MET'<DU[7FU1L=(U/RK_4^_\ +H.Y.37JX3">S]Z6_P"1E*5PHHHKL)"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWAOPV=0/FR<1 _BWL/;U/X#G)!X;\-G4#YLG$0/XM[#V]3^ YR1W:($ 4#
MP .E<.+Q?)[D=_R+A"^H(@0!0, #  Z4ZBBO,- HHHI %%%% !1110 4444
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MZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)'=H@0!0, #  Z5PXO%\GN1W_(N$+Z@B! % P , #I3J**\PT"BBBD 4444
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MS@^E<-XB\9MK$8A";%SEOF)SCH.@X[]^<=,5U/C^T>Z@58U9B)0<*"QQM;G
MKSJZL)+3'F(R9SC<I7..O45GEM"C*"F_BOW_ $*Q,YIM="O7=?\ "SO^F/\
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M>K45'! +=1&HPJ@ #V P.M25XC.T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?H>5UTWA'Q!!HP=I%<R.<94*0%';)(/)Z]N!7,UI:;X=GU)3)"FY0<9W*.<
M]R/6NS$1IR@U-V7K8QIN2E=;G;?\+(M_[LG_ 'RO_P 56-XI\4V^LQ;%5Q(I
M!4D*!Z$$Y)P1Z=P*S?\ A"+S_GG_ ./I_P#%4?\ "$7G_//_ ,?3_P"*KCIT
M,'3DI*2NO[R-I3K25FOP,*O5/ ]W]HM4&22A93G/&#D#GT4C'Y5Q'_"$7G_/
M/_Q]/_BJ[OPAI#:7 (W!#LS,P)!P>@QCV ]:G,ZM*=))23=^C'AH2C/5&#\3
MO^6/_;3_ -DKA:[KXG?\L?\ MI_[)7"UT9=_NT?G^;,\1_$9[G1117SIZ)XW
MKW_'Q-_UUD_]"-;GPW_X^&_ZY-_Z$M<_JTXN)I)%.5:1R#[%B1UKH/AO_P ?
M#?\ 7)O_ $):^CQ*MA7Z'G4_XJ]3TBN&^)W_ "Q_[:?^R5W-<-\3O^6/_;3_
M -DKQ\N_WF/S_)G7B/X;.%KW.O#*]SKLSC['S_0RP?VOD%<I\2/^/=?^NJ_^
M@M75URGQ(_X]U_ZZK_Z"U<."_CP]3>O_  V>;U[)H/\ Q[P_]<H__017C=>R
M:#_Q[P_]<H__ $$5Z.<?!'U.;";L\T\87OVNZD/.%.T9[;>#CVSD_CGK2>%=
M(&J3K$P)0 LV#C@?XG ..>>W6H_$]L;>ZE4XR7+<>C_,/T/-7O =Z+6Z"G&)
M%*Y)Q@G!'UR1@#WKIDW'"WC_ "Z?<9K6KKW/3XXQ& J@  8 '  '08IU%%?.
M'HE*ST:&R9I8D56< $J,<#L!T'OC&>IJ>[MA=(T+9PZE3CKAA@U-15.<F[MZ
MBLK6/%+ZR:RD:%_O(2#U_,9QP>H]JGTG6I=);?$<9QD'E3@YP1_48/)P1FO4
M-:\.0ZOCS0=P& RG# 9SCT/X@XR<8KBM0^'D\',1609'0[6Z=2&XZ^Y_P]RC
MCZ-:/+/1];['#.A.#NC3TOXD!R%N$V^K)R.O]T\@ =>2?0<UUNGZC'J"^;$P
M9<D9&1R.Q!Y'X_6O&[FT>U.V164D9PP*G'K@U+I>J2:9()HCAA^1'<$=P?\
MZXYQ45\LIS5X:/\  J&)E%VD>T454TK41J,27"]'&<>AZ$=!T.1GO5NO%E%Q
M;3W1V)W5PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KGO'.G&]MB5ZQ'?]0 0>XZ Y_#%=#15TJCIS4ET)
MG%231X916[XPT7^RYSM&(Y/F7T'JO0#@]NP(K"KZBG452"DMF>9*+BVF%%%%
M6(***EM[=KEA&@RS'@"DW8 M[=KEA&@RS'@"O0=!T%=+7/61A\S?T'M_/J>P
M!H.@KI:YZR,/F;^@]OY]3V U:\K%XOVGNQV_,UC&P5R_B?Q/Y&;>$_-T9AV]
MA[^I[?7H>)_$_D9MX3\W1F';V'OZGM]>G&5IA,)?WY?)"G/H%%%%>D9A1110
M 4444 %;WAOPV=0/FR<1 _BWL/;U/X#G)!X;\-G4#YLG$0/XM[#V]3^ YR1W
M:($ 4#  P .E<.+Q?)[D=_R+A"^H(@0!0, #  Z4ZBBO,- HHHI %%%% !11
M10 4444 %%%% !1110 5:L8LG?Z561-YP.]:D:>6 OI6=65E8VHPN[CZ***Y
MSI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&^)W_+'_
M +:?^R5W-<;\1+"2[\GRT9\>9G:I;&=N.@KKR]I8B+?G^3,L0KTV>?5[)H/_
M ![P_P#7*/\ ]!%>5?V#<?\ /&3_ +]M_A7J^BQF.")6!!$2 @\$$*,C%=N;
M3C*$;/J881--EVBBBO'.P\;U[_CXF_ZZR?\ H1K<^&__ !\-_P!<F_\ 0EK/
MUK19Y)Y66*0@RN00C$$%C@YQ6SX TR6UG9I(W4&(C+*5&=R\9(KZ#$5(O"M7
M6QY].+]JO4[^J&O?\>\W_7*3_P!!-7ZI:U&9()54$DQ. !R22IP,5X5/XX^I
MWRV9XS7I'PW_ ./=O^NK?^@K7#?V#<?\\9/^_;?X5WW@"T>U@99%9292<,"I
MQM7G!KVLSG%T&DUNCBPT6IEGQCHW]IP':,R1_,O')QU7H3R.PZD"O*:]SKEO
M$?@==1)GA(25B,@_</J> 2"?4=<=,DFN3+\;&DN26W1FN(H.7O+<P/#?CDZ<
MH@F!=!T(/S*,=.>H].1@>HP!N_\ "R+?^[)_WRO_ ,57#7VA3V.?,C8!<9.,
MKST^89'?UZ\=:I1QF0A5!))P .22>@Q7?+ X>JW/OV9@J]2&ATFM>.YK_"Q9
MB7'.ULL3G/WL C\,=\D]NU\,Z^-:BWX =3A@#W]1WP>V?<<XS7G^G^#;J]_@
M*#)&9/E[9Z'YOQ /\Z[_ ,.^&(]%!P=TC=7(QQZ <X'KSR>O8#CQZPL::C&W
M,MK?J;4'5<KO8V:\;U[_ (^)O^NLG_H1KV2O)]:T6>2>5EBD(,KD$(Q!!8X.
M<5.4R49RN^@\6FTC0^&__'PW_7)O_0EKTBN \ :9+:SLTD;J#$1EE*C.Y>,D
M5W]8YFTZ[:[(K#*T KQO7O\ CXF_ZZR?^A&O9*XOQIX2>\8W<."=OS+SN)'&
M1Z\=N.G&2:K+*\:=1J6ET&)@Y1TZ'-^$=:729_,D!VLI4D=LD'.._3G^O0]I
M>^/K:%=R$NW90I';N6 P/S/L:\TG@:W)1P58=0P(/KT-:&D>&Y]4($:D*03O
M8$)QQUQSSQ@9_0UZ6)PE"H_:2=OGH<U.K.*Y45M4U234Y#-*<L?R [ #L!_]
M<\U)H/\ Q\0_]=8__0A6KXB\)O8ND<".X\L;F"L<MN;/3('&./3'4\FMHNBS
MQSQ,T4@ E0DE&  ##)SBM%6I.C[K25M">22GJ>L5YO\ $C_CX7_KDO\ Z$U>
MD5YO\2/^/A?^N2_^A-7D97_'7HSKQ7\,Y2NJ\/>.FTU1!*I= 1@YPRCN/?'8
M<8Z9QC&%HL8DGB5@"#*@(/((+#(Q6]XD\#R6C&2W4O&><#EEYZ8ZD>A&3CKT
MR?6Q$J,I*G/KJCDIJ:7-$U+WXE(!^YC8D@\N0H![< G/OR/KZ<-=W;7;&60E
MF8Y)/^?R':HY(S&2K @@X(/!!'48K7T?PG/J1&%*H<$NPP,'G(!QN_#VR0#F
MBG1H86+DM/-A*<ZKL'A/1SJ4ZC&40AG)&5P.0#G^]C'YG! ->L21B0%6 ((P
M0>00>HQ6?H6A1Z/'Y:<L?O,>K'^@'8=OKDG2KQL=BO;U+K9;';0I<D?,\=U[
M23I4S0'. <J3W4]#G SZ''&0:70M=DT>3S$Y4_>4]&']".Q[?3(/J.M:'%K"
MB.4'@Y#+PP]<'!Z]Q_4"O.]6\%W%@?E4R+G@Q@D]\97J.!SU';->EAL92KPY
M)[];]3FJ494Y76QT\?Q(@(&Y) <<@!2,]^=PS^0^E4]4^) 8%;=""1PSXX/^
MZ,@\=.>O48Z\/)&8R58$$'!!X((ZC%7;'0I[['EQL0V<'&%XZ_,<#MZ]>.M5
M_9^&A[SV\WH+ZQ5EH=3X-\7-)(;:X)8RL2K$]"1]WG@ XX Z'C'/'=UQ/A_X
M?^41-<D''/ECD=L;CWQSD#@^I'%=M7EX]T74O#Y]CJH*:C[QR'Q&TXS1)<#I
M$2"/9\#/7L0!CW]J\[KV^> 7"F-AE6!!'L1@]*\RUSP7-8,?*5I(R>"HRW.>
M"!SQZXQTZ$X';EF+BH>SD[6V,,32=^9%G1_B!)8QB%T#A  I!VG ]>"#Q@#@
M=.<FDUKQ[)?IY,:B,,"&Y#D@C&.5&/Y],$=^7CC,A"J"23@ <DD]!BNI\-^!
MY+MA)<*4C'.#PS<],=0/4G!QTZY'35HX6B_:22OO_2,X3JS]U,Y2NK^&_P#Q
M\-_UR;_T):S=6T&;SI-D+[/,?;MC;;C<<8P,8QTK;\ :9+:SLTD;J#$1EE*C
M.Y>,D4\75C+#RU6J"E%JHCOZY#XD67F0I,,YC?''0!AR3^( 'U^E=?4%]9+>
MQM"_W7!!Z?F,YY'4>]>%AZOLJL9]CMJ1YHM'B==;I'Q :QB6!XP^P8!#;>!T
M!&T]/7^O)R]8\)SZ:3E2R#)#J,C YR0,[?Q]\$@9K&KZ*4*.)@KVDCSTYTGV
M9Z[X;UW^VHS-MV8<KC=NZ '.<#UK*^)'_'NO_75?_06J7P!:/:P,LBLI,I.&
M!4XVKS@T>/[1[J!5C5F(E!PH+'&UN<"O&@H0QB2V3.R3<J.N]CS*O9-!_P"/
M>'_KE'_Z"*\J_L&X_P">,G_?MO\ "O5]%C,<$2L""(D!!X((49&*ZLVG&4(V
M?4RPB:;.3^(NC?=O4'^R^!_WRW _ DG^Z!7#QR&,AE)!!R"."".AS7M\D8D!
M5@"",$'D$'J,5PFN_#TJ?,M>1W1CSU[$\8QZG/'4DTL!CH**IST[,>(H-OF0
MW2/B,T0"7*EN3EUP#CM\N #S[CCMGK-JGQ(# K;H02.&?'!_W1D'CISUZC'7
MC;JPDM,>8C)G.-RE<XZ]13;:T>Z.V-68@9PH+''K@5U?4<,WSV_R,O;U+6N:
M6F>*)K*8W))8N?G!/##^F.V.G3&,@^F0:U%+"+S.(\9RW&,'!&/7/'&<GIGB
MN-T+X?/(=]U\JJ?N @EOQ!X'ZGGIP:[J>QCGC,#*#&1C;C P.F,=,=L=.U<&
M85,/.<5'INUV-\/&HD[_ (GF5[XPFEN/M2,0%)"*>FTGH1GO@9YZ]",#'167
MQ)C*_OD8/_L8*GCKR01SVY^IK-UGX>R0G-M\Z''#$!QZ]< C]><8XS7+7-H]
MJ=LBLI(SA@5./7!KMC1PN)BDK:=MS%SJTV[G2^+O%T>L1K#&K##[B6P.@( P
M"?7VZ=\\<I4UM:/=';&K,0,X4%CCUP*ZGP_X"DG(EN1MCZ[<_.>A ./NCU_B
MXQ@=1KS4<)3M>R_$BTZLKG5^#H##:1*PP2"?P9BP_,$5LTV.,1@*H  & !P
M!T&*=7SU2?/.4N[N>C%<J2"BBBH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0C-+10!YIXJ\'-IQ,T(+0G)P,DIW.?]GT/;H>Q/+U[G7&^(_ 0G_>VH"MSE
M"<*>IX]#VQPOTQS[&#S).T*GW_YG'6PW6/W'GU%23P-;DHX*L.H8$'UZ&HZ]
M5.YRA1113 *WO#?ALZ@?-DXB!_%O8>WJ?P'.2#PWX;.H'S9.(@?Q;V'MZG\!
MSDCNT0( H& !@ =*X<7B^3W([_D7"%]01 @"@8 & !TIU%%>8:!1112 ****
M "BBB@ HHHH **** "BBB@ HHJQ;VADY/ I.22*C%R=D1PP&4\=/6M&.(1C
MIRJ%&!2USSJ.1TTZ:CZA1114&@4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\^\8^,?M.;2W/R='<?Q?[(_V?4]_IUD\#^*6!6QERP/"$ DC_9/^SZ'^'O\
M+]WL>7U51]I^'D8_6(\_+^)WM%%%<9L%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63X
MGL);Z!HH&PQZCIN'=<]L_KT/!-3:=KT.HL\43 M&>?<>H]1GC/\ 0@G0K1<U
M*:=M5KJ2[31XI!8R3R"!5)D)QMQ@Y'7.>F.^>G>O4/#/AE=&7)PTK#YF_P#9
M1[?SZGL!J)8QI(9PH$C  MCD@?Y_' ST&)ZZL7F$JZ45HNIE2PZ@[[L****X
M3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\^\8^,?M.;2W/R='<?Q?[(_V?4]_IU[^2,2 J
MP!!&"#R"#U&*\]USP%)'*!;#,<A[G[G?D_W?0]>W)QGMR[V/M+SW6U]C'$<_
M+H8.@VTUQ,HMLB0'(/8#N3[>OKTP<XKUZ#=M&_&_ W;<[<XYQGG&>E4="T*/
M1X_+3EC]YCU8_P! .P[?7).E2QV*5>>BT77J%"DZ:U"BBBN,V"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"&[NUM%,LA"JHR2?\_D.]<9:_$7=.=ZX@. /[R_[1QUSW Z#&,D'=C>,=<E
MOI3"X*)&>$/7_>.."2.F. .F<DFIH7AN76#\@P@.&<]!WZ=S[#U&< YKV*&!
MI0I.=3JON_X)QU*\I3M$];CD$@#*001D$<@@]#FG56T[3UT^-8(\[4'&3D\G
M)/XGG^56:\B5KNVQUK8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJFJ:I'ID9FE.%'YD]@
M!W)_^N>*<8N3LMQ-VU++2!< D L<#/<X)P/P!/X4ZO(-:\0RZI*)R2NT_(%/
MW?H?7U/\@ !Z!X/U]M7B)D4[HR 6Q\K?_7]1[@]\#LQ& G1IJ;^?D94\1&<K
M$^O^&8M9VE\JRD?,O7&>5_P]#SZ@Z5I:+:*(HP%51@ ?Y_,]ZFHKE=2;BHMZ
M+H:J*3OU"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4454U35(],C,TIPH_,GL .Y/_USQ3C%
MR=EN)NVI;KB?B!H<L^+M261!RG]WU88Z@]^X^GW>KTO5(]3C$T1RI_,'N".Q
M'_UQQBK=:T:LL/4YK:KHR9Q52-CR?PSX9;66R<K$I^9O_91[_P NI[ ^I6EH
MMHHBC 55& !_G\SWIT$"VX"( JCH%  ]>@J2M,7BY8B79+9$TJ*IKS"BBBN4
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAIH$TQ:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-V,ZM54U<W;K6([;()R1V7D]<?3]:R+KQ([Y$8"CU/)Z_E_/ZU4M='DN<$#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMJ.J*Y;"_6I:S]0R3QV%;RGR+FM>QER\VE[7+L*[0!3ZQX[MH^A_/FKEM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]WZG/4445[YPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBF/+MH ?3#*!4+.6IM $QGIOGFHZ* )//-'GFHZ* )//-'GFHZ*
M)//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'
MGFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ*
M )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-
M'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ
M* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//
M-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFH
MZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )/
M/-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GF
MHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )
M//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'G
MFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ*
M)//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'
MGFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ*
M )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-
M'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ
M* )//-*LQ/%14J=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ\PXZ^HR<?RZ<YXJ;1O%3V.(Y/GC  'J.>Q[\=C[8(%=W63_ ,(O;[_-V_\
M <_+G.<X_ITQVKKCC(SARU%<7LVG=&M1117":!1110 4A..:6FNNX8H!BAMW
M2EJB"8#5N*42#-5*%B(SOIU'T445)84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%-9PM0M*6H F+A:89ZAHH E,])YYJ.B@"3SS1YYJ.B@"3SS1
MYYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B
M@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS
M1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ
M.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3
MSS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YY
MJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"
M3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1Y
MYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@
M"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1
MYYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B
M@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS
M1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS4RG/-5:LIT'TH =1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445#
M+)V% !)+V%1444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5E.@^E5JLIT'TH =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MV1MHJM4DS9./2HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"E3J*2E3J* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !116)XPN9K>W9X,YS\Q'4+@Y(_3GL,G
MC&1=.'/-1[BE+E39E>+?&GV,_9K8CS ?F;@A<?PC/!/KZ=.O2UX2\6C5!Y$N
M!,!] P'<>_J/Q'&0/-(XS(0J@DDX '))/08KTOPEX2&ECSY<&8CZA0>P]_4_
M@.,D^KB\/AZ%#E?Q='U;_P OZW.6E4J3G?H=-1117CG6%%%% !1110 4444
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M/0Y';\".M=IH6NKJ:XZ2*/F7^H]OY?D3U5\+[.*E%W1$9WT-6BBBN4L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0G%+44[=J (F;=S2444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(3CFEIDIP* *Y.:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "E3J*2E3J* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<;XQ\8_9LVEN?GZ.X_A_V1_M>I[?7
MIK0H3K3Y8DSFH*[.NBG6;.T@[20<$'!'4''0CTJ2O(/#VM2Z7*&B!;<0"G][
MT'U]#_,$@^OUKC,(\/)*]T]B*-7VB,FP\,06,K7,:X9N@_A7/7:.V?TZ# XK
M6HHKGG.4W=NYHHI;!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F2]*?3)>E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>@'_ -<]S72>)](DO'147Y0#\Q/ )YP0,G^'KTYQ5SPSH@T]2[$%VX..@ [
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MGL3GOT/3_'%0ZOX8CO\ YQ\C^H P><DD<9/7G(]\US$NEW&FD;"3OR/W>X]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYH?,_"I**
M:=A-)JPU$"# IU%%(85'-+Y8S3V;;R:I$F<U4(W]")RMIU%@B\PY/2KM-1=@
MP*=1*5V.$>5!1114E&)XOG:* [/XF 8C/ .?3U.!^..]<YX6TMKJ02X^1,Y)
MZ9QP![]_;\L]]16D:O+&P[Z6*T+^3B,\ # QTQV_"K-,DC$G!J!7,!P>E*W-
MZF=W'?8M5A>(_$8T\>5'S*1^"^Y]_0?B>, R>(==&GIA#^\8?+WQZL?Z>_8X
M-<39V<FI2;%Y9CDD_J2?\_G5TJ=]7L:)=272]+DU:3:/7+,><9[^Y/Z_F:]!
ML+!+!!%&, ?F3ZGW_P ]*+"P2P011C 'YD^I]_\ /2K-34J<WH#=R&:'?R.M
M$,V_@]:FJIJ,BVZF9C@+C)Y]<#I4IWT,VFG=$]Q<+;*9'.%4<DUP>N>)7U+,
M8^6//3N?3/\ /'3ZX!IGB#6VU%MH/[M>@Z9/]X_T]NPYK6T'PE]V>?ZA"/RS
M_A],]Q6T8*FKO<U6BN5-!\*M=[9I>(SSC^)O3Z ^O7TZ@UW%%%8SFYL3=PJM
M(GDG>.E6:1EW<&E%V(E&X*VX9I:JAOLYP>AJ&>[,G X%6J;;TV)=5):[EB>[
M$? Y-49)3(<FFT5M&"B<\ZCD%%%%40%%%% !1110 4444 %>::_ 8+B13W<G
MC_:^8?H:]+KC/'-CL=9P.&&#@=QT)/J0?R'Y=F GRU+=T346AR]%%%>L9!11
M10 4444 %%%% !1110 4444 %%%% !1110!VW@:UV1M+SEVQSTPHZC\21^%=
M+572[+[%$D/]U1G&2,]2>?4YJU7A5Y\]24C:*L@HHHK(84444 %%%% !1110
M!+#<F+Z>E3F7[20HJG0#BI<$]>I:FTK=#7 QQ2U2M[W'#?G5P'-<\HN+U.J$
MU):"T44R63RQFI2N4W8I:O8QWH".,D'(QP1Z\^_0_P".*KZ1X=73G:8$_,,!
M?0$@GGOTX_KUK0MX\_.>IJQ6KJRC'D3T(BKOF85#<3;?E'4U#JMVUK&SIC<H
MR-V<<<GI[=/>L'2_%BR2;9!M#=&SG!]^G!]>W?@\.G0E*+DE>P3EK8Z6"'RQ
M[U+1163=RDK*QB:_X;&H_O$PLGJ>A'OCN.Q_#TQ6\*Z)+8LTDGR@C&W.<]\\
M'''0=^3T[])37<(,FM5B)^S]GT$XJ]P9PG)JOS<'_9%*JF<[CTJPJ[>!4?#Z
MBUGZ J[>!5+5M)34TV-P1]UNX/\ AZCO]<&KU%3&3B[K<JW0Y?0_"TEC*)G9
M<*#PN23D8[@>M=1115U:LJKNPC%(****S&0WL)GC>,=65@,].1BN!M[E]-DR
MO#*2".HXZ@^H_P BO1*YWQ3H_FC[2G51\PQU'KQW'?/;Z<Q-=3KP=51;@]F;
MEG=K=H)4Z-Z]?0U-7$>'-6^Q/L8_(_!YX!_O<_K[?05V].,KHRQ%!TIVZ= H
MHHJC$;Y@!QWIU4[F/8=P[U8AE\P9[U3CI<B,KMIDE%%%26%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5*MU4H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K*=!]*K593H/
MI0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K*=!]*K593H/I
M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4452E?S&P/PJHQN3*7*7:***DH***AEN/+..M-)
ML3:1-12#FEI#"HI+</\ 6I:R?$VJ?8(C@_._RKZ^YZ@\#OV.*J-V[(&D]#G?
M%.H?:F6W0EBC,"!G&[.,>Y'/Y\5L^$M*:Q5F?[SD?+UQMSW]\_Y[<QX>TPWT
MJ@9VJ06([8Y SD<GH,<]^U=^]MW7@UM4:2Y0E>*LB>BJZW!7AJF:0*-Q(P!D
MG/''O6#BT)23'45P&M>)9+J0^6Q5%)"[21GW/0\_I^9/<6+,\:,_WBB[LC!S
M@9X[<U4J;BDV4U8GI",\4M%0(K-"8^5_*E6\48W$ DX&3C)/0#W]JK:YJXTR
M,OP7/"@]S_@.I_+/(KA]-CDU*9 <N<@G<<_*#DYSV_SU-;1ASJ[$H6U6QZ31
M5=)RGRM^=3@YK)IH%),9+")*BCE\KY6JS37C#\&FI=&)QZK<4'-4+FY\S@=/
MYTV28KE >*AK:G3MJ85*MU9!1116AB%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 53U?_42_P#7-_\ T$U<JGJ_^HE_ZYO_ .@FKA\2]0>QYA11
M17OF 4444 %%%% !1110 4444 %=%X&_U[?]<S_Z$M<[6UX0E*7*@=&# _3!
M/\P*QQ*O2EZ#CNCT&BBBO#-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"U%>'&WOV-6(8=G)ZUFUH6USYG!Z_SK*I&RT-Z4[O7Y%BBBFL
MX3DU@=!7U*Q%_&T).-PZCV.1^HKS^>VETEP>C G:PY!QQQ_@>QY'->@%C/P.
M!6=XAT#[>@*'YTS@'H<XR/KQQV]>N1V86M[)\LMF923EJB]I.IKJ2"5>.<$'
ML?3W_P _2KM<OX3TF:S=GD&U2N,$]2#UP/3!Y]^,@UT[-MY-85X1C-J+NBXM
MM:BUC>(M+%\HVX$BG@GT]#C\QU_4UH-,9.%_.GQVX7D\FH<5;4<*LHRO'[SB
M=,U$Z:S(PR"0&P>1M/Y'J?\ &NYB QE<8/<=_P :Y'Q3I/V9O/7[KGGG^(Y)
M_ ]?SZ<5<\):ID?96ZC)7IT[CZ]^_?TK*,FO=._$4HU8>VCOU.EHHHJSA.'\
M1Z7]ADROW'R1TX/<<=AV^N.U;GA;4_M*>2WWH\8]UZ#\NA_#O6CJE@+Z-HNY
MZ'T(Z=C^/MFN$L[EK"028Y0\@\'T(YZ>GM6;]V1Z--_6:+B_B1Z-13(I1* Z
M\A@"/H:5W"=:T/.>AF>(M,^VQY'WTR5_J,=\XX]\5@>%9FCE./N$'=Z>WXY_
M3-=6TYDX44Y+8#D\FATU>[-88N2INFE=/KV&[VF^[P*?';!.>IJ4#%+5.71&
M"AU>HR6(2@HW(8$'Z&O/KF!M.E*Y^:-L@\=N0<<_7%>B5S_BK2C<A9D!++P0
M.3CM^1]!W]JRFKH[<%64)\KV9L6-V+Q%E'1A^1[C\#5BL/PI:26Z-Y@P&.0"
M,'T)_'C\OSW*I.Z,*T5&;2V"BBBF9A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 54JW52@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **S?$6I-IL#W" %EVXW9QRP'8CUKBO\ A8]Q
M_=C_ .^6_P#BJ:5PN>CT5YQ_PL>X_NQ_]\M_\51_PL>X_NQ_]\M_\51RL5ST
M>BN(T_XE#I/&<X/,9SSGCY6/''^T?\.LT_58M1&^%@P'7'4=>H/(Z<9'-%AW
M+=%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK-\1
M:DVFP/<( 67;C=G'+ =B/6N<\.^-IM2G2W=4"MNSM#9X4GNQ]*=@N=K1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Q/%NMOH\2R
MQA22X7Y@2,$,>Q'I6=X2\6RZQ*T4@0 (6^4$'(*CNQ]:=@N=9117->(/&RZ3
M)Y"H78#YN=H&0"!T.>.?\G" Z6BLOP[K@UF+S@I4ABI!.>1@\'CL1V']:U*
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M-N!&0#V&.H]?P[]%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1\14E^6Y78?[RY*]^W)'8=\GT%%F%SLJ*;'() &4@@C((Y!!Z'-.I#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JRG0?2JU64Z#
MZ4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ IDO2GTR7I0!7HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *5.HI*5.HH M4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 1SOL%0VD>?F]*LD9XH QQ5*5E8EQO*XM%%%24(
MS;1FJ4:^:W-2W;_PT^VCVC/K6B]V-S.7O2MV)J***S- KS?7M2_M"5I!]T<+
M]!^ Z]>>F<5Z163_ ,(S%YOVGYMV[=C/RYZYZ9Z\]?TXK2E-1;;&G8/#.E_8
M(AD?._S-Z^PZ \#MV.:UJ**B3N[B&L@?@USOB;4$LE,'):13P., \9)_/COC
M!X-;UW=+:HTK=%&?_K<]ST'O7FUQ.^IR[CR\C 8' ] /Z?SK6C%MWZ!R)NYK
M>&M"^T,L\F/+&< \YQQ],9]>N,8P:[FJ=EIBVL:PC^$=?4]2>_4_E3OF@]Q2
MF^=DRDT]=BU3)I1"I=N H)/T')HCF$G2N7\;ZB5VVP[C<WOR0!U]02>/2HC!
MN5BEJ<_K.IG4I#*>G11C&%!X_'U]_:NU\.:-_9L?S?ZQ^6YSTS@?AG\\\XQ6
M%X/T7SF^U./E4_+D#!/KSZ?S[\&NSK2M/[**;Z#7C#\&J_,'N*M4A&:S4K&<
MHWUZC4D#\BH+NXV?*.M)<KY/S#C/:J1.:TA33UZ&52HTK=0HHHK8YPHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\6N%MG!/4J![_,#_
M "%;%<MXZNP%2#N6W=>1@8''OD_E6V&CS58^HI;'&T445[AB%%%% !1110 4
M444 %%%% !6CX>N/(N(VQG+8_P"^OES^&:SJ?#*86#KP5((^HY%3./-%KN"/
M6**CMIQ<*L@Z,H(SUY&:DKP&K&X4444@"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *53MY%)10,OI> C/?TH6(R_,WY52C?80?2M2-PXW#O6$U
MR;'13ES[B@8XI::SA.34!E:7A>!ZUFHMFCDD/EN G ZTP0F7EJDB@$?/>N)U
M\R1SL7)R#E3TP.JXZ=/;OFB4U!:&N'PSKRLW8[I5"\"EK/T34A?QAL_..&'?
M/KVZ]?3MVK0I7OJ3*#@W%]"*ZMA<J8VZ,,?_ %_J.U9>E^&EL7\W<6(SMR,8
MSZ^IQ]/IZ;-%*R94:LXQ<4]&%%%(3BF0+7+>*M)9F$\8)W<-@9Y'0_B..F./
M>NB>Y[+R::("_+&FX76I5+$.E.\=3.T&&2TC\IN3G(YS@$#C\_PK26WW<M4Z
MJ%X%+3O961$[SDY2W8@&.*6BBI&5UN<MM/2K%5+J/:<^M6(GWC-7)*R:(@W=
MICZ***@L**1FVC--CE$G2G85U>P^BBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JE6ZJ4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &'XW_ ./.7_@'_H:UY_X6L4OKE(9!E&W9
M&2.BDCD8/45Z!XW_ ./.7_@'_H:UPW@C_C\B_P"!_P#H#52V$]SN?^$(L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ JI5NJE !1110 4444 %%%% !1110 4444
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MO9:30(****0RGJ^J+ID33OC@< G&3V4=>OZ=>@KR?4-3FUB3<Y+,3\JC.!G
MPJ_E[GODUT7Q'U O*EL"-J+N(!_B;/49[#&._)]:O?#S1 BF]<#<Q(3/8#AB
M.>YXZ9X]#5+1"W,B#X>7,@#$HI/9F.1_WR"/UJ#4/ US9#> ''?RR21T[$ G
MKV!]\5ZE12YF%CQ^?79+BW%F_*HX*D]0 "-ON.>/3ITQC9^''_'PW_7)O_0E
MIWQ T46L@NDSB4G<,<!@!W'][KZY!/T;\./^/AO^N3?^A+3Z"ZGH]><?$?\
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M44 %%%% !7E7C?\ X_)?^ ?^@+7JM>5>-_\ C\E_X!_Z M.(F=SX(_X\XO\
M@?\ Z&U;E>,0:M-;@(DCJHZ!78#UZ T_^WKC_GM)_P!_&_QI\H7/9*YCQOKZ
MVD+6Z,#))\I ()"D9)(P>HX&<'G(Z5P7]O7'_/:3_OXW^-2:;HL^LL2@+9/S
M.WW<DC)+'J><D<GOBBP7)_".GF]N4 Z1D.3[*0?4=3@?CFO6:R/#.@#1HMF0
M78Y8@=_0=\#MGW/&<5KTF[@@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ HHHH
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M&;&<9V@G&:Y2P^(GVN1(?*QO=5SYF<;B!G&VNDU[_CWF_P"N4G_H)KRG0?\
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MKSCXC_\ 'PO_ %R7_P!":A SLO#>N_VU&9MNS#E<;MW0 YS@>M:<D@C!9B
M,DG@ #J<URWPX_X]V_ZZM_Z"M=)?VOVN-X<XWHRYQG&X$9Q0]QG/_P#"P[;=
MLP^,XW;1MZ]>N<=^F?;-=/7EO_""7>[9L&,XW;UV]>O7.._3/MFO4(TV *,X
M QR23Q[GD_4T.PD.HHKS3QAJTUO=2(DCJHV8"NP'W%/0&A*XV>ET53T60R01
M,Q))B0DGDDE1DYJY2 **** "BBB@ HHHH **** "BL;QA.UO:R.A*L-F"I(/
MWU'45S7@'4I;J=ED=V B)PS%AG<O.":=@N=]1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH *X;_A9O_3'_ ,B?_85W->&TTA,]RJIJ>IQZ9&9I3A1^9/8
M=R?_ *YXJW6)XNT9M6@\N,C<K!@#WP",9[=>/Z=0AC-(\9P:I(($#AF!QN P
M<#..">W/X5O5Y_X7\(W%K<)-*NU$R<[QD\$ ?*2>IYSP1D'T/H%-@@HHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %*G44E*G44 6J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **8\H3J:K27_]T?G51@Y$RG&.Y<ICRA.IK.>=GZFHZT5'N9.O
MV1H->J/?Z?\ UZC.H>@_6J=%6J42'6D6FOSV I/M[>W^?QJM13]G'L3[27<L
M_;V]O\_C2KJ![C\N*JT4>SCV#VLNY=74!W%2+>J?:LZBDZ42E6D:RN&Z'/TI
MU8]2I<LO?\^:AT>Q:KKJC3HJG'?Y^\/RJRD@DY!K.4'$UC.,MA]%%%24%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1N;!!Y.0 >XP.>O.[ITK&\'ZL--N%9L;7&QB>P8C!SD 8(&3Z9JC=SMJTY<
MEI7X!.?O'"KDXZ< =*=M17T.Q^'&E[%>[.<L=JY!' P21V.3QTXV]>M=I5;3
M;(6,20#&$4#(&,D=3CW/)JS4LH\;U[_CXF_ZZR?^A&K<'@^ZN%$BQY5@"#N3
MH1D=6J[X]TO[)/YPQMF&1@ <C ;^A)[Y^M;GP_UQ9(Q9,0'0L5]P3N/?D@D\
M<<>N#5WT).:_X0B\_P">?_CZ?_%4?\(1>?\ //\ \?3_ .*KU6BIYAV/*O\
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MD)!+$H2>.<?+[<\CU)/?&:>PNIW=%%%2,Y3XC_\ 'NO_ %U7_P!!:L/X<?\
M'PW_ %R;_P!"6HO'.N+J4JQQD%(@1N'<GK@YY' P?KU&*E^''_'PW_7)O_0E
MJN@NIZ/7G'Q'_P"/A?\ KDO_ *$U>CUYQ\1_^/A?^N2_^A-2CN#-SX<?\>[?
M]=6_]!6NKKE/AQ_Q[M_UU;_T%:ZNA[C1Y5XW_P"/R7_@'_H"UW/@C_CSB_X'
M_P"AM7#>-_\ C\E_X!_Z M=SX(_X\XO^!_\ H;4WL);FY7*?$?\ X]U_ZZK_
M .@M75URGQ'_ ./=?^NJ_P#H+4EN-E'X9?\ +;_MG_[/7<UPWPR_Y;?]L_\
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MZY2?^@FO*=!_X^(?^NL?_H0JHB9[)4<\ZVX+N0JCJ6( ].IJ2L/QO_QYR_\
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M UG>-_\ CSE_X!_Z&M<-X(_X_(O^!_\ H#4TM!7/5:\X^(__ !\+_P!<E_\
M0FKT>O./B/\ \?"_]<E_]":B.X,W/AQ_Q[M_UU;_ -!6NKKE/AQ_Q[M_UU;_
M -!6NKH>XT4?[>M_^>T?_?Q?\:O5X;7N5#5A)E2?5H;<E'D16'4,Z@^O0FO+
M_%MVMW=221D,I*@$=.% /ZCKW[5M^*?"US?7+S1IE&VX.Y1T4 \$@]17*7UB
M]BYAD&'7&1D'J,CD9'0TT@9ZAHNM01P1*TL8(B0$%U!!"C(QFM:VNTNANC96
M .,J0PSZ9%>5P>#[JX42+'E6 (.Y.A&1U:NY\$Z7)IL+1S+M8R$XR#QM4=B?
M2DT"-+^WK?\ Y[1_]_%_QJ]7EOC?3#97+.!A)?F'7J?O<GOGG Z BNR\$:F+
MVV5"<O%\IZ=!]W@=L<9/4@T-!<Z"BBHYYQ;J9&.%4$D^P&3TI#()]6AMR4>1
M%8=0SJ#Z]":G@G6X ="&4]"I!'IU%>/7<[:M.7 ):5^ 3G[QPJY..G '2O7-
M-LA8Q) ,810,@8R1U./<\FFU8299J.>=;<%W(51U+$ >G4U)65XIL7OK9X8Q
MEVVX&0.C GDX'04AF7XRUF":U>-)$9F*@!6#'A@>V>PZUSG@&[2UG9I&508B
M,L0HSN7C)K/OO"US8H9I$PBXR=RGJ<#@$GJ:J:;I<FI,8X5W,!G&0.,@=R/6
MKMH2>MQZU!(0JRQDDX #J22>@QFKE>::3X/NK>:.1H\*LB$G<G0,">C5Z74L
MI!39)!&"S$  9)/  '4YK/UW78]'C\Q^6/W5'5C_ $ [GM]< ^8W^ISZ[(-V
M7;G:JCIW( '\^3@<GBA*XFSTNZ\56MMC=*ISG[OS]/\ =SC\:N6VI171VQNC
M$#.%8,<>N :\QC\%W;@,(S@C/+(#S[%LCZ&JE]H\^DD/(K(<@A@<C/;YE)&>
M,XSGO3L@N>Q45PWA3QLTC+:W'.<*K\[LYX#>N>F?SSDD=S4M6&%%%% !117#
M>,?&+PN;6W.W;P[C!.2/NCTQW/7/ICD2N!UU[JT-E_K752!G!8;L>PZGIVJK
M:^*K6YSME48Q][Y.O^]C/X5YE8Z//JQ+QJSG))8G SW^9B!GG.,Y[U;D\%W:
M L8S@#/#(3Q[!LGZ"JLA7/5Z\-K>\/\ B:71'\M]QC!PR'JO/. >A!SD<9[\
MX(P::5A-GN51SSK;@NY"J.I8@#TZFI*P_&__ !YR_P# /_0UJ"C1@U:&X(1)
M$9CT"NI/KT!JW7E7@C_C\B_X'_Z U>JTVK @K-O?$=M9??D7(." =S ^X7)'
M2N,\:>*'GD:UB)6-"5;!(+'&&!Z<#D8Z'KSQC)M/"5U=J)4C)5AD$LHX]<$@
M_3UZT6%<]-L=<@OL>7(I+9P,X;CK\IP>WITYZ5>KQ_4/#EQIPWRQD+ZC# =!
MR5)QUXSU[5V7@">YE0^8<P*,)N^]D'L>ZCISTX Z&AH+G7445S7BWQ:-+'D1
M8,Q'U"@]S[^@_$\8!0SH+F[2U&Z1E4$XRQ"C/IDUG_\ "56N_P KS5W>O\/3
M/W_N_KUXZUY>L<VL2D@-)(YR<?@,GL .!V ]A6A_PA%Y_P \_P#Q]/\ XJJL
M*YZA;7:70W1LK '&5(89],BI:\;_ '^B2?Q1R#\,@'\F7(]P<=Z] \(>*?[7
M'DR?ZY!DD#AATW>QYY'XCT":"YTE%-DD$8+,0 !DD\  =3FO./%'C1K\M# 2
ML."">A;U]P/;N.O7 $KCN=[=ZS!:9$DB*5&2"PW=,_=Z].@QS5>V\3VMP-RR
MH!G'S'8?R;!_&O-;+PS<WHW1QMC .3A00>A!8C/X5+/X/NX07,1P/[I5C^2D
MD_E3LA7/6:*\FT+Q5-I!PIW1_P!QB<#G)QZ'K[<Y(->H:=J"ZA&L\>=KCC(P
M>#@C\#Q_*DU8$QUU?QVF/,=4SG&Y@N<=>IHM;^.[SY;J^,9VL&QGIT-9OB[3
M#J-LZ*,NN&7KU7K@#J2,@#U->?\ A'4QIURCL<(V5;IT;IDGH <$GT%"07/6
M:***0R.>=;<%W(51U+$ >G4U!!JT-P0B2(S'H%=2?7H#7+?$?5-BI:#.6.YL
M$C@9 ![')YZ\;>G2JOPXTO>SW9QA1M7(!Y."2.XP..G.[KUIVT%<[ZBFR2",
M%F(  R2>  .IS7G'BCQHU^6A@)6'!!/0MZ^X'MW'7K@"5QW.[OM<@L<^9(H*
MXR,Y;GI\HR>_ITYZ5#;>)[6X&Y94 SCYCL/Y-@_C7F]EX5N;U?,2,[3T)(7/
M&<C<1D<]>E/G\'W<(+F(X']TJQ_)22?RIV0KGK-%>3:%XJFT@X4[H_[C$X'.
M3CT/7VYR0:]4M+M;M1+&0RL,@C_/YCM2:L-,?)((P68@ #))X  ZG-5H-6AN
M"$21&8] KJ3Z] :9KW_'O-_URD_]!->5Z#J8TR9;@@D(&X'<E2!^IY_K0E<3
M9Z]/.MN"[D*HZEB /3J:HP>([>XD%LD@9ST"Y(Z9^\!MZ>_MUKS.XN;CQ#+_
M !.Q/"KG:H.!P.BCIDGZD]ZWO"WA:YL;E)I$PB[LG<IZJ0. 2>IHL%ST"BBB
MD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44A.*JSWN.%_.G&+EL3*2C
MN3RS"/K526]+<#@?K5<MNY-)71&DD<\ZS8$YHHHJS,****!!1110 4444 %%
M%% !1110 4444 %*&V\BDHH&6HKXCAN?I5M)!)R#652HY3D5G*DGL:PK-;FO
M156"]#<-^=6JPE%QW-XR4EH%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M15G"5;M,'-3PMN --N5W#Z5'9MU6KWAZ&>T_4LT445!H%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5*MU4H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,/QO_QYR_\  /\ T-:\M@G:W(="
M58="I(/IU%>U3P+< HX#*>H8 CUZ&JO]@V__ #QC_P"_:_X4T[":/*?[>N/^
M>TG_ '\;_&C^WKC_ )[2?]_&_P :]6_L&W_YXQ_]^U_PH_L&W_YXQ_\ ?M?\
M*?,%CR:UL9M28[%9V)&2 3RQZD]L^IKLO#_@#RB)KD@XY\L<CMC<>^.<@<'U
M(XKM:*3D%AL<8C 50  , #@ #H,4ZBBD,;)&) 58 @C!!Y!!ZC%>;>*O!S:<
M3-""T)R<#)*=SG_9]#VZ'U/I=%-.P6/)-(\53Z6 D; H"3M89'/ZCUP".?J:
MNW7C^ZFQM*IC/W5SG_OK=^F*[R]\.6U[]^-<DY) VL3[E<$]:@@\'VD)#B(9
M']XLP_)B0?RIW0K,\XL-,GUV0[<NW&YF/3L"2?Y<G X'%>I:+I(TJ)8%);'4
MD]SUP.P]A^IR3<CC$8"J  !@ <  =!BG4F[@D%%%%(9X_P"(M,.FSO#C"YRO
M7&T\CD]<=#[@\UJ^ -,%W.9F&5A&>V-QX7@_B1CH0.:]"N=-BNCND1&(&,LH
M8X],D5);6B6HVQJJ@G.% 49]<"GS"L2T444AE34],CU.,PRC*G\P>Q![$?\
MUCQ7EFN>'I=(8JX)3/RN!\ISG'T/'(_F.:]>ILD8D!5@"",$'D$'J,4T[":/
M,;+QY=6HVDJXP -XR1CW!!.>Y.:BOO&MU=Y&_8IQP@VXQZ-][]?TXKOKGPE:
MW!W-$H.,?+E!^2D#\:?9>&;:R.Z.-<Y!R<L01T(+$X_"G=!9GG_ASPE)JQ$C
M96')RW&3CJ /Z]!SU(Q7J4:; %&< 8Y))X]SR?J:=12;N-(P_&__ !YR_P#
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M5KG38KH[I$1B!C+*&./3)%"=ALYWX<?\>[?]=6_]!6NKJ*VM$M1MC55!.<*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 593H/I5:K*=!]* '4444
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M;_\ 'G+_ , _]#6I0SS?0]-_M*9+?. QY^@&3C@\X''O7K]I:+:*(HP%51@
M?Y_,]Z\]^''_ !\-_P!<F_\ 0EKT>G(2"O.OB'I:VLJ3I@>:&W #NN,M^.>?
MIGJ:]%KAOB;_ ,L?^VG_ +)0MP99^&]Z9(I(#G$; @D]GSP!VY4G\:["N&^&
M7_+;_MG_ .SUW-#W!'C>O?\ 'Q-_UUD_]"->K:#_ ,>\/_7*/_T$5Y3KW_'Q
M-_UUD_\ 0C7JV@_\>\/_ %RC_P#013D".?\ B-J!AB2W'24DD^R8..G<D'/M
M[UA>!O#XU&0S2C,<>.#T+=ATP0!R1GTSD&I/B/\ \?"_]<E_]":MSX<?\>[?
M]=6_]!6CH'4ZNBBBI&>?_$'0A;D7B8 <X8#^\<G=Z<@<].>>2365X(_X_(O^
M!_\ H#5W/C?_ (\Y?^ ?^AK7#>"/^/R+_@?_ * U4MA=3U6O./B/_P ?"_\
M7)?_ $)J]'KSCXC_ /'PO_7)?_0FI1W!G5^"/^/.+_@?_H;5N5A^"/\ CSB_
MX'_Z&U;E)C"O&]>_X^)O^NLG_H1KV2O&]>_X^)O^NLG_ *$:J(F>K:#_ ,>\
M/_7*/_T$5S_Q&U PQ);CI*22?9,''3N2#GV]ZZ#0?^/>'_KE'_Z"*X;XC_\
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MD,0?SZ]:J:WHCZ.XBD*DE0WRDD8)([@>E-(&>A>!;W[3:J.28RRG/MR,>P!
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MO12<4U8J,G%W1KJP89%+69!<&+Z>E:$<@D&17/.#B=5.HI>H^BBBH+"BBB@
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M]R,#G!R>./<=?PJ_7,^,KOA(!_O'U]!_6B3LA8>'/4BC)\.VGVF=?1?F./\
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MF1Z9&(8AA1^9/<D]R?\ ZPXIO16 MUA^-_\ CSE_X!_Z&M;E8?C?_CSE_P"
M?^AK4H9RGPX_X^&_ZY-_Z$M>CUYQ\./^/AO^N3?^A+7H].6XD%<-\3?^6/\
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M6489T#8[@$D#/H>.GY\\4)6!L[SX<?\ 'NW_ %U;_P!!6NKKE/AQ_P >[?\
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M@@CJ,5WGPXTO8KW9SECM7((X&"2.QR>.G&WKUJGH2=I1114%!1110!A^-_\
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MV R!G /4X]AR:OS)/0O &F&T@,S##3'/?.T<+P?Q(QU!'-=/4<$ MU$:C"J
M /8# ZU)4,HXKXD:87"7:C[ORL>>AY7V !SSZD#FJ'P]U@6TC6SG EP5R>-P
MXQCIE@>O'0#DD5W]W:+=J8I &5A@@_Y_(]J\M\3>&6T9LC+1,?E;_P!E/O\
MSZCN!2UT$SU>BO,](\>3V("28D4$_>)W\]MW/?U!]/3%RZ^)4C8\N-5ZYW$M
M].FW'ZTN5A<[6_U6+3]OFL%WG S_ )X [D\#N:MUXZ[SZ]+D[I)" .!T'3M@
M 9/)X'.37J6@Z<VG0K#(Y=E'7L/]D=\#MG]!@ :L"8[7O^/>;_KE)_Z":\X\
M$?\ 'Y%_P/\ ] :O1]>_X]YO^N4G_H)KSCP1_P ?D7_ _P#T!J:V!GJM%%%2
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 8'6I** "HYX%N 4<!E/4, 1Z]#4E% '-W7@"UFQM#)C/W6SG_OK=^F*=9>
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M>6T9#$NP'9F&#_WR ?UK>LM-BL1MB15& #@8)QTR>I^IJS11< HHHH ****
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M9]3U)ZGJ<G':N#\ :-]JE-RP^2+ID<%CTZC' YZY!VFO1Z)"04444AA1110
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M1110!4U+2X]241S+N4'.,D<X([$>M5M/\,V^GMYL2 , 1DEFQGTW$X^M:E%
M!1110 4V2,2 JP!!&"#R"#U&*=10!S][X%M;GD*4).<HV/PP<@#Z >W%00?#
MRVC(8EV [,PP?^^0#^M=/13NPL5K+38K$;8D51@ X&"<=,GJ?J:LT44@(YX!
M<*8V&58$$>Q&#TK.L?"UM8N)HTPZYP=S'J,'@DCH:U:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%% !1110
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M24.QUTY<T4PHHHK(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8_ZY0?S2O-ZY\-B/;1;M:SL74I\C2\@HHHKH("BBB@":TM&NV$48+,QP /\
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MZ,)_U_6AJ45&TZKWJ/[5GH,UJHMGG.:1P-P/L<K!#_JW.">3\IX_E7H<4HE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .A-3CN)FY\./^/=O^NK?^@K75URGPX_X]V_ZZM_Z"M=70]QH****0!1110
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M Y.>PZ]NYJ*VM$M1MC55!.<* HSZX%2TF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 593H/I5:K*=!]* '4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R7I3Z9+TH
M KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F^(M-;
M4H'MT(#-MQNSCA@>P/I7.>'?!,VFSI<.R%5W9VEL\J1W4>M=K13N%@HHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% ',>*_"#:PXG1P&5 H5@<
M'#$YW#..OH:R]/\ AJ>L\@QD\1C/&./F8<<_[)_P[NBG=BL16EHMHHBC 55&
M !_G\SWJ6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<'XBG\Z=R#D# ^F!@C\\UV.DP>1"B8Q\HR#UR>3U]S7.WGAB6:8GC8[$[L]
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M]KGSI/\ 4H<$ \L>NWV'/)_ >H[Z/P];( HBCP!CE%)X]R,GZFGH@W//]/\
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M9;/7YEY.>%.0/P''0<5W&B^"(;)5,JB23J2<E>1T"G@@>I&<\\< :W]@V_\
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MO^%.Z0M3B-)^(<L!Q.!(I/4 *PZ>F <<\8&3WJ#Q[=K=S1RQD,K0J01_O/\
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M%))/4YQ0@9XW)(9"68DDG))Y))ZG-;?_  F]Y_ST_P#'$_\ B:S]:C$<\JJ
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M,O\ EM_VS_\ 9Z[>201@LQ  &23P !U.:'N"*VIZG'ID9FE.%'YD]@!W)_\
MKGBN#U/XA33$B'")G@X!?'OG(YZ\#CID]\KQ)KIUB4R<A!PBGL.YX[GJ>OID
M@"NN\/\ @*. "6Y&Z3KMS\@Z$ XZGU_AYQ@]2[6#<Y'_ (2JZW^;YK;O3^'I
MC[GW?TZ\]:U])^(<L!Q.!(I/4 *PZ>F <<\8&3WKM_[!M_\ GC'_ -^U_P *
MY_Q!X"CG!EMAMDZ[<_(>I(&>A]/X>,8'4%T%F='IFIQZG&)HCE3^8/<$=B/_
M *XXJW7*>!O#LFG SRDAI !L]!U!8?WO0=@3GDX'5U+&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOUJHB9[):7(ND65<X=0PSUPPR*\8N[DW3M*V,NQ8XZ98Y->T00"W41J,*H
M]@,#K7B]W;&U=HFQE&*G'3*G!HB#/:((!;J(U&%4  >P&!UJ2HK2Y%TBRKG#
MJ&&>N&&14M2,*\S^(-L(;K<,YD16.?497C\%%>F5Y?X\O1=7148Q&H7(.<D9
M)^F"<$>U..XF=+\./^/=O^NK?^@K75URGPX_X]V_ZZM_Z"M=70]QH\S\>Z7]
MDG\X8VS#(P .1@-_0D]\_6NL\$:F+VV5"<O%\IZ=!]W@=L<9/4@T>-],%[;,
MX&7B^8=.@^]R>V.<#J0*Y/P%JGV2?R3C;,,') Y&2O\ 4 =\_2GNA=3L_%VI
MG3K9W4X=L*O7JW7!'0@9(/J*\_\ ".F#4;E$891<LW3HO3(/4$X!'H:TOB'J
M7VB86X'$(_5P">_3&/3G-;GP\TW[/";@GF8_HA(';KG/KQBC9!U.KHHHJ1A1
M110!XWKW_'Q-_P!=9/\ T(U[)7C>O?\ 'Q-_UUD_]"->R54A(*HZ]_Q[S?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%%
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MXB2"2=&4@@PJ01R""S8.::5F#-[X<?\ 'NW_ %U;_P!!6NKKE/AQ_P >[?\
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MQ@'GC.*+"N=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBBB@ HHHH **** "BBB@
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M -=5_P#06KS>O2/B1_Q[K_UU7_T%J\WK7*_X"]63BOXA[)H/_'O#_P!<H_\
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M>?\ /3_QQ/\ XFO5J\/$X2>'MS-:]CNIUE4O8****YC0**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<9XSZ]NM5&#E?R&E<[:BBBI$,F7<"*BM%*YS[58HIJ6EB7'6X4444B@HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCMV"D8'YGW-9_P -;(!)+CC)8*..0% )Y]\CCV_+M*;8)'+:I\/X)U/D QN
M<?,2I/OG)_+IG//2N!@FDTJ8,.)(GY&>ZG!!P>0>AP>17L]>5>-_^/R7_@'_
M * M"8,]0M+D72+*N<.H89ZX89%1ZCJ"Z?&T\F=J#G R>3@#\3Q_.LSP1_QY
MQ?\  _\ T-JR?B5=;8XX<?><MG/]T8QCWW?I2MJ,X^YN9M>FR<M(YP .@'H/
M0#_$D]37;Z9\/880#-EWQR,D)GVQ@\=.3SUP.V5\-K)9)))C]Z,*%Z<;LY/U
MXQ]":] IMB2,&3P-:," A!(ZAWR/?DD?F#7%^*/"9T7$BMNC8X!/# \D ^O
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M.W8*1@?F?<UR_A'Q!!HP=I%<R.<94*0%';)(/)Z]N!70_P#"Q[?^[)_WRO\
M\53=Q(MS^!+20%0A4GNKMD?]]$C]*\_UW0I-'D\M^5/W6'1A_0CN.WTP3VO_
M  L>W_NR?]\K_P#%5B^*_%$&LQ!$5PZMD%E7IT(R&)&>O?H/J!7!V.G\'^(#
MK$1WX\R,@-CN#T;I@9P<@>F> 0*WJ\Z^&\A$[KDX,1)';(9<''MD_G7HM)[@
M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MST^G?VJ9JZ-<+*,*J;V&>#O]2W_70_\ H*UN,H;K532+#[!&(N"1DD@=2?\
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M HHHH **** "BBB@ HHHH **** "KFD?Z^+_ *Z)_P"A"J=7-(_U\7_71/\
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MQQ:/3**C-PH[TGVE?6L>5D\R[DM0QW:2L8U92PSD @D8X/%0WD_F(R(2&*L
M>F"1P<]:XCPI_P ?,?\ P+_T$U<:5TWV'%J1Z'11168!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %5*MU4H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***QO&$#7%K(B LQV8"@D_?4]!0!KR2",%F(  R2>  .IS7DOB?5_[5G:4
M?<'RI_NCOT!Y.3SR,X[54?SKHBW.]F3(5#N8C'4!>V,<CV]JZSPEX+9&%U<
MKM(*+W)Z@G'3'IUSUP!@U:PMSIO#&D?V5 L1^^?F?_>/;J1P,#C@XSWK5HHJ
M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'C>O?\ 'Q-_UUD_]"->R5XWKW_'Q-_UUD_]"->R
M54A(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT'TH
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MXC&6Y.,L!CCV'?G[V/6M+X=:7Y,;738S(<+P,X4G//N>W'W<^E<5=SMJTY<
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MC^7?D^N!%X(_X_(O^!_^@-3Z"ZGJM>5>-_\ C\E_X!_Z M>JUY5XW_X_)?\
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M<I\./^/=O^NK?^@K75T/<:"O*O&__'Y+_P  _P#0%KU6O*O&_P#Q^2_\ _\
M0%HB)G<^"/\ CSB_X'_Z&U8WQ,@++%)CY5+@GW8 C_T$UL^"/^/.+_@?_H;5
M<U[21JL+0'&2,J3V8=#G!QZ''.":.H=#D_AG.%:6//S,$('LI(/_ *$*[RO'
M;:YFT&;(RLB'!!Z$>A]0?\"#T->DZ/XK@U(##!7. 48X.3Q@$XW?A[9 )Q0T
M"-FHKNY%JC2MG"*6..N%&31<W:6HW2,J@G&6(49],FN \8>,!J ^RP<QG!9B
M,9QR  >0 >IZD^W42N,YK3;874L<39P[JIQUPQ ->TUP/P\T0NQO7!VJ"$SW
M)X8CGL..F.?45WU$A(QO%VF'4;9T49=<,O7JO7 '4D9 'J:X/P7J7V&Y7C(D
M^0^OS$8[CN!GVSWKU6O'_$6F'39WAQA<Y7KC:>1R>N.A]P>::!G6?$?5-BI:
M#.6.YL$C@9 ![')YZ\;>G2JOPXTO>SW9QA1M7(!Y."2.XP..G.[KUKF-6U1M
M3?SGSG:HY/\ = !QT R<G Z9KU/P[I@TV!(<8;&6Z9W'D\CKCH/8#FAZ(.II
M5YW\28"LR28^5H\ ^ZL2?_0A7HE8GBW0_P"UH=J >8ARO0?5<D=Q].0,G%)#
M9Q_A#PW#K2OYA<.A'W2H7##CJ"<Y!S^%=!_PKBW_ +TG_?2__$UQ6C:M)H<W
MF <C*LK#&1GD>H.1^!'.1D5Z9I'B2#5 #&P#$D;&(#\<],\\<Y&?T--W$C(_
MX5Q;_P!Z3_OI?_B:/^%<6_\ >D_[Z7_XFNDNK^.TQYCJF<XW,%SCKU-<7K_Q
M (95M"-JD$LR_>_V<'D#U/!],=2E=AH=!HGA*+1W,L9<DJ5^8@C!(/91Z5MU
M1T75AJL2SJ"N>H([CK@]Q[C]#D"]2&>&U[E7AM>Y54A(****D9Q7Q,@++%)C
MY5+@GW8 C_T$U!\,YPK2QY^9@A ]E)!_]"%=9KVDC586@.,D94GLPZ'.#CT.
M.<$UY5I^H2Z1+YB95U)!!'YJ1_G'L15+5">Y[+16-H_BN#4@,,%<X!1C@Y/&
M 3C=^'MD G%:%[J45B-TKJHP2,G!..N!U/T%2,J>)[D6]K*QS@H5X]7^4?J>
M:\OT'_CXA_ZZQ_\ H0K6\7^*?[7/DQ_ZE#D$CECTW>PYX'XGT&3H/_'Q#_UU
MC_\ 0A5):$L]DKE/B/\ \>Z_]=5_]!:NKKE/B/\ \>Z_]=5_]!:DMRF8?PX_
MX^&_ZY-_Z$M>CUYQ\./^/AO^N3?^A+7?:CJ"Z?&T\F=J#G R>3@#\3Q_.A[B
M1+/ MP"C@,IZA@"/7H:YK4/AY!/S$6C.!T.Y>O4AN>GN/\:.C_$/S)&%P L;
M'*D G;QT..3GUQU[8/R]E;7:70W1LK '&5(89],BC5!N>4:YX:FT;!DP5;HR
MY*Y].0,'O[]NAQU'P]UQKC=9N2=BY0^@!P5SGMD8_$9Q@5-XZU^+R6M%8-(Q
M4$ YVX;)R0,9RN,9!YS6#\/[(SW(EYQ$K$\9&6&T#/;J3^%/=!U.E^(<!DM@
MP'"2*3[#!7^9%<5X9TV/4IA;RE@&!QLQU SSD'C /XXKU6^LEO8VA?[K@@]/
MS&<\CJ/>O(KRRET6;:WRNA#*>H.#D,,]1Q_0C.10@9W/_"N+?^])_P!]+_\
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MR!WQC\,5T?PX_P"/=O\ KJW_ *"M>?WUZU[(TS_><DGK^0SG@=![5Z!\./\
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M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSZ'_ .M50^)$5/A9GT445U'$%%%% !1110 5D>*_^/:3_@/_ *&*UZR/%?\
MQ[2?\!_]#%:T/XD?5"ELSSNBBBO=,0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***UM(\,3ZKS&N$_OMPO?\3R,< X/7%1.<8*[=D-1<G9&317;0?#-
MF +R@-W"H6'YDK_*JE]\.IX<F-E<#&!]UCZ\'@8_WNGOQ6"Q^';MS%NA42O8
MY2BI)X&MR4<%6'4,"#Z]#4==*=S,****8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4J=124J=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 5+3K^%6ZI6Q^85=JZFYG2^$*R_$O_'N_P#P
M'_T(5J5E^)?^/=_^ _\ H0K.6S.BA_$CZHPO"/S2,G0E<Y[\$<?CG]*ZDP-V
M/\ZY;P=_KF_ZYG_T):[&BG)J)ICX)UF5O(?U_4U5U'2/[0 $G;."#@C.,]L=
MJTZ*MRN<T4X.Z;3,_3],-@OEH>,YYY.?RJSL?U'^?PJ>BDI6"2<G=MW(-C^H
M_P _A7*^+N)%!^]MY/;&3C^M=C63K.@#4BK[MI P>,Y';N.G/YTIMM6-L)*-
M.JI-NP:'DP(4X&.GODY_7-7?WG^<4:=9"RC6$'.WN?<Y/\ZLTXRLMD958J4Y
M--[E<,X[5QWB7'GD]R%S[''^&*[FL/5/# OI#,'V[L9&W/08]14U/>6QO@IQ
MI5+MNUB_9$K&@3E=JX)ZXQQZ5-O?T'^?QI]O"(%6,=%  SUX&*DJN;R.>4;M
MZL@WOZ#_ #^-1W#,5.1Q_GWJW4-W]T_A_.JC+5:$3C[KU,VBBBNDY HHHH *
M*** "LCQ7_Q[2?\  ?\ T,5KUD>*_P#CVD_X#_Z&*UH?Q(^J%+9GG=%%%>Z8
MA1110 4444 %%%% !1110!=TBW^TR>6!DLDF <==C8Z^]4JZ'P0@:<DCI&2/
M;E1_(UBW\ MY'C'178#/7@D5E&=ZLH^2_4=M""BBBM1!1110!UO@CPN+\_:9
M@?+4_*".&/?Z@?D3QG@BND\3>,%TC]T@#RD=,\+QP3_AQQW'&;UK#_8EKC )
MAB)(!."0"S<GU.>WX=J\DGG-PQD8Y9B23[DY/2O(I0^NUI3E\*T2.N<O8P26
M[-N3QS=L20X )Z!$P/;D$_F35[2?B'+ <3@2*3U "L.GI@''/&!D]ZY*BN^6
M#H25N5?<<ZK33O<[OQ7K5GJ$ D #2N/EQ@.N/[QYP!D\=^W]X<)16EX?TM=3
MF$+N$7N20">0-JY_B.>/SYQ@E*E'#4WJ[+4)2=67F9M%>GW0T[2,0R+&",\%
M/,8=^3ACWXSVZ<4Z'3K#7D81*F%/)1?+8$C@] ?ID$$COBN?^TE;F<)<O<T^
MK=+JYY=16CKFBMH\I@<@\94CN#G!QVZ<C^8YKH?AW81W?G>8BOCR\;E#8SNS
MU%=-7$1A2]JM49QIN4^7J<;17IMYX?L]-=KZ?:%) "%1L&0!P@!R>"?QSCC-
M2:?<:=J#>5$L18@G!B"YQZ;E&?I7-_:2<>91;75FGU9WLVKGEU%=1XR\++I.
MV:+/EN2""0=IZ@ ]2",^N,<DYKG;2T:[811@LS'  _S^9[5UTJT*D.=;&4H.
M,N5[D-%>E:7X-M]*437!5F &2Y'E@GC@' [X^;/." .E+!J>F3$(!%D_WHMH
M_-E 'YURO,8MOEBY)=4:_5WU:1YI17=>,?"<-LANHV$>/X3G:Q)S@>AZ\ 8X
M_A )KE]"T*36)/+3A1]YCT4?U)[#O],D;TL53J4_:;);W,Y4I1ER]3-HKTV7
M3]/T$!90F2!]\>8QZ\[<'&><D #/X46S:=JY^SQK&6(S@(8SQSP<*?P!Z9[9
MKG_M%6YE"7+WL:?5NEU<\RHKHO%?A3^QL2(2T3''S8W XS@XQG."00/8]B9/
M %HEU.RR*K 1$X8!AG<O.#70\3#V3JK5&?LGS\KW.9HKU2[\+VJ2?:I BHJJ
M-N B [B=QQ@'.0,'CUSD8YCQ;J%G<1*MJ$#[P3MC*'&&SSM'?'%94<>JLDHQ
M?F^B+G0<$VVCDJ***[3$**** +FGV/VL2>J1EQ_P$C/Z9_'%4ZZCPI:-+!<;
M1]]=J\CD[6X_\>%<O64)\TY+M;\AM:(****U$%%%% !1110 4444 %7-(_U\
M7_71/_0A5.KFD?Z^+_KHG_H0J9_"_0%N>GT445\^;A1110 4444 %%%% &NH
MV\"EJ#[6/>C[6/>N7DD=O/$GHJ#[6/>E%TIHY6'/'N2(@0!0, #  Z4ZHOM*
M^M'VE?6ERL?,NY+56^U..P :5MN3QU)_(9-2_:5]:XWQL-TJN.A3'X@DG^8J
MX4^9V8XM-V.U1PX# Y!&01TIU8_AMO)MXU;@X)_ L2/T-:?VE?6I<&G83DNY
M+6/J7A>*_<S,6#$#.TC!QQGD'M6H+A3WI?-'J/SH7-$%)!#$(5"+P%  ^@X%
M/IGFCU'YT>:/4?G2LPNA]%,\T>H_.N)MO$$\URN6(#2!2IQ@ MTQCJ.F<9JH
MTW*XUJ=S1114 %%%5+0Y/X4U&Z;)<K-(MT444B@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JE6ZJ4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M R!C)'4X]SR:LTAA1110 4444 %%%% !1110 4444 %%%<-\3?\ EC_VT_\
M9*$!W-%<I\./^/=O^NK?^@K75T, HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/PW_ ./AO^N3?^A+3A1]GA)VE=/704I\U:.EB?XDWK&1+?\ @";N_))(Y[<
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M_P!M/_9*YB#79+>W-FG"NY+$=2" -OL..?7ITSEVT%<]+O?%5M9-Y;R#<.H
M+8YQ@[0<'CIUJA:^/[6;.XLF,?>7.?\ OG=^N*X_2_!5QJ*B4!54@$%R1D'N
M  3^>,Y!&:LS_#RYC!8%&([*QR?^^@!^M.R"[/1K:[2Z&Z-E8 XRI##/ID5+
M7C6GZA+I$OF)E74D$$?FI'^<>Q%>JZ'K*ZO$)D!'.&![$8R,]^O!_D>*35@3
M-"L:?QA:V[&-I,,I((VOU!P>BULUXWKW_'Q-_P!=9/\ T(T)7!L]@GG6W!=R
M%4=2Q 'IU-<_=>/[6'&TL^<_=7&/^^MOZ9KBM0OY_$TWRJ3_ '47D*"0.OY9
M8X_ 8 T(_AU<L 28P2.A9LCVX4C\B:=D%STFBBO-/%7C%M1)AA)6$9&1D%^Q
MS_L^@[]3Z!)7&=I<^+;6W.UI5)QGY<N/S4$?A5*U\?VLV=Q9,8^\N<_]\[OU
MQ7':9X,N=0 D "HPR&<XS^ R>>HXQCOTJY)\.KE02#&2!T#-D^W*@?F13LA7
M9Z%97T=ZOF1,&4]P?;.#Z'GH>:GKQU'GT&7(W1R $<CJ.G?((R.#R.,BO2_#
M.OC68M^ '4X8 ]_4=\'MGW'.,TF@3->BBN3\;^*#8C[-"1YC#YB#RH[?0G\P
M.>X-)#-[4M<ATW'G.%)[<EN_.!DXXZ]*R$^(-JS;#O R?F*_+QWX);GMQ]<5
MP6F:1-K3D1@L<Y9F/ R>I)_/N3S@&MO_ (5Q<?WH_P#OIO\ XFJLA79WFGZK
M%J(WPL& ZXZCKU!Y'3C(YKS7QO\ \?DO_ /_ $!:@N],N?#\@D(*E3\KKRIZ
M]^G(!X/..HQ5;6-3.IRM<, "P7('3(4 _GC/M[T)";/2?!'_ !YQ?\#_ /0V
MK8GG%NID8X5023[ 9/2L?P1_QYQ?\#_]#:KVO?\ 'O-_URD_]!-)[E$%CXIM
MKYQ#&^7;.!M8=!D\D =!6K7E7@C_ (_(O^!_^@-7JM#5A(*J:EJD>FJ))FVJ
M3C."><$]@?2K=<I\1_\ CW7_ *ZK_P"@M20S9TWQ%!J3&.%]S 9QM8<9 [@>
MM:5><?#C_CX;_KDW_H2UZ/3:L""J>H:S#I_^M=5. <$Y;!.,A1R?P%8_B_Q3
M_9 \F/\ USC()'"CIN]SQP/Q/H?/[6QGUESL#2/QDDY[<98\#@<9/L*$A-GH
M$OC^U1@@+,#CY@ORC)[YP>.O /MS6EI_B.WU$[(I 6]#E2>IX# 9Z<XZ=ZXK
M_A7%Q_>C_P"^F_\ B:RM7\,3Z5S(N4_OKRO;\1R<<@9/3-.R"[/7*J:EJD>F
MJ))FVJ3C."><$]@?2N3\#>)I;AOLDNY^"0_4C')W'T]#V.!T(QN>+=$?6(EB
MC*@APWS$@8 8=@?6E;49SGC;Q)!J42Q0L6._<?E(  !'<#KGM5;P+K<.E^;Y
MS;=^S'#'INST!]:S];\)2Z.@ED*$%@ORDDY()[J/2HM"\-R:UN\LJ-FW.XD?
M>SCH#Z56EB3T>Q\4VU\XAC?+MG VL.@R>2 .@K5KBO#O@F;39TN'9"J[L[2V
M>5([J/6NUJ64B.>=;<%W(51U+$ >G4US]UX_M8<;2SYS]U<8_P"^MOZ9KA]=
MUF37)L\E<XC4#H">.!GYCWZY/'0 5IQ_#JY8 DQ@D="S9'MPI'Y$T["N=A9>
M+[6[X$@4XSA_EQ[9/&?H3[<5LUY-K/A.?21YC@,G&60Y SV.0"/KC'(&<UW/
M@RPGM(?](8_-C:C<E0!CJ>F>/E[8]20$T"9T%%%%(8445Q'C_6YH#]E4%8W4
M9;'+=<@'/3ID8!_X">1*X'17OBJVLF\MY!N'4 %L<XP=H.#QTZU0M?']K-G<
M63&/O+G/_?.[]<5Q6C>$Y]6'F( J<X9S@''88!)^N,<$9S6A)\.KE02#&2!T
M#-D^W*@?F1560KL]"LKZ.]7S(F#*>X/MG!]#ST/-3UX[;7,V@S9&5D0X(/0C
MT/J#_@0>AKU?2M0&HQ)<+T<9QZ'H1T'0Y&>])JP)ENBBO,_%OBTZH?(BR(0?
MH6([GV]!^)YP )7&=C=^,K6VR#(&*CH@+9XS@$#;^OUQ45EXZM;G@L4).,.N
M/QR,@#ZD>_%<1I/@^XU(;U4*I'#294'IC P2<@\'&/>KTGPZN5!(,9('0,V3
M[<J!^9%.R%=GH%UJ,=K']H=AY8 .X9888@ \9SG-4['Q3;7SB&-\NV<#:PZ#
M)Y( Z"O,I+F;3EDL7R Q&Y3V((((^N.O0CUX(N^"/^/R+_@?_H#4<H7/5:**
MXCQ_K<T!^RJ"L;J,MCENN0#GITR, _\  3S*5QG17OBJVLF\MY!N'4 %L<XP
M=H.#QTZU0M?']K-G<63&/O+G/_?.[]<5Q6C>$Y]6'F( J<X9S@''88!)^N,<
M$9S6A)\.KE02#&2!T#-D^W*@?F1560KL]"LKZ.]7S(F#*>X/MG!]#ST/-3UX
M[;7,V@S9&5D0X(/0CT/J#_@0>AKU?2M0&HQ)<+T<9QZ'H1T'0Y&>])JP)ENL
M:?QA:V[&-I,,I((VOU!P>BULUXWKW_'Q-_UUD_\ 0C0E<&SV""<7"B13E6 (
M/L1D=:)YQ;J9&.%4$D^P&3TJKH/_ ![P_P#7*/\ ]!%&O?\ 'O-_URD_]!-(
M9!8^*;:^<0QOEVS@;6'09/) '05:U#58M.&^9@H/3/4].@')Z\X'%>2Z/J9T
MR5;A0"5#8!Z9*D#\LY]_:KEAHUSXB=IASD_,[G"YQT_I@#CCH*KE%<[7_A/[
M7?Y>6V_W]OR],]/O>WW>OMS6SI^JQ:B-\+!@.N.HZ]0>1TXR.:X&3X=7*@D&
M,D#H&;)]N5 _,BL'][I,O=)8S^(_H01^!'J#19!<]GHK+\.:S_:\(FP V2&
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MTR7I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **S]9UR+2%$DI/)P%7ECZX&1T[G^I%5M#\5PZPQCC#!E&<, ,C.#T)Z9
M'Y_6BP&S1139)!&"S$  9)/  '4YH =17":I\1V5BMNJE03\SYY]P 1COUSG
MCITI-)\?S7,T<3JFUW53M# _,<9R6/3/I^76G9BN=Y15;4=073XVGDSM0<X&
M3R< ?B>/YUD:9XWM]0D$(W*S=-X !/ID$\GM^77%*PSH**** "BBB@ HHHH
M**** "BBB@ HHHH ***RO$FN_P!BQB;;ORX7&[;U!.<X/I0!JT5S?AOQA_;4
MAA\O9A"V=^[H0,8VCUKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^1S5JTN>R9ZQX>O9+Z%9Y@ SY( 4K@9P.I.<]<^A'U-R[NUM%,LA"JHR2?\
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MRD3"/^%\Y'KA2179_9E]*X+1Y3'-&1UW@?@3@_H:]"J:<G8Z<PIKVB=MT1K
MH[5E>*;?,!8<;2I.._.,?KG\*V:H:[!YT$BYQA<_]\_-_2JDVTSGH6C4B_-&
M%X-N"':+^$KG\00/Z\_A765P_A>4I.H'1@P/TP3_ # KN*BF]#?'1M5]4%<W
MXSA)5).P)'O\P!'\JZ2L;Q7!YD!;/W&4_7^'^M.6S,\++EJQ*W@R?*/'C[K
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M[RP"X.#DGCGMSWJD)GM4D@C!9B  ,DG@ #J<UXU/-)JLQ8\R2OP,]V. !D\
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M4KTQM/(&3R1WX K<^&MUNCDAQ]UPV<_WAC&/;;^M<UXC\,G1!'N<,9 V0!@
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MU;GPX_X]V_ZZM_Z"M#V#J=77C>O?\?$W_763_P!"->R5XWKW_'Q-_P!=9/\
MT(T1!GJV@_\ 'O#_ -<H_P#T$5S/Q(U HL=LI&')9@#SA<;<C/0G/7N..E=-
MH/\ Q[P_]<H__017#?$?_CX7_KDO_H34EN#V)?A[H@N&:[< K&<+G^]USU_A
M&,9'?(Y%>A5RGPX_X]V_ZZM_Z"M=70]P05Q'Q$T48%ZN<Y"L .,<X8D?ESUX
M'&.>WK#\;_\ 'G+_ , _]#6A;C9PW@C_ (_(O^!_^@-7JM>5>"/^/R+_ ('_
M .@-7JM$A(@O+&.]&R50R@@X(SR.G^>XR#P:GKB/%'CEH':WML H2&<C)R#R
M #QQT)(.>W0$\U;V5WKO3?(%SRS?*.F1ECC/3CK18+GJ,^K0VY*/(BL.H9U!
M]>A->>>-K^WU"19K=LL00_RE>F-IY R>2._ %.MOA]=3#+;$.>C-D_7Y0P_6
MJGB/PR=$$>YPQD#9 & "N,\YYZ^@II(&=+\-;K=')#C[KALY_O#&,>VW]:[*
MN&^&7_+;_MG_ .SUW-)[@CAOB;_RQ_[:?^R5>^''_'NW_75O_05JC\3?^6/_
M &T_]DJ]\./^/=O^NK?^@K3Z!U.KJIJU[]BADFXRB,1NZ9QP.W4\5;K#\;_\
M><O_  #_ -#6I0SS;3K)M5F6+)+2-R3R?5FY(S@9/7FO8+2T6T411@*JC  _
MS^9[UXS8V+WSB&,9=LX&0.@R>3@=!6M_PA%Y_P \_P#Q]/\ XJJ:)1ZK5/5]
M+74XF@?'(X)&<'LPZ=/UZ=#7FW_"$7G_ #S_ /'T_P#BJ/\ A"+S_GG_ ./I
M_P#%4K#N9MC=-ILRRX(:-QD9*G@\J?3/0U[/7E7_  A%Y_SS_P#'T_\ BJ]5
MIR!'D/B74#?W$DA((#%5P<C:IP,<GKUXXR2>]>C^%]$&DPJA \Q@"Y[Y],Y/
MW>G''?N:\DKW*B0(*;)&) 58 @C!!Y!!ZC%.HJ1GC_B'2?[*F: 9*C!4D8R"
M,_CCID=P>G2NU^''_'NW_75O_05K#^(__'PO_7)?_0FK<^''_'NW_75O_05J
MGL);G5T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JRG0?2JU64Z#Z4 .HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDO2
MGTR7I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BLJZ\56MMC=*ISG[OS]/]W./QJU9:M#>_ZIU8D9P&&['N.HZ]Z +=
M%%% !15./6H)"%66,DG  =223T&,U:DD$8+,0 !DD\  =3F@!U%95UXJM;;&
MZ53G/W?GZ?[N<?C5ZUOX[O/ENKXQG:P;&>G0T 3T444 %%%% !16;>^([:R^
M_(N0<$ [F!]PN2.E.M/$%O=XV2H2QP 6 ;.<8VG!^G'- &A1110 4444 %%5
MKG4HK4[9'121G#,%./7!-4[7Q5:W.=LJC&/O?)U_WL9_"@#5HIL<@D 92"",
M@CD$'H<TZ@#FO&WA^35E1HL%HR?E.!D-CH2<<8[_ /UCG^"_#$VGS&:9=H"$
M#Y@<DD=E)!  []\$#(X["YNTM1ND95!.,L0HSZ9-1VVI171VQNC$#.%8,<>N
M :=]!6+-<I\1;[R8%A!P9'Y&.JKR>>V#M]_PS73SSK;@NY"J.I8@#TZFN#^(
ME_'=^3Y;J^/,SM8-C.W'0T+<&9O@_P .C6)"7/[N/!8#J<YP/8<<GKV'7([9
M?!=M&R2(I5D=6!#$YVG.#N)X_7WKF_AW?QVGG>8ZIGR\;F"YQNSU-=E_;UO_
M ,]H_P#OXO\ C3=[@BIXLT8ZM 8T^^I#*,X!(R,?B"<=.<9.*Y/0/!5Q'.DD
MJA%1@V25;.T@X 4GK^GZ'M_[>M_^>T?_ '\7_&GP:M#<$(DB,QZ!74GUZ TK
ML"W1112&%%%9=SXGM;<;FE0C./E.\_DN3^- &I15.TUF"[P(Y$8L,@!ANZ9^
M[UZ=1CBKE !1110 4444 %%%95UXJM;;&Z53G/W?GZ?[N<?C0!JURGQ'_P"/
M=?\ KJO_ *"U=!9:M#>_ZIU8D9P&&['N.HZ]ZY_XC_\ 'NO_ %U7_P!!:FMP
M9A_#C_CX;_KDW_H2UZ/7G'PX_P"/AO\ KDW_ *$M>CT2W$@HJI/JT-N2CR(K
M#J&=0?7H35F.02 ,I!!&01R"#T.:0QU%9M[XCMK+[\BY!P0#N8'W"Y(Z5>@G
M%PHD4Y5@"#[$9'6@"2BJ<FM01DJTL8(.""Z@@CJ,9JY0 444V201@LQ  &23
MP !U.: '453CUJ"0A5EC))P '4DD]!C-7* "BBHYYUMP7<A5'4L0!Z=30!)1
M65+XJM8F$9E7+8Z?,O)QRPR!^)XZGBM"VNTNANC96 .,J0PSZ9% $M%5)]6A
MMR4>1%8=0SJ#Z]":G@G6X ="&4]"I!'IU% $E%%% !6-XPG:WM9'0E6&S!4D
M'[ZCJ*U9YUMP7<A5'4L0!Z=37->,M9@FM7C21&9BH 5@QX8'MGL.M- S*\ Z
ME+=3LLCNP$1.&8L,[EYP37?5YGX!NTM9V:1E4&(C+$*,[EXR:] CUJ"0A5EC
M))P '4DD]!C-#W$BY1112&%%4[O68+3(DD12HR06&[IG[O7IT&.:KVWB>UN!
MN65 ,X^8[#^38/XT :E%%% !115./6H)"%66,DG  =223T&,T 7**;)((P68
M@ #))X  ZG-9K>)K8.L(D4LY &W+#). ,J"!SZF@#4HHHH **R[GQ/:VXW-*
MA&<?*=Y_)<G\:LV6K0WO^J=6)&<!ANQ[CJ.O>@"W14%U?QVF/,=4SG&Y@N<=
M>IHM;^.[SY;J^,9VL&QGIT- $]%%% !145S=I:C=(RJ"<98A1GTR:S4\6VKM
MY0E7.2.<A>/]HC;]#GGM0!KT5%;7:70W1LK '&5(89],BI: "J>M2&."5E)!
M$3D$<$$*<'-6I)!&"S$  9)/  '4YK%UW7;<V\H$J$M&P 5@Q)8$#@$GJ?ZG
MB@#D/!^K37%U&CR.RG?D,[$?<8]":]+KR;P?.MO=1NY"J-^2Q 'W&'4UZ7_;
MUO\ \]H_^_B_XTY"1>HHHI#"BJ-]KD%CGS)%!7&1G+<]/E&3W].G/2H[+Q';
M7OW)%R3@ G:Q/L&P3UH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E3J*2E3J*
M +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:]BW
M#/I5"M=ANX-94B>62OI6]&6ECGKQUN-HHHK4P"G12&,Y%-HH:N-.QKJP89%+
M5"TN-GRGI5^N6<>5G9"?,KA1114E!5*XL_XE_*KM%5&3BR904E9F/16C/:"3
MD<&J,L)CZUT1J*1S3IN(RBBBJ,PHHHH **** "BBB@ H S4D5N9.G3U-7H;8
M1?7UJ)U%$TA2<B.VM-GS-UJU117/*3D[G3&*BK(****104R1_+!;TI]9UU<>
M:<#H*N$.9D5)\J(7?><GO2445TG(%%%% @K1M(MB_7FJ5O%YAQV[UJ5C6ET-
MZ$>H4445B= 4444 %%%% !1110 5X97N=>&5Z^3_ &_E^IR8S[/S.K^&_P#Q
M\-_UR;_T):](KS?X;_\ 'PW_ %R;_P!"6O2*YLT_COT1IA?X8445R_C'Q4-.
M4VT9S,PP<'[@(ZY'\7H.W4]@>6C2E5FHK<UG-05V<1XGO1>W,DJXQNP,'((4
M!0<^^,U4TRV%U+'"V<.ZJ<=<,0#5:NK^'NEF:;[20=D8.#VW$8Q[\$GCIQGK
MS]%5DJ%!^2T_0\Z*=2?JSTBO&]>_X^)O^NLG_H1KV2O&]>_X^)O^NLG_ *$:
M\W*/CEZ'3B]D;GPW_P"/AO\ KDW_ *$M=SKFF_VE"]OG!8<?4'(SP>,@9]JX
M;X;_ /'PW_7)O_0EKTBL\RDXXFZW5BL,KT['ATD9C)5@00<$'@@CJ,5I:+XC
MFTC/E$;2<E6&5)QC/J/P(S@9S7HFN>$H=7RYRLF/O+[ @9'0_H> ,XKB]1\!
M7-KDH!(HS]T_-@=/E..3Z#/IZ9[Z>-H8B/+*R\F82H5*;NOP-_2_B-'-A9U*
M' ^9<LN<<\8R/;[W7D]ZZJTNUNU$L9#*PR"/\_F.U>+3P-;DHX*L.H8$'UZ&
MKVA:[)H\GF)RI^\IZ,/Z$=CV^F0<L1E<)+FIZ/MT*IXJ2=I'I_B.]^Q6TLO(
M(0@%>H+?*#VZ$BO'J]8\3+_:%G(T9&&0."<C(4A_3/('%>3T\H25.7>X8M^\
MO0]!^'NBJL?VQA\[$A"<'"C@D#L2<@]\#C@G/95S/P_O1/;"+C,3,#SDX8[@
M<=NI'X&NFKS<;*3KSOW_  Z'3124%8@O;&.]7RY5#*>Q'MC(]#SU'-+:6BVB
MB*,!548 '^?S/>IJ*Y^9VM?0NRO<Y#XD7OEPI",YD?/'0A1R#^)!'T^E>=UW
M_P 2[8LD4W&%9E/KE@"/_03^E<!7T&6)?5U;S.#$W]HSUWPUHJZ5"J@8=@"Y
M."=V.1D=AT&./Q))UJK:;>B^B2<8PZ@X!S@GJ,^QX-6:\&K*4IMRWOJ=\4DE
M;8Y3X@Z2L\/VKH\6!T'(9@,$]>"<C\>.<CS>O4_'<XCM'4GER@'N=P;^0->6
M5[>52DZ&O1Z'#BDE,];\)7)N+6)CC(7;QZ(2H_0<UQWQ#T_R)Q/SB51U(ZK\
MI [],?G^76>"/^/.+_@?_H;4WQOI_P!LM6(SF,AQ@@?=X.<^BDG_ #BN"C5]
MEC'V;:_$WG'GHKTN><:-J']GS)/SA&&< $X/##GU&17L4\XMU,C'"J"2?8#)
MZ5XA7:7?B'=IJ("-[$1$ E2 G)^N5P#CCYOPKMS'#.K*FUWLS'#U>52^\Y&[
MN3=.TS8R[%CCIECDUU?PYTOSI&NFSB,87@XRP.>?8=N?O ^E<=7KOA;3O[/M
MHXR,,1N;C:<MS@CU'3GT_"KS*K[*CRKKI\A8:'-._8J^.KW[-:L.09"JC'OR
M<^Q (_''2O+*]-^(-L9K7<,8C=6.?0Y7C\6%>94LJ2]C\PQ5^?Y'7^%O%-OH
MT6QE<R,26("D>@ .0< >O<FMG_A9%O\ W9/^^5_^*KC;'PM<WR":-,HV<'<H
MZ'!X)!ZBI_\ A"+S_GG_ ./I_P#%4JN'PDIMRDK]=1QJ54DDM/0L^+O$$&LA
M&C5Q(AQE@H!4]L@D\'IVY-<S6[_PA%Y_SS_\?3_XJC_A"+S_ )Y_^/I_\56]
M*IAZ45%35O5&<XU).[3^X]&\/W?VNWBDR6)102<YR!ANON#SWKA_B1_Q\+_U
MR7_T)J[CP_I_]GP1P'.57G)!P6^9AQQP2<5P_P 2/^/A?^N2_P#H35YF M];
M=MM;'37O[)7\CF((#<,(U&68@ >Y.!UKV#1]'CTN,1H!G #,!@L1W/4]2<#/
M'0<5Y5H/_'Q#_P!=8_\ T(5[)6N;U)7C'IN3A(K5A5#7--_M*%[?."PX^H.1
MG@\9 S[5?HKRHR<9)K='4U=6/#*]#^'.J>=&UJV,QG*\C.&)SQ['OS]X#TKG
M?'&EFRN6<#"2_,.O4_>Y/?/.!T!%0^#=0^Q72'G$AV' '\7 Z_[6"?I^%?08
ME+$X:Z[77]?@<%-NG5M\CH/B5J'$=J,9R7/!SQE5YZ<_-^0_'AHXS(0J@DDX
M '))/08K4\4ZC_:%S)(#E0=J\[AA>,@^AZ\>OXU>\!:=]JN1(1\L0+<C(ST4
M9['G(^G'J'12PV&3?17^8I_O*IZ)I6G#3HDMUZ(,9]3U)ZGJ<G':K=%%?/2D
MY-M[L]!*RL%%%%(84444 %%%% !1110!') ).33P,4M%.XK(****0S@=?A$,
M[J/7//\ M ,?YUVUA*98T=N2R*3]2!7*^+H-DP<#[ZC)[$C(_EBMWPVX%N@S
M_>_]"-1#XFCNQ34J$)?UM_P#5HJ(W"CO3#=CTK7E9Y[G%=3*B\*+%*)E8A58
M$+CTYQG/3/MT_.MVJYG8]%_.CYV]O\_C25.Q=3$2J6O=V+%,FC$JE&Z$$'Z'
MK47DL>I_*@68[FG9=R.:71'#Z5&T<Z#D$,,]CCJ?T_.NZ:Z45E/X:#S?:"Y(
MW XP,\=!G_ZW3WYK9" <XJ()*YTXNK[5Q:[:^I#]JST&:@O8S=(T;#Y2.<9S
MQSQZG\/PJ_15W78YDI)WN<'X?D5)EW=3PIYZG@=/R_&NT^S%NIK+M/"B6\@E
MW$A<$ ]<CN2.OY#_ !V6D"]344^9*QTXV=.K-2788+0"G+ H[4UKH#IS3?.9
MN@K2TF<EX(@OH]I!'>JU6[E&*Y;M52MZ?PF%3X@HHHJC,**** "LCQ7_ ,>T
MG_ ?_0Q6O61XK_X]I/\ @/\ Z&*UH?Q(^J%+9GG=%%%>Z8A1110 4444 %%%
M% !5W1;?[1-&F,Y<9!QC Y/7V!JE6]X+@$EQN/\  C$?HO\ (UG6ERTY/R&M
M6=[4%_ ;B-XQU9& STY!%3T5X2=G<V/)**GOX!;R/&.BNP&>O!(J"OH$[JY@
M%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Z'P0@:<DCI&2/;E1_(USU=AX#B(61^Q*@?49)_F*Y\7*
MU&0X;G5UA^,K?S;<MG[C*?K_  X_\>K<JKJEO]IB>,#)9&P#CKCCK[UY-&7+
M.+\S9JZ/+J***]XP"BBB@ HHHH **** "KFD?Z^+_KHG_H0JG5S2/]?%_P!=
M$_\ 0A4S^%^@+<]/HHHKY\W"BBB@ HHHH *O6;A5Z\U1K2^RC&*SJM6L:T4[
MW1*5W=:8T"GM49M<?=.*!O7WK&W9F[?=$5_&((WE7JJ,1Z<#-<GX<U!KBY);
MK*""1QC R/?'&.ON<XK<\3SDV[@C&=O_ *$*QO!=MB0S,/E"D G'#<?CT[UM
M"Z@VQQ4+-G7;'7O_ )_&CS'7J*G#;NE+6/-Y"Y?,K_:L=1BB&_28;E.0>XY'
MZ5C>-IML*IG!9QQGJ #V[@''XXJCX&CWF0DG"A>,_+\V<G'K\M6H1<.8KEE:
M]SK!,#WIP.>:C-NI[4PV@]:BT17D6**I7$HML;Y N>FYL9Q]34B.[88$,",@
MC&#FCE\PYGV+-%5_.8=1^5 O!W%'(PYT8'CJXVHD6/O,3G_=&/\ V:F>!(B%
MD?L2H'U&2?YBJWC>8R-&/X0IP>^2>1^ Q6OX0@\B 9/+L6P>/0#\\9_&M6K4
MK%W7*;E%%%8"(;B[2WQO95STW$#./K4B.' 8'((R".E<%XOG,EP5/\"J!^6[
M^9KK?#D!@MXU/=<\?[1+#]#6DJ?+%/N-K0TJ***S$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 54JW52@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH X;XF_\ +'_MI_[)61X(UL:;-L<@1RC!)X (
M^Z<X^H[#G)Z5K_$W_EC_ -M/_9*P=/\ #+:A;-=19+HY!7U 53Q[C/3OVYX-
M+874]7HKR;3/$USH_P"Y4_*I.4<< ]QV8<\X!'/XU9O?'EU=#:"J#!!V#!.?
M<DD8[$8I<H7-SXAZV$462$;F(+X[ <J#QW//7/'H:S_AUIAEE:Z(^6,8!Y^\
MWIV.%SGTR.*Q=#\/2ZNP5 0F?F<CY1C&?J>>!_(<UZGIFF1Z9&(8AA1^9/<D
M]R?_ *PXIO16#<MUXWKW_'Q-_P!=9/\ T(U[)7C>O?\ 'Q-_UUD_]"-$09[)
M1114C.=\=:7]MMRZXW1'=T&< ?,,GIQS[XQBN,\(:Z-(FW/GRW&&QVYR&QWQ
M^>"<>A]5KS_Q7X*:(FXMAE6/,:J<KG'('.1G/ QCL,=&GT$SOHY!( RD$$9!
M'((/0YIU>0Z7XEGTS"QN=H(^5OF7KG&#TSGG&,UI7/Q!NIAA=B'/55R?I\Q8
M?I1RA<ZKQIKBV$+0Y!DE4@#KP>"QYXXSCW[$ XXWP7I)O[A6YVQ$.3[@_*,X
M(Y/;T!Q5.PTR?79#MR[<;F8].P))_ER<#@<5Z=H6A1Z/'Y:<L?O,>K'^@'8=
MOKDE[(-S0DC$@*L 01@@\@@]1BO'-1LFTJ9HLD-&W!'!]5;@G&1@]>*]EKF_
M%_A;^UQYT?\ KD& ">&'7;['G@_@?4),&:6A:['K$?F)PP^\IZJ?Z@]CW^N0
M-*O&(9YM*DRI:.1<9'*GL<$'J#P<'@UMI\0;I5V'83@_,5^;GOP0O';CZYI\
MH7/0=3U./3(S-*<*/S)[ #N3_P#7/%>/7=R;IVE;&78L<=,L<FKQDN?$4FW+
M2/@D#@ # R<<*O0>F3[U!K&F'3)6MV()4+DCIDJ"?RSCW]J:5A,])\$?\><7
M_ __ $-JT=6@-Q#)&HRS1N /<J0.M9W@C_CSB_X'_P"AM6Y4O<H\:T;4/[/F
M2?G",,X )P>&'/J,BO8XY!( RD$$9!'((/0YKSSQIX7>"1KJ(%HW)9L DJ<9
M8GKP>3GH.G'&<C2/$\^E<1ME/[C<KW_$<G/!&3US3:N+8]<K@?B%KBW&VS0@
M[&RY]"!@+G/;)S^ SG(K+U#QS<WHV A!W\L$$].Y)(Z=B/?-4[KP]+9P"ZE!
M7<X4*PPW0DDCMTX]>O3&1*P-FO\ #C_CX;_KDW_H2UZ+)&) 58 @C!!Y!!ZC
M%>=?#C_CX;_KDW_H2UZ/2EN"/&M1LFTJ9HLD-&W!'!]5;@G&1@]>*]1\/:XN
MKQ"0$;P '7I@_3)X/8_U!JOXH\,#6E!4A9%Z,1U&#\IQVSSGG'.!R:\W_?Z)
M)_%'(/PR ?R9<CW!QWI[AL>R5%=W:VBF60A549)/^?R'>O.8/B'<Q@*0C$=V
M4Y/_ 'R0/TK(OM8GU8A)&9SD *!@9[?*H SSC.,]J7*%STO0/$T6L[@F592?
ME;KC/#?X^AX]"=>N(\*>"#&4N[C((.Y4Z$$8*DG]=OTR>HKMZ&-'*?$?_CW7
M_KJO_H+5G_#*0 S+D9(0@=\#=DX]LC\ZZ3Q5I!U2!HE +@AER<<C_$9 SQSV
MZUY?9WTNER;XR4=<@\?F"#_(CK[BFM4)[GL]%>9W/Q!NIAA=B'/55R?I\Q8?
MI7H.JV']H1/!N*[QC*]?_K@]".XR*5K#N1:=KT.HL\43 M&>?<>H]1GC/]""
M="O';W3Y]$DPVY&!.UE) /')5N.Q_7!QTK6MOB#=0C#;'.>K+@_3Y2H_2GRB
MN='\0-/BD@-PV!(A4*<X)R>5]^,GVQGIG/-> )62Z 49#(P;@G ZY]N0!SZX
MZUEZMKTVJG,K$C/"CA1UQQ[9QDY..]=OX&\-MIP-Q*,/(  .<JO7GW/''48]
M20#9!U.KHHHJ1A7BEA$LTB(YPC.H8Y P"0"<G@8%>UUY5XJ\-MI$A8#]RY.T
MC/'?:<YY';U'/J!41,]3CC$8"J  !@ <  =!BG5YC9>/KFV78=KX[N"6Z8QD
M$9^IR?4U#J'B^ZU3]SD . NV->N3[Y;GI@'GICK2Y0N2>-];&I3;$(,<0P".
M02?O'./H.XXR.M:_PR_Y;?\ ;/\ ]GKF-3T*338XY)>&EW?+W 7;C/N<].W?
MG@=/\,O^6W_;/_V>F]@ZG5ZYIO\ :4+V^<%AQ]0<C/!XR.?:O*=+OVTB99MO
MS1D@JV1V*D>QY_ ]NU>R5R?BCP0+XM<0860@DKV8^N>Q/Y$]<<FDF#.@TO5X
MM3421,#P,C^(9[$=NGX]LBK4D@C!9B  ,DG@ #J<UXY/:3Z2P+!XV!(!Y7IP
M<,.O7J#WH:[GU'$1:20YR%)9^0#R!SVS3Y0N;WCGQ(NHD6\1RD9))XPS=./8
M<\]#GT )H^"/^/R+_@?_ * U2W/@V2QMWNIR 5"[5!!.2X4Y/3ITP3UYQC!B
M\$?\?D7_  /_ - :GT$>JUXI81+-(B.<(SJ&.0, D G)X&!7M=>5>*O#;:1(
M6 _<N3M(SQWVG.>1V]1SZ@*(V>IQQB,!5   P .  .@Q3J\QLO'US;+L.U\=
MW!+=,8R",_4Y/J:AU#Q?=:I^YR ' 7;&O7)]\MSTP#STQUI<H7)/&^MC4IMB
M$&.(8!'()/WCG'T'<<9'6M?X9?\ +;_MG_[/7,:GH4FFQQR2\-+N^7N NW&?
M<YZ=N_/ Z?X9?\MO^V?_ +/3>P=3N:\;U[_CXF_ZZR?^A&O9*\;U[_CXF_ZZ
MR?\ H1HB#/5M!_X]X?\ KE'_ .@BC7O^/>;_ *Y2?^@FC0?^/>'_ *Y1_P#H
M(HU[_CWF_P"N4G_H)J1GG'@C_C\B_P"!_P#H#5ZK7E7@C_C\B_X'_P"@-7JM
M.0D%<I\1_P#CW7_KJO\ Z"U=77*?$?\ X]U_ZZK_ .@M0MQLP_AQ_P ?#?\
M7)O_ $):]'KSCX<?\?#?]<F_]"6N\U6P_M")X-Q7>,97K_\ 7!Z$=QD4/<2(
MM.UZ'46>*)@6C//N/4>HSQG^A!.A7CM[I\^B28;<C G:RD@'CDJW'8_K@XZ5
MK6WQ!NH1AMCG/5EP?I\I4?I3Y0N='\0-/BD@-PV!(A4*<X)R>5]^,GVQGIG/
M-> )62Z 49#(P;@G ZY]N0!SZXZUEZMKTVJG,K$C/"CA1UQQ[9QDY..]=OX&
M\-MIP-Q*,/(  .<JO7GW/''48]20#9!U.KKAOB;_ ,L?^VG_ +)7<US?CG16
MU*$-&-SQ$G'.=I'S #N> ?7CCG@I;C97^&\@,#KD9$I)'?!5<''O@_E765XW
MI.M2Z4V^(XSC(/*G!S@C^HP>3@C-=!9>.+F^FBC.U5:10P5>H9@/XBWZ8IM"
M3/1****D85'/ +A3&PRK @CV(P>E244 >,?-I<W8O#)[E<HWX'&1[5I^,M:&
MJ2ADSL5%QSGEAN/ X!YP>OW:T/B+IABE6Z ^608)Y^\OKV&5QCUP>*Y[1M/_
M +0F2#G#L,X(!P.6//H,FK\R3T/P+I?V*W#MC=*=W09P1\HR.O'/MG&*Z*FQ
MQB,!5   P .  .@Q3J@H\X^(_P#Q\+_UR7_T)JZ+X?VR1VPD7!9V;=TR"#@#
MCGIS@^N>]0^.?#;:B!<1#+Q@@CG++UX]QSQU.?4 'C-&\1S:1GRB-I.2K#*D
MXQGU'X$9P,YJMT+J>O5S7CK6Q90F!2/,E&,=PI^\<8/7IVZY'2N9G^(=S("H
M"*3W53D?]]$C]*HP:3/K DO),[51G+L/O;0>!TSTQQPH_ $2"Y4T'_CXA_ZZ
MQ_\ H0KV2O&]!_X^(?\ KK'_ .A"O9*) CSCXC_\?"_]<E_]":MSX<?\>[?]
M=6_]!6L/XC_\?"_]<E_]":MSX<?\>[?]=6_]!6A[!U.KKQO7O^/B;_KK)_Z$
M:]DKQO7O^/B;_KK)_P"A&B(,]6T'_CWA_P"N4?\ Z"*YWXBZ7YT:W2XS&<-P
M,X8C'/L>W/WL^M=%H/\ Q[P_]<H__015J> 7"F-AE6!!'L1@]*749YUX&\0K
MIS-#*2$D(P2?E4CU';/<]L#/'(])KRKQ)X5DTABR@M">0V.G.,-CH>>O0]NX
M$>F>+KG3@%5MR#^%QN'3 &>H [ $"FU<5SUFN!^(6N+<;;-"#L;+GT(& N<]
MLG/X#.<BLG4/&]U><;@@('$8V]#G.3EA^!_K5=?#<H@:]<;4 4KGJVY@O3L.
M<Y/7C&0<@2L#9/X(_P"/R+_@?_H#5ZK7E7@C_C\B_P"!_P#H#5ZK2D"/%+")
M9I$1SA&=0QR!@$@$Y/ P*]ICC$8"J  !@ <  =!BO+/%7AMM(D+ ?N7)VD9X
M[[3G/([>HY]0)[+Q]<VR[#M?'=P2W3&,@C/U.3ZFFU<%H>G5Y?XWUL:E-L0@
MQQ# (Y!)^\<X^@[CC(ZU'J'B^ZU3]SD . NV->N3[Y;GI@'GICK5/4]"DTV.
M.27AI=WR]P%VXS[G/3MWYX E8&SI_AE_RV_[9_\ L]=S7#?#+_EM_P!L_P#V
M>NYI/<$<-\3?^6/_ &T_]DJ[\-Y 8'7(R)22.^"JX./?!_*K'CG16U*$-&-S
MQ$G'.=I'S #N> ?7CCG@^?Z3K4NE-OB.,XR#RIP<X(_J,'DX(S36J#J>R56U
M*R%]$\!QAU(R1G!/0X]CR*X2R\<7-]-%&=JJTBA@J]0S ?Q%OTQ7HE)JPSQ:
M-FTV4$@;XGZ'D90].#ZCL:]>TS4X]3C$T1RI_,'N".Q'_P!<<5B^+?"0U0>?
M%@3 ?0,!V/OZ'\#Q@CS^VNIM'DW+NCD P01@X(Z$$?CR/0T]Q;'LM17=VMHI
MED(55&23_G\AWKSG_A8=SMV83.,;MIW=.O7&>_3'MBLB^UB?5B$D9G.0 H&!
MGM\J@#/.,XSVI<H7/4M&UR+5U,D1/!P5;AAZ9&3U['^H-:%<GX-\)MII-S-D
M2$$!0> /?!P<]AR!UZ].LI,9Y)XKTO\ LVX=.-K'<N  ,,3Q@=,'(_#.*[WP
MEXA75(A&2?-C4!@QR3CC=GOGOZ'KV)E\3^'1K48&<2)DH>W/4'V..O4=?4'S
M&:";2I,,&CD7.#RI[C((Z@\C(X-5NA;'L]17=VMHIED(55&23_G\AWKSBV^(
M-U",-L<YZLN#]/E*C]*S9]1N==98F9G8GA1@#//.!@=SDGMU.*7*%R'7-2_M
M*9[C& QX^@&!GD\X'/O7<_#C_CW;_KJW_H*UQ&LZ,VDLD<A&YD#$#MDD8SWZ
M<_UZGM_AQ_Q[M_UU;_T%:;V!;G5T5GZ]JPTJ%ISC(&%![L>@QD9]3CG ->=^
M&-7NDE$4#!C*Q)$G*DX.6)Z].3@Y.._2DD%SU2BBBD,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JRG0?2JU64Z#Z4 .HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDO2GTR7I0!7HHHH **** "BBB@ HHHH ****
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MD.!D5ZMX5\-KI$88C]\X&XG''?:,9X'?U//H!;T)1PW_  A%Y_SS_P#'T_\
MBJS[W3IM*8>8K(P.0?<8.0PX.,CH>*]EJMJ&GIJ"&*0 @@]@2"01D9!P1G@T
MN8=CEO!WC'[3BUN#\_1'/\7^R?\ :]#W^O7LJ\:U&R;2IFBR0T;<$<'U5N"<
M9&#UXKUG1M0_M"%)^,NHS@$#(X8<^AR*30(GN[M;13+(0JJ,DG_/Y#O7F'B/
MQ;)JQ,:Y6'(PO&3CH2?Z=!QU(S6Q\2=0)9+7^$#>?<DE1V[8/?G/M1X \/B7
M-[(,[3B//3(ZMC'..@.>#GN!36FH,PH/!]W, XB.#_>*J?R8@C\J9>^%;FR7
MS'C.T=2"&QQG)VDX''7I7KE%+F"QYCX:\8R:<5BD.Z$D [LDJ.G!YX'I@].,
M9S7ID<@D 92"",@CD$'H<UYKXYT-=-E62, )*"=H[$=<#' Y&!]>@Q70?#K4
M/.A: YS$W' QA\D#\P3SZ_DWW!'65P?BKQN23!:MA1D,X[]L*>P']X<D]..3
MO>-=4;3K<M'D,[!00<$9!)/Y#';&<@\5PWA+0_[6FVN#Y:#+=1]%R!W/TX!P
M<TDNH,I:;H<VI9\E"P'?@+VXR<#//3K5V3P7=H"QC. ,\,A/'L&R?H*]5CC$
M8"J  !@ <  =!BG4^8+'C^FZU/HS$(2N#\R-]W((R"IZ'C!/![9KU#0]975X
MA,@(YPP/8C&1GOUX/\CQ4&O^&8M9VE\JRD?,O7&>5_P]#SZ@Z5I:+:*(HP%5
M1@ ?Y_,]Z3=P1S/Q'_X]U_ZZK_Z"U8?PX_X^&_ZY-_Z$M;GQ'_X]U_ZZK_Z"
MU8?PX_X^&_ZY-_Z$M-;!U.R\4V+WUL\,8R[;<#('1@3R<#H*\PU/1)M+V^<N
MW?G'*GIC/0GUKV2N&^)O_+'_ +:?^R4HL&<IIFB3:IN\E=VS&>5'7..I'I5_
M_A"+S_GG_P"/I_\ %5N?#+_EM_VS_P#9Z[FFV"1Y-/X/NK=3(T>%4$D[DZ 9
M/1JD\$?\?D7_  /_ - :O1]>_P"/>;_KE)_Z":\X\$?\?D7_  /_ - :B]T%
MCU6JFIZG'ID9FE.%'YD]@!W)_P#KGBK=>;?$#5&GG-MR$B"\9X)(SN_(X[X[
M=322N-F9KOB276#\YP@.50=!VZ]S[GU., XI\'@^[F <1'!_O%5/Y,01^5=7
MX"\/B",7CC]X^=N>R],X(ZGUY^7&.ISUU-NPK'C^H>'+C3AOEC(7U&& Z#DJ
M3CKQGKVK9\-^-Y+1A'<,7C/&3RR\]<]2/4')QTZ8/H]8=KX.@MIS=*/0JG\*
MMW8?T'0'..V"X6-RBBBI&%07UZME&TS_ '4!)Z?D,XY/0>]3UP?Q)U EDM?X
M0-Y]R25';M@]^<^U-*X,P-;\43:L2&)6,GA >,<8S_>Z9Y[],=*=!X/NY@'$
M1P?[Q53^3$$?E6[X \/B7-[(,[3B//3(ZMC'..@.>#GN!7>4V["L>0WN@7.E
M8E=&4 Y#*0<$$8.5)QR1C./:I]0\3-J%LMK+DNC@AO4!6'/N,]>_?GD^KUYC
MXWT(:9*)$P$ER0HXP1C</H<Y'Y8  H3N#1/\./\ CX;_ *Y-_P"A+7H]><?#
MC_CX;_KDW_H2UZ/2EN"/*O&__'Y+_P  _P#0%HU3Q5)<Q1VL9*1I&JM@X+$+
M@YQ_#Z#OU/8 \;_\?DO_  #_ - 6NE^'^AK'&+U@"[E@OL =I[<$D'GGCTR:
M?01RT'@^[F <1'!_O%5/Y,01^5>G:3 ;>&.-AAEC0$>X4 ]*MT4F[CL>-Z]_
MQ\3?]=9/_0C7LE>-Z]_Q\3?]=9/_ $(U[)3D""J.O?\ 'O-_URD_]!-7JHZ]
M_P >\W_7*3_T$U(SRG0?^/B'_KK'_P"A"O9*\;T'_CXA_P"NL?\ Z$*]DJI"
M1FZ[KL>CQ^8_+'[JCJQ_H!W/;ZX!\MU#4YM8DW.2S$_*HS@9P,*OY>Y[Y-:G
MCO4#=7+1Y!6(!1@Y&< MWQG/!^@!Z5U?@71!90B=@/,E&<]PI^Z,Y/7KVZX/
M2C9!N<;'X+NW 81G!&>60'GV+9'T-12V-UX?82D-&>/F!RIYS@D9!Z?=/XC%
M>N5%=VBW:F*0!E88(/\ G\CVI<P6/']8U,ZG*UPP +!<@=,A0#^>,^WO7I/@
MC_CSB_X'_P"AM7FFJZ>=.E>W;JAQGU'4'J>HP<=J]+\$?\><7_ __0VIRV!&
MY1114C,KQ38O?6SPQC+MMP,@=&!/)P.@KSB^\+7-BAFD3"+C)W*>IP. 2>IK
MURL/QO\ \><O_ /_ $-::8FCS33=+DU)C'"NY@,XR!QD#N1ZUN:3X/NK>:.1
MH\*LB$G<G0,">C5)\./^/AO^N3?^A+7H]-L$@K@_&7BZ1':SBRFPC+ D,> <
M#@$#/<?>&,'!Y[RL_4=!AU%DEE4%HSQ[CT/J,\X_H2"D-GE^G^'+C41OBC)7
MU.%!ZC@L1GISCIWJ>?P?=P@N8C@?W2K'\E))_*O5XXQ& J@  8 '  '08HDD
M$8+,0 !DD\  =3FGS"L>6>&_%4FD,%8EH3P5STYSE<]#STZ'OV(]3CD$@#*0
M01D$<@@]#FO*O&$427#/"RLL@W':=P!).1G)[C/XXQ7;^!;W[3:J.28RRG/M
MR,>P! _#'2A]P1T%>+:;<BUECE;.$=6..N%()KVFO#:(@S7U;69]?DQAB"?E
MC7) P#V'4XSDX_(<#0TGP?=6\T<C1X59$).Y.@8$]&KM_#VAKI$0C &\@%VZ
MY/UP.!V']2:U*5PL17=VMHIED(55&23_ )_(=Z\O\2>*I-78JI*PC@+GKSG+
M8ZGCIT';N3T/Q(U HL=LI&')9@#SA<;<C/0G/7N..E4?A[H@N&:[< K&<+G^
M]USU_A&,9'?(Y%-::@S%LO"MS>KYB1G:>A)"YXSD;B,CGKTI;GPS=:</.9&
M4YRI!(QSGY22,8Z]J];HI<P6/']3UV34HXXY>6BW?-W(;;C/N,=>_?GD]/\
M#+_EM_VS_P#9ZR/&^B#39MZ ".49 ' !'WAC/T/8<X'2M?X9?\MO^V?_ +/3
M>P=3N:YKQ;XM&ECR(L&8CZA0>Y]_0?B>, [U_=?9(WFQG8C-C.,[03C->/P0
MR:K,%',DK\G'=CDDX' '4X' I) R6&TGUR1F4-(['+'MTXR> .G XZ8%7?\
MA"+S_GG_ ./I_P#%5Z5IFF1Z9&(8AA1^9/<D]R?_ *PXJW3Y@L>-_O\ 1)/X
MHY!^&0#^3+D>X..]>C>%/$W]LJ0^T2J>57/([, ?R/)_#(JUXAT-=7B,9 W@
M$HW3!^N#P>X_J!7EVC:A_9\R3\X1AG !.#PPY]1D4;AL>M:M ;B&2-1EFC<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&*UH?Q(^J%+9GG=%%%>Z8A1110 4444 %%%% !79^!+?:DDN?O,!C_=&<_\
MCWZ5QE>E>'K?R+>-<YRN?^^OFQ^&:X\?.U*W=E4UJ:-%%%>2:GG'B:(17,@7
MID'\6 )_4UEUT/C= LX('6,$^_+#^0KGJ]W#N]*+\C&6X4445J(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N]\%P&.WW'^-V(_1?YBN"KTCPW 8+>-3W7/'^T2P_0UQ9A*U-+S+I[FG111
M7E&AY=JEO]FE>,# 5VP#GIGCK[55KH/&EKY4_F<XD4')Z9'&!^ 'YUS]>]1G
MSTXOR,6K,****T$%%%% !1110 5<TC_7Q?\ 71/_ $(53JYI'^OB_P"NB?\
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MY]P;()'([X!Q_CWK0JJE1222+Z6"BBBLQ!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5*MU4H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .&^)O\ RQ_[:?\ LE7OAQ_Q[M_UU;_T%:H_$W_EC_VT
M_P#9*O?#C_CW;_KJW_H*U7074W]0T:'4/]:BL< 9(PV <X##D?@:I0>#[2$A
MQ$,C^\68?DQ(/Y5LT5(QL<8C 50  , #@ #H,4ZBB@ JG)HL$A+-%&23DDHI
M))ZG.*N44 %%%% !1110!1OM#@OL^9&I+8R<8;CI\PP>WKTXZ54@\'VD)#B(
M9']XLP_)B0?RK9HHN V.,1@*H  & !P !T&*=110 4444 075A'=X\Q%?&<;
ME#8SUZBLK_A"+/\ YY_^/O\ _%5N44 16UHEJ-L:JH)SA0%&?7 J&?28;@EW
MC1F/4LBD^G4BK=% $<$"VX"( JCH%  ]>@J2BB@ K+O?#-M>G=)&N<DY&5))
MZDE2,_C6I10!FZ?X<M]..^*,!O4Y8CJ."Q..O..O>KMS:)=#;(JL <X8!AGU
MP:EHH K6VFQ6IW1HBDC&54*<>F0*LT44 %17-HET-LBJP!SA@&&?7!J6B@#$
MD\%VCDL8QDG/#.!S[!L#Z"M"RTF&R_U2*I QD*-V/<]3T[U;HH **** "J.I
M:'#J6/.0,1WY#=^,C!QSTZ5>HH R+;PE:VYW+$I.,?-EQ^3$C\:UZ** (YX%
MN 4<!E/4, 1Z]#61)X+M')8QC).>&<#GV#8'T%;=% %/3]&AT_\ U2*IP1D#
M+8)S@L>3^)JY110 4444 %-DC$@*L 01@@\@@]1BG44 8T_@^TF)<Q#)_NEE
M'Y*0!^57=/T:'3_]4BJ<$9 RV"<X+'D_B:N44 075A'=X\Q%?&<;E#8SUZBB
MUL([3/EHJ9QG:H7..G05/10 5 E]&\A@# R* 2N>0#_G\,C/49?.A=2JG:Q!
M ;&<''!P>N/2O([V*?19\N2)5.X-G.<_Q9/4'OGKR".HII7$V>P45P.G_$AD
M 69 QR,LIVG'&3MQ@GOU [<5+??$KJ(8_3#.?SRH_P#BO?VHLPN:'Q U18(#
M;<%Y2O&>0 <[OS&.V>W0US_P\T_SYS-SB)3T(ZM\H![],_E^>,[SZ]+D[I)"
M .!T'3M@ 9/)X'.37J'A_1AI$(A'WNK'.<L0,XZ<<8''3KSFGL@W-*FR1B0%
M6 ((P0>00>HQ3J*D9C3^#[28ES$,G^Z64?DI 'Y5=T_1H=/_ -4BJ<$9 RV"
M<X+'D_B:N44 075A'=X\Q%?&<;E#8SUZBBUL([3/EHJ9QG:H7..G05/10 53
MDT6"0EFBC))R244DD]3G%7** &QQB,!5   P .  .@Q1)&) 58 @C!!Y!!ZC
M%.HH J0:3#;D.D:*PZ%44'TZ@5;HHH *BN;1+H;9%5@#G# ,,^N#4M% %:VT
MV*U.Z-$4D8RJA3CTR!5FBB@".>!;@%' 93U# $>O0UD2>"[1R6,8R3GAG Y]
M@V!]!6W10!3T_1H=/_U2*IP1D#+8)S@L>3^)JY110 4444 9NH>'+?43OEC!
M;U&5)Z#DJ1GIQGIVIMEX9MK([HXUSD')RQ!'0@L3C\*U** "BBB@ HHHH BN
M;1+H;9%5@#G# ,,^N#4=MIL5J=T:(I(QE5"G'ID"K-% !1110 5GZAX?@U#F
M6-220<CY6.!CEEP3QVS6A10!D6WA*UMSN6)2<8^;+C\F)'XUJR1B0%6 ((P0
M>00>HQ3J* *<>BP1D,L48(.00B@@CH<XJY110!6N=-BNCND1&(&,LH8X],D5
M);6B6HVQJJ@G.% 49]<"I:* "J<FBP2$LT49).22BDDGJ<XJY10 V.,1@*H
M & !P !T&*=110 5E77A6UN<;HE&,_=^3K_NXS^-:M% &79>&;:R.Z.-<Y!R
M<L01T(+$X_"M">!;@%' 93U# $>O0U)10!4@TF&W(=(T5AT*HH/IU JW110
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M@ HHHH **** "BBB@ HHHH *LIT'TJM5E.@^E #J*** "BBB@ HHHH ****
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M8G##[RGJI_J#V/?ZY TJ\S^']Z8+D1<XE5@><#*C<#COT(_&O3*35AH\8TF
M7$T<;#*M(@(]BP!Z5[/7AM>Q:#JPU6%9QC)&& [,.HQDX]1GG!%.0D:%%%-D
MD$8+,0 !DD\  =3FI&><?$6,+<J0 "T2DX[G<PR?P 'X5UO@C_CSB_X'_P"A
MM7F^N:E_:4SW&,!CQ] ,#/)YP.?>O5/#^G_V?!'"<Y5><D'!;YF'''!)Q5/8
M2W/.O&__ !^2_P# /_0%J"Q^V;!Y/G>7SC9OV]><8XZ_K6Q\1=,,4JW0'RR#
M!//WE]>PRN,>N#Q5_P"'6L JUFQ^8'<F3U!'( ]L9]\DXX-%]!=3G_\ B8_]
M/'_D6C_B8_\ 3Q_Y%KU6BES#L>27-I>W0VR+.P!SAA(PSZX-=3\.["2T\[S$
M9,^7C<I7.-V>HKI[C58K>18'8!Y/N@]_\,]!GJ>!DU;H;"QPWQ-_Y8_]M/\
MV2CX9?\ +;_MG_[/6EX_TPW< F49:$Y[YVGAN!^!.>@!YKEO!&MC39MCD".4
M8)/ !'W3G'U'8<Y/2GT#J>H4445(PHJCJVM1:4 TIQN(  Y/N<>@ZG_$@&Y'
M() &4@@C((Y!!Z'- '+?$?\ X]U_ZZK_ .@M6'\./^/AO^N3?^A+6Y\1_P#C
MW7_KJO\ Z"U8?PX_X^&_ZY-_Z$M4MA=3T>N&^)O_ "Q_[:?^R5W-<-\3?^6/
M_;3_ -DI+<&'PR_Y;?\ ;/\ ]GKN:X;X9?\ +;_MG_[/7<T/<$4=>_X]YO\
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MQ?JBV-NZMC=(I51GD[A@GOT!S^F>14H9YMH/_'Q#_P!=8_\ T(5[)7C>@_\
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M#_UUC_\ 0A7LE>-Z#_Q\0_\ 76/_ -"%$09[)1114C/./B/_ ,?"_P#7)?\
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MQ^M/F"Q9JCKW_'O-_P!<I/\ T$U>JCKW_'O-_P!<I/\ T$U(SSCP1_Q^1?\
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M\G3BCD8^=$Y;;UJA>L'((JPMKGECFG2VX*D <U4'&+(FI21FT445T'*%%%%
M!61XK_X]I/\ @/\ Z&*UZY[QNY6  'K( ??AC_,5KAU>K'U%+9G"T445[IB%
M%%% !1110 4444 36=O]I=8LXWL!GKC)QFO5:X'P;;^;<!L_<5C]?X<?^/5W
MU>7F$[S4>R-*:T"BBBN$LY#QZ@!B;')#C/?C;C^9KDZ[?QR@,*MCD2 9[\J<
M_P A7$5[."=Z*,I[A111722%%%% !1110 4444 %%%% %_3-$FU3=Y*[MF,\
MJ,9SCJ1Z5!?6+V+F&08=<9&0>HR.1D=#79?#'_EM_P!L_P#V>L+QO_Q^2_\
M /\ T!:Y(8B4L3*EI9*_Y?YFLJ:5-2ZLRK&Q>^<0QC+MG R!T&3R<#H*U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5E.@^E5JLIT'TH =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)>E/IDO2@"O1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U6WDN(GCB;8[
M#AO3_#/3(Y'4<BO)HIYM$E.TE)%R#T[^QR".XZCH1VKV2JFH:5%J(V3*& Z9
MZCIT(Y'3G!YIIV$T<9;?$MU'[R)6.>JL5&/H0W\ZQ->\4RZS\K86,'(4#TS@
MDGDG!QV'M782?#JV8D@R $] RX'MRI/YDU>T_P '6ME_ '.",R?-WST/R_B
M/YT[H-3&^'NAM;[KQP1O7"#U!.2V,=\#'XG&,&NTHHJ6[C/%+"U^UR)#G&]U
M7.,XW$#.*T!)<>&9MN2K @D<[''.#CC(Z^X]B.*V@_\ 'Q#_ -=8_P#T(5Z[
M>V,=ZOERJ&4]B/;&1Z'GJ.:ILE(XJ#XF,H >(%NY5RH_(AOYU@:SXIGU;"N0
MJX^ZF0IYSD@DY[=>G;O7:3_#RVD)8%U![*PP/^^@3^M7M,\(VVG$,J[G'\3G
M<>N0<= 1V( -%T/4YKP7X2,A6]FR%!!1>A)'(8^WIZ]>G7OJ**ENXRIJ>F1Z
MG&891E3^8/8@]B/_ *QXKRS6=&ET.4*2>N4=>,X[CT([CM],$^O5'/ MP"C@
M,IZA@"/7H::=A-'GFF?$*:U 251(%&,Y*N?0D\@\>V3U)SU?>_$B:3B)%0$8
MYRS ^H/ _ @UT%UX M9L;0R8S]ULY_[ZW?IBDMOA]:PG+;W&.C-@?7Y0I_6G
M=!J<):V4^ORDC+NQ&YC]T9[D] ,#@>V .U>LV-N;:-8V8NR@ LW4^_\ G)]2
M3S3K:T2U&V-54$YPH"C/K@5+2;N"0V2,2 JP!!&"#R"#U&*\S\5^$VTLF:,9
M@)XY)*YQP>.F> >>V3D\^G44)V&T>6Z/XVGTX"(X=%P &Z@#L&']<XXP,<5J
M7/Q+=A^[B53GJS%ACZ +_.NBOO!5K=Y.S8QQRAVXQZ+]W]/UYJI!\/+:,AB7
M8#LS#!_[Y /ZT[H6IP4L\VMRC<2\C8 Z=O88 '<]!U)[UZ3X5T)](C*2.6)/
M0$E% )Z9]<Y/3],G0T_2HM.&R%0H/7'4]>I/)Z\9/%6Z38)'*?$?_CW7_KJO
M_H+5A_#C_CX;_KDW_H2UWFI:7'J2B.9=R@YQDCG!'8CUJ#3?#L&FL9(4VL1C
M.YCQD'N3Z47T"QI5PWQ-_P"6/_;3_P!DKN:HZGHD.J;?.7=LSCEAUQGH1Z4(
M;.4^&7_+;_MG_P"SUW-4=,T2'2]WDKMWXSRQZ9QU)]:O4,$4=>_X]YO^N4G_
M *":\X\$?\?D7_ __0&KU&> 7"F-AE6!!'L1@]*SK'PM;6+B:-,.N<'<QZC!
MX)(Z&A,5C5K+\0Z&NKQ&,@;P"4;I@_7!X/<?U K4HI#/';FVFT&;!RLB'((Z
M$>H]0?\ $$=17067Q(EC&)45S@8(.P^Y/##GV KN[VQCO5\N50RGL1[8R/0\
M]1S6#<_#ZUF.5WH,=%;(^OS!C^M5=,5CF=3\?SW8*1@1J?3E^F"-Q_/( (XY
MJCX<\.S:JV^,[%0C+G(P<CICJPZ]O<C(KN;+P+:VW)4N0<Y=L_A@8!'U!]^*
MWHXQ& J@  8 '  '08HN%AL$7DJ$R3M &6.6.!C)/<GO4E%%2,*HZUI*ZK$T
M#<9Y!P"01T//Y'IP2,C-7J* /&M0T^72)?+?*NI!!!_)@?\ ./8BN@T_XBS0
M\2JL@P>1\C9SW(!'MP!_CWU[8QWJ^7*H93V(]L9'H>>HYK!N?A]:S'*[T&.B
MMD?7Y@Q_6JNF*QS.I^/Y[L%(P(U/IR_3!&X_GD $<<UBR:1+%$+IU*H6"C/!
M.06R!Z8'7WXSSCT?3_!%K9\[2Y!/,AW=1C&!A3^(_I6GJ6EQZDHCF7<H.<9(
MYP1V(]:+A8X/X<?\?#?]<F_]"6O1ZS=-\.P::QDA3:Q&,[F/&0>Y/I6E2;N-
M'E7C?_C\E_X!_P"@+7H^@_\ 'O#_ -<H_P#T$5!?>%K:^<S2)EVQD[F'08'
M('05HP0"W41J,*H  ]@,#K0V*Q)1112&<5X_\/F7%[&,[1B3'7 Z-C'..A.>
M!CL#7+:-XCFTC/E$;2<E6&5)QC/J/P(S@9S7KU8VI^$;;4269=KG^)#M/7).
M.A)[D@FFF*QSD_Q,9@0D0#=BSEA^0"_SKG2L^O,\[$L8T+,QX "@G' P,XX
MZG)]37;P?#RVC(8EV [,PP?^^0#^M= ;&/RS % C((*J-HPW7IC&<]J=T@L>
M1:#_ ,?$/_76/_T(5[)6-!X/M;=A(L>&4@@[GZ@Y'5JV:3=P2,_7-&75XC"Y
M(YRI'8C.#COUY'\CS7E^L^'YM(.)!\O&&7)0Y[9P.>#P>>_3FO7I)!&"S$
M9)/  '4YIU"=@:/)H/&%W" @E.!_>"L?S8$G\Z@C@N=?D) :1^Y/09R<9. H
MZX' ["O4O[!M_P#GC'_W[7_"K4$"VX"( JCH%  ]>@IW"QX]K&F'3)6MV()4
M+DCIDJ"?RSCW]J])\$?\><7_  /_ -#:O/\ Q5>K>W,DJ<J2 #QSM 7(QG@X
MX]J](\,V1LK:.)LYVY.1@@L2Q&/;.*'L"-2BBBI&%9_B#3_[0@DA&<LO&"!D
MK\RCGCD@9K0HH \8L;R32Y1*O#QD\,/P((_,'O\ 0UU+_$MRN!$H? Y+$KGO
M\N ?I\W'O74ZOX8@U7F1</\ WUX;M^!X&.0<#IBLV#X>6T9#$NP'9F&#_P!\
M@']:JZ%9FS!_Q-+<;^/.B&[;Q]]><9SZ\=:\IO+*719MK?*Z$,IZ@X.0PSU'
M']",Y%>P00"W41J,*H  ]@,#K4&H:5%J(V3*& Z9ZCIT(Y'3G!YI)V!HXZ#X
MF,H >(%NY5RH_(AOYUFZUXYFU)6A4!$;K@DMC'(+<<'V XXZ9STLGPZMF)(,
M@!/0,N![<J3^9-:NE^&H-,PT:#< /F;YFZ8SD],YYQC-.Z#4\LU#3)-/*K*,
M,Z!L=P"2!GT/'3\^>*[SX<?\>[?]=6_]!6MG4O#L&I,))DW,!C.YAQDGL1ZU
M/INEQZ:ICA7:I.<9)YP!W)]*3=T%BW7C>@_\?$/_ %UC_P#0A7LE8T'@^UMV
M$BQX92"#N?J#D=6H3L#1LT444AD<\ N%,;#*L""/8C!Z5YGXA\&2Z9F1,O%D
M\@990!GY@!]>1QQSC(%>H4U) _(((R1QSR#@C\#P::=@L>0Z?XCN-.&R*0A?
M0X8#J> P..O..O>B[U2YUHB-V:0]E4>F>=JC&<9YQG'M7JL^DPW!+O&C,>I9
M%)].I%26MA':9\M%3.,[5"YQTZ"G<5CRC5_#\FDJC2X#2%_E&#@+CJ0<<Y[?
M_6'2_#+_ );?]L__ &>H/B3>K))'"/O1ABW3C=C ^O&?H16A\-[(QQ23G.)&
M  ([)GD'ORQ'X4/8.IV%<;XQ\'?:<W5N/GZN@_B_VA_M>H[_ %Z]E14IV&>/
MZ-X@FT@YC/R\Y5LE#GOC(YX'(Y[=.*Z3_A9C;<>4-^.N\[<XZ[<9QGMG\>]=
M5J'ARWU$[Y8P6]1E2>@Y*D9Z<9Z=JQO^%<6_]Z3_ +Z7_P")JKH5F<CK/BR?
M5AY;D*G&508!QW.22?IG' .,UTO@/0)K0FXD+(K#&PC!;'<@],=N_P"'WM_3
MO"UMI^"B L,?,WS-E>AYZ'OQC^5:M)L+!45W;"Z1HFSAU*G'7##!J6BD,\6>
M.33)<$%9(V!YQP1R#Z'U'8_2NK3XEN%P8E+X/(8A<]OEP3]?FY]JZ[5M!AU4
M8E4$XX8<,.N.?;.<'(SVK&C^'5LI!)D(!Z%EP?;A0?R(JKIBL:_AW4FU*!+A
MP S;L[<XX8CN3Z5YQXDL)].G+RL2S'<L@XSCH1CH1QQVXQQ@UZE8V*6*"&,8
M1<X&2>IR>3D]33YX%N 4<!E/4, 1Z]#23L%CS[3_ (BS0\2JL@P>1\C9SW(!
M'MP!_C#K/CV6_4Q(HC1@0W\3'(((R0  0?3/O737/P^M9CE=Z#'16R/K\P8_
MK3[+P':VIW$,YR"-YR!CV  .>X.:=T&IR/@O0VOYEFP1'$P)/3D<A1QSSC/M
MW!(SZA4<$"VX"( JCH%  ]>@J2DW<:"BBBD 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2IU%)
M2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH **** "BBB@ JI5NJE !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 51_MZW_Y[1_]_%_QJ]7AM-*X
MFSW*BBBD,**** "BN;\2>,/[%D$/E[\H&SOV]21C&T^E:VB:G_:D*W&W;OSQ
MG/1B.N!Z46 O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45E>)-=_L6,3;=^7"XW;>H)SG!]*@\,>)_[<W_)L\O;_
M !;L[L^P]*+ ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT'TH =1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3)>E/IDO2@"O1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!XWH/_'Q#_P!=8_\ T(5[)7 Z
M;X!GM98Y6:/".K'!;.%()_AKOJ<A(****0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:EZF115Z:Q#<KQ_*J;QF/@BMXS4CFE!Q&T4451 4444 %%%% !1110 4444
M%%%% !1110 4444 %%.CB,AP*NPV03D\G]*F4U$N%-R*T%L9>>U7XXQ&,"GT
M5A.;D=,*:B%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %)#Y;<^M7:J7:X.?6K*'< ?:KGJ
MDS.GHVAU%%%0:%*,^4WXU=JI=K@Y]:L1-O -7/5)F=/1M#Z9-$)E*-R&!!^A
MX-/HJ#0\VLY/[,GR^?W;,#M]1D>W&?S'6N^@B$X$F<A@"/H>1UKDO&=GY4PE
M[2+[=5X(_+'YUO>$;HSP '^!BN2<^A'Y X_"O0Q3YZ4:J^9C&*YFF:ZQ!.@I
M70."I&01@@]*=17GW-K6/,;B)M.E*C[T;\$C'0\'!]>M>D6ETMTBRKT89_\
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M!GKC)QFH:V_!\!DN%8?P*Q/Y;?YFHJRY(.79 E=GH%%%%> ;A1110!D>*_\
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MV#<?\\9/^_;?X5T'A_P%).1+<C;'UVY^<]" <?='K_%QC ZC9_X61;_W9/\
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M*** "BN4\=:W-I?E>2VW?OSPIZ;<=0?6H-'\9&&U:XN6WOYC*@  )PJG' '
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K
M*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ8]![\<_G7)U=UF\^VS/*.A;C&1P. >?852KW</3]G32.>3NPHHHK804444
M%%%% !75^ X@6D?N H'T.2?Y"N4KNO!"%8"2.LA(]^%'\Q7+C96HOS*AN=#1
M117CFH4444 4]7_U$O\ US?_ -!->85Z?J_^HE_ZYO\ ^@FO,*]/+OAEZF=3
M<****[R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH U_"G_'S'_P+_P! ->B5YWX4_P"/F/\ X%_Z :]$KRLP
M_B+T_P S6GL%%%%<104444 >3S1&%BC<%20?J.#3*T?$-OY%Q(N<Y;/_ 'U\
MV/PS6=7T$)<T4^Y@PHHHJ@"BBB@ HHHH *]&\,7GVJW3U0;3C/\ #T_3!KSF
MNK\"76&DA.>0&'IQP?Q.1^5<F.AS4K]BH/4["K=C#GY_2JT:>80OK5TVQCY2
MO%J2TL=5*+O<LT5 ESV;@U,#FN=IHZ5),6LW6KKRU\L=6_E_]?\ QK19MO)Z
M"N8NYS=.6]3@#^7^?6L*\^6-NYTX6GS3OT1;T.VWMYG9?YG_ .M_2MEX ],L
M[;[,H3OW^O>IZNC'DC8SQ$U4FWT*WEM%TY%-GOMBD@<@=#5NL+6[G<WECHHY
M]\\U56JHQ;9-"BYS26PNE7CR28))!SG/;_"MRLG2[8A!(N,G/UZU>6YQPPQ4
MT8/D3O<K$U(^T:M:VA8HI%8-R*I:EJ/V0 #ECZU4I**NR81<W9%ZBJ]C>?:U
MWXQSBK%"::N*47%V8A7=UJ%[<#G.,5/5'5[CRHR.[<#^OZ4W/D381I^TDD8L
M[_:7R.K8'/7TKI((?)4(.P^GXUA:-!YDF[LHST_+_'\*Z&L*"O>3ZG3BVH\L
M%LD%%%-D;8":W.4:)P3MJ2J=JN3GTJY5323L3!MJX4445)04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 54JW52@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XF_P#+'_MI_P"R5RVAZ,VK
MRB%"!QEB>P&,G'?KP/Y#FNI^)O\ RQ_[:?\ LE6?AK;!8I)><LX4^F% (_\
M0C57T%U-NR\+6UHNP1JWNX#,>,9R?Y# ]!4.J>$+>^4J$5&P<,@"X/N!@'IW
M]\8ZUMT5-QGC$\,FE3%3Q)$_!QW4Y!&1R#U&1R*]>TV]%]$DXQAU!P#G!/49
M]CP:\S\;_P#'Y+_P#_T!:[GP1_QYQ?\  _\ T-JI["1>UK5ETJ)IVYQP!D D
MGH.?S/7@$X.*\I@BEUN8+G=)*>K'';)/T '0=A@#M78?$NY*I%%QAF9CZY4
M#_T(U7^&< 9I9,?,H0 ^S$D_^@BA:('N=!IG@VVL0,H'?&"SC.>^=IR![=\=
MSSFY)X>MG!4Q1X(QPB@\^X&1]16A14W&><>+_" TP?:(<F,G#*>=N>AS_=[<
M\YQR<\6_A[KI4_87Z')0\]>I7TQC)[<YZDUVM]9+>QM"_P!UP0>GYC.>1U'O
M7C^DWOV*:.;G".I.WKC/([=1Q5+5"V/8YX!<*8V&58$$>Q&#TKQR>&32IBIX
MDB?@X[J<@C(Y!ZC(Y%>SUY[\1=+\F1;I<XD&&X.,J!CGW';C[N?6E$&=W8WJ
MWL:S)]UP".GY'&>1T/O4]<C\.M3$L36I/S1G(''W6].YPV<^F1S71:SJ']GP
MO/QE%.,@D9/"CCU.!189YWXZU3[;<%%SMB&WJ<9!^8X/3GCWQG-==X%TO[%;
MAVQNE.[H,X(^49'7CGVSC%>>Z59G5)TB.29'^8Y^;'5CD]\9/^->Q1QB,!5
M  P .  .@Q3?82,;Q;KG]DP[D(\QSA>A^K8)[#Z\D9&*\ZT;29-<F\L'DY9F
M8YP,\GU)R?Q)YP,FM[XE7):6.+C"H6'KEB0?_016?X:\4C1%9?+W,Y!+;]O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %,EZ4^F2]* *]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !2IU%)2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$\9*PG^8
M\%%V^PYX_/-=W6#XPL/M$7F 9,9SW^Z>O'Y'V -=.#FH55?KH145XEOPY?\
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MH5$JBYMKZBJ4KQTW/'Z*=)&8R58$$'!!X((ZC%-KZ<\X****8!1110 4444
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MA$;DGACQQSG?@#\\<\>F;MUXJM;;&Z53G/W?GZ?[N<?C2U#0@_X0BS_YY_\
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M.B^/8KL;9\1OD#N5.>^<?+SZ]!W/.&[@B[_PA%G_ ,\__'W_ /BJ/^$(L_\
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M.(E/0CJWR@'OTS^7YOH'4])HHHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT'TH =1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !3)>E/IDO2@"O1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4J=124J=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID
MT0F4HW(8$'Z'@T^B@#S81?V=<!6_Y9R#DC' /7'N.:[VV NU$H;(8<$?Y_2L
M/Q=HC3D7$2Y.,, .?8X R?0^V.P-:/A:S>TAVR<$L2 >H!QQ[<Y./?US7?B*
MD:E*,[Z[&,8>];H:J($Z4ZBBN V/._$=A]BF90,*WS+TZ'Z= #D#VKL_#]TU
MU CMUP1GUVDC//?CGWJW/:)<8WJK8Z;@#U^M2(@0!0, #  Z5TUL3[2G&+6J
MZD1A9MCJ***YBPHHK"UGQ4NG/Y(7<P'/.T#/('0YX_SZ73IRJ.R5V)M(W:*A
MM+I;I%E7HPS_ /6X[CO[TLMP$XZFIY7>P-I*X^10PP:@\T1_*O- 1I>O J9(
M@G2JT1.LG=:$(A,O+5,JB/VILLXCX[U&(C+RW2C5[Z(6B>FK!YR_RK7.ZAX/
M:>3<A54./7\<  #\,\^HSQU*H$X%.JZ=>5-^Z/DON%%%%8EA36<)R:;+.(_K
M42Q&7YF_*J4>K)<NBW.,\<:"9R;Z)2<#]YSG@  -CV'7'08..IKB*]P>(."A
M *D$$$<$'J,5Y=XM\.'29-R ^2Y^4YS@XY4G^7J.Y(->QEN,4E[)]-O\CDQ%
M%KWOO,"BBBO4.8**** "BBB@ KU+38C#%&C<%44'Z@ &O+:];KS\R>D5ZET^
MH4445YIH%%%% %'7)1%!(6Z;&'XL,#]37F5>B>*_^/:3_@/_ *&*\[KU,N7[
MMOS,ZFX4445W$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!K^%/^/F/_ (%_Z :]$KSOPI_Q\Q_\"_\ 0#7H
ME>5F'\1>G^9K3V"BBBN(H**** .2\>_\LO\ @?\ [+7(UV?CNWW)'+G[K$8_
MWAG/_COZUQE>S@G^Y7S_ #,I[A111722%%%% !113HXS(0J@DDX '))/08I
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M444 %%%% !1110 54JW52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /6'%6Z*&[CL%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JRG0?2JU64Z#Z4 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID
MO2GTR7I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M5.HI*5.HH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%17#E!
MD>M-*[$W97):*B@E\P<]14M#5F"=U<*@O+U+-?,D.%SC\_8<U/6-XKLC=0$K
MU0[OJ "#^AS^&*JE%2FD]F#=D:5G>I>+YD9RN<?E['FIZX#PQJWV"3:WW),
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JRG0?2JU64Z#Z4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDO2GTR7I0!7HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5.HI*5.HH M4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<_ZA?^N@_P#06KAJZ_QZY B7/!+G';C;C^9KD*]C JU%&4]PHHHKJ)"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC/;;P?PSD_C677N8:/+2BO(QD[L****V$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7IVBN'@B(.?W:CCV
M!_(UYC7>>"[KS8/+XS&Q&!UP><G\2?RKBS"-Z:?9ETWJ;]%%%>4:!1110 5R
M?CJRX2X'KM/7/J/;CG\ZZRL[Q!8_;('0#D#(XR<KS@>YZ?C6V'GR5(L4E='F
MM=%X9\'MJ_[UR4B!ZXY;GD#_ !YY['G%WPYX%:Z!FN05'\*=&.#SG/(';L3U
MX&,]Y9D*!&!C:,  8&!P!^%=.-S#E3C!Z]7V*HT+M.0ZTM%M%$48"JHP /\
M/YGO4I&:6BO%;;=SN*S*8#N'2IT<.,BE(S5=E,!W#I5?%ZD?#Z$6J:A]E&U?
MO']/?_"L:TM&O&P/Q)_SUK9N[!;[#9P<8S_]:I[2S6U&U>_4GK7+.E*<]=CM
MIUX4Z?N_$QUO;BW&Q>G^>:66$2?6I**W7N['++WMRO'*8SM;\ZG!S45TZH-S
MG J""Y"]#E?;_/Z56DO7L3:45=[=S(CTZ25L$'KR3]>3GO7000"!0B]!3U;=
MR*6L:=)0-ZM>56W80C-5VA,9W+5FH;R?[.A?T'_UA6O-RJYCR<[2ZE'4-3,2
M@+P3W^G^-.T6X:4$-R 1@GWZC-9$<;7;8')/Y>YKI+>W%N-B]/\ /-<\).I/
MFV1UU81I4E!ZR[DM%%%;G*%<WJER9G(/120/P/7\:Z2JITV,MOQSSUY'/L:S
MK0<U9&V'J1IR;9'I5G]G7)^\W)_H*O445<8J*L9SFYR;9#);!^>AJEJ%R8D*
M$C)'XX)Q6G6#JUL[R$@$C Q@$]O\:FM4:A;<K#THRJ)WM;4CTFU,SANRD$_T
MKHJKV%I]E4)WZGZU8I48<D?,K$5?:3\@HHHK0Q"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J5;JI0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %64Z#Z56JRG0?2@!U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %,EZ4^F2]* *]%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2IU%)2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *9-$)E*-R&!!^AX-/HH \[OK9]$GX[<J3SE3D<]/H>GMV-
M=AX?U1=0CW8PR\,/Z^N#VS[CM3?$>C_VE'\O^L3E><=<9'XX_/'.,UQVB:L=
M-D#\E#PP'<?XCJ/RSS7I66*HW^TC'X)>1Z/134<. P.01D$=*=7FFQ'/%Y@]
MZKV\NPX/2KE036^\Y%7&2M9D3B[W6Y/1114%A7/W_@]+I_-#%=S98=<YZX].
M_K].U=!15TZLJ;O%V$TF,AB$*A%X"@ ?0<"GT51MM:ANG\I'!;GCGG'7!Q@_
MAVYZ4E&4KO<=TB]1114@1- "=U2$XH)Q5=F,YVCI5*\B6U$'E,ORK4T40C&*
M$PGRBGT-].@175[A6-K7AI-2(D!V/W(&<CW&1S[^G'IC9HHA4E!W3LQM)E32
M].73XQ"O..IQC)/4_P">V!5NBLK7==&E!?EW%R>^!QC/.#ZTTI59]VPT2-6B
MLS1=>35 <?*XZJ3GCU!XR/Y'\,WYIO+^M*5.49<K6H<RM<;<3;?E'4U&0(1C
M^(TL:^6"[=:6!-YWFJT2\C/5OS_(KO9$#</RJN1BMBH9[42\]#ZU4:W<F=#L
M9M%/EA,?6F5LG<P::"H[F<6ZM(>BJ2<=>!FI*Q?%UUY%NPYRY"C'YG\" 15T
MX<\U'NQ-V1P#N7)8G))R2>M-HHKWC ****8!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5TO@:ZV2-%QAUSS
MURIZ#\"3^%<U5_0[K[+/')QC< 2>@#<$_@#65>'/3DO(<79GIE%%%>$;!114
MT%J9>>@]:&TAI-NR(0,U?@LPG)Y/Z4_[, -HI+9_X3U%8SJ<RT-X4U%ZD]5[
MB/'SCJ*L45DG9FTE=#(I/,&:?59QY!R.AK.UK6?*_=1_>[GTSV'O_+Z]"2MK
MT,W54(ZEC4-;6T.T?,W< ]/QYY]JM65V+Q X[]1UP?3_ #VKE;#3FO#@<#NW
M8?\ U_:NMMK<6RB->@J4V10J3J-M[$3CR#D=#5E6W#-#+NX-5N;<_P"R:T^+
MU-?@?D6JBN+@6XWMT_SQ3GF"#>3P.]<YJ%[]K;/0#H/Z_6L*M3D7F=.'HNJ_
M(2[NVO&R?P _SUK;TZS,";6ZDY(_I5?2M,\K]Z_7L/3Z^_\ GZ:E11IM/F>Y
MIB:L6N2.R*I!@Y'2K".'&12D9JN\1B^9:ZM)>IQ6<?0LU'/ )U*-T-9ESK9C
M;:H&!C/K[UKUDI*5UV-G"4%&7?5%>TL%M?N]?4]:L444TDE9$RDY.["D)QS2
MU2GE\PX'2KC'F9$Y<J+@.>:6F1)L&*?4LI;!1139'V#- ;#J*JP2%VSV_2K5
M.4;$QES*X4444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JI5NJE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 593H/I5:K*=!]* '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R7I
M3Z9+TH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*G
M44E*G44 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *YW5O"(O)#*C;=Q^8;<]NHQCJ<9_$Y[5T5%73JRIN\6)Q3([> 6ZK&.BJ ,
M]>!BI*0G'-"L&Y%2[O48M%%%( HHJHTIC:G&-R92Y2W134;>,BG4BAKKO!![
MCL2#^8YKS6_LGTV0H<@J<J>F1GAA_G@\=17IE4=6TE-338W!'W6[@_X>H[_7
M!KIPN(]E+79D3CS(K^'];74DVD_O% W ]_\ :'L?T/'IG59MO)KS']YITG=9
M$/\ GZ@_D1[5W>FWXU10P(X W =B>O'7KG%7B<*H/F7PLF-1VMU+1)N.G JP
MB!!@4JKMX%+7*Y7TZ%QC;7J5+J(@[NU/M[C/RFK%5;BWQ\PJDU)69,HN+YD6
MJ*KP7&>#^=6*AIHN,E)!6=K&BIJB@,2"N<$>_MW'3W]Q6C2,VWDTX2<7=;@T
MFCS.[L9-/<JP(9,'(STSPP/IGOZ\=:ZK1_$D=TRI(2'VCD@ $X]O7MP/SXK6
MEM_MP96X4@CCKR*Y#5/#QL-TR-E4/'4-C( Z=\GV]>^!Z*J0Q"Y9:2,-M>AV
M0'GG/859 Q7'Z%XID+K#+\P=L @ $$X Z8&/U]^U=C7%7I2IRLS6G9JX4445
MB6(5W<&J5S:!/F'Y5>JL?W[8["KIMIF=1)KS*!&*XWQU=DLD'8+NZ\')P./;
M!_.O1WC$G!%<)XL\'32R-=1?.I RHX88&.G?IVYR<8KNP%:'M4Y.QSUJ,DM-
M3BJ*=)&8R58$$'!!X((ZC%-KW#E"BBBF 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%36EF]VWEQJ6;T'Y
M9/H/<\4FTE<#TS3KK[7&DO&64$XZ9QR/P/%6TC,G %5O"^BO9PK'-C(R0%]#
MS@GUR3TXZ<UO*H48%?.5JD8R:CKJ=E.BVKLKPV03D\G]*LT45S.3>YTQBH[!
M5>X7;\X[58I",T)V825T)&^\9IU4+BY^P D\C' R!FN?FU66Y;()!.  A('Y
M42T9C/$*&CW.N9=W!K)N]*2=AO)''4'_ !!K2M6+(I;[Q49[<XYI9HO,&.].
M+Z/8N<%-"PPB$!%& .@I]002?P'J*GI-6+BTT%(R[N#2T4AF)JL+9$:Y(Y/M
M_P#K']:FTO2]G[Q^O8>GO]?Y?7IJ,N[@U6R;<^QJ?8J4G)[E_6)0@H+1%JBD
M!SS2U1 5AZKJ?F_NDZ=SZ_3V_P _6;5M3VYB3J>"?Z?7^7UZ4=/T\W1]%'4_
MT'O7/5J.3Y(G9AZ*@O:2^1+IED9,R$9';/?\*VHI]_!X-2*NW@=!44T&_D=:
MWI048\OXG+7J2G/F_ FHJ"*?^%NM$EZD;;"P!_SWZ4Y>[N3#W]B292P(%1V\
M&SD]:GHIJ32L2XINX4444B@JE-+YIP.E2W,N/E%%K%CYC6D5RJYG)\SY420Q
M>6,=ZDHHK-NY:5@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5*MU4H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "F2]*?3)>E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT
M'TH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !3)>E/IDO2@"O1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4Y.HIM/A&30!8HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTR*U.Z.-%)&,JH4X],@5E/-H+:+?]?,J.%;5[GCUMIDMT-T<;L <952PSZ9
MK9MO 5U,<,JH,=68$?3Y=Q_2O4:*YYYO4>R2_$UCA(K=G"P?#E8L&:0G(Y"#
M&#QW.<CKV%=#9>#[6TY$88XQE_FS[X/&?H![<5J7*Y7Z4Z%MP!KEJ8NM46LG
M^1<:4(RM8?4%TN1GTJ>D8;N*YT[.YK)75A(VW@&G57M6QE3VJQ1)681=T,F3
M>,4RV?</I4U5A^[?V--:IHF6C3)W3>,52?4%LUR^>#@8ZU+J6_RV\O.['&.O
M7G]/_K5SEOI+S?>RH']X'OZ9Q23>QE6J2C)66I/+XDD9LJ  .QYS]3Q^F*Z2
M-]X#8(R,X/6LVRT&.'YF^<^XX_+_ !S6I4JY5&-17<GN%%%%,V"D9=W!I:I7
M^K)9\'EO0=>G?TH%*2BKL?&_D$JQXZY/%9=SXFPV$4%0>ISD_3T_6LRZU62Y
M)R< C&!TK0T_P_O.9#P,<+_4X_S[42?-JCC]K.;Y8&]#*)5#CHP!_.G$9XH5
M0HP. *6@[2JI\@X/0U9!S39$WC%102;3L/X5;]Y7ZD+W7;H6*@FN=O ZU/5=
M;7G)YI1MU'/FZ#+:,D[JLN@<8-*!BEHE*[N$8I*Q51S =IZ5:IDL0D&*ABE,
M9V-3?O:]1+W7;H6:Y>[D:=SNZYQCKCGI744W8,[L<XQGO6%6GSI*YTT*RI-N
MURKIU@+49/WB.?\ #_/6KE%%7&*BK(SG)R=V%(3BEJ&Y!(P/6J2NR&[*Y!+*
M93@=.U6T&T >U1P0;.3UJ:JFULB81>["BBBH+"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J5;JI0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6E&!58#/%6
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J> 8&:A4;N*L@8XH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** )(1DYJ>FQKM%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+TI],EZ4 5Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "I84SS21Q[N>U3T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M3)>E/ID@R* *]%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I3A"30 RE"[NE2K!CK4@&* &)%MY-2444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JI5NJNP^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44\1$TX0>M $52I#Z
MU(J!>E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .4\7^$&U0_:(3\X&"K$X('3'H?;@
M'.>#G/G<\#6Y*."K#J&!!]>AKV^LO6O#D.KX\T'<!@,IPP&<X]#^(.,G&*]'
M!YBZ24):Q_(YZV'YM5N9'@2]N;I"9N8AG:S9+DYZ9[J.>3WX!XP.KJ&TM%M%
M$48"JHP /\_F>],U'4%T^-IY,[4'.!D\G 'XGC^=<E:?MJK<5:[T2-8+DCJR
MS16/H'B:+6@0F5=0,JW7ZCU&>,_F!D5L5G.G*G+E:LRHR4E=!1114C"BBB@
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M?AW_ )UT\,(A 11@#H*?10E8ZJ5&--:;A1113- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/R-2BBJFG:K%J(WPL& ZXZCKU!Y'3C(YKRU%M-]#INBW1112&%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &N@<8/0UG3Z<4Y7D?K
M6G16=6C&IN7"HX[&-%.T)X_*KL6HAQ@CG]*L36ZR]1^/>J$^G%.5Y'ZUSJ%6
MB]-5V-'*%1=F7+9,#<>IJ>J>G1E <@CIUJY75"HZBYK6,7!0T"BBBJ$%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCJ1O8****YC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH6()T%/I2:Z(J*DMV(1FF"!1SBI**FXVDPHHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=9\/PZN,2#YN,,N
MXQVS@\<G@\=^O-:5%5"<H.Z=F)I-69PVA^ C!.3< -$GW>>&/;*\\#N#WP.1
MFNYHJ.>7R5+X)V@G"C+' S@#N3VK2OB)UY)R)A3C!: \ZH0A(#-G:"1DXY.!
MWQWJ2O&]4UB2_F-R20V<KS]T Y4 C'3UXYYZFNI\.>/M@$%UG !_><D\= 0!
MD_7Z9'4UU5<KJ0@I+5]490Q46[/0[NBFQR"0!E(((R".00>AS3J\\Z HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>C&FFKA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!?7JV4;3/]U 2>
MGY#..3T'O32;=D#=B>BN-@^),;R!6C*QDXW;LD#L2H'Y@$X[9[]E6E;#U*-N
M96N3"I&>P4445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5QOQ!UTVX%FF07&YB/[IR-OKR1STXXY!-=E5#5M%BU9=DHSC
M.".&&1C(/]#D<#(.*VPM2%.JI25TB*L7*+2///#?B^32,1-\T.>1_$,]=O\
M/!X/MDFO2=/U&/4%\V)@RY(R,CD=B#R/Q^M>8>(/"DNCG/+QX^^!@#H,$<XY
M/'//;G('6^ _#_V*/[4_WY1QSG"'!''J>O?C'0Y%>ACZ="=/VT7J^W4YZ$JB
MER,ZNBBBO).L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-OXCH<^CC,OA&+J0>G;_ ".>CB&WRL[VBBBO*.H**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K.O)=YQV%7I7V MZ5E$YK:C'6YC7EI8****V.8**** "
MBBB@ HHHH **** "BBB@ HHJCJ^KIIB;VY)^ZO<G_#U/;ZX!J,7)V6X!J^KI
MIB;VY)^ZO<G_  ]3V^N ?.[^_>_<RR')/Y >@]O\]:+^_>_<RR')/Y >@]O\
M]:K5Z^&PRI*_4RE*X4445TDA1110 445?TC2'U-]B\ ?>;L!_CZ#O],D3*2B
MKO8 TC2'U-]B\ ?>;L!_CZ#O],D>AV%@E@@BC& /S)]3[_YZ46%@E@@BC& /
MS)]3[_YZ5.[A 6)P ,DGI7D8G$NL[+8UC&PZBN,U7QH[,4@P%[,1EC[X/ !]
MQGZ'ICSZ_<3G<9&Z?PG:/R7 JX8"I)7=D#FCT>>Y6W&YV"C.,L0!^M9=QXLM
MX<_-N(/103GGL3@?K]*\\HKHCET%NVR749V4_CQ5/R1DC'\3!3^0#?SK*N/&
M5Q+C!5<?W5Z_]];JPJ*VCA*4>GWDN;+5QJDMSD.[$,>06..N>G2JM%%;I);"
M"BBBF 4444 %%%% !1110 4444 :VA>))='/R'*$Y9#T/;KV/N/09R!BO1]"
M\21:P/D.' RR'J.W7N/<>HS@G%>14Z.0QD,I((.01P01T.:X\5@*=?7:7?\
MS-:5>4--T>XT5PFA_$/;B.Z!//WU [D=5&.G/(]N">:[F.02 ,I!!&01R"#T
M.:\.OAJE!VDCNA4C-:#J***Q+"BBB@ HHHH **** "BBJVI7HL8GG.,(I."<
M9(Z#/N>!32;:2!NQ9HKRG_A-[S_GI_XXG_Q-'_";WG_/3_QQ/_B:]#^R*W=?
MC_D<_P!;AYGJU%5M-O1?1).,8=0< YP3U&?8\&K->>TTVF="=PHHHI %%%%
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MFX/=%0FIQN@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU$U9Z?J88MIJ+7F=U\,?^6W_ &S_ /9Z[FN&^&/_ "V_[9_^SUH:]XV.DRF
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M HHHH **** "BBF2G"GZ&A ]#+9MQSZTE%%=APA1110(**** "BBB@ HHHH
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MQ!%=?17'/,<1+K;T.B.'IKH9-KX5M;;.V)3G'WOGZ?[V<?A6I'&(P%4  #
MX  Z#%.HKEG4E/=M^IJHI;!1114C"BBB@ HHHH **** "BBB@ HHHH ****
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MLF&3[&?N29(XZ,!GKZ$#WYQC'-=/XW_X\Y?^ ?\ H:UYQH/_ !\0_P#76/\
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M&.>,<F'S7GFHR5K]36IA>573.-\-ZZ='E$G)0\.H[CL>>XZCIZ9 )KUN.02
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M>"/%!OQ]FF(\Q1\I)Y8=_J1^9'..":YWQOH0TR42)@)+DA1Q@C&X?0YR/RP
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M3Z+1'10ARP04445RFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/&?F)[X''J<^W#UUT*\,1#F6VVIE.#IRLSVVTN1=(LRYPZAAGKAAD5D>-_\
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M>)(]:W>6&&S;G< /O9QT)]*\K$X6K3E*36E]SJIU8R25]2#QO_QYR_\  /\
MT-:\IKU;QO\ \><O_ /_ $-:\IKT\H_@OU_1'-B_C7H>K>"/^/.+_@?_ *&U
M4?B1_P >Z_\ 75?_ $%JO>"/^/.+_@?_ *&U4?B1_P >Z_\ 75?_ $%JX*?^
M^_\ ;S_,WE_ ^1YO7L/AN<36T+*<@1J/Q4;3^1!KQZNB\,^,&TC]TX+Q$],\
MKSR1_AQSW'.?3S##2K4UR[IG-AZBA+4]1K-\23B&VF9C@&-A^+#:/S)%9[^/
M;55WAF)P/E"G=SVYPO'?GZ9KC_%'BPZUB-5VQJ<@'EB>0"?3@]![\GC'EX;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[G*^$O!?V,_:;D#S ?E7@A<?Q''!/IZ=>O3L***\RO7G6ES2.F$%!60V2,2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[U>9B\7S^Y';\S2$+:A1117"6%%%% !1110 4444 %%%% !6K#]T?05EJ-W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,NX7:Q^O\ZCJU?QX(;UJK77!WBCCFK284451U?5T
MTQ-[<D_=7N3_ (>I[?7 -QBY.RW(#5]733$WMR3]U>Y/^'J>WUP#YW?W[W[F
M60Y)_(#T'M_GK1?W[W[F60Y)_(#T'M_GK5:O7PV&5)7ZF4I7"BBBNDD****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN[%ZVCV*!4M%%<C=W<[4K*P4444AA1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N2^(6D&YC6Y1<M&?FP!]T\Y/<X/Y9)]:ZVFR1B0%6
M((P0>00>HQ6M"LZ-1370FI!3BT>'45HZ]I)TJ9H#G .5)[J>AS@9]#CC(-9U
M?3PDIQ4ELSS&FG8****H0445?TC2'U-]B\ ?>;L!_CZ#O],D3*2BKO8 TC2'
MU-]B\ ?>;L!_CZ#O],D>AV%@E@@BC& /S)]3[_YZ46%@E@@BC& /S)]3[_YZ
M5.[A 6)P ,DGI7D8G$NL[+8UC&P.X0%B< #))Z5PGB3Q(=0/E1\1 _BWN?;T
M'XGG !XD\2'4#Y4?$0/XM[GV]!^)YP!@UUX3"<GORW_(F<[Z!1117<0%%%%
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M5MUYO\2/^/A?^N2_^A-7+@:,:U7EEM8UKS<(W1T5IX_@NG6%5DR[!1D+C+'
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW2/-C%2J6\SO[+38K$;8D51@ [1@G'3)ZGZFN?\ '>AK<0M<JH\Q""2J\D<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%075A'=X\Q%?&<;E#8SUZBIZ*:;3N@:N4/[!M_\ GC'_ -^U_P *NQQB,!5
M  P .  .@Q3J*;G*6[$DD%%%%2,I2:+!(2S11DDY)**22>ISBI+;3(K4[HXT
M4D8RJA3CTR!5FBJ<Y-6NQ<J"FR1B0%6 ((P0>00>HQ3J*D90_L&W_P">,?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KF_$G@_^VI!-YFS"!<;-W0DYSN'K7245I2JSI2YHNS)E
M!25F<;8?#O[)(DWFYV.K8\O&=I!QG=79444ZV(J5FG)WL$*<8;!111610444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 (RANM5WL5/3BK-%-2:$XI[E%M//8_GQ4;6C#M6E15JM(S="+,K
MR6]#^5,(Q6Q15>W\B?JZ[F/0!FMBBCV_D'U?S,KR6]#^5/6T8]JTJ*7MF-4$
M45T\]S^7-3+9*/?Z_P#UJL45+J29:I17015"]*6BBH+"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img64161509_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img64161509_3.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /6!] # 2(  A$! Q$!_\0
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH
M\-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^%
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M-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\*
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH
M\-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^%
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M-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\*
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M9?K:O#/V@?\ D3-._P"QEL__ $U:U0 OP _Y$W4_^QFO/_35HU>Y5X;\ /\
MD3=3_P"QFO/_ $U:-7N5 !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7AG[0/_(F:=_V,MG_Z:M:KW.O#/V@?^1,T[_L9;/\
M]-6M4 +\ /\ D3=3_P"QFO/_ $U:-7N5>&_ #_D3=3_[&:\_]-6C5[E0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X9^T#_
M ,B9IW_8RV?_ *:M:KW.O#/V@?\ D3-._P"QEL__ $U:U0 OP _Y$W4_^QFO
M/_35HU>Y5X;\ /\ D3=3_P"QFO/_ $U:-7N5 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?D]^TM_P6>_8E_9M\0ZGX+E\4^(OC%XUT>62TU70_@WINE^
M)-/T?48]ZM8ZKXNU;6] \)_:+>=&M]3M='U?6M2TF=);:^T^*\B>V'S?_P %
MV/VX/$_[/GPF\*_L^_"S7)]!^(7QULM8N_%6OZ9<S6NM^&/A=IDT&GW4.F7,
M#Q2V-[XZU.6ZT2/487>2#1M'\36\:V]W=V5[;N_X)G_\$>O@3\-_@_X*^+/[
M2GPZT/XK?&GQ[H6G>*)_#'C[3;;7O!GPWTO6;>/4-+\-P^$=02?1-6\216,M
MK+XDU77;/46LM5,NE:)':6UE<7VK@%OP'_P<+_L7>)=9ATKQ?X-^./PWL[B6
M-!XDU;POX;\0Z%9QLVV274HO"GBS5O$B+'D.J:9X=U9Y$63Y4=8XY?VC^%OQ
M7^&_QL\$:-\1_A-XTT#Q]X'U^)Y-+\1^';Y+VQF>%O+N;2< )<6&I64P:WU#
M2]0@M=2TZY5[:^M;>X1XU^<?BE_P3N_8B^,.@7WA_P 7_LQ_!^V6]@$ UWP=
MX*T3P!XNLO++/;R6'BWP3::#X@MQ;RMYJ6QU!["8[HKNTN;>6:&3)_8/_8<\
M,?L&^!/B/\-_!?C[Q+XY\+>-/BCJ/Q"T2/Q/965GJ'AFQO/#?AOP_%H5S<:=
M*++7+]/^$?-S=^(+?3=!2^CGM+4Z+;MIYNKP ^G?BQ\8?A?\"O!.J?$?XP>.
M?#OP]\$Z/L2]\0>)+]+*U:YE21[;3K"'#WFK:O>B&5=/T;2K:]U;49$:*QL[
MB4;*_%+X@?\ !P]^R!X;U6\TWP/\/?C5\2+:U!6#7[?1_#GA30]1D$I7=9IK
M_B%/$4=N8AY@DU#P]8S[RL1M%&Z1?RS^-'B3XC_\%DO^"ED?P-\/^*]0TGX
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MWMMJ.EZIIM]"ES9:AIVH6<LUI?6-Y;R1W%K=VTTL%Q#(DL4CQNK'\H_VZ/\
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M-KJ-B[M-8W\%S9S[9H)%'\G'_!7S_E+M^S?_ -@K]FS_ -6WXAH _L!HHHH
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M9/=7NC^)EM(8YY;]?"NMZY)IT,$ESJ"6UJT,\OO!_92_9>/AX^$C^SC\"/\
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MO"FD:-J6E6^O6?AZ231[C0/''BB^DF^VW]I*L.IZ=I;&UEWG$R20)E_M2?\
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MBQ:^\0:1::/XJF.>5UZ-L(247[]=TC1I)&5$16=W=@J(B@LS,S$!54 EF)
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M,N9KL?I)_P '#G_)C?@O_LY'P'_Z@'Q6H RO^(BS]B;_ *)=^U-_X1/PE_\
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MU:P\,26$EQNDB*@'8?M7_P#!1O\ 9._8UE72/C!\0O/\<S6T=Y;?#+P39?\
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MR1PPC^WC]DCXZV'[3'[-7P9^.=@\!D^(/@?2M2UN"VV^18>+K$2:+XUTJ+:
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M\,Z/=SR^([74[O3I]+'ACQAXPMKBVV:3>QW!N;JSGBE1 ('CD62ON:OYD?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\8?LZ>(6T"WCFE\RZN/ASXNEO]=\&73L[;W33M1C\4^&88D0Q66EZ'H\1?\
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MXL\.   <  =!7PW_ ,&Z?_)DWQ1_[.F\;?\ JI?@A0!\W?\ !RI_R _V//\
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M[1J*** /YNO^#D/Q)>6OP2_9M\()-(NGZY\4_%GB2ZMQN\J6\\*^$H],L9G
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M7]AOXZ^,[&_%AXH\1^&F^&7@ITD\J[_X27XC/_PC*W>G/T%_H&BWFM>*(">
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M10 5_)1_P<D?\E2_9=_[$#XA_P#J1>'Z_K7K^2C_ (.2/^2I?LN_]B!\0_\
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MNJWTQ[16EA:SW$A[)&37\)7P!^-'[9'Q(_;6^*?[=?[._P"SI=_'OQY!XO\
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MMSX!:Q+$\T6D_ ;P?J4D,9"R3)8_%OXEW3Q(S?*KR+$44MP"03Q7]B-?Q_\
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MKH^@:A-9:I;V<=U&;C2K<Q3-<6\;W4,,=Y<?5=% !7\?W_!4_P#Y3._LZ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT>WB_=Q?U15FZEHVD:S''#K&E:;JL,+F6*+4K&UOHXI"I4R1I=12JCE25+J
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M?'-K9SO!<6VKR6\[^7);W5KXJT.STO4#_:510!_+M<_\')UE/HQ32OV0;_\
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MBO>7OPM\<VMG.\%Q;:O);SOY<EO=6OBK0[/2]0/V#<_\')UE/HQ32OV0;_\
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MC\@1)"Z3&=+AE51)_?'10!_+/_Q$*?&[_HQO_P OOQ=_\[:OWP_8J_:)UO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KPS]H'_D3-._[&6S_]-6M5[G7AG[0/_(F:=_V,MG_Z:M:H 7X
M?\B;J?\ V,UY_P"FK1J]RKPWX ?\B;J?_8S7G_IJT:O<J "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#/V@?^1,T[_L9;/_
M --6M5[G7AG[0/\ R)FG?]C+9_\ IJUJ@!?@!_R)NI_]C->?^FK1J]RKPWX
M?\B;J?\ V,UY_P"FK1J]RH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=EK^FZ2)EL[J;PC864LFE6WV3^RA^W-JWB+_ ()>Z9^V1\7HI=?\3^ ?AO\
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M%'!XP\0?$S2O!NJRVF!?ZGH/ACXK_#AK33+I8RDDEM>6OQ*\3Z:F6#2PWMW
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MJ<%A:^.]1U 0:%I-[86J7]O+XIU.\AOM$DDN/$>E@']+5%?S+?MF_L<_&/\
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MM9X]0LK(76M)H5GI[[M$B?0O$6O:_9Z[*_AW2+< _?.BOYK_ -KK]CWXP_\
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MX:U:_P!"UO3GN/B!X1LYWL-5TNXM;^S>>TN+BUF:WN(S+;SS0.6BE=6^*_\
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M_:$^)'Q#\=_M(?MF?M(^(/#&L^+?$6I?#OX4_"[Q/:?"_P"'WPZ\%W%]=_\
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MT70=?C#X#_\ !+SXX?%KX.>$?VDOB9^W3^U+X:_:Q^(GA2Q^(_A_5-"\<E/
M_@2Z\66]OXET7PYK?AR2WEU/5]/M[>?3X=>T?0=?\+Z!;R";2=/TF;3;"#[6
M >K?\$Y_B+\0?%7_  4)_P""I'A;Q1X[\9>)/#/A#XEZ5:^$_#FO>)];UC0O
M"]L/&7Q#M!;^'=(U"^N-/T6 6EK;6HATVWMHQ;V\$.WRX8U7]P*_F\_X(MV_
MQ3M/VR?^"D=I\;[S2M2^+]GXC\(V?Q(U/0EM4T;5/&%KXM^(UOK>J:6EE;6=
MI'8ZE>QRWMO'!96$:1SJ@L++!M8?Z0Z /-/C-\4O#WP1^$OQ(^+_ (K?;X>^
M&O@KQ'XTU2-9%CFNX/#^EW.HKIUJS!@U]JDT$6G:?$%=Y[VZMX8T=Y%4_A%_
MP3 _X*8_M/?&[]I&T^"_[6B>';.T^-GPKU#XK_ 633?"^F^&9I8=,U'4)1IN
MG?8)O.U'0=5\.:)XOU&RGUAK_6$;PH&-W)#>225[E_P6O\?>(/$7PU^!/[%7
MP\NMOQ"_;%^,?ACPC+%&TC?9O!/AW7=$GO[F^$!$EM9/XMU3PA/<7$SQV\FC
MZ7X@63?#!<M#X9_P5K^$4?[)FF_L'?M>?!G2);>+]CWQ1X(^$6HV=J52XO?A
MC86UO-X5TS4IHTB5=+QHGB+PK>N'B$\WQ!*%/WS21 ']%-%?/?Q;_:)\(_#7
M]F+QI^U!IY'B?P=X?^$=U\6/#Z6DJQ+XGT^X\.KKOA>VMYV)2%/$#W6FVT5P
M2RPK>K+A@N#^&W[(_P"P[\:O^"@/PKLOVROVGOVPOVD_"'CKXHZEX@\1?"CP
MW\'O&D7@[P[\/-'L=1O] T?4(-)GL]6MK.SNY;"YNK#1/"__  C,XT-[2XO]
M=N]7U2_GMP#Z-\"?$7X@W'_!=CXT?#BX\=^,I_AY8_LS:5J=EX#F\3ZW+X,L
M]2;0/A1<MJ%KX7>^;0[>^:YOKVX-W#8I.9[RZE,GF7$K/^X%?S ?L)^%/CSX
M$_X+2?%7P5^TAXXL?B9\3/"O[-]_H;_$2R@AMG\:>$K&W^%D?@?7]3MXDC>'
M7;OPK_92ZZEV);XZM%=M>7VJSL^K7WZG_M!_\$^_&?[4OQD\3^*OBK^U]\>_
M#?P->W\/6O@3X!?!C6;?X=:3I7]GZ'ID&O7OB_7MFLP^,+G6_$4>LZE"]UX>
M@U/2K"_BTZRUQ+>"*&  _3"BOYP/!NB^,_\ @G9_P4I_9Q^ GPQ_:#^)?Q>_
M9R_:8TO6M%USP%\4/&MOXWU#P=XFTN/5K)7L9[2&RL-+N-+U*/P[<V=Y::3I
ME_=:5)JN@ZLNH&UM=1KU?_@M7\3?C)\,_'7_  3[U#X(:O=VWCB[^.FO?V#X
M=EUK4=+\+^+?$\%U\.K?POI'C"UL]5TBUU/0Y]2U%K*\@U&[BMA8:A?Q//!#
M<W#D _>BBOP5^(/_  21^.?BCX?ZU\6=7_;O_:7UO]M&+0M2UZQU_1/&\GA_
MX4)XG%J^I1^"O"WAS2[+2?$?AKP[/J$,.C6&HZ5XBTNQLXO)U2/P=!'&-%7H
M?V,?$-__ ,%;/^"?&B^'_CG\2_BSX)\;?#KXK3^$O'/COX,^)=,^'WBSQ=JW
M@S1;35="O[^=]"UW39-.U?PYXXT@^(;+^R(K>_\ %6BRZI:1V A@AB /N3_@
MG_\ MN:+^WM\&_$WQ@T/X?ZI\.+3PW\3M;^&LFAZMKUIXBN+N?1O#'@[Q/\
MVLE[9Z;I<445S;^,+>V^QM;N\,UE,WVB5)4(O_%KPS^V_J/[6?P+U[X1?$7X
M>Z#^R1I>BR+\<O!6MZ3I5SXO\1:TEWX@:>33+ZY\*:GK,45QIMQX:AT4:)XF
M\/16>IV.I7&M)?64T=M/_/G_ ,$9OV ? ?[3?P#\0_&3Q'\;/VE?AUKG@O\
M:&U;P[I_AWX0?$G2/!_@Z_A\.>#/A=XIM-3U?2KSP=KM]<ZS=7FOSV-_?6VK
M68FTNQTRVABMYK5KF;]&/VL?''C32_\ @LW_ ,$_O!VF>+_%&G>$=9^&?BFY
MUCPM8>(-6M/#FJW$L/Q:$MQJ6AV]W'IE]-(-,TT22W5K+(XT^Q#,1:6_E@'[
ME45^"'AWQMXW_96_X+6^*/AIXL\9>*=1^#/[:?@$>)? >G>(_$&K:IH.@^.%
MMIKV*VTN.^O)K+39U\4^$O&'AS2],L8(1;Z=XR\.6/DK +.6NP_X++_$GQ]K
MT7[+'[&'P;\4:WX8^)/[4'QETJ'4]5\-:I>Z;J6E>!?#]U9Z9/)J$^G7-K=P
M:1<ZYXBLM=GE\Y(I+/P3JR2DQ1S4 ?M_17XV?\%)_C_\4_AA-^RS^Q%^SAXY
MNOAU\3/VC]9@\(7?QBUB[6_U/X??"_PW;Z?H6L:]_:UU<1ZBGB:^%X=2;Q'"
MZ:G#:Z!K;6%Y8ZW?Z?J5C\[_ !]_8"L?V=_@AXZ^/W[-_P"WC^T='^T)\(_"
M>I_$N;5O&?QRTSQ1H7Q''@K3+GQ!X@T+6/#$=I:K='6+"SOK?1=/U"ZUG3))
M98=*UZSUNVN[FY !_0W7-^,M;F\,^$/%?B2WABN;CP_X;US6X+>8NL-Q-I6E
MW5_%#,T9#K%*]NL<A0APC$J0<5\U?L(?M%7W[5_[)7P7^/&L65KIWB'QGX>O
M[;Q39V0"6B>*_"/B'6/!?B2YM( 2UI8ZGK/AZ\U73[-V=[73[ZUA,LP432>]
M?%C_ ));\2O^Q \9?^H[J5 '\^/[(O[0?_!9;]M?X0ZC\;/A)\3OV0M&\-67
MBO7O"(T/QQX7\2:1XBGU;0;#2M2N%M(-(\&>)M)^QW$6LVEO8SWNOP2-,LWV
MQ;:)%GD^S/V'?V^_CEX^_:,^(W[$7[9'PT\,^ ?VB_AWH$OB?3O$/@2XN6\'
M>.-$@72KQO*L+B]U7[)>3Z%KND^(-+U*PU6;3]7L&U.&YTSPWJ6EC3[W\HO^
M"3_[=/Q'_9P_94U;P-X4_8@_:>_:%TL_%#QCXE;Q_P#"3P7KNM^"X+J^T3PM
M!-H%UJVF^&]8MX-2TU-.BNM00S-);VVH6LK6^'7?[M_P3@^+'A+]J+_@IM\;
M_P!H_P".FLVOPC_:)F\,7'@?X3?LNZSI?B+3O$6B^&],T#2['5]3N]<US0]#
MM-8\0:3X8TFX:YT&%%UJ[36?$GB1]'TS1=)M8;< _9+XM>&?VW]1_:S^!>O?
M"+XB_#W0?V2-+T61?CEX*UO2=*N?%_B+6DN_$#3R:9?7/A34]9BBN--N/#4.
MBC1/$WAZ*SU.QU*XUI+ZRFCMI_M:OPU_:Q\<>--+_P""S?\ P3^\':9XO\4:
M=X1UGX9^*;G6/"UAX@U:T\.:K<2P_%H2W&I:';W<>F7TT@TS31)+=6LLCC3[
M$,Q%I;^7:_;P^-_Q^^-_[8WPG_X)M_LU_$?5/@F/$WA*;XB?'KXP>'W$'BO1
M_"/D7NHP:%X7OK>[LM6TNXCTO21/<R:/=V.H:SJ/B7P_I\FIZ;H5IX@^W@'[
M@45_/1^TE_P3*^(7[+/PB\9_M*?LF_MC?M6)\7_A#HVI?%'7K#XE?$:Q\6Z#
M\0=-\*V,^K>)XKW3K70M!MI]0.AVUU+#8^(8/%6DZU:Z?#X?OM,DDOWU-/M'
MX9Q:%_P5?_8#^#'B7QQXU^*GPFN_%,MIK/C'4?@CXLL_ _B%O'7P\U#Q%X)\
M1V*7EYH_B2T_X1'6];M;WQ!9Z+<V4\D=M)H,K7*W=@)" >P_\$__ -MS1?V]
MO@WXF^,&A_#_ %3X<6GAOXG:W\-9-#U;7K3Q%<7<^C>&/!WB?^UDO;/3=+BB
MBN;?QA;VWV-K=WAFLIF^T2I*A'W+7\CO_!&;]@'P'^TW\ _$/QD\1_&S]I7X
M=:YX+_:&U;P[I_AWX0?$G2/!_@Z_A\.>#/A=XIM-3U?2KSP=KM]<ZS=7FOSV
M-_?6VK68FTNQTRVABMYK5KF;]*?V]/C;\6OC'^V#\(O^"=?P;^+FI_L_^'_$
M/@R[^*'[0WQ?T*]M])\46O@Q6NY].\)>$]<6[MKW0[^]M]'DANIX);5K^Z\4
M:##<3RZ+9ZUIVJ '[<T5_-G^UM^S9J'_  3T^%$G[6O['?[8WQKU;Q1\+?$'
MAB]^(/PY^*GQ>T[XD^%OBEX:\0^(='\+WJ:AX>M;+1[6ZU%+W5K.[U+[3:7:
M'3$N[W1O[$UG3;"]/UK_ ,% ?^"@/C7X>_L+? OXH_ .WDT;XN?M@VWPRT_X
M7RXTK4KGP8OQ \+V/B_5;M(=3C>QO=8T^SNH/"UB]Q:-;V6LZQ;ZG<(AL%MY
M@#]EZ_&3_@NSX^\=?#G]B73=>^'WC/Q7X$UR?XW^ ],FUKP=XBU?PQJTFG7&
MA>-;B>P?4M%O+*\:SGGM+6::V,WDRR6\#NC-$A'&:?\ \$;O%]MX1L?&"?M[
M_M;6'[5*:;;ZA=?$U/B/=ZAX('BSR8YIK4^&I8+?Q;>^&8KOS[6*.?QTES/;
M323W,,D+_P!E+RO_  7)T[Q?I'_!-'X8:3\0=<L_$_CW2_B9\&-.\;^)=/ME
MLK#Q#XOLO 7C"V\2ZY8V:6]FEI9ZMK,5[?VULEI:K!#<)$MO $$2@'[I^"YI
MKGP=X3N+B:6XN+CPUH4T\\TCRS332Z7:R2S32R%GDED=F>21V9W=BS$DDUTM
M?@II_P#P2Z^/W[1'PMLOBK^T)^VE\<_#O[1NL^&;;6_A]X8^%'BQ?#OP-^#D
MTFEH_A7PO;^&[:TFU35XM*@-I!K>M>'M>\-7UU<-=N=0UZZB;7M6]X_X(Q?M
M*?%3]H?]E?7++XU:QJ'B7XB_!;XH:_\ "?4?$VL3BZUS7M*TO1] UG2+K7;Q
M8(3?:OIXUB[T"YU"XDN]1U.+1[?4]5O+K4;VYN)0#]<Z*_E _P"";GPG_:J_
M;A\'_&;P!XL_:C^*7PS_ &9/!WQ[\:ZIXGO_  #XNU&/XW?$/QKK^E:!!_PA
M4/C+69]9_P"$>^'/AW2=/MM>DL7L+G3M1U_Q'?\ VC1M:GE6^\-_1_P0TSXN
M_P#!/#_@J#\+_P!D"V^-OQ-^,/[-/[2/P]U;7/"VE_%/7V\1:MX,U;3-+\9W
MEJ8;G['%9Q:O9ZUX,GL[V;PY8>&M)U?1/%=G-JNFS7^BVLT0!_1A17X?_MX?
M&_X_?&_]L;X3_P#!-O\ 9K^(^J?!,>)O"4WQ$^/7Q@\/N(/%>C^$?(O=1@T+
MPO?6]W9:MI=Q'I>DB>YDT>[L=0UG4?$OA_3Y-3TW0K3Q!]O\H_:2_P""97Q"
M_99^$7C/]I3]DW]L;]JQ/B_\(=&U+XHZ]8?$KXC6/BW0?B#IOA6QGU;Q/%>Z
M=:Z%H-M/J!T.VNI8;'Q#!XJTG6K73X?#]]IDDE^^IH ?M3^TSJ>HZ+^S?^T%
MK&CW]YI6K:3\$/BOJ>EZIIUS-9:AINHV'@/7[JQO[&\MGCN+2\L[F**XM;F"
M2.:">-)8G5T5A\-_\$8/&/B_QY_P3]^%?B3QSXJ\2>,_$5WXE^*$-UK_ (KU
MS4_$6M7,-I\0O$-O:0W&JZQ=7E]-%:VZ)!;QR3LD,*)%&%10HW?A[^TA+^UI
M_P $K?%_QVO[.'3_ !!XM_9C^-ECXOL;=%BM8?&?A/PIXT\)>*I[*!7D^S:9
MJ>M:)>:OI%J\DLMOI.H6,,TCRH['Y8_X)>_&;1_V>/\ @CA#\;]>LIM4TWX8
MV?QT\6/I-O*EO/K%WIWC[Q,=,T:&XD#1VTFKZH]GIJ7+JZ6[70F9'"%& /W<
MHK^=7]F#]B[XR_\ !1SX5:=^U;^V3^U;^T)HC_%BZOO$'PV^$WP/\;67@+P1
MX'\,:?J5]IN@WPTBZTGQ/I"W<LEI_:>DQV=A;:K%:QZ??>)M;US6;W4HX.K_
M &7?&OQY_89_X*':7_P3]^+'QA\8_'?X(_&WP-JWCOX#>+/B!>?VKXN\+7UM
M:>(=733]1UF[N+N]%JZ^"/%GAN^T>&X_LNXU=_#_ (CT?2_#\>K:I8S '[_T
M5^%O[9/B/XI_M1_\%%OA9_P3[T;XO>._@A\$K/X077Q=^*^H_#35Y?"WCKXB
M3O-JTD7AVP\0".7_ (E=M;Z?HT$%NL-QIT<EYXFU#5+'6+C2])MK'X._;7_8
M6T+]FW]JC]B3X>^'OVB?VK-4^%'[4WQ'?X7^)]$'QBF;X@^&=2&N>"_#T/B+
MPUK\^AW>ESZ6)O'>GZAJ-AJ?AB_F@31[VV@O1_;%J^D '[V_M<^&?VW_ !#X
M@^ DG['_ ,1?A[X#\/:9X\FN/CW!XXTG2M2N/$/@LW?AV2RL](;4_"GB:6*W
MBL[?Q1!JD.BRZ#KUS-J&D-I^M6:V]Q-']K5^!_\ P5,U#Q=\&_&'_!*;X?>"
M_B+\1;?2;'X\>&?!NKZC<>,-537/&VG>'-1^$6@6U[XZOM,ETV'Q-JM]93W\
MFJ75Y:"*[N=5U5UMH8[^>)O<_P#@J)^TO\6_"/B+]G+]D']GOQE'\,?BM^U7
MXONM'U7XLR^0#\-OAOITEKI^OZOI\[3PW6G:S</J;WUMJ]D8KVPTWP]J\>F7
M=AK%WIVI6(!^OM%?SR?'W]@*Q_9W^"'CKX_?LW_MX_M'1_M"?"/PGJ?Q+FU;
MQG\<M,\4:%\1QX*TRY\0>(-"UCPQ':6JW1UBPL[ZWT73]0NM9TR266'2M>L]
M;MKNYN1Z5\;/V^OC/XJ_X(UZ;^U_\+X3X;^*WBW1M$\*^)]>T2W2;_A"=2@^
M(MQ\,?'?B_2;9UE731>ZCI%XWA]Y1(^@_P#"1:7>I+++913N ?NC17X+_LP_
M\$[OA!\4/AO\+?VA?@G^WE^T_KWQ2NK3P;XG\1_$W1OC-#XHTG4_$D2Q:SXF
M\)^+O"7D1:C;V3W>H:IIFH>$]<\0IK&GK-+:ZY-J$DFIQ:A^]% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5X9^T#_ ,B9IW_8RV?_ *:M:KW.O#/V@?\ D3-._P"QEL__ $U:U0 OP _Y
M$W4_^QFO/_35HU>Y5X;\ /\ D3=3_P"QFO/_ $U:-7N5 !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\N?MJ
M_'ZV_9@_98^-GQN>>&+4_!G@G4/^$42?8R77CG77B\.^![1XW5_-AF\5ZMI'
MVM5CD*62W,S(8XGQ^%W_  3^_P""8?[2&L_LR^ _BQX>_;O^-O[.MY\=+5_B
MKK?@7P+I%S+9W'_"0RR#PYXBU/5!XUT:?5]3\0^$H-"UJ:YN+&-X5U!;57G$
M)N9OZ"_CU^SQ\'OVG? ?_"LOCCX0_P"$X\#'6]+\1/H#>(/%'AR*75]%,[:;
M<SWOA+6]!U.>*W:YF8V,U[)87#,K7-K,T413U;1=&TKPYHVD^'M"L+?2]$T'
M3+#1M'TRS016FG:5I=K%8Z?86L0R([>SM((;>! 2$BC5>U '\HG[=?[+_P =
M?^"?'Q+_ &8?V]?$7[2_Q*_:FO\ P%\5_#G@_P 1ZGXZTLV.O:+X63^U]>MO
M#-OJ#>)=?GET#Q3IC^/=#NQ.]G:V-YK4$:2--JP6OL/_ (+ >(-'\6?$O_@D
M]XJ\/7T.J:!XE_:-T;Q!H>IVS;K?4='UG7_@QJ.F7UNV!NAN[*Y@N(FP,QR*
M<<U^VOQK^!_PL_:+^'&N_"3XS^$;7QO\/O$CZ;+J^@7-_K&DF:?2-1M=6TVY
MMM7\/:CI&N:9=6E_9V\T=UIFIV=P462W>1[:>>&7S3Q'^Q?^S-XN\/\ P$\+
M>(_AA;:KH7[,%UH=Y\"[*?Q/XV1O D_AN#2+;1?)O(/$L5_K\-E#H&C*+;Q5
M<Z[;7!TZVDNH9Y$+D Q?V_\ _DQO]K[_ +-N^,O_ *@&NUX'_P $;O\ E&Q^
MS)_V"OB/_P"KD^(E?H9X[\$>%OB9X*\6?#OQQI,>O>#?''AW6/"GBK1);F]L
MXM6\/Z_83Z9J^G27>FW-GJ%LEY8W,\#3V5W;7<0??;SQ2JKK@_"#X0_#KX"_
M#CPO\(_A+X;B\(?#SP9:WEGX:\.Q:CK&KKIT%_J=]K-Z#J?B#4-5UF]ENM4U
M*^O9KC4=1N[AYKF0F7;M50#\5O\ @G/_ ,I3?^"JG_8T:/\ ^I5KM>:_!#XC
M>$?V*O\ @L=^V%X0^/&MZ=\/O#'[4>DV'CSX;>.O%&I1:=X8U"ZU/5D\0Z=9
MW6LZ@8;+3+.\N[OQKX?BO=0NK2QM_$'A@:'&TKWMBY_<GX??LU?!'X6?%#XI
M?&;P#X$MO#WQ+^-5S:7GQ-\3Q:SXDOI/$]S92S3V\KZ7JFLWVB:21//--*NA
M:;I:7,LC27*ROAA6^/G[+?[/O[4.@V/AOX]_"OPQ\2--TJ>2XTB;5HKRRUO1
MI9U"W/\ 8OB;1+O2_$FCQW:K&+V'3-6M8;WR8#=1S&"$Q@'YC_\ !9']JWX/
MVW[(/C'X"^#/&WAGX@?&3X_7O@OP9X(\!^"M8TSQ9KTEO/XO\.:W>:S>Z;HT
M]_/96-SIU@=-T.:=(I=6US5--ATE;KRKN2UL?M>_"S6/@C_P0_U_X2^(T2+Q
M+X _9W^#/ASQ1#%<K>06_BBR\3_#T>)+:UNT)2XM+?7&OX+29,));1Q,@"D
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MS1+9]7UO3+\^'[F&71-*\1:Y'KUY?7^EG1_#7]L4 ?U U\L_MS?\F3?MA_\
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M+"VM]V+6X FT/C1_P2[_ &$?C_XNU+Q[\2OV?M N_&6M7D5_K7B#PSX@\:>
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MWKMH\NC1)9P/I^IVC61W7-B;:[DDG8 _GA_9D^!/Q>_X*8_M2_M??MM_#_\
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M;PW5G>036MU:W$:36]S;7$;13V\\,@:.6&:)VCEC=61T9E8%210!^2G[)?\
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M%GP[\<:3'KW@WQQX=UCPIXJT26YO;.+5O#^OV$^F:OITEWIMS9ZA;)>6-S/
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MS$#+,3DD _GS_P""-GA>?QQ^S/\ M^^"K:5(;CQA^T'\8O"]O-([1I%/X@\
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M8V1PDT$LD;%'5P&)5E." #\1/^#?3_DP_5_^R^?$+_U'/ 5?E%_P4<\&:_\
M\$]_B5^UK\*?#FE7Q_9H_P""@'@*V\5^#K2VC":1X/\ B=X5\>Z)XKU73+-?
MW<$2>'[I]:T]-/LXHUA\*^//""RR7+:"0/ZNO@'^SK\&?V8/ C_#/X%>"H/
M7@B37=4\32:)!K'B+70^N:R+9-1OWU'Q3K&N:L[3QV5I"D#7YMK6"VAM[2&"
M&-8PSX[_ +-WP._:;\+6'@SX[_#C0?B/X<TK5H]=TJRUDW]M/I>K1036OVW3
M=4TB\T[5K"26VGEM[E+2^ABNX'\JZCFC55 !^<OPC^/UM^S!_P $7?AS\;GG
MABU/P;^S%HG_  BB3[&2Z\<Z[$OAWP/:/&ZOYL,WBO5M(^UJL<A2R6YF9#'$
M^/A/_@G]_P $P_VD-9_9E\!_%CP]^W?\;?V=;SXZ6K_%76_ O@72+F6SN/\
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M\#O^"9/[#7[.OBNQ\=_"WX ^'=/\::5,USI'B;Q+K7B[Q]J>BW7FF2&]T/\
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ML-C;?\%8OVH(+*WMX[2WM(='N8[:&UAC6&*WBA7XDB-((XE6-(E4(L:A H4
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M%S_V#?B;X]UC3_"W@>\^ ?B'P8GB76[J#3-&AU_4+/\ :0\/6=I<:G?26]A
M9=7\?^%K1C)<*8GU2V,@430^9^Z7PX^&?P^^$'@[1_A]\+_!WA[P'X*T"%H=
M)\->&-,MM*TNT$CF2>;R+9$\^\O)F>YO[^Y::^O[J26[O;B>YEDE;RK]HO\
M9(_9S_:ST31?#_[0GPLT3XC6/AR[N+WP_<W5[KN@:[H<MY]G^WQZ3XH\)ZMH
M/B;3[/4OLEF=4TZTU>+3]4-E9-J%M<FSMC$ ? /_  6(\-VW[1__  3R^*>I
M?!W6M%^(W_"K?%WASQYK/_"$Z]IOB"&"R\%S'_A,H+F;1[NZMOM7AOPOK]SX
MEU/3IY%N;?3[+[7Y!D%LLGB_[)7[+'_!'7]HWX#?#_XB:=\-?@_+XAE\$Z+<
M_$71=3^)GBS2/$'A3Q98Z18#Q?:^(-%N/'UK/ID=CJTD[+>_9X]*N[.6VOM/
MN);"YMY7_8GX$?L[?!G]F;X>Q_"KX'^!K/P+X"CU/4M9;0H=2UW73<ZIJZP)
MJ-_?ZKXHU36]:U&XN8K:VMVDO]1N2EM;6]K%LMX(HD^1O'W_  2)_P""=OQ(
M\3WGB[Q%^S;H5IK&I:A<:EJB^$O%WQ%\!Z1?SW23>>C>'O!7B_0=!LHI+B9;
MQO[)T[3Y3<PH?-\F2ZAN !WP6_9Y_8=M/A;^U#\/OV(+?X8V]]XZ\'ZI\-/B
M3J'PW\;WGC*&WUV]\(^)K/PUINJ:W=>(/$=M8W&G+XHU*8V]E=1B&6><7L9N
M+8)#\'?\$//VE?A9X&_9X\7?LO?%7Q?X:^%OQB^#?Q5\=P:KX0\>:YI'A?4;
MW3M2O4N;N>P&KWEHE_>:'K]OK^BZ]8VK37.DFPM)[I4M[ZV8_M9\#_V>/@E^
MS9X4G\$_ SX;>&_AMX:N[XZIJ%CH%M-Y^JZD88[8:AK.JWT]YJ^LWJ6T,5M%
M=:K?WDT-M%';Q.D**@\ ^//_  38_8E_:7\7W'C_ .,'P(T+7?&U\;#^U/%&
MB:]XQ\#:MK0T]\1G79O WB+PY'K=Q+:_\2Z?4=5BN]4.GK;6\5[%]@TY[, ]
MG^$/[4/P'^/GC#XF^"?@U\1M!^(^J?" >$E\=W_A2=M7\-:;=>-/^$E.BV%C
MXHM5DT'7;Q1X4U?^TH]$O]0CTN1(;:]EANY&MX_R+_X(!?\ )%/VH_\ LZ;Q
M-_ZB?A:OV+^!W[._P1_9K\)-X&^!?PV\-?#?PU+<"\O;30;:5KW5[U4\I+_7
MM;U">]UWQ!?QPXMXK[6]2U"[BME2WCF2!$C6G\"?V:O@C^S/H_BG0/@=X$MO
M >D>-?%E]XX\365MK/B364U+Q1J4%O;7>I>9XDUG69K)'M[2WABT_3Y;33+6
M.)4M;*$9! /R5_;%_P"4T?\ P3<_[$+Q]_Z;OB765^V!_P IOO\ @G9_V2WQ
M+_Z*^-%?L'XN_9O^"OCSXQ_#C]H#Q9X'M]7^+WPDT_5-+^'OC%]9\26DWAZQ
MUF*]AU&!='L-8M?#VI^='J5\L<NLZ3J,UK]JF:TD@9LB/Q;^S5\$?'7QH^'?
M[0WBOP);:M\8_A1IE_HW@#QH^L^)+2?0--U-=32\M1I%AK-KX>U,.NLZIY,N
MLZ1J,UH;Z=K22!FR #YE_P""K_\ RCN_:G_[$"R_]2WPY7YF?M1_"CQ+\4_^
M""'P)E\+6-QJ5[\,OA3\#/BKJ%C:LXGD\.>&=!:P\37@B7Y9X=$T+7+_ ,07
MJ2%5CL=*N;E-TUO%&_\ 0#\4_A;X#^-?P]\5?"OXGZ!'XI\ ^-M-.D>)] EO
M]5TM-3T\W$%T(?[1T.^TS5[)TN+:":.XT^_M+F.2)6CF4BKG@/X>>#?AEX#\
M,?#'P/H<&A^!/!OAZP\*>&_#PN+W4;?3O#^F6B6-EIIN=6N;^_O8HK1%A:74
M+N[N9QEKB:5V9B ?''['O[;O[.'Q@_9D^&7CJ'XO_#CP[=:)\.O"]E\0M!\3
M>-/#WA_5/ GB#1=&L=+\067B"TUF^TZXL;&WU6WN%T[6+FWM]/U?3VM=1L97
MM[F/'YT_L0ZU:?M;?\%;OVLOVQ/AU'+J7P%\!_#C3?@YX6\:+'+:6GBGQ8;#
MP)HZ2Z<LL4+ZCI]W8^%O%^MK(P\^RTN^\)2WD,)U2U5?O3QA_P $D/\ @G=X
MY\6S^-=<_9G\,P:U=W\^I7L'ASQ-X_\ !WAZ[NKAFDD,GA/PEXMT7PO#"9F\
MXVUII%M;N^5DC>)Y(W^Y/AQ\,_A]\(/!VC_#[X7^#O#W@/P5H$+0Z3X:\,:9
M;:5I=H)',D\WD6R)Y]Y>3,]S?W]RTU]?W4DMW>W$]S+)*P!^(OP^_P"5@SXY
M?]FLZ1_ZC7P>KS7X(?$;PC^Q5_P6._;"\(?'C6].^'WAC]J/2;#QY\-O'7BC
M4HM.\,:A=:GJR>(=.L[K6=0,-EIEG>7=WXU\/Q7NH75I8V_B#PP-#C:5[VQ<
M_N38_LU?!'3?CYK7[3]CX$MK?XZ^(?"<'@?6?'JZSXD:>^\+VR:;%#IKZ%)K
M+^%XG6+2-,A;4(-#BU.2&R@BDO7C4J:WQ\_9;_9]_:AT&Q\-_'OX5^&/B1IN
ME3R7&D3:M%>66MZ-+.H6Y_L7Q-HEWI?B31X[M5C%[#IFK6L-[Y,!NHYC!"8P
M#\Q_^"R/[5OP?MOV0?&/P%\&>-O#/Q ^,GQ^O?!?@SP1X#\%:QIGBS7I+>?Q
M?X<UN\UF]TW1I[^>RL;G3K Z;H<TZ12ZMKFJ:;#I*W7E7<EKP/[?7@KX@?L\
M?\$5?!?P9_X0R/Q-K&C> O@7\//BS+'IR^*;?P'!91:9K7C+Q9: .MOY6C>+
MM'M]&TG6F*PZ<^J66HPR6DD$-U;_ *+? 7_@G'^Q5^S/XF@\:_!WX#>&_#_C
M*S%R-.\5ZSJOBGQQK^DFZ#1ROHFH^.M=\1S:%.;=VLS=:.;&Z>SDFMY)WCN;
MD3?'_P#P7#TCXR:S^RIX4MOAYHWC/Q)\-HOBWX9N_P!H;P_\/DN9/$VJ_"ZV
MMM0F:&6.T5[B3P^NN)I[:D5BEAMM2_L/4+]%TVSO9H@#\P_#%C^R!X[\#:+\
M#M1_X+9_%.3]F)M,T736^"7BCP+J_@G6X_"]I<VPB\&WWQ"\21P6,&D64,5M
M86VBR^&[G0M*M[57AT^;2H(XX_Z;OV?=%^"6B_!'X>^&/V?;WPEK7P4T3PO:
M:%X(NO".LV/B?P[?:):(\$KC6;.YOH-8N[NX-S-K5Y<7$]Y>ZK/?3ZD[WLUP
M3^+5Q^W3_P $'Y/AC#I(^'WPJU6WMO#5G:6GPW_X9.UVZ\9R_9+2*"ST.+7;
M_P"'B:#)XBC$<<::Q/X]$3WJ_:SXB:9OM;>P?\$0_@K\4/A5\$/C'XG\8^#_
M !-\+?A_\7?C!J'C7X,?"?Q<^H+K?A/P2+5K2'4[JSU55U*U&MVQTO3K:;45
MBO=8LO#-KKQC>RU2QO+P _'3XF?%;Q/_ ,$\+3_@I7_P3ST&UUD1_&GQ-X<O
MOV<X+&&XF@A\+_%FYT_2_%%G \2L+B^U3X2:GI'A03V_DG_A(?#-W#D3Q&V3
M^J3]CGX"V?[,?[,/P5^!UM% EYX%\#Z9;>));?:8;WQIJQEU_P <:C$R%@T6
MH>+M5UJ[@R\A2WEBC\QP@8_B_P#$[PQX8_;2_P""YW@/P]INB:;>^$?V+_A[
MHGB#XE:_! &?6_%7A#4Y_%GA[2+N[/[B[BT/Q[XX\*:2VF31O)C2/%\1,L"L
M+;^C:@#@/BQ_R2WXE?\ 8@>,O_4=U*OQV_X-]/\ DP_5_P#LOGQ"_P#4<\!5
M^W>I:=9:QIVH:3J5NEWIVJ65UIU_:R%U2YLKV"2VNK=S&R.$F@EDC8HZN Q*
MLIP1Y#\ _P!G7X,_LP>!'^&?P*\%0> O!$FNZIXFDT2#6/$6NA]<UD6R:C?O
MJ/BG6-<U9VGCLK2%(&OS;6L%M#;VD,$,:Q@ _'C_ ((!?\D4_:C_ .SIO$W_
M *B?A:M7]L7_ )31_P#!-S_L0O'W_IN^)=?K5\"?V:O@C^S/H_BG0/@=X$MO
M >D>-?%E]XX\365MK/B364U+Q1J4%O;7>I>9XDUG69K)'M[2WABT_3Y;33+6
M.)4M;*$9!D\7?LW_  5\>?&/X<?M >+/ ]OJ_P 7OA)I^J:7\/?&+ZSXDM)O
M#UCK,5[#J,"Z/8:Q:^'M3\Z/4KY8Y=9TG49K7[5,UI) S9 !^)/[1?C70_V3
M?^"WGPB^-WQ8O;?PS\)/CK\$#X&C\>:I*EOH&@ZS!IU]X;==2OIXS#86]AK6
ME^$1K-V\MM:Z3I7BF#5[^[CL8KP5[+_P6-_;$_9[M?V,OB1\&?#_ ,1_#7Q
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M6?$EI/H&FZFNII>6HTBPUFU\/:F'76=4\F76=(U&:T-].UI) S9':?%/X6^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$FHZ!I_A3P^E[!-'IFCW=Q8W.NZPENJ3ZQJ=\@U*6ZMM)T>&Q /U-\>?MG?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\,_:!_Y$S3O^QEL__35K5>YUX9^T#_R)FG?]C+9_
M^FK6J %^ '_(FZG_ -C->?\ IJT:O<J\-^ '_(FZG_V,UY_Z:M&KW*@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA=ZMI>C7MU8:%J,+64>HW]Q%I=[?SZ)K>DZ/+9Z-?^$TNM,43?T9T4 ?A_\
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M]H'_ )$S3O\ L9;/_P!-6M4 +\ /^1-U/_L9KS_TU:-7N5>&_ #_ )$W4_\
ML9KS_P!-6C5[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*\-_X4!X-_Z"?B;_ ,#-*_\ E-1_PH#P;_T$_$W_ (&:5_\ *:@#W*BO#?\
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M,TK_ .4U'_"@/!O_ $$_$W_@9I7_ ,IJ /<J*\-_X4!X-_Z"?B;_ ,#-*_\
ME-1_PH#P;_T$_$W_ (&:5_\ *:@#W*BO#?\ A0'@W_H)^)O_  ,TK_Y34?\
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M4?\ "@/!O_03\3?^!FE?_*:@#W*BO#?^% >#?^@GXF_\#-*_^4U'_"@/!O\
MT$_$W_@9I7_RFH ]RHKPW_A0'@W_ *"?B;_P,TK_ .4U'_"@/!O_ $$_$W_@
M9I7_ ,IJ /<J*\-_X4!X-_Z"?B;_ ,#-*_\ E-1_PH#P;_T$_$W_ (&:5_\
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M*\-_X4!X-_Z"?B;_ ,#-*_\ E-1_PH#P;_T$_$W_ (&:5_\ *:@#W*BO#?\
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M,TK_ .4U'_"@/!O_ $$_$W_@9I7_ ,IJ /<J*\-_X4!X-_Z"?B;_ ,#-*_\
ME-1_PH#P;_T$_$W_ (&:5_\ *:@#W*BO#?\ A0'@W_H)^)O_  ,TK_Y34?\
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M4?\ "@/!O_03\3?^!FE?_*:@#W*BO#?^% >#?^@GXF_\#-*_^4U'_"@/!O\
MT$_$W_@9I7_RFH ]RHKPW_A0'@W_ *"?B;_P,TK_ .4U'_"@/!O_ $$_$W_@
M9I7_ ,IJ /<J*\-_X4!X-_Z"?B;_ ,#-*_\ E-1_PH#P;_T$_$W_ (&:5_\
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MK]AM+N2%8XX[:^GM+2#P/OD4/OA,O@6:9YX93J$=PK(T_P"\M% 'Y!_L'?\
M!.3XA_!WXQ^-/VPOVN?BE8_&G]J[X@Z?-8-?Z/#,/#'@2RU"W@LM1CTN[ELM
M'34M2GT:ST_P_:+I_ASP_HGAC0H+K0=#L[NQNA=CLO\ @IK_ ,$\]4_;8\-_
M#KQA\+?&]O\ #/\ :&^".JW6K_#7Q5?3:A8:3?Q7MUIFH2Z1JVKZ);W6NZ'=
MZ=J^BZ7KGACQ)IUKJ<VAW\-_"NERC69;ZP_4JB@#^>/Q-\)?^"[OQR\!ZC\
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M+RUUKRDETNQTS6+FQTZ/Q!J4WB+Q7K.IZ=83^'["#0K&YBU*/^@.B@!
M     ,  <  #@ #H*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#/V@?^1,T[_L9;/_TU
M:U7N=>&?M _\B9IW_8RV?_IJUJ@!?@!_R)NI_P#8S7G_ *:M&KW*O#?@!_R)
MNI_]C->?^FK1J]RH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,T[_ +&6S_\ 35K5 "_ #_D3=3_[&:\_]-6C5[E7AOP _P"1-U/_ +&:\_\
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M;Q?XJC_LK0))K66\6>31]'UGQCJ_VJ>ZFAO)=#T2>:Y^R7TED+:;^9']F?\
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M_@0/_EO7N5% 'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44
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M );U[E10!X;_ ,)9\9?^A TW_P "!_\ +>C_ (2SXR_]"!IO_@0/_EO7N5%
M'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44 >&_\)9\9?^A
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M_@0/_EO7N5% 'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44
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M );U[E10!X;_ ,)9\9?^A TW_P "!_\ +>C_ (2SXR_]"!IO_@0/_EO7N5%
M'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44 >&_\)9\9?^A
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M_@0/_EO7N5% 'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44
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M );U[E10!X;_ ,)9\9?^A TW_P "!_\ +>C_ (2SXR_]"!IO_@0/_EO7N5%
M'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44 >&_\)9\9?^A
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M_@0/_EO7N5% 'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44
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M );U[E10!X;_ ,)9\9?^A TW_P "!_\ +>C_ (2SXR_]"!IO_@0/_EO7N5%
M'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44 >&_\)9\9?^A
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M_@0/_EO7N5% 'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44
M>&_\)9\9?^A TW_P('_RWH_X2SXR_P#0@:;_ .! _P#EO7N5% 'AO_"6?&7_
M *$#3?\ P('_ ,MZ/^$L^,O_ $(&F_\ @0/_ );U[E10!X;_ ,)9\9?^A TW
M_P "!_\ +>C_ (2SXR_]"!IO_@0/_EO7N5% 'AO_  EGQE_Z$#3?_ @?_+>C
M_A+/C+_T(&F_^! _^6]>Y44 >&_\)9\9?^A TW_P('_RWH_X2SXR_P#0@:;_
M .! _P#EO7N5% 'AO_"6?&7_ *$#3?\ P('_ ,MZ/^$L^,O_ $(&F_\ @0/_
M );U[E10!X;_ ,)9\9?^A TW_P "!_\ +>C_ (2SXR_]"!IO_@0/_EO7N5%
M'AO_  EGQE_Z$#3?_ @?_+>C_A+/C+_T(&F_^! _^6]>Y44 >&_\)9\9?^A
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M  $DDX  Y))/  '))Z4 >'?\)9\9?^A TW_P('_RWH_X2SXR_P#0@:;_ .!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]E[PT'.H_&_P%<B,%F_X1_5CXL) 56^0>%H=9,IPX 6,.Q8,@&]'5?#O$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M08[EM5\33*5)C,/AS24O=9,<I 1;F2RCM%8CS;B-<L/S4^*W_!62PA^TZ?\
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M***Z#F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P#
M;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H
M_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[
M_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&
MU#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]
M"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:
MWP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U
M_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_
M )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%
MK?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;
M7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y
M#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKS
MW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_
MZ&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P#
M;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H
M_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[
M_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&
MU#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]
M"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:
MWP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U
M_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_
M )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%
MK?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;
M7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y
M#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKS
MW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_
MZ&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P#
M;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H
M_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[
M_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&
MU#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]
M"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:
MWP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U
M_P# ;4/_ )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_
M )#H_P"%K?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%
MK?#[_H9;7_P&U#_Y#H ]"HKSW_A:WP^_Z&6U_P# ;4/_ )#H_P"%K?#[_H9;
M7_P&U#_Y#H ]"HKSJ3XL_#N)'EE\464<4:-))))!?HD:("SN[M:!515!9F8@
M* 22 *\&\=_MW?LO> 8YUO?B79^(-2A#8T;PAI^H^(;Z6120T!N+6V71[2=2
M"&CU+5;$J?E)!XKQLZXBR'AS#?7,_P YRO)<+9VKYGCL-@H3<=XTGB*E-U9Z
MI*G34YR;48Q;:3]O(^&^(>)L4L%P[D>:YYB[J]#*L!BL=4@I;2JK#4JBI4UJ
MY5*KA3C%.4I**;7U]17XG?$G_@K5?R^?:?"/X6V]FGSB#7OB%J#W<[*V55CX
M9\/3V\-O*@PX9O%%]$SML:$I&3+XEX+_ ."I/[0FA:N]SXOT_P &^.M&GF+S
M:5+I/_"-W=M"6!\G2M6T=MMN0 4675-.UI@I)96;##\4Q_TG_"/!9C3P$,VS
M+'TI3<*V9X#*,74R[#-;NI*NL/BZT$]%/!8/%QE:\7)6;_=<O^BEXR8[+:F8
M3R?*\NJQ@IT<KS#.L'3S+%)ZJ-..'>)P=";6KACL;@Y1VFHR32_H>HK\\_A9
M_P %+?V=_'D<%KXMN]8^%>MNJ*]MXGLY=1T*2=@I9+/Q'HD-U"L"[F_TG6['
M05/EM\@+1A_KW3_C/\+M6M(=0TKQII&IV%RN^WO=/-S>VDZ?WX;FVMY(95_V
MD=A[U^N\-\9\*<88?ZUPSQ!E><TU%3J0P>*A+%4$[6^M8*;AC,))W7N8FA2G
MJO=U1^,\4<#\7\%XGZIQ5P[FN257)PISQN%J1PN(DKM_5,=!3P6,BK.\\+B*
MT-&N:Z9Z?17GO_"UOA]_T,MK_P" VH?_ "'1_P +6^'W_0RVO_@-J'_R'7TY
M\J>A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[
M_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W
M_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-
MJ'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_P
MM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+
M:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'
M_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A
M45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +
M6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RV
MO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R
M'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X?
M?]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\
M@-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P A
MT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[
M_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W
M_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-
MJ'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_P
MM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+
M:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'
M_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A
M45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +
M6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RV
MO_@-J'_R'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R
M'1_PM;X??]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X?
M?]#+:_\ @-J'_P AT >A45Y[_P +6^'W_0RVO_@-J'_R'1_PM;X??]#+:_\
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M9>(=>MBK)XF\<%/%6L"9#E+FWCO85T72[E.0)]%TC3),$Y8U]6@
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MW_0RVO\ X#:A_P#(='_"UOA]_P!#+:_^ VH?_(= 'H5%>>_\+6^'W_0RVO\
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M /Q%=A10!Q__  K[P1_T*NA_^"^W_P#B*/\ A7W@C_H5=#_\%]O_ /$5V%%
M''_\*^\$?]"KH?\ X+[?_P"(H_X5]X(_Z%70_P#P7V__ ,17844 <?\ \*^\
M$?\ 0JZ'_P""^W_^(H_X5]X(_P"A5T/_ ,%]O_\ $5V%% ''_P#"OO!'_0JZ
M'_X+[?\ ^(H_X5]X(_Z%70__  7V_P#\17844 <?_P *^\$?]"KH?_@OM_\
MXBC_ (5]X(_Z%70__!?;_P#Q%=A10!Q__"OO!'_0JZ'_ ."^W_\ B*/^%?>"
M/^A5T/\ \%]O_P#$5V%% ''_ /"OO!'_ $*NA_\ @OM__B*/^%?>"/\ H5=#
M_P#!?;__ !%=A10!Q_\ PK[P1_T*NA_^"^W_ /B*/^%?>"/^A5T/_P %]O\
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M5=#_ /!?;_\ Q%=A10!Q_P#PK[P1_P!"KH?_ (+[?_XBC_A7W@C_ *%70_\
MP7V__P 17844 <?_ ,*^\$?]"KH?_@OM_P#XBC_A7W@C_H5=#_\ !?;_ /Q%
M=A10!Q__  K[P1_T*NA_^"^W_P#B*/\ A7W@C_H5=#_\%]O_ /$5V%% ''_\
M*^\$?]"KH?\ X+[?_P"(H_X5]X(_Z%70_P#P7V__ ,17844 <?\ \*^\$?\
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M_P#XBC_A7W@C_H5=#_\ !?;_ /Q%=A10!Q__  K[P1_T*NA_^"^W_P#B*/\
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M ''_ /"OO!'_ $*NA_\ @OM__B*/^%?>"/\ H5=#_P#!?;__ !%=A10!Q_\
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M /$5V%% ''_\*^\$?]"KH?\ X+[?_P"(H_X5]X(_Z%70_P#P7V__ ,17844
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M5HU>Y4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%:3Q-?1&1E5[=HXF$_XUQQO*Z11(\DDCK'''&I=Y'<A41$4%F=F(554$L2
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M (5NK?\ R11_PUC^TQ_T73XG?^%;JW_R17ZW?\.F/@S_ -%(^)W_ 'UX5_\
MF>H_X=,?!G_HI'Q._P"^O"O_ ,SU:?\ $#?I&?\ 0TQW_B<5/+_J._JWH9_\
M1\^C/_T*LO\ _$"A_P#,'DON/R1_X:Q_:8_Z+I\3O_"MU;_Y(H_X:Q_:8_Z+
MI\3O_"MU;_Y(K];O^'3'P9_Z*1\3O^^O"O\ \SU'_#ICX,_]%(^)W_?7A7_Y
MGJ/^(&_2,_Z&F._\3BIY?]1W]6] _P"(^?1G_P"A5E__ (@4/_F#R7W'Y(_\
M-8_M,?\ 1=/B=_X5NK?_ "11_P -8_M,?]%T^)W_ (5NK?\ R17ZW?\ #ICX
M,_\ 12/B=_WUX5_^9ZC_ (=,?!G_ **1\3O^^O"O_P SU'_$#?I&?]#3'?\
MB<5/+_J._JWH'_$?/HS_ /0JR_\ \0*'_P P>2^X_)'_ (:Q_:8_Z+I\3O\
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M=EN:9ED^,I9AE&88[*\?0=Z.-R[%U\%BZ+T=Z6(PU2E6@]%?EFKV/QS^*_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO ?B_^T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^0'\-OB=J/W?^0JOA71NH;?_ ,>GB#7?ND(%_OAF)V;0'\PU7_@KP?N:'\"
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MJ)-*7-&48E%%%>^?.A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDVVVVPHHHK0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD'(/((Z$>M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'"H8W&8*/".255&:S'/Z=6EBZU*5GS8+)HJ..K-Q:G3GBE@,+6@^:GBI;/\
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M7F;H05&AFN<TYY;E%&,%RTW@\HP[IX_$4%"RA'$5<HE3:M[&44K_ (_?!O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXK:WCN&BVF58(@^0BX /#O!__!17]AGQYK=GX<\,?M3?!N[UK4;B&TT^QO\
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M.FW4T44_B_XG?#'P[IJ2;=]Q>VVLS^+)(;?+ F5=.\+ZA<-M#MY$$QVA=S*
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M%<?$3_HJ6I?]^KW_ .6% 'N5%>&_\*X^(G_14M2_[]7O_P L*\(^,7Q0\-_
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M)!(UCH6DV]]/K'B#4_+/F+I>AV&H:@\8:1;8HK,/P+_:&_X+*?$.74+SP_\
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M#_'JTD,D7QH^*+LR%"+KQWXEO8]I96)$5[J5Q$KY48D5!(%+*&"NX;]-9O\
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M (5Q\1/^BI:E_P!^KW_Y84 >Y45X;_PKCXB?]%2U+_OU>_\ RPH_X5Q\1/\
MHJ6I?]^KW_Y84 >Y45X;_P *X^(G_14M2_[]7O\ \L*/^%<?$3_HJ6I?]^KW
M_P"6% 'N5%>&_P#"N/B)_P!%2U+_ +]7O_RPH_X5Q\1/^BI:E_WZO?\ Y84
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MJ7_?J]_^6%'_  KCXB?]%2U+_OU>_P#RPH ]RHKPW_A7'Q$_Z*EJ7_?J]_\
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M>_\ RPH ]RHKPW_A7'Q$_P"BI:E_WZO?_EA1_P *X^(G_14M2_[]7O\ \L*
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M\4@2V>H(?"]K*PU2X_3BB@#^=KXJ?$#_ (++?MK>#=2^!6B?LJ>$OV4? _Q
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M"WMX(TA@@@A01Q0PQ1JL<444:JD<:*J(BA54* *EHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HK#\0>)_#7A/3Y-6\5>(=#\,Z5%GS=3\0:M8:-I\>
MU2S>9>:C<6ULF%!8[I!A02>!7QE\0O\ @HM^S!X#-Q;V7BS4OB!J=ON4V/@3
M2)M2@:0$A-NN:G)I'AZ>)F&6ELM5O"J9<(Y**_SF?\8<*\+4G5XCXAR?)8\O
M-&&89AAL/7JK>U##3J+$8B5M5"A2J3:U46?3\.\%\7<6U?8\,\-YUGDN90G/
M+LNQ.)P])MV_VC%0IO#8>*;2<Z]6G!75Y(^Z:*_"OXA_\%9O'.H^?:_##X9^
M'O#,)WQQZMXNU&\\3ZBR$G;<1:;IRZ#I]A< $8AN+C6H%8$L90P5?A3XA_M9
M?M%?%$SQ^+?BOXJDL)\K)HVAW:>%M#>(\+#-I/AJ+2K.\1%P%:_BNIF(WR2R
M2LSM^!\2?2P\-\H]I2R2CG'%.(C=0GA,*\LR]R6ZGBLS]CBXJ^BE2RVO"2NU
M*W*Y?T-PO]$#Q.SGV=7/J^2\)X:5G.&,Q:S3,HQ>SA@\K=;"2=M90K9GAYQ=
MHN*ES*/]+GQ"_:$^"7PJ\^/Q_P#$_P (>';VW#-+I$VK0WWB !1DE?#FE_;M
M=DQP/W6G/EB%&6(!^%?B'_P59^#V@_:+7X=^#?%WC^\C++%?:B;;P=X?FSPD
MD-Q=+JNO. <L\5QX=LB1M59,LQC_  %))))))))))R23R22>22>23UKU7X?_
M  ,^,7Q3>,?#[X;>+_%%O(P0:GI^C72Z'&Q8J%N=?NDM]$M22"!]IOX<[7(X
M1B/PO-OI3>)_$^)>7<&9#@LHJ5FUAZ67X'$<29T[M)*,J]*6$JM72]W)T^9K
M75(_?LG^B7X4\*859EQQQ#C\YIT%'ZS6S',,-PQD6BNW.-"M'&4KV?Q9VURZ
M6NG(^J/BO_P4B_:*^)%I=:3H=_I'POT6Y#QNO@B"[A\02V[9_=S^)]1NKS4+
M:8$C_2=!30I"%52,&3S/@J\O;S4;NXO]0N[F^OKN:2XN[R\GENKNZN)6+RSW
M%Q.[S3S2.2TDLKL[L2S,2<U^FWP\_P""5GQO\1?9[GQ_XE\(_#FRD*>?:1S2
M>,/$-NIP9,V6DR6V@2%1POE^*&#.#G"@,WZ<?!']@SX ?!<6>I?\(\/B!XOM
MC%+_ ,)1XYBMM5-M=QX;SM'T'R1H>DB*8>;9SBTN]6M<(#JTS()#Y^#\&O'7
MQ7S"AC^-<5F&6X1:K&\68J<9X:G)WG3P'#]&3Q&'J-/F]C+"9=AYRNIUXRO;
MTL;XW> 'A!EU?+^!<)EN9XQ^Z\!P?A(2ABJD5:G4S'B.M'ZOB:::Y?;QQF9X
MF$;.%"<;'X<_!']BSX]_'0VFH:#X5?PUX2N=DG_":>,_/T/0Y;=N1-I<+V\V
MK:\KJ'$4VCZ==V(E3RKJ]M=P>OV!^"'_  37^"'PT^R:OX]67XN^*8?+E)\0
M6J6?@^TG4AL6OA2*:XBOU!W1R#Q%>ZQ:SJ%D2PM'RM?HL  , 8 X '0#THK^
MH^ _HW^'G!GL<7C<&^+,YI\LGC\]ITJN#I559\V#R=*6"HI22G3EB_K^)I37
M-3Q4=E_)OB#])WQ*XW]O@\#C5P?DE7FBLOR"K5I8VK2=URXW.GR8ZLW%RA4C
MA/[/PM:#Y:F$E:Y6LK*STVTMK#3K2VL+&SACMK2RLH(K6TM;>)0D4%M;0)'#
M!#$@"QQ1(J(H"JH  JS7A'Q _:9^!GPS$\7BGXBZ"NHP%D?1-&G;Q%K:S+NQ
M!/INAI?W%B[%2H?419P*?]9*B\U\'?%/_@I<&M[K3?@YX*>.Y<^7%XI\=[&C
MA7YXY9+7PMI%X?-D8%9K*ZO=?1(F5?MFC7"N\"_T!3A%<D$X4H)1BM&H0BK)
M>[",FHQ5M(1;26D=#^=9SE)RG+FJ3DW*3;O.<F[MN4VKRDVVW*6KU;/TR^(7
MQ)\ ?"?POJ'C;XE^,?#W@;PIIB@WFN^)M4M=*L$D<,8;6*6ZD0W5]<E3'9Z?
M:+/?7LV(+2WFF94/X8?M%?\ !9+Q'XD?4/!O[$GPSU7Q1*6FLY/C-XWT2XM]
M @<%XC<>%O#%X;6.5CN2:TU3QI>Z='#-%)#=>$+Z!A,/CSXC:AK'QB\4)XS^
M+NN:M\3?$<!D%A=>,;E=2TS18Y2C/!X;\+1Q6WA'PO S1QR21>'=!TM9IE^T
MW EN6:9JJ(D2)'&BQQQJJ)&BA$1% 5415 554 !5      %?;Y/FO".0<N)J
MY%5XNS2%I4XYQ6E@.'<-4CMS99@Y3QV<0YE>,L7C\MHS@^2METGJOG,=@L]S
M/FHPS*&1X.6DG@*:Q6:U8/=+%UXQPV!E;1JAAL7.,ES4\4EO\A>*OA1\>_CW
MXKG\>_M _%._UOQ#??ZZZU6^G\2ZI:P;BXTZPM(GLM T/3HR2+:PT60:;: G
MR+%% 1O0O#/[-GPN\/".2ZTNY\2WB8)N-?NFGAW<[L:=:+::>T9)PJ7-O<LJ
M@ R,VYF^QO OP>^*/Q,E2/P)X$\2>)(G=HS?V6G3)H\4BMM9+G7+H6^CVC!@
M5(NKZ'D,/X3C[<^'_P#P37^)6L_9[KXA^+/#_@FT?#RZ=I:2>*==0 $M#-Y,
MFGZ) ['"+/;ZMJ:)EG,3[1&_LYWXQ^(&<T(X*&=2R/+*<%2H95PU1IY'@Z%%
M:*A3>"Y,6Z*C:*I5<55@HKEY;-WX,OX"X8P%1XB67K,<7*7/4QF;5)9C7J5-
M_:26(YJ"J7][GA1A*^M]K?DM_P *C^&'_0A>%?\ P367_P :KZE\-_M!?&_P
MCI>DZ)X=^*GCC3M'T*Q@TS2-+'B"_N;#3].M8!;6EC;6MY+<0I:6=L$@L[<H
M8K2&*&.V2)(8@GZ(?$C_ ()F6*>"->E^$OC_ %%_B)!8O/X<MO'L%G+X2U&_
MA'F#3M4?0K2QU33H=0"FVCU."2]_LV21+F73]0CC:!_YO_'OQ[^,WPG\<>(?
MA[\2OAKI7ACQ=X4U&;2]?\/WZ:I:WMI=1J'C>.?[?=6US974+PWNGZA:&YL-
M3T^>WOM/N9[2Y@N'RX;X3XY\3J>)IY;F?]M5<L?M9Y?FF?VQ5*-11BL30PV8
M5_>HS=J,J])\D)J-.K*#E34KS;.^'.#YTIXO!_V?#&+DCBL'E=Z,W%MNE4K8
M6EI.*]]4IVE*-Y4U+EE;]5O^&LOVCO\ HKOBW_P(M?\ Y$H_X:R_:._Z*[XM
M_P# BU_^1*^ OV;/VE/A5X\^)>E^#?V@;N]^%WA/Q \=A8_$+09H-0TSP[JT
MKA+8^*['4K??!H-XS"&?7+6[5=$D$=QJ%G+ILMW?Z7_0):_\$S_AW>VUO>V7
MQ7\37=G=P175I=VNFZ'<6UU;7$:RP7%O/%(\4T$T3I)%+&[1R1LKHS*P)\'B
MW@?B?@?&4,%Q+ED\!4Q5)UL+5C5HXG"XF$6E45'%8:I5H3J49.*K4>=5:7-"
M4X*%6E*?I9'Q'D_$="IB,HQD<3&C-4ZT'"I1K49-7BZE&K&%2,)I-TZG*Z<^
M62C)RA-1^#5_;*_:9554?%C6"% 4%M+\-.Q &!N=]$9F/'+,2S'DDDDTO_#9
MG[37_15]7_\ !3X8_P#E'7W&?^"7^@9.WXP:P%R=H/@^R8@9X!8>(%!('4A5
M!/.!TI/^'7^@_P#18=7_ /"-LO\ YH:^2/</BNU_;=_:BM(S'%\4[EU9RY-U
MX5\"WLFXJJD"6]\,7$JIA1B-7$88LP4,[EK/_#<_[4W_ $5'_P LGX=?_,C7
MUY<_\$N[1Y ;/XV7$$6P I<_#R*[D+Y;+"6+QM9*$(V@(8200Q,A#!5K_P##
MKG_JN?\ YC+_ /&#0!\I6_[=G[44$HDE^(\%X@!'DW/@OP&L1)Z,3:>&;6;*
M]1B4+_>5AQ7(>,?VM/VA_'"-!K'Q0\065HR^6;/PRUKX3@:,C#QS-X;M],N+
MI)#DR+=SW 8,4_U05%^U;G_@EW=+'FT^-MO/-N V7/P[DM8]O.X^;%XWO&W#
MC"^3ALG++CG:\,_\$PM&AN!+XR^*^IZA:;@#9>&?#=KH]P4!!+#5-5U'7(E9
MAD!/[(81D!M\F[:H!^1=U=7-[<2W=Y<3W=U.YDGN;J:2>XFD/5Y9I6>21SW9
MV9CW-;'A[PKXH\6WHT[PKX<UWQ+J#%0+'0-)O]8N_FSMS;Z?;W$H!P<$H!@$
MYP#C^@GP7^Q;^SEX*,,T/P^M/$E]%MS?>,[JZ\2^=M^[YNE7TG_"/ @Y),6C
MQ%B<.654"?3&F:3I6B6<6G:-IFGZ1I\.?)L=,LK:PLXL@ ^5;6D<4$>0 #M0
M< #L* /P%\%?L(_M&>,#%+=>%]/\%V,N"+WQEJ]M8.%.-V_2M-&K:[$R@_=N
M-+@#'@-PQ7ZW\%_\$Q]%A\J?XA_$S4M0)P9M,\':5;:6B$8)5=9UEM5>=&Y!
M/]B6C@=""<K^J=% 'S'X+_8Y_9T\#F*6R^'&EZY?1;2;_P 827'BF21UP5D-
MEJ\MQH\,BD9#6FF6^&^8#(!'TA8:?8:7:Q6.F6-GIUE NV"SL+:&SM85_NQ6
M]ND<,:^R(![5<HH **** "BBB@ HHHH **** "BBB@ HHHH **** *UY96>H
M6TMG?VEM?6DZE)K6\@BN;:9#U66"9'BD4]U=2#Z5X-XL_94_9Y\9B4ZQ\*?"
MMO--EGN_#UK+X4NS*22)FG\,S:2TLNX[V,_FK*1B=94)4_05% 'YQ^+/^":G
MPEU3S)?"7B_QGX3N'+%8;TZ;XFTN'CY1';2V^E:F0#][SM:E+   H<L?F;Q9
M_P $U?BWI1>7PEXN\&>+;=,[8;Q]1\-:K+_=\NUFM]3TP C._P W6HMIVA0X
M+%?VUHH _FP\6?LK_M"^"S*=9^%/BJ:"+)>[\/VD7BNT6,9/G/<>&9M62&(K
M\Q:X,10'$JHP*CP>\L[S3[F6SO[6YL;N!BD]K>02VUS"XZI+!,B2QL.ZNJGV
MK^L>N>\0>$?"?BVW^R>*O#'A[Q-:[2GV;Q!HNFZS;["22ODZC;7,>TDDE=N,
MDG'- '\K5E?7NFW,=YIUY=6%W"<Q75E<36MS$?6.>!XY4/NK U]&>!/VO?VA
M/A_-$=/^(NL:]8Q[5?2?&<C>*[*2)#E8%EU=I]3LXAPH&FZC9.$ 0.$ 6OV'
M\5_L0_LV^*A+(? 0\.7<@8"\\*:MJ>C&+=DYBTX7-QHBE2<KNTI@.%QL^6OD
M3XB_\$RYHQ-=_"GX@B< $Q:'X\MQ'*0JYPOB/0K3RGD<_)'')X<MXP2IDNE7
M<P .@^'7_!3+0KL06?Q3\!7ND3$*DNN>"[A=3L&D8@&230M5FMKZRMTY+>3J
M^L3D?<A8\'[Q^'GQZ^#_ ,55C7P+X^T'6+V1<C1I+AM+U]>,MG0=6CL=69$.
M5::.S>W)!V2L,$_S]_$;]G#XU_"OSYO&/@#6[;3("=VO:9$FN: $ ++)+J^C
MO>6EF'52ZQ7[VEP &#PHRLJ^)*S(RNC,CHP9'4E65E(*LK @JRD @@@@@$'-
M ']9U%?SB_#O]KOX_?#7R(-)\>7^N:3!L T/QB#XFTXQ( $MXIM0=M6L+=0,
M"+2M4L% X'%?>GPZ_P""F'AF^\BS^*/@34=!G.R.76_"-PFL:8SMP\\VCZB]
MGJ-A;IR2EM?ZY<$?=1CQ0!^HU%>4?#WXY?"3XJ1QMX$\>:!KERZ[SI(NCI^O
M1J 26FT#4TLM9C088>:UB(6*MLD8#->KT %%%% !1110 4444 %%%% !7.^+
M/"7AKQUX=U7PGXPT33_$/AS6[5[/5-(U.!9[2Z@8AAD'#Q3PR*D]K=0/%=6=
MS'%=6LT-Q%'*G145E6HT<31JX?$4J5?#UZ<Z->A6IQJT:U&K%PJ4JM*:E"I3
MJ0DX3A.+C.+<9)IM&M"O6PU:CB<-6JX?$8>K3K4*]"I.E6H5J4E.E6HU:;C.
MG5ISC&=.I"49PDE*+329_.C^V#^P3XE^!\FH^/\ X;QW_BSX3-))<7D6UKKQ
M!X#1W9O)UA8U+ZCH$0(6V\0QINME'D:W'!(L&H:E\&>#?&GBKX>^)=*\8>"M
M=U#PYXDT6X%SINK:;-Y5Q"^"LD4BD-#<VES$SP7EE=1S6=[;22VUW!-;RR1M
M_8]+%'/')#-&DT,R/%+%*BR1RQR*4DCDC<%71U)5T8%64D$$$BORT^.7_!+S
MP#X]\07OBCX5^*1\+[C4IFN;[PO)HBZOX2%RX8R/HL-M>Z;=Z!#-*1(]E&=1
ML("7CT^TL;<1VZ?P]XJ_1CS+"YE'B;PFC*,GB8XFIP[#&T\#B,MQ49JK#%Y#
MCL17H4X485%[182KB*5;"32>#JU:<H8?#?WKX1?2JRO%97+A;Q@G&<5AI86E
MQ+/ U,PPV9X2</93P?$& PU#$5)UYTY.$L92PU6AC*;:QU*E5C4Q.*^+=%_X
M*G_M(Z:474M(^&'B*,,OFMJ'AO6;.Y9/,W.(I-&\3:;;QR%#Y:.]I,B@*S0R
M,&+>LZ+_ ,%<_%T&S_A(O@KX<U3"@2?V+XPU/0=S;&!*?;M$\2;%,FUPI\PA
M T98LPE7A]:_X)/?'.T#OH7COX7ZRB[B([R]\3Z-=2#$>T1QCPUJ5KO+&3<)
M;V)55%8.S2%$\FUG_@FW^UCI9?[%X+T'Q$%)PVC>-O#$0<!W7<BZ]J.AN1M4
M2;2@<I(@"F7?&GP[S+Z6?#W_ "[XZK^S_P"I5A.)D[=W]3S95/GSW\S[[^S/
MH><1_P#+S@##^T[9OC.%FK^2QN4.D_+W''R/NO1O^"MOPWG9!XA^$OC?2U)^
M=M&UC0=>91OC!V+?'PX'.PRM@O'ETC3($K21>LZ-_P %0?V8=4V?;G^(7AS=
MMW?VSX2AG\O=YF=__"/:QKV=FQ=WE[\^;'LWXE\O\8-9_8Y_:AT(2&]^"'CV
M<1J6;^QM*'B(D",2D1CP_-JAE;:<!8@[&3,(!E!0>3ZS\*_B?X<+KXA^''CW
M0FB8K(-9\'^(=+,;"00E7%]IT!1A*1$0V")"$(W'%'_$P'T@,A_Y'.5N?L[\
M_P#;G!U? ;;\_P!4I97RVZVY;>0?\2Z?1TXATR/-8P=2W(\AXUP^8/7;V?UR
MMFRE>Z2NIWOW/Z4=&_;P_9,UP+]D^,>CVK'ADUG1/%F@E&"QLRL^LZ!8Q';Y
MBKYD<CPNRR".1_+DV^M:+^T'\!_$6P:)\9_A;J4LA 6VM_'OA@WH)D:)0]BV
MIK>1F1U(B$D"F4;7CW(RL?Y&"""00002"",$$<$$'D$'@@]*2O4P/TQ.,J;7
M]I<*<,XM+?ZE4S3+V^^M?%YDEUZ.S]+'DX_Z%7!%5/\ LOB[BG!M_#]>IY3F
M27;3#X+*V_O6GWG]G.G:KI>KP"ZTG4K#5+9@I%SIUY;WL!#J'0B:VDEC(=&5
MU(;YE(89!!J_7\7]M=75E,MQ9W-Q:7"!@D]M-)!,H=2K!98F1U#*2K ,,J2#
MD$BO2]%^.?QK\.%3H'Q>^)VCA6#>7IOCOQ19PMAUD*RP0:HD,T;.BF2*6-XY
M-H$B,.*^PP/TR\#*RS/@+%T+6YIX'B"CBK]VJ6(RK!\OE%UI?XCXK'_0BQT+
MO*_$/"5[WY:>/X<K82W9.MA\WQO-YR5"'^$_KUHK^6/1?VX?VKM *&Q^-/B:
M?8 !_;5IH'B0$!9%&\>(M'U02'$C$EPQ9A&[$O%$R>B6W_!27]K*!XFE\::#
M>K& 'CN?!'A9$GPNTF4V>FVD@+'YSY#PC=P $^6OKL+]+WPYJQ7UK)>,,)4N
MN91P.48FDK]54CG5.I*V[O0B[?#S/1?&XOZ&/B92D_JF>\%XRG9M.6/SG#56
MULG3ED=2FG+I:O)7OS.*LW_2Q17\WH_X*;?M39_Y"W@L^Q\'6>#['%P#^1!]
MZVO^'I7[3'_/C\,?_"5U;_YIJ].'TL?"N=^:'$]*UK<^3T'>^]O9YC4VZWMY
M7/+G]#_Q<A;EGPI5O>_)G6(7+:V_M,LI[WTY;[.]M+_T445_/;#_ ,%7/VC(
MHHXW\)?!NY=%"M/-X<\9K+*1U>06_P 08( Q[B*&-/1!6M:?\%9/CFD1%]\/
MOA/<S;R5DM+'QA91"/"[5,,WBZ_<N&#$R"95(*J(U*EG[(?2G\))M*6.SNE=
M7O/),2TGIH_92J.^O1-:/7:_#4^B3XQP3<<!D56SM:GGN&3:O\2]K"FK==6I
M6^S?0_?RBOP8M/\ @K5\5T9_MWPN^'ERI \L6EWXDLF5LG<7:;4;\2 C  58
MRI!)9LX&K;?\%</'BS*UW\'O",]N-V^*V\1ZS:S,2I"[9Y;.\1-K[68&W?<H
M*@H2'7LI_2>\'IJ/-GV/I7=FJF0YPW%7M>7LL)532W]UR=ME?0XZGT4_&J'-
MR\/9=6LKIT^(<E7,[7Y8^UQE)IWT]Y1C=?%:S?[I45^(2?\ !7;Q"'0R? W1
MFC#*75/'E]&[("-RH[>%I%1BN0KF.0*2"48#:=G_ (>^_P#5O/\ YEG_ /%G
M79#Z2O@O*_-Q?.G;;GX>XG=_3V>35-NM[>5SBJ?1=\<86Y>#*=6][^SXDX47
M+;O[7.Z>_2U]M;:7_:2O-/B9\8_AA\'-'.N?$KQIHGA2S9'>UAO[DR:KJ1C^
M_'H^B6BW&L:Q,O\ '%IMC=2(,O(JHK,/Q-^+O_!4WXJ^,-.&D_"[PMIGPLBN
M+58[_69[Z/Q?XD69T(G32KJ[TO3=(T^ ;VB2>31;S4/D2ZMKG3YB(X_S0\1^
M)_$?C#6+OQ!XLU[5_$NN7[^9>:OKFHW>J:C<MDD>;>7LLT[*F2(T+[(UPD:J
MH 'YOQU]+7AK+(U,)P)EU7B3&N-HYIF-/$Y;DU&35U*.&J1HYIC7%WC.E*GE
ML-I4\3-71^G< ?0ZXHS6=/&>(&94N&,"I)RRG+:N%S/.ZT4_>C/%4IU\IP"D
MM:=6%3,YZ-5,+#1GZZ_'#_@JMJ5V+S1/@'X4&E0DO"OCGQK!#=:BPZ&?1_"T
M,LVGVC!UW07.M7FIK+"^+C1+:883\H_'GQ'\>?$_6Y?$?Q!\6:YXNUF3>JWF
MM7TMT+:)VW&VT^V)6TTRS# %++3X+6TC/^KA6O2?@S^S#\:_CS<H/A]X+OKG
M1O-,5SXMU?.C>$K,JY27=K5XJQ7TT##$]CH\>I:E&"&-D5.:_8'X'_\ !+OX
M8>#?LFM?&'5Y_B;KT9CF_L&R^U:)X)M)5^;9+'%*FM:_Y<BJRR7=UIEA<)NA
MN]$FC8Y_"*&2>._T@<13Q6.J8U9!.HITL3F#GDO">&A?W:F"P=*G?,94_@6(
MPN%S'%W25?$;R/Z!Q&>_1^^CEAJF#P%+ OB*G2=.MA<MC#/.,,5+E7-3Q^.J
MU/\ A-A5_B/#XO%Y;A'=O#89Z0?XK?"SX(?%7XU:K_9/PT\%:SXF>.:.&]U"
MW@%MH6E-)M(.K:]>-;Z1IOR-YBQW5Y'/,@;[/%,PVG]<?@?_ ,$J_#VF"SUO
MX]>*'\1WBE)F\$>#KBZT[0D/RM]GU;Q+)';:UJ*LK,DT.CV^@F&9 8=4O(3\
MWZUZ%H&A>%]*L]"\-:-I7A_1=/B$-AI&B:?::7IEG$.D=K8V,4%K F>=L42@
MDDD9)-:U?TOP%]%K@?AGV&-XFE/C'-H<LW3QE/ZMD=&HK.U/+(3G+%J+O"3S
M&OB*%:-I_4Z,M%_+GB%]+/CWBGV^!X5A#@G*)\T%4P57ZSG]>F]+U,UG3A'!
M.5E.*RW#X;$49-P^NUH^\^2\%> O!?PXT.#PWX#\+Z)X3T.W^9-.T/3[>P@D
MEP%:YN3"BR7EY+@&>]NY)[NX;+S32.2QZVBBOZ7P^&P^$H4L+A*%'"X:A"-*
MAA\/2A0H4:<%:-.E1I1C3IPBM(PA&,4M$D?RUB<3B<;B*V+QF(KXO%8BI*KB
M,3B:M2OB*]6;O.I6K593J5:DGK*<Y2E)ZMMA1116Q@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15>[O+33
M[::\O[JVLK.W0R7%W=SQ6UM!&" 7FGF9(HD!(!9W5<D#/-> >)OVL?V<_"5Q
M):ZQ\6?#$L\7$J:"VH>+/+;>L;1N_A6QUI%F1V EA+":+;(9$01R%0#Z'HKX
MYO/V]?V8K9G$/CG4M0"QEPUGX.\7(LC8)\I!?Z-8L)"0%S(J1989E W$<S=?
M\%$_V=[?9Y3^.+[?NW?9?#$2>5MVXW_;=4L\[\G;Y?F8VMOVY7< ?=E%?G5=
M_P#!2_X)QJ?L7@_XH74@DVXN-+\*6<+1C=F1)$\7W<I)(7:CVZ$JQ+,C+M;F
M;S_@IUX$3S?[/^&'BVZVX\C[9J^C6/F'"Y\WR%U'R<'=@I]HR I(7<0H!^G=
M%?D_=_\ !42U5MMA\%+B9#'GS+OX@QVK+*2PQY,/@R[#Q@!&W>?&S$LFU H=
MN6NO^"GOBQPGV+X3^'K<@MYANO$NI7@8'&T((M,L3&0=VXL9-V1@+@E@#]B:
M*_$^\_X*9?%YQ)_9_@7X;VS&0F(WEOXGO@D6XD)((/$>G&20+@&56B4L"WD@
M$*.9O/\ @H]^T#=&4P:?\.=.$B;46S\.:LX@.T+YD7]H>)+YBY(WXG,R;B0$
MV80 '[K45^ =W^W_ /M*W!!A\2^'[ !"I6T\):&X8DG$A^W6UXV\9P K*F ,
MH3DGD+W]M7]IZ_&)_BK?QCRWC_T+P]X.TT[7X)SIWAVU/F#/R2Y\V/JCJ0*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD_#.0\^&7$,>)\TC>-19!2E1R+#5%NUG..IJOF=GHX8/*Z.'G%\U/,KKE.[
M8_-\RY:SRMY/@Y6E'^TYQJ9E5B^CP&'G[+!W5[2KXRI5BU:>$MJ?EY\,_P#@
MFCKU_!::C\6/&]OH FCAFE\->$((]5U.%9H8I'MKSQ!?JFE6=_:R-);W":?I
MNOV#O'YEKJ5Q$5=ONKX?_L??L^?#KR)].\ V&OZI#M(UCQFQ\3WC2)]R=+74
M5;1K.=#\R2Z?I5FZOAU(95*_3=%?'-IMM)13Z*]EY+F;?WMOS/=6BM=OS=KO
M[DE]R1'###;Q106\4<$$,:10PPHL4444:A4CBC0*D<:* J(JA54   #%2444
MAA7YX_M]_P#!/SP#^VEX+%Y UCX1^-GA>PN$\#>/Q;8BO(E$LT?A'QD+>-[G
M4/"]W=.7@N42?4?#5W-+J6DQSPSZKI&L?H=17KY%GN:\-9KA,ZR7&5<#F."J
M>TH5Z33T>DZ56$DX5J%:#=.M0JQE3JTY2A.+3.',LMP6;8*OE^84(8G"XB'+
M4IS7SC.$E:5.I3DE.G4@U.$TI1::/\[GXJ?"KQ_\%/'GB#X:?$[PSJ'A/QGX
M9NS::II&H(H.& DMKZRN8F>UU+2M0MVCN],U2QFN+'4+.6*YM)Y89%8_KS_P
M3+_X*CZA\!+G1O@1\?\ 5K[5O@E<S0:=X1\77)DO=2^$TLTNR.UN3\]UJ'P_
M+R9EM$\Z[\,*#-I,4VG+)IJ?N[^W5^P?\./VT_ 1M-16T\+?%KPW93#X>_$F
M*T\RYL'W23CPYXC2$+/J_A#4+AW,]H2]UH]U,^JZ.5G:]M-2_BY^,_P8^(WP
M ^(GB#X6_%3PY=>&O%WAVX,=Q;3 O9ZC92,XL=;T2^"K!JNAZI$AGT[4K4M#
M/'NC<17,,\$7]X\+\5<'>/?"F(R#/\+1H9U0HQJ8_+HS4,3A<1!>SIYWD5>H
MIU%14YV:_>3PSJ2P6.C7PU:$\7_-><9+GWAGG5+,\LK5*N7U*CCAL5)7I5Z3
M?-++LRIPY8\[C'=<D:JBL1AG3JTY1H?Z%6GZA8:O866JZ5?6>IZ7J5I;W^G:
MEI]S#>V%_8W<27%I>V5Y;/+;W5I=021S6]S!))#-$Z21NR,K&Y7\A/\ P34_
MX*>ZS^S-?Z9\&OC3?7^O?L_ZA=O'I>J%+C4=:^$]]>S;VO=,B3S+G4/!<]R\
MDVL^'8$DN-/EGFUK0(WN?M^D:W_7%H>N:-XFT;2O$7AW5=/US0=<T^TU;1M9
MTF[@O],U73+^!+FRO["]MGDM[NTN[>2.:WN(9'CEC=71BI!K^.O$7PXSOPZS
MAX',8/$Y=B95)Y3G%*G*.%S"A%IN+NY*AC*,916*PDIRE2DU.G*K0J4JU3]Y
MX4XLR[BO +$X5JCBJ*C''8&<DZV%J-;K1.KAZC3=&NHI32<9*%6$Z<=2BBBO
MSP^I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OGKXC?LK_ CXH>=/XB\ :59ZM-N)U[PTA\-
MZP96)S<7$^D_9[?4Y@"0#K%KJ* 8&SY$V_0M% 'Y#?$;_@F;J<'GWGPI\?6^
MH1C<T6@^.+<V=V%4Y"1^(=&MY;6YF=251)M"TZ$.H,ERJ2%HO@SXB_L^_&3X
M5-,_C;P#KNFZ?"7W:Y:P+J_A\HI^5VUS2'O=-@\Q<.D-U<P7(4GS($='5?Z;
M*1E5E*L RL"K*P!5E(P00>""."#P1P: /Y,XY)(9$EB=XI8G62.2-F22.1&#
M(Z.I#(Z, RLI#*P!!!%?3?PZ_;#_ &@/AMY$&G>.;OQ'I,&T#1/&JMXFL6C4
MC9"EW=RIKEG @!1(=.UBSC5#M"@*FW]H?B-^R5\!/B=Y]QK7@/3](U>?>3KW
MA+_BF=4\Z08:YG&G*FFZE<<#$FKZ=J.,#BO@SXC?\$SO$%F9[SX5^.['6;<;
MGCT/QE VEZBJ*"1%%K>EPW.GWUP_ 7[1I>C0 _?E Y !Z+\._P#@I?X1U'R+
M/XG^!]4\-W#$1R:UX6N$UW22Q )GN-,NS8ZI80@[E\NUFUR;(4C(9O+^[_A_
M\:OA3\4H8Y? 7COP_P"()GC\PZ9#>"TUR%-NXM<Z!J"VFM6J@!OFN+"-"4?#
M'8V/YV?B'\"?B[\*WD_X3OP%K^BVD;;?[8%J-1T!R20JQZ_I;WNCM(P^80F]
M$Z@C?$I.*\IAFFMY8I[>62">&1)89H7:*6*6-@R212(5>.1& 9'5@RL 001F
M@#^LRBOYTOA[^V5^T'\.EAMK+QQ<>)M*A"JND>-HCXEMPB<1QI?W4D>O6\,:
MYC2"TUBWA5,*(\)'L^P?!O\ P4ZF'DP?$'X7QOT\_5/!NLM%CH&\G0M;BEW9
MY8;_ !&N,!3G.\ 'ZV45\A>#?VY_V</%_E12^,;GPC>RE0MEXRTB\TK;GJ9=
M4M!J6@1!20&\S5UZY7<H9A]0:!XH\,^*[0:AX7\1:%XDL"%(O= U?3]8M"'!
M*$7.G7%S#AP"5._Y@"1D"@#=HHHH **** "BBB@ HHHH **** ,#6/"GA;Q$
MK+X@\-:!KJL-K+K&CZ=J:LNQX]K"]MIP1Y<CQX/&QW3[K$'R?6_V7OV<O$)=
MM4^!_P +WEDW>9<6?@S0]*NY"QC):2[TFSLKJ1QY:A7>9F1=R*0DCJWN]%>7
MCLCR3,[K,LGRO,%+XECLOPF+YO7ZQ1J7^9ZV S_/<JY7E>=9MEKC\+P&98S!
M\MMN7ZO6IVMY'Q?K7_!/C]DG6BSGX6+I4[<>?HOBOQGIX4;I&(6S7Q!)IH^:
M4G=]B+A4CC#B&-8Z\DUK_@E?^SAJ(=M,UKXG^'I"#Y2V/B/1+VV5MBH/,BU?
MPQ?W$B;E,A5+R%R[L!(L81$_2NBOCL=X1^%^8W^L\ \*IR^*>%R;!8"HWW=3
M TL-4;\^:_F?:X#QE\5\LY?JOB'Q<U'2,,7G>-S"G%=E2S"KBJ:7DHVW5K-G
MX^:S_P $B_"DY?\ X1_XV>(=,!8F,:SX-TW72B>82%<V6O>'1(PAPA=5B!D!
ME"*I\D<$W_!(KQ*%8K\;]#+8.T-X'OU4MC@,P\2L5!. 6"L0.0IZ']P**^3Q
M/T;_  :Q,_:/@]49.]UAL[XAH0=]OW4,U]E&VMN2$=];V5OL,+])SQNPL/9K
MC-UXJUGBLBX;KS5M_P![/*/:ROI?GG*UKJS;O^$W_#I'XB_]%<\%?^"37?\
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M#@@CD$$<@@\@CI706OB[Q79%VLO$_B&T:0 2-:ZUJ5N7"DE0YBN4+ $D@-D
MDXZTQ']5]%?RZV?QB^+FG&)M/^*?Q&L6@3RX39^-_$UJ88]NSRXC!J:&--GR
M;$PNWY<8XKIK/]I+]H"Q""#XR_$AQ'()5^V>+=9U$E@P;$C:A=W+2QY !AE+
MQ%<J4*D@@'],E%?S@VO[7_[2EGO\KXM>(G\S;N^U0:-?8V[L;/MNF7'E9W'=
MY>S?A=^[:N.IM/VZ_P!J&V8&3XCP7J+'L$5WX-\#;>P#F2V\-VUPT@ QEYF#
M;B7#-@@ _H5HK\ K;]O_ /:6@D+R^)] O%VE?)N?".A+&"2"'!M+6UEW+@@
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MGXTDCSF*\L]#\N/PAH5Q@A9;/4(O&L!"EDN5+@)^E<*>$7'W&/LZN69%7PV
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MD@>@K^J#Q#X3\+>+K,Z?XJ\-Z#XEL"&'V/7](T_6+7#<-B#4+>XB!.!DA0>
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M+/X)W$\6T$O<_$..TDWY.Y?*B\$WJ[0,$/YP))(*+@$U_P#AZ-_U0S_S)O\
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MU_Q+?)IGAS0]8\0:E+CR]/T33+W5;Z3)P-EI807$[Y/ VQG)X'- 'Z+>.O\
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M_LE?LX7HE$WPB\*H)GWO]DBOM/*MO$F(FL+VV:!-PQY<!CCV9CV^62M?15%
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MB\O+B"TM+2"6YNKJYEC@MK:V@C:6>XN)Y62*&"&)&DEED98XXU9W8*"1\O\
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M=;3PF+S*$M.;5^[\!F_%'T?N$.;#<#<"YCX@9C2O&GQ!QYF&,H91SK:K3R+
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M=NV_8B_:BNXS+%\++A%#E"+GQ7X%LI,@*21#>>)X)2F&&) A0G<H8E6 L?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#E57N5% 'AO_"X-8_Z)MXF_*Z_^55'_"X-8_Z)MXF_*Z_^55>Y44 >&_\
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ME10!X;_PN#6/^B;>)ORNO_E51_PN#6/^B;>)ORNO_E57N5% 'AO_  N#6/\
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M>)ORNO\ Y55[E10!X;_PN#6/^B;>)ORNO_E51_PN#6/^B;>)ORNO_E57N5%
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MC_HFWB;\KK_Y54?\+@UC_HFWB;\KK_Y55[E10!X;_P +@UC_ *)MXF_*Z_\
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MN/&'AHZ;X#^/NDV CT;QF+8QZ5XOAM(=MGX<\?PVD33W=IL1+33?$<$4^LZ
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?&W[9/[$GPD_;.\"?\
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M\_RN,^C5XEX;F]C#(<QMM]3S5PYO3^T,+@=_[W+YV/:P_BWPC6M[26986_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>&?M _\ (F:=
M_P!C+9_^FK6J]SKPS]H'_D3-._[&6S_]-6M4 +\ /^1-U/\ [&:\_P#35HU>
MY5X;\ /^1-U/_L9KS_TU:-7N5 !1110 4444 %%%>._'[X[?#O\ 9H^$?C#X
MW?%;4+[2_ 7@>'29=<N],TZXU?4 VNZ]I7AG2K>STZU_?74]YK6M:=:(JE4C
M\\S321P1R2* >Q45SOA#Q3HWCGPGX7\;>')Y;KP]XP\.Z+XIT*YGMKBRGN-&
M\0:;;:MI<\UG=1Q75I+-8W<$DEM<Q1W$#L8IHTD1E'14 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#<J1"WB/P;X=\4JC^45#2+IFI>#C*HGQ(45X28@80X<_:!_0-17U.#\9?$_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(-6E4Y?K<+2YUB&TH_VY45\Z?LV?M4_!7]J[P1%XV^#_ (JAU5(4@3Q#X7U
M16'C'P??SQ[O[.\3:"9I9K1]XEBMM1M9+W0]4,$\FCZIJ$$3RCZ+K^-,?E^.
MRK&8C+\RPF(P..PE1TL3A,52G0Q%&I'>-2E4491=FFFU:46I1;BTW^^X;%8;
M&T*6*PE>EB<-7@IT:]&<:E*I![2C.+:>MT];IIII--!1117&;A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUW2_AOX.\0>+]0A(O?A1JNF6$\.@:;J4EG<:U'X?U6'36N8E2>6SN FXPN
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M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
MX-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W
M**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?
MPU_T,.A_^#:P_P#DBC_A)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#
M:P_^2*/^$G\-?]##H?\ X-K#_P"2* -RBL/_ (2?PU_T,.A_^#:P_P#DBC_A
M)_#7_0PZ'_X-K#_Y(H W**P_^$G\-?\ 0PZ'_P"#:P_^2*/^$G\-?]##H?\
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MPU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\
M@VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H
MW**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^$G\-
M?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,.A_^
M#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\ DBC_
M (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.
MA_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@VL/\
MY(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W**P_^
M$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?PU_T,
M.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:P_\
MDBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_
M $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H?_@V
ML/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(H W*
M*P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\ X2?P
MU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_ .#:
MP_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DBC_A)
M_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?]##H
M?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K#_Y(
MH W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RBL/\
MX2?PU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0PZ'_
M .#:P_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL/_DB
MC_A)_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$G\-?
M]##H?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_ (-K
M#_Y(H W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2* -RB
ML/\ X2?PU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_#7_0
MPZ'_ .#:P_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?_@VL
M/_DBC_A)_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H_P"$
MG\-?]##H?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!##H?_
M (-K#_Y(H W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_ .2*
M -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/_A)_
M#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]##H?
M_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_ )(H
M_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU_P!#
M#H?_ (-K#_Y(H W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X-K#_
M .2* -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -RBL/
M_A)_#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G\-?]
M##H?_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@VL/_
M )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(H_X2?PU
M_P!##H?_ (-K#_Y(H W**P_^$G\-?]##H?\ X-K#_P"2*/\ A)_#7_0PZ'_X
M-K#_ .2* -RBL/\ X2?PU_T,.A_^#:P_^2*/^$G\-?\ 0PZ'_P"#:P_^2* -
MRBL/_A)_#7_0PZ'_ .#:P_\ DBC_ (2?PU_T,.A_^#:P_P#DB@#<HK#_ .$G
M\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\ @VL/_DB@#<HK#_X2?PU_T,.A_P#@
MVL/_ )(H_P"$G\-?]##H?_@VL/\ Y(H W**P_P#A)_#7_0PZ'_X-K#_Y(K0L
M]1T_45=]/O[.^2-@LCV=U!=+&S#(5V@=PC$<@,02.0,4 7**** "BBB@ KPS
M]H'_ )$S3O\ L9;/_P!-6M5[G7AG[0/_ ")FG?\ 8RV?_IJUJ@!?@!_R)NI_
M]C->?^FK1J]RKPWX ?\ (FZG_P!C->?^FK1J]RH **** "BBB@#,U;6M&T"T
M6_UW5M,T6Q>[L;!;W5K^UTZT:^U2\@T[3+);F\EAA-WJ.H7-M8V-L',UW>7$
M%K;I)/+&C97C+P1X-^(GA[4/"/C_ ,)^&_&WA75HC#J?ASQ9HFF^(=#U"(AE
MV7>E:M;7=E< !FVF2%BA.4*GFO)?VH_V:_A]^UO\$O%_P(^)L^OV7A7Q<=(G
MEU/PO?6VG>(-)U+0=7LM<TG4M,N;ZQU.P,UO?6$(E@O].O;2YM9)X)(,R+)'
M_-K=_L@_M->!/V]/!G_!/WX:?\%&_P!J'1?AWK/P3E^+5SX@M?%'C:UE\$Z5
M9ZGXJMH?!]AX;TKXG:;I<C7(T32B^MZ?<:# 1K[)+X?N(;$)? '4?#WX8^#_
M -E+_@O)X+^%/[*MR]AX!\:^%-4E^)WP]T?5[BYT7PK;:W\.O%?B?7_">H%Y
M+B2'3='O-#\+_$'1M)OYG.GWMWHVF6C0VXL[=?ZI*_/?]BK_ ()N? G]BB\\
M1>+_  K>>*?B-\8/&=M<V7BWXO?$*_CU'Q/?V%WJ"ZG=:9IEO;QQ66CV%]?0
MVMYJCH+O5M8N[6WEU75KR.VLX+7B/VQ/^"?7Q(^/OQ?TC]H#X#_M=_%/]F#X
MH:=X*TGP)JD?AA=2U3PEXHT/0]6U[6=-CU+3-+\4>%;F*<77B&[6Z6]GUW1Y
MX[>U=-"AO#=7EP ?27[<]C\-[_\ 8[_:5A^+,.D2^!HO@WX\N]1.LK9F&'4;
M3P_>W'ANYTXWI$:^(H/$D>DR>%FA87I\1C2UT_-\UN#^4_\ P1$\&^+_ !A_
MP3'^+WA#565].\>^/OC9H'@*.\:=8$T77?A]X7\.W0$I=533W\8GQ&66W"^7
M<?;I6F:65EAU-1_X) ?M'?':ZT;3OVS/^"B/Q3^+OPVTO4EO+SX9>%]"NM!L
M-;%K/-)8W,NI:EXFOM"LM13]TS7ESX#UN^MDEN+6PU&V,<5XW[;?#'X9^"/@
MW\/O"/PM^&^@6GA?P-X&T2TT#PWH=EYC166GVBG#2SSO+<WM]=SO->ZEJ-Y-
M/?:GJ-S=:A?7$]Y<SS. ?AC_ ,&]'C2*#]GKX[? S6S_ &?X]^%GQWU35]:\
M.W12'4],TGQ5X:\/:+!'<VAQ('MO$W@CQ5:7,H+B*94@<1D1F7K/^#@7X@6&
ME?LB^!_A+:2M>>-?C!\9_"]KH'ART!FU/4]*\*66IZIJMY;6<;>=<16NMW?A
M/3"L4<K->ZY81JFY]R]O^T+_ ,$C]5U[X^>(OVG_ -CS]I3QA^R;\5O&LU]?
M^.K'0=/O=1\*^*=5U.9+W5KT#2==T&\TZ'Q!J<4>K^(M(U*W\4:)J6L$ZI!I
MMC.-KS? 7_@DIJNG?'3PU^TI^V7^TKXQ_:W^)W@6>RO? &EZ_I]UI?@WPMJ6
MF3?;=+O7MM2UO7;G4ET;5#_;&C:9I\/AK1;;5T74;[3=3G.% /U!_9\\!7OP
MK^ ?P0^&&IK$NI?#CX0?#7P%J"P2B:!;WP?X,T7P]=K#,JHLL0GTZ01RJBB1
M,.%4' ]?HHH **** "BBB@#SG5?A3X*UK4;O5=0TZXEO;Z4SW$B:A>Q*\A 4
MD1QS*B#"CA5 ]JS_ /A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?
M^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DB
MC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_
MZ!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#
M34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(K
MU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_
M (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^
M@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34
M/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2
MWP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U
M_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_
M )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@
M#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M
M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?
M^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DB
MC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_
MZ!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#
M34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(K
MU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_
M (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^
M@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34
M/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2
MWP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U
M_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_
M )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@
M#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M
M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?
M^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DB
MC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_
MZ!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#
M34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(K
MU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_
M (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^
M@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34
M/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2
MWP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U
M_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_
M )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@
M#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M
M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?
M^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DB
MC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_
MZ!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#
M34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(K
MU:B@#RG_ (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_
M (4M\/O^@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^
M@7=?^#34/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34
M/_DBC_A2WP^_Z!=U_P"#34/_ )(KU:B@#RG_ (4M\/O^@7=?^#34/_DBOC+]
MK#_@F%^S[^T_H-U<"UNOA_\ %*VM3'H/Q+T?=?78:*,K;:?XJTJXGBA\3Z&K
M;,02W-GJMDJ8TG5["*6[@N_TCHKU<DSS-^',QP^;9'C\1EN8X:5Z6)PT^65F
MUS4JD6G3KT*B2C5P]:%2C6C[E6G.+:.+,,NP.:X2K@<QPU+%X6LK3HU8W5UM
M.$E:=.I&]X5:<HU(/WH2B]3^!3]J#]D3XV_LC^,SX3^+7AI[>QO99_\ A%O&
M^D">^\%>,;6#:7N-!UEH(!]JA1XVOM&U"&QUO31+$][I\4%Q:SW&%^S[^TK\
M3?V;_%<7B'P+J27.E7%Q!)XC\%:Q)>3>%/%-O%\ODZI8VEU:3PW2QEDM=7TZ
MYL]5LPS)#=_9Y)[>;^\KXG?"SX>?&;P9J_P]^*/A'1O&W@[7(3%J&B:W;">
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MJ* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\
MA2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!
M=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_
M^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?
M#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_
M (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\
MDBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /
M*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP
M^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X
M--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/
M^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H
M%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--
M0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5
MJ* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\
MA2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!
M=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_
M^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?
M#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_
M (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\
MDBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /
M*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP
M^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X
M--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/
M^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H
M%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--
M0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5
MJ* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\
MA2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!
M=U_X--0_^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_
M^2*/^%+?#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?
M#[_H%W7_ (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_
M (--0_\ DBO5J* /*?\ A2WP^_Z!=U_X--0_^2*/^%+?#[_H%W7_ (--0_\
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M"VACQXWA@7'VL>'#XO\ L/\ PD!T$77^DC2#J']GBX_?"W\SYJ[2B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O#/V@?^1,T[_L9;/_TU:U7N=>&?
MM _\B9IW_8RV?_IJUJ@!?@!_R)NI_P#8S7G_ *:M&KW*O#?@!_R)NI_]C->?
M^FK1J]RH **** "BBB@ HHHH ***\3^/?[1?P6_9A\!W/Q)^.?C[1O /A2&X
M%C:W.HFXN=1UK5'AEN(M&\.Z'IT%YK7B#5Y8()[A=.TBQN[B.U@N+R=(K.VN
M+B( ]LHK^4G5/^"O/[/VM?\ !3?PI^T#+XS^+UC^S;X7^ ES\,XM,AT75([6
M^\:WFLZ]>R^(-1\#6^N%+C3TM]?+'59+&?6MVEZ?$NF-]FMGC_IV^%?Q3\ ?
M&WX>^%?BK\+?$EIXN\ >-=-_M7PUXBLH;VUAU"S6XGLYMUGJ5M9:C8W5I>VM
MU8WUAJ%G:WUC>VUQ:7=O#<0R1J >@45^:_[6G_!57]EO]D3QLGPK\3R^./B9
M\6S!;RW7PW^$>@6/B37=$;4+1+S28O$5UJNLZ!I&F7&HVTL-W'ID%_?Z_'IT
MT&HOHWV2[L7NN4_9>_X*_P#[*O[3?Q'LO@T+3XB?!CXKZI<FPT3PC\8= TS0
M4\1:JR^=!HVB:QI.N:W9#6+JW:-K+2]=&@W^I7+"RTBWU&X>V6X /U3HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNRU/0I<-\.T;>RR')J=NL,KP47TU;5!-O17;;;:3;NCYUTC]D#]D_00AT?\
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MAO*[C[>ER[_&TN[EIH>W\7Z>G+GSMK_N]"K^/LIW_P -WZ:GN?\ P_Y^+_\
MT0#X;?\ A3>*/_B*Z1?^#@/QB%4-^S)X:+8&XK\4-452V.2JGP4Q4$Y(4LQ
MX+'J?DH_\$4_VY0"?[ ^&YP.@^(FFY/L,VH&3[D#U(KF_P#AS?\ M\?]$N\-
M_P#AS?A__P#-!1_JW]&2O_S$<'1Y?^JJQF'OS?\ =8I\VWGR^5P_M;Q?I_\
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MFO/%2JTI0A"LJE"C35.E.4:ZES5)>TI048VDY+TJBBBOY8/V8**** "BBB@
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M_P"AU\,_^ EM_P#,E1_8/QX_Z'7PS_X"6W_S)4 >Y45X;_8/QX_Z'7PS_P"
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M\,_^ EM_\R5 'N5%>&_V#\>/^AU\,_\ @);?_,E1_8/QX_Z'7PS_ . EM_\
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M]@_'C_H=?#/_ ("6W_S)4?V#\>/^AU\,_P#@);?_ #)4 >Y45X;_ &#\>/\
MH=?#/_@);?\ S)4?V#\>/^AU\,_^ EM_\R5 'N5%>&_V#\>/^AU\,_\ @);?
M_,E1_8/QX_Z'7PS_ . EM_\ ,E0![E17AO\ 8/QX_P"AU\,_^ EM_P#,E1_8
M/QX_Z'7PS_X"6W_S)4 >Y45X;_8/QX_Z'7PS_P" EM_\R5']@_'C_H=?#/\
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M);?_ #)4 >Y45X;_ &#\>/\ H=?#/_@);?\ S)4?V#\>/^AU\,_^ EM_\R5
M'N5%>&_V#\>/^AU\,_\ @);?_,E1_8/QX_Z'7PS_ . EM_\ ,E0![E17AO\
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M ("6W_S)4?V#\>/^AU\,_P#@);?_ #)4 >Y45X;_ &#\>/\ H=?#/_@);?\
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M>/\ H=?#/_@);?\ S)4?V#\>/^AU\,_^ EM_\R5 'N5%>&_V#\>/^AU\,_\
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M #)4 >RW^FZ=JD*VVIV%EJ-NLBS+!?VL%Y"LJJR+*L5Q'(@D57=5<+N"NP!
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MAG_P$MO_ )DJR?CMXKM6_P!;J_;_ )%>1)_>LKNO5:_>R_\ B&_!7_0CI_\
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MDWA\![KI<"(1HO\ RZI;'FONK^P?CQ_T.OAG_P !+;_YDJ/[!^/'_0Z^&?\
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M\,_^ EM_\R5 'N5%>&_V#\>/^AU\,_\ @);?_,E1_8/QX_Z'7PS_ . EM_\
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MC[)OU?\ L"[TV#4'T1DU?1;GQ'I$%]JEM^GU !1110 4444 %%%% !17Q/\
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M^TS\$_V%;GQ-^PYX9N[R>[^(7C#7?[(^(WB_PCI%VD.J^-]$\/6FM?VGX?\
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M_P#IJUJO<Z\,_:!_Y$S3O^QEL_\ TU:U0 OP _Y$W4_^QFO/_35HU>Y5X;\
M/^1-U/\ [&:\_P#35HU>Y4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;SXHM#HNH:/>ZLGCI;W3M5L-1L]0:PU2Z?4?M%QJ^D:9X8BTWG_V8/AS=_\
M!/'_ (*77G[(O@C7-8N/V8/VJOAAK_Q4^%7A#6M2U'5_^$(^(7@V.]N]<TG3
MM0OVFEEDM]"\/:ZMY<22/>ZKH=UX/&MZAJ&IZ&+BX /U6_93_:=^&'[8_P #
MO#/QB^'5W;W6E>(++^S_ !5X8NWBN-3\&^*H;:)?$/@SQ%:LHQ=:?+/MBF>%
M;76=)GL=9L/.TS4K6:3\E/B?\-U_X)8?ML_"?XX_!LMHG[)/[8GQ'TCX.?&W
MX36?RZ#X*^)?B$ZC<>%O%GA:R)6WTW3(Y&U'7K2PM$=M'T_2_&7A_3UBTC6]
M$L-']$^,G_!/+X^?LZ_&K7OVJ/\ @F'XG\,^#M>\7&XO?BS^S)XTN&M?A;\1
M[@W$U^?^$<BEDMM*T>:ZO+BYEM=)O=1\-6WAZXN[Z3PKXM\-Z7=S:%)+X?\
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M+;PY\/? T,UI8W#Z1ID*PB]U"2QTY;];#1K5=/W:.^JZO^AE !1110 4444
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M$8!+;:?=>)-3TV"\N(S<VPDAMGDD0W$ 9098]WH=?@S^SG^P9I7[=.K?%?\
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M]J,.D6MW;RZ)HOBB6VV?^"?.A>(OV,_VVOVB/^"=[^*=9\2_!:;X?Z=^T?\
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M=HFC65_J^I3#R+"RN)L)0!U7C'Q7H?@/PCXI\<^)[S^S_#7@SPYKGBOQ#?\
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M7PA/JVL:3>V-QJEU:76@SZ?=V6DZYKV@G4AID4C64NE7HT^07-HQ:0 _//\
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M%:R+XO\ *M]-TK2'FN+FW2\U&ST3PH_AB2>R?Q'X2L-"U"+Q/'YWX8^(L_\
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MA)J>O^)?$6H6^F:1I5E$50RW5Y<ND:M+*\=O;0*6N+NZF@M+6*:YGBB?XF^
MO_!4']B']IKXB/\ "3X6_&"#4?&M\;F+0-&\3>%O%7@^+QG';P/-=)X8N/%6
MC:7:ZG=+;K)*-%F>UUVYMHKBYMM*GM;:ZFA /B?1?B__ ,%"/^"BM]\0OB5^
MQK\9/ ?[+G[-W@3QGJW@GX7Z[XD\&:9XO\5_'+6/#,T7]H^*=5DUGP]XECT'
MP@]PT*64>G6*H5GGTK4;'7KNQU![7T3]FS_@HA\7?!'QPL_V-_\ @HOX(T3X
M4_''6;FWM/A3\6/#,,L'PE^-,,\BV>GK:7LL\UGI^MZU=!5TR[LFM-+U#5+A
M_#6HZ'X+\2VUKHFJ>&?L>?$]?^"8W[1OCK]@']H"1?"_P/\ B9XYUSXB?LA?
M%_5I5@\,SZ;XCO(H9O 7B+7;AA;VUXC1Z=8R7-_- ^E^+4O5OVDTGQ?X9O(_
MT^_;L_9 \ _MF? /Q1\.O%-MI]AXNTG3]2\0?"KQY,L<&H> ?'5I9M+IFIPZ
MEM\^#0]0GM[>P\5V*R+#J.C-(W[G4+/3+ZQ /DG_ (+@-:VW[%NF:M=$QC0O
MC_\ !C5XIU.U[9X-;O8)9T;@JZ6MS<@,K*1N^\!G.5KG[3WQQ_;K_:'M?@U^
MQ!XON/A]^SK\%/&6EWO[07[6%AI]CJEOXQUG1;N&^_X5-\(QJ=M=:5K=O>^6
ML>LZP(KBSU"UD%[*P\)_8+?X@U_V6_#^D?\ !5;_ ():?#[P;^T9>>+$O[R1
M/"VN^-=&U*&+Q3J'B'X2^)C8:/XWM=1U:PU*TO=3UK3K"VC\1R:E87\=YJ%[
MKWW;EH;F#]4?@W\&_AO\ /AOX7^$WPF\+V'A'P-X1L%L=)TFQ4EG8DR7>I:E
M=R%KK5-9U2Z:6^U;5KZ6:^U&^FFN;F9Y')H ]/HHHH **** "ORN_:L_:1_:
M-\:_M':/^PO^Q3?>%/!_Q97X?K\6/C#\</'6FV^MZ'\(_ <^H6^FZ59Z!X<O
M;+4K/Q!XQUBZO-/D6*_TO4=/M[35-,C6 BXU;5_#':_$7_@K-^P1\+/BK<?!
M[Q=\=M/C\5:;J8T37K[1O#GBKQ%X2\-ZR9DMWTS6O%NAZ-?Z'#<6D[F'57M;
MN[M="GANH-=N--GM+J.'XS_;7U+Q;^QO^U_\,_\ @J/\.M-E^)_[._Q"^&VA
M_![]H^#PG-;:Q-8>#M7N]-NO"/Q T.]BFEL9M&U,0>$+G2;Z%X],N-5\.VNC
M7.K6D?CRTN80"GK/[3__  4'_P"";OB71+G]M^31/VJOV5/$&J6NE77[07PU
M\+6FC>.?AI=WS);62>*-!TJPT"P-FURQ/V;5["\;5C/!#H_CJ75HU\,7/[>>
M%?%G@GXP_#W2?%_@GQ!IOBWP%\0/#:ZAH?B'1YA<6&K:)K5HR)<0,RJ\;^7*
M\5Q:W,45U9W4<UG>V\%U!-"G-^'/$GP;_:@^#UOK>@WGA7XM?!OXJ^&9X&W1
M0:MX>\1Z#JD,EKJ&E:II]W'OAN(B9]/U?1]2M[;4M)U""XL-0M;/4+66&+\F
M?^"<^D:W^RI^VI^U[_P3[TO5-0\0_!/POHFB_M!?!DZAJ5QJ,_@#2/&%UH*:
MKX*EDN#*Z?:9/%5CLC>2(W4_AJ^\1-%)=^);^50#XH_8:_;G\5?#?_@G_P#L
MZ_LJ?LP>'X/BM^V=\2-7^+6G^"_"T(6[T+X3^&[[XH^,;^X^)?Q*FE=['3K'
M34O;S4]+TN_:WM)X(?[9UI$T>..+7?Z+/V<_ /Q,^&/P6\!>"/C'\4]0^-'Q
M-T727'C'XBZC96EC)K>KWM[=:A+!:0VMK:/+I>C)=1Z)I5[J$7]JZAI^GV]_
MJ>R]N)H8O$OV.O\ @G_^SO\ L/V?C-?@WH>HSZ[XYUB^O-8\8>*[NVUCQ3%H
M#WSW>C>"=/U..RLS:>%M!C,2PVJ1&[U6\B74]=N]1O([1[3[:H **** "BBO
ME']I3]N#]EO]D4:/%\?OBSH_@K5?$$+W6B^&[?3M=\4>*M0LHYO(?4E\-^$]
M+UO6+72O.66%-7U"TM-,FG@N+:"[EN8)(5 .7_;M_:VG_9%^$6D>(?#'@Z3X
MC_%WXG>.-!^$OP3^'R2/'!XF^(_BL7(TD:L\$L-X-$L$M99[R.R>.ZU"[;3M
M$BN],?5EU6Q_/?QEK/\ P6W_ &:M-/QT\2Z_\"_VL/!]M:#5?B!^SYX*\)0Z
M!KO@[3BQNM13P#JNC^$_#WB?Q(=)M%:W%]=:QXPU*.0F=/"'B"VAFO!Z9^W/
MI6C?M^?LC>"?VB_V(_&6E_$_XA?L[_%#0/CA\)KCP^+D7FHZ_P"!Y8;S7_!U
M_P"'=7M++6M.\41Z=+9>(+'PKK.FZ7KU[J.EZ+IZ6\::U%]H^P_V'?VU_AG^
MVY\'].\?>$+FVT?QOI$-KIGQ5^&5S=(?$'P^\6!'CNK2YM9"MU<>'M2N+>YN
M?"^O&%(-5T]6AG6SUNPUG2=- .E_9!_;#^#W[:GPIM?BC\)=3F#6LT6E>,_!
MFKB*#Q5X#\2FW2XET37K.-WC>.2-C/I.LV3S:5K-JKR6EP+FVO[.R_**\_:B
M^#W['?\ P4G_ ."G/Q2^+&M'2='/PN_9CGTKP_IVR;7_ !YXL3X;^'X-/\.>
M&-)>:%=2\0Z@)0$),5II]D-1UG5KNQTNTU&^CZ;]HOX?6/["W_!1K]F#]H_X
M,JV@^"_VT?B?;? +]H#X8:07AT;7_%OB^_M+70_B%9:-"3$+Z+5-9B\1:L;*
M!)4U71;J>!9;CQGK:77W5XA_X)R?LZ^+_P!LO_AMGQ?IFJ>*/B)#HGAVVT_P
MKK4MC>>!=/\ %GA:RMM(T7Q]'I360NKKQ#IFB:?IMEI<-[>7.DZ=?6<>O6]B
M-;AL+VQ */[".H?MC?$2S^(7Q]_:IN[?P+HOQ>N=$U#X.?LU0:5:I=?!KP1I
MT5Z+*[\2:Y+:6NMW/BSQ;:7=G=ZUI6I 264EHEW<VFB7=\_A7PY^@M%% !11
M10 5@^*?$VB^"_#'B/QCXEO4TWP[X3T'5_$VOZC(DDB6&BZ#I]QJFJWKQQ*\
MKI:V-K/.R1(\C",JBLQ /)_%SXQ?##X#> ];^)WQ@\:Z)X!\"^'HEDU/Q!KL
M[QPB23<+:PL+2WCN-1UC5[YU,.FZ)H]G?ZOJ=QBVT^QN;AEC/QY\(?VZ/V*_
MV_\ 2_B-\"OAI\41K.K>)_!?BKPYKG@_6]$UWP9XDU;PGKVE:AH>L:CX;MO$
MNG6$>N11:=<SW%RFE27E]I-N\-SJ]C8Q2(6 /B+P?XL_X*K_ +=/A-_VG_V>
M_C/\,/V7/A#JVHZS/\"O@_XE\(:/XIUOQUX=T+4;W2H->^)GB6^\*^*)M)?Q
M'=V=W EOIHELH84%S::/#''8:[JGT'^QO_P47\3^.?BKJ/[(7[9O@"V^ ?[7
MN@^9_9FE0K-%X#^+>FPVLMVFK>!KZXO=3ACU"XL[:ZOHM/AU?5=,UJSMYK_P
M]JL\D=_HFD> ?\$U_C]K'[)7C/4/^"77[5L]GX3\??#_ %;4[G]G/QU>-'8^
M%/B]X!\4:WJ&K:9I>CZA.L:/JUUJ5WJ=YX:2XGDFOUEO_!<RV7B3PLNFZE]6
M?\%5/V6/"WQW_9I\8_%"RF'A+XW?LV^&]>^,OPC^)^F7']D>(O#][X L)O%^
MHZ&-=@:"ZM],UJVT9_LY:[@ATCQ%#H_B&.6%].D\X \Q_P""L6IZ5X;\8_\
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M>'K3Q;+HFO>+[7[7X<^'G@3P]?66IZ9-J5UI_P!KFOM3OK6.X:YTS7;>QO\
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M3]F4WD<_Q+UOP7X0TSP=\3?A;8SRDWVL6>FZ)I7AZS31;<R&>&[U*+Q%H"+
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M*/'5QI5EH<WB_7[#3K>VU7Q%)HVG?Z#I;:O>QS7IL;4M%;>=Y2O)M+MV=%%
M!1110 4444 %%%% !1110 5X9^T#_P B9IW_ &,MG_Z:M:KW.O#/V@?^1,T[
M_L9;/_TU:U0 OP _Y$W4_P#L9KS_ --6C5[E7AOP _Y$W4_^QFO/_35HU>Y4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XBU=] \/Z[KT6DZKKTF
MB:-J>KQZ'H4$-UK>M/IME/>)I.C6UQ/:P7&JZBT(L]/@GNK:&6[FACDGA1FD
M79JO:7EI?P+<V-U;7ELSS1+<6D\5Q TEM-);7$:RPL\9>"XBE@F0-NBFBDB<
M*Z,H /S0N?VA_'W[=O\ P3B^(?Q._8_TN70OC%X_\'>*?!FA^$=5\3:9IFN^
M$/%]KK(\/>*M#;Q+<'3M,TSQ)'X;>]U;PGJ=[)H]N9M2\.ZA<W.CQSM<VO9?
M#'_@FM^RSX,_99TW]F;Q!\)_!'B2QO\ P:FD^._%]SX?TN?QAXB\9:AI\(UW
MQS!XJN;%M;LM=764_M#PY>P7$,GAV*STFSTQ+:TTVUMX_D3X$A?V%O\ @IS\
M5/V;YUATGX#?MR6=U\<O@DAE\C2O#OQ@TF*X;Q[X/LHF,5G9-K0BU:2*UA51
M'86WPWT6Q1Y9FC7]P* /QJ_X)$PW6L?LP_'?]DKXO+9>/[;]FG]H3XQ?LWZC
MI_B*SM=6TG7/ NGW%O(FFWUC>_:XKK2I=2U#Q/86^G77VJUM](ALK&VE:TAB
M@M^'E_X)@?M1_LU^/O$6N_\ !.+]KB+X*_#+QKJLFJZW\$?BEHTGC?P7X>O+
MC:;JY\,_VMI/C*SN&98;2TM+BYT'3?$\.G6L%C?>,-6@AB1?D/X=?M;_ !"^
M"W[0?_!0S]G']F?P->?$7]JSX]_MI>/)?AAI$UD\OA+P'I16\B\4?%/QGJ-T
MOV :9H4L@N+>PNIQIRS6TMYK!@TJT%CJW[B?L3_LK7G[*OPMU31/%?Q&\2_%
MKXL_$?Q3>_$OXS?$+Q!JNI7MOXC^(FMVMI;ZK-H.GWTI33-&M(;.VL;20P1:
MCJD=LM]J7E;K33=, ,#]BS]BZT_97L/'_B_QC\0M9^-O[0_QKU>S\0_&?XS^
M([9;.]\17FGI<1Z1H.@Z9Y]W_8GA;08;J:&RLUN9)+J1O-=;/3K;1M#T3[DH
MHH **** "ODKX??M=>$/'7[6'QR_9&G\-:_X6\>?!OPMX,\9V&H:[):)8_$?
MPQXFL+&XU77/"MO 7E_LSPQ?:QH>DWEQ/*[W5YJ,BK#;/8W4:_6M?C!_P5(T
M#6OV?_B%^SC_ ,%*/ &F7M]JG[/'BJQ^'_QRTK2T"S^*/@%X^OI]+ODNWRJR
M-H&JZS>V.D+<B6VMM5\96NKS*JZ+&P /5/V3/V'KS3_BI^TS^TA^USX+\(>/
M?CG\6OC+XQM_!MSKRZ+X[T7P?\"]&NHK'X>:3X1COHKV+1H[[2X@LPGM[+74
MT2QT/3M5MK.\AU*.Y^?_ (3?#?1/V,O^"OVJ?"WX5:;#X4^"7[8?[/>I_$'_
M (0'2$2R\+:!\3_ .K:G<7DVA:5$%ATZVM=,TC7+RUL+4)862^.KVPL+>VT^
MPT^UL_VS\/>(-&\6:!H?BGPYJ-KK'A[Q+H^F>(-!U>QD6:RU31M9LH-1TO4;
M29?EEM;ZQN8+FWD7Y9(I48<&OPL_X*1?'_P/^RQ_P40_8A^/'Q!AU6?PWX.^
M#7[22SV.@6+WVMZ_J>I^%+_1?#7AO3XEVHUSJ_B+6-/T^WEO)8=/L)+XWU[/
M;6L<\R@'T+^U?_P3#3XD?%>W_:?_ &2_BQJ/[)_[3T!G?7/%?A>SF/A#XD?:
M'@EG'C71-/GMT%[?2V\7]M:@MGJ^G>)(@P\4>&]=NC%>V[_@/^P3\?-7^-?@
M;]H_]OC]HJP_:*^(GPAM+B#X,^"O"7AFR\*?#'P)K-Y%';ZAXZFT^RT?PY:Z
MUXNOX[>TN8IH_#&D1Z=J-M;737&IC3/#T>AQ?L9? G]H7XN?&!?V_?VP[[6_
M"'CW5/#VKZ!\ OV<=,U34;'P[\$?ACXGC07/_"76"M:G6?&_B6R2UN-4LM7M
MO,L[B.WU'6[2#7;30M#\!_K10 4444 %%%% 'R-^TW^U_P"#/V6/%W[.V@^/
MO#NNR^'/C_\ $]_A>WQ!MI+6W\*_#W5KC3TET.?Q3<W!+XUW4KB"VM84\B&W
MTFQ\2:[=7L<6A?8[_P $_:2_9 \7?M2_ML? 37/BQI.E>)/V.?@I\,_$/C1/
M"%[J5G<6'BO]H6^\1C3++3?&'A.26.XU;0[7PJVEZWIMQ/;:AI!?1M<T'43%
M:>([NQU/W7]O#]F6R_:X_9:^*7P9*Q1^)M1T@>(?AUJ3F.-](^(_A=CK'A&Y
MCNI2HLH+^_@.@:M=(RR)H6LZK&C*9,UY]_P3/_:<O_VHOV4O!OB'Q=+=+\7/
MAS<WGPA^-.GZG%);ZQ;?$3P-';65[?ZI;S;9H[WQ'I,ND^(K[,444.J:GJ.G
MHB/831Q@'Q-_P5L^!O@CX"^$O@_^WM\%O"&@?#WXI?LR_%[X?WVO:AX+T?2_
M#B>+/AUX@UZ'0M0\/ZY::9#96^JLVJZCINFP274<S#0]<\1:7,'L[\^1^A'[
M8W[$?P0_;G^'5AH'Q!MI]*\2Z,G]K?#3XL^&4AM_&G@;4+A8[B.YTR]=5.H:
M%?LEN^K^'+Y_L&H"."[@;3]:L=*UC3O"_P#@M#9_;?\ @FE^TJ@$>^&#X3WB
M-(N=GV/XX_#.XD*'#%9'@CEB5AC/F%6(1FKX]\+ZM\5?^"N^J>%?"GAZ7Q=\
M(?\ @G5\*6\-V_C7Q+:RWWAWQK^U)X]\*PV$D_AS0+I5M;_3/A[H&L6@$EVB
MQ217%O'J5VG_  EITS3O 8!U]K_P3B_X*#?$308/@%^T?_P4%?QO^RO%=64.
MNZ?X9\)167QA^('A?3YTG_X1?Q#XQU+23K-K:ZG@K>W.M>,_'P55BCN;/5;>
M*&"+]M/!OA#PW\/O"/A?P'X-TFVT#PCX+\/Z/X5\,:)9^9]DTC0- T^WTO2-
M-MS*\DS16=A:P6Z/-+),XCWRR22,SG?@A2V@AMXC(8X(HX8S---<2E(D5$,M
MQ<22W$\FU1OFGEDFE;+RR.[,QEH **** "O(?C]\7;/X!_!3XH?&G4?#FN>+
MM/\ AAX,USQG?>'?#BP-J^IV>AVCWES' ]RZ6]M!!"CW6H7TN]-/TZ"[OC#<
M?9_(D]>JCJ>F:?K6FZAH^KV5KJ6E:M8W>F:GIU[#'<V5_I]_!):WME=V\JM%
M<6MU;2RP7$,BM'+%(Z.I5B" ?FA^UI)\2_VZ/V%_ D7[)>I/%H?[2^L?":U\
M;:W%JUCI&M^&?@?XNU*'_A9,JFXN;:.YU'P^!'H_C'P];W/VR]T6'Q5I$,%]
M,QT^[O?&_P#X)=_LH^-/V4=?_9^\$?!GP1X8U+1/!E_%\,_&FFZ!I4/CS2O'
M6G:9))H7B#4?&*P6^NZW=:KJ\%J/%:ZIJ;1>(;*>ZM;UHT-O):^"?\$UM5U#
M]EWX_?M*_P#!-3QA?W4NF?#S6[SXW?LRW>H/*ZZK\$_'5[#?:CH5E<W##SYO
M#&JZI8S7B1&:2[\0WWCF96%OI3;?VJH _*+]@"X\,_MW?\$R?A5X;_:,T*S^
M)-EJ?AS7?AEXXM/$(DFNM1G^'?B;5O"^@:V=2CDCU2T\41:)I6@ZLGB.UN;;
M7+;7C)JD%ZE[BY;YZ\/_ /!/#_@HW^S,]W\-/V+OVY/#>G_L[ZG-?MIOAWXX
M>&U\0>,/A=:7DD[+:^"6;P5XRTC4)(WNKB\D>PN?A]I-UJ+?:YO#YNGENG^'
M/V)?VJOC#)^SG8_L*?L6Z++J/[3/CCXL_&75?$WQ!U"TGB\#_LX?"S4/%S6T
MOCO5[^6UGM&UEXVE.@VD4-XEG<RVLB66J:[J&A:#JO\ 2#^RU\ +/]F/X(>#
MO@];>-O%_P 1KK0$U*_UWQOXWU6]U36_$OB;Q#J5UKGB/50M[=WITK3[S6;Z
M\GT_1X;FX6QMG475YJ6I27VJWP!QW[&W[)'A/]C_ .%MWX*TG7]7\>^-_&'B
M34O'WQ<^*GB4$^)?B5\0]=*/J_B#4=\]W):6:E1;Z5I9O+PVEN)+F\O-1UB_
MU;5=0^M:** "BBB@ KY"^ G[7GAKX^_$S]I_X.Z3X5UCP;\1/V9OB _@O4]"
M\875M!+XITB\M)SX;\>V"6*7,UIX:\1W^GZG]B*1ZC-'HG]B:Q,RRZ]!IMM]
M>U^(G[;L+?L6?MS?L\_M_P"CVXL/A=\6)K3]F?\ :PFA=H;.WTW6OLP\"_$#
M5E16R-%BTNVEU&_E_=):> ="T:!5N]:#R 'M'[!/[!EG\/OAIXN^('[7'P]\
M%?$+]JKX[^+_ !CXN^-6M>,+#PU\0TM;?4M>U&'1?".AWURFL:5!X:_L..SU
M6?3]-<0M=ZI)IMT9;31]*M;#Q?\ 85\%6'[)_P#P4<_;/_8]\$>?IWP:\7_#
M_P &?M/?#'PDUR\]AX1^U7FB^%_%MEI<<LCRV]M)K'B6'1H [2RG0_"_AV*X
MF>6V\R7]N4=)$62-E='571T8,CHP#*RLI(96!!5@2"""#@U_/)^UY^U+X<_8
MX_X*QZO\4-3\-^(?&>N^*?\ @G[HW@/P#\/_  O9W=[K7Q&^)?B3X\2?\(IX
M4M7@MKTZ?%>MX>:>[ODMY7CM=-GCT^RU76;BRTG40#Z+^/G_  2V\5Z?\8[[
M]I;_ ()__'"3]DCXQ:\Q;QQX;M=,-Y\)/'D\EP]U-?ZIX;AM]1TRREN;IEO-
M3TF^\+^)O"^IW\46IQZ%IFKO?:E?^M_LN_L+?$_PM\:7_:N_;'^.*?M%?M'V
M7ANX\'> Y='T*#PS\./A+X;OHI[;5HO!NB6]IIL4VL:S;7-Y;W>L1Z+H"+:Z
MGJT,NG7MY?S:HS_V%_V9_CGHWC'QG^V'^UYXPU+5/VEOC3X=M] _X5SI&JW<
M'P\^"/PR748-<T?X;:1HMO>3Z9?:M8W4,%QJ5_*]^-.O3>Q6=_J&IZCXD\1^
M(OTTH **** "BBB@#Y*^*_[77A#X._M+_L\_LX>+?#6OVLW[1EEXR7PI\197
MM;?P?9^)_"\-K+9>#I6<O=7FMZXUQ';(D8@2SN]2\.P*+TZS(VG?/7B7]C7Q
M%\<?^"A>L_'C]H?P_H/C3X!?![X4^$-%_9H\):O>:=KOAU_'WB">ZO/B!XEU
M[P;<B4)X@\/7M@!;W.JV$NG7]KJ?@[4-/O+S5/"Q@T#HO^"HO[-^M?M"_LL:
M_>_#_P"VVGQK^!FK6'QU^"VJZ/&#KT'C3P DVI2Z3I,B*+AKS7M'%_9Z9;1R
M)$_B6/P[>S)*=.B2O>?V-/VD-&_:S_9J^%7QUTE;6VO/%_AZ./Q7I%K*LB>'
M_'&C2R:/XPT4+YCS1V]KKMG>2:6;H1W%UHL^F7[QJEVF0#\POV]OA!X)_9-_
M:K_8<_;5^#?AW2/AQ>>(/V@_"G[._P ;+#PAIMIH>C>,?!WQ*M+RUCU'5=%T
MZ*UTN;4M+\/Z9XGMGOYK;SKZX7PNUQ<)/H&E30?:_P"W#_P3P^%G[9VG:+XC
M;5M2^$OQ\\#-;7/PW^/'@N)H/%GA^XL+AKW3[#5_L=YI5UKNB6E^?M]A"NJ:
M=JVAWY>]\/ZQI;W6HQW_ ,Z?\%O-8T[PW^RY\(O%&K;$T[PO^UQ\$/$-[</'
M))]EL]*A\875Y<*(8;B=2MHDZ$V\$LS([QQQR&3RWXCX9V7Q?_X*I?&'PE\>
M_%Y\8_!W]@CX->-;/Q3\"O 4-Y?>&?&O[1'CCPIJ/FZ5\2_%4]A/#>:=X4TS
M4+;S-,CMKC; %ET?0KB749?$/B*  L:7_P $XOVT?C=/X4\ _MX_MHV?QD_9
MT\#Z[8ZX?AIX$\+0>&]:^*SZ)-!+H.G?$[Q/;Z'X<OY]-MY[2WO;Y+RY\7:G
M<S&Y-OJUGK#VOB.R_;FVMK:RMK>SL[>"TM+2"*VM;6VBC@MK:V@C6*"WMX(E
M2*&"&)%CBBC58XXU5$4* !-10 4444 %?.7[6?[1-C^RC\ ?'OQ[U3P3XE^(
M&F^ H=&N+_PWX5:TBU26UU;7]+T*2_DN+UO)M--TK^TQJ&J7GE7!MK&WFF,)
MC222/Z-KF?&GA#P]\0?!_BGP'XMTZ#6/"WC3P[K/A7Q'I5RJO!J.AZ_IUQI6
MJ64JLK*4N;*ZFB)*G;NW#D"@#\\?VV?A?XX_;Q^!?[.WA/X(>((+KX _&3XG
M?#+QC\<?$.E:Y;Z-K&I?L]3:9/XHD&DI=RP?;%U"Z_L=KC3[9YM6M]6CT@G3
M;JP@UE8,;]N__@G[^SWX_P#V+_B+X,\!_"7P)X&\3?"?X=ZQXO\ @[KGA/P[
MI6A:YH/B#P%H<^L:;I2ZY:00ZA<:?XGATO\ L'7SJ=W>B[6__MJZ$^LV%C?0
M>;?\$H_&/B/X1:M^T!_P3F^)^K76H>-_V4/&5_J/PRU'48VBN?%GP!\8WL>J
M^&=6MU;<TB:9=ZO:WEP-XM].L?&?A_0[(-%I;^7^LWQ"MX;OP#XXM;A!)!<^
M#_$UO/&2RB2&;1;V.5"5*L Z,RDJP89R"#@T ?"O[/&D>!/^"A/_  3I^"</
M[0WA^T^(>G_$;X7:);>+Y]2^74Y/&WA07GA'5?&FDZG#LN]$\4'7='U+5+;5
M=-DM[BUGO+B!<VD\]M+\;^&/^";W_!1'X(V5_P#!G]G7_@H@WA[]FC45GT[2
M[+QSX*@\0_$OX>>'[UQYEAX+O)=-OS975A;--!:2^&O%W@'37GN)]3L](T34
M6AFM_C+]AGX]_'C]HK]COX!?L!_L>_VKX%\2:3H7C=OVI/VDKFSO(M+^!_@?
MQ'\6?B!J&G:!X+N1]C?4_B3XT\-W5O>Z9+I]Q%-I]M??9](OK6^MM>\3^!OZ
M5?@1\&?"?[//P?\ A_\ !7P/<:Y=^%?AWX?@T#2;SQ)JUSK>N7D:2S75S>:C
MJ%R?FFN[VYN;A;2TCM=+TR*6/3-&L-.TFTLK&W .._96_9C^'/[(OP9\/?!C
MX:1WT^EZ7/>:QKWB+694N/$/C3Q?K!BDU[Q;XAN8T1)M3U26&&)(XU$%AIMI
MI^E6H%I80*/HNBB@ HHHH *^ ?AK^UKJG[8?[*'QW\>_LR^']2\.?&KPHGQC
M^&>@> _'-SI>F:]X9^+7AFPU&#P?#KS222:597&HI=^'=<2*[N/[+M+V[GT2
M^U3;IM_J"??U?B/<-_PPK_P57AGW'3/V??\ @I%IZV[PQQM'I'AS]I[PQ-;Q
M13/]](9_&]SJV"ZE)M8U_P"(DSR(MEX;5XP#W/\ 9(_X)H_ 'X>_LN:#X"^-
MWP=\&_$7XJ?$GPO#X@^/WBKQ[I.F>*_&>J^/_%MF-2\3V$?C*X-[JUDGAC4;
MV?2M%U#P_JME(MS8?\)+!<#7=0O-2G\9_P""3FEWGP]N?VY/V#_%5U)XQ\%_
MLS_&J72O!EKXHM[;45N?A/\ &&V\2WVDZ'J-I,DMA=V&IVV@:AK.HZ?)"]L]
MYXEU2.2,VUQ'!'^U=?S/Z[^V(O[)?_!1;_@I=H?@GP!J_P 5/CU\;=5_9=\)
M_ 7X8:+97<T?B;QG;_"F26^OM<GM53[)X>T0Z]:ZGK)CNK>]O1)':P26=O-?
MZWHX!],>)O\ @F!^T7^SI\1O$_Q'_P""8O[2&C_ W1?'NH?;?%GP$^*=I?:W
M\);>ZEB,4NI:!-_8'CKRFMLYTFROO",VJ:4ADL;/Q;#HK1Z1!]=?L;_L4>*O
M@GXV^('[17[1'Q5?X]_M7_%G3K30?%/Q!CTR+1?#'A+P;836T]IX$^'VBQ6]
MG'I^B/<6.GW6HSII^E17DNGZ>EMH^G>1>3:GN?L*?LT?%CX(>'?'GQ&_:)^*
M>N_%#]HKX_:OH_B_XK2/J]Q/X%\'W.E6M[;Z'X+\!:*K)I=A8>';'4IM-N]1
MTZUM8-06VL;*R@BT?1]*6OO*@ HHHH **** /DG4?VNO".B_MF:%^QIKGAC7
MM%\3>+O@_<_%7P7XWU&6SB\->,+G3]5U"VU7P=H,"-)=W.K:9H^DZIKMW/(\
M(C@TR^A>T5%L[J]^<OAU^Q;K7CG]N']I+]J7]J?PIX;\;V5E+X6^'7[*.C:W
M/I/B[PUX:^&-EX>ANM?\0V?AV[6[32->U/7+VYM9?[5L;34;#5Y?&=SIPN=(
MUO3M2N.7_P""MWP@\4W/PH\ _M??"*R5OC?^Q/XTLOC#H<T0D636/AU9W-G<
M?$?PYJ"P!'O=&33["S\0ZI;33+&=!T?Q#8PJQU>>&?\ 1GX)?%SPK\>OA%\.
M?C+X)N!/X8^)'A+1O%>EKYL<TUB-3M$EO-'OFC 1=3T/4!=:-JT.%:VU*PN[
M=U5XF4 'Y _%KX4^%/V.?^"JG[(7Q9^#VA6/@3P3^U]9?$GX,_&+PAX6MK;1
M_#.I^*--TFRU3PWKRZ+:I#I]C?:QKNH>&M0OOL$$4=U=>%KZ^:)-3UK4[K4/
MI[]M;_@FQX._:=\3:%\;OA9XXUC]G']JGP<\,OAWXW>!8[BVO=7CM;9K.VTW
MQG:Z5?Z1>:F(;(MIMEKMIJ%OK-CILATVZ;6=#BCT2O ?^"O7Q%\)_![X@_\
M!.SXM^.;N;3?"7PY_:D/BGQ)J=K97&H7MKH6D:-9:CJ:6EI:1R75U-/;V>V.
MS@!:ZE6*,C@,M_\ 9F\#?'K]N[XW>"OVZ?V@QXK^$/P+^'=]=:W^Q_\ LZVN
MJ7NCZKJ45_9W%A%\8_BF]A-;R74VNZ3=RC2])=C;ZQIUV8$4>"&=O'X!:\ ?
M\$]/VJ_BSX_^&?BK_@HA^U3I'Q]\&?!37K3Q;X!^$7@/PG8>%_"/B'QKIDKR
M:'XN^(]Q9>'?"46O3Z+'+-;1:5)H-XU[ WDW&MQV%[XAT[Q!^R]%% !1110
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MM4M1M G71;W6+"\U%X_+M]/'C;2=!@A1M(N%0 ]5_;@_X)\_LZ?$#]C3XB>
M_ WP>\!^"_$?PP^'.N^)O@YK/A/PYI>AZ[X?\3^"]#N-6T>Q37+.VCU2[LO$
MDFFIH_B,:E=7S:G'?2:K=^?K-M9W\&Y^R_I7@C_@H'_P3>^!]M^T5X>M/B-I
MWC[X:66D^+9=8!_M.Y\6>";S5/ ]YXST[5(2E[H_BJ35-"O-6@UK3)K6\MKN
M\N!$R0330/\ ?GCV))O WC2&2-94E\)^(XGB=!(DJ2:/>*T;(P(=7!*LA!#
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MGPGI7BC38Y75[G3VOH!_:&BWY0!!J>@ZFEYHNJ(F4CU&PNHT+*H)_*O_ (+
M^/O"_P )/%'_  3R^+?C*]ETOPS\.?VQ/#/B;Q+JL%K<W]Q8^%]+T\:GXB>"
MPM(YKB\E;3]/8I;V\$ES*Z+';X=^0#WW]M?_ ()M^"OVH_$6@_&GX;^-=9_9
MV_:F\%/;3>%_CCX%BF@U#45L(6@LM-\96>FWVD7>K1V]L38V&MVNHVNN:;8L
MMA+-JNAPC0I/#_ W_!/#]JWXO^-_ASKG_!1/]JO1_C_\/_@UX@M/%G@CX/\
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M>:-I5QX>_M&9GFU;4_">K:G)M%VF0#Q#_@J[^QI\*?#O[+]U^T5\!?A_X/\
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MSMHX5X^[_P""7O[2_P"SA\0_$GBG_@F]^UE'\#/A]XVU,ZKKWP-^)FC2^-?
M.CWTXB%Y=>'AJFF>+[24O';6MG9377AVU\3V6FPII\GC*\M4BBC^2/"'[6_C
MGX%?M2?\%%O@3^SMX O?B3^U9^T!^U4UI\)/#8L'/A7PM9VFCZJ/$GQ,\9WL
MHBTZ+2/#WVV.^D@N;B&WN98Y+[6;BVTBTNGG_;']B+]E+4_V6?AQKUOXW^(_
MB+XM_&CXK>)I?B/\;?B#K>JZC=V.N^/=0LX+6YC\-Z9=NL.F:'I=K!#IMG.+
M2VU#5(;:*XO8[2TCTO1-& ,;]B[]BV/]F!/B%X_\?_$?6?CG^TA\;-2L=8^,
M/QF\0VB6$^K'3$EBT7PQX9TE9KE=!\*:%!*8;:SBFS>/';L8;#2M/T'0="^Z
M:** "BBB@ KY&\&?M?\ @SQ7^U[\7OV.;WP[KOA;Q[\,O!'A#Q_H>KZY):1Z
M7\3/#WB"RL[G7;[PC#&3*UKX4N=7T;3;J2:5[B_O7UL16EM#X?NIIOKFOQC_
M ."J_A;Q%\$_$W[//_!1_P"&EA>77BG]F#QAI_AGXNZ;ID2&X\6? #QSJ+:7
MKVGWA+*9ETF^U>]T_3UDS;Z>WC:_UZ=HSH\4L8!ZE^R[^Q%J*_'3]J?]IO\
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M?BUHUU(K:E%-X+EGTGPGK5TH+-,FHZ'IIT>?4GDD.K:]X:\07JL5<5]O:_\
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MB_\ #?2K<GPC)X1U&>.U@U#4M*\.):PZ7;1Q13^(?"-OIFKVD=QJ=KXGM]-
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M>(]9TN.]BM9H+J>U,L-O<VTKI<1_,/\ P3T_X*'Z5^UMI>L?##XIZ!_PJ/\
M:R^&4;VGQ/\ A+JUI>Z)-?BR>.WN?%GA'3-9<ZI_9+RR0C5]$NI+G5/"UW<0
MP7<U[IEWI.L:EZOK=M^S=_P4X_9RT<^$?B)=>+/A'JGCKP3XFO[CPI,FGWL^
MK?#OQ-HWBR7P+XTT37=,DOM-6[:VM(-:T/5-.LM12TO+'5;&18Y-/O)O#_\
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MLYM4EOOA;J!N4U0P7836?!$E[?VMC%;MXAT76=RW:SVFD_H]^R;\2?'/Q?\
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MOC9X)_;E\+6,<6K_ !3^"3^ [;PMKMG8QQ1OJUU\-1H&DV6IW46F6T,ZV_\
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MOQ1??L__ !4TW4)_.U-_^$1DGL/"&NSEQ]HE@O\ 1+%M#;4;DO-JVL^%M;U
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MN[NYEBM[:WBDFFD2-&8 &C7XD_M??\%5?%_[+7[8R?#C_A5,_C/]FOX8>%?
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M5MK7ASQ'HMR+K3M4TZZ!\N:&0!9(I8I%DMKRSN8X;VPO8;BQOK>WO+>>"/\
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MR^)G@:.VT[7+G4[5E22RNO$=J^F^+#9R1H]DNO"R<>9;25\(?"?P#8_L._\
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MS2QK(;>Y6&6:%9X2QCF$4TL8D5@DLBX<@$RJJJJJH55 554 *J@8"J!@
M # ' I:** "BBN6\;>-_"'PV\)Z]X[\?>)=&\'^#?"^GS:KXA\2^(+^WTS1]
M)L(2JO<7EY<ND48>1XX((P6FN;F6&UMHY;B:*)P#J:_#KQ;_ ,%@[7X5_MP_
M$+X-?%3P%'HG[*?AOQCI_P %;+X]Z?::S<KX=^,ECHUEK/B-/&-]F31ET-9M
M3DTJ72K&&/6=%L=$?Q.\FI64VI6>E_8_[//_  4\_8M_:A^(]Q\*/A'\61J'
MCEA>R:#H_B+PSXE\'MXRMM/MWN[R?PE+XETO34U6:"TBGO'TA_LNO_8;6\U
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M1=:T^*95E5P/I.@ HHHH **9)(D2/+*Z1Q1HTDDDC!$C1 6=W=B%5%4%F9B
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M.6UMY)X].L!=SVMJ;V]>,6UJ+FZMK<SRQB:>&/=(M^B@#\Q?#_[2GCO]OO\
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MQ!\':GH-E>W(,T&@^*HH8-9\'ZW=11)+*#H/B2VT+7O)6,S216L9C7]ZA/\
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M?P%X@>Z\O7)+O3_%,7B?P'.@U.VMKVTL+C7+79T'_@E]^V;\#HM9^%O[*?\
MP43\7?#C]G#Q%+,B^$?&G@G3/&OC/P'IVHS7(U*S\#:[<;1I$XCN9KZ'4/!M
MW\-IKG4YFN;A(K^/^UIL']LGXN^!_P#@I_XS^'O[#'[+ES'\3_"FC?$OPK\2
M_P!HKX^:''<W/PW^&?@OPLVI(-(\-^*H%2TU_P 8>)1=W-OH]UH=V^G3.L=A
M8ZC>)/K]YX8_?&@#YS_96_9A^''[(GP<T+X-?#--1N=,L+N^USQ!XCUR=+OQ
M'XT\8:R87UWQ;XBNXTBCFU34VM[>%4BC2"RTZST_3;91;V45?1E%% !1110
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M;^/[33/"=MJ?P<L8+*)8HO$'A#5]8N-1M?$-M]M#"SU>QU&&UE:S6>V^"_\
M@K]I/P0\+>*_V)?#7PM^'0N_VI]"^/7@;Q9X"\*? _PCIS_$Z/X0>#FU'4-<
MM++2=$2P"Z6^OZ;H)\*6^I26EG;WVE:U?Z9<6UAI7B;/TS_P23^*GBFU^&_Q
M,_8O^+5Y+-\9OV)/&]Y\++^:Y$J?\)#\,)KS4&^&?B32_M"QS2Z0NFV5WHVE
M*J2"'PS8>%KR:9FU>(5^@&L_#SX ?#7QUXT_:C\2Z)X!\%>-[CP=8>'O&_QF
M\2W5AHLEGX+T.0/;6NI^(M8NX-,T738V-M'?72O8MJ$=GI-OJ5Q=1:5I<=H
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M^.O%6OPV=O+X]\?WMIMU/0M0UF-I?#EO/:7+6FEZE::#X=\!?K?110 4444
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MO-$N)K-]*AL8;+1[J]FL;B:0S30^(%T#0M> *>@?\$QOVAO@A?:EJ'_!.O\
M;OUKX0? WXEQ2:\WP\\:>'=+^*OA[0[77A#?0:I\/]1U:#5].>.[L+B)=/UJ
M+2]*\5&PM=/%_P",-=ED-[#^CG['7['_ (-_8_\  &M^'M)\1Z_\1OB%X_\
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MKVPU#3[N*>&1+>\LKF.5(I5 /YF/V'/VE?C%^SWX7_:K\0_L;_L._%G]H/\
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M\ :CKGB'P=J_Q _:W\=^/[;2_%5WXC\3>(DGU3Q-IVK>([I=0NM<BTBYOO\
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M+;)GT;Q1H]YH>II$Y!"2M97TZQL0=K$'!Q7X!? +XQ_MT_\ !-;1[O\ 8_\
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MP>!?"6A>%DUG4YGD=KS4QHUC9_;IH_-=+<W!D%K 1;VPA@58U]-HHH ****
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M=(2\NOB)X2L.8[.T;685OY5MX1%Y-J?AIX?M+>5YHG.)^WC_ ,$Q/V4/AO\
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M+<S6T"W5VMAH&EVDD<=U?RCP_K&EV[-=>*H8F_5F@ HHHH **** /F/]K_\
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M/#NM*GE+K&A#7M/O_P"R-46/]V-0T_[/=A/D$VWBNZ          P !P  .
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MSZEX*?5)_LM[IC:CXBM=CS::)I?OC]E;Q#\6_%?[.7P9U_X\^%[WP=\8M0\
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MSP[XATZ'4-.O8ED7;/9:EIMW#,BR)B2"8!TY*UE^ OAG\./A5HC>&OA?\/\
MP1\-_#CWD^H/X?\  7A30?!^B-?W.W[3?-I7AZPTZP:\N-B>?<F S2[5\QVV
MC'Y[_P#!*_P]\=?A1\'/B+^S1\;O#.OVL7[-7Q;\3?#CX6^/]4LI+32_B3\+
M[AD\0>&M4T&:XV3ZE9Z:FIRQ0WL4*V-KI5[HVA1R?VCHNK6MG^GU !1110 4
M444 ?G)_P4D_:+^)?P9^'/PM^&'P*N]-TKX\?M4_%WPQ\!/AKXGU=D&G^!)?
M%,HM]9\=R0R6]U'=7&AQW%A9V,3PRK:WNL6^KFWU :6=*O\ TGX.?#;X*?\
M!/;X&W=OX]^..J#2;[7W\1_$#XO?'[XFSM-XM^(.NV]O!J.II/XJUI]*T:YU
MN2Q067A[0O\ 2+LPHUU)K6KFZU.Z\H_X*A_LX_$;XY_ GPUXV^!GG_\ "_\
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M6VI1>(KV6XM88;6QO9=+T37=+T;1I-=UJ*7U;]D?X0?$S]E+]N[]J?X,>'O
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MBKXE\4?V:C0Z3HND6+WNK2>&O"NF0E?LVAKK.JN9$@6?4);'3M$L-)^W***
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M4I=/NHK3S?.EC\M69>HHH _,G]D7]E3XV#XV>-/VU?VS=4\+:C^T9XR\-0>
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ML>IZS!HMK/-;:3%J-U<QZ=!-+#9K#'(ZGHZ** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KPS]H'_D3-._[&6S_P#35K5>YUX9
M^T#_ ,B9IW_8RV?_ *:M:H 7X ?\B;J?_8S7G_IJT:O<J\-^ '_(FZG_ -C-
M>?\ IJT:O<J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O#/V@?^1,T[_L9;/_TU:U7N=>&?M _\B9IW_8RV?_IJUJ@!?@!_
MR)NI_P#8S7G_ *:M&KW*O#?@!_R)NI_]C->?^FK1J]RH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\,_:!_Y$S3O^QEL_\
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MI^H6\LUO-<Z;J-LS1SVDL8[#X@_M0?"CX9?'+X-?L\>*;W6H?B3\>(/$EQX
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MNDZ%!:Z#IZ:KKVL:UK4SQ6.EZ/ITMU8PW-TT,-W?3":\MHH+"QO+J254@8$
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MF[_PD/B?_P#/AH_X?S?M??\ 1./V;O\ PD/B?_\ /AH_X<,_M??]%'_9N_\
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MQI\9YO#5V]EJ7B&2+0)K;3O#/@Z\N$6VBCM]/?6=/OX[_3SJ&J2V<\EKA_\
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MB:?I<<3:UXT\8RV5Q8W<^CZ9+=6J#3HM5T-KJU76-2.L6\.A3V]WA_!C4/\
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MP!^U5_P40_;IG\:?$/\ 8LT']G;X/_LX>&?%.J>%? ?C;X^V_C?6?%_Q@O\
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M6A:3J/P9NM3O8K&W!N;O[':)+<O;VR2W,L<3K;PS3%(G]6_X*Q?M6_ 74_\
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M$[XY_P#GC4?\/8/VB?\ H3/@M_X3OCG_ .>-1_PZ?_:)_P"AS^"W_A1>.?\
MYW-'_#I_]HG_ *'/X+?^%%XY_P#G<T?\=:?]5S_Y9>7_  /Q\P_XX[_ZH'_R
M^#_A[!^T3_T)GP6_\)WQS_\ /&H_X>P?M$_]"9\%O_"=\<__ #QJ/^'3_P"T
M3_T.?P6_\*+QS_\ .YH_X=/_ +1/_0Y_!;_PHO'/_P [FC_CK3_JN?\ RR\O
M^!^/F'_''?\ U0/_ )?'4^#_ /@K/\5(-:M&\??#CX?ZIX=:>%;^/P?%XCT'
M6HK5F9;B:TGUKQ)XCL;B>-666&VFM[:.9HV@>Z@$PN(/VAUC7]+\5_"?5/%&
MAW'VO1?$GP\O=?TBZV-']ITO6/#<NHZ?<>6X#Q^=:7,,FQP&7=M8 @BOQ/\
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M3:AJVN_MH:;>^!M4\/W\'[]-7EU:R;1I-/F@D,5[:ZD!&N7@NXE=7C ![O\
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M%>FSZ1XB\-Z]9Q7^E:KI\^TM#<V\H(#QR)'<6MQ$8[FRNX8+RSF@NK>&:/\
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M^'M2A%W:6]]IY<SJ;JV@N+7,T4;+RW_!32TT/]GCX[_\$H/C+J1OK?\ 9_\
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MKK+.ESY>E^( +F.PT-]-U#PU?V$ECJ]EJ>EZV>:_:'_;U_:@^'_[>VJ_L@?
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MJVL:E>:!I_@+0O#-EIEU+.VNWUS%J-EH[V,OJG[,_P"UQ^U7X:_;$U+]AO\
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MIXFT;Q!<W=AJWA8PVNJ+;O8VB:I+I.E7^L7FIQWNGKHVK_+G_!1;X9^#YO\
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M%% !7AG[0/\ R)FG?]C+9_\ IJUJO<Z\,_:!_P"1,T[_ +&6S_\ 35K5 "_
M#_D3=3_[&:\_]-6C5[E7AOP _P"1-U/_ +&:\_\ 35HU>Y4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'CT'P!^#UO\:[W]HN/P-IA^-5_X1C\"7'CZ:YU2YU-?"<4M
MO,NCVEI<7\ND:?$9+6+S+FPTZVO94,\4MR\5U<I-[#110!XS\)OV>O@S\"]0
M^(6J?"7P)IO@B\^*OBF?QKX^.EW>K2V^O^*+F:]GGU5K&_U"\L=-DDDU"[)M
M]'MM/LPLB1K;"*"!(O"%_P"";G["R_$E_BU_PS)\,V\<R:NVOM>R:??R:)_;
M3W_]IMJ8\&2:@W@M;W[?_I0G7P\KK+DJ0"17V[10!X[X%_9^^#/PULOB?IG@
MOX>Z!I&F?&?Q=XF\=?%+2Y([G5M,\:^)_&<(MO%%_K.G:U<ZC9/;ZW; V][I
M$$$&C-!)+"FGI'-*K_._@[_@F9^P;X!\777CKPK^S+\/-/\ $MT;\BZN%US6
M+#3VU*&YM[J30]!UK6-1\/\ AV58;N>.SET'2]-DTX%#I[6IAA,?W510!\??
M&7X->%/AC^PO\=O@K\%?!<FD>&](_9R^-WA[P-X&\/1ZMK-S]IUGP-XNN(-)
MTF"XFU/6=3OM3UG4Y?L]OYMW>75Y=B&$.SQQU\"_L0_\$[/V:OC-^Q+^RW?_
M +3W[->FW_Q1\+>$==L+V7Q5IWBKP+XUM[>/X@^+[K3=-\3Q:5?>&M8U2SAM
M+F*?3]/\2QWMM!:7*O:P)!<?/^W=% ')>!/ 7@OX8>$=!\!?#OPOHG@SP9X8
ML8]-T'PUX=T^WTS2=,LXRS>7;VMLB)YDTKR7%U<R;[F\NY9[N[FGNIYIG^9O
M'G_!/W]C;XF_%VT^._C?X!^#]9^*]IJFF:X?%:7'B#2FU#6='>*33M6UW1=&
MUG3O#OB/4K=H+?-[K^D:E<3BWMUN))5MX0GV-10!Y'HOP'^$GAWXP^,?C]HO
M@G3M/^,'Q \/Z7X5\8^.(KG5&U'7= T6+2H-+TZYM);^328H[2'1-)B6:TT^
MWN9$L+=9II IS5^.G[/7P8_:7\&6_P /OCIX!TCXB^#[37++Q+9Z-J\VI6J6
M>O:=;7UE9ZK9WFD7VG:C:7<5EJ>HV9DM[R,2VE]=6TPDAGD1O9J* .?\)^%?
M#O@7POX<\%>$-(L_#_A3PCH>E>&O#>A:=&8K#1]"T2Q@TW2M,LXRS,MO96-M
M!;Q!W=]D8+NS$L?DOXT_\$ZOV*/VA?%=UXZ^+?[/?@WQ)XQU![>75/$MA<^(
M_!^L:S/;21R17.N7O@G7/#DVN76(8H);K5FO+BXLT6QN));(>17VI10!XS\$
M?V=_@C^S=X8N?!WP,^&GA?X:^'KZ\74-2M/#MDT=SJ]^D*VT=]K6JW<MUJ^M
M7D5NBP0W.JWUY-#"/*B=$)4^M:CIUCJ^GW^DZI:07^F:I9W6G:C8W4:S6U[8
MWL#VUW:7$3@K+!<6\LD,T; J\;LK @FKE% 'YSV__!)/_@G3:W:7L7[+?@MI
MHY&D5+C6_'=Y:%F# A["[\63V,D8W';%);-$A"E$4JN/N+X>_#;X??"7PKI_
M@?X8>"?"WP^\'Z4'-AX:\'Z'IWA_1K>24+Y]R+'3+>V@DO+ID$M[?3+)>7L^
MZ>[GFF9I#VU% 'D?PX^ _P )/A'XE^)_C'X<^"=.\+>)?C-XH/C3XG:K97.J
M3S>+?%!FU&X.KWL5_?W=M;3M/JVI3-%IL-E;&2\F<P%F!'AGQD_X)X?L5_'_
M ,8S?$'XL_L]^"?$_C6[>&74O$EO)KOAC4M:F@4)%<>()?".L:"OB&X6)4@-
MQK::A.]O%#;/(T$,4:?9]% 'G_PQ^%7PV^"_@_3?A_\ "?P1X;^'W@O23,]C
MX<\+:7;:3IL<]PP>ZO)8K9%:[U"\<"2]U&[>>^O)1YEU<2R?-7@_QY_8/_9%
M_:;\5:7XX^./P/\ "_CKQ?I%K;V%KXCEO/$.@:M<6%I*9K2PUB[\*ZUH<GB"
MQM'9Q:V>O'4K:VBEG@AB2">:-_KBB@#S7QQ\&_A5\2_A[)\*/B!\/O"GC#X;
MR6%CI@\&Z_H]IJ.AP6FEPI;Z6+.TN(V%C<:7%'&-+O;-H+W3GCCELKB"5%<?
M)?@7_@EI_P $_P#X;^+++QOX3_9E\$0>(],U&VU;3;K6M1\7^+K'3]2LC;O9
MWECH?B[Q)KNA6DUI-:P7-LUOID8@NT-Y$$NI))G^_J* ///BE\)?AG\;?!NH
M?#[XM^!O#?Q"\%ZI)!/>>'?%.F6^J:>UU:,7M+Z!9E,EEJ-F[,]GJ-E);WUH
MS,UO<1EF)\$^!7[ W['O[-7B:3QI\%/@-X/\&>+WCOH8?%#RZYXF\0:=#J7F
MK?P:-J_B_5]?O]"@NX9I;2:'1I[")[!VT\I]A/V>OKZB@#R/1?@/\)/#OQA\
M8_'[1?!.G:?\8/B!X?TOPKXQ\<17.J-J.NZ!HL6E0:7IUS:2W\FDQ1VD.B:3
M$LUII]O<R)86ZS32!3F3Q=\#/A/X[^)/PT^+_BWP9I^M?$CX/?\ "0_\*V\4
MW%SJ<5YX6_X2JR33M>^RVUK?0:=>?;[.-(C_ &G9WWV8@RV?V>8M(?6** /(
M]%^ _P )/#OQA\8_'[1?!.G:?\8/B!X?TOPKXQ\<17.J-J.NZ!HL6E0:7IUS
M:2W\FDQ1VD.B:3$LUII]O<R)86ZS32!3F3Q=\#/A/X[^)/PT^+_BWP9I^M?$
MCX/?\)#_ ,*V\4W%SJ<5YX6_X2JR33M>^RVUK?0:=>?;[.-(C_:=G??9B#+9
M_9YBTA]8HH \@^-/P ^"_P"T5X57P3\;_AMX6^)/AJ&Z%]9V'B33Q<3:7?A#
M$;_1=3@>WU71+]H6:WDO=(OK*ZDMGDMI)6@DDC;R_P" W[#/[)7[,FL7'B/X
M'? SP=X%\2W-K/8/XGB&JZ_XFBL;HYNK*S\1>*M2US6K"SN\*MU:V-];P7*)
M''/'(D4:K]7T4 >1_$/X#_"3XK^+?A=XZ^(?@G3O$_BSX+>(+GQ5\+]:O+G5
M(+GPCK]X^F27.HV,=A?VEM<R32:-I<C0ZE!>VP>Q@=80RDGH/B5\+_AU\8_!
M^J_#_P"*G@OPYX_\%ZTB+J7AOQ3I=KJVF7#PMOMKE(;E'-M?6<N)['4+5H+Z
MQN%2XL[B"=%D'>44 ?%GP?\ ^"=?[$_P%\86OC_X5?L\>"/#?C/3YY+K2O$=
MV^O>*-3T2ZD4HUUH$WB_6->&@W2QL\<=QHZV,T,<DL<+HDLBM\!_MV>%O''A
MC]O?X*?M ?%[]G7XF?M6?L?^$?@]K/AS3O!/PW\$Q?%6'X;?%C5M1UB/5/&G
MB'X67%T++5Q-H\VDQOKNIVZVT=J+22Q>;6?"FG6MS^Y]% '\T/QN^'WAC]N7
MXB?LYZ'^QQ^PA\4?V:O$7P_^,_A/QYX]_:=\9? O1_V==-\(>"O#3W5S?>']
M-NK%(I_&NO&]N=,\0Z;IB^?=Z9?:=IZ65L;?6M4OM._H"^(?P'^$GQ7\6_"[
MQU\0_!.G>)_%GP6\07/BKX7ZU>7.J07/A'7[Q],DN=1L8["_M+:YDFDT;2Y&
MAU*"]M@]C ZPAE)/KE% 'C_QI_9_^"W[1?A5/!7QO^&OA7XE>&X;G[;96/B3
M3UN)]+OBOEM?:+JD#6^K:'?/%F"2]TB^LKJ6W9[>25H)'C;P7X-_\$XOV(O@
M!XOL?'_PH_9Y\'>'?&>E7,]YH_B._O?$_B_5-$O+DS^9=Z%/XTU[Q%_8ETJ7
M,\-O<:4MG+:6S_9;5X;=$B7[:HH ^-_CS_P3Z_8W_::\76WC[XV_ GPSXR\:
M6ZV$<GB>'4_%/A36=3BTN%;;3X/$%[X+U_P[+XEMK.U2.SM[;Q"VIP1V4,%F
M(_LT$,2>]?"+X,?"KX">"K'X=?!OP'X<^'7@O3YYKN'0O#5@EG!/?W*0QW6J
M:E<,9+[5]7NX[>VCN]7U:ZO=3NH[>W2XNY$@B">G44 %?)'QT_8._9!_:4UT
M^*?C7\!?!/C/Q2\-K;S^*0FJ^&_$][;V05+.#4O$7A+4M!UG4X;6)5@MXM0O
MKE(;8"VC5;?]W7UO10!X=\$/V:?@)^S;HMUH'P+^%'@SX::??F-M4E\.:5''
MJ^LM"7-NVN^(;MKK7]=-MYCBU.KZG>FU1V2W\M"5KR'XR?\ !/#]BOX_^,9O
MB#\6?V>_!/B?QK=O#+J7B2WDUWPQJ6M30*$BN/$$OA'6-!7Q#<+$J0&XUM-0
MG>WBAMGD:"&*-/L^B@#S_P"&/PJ^&WP7\'Z;\/\ X3^"/#?P^\%Z29GL?#GA
M;2[;2=-CGN&#W5Y+%;(K7>H7C@27NHW;SWUY*/,NKB63YJP_AQ\!_A)\(_$O
MQ/\ &/PY\$Z=X6\2_&;Q0?&GQ.U6RN=4GF\6^*#-J-P=7O8K^_N[:VG:?5M2
MF:+38;*V,EY,Y@+,"/7** /QL_X*5_#?Q5X]_:S_ ."6EWI/@+Q!XT\*>'?C
MUXPE\?7.G>%M2\1^'M"T'4+_ .$R2R>,)K:QO--TS2+ZTL]261]::"RN;:UO
M@Q>*"X"_77P^_P""<?[#_P *_B/!\6O /[-_@#P_X]LM2;6-+U>./6+^RT+5
M")!'?>'/#>JZM?\ ACPW<6IE9[!]!T;3O[/F6*:Q%O-#"Z?;-% &%XF\,>&_
M&GA_5_"?C#0-&\4^%_$%C/I>N^'?$.FV>L:)K&G7*[+BQU/3-0AN+*]M9EXD
M@N(9(VX)7(!'Q5X,_P""87[ WP_\8VOCWPM^S%\/;7Q-87\.J:?<ZD?$'B/3
M=.U&VD\ZUO-.\.^)-;U?PY83VLX6>T>STF$VL\<4T'ERPQ.GWE10!Y[\5?A3
M\/?C?X \1_"WXJ^&;/QCX \6P65OXB\-W\]];6NIPZ=J=EK-BLEQIEW8W\)M
MM4TVQO8GMKN"19K:/YBNY6ZCPWX=T7PAX=T'PGX;L(M*\.^%]%TOP[H.EP-*
M\&FZ+HEC!INEV$+SR2SO%9V-M!;QM-++*R1@R2.Y9CM44 ?$WQ)_X)Q?L/\
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M<6E_]KTZ?</M-G-L3;ZQ10 4444 %%%% !1110 4444 %%%% !1110 4444
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M[BMKJ32M2M-7TZ9+G3[FRU"TN+/4;*UNH;BRN[>=6BV>88GD1_E?PC_P2_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPS]H'_ )$S3O\
ML9;/_P!-6M5[G7AG[0/_ ")FG?\ 8RV?_IJUJ@!?@!_R)NI_]C->?^FK1J]R
MKPWX ?\ (FZG_P!C->?^FK1J]RH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\,_:!_Y$S3O^QEL_P#TU:U7N=>&?M _\B9I
MW_8RV?\ Z:M:H 7X ?\ (FZG_P!C->?^FK1J]RKPWX ?\B;J?_8S7G_IJT:O
M<J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO#/V@?\ D3-._P"QEL__ $U:U7N=>&?M _\ (F:=_P!C+9_^FK6J /#O#7Q*
M\0_#VWU#P_I]IHUU&FK7<\\MY!?3/]J6."RE$3P7]DOD;;)&C#PB3+.6."$3
MH_\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] S
MPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P N
MJ/\ AH/QA_T#/#7_ (!:I_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0
M,\-?^ 6J?_+JBB@ _P"&@_&'_0,\-?\ @%JG_P NJ/\ AH/QA_T#/#7_ (!:
MI_\ +JBB@ _X:#\8?] SPU_X!:I_\NJ/^&@_&'_0,\-?^ 6J?_+JBB@ _P"&
M@_&'_0,\-?\ @%JG_P NJYKQ1\2_$/Q M+'0-1M-&MHSJEM<02V4%]"_VDQ7
9%E&)7GO[U?(VWKLX2'S,JA5L HY10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img83932212_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img83932212_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !I 9@# 2(  A$! Q$!_\0
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MR/"_[0?AXW?AN*>7%O;?$WP!:W^K:?'#YA$-L=?\(R^)[.X92LNH:CIGARR
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MVG:G;VMQ-.VFW[ZIHRW=^NE_;KC_ #HU5G9416=W8*B*"S,S'"JJ@$LS$@
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M+J:QO?,T'PTSVT>LVVLW[WNAV/!X?>'?%?B?Q)AN%N$,N>.S&O"5>O5J3='
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MM8U97=5TVI<OLFK*"OS+:Q_<!17^<A^R%_P47_:0_9A^./@;XBS?%WXH>+/
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M@_RD_P#!N)\2?B+X[^)?[4-OXX\?>-?&5OIW@7X<S:?!XK\5:[XBAL9I]?\
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M"Z+_ #M<6<L$S/\ ,SD\U]&U_EX?\-#_ !__ .BY?&'_ ,.9XU_^7=?WM_\
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M/_\ $2E^U;_T0G]GO_OQ\1__ )NJ_$K]J/X_ZE^U)\=?'OQZUOP9X2\!:_\
M$6^L-6U_P_X(CU.'PY_;-MI-AI=_JUK#J^H:G?)>:Y-8G5]7:2\D6XU>\OKM
M0GV@H/I_H_X+Z0N22S3)?&9X/-\J6%CB<CSYYMEV/S;#XN%:G3K99C)8/EK8
MS#8BC4GB:&*Q*J5\-5P]2C.M4IXBA##\?%%3A7$JCB.'^>A7YW#$X7V%:E0G
M3<6XUJ:J>[3G"2Y)0@U&:DI*,7"3G^S'_!OM^V1JWPK_ &AKS]E;Q1JTK_#;
MX]QWU]X4M+J=OLGASXMZ%I4E]:W-F';RK6/QIX=TR[T#4(T7S-0UFP\((A4P
MR"4K\0_@%X]OOA7\=/@U\2]-G>VOO 'Q2\ ^,;>5&*D/X<\4Z5JQ1L$;HI4M
M&BFC;*2PN\;AD=@2OY[^E1]'/B#C#Q"PW%O V7X7_A:RBC_K!"4W0C4S?!59
MX:&-2A3DG4Q.7K!TZVD>:IA76DY5*U21]5P5Q9A<!E4\#F56?^SUY?579RM0
MJ*,G3O?:%5U)1[1GRJRBD?ZB$\\-M#-<W,L5O;V\4D\\\TBQ0PPQ(9)9997*
MI'%&BL\DCL%15+,0 37^;3_P4._:9F_:W_; ^,WQF@NY;KPKJ'B27PU\.D=G
M$=O\.O""_P!@>$I(8'_X]6UBPL_^$DU"W7*KJ^MZB^6,C,W]G?\ P6?_ &H/
M^&:/V&?B(FCZC]A\>_&LCX+^"_)EV7D">++*\/C/6(?+(N(!I?@>TU]+;4(2
MGV'7+_0_WL<L\ ?_ #[ZW^@9X>?5\!Q1XG8ZA:ICZG^JN03G&S6#PTZ.-SO$
MTVT^:GB,6LOPE.I&SC4R_&TFVI-*/$W->:K@LGI2TI)XW%)/3VDU*GAH/SA#
MVM1IWNJM.6ED=S\,?AYXE^+?Q&\!_"WP=:?;O%?Q%\7^'?!7AVU(;9+K'B;5
MK31[#SF16,5M'<7:274Y&R"W269R$C8C_3I^"WPJ\-? SX1_#7X.>#XA%X:^
M&?@KP[X+TEC&D4MU;Z!IEOI[ZE=JA(:_U6>&74M1F+,]Q?W=Q/([R2,Q_P Y
MW]A7]IOPM^Q[^T;X4_:$\2_"E_C#<>!-,\0-X5\*GQ='X,MK7Q3K.F2Z':>(
M+O4Y?"_BX3II&F:AJSV=FNE)(NJRZ?J,5Y#)IZI+^Y>K?\'-7CN;=_87[(OA
M+3LYV?VM\7]8UK;Z;OL?@#0-^.^-F>V*^M^EMX9>,/BUG'"N2\$\-+'<*Y#@
M\3F&)Q];/<@RZEBL^S&K["5-X3'9IA\;..6X##4O8U_JR@Y9CBZ<'+E;?#P+
MG&09'0QN(S'&.ECL34A2A2CAL55E#"THJ2:J4Z,J:=:K.7-'GNE1IMVO8_KE
MK\J/^"S7[-'_  TG^PE\3H]*T_[;XW^#:Q_&OP9Y46^ZD?P5:7K>+M-@" W$
M[:GX#O?$T=K80[OMFL0Z1^ZDEAA _"35O^#E7]J";?\ V%\ O@)IN<[/[6D^
M(6M;?3?]C\6Z!OQWQY>?:OZW?@SK7C#QU\$OA=XB^*^BZ'IOCOQE\,?!NM_$
M/PYI-C>6_A[3?$_B/PQI]_XGT&QT_6+[5[Y=+L=1O+S38K?4M0O[AK>$+<SR
MNSD_Q%G/AKXG?1PS[@?CKB3"9=E^*H\04L9E.&PN<83&U\7/*)X?%8[#UX8.
M=50PE;#UHX3$RYG&4,7[-I\Y^C8?-\FXMPV8Y;A*E6K3EA94Z\YX>I3C!5U*
M%.47446ZD91<X*VCIWOH?Y<E?T$_\&\W[3__  JS]J3Q-^SWK^H>1X4_:)\.
MXT..>7;;VWQ.\!6VH:SH?EF0^5;_ -N>&)O%6ER[-DNHZI%X;M/WKQ6\8_+?
M]OC]G"X_9/\ VN?C;\$EMIK?P_X<\7W6J>!9)0S"Y^'OBF./Q)X*=9VRMU+:
M:!J=EI>H31L5&K:?J$#!)89(T^<OAQX^\2_"KX@^"/B;X-O3IWBWX?>+/#_C
M/PW?#<5MM;\-:K:ZQILDJ*R&6#[7:1+<0%@D\!DA?*.P/^NO&>0Y-XS^$^9Y
M5A:M.MEG&_"]#'9)C*B3A2Q&*PU'-<@Q\E'F:^JXV."Q-2$6Y6ISIWU9^%9?
MB<1P]GE&M-.-;+L;*EB::WE"$Y4,526U^>FZD$WIJF?U-_\ !S;X8O)]!_8^
M\:11NVGZ7J_QI\,7TV#Y<=YKUG\--5TN,MT#S0>'-890<%EMV(R%./Y,*_O(
M_P""BGP_TS_@I+_P2RL_BE\*+%]6UZ'POX2_:5^'.DVV+O43J6AZ->CQEX-
M@4S7.N6WAK5_&?AY=-@1GNO%>GV5F(FD5"O\&]?CWT-L\ABO"&'".)B\-GGA
M_P 1<0</YQE]5J.*PM3%9KC,XI2K4[MQA*IC\5A(2?NRK8#$TTVZ4CWN/\,X
M9Z\?#W\-FF$PN*P]5:PFH4*>'DHONE2A-KI&I![21_HH_P#!([XD:/\ $[_@
MG=^S#J>DW,4TOA;P%'\-]9MT=3-I^L?#K4+WPE-;748YAEN+32[+5(4<!I+#
M4;.Y&4G0G]'Z_@._X)4?\%2]:_8#\4Z[X-\<:/J_C;]GCX@ZG;ZKXG\/Z-)
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M)%960,/\R3XN_"SQE\$/B?X\^$7Q!TR32/&?PZ\4:MX4\063JXC%]I-T]O\
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M\9O!&K^#OV9_!VKZ=XIN)_%6G7&EW/Q@N=,GCOM,\+>%],OHXKO4/"NH7<4
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M=WK$]I9I'%)?W&G:-I5E+<,ID>WT^UC)VQ*!_$A_P7^_Y2+>+/\ LEWPM_\
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M%]JTG2-2&OZ8;RSO^Q\.?'+QC\2_^"A7_!/GXE:G_:^FQ?%#_@FKJGQ?\1>
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M_:=]%X<MY;M!:BU62XF$,2*(PN/I?[$W@O2OCK^S?\>(O&/BB77?V;/@3=?
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)4445\(>D?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>adpt-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-03T02:18:11.9609+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adaptivebiotech.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:adpt="http://www.adaptivebiotech.com/20241231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity" id="DisclosureCybersecurity">
        <link:definition>100070 - Disclosure - Cybersecurity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>995475 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue" id="Role_DisclosureDeferredRevenue">
        <link:definition>995485 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995495 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>995505 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>995515 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>995525 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>995535 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995545 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement" id="DisclosureRevenueInterestPurchaseAgreement">
        <link:definition>995555 - Disclosure - Revenue Interest Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995565 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>995575 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>995585 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>995595 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995605 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders">
        <link:definition>995615 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>995625 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995635 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>995645 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>995655 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueTables" id="Role_DisclosureRevenueTables">
        <link:definition>995665 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables" id="Role_DisclosureDeferredRevenueTables">
        <link:definition>995675 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995685 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>995695 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995705 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>995715 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>995725 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995735 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables" id="DisclosureRevenueInterestPurchaseAgreementTables">
        <link:definition>995745 - Disclosure - Revenue Interest Purchase Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityTables" id="Role_DisclosureShareholdersEquityTables">
        <link:definition>995755 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>995765 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995775 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables">
        <link:definition>995785 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995795 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" id="Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
        <link:definition>995815 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" id="Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
        <link:definition>995825 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" id="DisclosureRevenueScheduleOfDisaggregatedRevenueDetails">
        <link:definition>995835 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" id="Role_DisclosureRevenueAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Deferred Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails1">
        <link:definition>995865 - Disclosure - Deferred Revenue - Additional Information (Details1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default">
        <link:definition>995865 - Disclosure - Deferred Revenue - Additional Information (Details1) [Default]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" id="Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails">
        <link:definition>995875 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995885 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" id="Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
        <link:definition>995895 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" id="Role_DisclosureInvestmentsAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" id="DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails">
        <link:definition>995915 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995925 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
        <link:definition>995955 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
        <link:definition>995965 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>995975 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" id="Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - Accrued Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Leases- Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" id="Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails">
        <link:definition>996005 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" id="Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2">
        <link:definition>996015 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" id="Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
        <link:definition>996025 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" id="DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails">
        <link:definition>996035 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" id="DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails">
        <link:definition>996045 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" id="Role_DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>996055 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" id="Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
        <link:definition>996065 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>996075 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
        <link:definition>996085 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails">
        <link:definition>996095 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails" id="DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails">
        <link:definition>996105 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" id="DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails">
        <link:definition>996115 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" id="DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails">
        <link:definition>996125 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" id="DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails">
        <link:definition>996135 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" id="DisclosureRestructuringAdditionalInformationDetails">
        <link:definition>996145 - Disclosure - Restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>996155 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996165 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996175 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
        <link:definition>996185 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail">
        <link:definition>996195 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
        <link:definition>996205 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>996215 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>996225 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>996235 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" id="DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
        <link:definition>996245 - Disclosure - Segment Information - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails" id="DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails">
        <link:definition>996255 - Disclosure - Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="adpt-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="adpt-20241231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="adpt-20241231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="adpt-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="adpt-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" xlink:href="adpt-20241231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="adpt-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="adpt-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="adpt-20241231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity" xlink:href="adpt-20241231.xsd#DisclosureCybersecurity" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="adpt-20241231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="adpt-20241231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue" xlink:href="adpt-20241231.xsd#Role_DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue" xlink:href="adpt-20241231.xsd#Role_DisclosureDeferredRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="adpt-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments" xlink:href="adpt-20241231.xsd#Role_DisclosureInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="adpt-20241231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="adpt-20241231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="adpt-20241231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:href="adpt-20241231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement" xlink:href="adpt-20241231.xsd#DisclosureRevenueInterestPurchaseAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="adpt-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:href="adpt-20241231.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:href="adpt-20241231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuring" xlink:href="adpt-20241231.xsd#DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" xlink:href="adpt-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:href="adpt-20241231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:href="adpt-20241231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="adpt-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:href="adpt-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueTables" xlink:href="adpt-20241231.xsd#Role_DisclosureRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables" xlink:href="adpt-20241231.xsd#Role_DisclosureDeferredRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="adpt-20241231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables" xlink:href="adpt-20241231.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="adpt-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="adpt-20241231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="adpt-20241231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="adpt-20241231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables" xlink:href="adpt-20241231.xsd#DisclosureRevenueInterestPurchaseAgreementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityTables" xlink:href="adpt-20241231.xsd#Role_DisclosureShareholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="adpt-20241231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" xlink:href="adpt-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="adpt-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" xlink:href="adpt-20241231.xsd#DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:href="adpt-20241231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" xlink:href="adpt-20241231.xsd#DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" xlink:href="adpt-20241231.xsd#DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails" xlink:href="adpt-20241231.xsd#DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" xlink:href="adpt-20241231.xsd#DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" xlink:href="adpt-20241231.xsd#DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" xlink:href="adpt-20241231.xsd#DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#DisclosureRestructuringAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:href="adpt-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="adpt-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:href="adpt-20241231.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails" xlink:href="adpt-20241231.xsd#DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" xlink:href="adpt-20241231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_InventoryReserve" xlink:label="adpt_InventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CustomerAMember" xlink:label="adpt_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImpairmentOfLongLivedAssets" xlink:label="adpt_ImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ItemsToReconcileNetLossToAdjustedEBITDA" xlink:label="adpt_ItemsToReconcileNetLossToAdjustedEBITDA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:label="adpt_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetCurrent" xlink:label="adpt_RevenueInterestLiabilityNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfNetVestedSharesOfCommonStock" xlink:label="adpt_PercentageOfNetVestedSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetNoncurrent" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MichelleGriffinMember" xlink:label="adpt_MichelleGriffinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DigitalBiotechnologiesIncMember" xlink:label="adpt_DigitalBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:label="adpt_ProceedsFromLandlordReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredRevenueTextBlock" xlink:label="adpt_DeferredRevenueTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPurchaseAgreementTextBlock" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementCostsIncurred" xlink:label="adpt_TenantImprovementCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PutOrCallOptionMember" xlink:label="adpt_PutOrCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MRDRevenueMember" xlink:label="adpt_MRDRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:label="adpt_GenentechCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AmortizationOfPurchaseAgreementObligation" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiability" xlink:label="adpt_RevenueInterestLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RegulatoryMilestonesMember" xlink:label="adpt_RegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:label="adpt_OperatingLeaseVariableLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPaid" xlink:label="adpt_RevenueInterestPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerSoftwareMember" xlink:label="adpt_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:label="adpt_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="us-gaap_ImpairmentOfLeasehold"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockWarrantOutstandingMember" xlink:label="adpt_CommonStockWarrantOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedStockOptionsMember" xlink:label="adpt_NonvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPaymentTerm" xlink:label="adpt_RevenueInterestPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MonteCarloValuationModelMember" xlink:label="adpt_MonteCarloValuationModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfCumulativePurchaserPayments" xlink:label="adpt_PercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommercialMilestonesMember" xlink:label="adpt_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementCostsReceivable" xlink:label="adpt_TenantImprovementCostsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NoncashInterestExpense" xlink:label="adpt_NoncashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonEmployeeDirectorsMember" xlink:label="adpt_NonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfOperatingAndReportableSegments" xlink:label="adpt_NumberOfOperatingAndReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CustomerBMember" xlink:label="adpt_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInventoryNoncurrent" xlink:label="us-gaap_OtherInventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustedEbitda" xlink:label="adpt_AdjustedEbitda"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RegulatoryMilestoneRevenueMember" xlink:label="adpt_RegulatoryMilestoneRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentMilestonesMember" xlink:label="adpt_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineRevenueMember" xlink:label="adpt_ImmuneMedicineRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:label="adpt_NumberOfRevenuePerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerAndSoftware" xlink:label="adpt_ComputerAndSoftware"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ContractBalancesPolicyTextBlock" xlink:label="adpt_ContractBalancesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:label="adpt_TenantImprovementAllowanceAndCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SpecificPatientsMember" xlink:label="adpt_SpecificPatientsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineServiceRevenueMember" xlink:label="adpt_ImmuneMedicineServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:label="adpt_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonCashInterestExpenseRecognized" xlink:label="adpt_NonCashInterestExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_UpfrontPaymentReceived" xlink:label="adpt_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementThirdPaymentDate" xlink:label="adpt_PurchaseAgreementThirdPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CollaborationRevenueMember" xlink:label="adpt_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MedicareRevenueMember" xlink:label="adpt_MedicareRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NoncashLeaseExpense" xlink:label="adpt_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfRevenueInterestPayments" xlink:label="adpt_PercentageOfRevenueInterestPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdditionalMilestonePayment" xlink:label="adpt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MedicareReimbursementsMember" xlink:label="adpt_MedicareReimbursementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncomeTaxesLineItems" xlink:label="adpt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxAssetTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:label="adpt_MRDDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:label="adpt_RevenueRecognitionExpectedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:label="adpt_SeriesCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:label="adpt_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementSecondPaymentDate" xlink:label="adpt_PurchaseAgreementSecondPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:label="adpt_GenentechIncAndRocheGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CumulativePurchaserPaymentsReceivableDate" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:label="adpt_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncomeTaxesTable" xlink:label="adpt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from settlement of stock option exercised in prior periods.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Settlement Of Stock Option Exercised In Prior Periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from settlement of stock option exercised in prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_InventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_InventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_InventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Restricted Stock Units And Maximum Market Based Restricted Stock Units Forfeited Canceled Or Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Awards Restricted Stock Units And Maximum Market Based Restricted Stock Units Forfeited Canceled Or Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock award vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restructuring expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of long lived assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Market Based Restricted Stock Units Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested market based restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Market-based Restricted Stock Units Outstanding Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ItemsToReconcileNetLossToAdjustedEBITDA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Items to reconcile net loss to adjusted EBITDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ItemsToReconcileNetLossToAdjustedEBITDA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Items To Reconcile Net Loss To Adjusted EBITDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ItemsToReconcileNetLossToAdjustedEBITDA_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Items to reconcile net loss to adjusted EBITDA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential revenue interest third payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Revenue Interest Third Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential revenue interest third payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Restricted Stock Units Granted And Maximum Market Based Restricted Stock Units Granted Eligible To Be Earned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, stock options restricted stock units granted and maximum market based restricted stock units granted eligible to be earned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual increases in number of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Increases In Number Of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increases in number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable payment percentage of quarterly revenue base for first, second and third payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Payment Percentage of quarterly Revenue Base for First, Second and Third Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Applicable payment percentage of quarterly revenue base for first, second and third payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One-time Termination Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time Termination Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability Net Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability net current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntersegmentEliminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inter-segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntersegmentEliminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intersegment Eliminations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntersegmentEliminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unallocated Corporate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, initial public offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Initial Public Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Units R S U [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested Restricted Stock Units R S U.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Advertising expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Share Based Compensation Expense And The Expected Weighted Average Remaining Recognition Period Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sequencing revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sequencing Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sequencing Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfNetVestedSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Net Vested Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfNetVestedSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net vested shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfNetVestedSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net vested shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and contract research organization costs, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Contract Research Organization Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and contract research organization costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue interest liability, net, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest liability, net, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability Net Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability net noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, lease not yet commenced termination option description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Termination Option Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, termination option description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update Extensible List</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MichelleGriffinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Michelle Griffin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MichelleGriffinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Michelle Griffin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MichelleGriffinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Michelle Griffin.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Digital Biotechnologies Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Digital Biotechnologies Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from landlord reimbursements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Landlord Reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from landlord reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Interest Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in return cap percentage of cumulative purchaser payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Return Cap Percentage of Cumulative Purchaser Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in return cap percentage of cumulative purchaser payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, common stock warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Common Stock Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock warrant, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Purchase Agreement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue Interest Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Requisite service period term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Requisite Service Period Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award requisite service period term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement costs incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal NOLs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PutOrCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Put or call option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PutOrCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put or Call Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PutOrCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Put/Call Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gains and losses on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current and non-current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue balance at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease rent commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, rent commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of deferred revenue by revenue classification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Revenue by Revenue Classification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nine equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nine Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2009 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRD Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M R D Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MRD Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of revenue interest liability, net activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue Interest Liability, Net Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Revenue Interest Liability, Net Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued tax withholding liability related to unsettled option exercises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Tax Withholding Liability Related To Unsettled Option Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued tax withholding liability related to unsettled option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Concentrations of Risk Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Vesting Of Outstanding Restricted Stock Units And Market Based Restricted Stock Units Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock vesting of outstanding restricted stock units and market-based restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury and Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in redemption value for vested convertible preferred stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Redemption Value For Vested Convertible Preferred Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in redemption value for vested Series E-1 convertible preferred stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2016-02</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Add: Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Upon the Exercise of Outstanding Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Exercise Of Outstanding Stock Options Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock exercise of outstanding stock options granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Costs Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Capitalized issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Capitalized issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of purchase agreement obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Purchase Agreement obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of purchase agreement obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities (amortized cost of $33,682)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to Adaptive Biotechnologies Corporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to Adaptive Biotechnologies Corporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash upon exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Stock Options, Stock Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest liability at inception</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative purchaser payments repayment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Purchaser Payments Repayment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cumulative purchaser payments repayment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential revenue interest second payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Revenue Interest Second Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential revenue interest second payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease variable lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Variable Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Interest Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Intangible Assets Subject to Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss attributable to Adaptive Biotechnologies Corporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reserved shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Reserved Shares Of Common Stock Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Ownership Percentage, Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock voting rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of vote for each share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition milestone method expected milestone receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Milestone Method Expected Milestone Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected revenue through milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Leasehold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Inventory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development inventory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Contributed Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial capital contributions for Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Disaggregated Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling and Marketing Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciles Undiscounted Operating Lease Cash Flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan reserve increase effective January 1, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares available for grant at September 30, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares available for grant at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockWarrantOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockWarrantOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockWarrantOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining Weighted-Average Recognition Period (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested Stock Options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Travel and entertainment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest payment term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Payment Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Stock Units Outstanding, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements and New Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance period term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Performance Period Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased compensation arrangement by sharebased payment award performance period term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of public offering costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Stock Units Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share-based compensation, shares available for grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MonteCarloValuationModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monte Carlo Valuation Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MonteCarloValuationModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monte Carlo Valuation Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MonteCarloValuationModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monte Carlo Valuation Model.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest liability, net, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue interest liability, net at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Stock Options, Stock Options expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards, Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cumulative purchaser payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Cumulative Purchaser Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of cumulative purchaser payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforward Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carryforward Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period for NOLs carryovers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Excluding Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest liability, net, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Outstanding Stock Options, Stock Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Grant Date Fair Values of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash received for tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, common stock warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">OrbiMed Royalty &amp; Credit Opportunities IV, LP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OrbiMed Royalty &amp; Credit Opportunities IV, LP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">OrbiMed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 months or greater, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Stock Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, expected to be recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential revenue interest payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Revenue Interest Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential revenue interest payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in carrying amount of goodwill since recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value change in redemption value for vested convertible preferred stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in redemption value for vested Series E-1 convertible preferred stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales and marketing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales And Marketing Expense Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of right-of-use and related long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Right-of-Use and Related Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of right-of-use and related long-lived assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment of right-of-use and related long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2023-09</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement costs receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Costs Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tenant improvement costs receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Market-Based Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Market Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested market-based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock warrant to common stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Adaptive Biotechnologies Corporation shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Employee Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions to deferred revenue during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting standards update adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfOperatingAndReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating and Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfOperatingAndReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating and reportable segments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfOperatingAndReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating and reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Compensation Costs Related to Stock Options and RSUs Included on Consolidated Statements of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment awards forfeited, canceled or expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized Share-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees maximum annual contribution of their compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustedEbitda_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjusted EBITDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustedEbitda_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjusted EBITDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustedEbitda_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjusted EBITDA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustedEbitda_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Adjusted EBITDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from revenue interest purchase agreement, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from revenue interest purchase agreement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestoneRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestoneRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestoneRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory Milestone Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease termination period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Termination Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease termination period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable payment percentage of quarterly revenue base for first payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Payment Percentage of quarterly Revenue Base for First Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Applicable payment percentage of quarterly revenue base for first payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immune Medicine Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Immune Medicine Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Immune Medicine Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring and Related Cost, Expected Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Expected Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated aggregate restructuring costs recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right-of-use assets and liabilities .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of revenue performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Revenue Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of revenue performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employee service period for vesting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employee Service Period For Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee service period for vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended term of contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Term Of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, extended term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable payment percentage of quarterly revenue base for first and second payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Payment Percentage of quarterly Revenue Base for First and Second Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Applicable payment percentage of quarterly revenue base for first and second payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerAndSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerAndSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerAndSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract balances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Balances Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Stock Option outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, option to extend description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance and commenced.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance And Commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance and commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of reporting segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specific patients.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specific Patients [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specific Patients</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring, reduction in workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market-Based Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Based Restricted Stock Units R S U [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market-Based Restricted Stock Units R S U.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, tangible and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Tangible And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tangible and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immune Medicine Service Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Immune Medicine Service Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Immune medicine service revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offering of common stock, net of underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commenced moth and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual life stock options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets, held for use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonCashInterestExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash interest expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonCashInterestExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonCashInterestExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncash interest expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity Under 2009 Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementThirdPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement third payment date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementThirdPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Third Payment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementThirdPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase agreement, third payment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Add: Comprehensive loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Option Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Valuation Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfRevenueInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue interest payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfRevenueInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Revenue Interest Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfRevenueInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of revenue interest payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software Enhancements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability, net and related imputed interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability, Net and Related Imputed Interest [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Liability, Net and Related Imputed Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting standards update adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Stock Options, Stock Options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of equipment included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital capital contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Capital Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital contributions for Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease lease not yet commenced tenant improvement receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced landlord agreed to fund for improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional transaction price of regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Transaction Price Of Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional transaction price of regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Immune Medicine Business [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Immune medicine business member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Immune Medicine</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued purchase of property and equipment current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Purchase Of Property And Equipment Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareReimbursementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare Reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareReimbursementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare Reimbursements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareReimbursementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare Reimbursements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Landlord contribution for leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less than 12 months, Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Loss Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase reserve shares available for grant,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, 2019 Equity Incentive Plan reserve increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired Developed Technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MrdBusinessSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MrdBusinessSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MRD Business Segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MrdBusinessSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MRD business segment member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Tangible And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset tangible and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tangible and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reporting units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reporting Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRD Development Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MRD development agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M R D Development Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition expected period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Expected Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition expected period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities (amortized cost of $174,186 and $281,122, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Security Category [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 months, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementSecondPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement second payment date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementSecondPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Second Payment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementSecondPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase agreement, second payment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_WA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WASHINGTON</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_WA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seattle, Washington</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and principles of consolidation policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2024 and 2023; 147,773,744 and 145,082,271 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Amortization Expense for Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease rent obligations commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Obligations Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent obligations, commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock that may be earned under the award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Earned Under The Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares earned under the award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">12 months or greater, Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Information, Including Significant Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech, Inc. and Roche Group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc And Roche Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc. and Roche Group</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative purchaser payments receivable date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Purchaser Payments Receivable Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cumulative purchaser payments receivable date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability milestone method revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Milestone Method Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award outstanding number.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity awards outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, non qualified stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Non Qualified Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonqualifying stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment awards granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Options and restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options and restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options And Restricted Stock Units Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Restricted Stock Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual life vested and exercisable stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Useful Lives Assigned to Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of estimated useful lives of property plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, option to extend term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:to="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_InventoryReserve" xlink:to="adpt_InventoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerAMember" xlink:to="adpt_CustomerAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImpairmentOfLongLivedAssets" xlink:to="adpt_ImpairmentOfLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ItemsToReconcileNetLossToAdjustedEBITDA" xlink:to="adpt_ItemsToReconcileNetLossToAdjustedEBITDA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerEquipmentAndSoftwareMember" xlink:to="adpt_ComputerEquipmentAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:to="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiabilityNetCurrent" xlink:to="adpt_RevenueInterestLiabilityNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntersegmentEliminationMember" xlink:to="us-gaap_IntersegmentEliminationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:to="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" xlink:to="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SequencingRevenueMember" xlink:to="adpt_SequencingRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfNetVestedSharesOfCommonStock" xlink:to="adpt_PercentageOfNetVestedSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiabilityNetNoncurrent" xlink:to="adpt_RevenueInterestLiabilityNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MichelleGriffinMember" xlink:to="adpt_MichelleGriffinMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DigitalBiotechnologiesIncMember" xlink:to="adpt_DigitalBiotechnologiesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromLandlordReimbursements" xlink:to="adpt_ProceedsFromLandlordReimbursements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPayable" xlink:to="adpt_RevenueInterestPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:to="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredRevenueTextBlock" xlink:to="adpt_DeferredRevenueTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPurchaseAgreementTextBlock" xlink:to="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementCostsIncurred" xlink:to="adpt_TenantImprovementCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PutOrCallOptionMember" xlink:to="adpt_PutOrCallOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:to="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MRDRevenueMember" xlink:to="adpt_MRDRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" xlink:to="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:to="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:to="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechCollaborationAgreementMember" xlink:to="adpt_GenentechCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:to="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsCapitalized" xlink:to="us-gaap_InterestCostsCapitalized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AmortizationOfPurchaseAgreementObligation" xlink:to="adpt_AmortizationOfPurchaseAgreementObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiability" xlink:to="adpt_RevenueInterestLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:to="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RegulatoryMilestonesMember" xlink:to="adpt_RegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:to="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OperatingLeaseVariableLeaseExpense" xlink:to="adpt_OperatingLeaseVariableLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPaid" xlink:to="adpt_RevenueInterestPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:to="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerSoftwareMember" xlink:to="adpt_ComputerSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfCommonStockVotingRights" xlink:to="adpt_NumberOfCommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ResearchAndDevelopmentInventoryReserve" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockWarrantOutstandingMember" xlink:to="adpt_CommonStockWarrantOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedStockOptionsMember" xlink:to="adpt_NonvestedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPaymentTerm" xlink:to="adpt_RevenueInterestPaymentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:to="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:to="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MonteCarloValuationModelMember" xlink:to="adpt_MonteCarloValuationModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiabilityNet" xlink:to="adpt_RevenueInterestLiabilityNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OperatingLossCarryforwardsExpirationYear" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfCumulativePurchaserPayments" xlink:to="adpt_PercentageOfCumulativePurchaserPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LaboratoryEquipmentMember" xlink:to="adpt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:to="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:to="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_FurnitureAndOfficeEquipmentMember" xlink:to="adpt_FurnitureAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommercialMilestonesMember" xlink:to="adpt_CommercialMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PurchaseAgreementMember" xlink:to="adpt_PurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementCostsReceivable" xlink:to="adpt_TenantImprovementCostsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NoncashInterestExpense" xlink:to="adpt_NoncashInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonEmployeeDirectorsMember" xlink:to="adpt_NonEmployeeDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfOperatingAndReportableSegments" xlink:to="adpt_NumberOfOperatingAndReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerBMember" xlink:to="adpt_CustomerBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryNoncurrent" xlink:to="us-gaap_OtherInventoryNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustedEbitda" xlink:to="adpt_AdjustedEbitda_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:to="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RegulatoryMilestoneRevenueMember" xlink:to="adpt_RegulatoryMilestoneRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseTerminationPeriod" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentMilestonesMember" xlink:to="adpt_DevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImmuneMedicineRevenueMember" xlink:to="adpt_ImmuneMedicineRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfRevenuePerformanceObligation" xlink:to="adpt_NumberOfRevenuePerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:to="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechIncMember" xlink:to="adpt_GenentechIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerAndSoftware" xlink:to="adpt_ComputerAndSoftware_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractBalancesPolicyTextBlock" xlink:to="adpt_ContractBalancesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementAllowanceAndCommenced" xlink:to="adpt_TenantImprovementAllowanceAndCommenced_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SpecificPatientsMember" xlink:to="adpt_SpecificPatientsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImmuneMedicineServiceRevenueMember" xlink:to="adpt_ImmuneMedicineServiceRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LeaseCommencementMonthAndYear" xlink:to="adpt_LeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonCashInterestExpenseRecognized" xlink:to="adpt_NonCashInterestExpenseRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_UpfrontPaymentReceived" xlink:to="adpt_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PurchaseAgreementThirdPaymentDate" xlink:to="adpt_PurchaseAgreementThirdPaymentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CollaborationRevenueMember" xlink:to="adpt_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MedicareRevenueMember" xlink:to="adpt_MedicareRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentRevenueMember" xlink:to="adpt_DevelopmentRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NoncashLeaseExpense" xlink:to="adpt_NoncashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfRevenueInterestPayments" xlink:to="adpt_PercentageOfRevenueInterestPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" xlink:to="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdditionalMilestonePayment" xlink:to="adpt_AdditionalMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:to="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImmuneMedicineBusinessMember" xlink:to="adpt_ImmuneMedicineBusinessMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MedicareReimbursementsMember" xlink:to="adpt_MedicareReimbursementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MrdBusinessSegmentMember" xlink:to="adpt_MrdBusinessSegmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetTangibleAndIntangibleAssets" xlink:to="adpt_DeferredTaxAssetTangibleAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MRDDevelopmentAgreementsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognitionExpectedPeriod" xlink:to="adpt_RevenueRecognitionExpectedPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SeriesCConvertiblePreferredStockMember" xlink:to="adpt_SeriesCConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LeaseExpirationMonthAndYear" xlink:to="adpt_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PurchaseAgreementSecondPaymentDate" xlink:to="adpt_PurchaseAgreementSecondPaymentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WA" xlink:to="stpr_WA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:to="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:to="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonRefundableUpfrontPaymentsReceived" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:to="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechIncAndRocheGroupMember" xlink:to="adpt_GenentechIncAndRocheGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CumulativePurchaserPaymentsReceivableDate" xlink:to="adpt_CumulativePurchaserPaymentsReceivableDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_UnvestedRestrictedStockUnitsMember" xlink:to="adpt_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncomeTaxesTable" xlink:to="adpt_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NoncashLeaseExpense" xlink:label="adpt_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImpairmentOfLongLivedAssets" xlink:label="adpt_ImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_InventoryReserve" xlink:label="adpt_InventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NoncashInterestExpense" xlink:label="adpt_NoncashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_NoncashLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributedCapital" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_ImpairmentOfLongLivedAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_InventoryReserve" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_NoncashInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MichelleGriffinMember" xlink:label="adpt_MichelleGriffinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfNetVestedSharesOfCommonStock" xlink:label="adpt_PercentageOfNetVestedSharesOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="adpt_MichelleGriffinMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="adpt_PercentageOfNetVestedSharesOfCommonStock" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredRevenueTextBlock" xlink:label="adpt_DeferredRevenueTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="adpt_DeferredRevenueTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPurchaseAgreementTextBlock" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adpt_RevenueInterestPurchaseAgreementTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ContractBalancesPolicyTextBlock" xlink:label="adpt_ContractBalancesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ContractBalancesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SalesAndMarketingExpensePolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:label="adpt_SeriesCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DigitalBiotechnologiesIncMember" xlink:label="adpt_DigitalBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInventoryNoncurrent" xlink:label="us-gaap_OtherInventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfOperatingAndReportableSegments" xlink:label="adpt_NumberOfOperatingAndReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:label="adpt_NumberOfRevenuePerformanceObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="adpt_DigitalBiotechnologiesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventoryNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfOperatingAndReportableSegments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfRevenuePerformanceObligation" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CustomerAMember" xlink:label="adpt_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CustomerBMember" xlink:label="adpt_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:label="adpt_GenentechIncAndRocheGroupMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncAndRocheGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:label="adpt_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerEquipmentAndSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MRDRevenueMember" xlink:label="adpt_MRDRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineRevenueMember" xlink:label="adpt_ImmuneMedicineRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CollaborationRevenueMember" xlink:label="adpt_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RegulatoryMilestoneRevenueMember" xlink:label="adpt_RegulatoryMilestoneRevenueMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_ImmuneMedicineRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_CollaborationRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_RegulatoryMilestoneRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MedicareReimbursementsMember" xlink:label="adpt_MedicareReimbursementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineServiceRevenueMember" xlink:label="adpt_ImmuneMedicineServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RegulatoryMilestonesMember" xlink:label="adpt_RegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:label="adpt_MRDDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentMilestonesMember" xlink:label="adpt_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:label="adpt_GenentechCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdditionalMilestonePayment" xlink:label="adpt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommercialMilestonesMember" xlink:label="adpt_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:label="adpt_RevenueRecognitionExpectedPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MedicareReimbursementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_ImmuneMedicineServiceRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_RegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_DevelopmentMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_GenentechCollaborationAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalMilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_CommercialMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionExpectedPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SpecificPatientsMember" xlink:label="adpt_SpecificPatientsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MedicareRevenueMember" xlink:label="adpt_MedicareRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_SpecificPatientsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_MedicareRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerSoftwareMember" xlink:label="adpt_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerSoftwareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_MrdBusinessSegmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_NumberOfReportingUnits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_ImmuneMedicineBusinessMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerAndSoftware" xlink:label="adpt_ComputerAndSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_ComputerAndSoftware" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:label="adpt_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="us-gaap_ImpairmentOfLeasehold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:label="adpt_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:label="adpt_ProceedsFromLandlordReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementCostsIncurred" xlink:label="adpt_TenantImprovementCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementCostsReceivable" xlink:label="adpt_TenantImprovementCostsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:label="adpt_TenantImprovementAllowanceAndCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:label="adpt_OperatingLeaseVariableLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseExpirationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLeasehold" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseCommencementMonthAndYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ProceedsFromLandlordReimbursements" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsIncurred" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsReceivable" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementAllowanceAndCommenced" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_OperatingLeaseVariableLeaseExpense" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PutOrCallOptionMember" xlink:label="adpt_PutOrCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_UpfrontPaymentReceived" xlink:label="adpt_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementSecondPaymentDate" xlink:label="adpt_PurchaseAgreementSecondPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementThirdPaymentDate" xlink:label="adpt_PurchaseAgreementThirdPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPaymentTerm" xlink:label="adpt_RevenueInterestPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CumulativePurchaserPaymentsReceivableDate" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfRevenueInterestPayments" xlink:label="adpt_PercentageOfRevenueInterestPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfCumulativePurchaserPayments" xlink:label="adpt_PercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AmortizationOfPurchaseAgreementObligation" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonCashInterestExpenseRecognized" xlink:label="adpt_NonCashInterestExpenseRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="adpt_PutOrCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_UpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestPaymentToBeReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementSecondPaymentDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementThirdPaymentDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaymentTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsReceivableDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfRevenueInterestPayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfCumulativePurchaserPayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsRepaymentDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_AmortizationOfPurchaseAgreementObligation" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_NonCashInterestExpenseRecognized" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiability" xlink:label="adpt_RevenueInterestLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPaid" xlink:label="adpt_RevenueInterestPaid"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet_6"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetCurrent" xlink:label="adpt_RevenueInterestLiabilityNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetNoncurrent" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestCostsCapitalized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNet_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNetCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNetNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:label="adpt_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_2"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_NumberOfCommonStockVotingRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonEmployeeDirectorsMember" xlink:label="adpt_NonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MonteCarloValuationModelMember" xlink:label="adpt_MonteCarloValuationModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adpt_NonEmployeeDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="adpt_MonteCarloValuationModelMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedStockOptionsMember" xlink:label="adpt_NonvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedRestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxAssetTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetTangibleAndIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncomeTaxesTable" xlink:label="adpt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncomeTaxesLineItems" xlink:label="adpt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adpt_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesTable" xlink:to="adpt_IncomeTaxesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:label="adpt_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockWarrantOutstandingMember" xlink:label="adpt_CommonStockWarrantOutstandingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_UnvestedRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_CommonStockWarrantOutstandingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_IntersegmentEliminationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ItemsToReconcileNetLossToAdjustedEBITDA" xlink:label="adpt_ItemsToReconcileNetLossToAdjustedEBITDA"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustedEbitda" xlink:label="adpt_AdjustedEbitda"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_MrdBusinessSegmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_IntersegmentEliminationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_ImmuneMedicineBusinessMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_ItemsToReconcileNetLossToAdjustedEBITDA" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_AdjustedEbitda" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustedEbitda" xlink:label="adpt_AdjustedEbitda"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_MrdBusinessSegmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_AdjustedEbitda" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_IntersegmentEliminationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_ImmuneMedicineBusinessMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestructuringCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfitLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MichelleGriffinMember" xlink:label="adpt_MichelleGriffinMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="adpt_MichelleGriffinMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:label="adpt_SeriesCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DigitalBiotechnologiesIncMember" xlink:label="adpt_DigitalBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInventoryNoncurrent" xlink:label="us-gaap_OtherInventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfOperatingAndReportableSegments" xlink:label="adpt_NumberOfOperatingAndReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:label="adpt_NumberOfRevenuePerformanceObligation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="adpt_DigitalBiotechnologiesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventoryNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfOperatingAndReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfRevenuePerformanceObligation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CustomerAMember" xlink:label="adpt_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CustomerBMember" xlink:label="adpt_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:label="adpt_GenentechIncAndRocheGroupMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncAndRocheGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:label="adpt_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MRDRevenueMember" xlink:label="adpt_MRDRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineRevenueMember" xlink:label="adpt_ImmuneMedicineRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CollaborationRevenueMember" xlink:label="adpt_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RegulatoryMilestoneRevenueMember" xlink:label="adpt_RegulatoryMilestoneRevenueMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_ImmuneMedicineRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_RegulatoryMilestoneRevenueMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MedicareReimbursementsMember" xlink:label="adpt_MedicareReimbursementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineServiceRevenueMember" xlink:label="adpt_ImmuneMedicineServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RegulatoryMilestonesMember" xlink:label="adpt_RegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:label="adpt_MRDDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentMilestonesMember" xlink:label="adpt_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:label="adpt_GenentechCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdditionalMilestonePayment" xlink:label="adpt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommercialMilestonesMember" xlink:label="adpt_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:label="adpt_RevenueRecognitionExpectedPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MedicareReimbursementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_ImmuneMedicineServiceRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_RegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_DevelopmentMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_GenentechCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_CommercialMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionExpectedPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SpecificPatientsMember" xlink:label="adpt_SpecificPatientsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MedicareRevenueMember" xlink:label="adpt_MedicareRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_SpecificPatientsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_MedicareRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerSoftwareMember" xlink:label="adpt_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_MrdBusinessSegmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_NumberOfReportingUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_ImmuneMedicineBusinessMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:label="adpt_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="us-gaap_ImpairmentOfLeasehold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:label="adpt_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:label="adpt_ProceedsFromLandlordReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementCostsIncurred" xlink:label="adpt_TenantImprovementCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementCostsReceivable" xlink:label="adpt_TenantImprovementCostsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:label="adpt_TenantImprovementAllowanceAndCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:label="adpt_OperatingLeaseVariableLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLeasehold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ProceedsFromLandlordReimbursements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementAllowanceAndCommenced" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_OperatingLeaseVariableLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PutOrCallOptionMember" xlink:label="adpt_PutOrCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_UpfrontPaymentReceived" xlink:label="adpt_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementSecondPaymentDate" xlink:label="adpt_PurchaseAgreementSecondPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementThirdPaymentDate" xlink:label="adpt_PurchaseAgreementThirdPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPaymentTerm" xlink:label="adpt_RevenueInterestPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CumulativePurchaserPaymentsReceivableDate" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfRevenueInterestPayments" xlink:label="adpt_PercentageOfRevenueInterestPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfCumulativePurchaserPayments" xlink:label="adpt_PercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AmortizationOfPurchaseAgreementObligation" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonCashInterestExpenseRecognized" xlink:label="adpt_NonCashInterestExpenseRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="adpt_PutOrCallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementSecondPaymentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementThirdPaymentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaymentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsReceivableDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfRevenueInterestPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfCumulativePurchaserPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsRepaymentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_AmortizationOfPurchaseAgreementObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_NonCashInterestExpenseRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiability" xlink:label="adpt_RevenueInterestLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPaid" xlink:label="adpt_RevenueInterestPaid"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetCurrent" xlink:label="adpt_RevenueInterestLiabilityNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RevenueInterestLiabilityNetNoncurrent" xlink:label="adpt_RevenueInterestLiabilityNetNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestCostsCapitalized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNetNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:label="adpt_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_NumberOfCommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonEmployeeDirectorsMember" xlink:label="adpt_NonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MonteCarloValuationModelMember" xlink:label="adpt_MonteCarloValuationModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adpt_NonEmployeeDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="adpt_MonteCarloValuationModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedStockOptionsMember" xlink:label="adpt_NonvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedRestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="us-gaap_OneTimeTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncomeTaxesLineItems" xlink:label="adpt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncomeTaxesTable" xlink:label="adpt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:label="adpt_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_CommonStockWarrantOutstandingMember" xlink:label="adpt_CommonStockWarrantOutstandingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_CommonStockWarrantOutstandingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_IntersegmentEliminationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ItemsToReconcileNetLossToAdjustedEBITDA" xlink:label="adpt_ItemsToReconcileNetLossToAdjustedEBITDA"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustedEbitda" xlink:label="adpt_AdjustedEbitda"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_MrdBusinessSegmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_IntersegmentEliminationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_ImmuneMedicineBusinessMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_ItemsToReconcileNetLossToAdjustedEBITDA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_AdjustedEbitda" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_MrdBusinessSegmentMember" xlink:label="adpt_MrdBusinessSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AdjustedEbitda" xlink:label="adpt_AdjustedEbitda"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="us-gaap_IntersegmentEliminationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImmuneMedicineBusinessMember" xlink:label="adpt_ImmuneMedicineBusinessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_MrdBusinessSegmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_AdjustedEbitda" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_IntersegmentEliminationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="adpt_ImmuneMedicineBusinessMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_NoncashLeaseExpense" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromContributedCapital" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_ImpairmentOfLongLivedAssets" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_InventoryReserve" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_NoncashInterestExpense" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="13" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="14" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="15" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="17" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" order="19" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="20" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="21" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NoncashLeaseExpense" xlink:label="adpt_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ImpairmentOfLongLivedAssets" xlink:label="adpt_ImpairmentOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_InventoryReserve" xlink:label="adpt_InventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_NoncashInterestExpense" xlink:label="adpt_NoncashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_ComputerAndSoftware" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_ComputerAndSoftware" xlink:label="adpt_ComputerAndSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetTangibleAndIntangibleAssets" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_DeferredTaxAssetTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxAssetTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20241231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="adpt_AmortizationOfPurchaseAgreementObligation" name="AmortizationOfPurchaseAgreementObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ImmuneMedicineRevenueMember" name="ImmuneMedicineRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" name="AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_RevenueInterestLiabilityNetCurrent" name="RevenueInterestLiabilityNetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_NumberOfOperatingAndReportableSegments" name="NumberOfOperatingAndReportableSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_GenentechCollaborationAgreementMember" name="GenentechCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_NetOperatingLossCarryforwardExpirationPeriod" name="NetOperatingLossCarryforwardExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" name="AccruedPurchaseOfPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PercentageOfRevenueInterestPayments" name="PercentageOfRevenueInterestPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" name="RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" type="enum2:enumerationSetItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" enum2:domain="us-gaap:IncomeStatementAbstract" enum2:headUsable="false" enum2:linkrole="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_RevenueInterestPaid" name="RevenueInterestPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" name="PotentialRevenueInterestThirdPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" name="AccruedClinicalAndContractResearchOrganizationCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" name="AdjustmentsToAdditionalPaidInCapitalCapitalContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_RevenueRecognitionExpectedPeriod" name="RevenueRecognitionExpectedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" name="DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_InventoryReserve" name="InventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_NonCashInterestExpenseRecognized" name="NonCashInterestExpenseRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_MarketBasedRestrictedStockUnitsRSUMember" name="MarketBasedRestrictedStockUnitsRSUMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" name="AdditionalTransactionPriceOfRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ItemsToReconcileNetLossToAdjustedEBITDA" name="ItemsToReconcileNetLossToAdjustedEBITDA" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MedicareRevenueMember" name="MedicareRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PercentageOfCumulativePurchaserPayments" name="PercentageOfCumulativePurchaserPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NumberOfCommonStockVotingRights" name="NumberOfCommonStockVotingRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ContractBalancesPolicyTextBlock" name="ContractBalancesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" name="PotentialRevenueInterestSecondPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_AdditionalMilestonePayment" name="AdditionalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" name="LesseeOperatingLeaseRentCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" name="ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_RevenueInterestLiabilityNet" name="RevenueInterestLiabilityNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" name="LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_PercentageOfAnnualIncreasesInNumberOfShares" name="PercentageOfAnnualIncreasesInNumberOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MedicareReimbursementsMember" name="MedicareReimbursementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" name="LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" name="DeferredTaxLiabilitiesTangibleAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" name="ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PotentialRevenueInterestPaymentToBeReceived" name="PotentialRevenueInterestPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" name="ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_RevenueInterestLiability" name="RevenueInterestLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" name="TwoThousandAndNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" name="AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" name="OrbimedRoyaltyCreditOpportunitiesIvLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LesseeOperatingLeaseExtendedTermOfContract" name="LesseeOperatingLeaseExtendedTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PurchaseAgreementSecondPaymentDate" name="PurchaseAgreementSecondPaymentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" name="RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" name="Deferredtaxassetscapitalizedresearchanddevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_NonRefundableUpfrontPaymentsReceived" name="NonRefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" name="TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_CustomerAMember" name="CustomerAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" name="NonvestedMarketBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SalesAndMarketingExpensePolicyTextBlock" name="SalesAndMarketingExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ProceedsFromLandlordReimbursements" name="ProceedsFromLandlordReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ImmuneMedicineServiceRevenueMember" name="ImmuneMedicineServiceRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PercentageOfNetVestedSharesOfCommonStock" name="PercentageOfNetVestedSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" name="CommonStockOptionsAndRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestPaymentTerm" name="RevenueInterestPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NonvestedStockOptionsMember" name="NonvestedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_MichelleGriffinMember" name="MichelleGriffinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_TenantImprovementAllowanceAndCommenced" name="TenantImprovementAllowanceAndCommenced" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_DevelopmentRevenueMember" name="DevelopmentRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" name="CommonStockExerciseOfOutstandingStockOptionsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ResearchAndDevelopmentInventoryReserve" name="ResearchAndDevelopmentInventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" name="ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_TwoThousandAndNineEquityIncentivePlanMember" name="TwoThousandAndNineEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ImpairmentOfLongLivedAssets" name="ImpairmentOfLongLivedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_GenentechIncAndRocheGroupMember" name="GenentechIncAndRocheGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ComputerSoftwareMember" name="ComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DeferredTaxAssetTangibleAndIntangibleAssets" name="DeferredTaxAssetTangibleAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" name="DefinedContributionPlanEmployeeServicePeriodForVesting" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NoncashInterestExpense" name="NoncashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" name="ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_OperatingLeaseVariableLeaseExpense" name="OperatingLeaseVariableLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_MonteCarloValuationModelMember" name="MonteCarloValuationModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PurchaseAgreementThirdPaymentDate" name="PurchaseAgreementThirdPaymentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CumulativePurchaserPaymentsReceivableDate" name="CumulativePurchaserPaymentsReceivableDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" name="ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PutOrCallOptionMember" name="PutOrCallOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_CommonStockWarrantOutstandingMember" name="CommonStockWarrantOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SpecificPatientsMember" name="SpecificPatientsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestPayable" name="RevenueInterestPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_DigitalBiotechnologiesIncMember" name="DigitalBiotechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" name="RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ImmuneMedicineBusinessMember" name="ImmuneMedicineBusinessMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" name="ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" name="AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_SequencingRevenueMember" name="SequencingRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" name="IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" name="NonvestedMarketBasedRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdjustedEbitda" name="AdjustedEbitda" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" name="ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CumulativePurchaserPaymentsRepaymentDate" name="CumulativePurchaserPaymentsRepaymentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MRDRevenueMember" name="MRDRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RegulatoryMilestoneRevenueMember" name="RegulatoryMilestoneRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestPurchaseAgreementTextBlock" name="RevenueInterestPurchaseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" name="AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_NumberOfRevenuePerformanceObligation" name="NumberOfRevenuePerformanceObligation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" name="ImpairmentOfRightOfUseAndRelatedLongLivedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" name="ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NonvestedRestrictedStockUnitsRSUMember" name="NonvestedRestrictedStockUnitsRSUMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_GenentechIncMember" name="GenentechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestLiabilityNetNoncurrent" name="RevenueInterestLiabilityNetNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_MRDDevelopmentAgreementsMember" name="MRDDevelopmentAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" name="ScheduleOfReservedSharesOfCommonStockTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ComputerAndSoftware" name="ComputerAndSoftware" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TenantImprovementCostsIncurred" name="TenantImprovementCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DeferredTaxAssetsNonQualifiedStockOptions" name="DeferredTaxAssetsNonQualifiedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_TenantImprovementCostsReceivable" name="TenantImprovementCostsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" name="ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_DeferredRevenueTextBlock" name="DeferredRevenueTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" name="LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" name="ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_CustomerBMember" name="CustomerBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_MrdBusinessSegmentMember" name="MrdBusinessSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" name="CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" name="ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629623568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIVE BIOTECHNOLOGIES CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001478320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,582,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0907024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1165 Eastlake Avenue East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the Registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2025.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822626883472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,920<span></span>
</td>
<td class="nump">$ 65,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities (amortized cost of $174,186 and $281,122, respectively)</a></td>
<td class="nump">174,374<span></span>
</td>
<td class="nump">281,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">41,731<span></span>
</td>
<td class="nump">37,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">8,440<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,287<span></span>
</td>
<td class="nump">11,370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">283,752<span></span>
</td>
<td class="nump">410,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">48,616<span></span>
</td>
<td class="nump">68,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">45,767<span></span>
</td>
<td class="nump">52,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities (amortized cost of $33,682)</a></td>
<td class="nump">33,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">5,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">118,972<span></span>
</td>
<td class="nump">118,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">3,591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">539,376<span></span>
</td>
<td class="nump">661,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">7,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,157<span></span>
</td>
<td class="nump">8,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">15,838<span></span>
</td>
<td class="nump">13,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">10,239<span></span>
</td>
<td class="nump">9,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">55,689<span></span>
</td>
<td class="nump">48,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of revenue interest liability, net</a></td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">98,053<span></span>
</td>
<td class="nump">88,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">79,148<span></span>
</td>
<td class="nump">89,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">27,256<span></span>
</td>
<td class="nump">44,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Revenue interest liability, net, less current portion</a></td>
<td class="nump">132,414<span></span>
</td>
<td class="nump">130,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">336,891<span></span>
</td>
<td class="nump">352,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2024 and 2023; 147,773,744 and 145,082,271 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,506,353<span></span>
</td>
<td class="nump">1,452,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,303,824)<span></span>
</td>
<td class="num">(1,144,332)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Adaptive Biotechnologies Corporation shareholders&#8217; equity</a></td>
<td class="nump">202,709<span></span>
</td>
<td class="nump">308,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">202,485<span></span>
</td>
<td class="nump">308,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 539,376<span></span>
</td>
<td class="nump">$ 661,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624111600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost of short-term marketable securities</a></td>
<td class="nump">$ 174,186<span></span>
</td>
<td class="nump">$ 281,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost of long-term marketable securities</a></td>
<td class="nump">$ 33,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">147,773,744<span></span>
</td>
<td class="nump">145,082,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">147,773,744<span></span>
</td>
<td class="nump">145,082,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627859696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 178,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 170,276<span></span>
</td>
<td class="nump">$ 185,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">75,553<span></span>
</td>
<td class="nump">57,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102,953<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">122,117<span></span>
</td>
<td class="nump">141,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,759<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">88,579<span></span>
</td>
<td class="nump">95,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">83,934<span></span>
</td>
<td class="nump">88,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">25,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">341,506<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">397,311<span></span>
</td>
<td class="nump">385,494<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(162,549)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(227,035)<span></span>
</td>
<td class="num">(200,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,534<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,531<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(11,580)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(4,238)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(159,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(225,304)<span></span>
</td>
<td class="num">(200,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Add: Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (159,492)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (225,250)<span></span>
</td>
<td class="num">$ (200,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,101,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,101,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on the Purchase Agreement.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822722232128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (159,595)<span></span>
</td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains and losses on investments</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(159,644)<span></span>
</td>
<td class="num">(220,973)<span></span>
</td>
<td class="num">(203,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Add: Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="num">$ (159,541)<span></span>
</td>
<td class="num">$ (220,919)<span></span>
</td>
<td class="num">$ (203,170)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627030096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 604,102<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,324,006<span></span>
</td>
<td class="num">$ (1,137)<span></span>
</td>
<td class="num">$ (718,891)<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,393,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">55,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(2,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(200,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,191)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">464,098<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">1,387,349<span></span>
</td>
<td class="num">(4,116)<span></span>
</td>
<td class="num">(919,082)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,105,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,506,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">62,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(225,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,250)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">308,278<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">1,452,502<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="num">(1,144,332)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,082,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="nump">103,800<span></span>
</td>
<td class="nump">103,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,587,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 53,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(159,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159,492)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 202,485<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,506,353<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="num">$ (1,303,824)<span></span>
</td>
<td class="num">$ (224)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,773,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock award vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627813584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (159,595)<span></span>
</td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">17,553<span></span>
</td>
<td class="nump">20,532<span></span>
</td>
<td class="nump">19,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">5,277<span></span>
</td>
<td class="nump">6,920<span></span>
</td>
<td class="nump">7,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">53,610<span></span>
</td>
<td class="nump">62,908<span></span>
</td>
<td class="nump">55,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets amortization</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Investment amortization</a></td>
<td class="num">(8,208)<span></span>
</td>
<td class="num">(9,184)<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfLongLivedAssets', window );">Impairment of long-lived assets</a></td>
<td class="nump">7,205<span></span>
</td>
<td class="nump">25,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_InventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NoncashInterestExpense', window );">Noncash interest expense</a></td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(3,744)<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="num">(22,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="num">(2,838)<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(1,930)<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">671<span></span>
</td>
<td class="num">(5,407)<span></span>
</td>
<td class="nump">7,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(9,385)<span></span>
</td>
<td class="num">(8,676)<span></span>
</td>
<td class="num">(4,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(10,478)<span></span>
</td>
<td class="num">(29,291)<span></span>
</td>
<td class="num">(56,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(95,212)<span></span>
</td>
<td class="num">(156,324)<span></span>
</td>
<td class="num">(183,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,664)<span></span>
</td>
<td class="num">(10,697)<span></span>
</td>
<td class="num">(16,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(244,257)<span></span>
</td>
<td class="num">(429,558)<span></span>
</td>
<td class="num">(278,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">325,713<span></span>
</td>
<td class="nump">569,902<span></span>
</td>
<td class="nump">298,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">77,792<span></span>
</td>
<td class="nump">129,647<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">7,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts', window );">Proceeds from revenue interest purchase agreement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">132,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(17,179)<span></span>
</td>
<td class="num">(24,432)<span></span>
</td>
<td class="num">(48,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">67,996<span></span>
</td>
<td class="nump">92,428<span></span>
</td>
<td class="nump">141,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">50,817<span></span>
</td>
<td class="nump">67,996<span></span>
</td>
<td class="nump">92,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 8,864<span></span>
</td>
<td class="nump">$ 8,985<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ImpairmentOfLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of long lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ImpairmentOfLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right-of-use assets and liabilities .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_InventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_InventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from revenue interest purchase agreement, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822626741328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As trusted partners to healthcare providers, patients, biopharmaceutical companies, academic and non-profit institutions, business partners and employees, we appreciate the importance of maintaining a comprehensive and trustworthy information security program. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security program is fully </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our operations, and a hallmark of our program is its cross-functional approach with our internal privacy objectives and stakeholders.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is based on the ISO 27001 security controls set, and in particular, it focuses on the principles of confidentiality, integrity and availability. We maintain an ISO 27001 certification with a fully integrated set of operational policies and procedures to adhere to the domains of ISO 27001. This includes but is not limited to the organization of information security to assign roles and responsibilities within Adaptive, access control to restrict employees&#8217; access to view only that information that is relevant to their roles, information security incident management, and compliance to broadly ensure alignment with applicable laws and regulations.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We perform an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annual risk assessment conducted by an outside assessor and conduct vendor risk assessments for third party vendors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to evaluate how their systems may impact our business in the event of a cybersecurity incident. We also provide annual, mandatory cybersecurity training for employees to equip our workforce with the knowledge to identify and respond to cybersecurity threats, such as phishing attempts.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#8220;PISSC&#8221;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PISSC is made up of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.</span></span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding our information security and privacy governance and reports on information security and privacy incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cybersecurity threats, including as a result of any past cybersecurity incidents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#8220;Risk Factors&#8221; section.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security program is fully </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our operations, and a hallmark of our program is its cross-functional approach with our internal privacy objectives and stakeholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is based on the ISO 27001 security controls set, and in particular, it focuses on the principles of confidentiality, integrity and availability. We maintain an ISO 27001 certification with a fully integrated set of operational policies and procedures to adhere to the domains of ISO 27001. This includes but is not limited to the organization of information security to assign roles and responsibilities within Adaptive, access control to restrict employees&#8217; access to view only that information that is relevant to their roles, information security incident management, and compliance to broadly ensure alignment with applicable laws and regulations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#8220;PISSC&#8221;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PISSC is made up of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.</span></span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding our information security and privacy governance and reports on information security and privacy incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cybersecurity threats, including as a result of any past cybersecurity incidents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#8220;Risk Factors&#8221; section.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding our information security and privacy governance and reports on information security and privacy incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cybersecurity threats, including as a result of any past cybersecurity incidents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#8220;Risk Factors&#8221; section.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#8220;PISSC&#8221;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PISSC is made up of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PISSC is made up of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> regarding our information security and privacy governance and reports on information security and privacy incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cybersecurity threats, including as a result of any past cybersecurity incidents</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625463008">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (159,492)<span></span>
</td>
<td class="num">$ (225,250)<span></span>
</td>
<td class="num">$ (200,191)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625359008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 18, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michelle Griffin</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a member of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading plan. Ms. Griffin&#8217;s plan provides for the sale of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net vested shares of our common stock received in connection with the vesting of certain restricted stock units. The plan's expiration date is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 14, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding transactions in our securities.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=adpt_MichelleGriffinMember', window );">Michelle Griffin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Michelle Griffin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board of Directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 18, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">March 14, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfNetVestedSharesOfCommonStock', window );">Percentage of net vested shares of common stock</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfNetVestedSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net vested shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfNetVestedSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=adpt_MichelleGriffinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=adpt_MichelleGriffinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715292720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adaptive Biotechnologies Corporation (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822722240480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#8220;Purchase Agreement&#8221;), the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segments: Minimal Residual Disease (&#8220;MRD&#8221;) and Immune Medicine. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM regularly reviews operating results and other financial information presented at the MRD and Immune Medicine segment level, as well as on a consolidated basis, to make resource allocation decisions. The MRD and Immune Medicine segments are also our two reporting units.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had a restricted cash balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our facility leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are classified as available-for-sale, consist of United States (&#8220;U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2024 or 2023.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively. There were no customers that represented more than ten percent of our accounts receivable, net balances as of December 31, 2024 or 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.211%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Genentech, Inc. and Roche Group</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.8</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.4</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by our MRD segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by both our MRD and Immune Medicine segments.</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included within the other assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:49.14%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment losses on intangible assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of attributed identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of one or both of our reporting units below its respective carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the allocated goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment of goodwill.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for commenced leases that existed as of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 842).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the right-of-use asset and related long-lived asset impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our MRD and Immune Medicine business areas. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#8220;Genentech&#8221;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#8217; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#8217; therapeutic development efforts, including regulatory support where our technology is intended to be utilized as part of our customers&#8217; registrational trials, developing analytical plans for our data, participating on joint committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#8217; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For research customers who utilize either our MRD or Adaptive Immunosequencing services, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> typical performance obligations under the terms of our research service contracts: (1) the delivery of our MRD data or Adaptive Immunosequencing for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract Balances</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising costs are expensed as incurred. Advertising expenses were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales and Marketing Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets expenses include our impairment charges for certain leased office and laboratory space, related long-lived assets (including leasehold improvements and laboratory equipment) and long-lived assets associated with our halted software enhancements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 280): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which intends to enhance reportable segment disclosures with an emphasis on significant segment expenses. We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this guidance in the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fourth quarter of 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and applied it retrospectively. See Note 19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more information.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">: Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715317872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our disaggregated revenue for the periods presented (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MRD revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total MRD revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Immune Medicine revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,777</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,452</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,957</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,308</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2024, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and cancelled customer contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we could receive up to an additional </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">418.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestone payments in future periods if certain regulatory approvals are obtained by our customers&#8217; therapeutics in connection with MRD data generated from our MRD product.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Genentech Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the &#8220;Genentech Agreement&#8221;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in February 2019. We also received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone in 2023. We may be eligible to receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion over time, including payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified regulatory milestones, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified development milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,430.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell therapeutic products in which Genentech intends to use T cell receptors (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;TCRs&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) screened by our immune medicine platform to engineer and manufacture cellular medicines:</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shared Products. The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;ASC&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) Topic 808, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 808&#8221;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#8217;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;ASC 606&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to account for the activities related to the Genentech Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In applying ASC 606, we identified the following performance obligations at the inception of the agreement:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License to existing shared antigen data packages. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development services for Shared Products development, including expansion of shared antigen data packages. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development services for private product development. </span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations to participate on various joint research, development and project committees. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#8217;s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined the initial transaction price shall be made up of only the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million addition to the transaction price, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which was recognized as revenue in the three months ended June 30, 2023, with the remainder included in deferred revenue to be recognized as revenue over the remaining research and development period. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize revenue generated from the Genentech Agreement over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6a683fd2-b719-4e8e-9163-23af35cb1311;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nine</span></span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In total, we recognized </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.6</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in Immune Medicine collaboration revenue during the year ended December 31, 2024, 2023 and 2022, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715346080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredRevenueTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue from the Genentech Agreement represents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2023. We expect our current deferred revenue to be recognized as revenue within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from December 31, 2024. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in deferred revenue during the year ended December 31, 2024 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,423</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,414</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,945</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized as revenue that was included in the deferred revenue balance at December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715228272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair values of financial assets as of December 31, 2024 and 2023 that were measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,790</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,034</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,824</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,123</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,123</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,123</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,337</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326,460</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715312576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available-for-sale investments consisted of the following as of December 31, 2024 and 2023 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,476</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,353</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,521</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,186</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,374</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,682</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,660</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,214</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,337</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was presented separately within the prepaid expenses and other current assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2024 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months Or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,782</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2024 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624765904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net as of December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,950</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,567</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,040</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,820</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,965</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,571</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,277</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,734</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,461</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,817</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,616</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715294448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill and Intangible Assets</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> changes in the carrying amount of goodwill since its recognition in 2015. In conjunction with our organizational realignment in 2024, we allocated goodwill among our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reporting units using a relative fair value approach. Goodwill allocated to the MRD and Immune Medicine reporting units as of December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets subject to amortization as of December 31, 2024 and 2023 consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,359</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,900</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,970</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,325</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,197</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,128</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed technology and the purchased intellectual property is expected to be amortized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, approximately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, expected future amortization expense for intangible assets was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,699</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,699</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,425</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624746112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,922</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical and contract research organization costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Travel and entertainment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">687</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">763</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,597</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822719466496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash payment for rent of the expanded premises commenced </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to our option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount of the asset group to future net undiscounted cash flows projected to be generated over the remaining lease term. These projections include management's estimates of cash inflows from potential sublease income and outflows for operating and maintenance expenses. The carrying amount was found to be unrecoverable, thus we assessed the asset group's fair value. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Fair value was determined using the income approach, whereby we discounted estimated net cash flows using a rate commensurate with our estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, we determined that the asset group was to be fully impaired. As such, an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_66782f0d-d53d-4c13-bd13-17f76499cf21;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment charge</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized during the year ended December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which related to the right-of-use asset and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which related to the long-lived leasehold improvements, all of which were held for use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2019, we entered into an agreement to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million letter of credit with one of our existing financial institutions. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash payment for rent began in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the lease term ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to our option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twice extend the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with this lease, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in improvements, which was subsequently reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as a result of our change requests made during landlord construction of the building, net of an administration fee. We incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in certain tenant improvement costs, all of which had been reimbursed by the landlord as of December 31, 2022. The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2018, we entered into a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet in South San Francisco, California. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term is through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and provides for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> extension option</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are responsible for our share of allocable operating expenses, tax expenses and utilities costs during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,900</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional square feet and provides for a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million tenant improvement allowance. In 2024, as part of a restructuring, we vacated certain of the leased space in South San Francisco, California and incurred a related impairment charge. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, we executed a lease to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the lease expires </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to an early termination option after the seventh year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in improvements in connection with this lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we were not party to any finance leases. Our leases have remaining terms ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and include </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">options to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend certain of the leases</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and terminate certain of the leases after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years of leasing. We adjust lease terms for these options only when it is reasonably certain we will exercise these options.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other information related to our operating leases as of December 31, 2024 and 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.379999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.379999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.06</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.91</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,282</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,630</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,616</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,229</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,387</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively. Variable lease expense for operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash received for tenant improvement allowances during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624765904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPurchaseAgreementTextBlock', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text"><div class="item-list-element-wrapper" style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty &amp; Credit Opportunities IV, LP (&#8220;OrbiMed&#8221;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Purchasers at closing (the &#8220;First Payment&#8221;), less certain transaction expenses. We are also entitled to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in subsequent installments as follows: (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon our request occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 12, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Second Payment&#8221;) and (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon our request in connection with certain permitted acquisitions occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 12, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Third Payment&#8221;), in each case subject to certain funding conditions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Payments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from us based on a percentage (the &#8220;Applicable Payment Percentage&#8221;) of all GAAP revenue (the &#8220;Revenue Base&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments in respect of the Revenue Interests shall be made quarterly within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days following the end of each fiscal quarter (each, a &#8220;Revenue Interest Payment&#8221;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;Cumulative Purchaser Payments&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Return Cap</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OrbiMed will be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Revenue Interest Payments until it has received a total cumulative value of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Cumulative Purchaser Payments (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 12, 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in which case the Return Cap shall be increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Put/Call Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by us, a change in control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation ("the Put Option") to require us to repurchase all of the outstanding Revenue Interests at the applicable price (the &#8220;Put/Call Price&#8221;). Additionally, at any time following receipt of the First Payment, we may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap. For a change of control or a material divestiture, the Put/Call Price shall be equal to the applicable Return Cap.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Treatment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the terms of the Purchase Agreement and concluded that the features of the Cumulative Purchaser Payments are similar to those of a debt instrument. Accordingly, we accounted for the transaction as debt recorded at amortized cost using the effective interest rate method. We further evaluated the terms of the debt and determined that the Put Option that is exercisable by the Purchasers upon certain contingent events requires bifurcation as a derivative. However, the value of the Put Option was determined to be immaterial due to the remote possibility of exercise. We assess the value of the Put Option periodically.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> over the amortization period. The calculated effective interest rate as of December 31, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Purchase Agreement, we incurred debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Debt issuance costs have been recorded to debt and are being amortized over the estimated term of the debt using the effective interest method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the issuance costs, as well as the effective interest rate.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,360</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,275</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,279</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">865</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net, less current portion at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,414</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2022. Revenue interest payable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715185760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624694544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders&#8217; Equity</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has no preferences or privileges and is not redeemable. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share of common stock held</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective January 1, 2024, our 2019 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,254,113</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,450,822</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively. Our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2025.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had reserved shares of common stock for the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issuable upon the exercise of outstanding stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,295,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,005,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grant under the 2019 Equity Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,018,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grant under the Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,686,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,005,745</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715210192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2009 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We adopted an equity incentive plan in 2009 (the &#8220;2009 Plan&#8221;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date and vesting is established at the time of grant. Except for certain awards granted to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period, subject to continuous service through each applicable vesting date. As of December 31, 2024, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,683,842</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock authorized for issuance under the 2019 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in shares available for grant during the year ended December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Available for Grant</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,299,763</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan reserve increase effective January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,254,113</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,841,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,305,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,018,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2024 was as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.2%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.780000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.780000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Subject to<br/>Outstanding Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise<br/>Price per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,875,045</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,008,364</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.99</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">718,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,295,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested and exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,027,350</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining contractual life for stock options outstanding as of December 31, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The weighted-average remaining contractual life for vested and exercisable stock options as of December 31, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.9</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value of stock options exercised during the year ended December 31, 2024, 2023 and 2022 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units<br/>Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,669,460</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,619,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,525,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,587,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.28</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,174,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of restricted stock units vested during the year ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market-Based Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our executive officers have been granted awards of market-based restricted stock units. The number of shares of common stock that may be earned under the respective awards range</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares to a defined maximum number of shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and are c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alculated based on our total shareholder return during a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance period as measured against that of the group of companies comprising the S&amp;P Biotechnology Select Industry Index as of the grant date or other applicable date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market-based restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maximum Market-Based Restricted Stock Units Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested maximum market-based restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,912,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.13</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum market-based restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,214,020</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum market-based restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested maximum market-based restricted stock units outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,831,114</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated grant date fair values of stock options granted during the years ended December 31, 2024, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.189%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.238%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.99</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.46</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.30</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.95</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are subjective and generally require judgment to determine. The valuation assumptions were determined as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair value of common stock&#8212;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term of stock options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based on the midpoint between the vesting date and the end of the contractual term of the stock option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Until 2024, as we did not have sufficient trading history for our common stock, expected volatility was based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning in 2024, expected volatility was based on a weighted average of our historical volatility and the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend yield</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the option valuation model.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2024, 2023 and 2022 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.70</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.61</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.36</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant date fair value of restricted stock units granted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.29</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.43</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of the market-based restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The aggregate share-based compensation expense of the market-based restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million respectively. Aggregate share-based compensation expense is calculated based on the target payout level of shares granted and is recognized on a straight-line basis over the respective grants' performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense is reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2024, 2023 and 2022 are included on the consolidated statements of operations as follows (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,632</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,910</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,370</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,553</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,597</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,908</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Share-Based<br/>Compensation Expense<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Weighted-Average<br/>Recognition Period<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,803</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.23</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested market-based restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,611</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.66</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822721638224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restructurings</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> employees. We incurred aggregate restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees&#8217; execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to this reduction in workforce were primarily completed in March 2022 and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate restructuring costs were paid as of December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2024, we implemented a restructuring plan to better align our organization to our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segments: MRD and Immune Medicine. We incurred aggregate restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, primarily related to one-time termination benefits and ongoing benefit arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended June 30, 2024, we implemented additional restructuring initiatives which impacted certain planned software enhancements and resulted in the consolidation of certain research and development workflows. The impacted software enhancements were primarily associated with our laboratory information management systems. As part of these restructurings, we had long-lived assets that were no longer being utilized and we vacated certain leased space in South San Francisco, California. As such, we assessed the related assets for impairment by first comparing their carrying amounts to the future net undiscounted cash flows projected to be generated over their remaining lease terms or depreciable lives, as applicable. The carrying amounts were all found to be unrecoverable, thus we assessed the fair values of the assets. The extent to which the carrying amounts of the assets exceed their fair values represents the impairment costs to be recognized. As a result of our assessments, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of impairment charges. Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million charges recognized, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million relates to the right-of-use asset and related long-lived assets (namely laboratory equipment and leasehold improvements), respectively, associated with certain of our leased space in South San Francisco, California. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized relates to the impairment of long-lived assets associated with our halted software enhancements. We also incurred an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in restructuring costs primarily related to one-time termination benefits and ongoing benefit arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended December 31, 2024, we incurred an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate restructuring costs, which primarily related to one-time termination benefits and ongoing benefit arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In total, we recognized restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024. The activities and payments related to these restructurings were completed and paid as of December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822630169968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of loss before provision for income taxes for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,427</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total loss before provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,724</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit carryforward</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,942</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,528</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonqualifying stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,010</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,996</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,550</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,134</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,963</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,146</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447,090</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416,929</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,509</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402,424</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,581</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,581</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of December 31, 2024, we had U.S. federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and U.S. federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">856.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of NOLs as of December 31, 2024 that do not expire.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.36%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:14.4%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:14.4%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:14.4%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Credits</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for global intangible low-taxed income as period costs when incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,915</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,303</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,407</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, 2023 and 2022, we recognized uncertain tax positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties related to uncertain tax positions as of December 31, 2024 and 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624676336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022 (in thousands, except share and per share amounts):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,101,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,383,294</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,515,917</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.08</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022, as they had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.255%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.255%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.255%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,744,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,839,067</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,892,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,584,853</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,630,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,799,850</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum nonvested market-based restricted stock units outstanding eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,497,226</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,663,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410,282</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,826,977</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,133,607</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,102,419</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625505792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Retirement Plan</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retirement Plan</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a salary deferral 401(k) plan (&#8220;401(k) Plan&#8221;) covering employees who have met certain eligibility requirements. Employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their compensation to the 401(k) Plan, subject to federal limits. We made $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#231f20;">2.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in discretionary contributions during the year ended December 31, 2024, 2023 and 2022, respectively, which are fully vested after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one year</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of employee service.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624702352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, in connection with an organizational realignment, we began operating our business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segments: MRD and Immune Medicine. These segments are organized by market opportunity in commercial diagnostics and drug discovery, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MRD business focuses on the use of our highly sensitive, next-generation sequencing assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ assay, offered to biopharmaceutical partners to advance drug development efforts. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Immune Medicine business leverages our proprietary ability to sequence, map, pair and characterize TCRs and B cell receptors at scale. We have created a powerful data engine to drive the development of novel therapies. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> inter-segment revenues. See Note 3, Revenue for more information about each segment's revenue. Our CODM, which is our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8759c879-be95-43bb-8de5-203e18a7141c;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluates performance of the MRD segment based on both revenue and Adjusted EBITDA and evaluates performance of the Immune Medicine segment based on Adjusted EBITDA. These measures help our CODM assess the trends and operating margin profile of the respective segments, which helps drive the level of investment made in each business. These measures also help our CODM assess and manage the potential capital utilization of each segment. Adjusted EBITDA for each of our segments includes costs that are directly aligned to each segment, as well as certain allocated shared expenses.</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions.</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, we do not allocate costs related to our idle facility in Seattle, Washington, interest expense related to our Purchase Agreement nor interest and other income, net. Given these unallocated costs and income are not included in the measurements reviewed by the CODM to assess each segment's performance, they are included in an "Unallocated Corporate" category. Our allocation methodology will be periodically evaluated and may change. Our CODM is not regularly provided and does not review assets to assess each segment's performance, make strategic decisions or allocate resources. As such, assets for reportable segments are not disclosed.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment information for the years ended December 31, 2023 and 2022 are presented on a comparable basis to that of the current period and is based on judgments and allocation methods from our organizational changes implemented during the three months ended March 31, 2024.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></p><p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,153</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add back:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Items to reconcile net loss to adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,844</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,210</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,842</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,067</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,016</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add back:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Items to reconcile net loss to adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,366</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,371</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,848</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,205</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,733</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,256</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,844</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,441</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,413</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,657</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,908</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,439</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,892</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,586</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_75bb2233-9ac9-45f1-8031-2e009382d5f2;"><span style="-sec-ix-hidden:F_83fd51e3-9860-4816-b7d4-990a29a9c263;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span></span></span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,294</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,984</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes MRD impairment of long-lived assets expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes all Immune Medicine operating expenses, other than research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on the Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on our impairment expense.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629822176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#8220;Purchase Agreement&#8221;), the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segments: Minimal Residual Disease (&#8220;MRD&#8221;) and Immune Medicine. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM regularly reviews operating results and other financial information presented at the MRD and Immune Medicine segment level, as well as on a consolidated basis, to make resource allocation decisions. The MRD and Immune Medicine segments are also our two reporting units.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had a restricted cash balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our facility leases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities are classified as available-for-sale, consist of United States (&#8220;U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2024 or 2023.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively. There were no customers that represented more than ten percent of our accounts receivable, net balances as of December 31, 2024 or 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.211%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Genentech, Inc. and Roche Group</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.8</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.4</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by our MRD segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by both our MRD and Immune Medicine segments.</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included within the other assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:49.14%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment losses on intangible assets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of attributed identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of one or both of our reporting units below its respective carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the allocated goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment of goodwill.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for commenced leases that existed as of our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 842).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for more information regarding the right-of-use asset and related long-lived asset impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock', window );">Revenue Interest Liability, Net and Related Imputed Interest</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our MRD and Immune Medicine business areas. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#8220;Genentech&#8221;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#8217; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#8217; therapeutic development efforts, including regulatory support where our technology is intended to be utilized as part of our customers&#8217; registrational trials, developing analytical plans for our data, participating on joint committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#8217; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For research customers who utilize either our MRD or Adaptive Immunosequencing services, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> typical performance obligations under the terms of our research service contracts: (1) the delivery of our MRD data or Adaptive Immunosequencing for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ContractBalancesPolicyTextBlock', window );">Contract Balances</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract Balances</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising costs are expensed as incurred. Advertising expenses were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SalesAndMarketingExpensePolicyTextBlock', window );">Sales and Marketing Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales and Marketing Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets expenses include our impairment charges for certain leased office and laboratory space, related long-lived assets (including leasehold improvements and laboratory equipment) and long-lived assets associated with our halted software enhancements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 280): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which intends to enhance reportable segment disclosures with an emphasis on significant segment expenses. We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this guidance in the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fourth quarter of 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and applied it retrospectively. See Note 19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for more information.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">: Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and principles of consolidation policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ContractBalancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ContractBalancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability, net and related imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SalesAndMarketingExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SalesAndMarketingExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715202352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentrations of Risk Percentage</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.211%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
          <td style="width:1.48%;box-sizing:content-box;"></td>
          <td style="width:12.783%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Genentech, Inc. and Roche Group</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.8</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.4</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by our MRD segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The related revenue was recognized and reported by both our MRD and Immune Medicine segments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Useful Lives Assigned to Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:49.14%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715340976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our disaggregated revenue for the periods presented (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MRD revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total MRD revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Immune Medicine revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Service revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,777</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,452</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,957</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,308</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715216208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in deferred revenue during the year ended December 31, 2024 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,423</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions to deferred revenue during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,414</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,945</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625529472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth the fair values of financial assets as of December 31, 2024 and 2023 that were measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,790</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,034</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,824</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,123</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,123</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,123</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,337</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326,460</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715255120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available-for-sale investments consisted of the following as of December 31, 2024 and 2023 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,476</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,353</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,521</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,186</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,374</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,682</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,660</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,630</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,214</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,278</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,122</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,337</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2024 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months Or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,782</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total available-for-sale securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822721491952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net as of December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,950</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,567</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,040</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,820</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,965</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,571</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,405</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,277</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,734</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,461</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,817</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,616</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715314320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets Subject to Amortization</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets subject to amortization as of December 31, 2024 and 2023 consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,359</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,325</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,900</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,970</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,030</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,325</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,197</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,128</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense for Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, expected future amortization expense for intangible assets was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,699</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,699</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,425</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629770304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,922</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical and contract research organization costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Travel and entertainment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">687</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">763</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,597</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625541104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Other Information Related to Operating Lease</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other information related to our operating leases as of December 31, 2024 and 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.379999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.379999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.06</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.91</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Reconciles Undiscounted Operating Lease Cash Flows</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,098</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,944</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,282</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,630</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,616</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,229</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,387</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624689200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock', window );">Schedule of Revenue Interest Liability, Net Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,360</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,275</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,279</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">865</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue interest liability, net, less current portion at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,414</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of revenue interest liability, net activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715307136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock', window );">Summary of Reserved Shares of Common Stock</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had reserved shares of common stock for the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issuable upon the exercise of outstanding stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,295,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,005,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grant under the 2019 Equity Incentive Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,018,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future grant under the Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,686,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,005,745</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reserved shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625450784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock', window );">Summary of Changes in Shares Available for Grant</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in shares available for grant during the year ended December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Available for Grant</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,299,763</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan reserve increase effective January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,254,113</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,841,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,305,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,018,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under 2009 Plan and 2019 Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2024 was as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.2%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.780000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.780000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Subject to<br/>Outstanding Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise<br/>Price per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,875,045</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,008,364</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.99</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">718,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,295,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested and exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,027,350</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units<br/>Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,669,460</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,619,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,525,936</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,587,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.28</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,174,852</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market-based restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maximum Market-Based Restricted Stock Units Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested maximum market-based restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,912,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.13</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum market-based restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,214,020</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum market-based restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested maximum market-based restricted stock units outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,831,114</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Grant Date Fair Values of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated grant date fair values of stock options granted during the years ended December 31, 2024, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.189%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.238%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.99</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.46</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.30</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.95</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Costs Related to Stock Options and RSUs Included on Consolidated Statements of Operations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2024, 2023 and 2022 are included on the consolidated statements of operations as follows (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,632</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,910</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,370</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,553</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,597</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,908</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock', window );">Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Share-Based<br/>Compensation Expense<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Weighted-Average<br/>Recognition Period<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,943</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,803</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.23</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested market-based restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,611</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.66</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share-based compensation, shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715185760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of loss before provision for income taxes for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,635</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,427</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total loss before provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,724</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit carryforward</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,942</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,528</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonqualifying stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,010</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,996</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,550</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,134</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,963</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,146</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447,090</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416,929</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">435,509</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402,424</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,581</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,581</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.36%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:14.4%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:14.4%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:14.4%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Credits</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Change in Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;box-sizing:content-box;"></td>
        <td style="width:2.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,915</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,303</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions in 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,407</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715182464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022 (in thousands, except share and per share amounts):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.782%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,101,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,383,294</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,515,917</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.08</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022, as they had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.255%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.255%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.255%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,744,898</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,839,067</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,892,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested restricted stock units outstanding</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,584,853</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,630,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,799,850</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maximum nonvested market-based restricted stock units outstanding eligible to be earned</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,497,226</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,663,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410,282</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,826,977</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,133,607</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,102,419</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624676336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information, Including Significant Segment Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></p><p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.32%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,153</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,349</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add back:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Items to reconcile net loss to adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,012</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,546</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,844</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,210</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,842</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,067</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,016</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add back:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Items to reconcile net loss to adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,366</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,371</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,848</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,051</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,205</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,073</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,450</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,733</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,256</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,580</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,844</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,441</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,413</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,657</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,908</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.741%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.096%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MRD</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Immune Medicine</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Corporate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;to Net Loss:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,654</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,439</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,892</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,586</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_75bb2233-9ac9-45f1-8031-2e009382d5f2;"><span style="-sec-ix-hidden:F_83fd51e3-9860-4816-b7d4-990a29a9c263;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring expense</span></span></span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,294</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,984</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,920</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to noncontrolling interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,368</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes MRD impairment of long-lived assets expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes all Immune Medicine operating expenses, other than research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on the Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on our impairment expense.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629607024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Performance_Obligation </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,897,000<span></span>
</td>
<td class="nump">$ 2,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryNoncurrent', window );">Long-term inventory</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment losses on intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NumberOfOperatingAndReportableSegments', window );">Number of operating and reportable segments | Segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adpt_DigitalBiotechnologiesIncMember', window );">Digital Biotechnologies Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NumberOfRevenuePerformanceObligation', window );">Number of revenue performance obligations | Performance_Obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting standards update adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting standards update adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">Accounting Standards Update 2023-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting standards update adoption date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting standards update adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfOperatingAndReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating and reportable segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfOperatingAndReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfRevenuePerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of revenue performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfRevenuePerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle (such as inventory related to long-term contracts or program rights).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adpt_DigitalBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adpt_DigitalBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715005376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Revenue - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember', window );">Genentech, Inc. and Roche Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
<td class="nump">36.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629244720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627357552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Disaggregated Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 178,957<span></span>
</td>
<td class="nump">$ 170,276<span></span>
</td>
<td class="nump">$ 185,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember', window );">MRD Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">145,529<span></span>
</td>
<td class="nump">102,739<span></span>
</td>
<td class="nump">87,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember', window );">MRD Revenue | Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">133,029<span></span>
</td>
<td class="nump">102,739<span></span>
</td>
<td class="nump">81,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember', window );">MRD Revenue | Regulatory Milestone Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember', window );">Immune Medicine Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">33,428<span></span>
</td>
<td class="nump">67,537<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember', window );">Immune Medicine Revenue | Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">19,976<span></span>
</td>
<td class="nump">24,959<span></span>
</td>
<td class="nump">31,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember', window );">Immune Medicine Revenue | Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 13,452<span></span>
</td>
<td class="nump">$ 42,578<span></span>
</td>
<td class="nump">$ 66,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_RegulatoryMilestoneRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_RegulatoryMilestoneRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627758896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,957,000<span></span>
</td>
<td class="nump">$ 170,276,000<span></span>
</td>
<td class="nump">$ 185,308,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_ImmuneMedicineServiceRevenueMember', window );">Immune Medicine Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">42,600,000<span></span>
</td>
<td class="nump">62,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember', window );">Medicare Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember', window );">Medicare Reimbursements | Immune Medicine Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember', window );">MRD Development Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdditionalMilestonePayment', window );">Additional milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NonRefundableUpfrontPaymentsReceived', window );">Non-refundable upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdditionalTransactionPriceOfRegulatoryMilestone', window );">Additional transaction price of regulatory milestone</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdditionalTransactionPriceOfRegulatoryMilestone', window );">Additional transaction price of regulatory milestone</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionExpectedPeriod', window );">Revenue recognition expected period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,430,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionExpectedPeriod', window );">Revenue recognition expected period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdditionalTransactionPriceOfRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional transaction price of regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdditionalTransactionPriceOfRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NonRefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NonRefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognitionExpectedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition expected period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognitionExpectedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition milestone method expected milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_ImmuneMedicineServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_ImmuneMedicineServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629519328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">$ 55,689<span></span>
</td>
<td class="nump">$ 55,689<span></span>
</td>
<td class="nump">$ 48,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">27,256<span></span>
</td>
<td class="nump">27,256<span></span>
</td>
<td class="nump">44,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">35,900<span></span>
</td>
<td class="num">(62,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue | Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">15,900<span></span>
</td>
<td class="nump">15,900<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">$ 41,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624711792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Details1)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncMember', window );">Genentech, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, expected to be recognized</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627867840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue balance at December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions to deferred revenue during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized during the period</a></td>
<td class="nump">$ 35,900<span></span>
</td>
<td class="num">(62,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue balance at December 31, 2022</a></td>
<td class="nump">$ 82,945<span></span>
</td>
<td class="nump">$ 82,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822630163152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 243,824<span></span>
</td>
<td class="nump">$ 326,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">35,790<span></span>
</td>
<td class="nump">45,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">208,034<span></span>
</td>
<td class="nump">281,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">35,790<span></span>
</td>
<td class="nump">45,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">35,790<span></span>
</td>
<td class="nump">45,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">10,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">10,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury and Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury and Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">187,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">187,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">18,374<span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 18,374<span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629062608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Available-for-sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember', window );">Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 174,186<span></span>
</td>
<td class="nump">$ 281,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">174,374<span></span>
</td>
<td class="nump">281,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember', window );">Long-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">33,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">10,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">10,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Government Treasury and Agency Securities | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Government Treasury Securities | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">153,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">153,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Government Treasury Securities | Long-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">33,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,357<span></span>
</td>
<td class="nump">6,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 18,374<span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625505792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822630093040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">$ 37,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Government Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">34,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">2,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629787184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 136,433<span></span>
</td>
<td class="nump">$ 141,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(87,817)<span></span>
</td>
<td class="num">(73,234)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">48,616<span></span>
</td>
<td class="nump">68,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">46,950<span></span>
</td>
<td class="nump">49,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">8,337<span></span>
</td>
<td class="nump">7,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">3,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 73,277<span></span>
</td>
<td class="nump">$ 74,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625468848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 17,553<span></span>
</td>
<td class="nump">$ 20,532<span></span>
</td>
<td class="nump">$ 19,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629305152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">120 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Unit</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Changes in carrying amount of goodwill since recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | Unit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 118,972,000<span></span>
</td>
<td class="nump">118,972,000<span></span>
</td>
<td class="nump">$ 118,972,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember', window );">MRD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">96,400,000<span></span>
</td>
<td class="nump">96,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember', window );">Immune Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Purchased Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822630003984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,325<span></span>
</td>
<td class="nump">$ 20,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(16,900)<span></span>
</td>
<td class="num">(15,197)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">5,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Acquired Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(16,641)<span></span>
</td>
<td class="num">(14,970)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,359<span></span>
</td>
<td class="nump">5,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Purchased Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822728815568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3,425<span></span>
</td>
<td class="nump">$ 5,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624694912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 2,922<span></span>
</td>
<td class="nump">$ 4,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent', window );">Clinical and contract research organization costs</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Travel and entertainment</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Tax liabilities</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent', window );">Purchases of property and equipment</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ComputerAndSoftware', window );">Computer and software</a></td>
<td class="nump">3,065<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 8,157<span></span>
</td>
<td class="nump">$ 8,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and contract research organization costs, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued purchase of property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ComputerAndSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computer and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ComputerAndSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822626863664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases- Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">19,900<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">cash payment for rent began in October 2021 and the lease term ends in August 2033, <span></span>
</td>
<td class="text">The lease term is through March 2026 and provides for one five-year extension option.<span></span>
</td>
<td class="text">options to extend certain of the leases up to 10.0 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear', window );">Lessee, operating lease, rent commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseExtendedTermOfContract', window );">Lessee, operating lease, extended term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033-08<span></span>
</td>
<td class="text">2026-03<span></span>
</td>
<td class="text">2031-10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets, held for use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">25,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of long-lived leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LeaseCommencementMonthAndYear', window );">Lease commenced moth and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Landlord contribution for leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ProceedsFromLandlordReimbursements', window );">Proceeds from landlord reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_TenantImprovementCostsIncurred', window );">Tenant improvement costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear', window );">Rent obligations, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_TenantImprovementAllowanceAndCommenced', window );">Tenant improvement allowance and commenced</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription', window );">Lease not yet commenced, termination option description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">subject to an early termination option after the seventh year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend', window );">Lease not yet commenced, option to extend description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to twice extend the lease for five years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable', window );">Lease not yet commenced landlord agreed to fund for improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease not yet commenced, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,400<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_OperatingLeaseVariableLeaseExpense', window );">Operating lease variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Cash received for tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Impairment of long-lived assets, held for use<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Landlord contribution for leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Seattle, Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear', window );">Lessee, operating lease, rent commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseExtendedTermOfContract', window );">Lessee, operating lease, extended term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseExtendedTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended term of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseExtendedTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease lease not yet commenced tenant improvement receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, lease not yet commenced termination option description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease rent commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseRentCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease rent obligations commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease termination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_OperatingLeaseVariableLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease variable lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_OperatingLeaseVariableLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromLandlordReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from landlord reimbursements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromLandlordReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementAllowanceAndCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance and commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementAllowanceAndCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822628389392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases- Summary of Other Information Related to Operating Lease (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 years 21 days<span></span>
</td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625416160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 14,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">12,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">11,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">12,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">12,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">44,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">107,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest rate</a></td>
<td class="num">(18,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">89,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(10,239)<span></span>
</td>
<td class="num">$ (9,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 79,148<span></span>
</td>
<td class="nump">$ 89,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629641872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PotentialRevenueInterestSecondPaymentToBeReceived', window );">Potential revenue interest second payment to be received</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PurchaseAgreementSecondPaymentDate', window );">Purchase agreement, second payment date</a></td>
<td class="text">Sep. 12,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PotentialRevenueInterestThirdPaymentToBeReceived', window );">Potential revenue interest third payment to be received</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PurchaseAgreementThirdPaymentDate', window );">Purchase agreement, third payment date</a></td>
<td class="text">Sep. 12,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPaymentTerm', window );">Revenue interest payment term</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfRevenueInterestPayments', window );">Percentage of revenue interest payments</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfCumulativePurchaserPayments', window );">Percentage of cumulative purchaser payments</a></td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_CumulativePurchaserPaymentsRepaymentDate', window );">Cumulative purchaser payments repayment date</a></td>
<td class="text">Sep. 12,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments', window );">Increase in return cap percentage of cumulative purchaser payments</a></td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AmortizationOfPurchaseAgreementObligation', window );">Amortization of purchase agreement obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,580,000<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPayable', window );">Revenue interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,372,000<span></span>
</td>
<td class="nump">$ 2,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PotentialRevenueInterestPaymentToBeReceived', window );">Potential revenue interest payment to be received</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AmortizationOfPurchaseAgreementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of purchase agreement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AmortizationOfPurchaseAgreementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_CumulativePurchaserPaymentsRepaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative purchaser payments repayment date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_CumulativePurchaserPaymentsRepaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in return cap percentage of cumulative purchaser payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfCumulativePurchaserPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative purchaser payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfCumulativePurchaserPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfRevenueInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfRevenueInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PotentialRevenueInterestPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential revenue interest payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PotentialRevenueInterestPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PotentialRevenueInterestSecondPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential revenue interest second payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PotentialRevenueInterestSecondPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PotentialRevenueInterestThirdPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential revenue interest third payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PotentialRevenueInterestThirdPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PurchaseAgreementSecondPaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement second payment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PurchaseAgreementSecondPaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PurchaseAgreementThirdPaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement third payment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PurchaseAgreementThirdPaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest payment term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627053200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details) - OrbiMed - Purchase Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNet', window );">Revenue interest liability, net</a></td>
<td class="nump">$ 130,660<span></span>
</td>
<td class="nump">$ 125,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">11,580<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPaid', window );">Revenue interest paid</a></td>
<td class="num">(6,589)<span></span>
</td>
<td class="num">(6,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPayable', window );">Revenue interest payable</a></td>
<td class="num">(2,372)<span></span>
</td>
<td class="num">(2,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNet', window );">Revenue interest liability, net</a></td>
<td class="nump">133,279<span></span>
</td>
<td class="nump">$ 130,660<span></span>
</td>
<td class="nump">$ 125,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNetCurrent', window );">Less: Current portion</a></td>
<td class="num">(865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNetNoncurrent', window );">Revenue interest liability, net, less current portion</a></td>
<td class="nump">$ 132,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiabilityNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability net current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiabilityNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiabilityNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability net noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiabilityNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822626867840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Vote</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of our common stock are entitled to one vote for each share of common stock held<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NumberOfCommonStockVotingRights', window );">Number of vote for each share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="nump">1,450,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares', window );">Percentage of annual increases in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="nump">7,254,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares', window );">Percentage of annual increases in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfCommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfCommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual increases in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfAnnualIncreasesInNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629985696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">50,005,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember', window );">Shares Issuable Upon the Exercise of Outstanding Stock Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">12,295,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember', window );">Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">14,005,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">18,018,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">5,686,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629100864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life stock options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted-average remaining contractual life vested and exercisable stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">241<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">7,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 53,610<span></span>
</td>
<td class="nump">62,908<span></span>
</td>
<td class="nump">55,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Option Valuation Model</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=adpt_MonteCarloValuationModelMember', window );">Monte Carlo Valuation Model</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Monte Carlo Valuation Model</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="nump">$ 18.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Chief Executive Officer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm', window );">Performance period term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Minimum | Chief Executive Officer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward', window );">Common stock that may be earned under the award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember', window );">2009 Equity Incentive Plan | Grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember', window );">2009 Equity Incentive Plan | Grant | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,018,312<span></span>
</td>
<td class="nump">15,299,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,683,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant | Non Employee Directors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="nump">$ 8.29<span></span>
</td>
<td class="nump">$ 11.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,174,852<span></span>
</td>
<td class="nump">9,669,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Market-Based Restricted Stock Units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,831,114<span></span>
</td>
<td class="nump">1,912,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares earned under the award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award performance period term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=adpt_MonteCarloValuationModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=adpt_MonteCarloValuationModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adpt_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adpt_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822715229072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant at December 31, 2023</a></td>
<td class="nump">15,299,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve', window );">2019 Equity Incentive Plan reserve increase effective January 1, 2024</a></td>
<td class="nump">7,254,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned', window );">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</a></td>
<td class="num">(8,841,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired', window );">Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired</a></td>
<td class="nump">4,305,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant at September 30, 2023</a></td>
<td class="nump">18,018,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, stock options restricted stock units granted and maximum market based restricted stock units granted eligible to be earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Awards Restricted Stock Units And Maximum Market Based Restricted Stock Units Forfeited Canceled Or Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627350032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance | shares</a></td>
<td class="nump">12,875,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Subject to Outstanding Stock Options, Stock Options granted | shares</a></td>
<td class="nump">1,008,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares Subject to Outstanding Stock Options, Stock Options forfeited | shares</a></td>
<td class="num">(718,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares Subject to Outstanding Stock Options, Stock Options expired | shares</a></td>
<td class="num">(765,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Subject to Outstanding Stock Options, Stock Options exercised | shares</a></td>
<td class="num">(103,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance | shares</a></td>
<td class="nump">12,295,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable', window );">Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable | shares</a></td>
<td class="nump">10,027,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 15.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options granted | $ / shares</a></td>
<td class="nump">3.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled | $ / shares</a></td>
<td class="nump">11.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options expired | $ / shares</a></td>
<td class="nump">18.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options exercised | $ / shares</a></td>
<td class="nump">2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">15.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options vested and exercisable | $ / shares</a></td>
<td class="nump">$ 16.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Stock Option outstanding | $</a></td>
<td class="nump">$ 2,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue', window );">Aggregate Intrinsic Value, Stock Options vested and exercisable | $</a></td>
<td class="nump">$ 497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822630107280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">9,669,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Stock Units Outstanding, Granted</a></td>
<td class="nump">5,619,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted Stock Units Outstanding, Forfeited</a></td>
<td class="num">(2,525,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted Stock Units Outstanding, Vested</a></td>
<td class="num">(2,587,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">10,174,852<span></span>
</td>
<td class="nump">9,669,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</a></td>
<td class="nump">4.03<span></span>
</td>
<td class="nump">$ 8.29<span></span>
</td>
<td class="nump">$ 11.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited</a></td>
<td class="nump">7.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested</a></td>
<td class="nump">11.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">1,912,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Stock Units Outstanding, Granted</a></td>
<td class="nump">2,214,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted Stock Units Outstanding, Forfeited</a></td>
<td class="num">(295,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">3,831,114<span></span>
</td>
<td class="nump">1,912,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</a></td>
<td class="nump">6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited</a></td>
<td class="nump">6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822626882240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="nump">71.20%<span></span>
</td>
<td class="nump">68.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">71.60%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624813360">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 53,610<span></span>
</td>
<td class="nump">$ 62,908<span></span>
</td>
<td class="nump">$ 55,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,632<span></span>
</td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,081<span></span>
</td>
<td class="nump">20,465<span></span>
</td>
<td class="nump">17,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,370<span></span>
</td>
<td class="nump">14,553<span></span>
</td>
<td class="nump">13,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,527<span></span>
</td>
<td class="nump">$ 23,704<span></span>
</td>
<td class="nump">$ 20,281<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627871344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_NonvestedStockOptionsMember', window );">Nonvested Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Share-Based Compensation Expense</a></td>
<td class="nump">$ 12,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">1 year 6 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_NonvestedRestrictedStockUnitsRSUMember', window );">Nonvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Share-Based Compensation Expense</a></td>
<td class="nump">$ 50,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">2 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsMember', window );">Nonvested Market-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Share-Based Compensation Expense</a></td>
<td class="nump">$ 8,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_NonvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_NonvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_NonvestedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_NonvestedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627459968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring, reduction in workforce | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated aggregate restructuring costs recognized</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Enhancements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624675104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (159,635)<span></span>
</td>
<td class="num">$ (225,335)<span></span>
</td>
<td class="num">$ (200,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total loss before provision for income taxes</a></td>
<td class="num">$ (159,595)<span></span>
</td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822629302544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 274,535<span></span>
</td>
<td class="nump">$ 251,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">Tax credit carryforward</a></td>
<td class="nump">45,942<span></span>
</td>
<td class="nump">43,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxAssetsNonQualifiedStockOptions', window );">Nonqualifying stock options</a></td>
<td class="nump">31,010<span></span>
</td>
<td class="nump">29,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">22,912<span></span>
</td>
<td class="nump">25,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">14,996<span></span>
</td>
<td class="nump">18,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment', window );">Capitalized research and development</a></td>
<td class="nump">49,550<span></span>
</td>
<td class="nump">42,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxAssetTangibleAndIntangibleAssets', window );">Tangible and intangible assets</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,182<span></span>
</td>
<td class="nump">6,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">447,090<span></span>
</td>
<td class="nump">416,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(435,509)<span></span>
</td>
<td class="num">(402,424)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">11,581<span></span>
</td>
<td class="nump">14,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets', window );">Tangible and intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(11,581)<span></span>
</td>
<td class="num">(13,224)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetTangibleAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset tangible and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetTangibleAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetsNonQualifiedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, non qualified stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetsNonQualifiedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, tangible and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_Deferredtaxassetscapitalizedresearchanddevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627359584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 33,100,000<span></span>
</td>
<td class="nump">$ 55,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NetOperatingLossCarryforwardExpirationPeriod', window );">Maturity period for NOLs carryovers</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. federal NOLs</a></td>
<td class="nump">$ 856,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">10,710,000<span></span>
</td>
<td class="nump">9,303,000<span></span>
</td>
<td class="nump">$ 8,117,000<span></span>
</td>
<td class="nump">$ 6,915,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">1,407,000<span></span>
</td>
<td class="nump">1,186,000<span></span>
</td>
<td class="nump">$ 1,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment', window );">Deferred tax asset</a></td>
<td class="nump">49,550,000<span></span>
</td>
<td class="nump">$ 42,134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. federal NOLs</a></td>
<td class="nump">192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">U.S. federal tax credits</a></td>
<td class="nump">$ 51,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_OperatingLossCarryforwardsExpirationYear', window );">NOLs expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_Deferredtaxassetscapitalizedresearchanddevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NetOperatingLossCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforward Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NetOperatingLossCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627503472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.70%)<span></span>
</td>
<td class="num">(25.30%)<span></span>
</td>
<td class="num">(24.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625543728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 9,303<span></span>
</td>
<td class="nump">$ 8,117<span></span>
</td>
<td class="nump">$ 6,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 10,710<span></span>
</td>
<td class="nump">$ 9,303<span></span>
</td>
<td class="nump">$ 8,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822624745376">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (159,492)<span></span>
</td>
<td class="num">$ (225,250)<span></span>
</td>
<td class="num">$ (200,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,101,648<span></span>
</td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,101,648<span></span>
</td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822625110960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">26,826,977<span></span>
</td>
<td class="nump">25,133,607<span></span>
</td>
<td class="nump">19,102,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">12,744,898<span></span>
</td>
<td class="nump">13,839,067<span></span>
</td>
<td class="nump">13,892,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember', window );">Nonvested Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,584,853<span></span>
</td>
<td class="nump">9,630,579<span></span>
</td>
<td class="nump">4,799,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember', window );">Nonvested Market-based Restricted Stock Units Outstanding Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">3,497,226<span></span>
</td>
<td class="nump">1,663,961<span></span>
</td>
<td class="nump">410,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822722184912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees maximum annual contribution of their compensation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DefinedContributionPlanEmployeeServicePeriodForVesting', window );">Employee service period for vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DefinedContributionPlanEmployeeServicePeriodForVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employee service period for vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DefinedContributionPlanEmployeeServicePeriodForVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822628224768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">Chief Executive Officer [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">evaluates performance of the MRD segment based on both revenue and Adjusted EBITDA and evaluates performance of the Immune Medicine segment based on Adjusted EBITDA. These measures help our CODM assess the trends and operating margin profile of the respective segments, which helps drive the level of investment made in each business. These measures also help our CODM assess and manage the potential capital utilization of each segment. Adjusted EBITDA for each of our segments includes costs that are directly aligned to each segment, as well as certain allocated shared expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">These shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Inter-segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822627862912">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 178,957<span></span>
</td>
<td class="nump">$ 170,276<span></span>
</td>
<td class="nump">$ 185,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,080<span></span>
</td>
<td class="nump">75,553<span></span>
</td>
<td class="nump">57,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102,953<span></span>
</td>
<td class="nump">122,117<span></span>
</td>
<td class="nump">141,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,759<span></span>
</td>
<td class="nump">88,579<span></span>
</td>
<td class="nump">95,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,806<span></span>
</td>
<td class="nump">83,934<span></span>
</td>
<td class="nump">88,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(80,371)<span></span>
</td>
<td class="num">(116,413)<span></span>
</td>
<td class="num">(121,589)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MRD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145,529<span></span>
</td>
<td class="nump">102,739<span></span>
</td>
<td class="nump">87,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64,177<span></span>
</td>
<td class="nump">63,273<span></span>
</td>
<td class="nump">42,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,743<span></span>
</td>
<td class="nump">42,153<span></span>
</td>
<td class="nump">31,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,579<span></span>
</td>
<td class="nump">76,742<span></span>
</td>
<td class="nump">65,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,446<span></span>
</td>
<td class="nump">46,961<span></span>
</td>
<td class="nump">32,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ItemsToReconcileNetLossToAdjustedEBITDA', window );">Items to reconcile net loss to adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39,012<span></span>
</td>
<td class="nump">37,546<span></span>
</td>
<td class="nump">24,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(41,223)<span></span>
</td>
<td class="num">(88,844)<span></span>
</td>
<td class="num">(60,496)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | IM</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,428<span></span>
</td>
<td class="nump">67,537<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,210<span></span>
</td>
<td class="nump">79,964<span></span>
</td>
<td class="nump">109,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ItemsToReconcileNetLossToAdjustedEBITDA', window );">Items to reconcile net loss to adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">31,619<span></span>
</td>
<td class="nump">33,366<span></span>
</td>
<td class="nump">36,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(26,005)<span></span>
</td>
<td class="num">(14,128)<span></span>
</td>
<td class="num">(45,654)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Unallocated Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13,143)<span></span>
</td>
<td class="num">(13,441)<span></span>
</td>
<td class="num">(15,439)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Unallocated Corporate | MRD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Unallocated Corporate | IM</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 28,842<span></span>
</td>
<td class="nump">$ 35,067<span></span>
</td>
<td class="nump">$ 70,016<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes MRD impairment of long-lived assets expenses.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes all Immune Medicine operating expenses, other than research and development expenses.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdjustedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted EBITDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdjustedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ItemsToReconcileNetLossToAdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Items to reconcile net loss to adjusted EBITDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ItemsToReconcileNetLossToAdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45822630789376">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (80,371)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (116,413)<span></span>
</td>
<td class="num">$ (121,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(53,610)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(62,908)<span></span>
</td>
<td class="num">(55,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(2,004)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Restructuring expense<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(25,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets', window );">Impairment of right-of-use and related long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(19,256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22,231)<span></span>
</td>
<td class="num">$ (20,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(11,580)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(4,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,534<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,531<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(159,492)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(225,250)<span></span>
</td>
<td class="num">(200,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(103)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(159,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(225,304)<span></span>
</td>
<td class="num">(200,368)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MRD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(41,223)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(88,844)<span></span>
</td>
<td class="num">(60,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(24,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28,321)<span></span>
</td>
<td class="num">(17,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(1,272)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(2,819)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(10,073)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,225)<span></span>
</td>
<td class="num">(6,642)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | IM</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(26,005)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,128)<span></span>
</td>
<td class="num">(45,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(19,051)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(23,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(732)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(4,386)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,436)<span></span>
</td>
<td class="num">(12,294)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Unallocated Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustedEbitda', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13,143)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,441)<span></span>
</td>
<td class="num">(15,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(9,711)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,657)<span></span>
</td>
<td class="num">(13,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Restructuring expense<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets', window );">Impairment of right-of-use and related long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,733)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,570)<span></span>
</td>
<td class="num">$ (1,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(11,580)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(4,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,534<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,531<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (159,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Adjusted EBITDA&#8221; for an explanation of how it is calculated and used by management.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on our impairment expense.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on the Purchase Agreement.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdjustedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted EBITDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdjustedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right-of-use and related long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adpt_MrdBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adpt_ImmuneMedicineBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPO3;I>NW]48]IW6;(+J6CO97H< WP"?)%F)U/Z87K,=FU/V;4JMB*_V_W1
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M2(1XM3EK4%UL$(@.)JI2]%\:T9WN#%(.IM.IO*',-Q&K=JA _EZB#LAY@&>
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MA^[>8]DM<++-WNQ8$LY)DGW<("C&";F!^'Y%"-\OR!T4;Q.-_P=02P,$%
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M[B>A32,+JZ@LZWH#H9Z#GCNKXK'**1E9E)YJ<9AK/]:&URMIEZ+;..-[WN5
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MH$UD=4!5_=!B;P]4'H76(K=?=XQ"CS$&<'\C@-?ZAQF@.29<_ E02P,$%
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MI,48$BP! NLE@'=( .]9$^"QCI@2P6IY:-GP#&7#\3W'48H&I-$($BR&!$N
MP'HYXQ]RQK?FS%>QN<NM1.2"W.?K/)/'AUU:;,N<BZ0HF>D<<67%'9H1OI81
MKD-]====0-J,(,%B2+ $"*R7$,$A(0)K0K0E8"Q;M:4L(J)_;5)9'4PI$&A1
M\SP:*$&;6^T-W1[.,AE!FHPAP1(@L%YHPT-H0VMH=QU'UN\XBK;CR,6I?\U,
M,0XUAX_)-)@J,;8:'AIC2+#HK/''D"83(+!>C*>'&$^M,?[(.)(A-85R:G"%
MX[A^J 33:F%H,"'!(DBPV.P.K+5P!CE\5'%Z8<).1Z(XUD!%Y=+2"Q,C.>)H
M(Z$^=:9J_/9RUF[8@(7=,'"ILC(B@^"88JR<R&.3V!1/G5#IU!.3H'_*FT>4
M%![@S5,-L=FK5N2A!YD]6O]LZV)''&Z)&@)(PQ$H6@R*ED"A]9.C(YZPG7EZ
MCL9X;_(XSH103UV)UH$-+:5GV8Q ;<:@: D46C\1.N(,VYFSYVR0[:8'EQ&=
M6:.!0QV55@.U&H&BQ:!H"11:/W4Z;@W;R;6G]\EVX,&)H?-CV'/\T-<V>$BS
M$2A:#(J60*'U,Z,CW;"==1O2,&.=^?*)."2IVP8DO;0XSV@$:C0&14N@T/HA
M[C@R;"?)GM0X8YW3HJZ+U5!#$D<+4+3HK!G$H#83*+1^I#OR"]O9+UO[C'7N
M:4R(YSI4C2DHXP6*%H&BQ2=<0CQ'[?H,@AX]T?5U?!:V$UKV'MHU!E'G@US1
MI 9:"0[/Z*%U+$SEY(E:6G5!@CUU'1F8*HRI6'%:"VV2)/B$-SOF"-NIH_-Z
M:+-7(8F9.=89%^%7$2428#4$H/02*%H,BI9 H?5_N]'15<1.5SU'#TUTGHI0
M=8.TCVMH,24Z^Z29C$!-QJ!H"11:/PTZGHW8>;;G[*")@3ISW%#]5GA^IMS"
M/I6AM0$4+09%2Z#0^DEQ],,N.[_V]-[8#CQTWR &?LP+ S]PU<R -!N!HL6@
M: D46C\S.L*-V FW(;WQ'NIX-_!<'VNK'Y)56A"=9S,8C4"-QJ!H"11:/\0=
M,4;LQ-B3>F.BLUAC]9NGN=WPX$B#\F'G3" &-9E H?7CW-%<Q$YSV3ICHC-,
M8^Q-Q9\:4E!B"Q0M D6+3[B$3M5FSBCHN.9FCG24%;%35O;6F!JCZ.O'<2$:
M:D'4Y?0?6QMD/,=W/5>MK 9!]>>>L4%HC%UQYB-4]:9!DI 31 /I:"%BIX7.
M:XW-7H4D7.9$YU$P#8+ #:@6 E#>"!0M!D5+H-!VR3$Y>C)&/EKU=UK?Y66#
M"G8KX)TW@4BN>O>TTNZ"5YOV89EO%>?5NGV[8NF2U5) W+^M*OYX(9^_.3PS
M-OL/4$L#!!0    ( (2$8UK"U7F1(P@  ,HG   8    >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULK5IK;^.X%?TK@KLH6F \%DD]IXF!&:N#W0_;#3;=]C,C
MT;8ZLNBEZ&327U]24B2+O**=K3' Q)8/KWBN[N.0XMT+%]^:/6/2^WZHZN9^
ML9?R^&FU:O(].]#F(S^R6OVRY>) I?HJ=JOF*!@MVD&':H5]/UH=:%DOUG?M
MM0>QON,G694U>Q!><SH<J'C]PBK^<K] B[<+OY:[O=075NN[(]VQ1R9_.SX(
M]6TU6"G* ZN;DM>>8-O[Q6?T*2.I'M B_E6RE^;LLZ>I/''^37_YJ;A?^'I&
MK&*YU":H^O/,-JRJM"4UC]][HXOAGGK@^><WZU];\HK,$VW8AE?_+@NYOU\D
M"Z]@6WJJY*_\Y4?6$PJUO9Q73?N_]])AXVCAY:=&\D,_6,W@4-;=7_J]=\39
M #0W /<#L#D@F!E ^@'DV@%!/R!H/=-1:?V044G7=X*_>$*CE37]H75F.UK1
M+VO]W!^E4+^6:IQ<;WC=\*HLJ&2%]RC5'_509>/QK;>AS=[[J@*C\9;>;X^9
M]Y<?_NK]X)6U]\\]/S6T+IJ[E51ST)96>7^_+]W]\,S]$/9^YK7<-][?ZX(5
M4P,K-?F! 7YC\ 4[+68L_^@1],'#/@Z "6VN'TZ X=GUP[&##1F>!VGMD1E[
MOQR9H+*L=UU&E+)DH)<[*P%L11>+3\V1YNQ^H:I!P\0S6ZS__"<4^7^#/'1+
M8]F-C$V\%PS>"US6U_]0A;+B#>BQ;F38CM35\'F]1&&J_MVMGL^= > P#HD?
M3'$9A/-]$B4#;D(A'"B$S@#X7/Q'97V7A)*KTIKS.B\KYM4]-WU5?\YU>IX:
ME;8J(_F581/>,FQN:2R[D;&)SZ/!YY$S;#*FC.8E;3L1^ZYZ:L,@[W56HK-'
MCN(P)$8 V2CLAP0;X0/82C%&</#$ Y'8'?\J5G185$RU0A>3V+I[B./8(&*#
MHA3[!@\;%&,<PS22@4;BI/&XIX(M=3LOO)P?-(N+SR:Q&9$(&;/=V*@(IWYB
M< )LA4$\0RH=2*5.4C_5DM:[\DFE,FT:IM*;'KB0Y7];:A"E% @WWXPV !2E
MJ4'H FC"!_FC=/ O,'IF7:FZ2*6W=#Z#98)-QV\@6(H2L_0"L#B821UTIH20
MF\[A2$O1TE'JI^+U;EDI35KTCPNDA8#H]\V. J!P&&#S(;FG]P=+(,(C?7SQ
M:=:2BU>OMPX2QD#9(M9C!% DB4V^-@I'9*9]HE% (:?"&&I@64NFF$A7T>A-
M3:> +#HV2ND!LQ "J#0)9]B,@@:Y%<TO<L\$./7 ]O%9#O0S!T"QV8D T!+-
M%8=1QB"WCMGL5;5CC2%.^L)7%UY5TJ>RFA4JZ*9*Y:;6LEM9FWIV%"O(K58^
MYSD_:7FH- LKGZGJ*!^T(@3=:,N,)8F#P(P32+-8D@4RAG$4S*7LJ%J06[8,
MI0>D &@58@;Q!D M<6)6I@R )6BFL:-1KB"W7GD03+6.XJW2= '.=>:J);P0
M;8.<[R&VVDC,)@]@5(H2JP39,!*&<XUQ%"[(K5R&@#O25]KJ%T6/YKDXL<MY
M;$N/*+;*E U:AH%O-0P;%B,T0P^/,@:[9<RXY.YDL]!;14N^7:K%U3LJ%H:T
M"TE,,0#!DBB.#*X0+/!#?X;L*'*P6^1D;,M41!:J>*B<.X%=$=MZ98G\(#;[
M(H3#*4Z1R07 A5&01C-D1LF"W9)EMCEB0%J8JQL LXR).75 R40SO1&/$@5?
MD"A_=/F.;8VQ3$.,S&H(X5 8$6PJ:1"8D#28$2YX%"XX</;_;G%P!26G_GEO
MH[^IM>Q6UJ8N'"44=@J)]<-)Y'NJ^XE:CQR%#A+YVI8B]ONI/.J5"NC1$.CY
M463V? B&_"@UJRZ(BT@PEP6CCL%N'3.A=Z#B&Y-M=VF8:IKS\0*)D"# H97?
M % MNL+0U 2@Q3B)XQE=@T==@]VZYD'PG+&B\;:"'Q1%V?-Z'V%;LA#%%ID:
M <"%:I'OFRH.P.$T.5=[4[:C"L)N%314-16JSV6A*MO3JRIN5Y8!6[K$<9Q:
MA<V&(9Q&@16T-@ZG_EQ1&Y403IU%[6M9TSJ_@HU34+V[J-W26G8K:]/7&Z/:
M(FZU-<T)]IV)O%0Z2V5$(WG^3;5"O8<$O_.P-1&VEKP0" >&"LL 5)RD,^J*
MC.J*N-75E%POL<:=B&-?\3RZ$ZQ]T=8NW#3YLFE.*K28E_,&7B>X;_WN5SZW
MM)816^$A')!X)N'(J/"(6^&!-65[91820 7:\0* @'B!=K34VG>.X-GKOLM2
ML&"Y:%<>2@EJLA\ZRKK)/].J?1.DF[X.(5'F^D6M_AUD#,FY&,6I21K J29J
MK?@A7* ZXQSM41T2][;6YFJ:'I7>$]N5=:T?N,J45T9!S4_L;:PH3M/(I&[#
M4AQ@4Q0 ,!0@?+;]/F4^BCKB%G7O8\[T1H*#LZW-0O]\0Z/G;,, UV0 ;.J:
M*>51Z)'(V37''=GKM !QZL9W5[I;6LMN96WJRE%1D@N*\EPS#ZL Y=F\.A7=
M6I+^'[LUQ-:&",?F%@: BJS=?<A4/+>M3$:121)G+#V>CL>J;9VT\HJRR2O>
MG$2K']H8VU;*8EEW!Z)F7D81IXY]=WS=TEIV*VM3]XX"E[BW^MHS/^U>IO+@
M(%Q )W:&SL\_)(FUR(10J;DGE@&H( V,4%F='7(Z,+%K#XLU7AOLW6FAX>IP
M(.US>PS+N/X%?<JZ8V6CF>Z4V\]4J$;3>!7;*I/^QUC-2'0'Q[HODA_;HU1/
M7$I^:#_N&2V8T #U^Y9S^?9%WV XOK?^'U!+ P04    " "$A&-:4K!E#)@(
M   F*P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;.U::V_;1A;]*P,5
M*%I M1YY.$UL [;3M%XTL&&GVP_!?AB1E^*L20XS,Y2B_?4]=X8/R9$IN\XN
MNH4^).9CYMYS7^=>4CQ::G-K4R(G/N=988\'J7/EZ]'(1BGETA[HD@K<2;3)
MI<.IF8]L:4C&?E.>C:;C\<M1+E4Q.#GRUZ[,R9&N7*8*NC+"5GDNS>J,,KT\
M'DP&S85K-4\=7QB=')5R3C?D?BNO#,Y&K918Y518I0MA*#D>G$Y>GTT.>8-?
M\4]%2[MV+-B4F=:W?'(1'P_&C(@RBAR+D/BSH'/*,I8$')]JH8-6)V]</VZD
MO_/&PYB9M'2NL]]5[-+CP:N!B"F15>:N]?(7J@UZP?(BG5G_OUC6:\<#$576
MZ;S># 2Y*L)?^;EVQ$,V3.L-4X\[*/(HWTHG3XZ,7@K#JR&-#[RI?C? J8*C
M<N,,[BKL<R?GJQD92U%EE%L=C1Q$\HU15&\_"]NG]VR?3,5[7;C4BI^*F.)-
M 2-@:0%-&T!GTUZ);RDZ$,\F0S$=3Y_WR'O6&OC,RWOV$ /%M;*WXKTLD'!(
M+3<46"H=S5=#(8M8_*P79 I91"0^_@I!XL)1;O^US2]!Z_/M6KF67MM21G0\
M0+%8,@L:G'S[S>3E^$V/3<];FY[W2>^W25P9'9&U9 6*5ISRD57%?"@N8MQ6
MR<J?L+E^$\[$AQ05[:SX^($^.W&6Z>AVJ]']L-A98G)^(#;QG5KA##*98E%*
MXPK<$DZ+E&3FTD@:$J71"Q7C^A KG )*',V4+E.)PHNH<BJ2F8AT7LI"$6[*
M2,:4J\B;4>CB!XA(E!.JL$ZYB@N>150P'-9W>GDYY66F5\1BEB1DB0!%"DD@
M7$I"Y:4VSF> 3@33FL,_]I'T^@VE3$D+\J*\7: =EZZ@.G D<TUK.V#-C<P/
MQ&5E>E<(A7!56<9RD(^<E#$?:J&Q$R1L9&T4ZY4BE5D&&KUEE+QB38Q"(".C
MK?TAJ0K/?? =FZEEE()>7.IWL![#MTJC%C):"3W[-WF.#&ZR3MY2JC..2\ ?
M;81U32/38BQ@%7OPXN923 _'XTEG8P2*," J7''! %7XF*BHRJ09 C)R%6P'
MU;44@"HB569\)6$!B?+9*S,('-9.8MG>'0NI,CE3?.] _$YMW'!W#4]$T)@@
ME7P$O"/DETX'1N_4QN7L(9VI2-5^*;F\X@I5S5DLXY20P3ABU+%FS1YRJ_8
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MWTR%A?[2"[.@]($0,6S,=RP"B &PW,#4OFS@F)T0,F-]XU42'"!7C-(?^ Q
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MF2DOHQ3-=\H9[PZ=JN)Y)TJM39X;(T3_9W'?EW#7;;@7(U+TKC*-PC<[C(3
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MX>;:W_2LY]/M_Q1Q&=HW>2/B2=A=KDPHI9\%A]3]-Q_R &>>%J'EODX0W9F
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M'G%/@/X!/(Q#8LU9[];T<V4-Z&!\ .XO',A\^0,GP.@[@??\?P!02P,$%
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M<@XHX7JY^,P1&@-8+QUXW&YT&H,#  :9C]76 $3";C)%17V5>-8BQ^=WGVR
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M)%&2O8&7]E13CY?^-]5K;G*A'%L#?U\LC=7T=?SS&ND6,GL=TE7,N:E9CO.
M2L*@?L)@\?Y=/(X^O9%PUB><O87^*WOS-M#9$$Y@P;<28:4$U2:7:[!L*4@2
M0X<!U;LMP;II%_KD0@VH%:RX9#+G3  SY&BH<<.T6U@M4?<[!DP6KI,2"+.P
M08U0M4L70 ,[6'#5216>-UJ[+*C*N('?N:1(U1C",1_.!R\6&'S!)Q000]LF
M79O"-V69&-P<Y3F@SQ.?J7;T@Z/7$"K\!NE9./D84>?]NVD2)Y\.>NWDX$I5
M%6H/5;.:,MAZ)&$V^7AH#;X/[X>P5D^HI5,8K/:<GTE4XL<M)Q6W$?%T$L;3
M^-BF!76M-+,(2^72W,V'Z20[,@>>[LMMV>.61-,P2K,#;DF6AE,2\5C6]'^1
M-3L+8]KYUV5M)T_+&D?A.(V.S-/"NN^,[@^9OZIQ,L["+!D?VR<U'H?)WHYX
MZ[3"/4WR"M-T<OCU).,P&T>PU7,O.2YST10()=T9XAD$?VQX =4+)4-7AK I
M>5Y2 6W+YZ@J_:U4N")Z;)2E7JUY[A?I[KP.TG@P7I!X/-^QH#'!V9(+G]JP
MW_:]='-%E["QKLQ_;1=""CV4V;GE1QL?ML%$S/,I=H3H3&@7845[^!QH2+\C
M@L1E)T,G9*>&"^85%XPDD'3@-^WYYU96I">]4_A:\A4I0PMR63<T6: F] )6
M6E4.F\AHM?1T*,EG4$MWY+LS<[M807?P\+6C?[1W11/YM7^(.&4;:=O;NA_M
MWSH7[16_<V\?2K=,KXD""%Q1:#2<G 6@V\=':UA5^PM_J2P]'WRWI/<::N=
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MM)@%H(?Y,VRLZGS/WRA+$\0O=S2R43L%DM>*$G;<. ?CGX#5/U!+ P04
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MVS ,Q]_]*0BO&#:@J*\<;I<$Z+%A U8LV/DP[$&QZ5BH++F2W+3[]*/DQ,N
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M/7%TF.B*Y<*TK,!Y2-5@4#]@N'CY(IG$;X[D.QKR'1VC_^^S'(4<3O'\# [
MASVQM\<,J KH*;!9H=X]Q\C?H7L7*!05I['D1G:V1JB4H"KG<@VON*0=U1DR
M-J\O@GU*X"F.$"RUJM"X"F<"*J2@)Y">GJ<IC2,:X^":5/&"3EU4"NC?"YP<
MIHL:J!TQR7\S7^*%,M9 /AU!/LF"KYH]8.^'TJ*VU**HG5@7&9+Q*/C*'O_1
MFTPG,#X/EAV!J="]^E93_]/VJ<?<=[SUB#R'23X-KE73=H3VIT95=L,T0G8:
M3\:0G";C)/A$UZ(ASV*8NI24=4H.W/4)Y&0_]>/X? J'OJ%HK\P;U&O?S RI
M[J3M*W[8'?KE9=\F_IKWS?:6Z367!@16Y!J?3<<AZ+Z!]0NK6M\T5LI2"_+3
MFGH^:F= YY52=K=P 89_D<4?4$L#!!0    ( (2$8UISIC4 V H  !T>   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;+59VY+;N!%]]U>@E$EB5W$T
M(J6Y.?94^1)7O)6-7;:S?DCE 2(A";L0(0/@:"9?G],-D"(U&L5)=E]F2 IH
MG+Z=[B9?;*W[Q:^4"N)N;6K_<K0*8?/\[,R7*[66?FPWJL8O"^O6,N#6+<_\
MQBE9\::U.2LFDXNSM=3UZ.8%/_OH;E[8)AA=JX].^&:]EN[^M3)V^W*4C]H'
MG_1R%>C!V<V+C5RJSRK\??/1X>ZLDU+IM:J]MK5P:O%R]"I__GI&ZWG!3UIM
M?>]:D"9S:W^AF_?5R]&$ "FCRD 2)/[=JC?*&!($&-^2S%%W)&WL7[?2W['N
MT&4NO7ICS5==A=7+T=5(5&HA&Q,^V>U?5-+GG.25UGC^*[9Q;7$]$F7C@UVG
MS4"PUG7\+^^2'7H;KB:/;"C2AH)QQX,8Y5L9Y,T+9[?"T6I(HPM6E7<#G*[)
M*9^#PZ\:^\+-7Q54\B_. F31D[,R[7L=]Q6/[,L+\:.MP\J+/]>5JH8"S@"B
M0U*T2%X71R6^5>583/-,%)-B=D3>M--LRO*FCVKFO5+BK?:EL;YQ2OSCU=P'
MASCXYR%]H[3986F4&\_]1I;JY0C![Y6[5:.;/_PNOYC\Z0C668=U=DSZ$2\<
MW7<853X9BRA0?%5B)6^50 X[&72]%(9^$'+IE$)J!2^0U\+(N<7OUMUGPBX6
MNL2*NA);Z=3*-EB_D*4V.FB(#"L9Q!8BR[+9W M=BUOI-%8)8TM)F>;'XGTM
M?FC,/5R9PZ%8C:.44Q66!RNDJ&U]6LJZ5#C9J'U02(&P H),X*BP4B* !C**
M?NMTN!=^Q<!,I1S#[T'>:2+8+H3OLY(A& CX*OT*-@BV'HLOJ_98 %M[8$2
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M?@E\F$/FA!8WI<+ ^.)IL$N%[2YC(:.X<>ELLQD]8^Q8+K7CR)K?PRX.$8P
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MWSY?Q4]^N^7QPRE:,E0]*K,+;)V,+\]'\75/>Q/LAC\ SFT(=LV7]$I$.5J
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MYX-PA.Q^>-/P%]>9\=Y4_.=22<R'M #OYP;#7/Q!"M(G^*O_ E!+ P04
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M!E=,\FR _U<.1]8O.,#^TKK\"E!+ P04    " "$A&-:^*+:/>,$  "\#
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M:_IY@98-Z'UE:#3H%AR@_\%R^2=02P,$%     @ A(1C6C3&3/7&#@  %C
M !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULS5M;;]M&%G[WKQBX:9,
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M@S@WO"H'$4 /F_R*32XWLD@,;Z!6ZS2_4<IX(M$%X"$O[%,S/(YHEAEP3GR
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MY=%QCC=%X@_]87C_B=4P\"8H'2(_&FS-1.]W\@E4&V*7T4CTO?M[VGE7>Z6
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M4/'%(+6 ]B'8*GX"8S''!W7\69#,R?$%O%]:&]H'-M#]3>3T?U!+ P04
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M);[P5:40<N_E'R2NL,&AY37:V'^A%*B'\9!"%;*UNV(+]%%!Y027^R3!]3V
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M$@=).AN]L]37A]?P6MOM0AQ,HQG[X;MI',7/N^\1B!R(+3Z=CB[M2$/G&]B
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MW6:]DLWBJ$*"E5TI<G)<!M%5&B33;$O2)(C)XM$%1Q$IO$-MRM9T'OOGCG%
M8A!.$J=4D(Y#9R*X)^F,C<<V)7:;H</LV6X2T_@H&$^]$'^YF;JW(;HG!'@;
M)ZG_&OW2X1H-FA(WGM4!A?ZXX+60_<F- )5UX"([H<5XAJ2&MQ^6A/T X&<4
MZI0[B_+JDG.2X<3OO;SQ;/QX!B3_9 9L4=I6\B(#TC3J?D19D$;)-Z3 -$AB
MA_8X#F9)'^5L/+&7H+A9.+V'8D6O:X[D_(AV1@2!KHW> ^_)/DS%8U"NPWMW
M^61X [[QV"D*<D\R)P75+>P,B9/H&^"=!-/0&^XOOQG>J*98TGW];7C#.B1H
M^-?@;8E\"]TD+@F_PN_Q/XGNKD9O52.?F0CPK/L1$_O,GH[N:!+,9AYDB.PL
M[H(\GCK0C"$>K=9C#+\'ND$8)QYS]NK)P,W0PW@=@-%9ZGEY-G57<1C,XO#I
MP$V!\ZDO&?;J6V&;HNAE[O/O@S8,@V@6_45.MD'81BWD)9DU#_WE97<\9=\,
M?:6@;DY("&"[H,,N*K?'16_/SMZSN;!OD= "^QVX.V$E#\7A\RM[\.;WGQ?8
M$K9:=S$^0V[<T<8-.OS82SF7C3N\L&.N_7L+#'FW\B^^M/?^CEYVQ>BYW:GD
M%C15WO2IM91K=)+V+5=>%6W5[[M;W;WIZS0]MLUF[S D\+VTWAQY;LZ)'%JP
M^6HVQ_B[_>[ L<BO:^ZWM-J=YSV6CX-3%FUD\0DJN$TA 4")PIX$V0?TEG*P
M<_%"'QBVSE4Y/!-'961O/K=T  0'T$$I</L>CG0;_I*;7%3V=:7=I7Y%ZV-+
M  ,S!R=@A5RXMZSN3? ?_O3*O7I06VQB_SH!3&R=WH/8V!;I[-50[:,E<G^V
MI9<_9=):$@E!*:N%$^#V.'VN@:[]2RSR,65DKI>;Q_LET<YYB]+ZPTT7U9+/
MN:(#7:%UNSE5')H;;=Y6]"2UYZQMQP>TR/U1Q[:G&-@_( 1G (GICD*?WJH,
M]0T#]C,(@>\-RV"]#BK[_KEP,OAC2<W5POY]AJ+5-L;]QZ2_V_]#Y\S],64S
MW/V]Y\J^FJ!WDW-,#8\GXP-G6/?#R)7]F\J--$;6]I(.I[FB 7@^ES#+_Z %
M^O\MO?H_4$L#!!0    ( (2$8UKZG]LPFRD  !V1   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;.T]:Y/;1G+?_2NFE%PB76&I7:XLR9*MJM7*=C9E
MV8I6LBN5R@<0&)(X@1@>'DOQ?GWZ.3, 0>RN[*M+JE)W97%)8![=/?WNGF]W
MKO[4K*UMS>=-637?/5BW[?;%X\=-MK:;M)FYK:W@EZ6K-VD+?]:KQ\VVMFE.
M+VW*Q_/3TZ>/-VE1/7CU+7WWKG[UK>O:LJCLN]HTW6:3UOO7MG2[[QZ</= O
MWA>K=8M?/'[U[39=V6O;?MR^J^&OQWZ4O-C8JBE<96J[_.[!Q=F+U^>G^ (]
M\6MA=TWTV>!6%LY]PC^N\N\>G.**;&FS%H=(X9\;>VG+$D>"=?Q5!GW@Y\07
MX\\Z^@^T>=C,(FWLI2M_*_)V_=V#YP],;I=I5[;OW>[?K&SH:QPO<V5#_S4[
M>?;T@<FZIG4;>1E6L"DJ_C?]+("XRPMS>6%.Z^:):)5OTC9]]6WM=J;&IV$T
M_$!;I;=A<46%6+EN:_BU@/?:5]?%JBJ61996K;G(,M=5;5&MS#M7%EEA&_-0
M/SWZ]G$+\^%;CS,9^S6//3\R]MG<O'55NV[,]U5N\_X CV&A?K5S7>WK^>2(
M;VPV,^=GB9F?SI],C'?N=W].XYT?&6]LQ_]UL6C:&JCEO\=VS.,]&1\/C]"+
M9IMF]KL'<$8:6]_8!Z_^Y9_.GIZ^G%CM$[_:)U.COWJ=-D5CW-*\P[&K-F6Z
MKG+XHJBR8EM:^OG250WL)J??QS;Q=YC&?%A;D_EO;&Z6197"TVEI&AC"PDEN
M&P/OEUUN30M/IPQ\&NLB3[=X/,WKPK4V6U>N="O$QJ6KMZZF*9+C3[V>_3I+
MC.MJLUN[LMR?N%T%2VBZ15/D!7";A-;_IE@5+2QH\'IBKJH,WD]A SR;C5XU
M.VO6*4SZ[-3\R># =;,NMK"5U@* 6O@PH]W7%KD@TE+TTVUSKFV9F\7>9+9N
MX6V$!6ZCMB4!<9O6+6X05P\P*\(ORW13E'O3UL C8+2TAC6O874X9WLG7*2-
MJ5P%S[4UP"Q>]\Q<E"7_E;G--JUPGK1J4N*DO)I%6L*0L#2"S<+:RMBR  Y%
M$W9;((DL)I#9Q 'XVA^ KR<I\V-C$4#?-VT!_-@V8[1]OQ$(<7!4 <Y,QO#C
M7:@8'T*16+1 'T6[5F)&*&[#*5E9H)84"!)_MUL<4-#SL2KPK^N65H$G8&-K
M8,/FX;_\T_/Y_/3ECQ<7[^CCV<M'@/2_=@5@!CA_!;(25V%:!W]]LIYRK.XI
M,7_I\I7@&#"5-B!RMXRY=IVV)ETN02;2,F#GKL:%I!M_%N%Y*Z^61;HHRB(F
M04^ >=%DI6LZ7%;*HR'(<(0[T5^"!+@#<8S_'EM+;6]LU<GL]C/H(@W\D7<U
M AI?V@+47-Z8+?,JF\_,;Y;D-)TC#Q0#N%T7($X1R"4-51<6")A&=C 4'2U[
M@X+P &([I/"R@,4@V!>XUK1Q5;HHK>E MM6\Y:+.N@WL$,_%+"(R/)Q=P\AO
M8! @"?PN57X(FTG,HFOA/+8&#Q%"H75)O/PE;-&M8)<-+H$@#03HL0_;(14-
M=^069;%*PU'%M47G%PDTZ[]-3 !^;9B86>\ /I< 3X&%GB \<X.\ ! @S+C8
M;+NVQ^UP1&9>A+3PP[:KLS6B)(4-,/4^Q$4)J;_3GR_T9R7\A'%<NYN"U$"<
M 4 &:S-M^AE)W0/0TZ7(W8;?A?-2[D6>K9S+=P5R-N!I14WK"%2=.40,D?N>
MOHZ>@I=+5ZU.2A ^N1Z0! D5)B;B:4@&P!X"RL+A+ZH;5]Y8 F!I/YL"Z$MH
M6DYV.+*)?WJX_(A\88^@=?((0/EYD2GS6G8MG$A MZUR& OT.C^%_=Q:U,/\
MF<&36FR(I&% FI/X14WB[R_$(YP!U%0K()?:;>1-_)8_@:#(VBY:T";= V,
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M(4<F7BF(W9$Y)NCMN:>WYY-$ BRG!3&!F\ %CU'9O09@3@34@R=.?R (B V
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MCP,B5G-^&L$-F*Q[8"4D4)[QQZ]^&L66N48[DYG&*!B0BX3D-8Z>X!'^ZO*
M=)C!"M'$2_A:EO##-&$<+CJ2QH<I%N0[BP5PU1'S<C6Q:TRE,<AOV23NY=\
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M\ '1TB%A>AT&>GI2\7^A@^GJP#;[?T?1T%%TB$-QVW)P=.A!_/LZEGZ*S_/
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MFC86,B>ALKX55/S%%90AL-D4;4O4@I[\1GJF23,P*?7K;7 !=GFC>?)] ^I
MVU<'61M*OTY$[\S%1(A, MWTOXY/",C^42/3''!6:.M\"69>"5+&UI/XN)CW
M!?2C%F/^ '$$=1*TY.BJ1"VYFP=3ZS$3^L.HOA?27T1CBY708]3<]+( I>F1
M#Z-JF;A/Y.%CB.:]IG&,4&IPJZ JA:$28"6EHQJLR+7@AP@K&(,P2%EDS%/6
M-(FU \:DR-< +NE9DIZ&B2V^BH:#+))@A(O6@) D&_7'H31VW]\O,/VI!18^
MR$>JLLW]T8S)0N)W0R]+1/&C)\)+XX! $-A8'S^L"1 O&"6$,:^7!:O='U0<
MFK2X\?XCKE@,CKK!BUXI9R;DQTE8J@Y^IL8:[1I33G-0>'TO/VWX2(#H&BDU
M2S>^ND'"L@R?6ZA/Z.8/@8;@[Y[;(((3?DR)+E6T#,$5A2NDW>0&%/_RT"/'
M);,D(Y2'8J#^FI,%1'M6YV+<-I.L)1Z$#]V@G:;O81)[Q;4OX\Q\_QG3NJ3E
MRWY:+0BE2\AF?!F.-L\,V:Q'[$90)-O 'GU"&4$0>V/L@_E)B^F]')^0B""\
M#L*=5SG3NZ=F4)9 >(Q:2<1&;U'G)WA0]V.*B/?F'TA6C!1'0DU;])ULTD^D
M%?XZ"H);=S'&K GUCL)OE" J!Y1I3'M;C(.<S#<%*H5=L<,3)\? #A>LJ[/"
M&Q,(LJ6Z2:D-1V0C]4(B>%@P5Z^>F;=>$^SY8,8TN]A*QQ%$D(YJ+]+%.8C?
MF+?JZK$EG:5CIL$CWB27O_MY-78LF6MO)'H0>_S'$!(V1.$#G90SR"CCI-\I
M:/R475&32L8EM:7HY<SZD%F3%6(-)]XEE_2@&+KZ%LVGPV;#OG6*<))^=SX3
M=Y<3: UU"+]Q=@!Z'VNP2'9KY_F=F&OJJH<7CKI@(V4J].4]S/A!J#)YHRDI
M^>G8-HH;\GEYJ/Y5X5 ][VKD[Q'_"-7Y#Q@_A79B:S\^YC/S45B?5F+[[EC]
M>KY#JU8)?!>+^<AA1O81!U'2($V.F2F_'7I.L:&G .ZHRA?:-_L,AUZAKL Q
MH()C;T/'JR*6FAI-8I>R#E6'&JKJXJ>>/_+LCP;L52\?JD1+37*/]GZT(?1]
MT7M5>5]@L+EDB+XK15/+44+VMD@B!/DKKH9HE;7*2H\%-E<)ON_@L?! .*2<
M,3AX)2+P8;  LO5)MPV:^JT*SXAKZXC^I\\?4_>F$F3FH<'>?+H5WJ7J :^E
M%<=8\/J^8_0Z/\5I;8GWE*)CA*16B)1XIL)R).JIH$R@)P2F#W\4J.XWS?K-
M9[WM1SQAWLOJ_<#B4T2Z/$;U)(87-BB,L5E:H4W:2TI\:=9NAX*=""W*:049
MJRY528,X>I19+"C[8%=4+R[&';6*OE'-LCC2?>A2"U>7^0Y#28,AJ%(IXV0*
MGZLRC+(%,V\J\JWQ$#Y14V"GEFG5B?X9^8BCE!#/&]$2ZZDR'F"9<Q@52$E]
M/TZ.(ZQ$VO0%=A(G1.>!7 ^B8^2?+"6L+Z1,80A+35/"5-XQVO7IFA;*7K7!
M,D<9$E%HTV$V+WE(+5)(Q0$=MVC3T-4[[2F2/IVLT>J !>>(_F:UJG)TJ@/_
M;X]-,7?R="J5^?W<\]A7V$0<W?>JS*1VTQ]=WR H-LQ#+.>/]R+[M-+SQ,<_
MO"MN2+>22?X''JA)IAY:H<VG.YA=T[T*K^GL7$:FX2AOGQQJ/*/QV/CF^LB%
M#JI7-OUO-5>+FIQ@[S%Q^U NK'9OYA^PH"[J0"9SC#]&R:U29(,IVT"@;J_>
M<N0N_ALX<5$;*^9A]+;<@7'0B5&&/HR8^(1!4NXQ7\-S9TD^T[2_'59T)*!.
M=+XCY8VXF?C)Y&C";*+)F!(2!;@M+35$: [C8T?W$4/ZGB -AO#K,LT^G5QG
M:T<7-M%@)^@,).%.SA6UV?&:+FLNT[IT4=]%>N8>U?3ST"YJ?DNCIQQP 7H]
MK&24X._\MHD_<ZKKL5*,6>]9?Y<,]13[9_-T=J;-:!+X\_GLZ:!;S=GY[)G_
M2EVU4VGC"3<@D^3Q^=U;SLQ#>Z7Y=(ND2^D(+5QP%)3W&L'HWR&?69@".V:U
M ;6T6TKP.#2NJFQYHAS6 _9A"-^ 5$MK4G06P$67V@W_V-TRC_#:F6*[U0LV
MUO"?,D9:TFMUP_=?>6^_;^TNY#!(NP;QETGEL<I%";,L+3FH4&"*[Y1'&,@.
MY1E>,_)Z'%V;-;X*-=I[G6SZ3:RBKCN1KV)D7U3UF5+;57):A-!T% F3BI[+
M.\-@H*X+J,FG MRPC*KM@^X;7/(^^V"2L$,OI?ET+Z7W<9NL-U%L\'NA@%%2
M_YUCFO?'FG-YFH[BQ*/MQX08_UZGXBY4?QM-B"4BRIL2LZYO=AP(@<[]^1C$
MVZ,F>=AJ6]W*%$B2(N%T[X\;)B)B@%53]"C6;G>F=['?R*49E$K.290;3:+$
M=![<<E"0]<!Q#>(M:%7F=GA2?*NC^#V4[MAB+DM]86: "%6Y1KF7CGY "5W8
MOAOR"'"CT>+TTBPME1_B/:?+TNU0HJEZC ';M'_;P62_.;]W,LEH[S(K25+-
M<N3B:!_W!MU KO.C=;(),QH-0 FIP-#!%.E,YCXN=93B;I/G!SX'G/0PFYTK
M:L0!0#T!R5U;L7<\6NA18$7885H0(X.O@O&-OBCN<]"?)^42ZM!!C#0_6B7#
MON+V(CZ /+!/HV1\W#1S]$%NQ>^Q9\(=2%]"/Y/\/G17FD]W1KI.50[S529(
M@Y.L_LN',^''C?_1GP:?SO)WX>"AXIQY UX*TB1Z+B2U.N.0E;\M+0GK3/I)
MGHG/PT4S/6#<Y_S'"/,[XO,05)R0'N6U$O*D"4OUIY9<'VJ/:VK1 >"PC+JN
M*!>4>0H7'J<CJG<2'#O]]6-EBA.K/SRLR1=Z(UXTC*O@0))?1<*O=8K1G<#C
M$+#W%Y63M!W:(,VG>QE=];J;4'_,GR@\(CW )NG\CQG:7-URE>$!&EG(#IK
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M#VUTD!\_DB+-X5*J)YT#&/*K+(0>>;DQU640Z#2'DNES68' FYE4)3.X5?-
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M@[(">#^3TJPVUL!Z5!__!U!+ P04    " "$A&-:Y7%):"0#  ##!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R%5=MNVS@0??=7#+2+10(0T=62
MXK4-)&F+7:!=&$TO#\4^T-+($DJ1*DG%S=_O4')D!W"]+]*0.G/FS PY6NZ5
M_FYJ1 L_6R'-RJNM[1:^;XH:6VYN5(>2OE1*M]S24N]\TVGDY>#4"C\*@M1O
M>2.]]7+8V^CU4O56-!(W&DS?MEP_WZ-0^Y47>B\;'YM=;=V&OUYV?(>/:#]W
M&TTK?V(IFQ:E:90$C=7*NPL7]XG##X O#>[-B0TNDZU2W]WB[W+E!4X0"BRL
M8^#T>L('%,(1D8P?!TYO"ND<3^T7]G=#[I3+EAM\4.)K4]IZY>4>E%CQ7MB/
M:O\7'O*9.[Y""3,\83]B$XI8],:J]N!,Z[:1XYO_/-3AQ"$/?N$0'1RB0?<8
M:%#YAEN^7FJU!^W0Q.:,(=7!F\0UTC7ET6KZVI"?76\T]5?;9^"RA+<_^J:C
MBEL&_]!YN/K$MP+-]=*W%,GA_>+ >C^R1K]@#2/XH*2M#;R5)9:O"7R2..F,
M7G3>1Q<9WV!Q W'(( JBY )?/.4=#WSQ_^3-8".XM*_3AV]W6V,UG9A_S^4^
M,B?GF=TM6IB.%[CRZ)H8U$_HK?_X+4R#/R_H3B;=R27V]2/=RK(7"*J"\[T[
MI_@BYWG%K\CQ># D'0QN7'AJ";9;U%-;!B@9,12*;JVQ6#J<K1$J)>CZ-W('
M5XVD'=4; IOKQ>R493:P.(;9>[Y5FENEGX_!X7=(4G8[#YQQR^9I-GM0;==;
M\CZ"<A;'&63L-@MF[WHM&]MK'*2IJFH*/($F+$@"B%D>!4<FHRJ[Y^02LFB>
MT_,VG=-720>B'R<)9=!IM:-2&8C8/ N)(@GFL_=(XZ%6HH2F)< 3NB &LIA%
M&2E*6!8GLT_*<N'\SU:76ZJ=L1#&*4OB&,(D9$D:$K4Q"[@KBK[M!7>%+9%Z
M531\4'0%><;R,(-K,EV\.('KV:464@5SEH8I&6G.HBB#<X?3/QDL+>K=,#X-
M2>RE'6?,M#M-Z+MQ,!WAXWC_P/6ND08$5N0:W&1S#_0X,L>%5=TPIK;*TM ;
MS)K^,J@=@+Y72MF7A0LP_;?6_P%02P,$%     @ A(1C6@N%!#%R P  XP@
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M?L<A;AWB.N\&J,[RAEFVG&MU .VL*9H;U%1K;TJ.2[<I=U;36TY^=OE&J?S
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M=V]R:W-H965T<R]S:&5E=#,Y+GAM;)56VV[;.!!]]U<,U.XB 53K8L667=M
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M,5XMR!3\8[*"K^])3&/?H5[BDJ-MA^@NC?_&"UCD&<_Q*ZPV?UCF$H8^]>R
MQF[\RJ3XQ(FI#7\>5(8]' @Z#@2'<J!9@:]F!<@8$XC)O@'<2;!L)TVV<04,
M&/"MCQ%[[?4S8G/MF\:"EFMC&5=[A_7#.0+\Z*'(=3W]$X"*J/C5M!N>'8_O
MN(3N22X?N$QS /-X/I=\SC0'V$-VH7VFY!=6U/P)A*%#*PWNH4/]9')I' 74
M]@/R!IAE)?83#2NT.M2V(;^A3SPK29X(K<'TGD0 @\2UR1%Q'"N*GTBND 9R
M8=" '+!CA<XSN292E'1LC\8V:G0MSWU=A#Y&Z"98,J(F0L>!ITN=('JBZ0Z(
MTE*ZM6Z WZ_4IK8;42^P46EH>?CTP<0>\(<=^,-#P3]9<[?Q]0:X:SS\TE"\
M:7"]8JIC2Q\?]KK0SX=)7R'I)\9_I<*.@)[QP300 GLB/OA95&T"=Q2\%ZF0
MT#!,J!^:E-J(M-Z(UY0(:.@D2 OB6[:W2WJ3&RX-W( F7@A8CJS$V36GC<1,
MB",:QBV=H##_US@-=IW(IW'@0J"1!53]\F*_^'_2_*7M5X> ^>M&6(?AX#7=
M\.4Z21,H)&'DMT7$ZYQ_3<N'4N3X4#EL$EI^\BH56S"">A883!@U_TO(4.=I
M#&/'\1L^@+T]Q2WJBEMT:'&[5#J'$Q>XM4X?^<ARV70R];3[JT;NZ7&CJ6=[
MK?;7LV\ 5][YT.YOT8<9^G#7^:!Z^^$3S*M=H&_QTVP17+?9&:_-UFJEY:)@
MZ>WQ=;H0!=HUYHZ7D#@4*$7&\=2H%T:V89#)G(*3=N/:R> W)-_E,S\&)IW&
M#71A\+&+#\-+15G"!J>)\HWI[O"(+3\TY0$ZVS$"P+>28'#YL.0&2)K+DKR'
MLX*)_8@$EAN!7&A!,=PQ'DQR=7L\DQSWY# ?UH!(7&[?<LG;]O\Q/#UXPL[!
MO($WY.W:[)THF,X+K$.1;P5&) HL&P:1TRJ 00B#,%Z_VYLZ,JAC&22+/.:\
MR,B[[V+7<;]_]MR#];C#>GSP24Z42UXI9O:2'X0"_DUX81  ^[QME"-4)M<W
M"D\T18W)-',J)8H\8TU=A <>8PT^ORZA")JI?<38Z^)N8J2;#J<"<[7V5QU\
M*CFPLKV>1K!5QJ-=MS[:^+RQ1FIKC42W1AL-R !8+T2M0*TZ.I@_F#]4*OD=
MKX!$0!H:>MA-X109A^8]<6QL[J P71BO,Q NQ-)</C@1M6,'E,%N(\"W,(8=
M-4/>KQ<-V0TMQXML(!\- NA!'@V2:/")5Q!,84195N95CC<9YF0+&@,@G.O1
MR$:/J1L[@V]"@[0YU+>)V$HN[,AAC%$$$(:#NY_0I0F0%[X$U(_V;FJ3C@O)
M?BZD"Y[5A:DX-Y7DJ9A7^=^(Y8V+FBV67+9^K0ZW$X[7C[WM?]*H,].NN,Q%
M;XO8ZV _$\8&/#U@K#=#>'%I5R'(+H3[50BL#4%NA+ T(3R_0]FY;KN79F-O
ML-W&WB"V$A] 907.RYO*P(83&,#?<KVM[<;+[(X!4PY8"<->&(TV;C5++N?F
M[E;!,M:5;BXXNZ_=]?"XN15=BS=WR["+G,-)F!1\!E-M*X(SOVSN:YL7+9;F
MCG0JM!:E&2XX@^TL"L#O,R'TZ@4-=)?FY_\ 4$L#!!0    ( (2$8UHJR"&U
MIP4  ,8.   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;)U766_;.!!^
MUZ\@W-VB 51;H@Y;:6(@1XLMT"-(TBX6BWV@I5%,5")=DHJ;_OH=4K)LMXZ:
MW1=)I.:>;V;(D[547_02P)!O=27TZ6AIS.IX,M'Y$FJFQW(% O^44M7,X%+=
M3?1* 2L<4UU-:!"DDYIQ,9J?N+TK-3^1C:FX@"M%=%/73#V<0R77IZ-PM-FX
MYG=+8S<F\Y,5NX,;,)]65PI7DUY*P6L0FDM!%)2GH[/P^'QJZ1W!9PYKO?--
MK"<+*;_8Q=OB=!18@Z""W%@)#%_W< %5906A&5\[F:->I67<_=Y(?^-\1U\6
M3,.%K/[DA5F>CF8C4D#)FLI<R_4?T/F36'FYK+1[DG5'&XQ(WF@CZXX9+:BY
M:-_L6Q>'IS#0CH$ZNUM%SLI+9MC\1,DU498:I=D/YZKC1N.XL$FY,0K_<N0S
M\[<BES606_8--'EQRQ85Z*.3B4'1EF"2=V+.6S'T$3$A)>^E,$M-7HL"BGT!
M$[2I-XQN##NG@Q(O(1^3*/0)#6@\("_J'8V<O.B7CI)+KO-*ZD8!^?MLH8U"
M:/QSR.=68GQ8HBV78[UB.9R.L!XTJ'L8S9\_"]/@U8"]<6]O/"1]?H/E5S05
M$%F2"UFOI !AM%V]DUJ3<\""!'*EY#UW!8)+LIO,0_X,:CSLS^T22+ZGOK+J
M%ZWZU9YZWJHW#DMVPR#S"A27A29.I#!0D#4@)[,4%;8$1!T72"D;S42ACXZ]
MOX"I%D8$00#U I0%@F>!8-$0V0?U+E&7-CPGOY$7)$PR/XT2<N16E"9^M%T%
M@1_3*3GRL(ZQ2@6) Q1(DLR[E8953_5HHR?)]O0$\8Z>*)WA:B#]29_^Y'^F
M_Q)*4 J#8Z%\IC7@-D:.O.-LP2MN^.'<#ZI[//<:X\5+GC-A?L"!;)1M?ZTM
M&"%,:6]+M;7%9AJI+10*9N"_ .%P]KW+GY5Z'W!\X:!2S'!QYQ+J$D:GL9\@
M$/ K"?TIC3T;M!R9.;K#E'K +*^9*DB<^%E,21SY"9UY'Z3XVK"*EP]6'#;A
M_ N*MV-$6V."," T\\,T]3YNE0(.ASW/*?4S;(P6),ET:[:">Q -D##VLRPE
MX<R?36/O@JTX@I%_=Q0::R!?NE@62%[)%0Y"0V)$7Q*0F/IA9'T1=QP;MB/C
MPO3+-A&AGZ41>?YL1D/ZRON(&5 D]<,9M<\X[<!_*(5Q//6##/6$J9_1S'L'
M6A^3SZQJ6#M*;;Z8R %1'T>)GP09HAZ_ XJ5AO5P*$<^$39));D_("<,_606
MVI D0;+/O1/17WG<^6KKU*<H[LASAXR7LGS9Z)[JQ4:;-3F,?.HLM@C:C87#
MST;@]FN@M-.^M-,GE_8UY%+DZ%X;$-QY79;@3BJNOJ^Q9.SNXWT>IQER**PB
M)6OR!@K$8T5N##.-D>K!23C4#X9MM*4/O24V#:JSQ);]0),L=JVQ15]V%NG>
M(B?I\?&P;0A/'@4W^[)I. [([_LO1^.,['&XL<QZMP !)?:$:)R2&.FC\<R[
M63(%+^V1KW"M#T^B;980Z..I0P\=9]T[0 A= 1X3;7\DW$!M@1:,(_<_&(?=
MFR+=A>L_6* HA2)%- ZZ\K04*5):DQ&;+?4240X8Y8.%8\?.QIBDTT;CL45T
M6]^!"\+.<P#!TQ[!TZ</I]Z\3T(AFG%<?.^&TWD;U(/C:%#!X7%T1M1/U6(A
MM( [+H1MP;8K@"C<9RV;;E UNW;M)'M[1OEQ,+'AN73.*A=[9O90:;$88JO
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M^M+TRB;2&B1Q(Y&ES'7/(OL<<P#PX!D[X:UXK9P8X(1&=HN7#1(,":=1-?6
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M,/KB8=NOV?9+]/X.MG4]IZQ<F#=5?;BUH]&- :[_;"/>[X#X44W\R%OF-T*
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M" P0T179)6+.#K_1NB&WX%NRA)>?X%#5^J$!ECLN6%J#Y0S2.*N^R9=:B!,
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M0C:9Y3"1'P[ %$ ^GU(JEA.5H/D4\?\ 4$L#!!0    ( (2$8UJ/]EJ$>@(
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M>/KFC!+=M<%N8E7K.\E:6>Q+?ECCEP.T"\#]4BF[F[CF-'R+LG]02P,$%
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MJ2X;,\Q5\P>N ]3[E#&YF>@-NK\3T1]02P,$%     @ A(1C6I'IX*8@!0
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MOW=#8-/TIR9 7?HGOM)(#<,/<VKI8%P"K:^UQGW@ND;W)Y'\!U!+ P04
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MPK_?M9-F+0L=#[PDOO8]Q_<K)Z.U5/>Z ##DL>1"C[W"F.K<]W560$GUB:Q
MX,E"JI(:--72UY4"FCM0R?TH"$[]DC+A)2.W-U/)2-:&,P$S171=EE0]38'+
M]=@+O<W&#5L6QF[XR:BB2[@%<U?-%%I^QY*S$H1F4A %B[$W"<_3@?5W#C\8
MK/76FMA,YE+>6^,J'WN!#0@X9,8R4'RMX (XMT08QD/+Z7576N#V>L/^Q>6.
MN<RIA@O)?[+<%&/OHT=R6-":FQNY_@IM/D/+ETFNW9.L6]_ (UFMC2Q;,$90
M,M&\Z6-;ARU >/H"(&H!T7/ X 5 W +BUP(&+<"5VF]2<75(J:')2,DU4=8;
MV>S"%=.A,7TF;-MOC<)3ACB3S!1.D#)/A(J<7#[4K,*>FF/R#2?N YGD.;/M
MH9Q<B6;&;+,.4S"4<7V$+G>W*3D\."('A GRO9"U1B8]\@T&9Z_PLS:0:1-(
M]$(@842NI3"%)I<BAWR7P,>LNM2B36K3:"]C"MD)B<-C$@71H">@B]?#XQYX
M^GIXM">;N&M4[/CB_S3JF,PX%6:W7^379*Z-PH_H=U_E&^9!/[,5EG-=T0S&
M'BJ'!K4"+WG_+CP-/O=5[2W)TC<BVZGHH*OH8!\[=@A),^9&NJ]J#7KHT%8]
M5TEX-ASB**RVR_&O5Q0,XVC7*^WA^A1%8>?5).!O?<<EJ*730TTR60O3S'VW
MVTGNQ"G-L_TI2G&CG']I&AV_IFK)A"8<%D@9G)QA3*K1QL8PLG)J,9<&M<<M
M"_R=@+(.>+Z0TFP,>T'W@TK^ %!+ P04    " "$A&-:@LUIJ-H#  "Q$P
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M^?H0@\0D%Q^GKE3#T# WJ;N\K[H,3G3I!^B14;D1Z">:0MH!6'P-X/407*5
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M=$(@@:C8@!>(%VYZ62R<.-A.N_'I.2=9UC5NX05O6MNY__EW=WZ:[X3\J0H
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MM@*&_XHF[?2T,TYBP';B;#8S26"!,[O=G;V<?MC9#\0H-BT&%T$N9\Z//Y+
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M6W#E8S*AR^)K9]2+ 7<QG]U0WT(]#"@M1-%4O;8>AKUO%896K^WH<C0MJ)B
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MPD63TY, =#>,.L.JUO?S4EF:#GY9T_Q&[1SH?*64?3;<B!C^$8I?4$L#!!0
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MW2A:8 I-9O[(8KH]F ^+M$AJYY W@Q35L^\JV+\:^:<":!O16P"3:($I-%D
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;*V8VV[C-A"&7X50@1Z
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MX&QD@%3S,F\Z*"OW&GZ0:-[6KIF;KQE0=H&97TJ)FXY]8'??1\G_4$L#!!0
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M;?SQ<'S;OK>Z9BDN/.I/C6J/7O++JW :O+O ;MRS&U_RGG0WS[Z[^9V[>6:
M4HK5%M4QK:,A^&V J0M@'XM]$DZBFYO9E+3W ] F/;3)16CGJPVZ/%#IIO1D
M:03,<W0/ ?S*1&,+O*N#(<"3%X!GT60<AF?P3GN\T\NI-#)]!%G;XJ",BLS"
M-(JGABI"N\-&<*/;])+,JI@";=_SJJGHJQ[17&U="?V++99\Q^U]&0E;XL^4
M^+&)6K+3%V2OXG@<CFZB8;:SGNWLO[-]>P[NSU"D"LR16RF5(C[57 TSF[U@
M-AX%DSB*AXG%/;'X?W3$!FO3M41POB7BERT1!V$\"G],NG_RQ%>H=FZ0:4AE
M(TS[VO?2?E8NVQ'QCWH[:#\SM>-4>"7F9!I<SZC,53N\VHV1M1L86VEH_+AE
M0?,>E56@\UQ*<]S8 /T_B.0;4$L#!!0    ( (2$8UJQ)W8S*P0  (P0   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;+V8WV_;-A#'_Q5"*X8.2"11
MLGYEM@&[R; ^%#7JI7T8]D#+M,Q5$E62MA-@?_R.DB(YM21GV;R7B)1XQ\_W
MCN29&1^X^"JWE"KTD*6YG!A;I8H;RY+QEF9$FKR@.7S9<)$1!5V16+(0E*Q+
MHRRU'-OVK8RPW)B.RW<+,1WSG4I93A<"R5V6$?$XIRD_3 QL/+WXQ)*MTB^L
MZ;@@"5U2=5\L!/2LQLN:9327C.=(T,W$F.&;.8ZT03GB,Z,'>=1&6LJ*\Z^Z
M\WX],6Q-1%,:*^V"P&-/W]$TU9Z XUOMU&CFU(;'[2?OOY3B0<R*2/J.IU_8
M6FTG1FB@-=V07:H^\<.OM!;D:7\Q3V7Y%QWJL;:!XIU4/*N-@2!C>?4D#W4@
MC@Q&?09.;>"4W-5$)>4M460Z%OR A!X-WG2CE%I: QS+=5:62L!7!G9J>O=M
MQ]0C>I_'--?Q08N4Y!)=HV65)L0W:*EX_!5]+,HPSG08M<E]OJ8"0?:CT@:1
M? T]7/?>WE)%6"I_0F^0A>26""H1R\&**7D%+Z']VY;O))C)L:5 B@:RXAI[
M7F$[/=C801]XKK82W0'&^KD#"V+0!,)Y"L3<&?1X2V,3N?@*-#@C=+^\16_?
M/(.O'@,SN4W(W7(FMV>FI79T/8>EM$8+\@A+7*&9$"1/:-G^?;:22L!R_:,K
M+I7O4;=OO8=O9$%B.C%@DTHJ]M28_O@#]NV?!\A'#?EHR'M%+F%IK/Z$3844
M1Q]W2BI((<N39\L$4ORLBW@[\ K-:<+R7-O,"2R6F**_.L-;*:Z8_)))'S)[
MR'X8>/;(&UO[#C5>H\:[E)H$LJ4@?4/8WBFV;8>N/^JF]AMJ_U+4<(9O*#O'
M[9]P7P<XC!R[FSMHN(-+<=.'@HDSU$$'M>^YD=--'3;4X>6HJ8B9/,,=GG)C
MVPWMGFA'#7?TO^S4N\K@)=LTZMBF3N0Y4= M!=MMB;(O)69/I5[ONC;5^2"K
M=%A'#?/=QG4"U^O)"3ZJM7A0R)?R-P+PS/94P&\>=%>O$;00#,);0$$MQ?[C
MT[.M4YV2*JSH6))G1CURG%:.<QDY[?%YAKN:'SM'X*X9]8&W!1@/5LG7@[<G
M*!<HUK%/TY?H<$]U8&P&88^0MA[CX8+\:B'MD7J&?-1!'IH^[B%O:R\>+K[_
M@KP]5L^P>Z?LCNGV5 3<%F \7('_FUU\<K*>$>-W),(S<5\BVK*,A^ORJ]7T
M'JUGA 2G9Y%ONCTRVCJ-APOU+$D$38BB<)51@L&M,4:?2;K[#OLX!QJUD[":
MR3M>-MCKJV)M1<;#)?F%A$.![:2-3FA')R77.KH@9E0DY358HICO<E7=%9NW
MS55[5ETPV^'5/?T#$5!^)$KI!DQM,X"9177UK3J*%^5U<\457%[+YI82N"OJ
M ?!]P[EZZN@)FG] 3/\&4$L#!!0    ( (2$8UKHU=GS=@4    F   9
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MI:%RUS53^L% 91?0_$1*L^[8#:I?EOXW4$L#!!0    ( (2$8UI(&$'-[ 0
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MIX/D0EH/V=RM;=9IFPUK*[& ]Z;]YTB7O'XG2MNS7'*&F6Z2R6WPLZL7K4>
MT>3.#4Q'@<'_@&=1N.VB<#O(M ']'F3 %"(**ND2/TQP$TSB'O&CP+!'_"@P
M&A8_[\3/!YG6 G*BG*+GSIH+;R\*V&UF^OA9!<^==1Z["_BN\_YNT/O?50G"
MY?LP3(=OUI.P.Z>;EYUFA#X<RTX8O(T9P7!^2LQV@ A#!TSK9J+ 5$^=F&7.
MACK"=Q,%O2=U%#KMJ_-T%)I,DI&0G$Q>X2#95ZXP=4H/'<F[J-8K;-)AF\9K
M_V1TK$#L[ @N=1>MF6KFIFZW&_,?['![L?]HQG\[DK[1--\.7[#8$281A4)3
MZK3IEX!HQO%FH?C>#JA;KO2X:R]+_0D#PACH^P7GZG5A'M!]%*W^ U!+ P04
M    " "$A&-: (9+O\H"   :"   &0   'AL+W=O<FMS:&5E=',O<VAE970X
M,RYX;6RM5EMOTS 4_BM6F-"08+DVN]!&:AL0>Y@TK1L\(![<Y*2QYMC%=MK!
MK\=VTM!+5B:TE\:7[_O\G>/DG [77#S*$D"AIXHR.7)*I997KBNS$BHLS_@2
MF-XIN*BPTE.Q<.52 ,XMJ:)NX'FQ6V'"G&1HUVY%,N2UHH3!K4"RKBHL?DV
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M86E^2T!: _-](83>3JR#]D<G_0-02P,$%     @ A(1C6M-AI!S^!   :PT
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MTIE0%$3^>Z27-$T5D^S'/Q7IJ&Y3!6X?/[-_+,5+,?>$TTN6_IG,Q?)\%([
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M5S\4SXA[FVR"*"N85_D[YNGJ.%9<+U$@!)-@2O9VQ^.,6$Y[/-Z8F^T?[G,
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M/IPO9%4LG.C^=$^:17'2[:)>M57U/IS[;*ZM+/>_F=S_WO/=?U!+ P04
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M]<X_J?<P?AW+<.OY7L/S5S])]7BYM]P>?UU^GT2<5U><Z_N*X>DO4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ A(1C6IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "$A&-:KXAD:VD(  !9-   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ A(1C6O)2R$["!P  62,  !@
M             ("!K!   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( (2$8UJW//0@2 ,  '4+   8              " @:08  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "$A&-:H3*K]2,'   R
M'   &               @($B'   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ A(1C6G,'_BJ& P  C@L  !@              ("!>R,
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (2$8UHR+F-J
M*P<  #\V   8              " @3<G  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " "$A&-:PM5YD2,(  #*)P  &
M@(&8+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ A(1C
M6E*P90R8"   )BL  !@              ("!\38  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( (2$8UHDV#&C(0,  &H(   8
M      " @;\_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (2$8UJ4E/I6RP,  +P)   9              "
M@9*#  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ A(1C
M6AK7)M$!!   #0H  !D              ("!E(<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " "$A&-:<81%T6H&   D$0  &0
M        @(',BP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( (2$8UH"UXL.GP,  ! (   9              " @6V2  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ A(1C6HFW-E)5!   K H
M !D              ("!0Y8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " "$A&-:_C=-->8"  !1!@  &0              @('/F@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (2$8UISIC4
MV H  !T>   9              " @>R=  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ A(1C6M7@[VW&"@  CA\  !D
M ("!^Z@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "$
MA&-:IF\"9:,$  # "@  &0              @('XLP  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (2$8UKXHMH]XP0  +P,   9
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M970R-RYX;6Q02P$"% ,4    " "$A&-:58!FU?("  !B!@  &0
M    @(%FX@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M (2$8UJ;=V4Y6PT  ,,D   9              " @8_E  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ A(1C6OJ?VS";*0  '9$  !D
M             ("!(?,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " "$A&-:FAYT#:<#  !$"   &0              @('S' $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (2$8UI^[(VJ' ,
M *8&   9              " @=$@ 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ A(1C6L<:716B @  "P8  !D              ("!
M)"0! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "$A&-:
M2'OF0& #  !?"   &0              @('])@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( (2$8UHV%$(Y400  +8+   9
M      " @90J 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ A(1C6N5Q26@D P  PP8  !D              ("!'"\! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "$A&-:"X4$,7(#  #C"
M&0              @(%W,@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( (2$8UHJ1J93\P(  $\&   9              " @2 V 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ A(1C6M;P,\6$
M P  4P@  !D              ("!2CD! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " "$A&-:O(?9CA<#  "8!P  &0
M@($%/0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (2$
M8UII>BMM#P,  /L&   9              " @5-  0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ A(1C6JOO2GMW!P  0!<  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( (2$8UHS';G"/0,  ,$/   9
M  " @3%C 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
MA(1C6AG@E^BF P  !!(  !D              ("!I68! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " "$A&-:)5J/VET$   0&P  &0
M            @(&":@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( (2$8UKZ-8R@^0<  -%8   9              " @19O 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ A(1C6K9VQ)D] P
ME@P  !D              ("!1G<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " "$A&-:C_9:A'H"  "7!@  &0              @(&Z
M>@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( (2$8UK2
M'/KPY (  %H(   9              " @6M] 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ A(1C6I'IX*8@!0  ]B0  !D
M     ("!AH ! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (2$8UKX1,$I@P(  *P&   9              "
M@0J6 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ A(1C
M6H+-::C: P  L1,  !D              ("!Q)@! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " "$A&-:QOQ(IG<#  "'#@  &0
M        @('5G $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( (2$8UK<;&"ID0(  (@'   9              " @8.@ 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ A(1C6B,=^:TP P  H@D
M !D              ("!2Z,! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " "$A&-:1P9[U(H-  #.>P  &0              @(&RI@$
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( (2$8UJ?&9NB
M:@(  !T&   9              " @7.T 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ A(1C6A%J+Y%O P  YPP  !D
M ("!%+<! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "$
MA&-:H-L</U$%  #D(0  &0              @(&ZN@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( (2$8UHYY 1%BP,  "H-   9
M          " @4+  0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#
M%     @ A(1C6FQ0T.DN!   ;1<  !D              ("!!,0! 'AL+W=O
M<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "$A&-:7N+C\E\#   K
M#0  &0              @(%IR $ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM
M;%!+ 0(4 Q0    ( (2$8UJY<(VQ+ H  '1*   9              " @?_+
M 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ A(1C6A6M
M#^LT P  30@  !D              ("!8M8! 'AL+W=O<FMS:&5E=',O<VAE
M970W,BYX;6Q02P$"% ,4    " "$A&-:L2=V,RL$  ",$   &0
M    @('-V0$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (
M (2$8UKHU=GS=@4    F   9              " @2_> 0!X;"]W;W)K<VAE
M971S+W-H965T-S0N>&UL4$L! A0#%     @ A(1C6N#1#_Q#!    !8  !D
M             ("!W.,! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"
M% ,4    " "$A&-:1R"8X4,%  !X&   &0              @(%6Z $ >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( (2$8UKR1\8\6@,
M +X,   9              " @=#M 0!X;"]W;W)K<VAE971S+W-H965T-S<N
M>&UL4$L! A0#%     @ A(1C6D@80<WL!   LR$  !D              ("!
M8?$! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " "$A&-:
MYXN[!^8"  !;"   &0              @(&$]@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<Y+GAM;%!+ 0(4 Q0    ( (2$8UK2;%]##00  +D.   9
M      " @:'Y 0!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%
M  @ A(1C6H9V"@^6!   D!@  !D              ("!Y?T! 'AL+W=O<FMS
M:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " "$A&-:K57:"Z #   @#0
M&0              @(&R @( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+
M 0(4 Q0    ( (2$8UH ADN_R@(  !H(   9              " @8D& @!X
M;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ A(1C6K^^9ETV
M!   ( X  !D              ("!B@D" 'AL+W=O<FMS:&5E=',O<VAE970X
M-"YX;6Q02P$"% ,4    " "$A&-:DO1D1A@$  !T$@  &0
M@('W#0( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( (2$
M8UJ.$G/GZ0(  /0(   9              " @482 @!X;"]W;W)K<VAE971S
M+W-H965T.#8N>&UL4$L! A0#%     @ A(1C6M-AI!S^!   :PT  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "$A&-:EXJ[',     3 @  "P
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52P4&     &$ 80">&@  1#P"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>269</ContextCount>
  <ElementCount>445</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>91</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Cybersecurity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity</Role>
      <ShortName>Cybersecurity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Revenue Interest Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement</Role>
      <ShortName>Revenue Interest Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Revenue Interest Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables</Role>
      <ShortName>Revenue Interest Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Disaggregated Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Deferred Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails</Role>
      <ShortName>Deferred Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Deferred Revenue - Additional Information (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1</Role>
      <ShortName>Deferred Revenue - Additional Information (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails</Role>
      <ShortName>Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails</Role>
      <ShortName>Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Leases- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails</Role>
      <ShortName>Leases- Summary of Other Information Related to Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails</Role>
      <ShortName>Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Revenue Interest Purchase Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails</Role>
      <ShortName>Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails</Role>
      <ShortName>Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails</Role>
      <ShortName>Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996155 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996165 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996175 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996185 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996195 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996205 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996225 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996235 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996245 - Disclosure - Segment Information - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="adpt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996255 - Disclosure - Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails</Role>
      <ShortName>Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="adpt-20241231.htm">adpt-20241231.htm</File>
    <File>adpt-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img64161509_0.jpg</File>
    <File>img64161509_1.jpg</File>
    <File>img64161509_2.jpg</File>
    <File>img64161509_3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="894">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "adpt-20241231.htm": {
   "nsprefix": "adpt",
   "nsuri": "http://www.adaptivebiotech.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "adpt-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "adpt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 362,
   "keyCustom": 83,
   "axisStandard": 34,
   "axisCustom": 0,
   "memberStandard": 44,
   "memberCustom": 41,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2024": 7,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.adaptivebiotech.com/20241231": 3
   },
   "contextCount": 269,
   "entityCount": 1,
   "segmentCount": 91,
   "elementCount": 842,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 894,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 14,
    "http://xbrl.sec.gov/ecd/2024": 6
   },
   "report": {
    "R1": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_ef19e8e5-6015-4341-bc3d-e83a1af8333d",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ef19e8e5-6015-4341-bc3d-e83a1af8333d",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:NoncashLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity",
     "longName": "100070 - Disclosure - Cybersecurity",
     "shortName": "Cybersecurity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_e4fca2f4-8e1d-432d-80ec-6c3440952998",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4fca2f4-8e1d-432d-80ec-6c3440952998",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue",
     "longName": "995475 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue",
     "longName": "995485 - Disclosure - Deferred Revenue",
     "shortName": "Deferred Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:DeferredRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:DeferredRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995495 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments",
     "longName": "995505 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "995515 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "longName": "995525 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "longName": "995535 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_2f55e0e9-b954-452c-a685-f7ac38e3d535",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2f55e0e9-b954-452c-a685-f7ac38e3d535",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995545 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement",
     "longName": "995555 - Disclosure - Revenue Interest Purchase Agreement",
     "shortName": "Revenue Interest Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:RevenueInterestPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:RevenueInterestPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995565 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity",
     "longName": "995575 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans",
     "longName": "995585 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuring",
     "longName": "995595 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995605 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders",
     "longName": "995615 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan",
     "longName": "995625 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995635 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "995645 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables",
     "longName": "995655 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueTables",
     "longName": "995665 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables",
     "longName": "995675 - Disclosure - Deferred Revenue (Tables)",
     "shortName": "Deferred Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995685 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables",
     "longName": "995695 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "995705 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "longName": "995715 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "longName": "995725 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_2f55e0e9-b954-452c-a685-f7ac38e3d535",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2f55e0e9-b954-452c-a685-f7ac38e3d535",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995735 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables",
     "longName": "995745 - Disclosure - Revenue Interest Purchase Agreement (Tables)",
     "shortName": "Revenue Interest Purchase Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityTables",
     "longName": "995755 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
     "longName": "995765 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995775 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables",
     "longName": "995785 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995795 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:OtherInventoryNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails",
     "longName": "995815 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_41d2ea93-dc38-4500-b0a7-cd99c27e6352",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41d2ea93-dc38-4500-b0a7-cd99c27e6352",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails",
     "longName": "995825 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)",
     "shortName": "Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_57585e88-6f33-40e2-a08a-7f48691bb39b",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57585e88-6f33-40e2-a08a-7f48691bb39b",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
     "longName": "995835 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)",
     "shortName": "Revenue - Schedule of Disaggregated Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3e4b471-6ad7-4d54-aafa-1c355daee1b0",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61e08594-2216-4ede-9093-11ef2ff2f063",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Deferred Revenue - Additional Information (Details)",
     "shortName": "Deferred Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ccbf3cec-810a-407c-8e46-299bdc89be19",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
     "longName": "995865 - Disclosure - Deferred Revenue - Additional Information (Details1)",
     "shortName": "Deferred Revenue - Additional Information (Details1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_4c968389-ac05-4e80-a351-de3893d81820",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4c968389-ac05-4e80-a351-de3893d81820",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails",
     "longName": "995875 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995885 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_1c7dad97-0dc1-49c3-8e6a-213606328313",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c7dad97-0dc1-49c3-8e6a-213606328313",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
     "longName": "995895 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)",
     "shortName": "Investments - Schedule of Available-for-sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_af621409-f3a9-456c-8964-3694f64ce437",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_af621409-f3a9-456c-8964-3694f64ce437",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Investments - Additional Information (Details)",
     "shortName": "Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_419c90ac-d4cc-4e42-adb9-be55df808d8d",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_419c90ac-d4cc-4e42-adb9-be55df808d8d",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
     "longName": "995915 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)",
     "shortName": "Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "longName": "995925 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_99584d81-0d39-482d-9529-479e97a39b00",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_99584d81-0d39-482d-9529-479e97a39b00",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails",
     "longName": "995955 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)",
     "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
     "longName": "995965 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "longName": "995975 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Leases- Additional Information (Details)",
     "shortName": "Leases- Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_7869d22e-be80-4ab4-88aa-2651f1bd991b",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7869d22e-be80-4ab4-88aa-2651f1bd991b",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails",
     "longName": "996005 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)",
     "shortName": "Leases- Summary of Other Information Related to Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
     "longName": "996025 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)",
     "shortName": "Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
     "longName": "996035 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)",
     "shortName": "Revenue Interest Purchase Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_6bf4218c-4293-4f50-84e5-e19d61af2275",
      "name": "adpt:UpfrontPaymentReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6bf4218c-4293-4f50-84e5-e19d61af2275",
      "name": "adpt:UpfrontPaymentReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails",
     "longName": "996045 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)",
     "shortName": "Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_8f46490b-2478-46c6-9c66-ca4d59a7e377",
      "name": "adpt:RevenueInterestLiabilityNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57b874c8-f1ee-4024-bd76-aff00d4af5ec",
      "name": "adpt:RevenueInterestPaid",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
     "longName": "996055 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
     "longName": "996065 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "shortName": "Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
     "longName": "996075 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
     "longName": "996085 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)",
     "shortName": "Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_6b74a919-15ca-422a-bdd2-8538b4633aa6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_013827d3-b15c-4f85-88a8-bbae4386a47c",
      "name": "adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails",
     "longName": "996095 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)",
     "shortName": "Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
     "longName": "996105 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details)",
     "shortName": "Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
     "longName": "996115 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)",
     "shortName": "Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
     "longName": "996125 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)",
     "shortName": "Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_830ceebd-b448-4556-8cc3-345699e93087",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
     "longName": "996135 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_8c08d7f9-6ece-4397-98cb-7a4e690601d7",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8c08d7f9-6ece-4397-98cb-7a4e690601d7",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
     "longName": "996145 - Disclosure - Restructuring - Additional Information (Details)",
     "shortName": "Restructuring - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails",
     "longName": "996155 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996165 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4324bd6-f036-4a55-a048-f63024a406bc",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996175 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail",
     "longName": "996185 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail",
     "longName": "996195 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R84": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
     "longName": "996205 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "996215 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails",
     "longName": "996225 - Disclosure - Retirement Plan - Additional Information (Details)",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "996235 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
     "longName": "996245 - Disclosure - Segment Information - Schedule of Segment Information (Details)",
     "shortName": "Segment Information - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_da3ff03b-c852-4729-b32f-d1e13c53f431",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
     "longName": "996255 - Disclosure - Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details)",
     "shortName": "Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "adpt:AdjustedEbitda",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1afe7465-3d4e-4ad3-b563-56e6f8072164",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "Accounting Standards Update 2023-09",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update Extensible List",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r217",
      "r218",
      "r219",
      "r295",
      "r296",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r391",
      "r392",
      "r397",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r598",
      "r599",
      "r600",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r647",
      "r648",
      "r661",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r1199"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r71",
      "r1280"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1022"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Investment amortization",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AccruedClinicalAndContractResearchOrganizationCostsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and contract research organization costs, current.",
        "label": "Accrued Clinical And Contract Research Organization Costs Current",
        "terseLabel": "Clinical and contract research organization costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Travel and entertainment",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Tax liabilities",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r123"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AccruedPurchaseOfPropertyAndEquipmentCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued purchase of property and equipment current.",
        "label": "Accrued Purchase Of Property And Equipment Current",
        "terseLabel": "Purchases of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued tax withholding liability related to unsettled option exercises.",
        "label": "Accrued Tax Withholding Liability Related To Unsettled Option Exercises",
        "terseLabel": "Accrued tax withholding liability related to unsettled option exercises"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r168",
      "r779"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive gain",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r82",
      "r178",
      "r774",
      "r820",
      "r824"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Gain",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r18",
      "r603",
      "r606",
      "r683",
      "r815",
      "r816",
      "r1185",
      "r1186",
      "r1187",
      "r1196",
      "r1197",
      "r1198",
      "r1201"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "adpt_AdditionalMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdditionalMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1022",
      "r1358"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r1196",
      "r1197",
      "r1198",
      "r1201",
      "r1289",
      "r1359"
     ]
    },
    "adpt_AdditionalTransactionPriceOfRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdditionalTransactionPriceOfRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional transaction price of regulatory milestone",
        "label": "Additional Transaction Price Of Regulatory Milestone",
        "documentation": "Additional transaction price of regulatory milestone."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "adpt_AdjustedEbitda": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdjustedEbitda",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted EBITDA",
        "label": "Adjusted EBITDA",
        "documentation": "Adjusted EBITDA.",
        "totalLabel": "Adjusted EBITDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r217",
      "r218",
      "r219",
      "r220",
      "r232",
      "r295",
      "r296",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r391",
      "r392",
      "r397",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r647",
      "r648",
      "r660",
      "r661",
      "r662",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r723",
      "r724",
      "r725",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ]
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCapitalContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital capital contributions.",
        "label": "Adjustments To Additional Paid In Capital Capital Contributions",
        "terseLabel": "Capital contributions for Digital Biotechnologies, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.",
        "label": "Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant",
        "terseLabel": "Conversion of convertible preferred stock warrant to common stock warrant"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, initial public offering costs.",
        "label": "Adjustments To Additional Paid In Capital Initial Public Offering Costs",
        "terseLabel": "Initial public offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value",
        "terseLabel": "Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r486"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Expense",
        "verboseLabel": "Advertising expenses",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r1004"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1088",
      "r1098",
      "r1131"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1123",
      "r1132",
      "r1136",
      "r1144"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized share-based compensation expense",
        "totalLabel": "Total share-based compensation expense",
        "verboseLabel": "Total share-based compensation expense",
        "label": "Share-based compensation expense",
        "negatedLabel": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r528"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Intangible assets amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r378",
      "r384",
      "r979"
     ]
    },
    "adpt_AmortizationOfPurchaseAgreementObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AmortizationOfPurchaseAgreementObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of purchase agreement obligation.",
        "label": "Amortization of Purchase Agreement obligation",
        "verboseLabel": "Amortization of purchase agreement obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable payment percentage of quarterly revenue base for first and second payment.",
        "label": "Applicable Payment Percentage of quarterly Revenue Base for First and Second Payment",
        "verboseLabel": "Applicable payment percentage of quarterly revenue base for first and second payment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable payment percentage of quarterly revenue base for first payment.",
        "label": "Applicable Payment Percentage of quarterly Revenue Base for First Payment",
        "verboseLabel": "Applicable payment percentage of quarterly revenue base for first payment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable payment percentage of quarterly revenue base for first, second and third payment.",
        "label": "Applicable Payment Percentage of quarterly Revenue Base for First, Second and Third Payment",
        "verboseLabel": "Applicable payment percentage of quarterly revenue base for first, second and third payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Number of square feet",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "terseLabel": "Impairment charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r133",
      "r172",
      "r207",
      "r247",
      "r256",
      "r282",
      "r286",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r591",
      "r595",
      "r649",
      "r769",
      "r880",
      "r968",
      "r969",
      "r1022",
      "r1052",
      "r1246",
      "r1247",
      "r1311"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r181",
      "r207",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r591",
      "r595",
      "r649",
      "r1022",
      "r1246",
      "r1247",
      "r1311"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r1009"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Long-term assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1081"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1081"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1081"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r353",
      "r768"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r353",
      "r623",
      "r759",
      "r1009",
      "r1014",
      "r1214",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term marketable securities (amortized cost of $174,186 and $281,122, respectively)",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r353"
     ]
    },
    "adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities current.",
        "label": "Available For Sale Securities Debt Securities Current [Member]",
        "terseLabel": "Short-Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term marketable securities (amortized cost of $33,682)",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r303",
      "r353"
     ]
    },
    "adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities noncurrent.",
        "label": "Available For Sale Securities Debt Securities Noncurrent [Member]",
        "terseLabel": "Long-Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r1325",
      "r1326"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r396",
      "r1325",
      "r1326"
     ]
    },
    "adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and principles of consolidation policy.",
        "label": "Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r95",
      "r96"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of equipment included in accounts payable and accrued liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r165",
      "r953"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r121"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r92",
      "r204"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r92"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash investing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting standards update adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r159",
      "r216",
      "r295",
      "r337",
      "r338",
      "r339",
      "r344",
      "r345",
      "r391",
      "r397",
      "r564",
      "r572",
      "r573",
      "r581",
      "r582",
      "r584",
      "r598",
      "r599",
      "r611",
      "r612",
      "r647",
      "r648",
      "r661",
      "r678",
      "r679",
      "r723",
      "r724",
      "r813",
      "r814"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting standards update adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r159",
      "r295",
      "r337",
      "r338",
      "r339",
      "r344",
      "r345",
      "r346",
      "r391",
      "r397",
      "r564",
      "r572",
      "r573",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r597",
      "r598",
      "r599",
      "r600",
      "r611",
      "r612",
      "r613",
      "r616",
      "r647",
      "r648",
      "r661",
      "r678",
      "r679",
      "r723",
      "r724",
      "r813",
      "r814",
      "r1172"
     ]
    },
    "adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in redemption value for vested convertible preferred stock options.",
        "label": "Change In Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r175",
      "r176",
      "r177",
      "r207",
      "r236",
      "r237",
      "r239",
      "r241",
      "r249",
      "r250",
      "r336",
      "r417",
      "r420",
      "r421",
      "r422",
      "r426",
      "r427",
      "r436",
      "r437",
      "r440",
      "r443",
      "r450",
      "r649",
      "r830",
      "r831",
      "r832",
      "r833",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r868",
      "r889",
      "r907",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1167",
      "r1192",
      "r1202"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r249",
      "r436",
      "r437",
      "r438",
      "r440",
      "r443",
      "r448",
      "r450",
      "r830",
      "r831",
      "r832",
      "r833",
      "r988",
      "r1167",
      "r1192"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "adpt_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Revenue",
        "label": "Collaboration Revenue [Member]",
        "documentation": "Collaboration Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "adpt_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r416",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r124",
      "r770",
      "r867"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r410",
      "r411",
      "r937",
      "r1240",
      "r1243"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares of common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CommonStockExerciseOfOutstandingStockOptionsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Upon the Exercise of Outstanding Stock Options Granted",
        "label": "Common Stock Exercise Of Outstanding Stock Options Granted [Member]",
        "documentation": "Common stock exercise of outstanding stock options granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1043",
      "r1044",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1196",
      "r1197",
      "r1201",
      "r1289",
      "r1357",
      "r1359"
     ]
    },
    "adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CommonStockOptionsAndRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options and restricted stock units granted.",
        "label": "Common Stock Options And Restricted Stock Units Granted [Member]",
        "terseLabel": "Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r868"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r868",
      "r886",
      "r1359",
      "r1360"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2024 and 2023; 147,773,744 and 145,082,271 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r772",
      "r1022"
     ]
    },
    "adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted",
        "label": "Common Stock Vesting Of Outstanding Restricted Stock Units And Market Based Restricted Stock Units Granted [Member]",
        "documentation": "Common stock vesting of outstanding restricted stock units and market-based restricted stock units granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights description",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "adpt_CommonStockWarrantOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CommonStockWarrantOutstandingMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrant Outstanding",
        "label": "Common Stock Warrant Outstanding [Member]",
        "documentation": "Common stock warrant outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Retirement Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Adaptive Biotechnologies Corporation",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r186",
      "r188",
      "r196",
      "r762",
      "r787",
      "r789"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Add: Comprehensive loss attributable to noncontrolling interest",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r54",
      "r57",
      "r186",
      "r188",
      "r195",
      "r761",
      "r787",
      "r788"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r118",
      "r186",
      "r188",
      "r194",
      "r760",
      "r787"
     ]
    },
    "adpt_ComputerAndSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ComputerAndSoftware",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and software.",
        "label": "Computer And Software",
        "terseLabel": "Computer and software"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer software.",
        "label": "Computer Software [Member]",
        "terseLabel": "Computer Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r60",
      "r61",
      "r294",
      "r936"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r60",
      "r61",
      "r294",
      "r826",
      "r936"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r60",
      "r61",
      "r294",
      "r936",
      "r1171"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r142"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r60",
      "r61",
      "r294"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r60",
      "r61",
      "r294",
      "r936"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r212",
      "r247",
      "r258",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r968",
      "r969",
      "r1246",
      "r1247"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r212",
      "r247",
      "r258",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r968",
      "r969",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ContractBalancesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ContractBalancesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract balances.",
        "label": "Contract Balances Policy [Text Block]",
        "terseLabel": "Contract Balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total current and non-current deferred revenue",
        "periodStartLabel": "Deferred revenue balance at December 31, 2021",
        "periodEndLabel": "Deferred revenue balance at December 31, 2022",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r472"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current deferred revenue",
        "terseLabel": "Current portion of deferred revenue",
        "verboseLabel": "Total current deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r472"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "terseLabel": "Additions to deferred revenue during the period",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability milestone method revenue recognized.",
        "label": "Contract With Customer Liability Milestone Method Revenue Recognized",
        "terseLabel": "Milestone revenue recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, less current portion",
        "verboseLabel": "Non-current deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r472"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Revenue recognized during the period",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r440",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r999",
      "r1009",
      "r1023",
      "r1040",
      "r1354"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r721"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Revenue",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1173"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "terseLabel": "Operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r429",
      "r438",
      "r684",
      "r702",
      "r767",
      "r955",
      "r957"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CumulativePurchaserPaymentsReceivableDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CumulativePurchaserPaymentsReceivableDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative purchaser payments receivable date.",
        "label": "Cumulative Purchaser Payments Receivable Date",
        "verboseLabel": "Cumulative purchaser payments receivable date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CumulativePurchaserPaymentsRepaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CumulativePurchaserPaymentsRepaymentDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative purchaser payments repayment date",
        "label": "Cumulative Purchaser Payments Repayment Date",
        "verboseLabel": "Cumulative purchaser payments repayment date"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r294"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1155"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1155"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1157"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1157"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1159"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1157"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1154"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1154"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1155"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1158"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1156"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureCybersecurity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1153"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Effective interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r428"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Amortized cost of short-term marketable securities",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r1216"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Amortized cost of long-term marketable securities",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r1216"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 months or greater, Fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r355",
      "r977"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 months or greater, Unrealized loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r355"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months, Fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r355",
      "r977"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less than 12 months, Unrealized loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r355"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r977",
      "r1222"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "label": "Debt Issuance Costs, Net",
        "verboseLabel": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1249",
      "r1300",
      "r1301",
      "r1302"
     ]
    },
    "adpt_DeferredRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DeferredRevenueTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Text Block]",
        "documentation": "Deferred revenue.",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxAssetTangibleAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DeferredTaxAssetTangibleAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset Tangible And Intangible Assets",
        "documentation": "Deferred tax asset tangible and intangible assets.",
        "terseLabel": "Tangible and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "terseLabel": "Deferred tax asset",
        "verboseLabel": "Deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxAssetsNonQualifiedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DeferredTaxAssetsNonQualifiedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, non qualified stock options.",
        "label": "Deferred Tax Assets Non Qualified Stock Options",
        "terseLabel": "Nonqualifying stock options"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
        "terseLabel": "Tax credit carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DeferredTaxLiabilitiesTangibleAndIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, tangible and intangible assets.",
        "label": "Deferred Tax Liabilities Tangible And Intangible Assets",
        "negatedLabel": "Tangible and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_Deferredtaxassetscapitalizedresearchanddevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "Deferredtaxassetscapitalizedresearchanddevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research and development.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development",
        "verboseLabel": "Deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DefinedContributionPlanEmployeeServicePeriodForVesting": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DefinedContributionPlanEmployeeServicePeriodForVesting",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employee service period for vesting.",
        "label": "Defined Contribution Plan Employee Service Period For Vesting",
        "terseLabel": "Employee service period for vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Employees maximum annual contribution of their compensation",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "negatedLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40"
     ]
    },
    "adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.",
        "label": "Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease",
        "terseLabel": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Acquired Developed Technology",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1234",
      "r1236",
      "r1237"
     ]
    },
    "adpt_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DevelopmentRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DevelopmentRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development revenue.",
        "label": "Development Revenue [Member]",
        "terseLabel": "Development Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DigitalBiotechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "DigitalBiotechnologiesIncMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Digital Biotechnologies, Inc.",
        "label": "Digital Biotechnologies Inc [Member]",
        "terseLabel": "Digital Biotechnologies, Inc.",
        "verboseLabel": "Digital Biotechnologies Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregated Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r488",
      "r519",
      "r520",
      "r522",
      "r1001"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1081"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1081",
      "r1124"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Domestic Tax Authority [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r228",
      "r234",
      "r236",
      "r239",
      "r240",
      "r241",
      "r246",
      "r579",
      "r588",
      "r620",
      "r621",
      "r763",
      "r790",
      "r959"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r228",
      "r236",
      "r239",
      "r240",
      "r241",
      "r246",
      "r579",
      "r588",
      "r620",
      "r621",
      "r763",
      "r790",
      "r959"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r243"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r242",
      "r244",
      "r245"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r1006"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r538",
      "r567",
      "r1006"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r1006",
      "r1195",
      "r1281"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Share-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1195",
      "r1281",
      "r1283"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1195",
      "r1281",
      "r1282"
     ]
    },
    "adpt_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Items",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal tax benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r1006",
      "r1195",
      "r1281"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r544",
      "r1195",
      "r1281"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition",
        "verboseLabel": "Remaining Weighted-Average Recognition Period (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options",
        "verboseLabel": "Unrecognized Share-Based Compensation Expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Grant",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r156",
      "r190",
      "r191",
      "r192",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r229",
      "r231",
      "r248",
      "r341",
      "r347",
      "r392",
      "r451",
      "r562",
      "r563",
      "r575",
      "r576",
      "r577",
      "r580",
      "r587",
      "r588",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r619",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r661",
      "r664",
      "r683",
      "r785",
      "r815",
      "r816",
      "r817",
      "r838",
      "r907"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1082",
      "r1092",
      "r1125"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r637",
      "r1009"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r637",
      "r1009"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r638",
      "r1012"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r638",
      "r1012"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Level 2",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r636",
      "r637",
      "r639",
      "r689",
      "r690",
      "r691",
      "r984",
      "r985",
      "r997",
      "r998",
      "r999",
      "r1009",
      "r1014"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r627",
      "r1009",
      "r1294",
      "r1297"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r634",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r757",
      "r1009",
      "r1015"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r476",
      "r481",
      "r624",
      "r637",
      "r689",
      "r997",
      "r998",
      "r999",
      "r1009"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r476",
      "r481",
      "r624",
      "r625",
      "r637",
      "r690",
      "r984",
      "r985",
      "r997",
      "r998",
      "r999",
      "r1009"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r624",
      "r625",
      "r626",
      "r627",
      "r637",
      "r691",
      "r984",
      "r985",
      "r997",
      "r998",
      "r999",
      "r1009",
      "r1014"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r627",
      "r1009",
      "r1294",
      "r1297"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r636",
      "r637",
      "r639",
      "r689",
      "r690",
      "r691",
      "r984",
      "r985",
      "r997",
      "r998",
      "r999",
      "r1009",
      "r1014"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1297"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r1021"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r356",
      "r357",
      "r433",
      "r448",
      "r609",
      "r644",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r786",
      "r977",
      "r1009",
      "r1012",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1023",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1290",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization period of intangible assets",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r361",
      "r383",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r949",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r949",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r949",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r722",
      "r726",
      "r949"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r383",
      "r726",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r383",
      "r386",
      "r387",
      "r389",
      "r722",
      "r949",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r949"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r1234"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1132"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1132"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1132"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1132"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1132"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "adpt_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_GenentechCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "GenentechCollaborationAgreementMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech collaboration agreement.",
        "label": "Genentech Collaboration Agreement [Member]",
        "terseLabel": "Genentech Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_GenentechIncAndRocheGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "GenentechIncAndRocheGroupMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Inc. and Roche Group.",
        "label": "Genentech Inc And Roche Group [Member]",
        "terseLabel": "Genentech, Inc. and Roche Group"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_GenentechIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "GenentechIncMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech Inc.",
        "label": "Genentech Inc [Member]",
        "terseLabel": "Genentech, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r891"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Goodwill, Total",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r363",
      "r758",
      "r969",
      "r978",
      "r1011",
      "r1022",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1227"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r375",
      "r978"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r388",
      "r390"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r364",
      "r370",
      "r375",
      "r978",
      "r1011"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r978"
     ]
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillPeriodIncreaseDecrease",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in carrying amount of goodwill since recognition",
        "label": "Goodwill, Period Increase (Decrease)",
        "totalLabel": "Goodwill, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1081"
     ]
    },
    "adpt_ImmuneMedicineBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ImmuneMedicineBusinessMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immune Medicine Business [Member]",
        "documentation": "Immune medicine business member.",
        "terseLabel": "IM",
        "verboseLabel": "Immune Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ImmuneMedicineRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ImmuneMedicineRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immune Medicine Revenue",
        "label": "Immune Medicine Revenue [Member]",
        "documentation": "Immune Medicine Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ImmuneMedicineServiceRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ImmuneMedicineServiceRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immune Medicine Service Revenue",
        "label": "Immune Medicine Service Revenue [Member]",
        "documentation": "Immune medicine service revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment losses on intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r1190",
      "r1238"
     ]
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived leasehold improvements",
        "label": "Impairment of Leasehold",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39"
     ]
    },
    "adpt_ImpairmentOfLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ImpairmentOfLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long Lived Assets",
        "documentation": "Impairment of long lived assets.",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "verboseLabel": "Impairment of long-lived assets",
        "negatedLabel": "Impairment of long-lived assets",
        "terseLabel": "Impairment of long-lived assets, held for use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r101",
      "r1010"
     ]
    },
    "adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ImpairmentOfRightOfUseAndRelatedLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of right-of-use and related long-lived assets",
        "label": "Impairment of Right-of-Use and Related Long-Lived Assets",
        "documentation": "Impairment of right-of-use and related long-lived assets.",
        "verboseLabel": "Impairment of long-lived assets",
        "negatedLabel": "Impairment of right-of-use and related long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets Expenses",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r537"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r127",
      "r132",
      "r764",
      "r781",
      "r961",
      "r968",
      "r1204",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r537"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r396",
      "r402",
      "r629",
      "r633",
      "r638",
      "r810",
      "r812",
      "r892",
      "r949",
      "r1013",
      "r1327"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r402",
      "r629",
      "r633",
      "r638",
      "r810",
      "r812",
      "r892",
      "r949",
      "r1013",
      "r1327"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r538",
      "r539",
      "r549",
      "r559",
      "r1006",
      "r1287"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r538",
      "r539",
      "r549",
      "r559",
      "r1006",
      "r1287"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r533",
      "r538",
      "r545",
      "r546",
      "r547",
      "r552",
      "r558",
      "r568",
      "r569",
      "r570",
      "r571",
      "r835",
      "r1006"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r535",
      "r536",
      "r552",
      "r553",
      "r557",
      "r561",
      "r829"
     ]
    },
    "adpt_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r1189"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets and liabilities .",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets And Liabilities",
        "terseLabel": "Operating lease right-of-use assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other",
        "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "IncreaseInReturnCapPercentageOfCumulativePurchaserPayments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in return cap percentage of cumulative purchaser payments.",
        "label": "Increase in Return Cap Percentage of Cumulative Purchaser Payments",
        "verboseLabel": "Increase in return cap percentage of cumulative purchaser payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1123",
      "r1132",
      "r1136",
      "r1144"
     ]
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category",
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1148"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1148"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1148"
     ]
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "terseLabel": "Purchased Intellectual Property",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1234",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Costs Capitalized",
        "verboseLabel": "Capitalized issuance costs",
        "negatedLabel": "Capitalized issuance costs",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense, Operating and Nonoperating",
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r256",
      "r260",
      "r266",
      "r286",
      "r657",
      "r968",
      "r969"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Debt, Total",
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r432",
      "r434",
      "r986",
      "r987"
     ]
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpensePolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense",
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r1299",
      "r1302"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "netLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r201",
      "r202"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inter-segment",
        "label": "Intersegment Eliminations [Member]",
        "verboseLabel": "Unallocated Corporate",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r247",
      "r258",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r968"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Net, Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r954",
      "r1022"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r164",
      "r179",
      "r358",
      "r359",
      "r360",
      "r720",
      "r958"
     ]
    },
    "adpt_InventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "InventoryReserve",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory Reserve",
        "documentation": "Inventory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r852",
      "r853",
      "r855",
      "r857",
      "r912",
      "r914",
      "r916",
      "r919",
      "r920",
      "r921",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1044"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r852",
      "r853",
      "r855",
      "r857",
      "r912",
      "r914",
      "r916",
      "r919",
      "r920",
      "r921",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1044"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r153",
      "r302",
      "r304",
      "r645",
      "r646",
      "r1320"
     ]
    },
    "adpt_ItemsToReconcileNetLossToAdjustedEBITDA": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ItemsToReconcileNetLossToAdjustedEBITDA",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items to reconcile net loss to adjusted EBITDA",
        "label": "Items To Reconcile Net Loss To Adjusted EBITDA",
        "documentation": "Items to reconcile net loss to adjusted EBITDA."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commenced moth and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Other Information Related to Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1308"
     ]
    },
    "adpt_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Landlord contribution for leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r676"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r677"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r677"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "adpt_LesseeOperatingLeaseExtendedTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LesseeOperatingLeaseExtendedTermOfContract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended term of contract.",
        "label": "Lessee Operating Lease Extended Term Of Contract",
        "terseLabel": "Lessee, operating lease, extended term of contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend",
        "terseLabel": "Lease not yet commenced, option to extend description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease not yet commenced, option to extend term",
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease lease not yet commenced tenant improvement receivable.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Receivable",
        "terseLabel": "Lease not yet commenced landlord agreed to fund for improvements"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, lease not yet commenced termination option description.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Termination Option Description",
        "terseLabel": "Lease not yet commenced, termination option description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Reconciles Undiscounted Operating Lease Cash Flows",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest rate",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r1305"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "adpt_LesseeOperatingLeaseRentCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LesseeOperatingLeaseRentCommencementMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease rent commencement month and year.",
        "label": "Lessee Operating Lease Rent Commencement Month And Year",
        "terseLabel": "Lessee, operating lease, rent commencement month and year"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LesseeOperatingLeaseRentObligationsCommencementMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease rent obligations commencement month and year.",
        "label": "Lessee Operating Lease Rent Obligations Commencement Month And Year",
        "terseLabel": "Rent obligations, commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LesseeOperatingLeaseTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease termination period.",
        "label": "Lessee Operating Lease Termination Period",
        "terseLabel": "Operating lease termination period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r207",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r592",
      "r595",
      "r596",
      "r649",
      "r866",
      "r960",
      "r1052",
      "r1246",
      "r1311",
      "r1312"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r126",
      "r777",
      "r1022",
      "r1193",
      "r1221",
      "r1298"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r163",
      "r207",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r592",
      "r595",
      "r596",
      "r649",
      "r1022",
      "r1246",
      "r1311",
      "r1312"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "terseLabel": "Current portion of revenue interest liability, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total",
        "terseLabel": "Revenue interest liability, net, less current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "adpt_MRDDevelopmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MRDDevelopmentAgreementsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MRD Development Agreements",
        "documentation": "MRD development agreements.",
        "label": "M R D Development Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MRDRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MRDRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MRD Revenue",
        "label": "M R D Revenue [Member]",
        "documentation": "MRD Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r992",
      "r1033",
      "r1038",
      "r1251",
      "r1324",
      "r1328",
      "r1329",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "adpt_MarketBasedRestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MarketBasedRestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-Based Restricted Stock Units",
        "label": "Market Based Restricted Stock Units R S U [Member]",
        "documentation": "Market-Based Restricted Stock Units R S U."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r482",
      "r529",
      "r627",
      "r718",
      "r809",
      "r811",
      "r825",
      "r858",
      "r859",
      "r913",
      "r915",
      "r917",
      "r918",
      "r922",
      "r947",
      "r948",
      "r976",
      "r988",
      "r1000",
      "r1014",
      "r1015",
      "r1019",
      "r1020",
      "r1034",
      "r1248",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "adpt_MedicareReimbursementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MedicareReimbursementsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Reimbursements",
        "label": "Medicare Reimbursements [Member]",
        "documentation": "Medicare Reimbursements."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MedicareRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MedicareRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare revenue.",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MichelleGriffinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MichelleGriffinMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Michelle Griffin [Member]",
        "label": "Michelle Griffin [Member]",
        "documentation": "Michelle Griffin."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r482",
      "r529",
      "r627",
      "r718",
      "r809",
      "r811",
      "r825",
      "r858",
      "r859",
      "r913",
      "r915",
      "r917",
      "r918",
      "r922",
      "r947",
      "r948",
      "r976",
      "r988",
      "r1000",
      "r1014",
      "r1015",
      "r1019",
      "r1034",
      "r1248",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest",
        "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total",
        "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r125",
      "r207",
      "r336",
      "r417",
      "r420",
      "r421",
      "r422",
      "r426",
      "r427",
      "r649",
      "r776",
      "r870"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Ownership interest percentage",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "adpt_MonteCarloValuationModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MonteCarloValuationModelMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monte Carlo Valuation Model",
        "label": "Monte Carlo Valuation Model [Member]",
        "documentation": "Monte Carlo Valuation Model."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MrdBusinessSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "MrdBusinessSegmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MRD",
        "label": "MRD Business Segment [Member]",
        "documentation": "MRD business segment member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r992",
      "r1033",
      "r1038",
      "r1251",
      "r1324",
      "r1328",
      "r1329",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss attributable to Adaptive Biotechnologies Corporation",
        "verboseLabel": "Net loss attributable to Adaptive Biotechnologies Corporation",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r94",
      "r128",
      "r161",
      "r184",
      "r187",
      "r192",
      "r207",
      "r217",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r238",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r579",
      "r588",
      "r621",
      "r649",
      "r784",
      "r888",
      "r905",
      "r906",
      "r1050",
      "r1246"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Add: Net loss attributable to noncontrolling interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "verboseLabel": "Net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r119",
      "r184",
      "r187",
      "r226",
      "r230",
      "r231",
      "r783",
      "r1187"
     ]
    },
    "adpt_NetOperatingLossCarryforwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NetOperatingLossCarryforwardExpirationPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss Carryforward Expiration Period",
        "documentation": "Net Operating Loss Carryforward Expiration Period",
        "terseLabel": "Maturity period for NOLs carryovers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and New Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonCashInterestExpenseRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonCashInterestExpenseRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest expense recognized",
        "label": "Non Cash Interest Expense Recognized",
        "verboseLabel": "Noncash interest expense recognized"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonEmployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonEmployeeDirectorsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee directors.",
        "label": "Non Employee Directors [Member]",
        "terseLabel": "Non Employee Directors"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1089",
      "r1099",
      "r1123",
      "r1132"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "adpt_NonRefundableUpfrontPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonRefundableUpfrontPaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payments received.",
        "label": "Non Refundable Upfront Payments Received",
        "terseLabel": "Non-refundable upfront payments received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "adpt_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash interest expense.",
        "label": "Noncash Interest Expense",
        "terseLabel": "Noncash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r451",
      "r1196",
      "r1197",
      "r1198",
      "r1201",
      "r1359"
     ]
    },
    "adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonvestedMarketBasedRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Market Based Restricted Stock Units Granted [Member]",
        "documentation": "Nonvested market based restricted stock units granted.",
        "terseLabel": "Nonvested Market-based Restricted Stock Units Outstanding Granted"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonvestedMarketBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonvestedMarketBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Market-Based Restricted Stock Units",
        "label": "Nonvested Market Based Restricted Stock Units [Member]",
        "documentation": "Nonvested market-based restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonvestedRestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonvestedRestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Restricted Stock Units",
        "label": "Nonvested Restricted Stock Units R S U [Member]",
        "documentation": "Nonvested Restricted Stock Units R S U."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonvestedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NonvestedStockOptionsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Stock Options",
        "label": "Nonvested Stock Options [Member]",
        "documentation": "Nonvested Stock Options."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NumberOfCommonStockVotingRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NumberOfCommonStockVotingRights",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock voting rights.",
        "label": "Number Of Common Stock Voting Rights",
        "terseLabel": "Number of vote for each share"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NumberOfOperatingAndReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NumberOfOperatingAndReportableSegments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating and Reportable Segments",
        "documentation": "Number of operating and reportable segments.",
        "terseLabel": "Number of operating and reportable segments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1205"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "verboseLabel": "Number of reporting segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r974",
      "r1205"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NumberOfRevenuePerformanceObligation": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "NumberOfRevenuePerformanceObligation",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of revenue performance obligations",
        "label": "Number Of Revenue Performance Obligation",
        "documentation": "Number of revenue performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "One-time Termination Benefit",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r981",
      "r982",
      "r983"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r961",
      "r1204",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1304"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1303"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "negatedLabel": "Less: Current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r671"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "adpt_OperatingLeaseVariableLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "OperatingLeaseVariableLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease variable lease expense.",
        "label": "Operating Lease Variable Lease Expense",
        "terseLabel": "Operating lease variable lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r1021"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "U.S. federal NOLs",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "adpt_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration Year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "NOLs expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r968",
      "r969"
     ]
    },
    "adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "OrbimedRoyaltyCreditOpportunitiesIvLpMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OrbiMed Royalty &amp; Credit Opportunities IV, LP.",
        "label": "OrbiMed Royalty &amp; Credit Opportunities IV, LP [Member]",
        "verboseLabel": "OrbiMed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r118",
      "r185",
      "r188",
      "r226"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gains and losses on investments",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r335"
     ]
    },
    "us-gaap_OtherInventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Inventory, Noncurrent",
        "terseLabel": "Long-term inventory",
        "documentation": "Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle (such as inventory related to long-term contracts or program rights)."
       }
      }
     },
     "auth_ref": [
      "r1182"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments",
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1087",
      "r1097",
      "r1130"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1090",
      "r1100",
      "r1133"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1090",
      "r1100",
      "r1133"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedLabel": "Cash received for tenant improvement allowances",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r90"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring costs paid",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r1188"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of public offering costs, net",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "adpt_PercentageOfAnnualIncreasesInNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PercentageOfAnnualIncreasesInNumberOfShares",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual increases in number of shares.",
        "label": "Percentage Of Annual Increases In Number Of Shares",
        "terseLabel": "Percentage of annual increases in number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PercentageOfCumulativePurchaserPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PercentageOfCumulativePurchaserPayments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cumulative purchaser payments",
        "label": "Percentage of Cumulative Purchaser Payments",
        "verboseLabel": "Percentage of cumulative purchaser payments"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PercentageOfNetVestedSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PercentageOfNetVestedSharesOfCommonStock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Net Vested Shares of Common Stock",
        "documentation": "Percentage of net vested shares of common stock.",
        "terseLabel": "Percentage of net vested shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PercentageOfRevenueInterestPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PercentageOfRevenueInterestPayments",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interest payments.",
        "label": "Percentage of Revenue Interest Payments",
        "verboseLabel": "Percentage of revenue interest payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "adpt_PotentialRevenueInterestPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PotentialRevenueInterestPaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential revenue interest payment to be received.",
        "label": "Potential Revenue Interest Payment To Be Received",
        "verboseLabel": "Potential revenue interest payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PotentialRevenueInterestSecondPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PotentialRevenueInterestSecondPaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential revenue interest second payment to be received.",
        "label": "Potential Revenue Interest Second Payment To Be Received",
        "verboseLabel": "Potential revenue interest second payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PotentialRevenueInterestThirdPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PotentialRevenueInterestThirdPaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential revenue interest third payment to be received.",
        "label": "Potential Revenue Interest Third Payment To Be Received",
        "verboseLabel": "Potential revenue interest third payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r436"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r868"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r436"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r868",
      "r886",
      "r1359",
      "r1360"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock investment",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r771",
      "r1022"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from initial capital contributions for Digital Biotechnologies, Inc.",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of underwriting discounts and commissions",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "adpt_ProceedsFromLandlordReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ProceedsFromLandlordReimbursements",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from landlord reimbursements.",
        "label": "Proceeds From Landlord Reimbursements",
        "terseLabel": "Proceeds from landlord reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from revenue interest purchase agreement, net of issuance costs.",
        "label": "Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs",
        "terseLabel": "Proceeds from revenue interest purchase agreement, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from settlement of stock option exercised in prior periods.",
        "label": "Proceeds From Settlement Of Stock Option Exercised In Prior Periods",
        "terseLabel": "Proceeds from settlement of stock option exercised in prior periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r721",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r951",
      "r990",
      "r1032",
      "r1034",
      "r1035",
      "r1039",
      "r1041",
      "r1244",
      "r1245",
      "r1251",
      "r1324",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r721",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r951",
      "r990",
      "r1032",
      "r1034",
      "r1035",
      "r1039",
      "r1041",
      "r1244",
      "r1245",
      "r1251",
      "r1324",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r184",
      "r187",
      "r199",
      "r207",
      "r217",
      "r226",
      "r230",
      "r231",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r579",
      "r588",
      "r590",
      "r593",
      "r594",
      "r621",
      "r649",
      "r764",
      "r782",
      "r837",
      "r888",
      "r905",
      "r906",
      "r1007",
      "r1008",
      "r1051",
      "r1187",
      "r1246"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r143",
      "r147",
      "r148"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r167",
      "r780"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r676",
      "r766",
      "r780",
      "r1022"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r143",
      "r147",
      "r778"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1239"
     ]
    },
    "adpt_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement.",
        "label": "Purchase Agreement [Member]",
        "verboseLabel": "Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PurchaseAgreementSecondPaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PurchaseAgreementSecondPaymentDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement second payment date.",
        "label": "Purchase Agreement Second Payment Date",
        "verboseLabel": "Purchase agreement, second payment date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PurchaseAgreementThirdPaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PurchaseAgreementThirdPaymentDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement third payment date.",
        "label": "Purchase Agreement Third Payment Date",
        "verboseLabel": "Purchase agreement, third payment date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PutOrCallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "PutOrCallOptionMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put or call option.",
        "label": "Put or Call Option [Member]",
        "verboseLabel": "Put/Call Options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r475",
      "r482",
      "r514",
      "r515",
      "r516",
      "r529",
      "r627",
      "r692",
      "r701",
      "r718",
      "r809",
      "r811",
      "r825",
      "r858",
      "r859",
      "r913",
      "r915",
      "r917",
      "r918",
      "r922",
      "r947",
      "r948",
      "r976",
      "r988",
      "r1000",
      "r1014",
      "r1015",
      "r1019",
      "r1020",
      "r1034",
      "r1044",
      "r1241",
      "r1248",
      "r1294",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r475",
      "r482",
      "r514",
      "r515",
      "r516",
      "r529",
      "r627",
      "r692",
      "r701",
      "r718",
      "r809",
      "r811",
      "r825",
      "r858",
      "r859",
      "r913",
      "r915",
      "r917",
      "r918",
      "r922",
      "r947",
      "r948",
      "r976",
      "r988",
      "r1000",
      "r1014",
      "r1015",
      "r1019",
      "r1020",
      "r1034",
      "r1044",
      "r1241",
      "r1248",
      "r1294",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r1213"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1082",
      "r1092",
      "r1125"
     ]
    },
    "adpt_RegulatoryMilestoneRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RegulatoryMilestoneRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Milestone Revenue",
        "label": "Regulatory Milestone Revenue [Member]",
        "documentation": "Regulatory Milestone Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RegulatoryMilestonesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r429",
      "r438",
      "r684",
      "r702",
      "r767",
      "r956",
      "r957"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r949",
      "r968",
      "r1319"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "adpt_ResearchAndDevelopmentInventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ResearchAndDevelopmentInventoryReserve",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development inventory reserve",
        "label": "Research And Development Inventory Reserve",
        "documentation": "Research and development inventory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r246",
      "r342",
      "r343",
      "r576",
      "r577",
      "r579",
      "r580",
      "r587",
      "r588",
      "r615",
      "r619",
      "r620",
      "r621",
      "r660",
      "r662",
      "r682",
      "r683",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r827",
      "r1210"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1083",
      "r1093",
      "r1126"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1091",
      "r1101",
      "r1134"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r246",
      "r342",
      "r343",
      "r576",
      "r577",
      "r579",
      "r580",
      "r587",
      "r588",
      "r615",
      "r619",
      "r620",
      "r621",
      "r660",
      "r662",
      "r682",
      "r683",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r827",
      "r1210"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1182",
      "r1191"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "verboseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r401",
      "r404",
      "r409"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring and Related Cost, Expected Cost, Total",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Estimated aggregate restructuring costs recognized",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r403",
      "r406",
      "r408"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Restructuring, reduction in workforce",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "terseLabel": "Restructuring expense",
        "negatedLabel": "Restructuring expense",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r405",
      "r406",
      "r1242"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r406",
      "r407"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "label": "Restructuring Costs",
        "totalLabel": "Restructuring Costs, Total",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "adpt_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "documentation": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r109",
      "r775",
      "r819",
      "r824",
      "r834",
      "r869",
      "r1022"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r229",
      "r231",
      "r341",
      "r347",
      "r392",
      "r562",
      "r563",
      "r575",
      "r576",
      "r577",
      "r580",
      "r587",
      "r588",
      "r601",
      "r604",
      "r605",
      "r608",
      "r619",
      "r661",
      "r664",
      "r815",
      "r817",
      "r838",
      "r1359"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Revenue from collaboration agreement",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r247",
      "r257",
      "r258",
      "r280",
      "r286",
      "r290",
      "r292",
      "r294",
      "r470",
      "r471",
      "r721"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r950"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r474"
     ]
    },
    "adpt_RevenueInterestLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest liability.",
        "label": "Revenue Interest Liability",
        "verboseLabel": "Revenue interest liability at inception"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue interest liability, net",
        "terseLabel": "Revenue interest liability, net, less current portion",
        "documentation": "Revenue interest liability, net",
        "label": "Revenue Interest Liability, Net",
        "totalLabel": "Total revenue interest liability, net at December 31, 2022",
        "periodStartLabel": "Revenue interest liability, net",
        "periodEndLabel": "Revenue interest liability, net"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest liability, net and related imputed interest.",
        "label": "Revenue Interest Liability, Net and Related Imputed Interest [Policy Text Block]",
        "terseLabel": "Revenue Interest Liability, Net and Related Imputed Interest"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestLiabilityNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestLiabilityNetCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Liability Net Current",
        "documentation": "Revenue interest liability net current.",
        "terseLabel": "Less: Current portion"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestLiabilityNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestLiabilityNetNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue interest liability, net, less current portion",
        "terseLabel": "Revenue interest liability, net, less current portion",
        "label": "Revenue Interest Liability Net Noncurrent",
        "documentation": "Revenue interest liability net noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Paid",
        "label": "Revenue Interest Paid",
        "verboseLabel": "Revenue interest paid"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Payable",
        "label": "Revenue Interest Payable",
        "verboseLabel": "Revenue interest payable",
        "negatedLabel": "Revenue interest payable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestPaymentTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest payment term.",
        "label": "Revenue Interest Payment Term",
        "verboseLabel": "Revenue interest payment term"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueInterestPurchaseAgreementTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest purchase agreement.",
        "label": "Revenue Interest Purchase Agreement [Text Block]",
        "verboseLabel": "Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueRecognitionExpectedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueRecognitionExpectedPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition expected period.",
        "label": "Revenue Recognition Expected Period",
        "terseLabel": "Revenue recognition expected period"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition milestone method expected milestone receivable.",
        "label": "Revenue Recognition Milestone Method Expected Milestone Receivable",
        "terseLabel": "Expected revenue through milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Deferred revenue, expected to be recognized",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "totalLabel": "Revenues, Total",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r193",
      "r207",
      "r247",
      "r257",
      "r258",
      "r280",
      "r286",
      "r290",
      "r292",
      "r294",
      "r336",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r649",
      "r764",
      "r968",
      "r1246"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r217",
      "r218",
      "r224",
      "r232",
      "r342",
      "r343",
      "r576",
      "r577",
      "r579",
      "r580",
      "r587",
      "r588",
      "r615",
      "r621",
      "r660",
      "r682",
      "r683",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r1021"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SalesAndMarketingExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SalesAndMarketingExpensePolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing expenses.",
        "label": "Sales And Marketing Expense Policy [Text Block]",
        "terseLabel": "Sales and Marketing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r1170"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r483",
      "r1200"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r483",
      "r1168",
      "r1200"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Investments",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue by revenue classification.",
        "label": "Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]",
        "terseLabel": "Schedule of Deferred Revenue by Revenue Classification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r1006",
      "r1281"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Compensation Costs Related to Stock Options and RSUs Included on Consolidated Statements of Operations",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Useful Lives Assigned to Property and Equipment",
        "documentation": "Tabular disclosure of estimated useful lives of property plant and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1292"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r383",
      "r386",
      "r387",
      "r389",
      "r722",
      "r949",
      "r979"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets Subject to Amortization",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1233"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Table]",
        "terseLabel": "Schedule Of Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r978"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Loss Before Provision for Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1194"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r676"
     ]
    },
    "adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ScheduleOfReservedSharesOfCommonStockTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reserved shares of common stock.",
        "label": "Schedule Of Reserved Shares Of Common Stock Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408"
     ]
    },
    "adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of revenue interest liability, net activity.",
        "label": "Schedule of Revenue Interest Liability, Net Activity [Table Text Block]",
        "verboseLabel": "Schedule of Revenue Interest Liability, Net Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Information, Including Significant Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r487",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share-based compensation, shares available for grant.",
        "label": "Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]",
        "terseLabel": "Summary of Changes in Shares Available for Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under 2009 Plan and 2019 Plan",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r114"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Estimated Grant Date Fair Values of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r105",
      "r107",
      "r108",
      "r109",
      "r175",
      "r176",
      "r177",
      "r249",
      "r436",
      "r437",
      "r438",
      "r440",
      "r443",
      "r448",
      "r450",
      "r830",
      "r831",
      "r832",
      "r833",
      "r988",
      "r1167",
      "r1192"
     ]
    },
    "adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period",
        "label": "Schedule Of Unrecognized Share Based Compensation Expense And The Expected Weighted Average Remaining Recognition Period Table [Text Block]",
        "documentation": "Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Change in Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1005"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1235"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentrations of Risk Percentage",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r60",
      "r120"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r247",
      "r252",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r294",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r389",
      "r403",
      "r408",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r964",
      "r968",
      "r969",
      "r978",
      "r1037",
      "r1324",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r851",
      "r854",
      "r856",
      "r914",
      "r916",
      "r920",
      "r923",
      "r935",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r952",
      "r991",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1036",
      "r1044",
      "r1251",
      "r1324",
      "r1328",
      "r1329",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r967",
      "r975"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r964",
      "r972"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r269",
      "r271",
      "r272",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r294",
      "r962",
      "r965",
      "r966",
      "r968",
      "r970",
      "r973",
      "r974"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r272",
      "r286"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r271",
      "r272",
      "r286",
      "r968"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r289",
      "r292",
      "r963",
      "r964",
      "r971"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing",
        "totalLabel": "Selling and Marketing Expense, Total",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "adpt_SequencingRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SequencingRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sequencing revenue.",
        "label": "Sequencing Revenue [Member]",
        "terseLabel": "Sequencing Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SeriesCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SeriesCConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stock.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "terseLabel": "Service Revenue",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve",
        "documentation": "Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve",
        "terseLabel": "2019 Equity Incentive Plan reserve increase effective January 1, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted Stock Units Outstanding, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted Stock Units Outstanding, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted",
        "terseLabel": "Weighted-average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance",
        "periodStartLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted Stock Units Outstanding, Vested",
        "terseLabel": "Fair value of RSUs vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSUs vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase reserve shares available for grant,",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant",
        "terseLabel": "Shares Available for Grant, 2019 Equity Incentive Plan reserve increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r487",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares available for grant at September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future issuance",
        "periodStartLabel": "Shares available for grant at December 31, 2023",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock that may be earned under the award",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Earned Under The Award",
        "documentation": "Share based compensation arrangement by share based payment award number of shares earned under the award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Shares Subject to Outstanding Stock Options, Stock Options expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "negatedLabel": "Shares Subject to Outstanding Stock Options, Stock Options forfeited",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares Subject to Outstanding Stock Options, Stock Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of common stock",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Stock Option outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance",
        "periodEndLabel": "Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494"
     ]
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable",
        "terseLabel": "Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Stock Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number",
        "terseLabel": "Equity awards outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Requisite service period term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Requisite Service Period Term",
        "documentation": "Share based compensation arrangement by share based payment award requisite service period term."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Options Restricted Stock Units Granted And Maximum Market Based Restricted Stock Units Granted Eligible To Be Earned",
        "documentation": "Share based compensation arrangement by share based payment award, stock options restricted stock units granted and maximum market based restricted stock units granted eligible to be earned."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life vested and exercisable stock options"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment awards forfeited, canceled or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired",
        "terseLabel": "Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment awards granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Granted",
        "negatedLabel": "Shares Available for Grant, Options and restricted stock units granted"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Restricted Stock Units And Maximum Market Based Restricted Stock Units Forfeited Canceled Or Expired",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Awards Restricted Stock Units And Maximum Market Based Restricted Stock Units Forfeited Canceled Or Expired",
        "terseLabel": "Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r492",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r523",
      "r524",
      "r525",
      "r526"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life stock options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance period term",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Performance Period Term",
        "documentation": "Sharebased compensation arrangement by sharebased payment award performance period term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r205"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Software Enhancements",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SpecificPatientsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "SpecificPatientsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific patients.",
        "label": "Specific Patients [Member]",
        "terseLabel": "Specific Patients"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfAdjustedEbitdaToNetLossDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r160",
      "r247",
      "r252",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r294",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r389",
      "r395",
      "r403",
      "r408",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r964",
      "r968",
      "r969",
      "r978",
      "r1037",
      "r1324",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r175",
      "r176",
      "r177",
      "r207",
      "r236",
      "r237",
      "r239",
      "r241",
      "r249",
      "r250",
      "r336",
      "r417",
      "r420",
      "r421",
      "r422",
      "r426",
      "r427",
      "r436",
      "r437",
      "r440",
      "r443",
      "r450",
      "r649",
      "r830",
      "r831",
      "r832",
      "r833",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r868",
      "r889",
      "r907",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1167",
      "r1192",
      "r1202"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r79",
      "r80",
      "r156",
      "r190",
      "r191",
      "r192",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r229",
      "r231",
      "r248",
      "r341",
      "r347",
      "r392",
      "r451",
      "r562",
      "r563",
      "r575",
      "r576",
      "r577",
      "r580",
      "r587",
      "r588",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r619",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r661",
      "r664",
      "r683",
      "r785",
      "r815",
      "r816",
      "r817",
      "r838",
      "r907"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r851",
      "r854",
      "r856",
      "r914",
      "r916",
      "r920",
      "r923",
      "r935",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r952",
      "r991",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1036",
      "r1044",
      "r1251",
      "r1324",
      "r1328",
      "r1329",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r248",
      "r664",
      "r721",
      "r828",
      "r849",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r868",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r887",
      "r890",
      "r891",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r907",
      "r1045"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r483",
      "r1168",
      "r1169",
      "r1200"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r248",
      "r297",
      "r664",
      "r721",
      "r828",
      "r849",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r868",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r887",
      "r890",
      "r891",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r907",
      "r1045"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1086",
      "r1096",
      "r1129"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, common stock warrants exercised.",
        "label": "Stock Issued During Period Shares Common Stock Warrants Exercised",
        "verboseLabel": "Stock issued during period, common stock",
        "terseLabel": "Issuance of common stock upon exercise of common stock warrant, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r44",
      "r76",
      "r79",
      "r109",
      "r431"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r76",
      "r109",
      "r830",
      "r907",
      "r929"
     ]
    },
    "adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares restricted stock award vested.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Vested",
        "terseLabel": "Vesting of restricted stock units, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options, Shares",
        "negatedLabel": "Shares Subject to Outstanding Stock Options, Stock Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r76",
      "r109",
      "r498"
     ]
    },
    "adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, value, common stock warrants exercised.",
        "label": "Stock Issued During Period Value Common Stock Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of common stock warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r76",
      "r109",
      "r838",
      "r907",
      "r929",
      "r1051"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total Adaptive Biotechnologies Corporation shareholders\u2019 equity",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r98",
      "r870",
      "r886",
      "r908",
      "r909",
      "r1022",
      "r1052",
      "r1193",
      "r1221",
      "r1298",
      "r1359"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r55",
      "r156",
      "r157",
      "r191",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r229",
      "r341",
      "r347",
      "r392",
      "r451",
      "r562",
      "r563",
      "r575",
      "r576",
      "r577",
      "r580",
      "r587",
      "r588",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r619",
      "r650",
      "r651",
      "r655",
      "r662",
      "r683",
      "r816",
      "r817",
      "r836",
      "r870",
      "r886",
      "r908",
      "r909",
      "r933",
      "r1051",
      "r1193",
      "r1221",
      "r1298",
      "r1359"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Shareholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r206",
      "r435",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r451",
      "r610",
      "r910",
      "r911",
      "r934"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r685"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r685"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r685"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Change in Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure for tax position taken on unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "U.S. federal tax credits",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credit carryforwards expiration year",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Convertible preferred stock, Ending Balance",
        "periodStartLabel": "Convertible preferred stock, Beginning Balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r420",
      "r421",
      "r422",
      "r426",
      "r427",
      "r527",
      "r773"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Convertible preferred stock, Ending Balance, Shares",
        "periodStartLabel": "Convertible preferred stock, Beginning Balance, Shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, shares, new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity value change in redemption value for vested convertible preferred stock options.",
        "label": "Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TenantImprovementAllowanceAndCommenced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TenantImprovementAllowanceAndCommenced",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance and commenced.",
        "label": "Tenant Improvement Allowance And Commenced",
        "terseLabel": "Tenant improvement allowance and commenced"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TenantImprovementCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TenantImprovementCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement costs incurred.",
        "label": "Tenant Improvement Costs Incurred",
        "terseLabel": "Tenant improvement costs incurred"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TenantImprovementCostsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TenantImprovementCostsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement costs receivable.",
        "label": "Tenant Improvement Costs Receivable",
        "verboseLabel": "Tenant improvement costs receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1322",
      "r1323"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r1211",
      "r1310"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r433",
      "r448",
      "r609",
      "r644",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r786",
      "r1009",
      "r1012",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1023",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1290",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "adpt_TwoThousandAndNineEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TwoThousandAndNineEquityIncentivePlanMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nine equity incentive plan.",
        "label": "Two Thousand And Nine Equity Incentive Plan [Member]",
        "terseLabel": "2009 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitAndMarketbasedRestrictedStockUnitsActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen equity incentive plan.",
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r217",
      "r218",
      "r219",
      "r220",
      "r232",
      "r295",
      "r296",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r391",
      "r392",
      "r397",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r647",
      "r648",
      "r660",
      "r661",
      "r662",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r723",
      "r724",
      "r725",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r406",
      "r407"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. Government Treasury Securities",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Treasury and Agency Securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r997",
      "r1023",
      "r1040",
      "r1354"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r550",
      "r1005"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r1005"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r1005"
     ]
    },
    "adpt_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Nonvested Restricted Stock Units Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20241231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "verboseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r140",
      "r141",
      "r144",
      "r145"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r1014",
      "r1295"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r1014",
      "r1295"
     ]
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Valuation Model",
        "documentation": "Valuation technique calculating price of option."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1293",
      "r1294",
      "r1295"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "stpr_WA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "WA",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "Seattle, Washington"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r241"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r241"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0000950170-25-030913-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-030913-xbrl.zip
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MH5N'8$VJW"_E8.]@0O<>1:)]G(!R,Y&\M2D3KA'1DM197YP TLC"$Z:/!7P
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M4; G9YD,0>&V%#$(;N2:02M7:K>.U@?0_.(]I]8'!@0(/MCM?_EF]G)W=K"
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M.8/A9",4H'/@6M,U2J-SZ3?9Z'.B>WKGZ.LDKUR-XVVEB2[:+*"E+*PK@0Q
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M#^"$<4$V4Y$@=K=%]F]TM=*K.2QST28(&$75,O&N(_=VXL,R'57,SI70[RY
M5T%T5T2^'&VI*0N PD$NH8CDD" ;5X:.U537NMTTODUPZ0'I%Q_(OA2A'3W6
M1HTBM2!%E#87CJ)5L=LHJ=N ^:\*/6N2UBHII'-<X2VBR"Y%(3/Z8K-*IM^
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MSL1(77KA>&2X'01-C>_L@8X.\I1G46Z*UE3RP4K7L&^IQL2M=W>KH;9P0/C
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M\"S+KNX6/:TLYZ^AGV$9(4)6VL97A16V0)Q)($*!%G&GN6Q [L<TPR*I'HD
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M^$,"J]4B!W</^^FX_>M?+SI1OA^BO'<O1?D\OO$Q-FYP!<%LYADH$!+?HRI
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MR!-Z-DJ7%V'DR)$)CH%^@\EGK1#+3C@MBP9(H*J93C69Y'8GOPMV&^I?\]P
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M6WN#8_KT+!KI-/&^(ZU"AY#B=9"0K:5^@?:(; J1/_>19Q^*1J748\1YQ?N
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M4=*$S^3DH)U()GU=N9&H4AE$OY(>D9-=J&?HD4N6PV.- \)GI]_</-FDW1E
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MMBLR!.SME)Z_BEZ].NXQL16,V)H[O9/^5-<^3F">LJ7+_L[4.FAL&NN8 46
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MW2B30JTLU"N\ECQ#67QCZP2B2=9\Z G):ES9"Z0'CY\$[;@-2(4C*PZ0\#X
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MQ<*S>^HV\GEPP16W8R'<:X7!#Z*)@R2.2Y?P\^7==7[POLZ'YA&[Y/Y2!=F
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M5B1]ZD.96C860+<*;@&?@4)AX H!(A/@"Z'A5OFO"C9GF$"*V(,KZ(Z%:Q[
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M<_9=7G5K++G!%\"6#]871TQ3D3IJ_3Y,G'%KD;ARC$5VP('<3EFGD]S-Q_C
MS GV][=<(R]EC<0N!9+DM@T2%;1V4(_5- \>SVSB*3,/NT#[B5(B%J'LZC/
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M.!%K/=9- M4 $J<Q)K+0=0E4 >8XU+(AIII1 W5ICD<.\D'FZ'JH4=5:&"6
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M/63>1S2"Z9#<E&W0$GW+N!$&>&@C3D6!X+;S%2>X@-T(TJ-KV@L+E1AIJ'W
MS)J)]N P#9>"Z<(-W'9I:GW;V.%C,),D_B1JU<$R=M4XJDP[C!XJLDB-OA:V
MU+'B,70,Z8-F"P^8EEUWA/MP/D*:9Y3)S&=D/H[-<+0&"4F;4JLC6%[E3;E/
MX"6R[E)NQRX7+-,+.%PEEUQ\A5CML&/,IR/DL 8SV.7VLKBL@@Q3LH\M/^2Q
M]HK$8\A(:]0=PVU#13BB/$5;M>5NZ!WV!R*QR?S?5?,?J I#5XAQJX5$B;D-
MBCD/F2/(%RMYQ'IDOO-:EEIH:^YX@B]HK=FK)-'M.57\*-\R,:=EB%DA.]K8
MXKBGF'"<(T^XO"I5SFE5^ABRRH/NXMXM16I^QH+'!\F8*O>V_8SR=''<!990
M2]-M,S7%:0[M='VCRVJ>1\WB*+NF;B>37L8/^MXSBY\J'R5S\DN9*W,TR:&!
M_QYV,\ QQ7A6JKC&Q]D4;RSY'CZSR\FK6(, I7=.P20]%,9X"A>YDF.$R$W(
MZ,5<U6B!C=XC9GOLE)[MAH6<H^HR\]7^KN]TLGYWU?JQ*7Z4C0R!:S1QS3:-
M6YO@B\ ROJN2:P%K%T/9[C"4?6<^U;8""8\.!5P/JZ1X,/'@9WVQ.<(F=_#(
M!67?8G-C'@DNE  T\AH!9UROQ\G=Q/$I4%[)RFQBE,5S+;:]:57S,8T6]\@%
MY$&5"D6=;9L>G9!15T]Z6^T9!8,*S6@:GH#J]$K+<'R9\M90PY2)JX(TKK_6
M9NS(N150(P/2>DV._+=-<2!YUB*,NN*:>NE*H&$"94&!]P_[PE>%@Y=9AZ3)
MB$S+,L7$8A8)?W35D9"HJ,W_+XZ5Z]*@VYB=94PWA5;><!J4;ZNN1\Q_/OOE
M2OL^[;F/)V.L>+XZNG)@?#V#E#+*R7+$V<&9!%N=410K?'P@:=VF0$@B(4TD
M\\IG?3[;U8-+K.VRPA?;+),U8?06!SNY.[%24C*.#4(AO0GH(V8YF9^Z$GQM
MYX<WB":BTO10+>Z1=[DQ^9_449,^Y_&!I>-/%AR],=9P*$CJ=XFER<,M; FV
M+(!(:K<L5X4*+J)&RZN%W"$K62R_HI\BF][I +NC!UC6CNP8O%24W+WYU(!:
M>V=1-Y?-T(WMZ>$6+YP?A0B(@.%-NB%#BXF:+-X%_I6:<-T/1VNF%N++LI6?
MPD&][52;5N$=787/M[/GR[[! >:M/)H+>17R7C]WY=E3<9^99GG!YJM(+?A"
M'.@&R^3YKH*X#( Z# 2P.EZW9=&'0."%$RRH4,9F,VPU'1F(:!]^$:!WKWY^
M\>+YR]<9:3X2^;8IU.HF7W*XA)YUW]36%"P>B*/[B)(/PSMVSV_^^O(B@E"-
M=CVT1E%K1[RC,U_]*33!([8P+R2'6VF)8XPO8G\21W&%,WY^I+;C6=K(5!^G
M4K6SB;['B&.WR;C?>6"1"+G$74S[Z-G6J3*K-5R9%%&@ 8@_.9\]&5JVD"27
M0<H(  SUB(BI"ZT&+AS49209CHG( %&S5S'O5!NT*IG'8)I&9*-L?#[$4.YZ
MQ6 EQ14M"NT3U!^QSR?F_M@,J^=_[.W, ^@''/D4S I-\KP243)A#P$:O+(]
M!&]$)_K(,R^#@D? >[2QZ_ $1K0(C\@6?H6,R@M3^ WAH3F)JW:V<28])0S
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MZY+B?TCV60%6ASRTIN)>8O: .=GO%!=@>RVLVF9;[T=A>RQHA];0PE8=LRT
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MD14=4_**I+T"%T\B2L-DI^0$3GI1K*G&ROGZ@ H#N2EROO+.JG1JQ^7U7J6
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M0=(L(-@8;#,K%QJOFNC4S11,MHQ9=Z#@-6\7-CU D,0R'(>_Q.Y^&TL M!
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MZY&&AJ7ZOGUL*QN<!Z64?MZ"YV5;=BK,MRR=%<<Y"_42'FDL-=*3WQCI/6A
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M.AMD=&0;<H2>^4)0KL6\^H$,)%^H)Y[TBCAGQ4P.N4M-,%TU;?4/2^84RQ;
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M1'&M6NT^8,^&;(6/ZLI'HG@P 64LIK=>93Y[(W%&Z%G23M>(+%!T$&".34[
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MR9U.*!$T0]_A#=@Z^_G\U?GH??)AM.O;NQJ.)J%[$G/)NKTNMQ27G#NE.FN
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MWNZ$&Z(CJ2Q:"XBH()PEX$3V>1K]D%U2O$6[QM')& PMA"LA*(OS.%M'UHS
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MQ%3F&B 3N[95!U6"=^%KL[85ANO#1'T[&*EO[4Q]/!K5SRM&<9"X-.N<7+O
M%JX7J%EHF??59L#W(G3D@^J37\;^K_3;;/B1*$ $1@\+?)QK*P8A!W%L&#VX
MAF? 7,U$A8!+^Z3O<NO3IZ$ @FMSYKJ9Y#SBHG@C22YC\ZBHCW]R!(6N+&JF
M$5=*9$</8I<6:WWHE=FR++Z.5"\:.7;X\>2Y\JTW6>]-7'/VE$ =3G3NM'BH
M-CO#Q5Y+4^!&B#912D]NHV0&U<A[B:V3>B^=0Y5:2@&CK!]5@=TIJ4VA4A4
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M(5%"76ZZMD[CRVLJ9= SVKIU9]X1!40=]$_0TN'F3-0$!_%L(*4]"+%QLWW
M31?R2#(@ALOA;^(4HD]07=V/O>A#= 6R]6C1"WL/CQF,=I]T2KNK[<80.Q41
M?J@#BQNS%/D+!.)G+"'+U^RBI0R0BG7#ZP4VQ8VV%(%;_^,NFY9IB/A+.#PH
M"P)MEG 6N SO</[/H,I.UO&/+RZ^_/S1W](>R,#X)IL=J,U_!3-[0&=L_T&X
M0:K.CPPRWL/CB\>?__UO=\="'U]\^OGCS[[\Y(N'GSW\[--/'C]\_+>O;GR(
MSBV%?Q!PUE]G&9Z.M!_PD,X\%:%H_SS4SDT?@D_\Z.'#OPV.>E?6:4CU0;ET
M1D*8J(X:YAMB0N8P+R0PPAED]BO$+*"WT'X5#3SM%2V&OACZGV/H2'"FT*$:
M-YV;9;"AU&*KBZV^95LU = < 7+@7=!9!"*X2\3\IF3^%MM=;/<MVVZ^0=J:
M6=P?Q^G#,:G%&!=C?#?&F-H@MU_0I&DLAY?,9+G.6R9YT,4Z%^M\NR$IBA,N
M%$( (-@6%'JV<020^Z7-L<:$QM[EVW_W_M:IVXHXH0U3!PR,*(6U*1$B$811
M>S%GU1]TL>HG!%H^94W#?ZU )J7CP? ML?E32;-+*;V6ZM'BP3X #S9#WI+2
MI"QQWF*'[\ .>8!Q%R8/MHP88EV?E-+HF)_0N1(X"&-TBL.Z;UIF]<N;AH S
MAK-\6Q\<%&^Y!6CE*&++.^E?X22<BS."D5%,_-=0=%(E%*.I2_HGRYI9ULQ;
M7C/,@]QVK#) !2<%#$WS0J,BM=M!%KL=RC"<Z1PLIKR8\CMT_];I"\%$P0+F
M2?6?-@I7EI %C;0MD6^/X9_TJV]]5E51W6IUJ3H6BTDO)OW7F+3*K<XQGDB:
M/YP&S>:%%)-C.4Q8FR,NEKY8^CN(0YQH%.U4T6!(@I<EU'8"03!VND09BZ&^
M;4-E#5_E[NSJ01H8BK%+]V QQW?D-R,%@V9R'!&4Q'OI-W=UFHG*28H$IOJU
MD2FH(1]#]"IF]"DR6(QCB-F.PD+:<-](&QXMI WO(VG#A]C1(TJZZ[PI:"2/
MK"V.U<T.03&#3_2H&)'0H6O^U0Y3]6MB<VY[E+AX#,*./&R+LK=<.^T^;P*S
MO%P"G._%ZI)T+8<C%6;$A<Y" L4T8\^_5)H>J('36B#A,1R!8;>8T2BNB]+1
MK* HJ$+SK.:)$;T0,X<+":!Z\_(5MSJ:[>!C#OXL#&.8PYRZ0-4A>\,KI-<*
MLB#Z>'AJ>5S^>'[U-_4-U2EY9B#G.9LP@A($2>6Q@A/1)3(*.H3/T@+5S"R^
M?59"R6UTM4/9E*%0&'\PC06>ML%>NTYY5!N*S_P_VWUZ37B@83=67L:$/*V>
M@PSZ#ZX:.HK@LEB@%\^2%2M$WF*77]=-9&JZ'Q,V9[;G#V[:,V">  ]-X4VP
ME]\@I4N#R 0T86K2E\X.TT!_'C^G=#ROE-$Z8>F+?")&*V,L-@S\!/D[]8UN
MY!8I"'_TQ5>K^J;R_]H7QVR5C"5@H5/##G-OS%GBO]"GPB=2^UH&2._QMBTF
M+(->L&0.\I@@/]JRT/N[KHV*F.:78Q.WU@W3+9UT?U^IUA%$$8Q:=CJE%MIB
MP@O@=XYUS_3]*L%4U?;G=&Q:&8/KY+V"V13,M_G:A;:"0(I8X6B]I8MT3E$5
ME)9^&^<AVO2DF1UHU8/S0R?*B"TI"+DVH;4=')WQE)UCQ!JX0/*X<9K]9,CR
M)YLHO ](&\S[SF9.1C67JT:93\37;>41G%0B8=>78 J5K3+,M,=Q0KD=$4OW
MD<.!&#E)-:!2UA1FVK"D(+;K:7+FZZ)6>@\%[='%??/DYTM,K_HW2FTFX@/A
MH$_P98E]FR@O)1^&IT/XI$%/-G-YAFKHIJ$EZ^T2"\<_"!]U8$27%PVB@;K>
MLFPI/;B!P@<3:1BR%Z:!"(5:#HADNA+EATI9:L3;(X!+N\=A*IKB)WF/,D%&
MW!7#=QD6M1!8^K->U2DS@71#>,/SKB;GT,I07JBR#L>ED==B5V^8AE)*(]K(
M'IE*6%-F00K?95(*/+=Y9F>?;9"S2A_N_'.<>.S)RO<[)]@7L$+,5/K:5<[[
MVU;+/L;^,JL@(1%BEH:R9#.)Z[@?H>&'N(W^4J\46SSTJZ.W&#WM9E_7S$V-
M3(I#M,E$C#Q<H#,4;BJC]R9A'IE?".GT,#;N\\XPIN&<1%F/'[FN1XG*($D!
M];O95% :;8J-F[SX@A0";N@GU_#;Q"T_O=FDH702"V.<,$\?)65>8%GKVX"+
MF7Q<]V/E+$F50,,3>6$.&'_\Z7LN&/E([H9TLGB#4V(MV$N7_PXM>XH%75 A
MD?AN2''\0?LK#9(EU*&,LM--UB^EC03I%1%&JZ"HKE@'*A<!'E.TY6/UG%L?
M5D#R6YZ-("HN.7 X&1#]7/V3M^DC0>\6.)B3;_O=GSS!1Z .XS\)#R6 IE+%
M^F=>]314]"A;/7[XZ,N/X9<:%P3!*"#SMZ94%_GO\#3^2FK2KRBP+5^L_N5/
M'@2B=^?L#>6L=H+D,:=_D(A;QU1]_K)*-CT^[):9N5,7+71T\6NM%APA5_>"
M6S*K3[Y\K-3CST2J=/5<$-]/ZBV<[J._?_GYZB-TUQY^97Z(OSSZZF.N34E@
MS"R@.%7+U;5?$+D,+WHLS(&W$A[4^8>T=CNBT.OCP]6]@HCU]LJ#YE?#\(F,
MA(OX&&<]@9S44+GQL@\)H69-M(O8)PN-.-)< R&=\/<5]J*TT/C4;=QA[:W_
M$YC;XT^$?3$2K_L]K^B$ZD0/9>HVWC5=7='J,0_Y8A5(G, _KY=C^?98ZPO,
ML<JWYP-4O^0Y'XG64PMKZ]B>=\P 2T_/O^Y_!;#=+]YG/NFE=OG/>MVN+AD7
MXI?3%ZN/Z"MB5+\\^>>E6E.6'"^N;/_8:!G:F9Z3RYNP8.B]%6X;ECVY71\X
M^1=%?H(Y^*G$#?5$>?U*K9B>,9$'I61F:+P7_,4)G\%72/2PWB\7$GE,7%Q_
MY&_S+23O*0F65%%^Y6CE>I^9V<PHZ!1OV1**CK@_F5U25#'\WRN\9WR!R;'H
MA]*GP+;&622'>Q(T<=:1<Y))CVEHGY\.*!'-5:'7C*5 F3L)%_<B'5WZ4(T#
M6>&WGKN6N7,N^^RHO&8RV:&K:P=L3$,1QWVQDPPW!+>F:AO%I];D'#N*>&,(
M3CJD/CZ_C(?$EN?]BC?H"B]VN",._6ZKI*3NP6C;&COBN.%R92HYN"&0"PO7
M^*Z+U0O9G>*^A"> O8KLKLQON-Y.90HRX%,X!"Y2.-KRS:8_]%PHB#^.<>'@
M@4#@BI^*_\XHD)D6D '3;BPH //\JMAA*D9-ZQ1#ZL^$+#:6<I9<YK[D,O^J
M8M[\KXL7%Z@"EO6:P&O^6_6AV,2*4GO."F(==:(6Q:)3$\6KI35SC_>.GV9+
MDB'&'7,%4]J@4^G&LF2/26SO-"AM,L:7>/F3C8EJT%.V2C%70X7=MM_Z]T+Q
MA=;BY6R;G!URXPAV12++I1!2ESZ\Z]7MDTSPM6/.".]ZR]J??!O/N?7[CO>
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MZH0@'07\LG17$)^LC<Q*F=\,)&QYC!(R[=L$Z WJ*!E3D%%?0-?;8TTM529
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M'AJA"2J*+TE"1.UI\H2=6D@F@FJ1:;>I,4" Z!8/:/J'RM%*,^EN^RI*%QQ
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M>L&W['J7%YR7IBNB=JRU3J$<[+"#F.P>Y2J<!2=K?ZKC3/ >36F4</UOA]W
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MW7'[A;@=49\*:C!EQQCQZQD_!27"@IS,IC590>J1:9@8&C)PQ77HLS#9?,X
M]IK53R5OV&TY!'XZ-&EX0[_V:-;$150O%=X$_GO8DV_7EIOWF<Y>T)'!C ;'
M=)LS(QI[O#P#\CMYU!&OV7BZ5)>L:TE !3F;PAL%564W'CS6Q'22$(&,*Q#(
MH7#3D#B)!(+(?WWJ^6B^N;_1\E_B^L4._P9VV*^V]OWJO_.K8&X[27$R $'B
M&O^]MR>:C\HTL#$ (5;BE9*:S9G&[*%5ZOK+]^^LE3(\<U8?3<)JLCC<(A<
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M83YOZ'W6P"]$ FA:="B\=YU^!W\TTTG6.D?D$1VC"G; */&(I?'.NU9=":"
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MFI_3'I*B[WG.O P[8/\(2T-(Q+&&M>T7,0B#4<<(';O"V64;;"U<IC-XF>B
M$@S9%;.&($)DYO%G"B[QEUROL"9WC-.,:[AN#BYCZ,O:3T9-K@5WN$C=68'*
MHK(JI(:Y()TMI#G#,!CYE$6 2@2NW.EJ[Q=]'+WR1\< FGAOTU&ZX'*_DFP(
M@S";1S((M69: 6RDO20\8HS$V Y@_$+@I7_L?ME73=FOKKQ[A.42\6^AW-)=
M=]RYSET#F^F0B*ZXK"67AMN2?S'!/;'2(VQ?[!>3O:B4U4'AZ8I@H;1W1(Y!
M*:W)IJH0 :>KIR3*L:M@Q-[)3;$,;9VK.HEWE"E]G;__KHZE/*A4^/.,H$\
M?Z(1GRCKAT# .D9/K_YQZ*N8[S"=/P'B$E0[ +VFLZ5L)I//PD=2L.T2?J0
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M&,&K7ULBV;=")/M[1;"W1=#].P6GOT]J8[:!D$#Q-E!1AEW.SH><ZSROL%&
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M-F5:N*ULY5P5",+-_*+\CL0S<SAP!R2N\U0[S4\5=CL5LOU51H[#>Y6D:1_
M+I3O>2LOY8?YHV9@O%7:@F)?V\S_\>[MCV^TSYSVE^ 5I&Q,+]WL-?P!#29)
M4M-_MP[C%YX4EI5C438'^-%EZ:Y(%[L_(1,C/PIB$3YN)(Y(HZ00YB>XVOP*
M;*B#DH/.L9V=J,6N6:S@NJ?5:[FE*#DP<)*EY&$#C>?*O[*&!><&4"^CP)4
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MZ&G;WQ?.G]YM+ 21%S)A:.$/9OYLVN\H3SE 8,0(\O#BERJP-4<^]F[\,*/
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MA=<C'EYQ$%23$_[U#'AQ&B&F?B>0QWYKLXO/GG;ANDU;KA&?KKV-X@"7^29
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M7N9-5OP""KX7H. 7"RCX,P(%+R?.<N)\BB7&9<]K8;O /X 9<ZY/4JHV[P#
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MP65HTEQ8%NVR:&]?_=!QU=2"OEUHQ=.\X0$Z*T*>F+X^ YJ0O[@)YF)14#A
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M)K<1[\][ZH/*9VG]AA'J*]Y1!TJ;B@\\(S,JV6158M2R:ZP$L)8055U35;;
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MP(Y!B)&A6O(!R:=29J/L2[&M8GA%GGXU%9_=#-ON9CAD-\-S=#.\1"7O[W3
M+&S9:S:]QZRE]W,,6!)?#2&OTCW)$!V,9U+:%<!MD%3B0DPGMM)WJ7 BE_)W
MS52ZU0M.=U,-R;XO3,_:5&S,L*(>YE,,A:<#V)H"MZZ3K>EB4EI30 RI25*E
M4KFAUL52:3)>.YW^J2<H59D-5R[# J>D=4V8#-M4JM=84H794%(HHE+%HJJ+
M!W0OI&(P:OG,(,?B6=U.>7VC3/3R^J&X:E%.EABO"IJL4FC4K5@1ZJ\#9_4I
M>1DO2;VCNR,8N+H%B2E\J^8A:8N#H]("V8_,D875:/-2#5E]%J*;%_$2J;Y4
M04?^YN>%$ECD3$-N5K'9='A?EE60M@*"5AY-:Z:L35:F8EN5L5KE*4X%LVVF
M.;"+Z%2M>V&FM%+S,QP=#=60].([-TP?'W*M.J@#+J-;>9]9'@ETN8MU@VN-
M]91WX];=N.VN[ D[L[@$"XNKSK0X4I<1?'C:-!)XT)YY^)ZNND7DO<8#^Z3<
M'=K'!X>.-DXX!&YC'7G"0C&#(5[DM:R\?BOY(^HB($O3.^6AD45<4$87!7>B
M+(G#=5/I]IU3AL]OZZXZ30,$UK?[DVY6+\0%:D</E/?*0K'F/\/049*F.)R;
M?@C:LJ/34V)"!F V]$(-K_2V*G;HZW)SI&X(ZA0E?P+VGP5:[J#?GHX-CA?X
M'F''&QN^"I9+'14)&]P/38]IFZ(2I2Y*F]HNG ']HD[<%O,514K*3%MZ1ZD
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M*\/.9-(U_NW0Q"ZO'&MZHTZO5[EN.Z_I#3NCR7%F=*S5&IR &7EN+YY;?W"
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MC^,9;B'4HW-%2J;N8AD"V6 (^%$JDKO @Z' ]!_HNV/!&E$OLKO4NA>)L)8
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ME,M9*AZ4RW\3B:>N 3;M-&WC^);".I]<#GDCL)OQ\C7=E,1YZD9^:EOBFR>
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MH$&KT1!HV#WT[DPIQZ4'CH,7VTL/L*;!R<.;1^!6&8H9=;8L R=2.SN5A*&
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MN7!7I.4%/C!-X@*[X@'<EVP%'>B.8$S0EZM&-<WA.4 J JTE(@Y,((.!BMO
M _:]@SU"XZ ',O<K;'[_#E#)O25T5*HD=!4O43M$'9]X+B'5,(;!XEYS4V3M
M1JG,O >,ZAHS8@;W#O1X8NMG,__4#5%.R$> /0*4IPB=AL[ETI&BNCWP:)#.
M5M1]6"C#Y@8@W$/FUHB-:E#)UH8XL5#()UMDI0VC%5^I2P'[U&A!R.,=&O<-
M4>^+:69,T):R5DI:U_) ZH+J-7,]>6,(+[N19/89GHWH/!8D_M723>!K#?/P
M&(U"/DE=%!NH8_UN:!UJ4%+!V#HJ19<T#TF0^4&82^TU+D]B<SB\B"25FHE2
M44D<02^E/J/Z,Z7&)CT  ^9Q6EEW+\Y#4FCN '=HRY,_ ]!+MBV(*>!CT+'N
M@E#<HL8NH@ ^(;4FE@/!T9J*E"0&$'Q!XFM]VJB6H#H'^!4G27Q/9KJEH2\5
M*^06NI(<:;!8T@Q@!P; AOBXME-(X1ZM*8DX$C@"UP ITA[6'"&_W#CPOD0[
M^HLF8!-WP%#"L-$(Z =WEA>Z:8H.,;=P@I=N+#@4: N0"A]08_Z3$/+;VZO^
MNUDHOEWYL%N)@F]A-ODB>N<'Z3)T5V_QVPT?F<XPB&A8*KI(?H"!+,%LI4=(
MKUZ!3*S)A#*-OR$Y<(J%L\VW)SK/])S=,;MTC&K" DZ<B@L.+(_ZB:LY+T*X
MU'R"* 1)?P5HF61OW3R+WU6_ $K+C^7B4QP7'0?>NN&]NTK???>7@DUJ_:9P
M#0V^V%C?_2[C,5V&]KAF-9Z6>L4N6@,!!1;P@B07B+ 06B=!M;LV#D \EV?M
M !Z P564<90U(B$3:-E$]<9JP]7'"^,H_O+Q;[9J 92<**?#=Z$DTU$W@ZVS
M@"U% A_5&A>8V\WB9&7:'MQB)+H=-,R[H+;05SZ<1\)XN9 G9A@0[9C4-,K[
M27X+(C_U8A#2JX[U7KHK <U Y)+8#&"2/LZ@>J((4C5F>8>'1N/$IU-^X1Q5
MSLE:QF'@K6R#D/24:]T%L,YXEE7RD&X6DKNRC'RAS\'8T!(79>%*$@_70>J#
M<Q'2($#RBY5:!_WUUK6E8X[D"YCEWSM?.M8M$B&B 2/]TSQ95;0WF.(25P$.
M>[%NW&""I0LKP\=B<T/.05O3JC<>3I, =3GK#GA ^\D%D>%%I\ZE;D):#ZSS
MG=+%R54&/\/6L"4O*UZ39EC<!I)!:%UF.9V"0:E$,Y1<*^2LP)/W&;>@\76L
M&V);F <R5=DRG6/@JQPY79JEB'VP$>3JB#9B<5PANYF''",ZUJ^X6W'CT>ZI
M:P6),0OQSE/N*BG(M+Y=S H5/BO*R7X#+:GSKZWN6)!OD3!9L% L#&L%VPV6
M Y@WN+U5ZGJQV9?N2E<^E!IS\3RTZ:8P>SS1X$#);H?P8BP-R%4R !;&QGP)
MO^+.5LT6)L+R_/17$:&J V!4&AOER:X@E]G%+3R>R*LE[,1#]/-050:5+H8]
MAH>X>0"M5<\KBQB6F<S6J+\C% $3H/$<YH+FA%0"W=IXT406K2KC>'S!#64=
M[Z1"D0E LG@V2P%OIF5K::4YZ+%H"SY,<L,30D])GBO*20&]R"9X'R=?I>22
M\&A"<'.NP![%E9=<@>UXW_H>?DM<W&.A]>L49B!%)J-S2:)?E>:@R1279*+-
M4V,_UA>\AB$RI/UCODM7 MUQ9U1>"4@NA\-\*#PR1R+\1,$B7Y  #93F0]8^
M/#FC=4?N&$/Q(9JD\HK"S;)0V-8_0%V!061*6?@2YZ!5? '2_IB@0034&AM4
MFC" AJ/ +?2E>S)IY##N4._^']"<$H9FDRWTQF0W(^U/0&(AB-"0YDJ/DVUR
M4]YG*;%@ZL;P6,$A!G]WK$_;KWN4&4J^5-B-4G7O E+^E=/IF9=:($0R%-4X
M$&EMDOIS5)BT2L*@F3+(<CD*1C(S@8DVK*$>MWSTSM.N? [4IZ5QI=G1O(I<
MCUI0MZTYVJI1L5 .^C?+)>Q6DO*_*7WH-S@4B.*& Q_2;?U :B):RR,\4,(W
M/P8)!D2H-V%(H&$(T&Q<7]A/:#^=N_+2:(9#7LHO=*__SMT$Q@X];?0/JSJO
MZ9^ 5.!EHC&D.['CF$CR/V-0=-.I'JN,RUX?%([S=[2//SA,MQRF5E67Y3#I
MVV*W;RQW.0U@M*=.8C/216-+T1H.SW@?=SQ P6!H^>Y*7V9KH!(HLQ1=9B#1
M  ?4FT2O7Y-I\+/PB6M0-RWT\.W#4,<L]Q:VPRT>04"IE'=Z@)M:\Z3;:'SL
MO?05(9<UO6'*MM#4379Y:8O?N+Z>V"J2:2U.BD[1!3VTXNQ+LSM]22H#H/:L
M6*1$9$E,MA4A+3'RS%<,SUP& %Q2J8DEI%XM#17;R5)0@1PW<KI_P?$]2(!.
ML0#ZYM;T:.AUN]^O;__-CN&4$ "XRYU?K)]\!PZQ$;ITV? 4.H/ N3;$8T#E
M-$?18WGY5_E:P1;%KL!SROHJ]1VZU%%'$43*M5;J%ZHW'A:S>X1(-RF>Q-%Q
M@=:1*)%:\%AT:YS?I8TJM( Z 4AM/!YM3JZ4Q(0 I1S7) '=( R^*A:179Q;
MI%R3M+S3NHVNJWFL%E7MX>1D12"X[;QE'+!PSR6T-#E!;FER02NKM,^0>UL>
MS@#ME$T;M=Y(>BS:5AK/LGOR[BKM;; =/7(&-[I^1L/$1<#XTB=2^DHF\<H-
MLY79(E^+\K7H'J]%^WPM>H[7HL<-(#IH;,"NAE$T=_R(OE0-%I6/$F[?O(.>
M0L:Y2UX6Y@N\K/P3+X)!.\VUMZ6*JRAL1RA%'_/9']";\$O?>DVJ39RG\$GZ
MYNV)0]V>2^*]9#I1]-U,J$L@616.. 5\_ I$7IRK1V1/<+SJ=+_7SP/KA.XR
M%6]3.!WA$5*30B;'H?>^6T]-?!>D@;R(?*O?K\DY++L;=3O]:^=[$UK5/"6V
M_F7+>TYG..H]_[5=7AEVG$'_*%V=P:0>2%4]>7ZFZMJ-]*3TU9PG^8GYM)A0
M%4(!5^(W__W=Z+M]$.WEA0(T"6K(/-D3E5]V2MA0MYZT#/]$?Y2/&V+]D R\
M<]6 )JS&P;C^/ #[K)?H! B^+TJ=$, =!O!# CB>OQBM&0H8"A@*=BLJSE#
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MP^% "DT7IA'&\M:U&$FU;)KNA7;2-W*&,[JE@898 "Z$W8D5U8H)8S-X+,\
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MB0$@2QMV%WM>GG2L&VG^%6@=G4DYBW>_M+^S#9LM:6*P-H75EMY]G$Z/D8"
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MW "1V5W%B7('4";U,B@!-NI2N;[)YTBDP19=5?$(-VV<HP]*L)@"LLHC?U)
M'F!1(,\QZ1*W=9$*P;I)R?=O4]#6GN.GHL0'Z2" _BTH0=8/(#5V!@-5UPP-
MB)W;+ VF9XW4$\@M +K1C"B/F94!U)TM"X(9K@K:5\>3KAF;Q*,5,RFLEZL4
M%LJ_5+F[E&=&[<A 9SHZJ1%:IN8)KAB3*ST54/@K-]C298?O,)]B@ORD_75^
M4LY>0%YTET?R?U;'Z4_HW(/_JV<9K Q=?%Z*Y,+W23O.(=R$TF=US:"Y)7F$
M=B.CHS-M#=CUL#^^B&4FO5F=KN/()GY-IL'/PI>V'5#I(FP<?6)A)^>1RH-!
MWZ<YC4$IFL7-4.D"H$>9SH7(I&\<.71)H6B,?2,?1JF%"/(I1,@M'D(LT)H(
MM@G0X:&F0H[RVYY7P6=H9])S4 F1)#,:MQ) FS]%$I/51GE692"AE\IC3(L%
M[=;T^T.CU/+!\#A$L[#&Y4)QL.09")]!_+&BG)8%O;2DTFDJB(9>A_$#GHM@
M1LZ?FF?6O!@?(N2_<S>!O\/5VKG)]>;H02(OOXUN= ^V\J'7TP)]IY".>G%,
M29 :+F>Z#26UT!\,F]D C]_,2^UB>%_Q5M)PDBP)LXR7I+)2^#0H]9D66])*
M:?K7(^C+RP$7SYA**%:]]&XJULPBWP:(QTH6DDI,!$R6%G%60S/)?@:AT-]O
ML:3+77U ,G=!X3V)(E8=;J4;@>)!4ACJG-(Q0<E\M<2)*,<>04Z::#Q[X/[G
M40_RO=__F$E,#(*53%F0KH@$*,-MW,)QT,AK ^3]E]0@5(C$.EE9@#^T(G]5
M?J\LC#=I@AM/BL14'>,)1;0E2LM=J>,6T@-E9WE]HX]V*HQ%1I9XY'7K;^9Y
M0Y23JJQK35$H8G]P7)D&D8H_DU8Z'[7QF1LD%-DB"/VQ<7BZ<&0F?VC3F1EW
M!V:7B*Q?0<0@?/1H!/F2+D%7\C(F$<IE2H5F(;KAGLRD:XF.R+L3)@I6G-'-
M^"[@G("\.%S#:E..B@^LU0O!0H)O6T6*TD_23*TV+@Y@9T@Q8; DVF)5N8_6
M]J7_G[TW;VXC.=*'OPIBUMZ=B4#1=1^:]4;0TLRNXIT=Z3<:[\;^I:A3A T"
M-!K0X4__5G4#($B0% 4VB&X@)VR*!X#NRLY\GLRLK,QF ^_A@UG7.E4?DYO4
M[%?[!\M3<]=[<:7>HCZH-JYW>,M'C>HC)6NWH#Z36*=#:W.XZ:.L#@/<=?OU
M>;ARB,SZV30'N9/IY<@77S.,EL5+=<:Z[H>R[(P6<H0W*Z4!*\\O+MN%998O
M'NNU7[7:G+LN6-W,M]QQ0*-H[?P+6CHOF\M'9:G%7UA9R VYCU8G.XLW4^QK
M$C\L4[AU"7X1[>I]=UC,AI4,_K\M%^CFT<CU3O*FZQKBY=*7:RHJ-I.[JQ*)
M33=S+<1FH>O$Z-+.AVMN_C";?IHW^>6[A=BL;Y4COG&*J"E"7YT8O)$PWL@,
MW'XB=QP0N.%NU2<,S@;__< Y@BT7;7E,8NUI-C"X<:_+FNJP=0JG.3USG8,8
M3<ICKI/#B\E*KVMDG2Q/8*Q2-G4&PBXO/ESE'>XX(5'GH*[/0)13PI_BC?)"
M.S^X00_KK9KZSOS%=%HU2:HO5[9J^'+3M!N\:L[M;-11VO*B8E_-J^XZA9/7
M/Z\%L/&[^#GKRA(&UC>U7N5&:<RR+++YS*KI_M<\T0W!K$XSEP5?7Z-IJ7=]
MB&QT1\2[4;M?Q'FUS)L5U6\J7JYSO(TKNZZ *'AP\Q#1ZCZA1J#O-0(2:@2.
ML48 XL4ZX;MU%O+U#1C[I9R%_*4^"WE>ASM/J3\]P ('$)+<"$F66]O;W93O
MC2]G=0%]J07<"!QO1HAK)_<&@5]'S7;27&50%^&7;\H@O*O:0UIWAU@JXCC6
M;#M?G1:^>5IWN;5V64[:WW>UVE^XZW)-J[)E>FF9RRSA?3GB4]6EY:7PHK11
M2^/IIVK5S&7K&G4KE<5DY4DN)ALW7]_@O)PX6 ;PZ[OYM^K6_>1?W(KY5UU@
MRGN69Y_K(MY20%G.\R]K>J[?M=HZ6Q_\WRALWFH 4(( .VM2T*M%K@2R+AY>
M2:+9LEOF@)MZA_R!S=4>7-)M894L2^D-5WS/#2?M5BYFTU$KX=WMDS5GF[!4
MVIO7L4Y:U],,FX.0Q:]J-M[+9LBWN'AW]6.HZWBK^)!.-56DTW(.K#Y.6;SV
M^A+K.RCKGGZ:W'6@<C"NX\K\P]G@U>,Z*=XL^P@WAT6,)C>=ZJWFY*M@9MOZ
MEUM,L]63:!SD++G)<@=U67!_]_B)Q]X^V[K]S?[MC[__^YO$EV3TQ71<G^B?
M99MLL*Q>X]G@78S-06DBNG\69$/2W3H87>3=2!%W78J_%'5XDL?2MO"&&_'W
M^,NPV^+KE-H=ZCQ^[83429G1I$YB/7@^$(**)JB(MSH\S*:3:4FFU0\"7/*-
MEA@K3NI[\XXN8<4 P&(P"G_^KKB6[]G[S9SL^XTL[OM5RZZN-J1[G>]_H,[/
M!O]O,ZM<')#_MUK%4\HA]G[_^69?;71%.W?3Q7SPW\T^UV^CZN^=OOE[,R?/
MC<E[%<7.\V&652F_E;3'YK,$4JOS3'7#TL]7TZJ)W):;N[,LJ-MM:&_4LU7K
M4.YZ/,=R]F&=LZC[T99O2L+CHQW'59>C.Z=IW%M@5;]E'9!>V/# I]<3.=3&
M$*CRJC](<4:N>^/?<.H'%W&\>?\ED%Y.)2NY^>7]9OE]68FE-)FY_V;7]UA=
M9+Y!=0%B76I2HOCZIP=&U&"].>BLOK-\/W\]>W<V^%!R5I,F5S2K4TM?-MY>
M]MEG5].ZR-!-)ZLNQ)NU]E=Q=M]-L[MN^H';U&1STMU7;[,N _\0)_[V'=^\
MN^4MWUC&JL%F>3I?&A6MVYW<U-%Z#WZIE\M,7!4G96?E8Y.%K!-A9<N^KLML
MNE%OUA%>K+L!#<;EB%1=/'13TY<OJQ?YV$) @G'3JG)P-1UM5C5N&U)3<E=O
M5C8[TJM*I#^0FZ/"FBS4Y/;><JGQ774-1MEF42FUO"%N6ZU2L6$Y7(YL9*-6
MGWQWXUU64HNCZPW]&X<*[*:P-X_8+3.@U>I9-7>['H]6TJ[W(\OR</J[4HW2
MI!"7,II.QE^N.Q07,=6;X%7)(S6IV#*$J'$+UVV9EV.!OM2)VU4;ZW+!57GV
M]7OJ)E8SV]2X+F8%%!MK6N\DUYW9RAYR.57T<5D]L_9*2U_CV>)R59+2Y'AO
MUIS6^EUK[DJC8=^Y[_O."O:=8=]YUZA/OU_CQ_OKJ/9]1IWWU>+J:IQ_[G34
MI\\&/X\FG0Z0ENC\[CIG4##]W5*ZDWGQ+U[9N=TA_#\8B.U=:.?!7M7T]I?1
MM)S9GN0;^U#<P)=+-^V!MIGW"XP?K;Q>%\ MK/]R,V/U\]HWN-8^D-J-AI /
MAGWEFT,5LNPK^7*\3_/G91/8_ZMGL_QTW\[X>F!-.0WY[?([%I>C+'<99-_P
M$,MM-B[@3=>_+*:.\;)#/UTL7])<*4>;9_B/J]?7S52NJOAB5>NP$DJ]'=^\
M[[MR^7S]M7M:&GXTI3LO5N]?OBB_*JS%55_.T#-#_[CI-RZ7V3B.?[KG;>H,
MZZ^]Z]__-)_=OK6E^UH_B](II!1T3 ):JGVJ__OQ4UY[XRZ_:)SF\HN[C6%[
M63<]:$RRF_PQSNI(?JD[EZ,0QG$KA"K^]/)7LZ6/7;_[F9QG.[B8Q?3G[_ZE
MJ29_7[S^98^?][/X8535YY#?7RW<>.3?6^_O1XXBPKN$55\UE&+LIAM&W:2W
MSA?4+/=-NXW--DP:O+Z^S<%OZ]L<O*UO<W//ZN?1[')M,78WU/L&X_S^[<OS
M-W\9O'[UXL86WW_\^^AS>?NO.;2?Y1LLOOO/[ZV3CFM)$6,1(\Z40H9+@J(G
MU#%))<?BNU4+W]_*4WKYGM@4%9<"L< CXC8PY(1D2,@HD\:*$LF_&TSL95Y?
MB*,7YXM0NBP4,;P..Z+^H];/KW'XQEK_XRGD^Z@K_W C")N'_=OFG7RZ3VNM
MK[XK:3\N!6'NDB)@Z4Y8NFRG\+YIIW!(Q+P12OQEV>7A77U;FZ@(EK.[Y1@"
MEM.:Y6SDKZX+=CMC0.]N5!2_6=\@F%)+ID3!E/9A2F7K;A8ORD;;Q_B^;(AU
MU*1>;MYH/:<93*LETV)@6OLQK4E][VX<W^<E-\-HWU?SJ?_[^ZY:6=TSMAR=
MB+-J>=Q^\-,_%J/Y%["VEJR-@[7MQ=IL=?&^/K'74=-Z6:J_?BXW"*;4DBD)
M,*763*DNC'\_G]Y=,1"6&RWOV2&MZ]=5\?[CMT'!Q)YF8O(A$\O_ECVC4]Q;
M@^4>\W*A3+)O99*Z-V62%.HD6ZF3W'G1*\VMMUJ?OK=]V*J8A_:].UW;])A-
M^<X?J][#]*;UY)YE%F;=0/HO4SNK)^F]J@FFM-3,/^RGDO*$CJF_N1I-ZEF;
MS3F<;ZFIW..AOB+_CNKH_RY[']I2/A+#]A'K!\8'/%9C!]^73WW9?.8/]QP>
MVCR_UTQVN9[P^-5./_4QL8T-A;+S,<QW>6UX_U:?_UNV0[ON!U6?XZF'6:[&
MLN0 NNEWLS[,M6SS?F_WGI5)K^ZX.93^_6I42=U3?I4PKL]4->V1EF.-OWIJ
M?37T^"QS0C,'O='QX2,/O2][,M5'P<I)QG)>;#R^[M.^/.>X;-6YT2UVZ=2L
M)+-\?J6M]4//[EH:3<?4<D:N_'/=E:GN!CRO6GX*36NC<D"_/.6ZM5%SU+ Y
ML9>?05;K,EPCK,9/CYI)XWFU9:;=(?I<=QL7[+B:W@"'X7T-M:KUY.[E\UMZ
M BN5V? (WI3YLX46E@SX_5\GHW5VM?IAT-35_3#<5+E_JZXGU=73R*?CII?[
MM;)>M\B]!UTV1@GYV:A6_7).T>;[S&!6GZ)\O;K&R^8:]8X)_;'\^L.LR4V5
M07B?IK._UZ-6F@.BR_O,6C>/]2'+=V6 U+1NG?5F]L%.1O^\.6GN]QR A!QW
M-.]JYEM_3S%A@[3Z^!_64Q&7T\D:\_[O>F8@JQ<DRJ' ,J:N/F0X6$SJ'A#-
M?+(E!]:=K:&OS<-Z_I?ZX&W!GZ7K #!P:^A1%>_FE56WQALCT[[<8HM_VVQ?
MV!S3OO7Z49T"7BIS4>7I31=N^4'73<7ONI<;3<IKM&K&[=1MW0=-W+<)^RG'
M)8/KR'!C4E-=U5L?1:^'XBRG0#2M"S?"RG7OO*N-@6TKN+L')6LZ2C'4!\@W
M#LN/[:?KN* >5^_K4O_98KR>Q_-A.41GC2+OKM]?7O'3Y^6XE0U067UDO2:@
MM]OT5F85+.IC_M=*\WB"JV4Z^/VBM%2__NM28=;3O:[&MGD.JV;J]2,NEZH[
M8+BF\^&Z:WW=VW[6M-2O^\JLYD+<],QN&6&:-<2S]NB* JQ>,EQ_1EC4'1&R
M&UJF#93^]?E&&I-<+W[9'FEYMXV#-/4QU.?S:]=UW?^T'$RO[KWL2DYWW?17
M;FFX*;#;MU#DV@!(:*RNR+^^E643@(T77W=[^IS5I>C$L&E$4/>AK3LN# >Q
M3 0M K]NI%H_H[K1Z77[U%6[GZ4S>M>R;HBR]IVN;Z"9J+'^\+O\SU6_@'!C
MPM5UH]?59-QK.*V;-7R*97Q:=?L2JPD:2^??;CKR=]]\MHCE-(5&RAM&L9J;
M:C=5U:V)<R,F 5_CP7*" MBEXT=]5B.[<]EEG+65UKNUV5DML@5M+$R>J2/K
MR-UA=BD-EOWJ83=P?UD_[+J;S6(R:L9>9'N;?JH;SJS^;#.4U?[):K[M<J;U
M*OIM/NL!.UXR3]/%Y?I*=<_M&[[,C3\O_9?FT_TZF&D<"#M_,?B>_+!,;S0T
MT !8W2EZ$QWKBS?3K)><L/SDN[DK?_SW](?25F4Z_KCDX=JC&M7Q>O9HQN,X
M^5 #]W(V;DGN3&LQ9LS\//C;(GQ8XE<M\_6B-N#N[@<1IK&9&F['37^7NE5+
M"<LVX.RN$9K=LM?^]7R]VR.8V[_7[=6S*7RZF):6ZT4[/C4>?'Y,P[H7T_7C
M70U$O_/9UG8U7-)6G1-8M_+>>K)W?D AM<DF5=_6=%""I]W,NNW\:+["E1U<
MAV/9*#UTC0*%(H5=BA0,%"GTW_:>ITBA8XO>:B?QZ.X16CW8/.))K2(8/E/R
MVUM%2'-&^5-[1;19+<S(1DEIW:%C]<M;=)]?OXW.-]^^KDAE^ZDBENT%4=L!
M]6ZQY'_&2<'Y[!R<KT:Q?^.Y_SX]@"? Q*Z ]\C*^E,UB?;*B7;3_U>QRE')
MU68(>S-3=(I6T&H9_/ER(FM:E#1#J.7MFCW@>FP#6Z<.OE9<T6Q3WX%8ZT&\
M&^UPP]8$K&87VZZR._FJDWIR;!F5-EF6/ZQ30;'N2EP2(.5^FH1'7B::Q=)J
MNF;S<K^CL"RTJ)LP,X(W&@/7XU77%U]436R<X^1Z\WPZN376=]6D]WKTZN1J
M41KVSB^F&X.!RW"O:CVU:[!R+U>YG_DT6\"&$)J7YYLKJ>EZ1[M.LI>&RM.K
M9DI4RK=0<CJK)F$/3\]J+K 2^,8"2QKL#X2=B1MMOC=+=<*J+&?U[CN+6^H+
ME,E6?*.C]=E3XNEO3JH>KE-_2R97TBM%W>X8$[UN%[TJ_FD4YO-5TX3[7C5I
M%*F>REVR@?.EAJ]R@\W&Z7*&WBI1N#G<>76]]4#H5>OR^I?CY4UM7O%FM_1E
M84=IBCVJFBJTZX'3RSJ5<5,DLD:(,V#B_C#Q?TT_E6VQ\Q"6A3;77%RXHFSW
MU7I]Q,3<XB;+8_?EFUWQ55E3J=TLV^OU)L!RDW/Y)#)QYWM:5AS&:O7K9:5A
MQIHU8T[*IG4V[*515@WOWE5=4F\?5TU)RO)B]>N6P]NO;#.5?3EH=!,;UG2X
MN7V[AH;U]NVUKW!S!V9)LN5:?ZNG *RW89J-DK([T<!665D9J>@+BTXV$//1
MQ-HTKZ_]FQR2NV65+A#:MZQE-<ZV]LPV">Q;R*L>J+'TN.)J=^]VN<.JBF!8
MBA+RLR^#(V;YK5-7Q=G'U4[(/Q9VEG$IZ^AEC$5'JJ9Z9:/68.7\K,J4;CS]
M)3%GA[-L<RRJ:O7!Q=E=5-<>\>9[5I_X5>MHBK%*340SJ[B4<B^N5B6;8>KK
M20C-AY:9H-/9;.J: 1]9'!^6I6'AH9L9+@55.QF-"+*K-EG44R(RK2XNR^B6
MN.%0W[:S9S" P4/T#^=O8;D']I-:7OR?JC_=N>WX#1?[[NZ.JII0X454"$MI
M$2<)(VT%15I(JYP/@CG64D?57^U]8Q6>79X_S2:9<O[57E[]./B_#.L?!K_\
M\O8KW5A/3.56YYD*-]:CL.]T\VSS:+.O5O(<%!-QZ.WGIYN$8Y0FX2F*3$K$
MO3'(,.&1X%)R38ADD;=D$K],FQ*;CCSS=S''9*5FY']M=9%?/=^HX@>CR#=Q
MX^#(:5,OU%GTK<["X..OL]@<YX#/B%8/E<D^N55"1V<O?>/A]P.TEWA,N^_#
MR_'.5N"=GKIUJT_Y_HFIXY;P?7W,9+JH["24,RJ?R\'EYCC[ZG#,ZJ?FG,H/
MITWJ_1R-(\V9,%^M7-I^'SD37YV-<\>[=G@+.9-TA^$]NURJ]VMZ8!-/M]2G
M<ML(O[T)8F/13^Q;J?<*PWNK> ))?9.DLIZ6O_SY._E=&U);N[ZK\*A06O%3
M!JN8HC-RW;GD\9$%7M<%)OM4TP<$WF /9MT1^2'*' &7N_&(0%*[X3(%7&X3
METNM'^ Q&'NG) 7&OC=COW-0#AC[<YXQV?:^?)9,\ON>WG!79>6!1S<\G^J?
M5]7-;.LAL;F?9Z?V <T='D+13V< 9 ?&"L;:$X4[<MEU=8S5D3A"C]L77_;2
MLN#_ *1V Q8 4CLJ.S!64#@PULXF@A[EZFSV'FW.4=^UNI8<HLVJH_IBFU?'
M^ZCFW+^_5.9SK,>EE)/T'^TX3G9RG1XC^E.'Z,=);S+MI^QNJN;CA?:';FA;
M-_"Y5?M>GB+Z>69]TSNC.49$J/6.!J2E4XC3F)!5VJ"0K'/8.XSYUC&BQ!GE
M+DB4,).(6R&0Q5RC)!FFW'(LG5\=(UI4Z(.U5R\*NIQ/0OGGIVMH.9^_M+-9
M&3SU/W:\B-\-%I-1<Y6_OO_KNU?9=\E/,'\*^ZX^6W]IQ]6?OT/YI[IIS?S/
MWXT^SU],%I<H3.LIQ>45W_T'5T-#\>HPT&K!_W&BEOC,@ 5P?XI*!G#?#[AG
MB02E?$2$Z8@XT39#MQ1(,HHUDSII1F_#?50N4($38EJ9#/?4()VH1<R:&#46
M(EA\2+B78H@E![AO#^Y;3E]#^/8,X=N[B^ELCC)T70[R;?P]+@_)7,^-^MY>
ME@8L_USVY*O[!>Z]!<K=*&0M$4RI@(A6*:,0"<@H[9!-P@B2(HDTM.%TOHIN
M?CTYZ_RC'8V+5'Z>SMYEG#E?R>-E%L=RMZ E2"**#XF6]V+2WN3=V'2)X@_U
M;+F53,; D>6"(JX50SG P(@FGI^LLS(_[388YF#/EFHR))0^_[,=K@;0U3-F
M?^B&YP1^>J]DU\]@\&3<<QL2QEYKA(77B&=O'1F'"<H.%Q>,!.]B:H,8;\/E
M-9#>A-7V69$I\-1[;8L ^+V273^5[&0 GS#.@J0"!:FRMRQ##H(,94@SK E+
M/!IJV_"6#P/XQ55F3 '@'S(U SOKAT[-G*^F"LZBCZ./Q0R'@TG\UD;B0.A
MZ$#H'2=T)I5CB3J$<U2&N)866>)(:5SK _%,)F5:B>"6F/+;&E)^C2TGNC@9
M*D: O/ML=P#NO9)=/Y7L9, ]$!69"0HQPRSBU*D,U%$AE[#6E-*0L&HE6ML_
MN#,U--( N,.F^2E'9J\G'_,WT]F7;@ IL'6O9 =LW6FVQC[0DEW-?!M=#L42
M1\YXCW# UOO I).MA&)K$,DDW1([ZR'G4,#<:S,#+.^5[/JI9">#Y=&DQ!-E
M2#+M$0\Y_+*6<41EAGCJ9<*IE<AK#UA.> 9S#6 .>V"G'&F]G<4K.PKUJ,Q)
MM9QR6L^V'/BG-NH ]CX4>[?:7[+SN+-7-=Q1E"?C 6!'0[02(ZEH1)S:[ $$
MK9 QEEH<0Q#!M1'-+8'JIP:GSB?A30&IIHEBR^609$CUP8MC6NY<>MI&W!5!
M 9><M!H"ESS,)<(G([EW*&A"$%<JHOP-1S81Z:/T)FW/3MTEFGQ6+F'JX!G#
M4^.20V_YT><,1.EQ!**_3^=V##$G^ G]@!CP$P[H)RCO+%>.(9.H0EQ&B31-
M'FDKI&0N.6EC*\6<>_ (J&9#)>X_IGQX:SU*EP!H VCCV-40:.,K9:)"2<)*
M"XQ(6*: E)"CG.<56):I03M#MVACIS+1/= &)WA(],&W*T^--F!RTN$CPU^F
M112E@1*,#( NY!WII U=R#LJ.S!64#@PULZ.3(*BKF<IZII>9>%\J8NYRL2
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MC3T3%$#^J2G9$4+^O_Z+IH2"&L*NXBF%J[_%:CX;^7D)1VUUT0UT 0KKE>R
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MM$SJ>$@9E,/TVO( WGLENWXJV<G NQ=>2YRR?ZU91#SAB(S(>"V<B<Q017S
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M;7>,%, =P!W '<#]'L^=.$>\+&T'L4:<<H.,T@K9&*6)RF>/?.MTQ2Z9L^<
M=XR'1)]6W]=6P?W9B\OZQ1CMGF LL!6K>=T/?3J_B+/!J+:,X6 2YT"]0+U
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MC/V,ZK*2DYBC,B,4XBH:9)RD^8N/FC 3"-OJR[A+AFY_E$&I&#+\[66Z0!E
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M6?NG9I%N.@[[><[?W*MHI0//@9"U2W,-*N\+2LWB19Q4^8[?EZV_KHKUY29
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MXS!5;1STVA^1E*DE##]Q)#*8-A )$ D0"1#)KD2BM7">)HNL33DB(4(CZY)
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MS$]+Z E/+[4><BR' D.@!Z8(@1[H72_UKE4*J-L%4U!#4$. /]"[/NC=,WC
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M73_U#A)5H(8=4$. /] [@#]0PQ-50X _T#N /U##$U5#@#_0.X _4,,354.
M/] [@#]0PQ-50X _T#N OY-70VBT=OCZK+IB CE;Q5 :K5W%265+10.490$Q
M 3$!,8$:GI : OR!W@'\@1J>J!H"_('>]1[^[FF?FW2BQCD4L8N(DZ"03A(C
M*JV6G%%',6ZC>=AY^-NBFE_F6ZE^GYYGB9=[L..W=A1>3U[:J]'<CNN0LXXX
M7VX$G+_%?RQ&55[ZNSC[./*Q*>C_+?KIATG]*?7YNY:.V@DQY JJ^,%V@3-
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MI[-R9^?S^6SD%G/KQO'WZ5L[R_?_^%QXE9]7_NXK27$Z-,I 3OPN-7N\1OT
M:  L!"QT1"P$3CBH(< ?Z%U_] [@#]2P VH(\ =ZUWOX.U0.(IA(I.<"2:X-
MXC819+$EB%B"!<%*$RG;*-B#'$1W0:#5' 1TISM\@5XV*"C(ZY4_X+*NQ]GZ
M-V?B:CZHIN-1&*Q4HBO2[;S'L*,HC]"G.$Q(]8#\&Z3'#)3Y"-Q?@-F3UDR
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M[C?B8E(#=?6FI!9Z7GZ#;7]J1.FFX_ -3^HO=FPG/@[L?/ J^GCIXFS R'!
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M_P;I,0-E[IMG )AZTFH(F J8>C3*W!5! ::>M!H"I@*F'HTR=T50@*DGK8:
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MI J.G/3:U@#0>R6[?BK9R0"ZH(8*'!EBA)G2W%XCXSU' 1O.O5.8F*V@;"=
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M>5DFIM@$(%%H87.C".>%)90*#@ D$I*4!2L2:QFE6R$?QP5 11&@)T!/@)X
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M-,\1Z"T# U33[922_;@VG5@:3DK?B'FU$--?S&+O%N?!<PEOX4&/CG$6-G3
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MOOJ?9% M1ASH7Y/$\5\W'GA$1%C?4N^:<S&K_NV8S54%&+$DZED]IPZ[;H7
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ME8TX1\)5BS8"V3M4R3B+WBV;+6+#;E\X.H'HG2(CP'+""^MY4QF0&3":,9?
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MIO,H1J\_[_[#F1!Z5C ^_A]@_,\Y!HNS$B[:SG^_^S"_3KXY*A7U0/['HY*
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M!VS.8T&2.%FUDGTPDW&UV^6BFO:=-V 8* &Q+"9VF'"/U]A\H)Z[APRS<9T
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M?XP2\XP>JL(\Y6<)?7BQ]3)]Z+WW>/&113??.8?QI@V7TM7A_&Y=XW-,?\C
MYI]V@-8#0M[N$^]V>PK#O4C[!;+LJ#)#'L2$C\]Q-^C_LE!)9@4Q&C$3<ZJ9
M25(P+LN\$%;DUFP=%^5ESG(#P%I8]$Y@-H>(F2"EI:S@B909EW?6_WOPQ$SO
MD?U(6J->Z66# J$UL\?<-5ET;433#BN]:70]W$2]!Y\!UHW?M'NQ$L5+KHN"
MZ$1K(+PPA)5%231H+(R!!9<4:G.QLA*L?\$%B34L$56Q(%*G)4D%2V*C*#5)
M<D*+5=YIL8X^#>?Q@>I FN$=>WKO,J,"4ITX4NV)Y=9I@[*%5)_(1:5A<5[]
M^ =-#2TDF&@R926AB<@)3XTEFELPWYBT0F6/RKV_8MMD?P*RTXS&(Y'&7((I
MC;:X<QE$>!XQ+-#Z?X*H.F91]6;+7>1/^#I'49!906;=K*^5NE!E&9=$%=IB
M%W$&0JL O1GT-"LUBT6^I5RGL<BT2@01-.'HQ+)$I#PF,>.Q9&6:\#@_(7WM
M=)1K8[DHF.5$J(02:@4@C$D9B15+F$I8D6J[=<RFM;1I8DE!8U#($P DKG)+
M,LZ4SF#!!#TE2R@/RO7I(]:/MYY%!, *@'6S#+1E' L )Y++$N09@T],<DID
M428BRRD(R*W38!,K'>?*DE);D)N:62++4A!6*I999=)T.]3@B&7@Z0!6:=-8
MY[$DM#"&8&$BPG/!2:*E ,+'/*5;U1,U8%F"04*Y*7, +,,!L. ?Q71A;)(+
MFQ4GM%C[\08-Z<N[XRT>=C)WR 2)+V[4? QS/M19Y"I@' ,+"9Y)#J?W&&BY
M%B,^6[I01O@:@S?-1S04/[I3;PPJKQJUO&P7>)R.)^48^-B%="O1--?H'AC%
M=L_\6_!._P&5I7ET*:ZC6;W ,'$\Z(=7^#C'OXEJYF,DIS4&3?J >'\G)B/6
M;1^..AJQOW2"L>C]R?W$']!C'F1EJ_60I[6PIG:5-P3#19G@(A!P9B[TO-$N
M;@!O=S<O6]^F_<+LG)@;!$ZL/TL%.KI7#"/ P/7Z:A;9(75I&$+DHAJ )2[/
MHE^-B3#G*4KRR5/EPSXP?.>#\6$?RP8N;8\J>1<9Q5,Q/G8J.O?Q<5$/!<-E
MW6 TMT="#,UIS+EH=!^0L[4+QW$[VG&$NPX1+3);[8;O%#1X#*18JQ;P!!&,
MK"AB*Q-&\L0(C)7.B8Q334HCN5&:4B9W%)&^?P3CW^I:8^X.:$!O9R#3SS%7
MY[7#A<V_?4QC"&7\3$Y%3[3(4RU$,6Y3IM,[A *=N_&Y)"*2&.6'%>Q4?2D!
M&YVPZ:,%.X$R E6G%YQWW.MC$9V@JKK\LW%Y!I?A4361!5'ETS[ZK \W!)_/
M'J$^, &-IU(7/OX0Y9S3DKK;,1#P+*SGC>N).AUH9YBYURZG"[]$2.4^^\<I
MA-W:HP8'CW+Y@:!NKF+B'#,L&C%KNWP!EQ2C:],ZO>I?<'%EKW%5=O,,9OEL
M<5KC\@V;A>,'U#:[)=UQU(7!>B[I9SW6U*7[=-PAYC#:3^[&GC>6K3B'B8K%
M FAWTQ"\!@XOV]2X%^Y ;5WU=LJL4Z[KQNFF0W;E^%;SJ0*FQ"RD"_'1[-0>
MCBOO@[&RL)I1P@')T"'-"& =)UIR&V/^>%;N)TMRH-$[NXED/Z*8,,X&VDX#
M625_O/WEQVT7P&QY.;@ 9O51YWXLUFO47.]0UEP&W0:K/G6R1JGB)$M-3FC.
M&:&9S G'J![)DCSEHI#&/+:JT_\45)R[-)7HB!60<(,@F%B B:CH2T#8,Y\P
MF[WW%@P@.&_P[*('(9>Z/O*7+!9-)9>(2!42L;*5V*4R.0\)_(2QUY4/+X=-
M=9LJ=0D(LVR\.K12A!QT^/34E39UHT-H%KU3BQIM-S#=>N/0-N9?2[@.+@#,
M&CF*+F"/.1?1AL_HJEY.M;]W6OV)RIPK6HSHWN7\(UU&RAHZ9F8N L57UK)=
MSB]6W$(#$T5X&TDSK:^<>V5E1:Y<4JO9&OR(+JN;YBNO?9IO1Q>\VVD="U?N
M" :F'"2OE4&XNC ND:YR^;L[Y^;TF ?-#)ZXJNU\TP0]#X'J8:,K$[6CP4TZ
M=>(*TUWJNG7U$^3U7+2>3\>36V4J3_#Z/IM9X$7 C=U5 ^5&5 -=R+]]4SMI
M)^O.P6'F3@&?3FOE%+#5,]N.#71?YV%$L,5%4R_/,<][_!Z?Q;/**[J/H^\L
M^JWN=?^3T:*4C$N1E)J(,DDPJ1HPT\(_EADA$Y&H<K_N@94V]1,H#B]5:0*^
MZ;GTCI7[0HV^AP+\D=7H8Z%&WTNH,A=J](4:?;<<01]EC;[L837ZZ+YK]&4Y
M5XH7"3%*64)310D(+4V48#*A6*-#;H4:/D0G^0D45&/\<5FHLW#_(\9@MZ]B
M(C;JV$5@HZ#1VM=76/AHA"[= 6LS@0$[]U[FWN7:61)#4H0X;TPGY-"N=+6E
MA@S621^ZZ*I B<9<U!A0 "9E;\@[*Q$,D5JIY?SZ+'JW\7@7!4AJ2_"^K__S
M/U@*,O_#N]_=I^3;;\8.]LVAK3D,UD]6.M-4]Z$<KJ+#U!N6+KH!Q$:-A!8?
M134=*@RBM8H#Z<]?AE(,SN/AG2'K!I]=NBA.H'EUN;SL!C87UYUEUGM%5@DF
M9Q',;I@5'B]T96RZVEGNP"?R6G%7JV&M? ->M?&62Z'=:J+9;2S:ZJM7PBPO
ML6:78P%O%CK;V_]:N4Y<[HS ER/$8HRO6T>'J3_ /S<SH#JZ2W3M['[,!:O<
M<-&6@!V+/@+$<3"8H\:]82>U\)FW4PLLY8&!^RH9>!>,LG$3 ,( YS7UE:N@
M!J\"8_<"[6M<Y@J99%63L5L?E\:_P!DXOEB_'1G3>V\<B7&A1Z/<M98B:BO8
MIJ)Q:^F/?=IU-AD'%ZRX"[2(93L49[MI:5SP#0[]"TWV&R!-:I4F+*?$:,4(
MC6E,N-2,",HM370!<+=5I"HQG/$2P"]/73!BJ0@K4THD+P#9="Z2>"LU]8US
ME;V==95"@=SO&Z!P-9^:U5>@/<VT "OZ]SE._K6NG23Z'CZO%ZG"7\DE#.H"
MWT*TN"88?D$>'+6X;\'[?P6H.<UUY.,_XD>(2MU[^(<KI]KQG^ZWNI/5SL?E
MCXF[3?LXO%@*$:LRY22-<XR.!:5)<OBD<LZY8H5,V;9Z]92\B(=I8S:TU2>C
M2:>('<,BBF['G *_ 2NMJ!T-Y(X\O0?@?_WK"OA_J<]@.R4%B=/3B'4[*H)_
M_5L]A[T&EM$WQQMX]J+5]3>F07V\E[*=#.ZT],AO[=87\H([-.H&7C?J=5IW
MQ[<CU;(+#-'H#NVB,N ZC%/I'E;/IET!6W^NT\"M]0STD^M(=:-!C0A/+<PG
MTZBJ->M/ /V]'^K8,.@TPW[LH/E5&H-@O.YW#N H8-;&'Z.!'C43F\UB7C0G
M]*:7U^.CN7,"1&;J_>*C"%5_F :$->[TI^<9=QI7#]%D\/=LT##G\&)GNV'P
MTN:W$[S-'^TNW)G7A;EV/.2P[@Q$\/:#G)* U^!;W77NKZ[:G%XO-X=5B1M_
MXNL?U%TVXB-O5M[+I+R>=\6)>\MI>,F.F4^B=HDQ3N[T&+1( H\4T>6HAIXS
MLE8&L+/)'/&Q$+LG;5?A^;-U1%?&M2/3A1A]@?8"&B579HIKC?JLVQ#.'',5
M _N8L'X?B5&DV7P5.P9;U%N[6YO7"0N_;\/NVDX5<=MG[&\XPH21MULQ32'Q
M(R1^A,2/QT[\V)8+76U5WREO,\OL21)%7KSH_FFL,VP4T;TQIGGPN7J5N)-Q
M7M? 2.;!XWGNM%+=5?MUCK^5DN&OGW0JAN_8 &M]X>3M=3O9<CBWG>+M13 @
M\9K"\\#A/G'H:E:H4N1"D,(P26@N)&$LX22V*HGC/,Z5V.IM<._:O!]\YXNW
MG<OXI\Z)?_V+P;SE#W[#O74%?71_43@7NQ^.^=XB/?6B@<83>(,7;!V=HX[0
MP[5!]JSU2?6$'(XW^A.GZT'M!S2HL<IWIQ>YS?N^U]I?]R;RH+B[@ <7T8>Q
M@#/0CN8+#PJ  RF*N.[<I&L"!>)@.5NE>E1MNUS9+'>P1YQ94[DU]JVU5L,=
M)C7TK1G*DAMKNW#,M8.=KD!YUQMGJI;(0N[0Y8;K?7J)SVCJYM#9L)[Y:@G+
M[M$8R/%OT]0K<8CAF:J:=WUJNU.8KC<-'OO<,DI0K3^B/WX$PX/U=3%R7&"-
M=H!F9UFC>)XMW4K 95U,[%C\C\)_\8A-">=C^=OKU^][-FG7PW%O(^2_E@*K
MTV%?L?[HR 7,"G51F8_=2=_H-?T;)EVSH'Y:\Z8>(F?[Q7F]UO',G9TY"[+!
MJ,:F._;;"&A>5)>."G;'2[M>:*LW37T0H5ITAW,;;(1#=R2'K=>ME[.PAD6\
MS1_YV:"?PR3"WM AS>3*V*P@1:QS0EFFB4QB09(DBT6L&*+H?KHXNH7XL:DO
M,<P(PTS_ ;+F3==6[W9PW RFN<N@_T@>!5,1&4X?53]XI>_&T+F7")8_HO/
M98PX&A$?-.#.>E3'L>U: +X+G7"- ? :$#?SC02$]9:*O2C"0/^QVOTJ^CKY
MIL\LN>[!T+W/^YJ[=W\;?9U^LR.]H9.AEU7;1>P[#\_0H1)U_&[$OH_0@%=K
MT#!ZFG>?ZJJ%N:O%*' ?%VX5D^"'!:/*OND36;S,'.6)NKR:\6MZJ$<C8N8Z
MN0U^3]<[17<N'W@L_6;(1-C]W-[Q>\/L=O4@:<UTBL-P]P-%4<Y_G7^S6HT5
M8. )P]?.G_2-2]Z A[:P/ ;@[88W!IMW+8JK04#OR2FONY@;I+ZNQ/D,E#\
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M4BJ'<+4=*:[(77Z;HVNAJXRL/WK=SJ[T@CYZHI/4:[$3HU/,SE^&K+<)@"Z
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MRWN.TOWKMRG3) 'O%G>L=BO9>8!X#TP6>(&3UKY@F@K>2(RWOX5P#>\Z7FH
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M.K6"K?ZUI>B>='R&\04^&0'W2["S)8-=#/X;#LJXGJYSV0FPD."RHMPP%(,
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MJX-W!+YQZPZ.4=IFG\FVJ$-W==J*:Y!<]>#[/CDY6T?,QY]^K5O/2Y\.R@\
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M&5A%4D!04E_]'2D)Z3U AQGGY,LN/V$]BK+^F/!UU*1D=NI]H\DT24! Q]]
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M^'8I_\<^+N*ER'-AD3.IH":ER!B&D<^5X"2/B4;Y(?S(-13\80T$X>>QCS^
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M/^:3=@8_E[.+K)K7655_U)-%#I,>P[5I920N3]=&>_FSSP#(*IM./ZP>"&.
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MCU<M7W+#2+"(N-BU1VN+I'$!?#*I!"MRRXT_5)+C$F[>A?<+K'DS<3\ND>;
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M\H '\8[GG(X([T7"SXTJ]VR-B8%?!GX9^&7@E^YVIM?@7UJ'1%YXQ&2ND2)
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MN:1%(0CO1F .8I,\_TRA'BO4GC#.,E]DM.D'I3BC:],P3F,SP!68.<G!P;$
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M<YS&&MPY8L1CI*RCR&J;8V]-480'-?5X1IO3:R563T&-CG4\UCGM"F ZE(<
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MOV9A[9KK1'CK9J?C8MJ4L-GYI,01)8YX;J=5XHCC+3(J&C@W"24M\B*CA)B
MJX0D)3@JX21EG;8^"1./*1&(1]PL>"ODI,6(L^@UXX&Q%'H01_ !QF)@I"QQ
M1%_BB-+&YXA!Q&Z5WFI3:!,97"TUWEOV7&"^GS#?<^'U"./O(ZE7 _#8>2JD
M=$@T-)*Y;Y\S%M)_YIVP5'OO._O94K0ZX!"1=%Q#4. 3LD0K1+3US@+R^W#3
M?K:G G@]P/ ?(T_8U.^5&&/?9PEZ/@S/ANXW;0KHB>,M^'XWX956/H=3Q-+'
MY^88P1N<M.,6&2T@JP\F(>.;@G9/(C8Q:M+=\TZ("4I 9 #'0%S!&;+8P-F)
M:RZCIRF9YX\1Q$!J.2 */WN(<$J]=E[")$'I%/@X3_%Q"N9Y74G4IF1J*Q99
M;PLL<<8)QQG];J1S:I%&:9ZSIW A,FR,Q[FK,$0+-&ADH_5(1!]82(;[Y#KS
M$9Q1[H)$ )(2<0M!BL5<HR09IMQR+)WO0:R!FP4'Q9^PM]]#U/!5A!NW=-&Y
MF37_ND+Y.]=^WW#Y_H#2H6NI]Y4)7T^\Z(RT6$*FP8TS\,,8I',_ 6ZBU51)
MH:D_!,_6)<5B4_._V=_X6]ZSE+<\UHNZL[VQONMN@+N\Q>'H& L;X\/9&/G+
M8&/<NW17^A'<)C:*\1V6/?NT9>?)M\)DHO\PG;5E9)F 9=00.*]E-<L[DIO]
MQR#)788L?(4AJ^&Z6C'-A,WVF0UM#"23EY?-%6OP6)GN991&</A.GKFN:+^D
M/&L"LU416V8'#BV535Q-?->#JW3/</IRO+#@TX?5W[>6P5<//=BMJY_-,Q5S
MPW)S_2/N/MN&/K^MF6O:SC9,_<V>(3N:KRKOJL]VO(S[&147S<%Y(V/^OIG5
M'Z[F\*\4]6\F^W,3A#PD\>MLU#Q E?%LWM[Z2-28EA+%DD=2Y65!"[]9$1,*
M&FNF"*.Q2XW)HZ0I6H(TR9.#RBBD>9)(1XV3\\)@UJD5:N#8W4Y(X*X2$OR8
M9=$<_#=X[&GH<BJ&Y7S#J=@+JX-_FE9UERZ\O\2(*TK!L_6Z4Z.OV3K6Q:JY
M,]967XRU7C<DA)=Z_;?E/'N"Q9K>J66\7_'Z;-@/!@WG]VK^::O[R/7;7J:0
MQXPF#6_B56/9,OC6.[4,#/#\@[4!@<DW6\96S%@;QO9,+9^Y&1L#A9 *$K"+
M;5Z_]AU:MLB6V*K]LB&!!"N/U[%GS;;$L/)D^QY[)8[<FF0TWK]Y\AZ#_01D
MJSP$)9B)*'!J$63N#$&&SA!Q!C)W'R5AG01?26N)#0:YJ"&P)]8C0T)"0LD0
MI? TF,/3X:S(2M:C\]-T_I<L_WO. W2H6B?3?C.UKCEPYE<U\]J*L0U4CA:;
M_*?1_$]3L(;)CDFNXH8K"MW817/)TB3FAACU+J5YKSI&_;C#CP/^%3Q"%3=,
M8[NL;J,<>+;N.<\ ;'93Y-ANU+30F"T!J7SNM!%SFY(<WOZ_)9R;;]&R %_>
M;(<Y\6H\NU+W%7]B]@X-1!P[AB7;,>SVW:X&M+/U75?(E,/5N\6J]I++>76#
MU4[4C=!WHM:&VSC$M&;)N_*<RTES2X!<D/LH=_BXC*HO/4XCZKK%]%1]:(F(
M*H[-NXS2F[\ISV20J[BAZ4D*X+_I[/M^&IK'(D;+875)436^V#Q&,QI?LI0R
M:U/S%(/]6VF?,^J&0)DH[ -2,>:HFUOD$@F()L.%I59)T>D=+8,W2FB!I#08
M@:0"<A1;!($Z992S"'%WB;I?2-0]NDO0_>-7'V>+QL^L&Q9=Q>AISG+1V@M=
M^J"K-I'O?<L^M'W4UI_B),Z;Z/QSP^7Z.;>P.Y+-8!L5P3(@'0S-C#9@,TY
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M[3]\@HY[Q5A/<K*@A R/G%RX;['*5=+DNQ EK\]]:L+D_IM@B3?ZX<)*O'$
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M!7G.FK@BK =R SXA!_A:#'M$K9]B<?O^X>YC(E8W_^.?MN;LCZW7#Z:N[L,
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M.SNR//KMN&\%GVWLO%&WOP\_0'@ZC[9>@K']*\ZG<+_E+"=-$*7"<WX9+<X
ME\_M:-+X5-"LN@)W.AK;>3;.CF75^Q2O+IKWH"W7/=*ZOT-6/*XHIGSCPD=A
MKP\'-]0D4VL7GG+\U\G%8O>MJR_V2L397B*O!&P?MHH\9TL'@H;L*]^PP>Z0
M<?RBFL4((4%K(VU6-VN:]S6:"7+(OK*&*^>';?0[7^T&2.D34/P00<D;4P0+
M;T?C5DG:ZLNJ;6%EV[Z%:Q'NE^\:77HA_>(X'EIUV2/G\=^;@ _">G 3LSS4
M,WO1Z,?DHO*V/MN\1;T&+W <L8XQ3\)4:;E8SIO IXGFYC%_.8!(/W]VJ3*[
MDLC:M$\:]WC5NPKN,9U0O5!",HV$MAAQ3QTRR1)$*4N460;W[C#_!$^#T-@B
MI4GN:.8(L@;^-,&Q3/NHL-W?WN70%?M_7@G\/FRWM$NE/UF>YPKL.DZ^^5..
M0NY3I__TLV$W!E?#7CWJ:W"?=Y[Y6L,@6L/@_MEIP*O+&;']\Q)A.5]/,>06
M$#D1@T__''ULIH\9&:S &7ZR!E#A%]K <I_48V_SYYYY1V6-"M0@S?*N8I<;
MBS-P=X&QW&5<*<4ZWO%)N3U^_.<2PJ*?)Q#\+)OUN%\S/GT\LY/^=I"F0W6O
MK5#/,$W4IZ<Y 3,Q BLF@LCT@13,!$?D$B5(<>V(D5HXV]D!^J2;[T_13,10
MDEZ;28,L?7J@$[ 4%X767.2]TBKE1F$<P %@0H$1>/C"&R*>=8/L*5J*&K)[
M,5P\ Z! +CEK%^_'%R5&[VV,?FW!2)[;!F7-T7<;DV>MOHS(^S1)U^N%\U[A
MQ4.SLEN4H:1G3X6F<#$1DS>(29*;=BJ)+%,6,<>T!UC5C(9.7T>KA)<0G%IG
M)>(Z1F0PYTA;[KR6*7"K7C6:\B&^5\^*DI[UW4R"Y4)*HY!TTB-N@D)@!)"C
M"4:42()0TV$HQ<)0DS!#(G$(-;F7R!A'D9/68\EUD ><XSU%,]%#>B]N^.=)
MSTY .STS&'PX@_2&6<2C8\CX%!&Q"9(>)SSC'>W4&&>.Y91;\H)&>_#D&@Y'
MS =,$PZAX=Q]Q=I)R)#WW8OOS8GZEH8\>?C^T*"TJ=UJ@FS4AO_'BU(/Y%2.
M243FF2.8$X^H-QC@*U!D!%>())L@QG.:LDX_,D^XBHXDE$R>N&< F Y3C221
M GQ-HLJ\;J<BA_RP[5 .[U-.0#4I$4PH!QF'\C'SQ5-D@S;(1\^"(E$HU<4[
MJ2C&PB(,ZIO[- GD&!8H"DDA0/,QB-<]64[84!^6:K'/X=@QU5,%)W24%L)]
M SFUER)W](0\P&"F721)2WI5/1.S&/)GB-G@&,C#G<[IM$ >,@OA71+1OV[/
M2?10]]UU;H=C@T9;,]9W-C;8ZJ_YI.J]G8^G5\M/!A4\L3_+E5&[N]SJ)7P*
ME[LLY1M<6SV<;[TII5K7YH6FDC-'*Y?/F0.@1NP3'U=U?G6[W\U^^I3WU<'%
MFOAH%1'Y+45KJK8F=0F=.@Z &Z\(#PH9B)T0MPI^8P10AWKE,:%2T ZI?DC2
M0DQED,86,"U%R,>\, A[#4&3C='H>-4!O!N/ISZ/['Y/\&,[/KO6^>'/&_N3
MV_:'Q*U+1#U'!SA_# ]U$A$,YH+9O&"/N3*Y1Z! )C<_XH$H!<$(,;&SW.^,
MELD)@KS*#9,TG&,#J!;'$D)R9A4EG6G7)]40,]0GH2&G$D<8T!!.($;%5(!+
MX 8RL)@28M@'ZB-UE'8Z9$EL&)6$()88*)8* 9E@(9B0*0KP(4:G3NG4DRH)
M/W!?T*,IR<[<2O7N[G XJBL0C%^.&\S=64A<V/FGN,B5T]/EHAI'N'93HY@O
M>0F.63U'>5'03S]-X/56FP#R'L<<B*',FY*O"\=,/\<.I#>7J?]]'[2O@XL\
MX0'#-5V="N%@/<JO%N>?1]N!P+O%PHXFS8[X]5;CYNK_7F_?L 7^K(AAM%C;
M5[[RY6;\U1L"U$]6+YCWP^5 8 H?Y\+RT3D,[F+U0*WH;I7TI82&U8<[#,L<
M!#YOAV-\48W27LGE?:GKAYK-ISF(6G-*3)?U1D:+L_ET^>GL]GBJB;KR#JT<
MQ+7+P0N(M.''M&[V7L'9-3S.ZEYA79V\LQEKZPXV1_ [DWU;U#CW,(F-UUEQ
M-:V3%\VE=)JA8'+L0IQ%S@>)(G8T8FJH=AW^^0?5:_JS&);C^&OZ<;4=^$,K
MV6NRFM9'P6^_IM\VP][F)^^G]:+^"(_S QSS^S<0\'H[RW.?<TA-^C47^BP+
M]#OFX*<Y25A9V&*Z6Q\]N"YNSQ9[E_A^G6'DH+Z^:U2?O=%HXL?+L%5RL<V:
M4U]RY>3B"[ KV^9$EW0;U7>-V8"%PF7K[U\:^\:S\L.]FX_L^%Z;AJ[P^ZP)
M\1H^O'TL40T!V"[S6WZ-?#@:-V#9'M+>C6 \Q-^NC_=Y:F%6QS=UG-F<_:[%
MT7(*-N=]LZ_1P&< /=<DTF_6U[BF@T![6P$9$"'?;M.'K=ZYY0_[XPWGDB'7
M#SSS@:?AH=+T:6]9WO$$W_&6-ASZ0+V[NR[I&=M0ZZ-2T)UN[[*7*:U-IS*"
M#]*J;,,9N:85G2VJ)E:IUMEJ;X1[UR2ZPX9X)]G_3YZY_;$3XQU;=6^0?^N7
M,.O/"#QG"Z5#^>XG\M5[HM:7-5Q%>GWK.OE 5]X'61_7M><TO;=^O _B/UU'
M<5QI/4\GM>(6GLPML.(6BELH;J&XA5VW0(M;Z&D66!KI/F$CW;P4V>YO_1PG
MR_A HSANUZH;K.#(S3E*T[1#JNH#-ECV2@]?2O>T_<5;#'LB4S!(6.80CRHB
M&Y5%W"<3G(U4V$X-J(:38G3@D#G/1> BUX!ZAA@7TIAH&-:'KO!C.\5;[);B
M+3:0[/HJT%=HD<_@O H@%$ H@'!Z@*!3-%I2C)0)>5- U,A9RU'20BBE'=/=
M:E[O!>?14>3A3,0)40 B@B%%I *GW.#"LP("'Q!]/7'4*[3( @@%$ H@%$"X
M R"(2)W41J/DLW.7AB%C.7AXQEPTUAEE.H! K2>!6IEY007BG'OD-*066DMG
M1?#,,?_,&8(AUU/3OD*+?-Y9OAN+/<HLWP/M^;=81SO/^VCR/MN\BV<ZR^7I
MO72B!<Q?N^LH&'X\DAR3B!!<H(0-AZ0N6623R#\PP4E'%KL8KK6AU"E(_Q+'
MB&OF(!%4'#$G58K6.)XZ5 ]/BN%$#;"^GCB[6.)I6F(!@J)^!0B.11 JG<N.
M'0F2<J_YR+-3MX@$DRS#"C.'.WOU$X%D*9,UDMR_@4(JJ)FF*,88*#5)N"Y;
MVI," <4#+D4!@A=FB04(BOH5(#A6>Q)LK%1,(L !A3C#&#E#(_(Z A((JR3M
MT&8R9Y0C@2-)K<F$<7!.A!^48)V,2CJY3GN2I\X(Y WL:\422_'>"YC6^P"6
ML4UU 2?TTH$6_'[M7J/@]_'J]KSU+C"/@LD\C!B@&Y(R@[S7 -\Q"=QMQ&<]
MX0#5 A$30FXO1I%33B"XEG6*,^,/3KIV3_RF W9#Q\ABB:=IB04(BOH5(#@6
MB[<6F"81,O,=RX3QD)3Y1)&G-D6/#6:DD\@I3Z+AD/>13'_'92#($&60%)QS
MJ[E0X9F!@ ^$N+ZK2;'$T[3$ @1%_0H0'*M.#VO+:)"(49FC>Y6[:YF(B+<T
M1D^Y(YV=/$P(YR!A0$0FC+CB>4]/@K,=D1$2#,:[O=^>%@C80)CKF9B+)99"
MO1<PH_>7.(ES.V[F]&R HT:91#O3*/?2CQ88OZ_S."@7WTFXEZ,JZ.,9+EYV
M*.",Y(#W&@GO*.*9\MP)[Y'!FG.6?!+$7@T%3(X1+";(2>T@CPP<F;SYRR9J
MHB$F28^?N\I#T%Z$ @=F=BSV7 "G $ZO%;0 SLV $YF)%B>'/,NYIV<,N4 4
MRAW'4U1,.--9C:+4B1 (1H R$O%H*>2KUB(KC9:6Z20$?5[ 80.%>0&<%VC/
M!7 *X/1:00O@W PX5&+G<:Y$%\XB3GQ .E&.X#^AM1(F:=)M_^2#Q!$CI>%(
MKI1%AN.(C$S>1T4IH8=N77GO#(?V8T/3:P2<YRQQW&ZRU-SHF#.D*_DV'8V:
MFVW?'3]5=Z>#.HF/TX4=W]J(KS^AQC.8R<L(+.B09E\4ILO<HJMOH<5IT9H\
M6+*O)LIPB4OIM488*X@8B($H0U"+"%<BL,B9IYUYU(<TF7S2*$.P@>P']\F-
M"OABXXR"-@5M"MH4M.D6\$AMG>48$4AB$9>8(!.41([3B$U2Q-). 0]-0D0<
M#7(F[\T6U",KM4!)6<]T9$$P\:QH(^G 8%W0IJ!-09N"-@5M>H,V/,7$ K$
M&L9#;A,,H$VT2*>@2%3.)K^'YY<2CDE$5"62-Y Q9",Q\%O45FBX&G[>#>!"
M#+CJ88W(:T&;[3E4^#TW1O_3>C1^69['^<C#WV'TN4\8L;^;_-7;/4I$(('\
M_6BRM"N%S#( 0?T'_%OYL:WKK(&?(MKM+@_OD ]8O<*_FDG:KV\0>YO&\2L*
MHWEL%#PWAE^>3]Z&43T;VXLW^=N.4@X%Z%9^YM6$=OO!/Y;U8I0NUH_?G(KB
M)+R=3>M1<^UY'#>EJ-M-NC?:_?6.VDKH+>*]]T+I75WDH4>7D-V.DXTR;X;S
M;+-LL'JAT60\FL"3+>Q\\<8N%].WNU^ J-N/V]%OU@YL@O=]8\=?[$6]ZH&^
MK0:[GBH/XI9B= ;X(>.XO4* AT2K;X^Q*G#CN%)&$KU7"[!##_2[8&=97M4/
MH^DB^K,)/-BG$5SL_70^F\X;0][6A.NDQ]AKE-XO(+.Z6DQ!6I-FY3"' -5/
MHXF=^)$=5Q\6\$$FHZVK[]ZWKC&&[_?*LQ\ (8^)#UMHT(1KVV!Q6=-KL329
MM,U!Q&6,0=IZG3G<K*9*"DW]_[)=P+C'R&["Q!5,K^^J*5=.<J1L5(A;XI#3
MG",<L=7,$:N4>LP,N VSQ9L/_BR&Y3C^FOX^ 42;?IK (]\<+[Z;A(]G,?_A
M0:_^N]'F&-Y!> 9N]+=X;D=Y''YK+Y;/^QN\U#1\S!')1WC4'R H_?V;*D*4
M.8/'6,R7JZF51@_?+>[Z[O]+MOWF]D(J'XJ;+?\VA3K2>NK!W62=&\G].?IX
M[N*\8F10Y:[, PCH+\?RUJ799NO+XBQ6\_7855]6@XIL.ZK5_'(TJUDSG'#,
M'$ZM(2F +.-+_6:O_[C7J+R4F',=A#<Q^#YD:H*.W6@SOU ^'$$,.5VN#FGO
M1C D)]^NCP==&]M9'=_4<68!">-:,&T>TYSWS;Y:BL^C>N1&X]'BXLWZ&M<4
M2;2WE7*HZ+?;$<OJE=N0Y8\WG$H>?N8#3Z-#\\1W'%+YM#=D0Z:/>,=;2G#T
M_;<D[K7 .Y?EE(G09^[K?.+"*HV=[QN=/*RQ\W;86#5Q(VH"Q_]P\S_^:3MZ
MK%;A8_/%=Z,)A!S390VQ1_W]L;6^-(8N?J7XE=/R*YM$LEIGF&B58C8.9"N]
MK-K\<N-7+J*=%Y_R?#ZE[WRU_?=B!UV"_&4Z^1SK/ -8+Z;^]VHZRT93EZ*%
M$RQ:Z(O\3JL@X747&P0;E2?"(B$\05Q+@4SB 0DBE.,Q8L9TI_^4QSJH9)",
M/B+.C$)&>X>4Y5$:+#$)G2[S/Y[/QM.+&#_$^>>1C_NGD#?.Z-T7.P]ULW=D
M^_OWTWKQRW3Q/W'QV^5D='9;O[9>ZW!DMX87CL-2\U;@HRC;Z:#&->N$% N:
MFXA@BQ,X>*>1I=8AYVD4##M+4V>G#)7>."$P\L$!* BID<.*Y HT2QR)RL1.
MD^"C.?@V?_MI.M]*ZLB.!T=U]&_"<IY3NV,B*!D*LE&VJZ53Q5R?)3%\.MK#
M_H_$D1+#.?P#.GZ9(^8@JV2(!>*?WV>\-HA_PL000]@@*4N(Z"8&P #_S#(D
MO;.81QTEZ]07:2I=9)Y#M" @UE 2?B/:(..(LC@&GOA))X8"#S0NB>&+,.2"
M&B<GO]-5MCXFAII(K[QA2)!@<S%H0)E,%C&:J*7")AM$AY6>*<*%@H.$S:ST
M.B ;2$#2:<,4BS*&\ H30SJDK"2&_4H,RXKAT1/#\Z;)Y:IVN&2)!>][ZD!>
M&]X_89:HN.7<*H,LP1%Q2/Z0<Q2B B)#)G-4@7?9'F6DVAB%5&29S]XXI DD
MC4:1G%1&FI@YY2Q1#R3I!5=DL>,3%%8!C=>J;'U,$A.3G!),$54RSP(*A2P3
M!#F-DTL1R]B=!0R"R6B<0#%@C[AFD%@&+)%F7O/$A0F9<O[5)8ED*&5)$GO
M;W$SY\.UNWSONN?TALOW!TN>8I?C8?<[4V4"M2HAI7.A&DL":8$%(LXG@6/$
M5'6FJQ["^/E;SF.7?K&<PTN_FX3?,CD#N!R(XCZ#]XCUGT>U'T_KY?S:[<I_
MVN8.@1$X1^-1O4!QW&RK;T9A%N>;#0([W"#;S!RYRGLO"TC#6?&V&7>4KU^_
MR3EX9JWH:,CE@.4-MNK;.TX5/ =-P>H!MV9L?H]Q!L\ZWM"GK*@Y&DG=(!EP
MMF*X5L8M+=SLF/WVRA5[)(6K^QRVM/%R-N62VJ176]QOE=>AQ?/S)&]IIX/J
M2ZQ&$$(T!A9#9=OIJ+7@*ACJ2::\F,>P]+&:@OF!;X8O/(0,=;/%O?TJ5-/E
MO (5_!TB!#C2751@K//I5TCM%G%\4:V'H(-A=WNUNPKJ,0NW23(=(?P2%MPC
MIR(A32E#G@%H*1X]E>X0]&'7.,HF"%MFQH%?T]]6##?UC^,1O$3^>B?'7D=]
MV^GUS[_\=%MY+KZ>([D/2EG%U6O5P^J_02\G?CF?9Z7\]&D>/X$0KBAGJX/3
M5/VA_\HE,;4R\(!BPX1J(D=:BHAPH)K%E"(@= >%*>0*44+FD#!&/'*(G!C!
M"'M0KJ"U"+BS:'2#<JVI1?+OY-HI&[DS92-NZ^\Q[+E*P?EC>*A!!6B8505N
M[<^J+[:NMO;7AE:?,EE'3F:J"& 0.@0@=%A]/(MU7.G=; XBF,/C5?-6QME/
MPK.@!3QM!5EH8[A9 UR<1'BLUEU.)Y^F^6:K#RL[G]O)IY8W:% !;IQ=/B98
MP'B9'Z6.>8_>!/SJS%ZT%$/Y6J J[:-N[N"G*V:1>CF;3>>+YK"&4J2-K#_!
MN=5R-ITT+PN>WS8+#QO#^[?_HRE1;^'*T2^;A\\7 !&C>?R<20_S1_!\*Y:,
MY@ PSO;QA]6O@ $W6RNHU?3RO3QD778T:1XNJ\^.V)H3&IE7=A-$;@M[<3:J
M6_AI#6VRA3_-.U\.429H&<=\'ASU5SL'X>81W7"TG( '89A*RIE$,:@,,#2B
M/%;(A<@]P(S%O!/'/P2>_K;2L";UWQK 5^8Q;M'C5K_L*&2NGCUL072XG7#W
M*=9\<CJE/U]ZU\49^(KJ'+XZJU=>MC7&2XZE.P:D+B[ 5U3-VS:AYW3^R8(W
M;UU']L3PV6&,^IC+0%YJQX,ER),<<SI%D+6 \RD21U14V-AN6/" Y'P=6/ZZ
M#N _Q$^-E>]8]>K#FZ+*9M(/C#HGFW6<?/.GQ9?I?>SYR;5O*V>I5^_\IOKK
M;W]N7/_/Y^?+2:S^&L/(0S;[/&'G,?7+N""2YAX9 HD-UYXB;2E%UA#I8[28
MZ$X74P]!)\2:"4%"I"#LU!AIHR6B5GM.F>"1=KJ8/G'82>X'(D^O=)NP\PA1
M8D&6NR'+_\NFS?!UP!)"DV+;\17S'N6UCH96MEZ'X>LP>1VN9A":Y+!\FA9?
M+ 0"<7*6H_/+R!PNN1ROPLW\>'Y#&;H*H->7@@-C@X#YK !A_G@ZRY=I0]G,
M -A&P)MGV'_/*^&NK>NI'S7J]F64,PH P[%UF>)U.K^ AVJM*S\+2-RVBE75
M%W6>$QU6[R"[L9 \P',NFHQG1T)U(\LS&ZHQJ"D:@Z1R%%1'>([%F5VT#S.9
M-E\#1KN8Q0K9Q+A)MMJ,I/IL&PKUC2#&L:F&:M0F2^W#= D/_@&4[*><^8QJ
M/QU4[T$'X=$G(]L\9+WT9\W#Y+O7^?26;[$UM-4CP?&-]$;SYB7=195&\WK1
MI 1VK3^C>>7!QB[RG_9\NLPR;3*,6*4EO#:\3X3$:1+R<RP;!?*V/JN:$0+!
M3__1^+@V,JD@R\J8DR?%(!U;7?^2!K)YU<;V 4;F,.I@)3!:F=4P"Q/D"S&E
MG<W&(Y\_;!6@\W@M421DM2E7[ZWNW#)4YAP03AS G9=U1SX)1 'B'R]CO1KA
ME:C:&S5)Y2)?K]7^Q;Z;[YP'IP"6A-5[;E]^GE^M;C1TG6^NAJ$%T?:A+S/Q
M9E3MRGKR3;+BM@^_2I"_;!]^"@@L#";!48>DE@EQF0S2/FC$:!0Q425CZK3
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M7ZDMB/7:V]V=9+V&L8+?;MM_)<Q ,E'XUA_O$[[OCT\H2'1R\BM(5)!HBR]
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M7OB![\JD&3+*AEK:V_<TZ(M*ZYVIMA=*K<<*"X$7>12!]W;1[2)89LF3I"P
M;S&6 $)QPJ,)029O M_8F'^?Z/;3 Z\QGIL2,M&9:C QK"0V^4 2CY%9L#^L
MSCM\TYT!KQP**X;<7=?N$H'W )5:7XB%*(L,B2A[.Y05K/:P2\13#]@3O2(V
M:$J<D"8FJ^"OC?ZY]XF\/SW*>EHB$X62[!@\=<B9>)8"X27SHE,&=4]W^*8[
M0UD^5$P-';MNW ^B[-.W^,>2]IZ4M&-: >VN_;>[L+AB7PVPIRJN2,5SF:4C
MD7-+I/8UD.(T<25KP4'DJ-QHT;R-QJ.;IMR?\!%,H-I>M?FM'+=M&/V;VL=L
MUK2GG)=@T'4;B-^V N.&%M7141XS(TE$,.)2DL2K$NO4IB2**$;:#<-O&^^_
MM/@>E0+LB&*:HX<5*9CO0(N@;\R*%L'SM0@XX]8'0JT'=*/!$1OADU(Y.U84
M%7HK0Y/Z:A&4PKVUR1#PP36115GBF$X$D%W0D$OPFQ;!-M[_:2P"I=$B0(L
M P((_PC_"/]UY$%.07HJB:+4$^D\(P%, N*=*HHQ4S2SV\B$]!7^-;74!:,)
M?(!W\;208.#]LU>E>O>AY*UD@OH!__*ZO94(_SW:HK+?0Z"W.'.A1^.@'WW.
MQG^./N9N7F27K%I.)FMGCM1)5F?M'%#XH4ZXA)/2*OGT@'DFHZ:]80-:JPY
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M2A/062HQPXLQYB$@Y]/9_!NLEM_EV<=1K#;3:)I^G,[^+[PV4/,2ZY FQY=
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MVA"FI@L:5C5S)2/:20[8D16=3KL'6BLIGI^ +@(??C(_6;W7+VWT<%57C,6
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M?9%/K'+HRTIL5<!_!L'!2@8L$GMJPB&QD%@HDKTB'!(+B84BV2O"(;'Z7SF
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MSK &GU^]^-M7SF5'G-_SS'N>!B1R^G%OB>^([]C+=_Q&/M$^\?[UTU%*X_Q
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MF<!=/XS@N5]/9V?36;M_J3]6Q$&F$F"AZZ__\8*_0)OLZ6PR)"H2]:F)BJH
MN1:)BD1%58!<BT1%HF),&_GO6=0>JUBRMUD0YX6H^:I 0DAU(J;R)E/I2TC;
MB#C^FN==D/'G:7.'@=T-4!\^?2OBJ-Q0.MZ'D&-?A!MKD'N^)+N**\)9]:C9
M=#R&BPQ&RTA_?Y0WAA(/#PK[8HHA49&H3TU45 7(M4A4)"JJ N1:)"H2%<L3
M]R;8B.6)3QV.#$E)9;TG3-@Z/$UF8B.C1,=(?71<1EZV'HX\7@NA_#']]5(
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M7(%/G:2'Z3C=82W^._O9X.TDY31XDV,^#7DV$&PXX)2+7;/SO3/_?5B6G<I
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M 5_3EB[.F.GAX\)GPSMV)@*1BM@3+_2UOM 6/"3\&FW#X_S?K-78!+^/;D>
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M=@R-3(04)78FK@ [R=VGI\4P"CUVZ'E)$>?HCOH:-LX!WU48M0V^I[63IF+
MEN!+H@?1X_W0@]!,2[6]:;\K-//O&5SE.4:D-HED3I,;D2*..81AI;&X8Q_#
MV(L*W,B8Q++D1=U1-N%7XE?",(1AR$81/8@>A&$(P]S;LON^XEZE1\9J0=#J
M,U(Q #K*)&JLG)\"C@DG/&)'M\(K9-[U20!/ -R9%&E6<+7G[JR(!#,L_A__
M[IKZX,"P/_)?69*6UQU_]GH@$=$Y-)BJJEU'M]Z(QU>"'7K2'60,+%M5@_"3
M"29K-[\%[\GN6;I9-\73(8]%IIW<1@"^RE9,73<)9Q'.(CM*]"!Z$,XBG/4
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M96^8^'=_^[>_[(WR<?2W_P]02P,$%     @ A81C6@6MX6-/TP$ %M4; !$
M  !A9'!T+3(P,C0Q,C,Q+GAS9.R]>W/DN)4G^O]^"MR^-V+MN%+7H\<>MV,\
M&WJ6=5=5J4FENM?;L>&@DL@4NYEDF@^ITI_^GH,'";Y?(,$LY\2$6R4!!S@
M")SG[_S'__BZ<\DK#4+']_[RW8?OWW]'J+?V;<?;_N6[I\?SB\>KN[OO_L=_
M_K?_^+_.S\GU[=T7\H6^D8MUY+S2:R=<NWX8!Y3\[O'S[\G_NES>D\?U"]U9
MY-I?QSOJ1>2<O$31_L_OWKV]O7UO;QPO]-TX@N'"[]?^[ATY/Q?$KP)JX>_)
MM151\N>/[S_^X?S]#_#_J_<?__SA3W_^\.'['__X_L?_]_W[/[]_KW3S]X?
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MY8GDR,<AM1?>?[*?]P$(PAY?QWOXA>@LFM1T5#:F4[]T6I7=Q"_EMHVXF8_
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M73+:.3R.YR&,EXV$/9T5/6>ELQ;5MF_]6?BQ%HKNI#QI-Y:5?M*? C\,G[R
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M!/!?+,^/SX$DDQ#1QBK4\NF8Z3YF$A #?EV&E=#Y8+6DUW"4BGZ*FJ.48'K
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M6I9\JFG.86NFJ[([:&NFGJ;)G!-=6EY'DH:#>;0:J#M1G0TR3LNB8WW7HN=
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M?CY$R%#%XE>W-R_>7AZ2'__JP-49K%\.]R WN!=?G:J/HV7GB033BQ@^03]
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M L8M>LW&>-LN"*2IE[EX8.K!B<!(W@M[!T<B9'+F*Q65#FLENG9]S<EV2L'
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MS&?; (F2GL;8RH<,M/04-W:;EQ.HI "BXK'ZT,4AU$1JWH A9?;S!ZL)>6$
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M>3/XT.]>UZ:>D172&WLY"J9Q^0MN9.QYIB41 F0%DV<D^24G?62<J?=^PDG
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MF&5YH3PP8M9,E!H[#;'!4W1ERDKO;X*3(;](0J._:4-GGCU!HUKM4DLSQT%
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MQKA"JW[NTCN3<Y509N8P27NBH&'MW.7NQ3R+EL+B6)R% <,+M>'*6@0BU6*
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MXJ3R9!8U#H$[.5 N!B!+72A)DV?^1CW*HO1G M^? @Q!3H<F?P4EDL7N^LS
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M+(@<D8F@2>2Y')2HHW*WRR21,],M1^9KZ'HX9ENS) DNNX!O>B=2$9WPM]N
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M>+H'<=G2H#4'/GF)':9;7--P'3C[I S)H*)%9U)I4JA.!?B@D:=B-2)1@\D
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M#(ZO1"GOE<-%[!;Y?(7FD2N1I0.^AZZJA12)^5%H<Y%2,?CT."#5&I/D2<"
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MW]3@V#FG@ZT@IV-TSIJ.4YY))B_WPU2Z,"23M1+M]G,8$(U8Z28*+=*/76=
M-':1GSI(K@]&%=R@0]%Z,W 9<1^&5*_4;X/",F?)P"9JHCLU9K^WWCV4NE^\
M9+2KPY>W,RL;I2SJ_"(E3Q0K$<\(M$>PP:,? 7.6/W_\_--DXY$$]<(7*#B<
M7PD+W2\T>GX!'@=VVK&##']YSM1,]2&,%P:FBE;R'D-,A,Q:D;TFHMO\$0(=
M-Z+'OO.9J&P_K[C]8(J+OQP6Z876@5AGO9)8E-]="YR1,S]9+(-AL>*AE\ML
MB_5"!+!,27>^@+=/.?W'%@A@7P>A3M ""4H\"@!Q?=^=*X7@<!9IY[TZ+G/L
M)]]?<Z4(05YJHFR7!>83(K$SVE!.ED7TBO$,6L_KJ[U:38G84VZPT:U9B1L>
MU5H?PV!?EZT6G>MXNB09 ]>_OKE4:K5893ES7Y!^:##5VK9Q"1=RDHDV_N/?
M_OCYTT]_(=0+5ELMOP<%:+YZS'FF?M<LU_(5!,5^2%<?@)'%3UG!(6&U^<0S
M"6V;NZZCJH_<S29&[3:((7G^,D[?KI)5FJVY]MLOO\V4SG/S03XQ&O"0\.88
MJJTP&7A#?3B D@[H5X ^TFVZSU@P+C)P3A01MU0,EL&H19)3FM 5\.3ZF]*+
M( /W$9#ZX-7L/(JW78J3&'NJ%(ET1BAT1H183UZ_@4#%>_$<"1"+C([RJM-@
MK!?$XD'!B9;0EE^DY"0,-E!(DYQ&:4&7+TD:I\]P-IZEV285+#_RRFP<E3/V
MP7H9%CQ%H-&K]29+7[GEL->504DDIDAOK'$# K*"CFI1>=37^NN9$^YLJQ[I
MU'%RM5YO$WI#PV@9#1BYS,42*==+T/* 4.)6%'Y<6@/"*;D;&V Y\S<:"A#;
MY_'6]7,*FC9J[YVC!_FI@>)FA OD]Q'WG&'# +%YDK39F+QR,'@#R4E(\V46
M;7RHJ VV#,ACDMG0\/?W,_P9^UNS+0=$&YGH_)]>M#Q7N/>:KVH@'RM6*W5>
M$+.&)'A^SC &DM?Q4(. :6E$4XV[W4I+I;FODE8K0FZDD'<XS,N[K:IJ'JJJ
MYE%2R:*H,3?@2C$-2FXC0OR.DG(YB=&1K9*KI))^@2T#!9:R,N586-F#<C?"
MR+S3*%5>)=[".,Q8"_7#OT:LP]GR9=<KA\.(Z% "$>?MR<_>TCB< FV(7ZF@
M=1Z$BVNHG]M84M1Z\A3WZG+UIB78$CV9>&]I >;..W:%CD(:GN[8IA%>)3P'
M%PYDY3;J@PPL,VCCW(AV(!PDDFV00#5RO'!CC11MV7<&TA^@%8;W1Z(:,AR%
M7BK>BCO5'<W0OIPLZ?PICIY1)QBF (2,A-WH)DBJVC@^E+$%D!WV\K9M2"=:
M_-'A:ZS1W#Z1KJ. VTIYRCI%/(CJ,LU^YA]3[W!G7M/ HN7?L&8)%>V2G#<L
MDE$QT%M\R-_">(BEWEC;055N(*)!$9P'A26):/,;&(:ZV@TM,^^4K% 0##(P
ME!V<_:*=I! O44/#]-Q21X6DD3C)T3N5W](W_)4+7G;> C )O?$GQJ)?[PG5
M,KA+OI]2""K9;F!SW;+S9,E^MZ+0^HP$JP*J*--PNT3M:)N$-'O+(A#YG^@L
M!S85?K?DC$+\36&WV001*EK;7(ZF\]I!1EFZ1?!5NK>[5D4RB]PQ<43*.Q(8
MY11&3QF;@_;>S&@]KOXW%J LV$IZ\K22+M@7"5<:>I6P[QW*M0+?J4TAQ8DJ
MKQ+)4LD>XI=G,#;P.)0X3M]@Z+L&-,A>$-X-_)B@(R7&K9D@S;0X,^%98<U3
M'2*J1]ZJ5HT\DI872 W2JQJ00 J>;,H%_D?H@/Q@Z^HH&2"S!?^02K)CLIXI
MC)RY?"1J/Q0^==E?%U^CO*!P3U[Q1)Q%>O&5_: ?'U--[IMJ"!0>WA3$&_'&
MR*]%QB[4JR#.J8> &X?#8(?@3'8L&EFK>!_8?DFS-587ZA3>6,M#-BN[T&:$
MBM:0STK4&\(&_1.2#0/<^@HJ;C'9!M*3@<5,-G.D:.L6^^%S[)(!^2(IHF)W
M&<4T.V.ZP7.:=<U[X)((BB)2UL2[;MEI?/;_@ J$P^48M==D'"N[R"UT<V;;
M\3O=4KZP.U,"X<%, Q\DPDT)A&N)V\V_?]_E^C/[["?$L'_?K04DI<V<COI>
MEL6>210E8B>;U\E;2:BN?#R0U@8WUW JW$Z8!(<]FCC-4]^1$\NG/]\3C!CO
MR;2IG_H.V- <4-65YGH+.J=/A:9O+Q.["[XX'D[9N\ HM&65:*D2WL^(:E($
MEOHK0NIE*"QJ!P457!*P0&)5LW2MR[OD?DOL6MG$[!2,M\ "> ==39,3(SEJ
MD<(PP-4EC9FT9TE_T?5:@0WBP<N;)*)-<E+*R+*;5:4VOLW1*?M)_) R3@&S
MY5WQS>PY#O!J:-]XR?>2_&J1GBQ9@QFM*VO554$5LC&_DDOW6]#*#<A:QF19
M7P?)M;UNZZ@;@3E_RU8CJ#KIJGACRZFG0BTE<FU%R'2K$0\ 0JP\U7D(OI>R
MIM[W4I95=?0= ^#62;'SBE)VG0TVE=4D*C,^"?&N5]*@8-2J$B"D6%5]T(.=
MS04N>\65P+FT]8J8^,LH7P8QD"XR?>>\>[E9(8YP>9Q7DDE$*L!C@&'-PPA8
M*HDD==E!(KDDG"?W<*:)I#RF$67RG^S.'>7744*O"KKNJC3H').9M&@'=@:5
MY$X-";LUJ+[P/!2C-P2[0WZ%#A'LD;]$G#'&KR%1ISX+38_AW!S#D_''L-%:
M.LP>WFHT';.<K"O<I2J-V(;?DB;UEZ9>+H@&VX W[I(A(5E),^/8/%KID1\3
M&65+PXNO3#'(3];P+X<DT6:3A+=)>*/'/1(MM7:N4-\W"6!'JVH_0$B<"G73
MD67<Q@L)<)"\G^1' L[B:4.$3XAP:0;]T:-"9%B?WCMGGE@N^G)JS[=%7@1H
M0KV"Q* DCY93X3$W^@96<-&[X^ J'VQ<+?^((MXHC<9,E-L3@8*I;GR44P#^
M<YL6?Z,%4.! %&/H-G*4Q\ZQ)LD.<H=EH[-*Y.2W,1P5$C>2".A+#3U5T'EX
MG0_.(>Y\;BR&;3L4Q?5]D. @U2;ZCK$$MC8G,^1/A?EOX:IT'+3@8QC$AZ'A
M0S9IN5!ZR<TL.1W\Q"-Y&09;]4BSX@.&SX[B01%1%?<4*$1X#D UT5RR,BVB
M-7MDOGI@/\U7P.$ '&1!AI4L>I1A%9V8$=6-AI1[@ZB*]P4KGAJ]@:.%]8?7
M"O%3SG7<$;2+M;L81J??VX(F05(8A)XJB>DD"=7YTW.[Y8V02+>B4YK08J+.
M(;=[K!NPXAL2( WI.I$-S7^J@2/$:*[RPV?3?5#[/7V.(!@S*6Z#=><,1A[0
MKF41$#;USM>$Y'M"T,!F+OD;1$XMF%M[UZRS[H1H6Y4D$:(5-#;[+6+G$K9]
MFB@J=Q#JW/*J"&\V3"/B$1S/&-S1C\8G!1H?*9)(F<>#IHEZ24'*CPZ2'79;
M!@7JB&M,>%0],!4H6D7+._8I=:<H+^D:4BC9"*EN58IA,$AKF.R[E.;GSC4,
M!NM250;BW/ZV?*'A-J9,L=]GB<N;3'$+^*2ZSIQH'_7X VR:>:M1DQUGT!?W
M%5C&&C5KK<BAFXNA(_N&[G1G/3C*T)5K:?15=*IE0;SJ-(/!*1<'N8;B(!I3
M.13]H.(@DN;=".5UKYQ?K&GVS(;D2Y:^%2^P&(.D9\:O%$FX3"*$'@F6FON&
M9T!RL=ZD"=UQ8]WE-@G[G;DH3)C^"(KS%NLP# ZK[&,%C&L,I;*Z4D?EC&"&
M5PO"G99]'*J5FL1:;>6-V?X_;,^34]7I&,3=X1\U;G-9RX8^! )\SB%O.<<O
MA@QL\=Z2N*Q']>1C4%MJ,\@!ODOS"+W&%S$8CX/NQ<CN]U2ET(M,M4ETH]_&
M4-@F%Z/%&;L/(SDB6PALD;VEV6^K-'.7.H5W,;YWHV*+G8G 28#>^L<D*O+[
MA\<AB@-#&^+BH5L100'8SE%BC$UXI T>N2</Y-'/[=H5VI+=XX!)Y:B=LS)T
MCH4Q@[RW:QX8(_UD/Z?LV\=806#F$^6MQPLZLL/ 96<-MY[N+W(ASHBGBMS3
M'7SK_B"'Z55)GI&UGQ%:T#4<\]F.IZ4V\/+B4/1E(%9-$9F<W<9)+$*S_%$2
M^QB))H+B!R:;Z5P7'SX!>Q=3ZPID&MIDDAF44Q=#> Z&22*',?U*LV64OT<
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M\:QK6D OYRM^=AJFWEZZ@!"+Y@*N$AB2?6D$0V,SIY/+!GQ<'W".11M8^[%
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M1#;Q/WLGR,JVR1MKG"Q%ZRJY94?6LGVRQ@ZPSX-7I\E4%QSO?CY'1]_8^*A
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MN.I3XW]'^K,'C; :EVV:AT2G\0:$P7O+*D^#(@X20=[P'L_4:=981^W(!*:
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ML]QAF^?427.C>P?AJBS7:HU?L/3K\94<@[?$R(0OE>2IVJ\.>VU\>"UV;5A
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M37+KVO &@P#E"2N23KS',MVGYR+WZO0>DT33>UJQE93B)UZ#[,T0G);Z*B"
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MQ&VIITYT3*ZYC=)=!R_D N3V:GSWH^*O^-7PV(U\1OD ")1Q90J)!%+9N2
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M(VZ]$VV+@T"5WKAT7G2+OB^ 0-JC%] ()%';H?88\Y)2IU'D*U%/U7I+=J:
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M@9>_VHV7CC^XP,O?;,4+WP5=H.;OMJ*&Z?(NL&*ME-OC9\_Q\U=KI5Z&2[_
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MS8'-%(6FZ<T*_/2:\)I.+[ZQ;-;8DK*+$TR)#7>SQI'8@MWB1RV>91=BA *
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MF-/_M3'P,D1"Q^=$0Y2"#<KOFTCDT_>%R^.-)5]?Q7%Z*.[O$1%EX(8$(*#
M?<'\7S=CE/ZN.8.W3]?-BP1U8,R;PO(LX7*3H?"1%X0%A-A+T"N*/CVI2Z/Y
M,Y=W<WIEJDPK;+SXY@0\X6;,6S,S>F"#7\JF%-*8[KW^.W&"/X7)/U'R@C;A
M+B"FNKHXTF<9'?7;\T-M1D%W893_$QG'L[E/O(GY(;M:*9O4OM:3TW;??F#D
M#2@7@;"^ (2V6&VM15*YP<ZS/I3>D.>B.J]RL/&LT2:*2[:^\H0X!KJ.'G[
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M"/8X&%9>1G=[!I1P726W/X]>%O:85>QF'8K2?'-U#E6#V"#&K#%-XD+B$LV
M!<:#=_"RIS]>!^\QS_,J-U?S%>'30D7@_\3*/^MZ2,\U=ASU[GT8O47U',X!
M\$9#VSY^*R)B!XQ?4)SZY !H0'<:$:D_XT9X=)E]KP:MZN( D9,]I,\("^:T
M.A"UO= X]=5F$Z7<LH'GK#CC*">X/BV.>F"%$UJL9W3S/EA"O:6(XN?N<]2'
M6>.I5TVI(TA=,; *=]S")+S;:A5VF)0U0%&;=7Q"+TD)L&H58H1\2B)"<IX1
M&DI8$BK=LPXL.!]-7:5^UC$%\KQ<WJ(PZ_ !)0KCVBEF'2*@ T7*MI QX@@
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M8L*_+R8 [XL&EA]$R25Q'/Y!UU]A>'84%<,X@-BV;0+\'\'>A*;J[3CD@^Z
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M'[P0LS(78N>J=(H]QVJ]#R(6)V1SU+)4V)/^@:* ")>OPC1%O;DP0*L* ^B
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M)?99MMMCJYV$[N)"Y3VL:_'H>[D<08:H7->LV'"^<M<9E?34X@E2IUV[LN-
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M3B?3H&Z\0YAY$2==43G<.@ PDU)#;MXG;]B9I\=*B/^&MC3C5_+0F+7</JG
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MVE$@G<M-M7YKSK<%S%HT9+DB!/.DOYYM$SU5%H_\ 1('KSN*E@DI?Z>V(I)
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M#*[<SW),[=A!$!8;OX^W"=X7ME[+AL?6#BG7H%&6*"6\!ZE,BUI3 1@/VX=
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M[Y1L^-P[Z_E'.-OICC'S+LMSV&4C9]Z/KB>IOS_-F7:37_A>(>XM$8^W6.E
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M4HT4_GF$\4(%JXL&%))16,L+-TN43BO&@=IMHPN_G-*SEI5F"L-K$N\:GXG
M0I4,-.FA^Z0;M^4*D,=O1+\1MVPC?I2X9[3I;YP:-RL <I[+&=(M!XR:)@:%
M%8R;M[Z\2/=$I-VSA3#Z4S"5!!X#G*="\<*_&[6+PCT30%O;ZB<^&:HL8K5/
M+CG=@2-8:HH] ]9N&5,?0 <9IK_\1O ;X7'CLL:79G.&-D5N+"];AY-.8!%-
MWZ16B&MMQ&F:VB*+.OAU)U*:FU&V6G*OFY"M!]KNA<$[.2-@#Y,-&7#&]4V%
M5NHK/*?,5M8Z/DU.F;8,][%?;NANIXZ>0VIK"\),R+]/LVT))M4L ,OJPO1S
MDI>9[><D9C-"3%$'+.S6A%H+;:?SE,POD.+:Q<=.FZ)($X%-"HJ%R"4RP7%#
M :5[/5%UC<;MU5V8NKIL=;X/':!PVHD$.Q$3/9WO.+#!P_BKX^=]W</6K=MS
M&JNO\;BKQ_"4*SKPR"I3+&9<JLO.3I&<;H)1?98EG"#@K#6;3J/% X<:N')P
M)YDOB\&:#I8%E6R65QGWXG;/28+J3'55ICY_KZXYR/EM G /N;%W5PM<*IVU
MA[;#\:?/>[SEI+HR[;J[[A$&;])R$;#2/)<::S'G[D3N !!9-*E!&F'P5Z9]
MI3:=R*B++!;4^ AC_&C5@PAH#)[3,!,+ JS-@%AJ&+BYYZ"):F[5N<(9(')L
MHFE_;CQIYQ8;0T*/CIY[<&@_'.X?#(?8@P.\N(/Q&@;M9Q4;^@%D,"%H'L@-
M"6<RE6X&*\V(B9FY&ZO8M 6K4P#.[W!;QNK/2D6-\NI-,<)[ ?8"W(7,^T/6
MA**S"AO4!9K/@ Z4F,B(!DXK"?/E'"25Y9WAJE=6KI%&/9?G*JT*]/<8R I:
M>>6G7LJ]E#^"E'^JXP^NC'96"&9Y&E73DF0_4QDMO\.+46!^2S/\%\%+"FV
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M++A**SJXELCX+RX$<W1TS\\@B%): DWH(:GM!4V)Q)G&K9I<P;(_DR[)CW<
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M(YO"TS.DL,E,]'LB[36W$5^/*MT&V)I'E6[KPCVGL3YK5.E#F01#;PP\+V,
M:0VX,5Q==6>[NE'-:,V1PS1A\JN[31N));6(*0Y!&*X3W:^>,/#2VP471YSF
M3!G!M4%>$QU=B"*8@H^%Z*$K;A,0$0V4Z6^R( ;9@EHJ$HT4]DB3AH/]1A:>
M)G6?R2OOZ*Z.C-*#VY(]0M!Y^&6IR[!)0/%)68JCT5T2IC#L%Q0QIG?7E#<:
M6E&_K<DQ;*W+Z+??$]A^?W6Z!+GN)*-X+ 0:C@X&LG.=[+RRJ? :$\X@B?W]
M ?]U-!P-.*?]:5=WS'"2'QV)YT&K+:R#^FAW17 4A-\^?OM\939AVD#NJ6)
MX75;DW59_AI*:DZVNOS\CMF6=3B-\2I.X_HBJB]@2MLNJ,8U"$K4=EA[0NT(
M;<.C9G96)0&BB%(T/8@<4SJPSC#XS33"Z4PD8[/F&JK4RGS#"Q -EL%7JM)
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MYV;8V^ZY=EN*I&_ZY%A+8\DK5E8)^1L/QC/R\>/)\_9OP_:? ;-60)=\8:9
M::ODEC)QK3'\6 X.4?5II_^58TK%9H# =0;:XT&#G<DM]^?]>)UQ[7J=DC%N
M95W*C3/+]5OX-P[HV)'NN+=_.;<5>N.DM!S]_8#OGRLDUQ?0</MW&Y0[/U"6
M8R>.F9BSQOB'#^.^>V Q>3'N^T<=_P)02P,$%     @ A81C6A': J9%"0
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MQD ]GXH)G6H;U8]V\!5KQS\=[=B7L_T+4$L#!!0    ( (6$8UJ8R<9Y=@8
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M'&U]<?4^7!UYT]O9$5??/6[K;&OI"0!PDN//O6RM'7!U85R=Q,- 3Q57EP,
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MP!<( L* *. ND BD NE %O 4* )*@-= !5 +- #-0#O0#?0#(\ $, ,L :O
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M]&=OJ.P]31&?S/<LCP!GQ>WS*\ZN5,LN]U+K46VO++,NQDY^P#DE[>0_'8^
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MUA+),63QRFM4@YDZ8YLM%8FV&DB 76N@T19N983*3$0"F\7WAZ:I@#9E.)1
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M3N&FS$+F-.)U2>/G>8(55'MA)P3F-ADMMZI,.Z6G;LUE0J','BZLS*+.WZ-
MOWC+QO6&#H^OT+5R;\ 'B,OR.5A448]N$M193FL6ON5XQXP)P6*"J<3@W)3
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M\9\(%IXG)M7AWC>N"Q=Q!%["!08V.'_KDE]JH.L=1<RPZSZ&&QONU/0\]TS
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M32U"'8?C\X3*SS[<L_<  *]-0[86;^Z^]#RS_-6-\_'$WM6PG>255H6P.T
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M!#&'WIC_UQK80N>M[ ##!(H0=,?XUK#.(<&@ZNJ(UH4J,U]@C\,G7#&F/.I
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MXD84FD]9WOOA./];CKMJAUOI>A5;8Y9>=](G]]" #51K7OJ@RQ30)N.'_9;
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M1<^$;-;44MR8'/X:DVP)KR. /$B:[?Y9&\B3UJ^9/I&H3H+)"EB7G#7];$T
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MVFU]=$&H@C1%$Z4$B8)@ T1#!Y&JTA5$FH*BH$!"KZ$((L;01 5#$Y%.0$1
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M<. ;W3-V9*PX4KW597QY(KDCDQ0QMPGL7W9>D["699A-AV& '018AO!3$H(
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M])FFT*R.N+PSK=J[>46L'_&<X-='^CMZ_.^;R7^X\GT)YD4C;SZDP4ZB>4[
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M8WWC&RR'=W3X%SOQ7(5D9Q3?"C\98E:^L3[%M-%;BF=;R*W:Z37I;]1_M-=
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MQ;\:N:9CL5]I'^K^I4(I \' R>P3J*F7K/-9N<HBYKV"+U[;0[FE7+C\VPK
MDWJL8U:VCNE-'J>U]I>R0DQN0.;K^07I'9I>_3'?7"0[<!U*4W*!8&[U!'?O
MR-J<\M!''WAZV7^<QTJLGE#Y/A$Y,-4J.=*64-!BJ&':=OSQ^U.)U%%&??UZ
M>X&DD+8OC#J3>WK/8VI,W(^H@A3=99LL_;2*[_9[EA(N6G!G?#*A/L6IS+"&
MP[X.SEF'"KMK:0BW)5&J"H ='@E^)?&ST<E.,H7G;)5D@BXV2B;%.\X(?;4-
M^QXB>!FIG'S8=O7:6[-C>_K/AM<\FI=08Q5PY^_O\/%[XS5G&.N!>*=+$41$
MFU-WE)>&D8X6])9/9<&-TK+$L+:*0F4D$):W[IC/@I;2^^ZLZ$X)3'HX8(]Y
MF?:7&^B(] JIXW-$>N/>1[Y->QXYJN_:UPDPZI*^#>^UYIVX"K><E&HW!8W,
M\:N\%"]>CG24JG56P^26">L_*MR0LK*_E?'1._DP9)&LL/N-3"M\M^7([#=R
MD^:%;_@%2:P[7D/99*\2GM[LZU@=[=\$>'2>Z_S(D B834*KI I&.KMH*]=F
M]!U==Y3W[P PR=%X;T'NU!?M0=(?KH\)P4*T!V[4\F@;L-M&9IR?AU0OD=J/
M_XXUW?L(W>@COM)3/FZH74>Q@9=4V07B++@#P,GUN\S?)J4*;KSX4E?SJ%8,
MN@D4Z'&G4E('36/5TH@NS\_>_Z9_)K-. -&VP^VT\2V-@95'K^+<[GR,:M22
M)*A^@TPU*3 WRFXG/C*-ZJ#+>YX-VK^@;]0^T+K7KWFW4/RHCQLH%CT7],%P
MQC0\[-[>^$!+#*_.U*@OR9. 9(4T>?,/D;_+)9RYW#D82T6)M' QP_)W)L6)
MU7VT@S%'!>J+F++V/6:= [YBXLB2=[3OFG9-K!\[E50*4G&+[634'[.Z_AL*
M]2(*W;BPUE<<27,:WDN_9D?G5LMRJ/TC>53;[G?]SLL8]%HB*I2%W,%D/QFL
M$*RV(1D_,_4@/CY7!&Y8A^:VO@@>9M6<U-,"!*8_X^U$3/AT $!:1XE%XM'9
M;R/)VQ*6SB,^Z_M>^CWAU#*L=Y)J;@W!^)#Y!_G^\?!:@<QCOKVFY6T'B@@)
MH\^*'H[OA8^A$]Y/6T=4O3$@'&(J#$H*<:%."Q/?:!,L.*W_<Z#7H[Q,BT$_
M-<3B@_MVO:4085:Y>J;0FGF\U(3E\5K'^CN<39('^'@.>UR$K[QB4 E#[1C(
MS"Z(="UN%RE7L(T6",)*Y@CXD/856]ENZV4<:3]J]H(_-LOK9;<^4T6$;LRI
M+,YO$#(HX[QK(+>1I#D-E_QI^4X>1)RR[\CR.FX6_/T+_+O)I?VSD#;>)[8M
M";-=$@FET5,G+(Z^O\\;<GC8))@+/BK9%""&(C2B.OAIV"SI[7]PQ_RM03J*
M/ID:5_H=ORT=TS[<U1$Q,1_Y6),&[1!R3KU::C5$F)U;D_>A9YF5B= D16>#
M3IC]_D?YB(DD!?O\F[^:.I.5:C&?8QV^6"1P:AX\^C%Z?N6<<"O_EQJ7DATP
M3<Z,5",V.#D3QT9/8J<2*$NVA9=<\RO#2'5*K66 E0*FG%*2'F&U7-O%GY<2
M!9?+<E5:2/#HL,M!0VKC2N %XM5@.>A][1N3>0,/_"4E)1^2A.,";HQ@;=R:
MO9H9<IVWY?TJFNEF8#B<#CT6QU1YCH2UX2P)R%:^VIH%7O]P,2K?I_()KB;;
MOL&ESET@C"PP 8=3\J7,^4ET5/Z.7Q4A ZB)IXO:6MA$5;(+F3NRA9PZ7[\[
MH>#0UG @D:U<L=!V;L4@NM[./OH=J*:']^:=21EO/FOP,_\]B_S?M+@@W8';
M\QRX\,4"[+$E\&A.T/Q*1'+K[K]@:)S,Z]:A"N(C]!HB,>(*9 2[X]C\RNV9
M'VF'QLD^<<WRY /)$AQ)9.;W/>+18.FD4&TH&?/\!4YD^F)OW6F&.V$3??XZ
M[^,$=13)$-("$1 @K0[&L-7<@ +L-%S :IQPP>S67;I?4(Y31<R[$E->WX,)
M'T6R*'5FRHUK:HU8B$54F*R22=>O&<_BJ)_\-P%5N&##IX(O0VU<G8;80=!K
M.\[YAF'E#,:$\'R?B[@ZW\N8_3Z<[M?K5_W2(T<B1FQ*KX3RB;(8MV0QT<RL
M:82#/&S5>77P.@0$NX[4= ';"2GMO/!+/R$F;K&8L)VR!J?]<UR .TV_:X8]
MD.1_U'3ZWR'E-.X\YUKU/$)BAV3?SQ'\9>'II,LHHO4Z@B9)"8IT P]>QM5]
MFUB2;SM5R)'A(FKS@H];H0P,)NHAT.01$S?GO;6YNBUG]TNP-P"'@2""'$6I
M&G?H7:7C^_1-()07H !0P'V=6';H+6H;[5*&3=E(^_^EWH92+"QD_LVO_$&4
M%N_#7DW7TJB,:1AE)E\!7WGLCL[#UUH\J34US;/<%I']\X*K2=6N/%>*:]D^
MGY,:WLVG)S<L\4C#M55T.?[V(.,K0'LPF^0[74=531AVZ[4Z>L'S?7_@&"8-
M9^ -(4 $.A[^3&$?J9]TSIN_'Z;-UET2&XN7ZE.2ZDL72'7MO9F]ZEL_DW.>
ML5ZU9_<@:('VG,DO]8W?+_]Z@+N1NOP=4_REKEOBQ+*.90,G)1?-@&'14ICP
MEZ*TOWRU.?C1KOZ[-].?SN]@%Q.8YT_UI#U+#;Z*\[N#D2PN0$.S3 F5&4,-
M2Z09N,EG.1^R\I<M3@@BVMQ'N47A9-&$,BM>>Z]%IT/H.'<Y)E3R)S?1$*NJ
M_DB>8\4\L4'0_C8/I4BE2,..5EB(3@[C]2;C2P_.&1YI*M:IAHO%L(]SI]^@
M3R&I;.=&NY7N<GM)\)SI@_.6<W #'_NLD18N/9EF5OYFU/OF-]3!Y*5&6LCJ
M3ID[V?4))W[)\YK97<Y.83T]5L"'<P=F[%Q"BU/,:54]Z?I&F9$8\2&.I(_I
M8P:C*:^YP(=K2,$RK<$,ZS[N\SGM_7L\(V\,W&PP-?Z#.^X,7'9<&=RA\L9F
M%XF%*8<!RR)L;: VA2;#(BZ8[3I4U3$Q+GTP6LWBNNMC"GA%\TI5AIZ/*>8G
M?B^';6T(9OPZ[$6?E05'H[JNO&HX("(=&^9N_#"GF3V_^>O,,?SP-PL0.H>%
M%A3@V'YF5KRP4P:7[?,8M^=I^0^7E'FB<6N* -8>RR41&5%Q]B2\XA/CN$N$
M/LJX#U2I$ 5O=JS''1>:^?2%KYD 2YY;X0IT.7S0Y?9\UE^.L/-O?5<L?K?B
MN1N6!*,90HK+0:T!-6*_E?5_,3'+CX:"FOB'*G?,N-[*/9HN%]K,HG>*SV=P
M$^#.G&CS9&W+DKWZ=(EZM+C E>G5U0[(?HL% ',FNJ4MP?K^G05-J3-K3SFC
MB^\!03W<YG/6?Y\$XWC@ZTJ>^EWRIPMWY[!\["-C:.%K&LJ&%@MW3 E[NAS!
M'_>XPR5"X.MZ>S'WL"%X>?*-YF'+YY_*:K,+B!8GMI[;3Q2HAW+9$W;_S9W^
MZT>O_Q/KTO%?[M!-QL7TG \OCZU@Q95DVN:'6<4@%% $Y05-,>\&ON)A'Y0@
MK<U64VWVS5WY>2Y1PDXAWU ^F%ZC#[\FS8^F7$1&4#)_O8^6.[U.TF_<R&_&
MF;$-[%4Z0Y=_\YZJ2S0\5B>Y.X*T]PAO+>=Z*0RT0"!;9M Q;$>P6'Q>7)GQ
M?OKMQZ&)SNZ'M7)$,,&BHV 3>*]VAZ;/-#Q2]8 J.V!B[#!P?JE+_'E*RE9U
MVJ?MX+* GH#Y"AVKFYG0-MKEG"N[VA;_\R);96Z,"O03.0<2FG-7<_,48AM(
MNQ)SOFGI)>OI*UWP>8*!27UK-(ER20O!<&2*SK"R=E4$9!^X47)/47&U)\EH
M4!QBCS\SC>AQ5[25&_4!616]&/Y\2UOTOBK)CO9M;,N45I.O=C,65@J9Y>[)
M$5_[\OB(%W6/!&N+K8J1OV/&BTYHKJ7O^RA'X+'!*][:S)4BO$RKYWG7[E1!
M1X<(=<4.M65?6$Q!&1@CT[E!71>>7$UZ5RK7/<)+-Z6\S=B)Q'\O>[FQ^\)!
MR)+\)K!C)R&?C=C+Y,D4LFHJ0^[;*R-C=L8E[3Y8J#);JH7K80\6 \@-0.F*
M38RU+R3%"]=]M(?R1S%J'30%]86)S3)UJ+\<G7%PK-S+R6KA+N@34M\,K_]1
M$3%5N_=4Q$&OIX>9!CE)#+%8>^=U#L&-G89%%;ZG=VGJOL7^ 5QX:](>'?-]
M1\=S:TX%SS".&;+#^;@$M6P[YSH7!/VEM66C_^2^G7],\G[H.^'%[SLAQZA(
M^ W;9 L](B)N/T5/5G/?.D7/%)>L]Z.!%>%7?X 59IP53F2&LA[P\3]X>/9@
MS]9NN^#"Z$P?<\_1=SU(A?^'O3</A[)_^\?'DD&R18V,I481U6U)9C#&$H-D
MWXHL42J%L:_90C3V;#4&D9U))3LC&I2,K5!D&++O^_X;][/<IKO[\WV>W_)]
MCN]Q_/ZXCJ.A.JZYKO?[/%_G>;[>K]<AO;K3CP&W0&[2DY;S,6;^1,KJFAO>
M T3":/D*[G3<R[5)4"*1]@"<8^7P2C:;P5/5-KIOM\ X!I?1J@LH](R0'?=4
MV8_SI6\LQ3\6C7,$ET#;Q-DFG>!7O0Z-=E2YIY0DW;:)2K&)OZR4ZOA^H\\N
M3O"A<;203P$ L0RQ2+"PGZ]EN#ORE"W!IEYA&A^]0]^31=7/?GF^GO[_;4S[
M7ZF9N+I=-98'5YH_2C*H?QQ!D\2;Y;U//&_8%8R_'/]9VW!G% [R5Y;C_T&*
MT=:MF+EH>.E70=5 L@ZWOXU@E#R/+9"/M6-G&)%T/QB;+"EE8MA#ZEP8@^I[
MLUYQP;JC,:@>4"$;50GUKRTG]SD<D]XFZ*+24QR6]F7SY=^\22P[G3I63(@B
M!Y,@C5_4,=T\4!=5;_&$>$:&;Y1/9GY!XAR"X=P7F5+]#+I+/=]^&)0* 69[
M8U,!(V1Y$LK0UVCX9,:'GU;';1[I^VQBU_D6^@,)+A:J7IYK4;=C$MUA0GN
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MAYKTY6!;U/#MQ4_>.>$/EM]Q:&V9H@-+H^EC*>\KJN'#N[)9P0BM*CLZ^ZB
M^!9=6>;A@T"EX@GOSQ)_::@5B([(^[183:*Y#5DC=XAH]M7WAF-6/!A])8#U
M X^#OR!TC#XX.O?SC+#A#?W3Y8K*M4Z\@'GU:9V7GFY4!B;/7IUY0'1Z-VGK
MSIR9=Q/ 0\XKOC<U#"\4/EQ#D,TG^2G<S%G^@+*0KBI_1BIJ_EXV*P+3S<D
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MFB6(!\[9OG.93(\V3R-DV=0-R5-P,[9NG;P'6)#.>3G9<2_B5DB9"%28WAD
MQZ_@6'&.'1?GIGLA96213*A09%.B_%*+4->]]UHUYJN9Y$]F?R2AG!F'):IR
MVSPXN7;I,;O239X]'S[G2;Q[/,P%A<)^*$W%;BL$UQGTLMZC]F'/?G$<+LD6
M;OSZE3Z?TNQ'<<1<HO!R<523;M2.;V^R)):T90=L7VI?%&N2%F UO]O_B1<
M$(I.4=-FN.8,A+]):\OH++UVL8)^ 2R^_7B6<9;RWLVM NZ,'L:2KVT6U[#&
MEQ$?5"U%)T2AT#OM?JIR:E_BC<+ME&'@ )?2JKR)KHGFL8QBN;^HOD*E/!W?
MUSL[AQ*%XL^- "Y!6X3I\K]$VC3&W 5K]=YD8J8YAUJ>P 9#^;=/+'R2R[PS
M)4D6^=@ E\PYE1FG<O)<8YR&4'R<QJ2+SE,3>(YRC\%UE8O6 2PF/P'@ +:;
M?O::%6P'Y+*+:U^B[U-!%G*UR["9UX-O?6"YVO[[<@$T@2W630XI1 C:Y8;
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M,RG5[2PIN@=XY*OH>C=88,4QY&$UR\XTZ]2RO"UK1<8TL,0$LZU;:W/.?0^
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MN&;YXDOCJ5123A=H(*WS95?M\:.?&X-YY-6D8J,4;M.!]P"O/>>(K./74["
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M"A3<' &(/8T?"L$+VQ/4M)G.L<JAWI*7$-<+LJ]&X>I/M#ZK_N-BX]&?KT
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M3G9A25_".ZD!MQI@B "BA:S!?87C,$1=K"(]"G1.?>[3H:8RX,3D;$@><=W
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M_$?YF"H?U?IPZZ&SA_1N7H@NO+1#%Q(AQ%W<*[G*G&;O<ZW*,>7-88;';X*
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M,3^QF"KO,L-6'Q@-/DAJ,5!E71Q]2.XBF]_7-K/N'ZRE]R-*,WM6 S06CY"
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MJ3\[]Z+,@CZ6&B]^W1]F'_TV+[ 3')IH>EY[GL5%<&@&DP_S T<G:(3&KN
M'>>]T B('>_747.!8K_4C ]] ,W EI$$=&%$4UZ:I!8*93@ ]][1L"3 U]J=
M730;U055Y9JIP:K:F^CWTN&X5->,<ZN,1Y!"_UV;O5%.-I%-9H+^P5+ TQY?
M:8YBBJR\?1EW+ME17(X_00(L4[$1M&91'Q*>9%+ U9S+XLR"/J_K4VX0"!C1
MF^:!1<QI@&PJ?74Z.,)UXO:,\B?[T(4U4Q&_6;B):J^;H?_#=;+!?B,/;I\\
M^W<4G2AE]D.O 8A@-!*8\+ T\L6_#8GO57M]T#53_6T^5UA8@IX[$QP)K9'*
MWJ=P"=4P6YOO=8OJ2YJNAE*?H)?8U$:XNDRC>^*NZV?F- KOE1ZN?B"J%?]L
MT.;"K.S@X&B"*AM]0K"J6S_#7$Q<WF:<,750=+FK##L7AB"4.:W^9H?&%_NS
M_WN 4BQH)7C(^^;]UAV7+\NZIV*&KV?=4_.152CQB&^.K9JQRY:L5CSRP/CJ
M\S>E#W<XXRF1ZC!\%P=/KY=TWE"YC]VL9!!5V$[E <47U>O%3?*>W#4GJ1NQ
M8F^N*^'OW#DXWR-)H^1U6R*ZBJXW05>F>JE:L"M+OR/HDRJ+X7\Z)?!O2ST@
M_SR$^N<;4;+0)4\VR=&8;"UR3+3AO6)=TZ+<+,)Q6'O++\NVW$KKPV*N[R&P
M27C^Q'69$/L>FO0$_2LJ_U.TI?S9A<6BDP[NB*+Y3?6P=27)+4\4=+=_[!OA
MNCHW.G%5_:LS."+U/9AX9HLI$6H>]YTIP53&T+8RT\*]8H5L_A/\PO3=?W_\
MG>$ (@[^53@Q,Y0X6YD=H@,ZW^?:MS@16;%Z/X!-12+C!CM<HGY!]+H[ 9SX
M"OFV>#RJAC^:AJHPR:F3,&H/KQ<FD^4*\F<(H%-)02:AV?R\4Z.,9HXWY6C.
M;(ZQ3<<_,D+>?F.$E/S$""%WDL"6:]SY@^E><>TH6/"#M_/J2:%$,HVLF#&\
M$/P%3O[>?\TAV>*Z*.9_)["8A@81Y15T)P9>V9@5K75N*-W#QE[] 6Q2]F[8
MKU6^\R3N7 .]U+/W[?X84_W^/>$M_&D9L5&U\1ZQBIB7'$M&+80CL^!Z:QT;
MB$CL[WL="O>O-!.L'K$JTL*Y65D,K'1] W]456TK2-RE>&)E[Z)4REP*T^^!
MU0:<\W>WOLRB='-(2:GAR<.(3WED@GVR_.P/PDOI6;/O^"I4BDA)4%NQ&N(@
M;,7.BR=^)\'(ZLTE9DS<G4-0$ Z;?(^KFA&VXJ2F*0])0.G;SZLICYDW3MO\
M8+R\PC4R3_,N1\RS?OZ,J+,,FZBYON,N:#^K5?\R]OR33(2?K'JUA%'$OA+9
MOC] &.P_[#$()0$! <\W=401E,-?-W.\NC'WSX.H97?^Z<X#[+W(I+]J:]P?
M+[K &AX?TCF/U2W5%:9H%\GWMU^L?\QG- 8(2.T-MQO_>NCNZ=&X%[>?7<(L
M9F%[BM'4Z+"6;V&7KUGS%VO,:<9;?P#'/C\[.JE?]?BNMGLQ1^94#\TDE"T3
M+/6H*LL-?!R00[[A*@TECUDFQM+*CJ2:!Y6Y01GN%L9W="?K^F;I'_^TB*9K
M!2MD=O-X! [FU>UFDNP4"&468FD=7&;1* T1S7M)WH ?3-F:U5NHJR!<.+EB
M:'&8R=\.LM30GY'I_#C,N!W0WT%VAH(FB_!&[>2;)P#RW@-9F1%TP<R*\6M;
M%) *EG7K\0[11*T27&D<8+:SD44?<N91(<K_ZW54^I07S]?>?F"?&J[S1#C*
M<-..XC7C"W^1P^:4/ 7<>1?PG8E@X] [T3JUN YS[^JU#BR@,G@MM5]!5560
M.MR! O3U+;RK&HT,HE'YIN[X[BR1ZD; @I++L*7SJR;T(<:BF_IH>@)UFR>K
M@FF)90ARS\=C'N,F#N5YUOQ/]2FO!?8C!Z^QTIM'>>CK4W_<;W<0D]E08Q%[
MC4(T.9ZKF;KJ:(TXMQV:DMP)RNY]U =*;(5F,\G73@T_1%>A=VRV+68A1^/2
MIUZ,9!0ZD0GA'61&NZD#^7!FI'A=L[_( _' "+/K_C2M*<46H#^I?Q!O,H$K
MO;#IT &P7$()4]"GCXD4-D0G:IFGC=D5.ME\(^1_K3V5J8(29WA/SB=#B\4-
MAY,NE3>!<__<B@Q:48!CX;?[%=*+73KH%-_;46C'5C?A-)T^LB]F6E[:X/S-
M.1UYL-B) =Y^Y"#>L#=;S>$DJ-9F:BRHUK1,061N(Z!=!D=9+&-/6Z->I CP
MM$/.Q"^8[C[. %.,]?IZZ];NN&_N"9VAEY)9$:_R(C;J^Q_H'1:%.Q0<V/>Z
M85Q,!:2YP4;:472 X!ZT$O)E6*S3YD(\,;GJL8HDH#5)2+[]CJMIN# DLK M
MKM18LTG:84>O8@S$3*U7,TL_O86 S2[5%6W7N2<,&1Z*L^ 9N@U"/1,?+7<[
MBN8+<)C?_8:Z-+8^!)WV3;"%@.+'D^T$QCPW5!R2#J@!.U[_O/>& YQLFE#J
M',3+#"&N]J]WQSP,FX.RW&Z2=MM[H<9HW!16Y &%R$QJ@-^/LND_(IH?R0(.
MI%??K5ZDD_R3RR\'1SN1O$Y/)N A'U_4Z$"I@4M;X_G<DT)P^-"P0*1R/ZD7
M$5(+G;C@K?N#?#*KZZ0@\)3$Z3@?V9%'2GU2$"I>'U@)AJ:??+G&-H3XNPJL
MG<#29NUX6[* 1H9#/AZR$AVA9RE,&;5R9TCB-]48G843:^]X5/ WY1%L'ETR
M7&'2KFO'H]:>9E%0-@P'/LGJB]!-M-3CUCF5:26]<??DYJA@0N6]]S[<-.@<
MC14_M'^(@/O@U8<4<EQ"!CUA! &%XXO\63:Z(]E9OKRAXG?X +Z7$ED\3ZKE
MYWM'.10<ZP3OU6L?%8S2%!R.@L=WJ>,;?1RBOX0%<YT"PI6%9KCP8R?#C\FU
M)P#-.HM#GP+G/\DV77HU'3;LN=ZW!L";\Z'ONZK->)=@+WJ/"B9*VKA+ML I
MJR:8572NMJAJ*G\_7?Q_*CL"2I\>CMQKH20SR(#45*!1>C2)I*VN\2EX/>7:
M*!:?%Z4Y'J6KIS5.Y/-!#KQ=NDP"3&D%*L6;HV36RP)7X@<[$)0KUQW:7! $
MMXN/DQJ:WJ3RU-'(\^R0J9?6/GW0FT@SN]IZL9<$3!YX=<(@,")60Z%6UX<K
MW@/I&#077KF9)VLC]$;YQH0B+L@O,:F*@X/UXX9*%_'5KD*5$^]V*C#M39JI
MA5.&/R[9;7DUXT/!QAT*_U$^ILI'M3[<>NBD:SN\E)CRF0LTE^HH;4[?''\[
MZ%T]QN11)U-WRO(1S+-15NI#9[_\E'*MKIZ0(%%PM*T-5:!9>A?T!37^T[G&
M?Y=L<T^DMKDGV]R3;>[)_Z+\ _<DB4R^C@/Q0A3+N)%_5@\!P[.K@_>C_QB%
M[$&)10QN(1Q!!T-*D(.X:+J%F@V5E'##6/<4.TH$(1.2Z+"TZ2 44VGVX$L%
M@5^%#;DS+]Q^T0#*DCH14.!"OM_L^.""(21<&+C<5V,<I1 />Z-VOI<3R'X@
MZ#42F^W1&M]9M8@V"Q]!_G_LO0DXE'O_,'Y+$LD2DL(HBJBT"5F&9"]CE[VB
MA.S9QC*62DDF>PECS4Z2+&%(69)]*V3?]VT88Y;W'J53YYSZ/>>\S_/\?^__
M.N>ZYKK.G?O^+I]]^WZ^!P)#',ZV=9(M]F U(673-Y!0:499+MS3Z<I>%,>5
MLYJI6TJ>WV1GZ29?C*<'CB9_M'PL"E BU^;O.A<C,'-B8*<T$P%<?^IP6*G2
MB@D<7LY& G*DF;KYX!&75@,\62A4PJ0&D]F,VUDQ'^_-\$@X-4"3M41Z_3"@
MAM,]O="VGV\WQAB&?\ASSD%7L6QUZ_)@1#?TCIK!_-F<*1+0D2:?A1P@('#M
MT"Y1Q"@>LL8PB1'?JTW5:5N53@) TLH#:0:3%F)Y!;?Q?N*Z @.^SX\$<.-*
M5=]U&Y. .S ]^\DK9X7(?TWY[9-48C-(@R(@B]5(Y6CF7G<EU[B_UT@@=I(
M<_+BM*Q3MQ$A-7]\U7W&N"_K_&+DE!;Q\\S&[!.I=X@0\+LLA94@R!J:FBB#
M@<<\Y*^E/)1.&,*DFFCWGB@@#ZG)ID;KN/%_ZH1$?Z(MR!://(U33&6GWT2"
M$$_[?G6;R_CAS2N@J"((C-%+Y4=T>9O&H,EYI=BH[(J'&_^'G.& +GDQX/U
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MS5D+6HJQH#7%.@J=CX&-$1*Q9]W<UIQQB%)BI^&Z1_YXL7-<\6TK";>NH<!
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MB"KD="$)>(U#+21.,B\2RV0(!;(OT0Q+S$3FNKXUT$T.XB,!S IXODCT$N@
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MI5EIVD*%2O1=Z6F!6'OYI*&MR<XSK3D?&G^<MOE'Q&23 "*CN-#:" E HDD
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M:K[\?KRL]HNZA LH\BJ6F8TEI Y.>FK;#M0UQ]J"CG&9A]IFL$<GYPYHUPZ
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MV/3[!O G;;9/H:S"S&&Q3XG%M61@Q>O^\&2BJ]*/C!]1<69]W8_$XA\0J4E
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M8YGD!\BGB!1FT&.!B-49Q)N7_'%TO_N'!&^>V,\V+%63[#"U<D;[1EDM$C
M>44"8D'5U@?R)&U3@O?ABL0*FS?G[[/ZGTN-"UQHHRT"J7UG>Y31PQ<"A=2B
MU^A.3?EI(_[PF4#7A%T79W,5:#1HLZI*GJ32!Z5NAE-RI;.+TEXQ2G8S'='E
M6E8&/,]*WU(5='T%/:#/HK;US"N+&V>JTKVC![3X&[.I+H)3J7IR[;A[4D+Q
M SQ"CG<H*$D+,8_L1C2"@)OK(@%W;JA+,U78O)KDD:--C%,#V,?BTL!]G?K]
M1J!_6"#MS>#[%#J [W;N0%\&]0"GWX%3,[%I9FA_!'_%5L;SEMMYXAL$,"R
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M]*O\O<<T0SNO%2X<CYZ.>+N[C/YDJK-G4N"0C7WL9P6I$BWT_&T2T K#.Y*
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M_Y5I^2O3\C\KTQ+'?V#F"-EQJHI-HV%8(B&S.^'[30HAP@R+&I:@FLM)K*$
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MH=-+<=MQ':4^75RYVU?1Y"7[$C;X/ D<M.\(=_,[)SB?8:%IYW.\A-VBXIW
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MK"++ND[.JXBI:JO&#YTW3W4<\#X_/2C1JI!1W>C)&9?1$@@4-0<&<SAOFBL
M[&_DV15LA$>\60HL2=V03E_"HA4LZ_*1#C@"G_O @XLE)I^\E94[NY&@\-YD
MWB ,2:M?>APX[XZFX6,@15XJV0*(H[S9-=!/Y=O-*J\'ZH,#' @-Y A5H/(F
M"L9)2:YEULGULD6EP!TVV7%1LN<^Z(L("R[L8,QCJM?&!RH."AC<)K;AM+".
M?@1(<M0*W")_2O81T_A=[MEP("IP^V !3%@^RKX3,-1;)V77#1Y-'N8/I.EE
MR'ARIE/CG"_J&VQ+USAB6Z>OV0TRP+YE+FFJ$$USID&Y*BYW<D6%(#P1?*]=
M2M<%<E"+-Q51?TI07/K1W TDO^BWH2:&5ZLQN#(=?!J4S@SJ>><;U:EQS(?M
M^,95=3^0BYMSJMC6 ;HO^HZG1(2@4N$>GM*P]<1Q*&V*\.WY\:;:TO#C/)NF
MN-R88O"L:G?I4Q;883XP78<-4UPB)?G4(PY)UK2$$MGKKO#?&O$7,1G\M3&$
M,&.K.'[9LVCS$\_ @RJK?C7-+4R#&J8Q1%:]A$PYYDF^P>83N=.FN*)1T8]D
MK=IGDR^X>0DPYAE^]#[7)$V-0[-+FOIS<<CQX,[,?N@Q\XA$UM;/J3;YPJ@8
MHIAQ-?5C\UL 4?+8=II]V!6[NR/>'&%1YD.>A,VIUXH4%?$+!DL "9EO?*K;
M-8]?.MN8$S6R#Z8#$AQY$; +RB?5P''%L<P5$JT 6&6ZO=,X%79S2>!N.D"M
MHL3Q@,<^$/!4"\EC:'W9:;K6J@#D#6\4F;^_U!)N18T#3[^DY#^NZ+-,D2 "
M?H#2L$Q(Y#@ERR(]S:< K0(Q'^E,-\?/0R;-L?<5_;^!0XM]4E(H!C>EBR$\
M\BRYK:I>IAO@F*=<]2:E\6J>KZ8I+J;4?G:J?5B06BU54IT6(FFMD>"AKX]*
M.5+C):U-I;I,ASV4UC0>5/038G #@^IQ*L4B[*$TT[IL3$_6;Y<UI&NQB36K
MX,7K)])8"W;QJ:>XFTQ!CW$^B51NR]C.1 =T$3%KZEJR,<E&8Q)/OK?;K*G@
M:W;#B;/4!SS]!2P9%J DTHR<O#QLU#AG- LL(]PT[MG6J;&)@=W O%[R])30
MFR8HK9%GA8 F+-3\JLF48KX>PUHC?J-#XKNR.BG,4(X(FH,>P? Z459B(0AV
M)XA].:EO_:,W:Z$XP250A&KU1?[-J9_6R4UQAZF]1\,-G@"JJ@]\A!+E.B7Y
M<72<NKR>\G/,#[:E-$')P1&H19-GKVY>ES5DU.Q]%NOK^Q7C].OZ3[[^YS@V
MGEY8;"T4?1'A$\R+IJ%8.NZ6-P+YF&V:L7J3O2YW(,,^)4NA]F7O-[.)WA>8
M7(^W+:VEX _CI+F35=#J$"N)?E!=D7Q)T!U3>$)7B%!,P_ '/^KN5[B?:9,V
MLD(M:8;UU06!,S3&GY^%FW=$?E:2JQ8"7^,X'-AMY.32H.R6)0VYJ2@5VN%$
MF_UTQO/:S.Y_,V,;;(J-FU"'/*692NP*[,'!_8V1,'-4K4GZ+EU2_+.:^]/3
MH!+"2\W:%'I9&Q/()8JF[MUK7V^&4+)H/D[92F+$>9<NQ-Y#6602G)-BWZ,T
MJ5MODX-,R*)*7.E2^36D2!3()SB(6E]U_R0^M%=!FTZ(C:6=65FA2)J]G[WR
M36S&_4G%5#U0Y>K:AAU,=[V5I]T=Q=?2D[H%W$Q,]3+:X)()K'+1@3WG"[3,
M;XW0".,KW>$A-7SO>?1^7KY0IW6Z-V9EV<<P!VN"L2>_B:I03'0PV?TUIX6B
M@)72,!NK403<3S?V?3!5T'%SSF&1+/.Z)QG\"9$/0^T\>1<7D[: /4E1?50-
MLZK4?Z09KED0N7D_*GT5,1NW3B:NN\#<K\.OMO:48E@29&^RV9OTY*[XH2![
MQ&SLC*)N7,&#&KI!YG[-L=2U$@FEJV;?#)JU2E!_TGW$;O?W>!F?U_SL$#E1
M#:JZI3FC24E(@=<L*37&\4UK!B@NZSLT>Z-%?5'],Z=9XML6LV[Z/3:_,[F5
M6] 99=O>D=9TO8)$@6I$5?XI9U9H%@8X[1.!>E&+YMCT+;M#0M4K&H6<G+!'
MTF9<KZN4+HS5HRN4-3? ;[^XX!,?<6 JC;PJK2@F+F(]IWE;(3X^[9N&Q1>:
MPJH?<U%1J#N!!1_Y$%Q:5P[\8^I52?-+&39*KLEC:>/]R3#G0+#ET-V6_SFO
MUU6L_I]A@,T/,JC'!*T-5DX'.__.99(2_KOL!WOP.-(;G58*4X@N6V4Q"&3/
MM.D7N_J)>6Y!<--I&[9Q\@/S%H PA4\&P=<.9Y[^Z_I4G/&LIJJ8LG+_!OS=
MDY@\!V08QH_R?]C[SK"HMF31348DB(""DA24)"HY-@TB67(4$% D2\X@-(B
M(I)!)4MJ<A(D2U*:(#E*AB8WF6Y" ]VO.6=.F)DW\^Y[]YZ9>]]W?A0?W7OW
MKK5J5:VJ6KO"KP=8>>!I(4D6-YVXGUZR$"G][!%DX7X08BWBPFW+B?^.9T/&
MQ7=X0$#Q+.M!3U3%CWN,?AZG[>M+/>DNW+#=N,: D*;MHAE)C;J$:"JX)KVJ
M(@W0SW^X982I0'/BQW*I57B'#IV%ITMH$-T/;U0N5XCC5N;$C[D-#\.Y IQ
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M 0>.K0JPP /P+NZ_QWJ"6."UZ;-XUEWG)?'BY]_AS@2B/TQ<3=Y"3X2.&?/
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MB]=!=Z$^'(4GZR@_^S39N;D=9A)2>/BIF5J6Y(,-PW0A/Y['$RAK +]OE'_
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M!N[W*DY'HLB<<C,"A/2EX2KR@2'A[O$<#L8^ O:X&_K>7=J/#I*'7Z7#.(H
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MZ79Z/S))!<6B/;H]AKVSV,LH&E**#LZ3#>;@MDSM3\/F]9;WG\6=^L%R-[#
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MD'1NG\4"$7X([O/0( GZ8I\-=@@W1ZWW3L,;\YQY];T2V3$=-*SB2T)E8XE
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MV%G[<%<P3DD<CS2\P7F/2NG_"M^;<?M\,%]I9REKY).[/GHB)]<N0?;.7@%
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MG 5'S,(R SMYX+IS#X1ROH*Z-:#IK)Y'"=\[,8E/=1QBB-2C7I_1ON?WW;#
MU!=#L,P0R[-]$ R.2!VO/B\CNM;+1I7BJFMKV^_K[9/23=N>?3$ T6Y&BF:6
MDZJFLI=8^Z/2.C5&&^'3CNA%#LP+NS;$C\K<[U'*^>=N<@"49P7D>#K!I0[@
MY?"T@XW&EH;P'.?P&YY#\&\YXR"69I:=Y<LG5%A UG:JT)&D:62_+/-%H<C"
M7=;3?1#%L]$/KSV+P/I'*8(8HA4<HJ=_P&FA,X9C1\)!>#NF3HTAE(2M%$E0
MLX5$: 3%EH5PT)!+BF7O/NK..U$EOWB:G.KZ8J:%ZJ/8R3'EZ4Z1B9+)Z[F0
MI([S_!L3+<LA3?#H":8&/XFD/%4Y8WC7WKEY#LX.[P(W%.^:N([/J_.L/8/1
M8\?A:&8L  _2>Q+\^"HM0&)V%WQ-/>-3W1A2YWK6HKVI!LXX_M<DXOX)?SC\
M;?GKMX-AF?IKR7FEQQI$G1&>W/P@FZC>L:$O9BA:/*->1\/$<^>7A6AW25;'
MT^QFMM,):]:X['TQM$>#3@=TAB)C9]V"<VZE'WS,.8\%1M))^M3$<MFJ.YJW
MU,[:8/<16=I/#D?R.5>!LZ5SC;(EVAV5 3/1I>*@5-LD>>TB@\_/PG%*H_)>
MR3 9T*CQR"-O-29G)PP(^3D/Y'-K8D4L<3I)_P,;Z2W--ZE^N?@^4+9-L0(!
MX7Y=714G3GRO!5UZ3+SQL?9)"#++NG/7&G_(OMJR8-(=.B%B:_2R5Q#X/ 6^
MDI O=[.S_ 9) Z"W-S$2?Y,]<$NKBY. SD0J$R%]Z;:XSEV_.;T43W)=*9WC
M,*!.3H%QKA8%99#>DJ;,*$A*]<MO$EL*(/LYHR3W=IT.LD/;ZQL@:S^Z72"D
M9/2XVU I2(-@)4<PW3/W6Z_4$!Y(._J <?A#DG5^?G8U+9ZD"W<X1+G8+P\C
MZZ,E:.$MB&<K/"F@:[%F:V2YH>22]DWZHLR!'*@'3VK8D,'#R4<W\BZ.<HZ@
M!IL=98/906@<=5@853TGOMW/"2K01ZUTZO%2\P&W^S5AH@X--FT:$GT$N?E+
MRVFVI3CCA;BC[Y0[RT]AY'^Q]QYP36;;WO^#H* B"((" D%!05":HK00$0&1
MD=Z4IH""(+V'$JI@1)!N 2(@AB)@H;?00Y$B77H/O2:4D/(/4\X=3[G_][WO
MF>,Y=YCY?",DX<G>._O9Z[=V62O[MQ_\A#O/^J0@='-VLSA3<9C+8C/>/9?<
M3(\[/0@W/54N /@7(+(-7B=GAI5Z2#@RK%+4820.=*=4)_$RIVXHLHTV&SC6
MH,V6[KV!RY*[B\OLE%N/O'JL<NJQ>K9^?$;&8HGOI>88DB 0Q5@B>#.+OE02
M+(A^ ;:BZM)1ES1)>'4J'D:Y@OPO1U)3B]7'W]4(MS+>!#YA (3U;N2,V^NT
MV<JR;\(TJ,UB/E:EE2QJ5FT&&\1>"=.@N?QSZNC8 L[NMR\D #FX^4U::)C1
M^N+58]TJ(XYXW7B*VON)?O7J,04>^;8[\)\LPV.63Y6?XSA=]@KX2&T'NAF5
MM2M"K%O^)E$\\T2: NTPZ\->ASKM*?6B-X?S=!Q;3^;><8QAP )S@L7%F'[D
M4+W5OO)=/1S*R7\VA=\1WTGI9V_VF1ULR,A^S<L=>S HW&JW[0 Y3'I:_O*6
M-N96S:"NU<B]%L X,U>,)@*:>)^V_(BH*2D?T-\-:W=%3?"9Z9M#K+X93:\9
M\U7IB<\ =<4K7[A34J(HHIL_Y?7)97:DQO[=1-J[>;1U57[]08/Z_Z"7^@Q2
M/(?!"C6P@'^UD_5I=U V9/=^.\N3 '_U[9/8K,:+&].A)Q_BVZF7H'##W=-0
M<BZ#X#J]9QN<[?O[,]>/WMC,Z-'P:N_<3P;F-?;#P.76M4-'M+,F+>% VL]9
M[%0Z[]49P+U7H.TT>=K>5?.:X+8T2@5.%XR]HKA7_-JX+$<LZ&;&;S\ CI+3
MZ9_MIM\/%E $:4FR70P5Y$71 *(C*S#\(>5FT+XCGFBU;U1J.@,$_?SH&QLV
M'7D+"7X&&%!JK'5S0$E1@7[  RP($X7"@6Q*/U'Y.>0<W]KCT=V,Z@+[6GY=
M/=P+*O\'4=\K*UD2L<RR&-W+"?II=U.B>;TXEI$^SIQO@HIA7V17."G(1Q*B
M5F[+6N:HR\N@FN J/G<L,S,_U^2+0.9F;Z/98WU)ZG7^=J_=TU-UZ/&'6MJ7
M5;1\QR#"8' H#MU;SN+0F?G:F)HU(NUQC/F%D='2Q"E6U9O=VEJWYJM GEZ!
M).X0_*1N?[VFHYM7HD:"M>)-X=E@%LT;;_YY4ZH9F=:1LY$OTR0UMZ/[J 81
MI.+Q!+/)A<)C;EV%BN8>[K6K\U=';2.AR5(37=SB8(]1W():BW3,E)J:N-X]
M]G-";U*22XN/IW=>=H ;3.2P6/1*D('#IT=V/L%&A,A G6YGLE9FF6Z=8&3X
MPMQ,YNY"=(R-@U_PHPFWBU6\'^5B[3['&!FJNUQ:RF'1NQ):ILX-/Z T>S*%
M.ARL@J'N#%=7FS3IP-W 2=9^Y<P@5"W1[0;1-G*$%RI9'W+[BF-.,"S4&F+1
MO!WS3U,).E?T'UJ53MY-'5E'%V]P]A[.],@T?'FE_J8@(H:Z=W #HA:(S+AR
MR$Y96.BD.GTLSB=RAO6+![+FP?P5,:>M[?A>:G;N4;?E@:225PR?)&YL3M C
MZ2'IRX'+2U+U-FI1=O29,;-FL^[J.JVF-=QL:V*.HMLEF4G#F)%V-SQV3B#E
MB4KCX'LY;I93S4=3X(*W OX-G*=_/X1>K-J']2H1OQ@\#!=G'-)<#I "AXQ[
M6>PCE8^_<+F58A1G!_<[CLYH9.,JWW&1C+B^&ESQ8?@.<VXK:_U!ZJ(J'N+%
MI(/U0HTB(MRK7SJ86]%\B/5M!C\'0<E)L>=--W@"Z"1YPD,DC%**EUWT+XPN
MLSTSH#OS2\C?")CF5K@XK?8?$C_DC^)OXI+\F@8YLV?29?KE%.)FJ2*@IVH&
M[0ZZ57;HSN[>H$#WTVDI?N=>A"[>_!#=G_WU*E,=0ZM7E[.2$8;5# Z$L_1)
MS6M1[A=E<7M.U_3QL.06@Q2_0QF35](,?YFQY8WC(FRF<S#+Z)8(['L1FM0M
MJV$[V96G07,QV3<QXVZ$Y5G*]0\]RB@R2Z1\]HV7:HZ$S!86#1IF0TRD)EOH
MHC[%:7]*)2'K$(0I5Z'<EXVG1]13_ 0OT6C1/=E]D8ZW$'T621FF!9'/AV/M
M?AFRPPW<UX??6-U8U)MY<\CLM)?.JGQAM-;7JT=;@_%N:0'@A%=QNWE0WXW!
M75FH;I^^+X5>RP);I?@)E1>F*9GQYAM1/B&[6$+6D0;Y]>I^\1N%G93K/*-B
M"3CMI=LDL(]N<;4Q8R;%CZE>GKO[]BF>P&6]]#?[,E\8K,/S%8'3.5_A=W:7
M[T,_-B"OIGE(7-A=NQFIT[=Q$NQFH?KINKIUY(7//>\UK](=D$R;5V2A,EXL
M%[S(Q)4YQ4*E:]N8Q83^3"D7X)JY;#NK1ZG^@],RVG&#KRB7%I<,T)[Y;]I4
M.\-N_V4Z>,*K)$KUV-WI=[=4TYR7RG+9S0]+*4Z&F7'J <0_:D6$Z'G1W43>
M91K/G:SK6#2H>C+9CE"^1B:H<T]JW)%!^&[";$KK"%:K6Q<J HJ<)SW!UI2:
MTK@,566VV"FK67?_O.T\]K3AL9[W7W^N'N7+R%R)4MG,$A %-G:_:8M(>TJ;
MLG+L.T=S?2,K1H.&:6 B6OW%<3;6,RQ4)@(WI"3,*'UU7I?^ *6ST95+S6LV
M'UA25%4$M,68^F/O\>=3"G0Z_,CN-#^+!K5%!(S5.+LA2T=COQ@3./-Z 2Z+
M4NZ.W9F>W(-\".BG0("14L1]95_CI>I4#CWBQ&50>GWJRROATETQ&OL]4@6<
MM2.3SEF].=3V2/EF!*7L;I0"%TSBQM_SW9/63O_+6+.7R/8/1*_K$A9E*BR/
MU@P,8*!KF\?F'-;M0-SR>=8 <2UE(LFEXN_VINJ<<%/QJ# *Y"5L<O8JG62>
ME;$+I_<UY?S)+B\>MBX9P2!_/NIQT 3( U$:<4T&\X'@4:_LHYM'!#\Z>CWQ
M@*=D8UL.0 9P.DN_+AUKU?9L?"[I*T,=Q%GKV>MG+81HWBZ!A9ZN<&8^%MG)
MRXZ'X59\2GIB[PO<9&@QF$7JL9ZX9-S[7%.1]<P_);2XYV8MUV4G,O#0O(3)
M[PV,X6JK$B1T$_.!_TVN_+M&MN>L=^EX:;CE:=/K[!_GS.AHYS=DJ2==EM7J
M6,QF4V47;'*B(P.0%\LF$6,BQY]I>#*/_D3;+LKU:^)7BET,"H_SWOITCW].
M)PD]T$ZB33C6@CX5]EA+GI8GG(XWN<5+]YQ6?>>T*7_?>!A220_\E.(+17BB
MYF,0^(.Y)W,5.F1O$8MIXB(B\M@2&/SD=,)EJ.<@3/57IV%C=&44)0O;/6*C
M^WA?GZ_'K;?+W?&FFW&.74O>3&2 VQ%620:PEY$>KVN;4X4/<.B!!,G  GI@
M&\O5@)GL':@IR+  =FX<B7Q>12W&DV#!+-\ >K+ >$)VT4&U^#PZPTP%.V<C
M;<!HJZ=[9F5HH,VT(:-W,@ ^7).SU+\8]HGYRR]VNKN# ,E/3!.O=SPZMB9.
M&55(FR@[HL/=E<(@AMR=;^(?PD8CRM #4J/N$+_E")6\/$-%)J5]F6$ I&W:
MJ^<%P>+4B9O2Y661EP0:*Q[<4F31A[O]4[Y9UL0LFZ^S'HQ1AI]&$Z!KRB!,
M3X[AX(6F)T>G#!P4962,@O68H^'0[*]HC^%A>9[G4>:\AV<8'7&2K5[810.W
MXXR^XP+U*@0_G-P()AMJ6U<RF/&L7C>$I]M'Y$;$3\:1X<@H*")C8Y'BH&:;
MW_E:J/TE-U:Z*-QK)U=_I!/?E_UF1B@M!]I0,VT_ T8AM/N.6 N\?VT[B)W5
M>B:07G=[=YG_^(^^Y?\],2H,\S:[]/SNTP-.<LE42SY$VG&/2A[:O_.DG"'?
MXVNWG_!%J?#S17=-/^$39_ZB0OE-BB\)*=&Y)5.%UCOMZ<1#.V,47C/01:).
MB/0Z5JQ?P\&B_^A,B6OXJ0;ZL=O;:':>Q88JB!^&CYN_/27/_$+6^TCN&_KT
MC:U25?QV:E0$1LFSF[7IM>YTF<"^_0"5'V!960<Z8LYL)/V!AHWMJ)+\_FA>
M%D__)N6?;VR:H_)5-"Y2N5HK[F%*[VF81]5HVR5_&Q'B5MT#7M\ROP3D\?-3
M\[V3DB(#ENT;,U['FK_[XU2'OLT2H? 59,2!-WK]$X=/ 0=(Q^5>+*A/JCF&
M[W>3."[PH]WQ_U,"?%'!REJ["1MF?K3L_M_"WF[_/YJ[6Q4/><-H=IX]GW1=
M],>"R8#PEDP710SQQ61[L9N=D\Z;.MQ/5!=6%E"@#I!FZBDA PP>84.(TZ85
MS@&T)EN2,\K;F&SUHUL6R>MOV&DS_1LVJ3L'"CO?Q8>4R9ZG?<TO#FKT"4%E
M$&BYO%99T[O2?,MEDL[2'H8G/YDR=%WHQ7TLI-C!5SY_S*:UW$M_3Y;,YGWW
MIIPP84$#3V/;;O;NMYE"W*<X'XNSJ]!P!OSLB??!JNM@O ]&1K!#]8,P+]#P
M1OW%-O6XE^.Y-,2@DT^]8]C/(Z,J)KJ5?2<R^"PY@[V>:-35J7IQZB<>;Y_]
M98R>C&[DPTGE1%>;,$LGKT\U!(&2S608[;6W&)SDQT0.<FELKTU>8VS_R!52
M2&DF*=Z.B3"E?>F4P9<6H&HW*_ZX11DX=XKLNS?(0,##:R%7RC;H)IC\,@'@
M+E4EX,*&U%3T"+'Z9S2=GESY^)D.TM6+IXS\^YS]5 A;W(DE/74/;/I%NWF_
M)8@G9)!"*A@+/V+8,H-S,\+Y^[W..7D;,\H4%=G$B4LUBTV^FO5FN#_81P9T
MPYT\ANK%T/Q<4,?>#YEX2)#)5$3"(<$H<./&G-AR^P:.*[N\9$#@V0%694"O
MVUKH-K>2H7_FG."G$L*W"Q2SB"GY\;;YWQ?+^97F2PQQ&.;(M80)% ]W;9B?
M%_=$MD=^_6++M*6OVN*WH81URO^X%J\6\SENEL*N,X89)\Z7*Z\42-MQK>*Q
M4IS::M56XX1SHQ?3]Q<7-=7?. 5[$I+C1;T=F6 >:!++:2;*>A4  .K='IBH
M>&30\@5!C:+68\A CA 92 :#Z&$34Q0Y^!0VHV*2J'BB7>_0.H)C2VCA6VD!
MB%]?GB#WGG;31WD%!Q(9PEH+J-7(,DM^"1(,4.$!#JCPOZGS,O&G_U#YQ,%9
M "36ZK5R<.EJ)7_Q$K3;!U(=A_?.=N48>_V&Q-IFG%H 4PNDAO<EES[959'_
M$<&:X3KG/=YY*KW7O,I*2%6.L:YCH3)MNK3WQ-X3_S%/_'!9\B>!G?MT#^IS
MIS73]!7U>\0%V'E2T>D/+I!C$I]M7\0I+:GP>>$GNGQYVQ<]0FJJ"9X?5WD(
MK_MV\*#*U<ZG184V;F)%-2(:-AW5G6E:\2(FY6W4XKGPU%#M?B&[D8N=FK]N
M&4/JBXPV6!BW>H1B:4NA$36!1$>TII%$QHY4T3#F8W#.?(>V=>\A@93/5_XI
MFZ:GR<#8_L"V'>45U[75M24<&7 G)KW<V+9YFY*'O..RW+3H=)^NV?%C/2^5
M#@!44OL!,V)J*? O;_X9/D..0BVWL)3H0))8 '$WS]_$MAN_:9VF*M^%*4[@
MH.-@KC=H6B:<&)&DUW4W"1GY:D)0V[=5VC1WFPOQ6%8=,SYLONZB!R9&H)*7
M<?-=^A?&4(<]/8H2O+_MUX\,XPSP(9:Z8Y#:FMKQKQ5R13:&Z[QNX=T+7V@J
MLM+>_8,/K_YO@2H^TR-N1/4>2UM^:,-)@Q45+G]LJNKJA8KT>@%39ZJHRQ]&
MC\KXSQN)_%>2YZ\K:)*<*:FHD!04L_@F!^K*HGGCCSQ@N\<>?WIT7+F.@Z]F
MW9 RF0A03MX@^M!E=6F')1CW!'4A.2*GHDHX0H_NIP9<J-,4?+SC!.X[^T'$
M?6A1V[-Z0O!5[ZA+_D;W#KB9/W<.2\#CPT<R>AE5^UN_3*/-3#B>1NE["8]<
MS.S$2>*H2BXFF/.L*/DH;W,_SNY]93 "?OI$8S2B(4)AD03M]7H[-YLA/#4:
M9D=;X#R2/$L&YK+%)/55=3/%FM<%QO7/YR$P,R8I<*$8[+4?OC=@%\%\(M[@
M5)S";XUQ39_E;<IK*)^*HT-!DX5SL&:CA*EJ]T17K[=E\B1WZAQX!X:?]^_&
M94A</H\^G,3"38OLVB$#:N=*SD<K\UA1B<P<D&?G\D'%&\%'^G8J+)^O/^VY
M*;A*,'TYF__2=JS/]NU%P;4;/-S7-D?=,&N+_G=<],[E03\C#^;UEQ=0S/$?
M&HC@?QNT!R=01XRLH]]_>#?%Y*<VQ?G8?##BCNS!L:QGPFYQ%OWOQ*D&D5%-
M7L=FC8=8EH3V[YFA/?;XX]%=?J^U3:_VEX1?@G4LG0^'#FEJW0)K2]J@#C6S
M!%S:CBVY+$J; YW ;V#@\R[9$BZ33"+@1G!;;N$VOKM)R+KH93?\I\F:^UB'
M=:?PY95#0C&K(J&W#09J'0N7164Q[4R=7#N8B.SLPW7[9D+OC^U<>0!I)P7A
M'00\[L YQV_'TM[NJ"@U3=OA.L*B:<"5_$/;A#4R9ROX4C?/O;<+Q;-+/K1S
M7M#'T7:UNEF'-)VB/TG,"3UU+=8^&9;%()\C<GW5O')2394W(<I34-UQ<4':
M#0LND71@XPP0IYM5TW!X(/E(5U:'J^)APO[>X'<J93%:.HA85 @WAI-I!$O+
M"TZ*?'OVQ>L34;[K[OP$,*U]CDJYHI2.DQ[_$;^T:W:J[EN485##-?C?P)G^
M3X(3_81@0PP1"&P>*::V]!U^&V;^$)M:PRU!&HRIFEKH#_Z,<K]V0"P/VBNV
M*D.2TR85Y9*"L-YB9" BG@SD7" #R6=T\UAQ8.D_*#+H'GOL\;=0H6V&V78$
MUI,;-1,KUY2+-HC*)IYH&1/D[8\>4+:WZ]T.RO($J38C*-Z-Z[%-1;A,W.6X
M\H@3)Z+/M=Q,C/+*&49,JJ0<E$U;KR #11BNS\L1R3B,!!2>FCZO.3NEI]#L
MQOD<K%XX/W/$\5M7]*=NK'*61_N[XJ2GJI]P+%T.HZ)2M,E<Y[H/_&* Y"46
M'+ARYI!?7U#C.Q33E<_UY[Q-JO*'/+^T;9QKYO-6Q"8K3B %KOC'#F<Z5TX\
ML8T0BW7N=*26Q+>?[="WZ-*URA=X)\/:%=TGRK]VX/W7NV$Q!>X4A\0_F$7/
M-0=UI MAJ=18)44Z%MA 6[R,9L-<ZGCT4B?LSJW^G1/"NB\-3M6PRJC,,$B"
M=WKCAVI72L^_'&:4FD<8;;;E^N;/Y<>G;SEQR=?F,"@;(T]^G"<45:%]7Y1H
M:THZ<[)\9%(3T=WDC L>0W9]/+5MWF:"Z04U@^6*3I?.F!U-5QP5 'QH]\4>
MY3ET & #7)!:"8,O"QAIZ2\]RK=W8]%4E._ZT>M[_XDX<_.OZ&],IL N/N@Z
M_.QU";-S8DU/!+V'T Z#-N0ERHFUOJ7\AE3KQ*PQF&7I.*4G//_1-GB//?Y,
MT,?" W0L_!PNAB752$S':Y7EW/EIF3\!UX8L ,OH(_7T\M^\2SG(=EOFLO0.
M2)-0"N5^?\:C(QIE@DQ\=1<3&N (S4DD Z,)%4_'3W0V*'SQZ2UJ<R1Q26]*
MY4P/C]FQW @1'*++X;^U\B5>I."JIGX&+Y8KHA<)N^H5=-5/@(WZ#9?@Q^&V
MEX:^!1<;NUT/(%>P%!NX4I.> I\ :S]=1>*G*,K6G Q<L\X:@VUMJ6^=( 58
M]SZ#](H0G4'X8[JFA\D NAI6B<(>,\F##,$6>[SK3+?9R,# _+JRCR*+?I2/
MY-^SVOI7W"= GTN5IS V3(FD$-!03E39B"X9,.8GNL"(=+TFAV($53*$DA[8
M/LFZQN3@5KI&O+6\I0:919 @9*!O-U< FGB1\MED8(=C*CUG)./KXM9G-*F[
MC@Q<&44US,'&),G .]@6&2 #YLH$?A!V-TD8&5BPB4N)V'WSAW_">XUU/>]#
M$QTGK*H1(H+Y2]!O2L(YO(C$X9Z"89\ N$#.Q6YQ;Y4<,F!6?W8 )7SB9 &.
M!B,I%]L*JVZE7 2R?8P,?,@:889,#,'F,\G S 43>Y-Z:EJE;.&'0J6;EF>@
MG6$++X=^_^Y4TG%W(L7C:$ 0@QWR]/4WW$YNPTZ0'D ,,@8W;AW3)G4%VUU>
M'$FZF' O=-Y_5G_^\.]#..0>*-.Q;A*R&)EVKRID(5"*^+Y)"K2ECIJ-_TNS
M;A+%?VW6R?0<U'T&]!>8M1GJ]8KII"MJ!0'K%"' R,#'5-*Q9?Q]BN=#!C8D
M&C65/X7<)775P7:;:!XV)D<IK^DO3:1]>VM@4?BCI\=PI:6O8W08L7]"<#B"
M5"&"GT'@C[Z=51I@5;]86_QVJO<3&>#MH@BC*;F8O]Z](?1L=7+LE>1.YL>-
M[5!J,B O\4W_R 0"-T\&C-"DH.XT4.AHRVL#R^FOVM6(U740@=(KKUIC;ZZC
M#L$HY5\1(5)E?3W7NQ7VR714E6"Z&QGU$UCAR2HCG-1#+SIYJG5:]M@"F(K0
MIB;5)AFN\9B6AC- NE=EW/X(VPO5?5'OU725''S\,+1KH%!6Y!L/3=O++2+B
M#(X$H5D<;R\2>=4F38TI/*1-IWK\(]OCM,Y<54^.$ME/S<QY$XP1Z+[(/GS$
M5+MQ"GS:#H.B6ZL3&A[:C9.Q%T?B?XCCL-AJ6/_Y9GKK(+8:[ZHGC0^X7D U
M1Y?96K)_:F](!\(*F]@X'VL.160[#8.[CY,F%V@\%9JET+H/&MGXPV'X;L;
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MA>X<_7M2Z%T)[?X;#10?=3<O 6)#%K3> ED.)@.''I6P,#][)U&%U4"NLTE
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MJPO(P,7!JGO= L9+9"!K_R,/4^)#,N! !L0,<!_'8#@DL890IW1X:P4G<H+
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M6;%\0@8^OOUV2DX51YV(#).#*(2G]@+Z[Y5YGA_0HN,Y*M_ @Y5ZV_WXQ9Q
MRO/?5D-9)0S-G8\IE:N);1VU>7I?T,&#MZ<4W]3C<L]-MG8,/;^(PT+\-];7
MZ4]F+:-=VY<JQV-%'!?P"6DL[]/4&&F@'?JA7G\Y3JTUP/A"1Q>,,*V.E "5
M-,=H*O(&_<.IHZ<H5*2% Y<?PQ ;'@%=%(HJ;Y^.4KY;=MQ,R@0S;Q)^6] Q
MH?C50$;;$ZV'!JG$-)'- 1(>,J&\$8,:L=^9(0//#,A D"]L"3;13)+06FI9
M9.AEX[-,AS256]T,&HH7\M63XD@O+"(#B^=@%2.;7\D !R0OC;0#&U$F6.=;
MD8%J"&03LCI%>3YCA\W;**NGVFBM?PKV7V^?OR1%_SQ+C"]A34U]6*+E]W\Q
MF^?E5OC$W/$Q>\-\5W1_V4*KRWT5IWPO;.$#EWLQ78G+']W@ KF<"[^8Q/?E
MSOH[=(=0/B5>C$8PX9$XH9LZ:7K60FX_3:;DH.>@_08$E.?6MC(J8Y& UY=R
MSFEQ)!@JIZSB<43K0#'SZ$:YO*T+_:.+5U4V<J&/#SRC&YK;^1S@BKFLK&A;
M-:8/JZCR6&S$NX&RI2>JPP,%JDI6E$::<[%9>!+WQK1I[XOR8%63.B%;-QO8
M^"#X)*(W=]Z8^V5VVF;SIBDB9@?*30;:LIVN7,ZV=I.L2N^&)X338=-S_5--
MKNBIIYKVI%TK&UUH4TC)G/VDPG>W270$$R4#LI]JOY.+2/"TZ#4OE\D*9M'4
M$DV!"P"9')./)6_'/%>2HJ5=/H2Z/4SIMQID8 5$I-/KNP]MQYF^9)6CG7%"
M]6N1 1_4<BI)HL?*B?V4GIF*U&0"HLP&GM-&&5SFCI'VDX%D#IRS@=(EW7C3
MKPE%>H,CR0^(\/I)AVM7U)-S+N[<-%TN)&)A]:475(G:9*!HI*'WH&9,M7A0
M3DG$\7ZK>6\)F5OLYU5DVK34[\W?P3T=,_TE5+RM/N*9BOZK=6D! AVE)V(N
M_2,9(S!$?Z4G)6.9%A(L_]/BNV4:RB@G_LLH=TY7E9-!!?N&ZI?P+HLN11QT
MW:!EJODD F.EH^XE6[8[C&+;SG@O'Q_U43#.9J!Y)3P*$[></#'Q\6;6I*%P
M,L59?>.PMX]CCSW^0"SG^_4W\B[8EMH1RR8D:P[,1L[.WV'1H*7Z;T]":-OE
MW[!E^,9WG<^2?@[)770VF6)I @9(7LID ':"\/#_:^_. ZE<]\6!OU*1L$H4
MPM)&1(,,F:UD(^S(+!F*RE29YU@BE+ ,22FSS$-"2"SSE PA(IFG99Y9EK5^
MKSVF[CGWG'/O/7O?WWW^^/Q1K=[W&;_/\[S3@RMKB7_&XG66Z3R[IPP%NW?+
MZ /._5Z-9R$Z15&(-EG(TX$AA@3MV55 6,$0B:?6VA(Z3PP?T=:MYX1V^BMR
MQ]:8[5BFUQ31>6 F<K[!\_GU)SS-21>@"W*F\ @C<XL$2260(.Q#HK!P5BK-
MIQZ6^\/4 P:Z0YU0RZXTGK0"O<0S?C=#?Z 3]'70P.@?.'LP)0.>L)T_@1W+
M0Z_.HVLR];YP=?4>YO.T";]2*?V4GDR87HM)^)USO?9C?AEV[Q^\*'&G(Z&2
M[\[F*K;34R!8!O*BE:&(>P^)^]\,I2R_P0[MX7P.46A$)GR=HY;=/@SR4K9?
MSC%<#P@]"YU/#'6EOI$-SP)D'9P?>]L'I.RIN>05@+_68?15PCR%>-)>OTD4
M,;UIRQ$LZ.-@@M$GUTZ!XM-Z+8*[65^=OW^^B:E#1<KZ@NRWIZ+)'#0(;'U5
M2,&D32TX$:(!GT@M3+\@(-S<9"<=I0 />U "4]+V[ B1Q<F=V98CNO,<NYYX
M0IRAUA"KBAE9NS::P'FP;[$;M;&&'5+!Z!<$^UPRX0R&Z(YQ1GLSQ>YM5[O8
M:\@5V\O!N\/F\94$Z:="9,+;Z[7]XS>Y@>OB^]Q >O&Y)&B _34)BH9G%7W5
M\/0AW](YPL3^9A99C98W-?[:Q9WM:IK7.D\,<>GIEN_THO:GY$C9:B3;3]<Q
M/DP'-<CLW$$IMI/-3PC"'7OU=98L,%_EYRPSO1;C\CL72JW' HH0V0^ABN.G
M(TO.[F*@Z1C4H_D@$,O-=(-*<"),"[T]85!+?%HW+K@W*J<NZ&P30T>0E#6-
M'CS@I3NDR9HYUO]PA$/45$MTN5P8L?UDFF<*'CB*R#?TLUS7Y6].DKL GTK^
M@NT7 :T7 ?O.L]?%>HD'W'CV3;W2=VW+D")[P$%C" I5+(,<Q&(IOONBL_BW
M#<[SE)K<UL?24D.Z>(->W(=,@Y(\.;\O[% :X[V^^Q-3&EUW.7 .17NV[&K@
M25MUO:?MO&B@X6A3XC7&:A-V]B#/]FZ4H6>QW]"TP<&]L*F&)F"IB0;2C?=/
MEL[95<SX15.;55;<2[#YG-F.D6_JJ.[DP8$?[Y<_6N*5H6!QH"?CHM_6SN"B
MVO9G/7I(3:W9^C7NFB-50JHQQ#24FH;>EFO(3$VS_R-[X55FI8#:6!UU%;%Q
M&GVX1K*=4N1,,<(=(J:'NT[:=#()&Q'I]EJM3R,W"4;SL314O"5)<0RC=Y)U
M>@*FKG0U_]3? 4^\T^PF]UW."1R1N]HNF,(AN70T85MD,R,_YQ^TUZ=0[0?^
MZU)4P3*UK'**<$5NRV'KMY6H:??YQ)NGK%XI.%W/W<XXLQU*?*BODI+*_DWB
M(?WX[Q(O1&;LW[PM*1;5WR2_99?_]\GW//E=*]'W&KA-?SZ 2?5<XCZ;6K6S
M=&K?1KJMT/!M\(N#L\FRNO=VDL*5-/''[&31XI')WT8AE6_:44<#]'T[TOJV
M]<$]*KW[FZ:D"]??MTW) K4]5*;T%U[VH>/8K=&2NI/%IEWS$?1=5I'?-I3_
M?;V!P6<PFRJI\"GC)<T[F23H58Q5.YN"]>WO:H=M_W<K80.D]UMC^U#VB*,[
M/%[LF9$J41@4JY-2#2((O?%R3^&_Q,'X[J46A^0Q;D];9^EDBARVRSI%$FRK
MV\;M*$.=_EG&*,[[7/6>,:GGW#!6:FM!MHC4;6OF5(OJH^+^/(F_K7-W:^<F
M[,T9Y:9%&5EEQQ$0!;P-FOUS"IE.R^H;RLI]I6*LE/UP&C-=UAI+M.[,MQ)-
M'0^Q3&1=LL!R^,>_/OE6D!-M[4N":E5Q-G@B0Y1P0/#PJV *#6],\PL78?YE
M\]F#KL'9*FY",G+TVO)WM6_Z&56D:ST[28)\CII>[K^>QA,?4O-W+_$T.*?_
MNL&R@8%M-.^O&R]W>N@0',8;3QM5GDYOY6N:;.5+$"-!$6A42S/%2BE\,IU@
M!Y]?)TXT-Z@$G,D_%DJ\2["?/D;D@%=D2,^LRLN/JO>&3& VQN'\B0]:?JJ'
M<Z4Z;#,XDO: Z^WN@7N6'4%\^6UY(SD&Z>W+4LWK4WR(BL<#O8FH"H@%[8:=
MP'>JZHX6/A#;$'[U.>.$4$(CG%P7/[5=(Y&]J8&U%(ML@[E"6-J'V@)BU#+K
M[M)8HY'9'@O_;D;_8&\O5P$N%0'SD@I_OL-5XJGY;.HL$DY+2".CQ5H&(;.&
MC/:#4W:17L7'<>*?'8V.C9103(3UK&]H"T7S!<>$:R+NA*T/HWFKTE^:M:F(
M\#YW"T8]99BN)/--0'HTOW^N4J)8@B)7ZJL.0,S2[Z_MK<,O-Z&5/K]JIUNZ
M+=N6,H-J'M'7ZGC6'95%232*D?W)UX2,-GFGO;#PJVYA$V<SPFN6TX(/<Z5V
MY[Z5(<)SQ7X4?E\ZL_MXB0S[;+LK4G6Q.WW->Q.>U92AEXX87J L'&2/QBDO
MBB>U)?6%U.B8#I"@Y3TD: <):@FT"?^TAMX\AR[#+G$8OK8B,!!/P8M?U4#\
M0>%3RZK$(32'/I>3:P0>CDXVV) LN@3N-2Z<I&E54'H%%H?9&%NGZLXPHOIU
MFTX^B[=36[MZVK<0F>$5;5'@W[I61550@F7.U+9R\Q#6BY3X96%\XZZ<,D-Z
MHT#:^96=)(CWP^NY]E!W @^A>5ATTU+)GE=S3>.& U];<O'Y>JWCUF+<']YD
M'I8_Z-WHH4^,[C/26$.X.8I;7*)F'VM?)N Z7-<D2]3O?.@@*D3XUXH_?"Q^
MJA$^QQ+MOO@__34[ /C_6P;Z8%^)3T98E?5D 06T[$#A13EN:9S>U\6%9^1B
MDJ^1/S\NP^*%4#O+=B+-X@,N@.MI 3\C!62]1\IS.<UALF_N[B=T\RF".SPE
M2-O^@I)^G?:I;=]GQ^Q#U^;U+=>H;N[L>.=\L%>;DU$3(NN$J&GS],\64+6*
M-A2R!SW=>64IE:F_(PZ.?&OK?L1B>,X71[4TNW9V"CL6090F000MZ;YRQ\=3
MKQ*=K[%[ES11BK'JI3_1%N$+WMHRF*V>!!E$D" 9UTE<=&IB=1J/__7/L</4
M(74['3D^OJ">PTT2&>$1]AT)ZCP(1]70-_!YOCKVY0\$8:L7.8_INZNN1#4Z
M<[(-X[7.\#&'CZ(.8(=&4)/^<$Y4#:,NN2;[9B[+TS4^>T)-7N0'A75A]!2[
M;LY;+,WZHN:GX*C]";M$GXGX^M#F$ZX_Z>D]B3-(4SE?+QE,8>M^K,"&4S^;
M;IZ"<.<]G.S$K2CO=NOJ9^>3'P8B=3#'AT.="NNYN1/45<I:ASJF2Y$D"&.&
MG@Q XRG3D%^7?$_!W5L=QC(^9R%6:ZAL4M9II[\'/!G"F&,G V+P>[+ILET*
M[]YFB+<)MY9A%: LG]"-^?J_'W@IY(+Q(T%#HTC\-))XCZ_'DO:[,B[@N=T?
M4G='!3[L-;A*X0*,+7$)= OZKI!SM[4#S;:70K9(:O30" F:?(@>5]PJ/"/?
MS*77 A7/= ,.%&%V>G^.46I/[*W!?+/I\S!?MX,JS>6M1B<"-SH[6C+N'+9\
M#>(^B5/K\-$P6!+$<.&T;O.:"5SO\!K! %Y%RBC!]1Z16/TBU9^A.W$X(*P>
M<N+^D*69$\TUB%A;?T8L5MRZ>MR<?;5PSN!%I5 VVZ5ZSEF;4!55^21T!<5U
M$B2)G5\E08-I13[&)&BK4+J1^"$DT8L'KB:W"W#:X-RW7-#?7N)R57NM,P\$
MI'M13@3+(Y1"HFGTV+9JZPEZ,@^-WY<-E]H]VG=$%_30+ FJUI@F'#*__8Y7
MP?<<I<3G?N^0#OAL)K9%B =]\U,QRY_02X>R2E-QD3_IQ=]/,FB@/5O/XJE@
M+&5QL9DV"SN (=S!;MI8;>[AR]YV5*V24Y7:^,M,5R]DR._Y7.LE,Z/Z0L,X
M)]709%Z"**U!+,PFWEN>Z(A(<[;HT[QZO+[(LTSB"=R1[R\G1ODV'\Q6V5Z.
M+=L.KOU]H3YSHI-KF#\%]^K&ON5NU4W*SM<?66N]ID\RO7!>:%+D=@L(M745
MYIRB89,R[-GJSBM^Q,):N-GXPR&!DC6"L #WPSX2Y)]9O#T:B%B?3X8K:^49
ML1#NS;&1\[RKS^X?'-#C9M+9N;^-/8 M_,'V \1)D"L\@6.-]%6X8<*KF?%S
M):]??E?&Z;:^,WM8_*IFUU94\5-8_-[.)YV%WQ6RI>#V]@4?^LA<+5':B%A8
M0+P7#I??BS6+/F63X\?R[Y=+/)D[+U6_E*ETX;/9(A*NO868Y6KT$G?6N9)D
MS;F.TI2*2V%V9)Y._/UT;OLGM;[I& P!).BK: %7^7<1@G=$F6G0<*LK/\5.
MYL7@]V?@5PYC=G7K"RK-CSP/55EEXAQ>LC EL#L:_?PL#9K("\?"?V_<_?K1
MS+ZTU94]'KY[Y-5R0D+%]RFP>[=K!LRE]7V]?7OQ]HBK>G6 [S+%@6HV5COO
MHN:+,OTYK#0Z_!DW=<CF=8BZZ![5S=!B?'.'/:/#K5+7F4_/[S2>?FXZ$S)^
M[$AN57KI&KRJ/D&"IF.(S0847Q=#]H0>M;C*[!''V1J/&V(U-JL/EH5ZZ.1]
M7! 8U-#*UOULS_S)#@P:/OFJX#LV@YRPHMJS4#\_ZR[.*>KYM.59,KAQ/3*:
M0VW2I&SO"24^7KKL7D?NZ?=?BTX,J^=<%H(;;([A+L,-7>2W497&;?K*MK"2
M[@$W0D8V2;A&CZ'[D7CFSN#.-]^-MI>^/9 U&UQTF"YL/QI/KI.M+>5W+_,F
MBRJ]LT,3[9B4#(57E;UP#ASUK9$,Z!&_S3P2](GO;O:M[PN-U^_K,HJ\TMI,
M@!>!CTG0"MSO3;.(N4N9NUFYG8*+G890@BQ#HAM5^,B6Q!K,D?DQ@L>[7UZ9
M./B2[Y,5@<O28]3%Y-UK 2?1<8AE-WELRO;6O>YS!:YT%[E?*KV[ /==L0D;
M)YK>53,LV=Z7$[9U/ZU&OL/+_\F[TKSRSEI6:P@B"H[7=^$&3V, -ZNO<IG\
M<BX\T_O!((:VJ/SS6 K[G&Z0+]QPS_!YKJ63H..HZ61BO<&F*>X-M?CK/BFG
MFTW2-QB;!%?/+]$'?QK4ZKOS=0%Y;TN=SG]06K<><)Q[ZP=WB8V?N\19O65<
M+19.P,;3$<S)KOK/0[&0-2.M5ZCC;N<.UU5/>'QI.+6&)/JV;V\FAA7EQ_?)
M[*LX:2V@JJXX'.H:>;B04S=[1[9[QK9)Q9XN9DG?DI67V^=>6+@M!"#8T+6/
ML'.(31K+.LM>JRFZ36JZ@ 03#DY[]B 9BI0,S#?'$45L-?FIK29/EMZ9SE99
MH?V:EMM?4GR,PBXZUKO<6)RY*Z[82Q3ACUVH)':CI\++.E]_7VH,LML#*+_9
M&)$!_0Z]84J"<CO1E_#:WK1AQ74&Q?,Q3X-LGKL/NE\P4S=1"%Y;)**N_[S?
MSUY=AJD"(ET^UDXR9Z2'2>*Y/41+3M:BN:U3W*EXZ8P@2L;_4N>W+B]_7V(Y
MZH)E*=F&VWJOVO;6EC;*$(C?_CX0KF33RRC.2^W1S6O7@N[MKV-?9N"0Y"T@
M4,"M*0==1H*6=F>1H&UYU.AR5OI87C6OX*??/V/7OL_YN(+L5LME*+L#AZ?'
MR)4V$G0-[ES+!KM9+UM%%[\V10I2FS)M)+I2G;\YSSM;^D?YR&Q/7_I_4%IG
MJD+B#&7A/K'Y<Y^(/>&Z;-*WIO1QLW&A-N+FM1F;%DB4FD)&48)<TJ+$K0P]
M/W*(@("#L\7V-I)]]<IC2O;[5P^),G&G<BXH2EV@^4QW7.>N3NG';8'T'CR
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M) B?+O"&YH=3)_G1;Q7'%HCGBFV[[RRW3:<&'=7V2]WZID"LY%S\7^"18@
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MIF.4>N.+OM ^2TMS$-%-\W^6O/6_Q_G_[*M+
M
M
M
M                             /#_*Q3IT_\#4$L#!!0    ( (6$8UHG
M]#6.:<X$  &A"0 1    :6UG-C0Q-C$U,#E?,2YJ<&?LO =<5,V6Z+N;)N<L
MN5% DH" Y"P" I*C""B2!"3G((V@H-CDH *"@(" T*("2I H2024)$D:FIRS
MQ.[7?-^=.>)\=^[<,^^],V=FE[]_6]6]]V;7JJJU5JU=M;'?L2B 6DM=4QV
MX$& -MP_ #M);JZIJGI=WU!/7?.*&@"!  #YY2M.;NYXU #@ZN;C9:AQD=/\
MJ@4G41> !Y  A( H -C8>GOH&*D; [BDJ:;*Z8T["#B1=@8 R/'_O4*7]3DY
M@?^[1&/KX>4# !!]7%[<SM[;%I>_A\O?]O?Q./Y^#9>GO^ERG,?#/\Y[X6X0
MEV<ZSCO^F3_WQS%_YI6/\W:N;G:X_/$]>]BYVAWGFW'Y!WZ^]K@\] HN'^GG
M9.^/R_?A\MRW?5V=</G=XW-=[6V\ 0"?_/A['WO;6[C\>5R>W,O84!67EP<
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M+[\_?SL>E@ !0 I0 ?0 ,\ !< %\@! @!D@!<H RH 9H 7J ,7 5L 9L@5N
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MQC#+#E&CU_\=HIC%\?5UJ2/?)"QP4>(B\D3I8^GC!IAJ1^H27TYTV3^ZG4%
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MUU$*346KF;,7:FY4%^J/%[HRZL,U\*%N]^HIV%@<9L\=(X \U,4"J4H[O5C
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M9Q$\#Y]M67"TFTCH""OHBI/G"L#/!U,'XUIY0-[3LC)L.K,O_6JB\CU[;2Z
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MTW7U;>X[RO#B?8]M*9XE 9,)1%D20+C+,[#F*5=+J)UYM2*3&KINM__!?<>
MRQ5.;?@$;P=W"XYYW/S]C/!]!ZQK^UA_FR,!X%5PID;#2NQO4U:T?Z./V)O<
M3^29."#W@-P#<@_(/2#W@-P#<O];R47>&5EX_3!NGI\K(B!@T($#6TF%EG)
ME^\H*SU^5!1Z"G'X+@?@D]"\F9'5]&445G'+-IXQ4WL7]80<!3K%_F6YN?)H
MW.F"TJ@KRY*FO52B#;/;//;*YKWY5G 9_;='Q(+H'"5YP^J8?,!I[RU_:US(
MZD^.[42P1+K=KQQIE1PQ'QNP_(^^B_[?Z1<\N*H'6^: W -R#\@](/> W -R
M#\@](/> W -R#\@](/> W -R#\@](/> W -R#\@](/> W -R#\@](/> W -R
M#\@](/> W -R#\@](/> W+^1ZS-B?;JL]/F%I1*S7N!,X_0VV/$P?%ZK\Y)[
M094..QW'V(JZ7 @_D<=8O\S(]@I;'NM-$7[G;^_G\";O0D7"N_[9?8D'., !
M#G"  QS@  <XP $.<( #'.  !SC  0YP@ ,<X  '., !#G"  QS@_PP(HW;J
MCLZ9>6CJN=#/T+3!:+.BQV1E2$!8_]YQG8<ZK^':;H<9%H<'WC/C#P=8SO"C
M SBSND>->,A/>>LS6[!W5)Y-4A;MQ7>A9^C;2, S_T&BIRH)\#E&L/J2FL0^
M\31-=Q Q9]+7=@/7&ZCKM91%-" !@W*[Z(PDP\69'&+&4?25&S,!5"^Q5/A<
MT)TU3@FK<H.ZU8+-.^*0"#YP]:UOV\ 9 ?LG&](&=64GDBWL&<6R.2P[3Z5B
MQ+=,3QYC+(6*LJBX-UA48XLT)JP[A:QJ%939M/YUU,_O7R]-?R;\>WQ> U*^
ME;T;";-G\# .D\-O[!U5ZEN8M(0ERAH32XJ)SZ+F$W/A+FR::J;_ TXJ_"_A
M[L(Z3?;RQ*?4.;SGX58I/#^\.Q1/Y)T2M_JA&UY69-?6G,PY&%:NFI1$&P\B
M\%\>7AVX\',K :_ZR_^-3$D #?LB884$8/%[)\S(Z;0_['#=GBWV=E@]TRJ:
M\$DC/7/\ZJIX+PD8.5FT-]O;9[B.!!R7V_?3RLT+M5>.OXLQO=G$2#N4'$ZQ
MH)IC2%XS=)M$#Q_\\E[UCV/BA&7VP ^!OF%6$5^':)-:V1AVAOK\PV4</[1U
MN)2D_,7;%*UYJN!7/QDRL'TM1#SS"W<73LZ3C:YQWR3*69  7Y^IPI37R;8-
MZV6>@26:IRY:P.C"%;!<RNKD=_*MQ#==V.(A(JRFSHB%_T<G_MXUR-$YH?3Q
M'C,M9ZU4!C:7-NON. E@D\./R\V&DH INYLB(65\G><6CHY<?5X=M2:L (*X
ML LX$0^1-X?0WIA'T:S$E'K_OYRMA"/<Q#>NE047*2MF%!\.8&T*Z _.<=6_
M^ZTL2#*.T_T;4LHBBO56S:WQ3*1U8/")OO.C;.9^D7 *=,J.=O0X#[/-V/54
M-Y#9X3X-/@H5^;5:2[YAV#9+R16S[JEL'YK!1CMKEALT]F"&+@;LHXT://([
M],L3+8Z_^IK:=O;I7SE-.%<+6"B@8S@W+#RRW/J+CN.+4O;:HQZTM\8RH#=<
MVC@ QK=8S=#'AC?[-O2%<Z/"(*+9I3_XY/LEI?T1JZT>BSH9]/_[#%7),*=[
MDPV+19" (KWI9Y.ZL7S&9IC0M5%;K(6RQ9:EMHW6]_.&0%O924<0O:JCEXB6
M7^"_=Z:EJD1-[<NY8PYT8O*-,*!-RTOXVDK8\Z(5@4[I@#S_.<$(WV1>N&E^
MQ"*:4)![>@Y>P1XV<L+CW/P#=3]&BI%/?B7SW'V&#H-I'#FA2GL38OA*2@Q<
MQ*0/:W;E ?3+75V7/V5?L337X@L7#W0Q"S.DO"<+(R^),WLF5=0Z;,N8!/!<
M( &&9$NH=.WQH]/K>7NG 9_\\T>^>U]G:D")_RLBQ;86)I:IEGA$6Q<TDL"M
MD6DHD)]YV*M?F(.;#3WG)5*>VOTLOB;Y>J#KH]I#C2^KF-3:^/B*/+6E,F7"
M&_(L/5[6X' +P@YM'),5'H*!3\:O.&12TT<>VGU^VWY[&BE& W-"IK$)V-MB
M/WY3=JAD6;<L"#G7'C%Y=$B!R%ZON_R]#48M2=5Q#??]I778B7M57^B3^7XF
MO86OWU8@S"K=[![IZGUZGH.Q9$8*J5#-B>6$;&#XVV5$+A>7?/'-ZD:%EZYQ
M@ 0KB[V388O^,A+G@RQ8YD_6N0L[0H<C&D (9-_DK':'XLW\5,] %;VO0%M\
M8C@M5I#RLW17-)[[],<8VW@!JH8%5QS/6];  ;$A5TI!'K=TS/V."'R0Q!OI
MND<G! 7M-=$>;;!I"=,TQ^[_B5;[]G<C@<1A$>%##J]-DF5C)"0<_K D_7*S
M'\F6!*S(ZJIZTSJSUM55^90D)517![I>)?% G4J^C F@BKP%4&:T>(35D("M
M;9^=T>&=X[J)[L%$6!H)R!7SF:*.TS&);Y]:'_104WXMI@Y0G(I4GQ*-K3 Z
M.;*XM1U +"/[XZ30C9WC'Y2'R-M)Z?_U+"21"W4#R8]=%QU]C]XL88B4-)%F
MGM6395B.&AAJH<_TI?GZ-,FOP8*K;Z?S R:CGVQ;@O:-*>CG9SXT)P^PJ$,!
MQK1+,ZO#(3OY60*QD4RY&]4_^_D![SBG7BHTBF[/QDSS+[=$F6=$F;- =?G"
M[%-XTD<+LUUH%GM;0@+.+("+[+W ,/"I\CBE)?.=)LY75JGV1R+%9Q&4G;VI
M[G,.4[)'OO%_>^<N4/^T1N%.N,+='>Y$I/STM)(Z[>56LCU.^>M1&X:5+\LU
MSP>.;RMHQ%1*5\NYV8KZPZQZ UPF>T8>OZ>C"<<TT7#0I97*%LR)S)K!X_C]
M>>\_!PZI"P(471/QAG)?3GAP0^,51)-LMJ9HJ[14)RCF46YCY%T3,:C*&P72
MHN%E4FC@79-,TP4O??IQ%:EK<M56]R&<18S#;_N0)YZK9$'(JBJ^_4_$'>#_
M5V#_58'W8G3#MU;_+FV.W#IE 0:355BSW/K WK#*HM[@1ZLYY<O7)NDB3PKF
M B8:U]8O;&F<K9S$$*$D@'!3\M"5J6SPK[_A64+?\VDS_MN$Z3CZE>.+G]E]
MOOK\M"0!^;V4]S=K,-MV). )"=B %^<)+<Z"#9:\/G_X8>:/J;_'2$N9U\"[
MZX &6J$Y3<L7F'RPS</K QJ[-%TIE^$+84G**1?>T.&AC3)YO&;\)$#!5\R>
MVEJQ'#L21GA:N>M@MTLKTIENIJ#LL?BB'-Y<_^/;A^23*5P_335,Y,HE!9,
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M"I\WG-!;4N?R6TLG7!@]W#/"8L]OQ*5JUK?:M\[E):8F\0)_@;HEISG_:@.
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MZRJBBC_?TD<4!@-^0V#]+LR%_163ZW3'/RA_9Q[:'UN>_XM@-8O[)/GU'Y.
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M;PTIX[T)C.=SPAOH9+_%I^OE[1Q*EKN55J3!KEJ#/F5SRN(K#W]"O*,K;LF
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M3G)T;<H77\_^\M1Q[)-7?+T?)FQT[]&:<N;?#]EU?*O+>S0N5">G0@G9$CM
MUWW%)0FS0;/C>S/ "6D<(<7D?!TK)<#.)_&G:5[1U2J]L;W;!+VG.(7VVP!R
MZ#&!^Q*2Y]9>J)8Q>VE%=@?XXVA?K??%,@DS<2Z+\ZJ0)9B;XA/>FO*$?7]^
M+_I- FNAJ@99 MDKAB74!)>\GHO_$;C4F?\>??:4$G=DN;^/KG+ #_1JSD>R
M]Z%L1K4>@_ Y_X=>5 M82YRZK[ARO?-5W)APA.Z(VLOB(]\\?K9&J9<XLD=4
MJ> \D95.?GMELJ;@NO@;YD'3B>$+T=&#]Z1;BC\#Y#S$!$%QCTKV:UW5HYF*
M.\ZVV=]=&K1FR%^(!AL\\E.-A4_&\N/X[WQC(=O-5$1@T4L(A;5ZS\$GV3<W
MOEZ/><;'(DVVIL$W>"#PJWF"<_.A+:JE5[Z(]3IJD>0YCS^'R#LU2#2@=K.D
MRQYR>/JMMSY;8+@=+5\@0QPU3PJG4/*N;<^G7=N>!;_=.[OVQ'B1T/L\FM_7
M;3_(Y3(9);PP'W4$1CW]%>E7R[[;;G*G]\_2^D];Y(3&A !L"JLVB^/NDXS.
M':FSK-?D]N&DZ3)3__81;9<&5B4BI)%;1[Z%O[\K?#^RP@9S=QNAW3^T3Q<[
MG7)Z/M#.ZVU/&,8:O>N*V@/ DV4CO'C2?UTRD90/FU'<0E$^3.F<^UY %LE"
M@>:%.\!R@^X6T#:I$/IB;W4Y[U8>W]X^HEF5CG$8)W1[7Z>1;Q^^\-P!_@4@
M82]6+^[:6Y_(4\I37,O9 <XHSJ1O-VK)QOZ7JA7(?[UK5C8<QP66Y8SKW=2^
MSUK96&H815Y<5Q^77LT9@(V<F(AZ_;:VAL'J\Z1GS$>L)0;5]]K"O:P^>_8U
M\Z9=,S/B>",L5][!IYJC=\VK]II,!9W#"2B, 53%((.V1RQ#R=3'[+Z>-!OC
MW8/2/[N_,C5]H(R(_&1S^X-Y#T%EU0@WL$:X9$29DKW+)>06^/[<VP8B2$-#
M[\,E[ '=>5=0GDX\,?4EY^78;:B&66< /#C6OW%<,A._J:EH8%(<67BJ(#[W
MP/8D,DI-][/:=:XE^&A$]T1KP(2G6?219VD"1@]B,.*Z<*K^!*T"D1Y%YV[9
M@'4=)G5@SC-"2?&6IU&'=]GU14;F$:Y>QT>6>B<$J/P"_ % G(H:D$7_[+).
M6?O:=U66(TP:<>@4.\[??#0(XPYM>:_B,[?=-A7UFD[ZE"1LKOICP!*H+VSQ
MQ^&UVTM'Z>O$$;+7&:P@1!@_I*4UL@Z<<B1CY:90_-RI[(WX_/MTPISL9W0T
M\=2\1%(IHE'Z_)>KS][3SUE_2G&=D4"*?"9PBQ-.57ZO$%QH*NRY) Y<L@UD
M4D)L1M".NR.D.?1.6"'MYZ4IH%A#- , -34#$&Y]"M8,IBR22XH+%-9RV_B8
MW\,S9TDWVA1C\3"R'W&X!9:T=!ZY+S_H)<[ /I\?T'21?CE\^.ZVUB@KCAQL
M5JEKYNC4Y!D9D"I^X^)UC$-M# Z4#YH#@7JS$L#WA^LX:19>%_V(D54&*7IU
M;,N1DG*F#E&WMRJS]#[!,L1T8#S@N+20)=JTN-I-O;8=H/,;95=<(F[V:)"F
M<#ZB,AT)AY8M)E=L?']\#L*%AJP 7%RH1G[<@.M?HH4G2I4RES\[EO05S/4%
M#'%E.4@3J;?ERZ^\O^ I&]]2-Z!-#+!M<!)RPC=T5,.Z,@T(29NH;>A]!>=P
M5_S(\> ADA,H!H=EZM\:<A]Y*V>?Z5,VJ](,DZ51@O143VQ_U?@1M&;T>LU8
M<_MCL<9UQK5/YE2+4G N*\0$;DCO[<$L\6WX ,16DL%"DT/'A\8XLEY]V,QG
MN.F.LT?PIU,+B<&<14,XB58R&NU%?N_)6V=\I.S]1Z>Q$D?I9H!O::E9-_]4
MB3U-K;T+HKCT2HURL&S8<#E#"+>GFS2>>R(GT#B>>5/8?N/V#A"M^),^+\-;
MPWBM%QPTYJ"\-;39<&5!)E+%5'V3[]JM10H!X(WYVRV$>YZ??AEWJL?SD%&Q
M@0M7H[P[N+@<KA]09''PR>JSCF^7$[+X:6>NY%ID&%0*56OPL.%1;_T9-IZI
MV7\BVUTMX?Y*HSX#Z;.+"0G1K]2,6,YSB1!CH4T$ (#*'Q@7,SNYWRK(D?U
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M6;_019+@4*",)6M06X7^2H,MO7G>0B.4(3T#(<T@T8':HFU6]?(QK'CW1-^
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M:X=DV57)4&^]9#:Q6%6#R$L!ZJ+K+L*41%1;?=:RR0D8H/O$(DKO1,03/K5
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M&HW5U=!J&(SOC@ZS#:O9H.'LTEJ>V/?D#_TDSY &3Q+?AH%.S0,RKKC^=!@
MN[P^BJG7(">/LO:M1;;C1,^?+^DX_%/-4>L9+1U)[C >!(%(CXM[84GM?X9%
M[T6RVZ9M8@WQTK4"MQ-,CKE=&+,9]F7? ?YQX5:BH==E!2&Y=8W,<FAWDE-$
M')[GO46,V[%KRKL_X>/FQ3;?'GLRX(9W%*5;UP$QCVJ2 1_KCUF#EF@M>E'*
MLZ6V9/%$&_*NJ>=4D=&W5F<4:S*UZDKZ(VME--IFVKANYQ]::B9]<I0A):Z
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MR#-A!)ZX$ZG[D:+ AV<<[TN?C^0Q,3J>/<LG@TUA'6Q=K?X1,<2#"EOXL93
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M?FLAG=JU'G;1L?AY'Y7 JVIKID:^#UR?'4(%;OQ/I[$7#CB-A3:SZ?>^L]+
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MA*@*#T-ON'Z,6.V?0_R[\%'01P*08+R]1[P[[2([\H&L.G]J'T!JA,RWF]B
M%1#D1TK2:=WK,+X>FV3O*L,H4N(A/-<S5XW+R+/+<G\>R?JN]+Q\E6.;9F<R
M!QH7Q_6(^*I'?PQ["ORQ>C_G@AQD0!)ZQ8?1E::8:S 3_NI\D>-?WX&-GW*
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MJI,'/ [V8D9V8W3;.V\.2HD!2?)I!)-L82A_)ILNV8KN@1YJ0&,_JG1W1$Z
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M&)4'M)1X#V1'SATV327=KDL']4QMZ)U'+6B<M *L!7BXW3&:LP"-9,L^^5)
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M[C+DV>1QKKP-[UV< ,',RIB&71OK"^?#:SD?U]W<H#N)Y2U\R@^XJ;JRC6=
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M,=G4U41:ON<.+-4AF"615H/H!MY,VYT1[MOJ8$6ZVFS5KF2:NBD:O44(9WX
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M/<G]O3*SFG>CGV?LMU1H?*L!R) K:;,8Y5CB2."E3=GO28F3'3$XMQR#GDH
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MD)S(*E66^U<O?F^3-AW"^#YL5@ZS=$=_(I7)D)QW95I.STJ6O-65S@! .8"
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M[7YEI9/YS1MG3P7KG)%2D+EM>$Y8UHG%_9?$A[E7G\ROZ1T\?EM9FI=;7\A
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M0O+[4]CD4KSR6Y&4@"'[8UHX;EVU9!8,2<_<*<U+*IZV[V@H!*U1U?-6&SP
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M6M1[!L[B]Y]5K\W@H)S@*Q'W/WL/G,W+@Z/DKL!RIR"%JFL*[NU#AC?DC(#
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M9$.DUJ@^E'\]7)62#39_Y-]D%%;*XFRUK2;IW!=P9/"=LAO<BE\-.PYUJOK
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M_ WDF9B.;/:B^A$CU;OYJ="><E\Z3J0#L[J277@(:EP6>K!^U/ZMID6Z?+P
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M^4')&W-,UPV*+J+)>,XC8(#0Z"VB6\V_.'O^!R9F#U"5H7 ^C;C?;V65 :C
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M2]'E6+5GQ)HBCU?.65F4:]_O18@:# X%O5]*KB%P[-9@X.Z26CKRKU*WD_<
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M/H=4*I.HQ@E'_%&EH<96U+K#Z<8^%XZL"2^*@6[L-KP2EXP,B>H(D.@<<0K
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MI.'==^S'CSL?6[8I(Z;:V/=<0M*;N"?$*!#Q(\>F97QO;LW!.WE9IAK4/C^
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M\_4P XDH9>W:0$7BI0="SJP6)O-3RVH3-62DW]*$W_NLT9*G)F:W/6XBA;>
M5W=BO ")9L4-%W_&E)]B\%UQ5UCF*'PDZ\?'.B,!FZ%9+T!2:Z '\Z2'5X'!
MSXM)H!=J8P &89*<64V(OL*:G^3@!V=S/6CZG@=MR]J;%G95>LRH,S]*$;(>
M/MU%YNVDZ=_(5X,;$_P..)"Q[5G(C4:0XHVU"J^;I=[[!M1/!#L>UQX?+N2Z
MI41;H!DJ[[%82VNS,,9A<E-*)/M8X*=B)R@/6GB>W\13H'-FWV[/.'5NP"2X
MO^>XQTRDQ+<B- D. 1>X4AC9+QFW_MUK4_NG_\I7USDVMON"[!?FO,VX_JI5
MO5-YR;$>_F@BF8D2//'1PT08%<-@"@N[-_^-W=18OX3]K"AN'<Z%FM5.HHJ3
M8W;6T?C+K''.(87??@'9_DBJHVI7<OZZN6*[;__]&TI]C/UMMG;\XLU8*+G?
MC@LO:K0KR/%4;_#/ 91IV52509F-O*H>?O5Y^M=[N8P';G--1-3'#6T*6&<)
M1FH6#![*6+QBS:5XMN',_B!4+KP7_G8+J&Y-GJO6_/+6]*E*DX1&'(26R-OD
M(V.Y!6A^\<-V$[^\,KPZ;DS@(3_ECJ3Q]^CVG*WVX2T6*IX>NWSX&?UML+&J
MES5\ *$8QO53B4SHS$%/'WHB9A_75/]ICB^!M6_(K0?/>D&KO4)&"YZ4J_A+
M?M_!T.)WD_GJ_PXF^"_=?.^;N>!VA_0H,<ZZB6^\@7^#UE A:/#; Q6[07U9
ME,:MXQ66S"$\+/UZ8S= C?O/!:FY*8QPLQ;1%D[AG;W@D9Z.]2/VD_4F5Z-?
M4+4<4A&K+VLVAQ-B-%EY3ADINXI0.!:^?'/(;^F#WXQK8MXR_L9MQ6,&5VW8
M],4%(I</\#+R!!&^5LON]'Z>>>E/GX$QQJE,BB/Q-IA:9F<MRCXB4MM5[.-Q
M_(TU&%GLB&KN=(U,7USKTJ$?J#^6V22W0!/E^=7VMY\>%OS?>ND=.;&OLJ57
MFN36&]&%ET*5M8*S]GK=_K^(D-D9L;9/1YG")2EV6S%J5(NZ+$<KK&4V+EJ"
M48">'\&J"\/[@)03JV_PAU7)5(S?/-9X&1T(XPL5C6+EE47AP* /Q1;[S>[8
MK#QRBR3I/,$ZL0QT*(2",CC:+]AFE)3>RA+X/B-)%E#7=Y:4*IY6&^[HKOK0
M,.+(,VPO->Q/118M<^W6U. COX-C14^D!?;E<ZF&7X]42HJ!MRKKQP6[Z+V7
MW22P/ELJG>N8))''-O$^&[ "U9WIAS?>!X@_.A@K$JDO,!@0)WCQJAX*.']-
M3^*='6&#1K5:V^R1L74PZ5S[L_&.(:RF0:BL"Q)I.[E$0I.#,#"FGWIU[3=,
MU;SHS0I]QK"J7ZVBQVI'"/)2&.X#WRG&R./6%B#O-X/; @;O/9P)?:Q8"M:A
M,HZ-8M75<J821 45^'K4DM.0V,N% H'*M):!,DC]KS+>SR:&+Z4_7Z3I!RL$
M83("+FC0U6L5W5LY1+N&5^+UDT).RR0JFY,677N&[;DE2AWH>ZVY<%>MD48P
M8BNCG_69!,@JF4N C\/);0T#4_1?D)>_8JT^L]]6PT?$,*"..*V.'1ZO+[ H
M *%22KS!@_WCMV<I$9<N62B@!4,_!<<)SO"%EL\8!>N9746*92L8;@'?M$I'
M607+%*QS$9X^ H.W!&RI0D4\28G>MB 0K\K9R5.11D$-BV\RX9(4+^81F-A<
MJ#9\_0BA0?@41R[D8VR4.$NM&AB"C+Q6CI=!_J@JR34>F;4HC6-_:MW%ZFVS
MRN*)H>-)+1][QS5#/:;#"&5GX56S[IKK6N#UD50_ER=T4\G 7R"005 @J/-F
M^1EZQ+GYIVN7\D(%N8UH+8E1#:AR7-_\J'*CZ_SS5K:O#YZUI]OQ\+'2(AW,
M/\HLK$XC1D6-ZC;%-NMOJ]&E^*KS*O/6"K%X\B64DT#5_Y^^I2;NE=^N%4T@
M*!SGK;,'NEG%2/FL5A@JFAJH/ >2 #(ZVW?LQK62"\&/QBAKK(L X\!RGVT.
MR[O7;PI$FD9^TN3R&9;7WP*TO?@V&]A@6O^(E(L'6!G\;MZ^SG#'V'H8WU:.
MIX>CB>SJB[S-C;]U_]5P4 BE,5\SIS-?TU1"[;P5^WBOX]V.AO]56+3;0?G%
M-SOS2":[+S(#(]D+S*?YUSU4M@!*[-K6716RJZMO%N.!Y2D5>\U^"60SN!<
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MYDOA12YSEPG]D[+X'OZ? (=-V\30\7CA9J&8JW<U(%EXD<Y#8PXI9[6S9>@
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M[P 6?NWE9[]\W]#VROT*4Q/10LNXY^%=>'@9#7)FS%QBD']Y)?&ODAOQ"UL
MJQ_N+?^VY 9@</:JZ?TVRC)?AFT!G,L%:S0?5J177M8\=CA/ZEK]/*#%N04X
MKB2>:#WC... 'U]CO4S>%/7[P+IVA[(E=*8S-DVW@![%#4QV]T'W3]9MPBGA
M,8'_P<=FWO RW&P.GG2;_%:*),$LJYU\?$03VWP%MH![5Y]^-^Q;*^]'6UUY
MT"TO?^\BKN9OG?553SGQ4?]]0YW*CFE[VM=JL?VYM_NCPQ+\</ [[#Z)]V2I
M*XMJ >32*#P(!5)$'.GM."?4F6KZ:*X8!^:2XSFP?"!22U,T=L;6OU__>>_[
MEGT!93!!6H"> 93)N[9$ILG\?#8Y_<+3EBNTH%BLAA!&(2/2@9PG?8_1?'A4
M."7J_<[O4N:C.&C1<UQ=#NV!RDF4@O8JX<^SFDR*-LC);P'\XGX$NRU@7N+:
M,9MQ+Q\7F2T -=@NM*;PU8W.W=J?"CS520+QL/A.G^LP.CC82O4N2Z(\^,EA
M&B=G50: F8U56W9I"@_D2KOD_MXW$/FB\[L?U#Q-_$_%PZMJ!D/_IH&W?ZQP
M^O#?->X_1VAV,\K??\#Y83D5V]^E^TBN>BWJO/O$J#KV?.+E4=$/F\+_T.3Y
M_C#_O6;3I-R90=:)+N3:>7OGLK[*)!"L=B$OG+1Y>(=H%WLE$Q^QA.G7Y_9W
M08/5X/ZN08^9Q%/@(K2M'01,;B_W 0VR+KYMMA^V[Z],6,%RE%Y+[?A:P<JV
MK1&S!2Q@M38 PG/$ODW%FW^57BYY]?1A:;:\;[F\UJ#8>2FN\V]HQ7A#Z!GF
M005R/*3.VQ4M1->"4%9WV6O<F1K<+@YXHO%P(5"W..3)KRNZOW<R;_+0@*$^
MS @(ZA! HHJ/7[2]>^J E=D I[YM/H>E?N?_MH[N!IT+0AW6]\*DBD%0L!R:
M:CDV4LM<E%5IIM>D*M&VNZFAI'>6@4:^@L>&%(W[?J+D7+7PW<+J-^S)M4,N
M@0R"D9GDGK(QLYJ'Z_2K9N]_W-;5YDUFA FQ.:OS4DWTUW"=,GGO7MYC:/%(
M3IDOC#]^O6@M6Z9HT]]=OKH9&#5ZOJX=]?+A531# (V<S1L;4C_-+,=Q-W8W
M94CCOD -?20SFIH+[49V:AU2B.M&:%G(#)VXK9UN>J>N24@DQJ=BGCQZ[^6T
M;="I*?O&C\3R*#1S'!-'W":[%-HVT1*DZSDA?2%44S7PW$9/S.72CS#M-!<,
MBRPY:Z)1VDJ5K+@%[)/L_S2[6/JLPU>6#.XA.,!:S7ON%1;(;@'!9M_=5^N&
M; L4;LM+1)1/H-=(Q9['(58YP11S;/4WCP<Z,QC)[6=U66!V:5+I6W]IEB!7
MMX\H_^:AT@WQ+: I<2/X@<E2D-77WFNBT*,7UM.5:H66],:NUTSG3-34G-F8
M3UQ7T2TZ\[R5\N?RMH"KBK.0+<!*;?V4XZK5%A"MN,9$KKJ5]"I,LO[ 36:K
M=S<9FV_S^L_G]3,OL^S7[3M] RTUV:2;Y-3@KC>BV604UZPX<,^O@W6=XCB[
MC*R21ON[V]+Q?95+<#2)V2@?E)'NL@7L^,L/XE6?5IA=N?\P[BJQA'$HMHO5
MY)E5SC.*W53YW=HXETW1&8M%T+-9QSEIOT.]]KBBA?S JBU@L/3O6GGGRM+&
M44'O,:*;_7,*.WQ:<L'=_F_BU?B^GO,S:%NQP_FL!>GP+8#);[AF@W) OXTE
MS4RM>US9 @#*\7]\T21,GGGC]TY?)=,L*Y7?7Y4:#WT9F]<P/C:Y+1*A_0=E
M3/^ $6O&^I4UFRQ0;*3$%Y<?MMR/P-BZL1N-B-#0&M(/UM4)_LV0DVE7$R(=
M4\)/<OQ+EB?>Z&;LZ[,[GK@.93>9;C[W&]+:?)\ZS1]BOZ!^Y'JL"R,#R(6%
M.FM<+>]!XG3 =;_6,^N^6ILBF(?YMZV[UG50ACUBMSBV #;[97+9^YGYYL5S
MWZY_/S[(F'HT.D29GSS'JTPDH)<+:J^D-S@D.QN<'[:@G85'*?&E(CW1BYF^
M/'=;'9U..5^^S(V<!JNZ^U[D?8/U9#IB>,1>5JHS\T]<X+_1]14H[MJ_Y@'F
M5)<,WE]+[?_Y+[C@_Q!E&UZ4K7"UU7[8X5MIPC)>7_I:!N$O6X%O6[5S6]WF
MT-O!_*L)T:.K/OT]QS1F(B4XB] D)Q"8]#77T(^RPMVLVV*D_J(7HI7_$[26
MWK<ZQ\_F_9*L^_T>+!Q=:%ZF\"ZN]:<BFU_QJRN.H@X;O5-X\?0*>SY,<3*I
M_V]"5*F'RG9L50V[*P[D@L\J'A1RZ[A".=OVBHN7-<SLO_$%J% .PKXMX._:
M9XPW@D\P]K9^72B;MUM?<4'Z4R-CM(9DJ#T$,_)LEVVQ$F-I6(ZT<$G]60FT
M4Z\G<HBERC;/>,8P8*.4-8;EJRY8Z[Z_*FM1JT."QT_G=3 1^QF<$1?@QJUT
M=0*K+!1#A5<;F,+P/=WOX/IDAXP4CV_U#&CMA&W);.G]'ORZK0CWJXZQL1OT
M03E^]RX\DW6;ZL.Z("7,R_@P<3_XY/].Y4_=J]GIMO6_/GPU^8#B433^,T_Y
MS\$YM.//WDF'2UL3?N;N)(^&P4?16T!8E37?PTNWKC35'U6C >-.M29CJ4;P
M,E]#PO)PN3AR(]HFD,LR4%&B+:A.WN<>*]:7V=[^*>(Y2.=M*+[7)DH90 ]M
M*G21]=Y7@!:%%#1D7X3=EG^MQ,57S[NZ0$KR-#;I[=I6>/R+S,>S&;6(FL)T
M-@^O)8'[4SV=T4A[A;A.HV?KVI0/^H3"\44I#+?Z;'XCQ,:=[_ ,:'%<U>?E
M^7(SA[XV&C31\_-@))N?U27(MQJ78.Q$M3(,SYINO7YFA[;@<7X.1=(WQ;'7
M%'+!JE+,.2^&L,#V][Q^+E?]4KO$??*G$O9\I,FV6=HF.A\H1.<0Q3"U5U\(
MR<4=WEZ'72IA;-_-C\>#TX[JJ&HHDF=Y-8A&H"QO7<AC!%82%D46Y%G/5J70
M;KN9'HS4IN!H*]S)WOG"I</(Z>LA[KYJO#-XF?B7==_I;URCZQT:%YK0"2@[
MR1,; X]2%6=UNANCP=;CT!2Y>2BX=>G8%O#.8@MXG!^DL1RWOX=A6 ]LC1R2
M9+U@&@@CO0+IPM%F9<M>MB)Q#/J)@T;W(]=^%FZ(QG[9Y+GF>"P7Y*FNWDQR
MU)OSLBX;1=0*4=O5?U?+4!-X M)E$&!3;A*8AV48^@:GYD<R]62=*LV"E(\%
M='FQ=@XE,,7\'J_;P_]&5(7B$F?6_N(6E$P61F?Y^?S^:HZI[C1<K4W)N^.6
M,FDW<']@2 4Z%F*YWY@P+_WYEC@,A,SB[1RB0?7!^-ZETK9%JD_;4MQGB?6W
MHWS.KC01]4@%Q8NHT X!(S5SSHS^<P\?R_@,":!JHK%0>=;,@EMMQ<%?!DT?
MDN0.1*D+9I+F>"49H. LNSL8Z]^/]W7^( WPX+ >(3.E_,PCZ:7ST5FAHF!%
MV2S9@%8:E/\J*B,H<C P8K\U]FGW]:Z/-^KJC*<;7$$0 >8#37B?'.G-0ZZE
M2T*4?6Y$V><%4BBIHTQ),>H 58S&3PF3@\O./VC9WVIR!+J\G3Z<)9B]"6T:
M@AO8B&)24Q$5_8;'H%VA @E(\5Y?RQD\%83_8D3VM,C"&6 YHACZD1W]X1!,
M_O*BO+.ZW$$4"2;4;G=0>N&:R:E3E]Z<_P(!B!AU2*%"7-WR5*/3Z*.GT^RU
MXC>[!)BI@3H 4SX_0BAI;9A:7M1:':]9W4=XWJ'.?=IN+J]JYC*9*>8H)!^P
MU+J\<&992ZR&7+ )W0+6KWGLY^@NR_>:<(DO11';A^^Y&XD];]9.<Z::K/]:
M(;-C1>_JEGWK&U&0#=*/L_]L)D6F"PRHA;SAO_QS[!>MQ>0<ZI.CW2DC\'/U
M@0824660&)"S_#V*:0Y.L-]H5IR*H_#%L8L[1.IFC]PQXY;_CO]Y(^5C>7UV
M8:N9>%-NA#M6_&?^T6BSF.1WVFF6,;*%\SGO^"F+9^<WAO1;9<@'_::?/G(\
M4RK]S7*8H]L84^X+-P/P/F11[:;(YZ]51HYIWJ_/6ZR%?7 ;E6%A\1 4?'6O
M26PR(C7W S)5E'F^!1V.TF!^^(9=0RA&4P.2]4E!NWQ<@6_FPKWT]6)+P7T?
M+-E-W2VUKGHNC>!D#6J]1;: IUO (H6MV^;]X;XQ[#QM=X_O;$D['GMSDH4)
M%R*8"8,!EBA5EPD*[W^35U,.V9BM6;_A@8:_8#"@C5$"F&.TE,/;$NN?B0O$
MI3BE'4S(\*_6X#6:P:H)AKLINW0^<#QL.MJ@QLTV=+ HA#OR(Q^L5HCT$UYL
M3F>>3N0_4)(!#M1[<1,'R3+'Y6N  N&]MD+QUZAMC<QWJ9LN=L^<8?/#?>Q?
MZ-;:8.AX))6_;+ %G-H")A(W6V]L./$SU?R=C=>D+='^ZC[^.X+OZ!_FDHRB
M$*&;"K9_S;3=KO:K[Y^9 /U%V5>)4[?KT>0G)N&4M#>MOYL_B@SOGZW?[/8;
M?^)]\K<5SUX3\DEM$\4_*'A$..RBMD\,X7% D_--B"7KC%&JD;\.)[RY:S[!
M:_"RZ4'.UZ&6\.IW9*Z1H*>34E&RR/!&ROY/=MEHJIEZMKW_]=Y3/JM.U#4W
M1EL>5>=*CU%UF! 2CI54!H\4P:<7\08B;%F*#?G?^)<^6ZWJ)%7_D*WW/??8
M1,&0Z0IR B*P\!.!!PE9\E_UO_; 8- $_V25YP>[IG9@KF0Y[T76S=(+#*V<
M8PI'OOJ5")@&^>..!J*)09'U\DY>!PAY)T(/NUS6H%6J9 -H8S0!FJQ/3IZX
MAHU0^VQJJK5V6U"!"BW_!4:!15']3<'E@*&HKJRC;">M.EP.E+E@E&CA.-A8
M@"[B8NT5Q&-WEYA<%L%A9QEZ2- D,"KN@CJ9]C2)P@-R*(3V GDMVJ^?PF8:
M"=<&MH!'!^ZB!%PE*OF?09PQS[D+8?(A$E,Q=,:QM8<T&2B&7"[4.])7@__Y
ML3)63H3!O'33APNX8<>-)VN;#YUE_>T:L^5#"KUO%2B$,7UBT[T:X&NI7F<H
M_V@^>Y.:@,JB;V:4O.2D,13E.X)72"TG0?(,EI.W +[F+> &Y7$K>6K<U?,\
ML.R'>S4(RZCHSCGT\3Y(J&02$'-&D#*<$4.W^KUUGI1.6FLG5'U\*K= ](=.
MX.6ON9CSM_6;/%%ZR"+9L*CCKRF[0/1<98X>@2]3-P/TDNHT,5.Q4W4TLX">
MVZ6<-XGMOI W4-,GV@\CX^4BW@VQ?YOHH&5>&+DQG#!H+A O">:R.;#I)]')
MM]^C %5U+%[=]#DBXI'NP]B@0&?&5A /.7FDKO;KLD46F/V*H2##16$(^KR[
MI6V2P ->+7F[.R:D:]]QKBH<^D]<-K=Y\,EM'BQQ#U_%BWCJKO/I*%,X3XQ?
MK^,L2!?!^?/=CG<TGYKH'G@J!+85H.H00K,4P[O"'-QE2AL6C43OAVL?G-.(
MK>P%C'A7AZ)1"2)Y-8W@+P&(M@*GRB>;-J6SYZK3UJ&EI<KD(,$HJ3E.;9^B
MH)4%K).,3HXWM+3LXA -MS]\[I"NSUSLR@.\DZ=NVRE!Z_K-XX]-E)J4O+V;
MM#Y*(#?4Y/@2+T:=RVEXV[-R%KR$#(D(KPB$ 0-/,&K0,3RK8)1HM_VNQ-?;
M^"(==ZC?0<2LS^F!B6CM;/LZRX;9I$6KL1MJ(:ZJ7TZU#]<RK[T^+.#4X YI
MK^J@A*9_Y2 J>>Z;U'\7-)7(*DZ*[2P@.7)<2?;PU=;[X8B?UNKK05I&FA2D
M(Q:N%554U#J*9^=:Q_IGI$K?GW4&:0[9*OZ6R7#!<$Q_N/>:$]_50=?JZ^(/
MRJHC)XW]9(@I?.E^;E)!&/_QLFJ %WTO;H[.+RIO_\%!R[B2&\+:+G-)]UF5
MC'XH5 6-X/1,=P;\95K<B%L/-#A3%2N?P;4]\R6B,:3H($+12(RHN'?3PO,A
M=O]195IJ!A@M7^C9T6%?GE'5R9X/-QG#PE'./4Y,9,@HZ#ZS6P[FW%>69_?Q
MY=_)-Z.["F$PV@/^+*SY)TUU"]);%(1FUCVMSQ[8/UL 2HS6DCO8&06/DAB)
M4A5]N=O^"-8K<-N[7>22-5"]7J@I#W+0ZG1BG B?-UZGLO&G 0M1-;LW+Q$#
M5H"3/\.^Q'E+DY87SAL?YS[N %(4Y(.",H7( )FRG8PP"*]-!4N*D?U,"5%N
M5M1P(?:+D:0-OU'!;(;+B#9\6KR:&B2(()=<QHXT2PYC[^(J<?T:J7F^,K1$
MY4)6*5W0P9:@;Z%Y[G$[H[R[-_43HD=\P5^X]4NO/ .D)IO, NH/]"9>_C!3
M&GZ\K:I&^.2<-!D!F9S BJOE&>^,1,UVAMF'B-]#0N)(7\YC1\>HJMYG%Z$T
MJ3'(OC?-3;RRT6C9R'"I-^S12>9UI1+K=19#HH+O,6![MPOE/4<LRZ?P3L "
M5&Z>UX=J7G%9*;>&_&Q3$;(%<%[[QGCCN2>DH4[T?H5V$IFLU,7G7_#1QP/4
M@7I5F;ES*<\-?3\_W?(S1E35S_WT8-*"F;6@/$X05&#= 2E:=LGBKG0\]>C$
M"1'8!_M:471B)F^A1'=(182T%Z^!L\+Q9?]XZY>()^I$'O2 024+"#HI*=$!
MPY]"S)G:2_8?0&N<[&: 6LJ\81V.1MKPD#EK$7KUI_*;C&2MKQZ67\$#?!D@
M3%!!TK$;%[22,W9;90TKTO+48%3FM[/P2CKK.%EEN0/(^68>_JO$^&)^?[$H
MP%K('W9Z16&=35& SEGA[+3)B.CB<TEK"'-&0CF>!;[DY8*'-[?2(\UGS\E)
MD9H7KCPL<54JJ#Q^D>9];%]D^O9:_I8HRB&,J,/=E54X=(4I<?/O+)\K9V*.
MG?AHC_="WQOHRG-K:&N?8)OVP]9CA&+RU]YKPMH7@E>4:8#8WD23]G8Y#X5G
M[#W'DO7Q^^@A,5JW^=XBYM0?7TFX&>R6A627U#K^G&(9*A09EE4)VL4H#^O>
MB4J("PI5Z\3%$IA7?)/=74:+>30BVS3]@S]XR>:TTL"C2:UT)S]*M/TW.7I'
M\V@KRWA/AF/<.BX!,9XQ6D*QG827NP-[X4G]DA/3S\)3VB:,%:YW&W8_)DR>
M@;39(F=]J.HRAY:3G31$H@-B_2\>1/5.@M=#V[,0LN\M>I#XH5R-.L$L2*'0
M 9P>H91GR-UOAY4(M1)]:_-3D5UWZ%&^ON#!B+$E6*L9NL *'=U+-+(W/S=8
MP,++8G%&*)4Y]4!/VV+3%*J!3RI\7I'JKH7]6R67YV$7HT!]=6;6G]7YRODC
M]KORF';]S(F=@422.L!)CQSC$'+KX1Y$3%H0,B#R:J"$YG+ (*A]T'A02*XA
MHOYUOK0E.:BI;K[U8I!9:&"5Z,;;'QJ21Y'(!>[()>4MH*V2B'1M8A_=/R^V
M!;QO*]\<LECZL 7,N!:EK%_5\+V2WN57Y1\WU>E<7TARTTK*#Y,[:1<VS*#'
M)2ATJWP+L%OOOXA&?:$$+^_OI-ECV"XYN$5INI5(BFLT-X%^JIDKT2,U?RXP
M[#:$ [[@>R<,[IT07+)V9G8)U)ST=%)?&EH<Z=.]VPAQ2@D?\A4<H\=3.933
M.RLKCN=+,P?*#+$0D>%7M!T:??XE-C;Z[*'W,==V_$?#LX)"%"YN ,K0S$#;
M.+G<F%H7,+28HWQ#_M@M(#S[\\$IJ7-R]PX5.\H9GSP3?;);4WG%-)D$Y8GV
M]Y&D.M>\\RXH9_./3@R''-T_XB53O9\0KU3"&-[5XA'A4*P&4RY"@U?5X$WP
M3= VJ7RTD\,^T=%UDW]VN4+:"2=E?>:(!.[JZ\![T@W?12,OZ$17J/[T)Z&&
MT#RLFC!YV6B7G71WF._,B_3*YV5U_4A+%(>5ED(VU1)>C2.FDGX\XH6"L!G[
MY31+&R); ZE4-L3OZ'Q.O&/C,6@9TAKR'"\N@6MI("<NAO*6D5W>K]*]5$KG
M/-Y$]^++]5(V1M"4/=9W$K$$.UZ:R#*1+\3NKV\K%NZKUTGZXH&[B&0&6(_V
MT:4],'0/0P3:-=E81:FMK..T$6?-?\E#Z4=CCU%Q;.M'BP.\]*(M<JZ#H$Z(
MG>0E[2+M:@6K>HDA,IK4YD:+3LL_/QYQX\K@XT.-59;"4Z<UY&5/<N'D\3[9
MN7X<IZGH8B0E)0%+>'\"CC]ZU9 07$7#H9-+$*U0[>[15#(?4"=!UFJ1;CA=
MMX)UWCN>XC<-!'BXL.^E^H=KH1-1:F.:/PVC^4/7;]&_>400/<D/K_:'@)(W
M6*B@U*4Y#6<F^"^629#)P75Z 3W,>2@U01#/ZI%%7E;=S?9 693DJ)2_4B_4
MJE6.3>5$[@%W08*<\J'P0 V-(:+(+(X 1'>4CRQ'L;*ZSER^#0L_JX-"7L?[
M)A7,KM]+FPD-V@)*)<1LQ%HDYFSOF)%!8*RDNH 77\,1:?]3XX DE6B@[VW^
M,W+6M]5'QF(Q/N*B--5X!\+@DQ87,;MZ7H[7/!L:CL/+!)^TT<^C16&#,+V5
MH-X#79&;94T"!.G!?GJEMF8X.VTT_=23J#*=IFY)&99:%R2F^*.WS#N[TT^/
M+MUBYG)9%S'FS\0J/%SM>&UWND/>O,S'?5"W1TKE?O+B%@!6/.V"!T;E9V$C
MT82D&>]/G&F-])H?K6FG<<R(>5VM$DE$@=CTEUQIO6RSDJX52!15+7X?NSAK
M)KD0ZTP;J)5<^B]'!/?,$.9?786MKO)/9NJ-?7%2(^O/L]+5I\I>+;^M^."=
M9"H/"7#V(/-"%YH?'+)5OEY!?G3LL[;&23DTG;GQ*I%=QEU>D9VJW./!J0.O
M[@]P/B?E<]@0(J[!I<-.TY->" FP5.K[T#NE9HWUHM'Q&F;.;M*_DKDL,5_A
M%NZESUF:F^8763QGU>7<2 HI%1&0VL6O3)*!:MA]4+P7^4Y+I(,4BHS^,L,:
M(%"EAF 3ZFJ9&-"@F9QHTOE?[+UY/)1]^S]\RC*2[,ID!C53MI0EF<%8R])B
M0E+VHB3KD&WL9*O)FJ3&4&0M4H20L61L&44A9!G[OAL,GNFZ[ON^N.ZNW^_[
M>SU_/,_S>CU_^*<FS?E9CN.]',=QINA'>:,69D+M!$U.EW&\^6@CA;=V49:&
MVS(%Z,>XN.A):I2;5J\W?!6]YKHGCG]!;H%'X>XHSL:Z9 :A4A/@_Q0+'E;2
MQ\0'8V-  &_[USLU#TIOW!_=!@90;[<!0B5U*(5V47B.T!5 MJ2YHK>./9#^
MH,@6MC!_O/47$9"EDV'5F GTGJQQ_V/%WP0^[9NQDM7Z#MD#<D'9/Z-FRK&^
MP''&E,+[Y]2J<4M#O,LDZ/Z]=_:/Z5=2TX<&6=L!M"Q/;52/N)G/@O_'-]TT
M_>2K!Q^RK>XK18^<#X#ITY3;'/.AN$Z[@_>TZ]IB7-5$1V!0F:".>)S'T\3@
M:><..]QAZ"$1KI4E 9122%1GQE2DL74Y<C"KB*AQTURMYV''!$K+BPQJ9[\?
M76>R.!;SZ@LSO/[@"!..W[HS^EP1_6APDEYH#XL>]U\4>A60"@UW=M5%!.Q0
MPL]GZZW YNBI^&*M&]J]Z(K4DTX.7<<>X.K0/$EO:+Z^Z2,U3=RYI^ZYDG?2
M<>_)*@#3C<<^'2XT/[IL=Z6786A!K>7;#"D3G2\:E5%Q@CPPG2[&W5[&T'3@
M>OP2.["R,H,^U1LK,37J\+MS4/99]$JT$0[-W9C2+-0?51NP7*?.4JK*XZOT
MH,G.4=U8/3GIN" 8SCY<+-1#P5GC.Z3Z/]\=E\N_&,>5'Q_(H.K3-KPZ'5OG
M=C9^7^$R*NR=.YGK[(O4. -O!%MYP3(1?G<&ZP]G=%T8,X%=Z*J6E"&9B37D
M'WHZZ,QCMI\DJZ,&]<A:9Q_0-NPH12)/Q94:_+_M_+;IYG*<&$:97HD^AR.+
M5T<W$X@<0]O <@MPK$1I]K[LX\WF.[S%27$D0CD7"%I*RG[%R67O:K_H-)2'
M.<30RDMB5)6AH%R]Q@#HQX=S/P7=MP&=30K^[O$<Q! [%QI%+F;$E\$O=G?6
M%%/3%-^</,0_<] UI?GQEE;920ZO'"D7KB3C2PHP]_5H?8)<U3+CD:P^7\6B
M9(\Z=L>N$#F/&0%\= 9GR:MM@)W*7+C6O%#,G=([!7>B9)/46]A6D2W&LQPU
M9O7CRA=S3B<ZK8HQV'0'=L$>,Q8(%351;4GQ$XE['2:"+#W.A8%"1<N$S_7L
M]*W-0(&5E)635.&M!W=X6@7;EX3!]N07&N_.\,6+6#[AD3:*OH&2;):?]EXN
MYCW'Q_7<_]*O<@#1[Q7AE[\>^<9W5G;FDBN+SM >)>Y)B^N4ST>D3KC?Y_^1
M(:W3H/SX.IWWP*Z?&TC_18N/_F)-^ /L:#BA&76GCR:U+V6&3GU\*[>!@Z9"
MW',/\Y[;0Q9(I=T>>J-0:&"_-)39(:":^>8VH%PYOZ9*S1%4BT<F2P[*?^KY
M4MTD)'3&,-1AX DCS6CLVZ"0$/UF/5&=+ Q8%\AW?D%'[8?+R\^?DM/1>(&+
M"R /*<83\T &U!>?"IP%V)2:XM!ZC5HR9+>4.XWS'1'"EY)3&[@U/FDLK86S
MD^();M'JG3QNE0/YX9@I7O.;#[*45&YV$[Q%@O647!CJ1T/.QK%T8\$8VJ42
MI@,Z]?7U#$$D?T^(O_:XN6T8S?Y H>\KOD0P'69-ML[C.72(*DG 4T=233?R
M<I9&^C; 4V83T'<V?/PJUK;F5G')?M@(_$=5HD2S'P)IQMT RI!I4+HHX%._
M]$OJ2WUQ7XQQEW]?]LN>??3+GA7X1MH-[3V$_M(1<@BU^9')S'Q&/AM+;:UD
M\1\/<'C>]D $0,A(?_&)GTP'PC[TA44%S#>H4I^J[HS12C+F4&;^Q)?4IWV7
MK?E.E@8V"%YU8842EW.V9+YW:Q?+9O;=X->394 B:0!BLD56YNF5?3'4^+J"
MVYF-5=Z8Y-1^CF0THGZ(G7<R4#U/>Y>[]BJ?8XQS4/R:)Q=P?$;=";T(7X^M
M0]]90OR=P4L4GIEH";A(3=<^R(VS6037L2#6KN(7MUHIQ9#5QW_#9O*?)OOV
MZU?%M298J5 @V>/$&ZY*R_7P%?Y6+^.:RDZ,]\T'2I!B42<_8*L"[4\4O9[[
MC$?G"'-G( "/<P&@>O8AWU5$IY0<+W%Q_HQ'H+!B(NM<NJ "D\QYX5I.>-@G
M7=:@\QS/GCRLP2\ L"@ZLV$KZ._;0W(7^%#*% EJ3+I))/]$5(T6.[BU>-D=
MS3K=_59L-]'X=EL%%7+YR+%F5QGB_L8XMT!!FMI0_ZW"$^7B=JZG"\4 Y)I6
MS5H>Y\#7\G>UZ\(KQT?8X])9##!QF>-CZM!WN'Y&+3K'6'FZ2,?S_Q)Y$]J\
M-*\I5GQH'#K(E-MO';ONRBH*L5D90Z;\1P9^3'E<]9<\_.&/NH-'OVP1@2(R
M;8=$G!>RHTY"H>3DO?Z=6-\XOR-F)T7(U_XMDGIA>L\#N?E/Z$MX]RE [S>I
M<5=\V>08'><-0-C["V# >I0/NRWLVXSR27O%1](9G*N7Q9<G2F"+S[OVFB>I
M"%.##F0-@@P%"]9</<7'@\H8XSNMA=9$C(W,MH+Z2^[:VB4>)\TDUEVVQEMQ
MH)4IF4*E8^)*?'E\^OH]IJ^K"_5D\UAA&>H"*'%VRG)EI/Z/@OO,BZSU/7J\
MJ(BZ\^S+XVW!ZI^O[]ZT;+NY"H,;7U6N,_'KKS[!RE $EL'UY-Z\^"WN?1<)
MZ$=E?MZ]':H!L_X5B'&CYZ?C97WEYQGD%0XL9#VL%T VOO.$1,EUVHQFN.&6
MOU$(,E\.:I?(B/98@;5<U9 "-%;$9)VLV].E2M8^^>57!I7'U9D66[Y+QN,7
M,/&SNGG/#[:2?R<X&'\MQV9T]II;*3PQNB+30#3\\NR]-Y(QTU4N9=YTZVI
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M,^X+U>>G"[^TD:3MHOS\EC:&*-I_<ME"^ :HT4QM_L&F2#J+^S& %,90O^:
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MTF(#3J$W>LP%%M75YHUGI4R0=TYQGD3[A@!A"K7LDQ(IFV86\M ''SLV[Z/
MZV7"U@QX/B&6_5,$^R;YO^@Q\_.?/C!Y\:$K,Y.=W"^=^!A -6Z'R1(2=6RC
MS\ZI6'&S3ES_.K^I-^X7+'^U.3KNJZ^?FU@6"K\MELIDS$8E09@Q$$#48YQ$
M<$6DVO.>%M,/5S.H97UO&N)>C8M7*1WYCW$L%,@H^6WG3ERX'R'C&;L$;'%.
MYMF?V&=R8JDX5=W.6:&KB_;^H>I'")L"QN1C1)4:P3<L*-]X>7]DP=46 U"A
MO[ZL+U!\8T9H]6X]O;-XG9XI!69K@1T.ZMP/(_$FNSE%K#_E3209P0]M0U)L
MB]^:(8+@+88?I\>'AC,<,:Y_=*>.OOT@A3%NKVY%A%(I9R'"-9^[XV:-%(4/
M'T\]"'\DFRV*2$!$Y+G)Y*_OSG>&1HGV T5B 8<A&0OB]Q90>++=HPL?!@1;
MV@_5 &X9;[)%;1F+,"*2GV&+A VJQ2L:O 77FNXODJ6N$VT3,[DX#CAB?D7"
M[ML-5U)# 99$?QF6%0C0(KWIM<52+3BHSG:-V?*!9%7=."@)#(IHW^R/.7(M
M-VEZ M:]<>^LUI.\*L?7S>@C;!K-YI0;I0J9/Z):#QE,<6+:Q)3^<'[@+DVK
M=@)T-V:^G"XH.?Q<5$)AFE+5. 78%&'R8!G>6BXDTQ]CSB>/D/E'\K3P25H
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M^ISL_X0WSLI=>IG9-'2=5+WE-C99CKEUYQ5YE-:M#-?-LZH:9=*VW>CS9"!
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MWI[.5='!!)Y)^R@4/O"75$63\CV.TU'V7/L/[E"C$V1PWXJBEP3 ^S .8 ^
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M(^;*13TK3+.TYL6+ESS.VV9MDDU]_"1?+!@^J:('#VUFF+-ZVZ*BM$$RA?)
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M3)M'F#/I&G_)\ 5&_JC5U_>T^7*\ *V&_EVUT/M*PF9DE4 H-'*8*,*;<IQ
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MN,T?-6X%PW</EM6(X^*<3.;*UV:/EJG\(WWH*MH66X@6D-B$JXWQS)?H_&?
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MNQ&*0OZK:8(+_W=!7CC7@B 'HIP:+L?W.?W8^RY;!>[*)-_WV9SI[&,$"4$
MK!V\G.-QA;+()WC^5;D]-#O47GH,WA@:B^&[D=ND2713&Y#]$BM+X@^T%TC^
M476P.H@0]J<BK>X=Z&G'3<-=>C?5 0F!?@US?T[W<O4\Z<1\<OBJ:X;=/%RQ
M9GO6#/@"P+2&\PQ[ ;B,-Z>%18^41$O+BJ&8-7\!9IJ:N'!D\%17>@C@6>-!
M;HND\R>[!64?#QWXM<;F;E '!T(HO.6D2^73 :&I;YI?-TG'C<12]-WUW</6
MR2Q BV#4:(#R8[CT%^YS)P&$<8Y&3X])0PX803GA^G#]'!?1.WO>8;#9S%Q<
M'OB(.N=#F&9'T&,:W!^.4Q22OAA(1++#)#"QRC,?2Q/VOXF!FXKQ\M%/!D7U
MOUA&S,M]QI^XF/GA!#I3$>?]!7=0J/QT("/**>-G@GP>;M'G:S?J\\9!4B ,
MFT??6_^H;43V/R;CCU;(1WL*'K7" <% #?O99F(-B")70 =M!EW\4[_GXOD!
MQ_MFXR5I-^_U20GK?'[FQC)K7"[="<PQ#&@7R;R>&%XE^_21ZUC=&1>6)1NF
MYF4PQ _A+W*ZP:/+HIHH@F8UWEFJ0@!XBQ0*$35YSN@&N#)/ P-E2)AGX:(*
MPZ5P4M3#+/5]&CRC967)=X_8?JO@K+Q_Q/#4"Q\23:'#AXQ;=_ 7#KH1JRP^
M<\B?"F^1AX8KMLP7$<A87D2U#);%/>Q_DP;5M<Z5-]4]:BVQ(]=;NZ/6*X"_
MBQ=D?.?@K[\!U[,8WSE!)H&!SW9M(+;8EOT-:.';</H->&_&%X/\)W: %FZ8
M==SL+EV;JKSEL7"JT2/CH_Z+E[.B?(*O2C4L;1X=N*3-_^GD '=*][YTE'1>
M?BC+=]MNZ=O9U[](0;F3FQQ$XY9R/"!CPE/#M(B?8>WRFR&,8/2&HA'VHCYK
MS5IG9K@6J00ANVK2-;/O?6H$Q3*^Q"_Q'01X3Z[?N:'J;VN?S^GJ(>]O:GT\
MKF?('7OO\L"*AJ^HD=&%R+,!*OEOFM\8.#X<2Z2 ;$ VR'4J-.7:-J+[XE*+
M!-P@U*0G=V- ;*.\:1*PWFW$=1O9[Q4 G3'F4I@+UR*LP.<Z\0CVU'NM@7*#
M+MZKTP>^W-?)G0:5*H88B1H=+?:9X]1^RWQ5ITF?-_-7NTC[Q4&%=M=[/IE/
M?&$9S*N/+)T$6Q[=[\]6;$D*@*"YYP>U ,EM7A,'HULL];Z_>>S $FV=T[])
M66?V?XO_<Y?>N5V[]"I1D1KGK_0X=/>WIA6C2;S[F+W"D7G-,+"TL.$AWV?J
M^YZ_*")( WRD10%+>-/N*H&[?L<JDU*M!$G\;PRH'HCRMFD[A"<OZOWVT?>=
MIGI0K2K2&56F 5HX&4\V'+$CYA?15..'ALY^2'V@1Y&=A:;"/D7T1!&(VCT8
M+SZ,<OYUXYAP<04C^0^R[R1\I']!;9B2U#<LCAEYB&U8LUIO6&47D2K/^Q])
ME:J'NFH/45F.2>6;YMS\$'!WGT6F__E/YF7+1>W' WP'4RJ(^C8P;I"VZ>"]
M*ZMV?\F8:9]K7\W_IUK;]?3'69]?Y\4+]V51T"G- #_I[^7M\;5_RJ_(>2S"
M#J[TT617^CQ9O(;DZ1;+AP'/KEEHR#E&SS;P-7G"E^J$QU0?)_K_<N)PM,,:
MK6W&:L&$@QH^YG6?%',9\]3Q:?SVB1;HF+<B'5]+PG,7EDB=CEWQN'L<9-[F
MKM3K[AFX+.IY\!N7%^Y5]2\NGS*3@S)FHLSA@'8$JV>Z"@WM9U(R8 --CKE%
M(-@H$F';\KK#+Z=U?HFBC=A6NPNNGI"6^D)A<QD+^ZBT-32PV&[%;?':(L+B
MW:JJF5KJ>W7(QS%+O-D$-A!;#EW/^'1?0O\07?W/XN2]I5:GE3!&\M(87&;>
MZ/$\"W+K8]C]X3\3 >G":VU=@Q\_E;>\SVV_4$3(+A7B^ONB^YAJO#YM\:!6
M@RQ3(Y?8E<5VS=4V-K9 SD9Z;<RK\HA9*:TC%VI,69O:;OCAP9H5$!^)PIN]
MI$U5?,T#F614KP%OM6?M!8R^W=2T@68+)%(+_"^ 5B58'5MW^<.RAQ(DB7U3
M.#ZQB>E,Q*&')F<-_N\3]O\W7YGEY;O)I*:I4>0T;M]+J5"(#(D<.<F^J5VW
M_ +\JZ^Q6#7N%WC[\/[3H(AR$C?.,RBEIQ< <LO:5(ED90MN6J78WVLO/37@
M35GH 9;AKMRH21_UQ_18D4AB+Z+J6+R5BWX#.&;F_B#02OT&C-[IN^54F'-^
M5#Q6X5Y 01G()"GM>!93$V1_\TPS%:-$5"!]]9Y0PE_$\N-3PIF009UC*S/)
MC5Z,>'MO>>4/=F0R(]%2CI):NU?4B)(.!U![;?A>C-Y[HO)1;"KW2L'F7>!6
M#XM8QI.V %']E_C]Q<\7 ^J3=.NE6YF(@S"'IG9K[4F%*6NR]56Z.&J_'[.#
MR-68(#OW/\2A)U'4;V?R"G-RB;M;]X46HYIO768:9-T[(7YMWUH\D0"O+B%B
M9HWHY+!+V3Q*G02#0S=SCA@M +S"-5,;_5<N;=SMCT"?8>9FUIP][ZB)-E@D
M;-X^;^RF,U=_47Y&Z!G6_Y[WTDEVT8]VFCCR4"5>:"JC]QV8QB4HK-W&)9[S
M@F6Y32'IHB[I*W3B41/ZU-PCUVK+;.UQ'9+ )/(@-52V22M"T?W"/30]N0PD
M]A.9ENE[Z,S8AVHU-R$K?LOCPTJ5OD  +E0"@(@%)H^KU/).CX@X.,(GV[37
M@ROU)YXNW)6V?H8:I*@,KK9_R8&U:=(TLS\@1Q#5_]B^'+9Y427MV*LYM ;_
M:>\#_(_LVT14H4(=%(!"?WJLJ%=C;#W"F]*KHA#9A*)J.&@A'WAT_M*@8CP7
M&E4MXFXFUTMQ\YL@5_^Q#V!W(^I5'^N2^EZQW?TJ\]=5D_F/9)&!M7!JKYT&
M32&]>W)7M\L9O>KD^GYP_\TO>I]#,&9A*0=->CTM;LUD?%K5X5,>J-&\&ZU#
M[9<U6ETB3%RI.4F3^7YYYE31[1ZF^N1R>Y) N"*\40U3A29WR<E_WC^%>/NE
M7D*/2#<I]UZ4N'0QX?,5\O:!.Q<.GM==,1A"Q$D:N7HE#Z.#>EY9_*T#^,KR
MGB_GV/9AIPR74D6F!1U=]PK8>#TB5CUQHVH=\RJSO,PR^C;.P8I?_T+DJ<!+
M9Y6]6D,/3MYP+#\%&770 &C..T1(XR\.JF>T=,J?C'YU^BON<#'$YQ/Z*5W^
M&2JCR!^Z(GM.E>21/&,=1>>Z>OEVW#T!3U-TU!=N%?T+7F5XN\[O3[OBJOE.
M8W6/G6S HJ I6-2DE_5C6LNE!9*S%ZYAP%VA9%YK:5)D81+)&_1)#*+V\("B
M#26[H<[D$0L*$](=PL:Q*;7JE[>%H>@9M9R2:[%Q?(/ST[@K/N<Q;MEU7L_G
M-T! &5G4+U*WEBWI[P+QL<.0$W*V9D/XCM#F4!L.1)S63T!S$^@7G!.9!L()
M+.9LGNNJ^>8N 6Z0A4F$4.L%^:R?!:Z(9YC1YBYLB+Y+2GQJ:YE:1SP+GH4-
M((?(705)*\EVN_1! XY45UHI-D0=IP#4[%,B?E2[_1?AV#RBS2.JD1WMHT1M
M3?*#E7G:/H_.)!2U%KPHG#@ZQYQP1+.3:W^".P1^*,:0200HA;/+G6IJ0^@4
M;^HR;*V3 67 R$7@I:S&T;?N8=Q+=MQ?;Q/'D@0S,ZIJGL=8P)<(OZH/CX[<
M[7[M%:V%0K@#FB>L4;N8DM4@HJ+(]&M9 YA)'9&U2V U*FK&\+SQ@XZ%NW97
MGS5X<3,.CNL@D##@SF8(1S1/30. 9=]##VDS1VG:!WLJZCCVB[BJ>09,1?2W
M'9<?-O+0T'<N='?G,]8F1:H=[-WKU$[WV6=_?"X?%PII%/A5.B"JIV/_/@DD
MX6XI72:=#FN'$*.4.[/:JE4,=&H, 2Q;<T:/ATOUP5_5MX7ZA_]@0.O_!C3\
MX$[\)4@$0],!P(R;X9I1\8(V?>-!,_ZQ<6'D7V'K,]+;,<[]4PT:C-,15V*<
MCA-R4>G<D0OCFTHD\^ZNP>M*LK5R40NE 0/G@74S TL3Z"GK8/E[+^>?UY/'
MADP+0V@O?@-BK<12?UKV%WQ\:W J%P L!(B(WCEGU1J<2^?B*NN897FR-N(I
M8N_[Y3TUN:FI7?-5=4V55^./*5;*FTQ 4MA^8R(^[VBU4?TP?0:TY9'X&Z"U
MCR*SI!>MNV?M2E>7Z<. X?M5(+;'KBLR;5=52 J7X#;J,DMOY=G&CQ6T=GRY
MP@1V>QCN"=9W#W'N"-[-=17_2V0T%36N>X[J\&)5152@]9L2UA3?:HH6Y',0
M>SB\RQ-U6.RF76('LC]H8(<&"\&V.YQE44448<HZ]C_:8.O?J )'+UQR?+Q:
M2<A$&7WX]#G3"L2K-Y(2K@=HHHI,JLTKW=<$3S:"GWY+;)$XHH\,"%'G+O2:
MBOCJER[),'BG':7'C'4F_*G=LJXZ?EK=:5-+%+&3=%WG2\*@%1E#@E+[72J,
MLKP("4R95)N.D0MXCF(Y*\D"X=?!07KN6PXH5Q[/=6_2!A6RPT5OQW,4=RS*
MQWQ[]?;QU9,!,KS[[-TY(%@U"K\242K%SGSU+LOD!7 "G=!\+"-XK&*BCES(
M%ZJ[QZ:^[0WA3C^C1TV^E5AT4(4 GO=B+J<VC9LRDI=U?EX8WGF/ZKJU0(!O
M#^96\'X[K!97RE0X8'T]/;#GPVK0-H)A1H4*C$-C?AC)%KWOLGW2&:XB   %
M)0'4<%V/ JJI]0%CN&AW6[O*5J]'E'GV2<L:?U"74,0W7=JO[\HRN@KP^OWJ
M,?HN-_VGFC37(.:&173DS?X[X>&ABVEU4]^T01V1!HCX']!TE9JN*\1#_%;\
M@E"612ID_TJ;I[IM_B5$ERY9G#N!\RP["J.=>@)-"1EI1&BW@:Q\E8=6A<Q#
M#'M/WWN4$+]?&DIBYJ-X#.#L<4\73EC.(.7[JH8V@@>W?S;.U<.6"W\#_BHH
M'ZN.5'^Z6Y_WRX=^BRH/M_U>Q[B&19HTR!K<]NMVB/SN/<9ZB/;EU,H% Y:W
M%_3T=2OT]$D&ZP?/VSQZ.U2V>ITYET_JT:S%G<2FF.U;%?('_.TV6+N8KT)9
M\B2 =6/^&B2!-@"<9/&N9_=*\*.SJL)V,=^\*X)U9>O*-_.[,;ZOZ 3I4G]@
MQ;2BOM=O &=-_P8CW1Q&,9ZM>=BGC#6WWP"7WX#EP$7.0UV'4Q,%Z6PQZ\>S
M01+T5*F/N'"/_ARIGBZ;C*NTQJR^YQ^\:H=LM!D!*X4@ZH'S;9.+^A^KZ+%O
M]GD[S!U<31HOXI,7<[D7W6ZC5G8!8F\C1M4(/QOP*V+D9_"9:5T $^L@QJ@U
M3-%(NA-C4! 6+RCD?C\E@E_"$?W(Y0]AZX_XV-(IX:>*&*L*-Z]R_+R)7I.J
M W+5;'EX^/'VNM'VX0HW8?]CBS>&)>4Y$!Y?*#2^WP!A0KL(Q/''G4,M)KX)
M7(Z\;W-$W>O9L"F'XF$9L6)0IV([.<?;K0SOW.V5[M'%[<Y$!7!.:>P.'-:H
MD:"8R,G]ER/M3585^@+7(YU_[(DL%PMTY'5;_V<"$0,^J'#NEK&Q*.N)\P_:
MUK3Y4X3,-FZ)PQM14\4)YSZCAF67B.1EEWKYE>&U;R6XE@E]%D+G-X5CTEC#
M$3)Q.1U3FTC:@)7^K\']YJ[QY2Q\R^_YI#O+0OWW*[O%R!0]*KVER*OE6:[Y
M$V"S+D2T0U/\'E[ZY>"92=0XD*<<W>40(,B/1N BQ@,AXL%VU8$S8[F5>M'%
ML>:7,>4WHZR/O.TOJ)IOB.+$PAA^W19T;47-<Q^?.ETUG/1]9F@,W')T@$U6
M_SC(0:PDFC3(JESQ%'P>('5B/HE75V:6KR"0[R\)ZK\)?M];%/J/?CBU^JSP
MD5XYZ89UZO)QMF#FAFACKTCBQ#@3HAAM+W2MF[!IEA3!;$]*XP"3I5QY$>_#
ME"ZZ'IW&7#;JI-)/3S.QZ;&FX4@V-K[B6@"(!P&(&4)&+Y, [9(PL$0N>.Z/
M<7.G6JZ";ANLL>:M%)8-V4CDHM1:C]/%(CU9XN/53 )/]K'R\,<)H32I7R:8
M"E%]*]HIA)Y!RLCP_8-#V@Y2H3,+Q8AGA8I&>E1,J(M=7GNV1:RU_+)#/?O]
M5L72[^Y&30-B3V8FXO>_NM-&Q4_U<3K?EGSXCBDJ. N8Q#Z[(Z.(_K#OV]$K
MML>UT:JMVO#C]>_$4J>5]U)LSN@?>>E5KPF,,BT[_]B1>^/]OER(@FC7NH5'
MEI/SZX;2)I1I&Y=-.@H1OO2VEBF,^'!GJZ1(=\<E%R?6OWG/[^!?*QD\U$>>
MPG7W,7,*;98I35)YKFLD<6-#T%F^^F<&72^Y&ZC<5V;!HD719+S$!L7CJAJQ
M82OV[AMFIHWOCB#\619Q'0Z)9;DK6/^^#1,[B(NVNY9!DE GSMUR&-XT$U]@
ML&+"APY6/'ULG^11.)MIJ5+R2JS($@@FZM';$T2Z>'5)W>:[X#45F2NXE'!V
M9#+1TP/KZ=Q:XO9AL_;.0M#,@M^&XZ%:;O+.',IN'=?L9?;9V_Y_R<;C98K*
ML!-5<1$GI$5$U]HUZ\'4"/0RWF(WF\_*L?Z\SZ/Q8MY+*G+3GOF;3[YCZH[X
MNO[<E+\GL7"]A?RKU_1DR/LLAD^VXDU]\#\AQO>;)J[%?:UO%5E<PH0/Q1KI
ML$)[!\PPR!'?K+JL#TCO!')OY+YE*EQTE5CM>VTY\FD?N\-Q@,WP,0"%63UJ
MRMIA-VP,Q96Q3R;*T,NB1SNJ:F6*%E2I :#9F<93H(*K-+>HFS]&G%X[LAA8
MC,FR,>?-YOS !YO_!CP27V:X%?L"OMV'\FJ=L^7)4(?WOF_\]0*V7/O7XJ2A
M3+U\YRBA<F%_U@\M7EAD;/[U_JPR2"G?7QH/W_V)EG?%!KYDA,29P9I8*%0:
M@(R'-34Z/UN]_!MPXC=@)F.[7?^SV]K-WX"[R.5S8;>%/AA:ZG:,T5E>FZ97
M^+EZI%.[TNOS-']*E26.A)0#E)H,V0QDV8+H'\@+R&MNGZ9\KD ?\J5EU6E^
M>9&XQ;[MTV<\]%(D7^SB: 8',I9^VO6"ZSEJ)@]A,T?4LX+B'L#"J\077ON/
MVNF#.XO(0X>K<2\QW\*]T/,B_+ E&'@&UY.^VX-F/^]X6HQP_1M,A[]U5O+'
MW,P8E;33\C^$ 303I2L0(>& 0".,O<+/<Z9)[IE1&*Y<*3H(U%?U]-/6XHI0
M@^]'*@BPQ"+&<*^O]PDY9DX@>5Y$:&<H:L+!DDHS:%51N,828<:B <EKQ[Y@
MZ<J;*:EXU0"8!#N1TI_2#G'$./]?X2+5NJ<3WQVMGT$E;T@#F$-7<EKF^J70
MOZICJCCU%SCLT%@C %/[.X*X]N>@F6.\H#C_V&U-1T84^!XV?NLCDGM5N,1'
MU>+"%_P7TN9,NI\@@1;DAPBTTZ#N0N]],S,_!LVA(J8 IAX -^^'_O?[S'XV
M#OU'E%Y_Y7I-K#N4V,Z55"]5:O98 Z.G%[ D/+-$3E<INR)_Q$R$)6KU?0PB
M!'7ZU:R@.0(3WTY;V0S2_E,^D/6VZ2-ARBZ1:>>>J2:-70+WW?J>CD5[M.P+
MY481:^4?%;SB4K7 32T\#>0R8R33JF_-KF8LDF@M$'*EH%6CZ<6QG58^G(6<
MG.[5Y4VQ>>#N/'AL%5EGON+.=;_6WYYB\SZZ3@IBDY*>DY,#22MQBS%I];,L
M2DQ.=7E/#G?W2D_32$EI-+7@<0KS>%G!?DV5+*NG[I%Z,ZJ.+%5SUD?-J&'E
MPHDO;"+BIX-5@7DL) HYNP.^?MGI_FF_:X8I8JDBD9+1XFF(9D0S WMS UBM
M<EWF!.DLWY*:ZB42%]8P+VAW[D1^JE(RKE9[^%5)M,8N94&P7UN#.P(G0X[H
M<%>WJ.A)6ZVO4X(6> $4H?>*@(\N$9,CFL$:-NYJB\VY*:>]?X3QW974PKSN
MY;U2S)WQP@945N89\+9K]<;!"X<"3F'.950WGE+E=@]H)DBXJU$\^HSB74^_
M/6[HRZQIOO8X"F>SV!;0R%'8KKV*?0P]Z_E2!.=VHZ(MD#(6Q$W!4)D?G(:.
MMGW?LY4QX,!_ZXI_T/=HMYV+#A;QZ=ZXT%;'U*>P\D2&R$(#D'CY=&"?7>[<
MX)9BO\"[08"R]6D38-8/T#@O'-^Y28W_H&5NBGLBDR_&P5.O^QQMX2[K;M"$
MT"8:A\B5T'KJ2ZKCC-Q;5<--)<6]YSF@8C7/8ZT-02=&Q5?7,K8K&:#SY=/E
M]3R%LV)>HS=BG1T$T@>?3+.\\]0<IR1IB2+4,3CTP1L\2T?+*N9!@T_X0^*9
M"8OK:(\>1'[''N1EK3TRM[H6M5W)N(HOX_?GBJ&7UQ>&!5?9@EJBCE\ .T"Q
M,RM&.9[Z#@081(S-Z*6%$#X8==[6MM1XFE>U;( L>LISL-$3Y)%\J=#TK=6[
M50]G5P4))P[@D2>Y35/AY5.S1CT]#^D943UG.(Z?C5?H\[.3_(AY,JG4C_:A
M7+ZU&A'D2]#320G??QH$S5@N@Z3C0LT>OPG!W]XP>EZL$5"Y3 5M##B"M^Y@
M[54PU)'LMRL>B$IL,+82A?ST\]/V(7_J2R* \_N>6/8;L N,C^\>W_P>]+!&
M*'QW7FA=:ZV])^+<=^7OI7&NK.^\H#*L^TPN73%#W#A__=+14D^=&D4+ $U[
MEN^UU:MP#6*C-4_LF>A;]W$I$C>>Y(G($M\GGBL@97!]+EQ+=[HY-MWX"30T
MB*.(GYO8_B^BZ=TW=(Y78#+KMP\\T!D>VZ]Y:V!.8FN + +\D;_Z5P OC*S8
M7?#[\&@,D0@M*W..N9+D@ L'7<"ZJ_6\[-T\&2<_EV6[M5G%"O&F" ;,-8:P
M>NV9:9QH3MF7-K;]7^M[HT8Q@44QMS[8S3=QF+0/W3"LE\.MD[RN[[C-OK!U
MLO1VN/,>C&[\O$/Y5N#@YT_]^>>HG.'80!)3RO<JKRL_;M$A]<@&G<9PFBJ$
M*05CY!FX 0 L9D":[-X_S),8T0=!#ACKC_+RE00H1V],S$K'S?BT\3)-LFOP
MZ^N>,;Z8GO@?Z^(E-_@WX6BIKW?+U=#WFATD>+5(I4:N1AH>Z7#\JI%;&!6_
M#1?_#1#2WY0NJ_UCG4/B;\#]G%L'XH;9G'-0SP-=DJ*#<0".C:$,^5H7C-+3
MY8.T8^*M1S"** T 2+,>$ (2GON0!=MYZ"8DDR9;R:XD;19^=VU17N<*VF]
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M-F9G+;-*M_A?=4*3N\R3ZV+#ULX!M*$ 1TDKD2>S"Y"Q"HU(M4=SZ4Q++*3
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MF/H%/<SGE)BME60P]E/?NGXK>1A8&K#.S11+KN5LSI]Y*GA>HO&3%HM0ER-
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M'G@UN0E-GEP/&>X_C*(G*@@7X<CN(##Y1T68^.K+#Y_W=^!0$M RN-FXPFP
M%2ZR))&PJWY>Y[^ML_*>&<7)SYT>90,3OR\]>?N\2=E+Z:A-\:V*-/LC-R\G
M/C[TP X&;E-(0DGU^DD5A\7ZNCQC?@<3AWE58C;' N8:$0K6(3='IPH0+ *H
MD@.P0\9+T/1S*5W=B7]'][&?K2%JD!IKE!Y83ZKLY4SRL&B<AJ/P>"BHQ[
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MNQBZ44+:^F399W]1W^,;]>6]*N-M$LRD+2"*Y=+$8L\FUI(PY(!M.4O6LL>
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MZ *[\[,_=*O(]C=?.#NF9ED]8>RRN(&NQS0K^#H&C[I6]HML.4FB0F#?FTV
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MW.-[7;_K5]>W[V^YG_M^KONY'W^\7QS.P_DZYS@_QV<[/O-Y$VFS^?VW<G8
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M?^Z4)0;"9?Z=XTW]&C#XM)JY9O7Q%4[K_Z1+(,TGO\&FXJ=/[Y2\5^L1L0/
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M6F=\;-^/ %[\*AA%\768H^5=,(=GP:W"(ON?R[%DOQ)XU_6K+/#(%#W:_V0
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M'W+V17:0\^2&*Y6!>M>;F<[IVDTOM0W:LYXOC[M'^).WRK&2GCT[0(.JZPZ
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M!?7'#D!J/;TNN!W=5>?W%U<Z$>%N)@N9]T)+'K7$__"DVEAF.;X:/)2M:5.
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MWJU[BJKV@2P/L2KF+$4=9F,@L6B@&,&&8(+PM/@QJ#U*#--F@4(%LJWARG?
MD\=GPU9:_\)/"#SJ)^*>QGB9+DD%8$G25XT]PC*Q,B>(#SJO=M&=?+]:#FI[
MJB]OGE3$)),H>%?<]O#M+W;L_C["\3;:RNH? FIC*,H"=P4?H$NVV@)*ML-\
M^&M:1'JZO/)7M-LX4064^FG5W6R'Z0BG:.4^Z%IDM>./EQIOZYC41LZJ[(^K
M=H^,0TJRP<(D+%S]HA]Y>;5\N4(U70Q$N MH21P^DZ"Z>6AU4Y?V3/7EX9R.
MKZ#]8FPIH:NV,YO)=;-:CP?]2B<7JAO%3F=IBF;9P^N4"UI6I ?9)T^][*^^
M]Y"ESP (&8<;T) QY2NPV.7!_>LV" @#L'0^;";)(R!!"L6R29/ X*&!B/3\
M=#+(S/OF=ZN4QYT*!R])H:TR.ZTV#Y4-%W.)5T%/H;0?-\;US]2#.X@+G5[+
ML*Z\_Y+_PU4N5;)NNP,(X'< B\<[@.KYJ:F$?_K#! (;\8;RT\'C-9Y,JI.P
M^GB[O&4'R$I7\5N-E^_#<Q<A"XYP!A 9Z):++^T MQ<_;@=0]U+\#M!$2/[6
M^[C,U 3B<QDR\1#^1TE-2<4V)73M:^@"CUM3=F$RKMN!B9-319$N*---13"-
MMAI_I9/O:D9>WY*V"G,%(B)_39&M8%K^R@Y $>/+G,/M ,&R.P#'U1-K MSH
M.)XZG/")CPE^>-NX;' 96#HE'),[-'!RXLJ$2Q-GV$A<FHWI]E5<K3EK2N[5
M$$&JFNX/<4(VSAV?S-N,[%E;%0HON&1@9)>@N4\" '1$B( \^NN+V^L9SQ\8
MOS%:>W\3N@P]74(W0L*H*/IRTL;\M>_TBTND3Q1D/KKXN(+@$4$+0G/*G=1R
M[_'0^DYGDGW9XK# A5R_U;&FL$]C0M,43(6R['>\-3I\XDN-PODNVRYAKB:/
MO"5PN7")X _W!-67GV[57]DL&+P?IWTT&84:?2W/Z>&/]8S+LIK^]BTWG=&6
MQE 3$"0O(71&OOC0J?]OC8I8NT%QE=6U;_ER'#NX4&^TLY729#H<E#DM&./&
M&2Z%;*+.3+48UL]\I6,SLLBCB!P87.I5WEJO)5E>)_&)NI)/NS5_;I:Z\TW;
MJ-^**]ZPPS/\R_U&VQZQME_.RC-CRL8F.\7L):2.Z;2K-+(] UFQJ:Z;G/JI
M.N$A<55V^Y?#FOB[@PO3F2O?0I</9O][0D5T/8,JN51!M7A$E>8 ^1AU$/5B
M4.T/]UL_F,0^RR TI'MZAR_.J+8SZ,. $!'25T+L4FVT\L+B#K#RH799I"AS
M^.2IHT].('DZ7[5 (%C$M@V;4MKD\9IZ%_=K\:C9=[*]J&9(=&=\Y#@#$03=
M/K<*I6'IC?H1?30QSX"QWF/+DR H"\Y3[\Z9O_GF0+)LFN0(1UB=78&(W<H$
MB@Q@&@OP!=><V"=C@TJO<H<G,"J>&3<I#69<>3(.EB"&\N"?ET1<[N>V;S-@
MD%.45<6KAF/D!;2G)VL>9O+'/KBK5B RI"F'",5;A\%I7QJ71/D/-NE><KX0
M93KBQ2"$+&J5JJBHDQE_8! V[SA[: @5]R%UY:0.#.HMXX3P&#[#<R,!  #M
M.D">Y>;;_ZAHQ,RNQR?F<-+W S8Z$IHZ,)&D;)@,>0?@JB6-*D_%[@#C^I89
M/U>/K(BYOXZ+'U[[//.I6NB6(^2>K!#M<P9PD:8_,0"ZH*;/:=Y\ 9+3(C(_
M#5:J"U.*C)T(X5_W4.@@& 'U>EU&S>V231%G_(0%XR'UQ9K/!B)P*>-*RIBF
MVZEIPGB%"J1<.U_M]6'\15JQSE._)$2IL?<.H*(K?CE)B/8\4Z^") G.2_0X
M@_#LL#(QF1\>_^3\EL31W"HQCNS?/AG*+(C4TA>).'/U#D"K P-H.L>J!YM"
MV7/*;\9VSNSFP<CY(O:S\7JR[NBX"*HBFS%^FIN>6;-TAIPU%'P'!H,NTI#>
MVX>YGNJZW]6892=TI"H<?ZE'.?KK%$:2YHEX5MN#ZMI$Q5''5JN,^ARQ\$YR
M'N]8L4,MN_A)I:O* 9BX$+<?@LF=:W@0B&><&M::A>(==H YJAF_[Q[*;E-6
MM<]W']8.S,K3^8851U.!TZ.!*\Z_M23Z7KOY-/V!L[N 3SE)&!P9H4PK,3'Q
MP2KH7'7@!6^';PEI*JTE1O<+L1HV0>*UAT=*R2Q/<(JT.<=)@TAR3\BAVI\.
M+L_WQJBCJ:_Z?J9>W)64=!T^*Y2"%,W::QU8&+P9B@&7M[U?<.TB^4=?N:Z"
M,J0&$F&A1LF33J$,?L'>::4MF:<8QG A*OLPW\B# *DS8,3]3MWEW7-Q%@"L
M&NN: TZ84)*J^-HOX9/H(7L292;<@TXDE 79<7P(B(YZ*5[,V0^#$%$1JOQ:
M@JD3":IUGSP&.=_:B9Z^K#=?;QH7I0V'C:L 6R2,A-F0]^HA,T^,"E+YMM50
M+5?B"@Y!SV8,?O)'_I>HJ+_ E&U+_X27WP[KCY\GHWQ:P(@JKH*%@Y?/^@SS
MP!WC%,@.HQ6"87*33*2O#^=/1Q\T\4FRNJ@M@4I\B'B- ,/HH"G3CKF=%[%4
MTQ5!W@ZDQK^A?!2GV0R2\PM!DKBDGLC&F\2XO#$*#4CY?L#R+Y\31Z@^SO"*
MZ<:^PU#Y^,>*M@A9+QRBDJ,[H\/T<>.V4+Q9_"<]WN!1A/$.8! HL-W$+H>_
M>^UV:8C^@^G'U6W3-A78-GN&RAJQ\_$74*KL#?%MF!',"%7]1 .TY?C8VL7&
M[=[0Z0=4C7<R2*;S:/52-<&^;Y04> #K2X;(E)$N1)>]33IG\_*L58$0JC+N
M:07^W\/2CI^"&O5^>:A6=+75*NMB^YS08GN7O>W#_O*I!#B>JL_\I$]7FWG[
M?;=.>=0AS&U ]2\$.T<VTXNS'$-[DW/?(Z&+ 4@&,Z@ DA4QU;,\(XF04<PW
M/C&"9L'H>^CI4 +=OSQ^3:?UI-FN+"HUZ:)ADDZ+2'[+)UN_,JQS=LC826D<
M!#R;OU8/Q30N(-Z\*9Q4_O9*QQUKJ"?)Q!?/#"<GJ12+=+PM[9X]<$2GWU?!
M0T^^I)T-E@6K@%#C>FOEN[-Y-F/V+=M3/())1+;6#.?AJA>V%3<]W.-3YP23
M[4(0S@2OWSY3@2.'D_-K.Q;PQ15^>8[F=KGZL8P&+.QV]<U*_.R-AC:I,*4I
M-I?DYEEECL$#%$=D]VJ2-NIR=!N/",<CPTZC:H4AT[>(#Y+M391/!#>_ZPLK
MBILT!^.52:V[13[1;RO#/P4I=!VK*K^1I(4\ F.9;E1XA.:RO&MI.X_;5KJ^
M75ZV?3MEHO,"4H/?0YV_NBTGXDA"!"OC83U6YW;*P9?Z[K[06V*O,S98IE4;
M),9U P[>42;UWMHDP;8CG-N"P%1]7/)'%3##LU*& -^?+C97_UH]6?6S1[9X
MFHUJ&-N45WJ5?S :LMN7$NB':P415>_>E=*HJ<M!%,)' #\2KT@D9H &,6,S
MB>$HZQPYR%G0S\#*"G(/1WOB;!@1<2JT27R*W?LO;1F<_%S=[ID\^DC('O$H
M?!HND'(VA13XF 'B><3^J#D945(^&E,&Q]NV!Y]W5=O'<FXVD<AR_(:E/ NM
M%M2F7%# ^4#E\YR$T@EC(N6ETB6FD11(_03>\X/TK/#[WQXY/EA/R;]@/[*A
MUU+5UHX50[M@D4Z"41Z<Q\S1( A(T6ZV!?<>/")6D_MF/YZQLCKP3:6FO9#M
MR0]Q"$DG!YF[,YV:297YXSP]-)@ D(7@7Q0[75[FB5D7'RHZ)9S8\X9_@VH3
M61L+"IW_JXGS2^]L>_YW9<ZMX/QLPR=+4^/<QV @!)05;'D?&["H,_KB2^&O
MMBYU?;.7(<&\KU(V+6,(HO^)X$.C'%C+V]PBYS2P;AUR(_:")UJS+D+/+V@>
M[,(#FPR5*,J*ZXX5+8 ,<SH_XJ0M/'F;795!4RBRTU;FRK[H,NLC$E?XF9,8
M\?P:@?I_)8DO+CX^J/@;T4WA-B[S2"1>[OS]:8_SP^(;\^08X<_9EP'_\HW!
M A&2$!14)AR.NXCQ<$H376RFZ'A"6(XE"T5^+($&<JIN"HA5SOO>;W_6T(U4
M;%"Z8MAH93?BH\C5(Y *M<_]7?0FAGWO>BSD S&YOT!T,!RK]>X4KF169O2]
M=#>LK"I).J5+LXW>![C!O<Q0<[XZ!I>YL/7'%S94KADR.#B]1R0^C?O.('2G
M4^?PUH?2,!588F1797)'F*3K;W;XE6W!=9NS]V_ET*!+CK<T1!WUC$MK#W:O
MYY7I[^AA__[_[ 3L+85^Z)QI]^J-MMNS%\EA\E#WEDDV15=AAO0.5MA/V;/"
MFH/#W*NH [9C6G5R(#\0*A*K7S1-YM?TM,PU!\<K"D,9;UG3G"5*AD?)'58%
MO!07Y05J/),FHN+&VA=.L^M"6%"2C#N <NHD&\/KH'_6?2:GYS]>Z9F[V60=
MO=("&N.E8R4+8ZKI)[HKK_^CF,O1S&#<\SKKBD[1+,0NL9_Q;J/"F?91,AWA
MJ4GJ'Y7/5)^[Z!1UNQT-\.;LY] R3\#=DCHN="='*#*"T2@R?:F6?HJKWP+'
MUSJ=%Z*NP(Y$!7!91OVLRI8$=ZMFIW>K9FD*"L,Q->8FJ"#/U2.NA7>6:#8R
M@2C</&J$:ZK':VHM0)F#:E6Z%_6D4BP9@:''HT:1.#K45@#A@=\MK6U"AFN[
M&OKA":DPAE"6Y999+<L'20QG_^R'$CJ"0A%WF20DM3"^'D1/M&Q([0=,*IW)
M,].)A9[3*9Q1ACUL+G:;&'F,KOUZ?&/BE,3K!,7^H/B."*DP/::^Y&9RD19<
M>C8"ES:)$4G7R7$82[9.;!WJWY\;!V_&\;_X)E;W8M A0;CY9V^[X*^/=,_\
MG+A2;AQDU1K=]PVP]_"QSWBB)Q4!=ZU;PO-BY;*S*M'Z%)&#RDN]^EOK@Z3=
MTOG#.FX?>3X/[$:I.!4FW'>!:C>R'((M1^?G0J9BP87H.Y6(^KM*)*!5*HFF
M&4=4Q5E*)*=S70P4^&#PSZ)\Y7JDV_U/.2=[FBVJ PZ?4%;%U[CO )PK1M(O
MG-@^\M+%A2P%K,+-;;_"TG6<%%*\?Y^EN?]+H.Q*/,U\!%OV1MP.YF&O2--!
MBM,W\"<Y\LKT?:U4*QFM/-UT?(;W)*XM/LR#81X, :,R+;ZURZ/&:B3_),;E
MMP3\-.'LWQMH7>MN@)@]U"* <?\1+T0 62)(LJM4X5L)KW6-A\I&- VHHIE<
M3!/@_602;/AG#RHT)B"'X,OR6GN6[MQ01JJ]QU*$<^X"F>)_80< J/%0=P7;
M3R'B$Q=^?;WG\B/1"OYI.G0:A^F@[&IH:-<D?@%,"=3=-6K4?]'5QB/F+4L0
M'_K=JXM:?4>D2L",N"<RG90_>>WNEKL5PCV[%<(@D^++B*9XYBJJVX=+G][R
MO#]M!IE"I7L7%<AD]4'CPM!#%@_L"0#!\2]+&)=Y[K[G_XX8J))&M9_+N9%:
M@NTB':M,%\T7%6L2(8B+T%^[2I4%%I0J.!_KW#>EW"2X,"/[PSV9&BU+?^52
MO/:K7?#:WM<-*Z^*DTWYID>)]A$:XET^5K#.MJULLP.$4P.*_98UNJ^T=V7<
MN2[_CE0!H3H4L7"<20*'.3L_XHXJ<\MLC"L7Z3X7(E*!BN;225 =[8E#W!7Z
MP<8S&0*='PF0=LIBDQ546!%!VX'"?$:0\(GD=EWSO\K5$2*KW;S/'G@3/L:Q
M^#J.#P03+B%BZI;K2(C[?KZ?<O ]U9R!*4?YYN'-J\7N.1W"IYL$A.+/Q7\*
M,?W1Q6]*5?T*F.\C84'M6Q_6 AZC%([#F%^-^E,#QI&1S63\^<)A"^/)1VQG
M/2H.RY,<AOP04IU;R1\"8-&?,/?8[]^XYP]4^<=Z#)K'@:TG9G5.6_4385VG
MWRX6"K?%R E8(UDEOI4KD1*G+*Y'*PD]SC-S#I.58.8/3 ZCN>[9[YX$!Z5/
MC!!.V=%?,[U#7?\[?ZQ_2[6ZW4//2K76S\DI)^JCV5PB KS(R:BUW8/C2C%8
M0]G89O=Q,SFQR.2D\TDYY$$(Q?E:CK6E^D]5^ $KOU:AF[Y;:.RYEIL#8JWX
MB!8H^A26P]$1IU^.4[\J^,M!*H9F_JDYK,_>H"Z)PY2V''I &+V40#.!6JH7
MB-2;H(\_WE$=B+@GFH9*9&6$GVII5Q?0$;A-@KK7"V3D#9ZB.,L'$X"XS$2L
M/S_;DR(^W'?N"UY;+LS<M*#G80?!877N<4A&?D^,W%&E@Y,7#UU07]/^CKAS
M6-_-,W$0%=BQTLFF5@1JV@'8T\^>N<81WGW1'KT#L/KA7!(\^TKD,SF\C>S=
M#AM%IY+>^\29):Z#,%D8A-PMVG5K;U_'8W1-D;PM$-L^X0X/I&J+)3;)0C7U
MEU-BBZ_5KMZVE!M8G:;,LQX2G93!,"'[A6++. E>YBQJ%$<3!HQ+F%K"YE$!
MK0\-#E@W!WF3>%V\H=Z3"K[T _3W?I\SM)0=VF^V)3DJ*"26<3\)Z&WR3/X*
M!L]CW2T32:>,)TK;)Y$S498U9D6,XVHCD9/*S+JT]O]?.16;<V=#%PIH]S.V
MHL\T8ZE[SFEA?64K0\E*)$G-)L%-7<QJQLVD $KB_Q!XU#^^J?#T]-*],+]4
MKV51 %%I*U!-[GTF;)]KUE[&3'V"<CJ!-#H[[P*QA^O^+X)?#[:(S-TFCB0O
MHE.4VVC:@<W+Q5"G3*MW02QIH3X()2N/@/@AL, ZB=O,$!-<N/[,.6TD2<["
MH*27(\/$@0BU1X4GSZ6OZ![Y_')8.\=F-GOLYM&[L.06,H1H7RK6%D2?RS>5
MXB&90,$5&Z[Y\Z]Y1G:"EHNO/553-==J*E0S4X:U^NQ^)U1B]SNAD18UW G_
M\U&$Q?*Q1LI!).% 8O/TU3C*0Y'D&.O.[G>CPU>?I/\/]MX[JLF]6Q<-!@D]
M@*!$6C H"!:*8 *$HM(L= 21#HHN.DCO1(H8J8*B,8 HH)2 2D<)10(*! 7I
M2"#T'FKH)ZQS]R>L3_>]]YQ]QBWC_/&.0=I(>'^S/+,]\P(/MUWB=K!P._;@
M-0L'REDCF<O%:9N%(9IC<^=QMN'U2&G?-Z:%TT9_,)'G]WKSDI!*L8='?S:5
MQ;UHQ,R#+L8@D*ICCUY9=;KLJN;I;T'".G>J;RO9!0#CSH? &Q3MUF=;W-KM
M92>2O1_XA-UIL+..TUC;).CZR-;Z+-9(X2-6. XY \5X#1*X.4 7B;#TJ4[$
MP\'DO,*?S5&U;%,)H"9)1H$6#:0/2UL>6!?)M1LS?/U=?NG?H;'IWO22R=YR
MJ5&KN8[VG[4<*80N,LCL57A36\SCM^Q<"DMG20!G;TJT; JD!3NV\%0OQ-U:
MCWTYS#XV[LK.KB82^GC_C'CW'Y!;UHU_Y,@[7*(V$8+O^4X"FPD-6XPP.#WI
M19EBC-^P!TI[_)2O7*%\G\ZI;'<<+,[/[K"()\X-1[]//2Q6+X7^H=KK_?-L
M17N?=;<6W"A2HA%/ (F*MF/]C%RX)K,,2WW?)S4R=?)IL%1/8+/ZL!+?%.4<
METSN.YRZV7"PM\D@>7W850&LXZXEQ]9R(%!_0T?\NV*#1_SH$0!9X#EJ%B%8
M](-J.\14[EE<"O3@2.\L@P-X5I$$""P$D8^]YMZA8O0Z*HP1VG"?PP]]N_)Y
MG9R6O<*K4WD0A'XNK]5*@VB6MB^<Z'>>+=8!IT!]\/;:7=<<&H"H8^?I5O<^
M#V<HGV,>>#YE\MIQ.)]=6TO\<F)J@#TE7VC/V./IZA@=H8^O/[C67[D6^7/A
M5F&R4RG1 "WH#L!7C_%R^22,7C!I/J$E&FF%6*&G6^(W-IJ?JKTKN7$O)"'W
MP@$E"ZG%C47\-".2$JN:=2^,D$P-'J(O!MFM)2M[+,;X(I3]<1<")55PNC&J
M4-97'"I05)SJN(>% ;D?<JZQ^L'E5P\KMEYT0T/7^;V(UJ'FN)"SGW[<21M^
M^E58M&O8MNLD<)YP6<A50YA\S<;?OPRF96[HB#>V8M#347%(3K@H?*HN04LD
M,4%KTL-B=?]LT"&&?9[0WXE;WYD43UX?+7,3J/ORK@&0K *(#P%(X>L=VC\@
M6)/GWW-I14MK(422( @<E(;Q IIW .:O:&CKD=]<Y Z W".T3A;:#CM9H!&K
MDZOCFDD#2SJZ+77\'JW/(CHH,^SCW7'QZ!P>^%(#SN2/H#(K\*!-9^U'?8>*
MB!LBW@>.N;8TR93Y5LMJU!M['W7Z^O(K5+WV[!Q8?2H$#)!3$411</KY%X>N
M/UF).HA7K/'SBX0*]GO$:LO,Z&,S"G-V/95VMY#(.[9'"5I]:1Z)G3 0I=[C
MIM'H#H!UV>6$^@<;-[$O"VYEJ@T$;8T@I7%^BD6X[[W3G)F.@SQ/R?G<=JT=
M&1I "JA.6DV^MV;ZI>Q:\6&#LK+J:@#)*O;-YOD 0$(EP] -2%-62---.BV!
M=2Z/5$?CYZ]<<HGAP(#OA_#P@S%:LZ[RV%*>&:_YT^6YFI+9 & ^@%?@[D>.
M^./<>OHR813+6&Q_3T\O(%T8@WZ!7P HNJ&Y5(G.(5B;WZ:A)DRS[CLM(P[6
MO?6F0Z%"^JSL^2E=86#;.$!.VU\<)C:B]V(!UE?$*:U67' R]ZR$X,W7/C]'
MJR/,&E(:C1%$1V>$]4R+3-=BJOYO\U"AE-%"A[=OM5B<D[3!7VI'H%@M/8P@
M9E71:.#?LE$G/X8*@!^=.?KSNQ9G=$%WV*LPZ4GYZ,$ 63*HP#O9VQ>4[)6C
MP%\\0C +K?==(AI4S^PR 0CJ_QW_R>)DYW_&;N'D>S'AB%.&]@#6;<A$8E_,
M1[&;0-'V2GO/H%YT.&#\V'&0R\7$MC+X3/2MV(?.N;U-7._](FTFU3W0A];1
M0A<MJNQO)]\11A]4XP4$IS8MBR::C=6Q0<[,](S=E:YC8%[NC2\5TJ43[<5=
M'2YG.:H$H1R=*DP!]'QQ_1KG-N[O&H2*T_BK"W>:ZA(X;+:F 4]BQ$\DK84J
MJS *67I8//A-SO951UJ,P^>?"AM /@='",-%J>&32X*Y"F.AK6'N(+#H@S-V
MQ]'?[1)\O("I5BI"JI\5+GSOO5EJ\D#4K6^F$3Y)@"MB0[##]GE^VR\R-3*S
MDIC#S1)#$QMGM1J58YWE#;XQC"6/;R/*VHA-]9=$XX5%5EKXLDEN[:QC/ :?
MY:/_,@;OED"NVEG-1S-N,A*RLGBFY(L?'7X;@3 49 =3SOBC>M-6D L2];(L
MAPOBTX(K[Z,Z%R$$4/8RM[!,=X R[0!::7$2+5Y:XC3E21W< 5!7(K=+"308
M'=WZ1DRB9?O87XFF9N($6)H4,-Q+[T5S"QWN$DYJMZ0H=)(F),8[@ M^;GU7
MW7VV9DYG1$B;.BJM)IY&OW>J]\-8+<8Q,(#A^,2Z)])<]7>EM105Z(@%4'#:
M4+D0P,=:EJW3 -"0=<<@M5*R&UD8(^G.KNWG,6$X&R>HD4$='=-1EH%P8"_=
M3^R%.V>$$G1E,,;9=TUS_5[9^,08;ENMTGO!=N?L&66_^NP :IE$;B\<IVL=
M64$[Z_N*T#72#V/A+5KX7)>(]1Q5Y6XMA>,@8#%))M7E,2?!0J8M=#)DNO+?
M$CXL@SA>)*KR?46#XONB&UTC)6?DA]EEB)E^6+#+GA8HWYC0USN O[23U_ >
MC1-XB*.K+QZ^FN[(6A@XU)M3O\B:^RF4]V4HA@S8SA)M[\P9=X><'KPMDLAM
ME^"N)2[MH7^WQ\[O+U_=;*-&.$01.XQ)I*Z07VO\3KSZ\?44%W2G^E:3R=T8
M:7"_WEP8 ADYY&]/M*<@VZ?-FM:4^VTR%LSHUO32[SKE]9VZE%@ZZS6,\;3%
M".JHZ+C+='P,UFZ#M1E\";^0KX5O'%X5&4XEE B<'$=Y-.0%&'LZ>I]JT99:
M%" O.,82\OQ OZT+\/U6J!J*)$1;\UFM0WU2-*V4T%F@^89A^XY'O(Y^LV7"
M,3]OZZMR:JJ"Z#FR0++DQ*E#?2<?C7@9M-.B?OZE$Q]3KU0=O:_E6EJ;#0?!
M1;.)A:2-Z"][74&"%5&TJ-+_8KF<G8BM^&=MI+3$>ZKWVVO>KE]%8DB7M"'=
M$=YGX2?>_C/+)E<-S9?Y@T8R5/T>8#4K2EGS3 \Z0ZX?IR\>[<;<T]5YH[@$
M;V&_*\(:</3U2MJ-#%_,F.C7,RHM_F>!7:Y(\2M"1_HG8MRGZ_BEFY.'[6P3
MXU'C&DB'MHS.T[9TUTU"  #Z*  PK=X!]MG%(5>EX7A40]IC)1M[I90^I14I
MH@#86GO09@<0$7#UV>1A7:/61U^TW3 D%$UF)L$D[1\^ ZBYYA?M5V4BK>X#
MT9%KOLO54')[D.R$H/0/[>>.LUGL7493/\I),??/:"IES-.L4$K\T)S 5NBC
MHF)6E/#3!>YU\'6!1?RX*@(8^>_ZET=54-GNQDB@1J!?EX74&@2(K21^_NCE
M'(5S[U59K<3%\,#-;?LWBL_\H'T+?&!>\QN8!Y (]4N1/O"913OT:C5H":<Q
MCXM.-+O*?^JMTJT=0'=DR2085"BW' M6S4%?3<-820Y&FGG,8$C#]MF9U.!:
MRGC\FM97H4I"CM XR+JW+^&R$QV>VF:"_3FK^=W8B$^2%F<\-F@].O(JKN&*
ME @-J0PG^&$Z/W8^\$%M*]VFG>_WX''U9U:U>\)$G-/+Z&M]7,PCGXY9(%^7
M?W!LN)IVR^1-?0?Y6/FSDZSS.1\OW&SRS2>6P']^+L26-F:93B::LA4VC#.U
MT"!?H"N;5^JOF: ](RCB<^ER)ZC>/JM>T]]E$%SQR38$/F/TLT@:$O07W?*R
MW#HXA:,AC7\]FKQ.'G=3.MI952@P"O3@_9(]D_#%/3!"P7."H&OYN_:G'0!H
M_&&N&6/JK-BI6K@(*VN0"'J)#$=\]ELZ/.7\\ISN6_F# %K8Q>S4Q3DL[X*>
MS>5SC2M%7GI5.C?I+K\"0RY:I*<Y/,B[)*JB ;?REZR&(=?G Y'L*F-*L#LT
M2[BFPAY^4?#YXQ<9:'=5&!9.-&-NHIK?NWY7F,S&:SN59 7:OA]\63 ;K/G_
M7U69?ORL /I/AHG_??V?765Y!H2XNXL/;9,!@]U^)Y<( <&'Y?TQT8#W;ZER
MO?K'N^4J@KD$LO*U"/TBJR*'UHU%<P)D$OB+*D 090GKFQ RAD3IG%TB>40O
MW1GF GQ1I3_ B* 7C#PWZ6UM6YU5XN E59YDW2X)12^V_FAF,7$Z9E2J[58-
M@7+XQ2A+==(#4=&302?ECSQ0/Q]NXS-V%^:BK-OG-=91^E=>(W(601\B':<*
M"&-7!:4W^YZ-/3=7:"[%6Y<&KQ:=LY/SF,2G7A6J^2A3NP.@S("WW&)W *H\
M#RA'+I]/'KH%N:/M/W9WL%0H%#%.-]9QG6Q_<G[58.-X SHUV<HX&4\T@L_Z
M]"C_)+<N*W-Y"KWOC6*0D6%G5/8,LE&=Z'2Q("PL*OCV]"<;PNV@J$YZ_IBB
M]T.T0'X'X*297\9<F%VOQ1?UU1.8KN Q< <I9>2DYL&U;S;0/^:)U3EJ0K_;
M?5UI!FD-@UB/QE79T2KPN=1B,]\ZMC@T)B3(-BYC+<ZW6NCR\F7]HXJI!'G@
MQ.('ZHF33^/Z@VR_GB398LCMWB*T,,I,MH*)!K/'#>/4?28E^F9?J?'9240J
MN-99/PQF!YNM>^??-*0Z'*QG%:GS7_9$^A_";,/)67Z'6'B/6M:]F5DX<4"O
M]Z7D1!^K[3P1Z6_LED[%LMDKZ2F$-%[GM9)!KX+F12&0:ME1OP'4[#G/17X&
M;>D&=SIDC IL"NW.X/'9[F9+Q_2[]%IA>L%2Z+#GR\9PHN]>DSB5_DU6:$8,
M5DH^DP&G9ZN-X%^LIC=&4A2VD8G;%6>WPY:2R?9/.S]UAAI_)$#C&/09H1RJ
M#= E1):P\ ^RH$3Y^?,&,K;'+E3ZB7[9+;'X(WT(T3/7BMJ_=#7&E0C&+H);
M%^<NJ49&%%6__+H2%MKR'2#**\J/0O7"QAVR=P#A.3N J\H+HCL :S-LZ.O,
M-V*APYRS0B<E*D[7'\F>ZL56>AXK)U*-+)<&=@#".X"5>PI,9NGY5(JGS[/^
MP7I?4!-]F+R@P3Q2F@D"R;]0,;?WK0U!D-SN;E?V[X:#=-4"JK7S&J^/J-Z^
M]PD4UVC/::-5RZ[MPXX'XUG!?RW._>*K:OL@(+%Q@J>XO^+VK!MZY.&]QN5E
MG!0-\@1]_>^0YW!XZ<_: #!OP@(4SYFLB%[@C%(.A0@N3_,,*^VMA^C'P8B?
MQ-7IP@ND+X5@/$)+@$K=RBGY9W4^;-B]87 ;E<]WPSA#[7EZ XQV ,E"*VT[
M +M\C5V=6 1O>=%TX@+/%6LDT6%?[M=LM8[Q\,WS-H@+]_T%JH/C9;]U@/[5
MY5'$XAXKC'/:WQ#GD^3OLB?6%W\EXBZT9\0V?^,7<8WKN8X:^T^=]RW,^4KN
M/H=XW89/)"-D9Y<'CR1G?NLY7*^7HBU_2YM-[-$+0JW 21,D&:"I8+C*?^MC
M&3WK\B0<A-VNW!A,+C@4F&AU6*&SC\0@$ B TK5*R8Z?PY*B7$Y]I[!* QIJ
MZ846UP33%L0UR9PA;W=[DW@!["@>MI5T@;"U=P5& HTK+: WY+3A]F\-(G2/
MPQCI.=P9D>QW63W_7[ I^;>7ZYX;6I4/_'5#94M3TO>2D?T[-=F"T"_)Z\S9
M5VM]><P^>$\&UZ4#M&<8H$H+O2CT8("RD+K\.7A)-+\*'TP9^9LEZ.)?PTI_
MHG-ZBZV9=!7\-;+;WF,?DMF><3/J)S(?WNCJ X?->L$$L1AC#0I,];Q827R8
MJ50D0?FL*#+X_AA<@%WG0!F.B5K]0;'N:_D)!-05/\\D6,D>V>J.:&Q5(U*O
MGU<>B-U>=]D^%KOG[_(JJLEA?^\Y1+W7M%,WH7^B!%E.'N!I=@CF$B2][3VI
M=IT^>:,9+? *B">:<6G.,JC*"D9>).%8KZ2O8>\:C#K6U^CT]V.&P:8_.L\Q
M%KWB_ (&"3^)$"P5$?Q(T*D[(/+-4_5MS1-QYD@0JH511# H(]:YILSED,_R
MA[4ZSK.<J:FN,&\!!C]V=[ZR>B7+RB)'UH<TG/*$8[CN*Y07W]*!E*E>4U?^
M.3'WV48#28Q\)<YR::MZW"T>PY_#7JH8,_21F3 DD#M5?L'6>=+H>8E-VG"@
M:V"X^T]YRE6_3UW6@+?\<] P+0$&5Y5EHC[(.N$'?J928D@X7VW4"F00J>N_
M'D-%ON_C;)&Q\-Y3_O)49CW%JJ?EZO& %\!(8,*JSB74!6H,!VBV7OMR>M@J
M&6U-(7YM)%H.(EI %Q/QZ7=JTUON8@\\UW_D#/-9*24?KR:18LNZT'Y^;M>K
M!DWZ=@!!RAL35=3HK$%E7KG(IRG>EP@B[+R"=+#.T-9U=@W$S Y@T.K&S$#E
M&*2WL,1>R#NS;V4J-D!W]BA_UKY>=7/EL$JI,Y&COJ]U4M[S,2E[>WG$(1VP
M'=LBR&JC8OWH7*;3J\]Y%31!H=A2D?@^5E3_G?*T']97D@Y>1%6/T7.!E?4(
M)=9:?3P/V_74A+'[4IB])50W9$UN-B7)E1'A%J>N89@SP'6/*^9L'%<N(, +
M%BZ*)<<\I?=[EC6H(Q!LEU:<=$6=J=K,V6PX'A7B'EC-OTQB&=><^Y.HE6U#
M;]2]1B7#WF78[0 &5, =9;2S?B"M):YX)2I#5%SG+"9&<Z*:Y$XW/(NO:?<3
M<$%]$/UF?<=.7"NNY(L6KWA&J6!2A6YW/\N'&T_@GM<A4Q$0'J(/N6Z@6VKM
MY':QKJMJ_;<V;Q!B>ZY45-$JK]Y]@%.VKOVX"8=0WQ%Z[+0K([#7Q6*L-_'!
M8+_N76,F=WS<_6'V4BO#[1O$JJLQ11DD(FNP8^,GE8#'DQI\L;Q7M[,$0)FJ
M>3N * O>1;JJ**Y:02O^>8;S&[8 ?J\Q-)?%<RZOE7_0J2RF1GXZL:' PJ0T
ME5B0V)HZ.+R$+-S42"<*/M+*X?:Y_>3>Z1,QMUNX+MG&E%ZG[RSK#-. Q(7K
M:HD  (TB2[SY [5"'&IO3Q?A%0P/LG\,P0-P!;,(//^A9H0P[)L$S6=I,H6[
M2]/?1R^B2D""5.7X/-H]C.HH)J_>>B4BR',9'9-R.N83?DNB9<[E=>=MUH%S
M"1QOY>D20S*0(.5VS'!KG)SW &LPN7L',/4^>/RDR4\9"B;S>E%H]#&!5SA6
M$UM%$F>8%,'"%TKINW/4<L6,R07SF!];F9A, *(38_]:T.%2MRU[*@E=R_?E
M)15"MZ'#_KI%5E_7=4*=/46X0K)?'<B\H*XZ"Z#?]FF HJ/;*ZF.3L)W>_0>
M/WJ:K2V=DR!3L4P8--=^3O9W:-CL<$5GG,KU%? 1^CE1+^UG=\#-C/ HP$$P
M0ZC;:<$P[D84'NH. &$_Z@@HH-2Z[MCN[Q&PN+B'N\YO^>0!Q2MU0I3%\UM>
MB30'+3M3-&0!I9G3E*JI#ZGKG#BG+*CJ?U+D?LFZ-+?;\?A!>;E>>8O>.'YO
MT/S1>Q\>KMU4;Q5$L"V$Z=5$(+T*^#1X21P@Q45L"G<'B7BIY(4SSZV+-"5"
M2C,V3.D;/Z5>(<"T=-XWO<Z B.NRU8J*\,?'MWBT^Z-MWY13(^\R?GF/(*I=
M '>.]BB;?2\PRZ!<\#2!1:6FO&H0_/)*:(O12/E7+^X7*JJ.R\'=%U<36Y[Q
M,G92QV.@"P RFL_9OKD#Z%7>PK[XP)[^KSZ.LCQ@S7>'4/35D'0(JXF@GR!W
MC*O_6.QK/_OH)<L9?Z^H0,JBZ$9MVB0(!L,R>/145ESJ$&F]O:@R?,O<Q!:F
MB,M&"(7R#]MQ.K+VTA"AK<<6=0<PE[D#&!+;_U BJY :Z2 _&_>TMSSI]DP7
M[7-F0M8W_#KKBIAMB_1-AEVL (+H(Y@QC#TO&;H@5L$&K+6@3[U2>B723OSY
M.^Y"Q3<"[7X_B+_&+W(L&"B</UY*E2H,,K/8*X2V@!7'8@+7YD)S<!/!/7'(
M3ZYFKG[N[,:*@M(,@6\L=<?=JEA$C>Z^%!VUN@^^=0J\?5^B-:<N[9DY@VM7
M[RF-#-9E7E@?+4(B0)=DQY.%./.<07,LZBK\TLD0I*LQ$HE?]Y,+E7F#8^\0
MO?E@)(G=:-@=?#6L+J:HRR=Q2"R%5>YYJ$C8L&WLBB]1*8N>O7O8]9X:$+D2
M+?9FE[26+O1/\YWFP;\P8$/ ODR;?I>YCO9_D"KZ>/US ,H-)T'9#G.T/\\,
M?B+5XL^@[&,OBOLYTQ[Z_4/E6<I!)]N;_G%!5\7?A019I$J29]?1"0KVB3IZ
MI\$77I8]G(OR*C@SWAA?(7;=HO\K7>A2XXILDVG A5('U(G^!JH>+>@BN+IJ
M3V.UE9R?;I1>M_; [4T=5E:I?[]I%'<S0_P]\%%W-;Z1']@KBH4OX^XF"'N%
M\_/+QWW1@5N'26>M":7CCK8[BK3:=[D?E6-%JPP#DZP0_.0LQ7E?!HSJ\ZKY
M7.?@*J&MI8%--:$]?SN/[P"XK#$V)-XN]K3#!FUM(G9C: X0Y?:K]B"1WEX*
MQUUV!DDYG(7J::)VT(10:P4;N_\VSR/B*GD'\.DYS>;AM/,/56-E$M9M791/
MZ-_0'"^UK$!O];$KC.5[Q/=_M_J?G]LT_RVD@2O\ : X4)\3\K):H ]\T)L;
MH7REXS*M'G']+5(+6S,L0E%>[_,GF!Y5O+GNW!^-BE^N7N%.:KWC.^W11_6[
MD/9!IT\PDA8L?BF80C7,2K1M_A:BF.G$5!H(XHIY5<0C%1J@"1JJ& ZD1WMH
ME]W,IF2!E-KQZA81*P",_X0OZ-,5SF6A1/\#"J9B+U_9/Z<2Z]U33#L8Q**\
M$BJEK-&+(>J,! '?852]12+IY@LM^C3QDX W<?%Q_B%TREAI1MBQ;)\$&8&F
MZE!0LT<#X> #$ 4$Z_DH<XWRL6@XR &NKI=\73&F$CQWCPQ!2M/!WW8SCN"4
M^/@T3;T>WX+=%C^$?CN,GMURHU[7V;VE*[NW-.1'(=GR*"&;L'(S($GDL(TD
M(W\(W1C.@*!-ZE#^]:YV!VO!CQ;'=\LH:Y';%1HT/6%>Z:'L:T;G?-][YV5T
M_'[TLONF7PQ^G<4_-#7G9P0]2[ GS0;U+XDLXUF9)BS(%CKD%W1+:ST!A[B;
M-)VKI$8>STNUN$TJ)+#+_E&G$I"J@N$6_A1MS]L1T*!;[)HK-FG!XR>*7;9A
MIKVQ_<EQ<3Y&XM+R=L7R&\ EW/D?GC=DM5@7,(6;(=. :9IS,AM.N*/)AV3Y
M,UW/*UJTL;_/[\[UX%^]TW?IABUVN1.?!D]]"%[GP#GA6+_/AK_ZUM1=HXEV
MZV3&/UO2H=[H&.A+W%ZSW#[S5E-S:@I-33_P@?.+1M,[*Z';^CJTX'+O6TIQ
MAWQ2ECM9\>)0!4-^,KQ1%(@@M(+K'L?).09(QCV,-,/P/H IVDF3R+VBB[(3
M25]\0+6/,M7M']O<<*N>/%(P$:<UC%Z!5#.4EPN2PO82&T^UY3RCC(9Y:IZO
M9TJ Q8%$4*L1,DM((J_ G9LH@?EMS^1F;D'=4B6"F\NPVCU/\B<>BLP=_</U
MM@$@ 6H+HU*&:$QD5KK IA#'J1'=SU\2N^/?*<_%:4Q=5$GY]LW" ;>IYI][
MO$ J&SH+[W-#H=T!1 MMC;0&9&2X9V>'S2)6^BF\)>@Z05]A>3VF6Q1^2@%[
MX[\8Y#+_KP:YA !MVFD_IKD)"=I/1OJIO6BM4$OQB#2RQI9:QUNX_)=/,+:)
MH#69"^@Y5.GM./S0QBG["T)>6''*D15^"RO]%@)+=6^J?G"606\9D&:2'(18
M2UYTY -$9QLQ[!]Y#P0"Z _U%;FO/XF8O6<[6A['/3_NSL!8W3#B6R^#HG;>
M2-O4TCB@D&84LC$IG84[K@$KN1H6>-"L(R#8L5 RZH%YQ($DJ\KETZ6LL7KM
M2^1LOX@(E[#*OQ;A'\H42EQC7!FAKJ\H&#*J4Y%_+&:[TJ5ZA6%A\CBD1M)=
MI>5 0-^Z78C,9##SRF7]7=9/8>P^K.>])\\BT;09"+G2R$3/P*BNH5? &EO'
MN<S33O4F)#<R7SPI]NTE#EH YVT0!V=JJTR%8HMTK&'O_UFP73HM:FBN?[Q4
MY<(G5S[ O.:TSFO?N5\-7M]OHOYQ+N7KPTK_>$*0K$'WIY;;]]N_F+^N[Q))
MK 2O3P^L,QN,G\D$_?J>CJ 'I$;/IYO4%*D$1AM\F#))Y!YT7L?2=#; -^V%
M/ALES"YJF*X1NC6(W@)[U(-,28HR0_:MF'<A#21G?3>,/3T_OZWR!>4#!PL\
M9?>%JLI['TR2J*'VXA%G#+%-CW9)V<*43<>*:'(M=/<BS]MWSOP55I)3<0!1
M@;(6/Q(0I9Z>GD6: UU[V=2FV:"*QGTQP20;]&N\5MB3W+2LZ5E=Z5-RXS/A
MRE6P [@C8_R7)H@&\7O2F^61%Y4'C3=+=@#%P1M([V5\ .V6).\ 5H@[ /O\
M[<A2V-Z%&?_][OZ+([6<)N[_,6'@\/<TNM!9VMG10/*%RPY6DWZ>N\TB(=2<
M'< IY9FL[49CI2,M>?3QP,53*;#NQ[LR\ZR78O%P"^?\#?Q)B:;+/O<$5(;M
M// M_L9/[CRK>\;Z\PX_.B>'U<X^:1D$FX=AT*@KAF>R/GPS^X&K4]"*N)'"
M[B?-%51U9G!]M*!2@W*DY7I8.R=6L;::@.A1L$<?:A@+<;U[(V8LW?B7$!17
M'AFZ(?OXV"4$&F#'VT-HX[<BTY-A6WTA;D&_Y$&WY%"7TK]V)W2J[H&>'CL
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MM3+WTP,]T]7[/K:BS=G?D_#I9$5$),TC,->/;5!HWIYVYG7&.K_+CHX553T
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M],=ANP,7(D6!:5WJ.D,JZ\_F O98H]RJ2 LAN2@7R[G+DAEQ%\9PFRR &'F
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M"$D? _Y-['^]J@:WYK(#<*0%\WYX2N2#B+)CC^G54<Q\D,8-0BS>5C33_]G
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M@X7TX_-%,,X>+<?P)"MP51>KW_JB>1YWOC0VZ;7&ZWIHE+7&J(Z[CGOP>BV
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MA&CSLHX)5&^JUFM+7G,K^3>;B-/</2.VS$U)S8:[PZ<DI=_*H2GQ%2+Q[?=
M53R]!%[T0=U=HX@'W./-TKO\]WVV]GE2(S65*G7\%@! %@W1JC8+\4N]B*4.
ME6E0S24#3D49P!)XY10V2V$3BQZ3$M_%LKP.(YQD\)PF&?E#WQOY3BS S?'H
M<&+Z6$(@(WUTI"K-[US]ZC$ZVUWQZ&F+(<Z<T+GK=RI8#KH=#:ZU+/R2N-:]
MT']3T$+F PH]E_\SVGC7OP'_J*$1"\UG.6JAK&A)5=J1QD^"CY5>TQATX^]M
MD(JO0_'RCHWJ>A W8#&;'N/G#+3QOBLOYDNQSB*\C4-2&+3;HB3OV%8B(<BG
MJR/@H,"D!K?(I<(G<&;+XRL+6E;^WD3^>SSMW]2Z3 CSA,@=0,&0I/- V5=[
MYY]IK+:BWXO%7L8=-&X_K=1]J!KC&_458\\7"OEL\C($#MX[4QU<\W8'D+D#
M6*/!N/?YV[NF"+_ON;SF(_CD=5LF;0NUZH/E!Q3"A9ZVN-6S^^;'1)\A_$M#
M6GQ0^/E)0I-E?^/6"! D*O*.DMB)01$1>)XFG?E/GC9<ER2ZBD>4X]@VI[[O
MBAV_5^)\CX0&U^71:Z\X*KQP0]+=,P1@)W2HG+IWBIA[\J29K=V^1F/AG "Y
MZ)FF>$2LFTA^_U<J:[X"I6$)SYM?3U.D9]7SG[RL!"^Q].6/*L>S;$Z];@T
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MNZM/7QR"P<)5+M*PD?,0YK0LH6D*JBV=("#M86[.33=:-9\SUA\K)6>/:ZZ
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M<@FOX,JJZ[<3,\ <;YG!Z@7:2[!))Q(O;A(E%.*V8!:U!7ST]-X"4/ZS-5O
MP.VE> 8DZP_7JE-PB2Y\[\ADP8!D!O1(!J+.^ =$'?>WXD=4?4:>XC<UR2_*
MGXKY,U#ZW.2\7(TZLHBD^,"GF[]^G]U<@?GBF&Q$BY_D@7I^\PQ=*='.*1=2
MB;)%M3*\I#+WVV/&"@E'E%V(VVMIE68UET=O]*TXCQ6KHZ3_S4/:F9NA;D?,
ME?*&=9K2EH.M60@0+2)/L2SA V53MO7X$2LW[).?FN:++!YBCMZ13FM0G))5
M;TMR2>2>E2^N]WH_A3RC2FQVP%;@L5U^4N^PF7_%Z+?TS5#.#,BO.G#N4X5
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M:NY)_H1T<Y?NL"!4Y.F6I*_MA_690*+Y)TFT(WAB0G4+P'IQEC=D?T=T;8=
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MDU37N"=!PQ $&;H^"8)\<K[.4VALZVB%"7Z&>7>2QRQV)8"02D"AM/1K<*\
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M&$8YLU_\4=^.P;2R(6"CRB1:X<"M8;"_=+WB&PN/G,J6'GYMNR2!&UH_0#8
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M)\#D.@X=V+[!:'UMR3ZLQ.P7689V47Q\[$B4G&N3KP>QW'495L9DE\D&%@$
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M:NA^CV]I@E(&(X]_NOWJ/A>]>-SZ5?:8!N_TI6Q"&/W^0()GY._$U\KOQ%?
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M[\KUU.1W8_E!]%/C[N:"D: \1O[AJ]'B-P(#9K*+%%=;0$M9O;P#SVM*QJL
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MU<794O<O/M:N\9>]NT@3R]%[:R:SGQ)DV2=O?!"/H]7@'A$ '[;HY#7*).>
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M@8:6@2$WKG,X23;%L-*L\^U=JM!SF!3K-)C$>YJD7/4WU,O-V_5")<H+USN
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M+UBD8]42T@G$D6>2%N0CT*4P/D)\20;0"%I/*,LS"/(4$6E'2DJN_6[X1W.
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M6,L%5-Z%FTOBW$'S("YXU<4V=K'$M22@T 7NL)GC-I#&N&V]QX/^O-(I[_H
M-R57'RM*@ETJQV1'8Z/')%@P"8Q5@@]KP3@@CY:<<Q%Z@?=*<9J/9!#+O7M1
M0W,*EPER 9J3)+ "/D>IG;#F/4 HBC*M4W2+_X6?;H/SOUTD\4J+-U-:,_+V
MMO 2;G]=5/U$*.7?\^2G4WR$U#X6GO\=[/.]LY-FLZC)23W+4>'<?-V/V*FY
M#,,FIN- QZHZ("W9$;>L4(.8\M$=L,BA76_@K*\B#(01/.J68%L>2U_SULR@
MUTMN,Z5O'RF5)#G'$MM /;KZ[,57_[AL3!]?WY=,TTHJQ>R^.*7_Z!$F!SC
M?V9XDI[ZG';U=Q685W]F6R07Y7(9%%2Y?-3C:K6!_G$=TEF/R[VQQ9!;YG"P
MMJYIQ&6Y)U67C]X\Z!IP@ ,<X  '., !#G"  QS@  <XP $.<( #'.  !SC
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MP%KS]_38?TV%.<3]K39?]6*(B%"]('5;-0/)N+@Y^X3M^5;C _8"ZG/D,CD
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M,I]KO;Y],R8!SOKD$T,K"90\<[='Z3)\"_C 6K1'+RVD!?+NXCNNJ,2 D\K
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MYKH,P TG F"S)_C6,>MGS>6UN85M5HH-!:B5J()*@H0(?-^.PVIW[4_PNS<
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MN6IQ]*&?FD>C7V5,I/(4^)Y.GUR)+[M/O7P[]>_F^&**9U0JFG'"I^]^$'O
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M<<K6O]M1-R62.;>$11-WBTIMX-5(W=8[NA9NT;9KO"JJWAZ9D7<=C.IS.^&
M:%6C:EPO-_Y+W959*J&H^=MT<>GV,R<+?__;NWLB8U7?EWX*K%-'C9?#=+KX
M]?0U>.G%)\H2R JS^8KG6H)C8 "5*-DKMER]\1##YTT./=XV=;-N1=;@4+6#
MK'%/>Y"OLV@#YWO/6O-'%R32/=!!1IT$E4Y8]AI4W)3C2H$$@[#/NAE6?\*1
M0A^585V4_";V&\,FOL [GP\JT"RNC3BMI>I=C_DY2?*]S\KR/5.N[7^O64/H
M4'*V P/$-X+55!2"'MPH/,R[.,!_DA6;ZPCV.(*1H:R>D4N#QG91<P_47E%$
MF[6I(("MW;[2;/N8\2FQG^AZ&)OYKSU7!"0Y#W:QG(N\@1;%SUU(8XO7X'4S
M,=2*0&HN3DA)LXSH1N D+G"-JT!I.QE_K_XKOOV$;*)9\4U'Q/@:3#?R0([8
ML#C4_FPXBYI\%I7!87?RXBQ+>Z*\"TXS&\INA/5K*0=68/@S9]V0-"IJLKWR
MZ/!*,:+;T>X-[T%>[7YCH. <O?V^!F;7.8.QR<B59^'7HO G(KB@\V]S!LA=
M1U%EB_DEZQ?P-7Z]EP[A:>O.H"Y&NYM+T\;-8:6\,QJ5JR;8/:C&B0%EE> @
M7]Y90^$8E< AJP<1B7) O7:;F/IK]$SP*L^DWS:AT&42QY>KYTJ;0X0,O 3T
M1/DC(?,UXP0EXM?4OXX^O.$;=K+Y]T9FP=Y9Z8V 3UL B+44XN\Q$>S_.!ZU
M\NSVF"_RLWCHN\;D/0W3\H^9X8:30:*[.G+W.9=]8:'6VWV]]!G;H^OKH3_*
MUGO)-IK%]IG.$=XA3,WK+(SJ"!S3>^_UV_K2_KWC6<T?1/',24L%DJ>J9B&;
M;"X]+W_+HYX+.&=Y;R]D5S[:9@W')S]LWV3DGW'"[&K((;)4ABC/,PK+:+BU
M@?NB68%UGYFDP#D%#TU>!E%/MC@%J\:75LIC[@REL 4IM=D@X8QO;:XE$XZ>
M/!DY]H 8-2>]L(C:@_%?'-7H2EFB2WS5J\=0][UK"_.\=_/NYWVO=QU$.!U"
M%_O4O!C<T,7^,(_@IS7.0]FU)SA1/C5P1X<7AM2<WR?2"_\O]MX[JLFM6Q</
M! @@@E(TD22@08.@2)4 "56:(@@HH%0)B@HB15KH($4,H=D- 4$%5)I*;Z%(
M B*@H*" ! *$WGOSAOV=NS?XN4_Y_<Z]=YPQOC_6&)"\2=YWKK7F?)ZY9M%5
MZF,:\*#K?1;4\V>Q@TV?BYMXY? .<>H+F*C9XKD[63!\.(P[:!\#B Z8IQ/I
M.?FXR_ETL/RC/:!ZL;5.WPY.6G)K2)/2',B,<H:P[M_Q4)9$6W4$M<RVS(B?
M3LD;Q!G5JMQ!<[E) #B$(VA!/GR-<?H4NDW\;T+RVD'3!U2N=)^PXYI]\!T
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M=O#Q87VQ! ,7?61FD^2W":2EYU6KWC/\1E8 69P9*&+-$?YF<F^7<U+P_"6
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M;J1/]>!0Q;6C(_.QW#T3B56CWP@HB$HYNT+1HRP:N/I\G3H@S]U5.:G?80/
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MN]P(1=4$#3'/.>!!*Z]C2U+=6>.(F+97.Y=Y.!%2E*=9#>*_.5?<6B1=P5@
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MC+\G71^GUPLF8,BBZ[I"Z2_6U$I*$;BHEF#W6D>02#6O!X$"OQ5])#SSZY)
M[4_ ]ZL+5[GD=.02FP::Y)*-XWA],>[N;E^^BD2N(7CQBN+=R,4.'H*TUT_
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MO+*Z8*XG<J_BSMMN_(3^2&2.>OIL/<SGXQZ]"TDYM_QU%#**FY^ SRQ/&.F
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M,3W>?')?KE6^MA #]\\MW$URX;>U7;__!-3&OE6*_G)N@63]YNP\%;";U,6
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MEUFJ^<J;>CY@N]@#Q8S[G"LUL:$Y?B+#1X)['I70A9>FNO7V+9X[9?OY3O!
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MCE@JU/:DXE"31L'\$+<!12[\3R4T>U+['A*S.%JFYD)5L3NP4XEZ[$7H578
MWOA\5;LQTWKKV[3EP!-F@]=I4\8]702;Z+.SE5[G Z[4?^ "R5K?W:+(BVV<
M?QJU%:NRT>LL;_<'?R_->Z)=C]).TOBYD7'&ER0*A[[L_"A^LOAH!$!EHL$R
MI$ZD.\7P.*?#WO^$#Y$S"72<OIQ],"Z^D<!E=7IUA2&J[H7%B7($ +-'MED\
MH$\?]K0U/<C?H3J(2Y)?>3H1/:WFT^4>S!DXYU,S_-$ V1;'BPW]\)(_>?QW
MF2)/GI:\LZO%."%TAJFA70-7)^-C&R#(=D"8Y;V5?:,I$^P"W[_X!V"'$7L!
MJ4<Q7@7=*J=U90"V+J;3P$9/#30S8@S&MI?[_6K>>/QO)T7._Z-Z*-Q$8V4$
M;8R</<8[CSP_]WX[W]$!0\_XF$#S(6\:6,9&\ECPNI0=J/A/L'&H_0Y];WMH
MK;HCHKK=7@XN^UP[ #;?7;'"V>-CXT<>[9,G[7I*F']-X&-X&$?>VQYOP)?C
M;0#7U7'@JQ?NSQW=/"TN>X'./LI?.=Z?-;<;*I[A'"F$FC"HK9ECQK>6POQ_
MWSXQN= ]U\36VI-1,G@\A&*L1+*QBTZX1<>-"VG@Z7^0VIQ7_VO1T^#WM)\,
MIL9<O?'79Z(NBJ/4U,@%&!0)(PFL;ZXD1LFK6;;WMYPPV(LAL>?-MW]-&YV#
M67EJ94OI*I(]E"BEEMM*]#:Q->L[VZNW73+[WM!R4WWO1?2WN-ZWTW\7[;)/
M?<V?261#R(CU-LQ:^'H;)B%4T)(=-]D:W'OU(%7QKT=Z@ $6W_,.%S05'TN\
M3\/3@WZ*0G?V(F[-RE4YLA0/;^7)M-Y'$JSYJM)-8F31C2I]I 3:'0SK^/[A
M7^UC;:[$3W[@)R<<\7D?_897)_#;H;V]EW2$?&?T,9Y,S4?E3I+G;UM8*V^G
M*<5XV^C3>-;2I1@,THEFR^;U!B<+,ENIYEU76[6949D<M&N%=)$_TZLT+-(V
M2UCWC_5THT=1+,QQYNDY<Q&.08,>';O+X_%AC6-*K?%$Y9ON[K]HWLS'_D86
MT@IFUY\A$7F+QE(<[2 R"C8U]N>-&[&'N>S%G"5SEVS$F;<OP(47KD%.N04(
MOF+R6[V1>7;%Y+[Q)$(7,O3X+FOD:- !2HJ\&%U_@XO;U8F(O#?/I>-V>:/D
MNA7G&D#S8[Z!4B%'-_#)MC-1PNNNHV/KKJ,<S]81AIO6SJ/#VD<NC3Y8.2O'
MNQL9'_SLK:0EIYX1*[-?"\-.G=N0EW8CM"K#G.V60ZN;;D2X?<C*0Q<LI<E>
M[]5]K#'6<(%N90 F=CNT63BECQ9<'1T\_)FB+"S "ZV5;+.'P;9&[>1_L,W$
MLJB:N?2J6/'1?;CQ^[!"/4L"8T:#8-<K%:7E<?"7X<Q+\S<XEW@Z]^2>((+D
M/313:DYB&3-?,_1W*HAZ.ZV0U7F^O%N**]X9:$\\+53O^P&:?00OL7.:V:NQ
MFFFK![MXZT1=NNP$M3T5BH0\W=&[;??^[TEM2*?E?3ZCM0!\%\GW 5N6#;6=
M.J\PU%,'>T^HN$R%*S?Q/OTV6+T]*M3 8( A-T-M!\2VE@XOQ?!!'Q_QR?EU
M(#+^- 1F7]=_K7E@=.Z;9WGW^1T@#1A%&0=0D$F,BXN1_&%V*?5GG>%X)[X_
MH!9Y59?;B$/ 2,/M;SL63W[R?2N=#9+771U7W\-R^@#@_=[" F:>DDDQU9=9
MX+=D$65$K?39,5UW?9+M9 P^,+=UR/+^3YP _Z\?(_SO];_7__P%K'G6^LHZ
M(N8(1 U00>"P.1V<62)NS# RPL=&,?Q_L5P\M4?&14)Q"F->(/[PHM03-86C
M@A4#L_&QL607P)Z29,TW>0.GMTZB 1XK-)6:D0 NOP,_V;6.F\"U:5B.Y/<I
M=:/Z)^2S/8&)^^J00Q".\?%NLF/B-/U&O $_7EBD@.]D'#L.:*,93-*<)A78
M^NP7ZK;!B*!8(.2J[E]Q'R-?;VGB90DF=T"'>.!@,_K9$8]5L^\*X!**H1#8
MRN U*Y:B3R]TP?TCX$7G;(1.1&O.X^G=E$^VYQOW#3@ /#"!6BXJ(6]\G2+"
MQJ]10%>IP#W:%22OY1?<?@R.;Q8)5_#=HF<[#&(4CVF_#.M(F*<.G\5-*_\
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MU0<)V\YTGCMQJMGATE%NB@$0[40M1C$AK$-=?V^E\54N5.A8$O3PRED 7GL
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MC2OJZX=>/8"S'4=#78YI3\=V),S11RW^'4@?'M9MO[,B#K]A.](MQJ?ET8@
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MZW^O__E+^)=G_OV<?)RC&>7E/OT)S-<9D09?(@"*R'2+;+.8V$W/8<Q*;J@
MV@HC=_;SVFHG>G=SM,ID Y^[_)%JT5S$[7MH4SUW/N!/E,,T9U77E U=B^>+
MH^:LQ_T\(P.F9Y'?ZU)'P @$F=NMLY3^1PB%3K?^=+2 8TI'ZZTIPYA3P13#
ME+PTP )-*4;0]\O#9V^R<Y<L%>'X-H\1802*B7C JC!FR+3=(HN*FB.D5NM&
MO$&A 7I@&"'.,:)\ZDY/KMI?5/3WI$!RN4HTA4Q0Q>J=FMY?E2B<Q'19XT+[
M,Z6<X"HC+NINIRKV]V>T;R-N/X7<NT8+-,5ZUR")?H C/O,1(<Z3BI[7S.G*
M6THHOGE?5K'?W*S"^O)XJ&DK-8EW0_E)1%XPAZO6$-;(CQEU7$K-\7?P][GT
M)86)+]Z/O:>R=XEZI=4(\ ZU23EDFP=MZ#8]G/VK'[ .IG@3>/R?K&2S&_0'
M-C86YF\V("BK_MUZ_Q,N!',(_YCVX=W#DQ0MC;LS9XQM _;."67J]5?N^&[5
M\TC2W[]Q;6I(/:2A@15"6LA3G**4KMY!I8"RN4X+V&=_^[9%^!H3"FA_V;Z[
M/XAC3\:QJ9BX BAX0M*L1F;K" HU8!]OH.B@=^'ID2S!YK*2&N251NAP;%N
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MC<-86)?Z.68J)E2NNGY<MNQQ?W3Y3 $K[6M ,!B!<=5B%;O!;!7%M-A%-Q#
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M8H>:X"V\*'$@ IFGE3G;"/=^K\%>#)U_,OFZM*&B/ZNN>4<BAGQ,*H1$BC-
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M7@YWZ$G-#KS?_5FN#8&7X^?X4?;CZ5KX3"HO)9U@(?S*UB=S]\[5[/_V90,
M
M
M             /[S$I:Z_@E02P,$%     @ A81C6B9MM"16[0( K[$& !$
M  !I;6<V-#$V,34P.5\R+FIP9^S=!5Q4V[\H\#UT-PI**=TE,< P(I(*2".-
ME'1WC$JHB" IDA+2J=(@*2$E(2B@='?WS!O.N?]S/.?\_[?>N_?_WKM[^_GB
M8K/WS*RU8ZW?6GOO07U%30)DRO)*\@ $ P)TH/\!J&DB/25969,[&FKR2K?E
M  @$ (@4;]LX.F&0 8"#H[NKAL(-)KV[^DRXO0 &@ _@ (( 8&;NYJRB*:\%
MH"<E.5DF-_1"P!^F_6$ <O[_(*_B'28FX#\VD9L[N[H# .0..BUL8>EFCDX'
MH]/V7N[.Y_,WT6FJ>W;G:0RL\[0K^@.BTS3G:>M?TSR_+/-K^OIYVL+!T0*=
M/O_,SA8.%N?I5G3ZB:>')3J->1N=#O6TL?1"IX?0:19[#P<;=/KP?%T'2S,W
M , B.I_O;FE^'YT60*>)7+4T9-%I*0# ([+^*7WOI[2[I;?[>:9DG9Q]7&VL
M[[LS<9AS,@E"H>),BI9>]I;N[KQWS,SMS%PMF&2=')S-''T X-<\_S)1G)<M
M$[J0106AHJ*\0GR"/Q74O_K'?^=TOFU_3>VH_[+-(!>Z?Y_W]Y9SR@  \3UT
MV;SX?=Z]5P!0&0( -*._SV-Y#0"DZ.U6T?=3?BZ<[R_WW=V=)?CYO;R\^&PL
MS?G."_2WZ=]<X-\Q_?1^?.<O]UOQ,-VTM#+SL'=G.B\W<R=[)P]7)C=G,W-+
M)MX_[\3_Z17__N?@T;"TLG2U=$2OH8/>RVP<K=&;V]'"QMW&R9')QO$?;<3_
MY&I_FG[=K]$39182H#+A \CZJ #,M6X BY(0P#1,1?\%\MMVNXVO YP?>;J,
M"[_N][],D+^^*D;D^0\W&^M?UI/5T&(R]W#U_/5OYX<E@ T0 *0 %4 +, #,
M  ? "P@!8H D<!V0 Y0!-4 +N L8 ^; ?< !< 6\ '_@(1 */ -> '% (I &
M9 %Y0#'P%J@$ZH FH WH CX#7X Q8!*8 U: 36 ?.(% (+@08@@EA!;""&&%
M<$.$(.(0:8@<Y#9$ W(78@JQACA"/"#^D"#(,T@T)!&2#LF#E$&J(4V03D@_
MY!MD"K($V88<8V!B$&%08=!CL&'P8XACR&#<PM#",,*PQG#!\,4(QHC 2,#(
MP"C$J,!HPNC"^((QB;&"L8<)8!)B7L"\@LF+*8XIBZF&J8]IA>F*&8@9AAF/
MF8%9C%F#V8XYB#F)N8IYA(6#18G%A,6+)8FEB*6-98[E@A6(%8Z5B)6+58'5
MBC6(-86UB87$)L:FP^;&EL!6PM;#ML;VP@[%CL?.QB['_HC]!7L.>Q\'!^<"
M#CN.&(XBSET<6QP_G'"<%)P2G$:<?IP9G#U<7%Q:7&Y<&*X:KAFN.VXH[BO<
M0MP&W '<.=Q#/$(\1CPA/'D\?3Q'O$=X\7CY>!_P!O 6\$[PR?!9\27PU? M
M\'WP(_&S\&OP^_#G\$\(R G8"6 $6@2V! \)$@B*"3X2C!/L$!(27B6$$JH3
MVA ^($P@+"7L()PB/"*B(.(BDB4R)/(@BB#*(6HD^D:T0TQ,S$9\G5B?V)TX
M@CB/N(7X!_$A"24)'XD2B04)@B2)I()D@&2=%)^4E52&U)C4ES2>]!UI'^DJ
M&3X9&YDLF1E9(%D26379"-D>.26Y(+D:N0-Y.'D^>2?Y(@4N!1N%'(4%13!%
M)D4+Q0PE)B4SI2RE.64091;E1\HY*APJ=BHE*ENJ9U1%5+U4F]04U->H=:B]
MJ9.HZZDG+V!>8+N@=,'^0N2%MQ>&+QQ?I+\H<]'RXM.+Q1<'+A[07*:Y3F-)
M$T930O.%YIB6B5:.UHXVBK:2]OLEK$M<E]0O>5U*O?3QTNIEJLN2E\TOAUU^
M>WF4#H..BTZ#SH\NDZZ;;H^>@5Z!WIG^%7T+_2K#!8;K#+8,L0P?&)88*1FE
M&6T88QD;&)>9J)EDF.R9$IA:F3:OT%U1O.)Q)?U*[Y63J^Q7M:\^NEIR]3LS
M ;,XLQ5S+',S\R8+(XL*BS]+ <LH*SZK..M]UI>L[:P';.QLNFR/V2K9%MEI
MV)78?=D+V,<YB#G@'"X<&1Q#G#B<XIQVG"F<G[DPN$2X[G,E<?5Q8W"+<MMP
MIW#W\V#S0'D<>3)X1GB)>&5X/7D+>*?X+O#=YGO$5\FWSL_"K\\?Q=_.CQ00
M$; 7R!(8$Z005!9\)%@CN"W$)60NE"0T)$PL+"^,$*X2WKK&?<WR6NJUKR*4
M(BHBCT6:1<Y$Q41=18M%E\18Q$S%DL5&Q*G$[XB'BW= L:$WH AH'?1(0E3"
M7>*MQ(8DKZ2=9+[DHA2[E*54EM0,["K,#)8.FY1FDC:5?BT]";\"-X-GP*>O
M,U^WN)Y]?4&&4\96IE!F_8; #=<;Y3<.9"5D V0;;V+>5+@9=K-7CD).6RY1
M[H?\57EK^0+Y3041!3^%1D5LQ5N*48HC2O1*YDIY2IO*8LH!RJVWB&YIWDJ\
M-7V;Z[;K[1H5#!5EE1B5<55654?52C5 34DM1NW['?8[+G=JU7'4[Z@GJ<]K
M"&KX:[1K4FJ::.9K[FO=T(K4&M/FT/;0;M8AU3'4R=,YT+VI&ZT[J<>O%Z#7
M=??279N[5?JX^CKZV?I[!G(&<09SAB*&H8;#1NQ&WD:=QI>,[8WK34A-S$S>
MF6*;ZIKFFYZ:J9EEF.W=4[J7?&_37-;\I?F*Q76+6(LE2YAEM.6"%<PJVFK1
M&F8=8[UT'WX__OZJC:Q-HLV6K:)MFNV!G9I=CAW*7M>^Q '/P=2AVI'"T<ZQ
MU8G!R=NIWYG;.=1YTD7")<YET_66:[8;Q,W(K<J="MV8ZO;@\ CQF/*4]DSR
M//32\7KG3>[MZ-WMP^7SU&?!5][WC1^6G[E?L_\5_X?^4P$R >F!D,![@<T(
M9D0P8NZ!PH/<AP0/[1[V/!)X%/UH-T@WJ":8/OA!\$R(0DA!*$FH:^C(8\G'
M:4^PGM@\Z7TJ_/354V281=BG9P+/XI^=AIN'?WHN^#SA.2K"*J(W4C0R]07.
M"\<7PU'PJ-QH\FC?Z)D8E9B*6*;8L-C=.).XSOAK\6DO"5YZO)Q,N)U0]8KE
MU8M7IXGW$[\DW4@J2:9+?II\D&*1,I!Z/;4XC3[M6=KQ:YO77],5TBLRV#+B
M,W$R/3/GLW2RVM^(O\G+OI3]+/LLQS%G,E<CMS5/+"\OGRX_L@"CP*-@J="P
M\'/1S:*J8M[B])(+)<]*@5*/TN4RT[+AM[?>-K\3?U?\GO5]<CEE>5@%I,*G
M8K/R?N5DU=VJ_FKEZN8:R9KR6K[:G+HK=4GUU/61'P@^!'] -?@V[#4Z-ZXV
M63?--)LTC[7HM0RUJK?V?KSUL:--OJVE7::]H0/64=<IT5G]2?Q399=H5T6W
M2'=YCTA/>:]H;T6?6%_59^CGFGZI_@\#\(&FP9N#;4-*0UU?5+_T#VL/?QTQ
M')G\:O%U\9O]MZU1S]&3L0?CV.-AW\F^Q_^@^Y$QP3E1,BDZ63]U<ZI[6G-Z
M;,9\9F76;?9T+GB>>#Y^@7$A;U%HL6Y)?NGSLL'RW(KSRLEJZ!KY6O(ZQ_K[
MC>L;W9MZFW-;KENH[? =VIV<W6N[S7MW]G[L.^R?'(0=TA[F'HD?M1_K'B^<
M>)WBGB:<<9[5(&\AQU$.*!1J'2"1L7"Z9PE8_-)^0(T!L@ 1'MYE@LM7R2^R
M<+'0769BX>;@8&+A9&45Y&?EY./BYH9R<_'Q7Q,1$;G&+_GWIO,7@1 3$I*1
MD*'/P"Q"'%<XA"2O"0D)_67)Z^?3KS__/)V_",;_]HLT N1XA%54PYC 50!"
M#L$@QT"U HSHC&)#?IG^UDJ"8&!B8>/@XN$3$*(7*"<#,""8F!A8F-C86.A&
M$B0 _7< BQR;XHJ@# ZENAGN51<JH8=1Z7C,-\J:J#7Z-UF$[[D^PB>X<)&&
M]A(K&SL')]<U$5$Q<:B$[$TY>05%)65-+6T=773KS=S"TLKZOHVMF[N'IY>W
MCV]0<$CHXR=/PZ)C8N/B7R:\2LS(S'J3G9.;E__VW?ORBLJJZIKFEM:/;>T=
MG9\&!H>^#(]\_38Z-3TS.S>_L+BTO+6]L[NW?W!X='R>+PB "?G;]'?S18[.
M%P86%B86[GF^(!A>YPN08V%?$<2AD%''-7.AO"KT$(_J1E1Z61,^L[#&)O4]
MUWZ""RS7IEBWSK/V2\[^?1E[])_*V6\9^SU?HP 1)CHCY!CD !S8T^?(>$
M H% (! (! *!0" 0" 0"@4 @$ @$ H% (! (! *!0" 0" 0"@4 @$ @$ H%
M(! (! *!0" 0" 0"@4 @$ @$ H% (! (! *!0" 0" 0"@4 @$ @$ H% (! (
M! *!0" 0" 0"@4 @$ @$ H% (! (! *!0" 0" 0"@4 @$ @$ H% (! (! *!
M0" 0" 0"@4 @$ @$ H% (! (! *!0" 0" 0"@4"@_X1BPH_&XBP)O 8$0K3M
M@5\UOY)ND"@MM;/;2S-XS'51<&G=T;56*SA,)>9^>IG_[.-<;2!F4*IBQU+B
M7$D@*Q1>_?PZUO9L&7,E$.ZW'?BASLC.Y@=MXJ$CINW,HU/,P1RL@Y5POY$2
MH@92.6/]8Q00U<YS>ZXB& 5L)OU ]*F=NL /$^%38G4H(#7M<!JQ)1(@A:5(
M&X-+-R4$A[4<:39,8:" [(;#!11@J=L7M,98BX30?9%LJ#/@?TJIT)I;#+33
MZK /I2I, LBXH25I@<JAB(_W"M4(V:A2$YHZ<5DVA=-L)YW\66&YWQ_,G(5'
MPS$@\-" E0O9WG0P2^^E):1<.[F&Y+)?"O4\DF;KG=Y:95K"8T@USX<T;8:4
MZTN?"7;OSU( GV2P+,@[F':A)<R4(2GX=]?Z4]R7\\,6/:C4]2YA4ZE?!X%
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MVXTL]-M3J<OYLD._^PNB@/B)_3X48%T\7^44"M\>0WY# :M[XR.]5O -H:-
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MG?;9[CJ_LJ?26@Z8F'?3;JW=;EU"_'1XUN:<*L/8P\W9$WK%VQFY&7Q0P/T
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M_-Z#*;2=MG-4%9?>5_?UHNG@W('3Z'$R<J"\)._'HO&UQUK2!H'K:O+,N.P
M9IN:J@"IE#7U9]VG?[Z%VN&63<5)SKTU"HI6#TD9V%8RB9#O'LRNMWWJBORM
MN(W/B^GZFJIG$G%[*(!2+N,!(\\J";7OF=KK/MK3ATW%\G_-2O6SVHI:<Y[@
M=X*_?%=4N4&_.]0C5+ 5%Y,U*83AE3C,CW21V$NS\4XF89_Q6H)RW0(WLQWR
M@ES[@3D*^&"  L**DVYNU4E$D5>81T4 CC+LXI"&5A)5'+L7]9OT7W+',:J:
MV,TZ:?:9*%,;K3(V-T(LOEA<>:CX>:J3!DJO97U8'R"1VOA1GP8ZZ*K"[6$R
MJV6K$U[H6TY-1T;H09[;G N0F@I(#,5-"[__YW_5%@@$^G^515X=]5YA_M?"
M% VY]]W%SJ\M8I !?CI##!4")?1\LO_!:X?G_^7:8;K_D?$SE;IR0=7,\,.7
M]I287B6[!5IAM?(P3KMHU?4%"_-/T00<&5$R_U;_AJ%8Z\81NA9Q@.\KK]O]
M?&>SC]=)=R B1K 509S,Z\<6A (8-M'M! X4L$MN+/;'R#K095-AJ 6_EK]?
MCGHZ)>?YRD^QLEO3L>)0,;7!Y3M.IGXAS)@T3+-144N).26(]M:)O6&U,[SA
MA1;$X:'3\>S$,<7(@$Y,!&UY ^=\$[O&#^LL'?;P]RB@8K1J1O#Y# L*(&7/
M.8%BKAP.?[^#;J?]<#J>8T<^LEM85&K+TE^/O&&[=7^K9K?A<<PKWK"89L5&
M/R(<I,5(HFZ6OQ@*B/1$ <5%*.!UD9]/QEE[#YV>27C/X4N_^(AQZP=Z*,!]
M=@I!'G1TDCAM5W889Z^C-S]#%*)0K!6-V+UR/$*O;TJAYVUP/)0L=Y8)PVEO
M]ZQ0+^2(=K@.'&GNB)MU+@<L(P[O7D !WV.01R9(KFJUGRY(9MP,-D;TP4\#
MX(?Y\][VE%ZN)H<4U[3M^-(>&K1Z]9MT6P<+/09>-)(F50/6)2:&\Z_[BY&=
M4J[16MQY+-;9@8[)N[T*OI]10/#5'22Z53ZSA([>M"I2<:JMU:^2A81.TPOA
M^,#4G,R-C$>#;;9WN/7',OF4(W3?G42JEUS^J47[C;MM;^/P, E9TXD"TB_M
M;$=&&#^6Y[=0FWK.?*+C\>2L:0=^DEEYQT><SE4X]<N*P/6*R:M O@0V0&K\
MJ&[CI_;P )>P?K2'CR^+S@7.&U-RU/-(\2UFHX[A)RYTUKBT1PD>?:52D$%F
MJ:T(0]%+>D^W2Y)$"M0U=24XI30M,S&I]."BBD\L+*O9I3AW)[<:VW"I' -9
M,]*^MW8+?DG@[/N,@T2$N$@$IK"]_J&E?+=4%0<7LYK]X>$9=V[%H1TWXP_%
M,,$O,N9IZ82G*(!@=R&D63WPI'8',>N:7VZ]643B=??+F$Y,KX>V/>")(1RQ
MP#*[?PR11^_$C&3HG1B]L7>O:![&W$!^?"%;&WA'U'-M6;%-*("+&!<I?06]
MEZ #Y,4;M9I!F=YK#D0>FB-^J9U_"#Z7J.=1  5\9@JQ$HU>5,585/?48[&W
M6W>SUTOEK=A %B;4$Y/)&M@3WZ=+W+]U2^Z].I4I5VXCYBG2NMZ'_3%_X$<W
MJCJ #L/@-?%VS-AKMOK0RIXYOOO%\:>*S:Q6QR$^$ZTP.@/%2@X!U@Y[$C$2
MM]17IKXNGU.51!;C6DZ5A\0CALRA?-[0&:XZ=-!X^GBF)_Z3<IW#SK76-ZO?
M>R_]X7[#X;V>.W+W#SA4+\%C2W 7IM3N09F.(XM\J'VS&[*I2^V<901;ZU*%
MF)NDZV]LG:Y\[M8R7#)IF$KO>^P4'_@X;D1EBI%,)A/7AKH[PB6.X+KZ&$M0
MY\K80\,>&YL/]&D:FBR<U3)M7AP+P 'S<*T@>0Z'B)CEBODE1V5=@Y3*4YYG
MB'7TON9?@@*H]7YP;JE\>'?AHRX%)[82 6XZUFPR^=(X0<\?=VQU%( GMW"Z
M@S[##)XW;B7<!=QGL[**&^J>OY$8T+';%"CX(D7JM?],BY8EW1+:1P/%3)-C
M9HQS^?DP6S^]DB7Z$GC>1-+=W?C"V9?(_"NI?G)O$>> DI)88+CW?67A+S3P
MWQ_>$%*\\OOMH,[E_2\1M0H+1^^D%+9HU]W5Y?R7%E/%_L$Y"UZ@RL<6+0?5
MB>J0_OB4WN[UH1-Z1R-&QT5)Z#.@_K&4<@7U,8,'?+I$<^ ?/SVBO:OAA_G.
MZ:N1)\C+XOH'$IN?#B16>Z7;^W:%FLY*7NC^_ "F+R,__];R""D%4UE! <2I
M3O]JE^?B B-6@*H]V^J.&HWQ6?&R;"_5&NU:95"D_2P2NJ(T9<1D&U-X&_\Z
MH2B)...T,PETH5(_LG6_[<>RMGBGZ[@OO!LNVV.\2;]87D/@\I2J6*D-OXG1
M,.H!;"5;I9W0&P7PI;DD#A?7]ZE%"-(0O 9P #H 5R;,@TJWE^&I<I]\:&>B
M7I1V,J <[BP)^>PW0[MLZU=KYOZ<T)KDC:K$5"BQBIQF<E*M;]BG82F-X\["
MK/LF&U>8]D[;7)J68?D![/HOE1RVZ*QI<>/$H4V,0Z;;SO)V0R(E)+(%,SVX
MSC1$.40X;I&RAT'AR?>JBF2G9C?=R._B*,B6UWA<J5I91[2,9T9FZDN]Z]_[
MT$ZTJ$JR.#B 9,&]XDCI5,#.7'*@Q@09B0[ %1E>.@[W?714)F#924M+%]'*
MH#"S5W*Y^KV?9H6<)8LU$4&R[^10C7$>VRNF1.90QBCZ)OHF%+ 2X:)NPI,C
MXGT?!6"D/XTURO*3H]94'I+/I##D5Z!M3U]4D/D\:UUO4')!W<4!UO\UY0NZ
MS9(ED/%/?\H>" 3Z?U&Q7[N$2WT%JV^KU]EU+(:9U]!302-B:O=\"3<-(_QD
MK1B%4'6##P+]B+<+DO+,,?,F,LOUP.3^*EXAUW&8![4B)^^K>64^WFQT-*'W
MZ']0W"0'4-NV\:0@X^Y2^C1NZ$?EQ&,<ZWA86IK;"M16'7-D5/>^^'<5_Q\>
M(-%V>K,T>J-SNS^-P<HSS][:48)@I6M4[TGEPI$PSXUZ49^]/T=1VG_HT5T^
MYK$2OZJ#14Z!08I%ELE,/9:D*A1L?YQ@1JGR\GY&V%9ORQ_:[N-_;&7T#;^_
M.YNJHY?%]&F6+%P&.X+$Q4 :&&0M3TE4_"[S)/QM'.UXG478,9&<8AVWK@%#
M@'B#;;TJ,M=N8FL#W:1'QVHR(H%Y=NJOF.*T*&ZK G31RLE$NB%J,Y%Y$[RO
M9D26SM]JYGO#2@%BD=M0[/<[.W4#)@D5RA_&RUFR:3@WYK5]6<"I+^QU<;^D
MXAC!<TW_E76;A-A^,N[][JC3KG9V>MUTJ8B6/(RZ[/K>:B?R0WH/"NO@X+@G
M'7#GXU0(4YKZ"+V04O'MALN7;D4;N%M5A9$8;X\W;DY$J"9GX#]TI\>#"X6[
M+^3NSIKZAD-JSX>S)D[>(B:XST>SB /2U<S3A$0A+C'A)3!ILZB)D1)ZVUB7
M5WC:6-'.P&RT+Y&N?ZFX;U%?@Y5IP5#H8Z4B[W6[4YZ[3UUZA[LHD\]6,>!$
M7IVP6A.BE1G]9X& A[@I*4)] K<BH%V\QP>9-CE6,#')(21O<>1GG7[40$:Z
M4XP"6C[01,KAXKH__]+1SO# [>%*'WN)J?C6"N$E6\%*H=&)O')<[4\;YE9U
M3L;H&/1IPTIAVC%YB44)^U\WF&9LI[QK[:*4O@.S[,^A%O>#39Q7O(6K _++
M1#<M8W-[YV98=!%Z\PX2:\4=A4+O,?[TVL7\;:D4?FUBSI,I#4([55%M"B7T
M54MM2OE=W&TI\F_>?+YG.D<O03<1[/%FP'J'!=>.4T/!_H5;Q!D464]JXS>S
M<E_7E6+MVXVHL6I3 ;CPJET/^\\C>?=M&"ZG:3')9W%B;9C><&DW=.NCH3TC
M]M5+9B6('%4:6TCO42V<KE8WT/K",C0KK.S:OHU9BEG*>.;6HW3>.FV%[PW#
MS_!T2I[4L>WS135&S'1=3N"FJYCON_VP37RW7;.S*&/Q7;O4[7Y%( Z?E0;
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M;YRR"$-R3[$]:E5U/QL@;$[M==3MLN5.ZDHE]D2;WBON\OID8ETQ81]":L+
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MXLOGG82-URZSG$;C>E-QC&> >Y-K[EZ:\F/>C'*2VN&2]V9=2Z"R]HF_.F3
M@P</GG\)3 ^3&G67:#GH2.%AB:^=>U_B:LB)L&,N-62H7DJE*W+N!XQI6+.0
M,X#TY;Z\6X*<:&M85=2Z@%OZ37X59C^-^,NM$\_FG7O@)K5PUP+5S=X@+3D]
MI$"NQ(LSP!?YO_4?R8KC2P^R2WE2?V%TW@_G0T^Z2YU45>3^*B>#"K7R7)$L
M9>,3"0>J0KGQEQL?/'CPX/F34_VC58+O!\2:I[>C?\+GU@^6TV3UJ>61NB@^
M9J[Z:W*7Q/W)H8B=2<=Z-7F.FTU\[1[)E5/1IU,R(^7L-.N=->$EU0>ZAB;T
M\I*\060!UH+-GWD^L@*9]PDK);[6UMQW1.PM"5G3;=41NDRL]XBTNK?"-1FN
M2(?+AW="M$\70-IG@$=B9%-ZT1F*# C-152_\PHEIZB5*@K!'3+ZJ[.T>/#@
MP?-GYV74I887S !^\#1 %#ERW7GKULLYXP6"")_JJ772W;9G\)!%HM!2<8]\
M1=:@WHLL>HP^X?T5.":IU9%(O^YEN%X"TI\Z2!OWR)5UG_ ,D"M27V (]/5'
MKW,Y&SI\=X 5\-IH)[58N)1;LH4$P6B(?)*[7# YDC+]6O)O'KU*<F@^8*<1
M7A_T.^D53#70P&HD\^:D#M&-ZS<B.##4_S<+S?'@P8/G7Y^'8*)GQ=< -*R;
M  :(.0%6*]ZMO 6M(?'XZ;6 W=_D'=>7)&_T );$R6=?8!]8\2JBYH6RB,B\
M6N$'&[WL'S,-U2AKTH[R6_F:Y=2_/=R;) $92_(<&AUH.ZN?2GT7.[632C6'
M+FT=670R5;?E,"T!C<97HYRR\GVL)2"*/VI"15BZN['GEJ0K!?7KTZ5X\.#!
M\R<FZ/NZ-67G;9)L?O 90#)B0_GNI&]"Y13=<K1ATQMP(_(C6:Z8E_T( RZ%
M9*#?N;TTD/^Q"O"B;A!C/ W(@VGEJCDL(B9+ S*6'Q(7,V<3LK5^13I:.[H3
M0NFU *+T4?,@.P,H1:XD&$3>C$,)QY 1JVS1N[+7&3:577R*N/A:[!%=,#N
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MW7):A,\2^DI6UZW3._?:B9*:L#*,?N4;8:N-:9Q&R;G)C)S.A5UFR10FS'0
M8U+=;/2?G01<(J/IE9I".ZZ!Y.S(K$93_3)((,ZB!9]PE]O4JC/$'N]5S%,
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M<*@[&/8Z:]I^%*YEG6EID85.B&]]PAQR399JLS@C9\CU4O>3<EE*V$6:A+)
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MXZ;_?H;M2J\HZ/C>Y;WYWBS+/.6RTF[2G_"-CQ^ '_"[!JAS]@K"<M%2NRG
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MSJL7FIPGK+X0B#N#6]O@5GX99L5EV:%6/;0^>=MMH:RI6QIEK1=_<I?7;[9
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MQ^]EOQJ#W:@:C4+XT]0%5F'W>+1O5*@_;70PC]PG'>)76D":^$B;B5E@RZ*
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MHR@FMUT(0]V0F='U!I4[JF;_B-?*HP.DBE6.?%XI[9)M8>ZPDA.@5/Y;)=C
M:_\9.QYMP[=I3E-33H!.9?U<M[J#-_"E^!-@_F8AA&8;5#Q'JR[K/O<WEQE<
M\:D;*#^VAQW0#$CH&5Z(SFCSZ?(CQC7 ?I*C:(J4#/V0\[BK'*DU@D9_0CK.
M].H$,;CO"#VG=[)SZ[=\I:>_G\!<U_$YAX&'<D%E[6G$\Q#._"DQ(9].G=^O
M\]K:7\GHUF=&G!MN"K=%02;=F>6%YL\BCJC.FKH$21^ZG0G"/IQD#A)M.=A
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M5Q5U;YA#904X[Z>(;]*?D0J,&677[=Q*"C0-+D5_047L]MR 9Z,\,&$>VJ"
MEZ]F10_]F<:3)I#PAP/:/;&BZBH/C,0DXYB$W$L>/Y_)J3(SD*H-7#/[NG8F
MF>F3BEM<-(5&GYB#'#F38=J-8"5RD6L^H'D+=*&1I;A&Y7[::S^4E0P*IJ^3
MJ@.;+N 8#8@ENE5S04QT91\B,S'\.:Y*PD8KFKUMY^7WT,$:V6B'9_O,F'6A
MYY^..,UN5(E\X*.?.</G>>[(Y:@.VI:^BN"6E;/D\25@L9=_-MA/IU'0I_3G
MH^'Y$Q?-E3/K=\F(7HR$#J%N@9Y#+4).@( PV^/!$V#MW0DPG9-A4SF/TTF
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MQF9\;0JL%ML@4&HG:3L=XU9!!>\,%S(CF+@GI]#K#X?\J10WUVYX%F212J/
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M)!05K[#@UI;MR%;%D?Y.16KK.Q55-7>EY=8!QP4_7.OD#JSWZL^-523O1Q'
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M--HN4LL<"[!(LOP;1?:&=NM59&)Z^MMP-^<=,1)G)OF[$CJ?=?@Q8XP&=ZV
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MW.,A(96>J:!IYX=85>\@6I4O<(+\<5 %1FSQ-K.MJT5:49HA[+FX"=:GM?7
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MB'W+<M$..W%W#%3"M,S-P*4Y)IM)_%&%8;9]F'HG,BB[!6V^P_V@K%K]EHG
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M/<5=]>]2AE$\L7>6+-3\-<95MVY4>GX>Y Q:\EO:7_PM APF49!VN$,<6XC
M5$_NMJF<$&)C%H3?]]\Q"+ATD<Y_+(;)-S-Q64KGJD6AROF5F@IZM;K&<JV5
MR0)V8085>U1GM[B^.E3=]7T.UX2/1J\6BW+,6P?ZURVD9B@<1DV45]^;MOE
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MN'/UE-QVXI-HI#NLI;O,&YO3'\X<L?\FB]94T:E/74&L-1"5T H2F]A].>5
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MF*T<CN.,+S>T@Z#EE'889ESTMF3-;NM>D:P'!5Q<XGD\W_CFOFG-MR[=5<,
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M9-N-,XRS3T:@=">J(.0Q\YV=;Y74=[-*WXEONNQ4BS7T:"0%W;IYVT-?A!3
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M2&0YC;"\B@?;NKIMBI1%DKZ,]""0%#!/92=H[=VZA&*JN,1C^ARE-\2\=36
MT1FJ*#S @*Q%,1DK1SC)*YQTEHFA3>ES(P"-E%W0UW2,C33Y:JF#W@36AQ--
MMTOO"%C1>S>C]P3LD/?'#)D']!5.!%%"WZ__Z'F_B=6&?O.N&_%>:%19GG C
M SW_@)\A9=JE^*-MO#%T_C-4#R63F0$J)"_/ND()U#U^P'\*J(2=/+:%;HQW
M9M(.BR?B!."!02=,/ A'OATFE#LP8"4)!U_"^WB6U).W53CN6096,FZ;LU'
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M^538_\W7C<'!4@)?+ZY ]1,^$,NQQ-Y<-<E?C2)3X3?8:?$Z  0W<[94N9/
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M%L G?TWJ$3W-CC;U*62!\;R85?BVUQI@7#BVR?$L)'9DP@WIR#?PQ[2MSR>
MR;[XAW&%+_8M68%)G\<2(RZ*;35/U3"])*?]U]$E(-@Z%Q5;0EP(373D!-Z1
M6,\R_P[U*KD&(UR=%B!*)>&UBL$ILK\D@&=3UD6#^PV.%AEB OLAHA"*8\GU
M@?4(D;]=2'V,,30Z:XG1]LR;"W26'")D>#$\HG[>"YRY-+Z^*GKD''L"D+D=
M/5%+_STM5.A76Z  60OK:)0GWK^Q;S;CB7UJS-4F4[""]\- \JA.KM\Q%7R!
MW;X4R/R2UG8H8V_$66M:&52#Z383$VW#>BW1Z_L) $!:F;X*/M%&(SM;360U
M [B<X.[40#$ 4U&R9OG-YLQOM^RI?M6>WRC]P,R1<O]UC+,*;A')EY_9&(E8
MKPT9ZE+X)!,_,DU \4&K=N!1WE:$"*'5LWLC \\KDOA9.:A6TKK9ZXAU"[@S
MWI _0#\L>;Z($0]C 4#2IVN.XEOF-%L !C^7NP(E7?53JC8!3KSF)P"OH*26
M8L49PTM9C=0<.M/G.:.<-J*2#^> &TL8I[XJ9<ES[ND! 0'>H6HP?R54/ M:
M8\_MUDCK=];Z"=]?V%T :0NB)@S/#**"?>]*;K+>=WUUF0NWL.A'?H@>EUSS
M64Q+GR^Q4?UP&4/@VL!3@.$'=/3J@':S]*:(WZK'9G\6WY*:H&RQ1AO$#VF/
MB"M<?K\JYT$9AFMO7AQ(WF5^KGS#>(8+PY!6"7WM>E''_K0Y^UO:H^Z'E(%?
MX*37*M<=O"AQ:5OU)O.P:>'ZE:*/4?F(#@%T?//6;=7&,9#I_=UL616@B>.(
M(VAO$V_9A-@GTGB >1D$V'O[@<<'',=Q1H)/W(>2, 7Y,@VAOE:\D+ER4;K
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ML;U$M',G/UI]_IG##3W6$O?,FM)O5FJPDZ**"/1UO_\'R+.WY(,Q=Q_S83:
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MNFF(RY>93 F^F29<IT+LL.\?#FP7W PUNA_+9BHB?/GKFO!SN.0A;L1OY,"
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M77C5<JF^2.14Y6T.@7J3"6;+X-@F,L3HGH\5N9/1Q>K7^IRNA;D"2BWUB*7
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MGGPC8/1KBL5^3&UK[GU?<1PD?M"$SMRO3^HSE HUMK#ZS;QDS_U7FW&*%M_
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M9'D"64G> >(36Q#VY"1(A_VAQ ");BE\DQ0CC P2!WC#9?9YV5F_@B$#317
MI\F?!)X9"]RP\-5K4-:,7V%U-)[E,)/KHJ^1H*'9S>\^%!6*_BI.QA[$W4CV
M5'Q<.?SVRU9P=D6L[JL7D@]'!53GF#B4I<R=B4% Z\?2/L=1<Y&;U:7YD0A4
MW %-BIR!5KR-NJ@NO]''+@P?OU'\V,HA[,F-ZU;:*++KV'R?IFWVP8MKX_]
M51LUC_C^2#S3P5WC")0<0B/CN9*QV<A(Y/19*.T)&?Z_0;$UF'R3&=WC>P?E
MU'SZ,[)>$'A^E,000XZ JRN'L2JS%0#$MDQYRZ#>.C=!YB(!<Y/PK+]=SYK\
MBCQ'B.CX*HNF(G.?]8G;0 *#)QA&"^CQUKR;HX?/G4\S4YC&9RI,-['"R2Y/
MP]GQR=*N@S\J:?U(R9O#O3%2_N6;]%V#%'0^_79>;T3318@K_BK7;TGSGQL/
M^6ZG0$\ZN$F_@ IIHMLK3A'[1Y#X5 $!. AWD&$D(=M)6Q+%%*@H>>8FS*M#
MC/E7C5&%2S,O%VZ^E@;^-$Z)*$X$JD3'?XY5BQ6)B_SQ]LB^\&1W8#%L/3-M
M%N"F SAR@6U<+LOPLTB/LY&;-.EIX%"HOC;$&Q>!)SN2VYXJ/TR;@PITK%4Q
M?8I@B&397&F.^J9;='^\IC%3I)TC> -]]DOIA4I+WI^RE> 0G?,'@ZEZ*,](
MA'1SA.0=<:(-DD-S"]+6Z?B-5VX_EF_DY-SH@$EM@U8)BD9W%KQU) R90D2Y
MR90"@@=7PLL-/JVT(>Z_7/HZ;WPAI^ K$ZZ\E7()L!R@POX4&B4Z]W"&3B--
M"$MA &F;<'0R]C[0+0.O(EJ$EI!ZPV]ZHDIO9MU3A'_[TE[-X/O.5[#S]C!-
M!0-FP4K++^LY4AN]IK,+?@'<9 __618%K"TKN):EEM;)A)I^NB3!X4]C49YS
M.PZCJ0HV8=+4#[-'G?'-+\\Q^UQXK^N(5LY:(K'R\%JG&>MUXD2@"/QO[:.F
MEDBNH'M3T>E0O1G)LM6")%V$];JI;%\1EA]]S6Y#YAK@';AH'/6G*/P,UZ!E
M1<4=V\_5L<UN7 %W?M&);\_WBA/35>D;NU]T!]1_U@0[+P"N1R*"R]@Y)-SR
M+]1!R]]+OKPJM/OF1%O2PZ\2#;VW]K E/?T!LTZ G(N2W J C.#9*0<J$#F4
MPD1<(&>);,?R$@X ?F5+04M;]O9E56P95N9TPIFW<-F*]TQ%<Q88YQGW7\2[
M\9Q3GLGT1WDSF!:D+0H6-%^558:8>S-$1.PN-A*4P]7US]\69/5G,1PM>979
MQ,_UJKB/G>.ED2@>N7MXLE%A8GE"V$]ES";]&YY_$.J&_Z6/*"N=A;HAHGXM
M.LTG3I6?W3]4%VO// :X78Q.C98@&,"C&LQI*0E@XP]D;QNYTZQ;=R95#E_D
M6%Z4OAHNV"'U$'^A3S6$49<A)B;:K 3W2R:X7GN.40\T8KSW:6!LV58'9?/S
M:U2''.=SK?+UH\+A,0.AJ!H,[FBS>OL+8L0F^(8;@ <@<*O5!H*;$/9:@+1(
M;A7$^DA@'J@(Q0)E.^*6VP/W8S1:]6S2#,R4D766]T$P9]_2X#FO.:^\1:SF
M;)=5ZW?V (;6!0F/5F[NX%;\Y=J;31)[ Q;C 6 -%M+Q/H_&Y11$IXAJZOW!
M]/#I0Z>I8 N9#BH../W;X/;(<7G_6^(KM#PBWEJ#EWH1LQ M;Q>C>@@(@B]6
M:X6%W2D<I5L3]K.HOPG>NX)9Q@XR-]HFWAWIC6&YYII@+463G)F"PTA-L([^
M+G5B5_C<W2/1K^!"NMCGQH#%R(SB!UY@2.M,S>#I_K&@U?N8M<,@>>IXJ&"Q
M ')WOA48W"D1\= !KBV!*G)N.-/H KS_'$#PQ%744E&5]O@P' ,X$']HD]PI
M>C%[8<$2_OR!JDR#Y5:A/YD_%G6R]4*;OU-+?->F_R _=.N\ZHHF>52X0S%*
M@>WG*(1-_RE(*AHH9UC^T_2D;ZWUI&^-5"^_J_]94+Z=82;2[L55AWP-D2"O
M1NG K0*W]C_:$=V. >B"$QTO'A$;]74FUCB62=]O%(CR4!!I)4=YUF^--W-;
M(Q^X\I$AI70IA/)^#9)&\2?G(YZSIS3H0E\>:A]%2[T]!@Q"6GF<,[)77;&D
MZS*AN.4G-@/&2[3<Z[$:WH@$*3H@2.;SLV?#<XQ[A'X6KFL-^)FS&Q')^XWX
M8L O5T-#_[#E[?,?^4F<%.)Y\R9N@>8[)3S0@@3F+]C=#*+-O3\&O"@L,FLZ
M/V_<BH&M%@N.KK.C7"A@]WL_GBT=%,C.RE?.SHVU'LG$0WA1YX<XU:8/::=L
M'=F68E?\J.C[(EP\.&$*0Q-/N=F2KW=SZK^P(.9P32<Y'(L[<""^'-3I.=H<
M;:=Y[4$)O!ZQKP( *#M+S);KKMT@>I:9_8X*OV_.V.RE+>! Z78]U;V,U 3Y
M9Q?.;L1JJ/!61:F]E%\;2QQ8O98[7"'Y@M,;,D>?I9O L^7-R31J!@D1^_K)
M^<Z'.6$O+KJ@<OOPM=4@ZUZ;>Z&6 M6E99^\M"1SM]$#6:_#9I,<&CTNZ;A=
MD^5(4G?=-866A[+=DW'=U6,A#O\3X1V:TV3 <O J[HIK6!]=0#($M!_EAY%Z
M"M!%^=.A]<_<-X_I*K7T=L[TN]O[ >U^P?1F>?6$"A,>XO^&8UC*9@Y6P5QJ
MJEZXI^'+XQ5)R@NR%">5CI3E7HQPH7 UP05?XRT+/;H4U?$J=RP> ,^;3Y8Q
M'=KF(>NZ^H?<\',F/0;\D>-C^F$=YE=]5B5?W5J!TA*6YIQ[5--J$T_UZ@0^
M?72Z/LT6^H#DB6L$.'5BO;?HP7]V"H9BSV;[0]\&"+B&N 8@ALP9_2JQ9#:B
M:;Q-!?%DP2"NIS3#,F.YG.^8=>6KI:G;#R3[-R^;MWL'+Z,X%7 *'3!320?7
M.\%WE'3O0KBVN+L.@@ED'"&U9FI]%!F,QC>50=BT.66YKFF;VJN%5 ESZ36X
M+W77)=(V+K<^XTRSD$QQDMM+=@;$M[B+^0F7?VH5IA"0X+J>+!(@.WIPA- T
M\%P8F WZ0@5I0D/9(P)D,KW7C97B)GZ]4G%Z2)WIW&,E-Q]!P^A"#V39+>CY
M.S>6:F(G-(+="7WT,X!N,H'% B!E(]ZA7;*N7KX9!O>IMB&UIPOFC07,"7[+
MQ+S7,+AFQB7$]GJ'*XCR %\L+^UY>?7/%G&7Y[B'Z>%34OY%'22_!()*JB(^
MB3MB +,Y]R.(#H9$JET/U&VZES_25E,1[0B6)2_IO.4>'(S5*)<?Q.Z4VB L
M6V0V9J&[G:N#S%\>_SB?HLMA <CK!'628!\%J![@V1E0 \]2Z- ZC#26@5TB
MEK]<4OTL'QI0+VT)"LZMZGU[$<R_0O_)V9=>FEY4VG.Y_-L(S3#(X-Q$<%>4
MP@+]WCDDZ[:OX /6"%7G6G8;CM T,% A)GDK\<-5HT+;PT?VCBUWXF@R@^[4
M/W!&7G\R^&IQ?'U=[,@M[A@@?_N*\Y,=2MZ+U#S:\>:4,LV6;NFG*7L%T,%$
M'[=&]"5\1%_(H'3*XZE87I#A_U2'H'%Z\V3"X5&7Y88LF-RP3U2_;++.FIK^
M_K:T!$G;8B>0>;I*)OMIF^ZD[!4%<XYW K*'I2G^=IA'&<9[+T8>=<*^K3AC
ML+#Y  @^-?\G<^<@X?PO$X*ID=/NSF&M2.^JM^^/NK&!SI3\+[FOUCZ82^!S
M%_LXE#6$Q=$4L% ] 2H*8=DYT$=?S .HL"!PM^I^;8\^;@J:1N9'A@Q6C#;>
M00K>;$K$[=1<?@(8OA302<)IIAD\#FKQ+%*+B<%)C :MR.<NZ =(2R3.KM3X
MV]/=2?"974$+'0-\'8Y$C&6J"]O0ZLEJLPRY8!(I9Y%-CB,7SSE $>2O:W3^
M?Z>%V]HAQR1,Q\4_K79"X+V@.?HBYV3Q08M^&@M&?:XGJ',R3Q"=]$YJ\W\C
MOJ!'C]YS5+_H]%9G]?NKS)3JB&W2@<0/(JEKL+#4$RRP;Z$E+YO^>KFRN:]@
M?J^/(D5F"\3,E03E\*A%=@58Y#7P8I+?[9EPRP/ %S\+N5; CO:BB=FSFBLW
MH@3O79*G9MY7Y>7)6\GH"357_D.;+2=OD<$VX'9S+CS O02TU0KDC#+[G-$K
MNB<JK'N11L<RXAQB,8C"GR[EE?*4R<U?&L!G<'=A#&G^AA *+BTR*CI3Q]H/
M+>55C72?I0U"B@$AG8A!\+JZ8/ALL:8B4XB<KT\"GW7TY$40A#>O8<)R6U0)
M^^7.8.>E5QO+*-I""9ID%=)4M-.41M;N=6)R^B2E0X_]R!6;4\M)6S9>[P[[
M!?"[/XR?C_3US1N5,UZQRT[+_Y)#NWGK =(F;[Z+#F;J#,F54LA5S?G<>[?Z
M'6*4BV9#A8R=9'Y;RKKF$]_5@9^2<EYL/%O+*\Z )0FZ /<TKB=;5#[^=A'G
M+I@C-LGWE6 ^$^N# ;Z8HNO09O>#%\-, 15I[7%]:RPT6[-@R4'FDT[[/_GD
M!I1*)]O*(KQ2'7A)7O]4;4$L0,^)!$?\L6+FHK4;?O XW&7STC"]12GU\TV.
M##X2B3H(@NEIM9PFX]:=_;/^-<#Y]\_W2S_O6UC\GX:I/&C:Y$:RJ<F[X2Z%
M),"AB,CR*YI_B@D+='P?&>%/D&?6L8PC^%_Z$8UMXXJX8 $@Y4D&D.9UF/_8
M6Q@8#?C2"OE\PY\==4;FV2^$,1UF"N3F?FWZ&:X]X# #A.W;/"&9Z/JX1MO1
MOBJI+8V*_BZ" B"V(#+I^9\QP_I[ P.KI'XMXI,M8_#^NM7%@W7E4\H'+3_V
M*&:&/5X51[:J.K[KI 3]D4O/%WYUHDF@HQO@#IE(TR6&^=/(S<781A?<G[0P
M"W^)NWJBN0H+QIF-#,02-FB;<@&?Q%OHNIP]YP<PXYR+KK)^[:F%CAG7(XW0
MLN+SO=S$F=0 DUIY-2F^_6B&BQHUB9I@=V<A2T$+-8(ZJ,@[!_Z33Z^V\@4O
M[,?<LI)NW.FD3YM-FZG9^4_>B75DQH'B241AF+/<G'+:-O"04II6D@NS]%!9
M>V"R9^<DID$T<;S%R?K:'NBFBK+$3B(AG=+T\A)TH=S2BVQ_0]"HTFF/E5@R
M3(N0OT=&&Q<$[(@4;UR>U_,Y/\5W>\A0/,4>1-4R<(*+YU2;W1ZG;4M?WJ1.
M^E52%K>+2$Y%]E7Q/LL:./<5)$O*O/\"R$4Z#"LR)49))F+-#^SNPY_OW@*U
M#+!;TDT@!^)=_!C77E=)%5U[3LFG]Y,'%9M#C+(6!4!R!@>A85R]>PF*9.=N
MR5B#0#_U>!#CS)U[V!:H=4<19O] ,FJ2F#'[ER]X^R)=JF"ALP-M3Z<M5SRD
M+#<'8V%='!G2MIF"254^<N760QZ!<9O,^YZKC==QCC*51;YBQJ%:N-C)L.56
MQ[&)"7QRK6#([]&__7GMGJO=QE0DVJ@"_HF);3(_WS \ES;1GH9RT4:-=0*$
M'@JJMUX-L1!2Y\71B*C[=.*S<2;J*I_S[5@+#9W'1<B!V<CD),#T]BQI>/NZ
M_POH1^Y1$(?K%A!%OPK? BWX.BMZ]9<7CC2_UWL:RQ"KVM8 5N5=FSZ@MJ4J
M[>*<HLW_U%@3$?7VYE><GXJCY/I6A_U\U;1$@L\;&F5'!?=9()!]>]Y8[#<9
M3P-D3NB-V_"96Q MRJ<\ 9Z-.#(7ST[Q>8W6&QVP?U):17,;#!CI6L;*B@F0
M\W@T\D*6!U/FN]Q/*\TI#%V8U3MQR?]J*5_@A!^K2%<[]> !Z7\%KOG?=?#'
M;N7T7IF799[[7W62PB,;XY<JFCR9&\[,7O#%P)A>#"'SH0/]%^=%&GC$+2M0
M$T!8)+@K^1UGRL!+DE)%IF$>AJ!OL@#+N : FW@J4-/X:MXZ.#Y\-#^>[!"7
M[-M !J\WGHU,XK^=PMGA>ALAD3WHIEUV"RK4XJ*_A<OY.9#T%NWQ^J&#\@,3
MF3O)]Y?E.BE@O  _WJA9 U:;5\O;5&3<+J5/?P#(#BS/MRWONWT1I)G[YP/X
M6*.*/@98M%P=K;]QD>W3-MDL1.8U28&BJQ_;>NA.7PCG3>MSGSQ6YF1;[D09
MSO]K]+W_)QW_$M7P_7BQ(&E%F7"2!7BWUO>K+3*'?0^'DOH[+Q0N$=.F,^#S
M2Y=J!778!Q3-/KYQ'D&&MY<]Q=12&0P1;[XN4%9'[(%71F1&EKKB[:65JW&Z
M0G,%;Q*. 2U0SO5\MWX0OR#*]>7+#\3 I(VZM5]*B)9@Q&9\#& \V.Q[*I7L
MG6(XF(X^_QK<^T'4-:1Z[6ZW99H>*0OA C00OTV, _*. 919N%WH^O0Q@'5+
M33 +OI#5';?4/>N_%D[\%E=B9 U;+QBHHXC9CXE7DK2*])6D;TU<SDW7/RC^
M2&\=47NS*7H>BPPR2GD7J8++O@6]OSW+G*?(_%6\W7%Y+/.$-5F%'& =7FOK
M5#HC;:NAQE<IUS:42%F3%AX;+AA?79UD:Z!/G%H*K*L?+'<*LQVP,N6.!V83
MG*^TT>%"'S$=AGKNU'SI94+4#TVP'&7Q%E^$A[>R>*U<TC&)BMMLGDQEFL:A
MCW]#+X7H809#](KCCNK?++C 97#?%@@GE83_$,6MO5PS/EG_#]65'L'WMPF2
M6TIOS2:?NQ"$UG+[=,9:A(0C4/1U@/G 0]/0>H51,'$\2H5YZJJ.]A#^ I$F
MP>PUNKP=U<.X5Z4T[-'B(,$C6?#F5N'X^>&S@N\N&\/=E2@ -*0D44^F\FW?
M7![0GWDR"=;'HYF"[.<6KIB^7!H\%)I5K(1U)_<;4^3@]Y>M8IGUUR+;A=D@
M6K($@=7%ENW5O;WWA*JV8T :ZX9P^ZT"?G[!.;<I&[XL>,7:FY=6 U<>6U("
MY,?YN*:9P4,'@T:F3J<VZL<\@Q\0<$&J+2X%+0#(]8V\V4@J4"Y6\QY#&[/]
M4/YYQZ1AA6:.6R^5973/MD4L P%/%[Q:E+G,?TV<LR=.K.<QB*,AXE*6<**.
MD!"K<.E:<ZR&JE0L3#NQK^M0]$YI',>98MTGSW$Y@.G=G=4^FYX0(+W2Q>3:
M4?$D9%Q"2(T_(R^9HTHKCHL""-X?0^QS9KDA.5\^ZE\+%KPJL^@-T*!7.."@
M:A$,Z9-B<+/I[)H@^6;CH1UA/ADU 2V"3=ZD C_8WYB6I^\J 8=6Y!T"Q;D%
M]GQX\L2SXZN*-P22U-IU_5_,E_WF%G/T$CVQ7Y0UX0Z@9@%G9[]](%IY[8#N
M"&8N-7:#5?_%1E%5:7;10W7CX7["Y4RSZQ]7H3^>/%\>#?*.')))_^@_:6GL
M[P[]];-^+_]G1D2K?"Y/7 "0)Z[+XA-\S60TX+-(D,A7+JE?%UH/6'=D\IX3
M;;_N"7ZGW'KKD/;]S1<:]*L96E3L:0*RJXV\,F-1Q3E660OK=N$\+P(G+/W/
MX2PDGQYZ6^K%VDGH5"&&A>-YLY$<2903V[/ \-&U&^]N;U+AKVC2?_L>MO)V
M-:4W>!#4=#$H=;XJQM;O?D^\'6JL6+O7[E-:+C:G^+T@N7%@7%S;$F":P&GH
MMKTPK-0+_2ZK.K]/@X_K\AZ,7:Q:2FQ.AJ]EK.2>2!J-[1Z8T[%ST$Y=&1%T
M1?;'B\X\38QJ3N"],'?GH"T6IM&N)+DKOI.?LO;Q!K2:\VAC_/"A:X*NL&G%
M&\8$^!"]C^4!'3)94(]P[B7N#QVQG&, LVE!TR/^N:5:@];\APGYLW)9ARIT
M\F-7QW4UE,U6DF5)BWD.Z.P_!KE5DG2%:'?ED2'=F*>TE.!7],_)-0*#*!>$
MC.H8UT$]EB/3^S?\'D5,X$-(]P\BFP/U+39:(1CM[IT5VWN,J[;@V7 WU:>5
M/GM!L85BCG,D>"F&<=)U-)1P01&["S\&U!D= \*+Y>H^&@V-7/R%II2&"J$V
M)**0ZUX3=Y;@CT*TY#@F)K8*-T:>VC7F\8P<AC>W.]OFI"WZL0_4ET^>-Z=H
MHZ%PICPXB.#8ZQ3Y8J>7XB/6YX/A&$IF=S1.7NPC69!KVS'[VF7_$J0\-/!:
M]SMM+BZ9ZBV!?Z SBAZ5>N$:LXNPL)?X-$<  ?*7'Y4Q=35KY\7S2G9YJ!X@
M^4@H2L-UV7CEO:53E@J%RQ*%;"?) F))7'1^8NUI/#E_T?8^>W_!O>2VY)+)
MQ>&;:08S )'I "8TA;-$'&H;E\:I[;*R[,#T]1)UOK#J,0 :O7KW\:?'3(^T
M1+&\ 4S(%+FQP7C/]V82?=5K\GR?@[R1R</2ZTOB+?;!]"$'_7H.W$>/G;2*
M/X8O=$;I[D65+7]Z( M%WI_8GDL-GI/C05J4'@-.S?[9IT<2ZG(UN:]+S5$T
M=$ 7&.GZ@>[BH4S5PQ]WS@=NA.QCEEO/8OW\WA6K3ZX]=0 9$FR$\PR1!8D'
M9LT!T]<_.VQ;3KL1YJ<!$ANPU)EJOM/\>:;\4K2.:A"!IEQSN>TY>^_&Y$N$
M;V^^NOCD40*CS\0%L*6T;D!F423Z4QM#$$SO>(7+O(7),G>??>R_ R;AIP"3
M>D2?=ZJ&^.5-[RNU@=BJDD^7-6Y579M/AB8OZ$]:1=$MY)"4AG!Q3A7YG_.<
MD8:\A;--LW/XR7HM(&/IA(&]7!%Z[Y5/%Z0E*%DGGLD:1,FFQBUVZ>5)5;V,
MC2]\HQ!O<36^*CEP$LK<47@?'LWW\%4D$T,<1G8!=C\%-Z^SG<)N/+\IQ<;]
M6:A%X7QP>S);96/N(4GV/7O)VS%5P0P@*P$1C&<;LUASDMB*23"AD?/]#<C!
M; H,^?-!:HE/@G&1[8)]!]2JPU>QR\?[RMA7FO9 XPEF&DK>'/<%S^5!\:GJ
M\+6Y::'H=A6N:8:38F_QXUXGQ2U52 M8KD&\45K)-XJB]-M:=R:>K^"J+FM!
M?.^U0:K"/8*103)+_)T,YOW&3KW@[I)!R ZZVJ /6CKIM=?.WR+'S?N<'8FB
M7D_TLKX@ZI5UQ>V#A5WE,'?MVFZ$HZA!PIE<IND2:BR YAC@';'5MJ)L&C^J
M=W$-?V^HV-TU05*/*Y*"BKND#9_#AMQ&]V!*"!VZB/"/9N^RZ&S.UJ4I,NGQ
MG^[F(=%5I?2QB13HUZYB@6KJ-G88)X2%2>N7:2K*V9!FF4*2.!%?A8-4V[BB
M;[F:;'MU-/QB+SQW#"AP#?*"\N/W]3)TM!<\X#TUA@M!>8L,5)>B.=Y3'<JV
M'BD:YZY<.E^@A+S%A2_F9GZ"#RZ+@]33M-_]#)WTF49.JC(/'[WS%0SJ_BG4
M 0)[!.Z=#SY@W1)(='&7<*6V'^%UZ&9MR"BW\LP>OW6!W4% 0W(SP@]S*&B=
M:__!JTL%TW(1NHOK.!+('+T_F_:X[^6FTL5@1TKWEWMJL^MD](NX21,K9\+%
MUYD+0"4:^EZR8\ MP<K<["TQK%*_[P,],3Q$52?N X_W80/#84%FH1-SXXRL
M$13Q^L@_]* WX1ON[ W#$D%/89\,;%15P^S19-110I7 M \;/Z.P.W_<-AE\
M/W$Q-^0+G-ON&U_VF[-]O>J?([?=;41L01]?908NV)9?::1ICHP'NQ5%\CN>
M8&CE_D#QG@;H(']OIE'8B]F63_BV6<677MM[[J_HY.Y#$8;PD5O?G6$3S3$'
MK)WK?;+-46,RP*X@V 9SO8W3CJ5^:5(X!=*&%)0O<S7LJP.7:25P38OJB-RS
M;,'OZ%[U84?B+@R2'BXX\F_,*'-/_=E@.20,3>D3@.^RX&#Z110B,%(P.;TT
M3XV9.1,="H)49W0Y^%UI&=[DMII_E2DVB![S*Y??G;H?>V,H@Q*[]](1"PX!
M0HVC[/"/T9X_AYZN?MU/E%)4JKAF.JZ*_&%9:!#EXKL9."<^!RF0N(&Y$=FB
M$C9M7N"2T\O-G0,_HBI<$,SJ?1DE:.@NHF4[GC=>W%PVHOJB8C: A1D+-@*!
MCP'/CGR%,M?[2C7>T&586I6PHNC?,K=)30<@\7,4ZJZW=<\U/'B^#.X >]5E
MK[XXA!UA2J>'?ZX0K@]_CWHTKQPB!3L*K9\>GW$@7*\<38$OZNOHINCF+!TE
MU?X8?R'38SSV_=[!CYRC/!%CA]%Z=AO(Y\!!TAZB:=BRY'Y1?!+F4.%:,'#H
M=I1WUFC?R .?M-_"PO%>.<OEM::F4@0?-D&@-:]3V\-&/6UOP43T[HWTNYH;
MTY.A]VDV&Y:$]B8L/AE-&3J0W1W=;+UV!I_\*B)Y_+-,70TY<_Q]<JJO[[!:
M>%.$+J8"[?G)P8S/N61VI;B$QW(;FCK!;EV2$=VBP,\5'*U,QM U\U[1B=HY
MAT._@%M<M>U[4OR;YG?<)A];P*'K%*/)DA$<?F\Y^AUWIPPC+T4D2V!(@4?=
MJ*AF/[!]4#KFATFHXV']N_1FG7*T67]YGIOU.'^G2 !$,PY%<J0!(^69REG[
M47WT\M)[Q\,T8\?1OF#4Q(&N.G-U!I#NGNU0A_KX^[RB*76/7W9R=[Z_E:W\
M7IW&*]ZP79C(ET.IQ*!IQ/4:E32DJ<AL09TP0NK\E67A&P"GH2$@T+LV=L8[
MK&_GR3JA]1I44UO<Y4M=ZX793#URO J9!UOH>GK<0?$&\X_!*_A6__Y6X&X@
MY."<R#Y^O9B75/"AJ77IT/3C]/ =FJ#_!R3X!1<$$PZHBW6OLV=KB&A#G[^!
M32GB6:1#?ZK?XE^^?Q'^(_D&TR[:6Q4L]I+50:??OO:"9.%%D&"OM*3[:F^M
M"1U;6HXFCD=&/_JLRPF(/:4E6@E?OW^8_X7)]<.THG^2[V),_1I^S/C6@U&C
M:T:V#;PHT@:I ^0OUN7<_%?*#)F#6A@,=U+][$86\5PYF=RB8B;/;3VX+PK8
M=]ZVO"EE3D-8AW$TG]^GW@(KW?PNT[CYY(FY*XH=#EY\N?:J6M49#6P/F-X!
M:0%G_'',17=>6[8_7UKQV-)4-"=1A._E;XTTJ,6"WLD*."N++VY1E-30K!@,
M0JO/QDHZ\D9U<2Z.%&G7&(<ZT+6$\^4RL"]B5)C!^<QMHA;A/B/ZR28G[3R7
M@_YGZ(S\AU5Y_V4R-7:Q/S$:W];NA%2]+N()8 HC+=OES5829V>/RM%,[/V3
M\E67P.:P8<8R/N/:ZW[G%68U8I8SJE9/SDUB@2\]TX9[_:S2>>6=QEU\@]2V
M%J*W[_QRBVNRX/G)F;1IC4>SC'ESP(?[@=('-IN'U2GG6AE'+%1(VQ$X]G@N
M^N8UP<X:AF, 9\P?)7F*?".J%631_X!VOON<3=:>MC+K$VJA4&=0&\N39%EQ
MP@IB'W5&_4FWXLFVZ4%@><5&7X"5>0X*7,F#3TF5_H#X@8&1/0[6>N\=  ^S
M#&[E.>J..((A6N@-!_\<HW+3S7V'8\"38\ .$AVTX'&;F'5_@[+,C8\X@S.$
ME3=OLJ/<3)]M2-)E4D]*@7-]P^?I(=%+$-*]2K#_2",4]KG6M$:C&_1=5VKU
MVIF)B>ED\64<,O.JMTXL9:,U%T!8=0(@@1I\!;N=6/@E2ECMD&87'D ! SP%
M25%O)WD3I&>(UJ+E/W>U)N=W]G3]GMOEO9?US[/3J;"TK6"+S7ISY/2(E]WR
MXG^60I3,,V #F9*B,AABA:(EV+TC%;W53[<<E6N>ETSY>YB#SFED1,'([J%W
MQS' .)-HL>HW,J3PC9SK^Q=/1"AD[;9_[U)Y'!VMQ[_.29 >)%05$X+Z^P=/
M/>J[WO+MA,%Y;7R[K7[K2K%BK!S+M68 A:H4 *B=N%G\YTOH65/BL+WJ%U^G
M'%"EK?!XW=Y4S?^FO\E3W(!SAP LUX!R<0W%1G]S,4QAJ<< ;#-T>P!Z1*GW
M43N:*[N-)9K9G)*;C$,.F/M%(CSF]=.D"]?YF,/@")ZXMAW0%ABX%ZN^P)=*
MIST%/?0N/G(S.R+/CSHU 6I/#4AY\LU_X#*)4UXR,7QER(3[[G!3GG9DY:-@
MK6XMD2\9UKU69(%UO'->((7>X 5)UFU:SB_.=K*/@C -?%@@;\091/7:3BO9
M5/HZ,'AJ@/Y];"R<+:!56B)2)+!!G&,?0#WE]C? ]!/E]GQ-4VBV9[CO[:CK
MG=V'O*\78V\A;?K,MV=J.9LX+K/V6>(9KY)&CFUQ#^%S-'N[7O<'S70P::H\
M>F"JCT7>44M[?<Y9R0L,Q2&B/46E$1Q\ZU]EEYT< AY$=RIIR$T#//%I/.P[
M<U2,I!7Y<0M=H[%1EP7ITI*(N86ZEUMM_(_J7I] UZ]B[1*65I$BO9'E:0YK
M!PN/$H9"I4$?_>KY'AWT?D"+M0SN'#Q[*5IM%7:)H%4K5+9! >/QF* >V[-W
MJQ*_A/WN/(S;#1&*<J@O<C7E7FOK)O-&"47?D64!H$4ZO1;G!+W_O,)B']S$
M?.Q]=^[I-3;)G$.@5GXU$?9QQX!BYL^>4%76^,\%<#O:)7KG3',X&7NLL+2(
MB4VS_]ZNV<%"_<%97<X_A1&[/@$Q<T0'K-()F^*(Y0TSH7$,"_#MCQ3J13$*
M=5*HN_PX549RQ?OO;?XAI)I6Y'SJA8?7G^U*ZZ;6E$1N/8E7X..:B-B0\$_&
M<ZW9(:>D-/$)@2,_1@%IEU 1J.!6P#I67D5\N>L\/\WR0N9!V9WIC-;PIER;
M![[(\Z8F3E8>Z*UQ+N.-CHW(=R!XQ!:^Z+&1CTS56ZM/EW!*3U**VUG\RI8$
M7ZV7']6E7>YP'+:@]']=?-]!*C"N#;QWID*&];MCI IBU_B.Z]'D'ZIUQH-A
MA\)/Y3AF:2QIHRD @A&;R<@#ZA][5L> Z_7+*02<^A)88Z;&Z<2L7M0O%J8<
M,!1;%K,-UN.GG X6>0G/'H>)])=Q[NV&$C#*QX#4<-'5O=WW!(SJ"37:[7_R
M?$RR:O8PV[P6":J:)%HD (GRIE/WOI*5/L(7?HM9QYR$X"_RHZ;^-V>11T6.
MJ&=\\KKE#6<+IY.C'-GF>!#D(,5PJ> ONI?W$*7<DT5M!I8O(X0I9#!:)YCD
M5QX5[I_G6:]V@M50;DTTK)OCIYR),M%->)8]&7F2&BW6?$3/S8=T]E6&FZ9E
M[*%I56ANZ4'(62:FUP,TQ/PXA@$H'5.N-1_#QDT7K?MP9Q P1[/%&0+D'N<B
M,=9(FWA9(.,>"J"#2U:AX$ :?Y(CV[DF>#]?,6>OE*),HG+"[&/"^7:W-A9I
MD85;R$W3J,DH!EH[8<2+\R181R3#$J(W=WY.S:[1U;K2Z47]!I8PXK\4/S9(
MNRY&T#\&C,*.8I]7"N^>[F[\2Z_CV&.^]'!9YND?-WHIDESF,BB'K.:[JR;H
M M@#I,F1'2XIY[;&R^1OD,R</Q '["RBD(C$Q_=[UB*SW=@LW<7=VBM,"WIY
MMGG,XQ;L357)S$O/ 4 \:P"PACW.#VQGS6_8EY(@%RW^Z^O\D)5KBC&=??KZ
M0-Z.H,O+5SU)M4K.RM^<D>O83ZZ)K'TWO%8*/-U4?VC&6OJ_AL]@%5G ZX$$
MT476.RE'*=1R+9I*SJH@J9+9ONG!I+V+]WXY-+AW#H6LA(* /T%@\=EQEB_(
MY^)GJ(,Z6R0O?;Q"G1D7(-2V2/"F(6DH'#^_%_:X)#BB=9]2$M&7\B@Y"0;3
MDMJ9-:WJ?XN>O=+(QMW*,AU3CEQ?C(O,CI5S[4<[]O0YQL3+0;Z>RY!Y)]JQ
M5VQ85O5\PI:IQ.1KQ<Q^B/MAPSEA3ZG@X%'1KW(3]S"46H%R*YV5G+MMO%L%
M+H<RL2/B5V/ZO![KDY.7EC$J:8P]W<VQI-![[EC7X78>+NY;B]@E&!- '<B?
MGC^"B0$',4\>)-ZNK4NF;7<#.1#$)> _=D8PIR110O_^^3+IX+S^WP XHDOQ
MOQ?E&2B0GWX#W1CCFE_)IF.?9#YJLP9L/F\9B]CBE?:.E-!3/UG1:J#;[= C
M,CW:/T_8ES"Q<V7/._ULB'T%H-#F;,JJ&\YLDJ5%V2=2$<G\%^I]9SECY69U
M)G-3M&MT(0#//OF"\XVT)SL\^<>'0R?BSW Y!C1 MT33'.^<=GEZ)PH9IT0V
M3 ON/@N[>0U>RW;E03LEA%LJ,F6VLE6*-;DRBLGS9ZI[Q:<&/A4;;EZN#8 4
MHBN6SOLIV:;NCAYR57V#''=MG&\^)@&"TY#H-L<LB/QE?9E]5;R\377!WOWK
M.87#+"3<=IHF666U@6G1*710F^93L_A<1]SVO@+]0+YG5!/O7885YQ;988#Y
MF4J<^&QQ:G8LQ=-Z6L<*91[(+S2;.&&M16BY8AO=7ND48O;OW17;8SW>09 _
M+=+[S_Y?NU,@Y=I3=_$ J%V0GUB^.I06ZR@<UNPXCW*6=)-Z6-5TNE$BBV;3
M0:*MW"#A6FR/&,^&KP&&&P*2]BHV_UV#=#!B:*AV,PP.<N^DD)T3]H* R>W]
M/S-X'0.DC@'K6\> J?S$*QP%.MN^U]T@B4 L=Y"2L_>M^=[M^:[!][^_,?=W
M%CBM#RO60]_OO!?^&L0J!@()>$KE;>$43A3!3X159_\05NT]V=I]F,.E'+WW
MYH'8+J.*"I?0P\;6D1Q2]N1:3SQ/\O8<X6(W11QU&NDW\[/)^UN=L._S6/"O
MQ VU70$>2OZ/2CSD^F<H&X'1<@M"&L0P/VHO5)70_BX5)'!+)R8B2&0/GZWL
MC'R*'CPE>4/_]]W6=LF?C9),F#2U_F4YT@+^+E^!\A.Y)UFZ_S=KD]GW>E+N
MO\D"Z/U+'_R(KGEH[_"J)Z_3;Q77>S2&7R_0-2P3JU](TH]!4;"5K$A$ULZ=
M^7Z2A#%K2-M143Y,$%9M(.F+A<E%].?]I49MH&<J4/ZI95YG%NHQ.T],<O;Z
M%XWV5C9_5M4))16R@>:[NLBV_J-)3-=A-6RYL.[P9;2SK.1;3F<,=Y9$;_.%
M7<]A 48LX ))*0INVWB Z #\6>=[B';C*](8!C/%H$3((=N-HAJ#7W0KQ$<%
M(N"K/DG^/UK\J0']Z>_9@V1!*EP10>)D'*&W%P S-0Z3^Z)62B_),WA_0D"T
MD<]0B,ACP!$\9:*>1CWGF_4[]X!G]&_98Y6M>,X!5L?):"(ES[XO*V?+M'J@
M(=S,A\M65W;(4WSJWC+73#.I+X1%D^3XDEL0ES@&IYJW%\XY6_HI2>1O>"T'
M5XRO=3S=[/PT41V=+Y' 1:^170D->[/^?5_&J #_K7. -F(9JR _!GH_<0R@
M>V4A;TQ8D;I FM?I+!U*G.&AQI'#/A<=V'C"L@S ^N>:9VT[Z:8\CWP7W^]Y
M^(-SDF8DLGUJ',TQ+4O;HL/^3D;' -SC8\#JU#'@E9AWD(!GJ9)$&<7M7PL*
M?)TDW-R<8;Q@\18-P;@N*68$^SQ//H-FL&7\DV6N"7+>XOD#CO%?R'&"-S%<
M\K]X:+MFUS5V[L5E$8Y $]7M.5K!#]>[_V#;,O"0X2VO8$O4X8;L:VSNWX#A
M95E?/Y14MSY;0SFM=$T8\*@ZVV_5-$D)4G":D,+*Q#-_8)0M2QMU-)Z2\PN#
M)7ZL_"^X\J<7_CK-%E-^CZ[LG:TY3\N&#Z+^8-8/(7Z#^HG$)%*:<4R%[Z\Y
M@$&D'!=-YCDE.?8@>H5$!;"B]8^]R)&OJZT8(!DI)G#W;*S$P[G3&--4*KY\
M%_L'2FIE)4%TE#=2@R0BK-$G%?R_(C!T\ .IT<\-X#PH %B59XNEPSCU3+B
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M[.V4.A)##1W_<*0PFR)MB_V0%"$.X=.<?W/_X!7/BA+GG@C1WGL'6"T.Z1Z
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M5?+Y5GC\S;N8/_IV8.3-L) ZLR1"OOQ0&=T,1K"\VUO7I@GNWSC>#;#((/E
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MQA7'W+Y588'9%^Z*!_HM_B2J5P+^:M YN"/+$66[35(W8?2C2;1H0FJ]:78
M!YFF<84NGG%Y<_3Z;M2+/H@T4WU%#1KYJT!2.K\H'M9P%'X0VR-U9]#_XV!K
MQ/18P :1 6)1M/^SIYMTOK$9WH/<,N+5>:++S9206N9AZ4 H1S2 ^.4B]?F]
MWW!:;KB3.*ZNZ+%0OI7/>YZW_P9.O1"BW:!EU,"68YYJ>3';9*S@K%^<%VWB
M4L\FX.1=%0\#=R_BF*M-SI:;?*IAPY:2AKD10N_$>) Z=/S>4UA+(197LY
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MWE_&WAMB'+=<]N(V8;0SKB57%<F6GK\"2CLC\"8?3#/ PW9@= ZZ)>7<?ON
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MJ7537<'( "4_"Z._+W3TPY?7U-<(HHB@-^O@[!>)[/NB.YZN;6MS79.+$7*
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MX_"LZ_O\_1OQ\%]R3'ZHBCCS,!&H-BZI-I^[H,)&_/%;TANV(B(ZRV[:,YB
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MQIS5K6(6,UT--;M$WO:\,[=5*GWE3V6ZJMH;/,_;7'N? O+&0+GS[&OQZ:Y
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MB8G#)'U[L_#^^J[IC107 IKYV376 ]60FF9V7S=F7FQ6_K?;-#YRTCE)V^\
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MXV_-:1[S\)DDZCWG2U-#%<^]FN<U U;O8N?69LU&UY;1AODBBSH0(;W.%?L
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M9QLT5#\37C]3JVO1Z0B^ C6^\X'39O6M\8(+%CPVD^]!R48VD ?3<7GC*,?
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MBT28#RY5D@(7X9&<]I"A<(YL+O[&785'"GQ29*EDX'MB5&Y^9X!^\4W=P,E
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MZMVC[JK@YF \5$-JXPI82CGS5O'M3\]?N9[ZYL%=.K5/P-_S$&$+ST6/WM'
ME)7^X^P+HA^K/*5(21:2X]QL8UN$1GZ4!9%T0Z1LTBN5(@>%C.3:;V&>#\@!
M:4L>I&D]%>W3Y,IF[/4@OOUC$/Y!N[PUV>!JE\JB;/Z'K&SNP;<FG^_ .H%R
M0*LGX>?[G\^[?P"/T 477/!/P),7#=ZY $FZ.UM70-*<.*7+W/PRGUY>UE=*
M#H*RA1^$0:=V=W-+X-R&4-&W"@"#=W6WO;'T]'0M2\+B^SFUX@7LW]9M-7\^
MM\_>O/E8.%EE=H.V61L?)K/O(;;9BZ;X*D+DS1<B24]D=P5$8=&TJW!/ASO
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MJ1:I@N7C-6PU+ULVRVWWCD&2&[/5+PV8/4Z0YX.=]3%L(?)[H!:5R(#G53+
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M??;9YW\JET*QEW;.G(#2Y5OCI7/#-0P##FO(,1_^.8Z2.K-3_"BPK(AW >>
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ME/)*4/Y\=T?%*B=5I-E*K_MS 5R\GXG.=/%)'.I[+>KH&JM Y("UW%$1[$7
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MQSYZ$M!OQ+G9N,9-"_&<Q(TOG@+*-LG@")LVJ9YZ^??$%I6N)_=H0I\4G$]
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M-Y>EL]:<[C4U3+_<W,(R,IM;BU9*O^$59Z^'QLYDI)*(C__P1W<"
M
M
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M=>]?]_YU[U_W_G7O7_?^=>]?]_YU[U_W_G7O7_?^=>]?]_YU[U_W_N>YYUG
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M]XE+4%S1?/1TG/J7JLC95(3<3H\1[Y%A(0:U:ZJ*LGK<8:[X@B/55?B.*==
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MQ#WK(Y#\>=6FN'9-*,">@TU$O$S6;_%O"I!>IT3]7IR5ZG=J[+II2UIJJTL
M<7O_W[SK]^S@;WOYBJO""\L\L<[YH,>](0+&FMBJ@/!U\+,40(^50:<*=YOQ
M= D]M=69G#BV,FGV<541I1$*G,E'0&<H>&YVEVYC<_MPU5Q3#?BYX=/96O2&
MM=Y8A%JLTZY0:]^2] O98A:P(X8T"M*1UU:2?JJIFB!$&J45)HDWKFT_?ZAM
M(@/O:>2-]CS^^G5OI&1B9< 8WC<J0,L^E^NOT5PKI_7Q /DU$=+VY,MGT$1
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MAXZ:W 5C9C8ZF?$273I=B[,L,DW,"@J8Q+,\KQ'7EY:(8K2MNSF.VJZDLS'
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M=Y"/8)#I'.U6$TH9B1Y0?M7$"TL$YUX7JC5=EQ4\]X$JNNB-9;@#VC\ZITK
MT.3FG7NNV]6O.E[92ZQ:$)X0 3-,-W4&WU1 )AS'*W+BD(E\IUEJHGE"0=F\
M3ZI!6Y?P.!3 =EPQ04@+"O)C0L9;#C%3(G62;;Y7U:N?K=E^T8Q[[.1VXCYJ
M77PKWU),@G<H-B7!WY,J5XAH%-U^;'G9^V"3*C:5;\(Q.V]^^X%6[R<OT[+=
MQ18V3C>N?ACL4W6"<[W+%Z()J:4+JCWD&$SIO(]+VG19^8)9G4-HX)6R#S:'
MQ$:FNBIK?.ETAIW^AKQCW_[S]M^6%)W@O7"^W)?W1'JJ4 K&T>.F#"VO!(+I
M\6P277X6U_Q(.T$O%-$[4:@%YL9%])5K_/HX[+2U57W.>#^E]?&SH>KB++.$
M84ZPQ+J9<.]^$9"M!J($?V?<$0'K %3E+R$"]HC+1EI7!&S;!OF6S4<3&910
ML*)#>!AZ.Q.N<,JYJ1UTR"!H]K.M3"<OWE[MJX1T%KM:8DL>&.17^;CH_[CI
MM.UP+.\_V$9=)G8<9*=C(1UQE77O&2I^V<="*-GI7WCV=G_-6PZ\)X7SYL'N
M%O.LZ@>[:[-V:F:>A/\B3N=M2/053A3W#!4Z5K4 1W,2E^;92H,&LWFHXPNS
MK('4$NH$7B5B:;EMQ'4T@..6<"59ICNPY&NTI9T(P">U)?*5S;CY(B!>D:>V
M@-H;X6*[U/ZKH"CR"&'_!^WC-UJ;0(/BHPLHN4AMOP6-\=DSL18=37%R1]U4
M*IYM3?"B:A.O\Y*1,X]1H'>&/%^I/7,M(XZIQ'<*!WEG5],9LC/$E VE0FT(
MB<\ZYAM%E,8]<Y'HS"M]/GW!FP9+D?SV9[_L,C'XB*]PM[@=V_XWF-BAYD*?
MZ(!-,MVMU3GZ,?$]F>&L@03E7A34'!6E8.\XJW&4TY'!NF\V6-\7&=*NVORP
M6^/S'8GY/OADD5 E5[CS""? ?NS&]MQT@@[_1#U$FQW2/F7QO &K!J5V;*CJ
M//JC^/;+@2<XTPE:M-7GRO1.=9\1]T=*1K]S,LZ($S5"!'QZVWY8!$R.X!@B
MX!*B8S<O6[B;\O-M011A]#4 0,1K@ 2PA3VP%P#V Y(V*&GQ)K00OU]C*A"7
MYBFA(N!%[DP\@)_Z3Y];/$?6#? 5M+@'0.P2 ]1UX""6G<" ,^-X$]"3Y9]6
M_748FG F>8V8A!IUF.\H$$L7\TO%3:IWVFK:4GPQK=<:T;]E'3F=\LQ,[T?L
M?[+OP-\E=O0 H1,E8[T3K\:92ZJ')?\!Q?4P=[=KX%K]LD;8ID48C$X=VVWG
MU\WWI=SQONM]H6$;377U1_44$X[7W#L5=Q+^%Q*\B&#L&!'NCN0LS@0MT7A:
M\ZKD-+X%:T5V0<D<D:0[TB!] !\Y.Z#HA"Z[O-#8:/8F-R_H+E[KR7S/@IL,
M)IJ0>W._6:'V*+9RN3[6>OC[RN89SHZR)\0.<S&VD"ZXF:PW5L"6)D%YEZ$;
M")VTF4:.9WI]O]S(J:$H&^W\Y2).1L:*_NQW2QKWTABEX5W7]NB?)S?[A/]0
M:_WS;U\!82RS1#XL\L7IAXO6VL=#_#4Y.0URQ]]R8]UZ- ZUC?$=K$G<>+/S
M7^>?=S^C7[9H2R\(V7G^)^]*RA$&L]'PO=;2PC[K_<TY+D%LCW81((</N'+-
M^]LGD!H?F.T )N1:O0C+8C.Z_ W;VD<-+OPZV2]>5JW=K_GI6V!\M7[0S?T5
M.-$K NAS/3IL$=!%DN-?(*A_57W_Q S%])J/DH%:V3MJYFI7FA.[_ ^/1>C=
M+MWS(A*^>UI/S_PSP5MLC H%^0D>4&>*2=N(8E;:^J%>R=K\%=C4I3+\40H3
MZMY#E0I;(^^%>+3W,CN'&5V%N[,[:9<>&O\Q+4:6JT'6-YU^YQ'K,I;UQ&63
M*LBUEL*IS;C1$)!N=<[T'E Z;;GT<129OPMBWB8O>*J65A&K%UJJFVZ7\L\-
MZQLVN#A[C*Y@#4OJ1_1#F_H_,^@=>\*[VJ5X!+Z/V+<GPG&J9.@-(AK^@0 '
M<+HL>W(4YQ<4''*?F>NF[@VQ5JL963-P[?,S+ZQA9VA %4Z-H!CB!D=-GAH^
M5M-OL2^(XC)PE9^]3R+K4#NABE.<B7C+8[-8*6;W"UQ0C[7&$/X2:\I5X\IH
M!$)FOI'>GDF4G3OF-[^1LR&[NJ&MR'\O+JEWI.\2@@SDDAYG0@0X6<MY?D2"
MITAT+:&RV=*E4KSU&+E]C,V<7.Q2)NY=D4.;3?7-+(H HRZ-+>V94>HY.9N1
MTT]9!E:WRK[A-6GH7ZX1$ZDSG]U^;!'VDKB*D'AJ,6G7X:VD3G$38<&"TQ!Q
MS#WMZBX\"[[#N DJD2F-5YDIQU[E8!-NU O<SX&D^+6I7=^*KC<T-]?7M3>_
M-#J B4F>N7?N[/$W\6IS,0)=[@OQRG'YX>!*\L@I4!P =3)CYEO1;=9;PY$N
M)?.EZ5U-G&TYT=5-1I,N)CEMLX@DPI&1^O[CX^+>\>20I19F;V:9;;A._N?I
MJ1#B,/(U\RYINU"7\(99]RV.(\]RH%%5T>9E2P*P5&\1*8>S.#F6@VWBFX/?
M_?ZI]?O@9-7VL7D:$?HYY?N)1[HI$87&F<3'\&2Z?9.8J'[N:3XN!@6J?VE'
M!B&3M%PFB@?[^Z=&HWL[F/(AV>AV0S!TT5FKNJ8:;SI6M8+@'S-8^KZ@[87S
M/#=:+;&P48B3Y!Z;H>X,AL,HZBSD%MR%+G2A$NB0$ '?B<.X>-[V=!NT-"FA
M?Z5;I;P]@-96RHM\5+_ET_4HV6]7O;)1;\W^P^<@1/]HPM. "B^OA9; J39A
M?ODD(T0U=KVXW*IJ.6WIR$UT5*AQ8%'>])=IQR\)%Z]FV2\L.&I.?%?AG2>^
MZQ2*\;AV@*<O A;:H="3\/&,#+X4BY0LW,[)I1%5T7T5D&UON_($7IT=>ZPX
M"]X4;*TU8AB1YC&I&Y^%00?6MCZ^TGQW. 9]QFU;LG[P+#0"/>(=%3*IH /B
M0>%!B,9#3BT6&D*(8]=R>UOLDZ9UP;"&&>C;] *#)@+4*.I )L7J=FFY3&/[
M8D#@G@VWFV*J]F+Z3_G010#FXH,7[]Z]4_%2#/QM=VWFO<J]-MOD=FIM^SU8
M KS)18@WXQM>$N(0G_"M!4_J<>T WFDL,,ZU@:- O],.(:L7+J1EWF7K322>
M RUSL\.ER2ER<_8-VP_F]\B[';1GUHB _9;B!\+OP97Y024?ZST+]T&7.!)=
MFY%3=4JXZ@C4S@5Z5<$_L'U_>!]J3/?*.]KUL,3V=]BJF)&VMXF?'H'?!3([
M$#)"<6'MPAL5XX]SRNY3;%BOK \$^ZLT- Q3#&;[C7K\M4;PQS3*1<!./@Q[
MI117X3J^GBKUEKQFX85LO%$V5CJ^C B;C;M0QX,+=RG.4A4)(RCP; \8E+8>
M:NL^&F$"%8!;F9?'=L4\YILIQ=THW(^J?^B_P#PU:.D9\,3W/>NS3/#;/6G:
M#^M>2GZ1Y*O=9+7ZDE-)]7.I'WT%3;;0S1DW:4;=3N&H ?X2.]37G2*3A6>%
M#4.F71_O[S Z2+]=?#01.;Y.% LI$%N6OBQ4(TQ05:QW0QTDFE";PZ05V+J.
MK%79Y4RSB2KX8QSMJ+S<!.'[_K8&C)_<2K=Y]NDG/SSH>TN][KU0X^U[LI7Z
M #79.274(':\]M<<KK]]VB.*6D]>U@KA<BLS?=/,NH6J4/[S LL>V=GO^FKN
M\1?4GQ0W'KL1')BFG<'3'UVW0MJ-1$H'>+8UC$14Z?2LN(^NJTT6-=:^'%G2
MS%K@<K^Q/;RJED-#G^7$)!<'IA\NBKJUNSAC-D.XZV80\F>!;$\4)Z%=,'>C
M%G(XQ7%;WL6A7'Z79:O8F#N[." +.7>T!(YF[#_;=!"N07?&7)_^W]A[SZBF
MNK9=-#X60,0(2)$6%025IM(4D"A($S$"TDM41)K @X)$#5DJTH4(/H+""U$0
M4:E"0F@2(105,=*;D()*C:P@A"5I)[S?O_U^9XPSOG'&V#_V_K'^)&&QYISW
MO,J:]SVG_^?>D&%71U5J*(:X82W_/Y?D*P$&?B'W)6Z4 MJ(M0U%,D\WAE-
M3L"Z31DFWGHA= 6"L [@-)X/&-RKBCYT(#RPBAH-,(]?^9YDNF9* :[+"5Y*
M[KH%AXY>%YZ):@6XUZS$^G=@(XL4'R>&E601[)]H83>=>Q J$\$\[#/V;UPB
M"R5E>=YA>>>%2$$"[L#'ZR\@?)LY/H7O#]:BAM79L:K']!8+#5/I,AT%M!QP
M<J;Q#8W%.W[$Y#9EF:#FYR?)Z#]G^ 4->M+^.)$7Z"+8A:I1,6!XT%/";PNE
MI4"S#LI;>W866"K<NADT'S0N,.IL,>E?$5SUU?M8.DM7L;12$<&\B8.N>]2
M$1%,T?*PS,27YR'9EGFDB2I\P._NS*4-AIE JVW+(<AB?4^+>XG"UO4JZ<U'
M>IA *D$:"!+!=GJ]QGQOJ*EOA.A3*2;Z2JZ8.S9ET&VWNB906)ZP5\;>J8'L
MZK'O&9RMDK;_&?SGO'"[#6??CZI6PU%RFY1Q>ND\82??F^54%MWT*>=W6XL<
M_LS;I^]5+3^(94I15N2%UL@K8\I*NFOBAFWJ!">J$H$+\%'DF5K%>85A\</
M,5D=U0_LN56[3&CIB^F2J6BBR:^&OX<O"\&)70_>G_&#]U"@H[7OE=86%TA@
M,DLA@[AZ"-HX=22TL<DZ,9OJR"$GQC[94A)SHOW&E,_7&'\]!Y29#ZG\ L)(
METOCR\ZS,E,Y-D(I#BA+;((J28;):V<K0$H[U^F@4W3QO-7VH:B(\H4J!:FE
M%\W@NZ[DV&ZO\9\JD567/F\\?&[#6A3Z*0!Z4>"^&/SZ6OKI\6\W3Z]=P3.
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M2MHBV+F6_JA%H1)V.Y0T?RW7(^Y(:&/474IP0^2>WHI?Q8\=DE$<$:P]PSC
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M99#X5OJXA^2#EUX_W(4NEL[KA[TL(,6*Y+K@F0@6HDJY6W@02FE$=J+Q2K>
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M#4$LH$1A%"#5?LGU3TDL/&>I7QIODX[52C=,Q2GUE#NH+]=>P_($9M2QPN)
MH'BR(,N90=N%.:TKZ5Q8H)60MGX$.O)[KG"(P+UF1EG#>W^5F(MCC_(<=19R
M>0?X%R!FY) A"RF#B>-9O,_)NW^%-<3K$FHW)E GX6FLCY>3?'FJSN$N=8/B
MY@8E.1K[6[@"5ILRIO&_5X52QW@8W%<$42?#RH2_05"1E!O.*7VO@DAHT<*$
MZ4;!9P-V#51AI5AEJJH9UC).9WH?F-\TW\V1N!>E;["'Z/14G^^QAY)50GI
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M#*#=YCC(J7_&B]=J^[%K2DY0EOONN+NI<!$6QBJ>#Q;.*.@.93L\#S5?';<
M]3+C>QT#B]K<\RK_87XGSW;L##;V]C3I<C8]?(_O?'SI,?QVXC^YAW;>\]FR
M*SY^V[DCE^V,\-^KM?K!@(I/7B+_B6K\0$*+QXZ$@*RB\)6@SC76CW.<T\C"
MS@7#] 2ODD\7OP0"O=F>^Z62ZI^GGNT:_;QZ)&U8NZ9+9P0!YKG#=(NL8,/X
MB[!1DCF@H"LK:]\:E3JT*X5?B\F5:0G.6;_?/]B_<\8)%6N'VA79_#+MV^<;
M&"^>Y!D".,$38904J%'"N$5YX1?U'6+P*?J>@>"P/.R?^4PFPXQR&;+VNW>P
M:O1H<?U4S,^BWN/O.?OK\)W;.^M<JBJE0PTO&W6"I(K,U+Y9A-G,BD4$Y>_0
M/G#8W[S!38!=,9'2U!AY\1S=F6$>LL:YP"JJL..?XH.&.;(QCY#^BWO^$CHG
M1O?+#OR-V<R3/"PS%?*NSMS1H><)Q&B2S/ _(G8Z=Q]^03P]"GP6GO U>@-<
M[_)K8 _'RPT$%PH-_-KODGX1UMNSCSQ."PX 3=R=%>[>#FICGXX4<3O<5#ND
M&RF 82/V1>5@(BFY*>(<DH6R2M!<?6O./U!KK(B>/YX]O?OK(DP41+8&_5\9
M==H1LB]>7-_]SR,],84]HYB3\#[$O1[?6(PUB*:8D'>IC_-:WJ.-U([O_Z3.
MF."-T@K7N!@$'=GZBLM\OY.18+/G36?)A9K)A:;:F@\X]S-4YGR2B" HML_3
M12T CF?SC,5=M!=9[;6L(\B$,!U2-C[V+"ZD$:[!B^-+#_SK:2UW$\Y$^&2[
ML,0"Z^[;KWY(.2U"$0*I_B+WSLOJ*(!^T5<F ;VY]!YE%I EJ4!OZG-N^?S'
MV3<R@ZU\C DGX<FD\D3A:7R/FZ#YW=VG=,$FCX]0]* #;G.#,6IV_Z^(?%H#
M2KT^58;-YWI,T1J"%;5 >Z]$K#CYQ*=NG$B>.N#[&^ FH!KL&8\)D_0AO[%L
M0D+3O-4>!D.M%='NL70Z1.BP<GKX%!L2/N&6.+1P9GXZC+*/!P31W1$_4=J\
M*9)"F@5IW_K?B7P!PM29L6KRA>@W[&0*/!/MJ/X%[[]G(F*'7>%P(<^$$U!5
M==;Y^?C8Z_J?8+R^!S 2715!'J:LPURDW1*Q.[$Y/<EI*Y*&1'JWU0X57B^F
MQEW V,=F A'Y9J7UJZWLFT&B_OG P03+;N^JJ(6T.4GF]\\>>'W>WS-ZQ$:M
M?KGJ6%2AV)*DCYD>5>TEF@J:>*/DM= %4,^O^27H+<ZRCWS9]VE ]./U.'IH
MRX"+A^FR>VD79]IN3?6$?F4B#46R[>6?*)+ZID*:V2*,@(7L':8ULB,9PS=9
MV.SG4^,._03+^[[#TYX^H&F;U>'*JK'-";F?96$6[<WY#V,M0T(3AJ_D;TQK
M]J9\_2_L_W[M@FV$P20P][4P2%^)@%I5D<3^*5D1GS :($E\ 'SI0JPK:;\?
MA3#AK'>J@&) O"_HIK9SM!M'O'1+X?Z94 #/,^R/233 A.Q]W:PM:R[*(NUV
MNQ^3/#\7 66%"4G(1_@R^Z$KK@L^6?%I 6&#L3]]VX5K]O[/0L9LV_66.T%-
MWU^>OZ/H] G1ZC+?%4:&V$K'"I]'R#"*K>",,AT:!+*4URD;\>.K(3? 6D*C
MTCUMUC6;4UU8 VPNJD5EV%@YM:?#1L$MJHFV*LM+JI]RY[ASAMS&$>^1SO[H
M7^$3)KG:ZW)L'@TX&C :J8R%(E!=!;F(C;Q+"%&OH/QU4#.JHS4:94HL?TW>
MC5>8\LWG"Q<$=0:MN1/N[%RUX[/P\*\IY)O54^,V)6>%J'CKO("#0M;E61J$
M3!)0[E ,.0F+L!7S'&@K(WQBW+4%4CWU?1QU"E]<?U]*,"<6=@="T5S+/D]\
M3'5TRNF0ZBQ4@OZP,"$T=/1/:8Q#X"#R[7OO) \C^'BSX[_M&KKN[DL1MNB-
MVG=DM*9^#CY:H"P W10$@,]/HJQ7^]><)0[%6$N/L/LM$WHMB(37ME;]SIJ]
M(4#9@XH/WK]K$427TWT.!;ZWQ@FK)\R3M$'W&U2_:'LIS$BU6:2$G;X(BR*(
M>I7%T$- _#JDBFI; -"D6=/29Q^()N]4)X S__1FL&9R*4:B'_[#SUQ01L3[
M'<VV# JAW+M:L'!(3VO77)A5];&M?!1&.<0,EE:K31QD79VM6V5)"JIJO8X,
M9-!)YXJ4X> G\_#EX)<<IV\)!BD_^$DI7W*8H75^+:,3#-8.YW\[[Y?CB[T+
MRY]&N[F[*3O+*[SCE>:))T;54I!_4D/G;J6T742[:7LQC5V=83[2M*("M!ZD
M?PR,I.H0S>]D0(;8D.Z) >8%X3M %)\']ZUMNX"7M_J<,(H*\5=D/,6.=LM*
MCW^W5ICX.GGZ5-Z@^)T._H%47=%V83;H;%R\"#.,63J-=X2B;-*4>P;7$?4Z
MN.M?0FU2PIUQYX).- )D%>2P4E'ZB[#HZ""KM/R,RT]Q0GQQV=U*;%39YA?#
MA"'A&>V@D.17-9F"K/BNZ5 1*6T'/8.!;J4=9 &&2NS_VR36,2.\*B#+/:G=
M;&"+,&$E0.)B@)ZLW 2#H$GA*0<_WJ!SJ-]4S/* 3,TVX05P5=WEFN@381-#
M%D%NOR*>SP9+\ZK5QM6"<#O@DNTVZ($JB3Q<G*5 )I5[SF.-G'DYC6\D=+B@
MZ&[K@-(]. MUM2#7B;0[IN:-B1\!GL?$YQUPU,=-=]ZJ'_*=P "^!!%%[M-A
M@%%F:1[R<%[16#,U07.7NZ7ZI@O!ZJ.S21BQD1\7#J7S%TCL^;MVUZ=2FNX_
M@U"A?@SC\X]:AN+I ?SYX._CT7DUV#$8N7W8&K0:[9SGP4E)D4#OR?YX2HX%
M>1WHS>8KL%BV6XAYD3QYUN\K9T?-5- 3_?MQ%1^F>B_$U8Q2\>DN_PT\O.D_
M[$)Q#_LU96T4!3@5(*(I&_HP>)HH4HZXX9D&\&6?&1+Q;41CUDVN?1OP3GP0
M(&2RQH*V#<;GK?KV-P05G.[_YDS53PM:A!UF^A_6_[KJ%>-\&"7Z:]X%U5K>
M*HZ?"DGF\Q#J-1:=N@EM[D1" 3QYOHZDVJJ]ASZWZ@1DSPZ._K-P(N4@VH%5
M[$A]14)=N]J/<Z<_2SG7)%X?9.Y.,B_LVZ17J^T*L5"<E(IOBIQ*5)>(PG:R
M)S3N0C,*>#HU;MC0?]59^#B@Q@,B=W[VTN.33?HN#UR=_GZ_M^JKZQ]_&C#C
M?).3S7H4764Z^HG1Z8$>"Z42<I,1[E@A^)I :4=UIM8!3S&X]'XN)D4H"+:(
M^SJ^ 4C*682Q[BE[_?MEN8XEE VAHVEY]#%I\=]75(=J?S;^=ZDT$(*VB)N&
MU29U4L0M\L_J"Y!".@$7T&RF?D##4K' -YZ "*>T>\@9EKB%Q)PT&<H(5[;#
M@FMS%I7.?1 7:8?WRGSHTO):N3OX-0TX3/B@]YK"%+_&&*DO@8C.7E&P=.B5
MA">R#@*^T:0Z1YC$%^A![EJ$(7&O-"DWQL4+>Y0#)+:DQ3T;"\?_^" 6AT8/
M78QQZCK6E.F83 _Y_!M\*C=7?7AI*5 = G6I?E,O+48DJ*VA5[7:7BT"A*<[
M:;>3WXLM9AU'TQPZS+GK@EIHQX&BVW,=+4VM[V=F8F:3-S>7K8D)T4YU6*US
M,^U^,C(5DEC[(U(1HW*-1@ ! 1DFY"%>@UB1!S*"0)]VL1'QXKP,SJ?ETBR8
M,SEH<ZA2RC""LGR ULEH6UO6BSY%+&M]Z^"S;W,HIBCLL=#DV_QAK6 H?E2_
M?YG&/O@30VU6K>1 0M56HH62,J35CRZVOUL#+<+DB252A*D_G4CN$N@G2 ?[
MOQ'JG3]L'EC><05U^9 ?M27>;S;GU\86YO5^MZ_S;82<((PE%T[Z&6JM"G&E
M5:M/0M<DM.S$E+BW;).)]\1N?@HA.T)8]?#,BOL?#'RFXYH$Z'@G2^.;)R&=
MX_66+<+>H):ZHTY_NLJ;L^4\@G^US?V? [M!B-\QOEJ3'4^/:"/O !&W79*@
M"6"A;PZK/Y52=K/6I5:7:A)CBE6^S<QF?%Q2)"[^PIX_>SKHG%'27ULNRV-Y
MDF($TTWA*]G!=='VT9HHG6)]<G\XLA].]=27(M*UCF@K: UP94'[^CP1SS</
MWY [/A4T^+C_2>I9EU;"?A">E6#=7=1R=PY)_N8Z//<;?"S%$91K5VM4021O
MJ$=E2Q0&Z@Q6/VDU?X<72;,EMBRUDU:'UOW-7FK?REM'C#L,NI1J6Q(WWYBT
MZBR*J1%_37*;WS,6[5Z1XL*M?#I^?M*-[;9'C5$A26803\=2*0/H'>1!# (3
MQ2A K.$:A*I]!CTW QY21!MM0RC1VSD&P^=='D3.>>3$QFN2#N!F_S/HW./^
MY:SV-4U@NPE<6<9(<JJK/OL!%_1LV1Q&<0ZTD!GJ[+SRON8F1^\)--,9XG-3
M[0L(!>SP+<"5(EE:++^]>*[W/IA [J,3$_L7D%M/TV)IOWE.3>W[U/'@T1@U
M*I$L"?[^( :XK[P)6>J&NJO)06\@_0ZU4L#>0\#G#-E-(%B&RAZS!WMF^/JM
MRV452I%;@=/'5N5CF=?R</<>ZF3P?$BZ^&Q:;FKJ!X65C<-1U0_E+#0*XN4(
M13I U:X9!@BRS]4J#$01H->U0(]5!TG8]XR86=KZ$&AWR+<TC_9PTV'S;Z+Y
M@[Q6=M^GS$GB-A9>Q5@?M>MC@!,UDHX3/=)3])BI1[1#XL8KCW6(,0N==%#@
M53;:#V*K.<)Z$E*G$U'D3>I]4"V8>AS2,9;<<"L0GAU/T1^O>BR="D7:#DV=
M]!L+>3=S2N5?*;+9[3033YCVC_1_WHHY11:7;8 :5<>TG8NPGW@QO)'4CO!]
M *:#EJ%=!] 49E+Q6F*DH/A%*%305K8#^)*EOB K6!?MOBU#8)64S1+#0]MP
M->=&QS^,N=;&5.*UYJJ5W5 &4@[3U#SA%??>H0$G RR6ZG_(EN2WV!=%T]2G
M8LA#GJ5P,6-]41C3HP(G$^F 0WNX>4LQ8N.YICJ<"WW:/*5R_$'-U/M> [55
M9KG$(\S#)RI\$=;5%#2A,2#M 0P? HU2\2VR]=?F3'8=CJP'=.9)J<A003-]
M_)7,YI2-;:<U2H'$!W'OA98HCFN>X%M&QAX8"-X]]UZGOW[WC207&8V)IH$_
MSD#>LCKX"#4,2I8R\NYS,Q9AJS-9X"F#(/EKY34?&?)GK#$%WU6.<__V^'.O
M]/80DME)/<+=_]0O\HN=L44+6]F\??F_E1HF96E9<2=A&@FT[(?8($'&F,Z1
MH0P@:I<(RR]Q1&6AUX.N#'H'?5)K P;GT.OKZ1Q_"67U!_O_%-H:#SPN(R;L
M^#;T+76#O*'0,M8)R1V%DB5B"(F'ZEXO5.=K]VH%%F*X6&!KR0,+:8]Q&"-3
M07"98<SAO^4"UY1]-.F9!T_QP5:;.>D!>Z/-"Z=(P+]%SP^OFY#2@&N1ZH=N
M[3,J=\**1=AD)23&MC1;J&_,$E0K<>(%7P,8>0=D(7,0Z#,@I]Y.0I8;>A^8
MT<4?\U!>Z9]SA/_D+PN[$K!J)!KU2+WC5=H!(1^>$N^7^N4EM[64L:7!+[/P
MV^>#FW&?D*IT;#>E"[-<^QZCT^T2-L\2C2"_XQG3R4;$H@[=[.)8ET-"V=TF
M5?@K"2$3*5F$92:1=PYRK&/M;XH[W4Z%3*38Y]CMV>_%+&8._SYIM?,/I];*
M#YJF15@DEHH CN9AI,&*5)67=H#'Q H<SVJW?PVWA#HDC#MEGM2.E*2\SH;J
MR>(B4:R<U>_<L\<?$9A^<"!>_R^75L?PH=F6UDB_(>>PZZ)%6(#I=KTY8V]R
MF&Y>!BS"KE(LM3W81NSM!/BMS@WDW=KWMKN!+CXV(X6N8.4-5F?6<WP(FNH:
M8O'GWL# &,^AD//X:EQ='#XN!D_'6\7,:4I[2DL[*A9A3F.Z$9%,'A0\;&N?
MKEV[577X(WGHX(&THXC<7E#U!KA3YG4V0]*$A=?:;F8#YYN?K X2:TVRAC;=
M+/RAB-T:MN<&)KFN!"QDNV62-LMX)J%\LYZN++5;/?[WT+=A%UZ6'.W_QI!E
M7KF3=;8R-2'_P.U?#F\[\@OCW0QDUZ7 R[&CRY7'7H %@HD+'*@$^-&Y,-^N
MTUV[O2/QB[ UKI52S=Y?AW4:S<0W(F*C:V&1>V:6+&V/^)3*[N3(QRE7J]+!
MBB#@:)/.XJFDLXNP>Z&@HU8 MZ1,>M2>T/NQU)M@1)>^VM7)4!?XI4VL3XD>
M1>FU26;RMYY]KS6&IGX%OJBWF@_1C)W7G.1)+9I+4=^NSBA8'2^I1W(M3[+P
M7JDG@*<$UY#1OS&1%,DCC+5GG&J?MHMFK74AN98<8X-=-YUM3);ZF.+=KT\V
M7PUV+[CCZ?'XW7Q(ZAN3\S<O/PU+COJ^\ASGU89=!_+4@]H>Q(OC.CVN,[J-
MYWY9+^Q@ KP+,2)7YD /P$CI9>T?]PQ29J.TZR%*DHRQ%A=L/NTDYPS%*]##
M07WEC4$ZO8[-Y+@1UN1=>5 W&RK'**Y5DW5W"!R"W^&9V\HZ2 F7EXZ[A#QD
MW+N1_W0ZT[+)""A#<H2%\WYBLG.:Y(-SI<EZMGQTIA(JIYJ:\AP_AGQ< =/@
M-'?0CL1&>=%T-6 JF\\7!Q1U8HS(UD2*@+NUZ.@+J\12I[JT6/^!IL(MYPK[
M=X1Y]FZVVUV^=W6[_0 V:ZD\B=>4U#DSTNL/60,%RK/YG?/*+.@?V5@8LR1Y
MULM-T#A"=&A/N:*YZ)?F& 2OXJ<]C1:5_:<P6'3'S5SNW^]Y9/.-CX><KFH+
M==Z*U-&06^0W/.5ASQV+L(KOP5_FIZ4[- T8"6,1QB0H]%'J8V0K<@?7I$#B
MP+>^Y:<+D/:$VC?U4>[:RHBM.YHX 4PX]93OM2@WJDU$^W?.C'$3[C7ZFVYH
MG':H:!'61)A^*"F@DNWO^RW",G(NU$QQ]:!20GDHO8RF=X?D%I_/-CJW4ZB_
MNYX8>0(0Y]@.'O6.L7^A5()TYLG(MQ1).86-$%!&JD] .CJ@3 :"<N0,48#R
M ;ASW I*BY%E$2!OM5L4N_C*G87/]!7N^0^W]?S32:>/'*SP24C&E^\W*VQX
M.F7:C:]<A%V9Q)C_?]S[,,M6FP4H=T!"\#/E%H)9,,VJ'0W5]O$:S5N=>%(L
M?%R70ZNI3/#IA.TFYJWVF=#1)Z6$_4/,L]^N,NF)H6GZ84*6/SY@P,&DQ"/U
M#T/W&)16OP0H"T-T68PC-8447)Z31TL =)1L%.7^&Y#YO#GM+:#A:8UY1N%$
MO/33WM[JT-:_FEI:P74OGOTQVKU4Y=D<'GIP+DF]?A&F+((*5-NT?Z%=H"Z@
M7&7L&5=-I+Y>,'^0(+-Q4V']7U %MO8-+P9B0_WW[K?Y^"5 Y=_:W./P8'W1
M3Y**O+7EI&25JRY<HCQ1M9#\.*2O^IVT$X1/EX "?WSE^>CPK<\'9G6V$U75
M>F:*]*F]BJ\*]7Z)8UC05S-A]> BC*W>N<FGY17(V>6</$.1M!Q"0 Y)!4<V
MI<MG,FX;75^-WLG<=.N73?F9-SP;VX,I0%B F7J)3E#6D0YH<M1G*B!A.]<2
M[+PK=>U7GZS&LZU\<IP]L,9GST;3"$!X>D5H&(L^8.[6-P+5!EF_RFX:\&]V
MF25WJ71>]>?X@9'RPPS5%O(P9K6U,E[S=);(L!/&GZW@H-=!Z1H:SK4Z%9%9
M=.K5 ,IYM+-_<TE(7T1!&!B>(8M9^VXFN(]S<H>KTD1[@_PWY3N>UTC0_(%)
MYRTP/#VPV30@U,8$\1-92 ..HPJX!K<<X3DZ'#1'M'_'GBOT#PP3DG;+ [+(
M6X"FTI_KGGS\,%&T,)^CJ,S0^F5S3KI4ODE-/O3;\@4WQN>],JS:7$\^GX&)
MM;DR==36%O.<<(L21==3QH''Z9A,YJMC1=TQ2!VR^<"I=QHF^R?-XR9LMX/D
M[*8BHZ@7Q!2^?U,SN[0^_+M<J7/XA.:15%-$N323Q[,Z]=DQ+8Z/-N T +_]
M<>L*.)/SB<I'KSUIJ/_11R][+@:]H-S>=J%*%/ZV9^-)WYV4?++54I5TSU-*
MF\%<P(HPW)Z/:BP8F?6-=_5,\H/*P7K/^!@Y>)QZT3Q*]$45=PKRN1PI259\
M*WGG'QS(/6=WL_3V;X@^Z'_J05=O^F24O,*X;46\"Z127:*T'4;;07AY?:EJ
M/5F -=C)W:T=M/I/4##:8=!%TD_R@,Y4A8<<K'F#YL2PD/OJ$SR06R:%IP>^
M#+ ,''\%U.Z9_RDRQ8M84\04#%'W)\^1^Q! O[@!WE9@*19K>!WCIGT%[3Q;
MSKWD82SP'S4ZWV!#./;-*RJ6F,XOYVM_?FE7ZQ"^XLF7*/6D[N?(#Q^(JJ7&
M:+>*U*0A>D]OG@LCCR!567=_OLORLN O+,+RN';$HN#^K>>LTUI+Y]Z52HD&
M+?5_!;<K@X:ZUR6^O;-,#%&/ZP: 2#N!GE[!LJ4J%GE%\Y62I+IH[-I9C.&Q
MYMF[HBXD?V+!?13RD/+Q23J\032_: "QH[$S6T)M7)''<9M5D1\Q0 !M5)<?
MV9%\FM'DT+@U%TH&0Z55U9>E8BIVW=R^8AD%'CW<$&9M$WKTU3U'?%T!'.]F
M%=N CVI^4)K/J(Y.<6541IO?V:E(0 ;,_L3[KWAD^?$L:9':@J+\!Z)(H\K9
M )N*MIPD[QEDJC:F9;C,&+\! F4V0]5VUQ[D.5T8TK%TZRM_.:X3]7S<;/;?
M]3#MG3J@1=FD>;8(B\470-L+,G@7*2,H 64EQU8TT^Z!L6JK59]][^*A<9<'
MLAO R&R76@8KS=$/-*^,HE=&-2G=8TH+,YP/3Z+V?"8.??:]H.EC?(8K>5 '
M0ZVGLYJ8B)!A,\EP]6%(4?=U$=8X5EF!,."N_SK</)^7$#^H=I2/[4EM]3@F
MG$ZPKJ7/9L=B P?"D'9&'T8#'%]L*8+9#H.ARKZEIV24-K0+=A4TJAP$**\Q
M>;3&^5S.F0@I$M\A7EX2TC_7NV[20ME+07P0!PO5OWR>QC6Y]XR59C9*[86L
M.OH>_]TD_\=OKN'B4-,^BM5B:](UU3ZH_8OR"$C()'F ]P5EUN]9 1GA3J#_
M@\HO68]"QP(.#]3'5C,'F6G77_?4$$^R_-*VS?F;:/\6GVYI*%OHH\O^ __,
MUZ[=H;H&U2G9Z9(OTQ-@ER2X0_SAH 3- @\>!!$"3.XB;"-II3QGKOO/>*K-
M@0TZG@6'8D?;@MY.11*>AD5C7A4K0[L'A'8M]X_T7YT1J91)VK6H>IS62'?3
MY]780>TZXM//?/Y"9'M E@ZDX:1@B=BHU]I/:JGVDX2Y^7#Z2#X583[(GLQ:
M:6W_-@ZS>7>T>\+HK>^A'U_^#F>3E^%X&V8IZ0B#V5Z1OL =GJMU.4<,#4B7
M^61S=N,)EQ]/CMN?B4A.B(B)K/Q:>,1RG>_U(2O7!Q>0H@"7_-)(G)TKN#!'
M=NU68?&4%UUJ8[&.^RC@"=MZ[Z"WO $LI%?RI+X<WZ2XIUPZJ-]IY9_YL&*2
MN[FYI5D56XNK]'7IRF81PQ6Q<WY>/\LZ/6KLFW7(&">949O(92C%5H#=CMV(
MP1>,>BCK6R QB#C8 -W$5ZD]H((J"-]&6R?N2#1?J"^IP+FO*S9LC+#Y7%H]
MYH.K]98F>[H\.OAE?*+8.[=C91-]N]X,G>0B[QV-\P90BG^ 0*4%3:JMK9G"
M6G(WZ+# A([>XLT("9U(66<51 .Q)[1O7@*JB1=CXN[?:6L9Y:I+(:4O#BVP
M'JL\GXS'B TI;6YH%W4J%*8ZK7W/ _S%HH,RVSHP_0RT3SJ*LE%O@FB,W27G
M!TFK9Z0C)<>&$JSKZC3!I^ZI#H/#&0EI3J.! ZQ0'MRK(,?9=;#^&=*Y!HGY
M9:ES"L9S>26E+7RI@\5(*=E5*[08WPBU 7$=%!,71G9*M:#'7B6;STKP%NJR
MP^FOXT;@':ZARO6A](T]8'-G[[EH*WMZ,K*))3MT_R0N87L5$Z9]5</XFW8G
M)3-'1\6+-#>XV_'A*\"B#@35O8I:>YY](P&5Q]W^'.1RN9Y05E+55_>=%DF%
M*<$9BDM 41;!C5@H]VYJS$REIL:$.+_$4Q=A+N@S4*!N,$66G-#>:TBZH*E:
M.ME49$\1+9WC$$.*B:N%4/+8(BE!G[1[T#.@NJJN"DKE:TU4&^L(%ED1K>G'
M!Z>94V,6?J6*R,;W5YGZWIDA,.V-[8Q.++2-K8@ ]PK&S31U6CUR']<5F\UU
MT623KM40(P.A%[&;7[6 PS<4D6!E7B$C.<F.>Z4A[;(;?^RZE#4U58MBV>P-
M[ L]UTP+]&L],/\),X*7L#L*(,=/%--%6#1*Y*#,A&: 7LE;FK'+(DR/!(=0
M +[3'+VNH8\9MKHCU;;ZZ5\+QUGET<'NOPW2G>\__1A%D!E$AO:S/+K'CB/M
MD7N/_P:?".'!>9),FC%Z$^DPA%'Y12.,2'%RN UV@L;LS7$><YWO1&\;(ODG
M5..ZI12#X\UIMQ<&%=--B8[.+XXV)?:8-;_9VMQI^2?M%28",Y(EZYUNL!"(
M5Q!;E%20T:6CQ.Z9U=*>@Q(!UN1SR6E0IVZFMM-9V:1 J292L-<R^)SP6Q@'
M8__'U6)=XG<M4N"DF@T?WZ(P901H6_4T'QQ6/@6&NW@KO$%5)^\GRF4Z0L[(
MF4-M'%7;#&X!YCLH.3PCPFSK%A$*SLZY?&O!R[I-M.HF[D+-<:=GJ*LLI,\9
M5V'4 K_+;#[S!H81[?AO+[2YBJ33OK>(E+839 OM7^9B:[*]^H*FF()#9#4W
MO9+&H&1EW/$M@QS+.EPQ]LX,\I@;)B+W'3*\-P2XI$QJ)%[G\T..,YX0Z]_%
M!/L7+\*\6<6.-.!4@)56F$)1F^DK]P&(Z6XY"^#E>^*!",&".35&YA]PBI)5
MG/8EUPF]_:N[^$["S#J?W^-+K^CT!A=A I7XYJN.#9+&"/R0U6EN9U0[K4BO
M$7W;S-3]Y%',<VPGZL,7'=BJ+JDW:UYBHBGFZB3H7+*48$0Z,,!)DM^MA9(Z
MBV-FLF=;K4]H_P9D(3/"607FQ*!T\!]@F.I2L/%K<+$-77OW&L'AX<:\A=T@
M6ZGF06=T<_\MT*N@V>9$N!5P4H'[TJ;'4@K\;ZL8*[&,(*!O/9:[.?'.U7\X
M[SENM6.3NDSS+";&M;HJJO_<?A=FT;6/AY<M9'F35Y*6-GB<)WEK*LCFD)\\
M2W%-%4D>'*98:[=^3<08(>/%613C6;$!<:^T!*IO%Y\1QN<Y[+^_?^AJ!$?(
M5-4H7+9S4 Z9S-4DU=C>(PUG'S4-5DY1)"4T*ZV7VDGSE!*%A>QG%)M!^!FH
M[:EZ(Z HRM<:D0*&_^RIC^:N2 *F>ZKP[GF#@]JZ6M^T<N)4>S.W**9V,H0N
MSBKK$A1;1P\'F1>?-K]A^K^UV'-3%S?__-:;CU7BW7VTY5B]6K0K4247*Q9A
MJC3BO-(>"@!+.FF-XFF%:I^.U09#8W)49G/N5YH1)TF64Q)P+M[+,9Q5YG7@
M[[_"\+Z/STW,M!S*F449XT6:LA9'*.D(&Z;Y\82GFUZB*:47Q%]R%12W5/6\
MB3S 8ZYJO0#TAKX?E17Q$7GH/4Q0G*F+*;'I5'%L>ER-[X7+E<0DWQ9?5L_1
MO_")P2DVXT_23[\$#3/H7RV*=_X4\!XQ&J$<'UXB+RMZBY1-T.YUQ9@<[G:B
MGC1A$7;3B4"7#GP"SO1V\!_G).A_>'O];'<=,=!_,,'L!;ZF2F@M&"I.&1L-
M#]D[\A%&KN[#OG/H0$'V9@.4!A05$Q46J6S35+-Z1=;^D$TMZ?HP)[A6?7[
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M=UK/F+1%2%6M04JAPKUF@.IK)]Y)%A3/" I&(K5K T ]Y?H">74>VHO<JW6
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MGJM#3#Y&A]BT?DRY/-MOL-??Q"\!OS/?667TUKN25[A,]<";O)J8U#GNIGG
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M=[X5KHK2<"D/0\-1=I"_4%($E OIZ5=SG7[P#0<8ZK]Z=$86XH@GV2CXZ^0
MW1.@WFOCEI@X:G$^G(,=W;Q*?FCX';K!0?;809RBA/RZE0H\T\5@5)SG1<&]
MYIU"]EW4)A![NSFHN+.*Y-:E,!PF[Q15ZL6$_Y'H PA2(YLJ#2_V3Q:\C<7_
M>WG0[MUHN?LNQJN&UQGF(0FDXG,/#J'WLL?OLG]DT&XOPR1;H)85:.S.^ADM
MTTM7>&!E.O.*#[EPN0=*:WA6*>^("?0-Z!!:,M\8<@$BVOM(^X6")"KC0Y+P
M4Y0ST5?/LR)LF#=9:CI=8#K(S B7^/=X>[4T9^/E)Z8#?M::5KAOQ_7*+LMS
M6>MD%"YJZ\PR3)^L3I@PPHX+TDW!;@Y^9(&N@T,(JS>[H/)OY/YU_;O!AZR-
M9?30_L@1.H;[=)#QYDIM_)?:&X^?:- 95%E>=S==:@K?3%U0&\8#31)[Z+QH
MI4[%8?0VF2U 2/I0*>K5(45/W"LP[+?Z7#Q95_D=JVM?K8-KM"_9=G0L;/$6
MTH_0;/-N2\>P^YKW-<>_4(\Y*I*>0:6'N;+]U2/F184DVO%!AC4>\V RS4EN
MX5V7AQF\]BR;?SS<U*/<*?5)=()/B<M]AI=ITJ5O[#4459FE_!_6]N\"==8&
MDA=B+1D%R);RN8^$$),0>]'?/R/DS.LAYL&\LZ#-\XH9!TQT6<#GBTT!T_MG
M;6.NQUS_S?4)O#=%IKM?<E.9YN<H_8(Z-&=RY<PB.UF?RM!*KK!I=@*Q1T $
MC7Q6V*O76XW+67KHC^<<,;8;,&T:6.C1XXZ>RY2ZU1S8]R_1ZIO>(M>A'E!4
M4=ZR5Z/'_Z&NIUA#KQ1O_+#MAM3T)4RB:OZ$&:#5H7FTVX";,2Z/\'GY6FI>
MKMF=UNR&*RI65!9.]=O:^DU;65<N7N:.JS-0=M0VI66_!*<I; :;8T%+">6C
MC2RX,M"%6DE*Y*!V@*6WJYCES,>[&AN'Q&1-$48+UY@E*7D!AMW*_WJ/5_PQ
MUS_Q5D.[Y:N6.DFL_+XRH'M'O+HOU,CI"AT24=@K^77SSYG<C#NY]34BH\L"
MS$_-C/KG(JK.M./PW04-?^]<W!-FXU!P0Z8(5[6&0JX]W@H_[OT3E"I-_MMK
M*WW)T9*=_LNPJ5&A,_70PKA"4_X8I4I&0;V@ON0.0+U=&4F\A]:+E 8@1&KW
M)KC-'M$.=ZVL^.W'_W \4%@Q!D5[F'LB,+&IC #34P7@[#C^3<B^Q$/P^VC@
M_'Q*@87\,>5W\MJ5'6X9O+]JCHE)HNSX*%.7'OZ>&W9W D1P\OU\&?Z:&*]@
M=9VXNE-#4?"4'%Z6\%6H311UE2=Q\]&C/]T.KA2^#JOW5OY AV7<.'C,,6J^
M^[^H<[G?*U9;6M+6^_"M&M:.7MFYX\^?>G$UPH8#FW/E/T%Z(MD2U&TOV D@
M,B,U$9TH+3#P4:PR.CF-/171N5>KGTUO8NC?],[^L=KXH&D0<[#BY;\ZH6:9
MH1,/R%BAPRQ-ZBA;#T5/8)/@ZJBM4P6J@'Z'ZQ"VZY;Q@W)2UC.NP*_/%)A\
M^@.OWSC$;PK]\;UOUS]:I=,W,ZY$7_R4AW]MEG\;70 ?>32.Z9R']M#$'E(L
M992JM0S#$>]BZ\)3@L!-Y%T05K0,@TUY\6>,=P*!.:5^W<;)X6IWD;_SG"MI
M=QCLE,:N4ORU8=/30\UN$7:B@SMCB,YG)=_^%^I]N;39'A#16?";O%FISOL$
MP/-?UFZBJG2 (U)-L>*YEL8)C6R7"%[3;W'-A(HW^,I1DM>W#GPQLXI^/2(&
M*1AY4(7XFR; QJ/KE$"U#!NA"Q?H[;WQ_/4, !YO%:5Y]$+*,>8@LR?XR^""
MKXZ'5-J#[<@MJ:L*<XA6W1VT?]H@:S"5N+:%<3); G04O(["$^((UX-CB)I#
M^5]T_<;\/KL^\O\\>M&U#T-$VJIF^EQ-Y1T,BKH2>?7"6O?-J_[;(]VE_+_N
M*/5119N@SJ*+SE/K!J$3!.J%@658"'TSB7:Z=BC*WY^:QM+NL_^;/]^I[W>^
M^+^^<1"5*@PEG[<I)3T/NLHRJ<5/55KGQHCEBY)\>=%*LNE0/L"U@Z$VD#I.
MI%$VSQ1H<8\MN= RFPU%30*=?R-'S&KJ@:OTDC"#@D*JJ U9/T"B$#9R"=Z>
M@YY51=>X8J+DKI2X1M'*KEGDS-]18H"6D!U/T2/>"?P=/,:W!Q'Q9/=8$68[
M3I]BE8>IZ4]F7U$<X,J.QBGU/]<@^(Y!7%=2=$E]-N%RSBFIU?B_9$NEG '<
M,)"%6G*SFW[J+/IJOO&/'_Q)C2:"4X?Q0:A01-OH@K1E]$Q"(1V4 T-V1D=X
MPK>IL_;^&G)DIT';EHK3R+X3JT"V3)O83D$#PS)=71%S\5[A(,$.K0_E3,!3
M%8:\L-.>VD0U]W%-#3?ZF0'9CV<XQYRT7U0=S]":KI<>M@'3F][8AAEV*Q-J
MC37T$W 0ILRB*Z>P.JS]LMU0S(NC8%WW$J.1F$DQ@8ZV>X,X+U)TFX9QZ:X"
M=@5N4;VTR?_BG9;0SCK#F/:W)[T(B@3Q+V>] 9<43G:NZV.<<"9NGYU_W'IN
M%U?@UM G8NJ=P9W&O>S(_G.J9B0>9_37Z4K&S=9##];=/O/?%P%PG 99F.[?
M)\]IWJVATX%(0YF^^/)/_@O6_O5%?>?6JMR&P4ZK?7.0;99*AH 4<<83B*A0
MGY)N"9.@M[-VD(D@[<Y.<#@-:5P[$Z@"")(B-6^\ZP /(<^7_E<?D1>'/]&'
M/"PBQ'H&8 X#\TEV^8'.)V:Q%_^V4A0KDR<%4JJ@E7,WWH>!1QR#T5Z1DY*A
MU\JS5C9.\9=BR\>PI  [+3THE2",N5+30F_S0Z0SF=ECH[.Y[R7'<[3?F'D-
M3R':Z".EXVJS\T$1I;)-$'H<GGQ=<.Q^F'?!%D"<E%E7SC&T[#1F5O_];#CJ
MK]2^P%U#]H8UAK WC)_G% XKMG0U%:=!3QG&&B)5B!-=D*_HK!(-5$8%^(+=
M Y%RRPYKR2%BU:\6-?]^AF#33KT+,Q(M;5[8TI\N#]:6C,RM>0+/1-?ER'0\
ME,Y:K0V=XF><I!206Z!%P#V\>7\QE.X'!8Q7JL9BM4@.G2AS1GH Z)H>>@F<
MR[7A=U]DM=2_&C2K860OA19\%8_;KCO[E6BL1*0,97"\4D[-?<7;91B<8D:.
M :G=U>LI?0Y^.1QL&GHSF5BZ# L.$ZF+/C9OB0D1^<=7X:NC2DG^)P?)ZJ(Q
M6]'TCX-5EX#*H>*6Y@=3UMBA?)*66%MJ0U:5E\MV/8,,);>A.!RHP3'0O[L#
M=*5=.L 4$3=^QBU];<F:^R<GF\>^$U6IXGLLUOK(''_RWVG5=M!(<ZQB?FW3
ML550M?()CZ1TL&LMQ M24R5\N(GM/#&!D/_33RY CNC++9L"HLTO)U],NEVZ
M=.I>[>&KPP4F@%N'II^6QM'HZ[AK_!U Y(%A?6XU]>J$1(V#;5";C18)UG:"
M:B[R4LK:AB3C#_V2;V<&61:DHT?I[OXSUR.((2)-A/\00^[/::RY*_(TO%CS
M<NB/++]M%?W!5^!'\"P=H#L-N:\,0G0LJ3X28=7Q!B=S]6J$O=J^AZM"EU@T
M._A5^JFA:U''FA*]F 5:8[U&TZ?,M]G.7W:7"9M6>F.MO'"OCOHIVD:].KK[
M6XQ9@>>! 1&Z<]1HU5Q@Z"[WY)20B>]VGTSO'/G87<IK4WT(?#Y5-_73X>''
MVY2K 3+/C^CQ,C;@38RODYDU>_HK0_+2999C"QC\MIL 3V4*-I >VW.'D<[!
M44B'G"57]D0L$0913XT1-U<6?5^BIQI;U&7S1Y9AI;_)J/)G2E%PG[U.%APK
MA*?2:VUJT4%8&ENS0M0 4--9>I]8Z4)"H*7/V XF&)[RU./2G\20-(]TR^K-
M4P/YF-,U[.;$S@O&>QEZV0>684^PM9(,Z1%2['AT0B2&1^]$:8/5W<[[HF;0
MVZ#J5D"#N'&F[Z@HX!+2H6RTHQ&>;*(?;;S%P'*:XI82&4IE9'STV/JOS3C\
M/ANXB$T2Z/RREV<OPPB]28YFC9+G4G/9,04?)&2U5"P2<45&L>T%UH#@[L+O
MXJ%\Y/ZGI)3V_3C*CK^L$G:3SQ,B;+N#"'%(;!%\S<H%[AIZ-R9E"4V+A/-4
MA,0D8T6G4G"HD8^!@B2D]@1Q/?\WK?JII<64YJ/EGP([ZJ.-KVE/2U*C"L,N
MF[_NCW*:\3)'$WHV..SM(5[?X*VWJ.V^ ? T\-CP\6WRP4NY>U3,'AR_]\8L
MO"+SWOGX-6FR[RNO=YT4ZGT3E>'$33/L.K4DPH)A>GGZFT?M_-U0QKBG];=&
MNE@7/@M7@=YQ&G4Z@I=AWN&-8:-MVT+_2/O=MVB'44&J%$.&R1OL:#R\A *I
M37PBQSZ'8H7)A4*Z+HE]-&%&L>EX-<4BE&4#3.;@"R$F+/%B;K^GHVAR_G2?
M27/_!76" #,X7^)11J ZH,>5WHA!Y6!6D]>!T;,/0/_.0#@4!'+&!9UL8]RB
M0AVL;RB!J%Y#UQ:,W,T:"1;24[''HYS=7$ KU(X^^TI+3.Z/GZ>DFEGB]LKZ
MTFO>D@FA6NO\'3B,O+M #4( W]JIFF2K!LV8 UG" )-1SX C\K[+<1[>32YX
M.?XL*2A-=7 AMGQ4TI"\5;,M>>L#I(KD]DI%:TH7E:EV%]L%-T"MA2(Z"O9F
M\RWQ=+TI1WIJLZ[("1*W>MP<6L"JS!08O1X.KD^]P.<3KC.W[6 >%P<%UZ?]
M_I?*CQP)!"6-SX]B)3)YO%(P8V_G*FC@;Q/C\QTC"FM9" B_$^7DB>7P-P-C
MF:_',X+.UJ%V#01^PQC4YP@%Z_'6L03-4==</E,8M]%7U_<UWH,RK]!P68;M
MJE:H1RNEB:>6HIBN-K/0H,RT0JFCXIW?J>(B\FK(4TA-T>.].\3KF?P[AY?)
MKJA\8M)O'=1I()^K% 5<X']LIN'P96'#>MS:W@@[;3?K]_/F.5V(D?)Q6K<X
M2)C)!J-;L_G[AA2:4"UZ._E "]T7-'^H, "/G9T:WO/<S3B^8NKT=*HDP\+S
M\2]YF+7'R6R/W<8>%GMR83^I_[]ZBS<NV$3%:26QZ_1E^D4B1 9J[XPM*:2M
MX#?(?KPWQ0MZ<=R 8,KQ*[TKTP:F%T\,(=VMKKR[],3Y0YK=Z-@9DUPCVX C
MO,73>DL7'8:Y;#9<BWVU.@&M@=I-]H)ZQN&K_4FQ(FQ7>9Y';RK+(MT7W/6K
MP.)U;39._#4.<8Y+9'B:I7[+Q7D?&8ADO,YV??@UF+Q7=I;6:JP!%2H):$Q>
MU+P6U&]OM,A ZHMH(XB3 PL"31+M5,/@KPRO'ME!("JA%W\CL^"*;K=19_%@
MK,VUZAW)<Q]";<2BQS!G)X4&6NI+WM(D3T=Z IA6^B:R$6@J"NF6A[0:&P,A
M2<UK1<Z670:,W'#Z!&TCB?43F]W+&79,+\F/VABOEU+L87HLRAGK6T?S]!?4
M\<VP#M0V3\4::&+<;7:/<L6_@0V2[4LMW;/8<K() \J_A(N9= F.=4A!P@EE
M_#=[W:V5,1*L1+I*)'KME"^E!WW7#A*E'0]YG+/0/5XJTS65&,@+9%%X$"'$
MMEJKN8%=>='6<ZG5,X$[P>J,$&#A_8OSX4AG_ 16!TK@N#0W;! -G!D0[Q@4
M'\M\&?AT4Y%8C#_6U^S^+"P0#NH]*,$O;:P+OEXR8V#.O(1[,650E1^M>S3Z
MTG-<0Q\F)"XX2J/96Z_A]+LU??O=S*Y5'(;]5\T1U'^;S1-A[WPD$VH@I71N
M'!5.?'^ S[E54CIAI(5A]^OXF[,(ICX?2UL,N'11Z,.#!#I'YU/^#8_OO+>\
MKMCL3 =9P\I.*H['[JS.0#<LBE_FVDL> !,3R[ N=SO!G1^"KFMSS#A]-]#B
MWD)+X'2LT0NM3Q4+['6X^;AMV=OL7\E<_JC-RW"<A=>8*;\(I>3HWY^!:-DN
M@M06(F$?!T:4=D]HI5Z'_OCP(U6)"NV[X!GZ' \=<E_Q0QR^U.KDV=DK9K'H
M8\U.PEXMZ.B1?C)"Z*EU'!A.9AAJQ"&. HKX4C^<@0VM9*3+A#GPJ\>VW3#6
MTM I-"LH@<?;6I@*.W=HM\H/C'*\LTIN7M.A'$0""7L6$K&U%8;?"_;4UN!3
MJ:'P9.RF2,0Z4I$R0,Z9>_A7&_OQ PZ77AS#F?#&GF&-OC\@)7=[,M-XG+/]
M.WX48_Y!CQ<LPPQ8^V2!RB\,I8PZAG2B#<*PFW\1D_P0W8(4K";%$H^(13V?
M0*S'L=6KB>?#$0M[=@TN^!-0'O]6V<W(3\7F'W&R]C,R$4UC9_\ZSIH#Z3(=
M?87Z\$2O_AAI-$">%^E$N*SX@9>[#G!0""6]]6X,'#O)OW0?\FX/1/21#UY)
MWX?+-;(\.3#^*OI2C-'[D'?5]9'H1/CZ9@10BTD(W ;H)\L<@ *LYK1"A[J:
M1,5XZA]&P8?%U=91[[15_R9<\1Z:&$04#U9G7RKC\P,#L)\#WL0A<S:L^J]2
M.55V2LB[+E.N6DVYJ%M10=,>_E< ',:DT3=0-BMZT$8*/?)Q*&6\>C4D:$<S
M>E,7K/%'P9347Y@-@:-32_1XUG;([^VL_TP.5Y=Q%L_2!%5S_=^N=BHWC__W
M<;W6&#$!K4+9HOB W1A)O"-01>[13V#!292X4S/N@,ROOJ7*NK*KKNSS-.^?
MGN=0SCEN5%YITZ#-G$U U<(VR3;DJ^976:;8Q\B5YC+M\D2%B>S<:VA()!@9
MY7@+M*N9GY"8LFF)\4Y0D,)H.=NQET\-9=65DXYR"BS[R=M>3.LO?JV.RLL_
MREFTQ3?<\+Q>D???U:S/*N!*';<  -Z.!;RQR8$'Y;4RRTLO*.^I#/UV$MF)
M*"+JA#E^R!<ZZW87;.Y_]K&(X.'5Q[2V_7F"=KRY'JB6_-4EC!RU1&SSGV[X
MXF=>Z%PZ1MDM3T:/IRO4@5:P-)T,ESI#U';BFL5-I,2ST$C5*"ZZ9O2ENVM^
MI$#G9MA9]?7MV;R8UZ^RA1,-:18%QS+8IUA[R3J0)ZA,G6BV%FH_28U#UR8;
MQ5EYVX:R3&OT]Q!B89=4BXKYQSY..QXH7_W&Y/"+*?ULQWO:[^S.!)A%G*@&
M%I.IXYDK!Q37XP7 _2DE<)W*H))RW*,((2*BH0P#AB<1F(0WRE2_$]'!MQ^*
MM!SUSE7Y$YC.C8/&KE\/KZC7-'KV!_P)?*,=? V$%2[&-SL W'>8 99Q*$H;
MF'PT[F^TZVO.22:0E/P 1Q#^>\V\P+VTH,_NKGB-[F=/^PY0G!M3G,5WE5DN
MPQ*5"N5+CN(-57+C ':)%NC]:Q4>3P@B$(.#B6OS\__9Q./Y^7&,6IB5S&;\
M9CT)<.SYYDV'=<Q.<W2LKG>]6.E+!\S3X'46K;T\_$D@FP:^:[W 0@Z0-45Y
M& .2'^^;'VB39L?6\77M.TR=A$)\^ZZVW.T0;UZZ6;2+GQ-MN'5NMO24$A38
MBHT:R[!'6OWH61;9>1DV&-'-E#J/8__301JN-%M.8?_J"PFD@O.2FY"]%$/2
MIAB0HP!/-HV\*7?NL>A<GXT]33OTLC/1S;_LU\RO022B_'ON"Z1VX%@[4 G4
MOTH0A887YEKLCDM^^V$44\<8F!5M\OTT>C@$MSH[.)G',TM>EY7_^).;CLGJ
MV?>'WNT[:*;RWT\EG!P@!5*W4]XOPQKF$RJ+CX<C+TD/RRX#+<W]3JX/,"(M
M&.[62:^F,JO4[3EAL],:N]?</M[IOM(X7EZDT"=I26Z"U;-O0.^N0#WH$A@[
M/MQ)-W(K)[EU.RIHPHPC/]T'YPC?7K%J%,,%;?;J#.JF42C1A2LF!#>_ZO?,
MN+=8N;;J>>ES^5/(2.H@VR+/8_3J*_7$6J06<3S.H9NR=[ Y5M2$CPOIR/TX
MU.Q;[K+&8>GYHX[<KCK[^]F&H28TS, 71K\X*,.+^W:M&5P-FE$.C2M/1>,0
M!CV@OFBQ-4XC$.R<S7X8QC?K6UB&;2-9GAG.^,>#J YJD$P[*,;I%^FS?9RP
M1=X_WHZIS 3^&%'/DG0>AC9FF5/ZL>O9.#ADO3B+HP+1 <;[@6J.IVDG6G-!
M:_M46([Q1E _K:+9'MS?X??>6(LK?.B!W33%LV^XRVCRJ/3KR<CJ^4(SI^^:
M_%OBER'&C X(HUNIZM2V ,HVTC?).Z R^;ETG^(C5ET(B-FIS>YE,X[1=WYA
MC$EG3SPZDL&T]G =9+SK^<W9Y,=H.YMWUC!IX%I%<S#QA>!!:.X=";W)SVTV
M6(J 8COH:V7^POE$UC9 \EJ*G%I2/ 9N$E830H[5 (3J-.LO]:"&VU/<K>*2
MU$K^](S=S\ PBMD ,^.$QVAZOIOXLD(4^]@9,:'6AK@C@,OT8X&?$PZWR0=!
M_;;A_LX(\W21D_:-[.&7JIO"' .^>&XL*@I[:?70S*#J04Q06=OV.I<M_6YV
M+\;A?[/^OV%/"T?2)7^NV*9H%=24T*K(B %&3%55L[50D(RM78;=9K0=* JI
M"/-VW* 7J'D@.\-LD9>3+-M7V*W:],+=JN= ,1Y'*+8'AA9&5>FF'#3@1H0L
MU)+LYZ'CD<NPD5)7=K/'L\;Z.M A0V$!-1RIY]5_40KP]H,BHL%TXQ9Q><^J
M5Z0H3Y0L_-6KA@O^JIG]Z'*4*>4MO&Z^LQHN,X/R05UA)RVU&0N84!DR\U>O
MN60,KA"R_1I^#6'ZNA8(SZL<(1U8$O%G3O1_8]*]/]IO(\!/#F34=5@1CAV"
MO\_A]"92MZ'',^";T5>U>#,B[\<B](JE4TNQ01DKAAJC"M+#PBGZ>);#T'!G
M__=L4TS#OET?4B^5?O<;JK@5NF_&<3$>21!*<961^?XN48I"%$+1)U!5K)7I
ML^5/6";0VV$,Y!%4"D6?PVZ9TLM1[$KTJ@4)<WFE4%B<P3!'PLN8JS2NBRB?
MZOK@O]4\9788'I[K4W$Y=Q+U:$*KC9U,A;.,2#2A0Y>6N@\D$"ZF[V F!@!B
M>5=AL-''FI;ZP8J0AL'(]!XG[P%$!5%L76W%-+(\73MH-7<ITQ__]S]7V19H
M)46.L#L53E"(=)^21.Q7SE$FLZR!;VW5>M C3Q:4 =K$.7096P(.;4H&P&Y$
MZ/LP^L)ET2+<0A2]TZ"@S$_*N65<+/(>JF(+C6H^WO>?:OS:#, H+;*#4)(0
MD8Y:#41W"%:%K93$!^=3[.A;('_O SF-L6$&QJ]#MBCR(R4&62TEA<%F]0,[
M'_9+N/QIOF<?9L.-HMUBRW2(""S#..CU*#C)5)B2,"O  #2.0!VBMA48U&6?
MO>[,2A56V@P?'_":%&;Y3<[,9C^P'QHH>S@Y_@9)1V8$%,,HJLKGZJ3_N"+0
M8,].->LNPU[D3,11YKYC?ZCTL6>WE%*GS.R_H!GZLT. FZ04",Q3)I0@WIJU
M W(Z#KKF37@ZN39RR>Z%UM6IC'2CLYXO!_L7VWD?4I[O2\=P%_!["&;-L8;E
M^"EA$S-_ZRHQZ+)=VV7-;M.TK?V[BP*WF&8<,=G]Z_PJMY=/M-K@*8(?+T.Z
M$5+[?--EV)GJQ*&5RT84)>>M- &J[0644M1=YH$MTT/7>;<9.4Q,,J683Y .
M3S!1?9=LH1:_0#>NJA.Y%DC;)6]*.C?F+FW.?0<%6O@P,FSU!G=\% U^27Z[
M[ED+:?!Y$S@AB86<I9XD=<56V77@"LH)L,O]D"-2_5C*11XM1$A8]WZP\DCV
M6AK32^8ODC_WVC+VD.L7M3W,'$[WZ-9NTE+*8<A:P(D5XR47Y%F4?1["O&I]
MDNDXK4-+#2L[U5?Y+"L(I0Y2,IY.#>\/?!8QNJ6N98C18LEQG;)(P^/IVKP[
M#[=.YI):!$*EP/97(KT/1!\WU$IE;0 <6GL\VJ)YA)+GYM4.G?0M4QSWA-E:
M,^.=]8.HG?X!I%N*;?W^'I5HG[0/<[P?VRI+4H,S_J*TCY$B#@TBT0YW%JP-
M/8>0^Z*>U2?&/ FK_S,LUU.2)F%?RO%@OQS4F>0KNF*1HQ?] ]V0WIOJW!S_
MK6A5_!G&!ESG(?.Y&I&*R(D^4GVRX75,R:N\4_VL'63O/C+:NJ..<WU[(F?)
M+;."D1Y*R-UCFH*I83 '##0>/WE=\RK#.ONSRG?!)VDKO=;[MF)K6#VU)I\=
MKR^\4#I!N+%XE@7%B)S8>M\-<C*L*AD]&G[YY,,QY7A"G)U>H^OCD+P 5_^U
M:?R#UJ[F,;LD@O]7?0%B^WP27).E#EFZ0Q% 7EL@'%!+L-MW< !Y4-BT;M8.
MVM7T> YA\T7]<=7\?+C1'(*I\28<41UR,W=:Y*L>)K:W=GSG,\#4M/!J\&AQ
M.E?;.% MOF+S/"(X=DWV\(6YH"M_/CIL]:#&S7M5ZH6S"3"T-GI<@/EOKQRK
M>/>M0SD"Y%KL7UC@3*\J?J6-"345RZQNIV_$>7=+E/R><)NT?K23LI%1?\_\
MP?@R+)6_!9Q+%;5XGZS#CK7ID"A3"Y7.=M+?BWS(EA.]ZZQJ+]8G'%)4L58I
M/K!5J5>U5J,YZ/C ]8FM@>L>!0PA/<U356M$UI&HUQ7I5P:)@C/@J9JJL \#
MW<&X]8>&)WE<C5"">&?"5N[>WDRE'(UNG><1V[G&&Z!Y8.(P1!/V6%Z@!?17
M,!]1":@<I<;@L@D#49XF/T\-59@I.8HPY]6_M+5JG/K;],&B\Z=7_?<.H$TL
M-,PJ\6M- !0!OOZ6;(UI8]?II2[#UCW%U#R<Z7:<]1 *5'C(\.I)CD/: L%4
M'%;SK]>;\*M7]G5 $$:A+E=^EB-_9D\?R6FEZB&=I=$R@CR?B'+T8W<&$%M9
M:_MM@NM>*0$RV5<M!>GR?#JQJ]%NB54J@JL?+L2?O?C9IPNH>E+_XN==S_>"
M)CY*3F.':*4*UB#W21V@ 6%Q22G@T5;*H0(9T/IW'2@$($_^AZ63[!&W>G\9
M%-%AX-H4J_E7Q/$KB:>';(3LQZR^LN*Q5E^WC[=L,HI)$:[]9.="'_^I6^:)
M)3ZA/-3CJPF6GDXG^L67:P9FK2]OTQX=X1W6;%ZGKKXYK*5,Y;]C\L9E6/ R
M+),-8&BIU#HM\8P(P<.*O,6>U'%$FF([0+V[@#;"7>T.["-;T7E+"PW)A 55
MT(:-;%1+B^P&YU)N6L0Z^1OVA*WK=\V[H(']6-4BC5:\8>E #X3H)(HM-"1$
MK(6*NMF:9&LPI,W;&-'XB$/1 QT29$%1Y;SOWKDA]Q9"Q61KB;2AK_2AM?G\
M!>:@S>57#/Q6FY%O'M0@:!A "T/$^L!$ .0.TML/L!R@.)';0/#0+XT\>9#[
M?LRSL .-]7D1A'(H]DR_?8_M=+_B S]TCM%SZL/XTS?A/YP9/SF(-)F+/)X:
M-)^.W=B\"J@6(5K9&E!IFT #N:\80@BG!5C20_AF$J8]U_[9!;_HE%_TNWJ.
M7ZMIHH&=#0G:NQ@%%EDVQ<E.Z6R44$\92=Y*K?L>*I+N(A^59U<T6U\2]28O
MP[278:'I[&VD@Q2-3Y"A[T<9=B)_;\#,!8P(=T49$C<"/,[6 *PZX<W!:]E<
MB0?!R6]XSDZ/D?GS3!WS!P,]7L(R!JOOL,?3!!N5L[5S#BM2QM NJ4THQ4X:
M/A$'3_W51-3TQ5]8_# W;[]07[A!LMBP<70N_&FV,,O *WW) G!2J#^2:E(^
ML"QK0$&[X#;*:$"&*SXY[.B6VNQ126KJYA6D1TT^WMGR<1DF= 35[E;:6;OV
MW>3@7X1*ZAW_VJ?:.?(0GVJ^1%/J"GHR'-ZL4BZS@3CC<H?N0)7AJP/A]ABM
ML(=8_[;KUXNF#_"J\JX;\1]'!Y7Q,#@J;LT;^_ROS?=> ,=[B7;@\54_W%JU
M>(L2+P ^VR1%(^ZQ<=C;"@.Z.[03R#LY>(U)30]<PQBLM'="PT)/CTW=P-W
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M_MOL%O$,IV=P)Z?>,3+:X;[+<U+I2IL .[G;^03^])SE-ID*]8]A<W^WLTF
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M[-W8,P-SLV1KD9QPY=*W$5PT7R?[Q]93S\/*'<14D9&:,$6FCY:LW#P>"\(
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M:L^PO9&/8KXK%\0[_9>1ZML]-N;^78HW XS_/-_O)@O,/<K"84: OR1&GD)
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M']"3&'!SA-H58\WUW,936:*_[6.EKV8O-V^990,^@E%=22Q3?H]E1MX&*$.
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MRF!'4XM.$NTQ\VJN?FW-C,VFFP8,H3[M]^Q)W4&+.*?P@Q=48EW5G+]\ZD"
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ML!6B4[[FZ59N>='TI#6I(^#=1,H",N)\]N1HH51.%M:.T(:=PM,\<CMEM$S
M:.]+1:A(-+D87=!9]$#H4%(=0OSE>VF8]+%X]&G FDE1\O9/C[^RTGXU+3RF
MC;YMT#5VOW/TA;?[U*W:/J[":&7MB]<A-1GL-4GV"/OF<WB^RJ=%@=*'='4F
M;XRDCK][DA6UJ#!58 >4WM^>J!OFDYU1$9J3>^::TP=:(JF^U%JI=-0;_YIS
MEF'0;ZDPC_Y-\D\]TL>90=U&K*6K$TB _R*S[_;D&N!3!T8>XZKY=RXJ9<[I
MM6_ B\T'RJ=C[EC89&8\?O'TR!]A34X?,HO77NG5\'39.E!YG7@>+!;)I-Y-
M%&C"E.LJ0 *DN659G"FTJ(\?X"N["RXVAY=,=D>T&>M$#Q)<1BN.&9DJ^H9^
M_,CW3<Z<W%$0JV;UK0Y2<@3$K@!\3B!6EYP'T;QG-4158H],\4E4S2F/IM1:
MV [W 6@5=@S@ A=ZC/^^>W3E3!W>]0 @K2F.MOALR6H^3]OCAOQRA#@']$E4
MQR"%-IY;'*2FAQ:%]E,7U:;-JZLD;@)2*H1\6]U8_=QJ%09DXO.ZFFH2X\*^
M[(_0USOMSM"M,4<.9[<5UY._.OL"R;<DKCRL+#+!9*;-^N<RZG D7NX44%#Y
MR L#7EF%.6:-^SB08XK&V\SS'?X,OTX3;\R>O_3SV=N'-??#$):^T"2Z=HZC
M< FR<A,?(NQZ BA_S%C_U)S:$ECD7/WB8KUK79$[+P1G(MPB//,SU&N=^'#0
M9(0^7AVL=^ONO(?D^TN![\%/3(8&FIN+V4@T!@]^C.M3(!P"\X# ;@?MEJ;Z
M9X,+$1);/F<-GHGI-X\P,Q^PK=SY:3!:*?1B_?-,V_10O<('6H>"$,%3#. (
M C0Q3^"_) 0%B??BK\8?96.Q>?'67L+@#IP*_I1M7J@1R<I]_2S]ER$",D[O
M14@6O_O$0,37$5>\R/OPYTG[$19#5\8^J#=D:3N&F8>^1=E"1$Q#*#"Z+"S7
MO*X,'V#O[ _TYB<5\J;,D5&AE\J S,J''+;CN=#HRZ%Z]UO'K[J'[F7WXHR?
M?YZ2&R HK<(,G!-(<V>!92C7;%:X%]J 7H49,42RC%W7+*1!Q9-;J1.NIK;A
M#F\&W>M2#@0'AJ_+?Z3HG:V+#<G:;.!Q-?C<UB,I2G6[Y<PZWE.V_%,.Y*G
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M@*E!KYF=1:,SJCV\"SFN>:Y"^11+,CS,AY$:'3>2^6:[F#T";1@56Q&LP0:
M)G">:^4C4BAUN-L.>C+N"OT\--=BR^=H@(/, &N@(*?R'09/>;$R498N<8WF
M;PBWPY1Z]Q;[^S'YH5'EVQC/XAV9/A^>I;VR)8.& 25%,QC C3-:'U)PRJEL
M>A6F$C5Q>,+(.8OCTPA2!:7#Q+>524F^8\\Q9XZ\5_S(AB;/->T[R?GZ^;K=
M:<'(O#;@*0H$D-T=I$R*2I1[,J21%EW7V#34.\PJK@HS+QD\"BS<*!GC8.D&
MPSK&L6RFTR"UYEQ]6MQ8"O]IX[-GZ5ST3[+\_KTH.:5@GY!(X<%![P(C(&Y6
MY_:U"#(?HX_7]0<^W;)<GWOXIM*TY3>#YPE. X^:7<PXIX5FUY E?_4?6[F5
MG=UO_^*;H^!P:C$T1 +\2,F8]42DCTF:@Q;TAK.6TP5M!;0:-")!S&EA0&&1
M#SX[_NB78\]O^L:?C;#4PS$C9U1>060"76E@#G=(Y)%CY8DHPP GJ#?0FXC6
MQ&ZTGL12@-XT14MN9RC:718@UL[D6'FX1G,7-4'K=G;V<]Y\H!,]2WW['T_\
MIY_XA"$"LT9Q%B[4K\U)8KWQE_L=G@J=,^R^=YU9BT_G;Z\C,H!4/*:]B9%A
MZ7^J3?>4.^ALX68@\*,SGF:^/+9R<Q5VT:?G\J7LFQY-NEJPCX?Z/G9GD+A/
M.4^H-XBZ$A1XOQS\TK&23^GL0?IZ -3$*+0\)P#/XCB^;?&MQB/.CM@Y%8V[
M!\LG?WUGY\2;OSC0VZ!WT+8ZPMYFYA-3U%2E<FR:CW["Z,"H$60"Z:8)-@;:
MU=(RU."N!/5QZLG7D4NZXP\BHA#K0^GV_2W(M1'[OR"_XC8R'X%$^2VV%M>?
M[CWZ=#=/-F4)G#I$FQ0M<DP0E!;R] P[.*J0&9C<I7.XM@:?XU;+,AJP,^6A
MU,)LUE-X[O"2.77GTI#E&"UKFX4GV3-W9W7R/RL?]:T,-W%.ZI!;LNZF-,:\
MP"7+B; D=3#A;&."Z,FPA;TI=W[(9GVQ<6.Q2<JE>B6IS6) ]A&>OFZM%632
MK]S!?I@Z[S:VI<AK'F>4\!ZG]3V:&-P"(EPH[;M>0S>;M1GP\G</K,!SVB?E
MA:@4B7QP;/@NIL6)69OPOT::WJ_I^;,!O7':9I(<N34<65-H$:[N\EE>HNWZ
M@@W/L//\_M "#"UWLLKGD;0D4<,2!=+ZI+>A=:-X$F:(J $2%_1^SE8(KPJB
M#4:\S^Q(]][6>"%=JB=P-X-Z9RA/RU[8.W+7%XOW^!+V  7W@2O+3&WBYH1V
M#Q_+!W6#61_;77<TC!U^ENF;P*_<YQ]]Q.ZDQ>?93]X9EJ&6VD/6?G_ +P#)
MZ1*D8!6F-.5@!3BG6% T\<Z=.D&E#;Q%U2G/MV$VAVM+.(>V-[0^:6V,2<('
M'9ZI?K[5XLJN(YGIWT:$/9#BLEB)L$Y84 E\Z4"H+Z&VX'OVMV 1JJ&(C2VH
MQ^ ;SH%GUQFBVSY)C+#LR<U9GYR\RL*O,-U9U ;D+M>X/->>'=2'V<-H0_1O
M.+82WYJ)^OX.RX.*J156Q?KG@&>7C"8A@$]^M>,7@%Y:YE<*#)57^+=&R]XI
M^@XA-85P5O.5/\M3YZ\8Y["'8RL,V7!> [< BSSGN=T IF-2^ZW%2X*O$-L^
M*^ @0.H<:V"6;C#4T'IPA?^F[\10A^JX2UF(S>7Z 8N)O3&CEUBLT,:>^)CX
MV*MKEMSG.L47B6\PC?#D!I0*81V8?H[?];;TB"SDQYI=Y^4[)_5#O:KKV;2D
MZ+PX>P\]AV6LDO+Y#>86<:.&!9,LR+?2]=FV=#YU/E^,)JB#?5S.#80ZX9Q)
MHAU60%Z#9_ #<F+*IVDG\<>9;9!\?XL;%4PX,T(XT1;5N\UW.F"34&_H\OBK
M)O>YQ1WW<A>Z;"DO&:D.&F^_OT@&FI/G..4$P\%J@DD1-(10M'/""0/;Z7J-
M#;6#EKU'/X[Q-WKZ5+'][YU@AFNRZGCP=6 I%,(_W#QB8>]ZIL![>PL=U4UJ
M.P9MQ#N*;LG6:"/4CI"7$&EU>-,NQ,8).[>@<Y'&][LJ'X40#<%\OF^K\@+W
MPO/&NI'3AZ&NH>#Z;-V77\6SI77/:$VJ;IOE9S[-R1C .GWIGZ1+''WP$X_S
M8B*R\UHCC>NV#4SZ_,D?R"SFS:.\ 6#H4GTV*\HV_:/8U;>FL'ST1;AENCWB
MK '.TN+CS7T7W#7!.[(+%4MO.NCC\TX#U=0.=W6)"_UM20%:)0RA1%"NP5<R
MFW:QWSSQ]W?ENZ@?ZX]VLYEXX+V$WC0YZQ.W_FS:1Q?W'$P)41?0OBY17?<H
M0!7 W9*8X$I#54(\7'F+\&F=K5=M-/],&0N5K>515G8[YVBC%O!GU8GJJH!C
MEVHK,HY(BOK_4<ZYK&V6HT)0EV8R@A&W&7K(%LW8V,#J:5(M96X5!D^Q4RK#
M7EV\K/F",3Q70[#'/986X4V0?'^#O@X/F]Q45+BEWN'M>W^1GS*9&Q&?E2A*
M:^R44!VH&_J_-@B3DH,(%M41PW.+]1DD9FYMRG$+CDJ(375K34F9NY')FX8'
MO#B]@RJ#TR,QOYL>05-0Z6C &Y[\2C8VVT&4@*I$\ 6?!XNWX0UYM-26G4)2
MFTK(-1:E#$M1#6P ^X)"']-N+%RX&>]=/-2 2<IBEH]WXB(O-?ED)VD-?LQH
M]804-/EQ;I&0HH+LBLK-P#(3K4.  YST2S(P4"#"\8O,>1Y"'>_L\5RX[L,8
M>Y:HJ1O8'W%JMD-G8B+C=L@=GVEV_>6Q1[_O>?AUD0V'/#9*DTAS+(+_*JQ\
M9#YY/P)#." M8YS'C,F+Y,$V(:[[,UCG+[U?G".6XVM$AC@8OR4<SR4G2=QX
MV'E+BUFD^9$ECV::$#F2N!@E[E'*>:JNH3UHI+5RZV2\O]@<U>9F* H![=$O
M0H+ZZ>N<@4].PQ!"^;S_4=UTC/SDJ)[/Y!=/2L?>GHKN: ,_M_@*MXHW0=[O
M"US\3VPD=,MN$?^]>B<TA!;M F60Z^%\<_9+I*@<+.&3DA#  ?CU)Z#GB=:!
M&LA(8@ZJ XPSC"?C=65)+4X/Z<5\5^T'!SY?6II .#8#HH<N)R\'5OIYRV+G
M*.QZ?+=0"5+"R%!'#)+XE1P%<IK.*BPS> !7]H35T)=<L&&DQ97GCYQ_[V74
MI&_X^5+]/,X-6Y8VH.S>/C#+LM[;JT K\/)SQ<028-)'#HK$H8"?&L&[P-[N
M)N=,"<JLZ\UG5U2]]PQ;J[1<W\VP(W=]B;(,F:6G+$QWC<XT6O5%A@$<;]T\
MI71LQ3/W=P(N@HFZ@:[3;B<G0>N KO3 XCY@N7UY<GN!K>X^$V%.BB4%/NJ/
M3^AP,'JNU;\*"\=@/7.L]_0BQR_NF+^0UL[2#;>99 \@7F%&#9FYGG/#LJ&K
MDE:A@U=AB:+:*<0&!V."[@!D^(H;KK_CM[=1< WG8"Y"C3T^]L[GT=65LP4/
M8OC4K=XA+)7N=0V9#_AQV,WG/Y^O8Z]9*10@Q@9%OX$QPCA^61L&(3GHOAY/
MXW8S=='I!6BZ<%,.*9"7;]VN/>*PN;Y!K$5[_TJKKL9O'.QA>H@"] <*FX<;
M;*L]=/5VL5:@??/G 5("&O!R?^<HR.EHM>:YWZ+OF,EU3FTY\)A9A#\NZ**K
MCMB9/,37G7EN:U85E8\]1?/UM6T]?"7[6A EA?&$:FE_$!MOTS[)7YEA3V+>
M]*D2%$&,<!E26A1^/S6@U;([5(!2!FVY90F0P3L\[NQ/\?*GA(CD%FV W7-X
M%78KP2TZQ+)ZUQNWB[[+_0M,+TR SVAIL?+$S?%1/S%"LG4-L-@N$#F#\<+3
M[@-5]60$ 0EV<GO@&_!EKHUI3-_^K_:!KD(-SVM:E')VE:?5-9PH(S.YDAF^
M-E6O 4H/LG^6.IP.(XKZO1PTZ<^&[7;S6H_.)34-1>GIKWRXIU)].:9L;/S8
M&;4..:/;^\TZ-CTJP%[[IV[__,O9#RWZ?Z!%XSHG-=_:Q?#<U4'#SFM1-MV)
MDB#>/+:=;C0081U/.?/6SK%T?%JG*]^AG?I^<GHDQVI@/B@\JW%@DW*4Q0GY
M+\[ W1<DX 0&-+)._][\G5?V(CQ2Q)9FV?G6S!#W BWZ:[-%<'T0=[K U-[^
MP[/&_GJ4.E;'HVG%/S-/J[G(B>>/8Q(-<U^/G  FJXLQO36^5!9=05K+X#XB
MU7_J0"5#6\ @\28P0>0)7@X7(. !$A_P@?C0JXH#C\EKIU=:,SZE6I W@-@.
MHC80/A9VK>NN'HL<%!U4"#YU+O@6Y&+W:_; ;#:F_NL)>9E&F%\66T$#C$TD
M+/46"3A)'H6WF0HQG?H;@![04(!H Z/7TUAV&%Y0YBK,-7/1L5;QXO"D>/\(
MRJ+GI<67F(JIW-)DGAO)#1 ]JPUK'^ESV$<<0=/0\Q5 70>ESOT%^9V\@-*F
M3.)WY41S42D,#0<[GS#]30#NA@15<P!)OHVL[W7V !9NYQ;2W]9LK[M[ABS+
MXHD3KZ<@S:$E;,;NNRMR1=<=U@.4N49&'56B3ND@/5V\X;'<R>Y+9@3CTB:W
M)L[]EAW'T9:EJ"X''>'%VIK>$K:F^'!O7%?!ST/H6HN/7[8W/'WV9-#QY6\>
M#EA9KHD$(X5R/,\Y58#61E%O4>=3D^FH6B&\H[EY40D_>&!(LI=OJAONWLV6
MBBC(A?2J,>\9*VQLD)VU!_\C>WOVI->'$R>'R3-Z&FLD"S(]$WN)X/\87P<I
M3)<2T,/A%BC],+1>BV,@-S]">K8JBJ3M/X-1"I=8/YZL])[9Q<HEUAG?GWC=
M2"&4;O;3M2W\$T$5<B0:2I"B%0.^M'AC-ZG-QN$7-C24DVN_F,#@A8"G1LX.
MT=>S9W+N6&41C<#(#@^VTYL49& LHSYJ3)>Q)1]QC&ZU6 ZF8>-BJRZL%$.*
MNV40ZB<M)QH2.PIV@><GM:!>4$DX.=8=X(!1Q>X-M=X-AC=0Y<*R_$-5N\LF
M:XKM5$"/%9,Z-4=;]\@+!MX&V-1PQJDIN<^1HF,R>HOS)9C)_EW!4T6V8$Z%
M;UD:9#$U:<URV!'&WCA/"BK$<[I6PK/S2WN*7\^J8:QOUD\HM7M03:QL:BH*
M_?TZ?-J7M.@H:0XI!#56#"F, 1_[1&= @7@C(0P4%TIL6H>C9!ER%::)#A8K
M>W;;F%<7AJTD3E:73(W0/'2TBI6\G<LYXTXEDYR^(NRUXV1D00:)9]$TJ.$F
MW=*_'Y&\"GM*F9.*7:$!3.-7"G 2PQ[D,24;!R7*W)Y5&$RF0M:BED['\R>4
MCK76C5BD+E&U#R$?[CZ<2TJW"]I-/M,P$!WNW&&S/,;KC\K0=9)E]GI+4A@F
M@:/9(E/@ZTC26PZF^#A>=T8T(RE@$WB9'X[N9*A84)5G1B XT+I\5WBBA))"
M<,)BS>\7C?=):25*7I:ZE:$H'9%F@W<>'L-NVB&7":;R*CE;)&AA7\+7^9-?
MW1P[B9N$UDE5EN5M>T*UFQ;2XTO8,W<2UZ6_<X_68U]70*K U#%ORN9V"F-$
MU'\<H=LEU)[+%Y!!D^1Y>:%C5U,PV>XL'[T!/\C;?HM-9I(W=U9G6/W*\0<3
MPDO#;(SOJ;A>&+-<RH4^RC1L?[W4]<!@Q/R6"'3)ZQUR0!RDP  HHL< 9_Z;
M&"OQD)82-7JY]AA^SDVB'G:V$A_GQJIQT.ZIP-9.^[!!VW:B!?WZ=,".88EF
MZ2MXLIT/^W!)!3.<CS0Y;1II_U=CC.<>V5HX3-P*O44HKL)P\%%3$03N!?9V
M,>KU$P%&6VXW4P9\IKRN_)@:?!.+>0*'>*>48N%OWN?)"B:?Z'?8A<]RU3O<
MX]@\^%7J?"@3>>6+6QK4'B,=+[J.UF>$(70)(=*G)&X.I3[Q*^+I8A<J$:-"
M<-*C9_!0"?H[^BWM'?DY*5$4.#CR8H4B>A^@EG!H<*DY%B=(]K)B[QB,0%V@
M#>A_GG0MCYB?Z5R>"^1CV(Z0@CI0)SHGU,O@7"?N')6QF,#+A=XR]U9AAYX!
MC [.NNDF8G%I:,#.IUEOPAU=&YN::,^ !?K34)HV.RBS+#92^3:-]:2#A EY
M"'^!N+$*HP7/]XA_E>P&:"_@F23@.)IMRR=U,))R-<G7";8"1N+*U>(:T+2;
M1=S<F'RT'Q5-U@@E(H3Z&8&7I1FA$='?*TQ34WX>-DGR]W%#NUNKCXV)*1)U
MF@SOQ?!N$AE-^S0?71P*;9*MG_VAC?3- (V)W'O"=Q'TE#'ZG -9]GO]/A=\
M9-E[S[4@N*U[W1I<9_.=CP]:^#Z/IB5[C5@JVQZ7ILN&5--.%8CC-^1(M.$"
M>)=K7[*^92/H6@GU7O-(+Y&XYC&OU1/7#5F6]#ML'G7(".9G-^B8K;3$V#B4
M;<WUB\D@;:[+]4:RMM5,4"5:@[S@#L9M1*T9I J>YB(V$UR$)\ Z8!5V6D;U
M<"\F]88))VOR;8:C7YHOCKCT5^-0!6\&7)M)#>-5ZW6]WJO[V?U>V00UG]R_
M]5-"=8V9Q)#G:_OL JVI'OB8'!Z)VW4O6Q8I/5ZE26<N:63MU+PS=+MRI_P=
M?[W_Y).*_RGVW]^V_(?]SS3-?\?M*\=GF>@0Q#=UBT7QEDNKL*_#U2=^^O\(
M$CSNWX72?_\B^&'_DP%'\P7HS*<RT8A9^J\ XX:$](_RAF1>:9UV,OWG$**N
M<-/]JAFZXDBPMH/'77Z<KE+%@D7X@<DN:$TX:>N>]&K;D_6[S*/$+W^3\*5/
M5F'<<AO2"_3M7.>Y-@#!S4F7T32V[YGZ!OJ0W1JN^)O%_-YVK=S$6[GW'XXL
MZ2KK=C3=:WHZG32(:1XX/X T,[.SCM&B5H+D(VE'U$BOJ:,,0?=\R3_VGQ+%
MSI)@Z<-5V&^H-!M: CK,/1TGQ'1#NX"+1;G5?<Q[P]%4C;!7%_^8RB6EUO>D
MZRI(/$FXX""^/Z9M_F-#0QUGS-7NQ,LU4J^3 >>$5#XCF;Z.8 B2A>3.JTW5
MJ[!DH@X>[2?,K"Z;NBKTG[5)K$D-1/(&OU;&?FIHO'N"@1\8&)SW]&A,M7BY
M'./!ZC%[!3)-YD=E]#,6O/OHE5!VLQ)U$I.-:O^4L82TZN-34H5"I;/]6K8/
MMC77 _.KL$SZ9GQ:[-(&^JN88*T\;O79[;?^G-,][=KCV@F3SA<Q?F%P_R(!
MI_SE13.#+=$\D@I><9&'ZEI,=+\DFQO-W@^]TK]$UMHY-N=84=Z+51831X>\
MPQJS0IL6$A^SE:0_K<39QIHOK6URO3&#IHW,?P 611M![U*PKU/'?C'#[K+
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MX\* K6S%Z>!'/'TO5^.S%E[OK#GU>I]A_=-!BVH[?__&O,+IW  *<OXKZVG
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M>QG*/KQIY9,I:C [[&FD@9@0#O>(1J'(:W-]QSFJEK0XB?3J+)9K_!PEX][
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MPG'<FI]>!UG/;4;[OF7:^H$EV(KAM+OFCGD56@#5O1K/[YE>8CW^.\@& 8\
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MB^J)'CI7//(H'^+#O:F27;J*^+6,:S](5?5'RI"@#@?7KJM^B\5G;Z@=R1A
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MQ-J^H[AI![Y) 8SQ!:8]1$VF]H$/6LRC5>Y\USCYFKHY8_,C*K+3B_T"O=.
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MM'2/X3X]1#:Q/_Y?Y($/X!-8E^Q)W%X'I0CL">8-;!/[S!BKJ40T,@ ,/])
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M_7ENK\*B'?(0X3<'Z.7NU,2*$&$E?;TK@Y<&RD2ZD5#K_QQE )! S"!PQ-%
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MU]+S]X,],.I*&E-)@4E+8T([5JJ1Y;L:O?;@%!JH[3%J+A-<S8A3#,H^B_)
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M&P_#71L/^F^;YM21Y?)39<.'\BG.&OJE?--Z29!RTH?Y]6+_=WL^[$U$70,
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M $M!%LK/:J?KSD9C+T[D!'3.M)-0EK<."E3$KL*^;L\26Z3>(EH4BB6/C$>
M<*-H4#=59./G%=R?WF5^;-RBXE.9*)\E35/IP;A65YJ+#>B^/AM=HUI2XKO?
MB4&B,A<VF&$!>M!WJ.KC7K2/02HD:O"HA?12NZ#3:'A'R7))MG#8#>Q"=BS:
MU-\1QJ9OU XZC8AM@MT*&YOVDV85&W:!-X9)Q><EZ2>(CQDFI?&<MR?O#UP#
M\E>B$!A=T;E,U&Q3_01>WP_+:A)F(9*]2O:@;"Z=B)_C&D"]K%6,\UAUN-V6
MRI*3)^G!_\E<S8PN\W@0#<'3VZ([.MS>=C#B%)"Y5!46M<BRG:'E1UB6$E8]
MQXX)BHB(_>R1-P$!<8R&)B.SJ>A7<=R(+RR\(570-+W&L3:Y N<60O6['E?)
M2EKMMBD?P2)VH^7>7N:#(NM%55J@\Z47*@U/FW26A@L5/CB%4#DA*+S]IK@O
M?>-/J6IV**BY_/M0P^+".E;AVP:)GYRGS33DF%PB^X9 7-VXT;7-:/J=UTW/
M2>)_H!SXM+VA((%JH$UVLI7@X^[W#M0AB7H64P7Q/_0\$P-KVO2NTBA6?<<V
MNZ+I:A8=XG[8UKQ*@(>Y20YOJ1N[H$U>AE"=6DA+"_<<C:7>>E26G[&97<AW
M=-@-B@,Q* E92/5U@R.5^+&OQ=,+:J:DS$,*Y@>T?4VVW"59I'-'%=Z^%9[T
M^/BC6KZVIGVR:G]/<E>A\MG%@6'P],# LGEY:WH6ZD%CPT?N#"<+3$UO[!X4
M,'-8C 3A>(P[5RBO<H[1#M%M6EB.<VG)%M>H:T"H!%(G-T.M,$*[N1U+MZ#-
MI1FIJ%I\J'4P_?,@AFJ+[X/2O9L,P-CI#!011(1I#*4NH-;R*'!B2)V/0Y/;
M7CXW$NLH+97]P6%WM3[TQ9#U^U<J8ZX+05Q<-RYW7TD.32ZBI?A<KWN0/KJR
MN_ED^7!!WF>:HB$[>1EBINO:J#X_?B1Q#2A$A%L(AA,&5T78>C:],?U("G)>
MF@0R#)YA<+;LBY.MGI9EYYM)6^[$.,. OO-AG-TE4=!$+@UAU+.#6(EX[( *
M'Z[$N=@8_L+E@^<\[5-?= -Y6Q_GUAV2GU<8$JX3B1N[T\!^L.C,'08)XI_,
MM%E[Y[U)>H&IA"LQCC%HWS*WV&'D,YSV80UTXW1YCMH>I#LWX+H+,W]8O15$
M?R$&!2,[1AI 1+'HK+=R;W8=FM*$!$HJ@UXVDK")4'IGFNGU(EG&7>7Z=V#2
M'I#QZIX@GC.X)QY)W&7"?*S\"H47B!>>\%T_2R^2-VE[*U!5[R[QHU2J4+:\
MH*^#-6ATA;CC7M\]G ]FH6N9M25*,:\<61QS$R?J'$NM?%B1LC\75UW4B7KO
M-9071V87]W2^CRD'G::MI[_3#2O^.%"+9S -+BP4X@6'W0B%B3%1SW".;/E7
M8SP'G8YIMN>[8L,2BFOT^NR9&[)[$^S&9DU#?8R1?39E"HW^-Q)!H[ZX'+*<
M.?4]/UH0COH?X4Q%X-J?O6W,VED,)@GJTB?OFP:SK^M'5=-O;],%W<<,GY01
MY72M3T;M%;^)=997GDFW+N'V@'_N\X4X^+G@%X+&@'6@;MA<:P_?"VQ<VH*W
MX+F]$A,V)YLNXBF6O>)-ELJ>)7S?B D#.3'O8WQ7>3F;<="E:7Z9NWNGZ9 #
M#\+X=E\#2'=R2+$;'VW1.A0NU'Z^&3[X-Q]VDRB6"KM=V8?#\QPWAVLGA8J"
MST9>URZ,LGV0"J)>(_GH1Q4UZYP>SSC[>Q'\+$&$439,X55?F4>]$(>7=I9%
M^5BMP;;M V8;C$L*<N%72)<!X2/&O._@ ::<7D>XYS+P,!A+WUSC)[1CU6&U
MHW'JT<RN4?L*.=.:8M;$/\ D]#9K2J<<+2!D!UJO._.[*@SB(@P3!%C^A(B&
M+<? A 31L#L[X@/>0!JS%VI_07^EUDP)C^5>*IC!=7WM?_=Q+LUJ^A8OP=1!
M-RG8/OO-ZL9B,J QG2R1$?IU\<18T5"?N]8Z]Z#V1X:RT6=S3%?Y7;XWU];'
MO)Z6V8HO^[7\W-?!!:=Y:4% YHA=Y4!$\*8H6",4B:+O^7$D-78OS1B3EZ.L
M)GD-8$"ZTJA\@L<W3 ?=;XQ^+'\&%A$L@0\NQ+BH$Y1Q7EB^7L1=O&D1=.$'
MR]5F1*!RH9)U:[V=8Y7P8FD.4K<N^7%58=%2F$'+]_9H%Z=)?NB?;V\1_19D
M: =V'%&W%%0AUO-&P]\O!F?2)QDG9K_D$9CP'8:Z,/('D,(%I>0[NNB#\N(R
MRAF%1(2GNI]?LB;@A3#7@&UZI#=T)KA.B)(ULNS5>I=#\GV4#K-1G.S"0W0L
M&]=IM$DTM7M^^4C:6?@=RN1D#^A-8CU)0&Y51\#>(!9<.D%PUS!$A%1U#12$
M'BZL<;D&D/7+68*Z!2$<EW'&7;2+"NH^=WH"8BH9G+BGO.$TB?-AL12EB$5#
M0CAFE/:WA742RFN9?<C1WM1-1&G=6;ATO"31Y]%LAKA&%2.]:KK K#\FS,RU
M:&WP82/!U4.'U(.$>-.D XBV:*1.V?@B%W BR(TR2LXTP,J:83P+HKN,=-WB
M>4-W]$J2-"S&DFUTE>D/<^7_WQ^?G(-_@:O!+*!$$GT041Q2OQ0?%-?^G-XT
MZE [A QIMJC!*P5$%0RF#NB#;%T*YZPL/B=RWC=>[^L%XP26HVS/VOE6(<'K
M,R(J6P78B'@&%PH>\]MWX=< \CGMC,(3!W?']<E3=H87WIR6\HZSM!A%.W3$
M7QAZ.24>-!L#+5W>*'E5;(Z$3,6W:LJ7K:1E:&O2C(<SU:2R;U809@+[05&=
M2G0>UX!(0YLF\PBQV2&N7)Z7\VU&9'SY$_#S8T7SPK"L[;EF%.:X,MK)C(Z/
M-_\:\%H4\O9D03/S2N5@OJMWA%G$[1#B$#T]/KW,(RKT1T:BS;V37(U,7:BJ
M))I, G"W^B-!'-:I>@VXD23A()>)0.'W7EB7[N^,D:90)9,US&_]KS\9<\2:
MX[6D-7U[B?LB*O$JAIC:%[EBX"Y@#! .Z@7'S4! W0D<+F;[N9F;YEO40RV0
M<"%3-;%,'<KM<I=O?4+.U,2_4VM7!JC-T#M.XIN#)U24N) >_\JJ,-1[*F,L
M0WT@6N$QU_.)JE-+C>W^6V\9C!Z->O SLS:H/ M)O>\%_KEH=](X4L>2.-BF
M^)/!JEQG]M>PA+_[D(19;>9Z$2;=\*Y!I_6NG*F*U,[&Y]*  *:!:<+/U=R\
M7N54O7@'M,Z]MOZQB(;JE#=3#JGK=+;$P[JV$H$OG-:PDG1^6>L1A<D#V<WM
M\(* JTQL$H&4]O)YH FCF5MVM3)F$,E(M$;HQ;!:.%W$GNWU.>\H\:>:2FU_
M$TN-1GDO9 -U6N+2[2<TLHR1=5K"W;6+%IK<QZ-<PY(3"II"XP,]OU--V>KZ
MN>.'#@YZLJ/LN1-=3I"K*WC:6VM\<83^,KSV)/PPS(P\C\?E;FC0?6PREH&<
MVCM3\,M)N\1(Y#VPWC3Q:7)\SKL$0:'/HKM4G8C9S+, G("KZ GH#A(-H9U/
M_JQHN19"%5G_I?B)]*(31@M"&5.@'=?4YU&P+2UC;5F0NF%X"\B5 N5? \>8
MS)N.LMC6S%DQ%&S$*\0(SD!;O.TGLL27@6'EUK;P@HA23?ZN886NPH/W.9"U
MXH]6E*O.OP,I/ORP;VIQ236AI$*BIBD+G9U_Y3AU>[6S661G\406FLOV/BUD
M21ZO Q$3*()Z$'#&WI5:,#2@,PD'0S):F5?'*CK;8PY">-J*UYN_F^ZO3YTV
M_4T1!7\LJO?15$-3\J4Q2&?W&H!1/XR;UDT/5%@;#6_!& X^#?! /R;=GOW.
M^AJ\)ZPW]I/$0V)Y@?S.+2]7HRM\/B+/,R'?-[Q)J'%GKC+P6'Z(-ZDTO<WW
MS)<[T:F"EXR,^56A>JMF$KV0CS(/WA?H37 ;"?JB]'"M#E1I1R=.GB <DEB8
M(D1REJ;(JBW*'-^C(;5K%%^SV:4J^FUB.D)\ _0EEP;6J01R 5)"D@CT"6?[
M9:_?WZAS7DQ':7/\<;T0J.'^U *1N/FES.#Y9]]#UX(?;>H8P37C4,5>+*@+
M''E!)W9'V*<$)]HM?<:CJ]@'/5S0N:3[&4FFT*.0[^H^1/H(.)--C]J /5\F
MKQXZBG^(?MFBO:_*3MXH67CG3#=.2-K8L.==BI-FV_(F(N6]E.QRA, (5"=<
M0K:W?Y!(7V+ >5AXL="</E-/SW^I-]1VGLP6U^P-72KX;,K._'ELLKR@5&!@
MX >]W?UP/:+;]U24I1$UA_=PC)T<(D8Z]#B%K@X^%;W8G >8L\^5@EP"_$:6
M&B._Z079G UBZ5_<MC:@(L8"]W0O!7'??OJ(!G=0P\53N7$>/J"_B87Y,K_,
M=&6$1W\&+ IPE@G!FLE^$PX0"D.$"#9US<Q+UMA:Q?<=5/N*=T#\D &P8:K7
MX$YSPKAG=5$?V?0Z86$U]E*TO7G9\,OZ>9^H+WU,O.KP[US14OPO*&2-I">!
MA.D:@*+%96)O(5WNZGUV#'J$O9-^AS[FMDO XV=,W)&)"ZA$Z>@G0U6Q%3\N
M#\.O 1#8/!*I9&:.-YV4<GFST+'0G<$7WO9T\[:1(8W5CIGB1=G5_M OYWMM
ML65V#K?H+P;1-SE\X]Y<!>0]QS%:-/2;8F^&3M1;'S)#+E\:9;0PK4ESHD23
MG=X9XY!3E(%?L,Y?6#X\C<BM#4T455R=RA,EK80H188D-P5MQ6%S3>QMUCL8
MHH7\9M*>< W7I,UK /KO]YPX8RO@D,?I _5M0I7'M^^OUA..?O7:>J9K2QMY
M7R5GI;7^G'"\ .$20"KQ(A.11XL=V1JMUX */ 5YX'DA?@H#94/?2_2_5#43
M$+=8W.G/X4.-X@1F^MHEN:T>8!*0.C1=!1O9DDL!+R:_N99]A9]EX"_<+>+6
M]=6?F6;=(:O17\'+W:AQ+PQ^@;9GA=@G6X%-W0LURF3JHG!N(6[J[,\;MAY8
M2%"9Y%EG_//ETSE8!I=$N N^?+'-JRXI[()"1*\2XTOV3I>,-2:9'EKX-5R,
MA#E8TZJ9!M^><M"MB4W@>"7S$9=TQG)5'BCR1F;E#OXYC(5A033\4%*4_NXG
M.>5$V4"%LAW?)^K("KV%'O>2Y^KDT-? BX63,I1@A1$PMH:._QI 8S+"BL3>
M81EKQ(IA!VM&!"_'>I\.@OUV@#N^8ZRQ;S%?<NXBT0(P2ED.OF[,!N_1-2#7
M+[!.\;;]-:!5D6X2E@)TPCM> X(K=C,JX1DZ/W))U%%A.<2F-Y#XQ?OJN45#
MRB_F.VFH5L'LY\\:$Y>?O##.*"0T$P^]#1SF7?HA=6ZX!@'B%M JS1YH, >T
MV!QKW^RI??.[2;Z.5-E!-X:S*,$O;]^N77XW-56&.+A]M W^>\Q0M350Z2H&
MYI00F?';7SBW"\* ,P*E5-4C(N5YRU?C*'L9%%X>6;I,2\_(+-QEK?1V>:S_
MJG.YX6WT$*(2> NT^B67-)#L[#$$/9+'UP.B45Y_Z1V7M&U%4IL=]#YW#CMX
M55 =F;M^+&7^1?*RJ5=$DHY<K^TB4&)M,X%I=G+$+MWZR-\G[;"NQ/ GU.LV
M>F\]=)!_++2F?C4SIC*\TU:,48,I]F40S]8DNKI@=.R82,"4<U",><I,Y,13
M;AQ-R=>G8E:R)F&6LLE&?Q=>5&)3,RLDE9G#2B%S@.BI#@75S?1< ^(S$F:#
M6*&"!M.5!9G]'3,;RA-M8H7?24=:(B)%8UG>ZG]SW8AAVLS4RR:Z%,[:#P-]
MA]U,+'69"%-3-Z,DO5N-)3&+[0/A.>?9TC)40X3M7C'U^/D1XJJA8;;))*I+
M7^?56K^V3HB@;5M/933&O2M)M.O&3AY+Z(S!XY3H&[Z/GY0+NBIHUS0^T^AT
ML'6@DY[^5<I=\:H[\JZL;I(9_974#Z *QVV4CG4<^N\.L1'^H]%,L6^E;^ "
M@J!%.U*?!Y'JRR*F*6_?\"8[D#^^ZXA(57QQ883[V+.\0H2,5Z1-G-R,$#$U
M,_0:.,F)6=@4#Q/X8C^NIRE8\+&4;" +2[]6WHTY#&][C&+G'$42Z'^=)% Z
M^@<&&<8GY&U/9UAE.F:K!0\,/'1=6PQRL(N5:!99_Y+X;BL?\<U)K_!9MKPD
M_T2!2C*7=HK JW^].O.PB^Z?#^IHW5B;9)M$=>Z$#=)ZYYERO7;_>D&C2CF#
M<K.*=;U*LR0W_5*];XO%<B-: _I)GDFN#0LWRA N\3]]N_8_]/4S//!!Y<*I
M\%$9OE>Q#; +Y^D2HG_?E6Z3^0];UR7_VO8N>S<?%O:[T=UTQ71)Q_IA\ 6K
MRQ>'U '/N_>6^FA;%P:><*N*%WRZN_#!Y7CPK.^?C=9 XJOX-OVO>-&IDURV
M0-.;>(P)4&AG1?%U#7,(.W3KFNU %,VT1AI]?+Q<'(HIS%S\;"?@@Z+[,!J+
MTO"#Q[>W9^XM(] )>RZ7@4\O60*=KLJ5^ A3H#KC?1X, HEHH.I3[^#:[A">
MZF#?F38#A\!CKB ]%]-1A<Z/<(DKR$;Y208&@F3N:"OFTIG1?F2,^_LX9-DP
M$@ S.=$%)X ;1O$,OF=N5XFG"HB_</+#"$=(C)GK6.-,(-?J*/7\-@<C)CW<
MFF*I,4;I?E4:6H%5V)E9\^E52('C\OU)5Q%TXHR5%NESHJQ;9PS1Q\!@,$T>
M;A3C@ +VLK[G!%,MX(UQMJO J%>.$E:\!=)15/%M@M]P^<*<KL\47"0[TK2T
M=-_^;M/4-&B!OMQU!7C0X"$WN$YZLVYACK#O(E&8:MW)('I<"+JC% ON9CD+
M*]BZ8&AW09W!(53SVQ*+ZCS=%]J-CY>F%B^6<UUM;5V+4]/CD%+=KFRZ%H"@
M&%WP1P3F0C0.=A*#F,\DX'$W.CGK*F@0?P>768:WQSW&7*)3&S&7W2ND]1!6
MG/^"10<N8(VI,**[@R'#CS?A$F2@OG>R_:>VN]'H2*=X=E@XNZ>M=FY!;9\4
MX+]$?RYU:7@-Z#16!&(4UC@)PXA;2J30:\!9PU6>\ L',(8$:7H@='(CE5J5
M(;[2V64N+;X1@78E6A5S3G_NPDKGG7*8$-_';)2T6\NV?9T\()!-Q!W$:LV\
M4C6V%8D @%RHYI+0OGNN:PB695,3J/QFWWQ*;QVJ\MFN8;JPI$?9CGQ?" &X
M(Z^54U,B-O'6)].5U?B7WN4;__AR:ZK<QTTD^X__5Q>W_S^&L0P:P833_Y$A
M/!/9YH!^S-@U3Y^1Y%&V.Y]2E?XFKC[=QK1J/<JN*<W)1-CZ6$2$N]M=F3NV
MS+/:*IXESD*%MU[H,>FC%(VIW<DP <G23BL?@:F2-5+W:*T!S\18O58GEE_(
MF1ZCPO"NL?*H;N,L)]V\9UF[1I5ZD%2Z;;UB9NUOO^=U0SG7>?>2'-0-ZMDU
MM<?VW.JUS B#FA-OK0-BEE1U6X('>D>6Q=+Y6EJ;$P4#H*\\CX8Y.>--PX+T
M MUNO+($RH5<<1D+(L&Y@=F=2]Y$*9JB3:HE87>?K3UPJ!U_VH"E;.9X:J09
MCAGWK$5Z>.8*!BD'6EWE*XD%>G7(P&@47<MVI3V&[&LQ>,H;$2DYS?SWVT#0
MZ_L3>MXO5<^VO^;JI=,'3?@I4$SAE_IR-3ANH2"N(:@_2N+#I<=/A5K*\A+'
M2N!79Q!9@W!.077E=;@8?",IM'P\M?PB 'F8'Q%I8;HGMJA2BM'6T4]UW? N
M!"M6:LT1-GE"MW4HEVL2A\682.%+Q6R/';>N 6Y!,K#.ET%D> 69#! RT@'7
MB';T[3F+$_ JP@F,>Z3P0FBT;H\[=]Y5?^7(P'C&J-[RH,+LYUWP3U#L2H-#
MWV'<T3!))-[.ZRO44Y471((3/@A40&'"&H5\8XB',G+@9>]JX[ST)E/EZ!3O
MWD5W^&.J0Q4-U[*=9Y YY)B->G3VNQ/T@OHO[X5VO0MEXN<#KON<*6N-,>Y.
M!W9W(1".-SDF:WK(4ZK5!#P-LD^)\Y*W#HOH]H#2:K@G-H8IR@CGU*/G?NWS
ML@[K7_$AY[GH>5(U83BUW\0O]<T6FA<10]"J1]B%O@I#"P1O04)QHG9!H3GQ
MY]XB7>0L5#HSW"ECNIPQ.HTK=CV\=VVW)5X$:L$&;H(96LN*;EV=^'?I#GFU
MG+^W.).<,F/:NS XSN'N'I'G7Y=3)A4W4;O4[)+-H@0_U==_U;-62#\2I$6C
MSGU#?8G:ZGR)ZHJ).MPY\)2K)XZ@[U1[:5][_E+%Y,P8-D7+&ID/!W0'"4\5
MMB;2";CQ-33/:'])?&F:X[@O).QJ^7/!K9S-.:>T@# $KBL*6<^66?7M^OD[
M4H6SJ04#BJ@7;!IRU#45E1(D:_WF61'8S_#ZF+;%Z%UG=4'G>RKH<EG,D&QF
MV/>L:4\3XXRU0K)=R+(=CFE TS[Y' +/F#S/\IW0^; M)]08!JUC'O1AMIG6
M3>MZ-[X[9R\7NL;8XL8V78]BA%;_KFIIY_H1)(LE2;L*61VEWPWR+%"^^HQ:
M NL=&ZD-C<%A-G69_OWWQ/,LPF,9+4IX$=5QP,X@2LR?M*N/*!"%8]"KIXQG
M2F&%VSDF4>0>D80>ESN=+!*<Q+W=-N4?U*I2.^I(3B2L]NJH[K$2G$V46#6O
M 43=QB.Y&3,411=[@4$*VRU76^L=;(7X>H]%'1B>C.HY%SA<\ "4Q,YU9GKU
M36HX0@?'C%7C_L@B5XUGK-IF..+^G*ZG=B 5H,#$P?<T)>6-6*+N<S=OBAT6
M$)[V\JQQ.K A 27<FWLK3%BI!IU+[!3T"CI4OF&V!(V3(L^A3E60<2Q\G21D
M!X:<7"F_MR+;"O@QN7=,R8.N,->2_EXWX"Z6TB)E+-RGSC<]H;V@_ECG4^^5
M).ZB6'RPR3S4/:J<+R;<(R$Y<*(P?1WKZE9]I]JEI[P8O^4$Q&A6SWOIS9WU
M*[%!83?AYH*K/8((BOGE@LXH0RHW*2Z3UL]SV^68(\1GBK>!&'50U(0?;&&%
M'D]2]#OHSR772^R=QN_GIIR@AJ>H?PKB<0G"Z_:B*Z]ECZ@.B>E/H:#\OM O
MY@&!E+Y?YLJOO!2ZD9G]UP"'OEL%NX,#IV.5PD=,*X6-L=#62_(@Y51+A?>:
MG$B#]6/PO,20E*5<<YKW:!\%%^$N;;XR?'>%K=Y\\0B[S7$+/GZVH?C6M%K1
ML (R)VT^_(@OG6GN=W<?](\.T0W?/0(YB)):%EX#HNRP:=VFMF^\:["4]0QI
M^>6]1%1G('(SQYD)>XM6I&_9XOS/CP]2EWYI;1+BQL"VJ5 J%(.^4?9;OEOK
M/@)ZB<D@N/,&<X^275TVVP)S7(&N4Y!9\CK=J<9FSP9"#<3L%2WE:(/[(UVH
M76'A<)6N*MSO_+!]4O -CHW8'U(L)?\YR5AKKBX! T&N_!6H,!'^>15$ G7I
MO'AW[W%UA*0E2$U][L[M1E>[V^)6VGX.32U^Q9\'%1,EZL3V'N8C#)'6WV?E
MZ3"S+Q^3B[#$&CQ$829+?^5ID#GJ%VJ(%6L+?K.E2[,]8M,6I(VK-J:/[3;N
M09?WCS3PT9H5^I_^<^SOE)U\"O?%@*?K/Z?^-C[Z+^4!B=.*L%4=RJ7W$=T<
M4IC4B(!&W]G3!!K'"[OI925(W?)RI_2RJH+8SXVZ/%PEIF7#('@%K?/!(>/9
M"W?D&I!R4/ 3V;W/1?DCW0^%GI  :'^Q  Y+JG05_5;]V+D2>JWH$M69=:D5
ME;])M-:0ED0WAJ6G1Y)^I5$'_*7E#.MZ^O4:\ NB=F.GE+1K ,=7"O^'MZD_
M>5+=CP_U'_OO)FWZ:J&*4U:%2M K> /B>T=CQLA9[]'?516'PB*VCF[";I7%
MJN'H9:@E.N.N+CI5YHV/G0T5ZG _YAIP>Z<5LWE6W7TX=ZG5/.E-M+F"BT 5
MU@[ZEFY%@_P>_PE)^I,F7Y2LY,?WZVZ2WD1-MM#*W,\&,X<#2_KS:T!D$ NF
M+\I/L;;J?M=\.[V<77H#^S/F5$,K)ZLB%GC^><FD1W2WM4 I"DL=Z[=:-E%@
ME+;5P0K-Z[%B=/ 8QGDQ^M-GRVXT*_&,^-E#(D)<]7IT8]-XG)WU+AK$8\+Y
M*/C5G[FE:$PZ7P.8,H+R2K;FPW)*"ZV6M\VJ,GTHUL/SK+T>IUR%[5?$"#$:
MI1D=TO=4#K>5U"I+BB3V<(:K& $2EH"SNP12KF+<X*4@*JVO\MF$&M;+3YH#
MB L#I3@40'.>Z;$& &E655T+=H]J_F+7>B&O4C87[U&T$JE2.A<TFXO16:)"
MKTX2N +O-TS@I;!RH8TM#<&*F4 JZ$'0FU15OL'&,44M=T^5XLMV!8,F$%;6
M1$2$;]H63X(EB:@?)77QSPW':WY;V3([B_,5#B__YIPZ/K<R:]GEP<W(<"SP
M,Y:(_%M<K4J_T-NQ%C$"<64$5F:KOV>@GO\]A*MO:CW.RJP6=<#;.>ZFD>WH
M)?-QV%'?M>18R(W43:]0G_Y#V7KT->"%(UI1\,( XU)@!M0?K=W1UBL<5E%4
M[VJ:+^.?RM-/$0K2M<J/]OJ=2L).S#1='#KTL 0%JB,5Q%"=R=\D2Z$WJTL^
MDH:96;-<_Q.IQ,$?C'R!=8FJ/KUQ#F1*-&O JN)@I5?767G<I_SA\FV&G;%9
MLDO92LERV'(VH]FXHNJW[?FSCZ6SNV8BU4X4A+2R[;17R]L782E==^^WP%L:
M_1[D,+\*KF;]_E@^F.1/6OCRPQN7F7LV)/Y2M:8/A2+.^/TE'7GY7*B2QT5;
M8) ZM)2;4!E? +0U$TS5B.>4<C]!C,)H\7SH:M*ZM#2'61@D#>V@N\Y\QD#K
MY^:B(G(-:,VJPLP.>+CLFI".GYUPGW_=116KTIIK1S^L'J<:>O;?7:\L0%9>
M;L[J$K.P\$5H;_]!(GKG8,=Q?[^R$O6<NVY11X+[%9)&4#'QYTYDM.D7@!;O
MI'YR1JQ-9G*F.G?*@NM6HEG#B9I';"$/4S&_>DFOF-: GEL_=[UK.XU98SY?
M/D)121;6J48@P3^ZR>>"N=/0*]&K*_=BD&FZ"U"5<90O16.'<*)@3$"/?GTG
MYC2GGNR8+LUH_(X@[AQ;?C:'NP9@FP_VZA,8!E%@TAMJA\IT"GOD.1ZZ+3+5
M*WPYX)GVZ>0,E>@I=S8VXC44-YN=%V3J6[7P.TG ' 8OO>6E9181''$Z5KT$
M<99J5#'$&1:+2,BXF0CPJ]\DJ\QK-09%S<[6MBV$2,SE5C]:ATV :=&>5)$K
MT5 W8\CKPL?)9E<O)5>:C#<Z7K[.P]E[,]J$7-A1R1E:^O8: "6($^81=9N=
M$CZVU;@1(#4N9\9?)E21YCZ6H9EMNTFJ'?]I\7F!8UT!\0JDTKGE_<B,*5>P
MH=3YXW^>=X1@8WH1SN,$1B=_WZY*4JVQJOPB(#5T %H[,.2CL&LP+MF3HRB3
M9EU0?Y45>LXR&5LN'&370U<WR'9/E7M"BU.97(Q+7:CV9R=7O.POQD1UMK 7
MKTR_A+U2_ZMC%2=SX\RXJSR"T%6:[J2B4BXY7DRI3WXF@6%-"Y%S!\DPT2;R
M60GAOL\JE'H$GM\V\QE_).9L00-*]0*S*KI@'5B->5<K*&4$NR;_V'U$R=.O
MQQ:KN);HB*'O%IJ3T5?8118:\R/5G62!T\VJ'Y6(<8\_%N9XC%A_&*[Q3I/T
MP%M'(ON(]>HELU"I[K]9"V+2D ]1.^,C8NZ^WCNFL[B9;B5N+%6,CTME0(_\
M00U:R^UT<-GYXJ#0[\:,6HE>C_?Q$XN#P7V.?G];?/I*>C(:!JQ;Z=6):W2!
M8!9^^"\CG'GN+>[&D3HML]2X+EA806/T K0X^6U?';$JMP9LZ\D1MU>,M%(=
MW+ - L=[#?@!#%>9T<,:9L_T5-,\,7KNA][*CT%ZO&Q5V=4A65#GS>7F_BLP
M+FBW6\$T/5&YZ_;EQD#OH!:\8>)D5\&<C$Q6;WE\8&!9T%S3')HLY&YN_N0S
M\K98">GG%]&17XE?W1'<A2IL)65O&'*E0R-R*YJ-<ANJ4^WH'WS9F+*3&=:U
M.3;;*2*ALAQ,'S#@MZ_)/MPWR&SL\VB< #X8V!X4PBQ$6-EO/=7-R]B4W/S7
M<[)!K=6C6(7BA.Y7KVI#/>@]H_2=EWMU-:X!"2MWK@&KR?Y2:7,^D/@@Z333
M)M8W,!(<=6'->,K'V\HET()7C5K:%WS/&QPEAT65$_D9'SDG]7K"= GL@=PX
M)TR2.HLH$D;LR'&OQDZY2=XP4?CJ&I#VAWO*QVEHOJ%:GI)AS:"]->LA*??\
M5ZH7^8@J69DN O&J@(>%%')6B)?_>:)?(;3-S=54RNEX0[;8F/9O _^1L+MC
M2/!J 5TBN!?OBD;<4(T>)%HVB3VV2^YX8L#]R(0M(ZX0ZFGW15F33,_[Y%6W
MS0,PO9W?3%9FTL/\Z,OCXZ__LZI!_Q=6CH)2+571HV'7 .M<G/ UH+<Z&E1O
MG_N^&$JUIAKBYMK!$JB/&!/Q,0=2.G5PU6 DY4&1%<K!5I9%*=^>HQ[[HM[5
M!Q3-+CJWN"?Z-L>O*.?JIL*V-;L(8CAU[%HGGR$F(DJ1".N+.FBG^BRU'%7J
MR"&#J2KFT#.J:[L4:HG/E.A&D9_).-L%OR%3%!L(,\[%K5TJ!-Z[*E3D[?@;
MMXV90 )I N7H:A=-%ES.$LGV.0Z@W1)@*,SR>\:H%68C3^C^<QY"6.GV3 +5
M0887<! \C-B?N\&4LVG$:KH2\!H0/GD5%B09^ +G9XV"T."\=+#5'T[?.UQ:
M+;-2P P35,>_U;>Y.*YBC<.33#IJ)NJ!?^-VD&":OE+U$I'J!Q],OY.</D"/
M4II"^[HZ>##Q!1XPIV)<,?)B-$+T %[^T:%TP=0EPV<DW<>CV!+N)5R)?V2I
MF.I+09Y/%A:OS_;Q7>YF H$T\Y(]:!1<<PW TXIV!]'@&#'7 "W,@B5>"V>4
M\P!KMVIIW&<EDDJA?9H*H\65[8#V64],8Y,6G-SKBT**-"77U,:]<870T0.2
MO3IL*F2>]<P3)XAM.-0*49U4X@V4QXQ&^[SGG1B5-GO7#"M6OFJU*ZX??(S<
MGI[O]AUS&A\YE&S0O)VHH,  RLS%6"'.54<C$7NE>/$;_\G>![P_OB2_!O0G
M!?7EGKF ZC8)9>"_9]:,\6Q4):9.,KG?XTM+%E6=BK<1C(%.)>"E ;7HZ8$1
M<+@OHS'-I[O4R-L0KD]W28L!.8)GQF?,UX DWJL$T-XTS&'TRJ"#NEH5UWP)
M"J3&G3OESP8ZXPQ7P='25JS-;:V_A-L@J"6%[GM;?\Q"7SU_KY23$2I!9NJ&
M;FB,1^7/VYEP4GV*^4!%B8'AZ6[^&+O1Z( :)0^:7+ES<%JI@F;]/]A[SZBF
MOG=K-(A*EPY2 ]*4*KV#@'3IO1=!FG2!(($@O2,@(%TZ2 D=*1*! -*E2R=!
M0)HDT@*$</F=\XYQQ_W_Q[CW?+GE?>_YL#/R8>^]YE[C>>8SY]I[K:6C,'@#
M&)BWQ%]?LZ;3]I!] E:ZSO8."/9]%.=Y:)^E';^3S@0J#:Z,D5:H0T/B'J&@
M46 #9+4)9V1_&/,\5NE1HRQGHOJ,8 "/*:]_8_K/".,= K8=V@N3JY>W?/SX
M!N#HS0+&PQ0%(?0BU@@Q*INI)"#J 05N%"1% ?BSB$@BH\Z54?Y/XZN KXK:
MA0MJ"RW:U9[W"NL\:\U7-7+?G%/MMLL$EM*6G[9/W@!0&M!X.TJ<PNV=!15$
M0'P#DIU9756@>[BG8#J48#6DYT\P5ERR;YS$'(5+/(O,JQG\X2UG$U"VI,J>
M6?<&U)*LL*;'O?:8#?!+<6-=CT )>03 S12UVB7@)NNP1I@B=+\)*@R*M%KV
M56AINPR+1_SC =B>NE/'"[*WHH7BPMC5@S\KT6!Z.G^T[ K=A;YTG;I4QS+3
MHKI4T(H'_@AH@I#S'5 S0FC FZPMH^[S8/;9$D$R6_>/@%5NOJ3@OOD;@(D>
MR9Z1*C7^60'5M&U:JP.DM[.'8P8*>PE+"&-( :5 $4=+''"9Z,/<[XRN)Y,4
M6'F,3Z?)01IJ:B@HJ'3?=(J*N,MM.M-1Y7,(/9:^"&YJ*82E7A^0\9R=4E5,
MQ/& A5%_<M,]UWU#/&LGD</L[:-WG&UD^RZC^ST?K#VG9BD.$@D/2PT;*92?
M#7ORSQ /#%[PRJ5C'AN,4D=X)XH/KS3++:UU;110&\P[O7KURG&I8&"*?VR@
M!\V9>SYR$7G&A8+C2*]3(,X04IM>@=:SU"MY,+!MMF[[GG.DB3?@M^A>HTS^
M!]=3!B_C8LX*B3-HY>__G7F[$ZU1DLFG+):X*UU,+*3\Y\K$]+(;>BCP94M2
M]!VN)R&,[PEYME293VJA&#,@I>+O:G>[\[WS&T 6#=X?8[.8&T#?%TS\#4!5
MV_ & #.#81M*<;1#<+U+7LOLZ\NO-X"M:$!()BT"AJI7> 29,IR%'<T=W0#X
M_UENQA=-C4O(*K\!A$$A%P[/6+=40=Y8OM2XHA/C5J&KTY ;P"BQ(L(:_/P&
M4%)>#5FO6<>9ZQ-T&-@RW0"(-Y$\U[0"VKAKVQO W[[4_P;WW^#^&]S_+\'Q
M]2D(@_51Z]_RS#*0/(<4;Z[-AH_KP *57&=09-?&=U8@CW+CK'-7>\P&Q:.>
MV>B4G'2YT=^#&L?'+Y;YAI^:-//O"/<Z6X2QV+9)/H5/]3E4'SGSSNT0/M$:
M5Y9;F0D[,'K+FF64L;UX)I-BD>[\Y6!9&"ZK_VWKIR5FS$1;+"^95([7V#=Y
M)O\BV/[KKEBKPBY4"I.)#D$4]5XS[\.HNEV*,5J]F>-->V86LP%T2<Z(:;$0
MYR+3>4$*ELG[.<Y!(MPV4P86L1O>\'7,X]2!<7?MKY*(^M9ZC)V&(UJUWKU=
M.P#I$:?[+,V3"GFL.;4ZE=#B.UPS3HTGT%/*M.G=V\.!5HR7<ZA9]<#Q+YP6
M47MDUS(>F2VT\HU;&7[AD'W>WCZCY[,7GL;((*$&X^6MN@/+E#K>=>FWT&O[
MAI*P,8KWG=J.&!<>:</G+!<O*9 1,3YF[E73K%92$2H7F]UUW%.'[$/)>V+S
M#?)#2"' 5\88.SQ!B^Y*/%Z&F%#+!^-]=:XC%199':J5#!W;)L5<O $-;\H_
M7T,PRS> >^9?L@]S>;[9$28Z]??U2*'AFER]TH]=IN6>>(@JT:T0>7J=UBEO
M@NS;WY*J6C#]C44"!X3BBNC$*]'D<.^''H6"<YH9(WFFW6X"M8:FY%P]F97/
M'\V\253N]VF>/N0_I.TP5ZI?WS@_6$"7;K8NJ:/V>V6R2LOCDR1M'\,,RC"&
M VEM8SP+T"A3(SV"M?1^/8_5%ZFG@894>-?Z&.=;15TQ+>9Z&" 4'R;5@E:H
M+>;,4)GF]SX$B]\MS6!:$Q_(@M:4-)"FR[U]+DBB[NL@0EW4Z^9L*Q?*YM'7
M(P@Z.@TK-Y$)0-=; (D<2L=!DV0QE?>NRV7LB.MB^[=!/W<//=Q_091-QGM2
MB]3YY5\H4#V\!S?>E3+IWS 6_2,RH)V]5IDP8%QU VA"6"'/'N;KFH3G=96J
M[3['AF,\4:E(LX%K)U=%LFZ&>E"[OFF2=8'$[ W 97=4^)%T:Z@MXM-T2T@0
MK_**>U#;^V:RSUL-Y/L\O4(8+KG'_*>PU# A4<5A41#PVPQ-_%NI2#.TS>P=
M"Q'RS""WDMT?!_:#DW:96L-VQ3@F##N2G,"-KI,@JMN%(.:-+'O;C,:/-Y%E
MN_,7 %%5EY<!=XF/6A@XB7J4)65%_:W^+0$O5<)Q"2NT_3U#3 ,!>[XQ+@\L
MKFU;N"*_5\V:!J;<+] T&_PK.S#*$E?(VN+YQ/Y)^PCL8[?2I;7O)-45F)Q0
MO[PWV/CB4Z.8"W,0A5G%$=U6:K6NV%.YO6F#;P[%\<5\@]+1)D<*DXB=OLE8
M.Z(3DUN;T9]*X!I&.?TM28<NXU7CJIV<4I;TJ8V6D6!ES2IO\^/N.2$AP82"
M"D>I>ER/#*8+&<JW(13-@VX?)%]2T4.1Q[(?T_&-^R'_RM9I(3FIQ%.BRY;7
M]6I!D49_)S]VVL8Z5+F3/W2C^UG23/X-ML2$(WF"?F"C?-Q_ V@.+*^WVJ70
MNL70UX<>[R(STZ?LL%-40;V?]7[=LNQ&3"3P)V _67D/N:3?SLB:[5=N=F47
MWLV+M.6+)B4@_$6#ZE"CY:4<N'KHG//@#D7@F7X-L6_)JFP-PD>L9B'!72M6
ML!*=2HN>M\DR@Z8BY9 ]HF(#FO.?:\QJ/K["C*3? +);;2PSZGAD(4!:0YI?
M<U_KYE+WMA-PKQ0=;@ 87LBMY 1-ZF(,KK3 6JR4L]U*_F2I40H\JDQNE_<F
M:GRVV*; +G>#SN9E^&Q'II9W<T_S)2XM)]!6[O-G&E;&WNMV_T+.M-D,/GH4
M*&[WOX7L?;RTE>0>T? ?&77OAO0[==O(*1#D'@^'_\Y&%>NV,EB*5QOY)8_%
MQOGU</;R!YK9S%8R^)F6&O(6<I 9+IP%[/IKI^MX,*@958H'Z?II+J]40<G^
MK;*H_VM1N>!8EA])0*W_:]& _&NY^$3N5](M^:\U _BOM0S_O]8LX)R7;VN=
M=L!_0QO2@ID\BYK&"A IHPM"3%.UT^UEK52":E7%1].?-BX/\:> 3'@2+E0&
MBUJ/;D.$A,%A"B<"FAPR\\W2*61 X<K)<D=DB,3)*?8Z.<D?O)VT;]]3?\RY
M^PSX6<QLHST.X@U,:"?CMWV8NZ\3M?6R<^[4XU#K-U3J@Y*G0'(+%67D5I=M
M2?Y6&4$J"5KR4!A]-##,+S,T8,>0J/FA+$O&MC6H9%&3\K9+1*UVR9W:A2\3
MH7)M>'YP_&? *9Y_'(@,BM23)QGLB_ FR7RV?[^UWNU,,N,)4WA;0V[ UZY
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MP2Z/:!OL+P9)0DL&_813)#*9\R,'GTS>2H_OJ$AN@1X.3#K/SG;AS(LONK%
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MB3WJO0HU.RFMQPV@OQZRUW';KL@- !WY#/C$"K=:U$I#%<^%2;V'!*AG^&_
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M(I/Y@*PYVS=>2HH_LU((E(E&<-53SX#"&*$SZ>L"N0>.6:.(P>QZ.]66O!O
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MG)I#L&JXH^VKU"1^&SOPBH[ 3O>7OY2.^%<C/^%9P'NX^=QZT2""I[M0JH8
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M7N/U9A!QC!821KM<M8.<530,L$)D"\DHN''636>"9MS?[T:ZL:ADU_HR5LM
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M9$7405/"!='0%ARVRG#QL\Y9->7(N6.N?=@BOW6:-&F2\F,Z\%\5O,39$$'
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MIJ+]F7.%_)M&^4_[\S)/DY1,_K9,%]K)V=#<2SW1B0.ZWP(6V?LMO<R,:O+
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MU9UMRWZ!UK'M>R83]\2#L/]Y<#?8X1#_%O#8/OL68".<B\MH*+N0_Y_*#@P
M< #P[W^ ?V#?_M\8SCC+34L6%#[N]8H.;L!E_$;*<?;( *"K3/M_;X%H B>
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ME.H\>76NE \E*8R(#81INU\^(;4XS-^!*H/JUK ,[EIHU3X6=S+<!)RTWAT
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M ( \7G1HX&0ND\%[\*^-M5X<O<UE8Z3./FCB%H"594!0W#PB[$O \BB*W2F
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MX@AOIQ/MIO5&$.D:$<N3K:2Y,9Y)48=/OHI7\8E^@D^' LU]IU/>$OXEO(.
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MA4/WO&#O[O6CV/<HOS+Z)E\C&<I5D^5ETY6EYB22<M."IN;@%U_9F!"V:3*
M+''QZJ&M(&!%M.!E.\K]T.7Z%89].$$#DXLD4YD2+C]GIU5D$VH4X\-[KX(F
ME8];J1< /&PTEJYD#DJLK3*XL5B_!6#X8?%"KS]B]A'S$8HOH_.83WLS4N^B
M%;=XX&9%-8@WLM+^ZRV ^=4YXY^DMRI*9H";U)]PWB/H>DE:*8\0CFA9AWY"
M<QG[*GY*ZU(A?3BF6Z:\GI02]Y$[B5@$3^H6@-A9^_<*>'J7F& Z?U#,10N>
MO-S&$4=]FJ1R0FD\Y/G5EPZDXFZ-%$7CTUH^K/NDMK/ZD62FW*OBCO[S@XY;
MP&M_M5M S_#%+>#['N &^A/. 43L,%_<4!URW0)(!-=P#N5\_]4 MGLG)X3A
M:/!Y ?O,W1P^!*& +&]9IC-6/OQSO6BL\RT@(AM\C(N*"(6C/"J@:#J5NUVX
MHJ7^/AA'K'WAB'E/FB[#QM'V=:BEMD>M@>6)@8 !@9C$ R,;3E(Z -!Q!]:O
M@_$K[D^XH@QD@ZXI<=\"-C?!V_&W #?8(N_ JA?]*G\]2B5;>OT#A*98M7"8
M-IBVJLZ/IQ#Y,-L@JZ&QW"UVT"^6+I:#\#@B$J*/R'WX1[H4":-R#&2>-O;9
MO_$WK)D2.LD7^HG$^8-C *J_'M7\ZN*.OF0?A#;-'URN'\N3"9K.8OU+!EN4
M1A'" BIUIJHKU"[,([OR7E]S2'2*M4H.]4_RJ_E!(9_'.JK \5=:.GWR8Y4P
M9[U;0.6,5+;*J4%G<A+4SS= \A3.G9OQ:HBWM-@QAVT>JPG)<(B0?&;3QYS2
M?')V0_.F8]:]8*AKP<GJ?M]Q<M<2T]"ZYW/VGZO_=7]+A[R<5=QWC\ ]1!V'
M'BY]>H)K\?!&QID:V I-%+CD._E,-9%:-]?.()]KN'U%:F#&!Z'U% ,)42JV
MZ/0^*(VSC^<1]:[TQ:#:1)8TV)5$V0*H!KEG(+$@$<;MII"I-+X.^O/J/!+]
M(]A_G&P71SA=M-AS.O YRT<B5%8TFT4[P6#^<:KQT:!?L6DXA#_QP;9.'83D
M%D PAM+._7NG@^BC#J3ZO,M0$<9M;+XWPQ&*#'9IJZO88_CX[^80?OYF=(
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MY,C>:3$FRN$:C2>WH"OS%I*; ,V^G,IGT\'CPU/\]4+X]%^BWYAGFABC\=2
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M,\^@F!F.8_/5K![>@/RNLN/H[4VR)_M]+L!8*9P!F"CO![0B;=TY6Y['"%:
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M33FV" BKG7[B7UEZVU-B3LJO,P#FZFD^[J_!,)A4]E\(G^3Z\97S#\W$4E[
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MI'U@G",^45K&HU2UV@X4#YFO)ND@\ ::!5J^;NAPWGGS.BVD_8'Y:HM.YC/
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M-\)I&T_*P(NI:D6KXX=^4#C/HUIEEFZYMK";;\+9T &9/+1K2-G3K!:@^QF
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M6]1#_$#"2S1!;9%[4K0FM"U%;Z!-^\^HP*ZQ)=@<Q89N=0*_PH:[C'>7RJ"
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M5ZBQ[;04\Y)'=NZDQO#J5/*5#_8Q+;B3FF="5*BYFGSD0#RX:YA5 <Q$?LJ
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M#+:CTA]H^KPLRGM4]S;SNDF/6;YIH?U\^P-M^Z@20UNC\NG^G_<"H]3M7\W
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M!VXCY[8(7.$*G=Y1681=UDV" $*&(8.AM6Z<]7.71/-++93VJ[.)@V5R273
MW\4R]L,&?TB46)"MCF[.J;B<KT;F4VY,S6A=W)5K'^VI$NX9?,)E<96%4>35
M<^!R<=EQWY:I+?[AOE)T@&MR+$?HJY/2!_89N=5G%CB3ZP5Y3*9.;_SNTT+F
MF4>QODSB>3F%<4J>!^JG#K51,S#N5XZ0#0H9D+,A067SA7:%IH]:)_W%V]QS
M0QK=XO0LS0U35"5\M3_3 83S9,9$.L#_LPQSCL6^IERB]\0DUKF6Q[()\=2J
M_?LXK1V>&4W3Y&'?QC1]$@1+!LE,M6YMK>93%39P1#LZX$O>P>U,,5*XK@G/
M&Y&ID-..$H^/TH( 4$W1:9&?3WKKQBL%CC._T.;WF-#CN]7I3 <\]+HYSXR)
M"[LR1MEW%IO6Y*7<?F-SOKK3&U$;HE')XWJ=S?!-V_V)2Z[FYS8H\9M@@*8Z
ME)G# W>*)@6-OQ'P @6*HLG5V63+%/5HKVO'Z-Y7S61,R4][^\CM^11%FN#%
MY1KJUMVZDY+Q4P Z;S:AR'SZ)=Z^0.;>K"7I[!J[^*78P>8 %_%76B"2E .W
M,V)1_@')#PHJ6P_R\K(GM(16V\>V=<Q7NW@J^H^2XRANQYUGEGHZ?132QF.T
M8;,U$%?DXCTSCJN'S%_-H0-.6U"?!YCKH*CO&W33U\Y?FT(+D.2UGWQ]MT#:
M$F*J35$)\\G)XO+Z>.Y>LX[X-_Y "J?H@?"T^FY]V"22\?(/]78Z *MY-5QW
M<6UW_BL=X"F2B95=;<HZ0"@/# :UJ7_Y=>P64U8BL/?]#/IT@!7AG&C1_+SY
M8,6</6P@PW&W:'IONL3S:MX>Q75TEN3[.2^4^E:V89\.:*I-]ZHQ#(:4T9ZK
MPK8#CZYYGGL-A33@OA^5&A'C7WAYDE+Q"[,&Y\YGIDRKW_6^S-C.?4M"=USM
MU"MQ"NI[*S">(DI(@X;($I+/D9,4+5U3;\TT+-ISF:0+9NT=Y40R57^KU.NJ
M+T]A!B!&7 NCH%ZK<7"1%,;EUU>CW.T+,OB<'Y*&.&,L5E*4[W_[UOGZN<O%
MYYY]O:&<OG,E^U+R_??3&PYG#*-[*WX?282Q%OT,W4<A0T'\M3Z(;3X&_O=T
M0(G*80,$IZYT*4S(P>WPM@EDO0R/P3*OS(;?=>X""71(P^_?!<3 802KA#W9
M\^8IBFQT@,N691L@">I\PB<B0PLD_D'S"#]*OD8'; _A[9%SR(:FGO@:"4<$
M7KA]$NV<YP0&4T2P3UO6D LE<C 5J+:/.L$XLR^4"Y[$0QLE5&9R4# /NIP_
M*.\?B,NL_O83&@;RRY79;=E(.>I@/M1$]<Q/8M4EZ8"31]7O,0F[YQ"=;@@8
M*W"(-DF:?8EV_I /(^MI"L M9X>Q$RG"QWI:>[2KF9V1"S3X(\;:^9I)PK!T
M.]F/QCQWI&<3,]D+.=O!Y#GX7%ROP(Z,Z[9B+^_GCT[?0=L1#'SD=>L&Q.]X
MLDBN7=>",?7_I%3+?YLF. CD?.F^]-FK:>JGU3F8\3:+U!G$KN_O+P<?:)+$
M1,]@/5?K8_<<TV;47\)85,7.#]*LP!4>XK_[B>N4"\PE+4G2/&%#OS(&>8-F
MERZ0:U@W7*!V5S7$S8CG\MC>/R\]@8KF&*ST\T[X*W@V&KR,1M1UO*OM)T"B
M<!?0-YY\*EJ:U28:M9?<)4A.7&I)[N</. (J!-VO@PKK,@U<:SJ='F;%MQP=
M!Y>">7;Q8F,A#X2D)?H7 Q.>6&_^#+0M&BP:[]4 ND;'O.6+:;H:'!T>*C[6
MYUAYI!S3/9F4:[\]K80"PTIKANB X^OJA'@8&I2BAHMK_14I\OKE97@R'I,<
MEPEE5P#ZX*DG(0TO[()>#?OXL+!I)TT.<0-@ >/@Y7Q<+3?&2V0Q>5N1^/[L
M^Z:4U50[$A/9XUL_)\<#N7X7@HI_Q4 URQ/5?B@+,$!AF[5!IGVX%VU*J99^
M3L8!<+,JX-@/&]!1L\N?IY5I_!A+_]7YQ=39.]C\'K1:K,$7MQ8-2]IGOPM7
MLO>C&\T@*@6;T@+P^2X(*T6$ !0D[_;PPR+1E_!>2BM6L_M4AV4[:V@C]T=8
MAE7WWZ=!9!PT?A!N"FSR[71S._7+KYL%V0>F<.K0F("$T7GYOI6[8^>*\,G/
M:>>GKL).D[5M; 5JSB_UK\TG"Y"[>!^YN\[LO OBT)\T,/3$YZH&/=Y^E'VX
M:SD5(!1/8[IS')2X2#S;+P@;(6S+GHDZ-ZEY:-%ROA"U OT4ZTTAU6FODUT=
M\B2+CEW9^[MOR+ [.<R%<_I2-9?XAX<_HGZ##FRH&1VBM!D<Y]YH%(35_\<)
M60B\OC?PU2#VS$MU)5'KZOUMCT?S;=[W;%VS...#*W%OOE<!/D]V4H/PP(C?
M@=%S#\@_D_) K#GC7:,\1GER)M9A_)VJ@>GZZ-GX88^N!RA^TPP^/4=W48>
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MX5B6OA0,P]I>;ML(Q#&$.#:E)7?3;LQ(BKP*\FT&P&NZ-/DB'RA .1C>7,R
MQ[7=KC?DV3_2"K4$;@@2HKB7<#*#]0*V=,"# >*K]C8ZP*WR'-4+)BXD=:4K
MZ5P5PBVJ#R]-!]PD'TXTE<QTU),7:)?0>G3 J4)J!UI&R  Y1P>837M--0XE
MLY+[\>LQGP>CN%P-)*_T-MF^9YV\9M'\(4KOKWND AV6ZKPS!.,O\P<-Q%@_
M G"N8B4]0BSW5P41TZ?<^O!2L3T&FQWV.J"$Y_*2S2FG;RV1=_'WI"\D4@_'
M(1;AA^8^ 6JAB&AX(&?&+M-/"<["=H\569+AOH=2Q[B!UHH5T?E*.JTJ>ZT!
M5E>U?^\VA,P 8L'^7IIO:J'Y/EN/4C? 9_76Q*IK5,/#ON:^QSV8@.UE#07Y
M#+_@HK:C(WZ;:4DIK0]E*!]5%^)G#V\]L+-;NB59M7!^T<XHZD;5SF6]Y6RE
MS93>ZPV^EW:JBXQ]'.X0P'.3!R&D\ '1^+!3%'[2O=0;*3;J.L3N3M7YH2OW
M?K$*)Y9]"[RW,]DV8A/K+(^.V'7JW_R T/^NT&+IV&FQ@5V8E@E:5?VULZ+=
M81.]NN7>^H,.X(%Q8UZFIR\)Q$!'&SQ7)TI@HJKPP:9]\]E\BCAM&%./Z,%A
MD82\6&(%/BS->U]#*W(&5;6H\Z3U3(0ZF"6FB29,$OG.9G"@H?19M="#JQHE
ML.'EWZXJD'O[!W;)>+O[P(B:%L87]@G"M+<;A0-*I! .+)HZ2#4).]L%\0ZD
MV5AVD%2HLT5 4#:SKH'!N?CWO>H9MB+AH7D,V6N>6ULX6W(@,17OUB4HMZY-
MMB#B/N+.*;3-2:Y-280 \?; +J*'E=(':AYSNZ&_G8!\F4/_.><CK]_-K0]'
M'%RE>@ZYPC0(F(069,QD02;^FN4 &<:R8N$RTEIF!XI+JN!X8U[">]LC=9(U
M,EGQNEP[5+_(BM'TJ(-I^0*(2;OX>KNN\T^/P?MPE&%7'G\XZAO>651,5,VA
MRFU(-6[,)((S;?!8,7&!;_UO5TS_:,,S"EZ@'E6OI<2:#5OOED)(_U<<U+8W
ML;JD>*F[63D]T#F8\Z!)=L<")N6>&WA-Y1-#0VEY0A&C]I.T?)4!?;EXGS07
M'OB@G*6'7N&DH<+TS'NHGLJ *'<V]/BC37%>HF*!L7;R""(!3-2'?8E?87ZP
M.$K,!D8=+G[RH;80DZ@4%F*FA V!N(I6SF.0@ZE1YBAB"A'/BSZ[O**94QX>
M1P@&\F"G=PWM5 AL#*W%BQ/!1'6(?IL-$^C0396X:,P%]U+<DKR]H_7;Z2=%
M,=_V=YLE%!^;;4T'%&^*[U4+D:)[O/F_1IV)K?WR5D(B@UG)9_C#PFMLFB:Z
MPK)[DK;#WBA8G6B/^^IG= I_#Y=M_;8 J-U03:M]87S:*HO:$FHS66+I$% V
M;5SN1@PEQ=,8J4</*2Q'%OU)M-/D$4/N2;\A N*L3?\*AE7G,>;ISJX5,:+U
MLZHA.DL T=B7)>/*-L#B^RK]AT-\E:>FP'3#(J(;VUB4[]FJL=I14.BIJK$_
MDE6^\2RR,%ZQZ@!9:F/ NIB^V%!>U^D'4_#3NARM8PF8/52=7<%L'X>K4ZED
MMR.=1#>"<2?R.S(2+.#&@7/H%6QI))[I$9\!"H?W9(<F2!TRM 7)GENZ/E[E
M>G2O2FTK6[/*S[<U,7,/?"KTZI.LC*MY-OU!KAR2);%Q[^L36JS*GB>L[ZBL
M$+E68VMT@"9*)0[I(7<?+I8[XK5&JL!#\.@N_B_Z<GU/EN0ZI/R1#8=1DI-1
M(GVJ)5&]9N9E(Y6V:.A(KJAP.[;Z?8+HC^CO(G3 Z7=1NT<">*OMR$!!U(#2
MH6LX:61FV@GUMI;-KILD;UB?Z%S_BOT5DG>#>\C=O%<ZQG]>*]Z$Q(D9-\HJ
MVVB=R76N=#^,3*HJW,S(.(S**H=F/H%L8!,CO^II%&TG;E>FS-MC[6]=-H3Y
MP21>C7(4OE:[P@!>SR=Y+O_JP;QP4)X.$PRQ)H;5+&-XH"R:X\4>'TH-<MQ<
MK14EK]/.Y!C/^,>W)\T\J\X,""Q9/(VXBA]4@=31 4X0LIAH'_++KDD#\8>Q
M<@_XY2Q/E#T$G]&$N%Z=T<3>D/DL^86BC26>(EV&3A;Y? !E[0LOO_>SG99U
ML%$P+>E/ GT[EE4,0@\,\>WW!%FTKV?WHO,2/2!??N>JQF.U&TUB$W)9N/3+
MEG*%8-\WT>,'9IW:DE-)'"0P7_ITDDGOZQ[S(NVP3N=-,^0LT3?\JS]IJC#]
MWMV+TT5FF5M/&EIF+C444%M,(*IAPTB4<2<$V];)!I]?/I8Q^=.FG"_4[^!#
M;VHYKH#.X$:%=K_O<KA?A;HVA!*LJU "-M+^&O<[U;,URTIO<0QJQM>LW N#
M) W6ODG R'4YR:A\%]$QX(CH-<UET>)_O:0H9FZ29I\-14&URK2:&W"[S8\M
M!01N9X@S.F2(LCHP^7N.O_4P+3O34*#2F-=D;%><#548,]'BZO/^5ZX#_U<U
M+CRR 4B)S0ZD)C0B#CUF*A:V_K'X]/V__B>+Y'#8/RRE__?%^#,Y(4[D,KSQ
M"QP3[2+E(:EG5H9LC,=$[-?P;&&<(A[@1ET*; R>/FXX\B55'B;E7]9Q+ND6
MKM617.UAE!CK&[Y,!Z@X"#<?!TLD'=#YB,8 CX.==8< POZB#0JID9B:HOQ'
M^3=I%X4ND@*:7J -3M7*DU-UB?T)BE5&DLJ]V1=>/]BTI/$1O;."2J&!2J]L
MAUDK&I!C/-N.Q%L8*&@.LZ+\\=-Q%L/]BV#\(B 9N*':OF Z[%+L61D;_ X"
MN7."8\#9J\K6VN#9*U=7E$W$K4)LR>^OU&3,<CZ"C0Y8SJ3QC1^+),A\_S*P
M!\(,M^M\AHFIH@E2C(DCV:V%\E#;/DPH@?6V\)'+=''L<2C%;F*G]Q>1L2%\
M-4OV&X<AQ&]UY&>;.Z/73AQ6'9W:!!--8 SDBOMDKJ-'(2ID][_K.0D21_I@
M44A^30'[.51C12C^:!=(?CK?F5U5E/'^^>"AX.?#]+1?86S$(@*K$+%V>J55
MYP-IE"P!V@X_TJ<-S4+JFJ+ KJ,<\. N[*\^'"\9U_VLZ@"#K^+ID374S!+M
MW@9WC[G93>[K*AS)!A&VRFIV)+\7MKK$L2;6*<?!)H''\?D@GWSZR)3L ..A
M,)!S\;B89X8Y=OT5=AMU"W.>V%._3!HR9FA7B'TUL!)R_,ULO"FD7JJJV%82
MEZIFJ[[!F8 YSJN)]J!H.H +;7&<<=KU(EAH["%ZY#HD,.PJ_*?MK#\FBG:.
M="9^_ZQN.]FD?".#H_L=M#4M(Y!_*@PT[3AINR:BMUK?S-C<M0SP0G1AZ(#P
M</"WEK]W05PCSM(!-PZI;\D"SB0_0_(=XD'_RDP]'G>>\JB1./PR1&LF1-2[
ML>,"AB1KZ;GA_\;,>,+9SF7AM7?\O=HH/><47:_WL>,Z*ZA1"@](G^Q7OM&(
M;!C]KG-D2AM5M:PHE\J%59%SNOW0)M$&-I$]&9K7Q]$G I\\1.7NPB3V4%,U
MIL.7,R:89YNM4_>M[,BKRTB!L*$P6>H[30YR]61/'DL;66T%(00W[K4U:8Z\
M&JU+[*L/20VRDL7BH(=1N<&.DB@:,O1T<4'1IF4FM_+!P6S&Y!W>,RLU26 O
MV#SR8)5:V"%&&\40C03-/B*9.W@I;&TY.J39[3,KAG)#UN%VTY>GKHY7,R"#
M2N&>_?PN4<ARW)<ML>4V08%NY>P=5/&WV3S13/N)*A$##>7$6?#CXTN&I'"8
MK8"ZVL\<[)%@+\'ND+E)0EX1-0;)J7XI'YIM6887N^S)NW_#"3-!$5O.B56$
M '6>MD[/Q!(21<WI@(C,NSP%MV>76^M;^*U*CUVS+8RG?A+AG!P;=OU(E?7X
M]C:(QDKN2']0WTH4[5XZ10YER/*\PGBASM9#-0JC[C(CBD,H?QJHT]F3)DN/
M1CU&C7[A7[=J?GE#"BU BL;/M)=\'LQ[Q &1:L/K??8>?,#H%:(CIUM;M_/;
MP,6,\\01A+/V@18GT>#"F"&_ <NXZ@!GK6[^2H;8^3J]"S&=XV/I+I?27MTJ
M$U^K^3+48Y4G17V%<$%R;,H-^)1YXNJ;.D/-S/*<MH4/T]>[D><,2S_O7I*^
ME+%?XG.%?2**G3W0M2/]/^SP^(3LX6=MF+!;V'JFA2;)ZCDB3>OCW!<";*ZD
MN/@[+MK<.BC%X$6)LU0651"-M1+\^_)SY6N58+(>19$.N'/N>-"'>P)IN@4T
M=@0K8JP[_SAN8+OI@)1K)WWCCM\CD-V0/9EO"++2!SK@:QSX#]4?JC]4?ZC^
M4/VA^D/U_R-5#P8J/>>\W+1MMQRKSD8*[_K@,?ZQB1T>W#/#H ;DA6O2_)D"
M0"Q;77QN=4\?11E4:>*E]NRMOA.U*J'9$6S"=W[S4AN/Z7(@_&#G=NV?/=J,
MM$L4KF;TCSUD;+9DPG.HF/H05U[NRO!U[N;4;O[4 0FE,8B><"M#E8^P[,9A
MYGQ1J@&*-OT/S2_SL*UY&9"K>:0WO2_-[-%J60+U<2R#9J>OI8:6;'(K^RCP
M6%K-6)D:> 5"_4ZBE;DG>X7E[VY?B/G4 YJFJ) "8T/4>VY',B4KX _3;]3:
M<%^O3.<:%I^JRK3T\/WHE%<U^%8TNG*1Q/NL[GXN.(XPPC"H4IQ6;A'7N>83
M6;IF[LAC,F>K0#+?Y8I[WZ"G;U)F"-6OY$ASH86"&3MD0@S(?"M>T@31+@3O
MEA C*>Q5_W=L=:I<9'/34VVDT;2$J%[#MIMNVX\QAPU55-%:[M/R]P2L847R
MYNP!Q['.:Z0H4 LPM1T"(>ZT3V0S4IW/Z<2T75^OD!,DAM^#6NQD7QHM"'1S
MMD8$)@5F]N3QHY:[QBIH0,Q;6E2]D/W@)AB%7: KL]^:7'8DM+DDV-!V-53'
MGBP00&!5$E!+"33P 7?;F_[8=ZK-O/$*#K;*E<BU-1]#&<AR14>OTP+VO40M
MQ@+$MP4>3,+V0IWOM68/F4Z@#-3B676,T4U^%PXR&ZU,>OT\_9A?IG2K0X4?
M,]6]%#^<Y\D@0_=>?+*49[15D'\KR=OK5-:5+G1QP$-_AU.6'.;I+",5,BB;
MMHF_OE31Z>0^NUX&[+GF1&[K9AGZ8A5>\;S*9& \K<1,XO/%RB(S5LO9;H*Y
M5]"U+K1&KT.B?DAMYJ&Z"63 [;LH'7#Z)>E7YXGW%!GJ^Z\S8:(A5\._'WJG
M$A;7[Y.CEP5D[MXO>/!@L X^U/U4]R;_TWSPP4Z.:X?#ZU)[[-P7<B@=4 H#
M4-S)AB2#KFSC)$U0R%UB<AQ:O-JN:"2W8B-[.E4;GVZSO5.UEB&PJ&:"<OU1
MLU>ECYTTFZRVV(9M2U8[IXC0%%9V68[UT.? #R,R2SBI*E.3CV[6NB-!88KB
M@S)^GCG,<5\-ISH)-SRJ;093:[2T&S A^#RI0942UFT9KO:\ZV_-:V^$NO$2
M/NS>71T*MBSX/)'XS"H<[0QV,VGUG'3_3_BF^,_)3=9!<> _^>P_N3Y@X?WQ
M^__H0,G_R/_N#]<?KC]<?[C^</WA^L/U7Y6K06)?$&QB%:I)&_E]Y6&=1NX4
MCX& S"<K=\$NV0O/>]AOG.0\X?OOLW;_DQU_P;G__,<F .0?3LFL8?WGHS3_
M^UF<GZ=150(W&^RH@9:3"G8\;;4?[!9M:;-&#9[;IC]8U>[5V>4,.$8L;JI&
M#J,2$S_X*2ZN]G W;@C_Z$M,7Y$^!5<FB$:C@&?)=$!7F "I*3+ /4$5&:UN
M\Q[:<6EL_VR,RUQ@D<?,[%,K (-7L:YU_HW;)=D_(-CD T]RZ)$=A9V$^)@<
M6[]UX,!%\ID0S30CMN\WYA)814W' H(E_?2F&H9RM@2-/@[#0AW/9C!350\F
MUF;TEE-8/M7I4+"+M$_@AMD78)@Q Z(3',:/Z-2F SP$>?!+]40C2+R5YD44
M22>QRH5HE.Y61B['@LY\@</TR;G%&[Z*G\85WA\N(7W>?=3N&)".WKE4RQAR
M8BI$@^R\3 ?,&="8!Y8QD>"ZJJ$O\#-]'9S3(N1<XB^=Z1TI?PC3O"?B'-J*
M$(KH>O8B2$HXVG!\5P',3+DUWI#S^^W&KZ9G2EGN8_/Q:@&T,O&?N(/KQR+
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MI7.SEV0]^*\V/19]WFQE#7M<HIWTTV#Z\5!#Z].:X@>V'MD!??/Q FU!TX]
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M-TQW83,G+&>H;+ M7S=3W=SHCS/,?"%1'(JO=0HLS_=J'=B:563'4+_,Y1V
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MT.S+D_!/!B)%G,]Q,H4YF^I^I\'-IWZF,'!F<8@.0/=1>;8Y_OE-@M,!0\S
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M()<4EWVG9RZ@?+3Z#=."NX+351EV>X$,'D&/:T]N+!<\IXE?)3^!CPY23.F
MKW@0'9 [\?%8\7%Z+BDQP:K^B]60,/BC^4I_8W1Q+EDI*4;]@?:XPA!^;.-T
M<9L!BK+7LH^G3HU".FAO&:!PAMJTKWJNF5IAH'1+0MF*#.H>7[O8.M32.EY^
M,:N(X_G]HF]2@X*=^='3",(\HBF3*L;5BZ5<$?ZGR3*VH\<*CYW,$,GAD6J3
MZQJ[<A=K\W(Z.]H4L5^J]R:G'E&\^Z'O+0LTYP99$24IJ"]'&^V%P/EB/LII
M?TB3-SX(QQ>^#Y\)6IJ;:,WJXVWR)7KW:>7Q5*L=$5]7*S:V1,D],&WZ)I-]
M.O^)8;[DI<X(?C11#P=.3DOL1IQK?8P[I>[<VN=$]&K[^-KUL+#W!1;[6\"_
M@0X *DZKTP&#]_:Q"<=R7KOHJ2M]2F^QZ].V"@(!_/-3 K'M:,=9,X,FYXE6
MOZ^]M"Z)GI]X?!W*9W^C_R9WP-60<0:GOM$&[8WA(DPR^(8)Q6&QYM2@:C*H
M:7].Y?8O+Z$XT&SMFQE/T5Y._8Z!9;L7_O!&]"9R\2L=,(M!(;X&*)N,>6L=
M(@3TF?F6DCBG\]BED(4MR5+0K-+8,Q>Q<:S.SR!_#@VC2-#2#"?VZ* TXL0!
M9J+^H0'/L3_4_Y5'0-C'MDW45-!@S9*MLMV!T&EA!#0@L\IUOO65\W_TS,I)
MS,([S*?VI]_SL2AD5__ [1<YI4-5I"RS?N[7MS&)P34VXA>>)A8+O4EQOBZ=
MK*?HW=>((2E"-L^4*Q0"4W4/DX7<'9@B5;J 282&YI>]]XV(7 G!@I2?EG_4
M-5)/)#W-T6].@O/OMY2%0[KGI1X#$UOU:C?J-=XS9QJ-:7)8SCPJ<8M32F_=
M].3.DDCC6.2D!*RVS8 ,:2>[^F8\&H9E/I9YR^Y_KV(W'BDXLC%]-S]978UJ
MB2P) 0M^SJM:[O*<OB72EO^I=ZIRQ=_#C9_JVW)@O%]6P^@#P7 /%Z7B8#J
M$Q9"%.*2]I7)6<"P.7:2[>14 Z+ZCC7ZF=+C63;QCUKST("S)!J:D<)'I*L
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M'P+7*:;/2X!]0-5$W,D%]5YCX/7OZR(KH_-FSF\[@?,K"JJY\\?$K.[[PK"
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MB%AE@7(5RAD[Z=H':GC7P7BHA'2^4KTW-[Z^9ZCJUK*;MX.=L"9)/'YYS'6
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MS8SE_5J,5\W# ??_:OTJGE&U=O(.3'-L!VY'1YT@,22[Y6SJQE7(M57(O<B
M#GRL]=/UV^D+.XA69].W\BD0XK/CQO7 <D*(WY'U^M^",&7[9=3R:0GL&E5&
MTEZ%N/;]:P1N43I3'U#4*0$+L?)#8)O(S3>^C;P>L/QSI8)9<BHNZ F\'^,9
M5$_(VVJ>6X:S?MQ3]"@_Z-75:'NW)@8]:>K)5O ]9;*:LDUZR"2.?$"*D=TE
M6Y 0LC](_J4<ST#JSH4EO5*9[^#)X<^;>*L0K9D)+>QFS'2)?]G1?A_[HF-\
M5W-A40#PGL$ON<Q@#KU&1>XKRU[GV]_HEAO8; )\+E0@8%1[I$LV+1#323W\
MT3.88TD+4,LMG'&WVG@:'4#QN[YAF/[F=/=/+V9^;V7\6\\WE@[2=!72XM&\
M:QR4\'5B67[H#U-\F!#/4X^Q+O\<+W+BI\8O><LT6K<2XQT/6])XO4I.A:!3
MQPUB)G] \R!BHT^H^0[G]QG/@SEPL6['U 2KDBFD -WB$?"(OPC/JP_6_2V=
M\[@K3AHRV13VE\%NP.K!P5TUM4-P_=]>D[)J=2?F1U8AIX;+6X^53#//.!EK
MZ]Z+C,LHOAWM\V]U()#XD[GU$7.]?)8220OT [(Z6/0,H95(M]4YH)6Z0:H*
M3W_T 0S>/\7,Z"##1IX/++T-=][9E%,@/FYF**K(<!SR9]7VP]_HN9]1[YLQ
M_2H16RIXY@\J1YW/O$^YRDUAK6\\*X&1!^3;!PO9Y<T[B57R$)?N3H.=<?NF
M:H>D%B_'OW VM&>DI_>*OX=WOJJK:>P_-K+H'.!!9PZ[.<J._9M>!]"< '$*
M&"+91](5X3L7[F<PSQ #6ON.[=2]^50SPGHAD2 \?A:71_1K&[G1@]<:J2SS
MK6J!9$9%V9S2GG(="BV'=YMVUZ)V(:#@ ;2P"XC$_R3%R5Y0+GXGZY*[)@X/
MT[OWD=SR9FFE4F=@;T;YQP+K4*; SHQ0VI 4<>@CIBS2(4&J#GQU=A7*VXIG
ME%:B<(X0%/E%6:KZ[ KL_J*J>@=2;ZB<0%4G9IP:),B4/2O_</9[^:6^XT_K
ME(P2KW>0;1RNY\<6 GX7Q/9P_IH>W'\I#2V,6-SK7-TP1-!KP*DB6SE18[.S
MHWQ&=54U(W&JKJ&A+EMP=X(SL7$B:.KIP+[+#FD.YUR/;L@T!:A\$ZFV%?^G
M$#XJ<14"H5RFW$?ILJY0(3/L^H@D5""%&>RK/\@H=38 O(BIOD#H'SF:PP^E
M5KGPL'>$)O09SZ+DT[,C\BT2N_:D%84.-!5XW$$%TN[YK@-'@8$5P1D W6ZG
M9H<_D2;^B G6+C0WA\O0CL-FKE[\FN%%L\O=9_H)@;MJZYE)KJ_J4S@S,QM2
M^$?5O?ZE+NY+W\C*6).YF=Q66.*4.%R6B5Q#;!"7R_+F%O4H6D16JX%F?98+
M,-4&4YUHK0YBRRW9Y?0>G]QAPK[/53EM1P\%R4-2\B\1PLJ\>EX$:4<^5YYN
MTOHNDRC))^IUA/EYTJ/]#$H\>3=H*F)-?J[&/2=Y@O;\IP'4LX!L>)9[S._%
MA_&)H,P]PH[DGI'')1\FO()UD=FE@9'9?XYXB >\>XJ",<5?5/\-S?_",J:$
M!$ B1H*$2P*H]G3FP@.2!U]X@]O"54%J$ZT_<$$V/R %L:&3RA,J=<(SS]T[
MU9>-/B>Q^\OS!*+Q9\R,+D/\N& &I2Z%*(JC %SVE>4VFDA^D;,I51D/6%<6
MM*5>7L8@XN5L9,?GIERP2)0M[^%U2TI[U8BW+@]=-=2WYIX=Q(AW$,:2?$Q=
M!^'[:2$_/8=6TO^%>3QS]HKVQDQRU7!RF,BE-"!741<<\Q(^;"L.<R_'.>YA
M[I=TBQE,37&4N7H&[M*E$+OAMLG']TTN;MK^7+7>%%#II #GL6/V9P!YJ>0W
MJ88L-I3D+%$C7IW_&L5*\/U9\6.11HH@69_@V+\$N;\"2T4,6;$"7M6Z-*WO
M%;MCUX-C]H/ED[AQ#PS3V^PT9TR<-8GM1"N3^Z@;D0;28& ]VQ5TXJ/BRD@.
M!8520]7CW<(U/-8 8=_9O^_;H4\,338.(+3N!@ECEQYWC8::FTE+_H8L1?ZK
M97G;"^Z/$,I$$6*X2/DU>I,4"IKA16X8,#=,@->832[IIGQRGJ3&:F-\FP2*
M(O3EGGKBFZK5RYO]SH )DTJCCW<?>U7CQ>^S=;0;:RF&D"O[L3;R;BY#O17-
M6>#MC17%3,KK$78:;FL'O?HKWOT,IK;D&,5M+QQJ-.676^Z_:GVSNGA'/C[=
ML8QANK\<$6TX+W%LKFJB?ODW@T_+1%W#IT9FS+$DAZ47P:5\HF-C6"GI%^!=
M9$4VCTK/<HH:ZQ9BG?N$\TMZ]PQN!'+@F7FSD9,UIA%[4XNQ#E>GPX%ZZ:U5
MR'JA(FD>CI&'3:, O"#NCA_P2/P*2,E6*BD#-;NN%WVA;B%91%S"ETY/6(+A
MF<F?%I?=(W3W"%-*;Q4ZE 1GT4M+L1I?,E:*XQ8RHW]9MQ3\ORR"2#5 9X6J
MSJJEBO-$"VTTCBGO'DJ9#)F!:MMZ QX\=$?0WW5I,#72KV!8%*X(3&WC:B]Y
MU&<Y5-<.L^B+R>Y!99<&<P$XIN*I01DB>^W,5 >'LO#;#>,7:>W3QJZ&;W<^
M?!7^<*>2@X/K^8=_QKF[VJ_=:*P+B?ZO"[*:'@*L5'-6/"DK05V%WH=6][:Q
M1EF\E&2!=^K.Z0EK,)G6\1+3_7*&;-U'UN1TE!%[>=RX@[N)H0<7RDFFQA.&
M0PS5(WC&][QH:^Y1.NY)Z,&E,^JCITT_44=5Q$W@"4F@U'! ;BK=-XR:2J$*
MH,K!&L=6(9NL;I.<_S[(](6*-I0YRQ<Y[J6;?YR?RB1WSRH\(78#:VCH7_WG
M_W]KTO^O0P%!3(=V.S\>>BY,XD24M%4&P_BJRI/<%,HK_X'<VIQE] C#67OJ
MY #CGO?9J0)=?7D^OLSWPNYC.'^_ZV'&#QU4WMR&GO7D?@A.KYR89M9D)O]9
M?N!$A%^8ZGA9*AZ>_JTL0GO!V*7OXXF#VU[6'>K1?/B+Q\FST@7Y>PJ=&<N:
M?$*ALX0^"L#ZH%)*A+:@=)&_@+WB1-!*-$-1G[7^'"-PMNI,P]A?+YKU0$('
M\+#8849V3K)6>XVE#H:<Q+_#3](_NSA[:[&[>Q7R,VCU@CR !4ZD@N>%HAL^
M%#Y[#B%*<@ ([!38M8/FH036Z(]['Q,6?9!3'8GXHM+>/36IL(0]0SN#OKP-
MX#=L?"!VP@EP3J7H+11[-D;G=2\'_3I'F[V$59,>!KG E _CE<CC'IYT[ <X
M$9?;=&J6SW:$72J;WE_N.>/NN%]%[Z#(0?_=MJY/;S_UJ!A"R&ND-T$?/@PT
MG>I ZT@ILF=9/F 0L H1^X+7*87D]ZB=<7=0L21'$5L@C$\,7X5HOH9G21KL
MK-K[I+; 1^L3(\EYP3<N>&-![X[(5EQ->L\><5.N@V2#HGJ_R@H96$ZO^!3H
M)DIM'YD.$D3-ZJ/;H%MVW1^<^]DJF:3W<AP,\QXR$VIN+"]?ZGJ5A(U[O_;R
M*^=S0:"CF7'R+[UC%N(T$6U.Q,/_1-HB>]*\'N3R=;I2$^NUIN+E/TTCU0!C
M\2IDLRUDEWV122+)F^_G'S(YKN<(1!X.CF^C!AXUFZRV[N\+5QD>[BHFMU*K
MUZ,JE^>:@-[)*YG/K.=9SQ4TV)5,F V_PAQNQ/&S76:Q(LV:N-^<S+.+Q[F4
MRT$Z&@4>5M8G,R[9#1VZ\/;P/F5V^#]81^L\K.Q*4^V@7R,C^N0 9T0\TV*^
M&S>&LYD.Y54UU#(\+-I";B%BI>[5;W4[KIL]_OA[ X/>8N;Q=17R4FHI8S"H
MJ2A&EU23*?8?091R]:0_RXIMHX'@V4FE.G]RB/QGDC)H4T3$MUG5B#'8+,WE
M ?K*M<%18M"E>/><SR-3[D!'3W%2&7S6^=JZV51P'SZ1Y",QDH^M0JI14DWU
M<P"Y3L"Z;6  AI1)(6!MCCY=-ZX8X,.VX')V#UUK#-K0\-+AVLJSG+TUS)3/
M40G7&!J\3J!QN=Y'D7[PQ/E;-,Z@N!1T4(#C(8 6A[J,^B!V 'M>2'W9TMT5
M4E>0:G*7=*P(]!!3P$N\'G(7=J31FW)+@%8+^NI)Y,A5[1;MU@[8J-.5AF#A
MG^H9;!@]RX8UD#JJ(ZX'S21$D@Y^!VAMZKCGJTZ;PJ8@-<''!Y=4 UHPPN'&
MQ&@>=UL0<TL"P4[OS+GZ$#U/2P7TQK@XAJDR9!6EA4'C\2D(V%UJ941+KQ[)
M'F"UO%F$;OIR?.S<,$E/@I*:O(JFM&,>"^>L0_Y@ %TQX>/6*@UUH0OYC@QG
M5R=G%/JN8\62V>F!X3U_0LA$A5^Q(% 3L-5=G:L0#DR^J5P$;8^0(P:0ZSY\
M685H4 *XVX.O8<\V@6;\[BR$M?[L#LLNG7@\87RMBG?@UN>5PZ%2YR*,+<:2
MFC=6+-0GGY.W<#?*?P:Y FP7%-RG+%2=+)%K$J<$$XF\A34D&&A%JB LQ'$W
M-)K#OQ]43OH[V[ ^M</7O'$@O-S/;=#<;&YJL,(L( ?GM*:D+?<+]>5_PO :
MUWEY:]M<WHIXX,W$>-LE?W'#DY!F-N7WG2W^N"GKZ+SYZSOC] *9/?L<]CW0
MJOP^J(C>)5!%I"=.E"62]Q!-><Z%G96"9!57@-EN9MI:4_JY5[#=5J.LK328
MK%?#W&3$#=;1O3S._5)_X=1@,.=S=E'0]<M.'4:?\.#^C->IB=":#*&'Y CY
MG:^2*(<%U*/BN4K-"HM3,X&LCG%+.LT435#+B7XM7+6_<9+]N]),A>O:WUYE
M>D3^1JOX8HV^/S5T+?=6A5E^1O\JY")E3-"YLIR\!/N0)1X=]."QA4G M$NV
M7_2+I"@S#4%.HG^H/T,$C3?/VQJ4X6M</VBH6P $!4BL.G1#5R%;P>M;-3P&
MX$?5G-HH@'?O:$ [=6W^2$5XK_8X>4!'UQ4,8OE[PS802\^(R$VBTP3=XT3[
MD\W,OOE%TYYU;FS/+K7</;SAW/YG71&\?O[19MT,/OHV=B/2FM)B)C\D?[,*
MV6X;4'9".685$HK?8=+:RXG@[7T:$'*)1XFC:))W$^/=1^2ZJY#6(Y>*-0>O
ML5LQH>4X_QOI_;XU?S;O%,UG%/F.!\H-!_(&*05.J!C6QL55R$X?J<LKT O@
M=_&=5ZJPI./5 "HNI/$Z,85Y8#:"_R:<SJ[0&ODJ]+HZM//P^(6[&W-\N&G(
MO1E\':EF@[@(M/?S!ZJ[5B&J*+_4475^GO2L2/E!\P'B24D+A]NY\&!"[=DH
MZ->6HPTP$W;3V2%26/YO*ZGB\O'AEP<YA E: (TS'=E8KQ4#(7/Z_T'I;CX#
M\"!C_U]/!$3<W)QP7\7"XM":\T?W//D#LO[1'1?:>X5;5$""U+N0W$[=*MTS
MN7U)243KQ&^1_@+NX-7!1<0B&]I]LFV?K05%Z^.(?0^3,;1HD^QQ4NU=I3.A
M!,/Y^<G'\L;7T/R?>U3?';K@W:/5T=1^MF<]\":M#7[X>=K^O/3#;XU=C4R[
M#"V,\I5<CRFQGE%N<^D]5.DV>SZ[BS5*%=< "TET5@QJB]P<;!.@7^-35G3B
M$:AM7^2[7XDNOM)-22S/VIXC7W"KKGS5[W;&>R/!S,%!M'&X?&E?UHGFOB6/
M+\WK2.%@@X*3GH,TWL*'97&G: /W <L?JN/3E#$W+'&Y,-:K'W^O7-KNV:@C
ML$K#51=\X41D_Z232>CYU)ZSX;!]E%\8!9#/3\PJX*IOSZ>X&'ZT]3ALCIZZ
M95IG[^!9AG<WSL[;Y5FN4ZF*A/#4W*QP'ZDAR^E%6XC-WM@6SM :Z=_2\Z"&
MR%2^>;!$BI95T,U@7=!U4F6 PL,H8.95]CSM&NF0 )_0C.ICO"%1""*G<PFG
MS.FLS;,9ND2 &F=>OC"A1UQR0FW[<(I@I^S*:)1%*^1Q)+D?TR4\+S$@:2F\
M6" ?K4.,.38$Q^^ 'SJQWHIL"O@VO23:7!C.JXE]X/YJEEVO-]O'<6"871X:
M&-_JBEAW1U;7;"H?J*F/CI_C2@Z0?A(Q[R/WD(*!<?$CG2ZGV>WAW#NL#7#5
MX][).A?84F=^I]4I6VQ!4*>/_:] >\W6[AN/,#.8*V2C!KK!]B%RC"R-%1"B
M(CXCRR9K2]< XN><'EJ;4,G;V=XGZM(5CB*5&-$NDG;D/C;RS9[L\MW#MB=*
M@R-NIN.OAXLM7;V]$#U=H^UE:Q9]_JD!;WDD-MN0M@ >BA2 $+L%)JVT3<1O
M%W#A_20-/CZ!O+6/Y%/:-('\JQX;M^3C.^@UI#ME-#<;Y'\HRZA;]>$%EO"L
M2*6+LAD5 $W&;FW>3L2>$5';T1NE-J*]M$F6VG3D-4[/IZD$_JLT._,IB>'$
MD5"$D\^!F7/#"XNSQ(FH,165K$"'IX;L3^C67M"0_1J;0*W^,,P*WD?""?"<
M'WHM?K"3NI4,#VZ&B5S!TI8)E,CN[HR#2__BI;(.7L,'6_VPF_#N%TM"0UGC
M,;OL=TS*E>H0F$O_;2-9N=0/-H=0P+0EZ"@)!&<Z5Q;$M\ EX [KJB(3?DX9
MF!&KQT;*FEE^?#,;MSKOP**?/_B:QS\/=EI;TM0X4&8;A<S&WR(4=P2A9E,[
M>A7>A16,O1=9W-:;L+(W4:3.RT@-3_+NOF68H_?".&[^@T]@S@&@IN[J5T1*
M88A^>V1*#%]U+\\_*=+YAQ:V=OJ>I*B1&7J6.$N6*K>4=V(9\U2<".8NRY8?
M)++% :+ZX&4=MD[D*B1.N@>1S(YA# \_59090E5;&+K(5<&-/+)_Z<T!W>Q'
M+C=9)R$&;V'O(=<J*-9E%3*9;961 Y'].6=K) DD=S,YA7]/; 24VRE:T[X:
M8#)02-AQK]3?@%8^2]8:]'#PKC/2V93'Q>F:?>QY,9O$@RFAHU^,_[7F"Q5P
MAFF0'&7/FI$_3.+=*]+S(H-\08C59/.= )&'^(:HHLC(*C.^11][=F"NH(_F
M[ZY'J839.CTWB[V;Z.$\I)Y$+]WO<70 ?NJ2[!7M'>7#(S$&_/1<B@%+)0%D
M-H<:5R KE%N 4;\!"-J=1I5=62V4C4CM:1WKD"7:W47)<%V3LYM;\Q \>N\W
M]]JX5<@Y1IP/PB3)<YB&L#L])W_VGPN-REL%"XDL5;GFER0^]CYJ"VDK,-:6
M&I[N2 ,E'9'J,?2336G[BYU.#)-.4(H]&8,M>-NWH2:'Z6=Z=AU_6(=]1P$/
M<.\P*!PCL7D_V93<RWF?)#)8F$1WP)3( [YZ3*!0R$Q:A$&GJ>H:[9B3#9>*
M/P9Z>-S$U ?5Z,[G5[Q)O_&Q^W=;NXA";W7&^#V:(8">N[H*84X)+22.I.NR
M.ND>@=-"/'1S\WXP8Q([-PX8M>O&WR=!>=WJFXCN-IOPR'UT:_/<_(F9MX+"
MID&&M^K)WC,X5=?I)2C]0O#*R:>\!/H$17P1#(M0Y(U($8P,7_*;YHUL1%+J
M:(SX)7B))CT'GN>IXER'"!3P.'(WT=)FK"G,<9"A(L[TNL+L:[2K*/_4GF8W
M7YH[3K3%1<;EEGRYS)]<M^0M=I,5D[>3/ZQ"UC5:B))XP^--(X_Y*K YA5PD
M7A;R:X>D>OP7(7G8+:!%NWM9O@Z&5"V\'Q ;0LC>&Z5_M>W](,+4JT#Z)T@%
MQBF3Z=":WE9*"DJI.Y!:A18FBJ"GP",B)@]![7X.FO*Q"2[YUWEX;2+FS6/F
M8/B;OT,<?.FOZ XA4/2 U)\GL[L\@&C:UN:PB'Y !="P5&HUK;,\2OQ"\<27
M0&H;4HW=>"$41CXH?Y<#K\5A8UE;YU7;V5/RK6\*T\9.]W^N;ZRM2V<[-@V1
M$"&\V:2&Z1]GSU6G(\("79T45NT.E8D7]H@HD[U)K%!T/'F][)E\O;S7X,B@
M?/\7E+*M/C_;HM-W+U@L0A\]#(M;2J9X#BA00R.(@X]==$B;_DG]EG]4V*6(
MDNF'T\S^V<K9%87L[/@G@IYO;JX<F,,C[%R^LET&PV>]DX3V9YIKXP8Z.SL'
M=&H;&AL;:HF3# ;C[A&3VMJ<7^.VG_W[X;#6$PSM+7Z,S<-W+'"ZQ?&R'(K?
M!Q8/ :3.5=*(81VH[:Q JBYXU69LHRWNTN2X:YM3?[,FI?7$&B?OB+JAA<7N
M9'O'VENZIQKMB\!T/:>W4K.?+JZ;?VM["X@0/P'4.Z 0Z0&P!^!VP5Z"3NW-
M*FR:7)\H:)5;45L?@5D.0W1X[1 /&*DDB:TL!]#PA\=NBJL<S:H[R\H>>'S3
MD&\4B=ZK*Q'5,8H8$*67JE)?H^B4N18:V.N4VLIY9%=-7'Z]0DMDH'6.\6D_
MO0U_10DN?#!A^.QT^O7#/D1WK"I8]-ZIP=E]:<Y66<R7/2#OI+18"I$[R!/<
MRM"'923S.O"0@*H42-DN50[B4S1GY=M%RZV*Y L6(W5926X&>T<03<="\;2*
M\.QU9YF2&YY<RC5[6F<-V:1?2-!C]5'&(N2;9#S8V%J8,BD$=!/8T&*P#/7;
M(?!Q;QZL"Z7F>.LJV[)FGI/S* ]DP%<AYBO+]GX1\,S0XFNL,>OU&8]LM\Y8
M7UC)B%\ZJGY8\939Y,X, ],^;S%;ECUO#-Z2^)+?ZUZ;0/8WGG_NH-7(VFIK
MRM/;OT"@;B;FC)YI*P_> D::'5?=[/2FPJ7T2@!PLESK<WSI43BMD76%FNJ.
MI2_/C0(1@H['+S^@VK%*H\&1S=2=^)VZ^/OP[_/A,)WIFLM>5Q_/*7Z95A"F
M)YT*3X-G:)\Y9L,K.(#:AZA6L!8#;)@L#Q![B5BMO;<G-E:+D!F$R=2=<G8F
M)0D>E66CJ-W9+>/3D1,,'FO=--)(/IK4H=N<%BH4_ R:G+0<>+='W@5$<8/J
M&:ES)G-+@$,KI9K2@HICK2-M86L0\3QF[%RC74 440O/B*('X1'9D3*CO=L7
MI,?*QV>LQQ?=>2&Y#:Q,TRLIXT;)1^W2_[FN5WL2+ 8Z;*]0U:A\J]N#_)\2
M/SM,NHLH\>Q.E[B]SZR)%V?6>5_YJE7TL<;XUNF!@(O&I$K%XVB"&2(:+WZN
M5!!M+R;V$9K\^ M)!/Q&*1Q(R<WUO!"L@U1O!./YINHJK =7G +-?=D2 U.Q
M,^H,\0KS%1L&SRI]3#1ZJ/?M6Q<4.,ZZW36Y886(PHKFN#5J3PNZ^;/J'$-)
M%_E@B'<'5/N:P)K]M"2P>G9;(.9J;!F8J*L2)3'=(+J9C+^.+T'SS;!NU3DX
M8-,J)'A!"TM^C0)<81OE8^1] X00#W&(K*!9;YJR1D%3.0,CLVXHE<;S!1>"
M\,]QU"M52N<&BRN!WK@%[8\=86%1_B&"WKD/Y@S/Q>X=JQ"L?+?4#K27H*70
M89*6P S5QM) :DB=@3ESXYHZQC \V\-IZ*)3DU$[4G_D6D'F+WBSI^4,O#HQ
MYG2M=Y;>FW*"/O+3GOM'E#NHK]BI<"RXST&JT?M:(([O"^="T?QL]0M@@"C&
M<23DKZX*W(0RNX*NB%;T,XQ3\>Q*>5%6+M@^,4VY6-=/LH\69^^>*ZIBI,'2
M2#:27926TZR+XVYN &O.1&3"2^W"CO8J.'6!9 -0Q$EI7\T\>/?J&1]=?PL7
M8EV&I!8(8>SS6Z%7'YT0N:3Z47['PXJ G?5-0\R,V_I<J8:R&WA'8B/]75:,
MFLRB;K%U*B%R[<'U<%C"*F1-X_D7PO3IYJW$_O(*E]BH71?-5B%5G]F--HBF
M!XY[FHHJH_G=-@[Q3M4#N30.1_I-ED"Y DO ;B#\N/V9KB[<+9!9\*E"+\G1
MCU\&2/8BM3N!(V0U@!)'LKEFUG@$6'[=UQ/D][N"(3>WP@B;#H9_8GFKZ@Z'
MRS@V,_6L+_[_N7EQB]V.>@#=A-R*F5[F:LGW2:W!2_ZE/7N:']\2J7=.[ #.
M5Q1?5SGZZ%CQ1^(CMT'#IDR3>H:78<TM']W/&_R5 MM((HF[O#=)<I%H,6E.
MY7%W?MD":K12Z3JML!3RWL#SB!X3A:^UU3$O?-'#*S<]-UA86_UUJ9/UBE4U
M=,['\Z/*+RT/#?_\#67%NDK[8/JKK'Z!;$)FLX SK'5@=[OO(?"1 +V3Z,'#
MMV"U<>1#P/F,%EBL7$.D5LH+@3G&._8AHM>=JQGI&4]Y4=G47HHS=( F&<7-
M>K.+AKNP/Y;P^Z2.$N@/&J>SI!KU4^V9S$3DEFFYZ@ K2'UT6&H?8?:^,%?A
M4$;H0O4.Z_46;W5/'#P[&_F)42#")$4%+6'5<,C==]^;9D>=]SSZ2R^')CX'
MUDF421=&6'C:!YT35LW:3684R5ER=XT*W%=7%!"7E^DTCNW(T1@XF/^'5Q+J
M\();/6- :,P"0J09UO([(01> VTKD8 ZB=16*-/C*']J(K<:SF+<D)X>L#4"
MVDXRXZ#ZE%9GJ\<5H')[V2['1GW:E_I(;K %F%P1NCO^5&6_D+'#UEFK(WLJ
MWL.UIKDF#5V]4-'<X7\KTJR"IEI8WL$>/7A98V(\.L<D8V[D=YT'S@1D[X$)
MPR_&CQ^JO#@"?<^<2U7,#0=8%NI(3I#L9=7-<*ER':@,V+3[VJ&U2'MD#Q&E
M43*[1H>*0"BNB@X^%46U,%/@0H,)G"3;SW- NFY#;'.VG;CZQ0GQI<G"%)0>
MA&*_8L L #-.]$L=GG/'9NJU6873*Q-)+[U83X-*@JS+"ZQ6"+*R)P;^39^>
M 1^/@GIY#[W7(4I.O52\<L\?/7\><N#%]LW/+_XX5_"S\MKT_V?CZ2V;(%-I
MY2#S^5 -' 8='ZYJ.+I " GS&;JVF S]K3K5P'\BOV1&PWO4R]OA87/44W[B
M8:M?WI0'2\-D)<T0XK+XDZS6UD:"E+K312-W))HD'?!LOM1==)):T%WZ1=>D
M"YLX8<2FP<=-VIC(/8/&C&\*QE$?';7IW5#X881^<I#PZ$KX;*K&-.=]SIJ5
MLY=$RJ]14+(^.(Q4(ET&*7P!)7>V6:]:Q&Q;T 0C^&J/>=0MP1@?80XUBF 2
MQT@J]3*'=S.=!HO?1N'@_%'^-\.W!&F)J%>Z3<4Q2^PJHY+, &9'.DIU%7(-
M-1K?FLZ$JB.MB6<FOHA7NAZ\+WE!;,/V,69K0P3#%;9&+\$NKY'013-7_H@S
MMDT#:R>U]-"VFM@%B*OY*+KZ''MR%0+NZ1+:2TSE0ZBJCQAJ&_>NHK+-B'CQ
M+5FN?/LJ!$^,]P':.=@4X\>+W*W>#N788,Y#)R<;LPB,=U33"6%X[[8O!OKR
MMZ=V#3-,'2EY]R%2NNRVXG-")T%.(5]]M%2<T>?!@PJ+@>2K@Z2(R1#7?? &
M=()VYH6-WXC<EK,'DP-0U*M],_7-CPJ="7YBO1<D-._I FE_)*U0)@2R!*FM
MZ!1.0"*#=<_ MH^\ZXM<393# "3MF.+XXO29UK:."0.G(P2?_>8YVW.;3UT:
M.EAAMF1V9'XQ^SCGLUZV]<J\\C8/ 5/X26("9HB7955R Y(%T-6:NE4*[6O>
M^$6LR^KH'3O@[3VN["[RN-?H5=R#R&A%W6-;5CM<$CC>]9G9'_5R)HF4HSY<
M.%*>PW6ILN)$I%#\Y*I2/1 /K..Q% A#V@LTQ=\CJ?+T-E0.A&=I[<E./.PS
M@WG\,;:"X1QPKCX(SPC!K'C1&'K3175U3_^^$;AN\)_7WIG^M9B:PEI/6(7L
MG)#^W-=\2&HZ(M\S735Q[(74=D#A0AQ<13WW5HBU.!!/VA-0VD/C=%\V"TW^
M.VQ:U/2JIM9B_9:WS+^IX'[?4HF](Z#3]N,@R-52_!9/<$K [5B%0$C;1IIW
M@^3W*Y\I]YJ5173.7>*C+J85)KSRXY>:]&E_7.X%7$%KO7]S'7PD8X7,D#V\
M@=PNRV=-/L!6T]JXHU1/$7YN%"> K94/<-?;6A!$)BU<'3,2CE^:J@'V=I W
M5>&WC!^K\.I^V9TWZ@LF+TYGG*H'1K*?O^7);OA8\T>P<V\8JJ@S$(E5!Q1P
M0<=3=.1[Y1RD&:@0DD]%.FT4AC%*F<[=].'814Y$0K-&$'4S22/L.<:7&.'Y
MQ(<2 #Z875ZV?J>;?=N2??W7=$YY<D>VN*38AV3TXU\<4=JLR72J-EW]0X.X
MGSW?>%9R&,R;<8*.1HESFU.N#-JBBHS[.X(F4_7&NXT%3OV+E7:,[![&IZ%J
MDFVF=X13TD(<D^-;PF.-H#_@!!7Y$B?R6^@:N24.C8<ED$(FO>WY)>6[M<5,
M Q@@%"['VF*OXZ^]+ E1[4H,-W,/+/=3LKGRQS&]MSN#A9-<X%RYNB<8+[&B
MO5Z%J)#?8U*%&@)\LGQ?-0"[DV<9UL'#QB)-TCM7Q(-\=E*C&^Z@0JA5 <EE
M.LR;F?<O>(W-6#R%.[M^M3,Z,[2K7C%C<IVN%H$HPAG<3-W2:(/JD'FW9*"V
ME)$VA80O8]ISU!AU#$9TJ'O-?6^]4P%1;PI?U30TW)6X53LUV;LPZE^]:JYC
M+KV42GZTY9:_1JZ5)2#US5AC#JED2[#4L5](-B%Y#OVZK+/R9Z3SX_*BIY-<
M%4>R[_(ID,++BK)QTM?[;5R3/>L7\B+X>F??=/W-ARN;_KG?J2I"=6!H=\BZ
M"E'1',_K<>BTYL8TJO*Y6H'RK0.[TF?=1>ZE/.&Z,\.+JQ"UH)LC,X,?@ZT_
MC3^S]O]S2ZD3HF?H;&?AZ F(50=+LWD'46G9:;"1(-)YG;-Y",$\M>BMK@TV
MM,EW-@W_G>ZV_OKTS?K.W  [R=M??L[#.)C:/N]\7COF"Y.<)O=8HNAQ)1+K
M\>") ]23??(-Y#ZD.K@<P5L<O#QTK3$D>C(9AHT_UC\_7E&.Z0A9BL:PS^C\
MBO5V#%(5/ENYMA"QH8?Z"34G4+#<2S!$XDG2214GRQKW@#$B$_$?LOSPAX+9
MY*MX'6)^ZPW2[C[IZ;09@ZW U#W;(_Y1^((QRX=YXZ,7DO7:5Y"5>5_2G QB
M+CWG>$U713,57OX1TAQ\.#DL*Z9<AMZ7[Z\5T1)0?JC$>FR<K1X_Z]N!&5UF
M*UZ7$\R<4$KYM3;MEKP7IQ0;$>V_GAD1DC^=^3F+!Q9:ZIZ/^44Y6\ZF5D$[
M>D>]^9]_W.J^5A%1\O1MXK--^%5($'2TOG5_?!SR$'CQ-SRC)^)XWYR#@=&Z
MWB&"F95+C.1XB#TEL?$P%?B#$AQ$WK<R]IH*G*.,:BC@H7H]E&%9(E+BMB*U
M&<V#C19\BG+P_KV%BNE0DQX?T@@GKT6K3!_Z.,/Y7'EC&_^;8^W M<_5PW ;
M7/8M8^;@',/DE6S-"&T^O$G/?6B.GB6,_.8R"%L0PNT.S>4-,4JSG+Q"=PV$
M?T>8ENI;VPA/>@Z\[U]8*)M+NY6/*RTEKG]DPD?-N2GF_DN-**"+MIW,5<BO
MJ1;:9NDA,%;0J]4M@,6BJLF/ \MS229^C&N->$&2ET50B=1CJ+&ZW'$SQFLT
M$",4Y_*]%KMA6ECO:?E6B*SE51-SJ.S:DI[]?@:+SFRJL1B[,/H^9#[7D6?A
M-6&/OX7;GW+BL+?/,=5WZO7[>2GGPKW/_6,%(LS77$2-D4._Z$R8BJ;N2Q&3
M5)7INT8EQ$<=G/D,7M,ZM,9??QS%,Y*OSG2[T#70QK^W!]2EOGL\ .^NBAE@
M\XO;H:.4=A1S63@N"CLM*U[$ZG)^[-!4=69-ANCQT&V;8(@%%2).H)Y*PO&&
MV01N@DYDSD/"I>NE02O;<3U:GP=H_"<G.>9/,D9.HK2G,;>51U%TAQ;H/2QP
M9A422_EI,5M%H!S?Z B4*BS^3M(&$:I=!Z6^9*?,5XZ1FP0A-T2)1Y [<-;I
M\14JQH,$B9T_2=*-DSRE9[VACY^@CZU"]MI$K)@(**U4-6D :":RF)QG%6,^
M?C%  ="$1JA9OG>[").-=JRE#U8(#??"[RZ<:K+,3,F AVB,8KTX'[W?_O2J
MRY!\<)JU;C$5W N3:OJ)H^F@EF7I<WDWM692I-P&W4ZR:!IA).,< 6J'NMJH
MPRV>L]/I^I%0&DT%.V-=\TCM'B?Y<^X+S.@X..7L]&9Q-MMZ8G!9?AME2IE,
MY6Z[-,R:S(2NLW42J%X=1%<#>Y-%.L=&&..7Q2KZ5J>!A3O2:+X$IU(Z*WEK
M6%,Y2,=OXDQ7HJ^'P6^*1T;0IHV_%[]=405B!"9ML-2<-?T*L[)+1,X64-?@
MOL[\'H0T'#1L9M;44T\.S2]&NVB$E' \9[0'.,&65I8+^L,%:BW:@</"3W%>
MJ"?0#R9BHNS%*@1'NW<36D5)H:]"-$@JL@?-6Z7GP#LOI/@A/Q][>U%7%TO7
M68 ;/]^L/;T0AL?9Q<<W(@[^/@8^:'TT^F'F[-NP6P@YPR"Q^ ME6/VN[58>
M-*YY*[!PNW$#;]RTE:P*Y#S&Y1'#VC+WO/2:SG1Y>C5K5TW-'=2DJS,\>4_'
M<'O:N(\3XMW 7Y/ZSO]8*]MX"I)V%++-\1>(FJ,Q -%W)H8P.VAW*7KETNL
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M1Z9"#?)=BC7J,641W61GH&&PDJO:FXS8.&7GU:&UKS7'M]8G;+G^,6C+11F
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M8R"CID?Y6-/@Q!Q'C3;XKWVE?\1%I1?Y?!E@&1G'S7>=B\>>4.:KQ2$,2%O
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M(NI!J1Q7\[P++/&[>9:'&(OV%R*L,BR.;WO0MP8A Y25#K?DZ% UAU;M4.@
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M^OX-(W/9NLJJ!<$J8GF7H-Z >I6'VJOP!;<%6M5"'B7OIU\0O82H)(L_&UX
MVBGQX=D3@O^/MS\/2RI]X\=Q9EJTS,@T+4VIU*Q,J=PF4YA6,\=HU924::P4
MB7A7FJ0(:;EG3CGII*/D2N9"*4NNI+A4CJ&BHK@@,)4;>4XIGI'%+WT^[_?O
MC]]U??_]_N-UH9>'YYS[?E[WZW7NY0FR?<Z.C;SNXGGB_8"VSY8]4%36645.
M"E9=_U_?FQTT#68V+\%J1+H?R71S=8S#>S)&RDMT@:^?>G6A_?&4V:=^/WM#
MA.]#KU2SOOG&DP1/A"\VY1G';6% ]DDV!M]WN004*!,@!Y4SM)V43-^LW3J!
M7MM@;?GW[5-3YOR@D=$I_Z]E$4*6 ]R;W:?C\>NFCMD\'I\4FV8_'RNI<!IM
M," N[V6TBQ?:F$.AVM5<E:,Z%K('G&1CF;(8P3JR.]'QZ_LI?C# 2_:PDQTO
MY8@\C*JFK3:#CAFETX^AV\-M=<&/7-K+&9,+.>>GQ&/X@;JX1F_KY&7_5-KC
M=+Q!1+D"'$M2G:?L!4-G-.,T0W*1+Q<4Q"W!+AO2^+?]HQ8%<?,&MV*EH^C6
MI@,#%!=\I9<L[]:)G ^+QR^!L_'7!D>.?1N! OUSC[%4QLH-NDLFD;'*ZLQ6
MFH%'C-3G>Q45&\-'L@/5IR!;F7,]NR%AKCZY@C2_!%N-*C(QRQ;O&O7]$3>9
M'>9"7SMRL8UT1U/ \"F=7N3^KB,/CNAKWI0@J;,F#84.I+74:2IY5XFN$NF'
MVO&NF]@8'[HEA&D>V'LA+'@7\&Z?<W17/SW)@07*C!A=,9::.C$T[)L?:X [
MR !Q@+\D[B6$:-8BOK\OHUC5<0$WQ2:5(T%KV%_5</BJXBI]G7K%<W*V+U I
MND\Y^;O'JA<&_N#JHYOJLMV3$JY3O*0^?S3=.R/<^@I6J_H/)&KFK>*-,W"
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M!T+=L4'DS-;%+XS09U#H$1^&]]$\]I>:YT-+,/R4 >GV8O CJX*RDCQY0%I
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MEHI86,HP\DEN0,M672-&"-8'FH4%#L\LLHRVLPLG1!S<+LIRH/VI;G.$Z=:
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M#Q+?@::_/0S 97[G_-[V_-:K*.DC?=3T!I+U#O4\.U\_<._M#PK$2\S,IE!
M)66D-6VABA!PR@;00/D"FI4MP39"]7(_MMP ;D@Y[(.-]0GNN]1#L2Z07"Q]
M57)0RISY:68^8$[CTNH0]<*[='03T3EVUP!?]] OX59<H+[3.<IIP3!:Z0EX
MT1D4<Y"F<YV55*%D#<5&A/1,ND_MOU,(X=HX@1=OOOTZ/.Q=0<ZR-(<I=C,.
M [RDWUX__<CY9JNI]?(VNIS^I*<_R'+C/O<]:RHJBA/]EF_X]?B6^+6&- \Z
M^[/"1RH8E&M7=Y2K3_6IW62(3=--.[^/VI@86P; ==]I,#0Z-HTS:K*%,N6M
M=""5?*9_G-/H3O&OE'[*__*OPT>R(F)(+IQA!UV5=7KW_8Q*@_[5Q5(.&$P'
M'ZJ46=\;R=3_R50>A]J8>TF;R==%O[C15WG<\<B&1[IHRZ2OB?.6^]YC<TNQ
M71CO)H"7TH LD[29,JP22L-G8\MPBY*9>I4!!0-PV[,UY;QKM(<[54>I/<I@
MB]= U-V//7,[/)P N129.%N8/^R7UEQGVUB::R)NKR'>ND.*JO JG-#GU.57
MKJF+5'Q4BXO02C/-4^W^B;&](%V1I/,G_IE^-)Z4CK+D=J.E%R?-*T<0<)2^
M>E_0,<-;7A"Q.(RSD#F9+6:G]^VY&.[_M1$2,GUG_*(6$QG/H<Q6ZC:-\W_+
M@78\@S]NLM>*@M=!!U0^6@&Z)BF-XL(4=ZF.!9#?47:"IOYL+A!+3U$C#2LX
MP6N?_-78_XE;Y=)Z^^VCY/4?9L\ ,ZN1)VNL\1)/<K;2!33K0$ [@FM N3()
MT-Z38^[B])I,H,-'-3D>MN5C>/%L$JYC;$O^U#>97DKD[,J1E$/D>WP1!X8=
MF>*LGQ0IZ^CWV(:HK]_. :_N_3S!&W_.JZ&R58>TG>::69U=.6(* =I4?H$2
M"3F\F #O,0_*,3 ;\1]U)S.W[7A-Z(KQ,E-&7V'=M,'(+J@/Q.P[$3'QN/&S
MTEE3[$P2"Y3AT'E0Y(W%$@1F4/1/:O_BP/?5=DGJ&T4^VS/DAB;(/[]YD0A5
M0V/>);D%EFT#::BG5/!%4.G/Z#T\$NF^U2I-)BV<-WA+V0^Y24>MI6V?D]%A
MZ-74#TLPB]T>6TO%8=%N#RB6X*[>KP.>7N=[(B8J(VK9#KIX&IJBR-<22.Z+
M4HJCR.Q[+LY73[P$X\+5QGQIJ"*/$=9D3<2>@7S ;V^ZB+< B;PC7A;F$2!5
MI1DD-@IG7&BOQO#^@5]2\%2JY-+JJ9S;E062[$9 ^ZJD<:#(<@GV@0Y@NT).
M I*96B"MS9S3*FQ JBY2UH&&"GZ'#?U*36^!#FH^MB1?>IUW0FPSX=NP_N^W
MLYMOO+W\59(,A5X!:=K5)6!2"\Y*'4P) :*4^I"+'(LV4:\&3-RRQS:!3(61
M/&-U..KZ$YT,/#N(,?R4)_5U.L7YYOQ64>7ZQC0(<>AU]NGL5M2VNS^V9_\?
M+<NBNF&D&)AV#,U)I[=CAH1O%A4/7U/-R<8MW612(%2Q:-/M\VQ28MR (15
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M1Q[PB:1)TZT(G;0DZK:DKA#GG*#V=$80^1:F\4!17P'PNO_2HX*^;<S2[PV
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M!MG,M^EOH9^?F_JG1MUK=Z\N(S%QZI$!U;^.6?/4@F6)NPPL:B7.'82\92+
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M]M74&-R-%[J>2 +AJXD9-H.,?>[QT]U'*BJS\"6!\#)D-.'(JZ1-0L'$$59
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MF*G,-.[9@>>CI))6['IGK"DB+7X'O=B78.?FDBFWM&[O'NG).-1(J?449$C
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M/(B>>:PXI?2%PB7NTY.G@U$26&,31K5Z3;M_\71(<KO;FY.UG4;Q53=[O7_
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MTOH62^^.'[C >8@I8@=^MLX*1J D[A%ZNGLGGQ'&HI_(UAVS/C8YG;BO)9:
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MY-<ZU$9?^(C=X*SJE+:7JA-CAB3K8! [@LT:-M<=ON0F8IW"LC:(5-$J,>#
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M)-'A;1 /"^TJT8(IO936*OF UAI/\4DZEAD%7T-. *@9:O>1[AM6JP2TUL3
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M5Y+\;% =CR7H2)O> ']E"@5M8?)*&73-/(3OJ3ZIBSDZJ;N-6K,]W\$9KC\
M6ONSP9<RHM[1GB_-YCFMED<)_B'LWHA:'.MA(4?AFN[AKMSFT <>0MOY[>A4
M9NH0>8-C ]0W6QF#5T<<3$7\@M7 T>124@3?S8;QUR^"F,0M0G=W^ZM;NVW:
M6A]O2_X8,N3K//2)[QL;YR0R\K6?F?Y/2@]&S7PK+(V,?U=2/+9N8JZ*43SN
MVG IQ:#/="\^/J7D;\$ ;BUFZ)+X7<CQS_LF1QM>+->/^\O/]5M/14 &1'VI
MC^),_N4_OC[[/0XQ()<W@1&*A':,VW/00='8,E6IH9T'HTO$I.YCM6!Y:"BU
M8AYR4?/X.M=RW$7\5FF6%9Z8(.W"GN]Q..-OF)FPG20!MXLF%2JCA8T\)^'&
MI)7<C:!12URNU;U"D#AR6.CFD@-K#4'+;KN>JKL7'5%U,)*[2<0F'%E344[Z
M/">[_JZDJ)MY8?QRMYM1-+\:MK#BAUD!1G0FPI4+=[2S<3] &O_?-\^_4C9J
M2LBN.^O-VV[_>FJ=/L/LPOC9>\0K)C.>:)D9C6 =4?_^@051"+-4+P?W*^P[
M&*NUV]0' =-D&=-"O?ZER!F:FJMEU;OJM00VJ -6/HTRK5O^*28O[U5,)6*\
MY<>YZB;&86XM[4Q/B6!*(-^Z1)$GU;$J:YG9Y. (;$#0PF#-0R9QJH-J5Q .
MNX4P5SN\U)21K^[UNOYD8LX_):9RS6A;@0-X'4X[,\K_ ^\:$&BUJ:#]1WM<
MP>:<X]K>!H%3TZ7O+>CMR%.\RV@J?=A)4Q#+-*"\B4?RF2:@1!8]AEA#P'?D
M9C]$)G-<@1_M?W2%RH@P6T8BKAQGM3?$SKO!-X^PG,1TB+5P+V?*!.3CRE,@
M-D0M7_""T/92()HJSO:K\Y"E4YK[;(,EH[QV:E;\5.I.#VP5*4"&7*=V V$C
M/'VP_K#"D3=*-R<U^IB)/0)S+\QY-B6--23V=WUC.(GLKQ%FF@LC=<E]LIL_
M#UDA5B,!6!)9+RPNEAH^PE@!$EM<XD15%YLX;& X*[P(/33TC\^>D M>%^]=
MV+^5537ITP4AUZO6:/F\E;Q0QBWA, 185H.WLA>N>S</D?FWYJGV/5+HT3T.
M+CWQ&)?$ZBHEQ9W 56T"1*F/7CP0'&,_P)7FSD.">/TSB=[R'?\?[C+_OSC,
MJ*L7&@-D-,AFDOTT?R-#L3<HN_.D.71J%'X>8CINM0^L+NO^1*))1<T2"(XQ
M:.60U^(U>\9;UKUN#,";-C@6$F.)T1?%SFV5'*&K6R6779QH+_TY#[G$ .U$
MS=#E)*-VV/J=G)4C?ING)F,\J:/$5L$3TKTV\[:W/_#F@D$L*>.G8VS(4=GG
M;Z-G7_1P]H8NSR][]MTYE1X:>3CL7R2XP[N%E^EF('E%'*Q74GL6+I094\.R
MJ%B1A_?(7]S>2PI>L\1XP"MB5(XP8:^[X..85]),<@QET^3V4@V^%75K><+0
MGI8W7YJ1H<1;\Y#%O)&2>JH9E= M]CX)B-KI:\':#HHUX,JG)W-M^@58':V*
MP-[*-7DKI)@ [4527WR;8%(=(;,_H+7F":],GAM^IM1N?I]R7UC]U'>77M\\
M!#@MN16/E--4%KX*]Q&]C!B8B4[@>%+#%;IJHM<*6SR!NM:X;+AI9$-Q4_]E
M#U?F5Y&92WWT^-SY@I*(,.(R 9IA.C:W-">J9NSIKW.U2A=-T316W*'$@^<5
MHF,NOPV!?/X?\(SIO/WZ';I,NW%LM=C_-LNARJ_UMP\3RIRRDZX[[H5$?A\3
MWSAK\*\.*W]AJR7\FRHS'4OQU^[5=O#T9KJ\SVC^IEAKNY4\5G@.7]5T9BH8
MMH(<#,N8[EY5DHN-.O,1LR.D9?:WNI^8><C9]S/,I=3+P^.!J,48WTEJ-;8%
MFBZIB9-7J%"4[CED$GL &0Y/?X^B"+"KR,'XDB[B2/=B4GV;^=_FT'2M!9]R
M*,BV\/?W?L30QVB_N(59P"5?W?Y6*GNBOO_S"E:LM0"W SDZH;-6':U(X,.@
M9(="]4DPAU 2#$YUF%/N$_72R'[XQRU_X( HLS>-;R/_&,R[?\-+4^10<GN.
M+BZK9MV%G?I?B\Q/],$P9;;_ %P9 C8J?L8T$HBG <?D2QZ>1<,^.P-0] R.
M3^48Q0C@F'4M=[0XZ9=PX?G+_G5#C_.G/S@*M\L_IH_.%7#QFN>\B$:8F*F,
M /G <J7&Z2%B"^F<.%+\C!M:UZL.+!Q'43,\-I1CO5>Q!&-U5@[OI]%-)\6&
MMB\%TI?UZ7=]SO<M^0+[4#&R;.H5=?&$CH_(80I!ZS "'% D-\<C,[6[25,=
M5OM?]'+-2'"O!V*XX2")R*=8ON (R!MTSW4-Z9#]/1RQ<BB(;_.W/M7TMGAY
M"A613;D/B-H8 _>47 #;BEQ,,I+1^,@LA&E_C&78@E:,0>J1&@\KC-]'8FQJ
MN#WPT/[++-7+J9V7V>C )II_GVV2.WKDKE_9QY-;')$,Y@TK1\647*Y8N,1G
MI%**LK$TE/=D\DCBR2^R*;Z^3O"\?CR!9$-;F4NQN#GH#8=OTNSOHM/]+ ?K
M5[K(4%157RV48+UE*X\R9?90^V-"IWQOKUGJX)02#4:H5I-4RE\UU;R+EJ;=
M(R+Z(U Q@KQE9:\C!6,6?@"S3:>#/C';M-ED#PQZ_8Q^)F&'WYXY^V.$2OCE
M&:C\X6V4DE:">:[7PP..^Z_7*9,CHHYNT"ZB=>A0 F,CY;65<Y\=>/5)E-\G
M"=@] LMRWLYFKB0E#2_NW;!)\+F?<"5B]QO"=*5KFW;#^Z(,ZU\ZL67#GCJL
MY<ERTBB6(%,&YTOT2=VMU)5L%<.8O$_H<;"D^0F&Y(5I3+)(R/(^=O>7PV=>
M*]'Z11LS'1K&49BLBJV^Y5_%YX<87Z#R6B!31N1+Q%/*(YHZ[2*2'4;!3)OD
M!)=1NF$PCITTP;6)JX U\ZPDOI8Y:8[R(L/!-FC2%-P9W9B//?4RM5?X4VU]
M]6D(*K+!YBV@K?\/Y=%]EIME>/@4@7OYB"T*6EI5&XVFWEX8I=TJ(M[^_?A.
M5J*^_XM^9_=:X^/?_W&8K(SXJ\/<B5X;9;\;HK4@>8?H4GBI=FA8GZ%D@ :*
M">F7R7*@$=WG;$&_@=1SIB^+Y-KW<<*E36:!'$&APJP-;H8%XUKKW8Z\:W2^
M7;AS>M 2ZYL0\Q9E>;_1NWR<48]  )>R%+!7!<[@==G6!_Y0\$<+QAJXU+C1
MH2:BAW.Z:#@R/O?POX9WV?>G)RP,KU7KZ9F RP#]49A<H*O/PIYONK*C2U/:
M#H8)#P];0D*?$\HT^0@'\@;!#+H)&0 ,EY=+HNK<S#*_3;)@Z\1?3147AC\.
MO7'.RW0(;%8^GFN^/#-E\&$,]6P3[ *E#0:<]C<#)V1UC:J-E &MOD"[2BL:
MACJ89%56JY!)6L<Q &71UN^Q>>\09M#KV05<A89IDO*@*+$8I)W8@[<R?QDD
MX_;$,/8J7E(_!&I7E4FQ::?RLMR5U 5J$30 ZK>_23,[#,S*+:0_-[&!.N:.
MUD/H;AENZED1.K/N]H40DJC#/.]Z-6XG@?NKIDQ71](CE.<UCWA$*CWW+<)(
MP[FL#I,RQ'M;YG*2V6&V^8 OGV?PKX UI4^&];#UPZX2RO/M6Y[^P$8%,+?&
M63D*./NW]SEO8U5H_#$:*TT)Q3 *"YR2@+:B5$?127-B&WV]VA(,5QTB.Z%]
MK%I&#X!<C[6AHY:V+2V?/B#^CCW:/T-<[A/SY6UUM>B*H\E=V8I/!Z ]Q TD
MNV;&6K)K.<E=!KU%WCW*7('?OC2^(X4<_@B'L0.&GSX0[1H>M"TIG+B6(P[_
MCAY&#PZ]J@^H2:OZ)974TKG.;>QKKE6FM-+._[W'_J(Q"NP]*R]HDE5I=E@@
M=ZJT.U%SBY J\!=<WIST[HW01N:>$!F6L;OED<F/J<EHQ1)91!M\(&$D)YN[
MA^3>BE@"EE2"9G[8C6!T&^IRKDL#=U-O\8L>HG-GUQ:2]$7O8T6<\G=2'=_O
M9:I%A:7[!59=0X9]6O&1.=3_O%UEK@>=58?5:S6%#N20ZP!:YI^JW8(&H6V!
M6GT%/M+,R/TK=[.@^.YVPI?4<7U<V?.&76_G$(T1ENW)S.:ELVY694\&FW<^
M6?0S7\%7EFA8R,AN^D(_YQ(<M MA\IDKT.3E#P9]08'J&#DHB^FQNXST[9L^
M#0;UL"N#K@%;MK,-7(XY[IQ!/^1L9[Z+S4)HAQ,(^L=KZOK)!P>U+; Z_PZF
M*3D4S%.9:<4%IL!L*A+7G1)O4G^;15\'G@ZK!^K;&+19HP%T?1KK12AR8!YR
MA9WH?Z+A1\RMFGI>35-#$F')@7ZR<U6P2"+1TRY6[P(-$5OA?#@T?QEE)_F4
MPKL=;D'D<OI@9Q22VP&O\.);9[%='LJZ.&@9WX&;8_RXO?G?%^AM!-F?K4A7
M7A1Z&QFV8.ZO@S6>]%UHDS0A0][DX; IN3-OJ@/Z6'1]T.H']OVDC;V%J:\!
MM9UWY?;N<-S65>0[JO>+)I' .<E -QJ<43F.:[> US\/J(F:@ID\*)VZG)VY
M(AGOHK4%%A'0IWMC.L[C,!/H'L(W@5_-S\IO9+\(Z>MOUL3J]M?3R,EHU=&O
M6';.I BH&"W(%N*B1V&K!^&9,7E''6 T=6S)DA*2Z,#W?R_E.TPO3#E)JG)%
M!VV:>HH%[$U)%A\RHVLI8N1J.!+O8*U$ M<>RNAI6,-1X!M;ADU'?4E^5AD+
MUR.;L0239W[XL,$[SSS_M2\=M]IRO^AY[?-:W\%.^PF-N>6AX8_CPD^4<$TZ
M D)&:>XCHR2#2Z0N#Z69U:HMI'G(F5X$@KQ9 9USJ,N48BW =Y^><=# E#?+
M)^#0)M_@32Y"P-?T?B')MV4V\"[J(^FN<2-$HP_B@4"I7G,%X==NJ5W+/ 1"
MWLM6K"EQ9%8UCV!71F),_2+./OSW&J>O/2LL0CE6]"/$H:OY#]2K(TW/4Y<%
MB021_YD96*6>AVA>4J/F(3"R(5(?L8K2C5DCH&S1]B-9EVHK2%2I=^I,^D,/
M5VF^_:%:WVX3M8^"<6_G7B@41+V+_':DL0MG\B6'>DVT#O6U7EFKO1&8$\5;
MCK# 4\W(U@K1&:#/#&;,,9#"UH%F?,PV5]=R9UHJ.?AZ&1;OEA!LTS(VZV#3
MGIO:^^VS$-VX@NE\[/+G5(>3,[80]47 NV,*W*XW>5UU3JT'^JM^(W5*11V2
M6TBV=X8,T+M%C@54_#E,.OP&8I/DX^ @;NZ$?PEI[ZL<O\OB!Y5EWK'A,D_[
M<[[RY4?[IATN":<."UEEFE3-8\1*$EJ9#6Y6N(Y0;S_.FH:E:8WZ.$B;SA9'
MV+&^?P]&/R)E"+?\8S4/X:,T=0^98\U_P0=9@[__]'NE)>C.I88FAZNN4OJY
M&]Z3SS_#(VO+)LM4;CO Y&:)H7J9S,^*F DSX\2-0J%M^*?C7,,7]?@!A%59
MBL._C>^W]+&[]@V/?<]L\O*M%6(QJ<35Y)D((*>="OCY#WY1^@/(%F@6S(1B
M2S;0/)_1H0'9SEO)W0;FJ\.??G43I<J=&B<85KC [::,595-DK3)V(1\C.<6
M>Q7:$]EJZL;6%N*?BBT,H974D;M(<_5I6?<-[59-'F7GL0?S$$MD&&R]A+Q<
M,5PPZQ\='2?MAG;%AH_ #%N_&PC&[HWE$F93GA&]=O51I6MSSEEL[G/@4^@8
M]4XP[ DX=1(L>4+>#UC.0UJ'K$^XV=Y3F,ZV6,$:%,,Y11OL_APSC\LL$Q0K
MECWX*[SAY1\?T%%K41L<[:CV,36FZE:P J#)XE[Q%FX%-L/%@2.B)+;$6.VN
M*?= )@#>RER!AWM)UU6<5.[/;[@83T]!;,.+HBK*Q@* ()R;F]^3(<[O;,:M
MV$K'7I\9I D:W34W]=^)WPWQGVO+P.C#0@^OBA.$Z29]WS[G_.._96U.]N^5
MVS9Q_MKRZ>\.PM+LM0<O#=Y\;0*.J2"DP Y8'2/-B0%N]VZ?AZ0A]J+](EH1
MGCK.<,G_II6YXDIM$=D3/#WB!\6**##L$'B7[_-"(%/0,V<&F\S.TP)SSJ9/
M=X*_9LS-"97;IPGVNA"LB<]FA%>,S<X%E%S)B;]6%AY;)A%W-G:^K&E*\L57
M7'?94_?ZT8-C$KP](2Q5;SGO7F8E>K1^LJGBH(ZI_*;@99:!P0!=QNO("^9:
M:@6!J+?Q:QE*M**TL!(_O NXDEZ.99G'TM/57DR;TELGXMPW*^!IY!!I_B'[
M2O?SO8Y5!Y EU!64?F2M?RLTS56RB@Q53$G-,KE;Q[I^ST&L!*;HZKT58%KG
M+_70<K1X3(CZ4R 9PMGC?Q.W529]_!@I,],*,@0;M;^03>R4YKK,S2"?U# <
M#\_%O:(/MHM.@Q(@\G6-@3Y?8A%SB], IDOMUX35L@B73'CW"=*UUUW*I&4T
MN<.GZX^CT__O[,MN9#@T57<PKK>YV\BK@"SZ*V2&I!:9#*?8D9'@0ZEGX'D!
MYPB5.F)_MLK2OE5<.]R9('- MVYI'?@ZUS7YY8* XXNX?S7\2<?%^MS8;Q*Y
M)_!%5B^_ISNO+DT^%0=;\V'<4"NDKB2O!/*4A6 BM7#@,1[%R&3-0Z!?<[_<
M=I@.0;2L>TM&EWK#,V+@T#%EI</GIE(0ZY.ZI^3.*V2H.@Z02"5M#NN0!N23
M@%F2UIKTN^5106#F 84DA84T^WHG2DS-4QJ<\;37A5=*4I0+)D9RL2EH65=]
M'OS>CNOT@CJA4-PN'G[S9EC?W7W?9C:+Q4YU3\"C\23A-@?Y2/J9;9N2MAXK
M3-T:-)IU?NWY<XM:U+:*P#1U-- H%=U6ATH-O'5Z*],C<(2A#]):A_7Z_[0M
MD5I2 WN>3<U0UPS;/;0N%A]1_QC8<_+,V.'-5T;J7ZYKACUZ_[]\74\VE<F%
MZ^I4O5G[5#95GQ=&ST28:AYR5U&Z$+L;P9!1Y&USWBTG'0D&13)LV]#F/.TZ
MN %(]>ZOO')Y&KL*_/7[Q\&0J&N]0=AA>S'6*_%9$'[/F'F@)<!4SFJ*YR$7
M_;.T&S0YO)&R!\.F"5"K6K1ZDZ;28S/>].$(T<QWR<"@+V%T125+ SM18Q@B
M^?!A7%R,@J56<;;')91^)-T[DL//;:O/%&0+G23B"NU*JLI?':-8\$VZ@7#1
ME.M^@"C.;)^CM5E,K5'#G_<Y(ZW4]F!.Y=#'"U'5I0]+QL3](]4-37VH=M=&
M03:](K(:3-PL9%6&'>%5]R6<T]"U6W58\_,X,MJ=-0^IX_']T"/4&VCIE7J
MI[P ;G@JN:X37@EQ3 DJ*K>^ [KAS_IJAK>BK;VH:,Q%:671Q+YY\L[27$Q]
M\>MP'"&1"8G% N=XT DJ1+N)TB4!SC!I :ZBW++)65D7_!5V(TNSV?HZ^;P*
M09HZE>??9]UP*3;C;-&X6YLVIYA5X>324);U;*;\G&.*?MFD8THE&-=!,>Y1
M>S\>"B8EMV#V $I&Y9AKQ?H7 G;W&C#3+W6N9>S7?)>N\')<SIWCUKD[?98.
M7CRQ&Z76G4S2I:A 'INA-D*)I,2.._ ,@IQ L:6\L]K65U(0?(5\1$J$=D9+
MY8YS^JJ_;G=12TGQ6O[Q6N$&U*0D\D[4W5U]JV_%P8#C^6:C]7SXS>%]FK\1
M;B1LZP-76"VVC6Y"AH.QHTV7WN%#[&7^_&.E(6%\5$=J:>/*JT]PYC'QM^H"
MS$YOS4VLRYASI"][S>V=<;?T6#)M_0IK@-BHWO%^'B)=#V)'H$O5KL#[AH)I
M4L(KC,E[#JPP<_"N^><IE1U?:!Y+$U>M7UXP.JF]7+S$NMID\/3_C'C]I*OP
M%!'5W,-&$:C3B==5EJ#[ 469W$=QEB^B.#6*/$*MH8O(YB >=_UJF=\HTVPG
M^G;OQR$=1$O%;VVR7=FW+/=>Z',FZ!T4(GIZYB&1]"3,)E @ZQX0>8-WI(U3
M605Z[V.81J0BZ<<XH]+&TLB&M[M#@B]\QI,FB:6^OGD60][^ J;CC*5YQ_D>
M8FRFKT4(WB?WNY_]")QO8#::D\&+''+GR_7:&.8DJ!=(E,$,\R9>AS4 ]33V
M=F=?BV,Q/\,3?/?_^T*U9?@CRGME4Z:OP#0V@OUCXY+OU!&>'*?Z3?N6QYKB
MPP9HVE6[YR&K1.WQ>G+]J[$EY W@/ 1X)W;8>XBXL5W8<W D_^0V#Z1T1=69
M[UK5\?>/4K\TSSG6XI[A&YP[Q#--5DI\I>L,49D!VDBI8N1(7.L\Y.;P[FSD
M)#+=:FV?VF.6N/@C-^NI[_J%1<1I\M!+1^Z= KK3'%C=AK@W;XWD8@)773I"
M=9V'C-2Y$=C,23[0*$-MIJ% I.HTV431GO6T9?B\,&]3WXR#N;3H+Z^]:>&$
MD^+ S##K"^*!"WN.*:LWJ^R4#S0LRGI=8K$% X&)L[WJTPJ8;+;=WP1GKG=3
M:ZAVJ6$).=>IQ4/C]OAG8/L7_Y><FGH!Q[4052+G8Z-< ^Y$F9D&FBI['2JS
MV4^^CL"<J,TV%%>0T8Y<Q/%2[2<'/=P,3JG,276S(Z[TZ;&M$0TO@5F:'4=
M@8&I+K&!#8*JF*P=4_R W#O+V(% \5RM.O<V'/[UZ'W@[(B6IK# @+PBLB-(
M+5$'*(ZP7"B;07J8U'+58/M<VS-3!<JF:1Z2+JL.^55FRZZOJ\^WFLS\B[!S
M],6/,[T?COP<&Z7>0)IJC:G-_EI32J]DJ=KA.I.\2U/DH5^EWJUY>OF97WX5
M0]HI61[9@P'WRAQ+'-X*WSOTBS]$FH<4W^F(I6X#M-4E@[4AI*?K\V8N_3^C
MN6$:YCP$QUM#^6<>LIA\5G$/TPOW./TDV+^4%-ULM4)@6=1/CAM=V#]2E2\E
MKL*]^^/C:PLL9N\0]J,7/NYJ1%'0>%R=T'76M"?X L6)C 6_Z,35'<U=M?MC
MR@!L(YN:;+47W"2NH[FV(0?*6E"V#Y?-MBRL["T*J*NN9B&LK<SJ%(9]TV-L
MWT3#B0")H4<8H0P_BXJ>",#8]&PJB$22N-O5ZT&"HG3PE9*QCNRLE_X+>%4!
M;YZ'F''6UWX<'J3^JCX V/3-8BQ$8:K_P]O;QS.]___C.EU(:*$H8J<4E8MU
MX>*$ME.2M+1*$8N=CL2LM5.1Q6PG8B["J0[>A\.*D)@E&V$L-IQR),9D8C:G
MY&*\7L6\CEWXSOOS?G\^[\_GG]]_/[?;ZQ\WM]?F\7P^[X_[X^K^M&Q[6>_"
M(#35%K;/7<0OU,;4N0S<JO&V,9.2M)R]A2<F*)[U>,"4MA3K7C9)C[(9JB#G
MU<E7@)(+?4Y3$Q[64MZ:J:!3]:60^U$@@LL1S0>'"F)+F!ES!X;8_JZI9;10
M' [?$#923;NV8M'Y$<$<D\'=700EO(5S(D(< 45!95 +[1IOPOQ44RD_;I5K
MS@,Z9F1P^-E%[!^6U/ ,OL$XR%+H/*"]'U<TJI^@1@O<OKX.'[6\L3B[7(:V
MX;W,%LV^HMJ2I2 NT>GU#)50(WW---[%O&34*"'C.H*$'7N".6V4-F4D]76A
MG1:)KT*Z?$GM<@'NM(HRH/F6#&MO-A BK<FA8_ LO[80.,0O@M*#$D_E'WO9
M.VWOM#,BY,MX=/M=</(G?I%SE^:^X\.*B.>1?O%:BZYVACQ!A#\P._VW$J_I
M;M83S?/$<"W5D]"YF+#189?6R3%!\SXH?&QWY1QOJ^I0O3!JBI"N_#LQ!.LP
MS#WQ%2\V[,[P?1#_;&Y&1^T"\EHER3B38W>1.RAN@*W 2!I_FE"XQ<H5R**K
M_#W<F7MNHRLC/$.$LUHNYNR5M1!Z6JCIOF7REPE1UOA(Y[]^7NG\I+/R9YW/
M>TH9T3OGDS*F10&Q5^MR;@V<G1B0K8B_M%.PVVXP1#]PANDU7'$P811[\</A
M\6.:DU^]:X_5_\_T76I=$"V--_H$7DMO[Z8W;X<2QV"KJ*]1U0%I*G>I_NP*
MB@=XK4)J&#/FW?YJ(68QN5S61>-_O3!U"VD!Q&L>QEPBA(;12#<MNW+RRR/J
M:MVR9RJNARX29#PQ0Q$!Z&9I _6[(\[0WT!6*\/869==QP8P*<W?0H23H"TC
MWMRG%!O\'C=Y_<-@\&3Y#D^?NCYD]\V*UTY&$Q/13J"=9H-F"(F$OFH9Y OU
M8Q0><V])1Y^"C)8DPNM0R8(\5,J56RXH71X^W<'Q2Z_AS=.$7U\*L\1!"\'@
M95/7'G&+[#O$ZA>=U\WN7).SD/V K<KX@&(7*)GNO"3M-L:+:6T\2\HQX -R
M-Z@K/Q_&^C!5B 0QF12OR\X6O)20+6 B3G)TT4E<THF;<+,XI$A\BI_Z9DJT
MV/_7PL+"#UO#Y6]82C/-D*2&I=H(\T'G8Y)1QG_5JG];THGLB?SF K^(L(?^
MJM"C_TW._26=ZJ W>K/7GAQ-_1: T=D1.[ 9A*L2=I H]1&YQE,;TLH<K(^#
MB&3NX;*+^(;V5.:%0(*;5=V3R0U.KK?,<_+C-W4EEY2%#!T'+P8->SIS_C1V
MNG$,K-;5.A %#$"EH(@DR,:L;4EG,'^,GI)U;QO0D=ELJ^DN-(#2;UJ/%'C[
M0N012Q'5@BQZ.R'(=:UM-@:]VIX$>7[XK2S_%-!64M!YT69)YX!< MG<XH!O
ME(JC@&Z2UD\S5D&Y+303ZD8<1!^=_PH5V29_;6M \3-\5(<>D6N[NVUF)ENG
M3M8E>@>'3-D*7!MVSJ9<_5C?.X_5KW^%[ /H"2I+8($OIMWEKEQNJ("WYITD
MFF9+L]9&N.&2N8=*C_X97"2<"S85=?J^R"CX;="!67164+WJ :'TWW6:+T(%
M2UV$BF"9:WI&+-1)M%!?;*MF-51R&YC7.%(N06-C#C:P#7C)6LW6@B")M[ (
MD"23B"1[#\\QP\A%F?@[*>]%8TT=_:QP@\/S1MZ Q\'%7%PZKW9@6;H-.VHK
MOR2%0[MRI_-'[1@9K@ZC:ZE&&BU?^H;-+N#ZC"%6M3QMB;G$)(?8[4)PW-6'
MJ=W%K>"$.;6X_',#/=G)T"L*MR$BMW 'NU;G"WRCII<!G&9 -C%I3I981:>(
M31*/*TZ"R#I2,4Z%!UR3M/&.H>H(A(^C[4)CY$R+4R]Z*M,P=KX[:W^KJ*W&
M/WO&+YN@NO;.;Z)[O5Q4:M;I JSCZEK4CQ':0$P'W%3;-$;3Z2BB]J)JLC(I
M]NUQ4ZP-D,L6YU]?O!O/=&ZBGQU@1_5%I1/W7R(Y,-*+>C(K")8CF>_X7V6'
M0>W;RL;@27FDMN[!NG9)C?=T,, 7+)($O*UDK$QU,Y \I4@"2^\;9$@Q>I[2
M(::K=Y^]QOR]Q6L2)W\J/4#HX44\B$77.Z^]VI[=0VMQF.O"C"(Z&$-"A85P
MWM<[$/)3(E7' -0]C9'ED9FQ,PR^U5:HJSAR9!>C]:SDXJY;V%W;>FWV?+-3
M]'+$IO_$EGF+U,LZ2J7"0?V$31,+%5<@/[#[Y%XOFHRWOHTH4^]?41V%L8JX
M)G:]-_=K:NH#]PO.2O=!=NFOUL,1=>9$X+!E;P ;BI&&\^&Z4'Z;E3.0RV>L
M@'#M(=^]5.(R*%BI9"V9=A1TO>?([7:5(W<-L+O<!LZ#JSORE1)W_\;&AW_^
MO7#M$^\ *G3V+LX$%88:RE6PH&U%9%>!&>I%7;NO2Z>B "+*\GV1%R@FP%1'
MT,QS)]AFB@>:Y>BP7W)6Y&C(?Q^1<_,#+HB,;6DVYRHW^M?%U&W0U/TKZ-LT
M9N6QG,>B[(72@6XI0@!+M;( R@28>ZYN265\FO[D@(GG;1FAP.FH3;)%TITY
M]<&9*IMT3.^:ZMME2SJDR"\V&8\+O/TOA7]O9:F\J1F@*[RA4*D<S;<RJ(<>
M@PQ9W3TV+QF^4F,V^ 9$RV8MIRZG6*E'483T([T_#KD\4CRS:6BJ[XT*JQ?F
M!P2?[?QJH44)]KAJ$TFQN1%@=&"&3G2/\MIX@V5MR&_?L6FIYJA6]\TR$/[J
M#XJ/<PF'G3 YQ&^V>EG?4-UX7VY-8'K+8'0.\:CA*C)CN2W?TI='T'Q+60U=
M E$RVQ9&6N$!X.]^"@& !8''FH!N/]>!7UJ*)>2.[Y>GC(*5_@5;B_A^F80(
MMG+*[S9IQR*UX@F^3J2E$C=+.G*H(R/KA:K;2A--?[-Y']%XWA9:":+/52?]
M?7Z XBPU#! T6]0KJVZ&R2RM3W(O.LK?&99@#720A=5-/1Z!CP8G_0_@%Q>2
M5>@GV)'!#[;9\253038UEQ\._7DGL>5VV:2+V>[M,P%ILI%+O_P!H=)I "9?
MB]>A//&4XE<M<;A!3OX+"UG[]3EJ&2!LT!];?P4>"<#2GNC+<&LF>H=-";7
M1&WRS@2;>YWE6NJ1]T?:\2JKX^KT43-Y',!77/NG3/.?$@O- 7+R!;;:=93$
MUS*[B#ROQYE?VZ@'09?T1S9WBLF>K7F$?+QS<,SI8(L?1LZ*6WOUF=@+O,23
M+YK[A'3U2^06RH]0_RCC_8)B6EV W$3N\%:74/7(%2TC=AP(+=,_A$*#;YG
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MG)%I4<(DOJ8UQ!6XEQ[C(:)N!1NZR\F[YWTTG7&E+L4RN^ LESR;W-FL0:P
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M @S\Q93%T@J#1D?3!4$L>B)OI&C68)]WU3 AZ.JVS/S=\+5XW!H*2KF*UA+
M"^>MUG1A4/3F#9K!PG700YB@.\'4+:G_4X94[2<=H#MG;1B$.KPY?5?JB0=.
M8?]XQ!5N-_;(BS(M=.EU*B>RXX\-G60OFK2B=)MMJ5T,X#S*&,J5\A(\/)F:
MM[3:;GY!:!MN(XF=?AO.IQDBG2@' Q&V(++^X)+.,:&P#4&]'\@43,6Q"$LZ
M1LXUEU;5:BP??/<SZA2SV92R[P7XZ3%XJEO:_;,<:1NIV(N/90D(I+5D*LPJ
M,C:,R;V5([[U6 :QY\#5\HRFRC/8P_B;3SM)AMSK_*T$\SV9,_^Z=I'U.XU
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M5<Y"K2AFT:IF5>RIQS\JQ.???(ALD-SE:BF+S7(SXE72&DT_=;_Z+NI:.LN
M_+7C%XHK*5VRCNI$1J&K>^VY85*+>'_+[3.]"J%/CX=SV8>A+>9?["S& 1']
M&5Y<1G=6NUZ()\D;_!_#)\V2D/H4)\!;P$NCF7'W2?.)=C*S]A+@K.H$N"K
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M0KR@-8Y0AC*G1$.#HY:N;4LZ&REH&<MB&(];A]P*N9])&VIKB$E4N4OIS2^
M4_1BLDOO\4L/0UYR;I;YJ&M,[\241+@5S',6^K6(V:7<3Q4AMX"S=R@K0#]I
M3'O&F@7/?I7#V.QZR+MM$9[R$0>#DM^.>_5M[X]2NR@(?S@5!(D^3;X=.AOA
MWZ[<S\SNZ[*0:RC(E1!/YBTO!V^.DE0F!$6?&=S B32(;C7_<TG'C++ZM@P_
M=PBK* >]?R[MF2,EY>W+OL9T/A1ZK!JXZ3WFZQ]O]64193H4&%FXAYVS:Y8=
MI]8?1HT6HUZ,MTK>^RM';>4URF^A. RT#SS0"M_BL0E8P *VB3L>HH&!-NWI
M;R))N8 0BB^+_RXR]Y:8HG!M?2L>=O:U6M(YT]QW,B_G?DD(]N=X0RW./0,#
M4JAZY!I%ZC+)4OGTL68IOLI]9-X9T+M%CCE_'INU2=,]XM*WO6_.77DC?^P7
M?%!R36AY2-(O;3^,N-2\(_[J2/<X3:V&&%(2'V%!T)B"N'L:2[))V\ANP&/!
M+&0=B$A564O5-!P0WS7T_4",E:G(.1@Y>P90+?@2(@=,\*XN#TZ*WFW9<F]?
MMJI5W4S=0/$%7.4'E-;4#Y*:A02*]UB6!63;+@YH@658K0>2GM0UL.Y1]<D:
MS:<NQVOV8YB:VU9FC?V<DGC,:=*+B=Q842(STB1H8L2<T(D:^)])^LX!9^8!
M?JQCM<SAFMS>B:B+[G-FABQZW<KL/-DKMVGF-=X/#;C_8$2D=R4ZP_+-X[65
M@I50X*AD(ZWE-(K4K3>)8O.F_P;'7Z%>T%J&/0-$)@HJ=*D2LO8";]6 *[V
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MM>F7FP:9,1_3'_<S"#MY7\X.!%FXW7_R.>_>HO&SWI()+6'XF7T![)TP!%K
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MB0-Z7=2Y;) .T19@;Z.IT,_=TE@ME4-\.VZYA2T&%F#[)S3:GC(N+<">.BS
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M9["%OMPE)0)N&F(;G5@6F9<3Z@K/N,I<,4W']+[]3:3VG=C+'L[>=V@1(%Z
M23?^];U,L@I%D(\I[H%S4W7R?N'6Q)I'/)5['WIY<89JOX2>5 \D(Z41KK&N
MSHUR-V8BK23$MIXY2B-LX"44U47% "45]\6?<LAIE3ZQ9DI/"A^A;T,WH+RF
M?;< "QS9_)*"@IJ5%T/FD](:%VG_:7+UQ"0XU@+HSE#U_*!:9?M\6V*Z==&+
M4J>QI(_/!QBYKE>^_M07:9S5IYD:#LG^/4EEE*VX Z$*M#K*V%&/("&NA.HZ
M,*8SYLB7[%6.:T1Y>#>Y2;+*KYR4%M GJF/WSN1MFYB8%K>Z)NZ?=1G(PE0]
MD%J77\@BG)AO>3OYQ5M1UXNBW1I%:J?>E01O$QA&= _C.H!%"[ K(1_3%/?D
M48DHI#GI2K]X6XJP6S<X7/7]P(S:'C?U@.'#U#,8PP[NGGXR$%C=Z^B^Q'E%
MXI6D,[!Y:@> T!;\IVP==BCN%J+&\HYFHZ9C/DW38\S:SH8 N0&0A-'_J8<N
M4R'"(G'Z))=S5?VH/U!.EAZ)?:ZN;CL_ZIHUF/66AEA02K+O3BSKE!+Y#HI*
MZ &HHTA5WT8;D2RZ6[(M3+7I^P.>M0Q*LF47"@036;QMN3&@IF\9.-)55%%\
ML$BP5A[P://[ -\)]P<;:]J>IV_+ #(QE]W@+P$+-AX!H_2P-["%#[4!K5U]
M)WFV"$@@.S]4Z4-'P.NX59"#"\A6;>%%2FDIY-/Y&S)Q- [+:G Z(H;_1^7
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M$%^GJ7E_64HD%>XG&/:;L+O.-;E.+3]GMN3:*C>#]R,^!\Z[QEZ]&[D 6[\
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ML78@WR'18V]SZ(:#B"]TZEWY;V=$$.2_(6J@<%>08J Z,N[&74[Q0:&G2TK
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MKRSK[<%9+(EOT$Y_NFGT'BTJ]P;'2&<S% FC\3DEL@FT#<4(0([?L*?NA/8
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MN]9-,N*/OJ95)4[7+WSF$(1.YW/>?/EDEX1.M Q.S#XB?R4FY;J?5=IJ#7V
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MU2M?YW5X."N2@]Y3VI7=JC8=OS_2O@S=#,PKO-2>T![-_5E:A&(_'VW=!R4
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MLIAD!C[H>?S>*E1EIU:W$/#BI.#C]Q\)SM;4[PG]_=.RUZN_O?IQN;)6NR8
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M#.K)?'FA/.2=M(/(\G/N5-G6MUSS*A!C[E5]C"GA4JWZ*%MEP_H=5,OJK,/
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MQ_^/8<%&!AM_TT:(I/J75B"+0U3OYR.4A#?(A5TA/,F^T17(5"7FP8;_+A*
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M+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( (6$8UJ)H)YB8D4  #W: @ -
M          "  9FF!@!A9'!T+65X,3DN:'1M4$L! A0#%     @ A81C6MS1
MSO4)!   \1@   \              ( !)NP& &%D<'0M97@R,U\Q+FAT;5!+
M 0(4 Q0    ( (6$8UH1V@*F10D  ,A'   /              "  5SP!@!A
M9'!T+65X,S%?,2YH=&U02P$"% ,4    " "%A&-:IDDIPUX)  "C30  #P
M            @ '.^08 861P="UE>#,Q7S(N:'1M4$L! A0#%     @ A81C
M6IC)QGEV!@  PBL   \              ( !60,' &%D<'0M97@S,E\Q+FAT
M;5!+ 0(4 Q0    ( (6$8UH=<>(3F 8  .@P   /              "  ?P)
M!P!A9'!T+65X,S)?,BYH=&U02P$"% ,4    " "%A&-:1>6R%AE5 @#*@ 8
M$0              @ '!$ < :6UG-C0Q-C$U,#E?,"YJ<&=02P$"% ,4
M" "%A&-:)_0UCFG.!  !H0D $0              @ $)9@D :6UG-C0Q-C$U
M,#E?,2YJ<&=02P$"% ,4    " "%A&-:)FVT)%;M @"OL08 $0
M    @ &A- X :6UG-C0Q-C$U,#E?,BYJ<&=02P$"% ,4    " "%A&-:W<:?
M^ ]J!0 X@ 8 $0              @ $F(A$ :6UG-C0Q-C$U,#E?,RYJ<&=0
52P4&      P # #F @  9(P6

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>adpt-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adpt="http://www.adaptivebiotech.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adpt-20241231.xsd" xlink:type="simple"/>
    <context id="C_800a8d4f-a9fc-4ca6-8af0-3cd02f0dd56b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_81bb5afe-4560-45fd-bd67-49459a4983ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_826be3c4-b05f-4764-b189-9b17a0ed4f47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_830ceebd-b448-4556-8cc3-345699e93087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_845f3c97-7e7c-4286-9701-ee7332f3f413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_848613df-8ebc-4107-bbad-5a337d92718b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8493c832-b379-44de-b19a-4bb6d192e6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_8672005a-0af6-4c35-b305-e5625f4ced55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_874675f7-b27f-4f96-93aa-3186a0017df4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_880b4bee-c006-4cb8-8920-ecb8a97fc49d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_88922b78-bf40-483b-ba74-3b67fea9b4fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_89099e56-2c94-45a0-bf9b-0e1751243cd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8949417c-8327-42ad-9e79-5c74d95818aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_8a711a70-7835-4547-9b99-bc3f849a6ee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8ae2ed18-baf4-42dd-a344-3979e49ff066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c08d7f9-6ece-4397-98cb-7a4e690601d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8dd592c7-dd5c-4673-a9f3-c1849fefa514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8f46490b-2478-46c6-9c66-ca4d59a7e377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9055c1c2-d88e-4bbe-b0ba-ea4735bc60b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_90e7cb01-e413-4073-b348-b2397b9dd2f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_90f05e58-9e8e-464c-86a0-007bf79714f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9272d326-ab2d-442b-b3a2-82c6a66a936a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_938538bd-3388-44c9-b50d-231541782951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_93957bc6-8913-431a-aa08-83e39673bc72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_93a61f54-9fc1-4164-ad0a-ecd149ef96a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9449b797-84c6-46c5-a338-60738ca67a56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9574ad63-2e26-40ad-9358-463b4132a65d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9636194e-e351-4fcc-97ab-4e132d735d9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_96e4eb5a-1de1-40a2-8f39-b8260ca0c7ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="C_99584d81-0d39-482d-9529-479e97a39b00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9abadd97-9d4e-4600-a895-663eefee5344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9bed03af-b144-4cd1-8808-efb75597dec9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9c86f6ae-1650-46f6-a8e7-0baaca9c4d6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9d69ac12-b7e7-4fba-a6e8-17f59c20625b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9dadad4b-2404-454e-8619-6c7106da8dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9eec2a01-b68b-4cd4-9ae8-af29e919f6c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a0289be5-fa32-463c-acef-732918e4cece">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a1e0e792-7995-4a69-9664-7d62b49d7305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a46c0838-63e1-46ff-badd-1a080dcfd4e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a49d0116-6be0-4342-bb34-064f2cb1779c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6daf5ec-996f-44a9-a1a1-176861ff844f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a7d99817-f47e-4c17-8910-f27cddac34f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8b15cb2-7331-4388-b91a-39842959aeaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a9e6d9f0-f84d-4295-b3ac-f1ae0043be0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ab192050-c968-4f59-b97c-0347bf2e6704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_abf475fb-d18b-494c-bb9c-bf8ac3104ace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac141085-19dd-4092-b7b5-3caab7439cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ade00613-56f9-431a-ba97-2bc4f44cf6b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae8e1030-1ab7-4183-8173-e30e69f625b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af621409-f3a9-456c-8964-3694f64ce437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b03c96cb-2be3-4399-a5cc-ad4279252dd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b0da9317-56fb-4a02-9287-ece7f5f4b6bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b171d937-1d83-4b19-9289-84b0ac31bda2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b28752cf-076a-4931-ad68-b484eab79e15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b2e59962-3ddd-4060-85da-417d16f3db74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b986fb51-c7d8-4885-ad77-406faf3a7217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bb6cf174-eaac-4064-a305-81f3eb2a9aeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc03cecf-836f-4bee-b7f1-33ef96865307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc1bccb4-0e9a-42e9-b42b-84b9f3eb6d85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc1ec203-aeac-49ca-bbbc-3d860034cbec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc4f3373-536d-41d1-b3a3-421bacc254af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bd08a3f3-19f2-4f0f-9fdc-39c4d781f8d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bd3ac93b-1e22-485d-bfed-003c41a39739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bd7b1034-af6a-470b-8700-f6950a6eba00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bdf418ac-63a7-4d7a-a22c-01620319ca13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_be240297-154f-4383-9264-3588023daa8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c00eaa13-213e-4380-87d4-07983d165569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c147eb1f-f94e-4397-b028-6165d4ff279b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c231ef4e-80b4-4315-a315-4a98c8a5a33b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c46025e5-021b-4f7b-a2ef-444e78692785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2024-12-29</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c57a4b94-c81c-408b-81ae-f08bfc651eca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c8814a61-92ce-4b2b-8aa0-402f4c13d4de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c8c4442e-e5ce-488d-9683-4a18e9b3cd7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c8ff48b7-0993-480b-9ebf-68a92b4acfce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cb262e8f-a1c3-4acd-b4cf-58e1bcae091b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb4e71eb-46c4-41f6-9ca9-4467ec43dcfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cb867f2c-9a12-4675-ab77-495ff41044b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc21401e-27f1-4093-ae19-40e8a58d1a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cc530114-c6ce-4f99-b1da-fe2970aacb2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_cc544eb2-c862-4117-ae53-7167dec34569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ccbf3cec-810a-407c-8e46-299bdc89be19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cdd9919b-7ab5-4a3b-856b-38b155fb4234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cfbee4bf-0f67-4e80-8986-2a8c42354e22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_cfd24335-f1d6-459a-a81e-c4653a33dd6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d2e2d8d1-07f1-4212-9f71-7af175f378a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d3e396ad-f474-4619-9772-0d0cf9c0f093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_d3e4b471-6ad7-4d54-aafa-1c355daee1b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d536e9b5-ed0c-483d-9d06-83c84f459d93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d6ec2ad5-f515-4f06-84a0-2aa770767702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="C_d8181a55-5e75-41e9-9ce9-c8d6ef15af36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da165782-cf35-4126-a330-0965f4347274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da3ff03b-c852-4729-b32f-d1e13c53f431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_db18a52f-bcfe-46a3-89ae-80288cdff126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_dc2d580a-7814-47b1-a90a-9db3f5a070a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_de48bc4d-6614-4d5d-ba6b-44f4d8a7fb54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dec1c67a-a4a6-4150-87ca-ce929f12f0f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_df6ab829-80ae-4fe6-8c59-0c879baee98e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_df90d480-536f-44ca-97f1-bc8815b053e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dfdfb869-6506-40d7-affa-2d14196aab88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e0cd05cf-7df4-4d8f-b77a-87c83fce22a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e16d035a-df2e-4300-bb99-13a2fe409ebb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e30f0baf-e7ad-4a6d-8333-cd12494dfbb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e4bc6147-a322-4ac9-983f-0be3e4e33863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4fca2f4-8e1d-432d-80ec-6c3440952998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e59b5618-2d7c-4271-a133-4a54a274bfa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adpt:DigitalBiotechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e9191c9f-9e40-4eef-8bb8-8c5bff219c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eb217ce2-c0bd-4ee9-98ca-e04bd1a4c870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_ebc8e107-4003-4674-8227-7ec4caf59826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockExerciseOfOutstandingStockOptionsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_edda825c-90de-4c1f-b5b3-c767c222382e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eddbf21f-640d-4187-9c5f-398cd390ba4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ee233ba5-9cea-4a85-9f15-e4b103298328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ef70f5dc-4521-45f8-a731-f46544a75c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f01c0215-4e04-4a37-b6a0-43ec834d33fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f2113807-0eb7-481d-81da-8e883e379e25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_f3a08a4e-1038-45b8-8a45-c1295cbf5ecb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f4324bd6-f036-4a55-a048-f63024a406bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6bd00d1-b48a-4bf4-8057-810a2bb6684a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb3ea207-d43b-4520-9dbf-4b33f273a3e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb6ff782-0ca3-4143-ad9b-7c8ef89ed646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fbb5807f-dfac-429b-964f-d08eebca81e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fc40783a-89f6-4d6a-8cdb-a7280da7107a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fd06ba76-408d-423e-bf02-573512c6c45c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fd819420-41b4-40d4-9e84-63652fd8d5a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_fd9b1278-cc4e-43c9-a7cf-005a24cec79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fea8d0de-6b48-42cf-a187-18acba215cd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0029b7a6-ee35-412e-80b4-c83f66b83283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_013827d3-b15c-4f85-88a8-bbae4386a47c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_01f6ee6c-fba7-496b-80dc-8365c221c856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_02627e80-13ae-4972-9edc-6d2d1f0cdb33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_03002793-4de6-465a-b177-09dbb4ca58f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_05929f03-5f49-44c6-99b2-b6ac0648d6a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_05b25161-4405-4484-9a79-0c9ef7d93c2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_06fe2942-7d85-4654-9ab0-33bc82a8bcd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_07b2fa42-3cff-4d55-9da4-b7ec997c914f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_099bbd21-af0c-4f39-ba1c-26dd5d66531e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0a49afd5-b03f-4f5c-bc78-5dfce07d3fbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0b1f2c34-a18a-449b-9a8f-3aa8bfcadbc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0bdc5c5e-908e-4299-8ae3-da0932a02def">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0c9ad877-d4fd-4667-9562-04fee6ec1601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0df3cf5d-7b89-4a27-bcce-445ba936b692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e18d051-aeae-44cb-ba16-8f0a32e2f029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1119d75f-ac1e-4443-a095-4f4846ec2ff9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_115005c9-cf96-423b-b5e8-3aaf79d6b164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_14fd86d7-b649-4d1e-b341-b684c139f7a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_16299617-ee7c-4dc4-96f4-999a18550372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_16e28997-7e3b-4c9b-81c4-971e637e2f39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1a256318-aca1-4e30-8e79-987a0c9de60a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1acd60e0-7824-477a-940e-96fcce72212e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1aeca0d4-12fc-4e19-b717-44dc51c65479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1afe7465-3d4e-4ad3-b563-56e6f8072164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1c7dad97-0dc1-49c3-8e6a-213606328313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e9897c4-5275-417c-8724-b96563d5a101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1fb577e9-9c40-4d2b-bc4e-1fc3181e8bb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="C_20a3dc1a-a419-4e0f-a290-0890b8721905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_22b5dd10-ae86-4ea2-9caa-a6986a38f552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_23197216-2be1-412a-babd-a86284108614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_236a64e1-b094-4db0-b4b0-f4b9a7cae648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2447145f-f97a-4de4-9722-96b5a9481f34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_256c43d6-4366-49a5-8b14-90aef18be10f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_26c9b550-cdb1-4568-b071-8fda1b1e79ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_28287282-43af-4ee0-9eb6-97361dbf3a49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28466158-15a5-4c86-9df3-08250c20e264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_28c5bcc4-c729-4e8c-bce9-751448cc3f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29395044-cf96-4b99-9148-86cf3018ed50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_29808493-b539-4763-a0cc-0c411c398bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_29b153aa-6e60-459b-8d8b-3607e4aecaf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29e591f1-b6b5-44c0-9273-a6ab4ed69a29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2ac1d2a6-7485-444c-b87e-886ba5dc3b3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2f55e0e9-b954-452c-a685-f7ac38e3d535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_30a5bbbe-6a9c-4d08-a5bf-c0ca07f38d71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_31033074-d98e-4051-a1dd-9611d85c39b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_31434234-729f-49fb-9bc5-a4c2db285d76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3242f9e3-dcb0-4a64-a6a1-9e8c5aa997e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_333af4a3-cffa-49c3-8566-6302b765c42b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3371457f-35a0-478d-ad1d-6b89373e6edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_348cb82b-d5ac-43f4-a398-22620b3796c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3505aa94-9150-444b-91e7-c7847006ec3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_355bb8fa-16f0-474d-b4fd-4b16eacb34a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_35bf3362-af08-41ac-b5ae-d51683a82d48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_374a2a9a-0d8a-4c0a-bd27-2a810ec44e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3a1d8a90-cba6-4a27-8976-dff0b00c047d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3b97b1d4-62a9-4c60-be60-2108f97f8fb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c36ec93-0b98-4985-917c-84fa8ef6964c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3d00688c-415e-4822-a136-7b16fe0014b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3da0eaaf-abe5-400c-a7d1-218bca3b9652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ed4ebec-bba3-4eee-a2b7-b31d8032bc49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4038584b-af9b-45c7-a179-a1aac6d8e18e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_419c90ac-d4cc-4e42-adb9-be55df808d8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41d2ea93-dc38-4500-b0a7-cd99c27e6352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4209531b-b000-47fb-8aa6-738c91148064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_425da08a-cc18-4b6b-b559-af896468cf59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_43334088-5e2d-486b-bae0-78c2ee15f270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_43977db9-b2fc-4eb0-8c06-461f1b087616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_46f8f010-ed88-453e-905a-2c7a307eadfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_485a9291-5f30-4382-b6a6-6d39f1a103e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_48e2fe0d-2cdf-4541-8c48-496992bb429b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4a469c78-301a-4529-b28e-24903923c651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4c968389-ac05-4e80-a351-de3893d81820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4e62fea1-8195-4797-84f6-8e80fbc5903d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_518ea4ca-bec1-4e07-8773-307a90cb3d09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_538c62e7-e31b-49fc-a740-3611b3bdd5b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_569de780-6224-4d27-819f-c41e8e9a86d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:ImmuneMedicineBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_57585e88-6f33-40e2-a08a-7f48691bb39b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57cc43f2-a758-4e93-85a5-3570f3deb3df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5849a7e8-d209-4520-ae06-42818b55c73d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c67024c-2523-482e-9f70-804bcc6d8184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5d904410-055f-498e-b598-0be6c4b19349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ec5d924-4867-4b17-91e0-bd4130ea3d71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5fb3a979-ff4c-4253-8408-395fb698c93b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6058a09d-5c33-4856-9a87-634891fd1ff1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_60932611-3f39-47dd-9da8-86fe5e9898f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_61e08594-2216-4ede-9093-11ef2ff2f063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_621e5196-e15c-4321-8f5f-959090207c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_64e80de6-0e67-4131-8ace-44a4d0c8b34e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_656c98bc-1902-4c80-b4fc-1e9db82df492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6591b0ed-3cfb-45af-b746-4190d5d17981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6712d8a7-de54-47f0-b34a-c94d59831861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6761f29f-952e-4394-b160-1a416c1945ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_68e4bc9a-5ec1-4697-aa56-4ddc7bb9b1f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69a8c3ab-a441-40a7-8a5f-6b8e7d9071e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_69fe0b18-2ecf-4cb8-92b2-378c77fd872e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a9f91b0-4738-40f9-b68a-82bd5973e387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6aac9fc4-61da-4969-864e-d3f27316dbe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">adpt:MichelleGriffinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6b2d4707-21b9-4599-a35b-221f9e77a609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b74a919-15ca-422a-bdd2-8538b4633aa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6bf4218c-4293-4f50-84e5-e19d61af2275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="C_6dc97585-6690-424d-b20a-80823243e590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6ee41dc2-3749-4243-b0eb-1ba3135232f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6f1910b3-9154-4298-8382-eeed229f5b9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f1d2824-9131-43aa-aab8-2a0a4ed4adce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_70d180be-d136-46d0-a6f1-b5c952fe6c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adpt:MrdBusinessSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_70fe95bd-0b9c-4b16-aab2-e8db1c249769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_7159e6a5-a720-4e55-b4d1-ebcad9b281df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7364eb6e-22be-4204-8475-fec3ce145680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_752e690e-a58f-4330-872e-b0e7486ee008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76aa1ad9-be8e-41ac-91df-576de65c2d91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_78553a5c-8e8c-41d6-9e26-df90b6ee5bb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7869d22e-be80-4ab4-88aa-2651f1bd991b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_791187a1-62e6-4444-ac40-4fce1c79f12a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_79c39ab7-5350-4de3-9055-afde44e88b1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7a426cce-3933-463c-a1eb-b6accca81255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7be5ebc7-1646-49da-a85c-c1f9911464ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7c1e94f7-1563-46d1-9179-65444a8457d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7cc0feec-e028-49cb-9eb1-10aee43d5810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_7f50006e-3aac-4a89-bd88-97a6fda0febc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f583a8c-c6f5-48ba-af7b-80283f1ac4cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7fc08718-7fea-4e2c-bb3c-69007782863d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adpt:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>adpt:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Employee">
        <measure>adpt:Employee</measure>
    </unit>
    <unit id="U_Performance_Obligation">
        <measure>adpt:Performance_Obligation</measure>
    </unit>
    <unit id="U_Unit">
        <measure>adpt:Unit</measure>
    </unit>
    <unit id="U_Vote">
        <measure>adpt:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2b3d04cf-0171-48b7-899e-f79d40eacafb">0001478320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_89ce6b46-9c36-4233-8c67-a6f4ff7d2345">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7b4121c4-bfa1-49e5-b9d7-ab6e646012dc">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      id="F_eef839ed-813e-4faa-9738-c5a903618713"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      id="F_c58c92e1-6822-4816-bcb5-bc958b91adbe"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      id="F_ae197273-22ff-4091-95b7-abf2afa45c8a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      id="F_b34944cc-62c5-46f4-b074-a8bc0e8fd618"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_9272d326-ab2d-442b-b3a2-82c6a66a936a"
      id="F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <adpt:RevenueRecognitionExpectedPeriod
      contextRef="C_c8814a61-92ce-4b2b-8aa0-402f4c13d4de"
      id="F_6a683fd2-b719-4e8e-9163-23af35cb1311">P9Y</adpt:RevenueRecognitionExpectedPeriod>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      id="F_66782f0d-d53d-4c13-bd13-17f76499cf21">http://fasb.org/us-gaap/2024#ImpairmentOfLongLivedAssetsHeldForUse</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_8759c879-be95-43bb-8de5-203e18a7141c">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <adpt:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      id="F_75bb2233-9ac9-45f1-8031-2e009382d5f2">http://fasb.org/us-gaap/2024#RestructuringCharges</adpt:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <adpt:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      id="F_83fd51e3-9860-4816-b7d4-990a29a9c263">http://fasb.org/us-gaap/2024#RestructuringCharges</adpt:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <dei:DocumentType
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_27420c95-316b-4636-9c4b-e2366ac268bb">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_04335601-bce9-4769-9b9d-928ec17057c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_c2c5e1a5-3014-4859-84dc-2b73a01e58d2">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_deefa33e-3d20-4a29-b24d-51d83f859156">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_1069b09a-7df2-4c35-8504-0a1465d3e75f">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_638a78d4-d389-40c2-8466-3032bc637f68">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_65476870-a320-450e-b24f-41d59a2447c2">001-38957</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ee71f4d0-2f42-4206-a3fe-30e9e705fd4b">ADAPTIVE BIOTECHNOLOGIES CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_8bb7bf69-4d6c-4ee6-8daa-ca7f97654660">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_29e25ed9-3598-4fff-891c-f7556a4fa0c5">27-0907024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_572d217f-8955-4381-afd4-781f6a7fa12e">1165 Eastlake Avenue East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_05ef40c5-7dab-4748-b563-9c32b4c5b4f8">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_a6fbb6a2-b48a-4df9-8afb-1cac3865a7aa">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_f3148605-08f7-4ed7-b09f-e51677cd76b8">98109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_d52bf324-41fe-4928-bfbd-e32416459235">(206)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_84a201f7-ae85-4d23-8f9c-946324fa70bf">659-0067</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_dc6e2795-1dd5-4a0a-9c7c-a0827b2bd15f">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_bbcf3a42-65ce-4406-a85e-2088b63261fa">ADPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_4af6807b-946f-4c7a-aa70-f133c05d4397">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_40a1f70c-afff-425c-a989-d75171fab657">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_d20544fc-56b2-4151-8796-9b8e433cce48">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_75e296d9-285f-4685-8cfe-c7d532bf201e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_c73f319b-cddf-41f1-a64d-28a368f5ddc3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_0a84a384-c184-4acd-b4ef-5e5920c18a42">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_550dc3ba-fcd5-4b60-ab4d-2962766d70ed">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_68217281-b8d2-435b-97e3-717a8781b187">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ed5f1b14-0570-4c1d-8a7d-c44fcffac805">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_1576d61c-6c19-4c69-bd68-46867db29bbe">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_e31fda89-1f04-49e1-98c3-4077005396a4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_115005c9-cf96-423b-b5e8-3aaf79d6b164"
      decimals="0"
      id="F_5a1d430d-39f5-4b84-88ea-83e86cf9f931"
      unitRef="U_USD">416000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_d6ec2ad5-f515-4f06-84a0-2aa770767702"
      decimals="0"
      id="F_39888bc5-bc13-4970-9666-9d9d4ba514cb"
      unitRef="U_shares">148582201</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_af79a80f-47d0-40b3-b65a-cf786ddfe3b0">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the Registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2025.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_9b6f88ed-21a3-49fc-b0ee-c7bd08c0c3e3">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As trusted partners to healthcare providers, patients, biopharmaceutical companies, academic and non-profit institutions, business partners and employees, we appreciate the importance of maintaining a comprehensive and trustworthy information security program. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security program is fully &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our operations, and a hallmark of our program is its cross-functional approach with our internal privacy objectives and stakeholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity program is based on the ISO 27001 security controls set, and in particular, it focuses on the principles of confidentiality, integrity and availability. We maintain an ISO 27001 certification with a fully integrated set of operational policies and procedures to adhere to the domains of ISO 27001. This includes but is not limited to the organization of information security to assign roles and responsibilities within Adaptive, access control to restrict employees&#x2019; access to view only that information that is relevant to their roles, information security incident management, and compliance to broadly ensure alignment with applicable laws and regulations.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We perform an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;annual risk assessment conducted by an outside assessor and conduct vendor risk assessments for third party vendors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to evaluate how their systems may impact our business in the event of a cybersecurity incident. We also provide annual, mandatory cybersecurity training for employees to equip our workforce with the knowledge to identify and respond to cybersecurity threats, such as phishing attempts.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#x201c;PISSC&#x201d;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The PISSC is made up of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding our information security and privacy governance and reports on information security and privacy incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Cybersecurity threats, including as a result of any past cybersecurity incidents&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#x201c;Risk Factors&#x201d; section.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_55533769-fbf9-459f-8575-690528b8fb2a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security program is fully &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our operations, and a hallmark of our program is its cross-functional approach with our internal privacy objectives and stakeholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity program is based on the ISO 27001 security controls set, and in particular, it focuses on the principles of confidentiality, integrity and availability. We maintain an ISO 27001 certification with a fully integrated set of operational policies and procedures to adhere to the domains of ISO 27001. This includes but is not limited to the organization of information security to assign roles and responsibilities within Adaptive, access control to restrict employees&#x2019; access to view only that information that is relevant to their roles, information security incident management, and compliance to broadly ensure alignment with applicable laws and regulations.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ae1950d8-c9ea-4697-9097-fcb1c3b89c91">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2da873c3-95af-4e99-8d63-42081b23ddb6">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_8dc36e81-09fd-4156-a1ad-8f638f9013b6">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_880e8c03-a194-4f36-9ce4-2475b6262d66">&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#x201c;PISSC&#x201d;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The PISSC is made up of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding our information security and privacy governance and reports on information security and privacy incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Cybersecurity threats, including as a result of any past cybersecurity incidents&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#x201c;Risk Factors&#x201d; section.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_25f38f39-e87d-4e8e-8c1a-9bb7b9e76042">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#x201c;PISSC&#x201d;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The PISSC is made up of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_1c47f4e2-bfc4-436c-ba62-ee84d45d2e24">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The PISSC is made up of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Privacy Officer, Chief Operations Officer (who is also acting as head of our security team), Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Julie Rubinstein, who serves as our Chief Operations Officer, is leading our security team on an interim basis and is supported by a fractional chief information security officer.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_6fb3143a-04c5-4e95-ba92-3f658369f9fa">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7aa61e2e-bed4-4645-a840-acf64406096e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding our information security and privacy governance and reports on information security and privacy incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Cybersecurity threats, including as a result of any past cybersecurity incidents&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#x201c;Risk Factors&#x201d; section.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_38dbc03f-84a4-4d72-8eec-84a338b91b5d">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; regarding our information security and privacy governance and reports on information security and privacy incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Cybersecurity threats, including as a result of any past cybersecurity incidents&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_4b7bf0f3-4759-4549-aa9f-50d43f401a82">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2efbdb09-76d3-4d21-9b59-8989ad4aa50d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_9474a859-55c4-4dbd-8f53-b9dd9cfda404">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ab6b4862-33e0-4377-9461-ec12b3626405">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_8125c5e7-066a-41f0-8a52-856a7bcd53b3">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b322f5c2-e366-4c99-935c-5466481163e4">Seattle, Washington</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_b12acb2d-86b7-42ef-a789-dfabb0cb0044"
      unitRef="U_USD">47920000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_3f1d77ce-138e-418a-a065-63208368f832"
      unitRef="U_USD">65064000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_aa15377d-187f-411d-978b-af5951fe1e2d"
      unitRef="U_USD">174186000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_4a636ed4-a452-4873-acb0-2f41feba611d"
      unitRef="U_USD">281122000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_adf00c88-05c8-43f1-9b01-bac4531dcbef"
      unitRef="U_USD">174374000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_1343d625-d672-46db-a923-830813f4e92a"
      unitRef="U_USD">281337000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_367b3f2b-0324-486a-a1b1-066cd1c36f79"
      unitRef="U_USD">41731000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_d17e39d7-393a-42b7-a0e7-bf088222df07"
      unitRef="U_USD">37969000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_0cd243d6-8feb-48f4-b9cc-0d0accd36b69"
      unitRef="U_USD">8440000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_e9ff4f23-638c-4d3a-aa34-262432c6f0f7"
      unitRef="U_USD">14448000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_0b2dea60-672e-42aa-ad87-99a2a0edd5db"
      unitRef="U_USD">11287000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_5cf964cb-d811-477e-8114-af16ce6c9fe4"
      unitRef="U_USD">11370000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_7cba47b3-9f27-46e6-82fc-8a5663bfb6ae"
      unitRef="U_USD">283752000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_d57613d4-ae13-4aff-b244-faa34bd8b92e"
      unitRef="U_USD">410188000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_1828030d-5a9a-40ee-bed1-ec9324df85ca"
      unitRef="U_USD">48616000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_876ccb9b-01d2-43bf-84a1-ecb164b8cb91"
      unitRef="U_USD">68227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_69a3c76c-fb29-4508-8d00-97e40516bf30"
      unitRef="U_USD">45767000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_2b0ca5bc-4e07-4f27-b26d-5861581026d7"
      unitRef="U_USD">52096000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_1fba5c33-d799-4ddd-bdae-30d5c343c0b6"
      unitRef="U_USD">33682000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_146e3399-ef6a-40c4-83dc-bbc085986a84"
      unitRef="U_USD">33660000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_9ddbaa52-0e5a-4f10-a570-3868082ab5ac"
      unitRef="U_USD">2897000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_2b6afd20-8042-43a7-98cf-c2887257775f"
      unitRef="U_USD">2932000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_13bd30e8-1189-4aec-8bdd-d2b745f9d555"
      unitRef="U_USD">3425000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_66841e7d-7f57-4a0f-aa95-6a190c7cbdc2"
      unitRef="U_USD">5128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_a363d4d0-94f4-46df-becd-bbe5b586326c"
      unitRef="U_USD">118972000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_a55a158e-a346-440c-aa61-52ef791885f3"
      unitRef="U_USD">118972000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_7ce8e2f5-f89c-4b9b-97c5-5ea619f96f44"
      unitRef="U_USD">2287000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_ddd4b66c-d5a7-4dcd-bb4b-42843e5b34fa"
      unitRef="U_USD">3591000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_9cf35dbe-8988-40be-8a47-03f671ea09b6"
      unitRef="U_USD">539376000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_8a272995-6e8a-4139-96be-0de63146bac1"
      unitRef="U_USD">661134000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_cbbd7ff7-a1e7-4c2f-b169-7432089e8a8e"
      unitRef="U_USD">7265000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_24bfb5d5-8e51-40d3-a25c-4d9c821c850a"
      unitRef="U_USD">7719000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_30d63c7d-59ce-4e95-8b8e-2c27102e03ae"
      unitRef="U_USD">8157000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_01c40f7d-1a49-4835-91c2-c1f1e2124031"
      unitRef="U_USD">8597000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_3e49cb20-4993-4e78-b9f2-4b2e22e68a27"
      unitRef="U_USD">15838000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_71d1087c-003c-4d01-b200-742de7cddf58"
      unitRef="U_USD">13685000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_e13a2b87-9800-40db-8915-5d4f6f67df43"
      unitRef="U_USD">10239000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c5c860fd-b83e-4f0e-9555-5b9e39271cd0"
      unitRef="U_USD">9384000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_17c54e3f-ed7d-4f68-b5ae-4c35bc5c1551"
      unitRef="U_USD">55689000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_8d4c45bd-52c9-4628-bbd7-43c5bc76de06"
      unitRef="U_USD">48630000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_2f43c2c8-f4c7-4d5b-ac2c-dd7803ab153d"
      unitRef="U_USD">865000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_83dda324-67a1-45ae-9769-f9fd2e7c4100"
      unitRef="U_USD">98053000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_032e0671-d3ac-4a5b-8963-ae626a929026"
      unitRef="U_USD">88015000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_8e252891-8d91-4e22-b3cc-4a4c4ba74cb3"
      unitRef="U_USD">79148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_d5b49d21-f151-49ea-b1ea-9cdf7bc59245"
      unitRef="U_USD">89388000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_1bce55f9-c97d-476a-b079-87ed4ce4fe25"
      unitRef="U_USD">27256000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_0cc5bf6e-8925-45b1-a6f1-26bf9776c0ba"
      unitRef="U_USD">44793000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_f57fbd79-5f6f-4e6f-b1ea-94ce70f5470c"
      unitRef="U_USD">132414000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_e1fc7327-79e6-4667-a6f7-c6ec280c10d8"
      unitRef="U_USD">130660000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_624a5bb2-d003-480e-b3b8-8b13197d21df"
      unitRef="U_USD">20000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_791ad43b-f76c-45c9-85f7-c626f4f09a1e"
      unitRef="U_USD">336891000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_02b066c1-455b-4f9b-9bc2-5cb93aacd40f"
      unitRef="U_USD">352856000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="4"
      id="F_f8516796-0827-444e-a3ee-f0878442be4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="4"
      id="F_99ed71b5-71e2-4199-906e-fe07556b2304"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_13115d43-f5b9-4965-8653-c6ac0d6f4604"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_2771fbeb-5e7b-4aca-b890-cf03bd456ee2"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_bd48479a-db28-4fdb-818f-184bfedab095"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_9b16b443-9eff-4d69-8172-caba7b1b65ed"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_2766bfeb-85c0-46b3-a727-a94d433bd818"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_b835e752-95cd-4023-809b-8ff7c45b8f70"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="4"
      id="F_7a9d7f22-4a8f-4433-a0d7-4a0c88267d9f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="4"
      id="F_42776a1f-efbe-417d-97d6-bd17c368ec29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_95df3118-fa73-4bb3-804d-9e340350947e"
      unitRef="U_shares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_6524a096-133b-4666-bc62-2c50ca6bf01a"
      unitRef="U_shares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_d254c895-ef46-45bf-94b8-69fab1c6989c"
      unitRef="U_shares">147773744</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_37f9463f-44c3-4a4c-9be6-e68aaa10d2c6"
      unitRef="U_shares">147773744</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_928b022d-2c21-4e2f-8baa-f8e2730bd12b"
      unitRef="U_shares">145082271</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_3e4e8454-c6c9-4c7e-9d6c-63517646978d"
      unitRef="U_shares">145082271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_de885df0-01ff-4303-a723-07e9f1a84592"
      unitRef="U_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_987e92a4-6e8b-4dd4-aae5-52762103ca60"
      unitRef="U_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_7e238d77-a0fa-4ac9-8b5b-26652d9cb912"
      unitRef="U_USD">1506353000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_8bb03746-96cc-4e9d-b99c-7ca00f8b8b17"
      unitRef="U_USD">1452502000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_657db199-76de-4a24-a8f8-72b9d59c9b29"
      unitRef="U_USD">166000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_e068c2a0-be36-45e8-ac44-666951d0012f"
      unitRef="U_USD">215000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_1f69b544-cef5-4c21-8ebc-2861f3dcee25"
      unitRef="U_USD">-1303824000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_ce8bf3f8-9e23-4aa0-84bb-8551fb773d48"
      unitRef="U_USD">-1144332000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_a8b7d8ca-3815-436c-953b-8db2c746a2bc"
      unitRef="U_USD">202709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_f14d1337-12bc-45ae-a279-635172e708e3"
      unitRef="U_USD">308399000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_75ba96a4-f05a-43ca-9557-83e860724344"
      unitRef="U_USD">-224000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c41b9a34-37da-49a9-8375-ccbd17850f67"
      unitRef="U_USD">-121000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_553c73d7-08b3-4fda-932f-a393e5681263"
      unitRef="U_USD">202485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_d6a52b4a-7a2a-473e-8787-eb7f8446efb6"
      unitRef="U_USD">308278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_ed210051-1b97-4cab-bda2-4a474a0a4e48"
      unitRef="U_USD">539376000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_de1fed0c-0f7d-4f87-a6d7-f44a3da715a3"
      unitRef="U_USD">661134000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_dc0d00bd-593a-4858-b826-8e0dbec2b3d5"
      unitRef="U_USD">178957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_9a5b9879-bed1-47cf-a9e7-4a7067a44b4f"
      unitRef="U_USD">170276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_b06be17b-24cb-4426-b925-f73cfb0805bf"
      unitRef="U_USD">185308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_6a9ec8f4-6c09-4c80-b107-b65de1f84517"
      unitRef="U_USD">72080000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_5bc59b55-d570-49a5-85ce-5f6b13c264ad"
      unitRef="U_USD">75553000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_3412f8ea-73d4-483b-86cf-878a464f479c"
      unitRef="U_USD">57909000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_56c887ed-f4d8-496e-85e3-ff4e632137c9"
      unitRef="U_USD">102953000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_9d56c660-14e2-4837-8f38-d514f617124e"
      unitRef="U_USD">122117000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_fd324f99-b8d4-4d0c-b255-6e6638f417d1"
      unitRef="U_USD">141756000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_a45230cd-4574-43bf-b650-081f9baf451b"
      unitRef="U_USD">84759000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_e701c86a-f7e1-47c5-95fb-d21871351fe7"
      unitRef="U_USD">88579000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_6bef76ac-e196-4364-9227-776c375adb4f"
      unitRef="U_USD">95603000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_20df25e3-b4e8-4999-bc0b-8242bd3db0c6"
      unitRef="U_USD">72806000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_790ace4e-3493-4180-a92e-26eef2b50acc"
      unitRef="U_USD">83934000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_5c1f3243-0ecf-41e7-ad98-1b9266c0e402"
      unitRef="U_USD">88527000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_190edab8-2bec-409e-b915-4dff954c7ee8"
      unitRef="U_USD">1703000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_c030725d-74b5-4e8c-889f-fbd22d32075c"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_65b83756-a614-437d-b024-4222a3b5f80d"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_d956cf78-5ea4-42d6-9cfc-f4b0631d96b9"
      unitRef="U_USD">7205000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_f5b1fea4-38ea-44c2-a1ec-23590227dab4"
      unitRef="U_USD">25429000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:CostsAndExpenses
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_09dc8cce-8f2e-478a-a862-f82082bb137d"
      unitRef="U_USD">341506000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_1196de10-5b8c-4a8a-af89-6e410f9e6fdf"
      unitRef="U_USD">397311000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_f66f43f2-d2ac-40bd-8eb1-89318fcd2770"
      unitRef="U_USD">385494000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_9f421e8b-3db9-4660-9aa5-5a0aa53084dc"
      unitRef="U_USD">-162549000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_3c3283cd-a777-4b90-8d9e-d2c6fdcd12f7"
      unitRef="U_USD">-227035000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_91bb1c6e-2608-4249-9787-aee69e7c5639"
      unitRef="U_USD">-200186000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_e1b64ee3-79a0-4359-a398-b59dcac7a42a"
      unitRef="U_USD">14534000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_c7b94c5c-702e-49c9-8460-98083c097710"
      unitRef="U_USD">15531000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_a6944338-9456-4497-b4a3-b2ddefaaf31e"
      unitRef="U_USD">4056000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_4569ac3e-a273-4ff9-84e0-e23ae48c2c57"
      unitRef="U_USD">11580000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_7a43f7f7-d0e3-486e-8999-4850abecacf5"
      unitRef="U_USD">13800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_1d737adf-fa0e-449a-b01a-efe3f7e88f3a"
      unitRef="U_USD">4238000</us-gaap:InterestExpense>
    <us-gaap:ProfitLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_e71fd1c4-4851-4f37-bbb5-6098419392de"
      unitRef="U_USD">-159595000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_65a641ee-2957-47e9-9b62-9bce8139d13d"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_4c6c07f4-5a31-409a-828b-6dcf7986e5b2"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_34ea8002-ee65-4ae5-8a0d-96e0cb208f9a"
      unitRef="U_USD">-103000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_a9899ddc-ba02-4a52-8dbf-24011f1b7c1a"
      unitRef="U_USD">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_da9c91fc-13e5-4455-9290-72e41c685a86"
      unitRef="U_USD">-177000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_9ff0ec71-e8f2-44a1-a782-c14df98265da"
      unitRef="U_USD">-159492000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_a86e15a5-20f0-4b4f-95dc-1f366fd63fdf"
      unitRef="U_USD">-225250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_17c5d280-3b2f-458d-834c-0a0605b339e0"
      unitRef="U_USD">-200191000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_b0fbda20-151d-41b1-b713-30299bd913cc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_a04898da-86b5-441c-a031-374899793eda"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="2"
      id="F_b0b1edb3-4a4a-4f6a-bc0b-404b3bc2ee10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="2"
      id="F_1d20fd4b-5b62-41ab-853f-d63ab4e20135"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="2"
      id="F_0511417d-65cd-4da1-8def-066ba40a1a11"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="2"
      id="F_eca7da3c-276a-42a4-b70a-f903d16d8da1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="0"
      id="F_e8d12acb-2f79-4cf4-899c-b94a6a90d5b2"
      unitRef="U_shares">147101648</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="0"
      id="F_e6c965b4-a01d-4662-b3f8-942ddbeaba0c"
      unitRef="U_shares">147101648</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="0"
      id="F_cb8c0951-465d-4189-9284-a89254fb688e"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="0"
      id="F_bcd58fc2-f2c8-4f14-b93b-f4fa0b6cffe5"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="0"
      id="F_b2a2692b-35dc-4057-afcf-7a4e1d4364e1"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="0"
      id="F_3d5db281-d1f5-4188-b229-3bc2a46a1801"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_318919f8-4c3b-4998-8f84-fefe0526b1ef"
      unitRef="U_USD">-159595000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_66a0f0d9-1176-4820-b293-3ac96c79b027"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_885bc2fa-aafb-4158-abf5-5189d327ef70"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_40e49bd3-be87-45e7-878f-f2fa82ea7afd"
      unitRef="U_USD">-49000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_52f53038-4f50-44ba-94c1-6ac09804a869"
      unitRef="U_USD">4331000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_83efcb90-d5d7-4b4e-b308-7b00172a7905"
      unitRef="U_USD">-2979000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_8ed6421c-5ff2-4234-87cb-3b452641ea25"
      unitRef="U_USD">-159644000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_e265b65e-41b8-4569-99a8-f42a1ec487d4"
      unitRef="U_USD">-220973000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_4f1a5a0d-5350-4813-9d82-9e6793c181b3"
      unitRef="U_USD">-203347000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_946a0f7e-22e7-41da-a2b9-7916e4cd4ed6"
      unitRef="U_USD">-103000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_5e5dc364-94d7-487c-86c9-52bf31f49c8d"
      unitRef="U_USD">-54000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_10f4ba03-ddec-4afa-8d99-5da49407c975"
      unitRef="U_USD">-177000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_5b0b5f39-a082-4fa9-b466-9045b153a43e"
      unitRef="U_USD">-159541000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_28eec2fa-5add-46f9-b354-f05fbd2e69a2"
      unitRef="U_USD">-220919000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_a40e1cd3-21bc-445c-9da4-ecb83f5ea1a1"
      unitRef="U_USD">-203170000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_4a469c78-301a-4529-b28e-24903923c651"
      decimals="INF"
      id="F_b3ca8647-4b3f-4f03-9503-dd9b6d96c97c"
      unitRef="U_shares">141393865</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4a469c78-301a-4529-b28e-24903923c651"
      decimals="-3"
      id="F_f9ab9e1a-7bc3-4eca-b34c-824d7a994d98"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_29e591f1-b6b5-44c0-9273-a6ab4ed69a29"
      decimals="-3"
      id="F_d2fc3983-1c2c-4866-a6ca-5c6bbadfeded"
      unitRef="U_USD">1324006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bd08a3f3-19f2-4f0f-9fdc-39c4d781f8d6"
      decimals="-3"
      id="F_18d8cc09-d029-4e71-b4c6-9165d8644cce"
      unitRef="U_USD">-1137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8949417c-8327-42ad-9e79-5c74d95818aa"
      decimals="-3"
      id="F_0000fea5-a05c-44a4-bbc0-e2ca0a0bc0ab"
      unitRef="U_USD">-718891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_48e2fe0d-2cdf-4541-8c48-496992bb429b"
      decimals="-3"
      id="F_aed5b7c8-7312-4b05-b72c-c1e26b78c3aa"
      unitRef="U_USD">110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d"
      decimals="-3"
      id="F_dfb86504-1542-400e-bc4f-bfe0df041abf"
      unitRef="U_USD">604102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9449b797-84c6-46c5-a338-60738ca67a56"
      decimals="INF"
      id="F_0c5dd246-ae65-4175-b622-2c1e68ebc4ba"
      unitRef="U_shares">1406500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_05b25161-4405-4484-9a79-0c9ef7d93c2d"
      decimals="-3"
      id="F_4b5f6206-b3a6-4907-990b-57ffe4626813"
      unitRef="U_USD">7866000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_f677e32c-58cb-4128-9a8d-382bf0f09b29"
      unitRef="U_USD">7866000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_9449b797-84c6-46c5-a338-60738ca67a56"
      decimals="INF"
      id="F_a8e1e29e-4762-4cf6-be31-a3f8a7aefbfb"
      unitRef="U_shares">304637</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_05b25161-4405-4484-9a79-0c9ef7d93c2d"
      decimals="-3"
      id="F_0f8f29bb-e0be-41d7-8f60-26a86432b200"
      unitRef="U_USD">55477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_732eb027-f2e7-455d-8a87-ebb55c53e124"
      unitRef="U_USD">55477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_c8ff48b7-0993-480b-9ebf-68a92b4acfce"
      decimals="-3"
      id="F_66ee7050-c91e-4873-b460-f4fe9b6d8628"
      unitRef="U_USD">-2979000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_d9e16c45-6489-4af1-a0a1-1a1051078166"
      unitRef="U_USD">-2979000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="C_9c86f6ae-1650-46f6-a8e7-0baaca9c4d6a"
      decimals="-3"
      id="F_d158c92b-bead-4702-9545-1c21fc6361e5"
      unitRef="U_USD">-200191000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_fb3ea207-d43b-4520-9dbf-4b33f273a3e4"
      decimals="-3"
      id="F_e5788549-071e-4585-a689-5078a0022cb4"
      unitRef="U_USD">-177000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_ef0a3f00-dd5b-40e7-874f-03184902fc77"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_93957bc6-8913-431a-aa08-83e39673bc72"
      decimals="INF"
      id="F_3361e752-f938-4f6a-8e5a-ab4adbd7bf83"
      unitRef="U_shares">143105002</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_93957bc6-8913-431a-aa08-83e39673bc72"
      decimals="-3"
      id="F_e5bfbee9-ebaf-4187-9207-b1bf8c0c3354"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a49d0116-6be0-4342-bb34-064f2cb1779c"
      decimals="-3"
      id="F_3c034cd1-e399-4930-8920-e8ca7682222d"
      unitRef="U_USD">1387349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_28287282-43af-4ee0-9eb6-97361dbf3a49"
      decimals="-3"
      id="F_b03b797c-d385-49d9-a082-c7433b0b4a80"
      unitRef="U_USD">-4116000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_78553a5c-8e8c-41d6-9e26-df90b6ee5bb0"
      decimals="-3"
      id="F_00b29c33-9677-4058-b5e8-58c140e6bb4e"
      unitRef="U_USD">-919082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_485a9291-5f30-4382-b6a6-6d39f1a103e1"
      decimals="-3"
      id="F_7360d64d-db0c-4473-99e3-76f747232cd2"
      unitRef="U_USD">-67000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d"
      decimals="-3"
      id="F_fdf898d6-4507-475d-ab80-aaad2e791f97"
      unitRef="U_USD">464098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_16299617-ee7c-4dc4-96f4-999a18550372"
      decimals="INF"
      id="F_3c494312-83e9-4b43-8c69-e5a5800cf89c"
      unitRef="U_shares">470405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_656c98bc-1902-4c80-b4fc-1e9db82df492"
      decimals="-3"
      id="F_5412ecc3-d9b7-4b7d-85bd-28cdf223f295"
      unitRef="U_USD">2245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_5a510f3e-0a99-41b2-a833-16ae57655172"
      unitRef="U_USD">2245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_16299617-ee7c-4dc4-96f4-999a18550372"
      decimals="INF"
      id="F_56ec5867-3fbe-458d-9a3b-41143884990c"
      unitRef="U_shares">1506864</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_656c98bc-1902-4c80-b4fc-1e9db82df492"
      decimals="-3"
      id="F_291e7add-d59f-45e1-94c9-3ce4f85c9f78"
      unitRef="U_USD">62908000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_7244cd06-7c3e-497c-9d22-9097555f7eb3"
      unitRef="U_USD">62908000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_93a61f54-9fc1-4164-ad0a-ecd149ef96a3"
      decimals="-3"
      id="F_143a86e7-6b42-4a65-83bf-b3227f970a97"
      unitRef="U_USD">4331000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_d4cec416-c48d-4bb3-8dc0-29c281d1f22e"
      unitRef="U_USD">4331000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="C_46f8f010-ed88-453e-905a-2c7a307eadfc"
      decimals="-3"
      id="F_ee09f0c2-ea28-4728-8939-cbc83da3dbb5"
      unitRef="U_USD">-225250000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3a1d8a90-cba6-4a27-8976-dff0b00c047d"
      decimals="-3"
      id="F_6ec80e73-5b34-4c69-807c-886e25c0a85e"
      unitRef="U_USD">-54000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_5168c7fa-82b3-4df4-8bc2-e6879fd3483e"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_cb262e8f-a1c3-4acd-b4cf-58e1bcae091b"
      decimals="INF"
      id="F_e78e858a-5fb9-4d45-8c53-f04d3c071e9a"
      unitRef="U_shares">145082271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cb262e8f-a1c3-4acd-b4cf-58e1bcae091b"
      decimals="-3"
      id="F_529250e3-3139-4978-9cc4-d0944cb7019e"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bd7b1034-af6a-470b-8700-f6950a6eba00"
      decimals="-3"
      id="F_788d8f35-479d-42f6-981f-1e14ccbb0a87"
      unitRef="U_USD">1452502000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bd3ac93b-1e22-485d-bfed-003c41a39739"
      decimals="-3"
      id="F_baf8d9ae-0866-461b-8f79-17b1d2baec80"
      unitRef="U_USD">215000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2447145f-f97a-4de4-9722-96b5a9481f34"
      decimals="-3"
      id="F_f49534bc-362c-4520-be7c-2d960d2dcbbd"
      unitRef="U_USD">-1144332000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7364eb6e-22be-4204-8475-fec3ce145680"
      decimals="-3"
      id="F_1d27c63a-6696-4bae-934f-b0eedb87e412"
      unitRef="U_USD">-121000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_b6656565-36df-4d4e-9c5b-76a610f8b7fd"
      unitRef="U_USD">308278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_348cb82b-d5ac-43f4-a398-22620b3796c6"
      decimals="INF"
      id="F_061f3350-297e-4b58-8464-759bafd2e247"
      unitRef="U_shares">103800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7be5ebc7-1646-49da-a85c-c1f9911464ad"
      decimals="-3"
      id="F_29f707a9-6521-44f3-9ccc-cdb97f550f2f"
      unitRef="U_USD">241000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_b46a5cb2-008e-4374-9698-a1419f7463b4"
      unitRef="U_USD">241000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_348cb82b-d5ac-43f4-a398-22620b3796c6"
      decimals="INF"
      id="F_5ab10938-6131-4b15-a6b6-036b597af4c8"
      unitRef="U_shares">2587673</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7be5ebc7-1646-49da-a85c-c1f9911464ad"
      decimals="-3"
      id="F_5b2eca53-e6e8-45b3-b804-17932675c536"
      unitRef="U_USD">53610000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_03ea8d81-40f9-41a0-ade8-0f60d0db99d1"
      unitRef="U_USD">53610000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_7a426cce-3933-463c-a1eb-b6accca81255"
      decimals="-3"
      id="F_4cbfba65-430b-404e-aeff-5fb1f903be51"
      unitRef="U_USD">-49000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_e1ea952a-81e5-462e-856e-c31d5c27f3da"
      unitRef="U_USD">-49000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="C_ee233ba5-9cea-4a85-9f15-e4b103298328"
      decimals="-3"
      id="F_8e8511bf-eb3d-46c2-9f46-e677ffbdda2c"
      unitRef="U_USD">-159492000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7159e6a5-a720-4e55-b4d1-ebcad9b281df"
      decimals="-3"
      id="F_e7c59128-e052-4110-8c4f-09a9572d285f"
      unitRef="U_USD">-103000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_38dcfdde-65cb-401a-976e-40c9304274d2"
      unitRef="U_USD">-159595000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_89099e56-2c94-45a0-bf9b-0e1751243cd9"
      decimals="INF"
      id="F_310986f4-906c-4db0-96df-5fb50f7f814f"
      unitRef="U_shares">147773744</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_89099e56-2c94-45a0-bf9b-0e1751243cd9"
      decimals="-3"
      id="F_85c7cf02-589a-4f55-afaf-307f2f0857e7"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_31033074-d98e-4051-a1dd-9611d85c39b8"
      decimals="-3"
      id="F_d3ed9f3c-3960-48b9-9c93-1f5f0c449175"
      unitRef="U_USD">1506353000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a6daf5ec-996f-44a9-a1a1-176861ff844f"
      decimals="-3"
      id="F_2582e7cd-13fd-4638-8a92-6ad6145771e6"
      unitRef="U_USD">166000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3c36ec93-0b98-4985-917c-84fa8ef6964c"
      decimals="-3"
      id="F_b261cb1e-3bc7-47b0-a929-4611c60f13f0"
      unitRef="U_USD">-1303824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_96e4eb5a-1de1-40a2-8f39-b8260ca0c7ee"
      decimals="-3"
      id="F_8996dc76-105b-40a8-9550-fdb2b5818760"
      unitRef="U_USD">-224000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_bd71d63d-1b40-456e-bc14-86b8dba87a03"
      unitRef="U_USD">202485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_55c2baf7-e352-4575-8ce0-02cfb29d5221"
      unitRef="U_USD">-159595000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_da942d8b-f3ea-4c0e-ab3a-a66150816c4b"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_64ea1369-50e3-4907-9fe3-0410a8b73594"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_786057ef-221d-4760-8499-6d288879e154"
      unitRef="U_USD">17553000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_c4c60c39-a6ac-47b1-8573-7ebed393b776"
      unitRef="U_USD">20532000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_ce1b15d9-c5f5-4df1-b678-f742c54bb318"
      unitRef="U_USD">19221000</us-gaap:Depreciation>
    <adpt:NoncashLeaseExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_841b0eea-230e-4e38-bc91-8aadabe4a068"
      unitRef="U_USD">5277000</adpt:NoncashLeaseExpense>
    <adpt:NoncashLeaseExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_ea34117b-9521-4fb8-ade6-6d460ba6aed9"
      unitRef="U_USD">6920000</adpt:NoncashLeaseExpense>
    <adpt:NoncashLeaseExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_116d341c-7903-4e62-913d-574d7331efd3"
      unitRef="U_USD">7227000</adpt:NoncashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_1c15c74a-b113-41a9-bfee-74a1383be06d"
      unitRef="U_USD">53610000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_367982fd-3be6-493f-a29c-458f17bcb31e"
      unitRef="U_USD">62908000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_a95abb5b-3047-4f09-85f0-08b962d6c333"
      unitRef="U_USD">55477000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_b3e6e3b4-29d8-4a10-b51e-374de13e3065"
      unitRef="U_USD">1703000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_939a7b2c-6325-409f-ae15-815190524496"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_6e44547f-0839-46e3-85c9-7cd03889441f"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_81ffcf36-ed74-43f6-a554-d518ed181c2b"
      unitRef="U_USD">8208000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_26cf4a5f-f24b-4b6f-9aca-15a1e876cf16"
      unitRef="U_USD">9184000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_2f4ac818-4c7c-49dc-a0f6-84a5aa553d91"
      unitRef="U_USD">-741000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <adpt:ImpairmentOfLongLivedAssets
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_45c769e4-1894-42dd-85b3-fae4eeea0389"
      unitRef="U_USD">7205000</adpt:ImpairmentOfLongLivedAssets>
    <adpt:ImpairmentOfLongLivedAssets
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_d0a47128-0683-4783-a119-e1522beee8e4"
      unitRef="U_USD">25429000</adpt:ImpairmentOfLongLivedAssets>
    <adpt:InventoryReserve
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_4ad7e1d7-2ddf-470c-9a69-5d7cf2088955"
      unitRef="U_USD">1938000</adpt:InventoryReserve>
    <adpt:InventoryReserve
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_6dc1b9e5-4761-4fce-9812-46f67d94d499"
      unitRef="U_USD">1387000</adpt:InventoryReserve>
    <adpt:InventoryReserve
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_aa37bcfd-d5c1-414e-9dcc-7464d05503c1"
      unitRef="U_USD">2638000</adpt:InventoryReserve>
    <adpt:NoncashInterestExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_1dc431f1-9775-4fe3-b5e0-4bde00fd0b29"
      unitRef="U_USD">2618000</adpt:NoncashInterestExpense>
    <adpt:NoncashInterestExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_0ac1e8f5-75f6-4600-a332-105c74fa0d66"
      unitRef="U_USD">5300000</adpt:NoncashInterestExpense>
    <adpt:NoncashInterestExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_2d5cef5e-b8c7-4fae-9abd-99fdcd1634e0"
      unitRef="U_USD">985000</adpt:NoncashInterestExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_8743c903-fa65-483a-bc57-dd5974a73ab9"
      unitRef="U_USD">-141000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_a15e6a09-7df4-444f-98e3-e5bce929969b"
      unitRef="U_USD">-172000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_e5353531-07e5-45c2-a8f8-a57ad36cdb12"
      unitRef="U_USD">19000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_63463d43-c25a-4e25-a3d1-94ee07d96a58"
      unitRef="U_USD">3744000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_4a3783e6-4a7a-4a18-ad42-94ef6f7f8fa8"
      unitRef="U_USD">-2032000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_df4dff39-ea39-438b-bfb3-02b2c1832c1d"
      unitRef="U_USD">22648000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_47d3ea35-63e4-4d1e-956e-dc5122a8991d"
      unitRef="U_USD">-5372000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_1a6440f7-e492-4951-8985-2a81f19eb10b"
      unitRef="U_USD">2838000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_413b86a1-4c2e-4504-b1ba-b0efee60bc92"
      unitRef="U_USD">-817000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_3bcbcc25-18de-45db-a811-3ad76348e6c7"
      unitRef="U_USD">-83000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_f73dd00c-44ac-4664-a9f4-3478fba8b52a"
      unitRef="U_USD">1930000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_aafc52fc-1ecc-4c3b-846e-87b43cef3d4e"
      unitRef="U_USD">-3551000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_668ad215-7089-4b14-bb8a-a4ba4b1fad47"
      unitRef="U_USD">671000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_86eb2be5-70e4-443b-b8fb-54c24d8188ec"
      unitRef="U_USD">-5407000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_f8e63725-adf1-4ca0-896f-37da7c656d35"
      unitRef="U_USD">7111000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_d7885627-94f8-4dd2-adf7-d347dbdc4c0d"
      unitRef="U_USD">-9385000</adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_a29725a6-2112-47e3-ad33-208a010b38ed"
      unitRef="U_USD">-8676000</adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_11704bb9-c38b-4321-9fec-442a184e36cd"
      unitRef="U_USD">-4050000</adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_94557ebf-03b4-4017-9737-d44c901ddbd7"
      unitRef="U_USD">-10478000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_688db365-e534-4de9-9870-3aa85a76b3fb"
      unitRef="U_USD">-29291000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_eae7f722-7b84-4bec-9f5d-aa7f46b9ec07"
      unitRef="U_USD">-56496000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_de7359eb-c0f7-4e97-8d95-409f8987d435"
      unitRef="U_USD">-27000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_e211dd41-cf44-444c-918c-608eb6630b0e"
      unitRef="U_USD">73000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_5af080fa-4b5b-4fe8-aec0-d9df69297c51"
      unitRef="U_USD">-169000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_d96c88d3-5cf3-460e-80c2-441d969595e1"
      unitRef="U_USD">-95212000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_62310785-dec2-436a-a49d-5dbc211ce2c3"
      unitRef="U_USD">-156324000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_d5b10af3-44d6-4b7a-88a6-b219ad1ec082"
      unitRef="U_USD">-183945000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_255557c9-ace5-488d-8ee5-60fc690db96b"
      unitRef="U_USD">3664000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_d800f27c-e9d4-49bb-bc9b-f941ec4f6f68"
      unitRef="U_USD">10697000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_e7366a3a-a7cc-4127-96bc-03d78826869d"
      unitRef="U_USD">16349000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_6cbc0ceb-f2ab-48b5-9e27-962aec1dbf69"
      unitRef="U_USD">244257000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_dfc16f53-d00a-4da8-a204-d7a7247b70ab"
      unitRef="U_USD">429558000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_d6639863-f0ed-48fc-9dec-fe0b1d9b307c"
      unitRef="U_USD">278778000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_5961d1b3-dff9-4930-a1ef-44ae1229d38b"
      unitRef="U_USD">325713000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_e1be72c8-bce5-4cfc-b886-a7d8d963d10d"
      unitRef="U_USD">569902000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_cbc2efbc-9903-4539-ad52-1caaaf563099"
      unitRef="U_USD">298032000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_8d221df9-5f91-4299-bf25-2dc09dfbc2bf"
      unitRef="U_USD">77792000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_8b54b9f0-74a9-4002-8d8b-e8e7a70662b6"
      unitRef="U_USD">129647000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_6d9728b4-789e-4980-acc9-82ba8cba5f04"
      unitRef="U_USD">2905000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_1a96207e-4021-403b-9a91-b2d1a9e12863"
      unitRef="U_USD">241000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_309e3fb9-beef-49ed-82c7-86fb9adeec1f"
      unitRef="U_USD">2245000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_3b4669b1-8c3c-4e9b-b7f3-2860c260330c"
      unitRef="U_USD">7890000</us-gaap:ProceedsFromStockOptionsExercised>
    <adpt:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_4bd98eb8-7692-489c-91c5-977b25075b9c"
      unitRef="U_USD">124375000</adpt:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_07523bdc-d1cc-41bf-b917-210c760d98b0"
      unitRef="U_USD">241000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_a366bb7a-fe01-42fc-af3a-34fc2f89e123"
      unitRef="U_USD">2245000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_ed49a443-c7f8-41bd-aebc-f28db7c4cd29"
      unitRef="U_USD">132265000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_e352ede8-f335-4492-b3d4-106e817da696"
      unitRef="U_USD">-17179000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_cf8094fa-1a61-4fd9-ba2d-0c76951c2c81"
      unitRef="U_USD">-24432000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_fbc916cb-9777-44c9-8f01-07672576f149"
      unitRef="U_USD">-48775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c449cae8-2e6e-4efd-8857-af041150a211"
      unitRef="U_USD">67996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d"
      decimals="-3"
      id="F_b1160525-01bc-4ba9-86b5-6c347f5169dc"
      unitRef="U_USD">92428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d"
      decimals="-3"
      id="F_463c7f3c-500c-4f46-828f-1bf78fdc339a"
      unitRef="U_USD">141203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_78571b74-8bbd-462f-b9aa-d5cc9fab31fa"
      unitRef="U_USD">50817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c7128189-a1b6-478c-a159-7e38f5381001"
      unitRef="U_USD">67996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d"
      decimals="-3"
      id="F_a81db82d-e1dc-49b4-95c5-1a50c2287e12"
      unitRef="U_USD">92428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_21feb4a3-ee7f-49a2-82b1-650774fe9d99"
      unitRef="U_USD">1275000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_36d26a4e-c9b6-4ef4-a581-f350093d0b49"
      unitRef="U_USD">687000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_5300d4fd-a44d-45c0-8a80-b6b9b6ae12e2"
      unitRef="U_USD">1719000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_c3c5b213-6bcf-4f3b-89f6-bd1f81a984df"
      unitRef="U_USD">8864000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_ce461447-f53d-4166-891a-27be3298bfdd"
      unitRef="U_USD">8985000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_2b13b631-70b8-4182-9aed-da6332586b47"
      unitRef="U_USD">494000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_0093788a-776c-409d-9782-89029d7a4289">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adaptive Biotechnologies Corporation (&#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#x2019;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#x2019;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_dc930d26-1e36-4400-bbfc-dc908becd842">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#x201c;Purchase Agreement&#x201d;), the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We operate as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segments: Minimal Residual Disease (&#x201c;MRD&#x201d;) and Immune Medicine. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have determined that our chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM regularly reviews operating results and other financial information presented at the MRD and Immune Medicine segment level, as well as on a consolidated basis, to make resource allocation decisions. The MRD and Immune Medicine segments are also our two reporting units.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We had a restricted cash balance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 and 2023. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our facility leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities are classified as available-for-sale, consist of United States (&#x201c;U.S.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#x2019; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2024 or 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively. There were no customers that represented more than ten percent of our accounts receivable, net balances as of December 31, 2024 or 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Genentech, Inc. and Roche Group&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;* less than 10%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The related revenue was recognized and reported by our MRD segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The related revenue was recognized and reported by both our MRD and Immune Medicine segments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was included within the other assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any impairment losses on intangible assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the net amount of attributed identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of one or both of our reporting units below its respective carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the allocated goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any impairment of goodwill.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for commenced leases that existed as of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 842).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for more information regarding the right-of-use asset and related long-lived asset impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Liability, Net and Related Imputed Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We derive revenue by providing diagnostic and research services in our MRD and Immune Medicine business areas. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#x201c;Genentech&#x201d;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#x2019;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#x2019;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#x2019;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#x2019; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#x2019; therapeutic development efforts, including regulatory support where our technology is intended to be utilized as part of our customers&#x2019; registrational trials, developing analytical plans for our data, participating on joint committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#x2019; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#x2019; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For research customers who utilize either our MRD or Adaptive Immunosequencing services, contracts typically include an amount billed in advance of services (&#x201c;upfront&#x201d;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; typical performance obligations under the terms of our research service contracts: (1) the delivery of our MRD data or Adaptive Immunosequencing for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#x2019;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Advertising costs are expensed as incurred. Advertising expenses were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets expenses include our impairment charges for certain leased office and laboratory space, related long-lived assets (including leasehold improvements and laboratory equipment) and long-lived assets associated with our halted software enhancements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 280): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which intends to enhance reportable segment disclosures with an emphasis on significant segment expenses. We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this guidance in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;fourth quarter of 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and applied it retrospectively. See Note 19, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for more information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 740): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;: Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_75f65355-da29-4628-b12e-1122c208f9e8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;</adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_e59b5618-2d7c-4271-a133-4a54a274bfa0"
      decimals="2"
      id="F_daa23742-c7b7-4b49-928c-485e578b5ebb"
      unitRef="U_pure">0.70</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:UseOfEstimates
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_32d73065-5815-4509-a068-c98c9b479b4b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#x201c;Purchase Agreement&#x201d;), the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ae36c902-ef38-422b-bfae-9c4a48366883">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We operate as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segments: Minimal Residual Disease (&#x201c;MRD&#x201d;) and Immune Medicine. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have determined that our chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM regularly reviews operating results and other financial information presented at the MRD and Immune Medicine segment level, as well as on a consolidated basis, to make resource allocation decisions. The MRD and Immune Medicine segments are also our two reporting units.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <adpt:NumberOfOperatingAndReportableSegments
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_c7dad336-dffa-456e-aead-d2c5854387ca"
      unitRef="U_Segment">2</adpt:NumberOfOperatingAndReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_24b87219-5f52-4f81-a720-7f12e307fdef">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_564c1005-7f73-434c-8d1d-1547b556870c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We had a restricted cash balance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 and 2023. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our facility leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-5"
      id="F_61ff6843-8f26-4251-877f-17a7a1f1747a"
      unitRef="U_USD">2900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-5"
      id="F_2b199b4f-eb98-4088-8738-4bc9554d5105"
      unitRef="U_USD">2900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_47485b53-b83a-4f12-8c7c-f298e7cb0715">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities are classified as available-for-sale, consist of United States (&#x201c;U.S.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#x2019; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_c0c8f6ce-b8a4-4f27-844b-1f8ca5a787fc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2024 or 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b04ecf29-51e8-4354-9298-5a6af9e9d2b2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively. There were no customers that represented more than ten percent of our accounts receivable, net balances as of December 31, 2024 or 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Genentech, Inc. and Roche Group&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;* less than 10%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The related revenue was recognized and reported by our MRD segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The related revenue was recognized and reported by both our MRD and Immune Medicine segments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_e2404800-d44a-4409-a83c-36418f8d0f52">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.783%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Genentech, Inc. and Roche Group&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;* less than 10%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The related revenue was recognized and reported by our MRD segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The related revenue was recognized and reported by both our MRD and Immune Medicine segments.&lt;/span&gt;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_41d2ea93-dc38-4500-b0a7-cd99c27e6352"
      decimals="3"
      id="F_dc77b06d-c1b5-48b5-a2f8-aeb1b593d8fd"
      unitRef="U_pure">0.152</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1a256318-aca1-4e30-8e79-987a0c9de60a"
      decimals="3"
      id="F_ffc26350-84be-43fe-b8c6-98d6ca31f0fe"
      unitRef="U_pure">0.116</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0df3cf5d-7b89-4a27-bcce-445ba936b692"
      decimals="3"
      id="F_9f7a09d6-8820-4fff-ac75-5549aa78151b"
      unitRef="U_pure">0.278</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_9abadd97-9d4e-4600-a895-663eefee5344"
      decimals="3"
      id="F_229790b9-3560-40e2-ba1d-3968e1fa956d"
      unitRef="U_pure">0.364</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7508ae34-1421-49dc-85f2-bebeede4ea99">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_c05fed39-f746-4d9c-bcc0-c4dcb7b8ac5a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was included within the other assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:OtherInventoryNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-5"
      id="F_a6909d4c-93b6-4abb-b933-4e8413455e40"
      unitRef="U_USD">1500000</us-gaap:OtherInventoryNoncurrent>
    <us-gaap:OtherInventoryNoncurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-5"
      id="F_6dab2607-9420-4afd-802c-21ea2a889d06"
      unitRef="U_USD">2800000</us-gaap:OtherInventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_dfdd7305-6795-4231-8d0c-288c4ad52e44">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_590e35b2-4806-4e02-b888-a893e31d4965">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:49.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_42e46b63-b287-41a5-92ef-d9f4ad8bfac3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_57585e88-6f33-40e2-a08a-7f48691bb39b"
      id="F_db6c13fa-ed06-4ca1-8e12-21756afa5fe9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_374a2a9a-0d8a-4c0a-bd27-2a810ec44e11"
      id="F_1c979d66-d1dd-40ae-8767-d5638867916c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20a3dc1a-a419-4e0f-a290-0890b8721905"
      id="F_7d6c7707-c6df-4358-b268-616cfbd80a59">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_eddbf21f-640d-4187-9c5f-398cd390ba4b"
      id="F_ef9a68f9-ac14-4fa3-be28-0c818c1862df">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e0cd05cf-7df4-4d8f-b77a-87c83fce22a0"
      id="F_f700a16c-5b7d-486c-8b94-b671a354a684">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d8181a55-5e75-41e9-9ce9-c8d6ef15af36"
      id="F_7f20d50b-46ee-45ba-95a9-1dba3fc0924e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_8660fb18-51ea-4e85-b02d-7eb9ecd448be">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any impairment losses on intangible assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_8876fd84-9eb9-4fa8-8669-db9f0becd37a"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7c0132e5-4598-43b5-9d8a-b81529a6beee">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the net amount of attributed identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of one or both of our reporting units below its respective carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of one or both of our reporting units is less than its respective carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the allocated goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any impairment of goodwill.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_cb07a17d-a711-4ab5-9fb5-f8eab1a1c7be"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_359cc961-eccf-42c4-addd-ca8b143a9ebf">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for commenced leases that existed as of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 842).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset or asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset or asset group, if not separately stated within its own financial statement line item. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for more information regarding the right-of-use asset and related long-lived asset impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_1e9897c4-5275-417c-8724-b96563d5a101"
      id="F_bdc21854-edc8-4040-9bd8-a49f41d6c966">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_1e9897c4-5275-417c-8724-b96563d5a101"
      id="F_7aa0c729-205b-4665-b95b-c5999c86b28f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <adpt:RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_36c7a5aa-6e8b-45ab-8819-0fc100505ca0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Liability, Net and Related Imputed Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</adpt:RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ce5cef36-60d5-483d-b10a-1130a0c86e8b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We derive revenue by providing diagnostic and research services in our MRD and Immune Medicine business areas. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#x201c;Genentech&#x201d;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#x2019;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#x2019;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#x2019;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#x2019; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#x2019; therapeutic development efforts, including regulatory support where our technology is intended to be utilized as part of our customers&#x2019; registrational trials, developing analytical plans for our data, participating on joint committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#x2019; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#x2019; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For research customers who utilize either our MRD or Adaptive Immunosequencing services, contracts typically include an amount billed in advance of services (&#x201c;upfront&#x201d;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; typical performance obligations under the terms of our research service contracts: (1) the delivery of our MRD data or Adaptive Immunosequencing for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <adpt:NumberOfRevenuePerformanceObligation
      contextRef="C_fbb5807f-dfac-429b-964f-d08eebca81e7"
      decimals="INF"
      id="F_5cd56bef-98e1-4d0a-af0e-dafdc7a81a3a"
      unitRef="U_Performance_Obligation">2</adpt:NumberOfRevenuePerformanceObligation>
    <adpt:ContractBalancesPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_e759fa64-a4de-4f8c-bee2-ae9963412604">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#x2019;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.&lt;/span&gt;&lt;/p&gt;</adpt:ContractBalancesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7023cc32-f6d6-427b-bc7e-0149091a692b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_6989b3e3-04aa-4cdc-b8c6-96240114ac7a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Advertising costs are expensed as incurred. Advertising expenses were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_4248db64-cc24-4f99-9f66-f823d4334391"
      unitRef="U_USD">6100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_ea39e9bd-b338-4e35-82d3-a63eafc8ee6d"
      unitRef="U_USD">8600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_9701cc38-2245-48e8-9f96-91f59a6cad76"
      unitRef="U_USD">13700000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_64b97e5a-a6f5-43fd-8106-66bbd80ddc70">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_0952709c-ac39-4d17-8e55-5989040999de">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <adpt:SalesAndMarketingExpensePolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b79f42bb-6f5e-464c-b66e-77a8d4e29daf">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.&lt;/span&gt;&lt;/p&gt;</adpt:SalesAndMarketingExpensePolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_4ce9f312-f519-4585-a85e-52f6abe1479b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets expenses include our impairment charges for certain leased office and laboratory space, related long-lived assets (including leasehold improvements and laboratory equipment) and long-lived assets associated with our halted software enhancements.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_887c758c-1e5f-4b38-b3ac-c57d2cdeaa80">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_4cd83df5-de58-4e14-a2f2-edc1edb94e3c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_f081cd69-fe1d-4e55-8348-2040635482f3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_a065ff9e-3801-4907-b233-8bf18dd2450e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 280): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which intends to enhance reportable segment disclosures with an emphasis on significant segment expenses. We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this guidance in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;fourth quarter of 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and applied it retrospectively. See Note 19, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for more information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Topic 740): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;: Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_5ec5d924-4867-4b17-91e0-bd4130ea3d71"
      id="F_7558bdca-001a-4fed-be89-767eb717c766">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_5ec5d924-4867-4b17-91e0-bd4130ea3d71"
      id="F_e173676d-3a9f-4782-ab15-d8fd5df202d5">2024-12-31</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7303db50-ff35-4053-8454-9327123d490a">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Regulatory milestone revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2024, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and cancelled customer contracts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2022, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2022, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, we could receive up to an additional &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;418.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;milestone payments in future periods if certain regulatory approvals are obtained by our customers&#x2019; therapeutics in connection with MRD data generated from our MRD product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Genentech Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the &#x201c;Genentech Agreement&#x201d;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in February 2019. We also received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone in 2023. We may be eligible to receive an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion over time, including payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specified regulatory milestones, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specified development milestones and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,430.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell therapeutic products in which Genentech intends to use T cell receptors (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;TCRs&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) screened by our immune medicine platform to engineer and manufacture cellular medicines:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shared Products. The shared products will use &#x201c;off-the-shelf&#x201d; TCRs identified against cancer antigens shared among patients (&#x201c;Shared Products&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#x201c;Personalized Product&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;ASC&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) Topic 808, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 808&#x201d;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#x2019;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;ASC 606&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) to account for the activities related to the Genentech Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In applying ASC 606, we identified the following performance obligations at the inception of the agreement:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License to existing shared antigen data packages. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development services for Shared Products development, including expansion of shared antigen data packages. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development services for private product development. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.4625837050543202%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Obligations to participate on various joint research, development and project committees. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#x2019;s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We determined the initial transaction price shall be made up of only the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million addition to the transaction price, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of which was recognized as revenue in the three months ended June 30, 2023, with the remainder included in deferred revenue to be recognized as revenue over the remaining research and development period. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize revenue generated from the Genentech Agreement over a period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6a683fd2-b719-4e8e-9163-23af35cb1311;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nine&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In total, we recognized &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.6&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in Immune Medicine collaboration revenue during the year ended December 31, 2024, 2023 and 2022, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_c33ac91e-48ab-4de6-9ac3-1568f08f4907">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Regulatory milestone revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6ee41dc2-3749-4243-b0eb-1ba3135232f3"
      decimals="-3"
      id="F_fd9a37d4-1ff8-4844-bd2b-d9c9f412d79c"
      unitRef="U_USD">133029000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9574ad63-2e26-40ad-9358-463b4132a65d"
      decimals="-3"
      id="F_f39fbf5b-ae6f-4405-b0ab-16a26adc6baf"
      unitRef="U_USD">102739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_01f6ee6c-fba7-496b-80dc-8365c221c856"
      decimals="-3"
      id="F_2541e382-2a02-4c9a-ad8f-f87bea82ad00"
      unitRef="U_USD">81144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cdd9919b-7ab5-4a3b-856b-38b155fb4234"
      decimals="-3"
      id="F_374e0ead-2ea7-4110-ad83-2b8f76c6ae9d"
      unitRef="U_USD">12500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e30f0baf-e7ad-4a6d-8333-cd12494dfbb4"
      decimals="-3"
      id="F_387c4db1-6c5f-4ecf-a2c3-6fbd8ca6c800"
      unitRef="U_USD">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d3e4b471-6ad7-4d54-aafa-1c355daee1b0"
      decimals="-3"
      id="F_c053d0cb-518d-4198-bea2-0ec91bbbbd33"
      unitRef="U_USD">145529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_02627e80-13ae-4972-9edc-6d2d1f0cdb33"
      decimals="-3"
      id="F_f1682d4c-251b-480d-b344-d56a669d0c46"
      unitRef="U_USD">102739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6b2d4707-21b9-4599-a35b-221f9e77a609"
      decimals="-3"
      id="F_dfe6a809-607f-4ced-9882-80a981e1aae0"
      unitRef="U_USD">87144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cb867f2c-9a12-4675-ab77-495ff41044b1"
      decimals="-3"
      id="F_50e05227-2c51-4570-b6bd-ca116058165e"
      unitRef="U_USD">19976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c8c4442e-e5ce-488d-9683-4a18e9b3cd7f"
      decimals="-3"
      id="F_8bb7f8f5-bb65-4061-9e81-61bae568c5ec"
      unitRef="U_USD">24959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9dadad4b-2404-454e-8619-6c7106da8dfc"
      decimals="-3"
      id="F_720ec592-0d8e-4bc9-b944-a345fd77531f"
      unitRef="U_USD">31777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_be240297-154f-4383-9264-3588023daa8f"
      decimals="-3"
      id="F_e62a0b8f-1b76-4ff5-b486-325448242639"
      unitRef="U_USD">13452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a7d99817-f47e-4c17-8910-f27cddac34f0"
      decimals="-3"
      id="F_25816ead-ce1b-4bf1-a892-df54936ebc6c"
      unitRef="U_USD">42578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6f1d2824-9131-43aa-aab8-2a0a4ed4adce"
      decimals="-3"
      id="F_1459a05c-21e4-4f2a-9ca5-ebba5f81fa82"
      unitRef="U_USD">66387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3ed4ebec-bba3-4eee-a2b7-b31d8032bc49"
      decimals="-3"
      id="F_359c4f50-9ca4-4a0d-b01f-905f45c8fbd8"
      unitRef="U_USD">33428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_64e80de6-0e67-4131-8ace-44a4d0c8b34e"
      decimals="-3"
      id="F_3711c5fa-7278-4b17-b30a-81724f692034"
      unitRef="U_USD">67537000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6712d8a7-de54-47f0-b34a-c94d59831861"
      decimals="-3"
      id="F_c37c5958-d31f-4a6e-9a99-619b81c15a16"
      unitRef="U_USD">98164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_d02f5b41-5a5b-4669-a064-74ca248db096"
      unitRef="U_USD">178957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_b2f37b28-7294-4fea-a457-1966d8b57076"
      unitRef="U_USD">170276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_0b581649-2092-44f6-a51d-0401ecc09b5c"
      unitRef="U_USD">185308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9bed03af-b144-4cd1-8808-efb75597dec9"
      decimals="-5"
      id="F_ae861d54-19b0-4c70-90f3-8e7451588b9a"
      unitRef="U_USD">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_90f05e58-9e8e-464c-86a0-007bf79714f8"
      decimals="-5"
      id="F_71e677d9-44f4-45c1-8d3e-42754b4505a3"
      unitRef="U_USD">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b171d937-1d83-4b19-9289-84b0ac31bda2"
      decimals="-5"
      id="F_94cf8fe7-1d10-4240-ab6a-ac179c02b3c4"
      unitRef="U_USD">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_dec1c67a-a4a6-4150-87ca-ce929f12f0f9"
      decimals="-5"
      id="F_2524294c-64af-4c38-b847-e37d7c13f7e5"
      unitRef="U_USD">5600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_df90d480-536f-44ca-97f1-bc8815b053e9"
      decimals="-5"
      id="F_e6eff38b-0d01-4115-bffd-a04f3a4fb9c0"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f6bd00d1-b48a-4bf4-8057-810a2bb6684a"
      decimals="-5"
      id="F_f1082494-08c3-4502-86d0-0b1a30fb96c3"
      unitRef="U_USD">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:AdditionalMilestonePayment
      contextRef="C_68e4bc9a-5ec1-4697-aa56-4ddc7bb9b1f9"
      decimals="INF"
      id="F_15798856-6558-4ed1-b509-d20e2993a0d7"
      unitRef="U_USD">418500000</adpt:AdditionalMilestonePayment>
    <adpt:NonRefundableUpfrontPaymentsReceived
      contextRef="C_eb217ce2-c0bd-4ee9-98ca-e04bd1a4c870"
      decimals="-5"
      id="F_2cc17ee4-9a3c-447a-be35-52ceae5ded17"
      unitRef="U_USD">300000000</adpt:NonRefundableUpfrontPaymentsReceived>
    <adpt:AdditionalTransactionPriceOfRegulatoryMilestone
      contextRef="C_cc530114-c6ce-4f99-b1da-fe2970aacb2e"
      decimals="INF"
      id="F_547624a3-fe5c-4f96-a4e3-b824b667053c"
      unitRef="U_USD">10000000</adpt:AdditionalTransactionPriceOfRegulatoryMilestone>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_29395044-cf96-4b99-9148-86cf3018ed50"
      decimals="INF"
      id="F_1d43ae1d-5916-4f1c-9366-78e5bc14f998"
      unitRef="U_USD">1800000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_1aeca0d4-12fc-4e19-b717-44dc51c65479"
      decimals="INF"
      id="F_ffd4eabb-93c7-4e16-93a5-da01df1458ef"
      unitRef="U_USD">65000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_81bb5afe-4560-45fd-bd67-49459a4983ba"
      decimals="INF"
      id="F_6caf5ef6-73fe-4c43-b4b7-4045e039933b"
      unitRef="U_USD">300000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_fd9b1278-cc4e-43c9-a7cf-005a24cec79b"
      decimals="INF"
      id="F_1bd185b6-4b60-4812-9331-13b5438128f2"
      unitRef="U_USD">1430000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:NonRefundableUpfrontPaymentsReceived
      contextRef="C_0b1f2c34-a18a-449b-9a8f-3aa8bfcadbc2"
      decimals="-5"
      id="F_9af4ccaf-2ea4-44c9-90f4-c327075bbd8e"
      unitRef="U_USD">300000000</adpt:NonRefundableUpfrontPaymentsReceived>
    <adpt:AdditionalTransactionPriceOfRegulatoryMilestone
      contextRef="C_fd819420-41b4-40d4-9e84-63652fd8d5a7"
      decimals="-5"
      id="F_426ed651-a194-46a3-b154-79724a12d648"
      unitRef="U_USD">10000000</adpt:AdditionalTransactionPriceOfRegulatoryMilestone>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9636194e-e351-4fcc-97ab-4e132d735d9a"
      decimals="-5"
      id="F_c7bd959d-4cab-4fd5-9a07-18815ae67bfa"
      unitRef="U_USD">7700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:RevenueRecognitionExpectedPeriod
      contextRef="C_69a8c3ab-a441-40a7-8a5f-6b8e7d9071e2"
      id="F_db5a94ee-f891-4e86-8073-c30f5e626cf3">P10Y</adpt:RevenueRecognitionExpectedPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_61e08594-2216-4ede-9093-11ef2ff2f063"
      decimals="-5"
      id="F_8aaf8472-3c44-4b71-af20-578b258f2220"
      unitRef="U_USD">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_28466158-15a5-4c86-9df3-08250c20e264"
      decimals="-5"
      id="F_63dfdef7-46a4-4988-b828-8593de5c0c16"
      unitRef="U_USD">42600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_69fe0b18-2ecf-4cb8-92b2-378c77fd872e"
      decimals="-5"
      id="F_8524da8b-b97e-47f0-ae09-b47301168830"
      unitRef="U_USD">62800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:DeferredRevenueTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_92cd2468-ffe3-4f03-ac68-c03ffa4513da">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue from the Genentech Agreement represents &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2024 and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2023. We expect our current deferred revenue to be recognized as revenue within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from December 31, 2024. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes in deferred revenue during the year ended December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions to deferred revenue during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized as revenue that was included in the deferred revenue balance at December 31, 2023.&lt;/span&gt;&lt;/p&gt;</adpt:DeferredRevenueTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_8a711a70-7835-4547-9b99-bc3f849a6ee6"
      decimals="-5"
      id="F_9e284005-0723-4cc9-ba9e-a7df56222e98"
      unitRef="U_USD">15900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_8a711a70-7835-4547-9b99-bc3f849a6ee6"
      decimals="-5"
      id="F_35830fb5-ade7-42dc-827e-230ff3e53511"
      unitRef="U_USD">25400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_ccbf3cec-810a-407c-8e46-299bdc89be19"
      decimals="-5"
      id="F_a00afffe-334c-4abd-a8a2-ba3c2675860a"
      unitRef="U_USD">13600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_ccbf3cec-810a-407c-8e46-299bdc89be19"
      decimals="-5"
      id="F_32a1e1c5-6b9b-4638-b390-a4b25815180f"
      unitRef="U_USD">41100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_4c968389-ac05-4e80-a351-de3893d81820"
      id="F_73227e0a-0787-45a7-8040-97bf4aa3dc05">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_90e7cb01-e413-4073-b348-b2397b9dd2f7"
      id="F_541cefcb-2078-43fd-9a8f-6f77d35b6372">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_df5fdb9b-ca16-4e3e-8614-8004106ea49b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes in deferred revenue during the year ended December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions to deferred revenue during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_8bd7bbcf-6ac6-4bb4-be0b-171927fb989f"
      unitRef="U_USD">93423000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_ccd6832b-8d4c-4a78-b810-3845b2e2f4be"
      unitRef="U_USD">51936000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_290e8e49-26ba-46f0-8bfc-9fae36df3b1a"
      unitRef="U_USD">-62414000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_bda88ece-0c99-46d9-a4ef-4fa2471a30ff"
      unitRef="U_USD">82945000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c46025e5-021b-4f7b-a2ef-444e78692785"
      decimals="-5"
      id="F_ef00d756-42e1-4d0c-9a4c-816dee1115d3"
      unitRef="U_USD">35900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_e35790b6-70e6-42d7-9d09-08c689c0debe">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth the fair values of financial assets as of December 31, 2024 and 2023 that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;326,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_191bce4e-07a9-4e48-ba50-7f45cdf84776">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth the fair values of financial assets as of December 31, 2024 and 2023 that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;326,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a0289be5-fa32-463c-acef-732918e4cece"
      decimals="-3"
      id="F_8b9a4a48-8db8-41e4-8b77-070a83f3a70e"
      unitRef="U_USD">35790000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5c67024c-2523-482e-9f70-804bcc6d8184"
      decimals="-3"
      id="F_2d1b2d73-4a26-4da9-bed9-232e81220fc0"
      unitRef="U_USD">35790000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bc03cecf-836f-4bee-b7f1-33ef96865307"
      decimals="-3"
      id="F_9b6e76f7-ebf4-4c51-b32f-ca8105249e76"
      unitRef="U_USD">2479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_880b4bee-c006-4cb8-8920-ecb8a97fc49d"
      decimals="-3"
      id="F_4d61b25b-70d8-4f85-82e7-0b86a7b62e55"
      unitRef="U_USD">2479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a9e6d9f0-f84d-4295-b3ac-f1ae0043be0d"
      decimals="-3"
      id="F_38856ec5-6472-492b-be18-3fc204bb7e72"
      unitRef="U_USD">187181000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_518ea4ca-bec1-4e07-8773-307a90cb3d09"
      decimals="-3"
      id="F_49780576-b1b8-4629-abbf-615856a04766"
      unitRef="U_USD">187181000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_06fe2942-7d85-4654-9ab0-33bc82a8bcd5"
      decimals="-3"
      id="F_ee69812d-d12f-4313-99f6-5c0704e52ebe"
      unitRef="U_USD">18374000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_da165782-cf35-4126-a330-0965f4347274"
      decimals="-3"
      id="F_78f27538-4ebc-45e4-8321-4e54ad0f0885"
      unitRef="U_USD">18374000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9d69ac12-b7e7-4fba-a6e8-17f59c20625b"
      decimals="-3"
      id="F_d2e77fc2-4caf-4b33-83df-1a31a0e4a262"
      unitRef="U_USD">35790000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0bdc5c5e-908e-4299-8ae3-da0932a02def"
      decimals="-3"
      id="F_a75ae07c-8d38-4539-b675-a6b6a061871f"
      unitRef="U_USD">208034000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1c7dad97-0dc1-49c3-8e6a-213606328313"
      decimals="-3"
      id="F_7f770e9f-de4a-4508-b22c-d9c9ff6f7271"
      unitRef="U_USD">243824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5d904410-055f-498e-b598-0be6c4b19349"
      decimals="-3"
      id="F_5e07bc55-b52f-4329-86fc-a0d5d981379f"
      unitRef="U_USD">45123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3da0eaaf-abe5-400c-a7d1-218bca3b9652"
      decimals="-3"
      id="F_1af73408-1d76-4649-bcb4-5f21485c22e3"
      unitRef="U_USD">45123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_29b153aa-6e60-459b-8d8b-3607e4aecaf2"
      decimals="-3"
      id="F_c18b8e69-e27b-4a8b-90e3-0b2fce71cc66"
      unitRef="U_USD">10630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_538c62e7-e31b-49fc-a740-3611b3bdd5b3"
      decimals="-3"
      id="F_592f71d4-6898-44c6-b85f-4f8822327d78"
      unitRef="U_USD">10630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e4bc6147-a322-4ac9-983f-0be3e4e33863"
      decimals="-3"
      id="F_074e3ce8-d9af-47ee-8b1d-1d308c761332"
      unitRef="U_USD">264426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6761f29f-952e-4394-b160-1a416c1945ba"
      decimals="-3"
      id="F_efe2a5fc-82b9-4053-98f5-348f3c989538"
      unitRef="U_USD">264426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a1e0e792-7995-4a69-9664-7d62b49d7305"
      decimals="-3"
      id="F_da54e7e8-d126-4436-b437-ffa5de407326"
      unitRef="U_USD">6281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7f583a8c-c6f5-48ba-af7b-80283f1ac4cc"
      decimals="-3"
      id="F_f46b84cb-ac89-406f-92ac-d13618f853df"
      unitRef="U_USD">6281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d2e2d8d1-07f1-4212-9f71-7af175f378a4"
      decimals="-3"
      id="F_bf6238e6-aad3-4130-95ab-9467a571057f"
      unitRef="U_USD">45123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_791187a1-62e6-4444-ac40-4fce1c79f12a"
      decimals="-3"
      id="F_6b28919d-f32b-44c3-9794-42d79919f94b"
      unitRef="U_USD">281337000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_abf475fb-d18b-494c-bb9c-bf8ac3104ace"
      decimals="-3"
      id="F_207e598f-7317-4a81-a6bf-7eb9fae3c080"
      unitRef="U_USD">326460000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ed31ab51-22b4-4bbc-8e1e-1e0291cbba84">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale investments consisted of the following as of December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was presented separately within the prepaid expenses and other current assets balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months Or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2024 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_19aee3a6-5ae2-4f34-8c36-ade1544a78d5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale investments consisted of the following as of December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6591b0ed-3cfb-45af-b746-4190d5d17981"
      decimals="-3"
      id="F_285a84b9-0005-4052-acfb-dbe039678b36"
      unitRef="U_USD">2476000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6591b0ed-3cfb-45af-b746-4190d5d17981"
      decimals="-3"
      id="F_3c51a635-2c5e-4a35-b3ef-975e4e00249f"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6591b0ed-3cfb-45af-b746-4190d5d17981"
      decimals="-3"
      id="F_9862e804-1f51-4a0b-b7aa-23fb38bb7094"
      unitRef="U_USD">2479000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4"
      decimals="-3"
      id="F_c64a511b-55e8-481e-a523-e444a41faa39"
      unitRef="U_USD">153353000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4"
      decimals="-3"
      id="F_85d70a55-5cc2-4a66-be48-bd203c9196d6"
      unitRef="U_USD">211000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4"
      decimals="-3"
      id="F_4be0a724-d3cf-4636-9765-2ed68fc6724c"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2b9d646e-296f-426e-b4d4-112b6bd2a6d4"
      decimals="-3"
      id="F_cfe1eaa3-46e4-435c-9f15-37aef4fab108"
      unitRef="U_USD">153521000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075"
      decimals="-3"
      id="F_acf3dbcc-3b2d-4eee-abf8-ffbbeae9bc30"
      unitRef="U_USD">18357000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075"
      decimals="-3"
      id="F_219c2b15-91e1-4972-8579-b84e6d56f454"
      unitRef="U_USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075"
      decimals="-3"
      id="F_21b23119-1908-4d3c-883c-b0813104dd50"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3b9d63b5-6a7f-4bbb-91af-44b14a7da075"
      decimals="-3"
      id="F_27be3ca3-1862-4e3d-8b5e-835ed7f1f2ae"
      unitRef="U_USD">18374000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_af621409-f3a9-456c-8964-3694f64ce437"
      decimals="-3"
      id="F_df177235-621d-48ca-b96f-117fafd36fbe"
      unitRef="U_USD">174186000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_af621409-f3a9-456c-8964-3694f64ce437"
      decimals="-3"
      id="F_4ee45bff-392d-4bd1-872d-dd5a5d8739d7"
      unitRef="U_USD">233000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_af621409-f3a9-456c-8964-3694f64ce437"
      decimals="-3"
      id="F_6ef58590-3dc3-48c7-a21c-bcb341d17568"
      unitRef="U_USD">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_af621409-f3a9-456c-8964-3694f64ce437"
      decimals="-3"
      id="F_d5b7e1e7-8fcf-44c6-b3e3-eed52fb6883a"
      unitRef="U_USD">174374000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3"
      decimals="-3"
      id="F_47df524f-57d8-44c8-847b-9cfdb934d3e6"
      unitRef="U_USD">33682000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3"
      decimals="-3"
      id="F_34a30351-f1a1-48c3-8bb7-52ba570d7ab6"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3"
      decimals="-3"
      id="F_539e397f-a2da-4ba1-93d4-5f44fae1a15c"
      unitRef="U_USD">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_daf43a0f-7fbb-4f41-bdf4-d1752b439cf3"
      decimals="-3"
      id="F_f79c2711-232a-417c-8706-a135902fdc7f"
      unitRef="U_USD">33660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4"
      decimals="-3"
      id="F_dcf1c815-e829-40d1-bd8c-9a9a2960722e"
      unitRef="U_USD">33682000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4"
      decimals="-3"
      id="F_72403fc6-df65-4b9b-bfa0-0e065110ae7d"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4"
      decimals="-3"
      id="F_fab749f7-4d5a-4f0f-9491-ed02759c0257"
      unitRef="U_USD">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0c69d39b-76e9-45ab-859e-d38547a4c6e4"
      decimals="-3"
      id="F_0bf8b36c-8492-485b-be21-a0b6b7d18f97"
      unitRef="U_USD">33660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b2e59962-3ddd-4060-85da-417d16f3db74"
      decimals="-3"
      id="F_2c8f0333-d0f5-4589-b9f8-0b1c785cbc99"
      unitRef="U_USD">10630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b2e59962-3ddd-4060-85da-417d16f3db74"
      decimals="-3"
      id="F_55ff150e-b9e7-4ebc-acae-33002b19db27"
      unitRef="U_USD">10630000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0"
      decimals="-3"
      id="F_3c8c7e06-2c59-48a5-9722-d38aef22b92d"
      unitRef="U_USD">264214000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0"
      decimals="-3"
      id="F_ed4f6025-92d3-41c7-9b33-c85e06b1fc71"
      unitRef="U_USD">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0"
      decimals="-3"
      id="F_fd0fc991-09eb-4267-b6da-169c37f4873e"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0d2b1db3-51e0-442f-a409-e2b11e0d22c0"
      decimals="-3"
      id="F_f1c4bc27-ebfc-4600-8997-cd12e47b8009"
      unitRef="U_USD">264426000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1"
      decimals="-3"
      id="F_9eec4782-6105-4474-85e2-0927f2f8d12f"
      unitRef="U_USD">6278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1"
      decimals="-3"
      id="F_41e837f5-079e-40e1-a4f4-5534c2a0b256"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5b84cd9b-aac0-477c-95e4-4cf308d3d5f1"
      decimals="-3"
      id="F_29553f33-c7fd-4082-98f2-5f523a079cff"
      unitRef="U_USD">6281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e"
      decimals="-3"
      id="F_3bf1bd92-f386-47ee-8eae-0a6aaf5cc78b"
      unitRef="U_USD">281122000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e"
      decimals="-3"
      id="F_ecdcc0be-504a-4252-ac93-5c71915f2092"
      unitRef="U_USD">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e"
      decimals="-3"
      id="F_ae01eec3-b869-4055-8c5c-557da8cd92eb"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e2a6e4c6-1ad4-47dd-a36a-d8dd76f6f60e"
      decimals="-3"
      id="F_6f3bc259-dd12-4b0b-ad6c-3f51f55bd4c5"
      unitRef="U_USD">281337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_419c90ac-d4cc-4e42-adb9-be55df808d8d"
      decimals="-5"
      id="F_43016ff3-4e8a-47a6-a53c-809fff79cc4b"
      unitRef="U_USD">1300000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_848613df-8ebc-4107-bbad-5a337d92718b"
      decimals="-5"
      id="F_d3f2f3f1-9077-4f39-9505-1697e27f8910"
      unitRef="U_USD">1000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_dc464964-f1d8-443e-a053-76ec4327217e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months Or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_874675f7-b27f-4f96-93aa-3186a0017df4"
      decimals="-3"
      id="F_977622ce-9d0e-4f2b-b4ea-d30e96251739"
      unitRef="U_USD">34782000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_874675f7-b27f-4f96-93aa-3186a0017df4"
      decimals="-3"
      id="F_95606858-fe46-4c7f-8057-c7d116152d8d"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_4209531b-b000-47fb-8aa6-738c91148064"
      decimals="-3"
      id="F_697a743c-e216-4bf8-b8b7-00a100e1020f"
      unitRef="U_USD">2847000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_4209531b-b000-47fb-8aa6-738c91148064"
      decimals="-3"
      id="F_53ec68c8-08fd-4273-a269-01f42e941dcf"
      unitRef="U_USD">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_275b40e6-9662-4f3e-84db-156f79d771aa"
      unitRef="U_USD">37629000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_ab610ac2-22d6-4e56-a92e-644be6332875"
      unitRef="U_USD">94000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_1e6b0561-e140-4dc3-8fb5-70617b6c94a9">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024, 2023 and 2022, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_67782f26-e2c1-4552-a54c-5bdf805dbd32">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b0da9317-56fb-4a02-9287-ece7f5f4b6bb"
      decimals="-3"
      id="F_c8aaceea-0b73-4181-b8e0-29090c647ded"
      unitRef="U_USD">46950000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ade00613-56f9-431a-ba97-2bc4f44cf6b1"
      decimals="-3"
      id="F_e8088fd1-360e-4a01-9a3b-0773e1a5ad17"
      unitRef="U_USD">49567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8ae2ed18-baf4-42dd-a344-3979e49ff066"
      decimals="-3"
      id="F_82a4f44b-49f5-4e07-b2d4-16b8bd23eb0a"
      unitRef="U_USD">8337000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_23197216-2be1-412a-babd-a86284108614"
      decimals="-3"
      id="F_93946990-f74a-441a-98e9-ff8eb7eef16c"
      unitRef="U_USD">7970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bc1ec203-aeac-49ca-bbbc-3d860034cbec"
      decimals="-3"
      id="F_c1c66a00-07b0-447c-9d80-ae0885ec22c1"
      unitRef="U_USD">4040000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bc1bccb4-0e9a-42e9-b42b-84b9f3eb6d85"
      decimals="-3"
      id="F_b2ced14b-66b6-45aa-9da9-90b6d4e25825"
      unitRef="U_USD">3820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fc40783a-89f6-4d6a-8cdb-a7280da7107a"
      decimals="-3"
      id="F_4fac8bed-72c2-48f8-b208-a2659da5f075"
      unitRef="U_USD">1258000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_621e5196-e15c-4321-8f5f-959090207c65"
      decimals="-3"
      id="F_0b10e0ca-a27c-4735-80ca-731b6ac87af7"
      unitRef="U_USD">1965000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_845f3c97-7e7c-4286-9701-ee7332f3f413"
      decimals="-3"
      id="F_df755c72-547a-4976-bf0f-94425ba6c62a"
      unitRef="U_USD">2571000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bb6cf174-eaac-4064-a305-81f3eb2a9aeb"
      decimals="-3"
      id="F_d4738498-9c87-48e6-ae74-a851bb98ff30"
      unitRef="U_USD">3405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9272d326-ab2d-442b-b3a2-82c6a66a936a"
      decimals="-3"
      id="F_dabe44a1-1a44-44e3-9f7b-0eec5ae8b81f"
      unitRef="U_USD">73277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_28c5bcc4-c729-4e8c-bce9-751448cc3f7e"
      decimals="-3"
      id="F_b86a827f-cc32-49be-a194-a2ab0c688815"
      unitRef="U_USD">74734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_e6e480c6-2445-42b1-83be-3257b333eceb"
      unitRef="U_USD">136433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_153501de-3dba-4e89-8f8c-ab7007bc6ef6"
      unitRef="U_USD">141461000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_0e86336c-db4b-4922-bb40-e3965131f3e3"
      unitRef="U_USD">87817000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c9d94804-f724-4194-b200-6aa4d00704a5"
      unitRef="U_USD">73234000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_0ac7a603-767e-4945-b194-44ff8d0e2adc"
      unitRef="U_USD">48616000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_239401ba-2485-46af-9f03-bb14c8a3dabe"
      unitRef="U_USD">68227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_ce80cd84-9d28-4b33-bf77-4a05db3543ff"
      unitRef="U_USD">17600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_96572ec2-56a1-4d16-a0cf-8d7769cfcb19"
      unitRef="U_USD">20500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_95f992f1-4cc3-4d5c-b739-2e288838b22d"
      unitRef="U_USD">19200000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_dcff5cd2-69a8-4492-8295-ce54941b3ed4">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; changes in the carrying amount of goodwill since its recognition in 2015. In conjunction with our organizational realignment in 2024, we allocated goodwill among our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reporting units using a relative fair value approach. Goodwill allocated to the MRD and Immune Medicine reporting units as of December 31, 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets subject to amortization as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed technology and the purchased intellectual property is expected to be amortized over the next &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, approximately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, expected future amortization expense for intangible assets was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_99584d81-0d39-482d-9529-479e97a39b00"
      decimals="INF"
      id="F_a9ce8b94-7067-4f50-b563-fd40acd4e9f3"
      unitRef="U_USD">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:NumberOfReportingUnits
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_a9465d44-f8de-4679-8ba6-4d4cc380d922"
      unitRef="U_Unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:Goodwill
      contextRef="C_236a64e1-b094-4db0-b4b0-f4b9a7cae648"
      decimals="-5"
      id="F_208d8da3-11e6-41ca-a802-c3b1c21f8d8b"
      unitRef="U_USD">96400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_569de780-6224-4d27-819f-c41e8e9a86d5"
      decimals="-5"
      id="F_26450225-aae0-404f-8c0b-1c8e4f0c7a55"
      unitRef="U_USD">22600000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_5dc8e950-38a2-43a8-a07c-dc90c2d428b9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets subject to amortization as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44"
      decimals="-3"
      id="F_df237992-22e2-4a58-95c8-a6c6e17fdc82"
      unitRef="U_USD">20000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44"
      decimals="-3"
      id="F_da386e01-d68c-4e16-a24a-7af6ac600875"
      unitRef="U_USD">16641000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_24251c2e-0d68-4b0f-9fad-3747ae78aa44"
      decimals="-3"
      id="F_371c5917-6048-4a8c-97af-8d68b2dab453"
      unitRef="U_USD">3359000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d"
      decimals="-3"
      id="F_a9d9595e-26f3-46b7-9069-82cdb6a4f0cf"
      unitRef="U_USD">325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d"
      decimals="-3"
      id="F_b0faad2e-a863-4303-a75d-63d9147984ba"
      unitRef="U_USD">259000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d"
      decimals="-3"
      id="F_e574e0c5-107b-4d2d-827d-a4e5501724df"
      unitRef="U_USD">66000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_b453aa85-b75d-4e5e-b899-edb8c78f2ffe"
      unitRef="U_USD">20325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_5f5b9faa-cfe6-4ff5-a54f-69fb83840940"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_82a24ddc-729d-4a66-8b24-5b019137c436"
      unitRef="U_USD">3425000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_ae8e1030-1ab7-4183-8173-e30e69f625b5"
      decimals="-3"
      id="F_038bf05e-7730-4052-a742-c1d7d542c276"
      unitRef="U_USD">20000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_ae8e1030-1ab7-4183-8173-e30e69f625b5"
      decimals="-3"
      id="F_09929e30-1698-47a8-a52c-00f4a8af764c"
      unitRef="U_USD">14970000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_ae8e1030-1ab7-4183-8173-e30e69f625b5"
      decimals="-3"
      id="F_0f7a5eed-7d2e-4d41-82c8-a02ff7631005"
      unitRef="U_USD">5030000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_43977db9-b2fc-4eb0-8c06-461f1b087616"
      decimals="-3"
      id="F_5ea74f2b-4c68-452e-8fdc-14881e9483e4"
      unitRef="U_USD">325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_43977db9-b2fc-4eb0-8c06-461f1b087616"
      decimals="-3"
      id="F_5bbb9499-ad1d-48e6-a623-4db24f10d0fc"
      unitRef="U_USD">227000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_43977db9-b2fc-4eb0-8c06-461f1b087616"
      decimals="-3"
      id="F_5ec2031e-0071-44d7-bd72-ee98662a38ba"
      unitRef="U_USD">98000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_6619ed30-3bc1-40ce-ac82-1856cbf60572"
      unitRef="U_USD">20325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_3b5fd3fb-5652-4947-bc41-25e48edf4afa"
      unitRef="U_USD">15197000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_f02c84e9-d60f-412c-9a0c-b6d182356697"
      unitRef="U_USD">5128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_d9d6dfa5-e03c-4ba5-a217-6449de15f92d"
      id="F_4d84168f-f556-40df-8a8b-9f1e8800bf46">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_4e9d686b-b62a-4528-90ad-ff86fe4a5986">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, expected future amortization expense for intangible assets was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_5b9e1709-61b1-4636-8092-0a157ee3c67c"
      unitRef="U_USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_431898f1-0437-43a9-a665-6f97ecab1672"
      unitRef="U_USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_052cf842-4255-4fbc-8e12-55efab8d944d"
      unitRef="U_USD">27000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_fdbcbc94-e615-474f-bfe1-eab23c683c32"
      unitRef="U_USD">3425000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      id="F_cebf14bd-d6b0-44e8-9bc0-f1ee41198874">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical and contract research organization costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Travel and entertainment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      id="F_98daca14-1dd5-4e60-bc7e-6e1b20063dfb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical and contract research organization costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Travel and entertainment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_43680e0a-578d-4826-a7d9-bfe6ce0fc6b5"
      unitRef="U_USD">2922000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_1e93a830-b748-4961-abc0-b224ea4aa9fc"
      unitRef="U_USD">4920000</us-gaap:AccruedProfessionalFeesCurrent>
    <adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_e2a033c1-c82d-4799-8329-f95af4a86223"
      unitRef="U_USD">874000</adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent>
    <adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_ebe345a8-d7b6-4efa-a2ab-97a19244f941"
      unitRef="U_USD">863000</adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_9e437d08-6b48-406f-b6f1-0275fa8de6a6"
      unitRef="U_USD">202000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_24cbeee5-faf7-434a-a191-a41b9189147a"
      unitRef="U_USD">154000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_47f7ce78-d3c1-418d-abba-d8f54553e262"
      unitRef="U_USD">176000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_b9dd4e0a-afa3-440e-9176-5d4ba757c26b"
      unitRef="U_USD">59000</us-gaap:AccruedIncomeTaxesCurrent>
    <adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_f85b41fc-1d55-4aac-8bdf-d8896473c5be"
      unitRef="U_USD">88000</adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent>
    <adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_bb28ff52-d6a1-4d6a-9815-610691e5e21d"
      unitRef="U_USD">687000</adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent>
    <adpt:ComputerAndSoftware
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_3b44cba6-9db6-4b06-984d-cd79143353ba"
      unitRef="U_USD">3065000</adpt:ComputerAndSoftware>
    <adpt:ComputerAndSoftware
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_e364a803-4b10-48ea-94c8-198aef45b5ea"
      unitRef="U_USD">1151000</adpt:ComputerAndSoftware>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_080d422e-eb20-41f5-9e29-be0e0272440d"
      unitRef="U_USD">830000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c1e90aab-8ac9-4f53-9a48-6d1bdb5f9a9b"
      unitRef="U_USD">763000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_b7d5a11a-3508-402a-b1f7-be2976c8b598"
      unitRef="U_USD">8157000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_eea805cd-637e-483a-9155-824f386bc8d9"
      unitRef="U_USD">8597000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2a86b840-0e16-46e3-94cb-ba2a65744d0c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash payment for rent of the expanded premises commenced &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to our option to twice extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The amended lease also requires us to pay additional amounts for operating and maintenance expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount of the asset group to future net undiscounted cash flows projected to be generated over the remaining lease term. These projections include management's estimates of cash inflows from potential sublease income and outflows for operating and maintenance expenses. The carrying amount was found to be unrecoverable, thus we assessed the asset group's fair value. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Fair value was determined using the income approach, whereby we discounted estimated net cash flows using a rate commensurate with our estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, we determined that the asset group was to be fully impaired. As such, an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_66782f0d-d53d-4c13-bd13-17f76499cf21;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized during the year ended December 31, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of which related to the right-of-use asset and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of which related to the long-lived leasehold improvements, all of which were held for use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2019, we entered into an agreement to rent approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million letter of credit with one of our existing financial institutions. The lease commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cash payment for rent began in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the lease term ends in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;subject to our option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twice extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In connection with this lease, the landlord agreed to fund $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in improvements, which was subsequently reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as a result of our change requests made during landlord construction of the building, net of an administration fee. We incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in certain tenant improvement costs, all of which had been reimbursed by the landlord as of December 31, 2022. The lease also requires us to pay additional amounts for operating and maintenance expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2018, we entered into a lease agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet in South San Francisco, California. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease term is through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and provides for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; extension option&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We are responsible for our share of allocable operating expenses, tax expenses and utilities costs during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,900&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional square feet and provides for a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million tenant improvement allowance. In 2024, as part of a restructuring, we vacated certain of the leased space in South San Francisco, California and incurred a related impairment charge. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for more information.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2021, we executed a lease to rent approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the lease expires &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;subject to an early termination option after the seventh year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to twice extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in improvements in connection with this lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, we were not party to any finance leases. Our leases have remaining terms ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;options to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extend certain of the leases&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and terminate certain of the leases after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years of leasing. We adjust lease terms for these options only when it is reasonably certain we will exercise these options.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other information related to our operating leases as of December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024, 2023 and 2022, respectively. Variable lease expense for operating leases was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Cash paid for amounts included in the measurement of lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash received for tenant improvement allowances during the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_07b2fa42-3cff-4d55-9da4-b7ec997c914f"
      decimals="0"
      id="F_d7b179d7-8c48-4c6f-9ba7-0bd054956156"
      unitRef="U_sqft">65500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9"
      id="F_a92b3e7a-268d-4c5d-b6e6-4b2da7a6e743">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LesseeOperatingLeaseRentCommencementMonthAndYear
      contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9"
      id="F_b963713c-e540-44b3-b812-ec00625c916e">2020-01</adpt:LesseeOperatingLeaseRentCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9"
      id="F_da94f5b8-0092-4b13-b919-7917251e2ca4">2032-10</adpt:LeaseExpirationMonthAndYear>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9"
      id="F_ad6670cd-8b10-4bfc-b6c5-fa6eca0ae770">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_50850346-ae66-43c8-854b-9c874b430f12"
      unitRef="U_USD">25400000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_9ae0132f-a370-471a-a623-b5c427d023a7"
      unitRef="U_USD">21200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_3e2e5eb9-f271-4dbc-bbb7-f18e90f8925f"
      unitRef="U_USD">4200000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:AreaOfLand
      contextRef="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb"
      decimals="0"
      id="F_4481ddd7-650b-49d9-9e59-d673960c7996"
      unitRef="U_sqft">100000</us-gaap:AreaOfLand>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb"
      decimals="-5"
      id="F_31c4ddce-b2c1-44f2-9752-a4f5770e8e9c"
      unitRef="U_USD">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <adpt:LeaseCommencementMonthAndYear
      contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"
      id="F_9e995599-2aaf-4e67-b25c-5a300f901165">2020-12</adpt:LeaseCommencementMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"
      id="F_5130c4cb-4830-4f89-9aaf-cadc1e55b359">cash payment for rent began in October 2021 and the lease term ends in August 2033, </us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LesseeOperatingLeaseRentCommencementMonthAndYear
      contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"
      id="F_2a795a71-30a6-42df-9862-1aa1d0f593f3">2021-10</adpt:LesseeOperatingLeaseRentCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"
      id="F_42af2e2f-8a35-40d9-88ab-02ffc685b96d">2033-08</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"
      id="F_5a95437c-a3bd-40eb-a983-393a365a7c80">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_8493c832-b379-44de-b19a-4bb6d192e6a9"
      id="F_328c67b4-f6b2-4ed6-9d07-66ceaf8a9e3c">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_522a5ec5-84f4-4fdd-b2b6-3880d0f44198"
      id="F_647254ed-bc99-46d5-8577-443827761596">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_8a2387a7-8618-47e9-9278-ff1d9bb97edb"
      decimals="-5"
      id="F_d704d85f-ccb4-4eee-a009-b1d08a0fc0a5"
      unitRef="U_USD">20000000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_3505aa94-9150-444b-91e7-c7847006ec3b"
      decimals="-5"
      id="F_4f0790af-9d76-4abc-a9f7-d4f608d716f8"
      unitRef="U_USD">14800000</us-gaap:LeaseholdImprovementsGross>
    <adpt:TenantImprovementCostsIncurred
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_647c90e0-5783-4cad-a92f-697528bc7321"
      unitRef="U_USD">14900000</adpt:TenantImprovementCostsIncurred>
    <adpt:ProceedsFromLandlordReimbursements
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_300b0afb-1754-4dec-b26d-07c1994dd1ad"
      unitRef="U_USD">14900000</adpt:ProceedsFromLandlordReimbursements>
    <us-gaap:AreaOfLand
      contextRef="C_f2113807-0eb7-481d-81da-8e883e379e25"
      decimals="0"
      id="F_4d148c87-cbdd-4d94-938d-17e5e0ba8c70"
      unitRef="U_sqft">13400</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6"
      id="F_189bb81f-3c06-40e9-9f76-f5f03b890e63">The lease term is through March 2026 and provides for one five-year extension option.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6"
      id="F_67825add-7a6f-4c53-bd72-a27f22f300b1">2026-03</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6"
      id="F_45a89834-07b4-42e1-a41b-e8c8b82ea86d">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_15747dcc-1cd0-4a7c-930d-17ee1ad971a6"
      id="F_d1eea147-8858-441b-9b7f-d3b1d5800b66">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:TenantImprovements
      contextRef="C_f2113807-0eb7-481d-81da-8e883e379e25"
      decimals="-5"
      id="F_c3c7dbe2-b1ed-4ec3-81fa-8fe4689cd13c"
      unitRef="U_USD">2400000</us-gaap:TenantImprovements>
    <us-gaap:AreaOfLand
      contextRef="C_7869d22e-be80-4ab4-88aa-2651f1bd991b"
      decimals="0"
      id="F_a22f328e-034b-4748-9542-f6850ae3360f"
      unitRef="U_sqft">19900</us-gaap:AreaOfLand>
    <adpt:TenantImprovementAllowanceAndCommenced
      contextRef="C_d3e396ad-f474-4619-9772-0d0cf9c0f093"
      decimals="-5"
      id="F_8a737faf-e5d6-4cd8-9925-5883e011bd5e"
      unitRef="U_USD">600000</adpt:TenantImprovementAllowanceAndCommenced>
    <us-gaap:AreaOfLand
      contextRef="C_7cc0feec-e028-49cb-9eb1-10aee43d5810"
      decimals="0"
      id="F_359546ff-f28c-40cd-bb08-38d57c293380"
      unitRef="U_sqft">27000</us-gaap:AreaOfLand>
    <adpt:LesseeOperatingLeaseRentObligationsCommencementMonthAndYear
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_31de8320-0164-406a-b3ce-8b39813bf582">2021-10</adpt:LesseeOperatingLeaseRentObligationsCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2453dd52-b7e3-41e0-9cd2-cac30ecb77fc">2031-10</adpt:LeaseExpirationMonthAndYear>
    <adpt:LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ddad7bb0-3ff6-486d-8d8b-33801d8a21fa">subject to an early termination option after the seventh year</adpt:LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_244025a9-47ca-4e17-94b2-e7429bd7eb28">option to twice extend the lease for five years</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      id="F_ee45fe6a-cf27-4dab-9f36-5c3ba70f9c38">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <adpt:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-5"
      id="F_f96fdea0-8aeb-4e57-9e63-1c17f25a792c"
      unitRef="U_USD">1200000</adpt:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_bdf418ac-63a7-4d7a-a22c-01620319ca13"
      id="F_76a37903-ce9a-41d8-a059-439694f12b6d">P1Y2M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_cfd24335-f1d6-459a-a81e-c4653a33dd6e"
      id="F_6b8f7c79-f4f4-4a5a-9dab-499726e974b3">P8Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_cbe35225-2e87-484a-980d-cab7062e3fd4">options to extend certain of the leases up to 10.0 years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_a7c29e0b-5972-4667-ab8e-ae815a3e170d">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      id="F_233cfdfd-3531-408e-93e7-7acb894846a2">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <adpt:LesseeOperatingLeaseTerminationPeriod
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2b4e5514-9f7e-497e-8785-5a5bf6787e94">P7Y</adpt:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_2af053b4-fbcb-4f21-bcdf-3c051d807b43">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other information related to our operating leases as of December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      id="F_a76c4d9c-c690-4697-9364-501f147905f5">P8Y21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      id="F_4cfdf0e4-45cc-43a4-8f52-6b5dc7508888">P8Y10M28D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="3"
      id="F_f8ce7f9f-7fee-40ff-be5e-1598c654cdb4"
      unitRef="U_pure">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="3"
      id="F_81d0ab9d-2069-410d-8a18-720ce6244c65"
      unitRef="U_pure">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b34ce157-9026-4db3-8d66-1f1ac6bf1f2d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_ac95b468-a66b-4e2d-9569-58d5103ce7ae"
      unitRef="U_USD">14098000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_7afc5626-4fc5-42ca-b489-b455748a8b0b"
      unitRef="U_USD">12330000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_2054cd0e-6e67-4c63-ae57-5434644347d1"
      unitRef="U_USD">11944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_188b7ab2-cb49-4030-a9c8-857a03d5bfe6"
      unitRef="U_USD">12282000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_645cbc64-2e5c-4637-a828-a236e3fe6989"
      unitRef="U_USD">12630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_cb5b5a43-3e80-418d-bbb7-982a5ea2cc1e"
      unitRef="U_USD">44332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_34d58262-3c00-463a-a618-b1bc66f59793"
      unitRef="U_USD">107616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_f8814dc4-c69c-45ab-b626-4940a6360ad1"
      unitRef="U_USD">18229000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_ef0dff10-17c7-4e59-bd19-00d49b897a18"
      unitRef="U_USD">89387000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_cff40f48-e87d-453c-902d-9bc8eb67fc6e"
      unitRef="U_USD">10239000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_a7bfd148-1a4b-4f81-a904-a8db6b6ce3d2"
      unitRef="U_USD">79148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_0c89d2e1-be66-475f-bc7b-3d06a63ff14c"
      unitRef="U_USD">9600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_a2427a4a-c2d9-47fa-8bf0-cc3fe83a2d3f"
      unitRef="U_USD">11400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_604576ac-84db-480f-958f-8ded64f30f5f"
      unitRef="U_USD">12400000</us-gaap:OperatingLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_e5c9cc4a-cd05-46fe-a0e4-879f490c34a3"
      unitRef="U_USD">7100000</adpt:OperatingLeaseVariableLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_ceb6f4bd-7f13-45fc-a116-bee5f50fa5d9"
      unitRef="U_USD">7100000</adpt:OperatingLeaseVariableLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_5be3cf3c-577b-4406-8e2e-e3730abb1f49"
      unitRef="U_USD">7200000</adpt:OperatingLeaseVariableLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_e8851b41-ae91-4ab6-b1a5-a35d62623e9e"
      unitRef="U_USD">13700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_8f5c1402-1350-4ac0-aa8c-10721ea4f320"
      unitRef="U_USD">13400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_22c09ee2-bb9e-4036-8522-bff8624af46d"
      unitRef="U_USD">9200000</us-gaap:OperatingLeasePayments>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_eb1788df-9cdd-497d-90e8-c21b24fa60b4"
      unitRef="U_USD">5200000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <adpt:RevenueInterestPurchaseAgreementTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_4d09d14d-710b-48f3-9908-edab84f90682">&lt;div class="item-list-element-wrapper" style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty &amp;amp; Credit Opportunities IV, LP (&#x201c;OrbiMed&#x201d;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, we received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the Purchasers at closing (the &#x201c;First Payment&#x201d;), less certain transaction expenses. We are also entitled to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in subsequent installments as follows: (i) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon our request occurring no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 12, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Second Payment&#x201d;) and (ii) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon our request in connection with certain permitted acquisitions occurring no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 12, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Third Payment&#x201d;), in each case subject to certain funding conditions. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#x201c;Revenue Interests&#x201d;) from us based on a percentage (the &#x201c;Applicable Payment Percentage&#x201d;) of all GAAP revenue (the &#x201c;Revenue Base&#x201d;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments in respect of the Revenue Interests shall be made quarterly within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days following the end of each fiscal quarter (each, a &#x201c;Revenue Interest Payment&#x201d;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#x201c;Cumulative Purchaser Payments&#x201d;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Return Cap&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;OrbiMed will be entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Revenue Interest Payments until it has received a total cumulative value of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Cumulative Purchaser Payments (the &#x201c;Return Cap&#x201d;), unless full repayment of the amount of the Return Cap has not been made by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 12, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, in which case the Return Cap shall be increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Cumulative Purchaser Payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Put/Call Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by us, a change in control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation ("the Put Option") to require us to repurchase all of the outstanding Revenue Interests at the applicable price (the &#x201c;Put/Call Price&#x201d;). Additionally, at any time following receipt of the First Payment, we may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap. For a change of control or a material divestiture, the Put/Call Price shall be equal to the applicable Return Cap.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Treatment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We evaluated the terms of the Purchase Agreement and concluded that the features of the Cumulative Purchaser Payments are similar to those of a debt instrument. Accordingly, we accounted for the transaction as debt recorded at amortized cost using the effective interest rate method. We further evaluated the terms of the debt and determined that the Put Option that is exercisable by the Purchasers upon certain contingent events requires bifurcation as a derivative. However, the value of the Put Option was determined to be immaterial due to the remote possibility of exercise. We assess the value of the Put Option periodically.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; over the amortization period. The calculated effective interest rate as of December 31, 2024 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Purchase Agreement, we incurred debt issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Debt issuance costs have been recorded to debt and are being amortized over the estimated term of the debt using the effective interest method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the issuance costs, as well as the effective interest rate.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Current portion at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net, less current portion at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2022. Revenue interest payable of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</adpt:RevenueInterestPurchaseAgreementTextBlock>
    <adpt:UpfrontPaymentReceived
      contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275"
      decimals="-5"
      id="F_e6d2c965-4533-43ce-8e7e-f7660a286cbc"
      unitRef="U_USD">125000000</adpt:UpfrontPaymentReceived>
    <adpt:PotentialRevenueInterestPaymentToBeReceived
      contextRef="C_1fb577e9-9c40-4d2b-bc4e-1fc3181e8bb2"
      decimals="-5"
      id="F_ee07bde4-827b-4236-aeb9-a9892aac81d7"
      unitRef="U_USD">125000000</adpt:PotentialRevenueInterestPaymentToBeReceived>
    <adpt:PotentialRevenueInterestSecondPaymentToBeReceived
      contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948"
      decimals="-5"
      id="F_89acf6e4-022f-4e10-ad9d-56aa85413231"
      unitRef="U_USD">75000000</adpt:PotentialRevenueInterestSecondPaymentToBeReceived>
    <adpt:PurchaseAgreementSecondPaymentDate
      contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275"
      id="F_212d0a36-b081-4b8e-aa84-ae1557d48624">2025-09-12</adpt:PurchaseAgreementSecondPaymentDate>
    <adpt:PotentialRevenueInterestThirdPaymentToBeReceived
      contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948"
      decimals="-5"
      id="F_acaf2e28-edbb-427e-b813-1c9e40ed8b8b"
      unitRef="U_USD">50000000</adpt:PotentialRevenueInterestThirdPaymentToBeReceived>
    <adpt:PurchaseAgreementThirdPaymentDate
      contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275"
      id="F_2e463e0f-7c26-4592-a870-d3902516f0f5">2025-09-12</adpt:PurchaseAgreementThirdPaymentDate>
    <adpt:RevenueInterestPaymentTerm
      contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275"
      id="F_9d85067b-74a1-476b-ac59-08d5ea24b771">P45D</adpt:RevenueInterestPaymentTerm>
    <adpt:PercentageOfRevenueInterestPayments
      contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948"
      decimals="2"
      id="F_e18ed711-8430-494e-9a56-0de220b8b2c1"
      unitRef="U_pure">1</adpt:PercentageOfRevenueInterestPayments>
    <adpt:PercentageOfCumulativePurchaserPayments
      contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948"
      decimals="2"
      id="F_2c1e65d7-2158-471a-9116-06528d2388e9"
      unitRef="U_pure">1.65</adpt:PercentageOfCumulativePurchaserPayments>
    <adpt:CumulativePurchaserPaymentsRepaymentDate
      contextRef="C_6bf4218c-4293-4f50-84e5-e19d61af2275"
      id="F_79efe166-bdc4-4a83-8427-3722f35cfe86">2032-09-12</adpt:CumulativePurchaserPaymentsRepaymentDate>
    <adpt:IncreaseInReturnCapPercentageOfCumulativePurchaserPayments
      contextRef="C_97452dd2-6a1c-43f9-ba87-cab54f7f3948"
      decimals="2"
      id="F_e8ada9fb-73ac-4c50-8819-09eb0c948e09"
      unitRef="U_pure">1.75</adpt:IncreaseInReturnCapPercentageOfCumulativePurchaserPayments>
    <adpt:AmortizationOfPurchaseAgreementObligation
      contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec"
      decimals="INF"
      id="F_eacf0ca1-30f3-4faf-a370-d4cd46191f63"
      unitRef="U_USD">0</adpt:AmortizationOfPurchaseAgreementObligation>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6"
      decimals="3"
      id="F_db953369-9149-463b-b868-d27649f6e090"
      unitRef="U_pure">0.088</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6"
      decimals="-5"
      id="F_4b13bc2f-dff6-49c3-bf6d-f3dfe2d237eb"
      unitRef="U_USD">600000</us-gaap:DeferredFinanceCostsNet>
    <adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_bcd05089-756e-4fed-96db-5f99cea80a46">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Current portion at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue interest liability, net, less current portion at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock>
    <adpt:RevenueInterestLiabilityNet
      contextRef="C_7f50006e-3aac-4a89-bd88-97a6fda0febc"
      decimals="-3"
      id="F_ea54a1fc-0e74-4ff7-9c54-3410bdec72f2"
      unitRef="U_USD">125360000</adpt:RevenueInterestLiabilityNet>
    <us-gaap:InterestExpenseDebt
      contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a"
      decimals="-3"
      id="F_221ba1d6-c431-457c-aa04-5cb5e416b0e0"
      unitRef="U_USD">13800000</us-gaap:InterestExpenseDebt>
    <adpt:RevenueInterestPaid
      contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a"
      decimals="-3"
      id="F_81b20960-7280-4516-b5fd-74670bf48069"
      unitRef="U_USD">-6225000</adpt:RevenueInterestPaid>
    <adpt:RevenueInterestPayable
      contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a"
      decimals="-3"
      id="F_d3927d96-3128-4966-92fc-bcf0e00c7945"
      unitRef="U_USD">2275000</adpt:RevenueInterestPayable>
    <adpt:RevenueInterestLiabilityNet
      contextRef="C_8f46490b-2478-46c6-9c66-ca4d59a7e377"
      decimals="-3"
      id="F_eb6c4fe7-104a-45bd-8c91-6ae3549bb345"
      unitRef="U_USD">130660000</adpt:RevenueInterestLiabilityNet>
    <us-gaap:InterestExpenseDebt
      contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec"
      decimals="-3"
      id="F_afbb3bb4-2ecd-496a-8132-21769ae1c676"
      unitRef="U_USD">11580000</us-gaap:InterestExpenseDebt>
    <adpt:RevenueInterestPaid
      contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec"
      decimals="-3"
      id="F_5f2a3a9d-8605-4461-b762-2660ef36ed2f"
      unitRef="U_USD">-6589000</adpt:RevenueInterestPaid>
    <adpt:RevenueInterestPayable
      contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec"
      decimals="-3"
      id="F_3245881d-52a4-4434-9bad-35c27d21a644"
      unitRef="U_USD">2372000</adpt:RevenueInterestPayable>
    <adpt:RevenueInterestLiabilityNet
      contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6"
      decimals="-3"
      id="F_411af40b-aa8e-46f5-a7e3-8c827a7b93bf"
      unitRef="U_USD">133279000</adpt:RevenueInterestLiabilityNet>
    <adpt:RevenueInterestLiabilityNetCurrent
      contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6"
      decimals="-3"
      id="F_450d16d1-6297-4194-82bb-5d2897315c53"
      unitRef="U_USD">-865000</adpt:RevenueInterestLiabilityNetCurrent>
    <adpt:RevenueInterestLiabilityNetNoncurrent
      contextRef="C_3d00688c-415e-4822-a136-7b16fe0014b6"
      decimals="-3"
      id="F_4baea06b-f1ba-48e3-93dd-ee245f5464fe"
      unitRef="U_USD">132414000</adpt:RevenueInterestLiabilityNetNoncurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="C_752e690e-a58f-4330-872e-b0e7486ee008"
      decimals="-5"
      id="F_29d1f144-2104-4d28-85cb-2555059d2d43"
      unitRef="U_USD">4200000</us-gaap:InterestExpenseDebt>
    <adpt:RevenueInterestPayable
      contextRef="C_57b874c8-f1ee-4024-bd76-aff00d4af5ec"
      decimals="-5"
      id="F_fc194db8-314e-4539-80a1-b7775c9ab377"
      unitRef="U_USD">2400000</adpt:RevenueInterestPayable>
    <adpt:RevenueInterestPayable
      contextRef="C_ef70f5dc-4521-45f8-a731-f46544a75c9a"
      decimals="-5"
      id="F_43ba7091-8c3e-40d0-ba48-80fcb01e8a61"
      unitRef="U_USD">2300000</adpt:RevenueInterestPayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_75df5473-c85f-48fa-aac8-6818a0b431fa">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_88f73eb6-4639-4709-86b0-7074ba0e4e8e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our common stock has no preferences or privileges and is not redeemable. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Holders of our common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote for each share of common stock held&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Furthermore, our Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Effective January 1, 2024, our 2019 Plan and ESPP reserves increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,254,113&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,450,822&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively. Our board of directors determined not to increase the 2019 Plan and ESPP reserves in 2025.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, we &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;had reserved shares of common stock for the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares issuable upon the exercise of outstanding stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,295,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,005,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future grant under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,018,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future grant under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,686,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,005,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_a1a65c8e-2a02-4888-ab6f-60e5b08a5de2">Holders of our common stock are entitled to one vote for each share of common stock held</us-gaap:CommonStockVotingRights>
    <adpt:NumberOfCommonStockVotingRights
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_a988ed61-9ace-45ee-a92d-a8c806e11557"
      unitRef="U_Vote">1</adpt:NumberOfCommonStockVotingRights>
    <adpt:PercentageOfAnnualIncreasesInNumberOfShares
      contextRef="C_70fe95bd-0b9c-4b16-aab2-e8db1c249769"
      decimals="INF"
      id="F_f09d709f-38e3-44a7-8e0d-1dbfd5c0db69"
      unitRef="U_pure">0.05</adpt:PercentageOfAnnualIncreasesInNumberOfShares>
    <adpt:PercentageOfAnnualIncreasesInNumberOfShares
      contextRef="C_6058a09d-5c33-4856-9a87-634891fd1ff1"
      decimals="2"
      id="F_b0d04c4f-01e7-4e19-89ce-5683b81138c8"
      unitRef="U_pure">0.01</adpt:PercentageOfAnnualIncreasesInNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_30a5bbbe-6a9c-4d08-a5bf-c0ca07f38d71"
      decimals="INF"
      id="F_7e2a8385-ad74-4a32-8580-721cfa05664a"
      unitRef="U_shares">7254113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_db18a52f-bcfe-46a3-89ae-80288cdff126"
      decimals="INF"
      id="F_91b90c99-573d-4222-8299-dea0e8cec86e"
      unitRef="U_shares">1450822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_376f13d0-e41d-4cde-8fa8-565644fbad16">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, we &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;had reserved shares of common stock for the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares issuable upon the exercise of outstanding stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,295,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,005,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future grant under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,018,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future grant under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,686,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,005,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ebc8e107-4003-4674-8227-7ec4caf59826"
      decimals="INF"
      id="F_25864832-cbb8-4983-9728-4bba4366e496"
      unitRef="U_shares">12295297</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f01c0215-4e04-4a37-b6a0-43ec834d33fd"
      decimals="INF"
      id="F_972d449f-f85d-4264-847f-6210e75b6234"
      unitRef="U_shares">14005966</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fea8d0de-6b48-42cf-a187-18acba215cd4"
      decimals="INF"
      id="F_0bc2566b-558f-4434-b9a3-43cb5a28ccc2"
      unitRef="U_shares">18018312</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1119d75f-ac1e-4443-a095-4f4846ec2ff9"
      decimals="INF"
      id="F_c90f8b4a-9855-4d9f-9c85-adc1e09ee812"
      unitRef="U_shares">5686170</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_2e3099c0-a7e5-42d8-aeac-5ecd3df94cfb"
      unitRef="U_shares">50005745</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b96a069f-49b9-4999-8ac8-49ea8276582c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2009 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We adopted an equity incentive plan in 2009 (the &#x201c;2009 Plan&#x201d;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the grant date and vesting is established at the time of grant. Except for certain awards granted to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period, subject to continuous service through each applicable vesting date. As of December 31, 2024, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,683,842&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock authorized for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes in shares available for grant during the year ended December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Available for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,299,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2019 Equity Incentive Plan reserve increase effective January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,254,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,841,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,305,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,018,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Subject to&lt;br/&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,875,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,008,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;718,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;765,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,295,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options vested and exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,027,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining contractual life for stock options outstanding as of December 31, 2024 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. The weighted-average remaining contractual life for vested and exercisable stock options as of December 31, 2024 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total intrinsic value of stock options exercised during the year ended December 31, 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Grant Date&lt;br/&gt;Fair Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,669,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,619,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,525,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,587,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,174,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total fair value of restricted stock units vested during the year ended December 31, 2024, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Market-Based Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of our executive officers have been granted awards of market-based restricted stock units. The number of shares of common stock that may be earned under the respective awards range&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares to a defined maximum number of shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and are c&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;alculated based on our total shareholder return during a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance period as measured against that of the group of companies comprising the S&amp;amp;P Biotechnology Select Industry Index as of the grant date or other applicable date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Market-based restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maximum Market-Based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Grant Date&lt;br/&gt;Fair Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested maximum market-based restricted stock units outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,912,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maximum market-based restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,214,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maximum market-based restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;295,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested maximum market-based restricted stock units outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,831,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated grant date fair values of stock options granted during the years ended December 31, 2024, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are subjective and generally require judgment to determine. The valuation assumptions were determined as follows:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&#x2014;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The expected term of stock options granted to employees and non-employee directors is determined using the &#x201c;simplified&#x201d; method, as illustrated in ASC Topic 718, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;based on the midpoint between the vesting date and the end of the contractual term of the stock option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Until 2024, as we did not have sufficient trading history for our common stock, expected volatility was based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Beginning in 2024, expected volatility was based on a weighted average of our historical volatility and the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the option valuation model.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.61&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The grant date fair value of restricted stock units granted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.43&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of the market-based restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The aggregate share-based compensation expense of the market-based restricted stock units granted during the year ended December 31, 2024, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million respectively. Aggregate share-based compensation expense is calculated based on the target payout level of shares granted and is recognized on a straight-line basis over the respective grants' performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense is reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2024, 2023 and 2022 are included on the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrecognized Share-Based&lt;br/&gt;Compensation Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested market-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_4e62fea1-8195-4797-84f6-8e80fbc5903d"
      id="F_aa2173fc-6748-4afc-a5ef-d80837132ee2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_76aa1ad9-be8e-41ac-91df-576de65c2d91"
      decimals="INF"
      id="F_4dd7539e-d42a-4323-a403-1b94a5ce613b"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_6dc97585-6690-424d-b20a-80823243e590"
      id="F_e80170cd-7ee8-4a4a-bf1d-2f945a2a7653">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_7fc08718-7fea-4e2c-bb3c-69007782863d"
      id="F_0ae7106d-8d92-470a-bb5a-4287fd6d42d2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_fea8d0de-6b48-42cf-a187-18acba215cd4"
      decimals="INF"
      id="F_46875355-7034-4a29-be21-01187f37ef3f"
      unitRef="U_shares">39683842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_9af5c0ad-6b34-4c68-96f7-65833a68ecfe">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes in shares available for grant during the year ended December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Available for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,299,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2019 Equity Incentive Plan reserve increase effective January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,254,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,841,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options, restricted stock units and the maximum market-based restricted stock units forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,305,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,018,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_6b74a919-15ca-422a-bdd2-8538b4633aa6"
      decimals="INF"
      id="F_f4814e17-75db-4225-96bb-84fa2dc7512d"
      unitRef="U_shares">15299763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve
      contextRef="C_013827d3-b15c-4f85-88a8-bbae4386a47c"
      decimals="INF"
      id="F_858a7111-d42c-4ef3-8193-440ca92bf288"
      unitRef="U_shares">7254113</adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned
      contextRef="C_013827d3-b15c-4f85-88a8-bbae4386a47c"
      decimals="INF"
      id="F_9aef913d-5f92-46a8-9c83-ee548b1688d0"
      unitRef="U_shares">-8841392</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired
      contextRef="C_013827d3-b15c-4f85-88a8-bbae4386a47c"
      decimals="INF"
      id="F_7cae9003-a357-475f-af12-8b3292740a27"
      unitRef="U_shares">4305828</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsRestrictedStockUnitsAndMaximumMarketBasedRestrictedStockUnitsForfeitedCanceledOrExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b03c96cb-2be3-4399-a5cc-ad4279252dd8"
      decimals="INF"
      id="F_048dc2c5-df04-4298-a855-62b746f28349"
      unitRef="U_shares">18018312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_5e4e398b-cff8-4b15-8c8b-093803b1c9b2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Subject to&lt;br/&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,875,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,008,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;718,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;765,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,295,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options vested and exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,027,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_3f9ce59b-e494-4dd2-a273-7abc5d974c08"
      unitRef="U_shares">12875045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="2"
      id="F_446ddf01-b178-4315-afa3-8cb1361d9435"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_21f44144-f179-40ba-8614-aeb9b1f6ba02"
      unitRef="U_shares">1008364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_71e21c2f-39e1-4201-9b28-5f42178edd2b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_1465a66e-03b2-4a64-98c9-4ff74f2efca0"
      unitRef="U_shares">718920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_f84d3537-8622-4131-9ff4-40f89f9a93c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_485f4d05-8c60-4392-b8fd-6d210a1a828c"
      unitRef="U_shares">765392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_87e09e81-27ba-4599-9524-1a8642085a3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_82ffb42f-cada-43e3-8ce3-9673fb3c7e0a"
      unitRef="U_shares">103800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_8e8edec4-3e66-44c3-9faf-8d8509ebc72d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_4ef08cd9-7144-4c97-9a61-aee441105f70"
      unitRef="U_shares">12295297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="2"
      id="F_4475acc4-7754-4cf0-9053-c897393df525"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_fd75ff00-a42b-4792-b1b2-9d5e1d6be657"
      unitRef="U_USD">2157000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_0c760635-c9a6-4c7f-95ba-2109ac8b513c"
      unitRef="U_shares">10027350</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="2"
      id="F_d718cd0c-f1ae-4b27-b3b9-cd879286f1f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.3</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_9bb66791-0a3f-497a-aed9-157bd11ce9d0"
      unitRef="U_USD">497000</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b60c74a0-a239-48d6-b6d6-1ccb1c31e5da">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_7fe0a300-d1cf-48ab-9969-241a1fa79107">P4Y10M24D</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_c61df55a-89b1-4293-b61d-a8830de8f884"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_7e1e3e67-87dd-4983-8afc-c038dc1ed353"
      unitRef="U_USD">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_7ac2f9ae-dcfd-4414-8653-a27db604e4ba"
      unitRef="U_USD">7600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_fa6c4d3b-c2c7-4dc6-8c0a-317a162347e2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Grant Date&lt;br/&gt;Fair Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,669,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,619,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,525,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,587,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,174,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Market-based restricted stock unit activity under the 2019 Plan during the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maximum Market-Based Restricted Stock Units Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Grant Date&lt;br/&gt;Fair Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested maximum market-based restricted stock units outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,912,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maximum market-based restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,214,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maximum market-based restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;295,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested maximum market-based restricted stock units outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,831,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_938538bd-3388-44c9-b50d-231541782951"
      decimals="INF"
      id="F_3a3cd839-ba65-4f14-87fb-f53f79afc361"
      unitRef="U_shares">9669460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_938538bd-3388-44c9-b50d-231541782951"
      decimals="2"
      id="F_5917b864-404e-4b04-9ff2-3f96f69f4d1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="0"
      id="F_04d26330-dc31-46e2-b54e-0f60b759d5db"
      unitRef="U_shares">5619008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="2"
      id="F_606468b0-62e8-4ad4-a8f3-2464cdc3df3d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="0"
      id="F_38678f89-2b45-4df5-a6a1-ff21f934af1b"
      unitRef="U_shares">2525936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="2"
      id="F_4777eaf7-00f7-4739-8fe3-c943ec333cef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="0"
      id="F_66555471-d7ae-4a75-90c3-35b75f427737"
      unitRef="U_shares">2587680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="2"
      id="F_8137d61e-466d-49ab-b108-b799f6dcb548"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0c9ad877-d4fd-4667-9562-04fee6ec1601"
      decimals="INF"
      id="F_f1282e36-8fd6-4ece-9e28-c5467feb15d8"
      unitRef="U_shares">10174852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0c9ad877-d4fd-4667-9562-04fee6ec1601"
      decimals="2"
      id="F_1e44a746-d264-47a0-bd1b-fbf31ebde5eb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_4038584b-af9b-45c7-a179-a1aac6d8e18e"
      decimals="-5"
      id="F_6f71e4b8-ca15-4520-b719-f6f8c472d428"
      unitRef="U_USD">10600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_a8b15cb2-7331-4388-b91a-39842959aeaa"
      decimals="-5"
      id="F_cc1b4bc2-f9ac-487b-8d70-77a887d05dda"
      unitRef="U_USD">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_5849a7e8-d209-4520-ae06-42818b55c73d"
      decimals="-5"
      id="F_7657c6f9-7ec4-4e40-a2bb-aca9d306a9c8"
      unitRef="U_USD">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward
      contextRef="C_e9191c9f-9e40-4eef-8bb8-8c5bff219c41"
      decimals="INF"
      id="F_a1e4c96b-f567-4746-8081-87696ec9bfa6"
      unitRef="U_shares">0</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward>
    <adpt:SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm
      contextRef="C_fb6ff782-0ca3-4143-ad9b-7c8ef89ed646"
      id="F_22865e16-f178-4d26-a83f-d9aba9875879">P3Y</adpt:SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0a49afd5-b03f-4f5c-bc78-5dfce07d3fbc"
      decimals="INF"
      id="F_29b5c0ba-5024-4df2-a487-6cdfecf046c4"
      unitRef="U_shares">1912674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0a49afd5-b03f-4f5c-bc78-5dfce07d3fbc"
      decimals="2"
      id="F_fbba250c-0558-4591-bdaf-bbe87da96327"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067"
      decimals="0"
      id="F_b945f559-d87a-4077-8990-234ac08929d8"
      unitRef="U_shares">2214020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067"
      decimals="2"
      id="F_32be3a21-4e96-4774-ba3e-bb49d80e6054"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067"
      decimals="0"
      id="F_f56e5b55-ffb3-413a-8df4-8c1ccde3667a"
      unitRef="U_shares">295580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_35fa55e5-da1a-4030-b0fd-1c3f63b3e067"
      decimals="2"
      id="F_99f43c1c-6726-4682-ac38-bba7e19cb03f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0029b7a6-ee35-412e-80b4-c83f66b83283"
      decimals="INF"
      id="F_c72bc661-5530-4046-bb4b-de16ebfdfe17"
      unitRef="U_shares">3831114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0029b7a6-ee35-412e-80b4-c83f66b83283"
      decimals="2"
      id="F_1deca409-a626-4470-8207-a0dc935d5466"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_29ed6452-88aa-41dd-bd9e-c9da3c931417">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated grant date fair values of stock options granted during the years ended December 31, 2024, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_845a7e07-1ea1-42e8-9eaa-f1a9c3489399"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="2"
      id="F_e350a257-e526-48c2-af47-0fbb14368056"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bc4f3373-536d-41d1-b3a3-421bacc254af"
      decimals="2"
      id="F_55e1a85c-dbf2-4262-8e47-97a7112797a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8dd592c7-dd5c-4673-a9f3-c1849fefa514"
      decimals="2"
      id="F_29f4fadb-9868-4836-9f05-d0c24117eabc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_79c39ab7-5350-4de3-9055-afde44e88b1a"
      id="F_7cabfb42-b4ba-4a27-9d32-4631a3bfd450">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_cb4e71eb-46c4-41f6-9ca9-4467ec43dcfb"
      id="F_5758daf0-17f4-47c8-aa31-896dbf687a26">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e16d035a-df2e-4300-bb99-13a2fe409ebb"
      id="F_0769750b-2bea-42fb-8d2e-f057eb11a84a">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_31434234-729f-49fb-9bc5-a4c2db285d76"
      id="F_8c274192-9e32-4e29-9849-7efc7277cdb6">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bc4f3373-536d-41d1-b3a3-421bacc254af"
      id="F_c7fbccd0-5c78-45e4-b0fd-2122c6f153a8">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8dd592c7-dd5c-4673-a9f3-c1849fefa514"
      id="F_69880cbd-4579-4bd2-8748-00d2862eedc2">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_bbe4d3a4-89b6-4158-acf5-62c05cb03804"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_14718e8b-863c-4f5a-b1e9-5bf5a053cd2f"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_e13b5c47-8eed-4ce2-87e4-5ad98d2d1f04"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_a2f6bd8f-0bd2-4c33-8ff6-d6099a844d39"
      unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_5fb06c1d-2525-4aeb-ad1a-4d8ca254275a"
      unitRef="U_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_106f0036-0cd8-4f1a-870f-595a82a8d496"
      unitRef="U_pure">0.745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_da486138-89b1-4b7d-bb24-9e4898a5356b"
      unitRef="U_pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_828aa817-5d64-495f-b2b8-e3ce9437d20e"
      unitRef="U_pure">0.712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_ee18999a-fcf8-4107-94ce-d5347fe90ccf"
      unitRef="U_pure">0.716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_ac8014a3-3e1f-4eeb-8432-61941388b753"
      unitRef="U_pure">0.682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_05a909a3-8336-4e8d-aa70-0bd904935ecc"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_dc2d580a-7814-47b1-a90a-9db3f5a070a6"
      decimals="2"
      id="F_2c575638-58a0-4c2b-9fa1-223f23a3231a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_27a97d29-83f8-4b62-83b1-d3342627773a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="2"
      id="F_950735d5-2522-4b0e-bf21-748b19685ba3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="2"
      id="F_be588453-3e7f-4214-b54e-7954c845c915"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8a75c621-aba6-48ee-9044-8a4bc86fd4a7"
      decimals="2"
      id="F_ace5efc9-3618-4576-a37a-3b38c54e832d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_05929f03-5f49-44c6-99b2-b6ac0648d6a6"
      decimals="2"
      id="F_da456697-6b6c-49d7-a75e-b53175f5129b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_800a8d4f-a9fc-4ca6-8af0-3cd02f0dd56b"
      decimals="2"
      id="F_c390fc93-273a-4eb3-9cfe-1af01eb5c34b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c147eb1f-f94e-4397-b028-6165d4ff279b"
      decimals="2"
      id="F_c3b1041c-2c90-44d2-9547-1faf6fdb8234"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8672005a-0af6-4c35-b305-e5625f4ced55"
      decimals="2"
      id="F_215357b4-87ce-4b72-ad89-cec3d71e577b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f3a08a4e-1038-45b8-8a45-c1295cbf5ecb"
      decimals="2"
      id="F_7db58e6a-9998-4c65-b1e3-59038be1f862"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_df6ab829-80ae-4fe6-8c59-0c879baee98e"
      decimals="-5"
      id="F_49c714d7-92c9-4a77-9316-42c7c012652e"
      unitRef="U_USD">7200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b986fb51-c7d8-4885-ad77-406faf3a7217"
      decimals="-5"
      id="F_0453a52c-0479-4d85-970f-4d1774ce19e3"
      unitRef="U_USD">9800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_60932611-3f39-47dd-9da8-86fe5e9898f4"
      decimals="-5"
      id="F_9a524105-025e-4492-9eff-30cd2ce2b226"
      unitRef="U_USD">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_78466b83-d9c9-41ba-bcd6-e0b2e02928bc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2024, 2023 and 2022 are included on the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_830ceebd-b448-4556-8cc3-345699e93087"
      decimals="-3"
      id="F_30c16fd9-5a3b-4e7e-ae7a-4cf9dbae25ae"
      unitRef="U_USD">3632000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc544eb2-c862-4117-ae53-7167dec34569"
      decimals="-3"
      id="F_8fe98620-79d9-4ae8-baa4-f855778b3826"
      unitRef="U_USD">4186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2ac1d2a6-7485-444c-b87e-886ba5dc3b3c"
      decimals="-3"
      id="F_5e2b6898-fc62-4693-9a47-a33be9ab9796"
      unitRef="U_USD">3910000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88922b78-bf40-483b-ba74-3b67fea9b4fb"
      decimals="-3"
      id="F_c9f15545-f094-4afa-af5a-af010f8e3e96"
      unitRef="U_USD">17081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6f1910b3-9154-4298-8382-eeed229f5b9b"
      decimals="-3"
      id="F_d6bb8892-51ff-49e4-ba7a-1d9fa30703b0"
      unitRef="U_USD">20465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3b97b1d4-62a9-4c60-be60-2108f97f8fb8"
      decimals="-3"
      id="F_b09a6736-1ff7-4300-b92e-c8e9fa5a7624"
      unitRef="U_USD">17689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ac141085-19dd-4092-b7b5-3caab7439cf4"
      decimals="-3"
      id="F_3cacbd3c-d9ae-402e-8389-cc8fa5ef50a3"
      unitRef="U_USD">12370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7c1e94f7-1563-46d1-9179-65444a8457d4"
      decimals="-3"
      id="F_78502f5d-e0b3-4c30-bcf2-c2afec090314"
      unitRef="U_USD">14553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_355bb8fa-16f0-474d-b4fd-4b16eacb34a6"
      decimals="-3"
      id="F_508a32d6-326d-4073-9c9e-1ca2eec24b1e"
      unitRef="U_USD">13597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9eec2a01-b68b-4cd4-9ae8-af29e919f6c0"
      decimals="-3"
      id="F_b96424b8-5cb2-4465-b5cc-908443fcf51a"
      unitRef="U_USD">20527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_22b5dd10-ae86-4ea2-9caa-a6986a38f552"
      decimals="-3"
      id="F_e39ea0fb-c36d-4c33-bd17-f512fe735b93"
      unitRef="U_USD">23704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1acd60e0-7824-477a-940e-96fcce72212e"
      decimals="-3"
      id="F_260bc098-85ba-41cd-8f24-f24588759f81"
      unitRef="U_USD">20281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_bf466c88-0074-419d-852a-1475d3e43c2a"
      unitRef="U_USD">53610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_568aba40-1245-4601-9d76-b42e09f71a2e"
      unitRef="U_USD">62908000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_4fef3d1a-459c-41d9-9dea-8fd71e7bafc6"
      unitRef="U_USD">55477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_b8247b64-7ae7-4a1b-b844-0e0a83b1a777">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrecognized Share-Based&lt;br/&gt;Compensation Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested market-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_8c08d7f9-6ece-4397-98cb-7a4e690601d7"
      decimals="-3"
      id="F_dae7c15a-55c1-4865-9f4d-5157b4ee0338"
      unitRef="U_USD">12943000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_26c9b550-cdb1-4568-b071-8fda1b1e79ec"
      id="F_b2052300-0a0f-48b8-a2ab-bc2e530ba2fa">P1Y6M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_826be3c4-b05f-4764-b189-9b17a0ed4f47"
      decimals="-3"
      id="F_0052623f-18b1-4501-83a3-6cba04e8e637"
      unitRef="U_USD">50803000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3371457f-35a0-478d-ad1d-6b89373e6edd"
      id="F_816c7c93-51da-4add-919f-32f2a25afad5">P2Y2M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_16e28997-7e3b-4c9b-81c4-971e637e2f39"
      decimals="-3"
      id="F_74a44a79-a10e-4e3c-bb2d-a16d78247d41"
      unitRef="U_USD">8611000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_d536e9b5-ed0c-483d-9d06-83c84f459d93"
      id="F_f3642102-2761-4557-a351-b80fbfe06e37">P1Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_279d2a7f-78c1-43f5-8505-1bcf50ee0275">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restructurings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; employees. We incurred aggregate restructuring costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees&#x2019; execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to this reduction in workforce were primarily completed in March 2022 and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million aggregate restructuring costs were paid as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended March 31, 2024, we implemented a restructuring plan to better align our organization to our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segments: MRD and Immune Medicine. We incurred aggregate restructuring costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, primarily related to one-time termination benefits and ongoing benefit arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended June 30, 2024, we implemented additional restructuring initiatives which impacted certain planned software enhancements and resulted in the consolidation of certain research and development workflows. The impacted software enhancements were primarily associated with our laboratory information management systems. As part of these restructurings, we had long-lived assets that were no longer being utilized and we vacated certain leased space in South San Francisco, California. As such, we assessed the related assets for impairment by first comparing their carrying amounts to the future net undiscounted cash flows projected to be generated over their remaining lease terms or depreciable lives, as applicable. The carrying amounts were all found to be unrecoverable, thus we assessed the fair values of the assets. The extent to which the carrying amounts of the assets exceed their fair values represents the impairment costs to be recognized. As a result of our assessments, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of impairment charges. Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million charges recognized, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million relates to the right-of-use asset and related long-lived assets (namely laboratory equipment and leasehold improvements), respectively, associated with certain of our leased space in South San Francisco, California. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recognized relates to the impairment of long-lived assets associated with our halted software enhancements. We also incurred an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in restructuring costs primarily related to one-time termination benefits and ongoing benefit arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the six months ended December 31, 2024, we incurred an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate restructuring costs, which primarily related to one-time termination benefits and ongoing benefit arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In total, we recognized restructuring costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2024. The activities and payments related to these restructurings were completed and paid as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="INF"
      id="F_0f638eb5-5a05-425f-8223-c34a174ec26b"
      unitRef="U_Employee">100</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d"
      decimals="-5"
      id="F_602a6d4d-e245-49e4-865e-0d283effea7f"
      unitRef="U_USD">2000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_30262436-ed79-402e-8217-bde4ca08a045"
      unitRef="U_USD">2000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_c68b4da1-c105-4b71-aa4b-fe1b17e709af"
      unitRef="U_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="C_cfbee4bf-0f67-4e80-8986-2a8c42354e22"
      decimals="-5"
      id="F_9bd5f84c-91b5-48c2-8a22-a916ceea0183"
      unitRef="U_USD">1000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_5901db2b-686f-46f9-8cd8-32e5ef276efe"
      unitRef="U_USD">7200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_87c36c68-cf35-48f6-b5ed-a680994219eb"
      unitRef="U_USD">7200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_edda825c-90de-4c1f-b5b3-c767c222382e"
      decimals="-5"
      id="F_bb9c5c5c-84a1-41d3-a4fb-79ea8ec8a372"
      unitRef="U_USD">1100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_ab192050-c968-4f59-b97c-0347bf2e6704"
      decimals="-5"
      id="F_cd886e3f-e134-4d63-a3cb-c3d90648701e"
      unitRef="U_USD">3300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_c00eaa13-213e-4380-87d4-07983d165569"
      decimals="-5"
      id="F_303f8b0f-f69e-4c0a-a44d-153ae8eb9d91"
      unitRef="U_USD">2800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-5"
      id="F_97fe3ee1-13c7-4533-9d30-26b8d516a50d"
      unitRef="U_USD">700000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCosts
      contextRef="C_03002793-4de6-465a-b177-09dbb4ca58f5"
      decimals="-5"
      id="F_bdb3bbd0-b6f8-48b9-9d81-7d30a27932b2"
      unitRef="U_USD">300000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_74dc7026-9dcd-4790-922e-0292966fbed2"
      unitRef="U_USD">9200000</us-gaap:RestructuringCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_46db21ea-4240-455e-b0a1-dff2989c4bb3">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of loss before provision for income taxes for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonqualifying stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tangible and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tangible and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. As of December 31, 2024, we had U.S. federal NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and U.S. federal tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We also had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;856.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of NOLs as of December 31, 2024 that do not expire.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We account for global intangible low-taxed income as period costs when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions in 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions in 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions in 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, 2023 and 2022, we recognized uncertain tax positions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties related to uncertain tax positions as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_e3be247c-62ef-451b-bc63-452dbc1c2016">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of loss before provision for income taxes for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_e79980be-a10c-4e2e-a47b-fd7f232974b9"
      unitRef="U_USD">-159635000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_57027b27-316f-4f29-b1f8-f82d9d4b0a8c"
      unitRef="U_USD">-225335000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_76a779ba-67f0-408c-b345-0c6a0763da52"
      unitRef="U_USD">-200427000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_8f75e57b-4603-41fa-87a2-22b3a72e8efc"
      unitRef="U_USD">40000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_555b9d7e-2730-46ac-bd35-521b0909cca1"
      unitRef="U_USD">31000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_03796521-6783-4978-ab71-0fb1dfff7bd0"
      unitRef="U_USD">59000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_dd30d579-cf3c-44f6-8f96-c1f0236ebe23"
      unitRef="U_USD">-159595000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_2d92786a-cb1d-4141-ad37-3dd705946b33"
      unitRef="U_USD">-225304000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_3de0b4a8-0a0f-4f04-aad0-a783ae3f03af"
      unitRef="U_USD">-200368000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_28de6449-18e7-4918-9bb7-286be4a9fdfa">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonqualifying stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tangible and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;435,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tangible and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_5ff4c4a9-6d08-4e15-b8f7-1401b9f5562f"
      unitRef="U_USD">274535000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_22744083-64fc-4daf-9357-cb09ee5b03f7"
      unitRef="U_USD">251724000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_0a93857b-95c6-4a87-a84c-262d1af6e20c"
      unitRef="U_USD">45942000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_fc8392f7-01cf-4721-b3f6-ed9a7d5f306a"
      unitRef="U_USD">43528000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <adpt:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_34131363-99f2-448a-980d-024106a9fdcd"
      unitRef="U_USD">31010000</adpt:DeferredTaxAssetsNonQualifiedStockOptions>
    <adpt:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_e32c07bc-2ff0-4ea1-bef7-b770d2054d57"
      unitRef="U_USD">29166000</adpt:DeferredTaxAssetsNonQualifiedStockOptions>
    <adpt:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_450e353c-546b-4a28-bda9-4eaf954f1830"
      unitRef="U_USD">22912000</adpt:DeferredTaxAssetsOperatingLeaseLiabilities>
    <adpt:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_142aa08f-418e-4d89-a6d8-a35cc78dc64e"
      unitRef="U_USD">25357000</adpt:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_fa8e44bc-1b58-4cc9-a3f3-9d49a7816238"
      unitRef="U_USD">14996000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_1e5c5268-a401-422b-ba0e-379bea88350c"
      unitRef="U_USD">18874000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <adpt:Deferredtaxassetscapitalizedresearchanddevelopment
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_fd468981-3b12-40f5-a864-37f8356f025a"
      unitRef="U_USD">49550000</adpt:Deferredtaxassetscapitalizedresearchanddevelopment>
    <adpt:Deferredtaxassetscapitalizedresearchanddevelopment
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_cc9f82c2-1568-47b6-9526-627c24418c2c"
      unitRef="U_USD">42134000</adpt:Deferredtaxassetscapitalizedresearchanddevelopment>
    <adpt:DeferredTaxAssetTangibleAndIntangibleAssets
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_9647efc8-7059-4295-a36d-2bd08edc6b9c"
      unitRef="U_USD">1963000</adpt:DeferredTaxAssetTangibleAndIntangibleAssets>
    <adpt:DeferredTaxAssetTangibleAndIntangibleAssets
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_efdc3d1f-8994-4248-8ca8-a52389d8c059"
      unitRef="U_USD">0</adpt:DeferredTaxAssetTangibleAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_f72435d5-1eae-4476-be44-2e9bd1e04858"
      unitRef="U_USD">6182000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_2771be9e-4bef-4077-863f-e6fe61412387"
      unitRef="U_USD">6146000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_9c85134d-b759-4d16-b018-912c2b51ffb1"
      unitRef="U_USD">447090000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_c6b43b64-b641-4123-b6c1-9ee25f79f633"
      unitRef="U_USD">416929000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_b2d8a381-6fd9-408e-9812-a8d8185234cb"
      unitRef="U_USD">435509000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_8b4f392e-0f82-4b27-b934-56581b75b222"
      unitRef="U_USD">402424000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_ad479862-3c53-482d-890f-e08ab6cfe0cd"
      unitRef="U_USD">11581000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_0239ffe5-f033-47c5-b813-eecbb846c7a6"
      unitRef="U_USD">14505000</us-gaap:DeferredTaxAssetsNet>
    <adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_c6d8d3ae-f1de-40f0-a052-e64c1119dc90"
      unitRef="U_USD">0</adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets>
    <adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_2536bd83-e363-4dd4-9d89-f17ac44ca7bf"
      unitRef="U_USD">1281000</adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets>
    <adpt:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_efe346f6-023e-4da2-9aab-4686a41b59ee"
      unitRef="U_USD">11581000</adpt:DeferredTaxLiabilitiesRightOfUseAssets>
    <adpt:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_47648c64-f10e-4254-bc84-101bf5e150df"
      unitRef="U_USD">13224000</adpt:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_fa8879b1-1ea9-4050-bfe7-7c44c84579c2"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_61903787-73ae-4cfb-9d26-6c1c73516c92"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_758842e0-f1a3-4a21-a709-1d62832b7819"
      unitRef="U_USD">33100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_55f3d2b3-a116-4892-80ac-5bcdf7986874"
      unitRef="U_USD">55800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <adpt:NetOperatingLossCarryforwardExpirationPeriod
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_ebc46338-48b2-4368-af92-56e51cbdd158">P20Y</adpt:NetOperatingLossCarryforwardExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_de48bc4d-6614-4d5d-ba6b-44f4d8a7fb54"
      decimals="-5"
      id="F_96f0284a-853b-4185-9e48-b030854dd2bb"
      unitRef="U_USD">192500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_de48bc4d-6614-4d5d-ba6b-44f4d8a7fb54"
      decimals="-5"
      id="F_057ef4a5-ce83-4a7e-ae71-10624bd89424"
      unitRef="U_USD">51100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_fd06ba76-408d-423e-bf02-573512c6c45c"
      id="F_9dc2ebf6-56b9-46b8-af1f-0181fc9c5fe7">2028</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <adpt:OperatingLossCarryforwardsExpirationYear
      contextRef="C_fd06ba76-408d-423e-bf02-573512c6c45c"
      id="F_19b76014-babe-42c9-bd75-615f07bf6d2a">2028</adpt:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-5"
      id="F_47987ab5-608d-4286-bb14-130620452ecc"
      unitRef="U_USD">856600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_819c96c1-5dfc-491c-af47-088534226716">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_db2037c4-a7af-4acb-9990-a1f0a1ae0f82"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="INF"
      id="F_a9ccc914-ce65-4d80-a666-712c3517f3c2"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="INF"
      id="F_c92390e5-7450-4592-b549-79ab9bc53eab"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_8bcfab35-10ae-4a45-8a75-058da4f12bf6"
      unitRef="U_pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="INF"
      id="F_289e494b-0481-42ac-9737-522e2da0e755"
      unitRef="U_pure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="INF"
      id="F_53063ee4-7b15-478d-ac27-983356938dc9"
      unitRef="U_pure">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_410d08f0-a5f9-4645-ad28-3214870ac2f3"
      unitRef="U_pure">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_383b51c2-8ab3-4c46-88b0-2f3de3258da2"
      unitRef="U_pure">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_91921fb1-7dd7-4e8c-a564-24b6576a80c0"
      unitRef="U_pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_53a5f629-6e90-4700-a07b-8de758c6861a"
      unitRef="U_pure">-0.003</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_9ee15589-92f6-45b7-a00d-ed6466330425"
      unitRef="U_pure">-0.001</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_d961c596-2bb5-4b22-adc5-66ad53dddbe3"
      unitRef="U_pure">-0.002</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_df653879-e140-4298-ac1a-9e967f219a8a"
      unitRef="U_pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_3df7111e-035e-4140-bb0b-bf95509991ce"
      unitRef="U_pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_d29c8776-60e3-4410-8292-e40e550073f0"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_b7daed51-9dfd-415a-a8b3-b064d2c81f07"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_bcb85a27-21af-4f1a-9620-71d7117a381e"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_15e00dba-4af4-4692-9404-fcb507a9d2d0"
      unitRef="U_pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_c56d8f0b-86da-446f-a22e-22e4b8b8f689"
      unitRef="U_pure">-0.207</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_87e2354e-9dca-42b2-a749-89fc61a3efab"
      unitRef="U_pure">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_4f433b42-3482-49e4-828a-a72744aa2817"
      unitRef="U_pure">-0.244</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="3"
      id="F_7cf40bf0-a867-4c90-adbc-12d66ec9721a"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="3"
      id="F_6d2f3222-5c31-4a09-8116-cc72ce9ee195"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="3"
      id="F_ec07e9e3-027b-4fb6-afb9-5595ee93ef64"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-5"
      id="F_f1c036f9-3cc2-48c8-8577-eaa5aacb0435"
      unitRef="U_USD">10700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_953857ef-8d5d-46dc-a40f-8852e7feeef2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions in 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions in 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions in 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ef19e8e5-6015-4341-bc3d-e83a1af8333d"
      decimals="-3"
      id="F_bf111243-2384-40b5-995e-98350720c9b0"
      unitRef="U_USD">6915000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_a5dc326d-cd5b-4d1e-8695-e34d05f504bf"
      unitRef="U_USD">1202000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_120fbe67-af00-4e4b-b310-0ce8ad885d0d"
      decimals="-3"
      id="F_c94f5764-ed35-445a-9e8f-9fa45af98e62"
      unitRef="U_USD">8117000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_58cb774f-3a95-442c-b63b-f2e4ce4f9dbd"
      unitRef="U_USD">1186000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="-3"
      id="F_81791bcb-4915-4dac-b59e-63e064b02017"
      unitRef="U_USD">9303000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_5c870d34-3630-44e8-bd84-eea0fb171539"
      unitRef="U_USD">1407000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="-3"
      id="F_d7a96271-2227-466e-b127-c2142a982403"
      unitRef="U_USD">10710000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_fe37879d-46fd-4ea3-accd-77fdac92e4ed"
      unitRef="U_USD">1400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_ef21817a-0075-46b6-8439-b04450e4febd"
      unitRef="U_USD">1200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_88ea27b9-2f02-4a97-ab3e-37b4ebd1dc9c"
      unitRef="U_USD">1200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_f4324bd6-f036-4a55-a048-f63024a406bc"
      decimals="INF"
      id="F_ea0fd234-a12b-4a71-b187-cbaea14c949a"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_e7bd250f-3879-4a29-8f2a-3a9ee8055da0"
      decimals="INF"
      id="F_fb103323-3222-4428-ac91-a845546d8264"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_fe5cac4b-e97a-446b-86e0-0e017389aa95">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;17.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,101,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,383,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,515,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022, as they had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.177%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,744,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,839,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,892,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,584,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,630,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,799,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maximum nonvested market-based restricted stock units outstanding eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,497,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,663,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,826,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,133,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,102,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_921b9e69-bc78-45ce-9390-f73fd1e4d76b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,101,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,383,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,515,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_bf58a510-ae93-4de9-83ed-b9250c80c771"
      unitRef="U_USD">-159492000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_a740cd21-abf8-45a9-96c2-096df79cd3c4"
      unitRef="U_USD">-225250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_80d67ac8-13aa-4b62-abd8-4e462fcacab4"
      unitRef="U_USD">-200191000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="0"
      id="F_c6c54f49-ecb8-44fa-aec9-72b9a62a34d9"
      unitRef="U_shares">147101648</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="0"
      id="F_afcc211a-6f4c-48ad-8a85-a3c6f9ec9f36"
      unitRef="U_shares">147101648</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="0"
      id="F_af31e1da-d588-4f78-afc2-2c7bb4da7b2b"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="0"
      id="F_77a27fbe-6e06-4484-8dab-d2cc186c586e"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="0"
      id="F_a313222d-a0a6-4ca5-8b60-9347cd85347d"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="0"
      id="F_a0fc13f0-e911-4bee-a1db-2fe2f6deff00"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_dfa24e49-c228-46a8-af96-9fe63216004a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_ec902ce1-d3c1-4dd4-a5fc-c21d3f3f7480"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="2"
      id="F_df2128ab-08ae-40b9-8cae-55ee91f5036d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="2"
      id="F_ff2a88d7-bac6-4f58-916d-f8030befba80"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="2"
      id="F_9edb4a04-500a-49a1-bdf2-a95f5117f618"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="2"
      id="F_60809b76-6081-4a0f-b7f2-ea5f6f80bfe0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_667f1d31-e80a-4995-a2f1-98733cfc3448">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022, as they had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.177%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,744,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,839,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,892,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,584,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,630,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,799,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maximum nonvested market-based restricted stock units outstanding eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,497,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,663,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,826,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,133,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,102,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c57a4b94-c81c-408b-81ae-f08bfc651eca"
      decimals="INF"
      id="F_d4822089-c09a-45b6-a2b4-35d9d1f85b8b"
      unitRef="U_shares">12744898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3242f9e3-dcb0-4a64-a6a1-9e8c5aa997e4"
      decimals="INF"
      id="F_51368ff4-2624-4c45-845e-ce37270d8e3d"
      unitRef="U_shares">13839067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c231ef4e-80b4-4315-a315-4a98c8a5a33b"
      decimals="INF"
      id="F_4fb1be18-4cc9-410d-8226-78d90e67b3a5"
      unitRef="U_shares">13892287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_29808493-b539-4763-a0cc-0c411c398bb5"
      decimals="INF"
      id="F_960d7d33-a909-4e1b-bac5-c7aad8e17bf5"
      unitRef="U_shares">10584853</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_099bbd21-af0c-4f39-ba1c-26dd5d66531e"
      decimals="INF"
      id="F_916d6684-4a44-42ca-8a6f-1bde2aabb1e0"
      unitRef="U_shares">9630579</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_57cc43f2-a758-4e93-85a5-3570f3deb3df"
      decimals="INF"
      id="F_4b129c90-edd6-4162-b3e1-e63d9e9f6cb0"
      unitRef="U_shares">4799850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_425da08a-cc18-4b6b-b559-af896468cf59"
      decimals="INF"
      id="F_cdd5f0ac-1462-44b6-bfba-8a8d6fdca75f"
      unitRef="U_shares">3497226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9055c1c2-d88e-4bbe-b0ba-ea4735bc60b3"
      decimals="INF"
      id="F_94e0ed93-4b2d-4e08-9970-dcc95de198cc"
      unitRef="U_shares">1663961</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dfdfb869-6506-40d7-affa-2d14196aab88"
      decimals="INF"
      id="F_71f801b8-3d9b-4e80-be08-8e07d7881faf"
      unitRef="U_shares">410282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_b99fd65f-eb9e-4492-89e9-76949d5e7b65"
      unitRef="U_shares">26826977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="INF"
      id="F_369b0c36-6efd-4de8-85df-1aa3eac9f5fa"
      unitRef="U_shares">25133607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="INF"
      id="F_1f2708af-217a-4cae-bae3-303af8719909"
      unitRef="U_shares">19102419</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_19bf5ea4-ad38-450b-9bbd-c5df590fed14">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;18.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Retirement Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain a salary deferral 401(k) plan (&#x201c;401(k) Plan&#x201d;) covering employees who have met certain eligibility requirements. Employees may defer up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their compensation to the 401(k) Plan, subject to federal limits. We made $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#231f20;"&gt;2.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in discretionary contributions during the year ended December 31, 2024, 2023 and 2022, respectively, which are fully vested after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of employee service.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="2"
      id="F_d912c895-b799-4a0c-875e-c6e76df7a226"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-5"
      id="F_f8768a9e-fa51-49a7-9328-a6b5096e3900"
      unitRef="U_USD">2000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-5"
      id="F_f8985db6-f6a4-41b4-9da1-2845f14e9e65"
      unitRef="U_USD">2300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-5"
      id="F_a0353bcd-5c21-4626-9ee2-8d5f1f106479"
      unitRef="U_USD">2800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_552cadbe-d43f-4448-b356-1b45d172f777">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      id="F_17e0b354-45a2-4bd1-85dc-a893e33f0b9d">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      id="F_be250134-b2e5-4314-ae13-fc512c9b7cc3">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_f2d2fafe-cd53-4604-87a4-66d2fbd32077">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;19.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2024, in connection with an organizational realignment, we began operating our business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segments: MRD and Immune Medicine. These segments are organized by market opportunity in commercial diagnostics and drug discovery, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The MRD business focuses on the use of our highly sensitive, next-generation sequencing assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ assay, offered to biopharmaceutical partners to advance drug development efforts. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Immune Medicine business leverages our proprietary ability to sequence, map, pair and characterize TCRs and B cell receptors at scale. We have created a powerful data engine to drive the development of novel therapies. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery; and (3) for years prior to 2023, providing our T-Detect COVID tests to clinical customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; inter-segment revenues. See Note 3, Revenue for more information about each segment's revenue. Our CODM, which is our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8759c879-be95-43bb-8de5-203e18a7141c;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;evaluates performance of the MRD segment based on both revenue and Adjusted EBITDA and evaluates performance of the Immune Medicine segment based on Adjusted EBITDA. These measures help our CODM assess the trends and operating margin profile of the respective segments, which helps drive the level of investment made in each business. These measures also help our CODM assess and manage the potential capital utilization of each segment. Adjusted EBITDA for each of our segments includes costs that are directly aligned to each segment, as well as certain allocated shared expenses.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Additionally, we do not allocate costs related to our idle facility in Seattle, Washington, interest expense related to our Purchase Agreement nor interest and other income, net. Given these unallocated costs and income are not included in the measurements reviewed by the CODM to assess each segment's performance, they are included in an "Unallocated Corporate" category. Our allocation methodology will be periodically evaluated and may change. Our CODM is not regularly provided and does not review assets to assess each segment's performance, make strategic decisions or allocate resources. As such, assets for reportable segments are not disclosed.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment information for the years ended December 31, 2023 and 2022 are presented on a comparable basis to that of the current period and is based on judgments and allocation methods from our organizational changes implemented during the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the years ended December 31, 2024, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add back:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Items to reconcile net loss to adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add back:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Items to reconcile net loss to adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unallocated Corporate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#160;to Net Loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unallocated Corporate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#160;to Net Loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of right-of-use and related long-lived assets&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(7)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unallocated Corporate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#160;to Net Loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_75bb2233-9ac9-45f1-8031-2e009382d5f2;"&gt;&lt;span style="-sec-ix-hidden:F_83fd51e3-9860-4816-b7d4-990a29a9c263;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes MRD impairment of long-lived assets expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA is a non-GAAP financial measure. See &#x201c;Management's Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Adjusted EBITDA&#x201d; for an explanation of how it is calculated and used by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes all Immune Medicine operating expenses, other than research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for details on our share-based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents expenses recognized in conjunction with restructuring activities. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for details on our restructuring expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(6) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Purchase Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for details on the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for details on our impairment expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="INF"
      id="F_dfe53bdd-6b90-47d7-a5af-daa51ae7aaf6"
      unitRef="U_Segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:Revenues
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="INF"
      id="F_008d7ba1-91f9-49a8-a5be-73307122acdf"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_a5feb4ad-3c56-4621-9373-b1fdf0a827ce">evaluates performance of the MRD segment based on both revenue and Adjusted EBITDA and evaluates performance of the Immune Medicine segment based on Adjusted EBITDA. These measures help our CODM assess the trends and operating margin profile of the respective segments, which helps drive the level of investment made in each business. These measures also help our CODM assess and manage the potential capital utilization of each segment. Adjusted EBITDA for each of our segments includes costs that are directly aligned to each segment, as well as certain allocated shared expenses.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_c6a1b0c9-c110-4046-becc-697cb00e8055">These shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      id="F_384582ec-88e0-41cd-abca-c946cd4a297d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the years ended December 31, 2024, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add back:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Items to reconcile net loss to adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add back:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Items to reconcile net loss to adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:0.92%;text-indent:4.575%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unallocated Corporate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#160;to Net Loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unallocated Corporate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#160;to Net Loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of right-of-use and related long-lived assets&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(7)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.096%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;MRD&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Immune Medicine&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unallocated Corporate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#160;to Net Loss:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_75bb2233-9ac9-45f1-8031-2e009382d5f2;"&gt;&lt;span style="-sec-ix-hidden:F_83fd51e3-9860-4816-b7d4-990a29a9c263;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes MRD impairment of long-lived assets expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adjusted EBITDA is a non-GAAP financial measure. See &#x201c;Management's Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Adjusted EBITDA&#x201d; for an explanation of how it is calculated and used by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes all Immune Medicine operating expenses, other than research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for details on our share-based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents expenses recognized in conjunction with restructuring activities. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructurings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for details on our restructuring expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(6) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Interest Purchase Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for details on the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for details on our impairment expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_5cc82bba-86f8-4f46-a7bf-43313bd64b7a"
      unitRef="U_USD">145529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_f827f3d1-23bc-4b13-b02d-9d9ee3650b8d"
      unitRef="U_USD">102739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_e8a8f31f-b0ee-4608-8b8c-de24420d9955"
      unitRef="U_USD">87144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_ba9ed500-b172-4b2d-9af9-9b41e3f69da1"
      unitRef="U_USD">64177000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_d48e2cd5-cefc-4a64-b3f0-8a213d2ad8d0"
      unitRef="U_USD">63273000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_b03e7da4-35e1-49e4-919d-708e59b4b581"
      unitRef="U_USD">42606000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_4c06a4e6-0b81-4792-a5fc-3e70cb09492c"
      unitRef="U_USD">40743000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_6f424d95-31e9-4cca-af5e-6e8d2eede1ed"
      unitRef="U_USD">42153000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_b23168b3-446e-48ad-8051-ad47791f4b6e"
      unitRef="U_USD">31768000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_c724e13f-e0ca-4d89-a6a2-0a299cb96608"
      unitRef="U_USD">77579000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_0c39f1e7-22ac-485e-89fc-785b228f2d75"
      unitRef="U_USD">76742000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_85cc692b-3eb3-49f3-bb2d-5b43eebe61de"
      unitRef="U_USD">65558000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_90c420f7-8cd5-4483-93bc-4afea2a99546"
      unitRef="U_USD">40446000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_a4c76fce-778c-4ec6-bd45-814534c83827"
      unitRef="U_USD">46961000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_be9b01ef-fa43-4545-9d9c-3a6da679b4b2"
      unitRef="U_USD">32349000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_6a9f91b0-4738-40f9-b68a-82bd5973e387"
      decimals="-3"
      id="F_b2cbe0a4-434b-4068-990b-ad81f9366b7a"
      unitRef="U_USD">2819000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_b28752cf-076a-4931-ad68-b484eab79e15"
      decimals="-3"
      id="F_b99294fd-d7bb-4937-8c90-b08044e85551"
      unitRef="U_USD">0</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_70d180be-d136-46d0-a6f1-b5c952fe6c15"
      decimals="-3"
      id="F_4438e2f0-9d58-4599-8f57-e22efbed9cda"
      unitRef="U_USD">0</us-gaap:SegmentReportingOtherItemAmount>
    <adpt:ItemsToReconcileNetLossToAdjustedEBITDA
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_94c50ece-9355-4a71-870f-c11753e361c8"
      unitRef="U_USD">39012000</adpt:ItemsToReconcileNetLossToAdjustedEBITDA>
    <adpt:ItemsToReconcileNetLossToAdjustedEBITDA
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_ea6e0b37-84f2-44d8-aef5-ffe0db092982"
      unitRef="U_USD">37546000</adpt:ItemsToReconcileNetLossToAdjustedEBITDA>
    <adpt:ItemsToReconcileNetLossToAdjustedEBITDA
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_65d343e9-bdf0-47a3-81b1-24c409997f28"
      unitRef="U_USD">24641000</adpt:ItemsToReconcileNetLossToAdjustedEBITDA>
    <adpt:AdjustedEbitda
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_dd9c5691-45e8-4094-8bf5-7c8622edfff2"
      unitRef="U_USD">-41223000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_41433281-99f1-4efb-a27b-d8892c89e29c"
      unitRef="U_USD">-88844000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_7c24df4d-9a6d-4cef-936a-d6ab503d8c61"
      unitRef="U_USD">-60496000</adpt:AdjustedEbitda>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_f00149bf-217b-44c8-86fb-64cdde225bdb"
      unitRef="U_USD">33428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_51697d37-c357-4078-9cbb-78d70bc137a8"
      unitRef="U_USD">67537000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_b52d3c56-8e36-43f8-995e-581b022835ff"
      unitRef="U_USD">98164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_e1067544-2889-48ea-b465-2b2a1ee7133e"
      unitRef="U_USD">62210000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_29a6ea78-341d-4f40-8002-6edad7640ceb"
      unitRef="U_USD">79964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_06498528-abb1-4843-9f44-4b923464ffff"
      unitRef="U_USD">109988000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_0e18d051-aeae-44cb-ba16-8f0a32e2f029"
      decimals="-3"
      id="F_96c3782c-44fa-417a-8f0c-ac63623e40eb"
      unitRef="U_USD">28842000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_a46c0838-63e1-46ff-badd-1a080dcfd4e8"
      decimals="-3"
      id="F_e89a95e0-f206-4819-856f-aaabb6b695ce"
      unitRef="U_USD">35067000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_256c43d6-4366-49a5-8b14-90aef18be10f"
      decimals="-3"
      id="F_b58366a1-3f90-4a0f-b814-ec4b8778b77a"
      unitRef="U_USD">70016000</us-gaap:SegmentReportingOtherItemAmount>
    <adpt:ItemsToReconcileNetLossToAdjustedEBITDA
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_17429eec-094a-43ea-927d-ef3fece81b04"
      unitRef="U_USD">31619000</adpt:ItemsToReconcileNetLossToAdjustedEBITDA>
    <adpt:ItemsToReconcileNetLossToAdjustedEBITDA
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_64e78d1b-cc17-45b4-810d-d6c1e95bc0ad"
      unitRef="U_USD">33366000</adpt:ItemsToReconcileNetLossToAdjustedEBITDA>
    <adpt:ItemsToReconcileNetLossToAdjustedEBITDA
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_80e9fe5b-1f9c-4343-85f9-ec20ab7c395f"
      unitRef="U_USD">36186000</adpt:ItemsToReconcileNetLossToAdjustedEBITDA>
    <adpt:AdjustedEbitda
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_71c477a7-f00d-434a-bd81-caf1f718e054"
      unitRef="U_USD">-26005000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_2d0ea309-cb98-4f04-b949-55dbe6294d3d"
      unitRef="U_USD">-14128000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_3637051c-7816-4b47-b5fb-f4e7c6985ade"
      unitRef="U_USD">-45654000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_74ff7f71-2430-4605-9e04-027595fb1748"
      unitRef="U_USD">-41223000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_795a954e-d486-46e7-a250-bdfa6ebc1cfc"
      unitRef="U_USD">-26005000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="-3"
      id="F_b4031824-8297-44ef-ba38-857587db2044"
      unitRef="U_USD">-13143000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_16f04e89-4028-40ca-bca2-293ab8b9b4fd"
      unitRef="U_USD">-80371000</adpt:AdjustedEbitda>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39"
      unitRef="U_USD">24848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838"
      unitRef="U_USD">19051000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="-3"
      id="F_d35974e6-5809-4ae2-a57a-55bc3d676e32"
      unitRef="U_USD">9711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_40b0137c-2980-4840-93bf-339330caf6b1"
      unitRef="U_USD">53610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RestructuringCharges
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4"
      unitRef="U_USD">1272000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_54732a37-6c04-468b-8af4-d2b05eb94ad3"
      unitRef="U_USD">732000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_a731ef80-93e5-44a8-9679-4a4c2c298fc8"
      unitRef="U_USD">2004000</us-gaap:RestructuringCharges>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_32d528e5-a231-49d7-97ff-426af9382caf"
      unitRef="U_USD">2819000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_6cedab5a-035d-4c63-89e7-abd4a482b92c"
      unitRef="U_USD">4386000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_4904d016-10c5-4490-9bce-ce972d3156f6"
      unitRef="U_USD">7205000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_da3ff03b-c852-4729-b32f-d1e13c53f431"
      decimals="-3"
      id="F_b8b15491-84e6-4093-a3dc-f6e4e3658c9a"
      unitRef="U_USD">10073000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1770533c-2b6b-443a-a51c-e765fd5b9fb5"
      decimals="-3"
      id="F_cfa836ec-6129-479e-a5ea-493663968b30"
      unitRef="U_USD">7450000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="-3"
      id="F_54f910ac-ddd1-4976-81c3-5ea636082b15"
      unitRef="U_USD">1733000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_cb03b45e-d983-4f77-9458-0b027a46cdcb"
      unitRef="U_USD">19256000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestExpense
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="-3"
      id="F_a064aff8-4d29-465b-8316-a8a35b77bc17"
      unitRef="U_USD">11580000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7"
      unitRef="U_USD">11580000</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="-3"
      id="F_6bd89d63-e965-4b90-9d0d-f1a53f27d8db"
      unitRef="U_USD">14534000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_806a258d-2394-4d13-9b00-dcf6e6a2afe4"
      unitRef="U_USD">14534000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_5cfea8e3-9a33-4b9b-bbd5-a25a7e04afbd"
      unitRef="U_USD">-159492000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_1afe7465-3d4e-4ad3-b563-56e6f8072164"
      decimals="-3"
      id="F_bd5458aa-1382-474e-8c10-6cc0ac924c2f"
      unitRef="U_USD">-103000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_333af4a3-cffa-49c3-8566-6302b765c42b"
      decimals="-3"
      id="F_c76bc330-bc03-47cd-b81d-78b57ae2d63a"
      unitRef="U_USD">-159595000</us-gaap:ProfitLoss>
    <adpt:AdjustedEbitda
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_1bf1199f-3bac-4b1a-a27b-7888cad246a7"
      unitRef="U_USD">-88844000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_84e4227f-a8d5-4b52-b64b-050736891da1"
      unitRef="U_USD">-14128000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_19d4a5a5-e0e3-430a-946a-aac10afdbff3"
      unitRef="U_USD">-13441000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_4de633d5-d71d-466c-859a-cd7f030ebc81"
      unitRef="U_USD">-116413000</adpt:AdjustedEbitda>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_13603129-bb53-47d1-9eb7-6f62807645d1"
      unitRef="U_USD">28321000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08"
      unitRef="U_USD">22930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_384876e2-fe72-44d1-8909-963c883b7b5f"
      unitRef="U_USD">11657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00"
      unitRef="U_USD">62908000</us-gaap:AllocatedShareBasedCompensationExpense>
    <adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_92c52fe6-c1cf-429e-b534-2bcd9b87c577"
      unitRef="U_USD">25429000</adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets>
    <adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_19c4e4ee-ca66-4b67-bf95-485edb301cb1"
      unitRef="U_USD">25429000</adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_5fb3a979-ff4c-4253-8408-395fb698c93b"
      decimals="-3"
      id="F_3970881c-267c-4c47-aa23-6eeb7b471754"
      unitRef="U_USD">9225000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_35bf3362-af08-41ac-b5ae-d51683a82d48"
      decimals="-3"
      id="F_4aa2c192-033b-4ea8-94ff-28f5a51ea829"
      unitRef="U_USD">10436000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_402df673-cbb4-4da2-8903-26c31f8f1d22"
      unitRef="U_USD">2570000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_cb99609e-f987-4efd-ad72-7c5cb386d178"
      unitRef="U_USD">22231000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestExpense
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_9ddbf605-964c-47bd-aba2-66217d8b9853"
      unitRef="U_USD">13800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_696d352b-815e-4bee-a1ad-5340543c473c"
      unitRef="U_USD">13800000</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_97abe44c-69b9-4c80-82b1-c30839f23053"
      unitRef="U_USD">15531000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_b7ddfab1-e5c2-4703-a546-88821c27493c"
      unitRef="U_USD">15531000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_51daeb26-7fb0-4369-9fd3-dddef7716b18"
      unitRef="U_USD">-225250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_2f55e0e9-b954-452c-a685-f7ac38e3d535"
      decimals="-3"
      id="F_fb6cf031-e6b5-47fc-affd-47c52b311ce4"
      unitRef="U_USD">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_14fd86d7-b649-4d1e-b341-b684c139f7a6"
      decimals="-3"
      id="F_77d9a80b-fad8-4746-a3fd-19f012a01870"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <adpt:AdjustedEbitda
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_807fcd58-d6d5-4803-b9c2-0fd4abe33853"
      unitRef="U_USD">-60496000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_db33ce64-269a-49ea-a4af-63a49a604a55"
      unitRef="U_USD">-45654000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_d81a33d0-17e3-43cd-898f-047561248f8c"
      unitRef="U_USD">-15439000</adpt:AdjustedEbitda>
    <adpt:AdjustedEbitda
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_05d1ab54-5f1d-4c3a-8fb0-4e8733fcf463"
      unitRef="U_USD">-121589000</adpt:AdjustedEbitda>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_51279202-faae-46b6-bb41-f7bdde771b6d"
      unitRef="U_USD">17999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_09ad6b64-fb8b-4678-8f92-59036e1480ab"
      unitRef="U_USD">23892000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_bd249654-3957-4805-bdf6-1da2df6b29a6"
      unitRef="U_USD">13586000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_5f934cfc-c961-465f-ab88-396d638ad6c1"
      unitRef="U_USD">55477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RestructuringCharges
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_bf83b944-d68e-48d4-bda8-c3986baaf736"
      unitRef="U_USD">2023000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_c3876f27-0b6e-4215-92be-69496800fdf2"
      unitRef="U_USD">2023000</us-gaap:RestructuringCharges>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_a2f7d5eb-d957-443a-9e91-6f51e2498f15"
      decimals="-3"
      id="F_7fd498b3-a25d-4a01-aac6-ade8e1e6f17a"
      unitRef="U_USD">6642000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_43334088-5e2d-486b-bae0-78c2ee15f270"
      decimals="-3"
      id="F_8dd0f46f-0033-4e86-b816-356a96205ae4"
      unitRef="U_USD">12294000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_4ed001e3-66e3-4969-8e54-995698d5b0e4"
      unitRef="U_USD">1984000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_eab68962-5a93-4f45-816f-53a003d9d744"
      unitRef="U_USD">20920000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestExpense
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599"
      unitRef="U_USD">4238000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_629e47f6-ada6-4b91-b878-080425e24779"
      unitRef="U_USD">4238000</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_3c0ff92a-11a4-4a2c-a6e8-8f27665470e5"
      unitRef="U_USD">4056000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_d5f6c67b-b008-42db-8396-bd5613e347b5"
      unitRef="U_USD">4056000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_867fcb0d-4c7f-4360-a60c-7ec9f6f55b5d"
      unitRef="U_USD">-200191000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_cc21401e-27f1-4093-ae19-40e8a58d1a08"
      decimals="-3"
      id="F_50718092-9e01-48a5-8e98-6b71a52c48db"
      unitRef="U_USD">-177000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_720f5d8b-e669-44e2-8c1b-34aef5e0e5b0"
      decimals="-3"
      id="F_5f91837c-ddd6-4581-bca7-a80e98e6e794"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_e4fca2f4-8e1d-432d-80ec-6c3440952998"
      id="F_f5c052f7-3dcb-4353-8eab-87eccc1e2c67">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 18, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Michelle Griffin&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a member of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Board of Directors&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a Rule 10b5-1 trading plan. Ms. Griffin&#x2019;s plan provides for the sale of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the net vested shares of our common stock received in connection with the vesting of certain restricted stock units. The plan's expiration date is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 14, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding transactions in our securities.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"
      id="F_0817447b-5c58-427d-9999-084f099b8400">November 18, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"
      id="F_646a88ee-994e-4dac-b2c3-dde917703ac2">Michelle Griffin</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"
      id="F_de68bcd9-eb1f-4f0e-b2e8-80245fcaf16d">Board of Directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"
      id="F_012dd716-ad4b-401c-bf5e-63d2d3af2170">true</ecd:Rule10b51ArrAdoptedFlag>
    <adpt:PercentageOfNetVestedSharesOfCommonStock
      contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"
      decimals="2"
      id="F_ed3ed606-5b70-4e2d-94e2-f058b061d575"
      unitRef="U_pure">0.50</adpt:PercentageOfNetVestedSharesOfCommonStock>
    <ecd:TrdArrExpirationDate
      contextRef="C_6aac9fc4-61da-4969-864e-d3f27316dbe9"
      id="F_626595a7-eb43-4814-b7df-afca35b31fbb">March 14, 2025</ecd:TrdArrExpirationDate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_b99294fd-d7bb-4937-8c90-b08044e85551"
          xlink:label="F_b99294fd-d7bb-4937-8c90-b08044e85551"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b2cbe0a4-434b-4068-990b-ad81f9366b7a"
          xlink:label="F_b2cbe0a4-434b-4068-990b-ad81f9366b7a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4438e2f0-9d58-4599-8f57-e22efbed9cda"
          xlink:label="F_4438e2f0-9d58-4599-8f57-e22efbed9cda"
          xlink:type="locator"/>
        <link:footnote id="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38" xlink:label="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes MRD impairment of long-lived assets expenses.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b99294fd-d7bb-4937-8c90-b08044e85551"
          xlink:to="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b2cbe0a4-434b-4068-990b-ad81f9366b7a"
          xlink:to="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4438e2f0-9d58-4599-8f57-e22efbed9cda"
          xlink:to="FNT_20da4c78-2630-434a-8ba2-4c63586b5e38"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_384876e2-fe72-44d1-8909-963c883b7b5f"
          xlink:label="F_384876e2-fe72-44d1-8909-963c883b7b5f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_54f910ac-ddd1-4976-81c3-5ea636082b15"
          xlink:label="F_54f910ac-ddd1-4976-81c3-5ea636082b15"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5f934cfc-c961-465f-ab88-396d638ad6c1"
          xlink:label="F_5f934cfc-c961-465f-ab88-396d638ad6c1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_dd9c5691-45e8-4094-8bf5-7c8622edfff2"
          xlink:label="F_dd9c5691-45e8-4094-8bf5-7c8622edfff2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_05d1ab54-5f1d-4c3a-8fb0-4e8733fcf463"
          xlink:label="F_05d1ab54-5f1d-4c3a-8fb0-4e8733fcf463"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7c24df4d-9a6d-4cef-936a-d6ab503d8c61"
          xlink:label="F_7c24df4d-9a6d-4cef-936a-d6ab503d8c61"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cfa836ec-6129-479e-a5ea-493663968b30"
          xlink:label="F_cfa836ec-6129-479e-a5ea-493663968b30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4aa2c192-033b-4ea8-94ff-28f5a51ea829"
          xlink:label="F_4aa2c192-033b-4ea8-94ff-28f5a51ea829"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39"
          xlink:label="F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d5f6c67b-b008-42db-8396-bd5613e347b5"
          xlink:label="F_d5f6c67b-b008-42db-8396-bd5613e347b5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_19c4e4ee-ca66-4b67-bf95-485edb301cb1"
          xlink:label="F_19c4e4ee-ca66-4b67-bf95-485edb301cb1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b7ddfab1-e5c2-4703-a546-88821c27493c"
          xlink:label="F_b7ddfab1-e5c2-4703-a546-88821c27493c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6cedab5a-035d-4c63-89e7-abd4a482b92c"
          xlink:label="F_6cedab5a-035d-4c63-89e7-abd4a482b92c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5f91837c-ddd6-4581-bca7-a80e98e6e794"
          xlink:label="F_5f91837c-ddd6-4581-bca7-a80e98e6e794"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_41433281-99f1-4efb-a27b-d8892c89e29c"
          xlink:label="F_41433281-99f1-4efb-a27b-d8892c89e29c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838"
          xlink:label="F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599"
          xlink:label="F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3637051c-7816-4b47-b5fb-f4e7c6985ade"
          xlink:label="F_3637051c-7816-4b47-b5fb-f4e7c6985ade"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cb99609e-f987-4efd-ad72-7c5cb386d178"
          xlink:label="F_cb99609e-f987-4efd-ad72-7c5cb386d178"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_40b0137c-2980-4840-93bf-339330caf6b1"
          xlink:label="F_40b0137c-2980-4840-93bf-339330caf6b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3970881c-267c-4c47-aa23-6eeb7b471754"
          xlink:label="F_3970881c-267c-4c47-aa23-6eeb7b471754"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7fd498b3-a25d-4a01-aac6-ade8e1e6f17a"
          xlink:label="F_7fd498b3-a25d-4a01-aac6-ade8e1e6f17a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_fb6cf031-e6b5-47fc-affd-47c52b311ce4"
          xlink:label="F_fb6cf031-e6b5-47fc-affd-47c52b311ce4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d35974e6-5809-4ae2-a57a-55bc3d676e32"
          xlink:label="F_d35974e6-5809-4ae2-a57a-55bc3d676e32"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_54732a37-6c04-468b-8af4-d2b05eb94ad3"
          xlink:label="F_54732a37-6c04-468b-8af4-d2b05eb94ad3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_16f04e89-4028-40ca-bca2-293ab8b9b4fd"
          xlink:label="F_16f04e89-4028-40ca-bca2-293ab8b9b4fd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bd5458aa-1382-474e-8c10-6cc0ac924c2f"
          xlink:label="F_bd5458aa-1382-474e-8c10-6cc0ac924c2f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_807fcd58-d6d5-4803-b9c2-0fd4abe33853"
          xlink:label="F_807fcd58-d6d5-4803-b9c2-0fd4abe33853"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cb03b45e-d983-4f77-9458-0b027a46cdcb"
          xlink:label="F_cb03b45e-d983-4f77-9458-0b027a46cdcb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ea6e0b37-84f2-44d8-aef5-ffe0db092982"
          xlink:label="F_ea6e0b37-84f2-44d8-aef5-ffe0db092982"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c3876f27-0b6e-4215-92be-69496800fdf2"
          xlink:label="F_c3876f27-0b6e-4215-92be-69496800fdf2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4"
          xlink:label="F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b4031824-8297-44ef-ba38-857587db2044"
          xlink:label="F_b4031824-8297-44ef-ba38-857587db2044"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_50718092-9e01-48a5-8e98-6b71a52c48db"
          xlink:label="F_50718092-9e01-48a5-8e98-6b71a52c48db"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_19d4a5a5-e0e3-430a-946a-aac10afdbff3"
          xlink:label="F_19d4a5a5-e0e3-430a-946a-aac10afdbff3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_806a258d-2394-4d13-9b00-dcf6e6a2afe4"
          xlink:label="F_806a258d-2394-4d13-9b00-dcf6e6a2afe4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_09ad6b64-fb8b-4678-8f92-59036e1480ab"
          xlink:label="F_09ad6b64-fb8b-4678-8f92-59036e1480ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8dd0f46f-0033-4e86-b816-356a96205ae4"
          xlink:label="F_8dd0f46f-0033-4e86-b816-356a96205ae4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_867fcb0d-4c7f-4360-a60c-7ec9f6f55b5d"
          xlink:label="F_867fcb0d-4c7f-4360-a60c-7ec9f6f55b5d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_94c50ece-9355-4a71-870f-c11753e361c8"
          xlink:label="F_94c50ece-9355-4a71-870f-c11753e361c8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_84e4227f-a8d5-4b52-b64b-050736891da1"
          xlink:label="F_84e4227f-a8d5-4b52-b64b-050736891da1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08"
          xlink:label="F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_97abe44c-69b9-4c80-82b1-c30839f23053"
          xlink:label="F_97abe44c-69b9-4c80-82b1-c30839f23053"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4904d016-10c5-4490-9bce-ce972d3156f6"
          xlink:label="F_4904d016-10c5-4490-9bce-ce972d3156f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_629e47f6-ada6-4b91-b878-080425e24779"
          xlink:label="F_629e47f6-ada6-4b91-b878-080425e24779"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_51279202-faae-46b6-bb41-f7bdde771b6d"
          xlink:label="F_51279202-faae-46b6-bb41-f7bdde771b6d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_92c52fe6-c1cf-429e-b534-2bcd9b87c577"
          xlink:label="F_92c52fe6-c1cf-429e-b534-2bcd9b87c577"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6bd89d63-e965-4b90-9d0d-f1a53f27d8db"
          xlink:label="F_6bd89d63-e965-4b90-9d0d-f1a53f27d8db"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a064aff8-4d29-465b-8316-a8a35b77bc17"
          xlink:label="F_a064aff8-4d29-465b-8316-a8a35b77bc17"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_51daeb26-7fb0-4369-9fd3-dddef7716b18"
          xlink:label="F_51daeb26-7fb0-4369-9fd3-dddef7716b18"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_80e9fe5b-1f9c-4343-85f9-ec20ab7c395f"
          xlink:label="F_80e9fe5b-1f9c-4343-85f9-ec20ab7c395f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00"
          xlink:label="F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9ddbf605-964c-47bd-aba2-66217d8b9853"
          xlink:label="F_9ddbf605-964c-47bd-aba2-66217d8b9853"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c76bc330-bc03-47cd-b81d-78b57ae2d63a"
          xlink:label="F_c76bc330-bc03-47cd-b81d-78b57ae2d63a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_64e78d1b-cc17-45b4-810d-d6c1e95bc0ad"
          xlink:label="F_64e78d1b-cc17-45b4-810d-d6c1e95bc0ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_71c477a7-f00d-434a-bd81-caf1f718e054"
          xlink:label="F_71c477a7-f00d-434a-bd81-caf1f718e054"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bf83b944-d68e-48d4-bda8-c3986baaf736"
          xlink:label="F_bf83b944-d68e-48d4-bda8-c3986baaf736"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4de633d5-d71d-466c-859a-cd7f030ebc81"
          xlink:label="F_4de633d5-d71d-466c-859a-cd7f030ebc81"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_17429eec-094a-43ea-927d-ef3fece81b04"
          xlink:label="F_17429eec-094a-43ea-927d-ef3fece81b04"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4ed001e3-66e3-4969-8e54-995698d5b0e4"
          xlink:label="F_4ed001e3-66e3-4969-8e54-995698d5b0e4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_eab68962-5a93-4f45-816f-53a003d9d744"
          xlink:label="F_eab68962-5a93-4f45-816f-53a003d9d744"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_65d343e9-bdf0-47a3-81b1-24c409997f28"
          xlink:label="F_65d343e9-bdf0-47a3-81b1-24c409997f28"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bd249654-3957-4805-bdf6-1da2df6b29a6"
          xlink:label="F_bd249654-3957-4805-bdf6-1da2df6b29a6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2d0ea309-cb98-4f04-b949-55dbe6294d3d"
          xlink:label="F_2d0ea309-cb98-4f04-b949-55dbe6294d3d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7"
          xlink:label="F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_77d9a80b-fad8-4746-a3fd-19f012a01870"
          xlink:label="F_77d9a80b-fad8-4746-a3fd-19f012a01870"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_db33ce64-269a-49ea-a4af-63a49a604a55"
          xlink:label="F_db33ce64-269a-49ea-a4af-63a49a604a55"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_795a954e-d486-46e7-a250-bdfa6ebc1cfc"
          xlink:label="F_795a954e-d486-46e7-a250-bdfa6ebc1cfc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b8b15491-84e6-4093-a3dc-f6e4e3658c9a"
          xlink:label="F_b8b15491-84e6-4093-a3dc-f6e4e3658c9a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_696d352b-815e-4bee-a1ad-5340543c473c"
          xlink:label="F_696d352b-815e-4bee-a1ad-5340543c473c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a731ef80-93e5-44a8-9679-4a4c2c298fc8"
          xlink:label="F_a731ef80-93e5-44a8-9679-4a4c2c298fc8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d81a33d0-17e3-43cd-898f-047561248f8c"
          xlink:label="F_d81a33d0-17e3-43cd-898f-047561248f8c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_402df673-cbb4-4da2-8903-26c31f8f1d22"
          xlink:label="F_402df673-cbb4-4da2-8903-26c31f8f1d22"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_13603129-bb53-47d1-9eb7-6f62807645d1"
          xlink:label="F_13603129-bb53-47d1-9eb7-6f62807645d1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1bf1199f-3bac-4b1a-a27b-7888cad246a7"
          xlink:label="F_1bf1199f-3bac-4b1a-a27b-7888cad246a7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5cfea8e3-9a33-4b9b-bbd5-a25a7e04afbd"
          xlink:label="F_5cfea8e3-9a33-4b9b-bbd5-a25a7e04afbd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_74ff7f71-2430-4605-9e04-027595fb1748"
          xlink:label="F_74ff7f71-2430-4605-9e04-027595fb1748"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_32d528e5-a231-49d7-97ff-426af9382caf"
          xlink:label="F_32d528e5-a231-49d7-97ff-426af9382caf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3c0ff92a-11a4-4a2c-a6e8-8f27665470e5"
          xlink:label="F_3c0ff92a-11a4-4a2c-a6e8-8f27665470e5"
          xlink:type="locator"/>
        <link:footnote id="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53" xlink:label="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure. See &#x201c;Management's Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Adjusted EBITDA&#x201d; for an explanation of how it is calculated and used by management.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_384876e2-fe72-44d1-8909-963c883b7b5f"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54f910ac-ddd1-4976-81c3-5ea636082b15"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5f934cfc-c961-465f-ab88-396d638ad6c1"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dd9c5691-45e8-4094-8bf5-7c8622edfff2"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_05d1ab54-5f1d-4c3a-8fb0-4e8733fcf463"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7c24df4d-9a6d-4cef-936a-d6ab503d8c61"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cfa836ec-6129-479e-a5ea-493663968b30"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4aa2c192-033b-4ea8-94ff-28f5a51ea829"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d5f6c67b-b008-42db-8396-bd5613e347b5"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_19c4e4ee-ca66-4b67-bf95-485edb301cb1"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b7ddfab1-e5c2-4703-a546-88821c27493c"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6cedab5a-035d-4c63-89e7-abd4a482b92c"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5f91837c-ddd6-4581-bca7-a80e98e6e794"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_41433281-99f1-4efb-a27b-d8892c89e29c"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3637051c-7816-4b47-b5fb-f4e7c6985ade"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cb99609e-f987-4efd-ad72-7c5cb386d178"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_40b0137c-2980-4840-93bf-339330caf6b1"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3970881c-267c-4c47-aa23-6eeb7b471754"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7fd498b3-a25d-4a01-aac6-ade8e1e6f17a"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fb6cf031-e6b5-47fc-affd-47c52b311ce4"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d35974e6-5809-4ae2-a57a-55bc3d676e32"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54732a37-6c04-468b-8af4-d2b05eb94ad3"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_16f04e89-4028-40ca-bca2-293ab8b9b4fd"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bd5458aa-1382-474e-8c10-6cc0ac924c2f"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_807fcd58-d6d5-4803-b9c2-0fd4abe33853"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cb03b45e-d983-4f77-9458-0b027a46cdcb"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ea6e0b37-84f2-44d8-aef5-ffe0db092982"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c3876f27-0b6e-4215-92be-69496800fdf2"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b4031824-8297-44ef-ba38-857587db2044"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_50718092-9e01-48a5-8e98-6b71a52c48db"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_19d4a5a5-e0e3-430a-946a-aac10afdbff3"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_806a258d-2394-4d13-9b00-dcf6e6a2afe4"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_09ad6b64-fb8b-4678-8f92-59036e1480ab"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8dd0f46f-0033-4e86-b816-356a96205ae4"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_867fcb0d-4c7f-4360-a60c-7ec9f6f55b5d"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_94c50ece-9355-4a71-870f-c11753e361c8"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_84e4227f-a8d5-4b52-b64b-050736891da1"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_97abe44c-69b9-4c80-82b1-c30839f23053"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4904d016-10c5-4490-9bce-ce972d3156f6"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_629e47f6-ada6-4b91-b878-080425e24779"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_51279202-faae-46b6-bb41-f7bdde771b6d"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_92c52fe6-c1cf-429e-b534-2bcd9b87c577"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6bd89d63-e965-4b90-9d0d-f1a53f27d8db"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a064aff8-4d29-465b-8316-a8a35b77bc17"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_51daeb26-7fb0-4369-9fd3-dddef7716b18"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_80e9fe5b-1f9c-4343-85f9-ec20ab7c395f"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9ddbf605-964c-47bd-aba2-66217d8b9853"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c76bc330-bc03-47cd-b81d-78b57ae2d63a"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_64e78d1b-cc17-45b4-810d-d6c1e95bc0ad"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_71c477a7-f00d-434a-bd81-caf1f718e054"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bf83b944-d68e-48d4-bda8-c3986baaf736"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4de633d5-d71d-466c-859a-cd7f030ebc81"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_17429eec-094a-43ea-927d-ef3fece81b04"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4ed001e3-66e3-4969-8e54-995698d5b0e4"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_eab68962-5a93-4f45-816f-53a003d9d744"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_65d343e9-bdf0-47a3-81b1-24c409997f28"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bd249654-3957-4805-bdf6-1da2df6b29a6"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2d0ea309-cb98-4f04-b949-55dbe6294d3d"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_77d9a80b-fad8-4746-a3fd-19f012a01870"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_db33ce64-269a-49ea-a4af-63a49a604a55"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_795a954e-d486-46e7-a250-bdfa6ebc1cfc"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b8b15491-84e6-4093-a3dc-f6e4e3658c9a"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_696d352b-815e-4bee-a1ad-5340543c473c"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a731ef80-93e5-44a8-9679-4a4c2c298fc8"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d81a33d0-17e3-43cd-898f-047561248f8c"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_402df673-cbb4-4da2-8903-26c31f8f1d22"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_13603129-bb53-47d1-9eb7-6f62807645d1"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1bf1199f-3bac-4b1a-a27b-7888cad246a7"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5cfea8e3-9a33-4b9b-bbd5-a25a7e04afbd"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_74ff7f71-2430-4605-9e04-027595fb1748"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_32d528e5-a231-49d7-97ff-426af9382caf"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3c0ff92a-11a4-4a2c-a6e8-8f27665470e5"
          xlink:to="FNT_1bdd50f8-16f1-4581-8e22-f324d5379c53"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_b58366a1-3f90-4a0f-b814-ec4b8778b77a"
          xlink:label="F_b58366a1-3f90-4a0f-b814-ec4b8778b77a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e89a95e0-f206-4819-856f-aaabb6b695ce"
          xlink:label="F_e89a95e0-f206-4819-856f-aaabb6b695ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_96c3782c-44fa-417a-8f0c-ac63623e40eb"
          xlink:label="F_96c3782c-44fa-417a-8f0c-ac63623e40eb"
          xlink:type="locator"/>
        <link:footnote id="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4" xlink:label="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes all Immune Medicine operating expenses, other than research and development expenses.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b58366a1-3f90-4a0f-b814-ec4b8778b77a"
          xlink:to="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e89a95e0-f206-4819-856f-aaabb6b695ce"
          xlink:to="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_96c3782c-44fa-417a-8f0c-ac63623e40eb"
          xlink:to="FNT_e97179a0-0bc6-4cf1-b7b3-ffe300c51dd4"
          xlink:type="arc"/>
        <link:footnote id="FNT_084cfe7e-e0f2-4045-be6c-16380249a676" xlink:label="FNT_084cfe7e-e0f2-4045-be6c-16380249a676" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our share-based compensation expense.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bd249654-3957-4805-bdf6-1da2df6b29a6"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_384876e2-fe72-44d1-8909-963c883b7b5f"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_13603129-bb53-47d1-9eb7-6f62807645d1"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_40b0137c-2980-4840-93bf-339330caf6b1"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9dc6893b-4b8c-4c2c-8b50-fddcbe071b39"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f3a3da07-bb0c-4cf6-8477-c5168ea91e08"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5f934cfc-c961-465f-ab88-396d638ad6c1"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_03a4a7e7-73d8-4d27-a128-aaf30d9a6838"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_09ad6b64-fb8b-4678-8f92-59036e1480ab"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d35974e6-5809-4ae2-a57a-55bc3d676e32"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2d810bc9-402c-40e6-a7c9-c7cfcd3bdf00"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_51279202-faae-46b6-bb41-f7bdde771b6d"
          xlink:to="FNT_084cfe7e-e0f2-4045-be6c-16380249a676"
          xlink:type="arc"/>
        <link:footnote id="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e" xlink:label="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents expenses recognized in conjunction with restructuring activities. See Note 15, </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructurings</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for details on our restructuring expenses.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_32d528e5-a231-49d7-97ff-426af9382caf"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4904d016-10c5-4490-9bce-ce972d3156f6"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54732a37-6c04-468b-8af4-d2b05eb94ad3"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a731ef80-93e5-44a8-9679-4a4c2c298fc8"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c3876f27-0b6e-4215-92be-69496800fdf2"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6cedab5a-035d-4c63-89e7-abd4a482b92c"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d69c2f27-c6ea-495c-a4c8-42a7381ed0e4"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bf83b944-d68e-48d4-bda8-c3986baaf736"
          xlink:to="FNT_31a6aff1-9fa8-4de9-a180-0b0e6bb7221e"
          xlink:type="arc"/>
        <link:footnote id="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9" xlink:label="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Purchase Agreement </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on the Purchase Agreement.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b17e92ac-3b63-4ab8-8b55-094b9b4048c7"
          xlink:to="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9ddbf605-964c-47bd-aba2-66217d8b9853"
          xlink:to="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a064aff8-4d29-465b-8316-a8a35b77bc17"
          xlink:to="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_696d352b-815e-4bee-a1ad-5340543c473c"
          xlink:to="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b9553d4f-6ae8-4f3e-9922-efbb9fabe599"
          xlink:to="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_629e47f6-ada6-4b91-b878-080425e24779"
          xlink:to="FNT_291c2765-6b26-4b08-9d8e-60578d9adfe9"
          xlink:type="arc"/>
        <link:footnote id="FNT_c863f931-5324-4e7c-879c-cbda888d3579" xlink:label="FNT_c863f931-5324-4e7c-879c-cbda888d3579" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for details on our impairment expense.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_19c4e4ee-ca66-4b67-bf95-485edb301cb1"
          xlink:to="FNT_c863f931-5324-4e7c-879c-cbda888d3579"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_92c52fe6-c1cf-429e-b534-2bcd9b87c577"
          xlink:to="FNT_c863f931-5324-4e7c-879c-cbda888d3579"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
